PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	CHEN, J; MATTHEWS, KS				CHEN, J; MATTHEWS, KS			DELETION OF LACTOSE REPRESSOR CARBOXYL-TERMINAL DOMAIN AFFECTS TETRAMER FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPSIN-RESISTANT CORE; OPERATOR DNA COMPLEX; LAC-REPRESSOR; CIRCULAR-DICHROISM; ESCHERICHIA-COLI; BINDING; PROTEIN; EQUILIBRIUM; SEQUENCE; GENE	The carboxyl-terminal sequence of the lac repressor protein contains heptad repeats of leucines at positions 342, 349, and 356 that are required for tetramer assembly, as substitution of these leucine residues yields solely dimeric species (Chakerian, A. E., Tesmer, V. M., Manly, S. P., Brackett, J. K., Lynch, M. J., Hoh, J. T., and Matthews, K. S. (1991) J. Biol. Chem. 266, 1371-1374; Alberti, S., Oehler, S., von Wilcken-Bergmann, B., Kramer, H., and Muller-Hill, B. (1991) New Biol. 3, 57-62). To further investigate this region, which may form a leucine zipper motif, a family of lac repressor carboxyl-terminal deletion mutants eliminating the last 4, 5, 11, 18, and 32 amino acids (aa) has been constructed. The -4 aa mutant, in which all of the leucines in the presumed leucine zipper are intact, is tetrameric and displays operator and inducer binding properties similar to wild-type repressor. The -5 aa, -11 aa, -18 aa, and -32 aa deletion mutants, depleted of 1, 2, or all 3 of the leucines in the heptad repeats, are all dimeric, as demonstrated by gel filtration chromatography. Circular dichroism spectra and protease digestion studies indicate similar secondary/tertiary structures for the mutant and wild-type proteins. Differences in reaction with a monoclonal antibody specific for a subunit interface are observed for the dimeric versus tetrameric proteins, indicative of exposure of the target epitope as a consequence of deletion. Inducer binding properties of the deletion mutants are similar to wild-type tetrameric repressor at neutral pH. Only small differences in affinity and cooperativity from wild-type are evident at elevated pH; thus, the cooperative unit within the tetramer appears to be the dimer. "Apparent" operator binding affinity for the dimeric proteins is diminished, although minimal change in operator dissociation rate constants was observed. The diminution in apparent operator affinity may therefore derive from either 1) dissociation of the dimeric mutants to monomer generating a linked equilibrium or 2) alterations in intrinsic operator affinity of the dimers; the former explanation is favored. This detailed characterization of the purified mutant proteins confirms that the carboxyl-terminal region is involved in the dimer-dimer interface and demonstrates that cooperativity for inducer binding is contained within the dimer unit of the tetramer structure.	RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251	Rice University				Chen, Jie/0000-0002-7887-3747	NIGMS NIH HHS [GM 22441] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022441] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER K, 1972, NATURE, V237, P322, DOI 10.1038/237322a0; ALBERTI S, 1991, NEW BIOL, V3, P57; BARKLEY MD, 1975, BIOCHEMISTRY-US, V14, P1700, DOI 10.1021/bi00679a024; BETZ JL, 1986, GENE, V42, P283, DOI 10.1016/0378-1119(86)90232-5; BOURGEOIS S, 1979, BIOPOLYMERS, V18, P2625, DOI 10.1002/bip.1979.360181017; BOURGEOIS S, 1971, METHODS ENZYMOLOGY D, V21, P491; BRENOWITZ M, 1991, J BIOL CHEM, V266, P1281; BRENOWITZ M, 1991, BIOCHEMISTRY-US, V30, P5986, DOI 10.1021/bi00238a024; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P1371; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P22206; CHOU PY, 1975, J MOL BIOL, V96, P29, DOI 10.1016/0022-2836(75)90180-1; CULARD F, 1982, FEBS LETT, V146, P153, DOI 10.1016/0014-5793(82)80724-2; CULARD F, 1981, NUCLEIC ACIDS RES, V9, P5175, DOI 10.1093/nar/9.19.5175; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5474, DOI 10.1021/bi00367a019; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; FARABAUGH PJ, 1978, NATURE, V274, P765, DOI 10.1038/274765a0; FILES JG, 1976, J BIOL CHEM, V251, P3386; FRIEDMAN BE, 1977, J MOL BIOL, V111, P27; GORDON AJE, 1988, J MOL BIOL, V200, P239, DOI 10.1016/0022-2836(88)90237-9; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; KRAMER H, 1988, EMBO J, V7, P547, DOI 10.1002/j.1460-2075.1988.tb02844.x; KRAMER H, 1987, EMBO J, V6, P1481, DOI 10.1002/j.1460-2075.1987.tb02390.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LECLERC JE, 1988, J MOL BIOL, V203, P619, DOI 10.1016/0022-2836(88)90197-0; LEHMING N, 1988, P NATL ACAD SCI USA, V85, P7947, DOI 10.1073/pnas.85.21.7947; LIN SY, 1975, BIOCHEM BIOPH RES CO, V62, P704, DOI 10.1016/0006-291X(75)90456-8; MANDAL N, 1990, GENE DEV, V4, P410, DOI 10.1101/gad.4.3.410; MATTHEWS KS, 1979, J BIOL CHEM, V254, P3348; Miller J. H., 1980, OPERON; MILLER JH, 1979, J MOL BIOL, V131, P249, DOI 10.1016/0022-2836(79)90075-5; MILLER JH, 1979, J MOL BIOL, V131, P191, DOI 10.1016/0022-2836(79)90073-1; MILLER JH, 1970, LACTOSE OPERON, P343; Muller-Hill B, 1975, Prog Biophys Mol Biol, V30, P227; OAS TG, 1990, BIOCHEMISTRY-US, V29, P2891, DOI 10.1021/bi00464a001; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; OGORMAN RB, 1980, J BIOL CHEM, V255, P107; OGORMAN RB, 1980, J BIOL CHEM, V255, P100; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PLATT T, 1973, J BIOL CHEM, V248, P110; RASMUSSEN R, 1991, P NATL ACAD SCI USA, V88, P561, DOI 10.1073/pnas.88.2.561; RIGGS AD, 1968, J MOL BIOL, V34, P361, DOI 10.1016/0022-2836(68)90260-X; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; RIGGS AD, 1968, J MOL BIOL, V34, P365, DOI 10.1016/0022-2836(68)90261-1; ROYER CA, 1990, BIOCHEMISTRY-US, V29, P4959, DOI 10.1021/bi00472a028; SAMS CF, 1985, J BIOL CHEM, V260, P1185; SAUDEK V, 1990, PROTEIN ENG, V4, P3, DOI 10.1093/protein/4.1.3; SCHMITZ A, 1976, J BIOL CHEM, V251, P3359; SHIRAI T, 1987, GENE, V57, P11; WHITSON PA, 1986, BIOCHEMISTRY-US, V25, P3852, DOI 10.1021/bi00361a017; WHITSON PA, 1986, BIOCHEMISTRY-US, V25, P3845, DOI 10.1021/bi00361a016; WHITSON PA, 1987, J BIOL CHEM, V262, P4943	52	104	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13843	13850						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629185				2022-12-25	WOS:A1992JD32500012
J	GOPALAN, V; PASTUSZYN, A; GALEY, WR; GLEW, RH				GOPALAN, V; PASTUSZYN, A; GALEY, WR; GLEW, RH			EXOLYTIC HYDROLYSIS OF TOXIC PLANT GLUCOSIDES BY GUINEA-PIG LIVER CYTOSOLIC BETA-GLUCOSIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY	We demonstrate that although the guinea pig liver cytosolic beta-glucosidase does not catalyze the hydrolysis of gentiobiose, it does hydrolyze, disaccharide-containing glycosides such as p-nitrophenyl-beta-D-gentiobioside (Glc-beta-1-->Glc-beta-pNP) and mandelonitrile-beta-D-gentiobioside (amygdalin). Furthermore, we establish that the enzyme attacks disaccharide glycosides exolytically; specifically, we document the exolytic deglucosylation of amygdalin and the generation of the intermediate monosaccharide glycoside mandelonitrile-beta-D-glucoside prior to the formation of the aglycone (mandelonitrile). We also show that the cytosolic beta-glucosidase catalyzes the hydrolysis of various phenolic (e.g. arbutin and salicin) and cyanogenic plant glucosides (e.g. prunasin). Using the everted gut-sack technique, we demonstrate that the plant glucosides, amygdalin, prunasin, and vicine, are transported across the small intestine of the guinea pig efficiently and without being hydrolyzed. Based on thess data we speculate that the cytosolic beta-glucosidase may participate in biotransformation of toxic plant glucosides.	UNIV NEW MEXICO,SCH MED,DEPT BIOCHEM,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,SCH MED,DEPT PHYSIOL,ALBUQUERQUE,NM 87131	University of New Mexico; University of New Mexico					NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM031357] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM31357] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONN EE, 1987, BIOCH PLANTS COMPREH, P479; DANIELS LB, 1981, J BIOL CHEM, V256, P3004; DISTLER JJ, 1977, ARCH BIOCHEM BIOPHYS, V178, P631, DOI 10.1016/0003-9861(77)90235-1; FREESE A, 1980, ARCH BIOCHEM BIOPHYS, V201, P363, DOI 10.1016/0003-9861(80)90523-8; GLEW RH, 1976, BIOCHIM BIOPHYS ACTA, V422, P179, DOI 10.1016/0005-2744(76)90018-8; GOPALAN V, 1989, BIOCHEM J, V262, P541, DOI 10.1042/bj2620541; HALIWELL B, 1989, FREE RADICAL BIO MED, P329; JAKOBY WB, 1990, J BIOL CHEM, V265, P20715; LAMARCO KL, 1986, BIOCHEM J, V237, P469, DOI 10.1042/bj2370469; LEGLER G, 1988, ARCH BIOCHEM BIOPHYS, V260, P429; MAGER J, 1980, TOXIC CONSTITUENTS P, P265; OSUNTOKUN BO, 1970, LANCET, V2, P372; OSUNTOKUN BO, 1968, BRAIN, V91, P215, DOI 10.1093/brain/91.2.215; PETERS SP, 1975, CLIN CHIM ACTA, V60, P391, DOI 10.1016/0009-8981(75)90083-2; POCSI I, 1988, BIOCHEM J, V256, P139, DOI 10.1042/bj2560139; REICHARDT PB, 1991, TOXICOLOGY PLANT FUN, P313; WILSON TH, 1954, J PHYSIOL-LONDON, V123, P116, DOI 10.1113/jphysiol.1954.sp005036	18	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14027	14032						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629201				2022-12-25	WOS:A1992JD32500040
J	SHIOI, J; ANDERSON, JP; RIPELLINO, JA; ROBAKIS, NK				SHIOI, J; ANDERSON, JP; RIPELLINO, JA; ROBAKIS, NK			CHONDROITIN SULFATE PROTEOGLYCAN FORM OF THE ALZHEIMERS BETA-AMYLOID PRECURSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEASE NEXIN-II; DISEASE; SURFACE; HEPARIN; PLAQUE; DOMAIN; BRAIN; CDNA; PURIFICATION; CHYMOTRYPSIN	The Alzheimer's amyloid beta-protein is derived from a family of membrane glycoproteins termed amyloid precursor proteins (APP). Here we show that APP exists as the core protein of a chondroitin sulfate (CS) proteoglycan, ranging in apparent molecular size from 140 to 250 kDa, secreted by glial cell line C6. After partial purification on ion-exchange and gel chromatography, the secreted APP proteoglycan was recognized on Western blots by several antibodies specific to different regions of APP. Chondroitinase AC or ABC treatment of our samples completely eliminated the high molecular weight proteoglycan with a concomitant increase in the APP protein. This digested product reacted with an anti-stub antibody which recognizes 4-sulfated disaccharide. Sequencing of the N terminus of the core protein of this CS proteoglycan yielded 18 residues identical to the N terminus sequence of the mature APP. Quantitative analysis showed that, in this cell line, about 90% of the secreted nexin II form of APP occurs in the proteoglycan form, suggesting that the CS chains have a role in the biological function of this protein. The close proximity of two consensus CS attachment sites to both the N terminus of the amyloid beta-protein and the secretase cleavage site, suggests that the CS chains may affect the proteolysis of APP and production of the amyloid beta-protein.	CUNY MT SINAI SCH MED, DEPT PSYCHIAT, 1 GUSTAVE LEVY PL, BOX 1229, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, FISHBERG RES CTR NEUROBIOL, NEW YORK, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			Robakis, Nikolaos/AAA-1838-2021		NATIONAL INSTITUTE ON AGING [P50AG005138, R01AG008200] Funding Source: NIH RePORTER; NIA NIH HHS [AG08200, AG05138] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; ANTONSSON P, 1989, J BIOL CHEM, V264, P16170; BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BREEN KC, 1991, J NEUROSCI RES, V28, P90, DOI 10.1002/jnr.490280109; BRITTIS PA, 1992, SCIENCE, V255, P733, DOI 10.1126/science.1738848; Caterson B, 1987, BIOL PROTEOGLYCANS, P1; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GODINOT C, 1989, BIOCHIMIE, V71, P917, DOI 10.1016/0300-9084(89)90074-6; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GOWDA DC, 1990, ARCH BIOCHEM BIOPHYS, V281, P219, DOI 10.1016/0003-9861(90)90435-2; IOZZO RV, 1987, J BIOL CHEM, V262, P1888; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landon, 1977, Methods Enzymol, V47, P145; Linker A., 1972, METHODS ENZYMOL, P902; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NELSON RB, 1990, J BIOL CHEM, V265, P3836; NEWMAN SA, 1987, P NATL ACAD SCI USA, V84, P4791, DOI 10.1073/pnas.84.14.4791; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; RAUCH U, 1991, J BIOL CHEM, V266, P14785; REFOLO LM, 1989, BIOCHEM BIOPH RES CO, V164, P664, DOI 10.1016/0006-291X(89)91511-8; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; ROBAKIS NK, 1991, GROWTH FACTORS ALZHE, P208; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SCHUBERT D, 1989, P NATL ACAD SCI USA, V86, P2066, DOI 10.1073/pnas.86.6.2066; SILVA ME, 1974, BIOCHEM BIOPH RES CO, V56, P965, DOI 10.1016/S0006-291X(74)80283-4; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VANNOSTRAND WE, 1987, J BIOL CHEM, V262, P8508; VANNOSTRAND WE, 1989, NATURE, V341, P546; WAGNER WD, 1986, ARTERIOSCLEROSIS, V6, P407, DOI 10.1161/01.ATV.6.4.407; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523	45	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13819	13822						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629183				2022-12-25	WOS:A1992JD32500008
J	IMLER, JL; ZURAWSKI, G				IMLER, JL; ZURAWSKI, G			RECEPTOR-BINDING AND INTERNALIZATION OF MOUSE INTERLEUKIN-2 DERIVATIVES THAT ARE PARTIAL AGONISTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; BETA-CHAIN; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; LIGAND-BINDING; GROWTH; IL-2; ALPHA; EXPRESSION; PROTEINS	Mouse interleukin-2 (mIL-2) mutant proteins with subunit-specific receptor binding defects have been previously described. Some of these mutant proteins are unable to trigger a maximum proliferative response of T cells. In this study, mIL-2 and mIL-2 mutant proteins were labeled with P-32, and their association and dissociation kinetics with the high affinity IL-2 receptor (IL-2R) were investigated. A mIL-2 mutant protein with a partial defect in binding to the low affinity component of IL-2R had a slower on-rate than mIL-2. On the other hand, a mIL-2 antagonist with a binding defect to the intermediate affinity component of IL-2R had a normal on-rate, whereas its off-rate at 37-degrees-C was faster than mIL-2. This fast off-rate at physiological temperature interfered with mIL-2 internalization. When three mIL-2 partial agonists, each inducing a different maximal response, were examined, no difference was found between their dissociation rates or their internalization properties. The significance of these findings for the function of each receptor subunit in the IL-2R complex, as well as for the mechanism of activation of the receptor, is discussed.	DNAX RES INST MOLEC & CELLULAR BIOL INC,MOLEC & CELLULAR BIOL RES INST,DEPT MOLEC BIOL,PALO ALTO,CA 94304	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Imler, Jean-Luc/GXH-4323-2022					CHOU CK, 1987, J BIOL CHEM, V262, P1842; DUPREZ V, 1991, J BIOL CHEM, V266, P1497; EARDLEY DD, 1991, SCIENCE, V251, P78, DOI 10.1126/science.1824727; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; FUJII M, 1986, J EXP MED, V163, P550, DOI 10.1084/jem.163.3.550; HASKILL S, 1991, P NATL ACAD SCI USA, V88, P3681, DOI 10.1073/pnas.88.9.3681; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; IMBER JL, 1992, IN PRESS EMBO J; KENAKIN TP, 1987, PHARM ANAL DRUG RECE, P190; KONO T, 1990, P NATL ACAD SCI USA, V87, P1806, DOI 10.1073/pnas.87.5.1806; KUMAR A, 1987, J IMMUNOL, V139, P3680; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LI BL, 1989, P NATL ACAD SCI USA, V86, P558, DOI 10.1073/pnas.86.2.558; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; LOWENTHAL JW, 1987, J EXP MED, V166, P1156, DOI 10.1084/jem.166.4.1156; MADDUX BA, 1991, J BIOL CHEM, V266, P6731; MERIDA I, 1990, P NATL ACAD SCI USA, V87, P9421, DOI 10.1073/pnas.87.23.9421; MINAMOTO S, 1990, J IMMUNOL, V145, P2177; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; PETERS DK, 1990, BLOOD, V76, P97; ROBB RJ, 1987, J EXP MED, V165, P1201, DOI 10.1084/jem.165.4.1201; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SMITH KA, 1989, ANNU REV CELL BIOL, V5, P397; TSUDO M, 1990, J IMMUNOL, V145, P599; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681; WANG HM, 1987, J EXP MED, V166, P1055, DOI 10.1084/jem.166.4.1055; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; ZURAWSKI SM, 1988, EMBO J, V7, P1061, DOI 10.1002/j.1460-2075.1988.tb02914.x; ZURAWSKI SM, 1990, EMBO J, V9, P3899, DOI 10.1002/j.1460-2075.1990.tb07610.x	35	22	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13185	13190						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618822				2022-12-25	WOS:A1992JB74600017
J	MASTERSON, C; BOEHMER, PE; MCDONALD, F; CHAUDHURI, S; HICKSON, ID; EMMERSON, PT				MASTERSON, C; BOEHMER, PE; MCDONALD, F; CHAUDHURI, S; HICKSON, ID; EMMERSON, PT			RECONSTITUTION OF THE ACTIVITIES OF THE RECBCD HOLOENZYME OF ESCHERICHIA-COLI FROM THE PURIFIED SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXONUCLEASE-V; DEPENDENT DEOXYRIBONUCLEASE; HOMOLOGOUS RECOMBINATION; GENETIC-RECOMBINATION; ADENYLATE KINASE; DUPLEX DNA; RECC GENE; ENZYME; PURIFICATION; PROTEINS	The Escherichia coli RecBCD holoenzyme and the individual constituent subunits have been purified from overproducing strains. The purified RecBCD holoenzyme has a native molecular mass of approximately 330 kDa, indicative of a heterotrimer subunit assembly. The RecB, RecC, and RecD subunits can associate in vitro to give nuclease, helicase, ATPase, and Chi-specific endonuclease activities which are indistinguishable from those of the RecBCD holoenzyme. At concentrations at which the reconstituted RecB+C+D enzyme is very active, none of the individual RecB, RecC, or RecD subunits have readily detectable activities of the holoenzyme, except RecB protein which had previously been shown to exhibit DNA-dependent ATPase activity (Hickson, I. D, Robson, C. N., Atkinson, K. E., Hutton, L., and Emmerson, P. T. (1985) J. Biol. Chem. 260, 1224-1229). At higher concentrations and with shorter DNA substrates reconstituted RecBC protein exhibits low levels of helicase and exonuclease activity.	UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT BIOCHEM & GENET,NEWCASTLE TYNE NE2 4HH,ENGLAND	Newcastle University - UK			Hickson, Ian/AAJ-7548-2020	Hickson, Ian/0000-0002-0583-566X; Boehmer, Paul/0000-0003-4479-0529				AMUNDSEN SK, 1990, GENETICS, V126, P25; AMUNDSEN SK, 1986, P NATL ACAD SCI USA, V83, P5558, DOI 10.1073/pnas.83.15.5558; BIEK DP, 1986, J BACTERIOL, V167, P594, DOI 10.1128/jb.167.2.594-603.1986; BOEHMER PE, 1991, GENE, V102, P1, DOI 10.1016/0378-1119(91)90529-K; BOEHMER PE, 1992, IN PRESS J BIOL CHEM; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAUDHURY AM, 1984, J BACTERIOL, V160, P788, DOI 10.1128/JB.160.2.788-791.1984; CHAUDHURY AM, 1984, P NATL ACAD SCI-BIOL, V81, P7850, DOI 10.1073/pnas.81.24.7850; CLAASSEN LA, 1991, J BIOL CHEM, V266, P11380; CLARK AJ, 1973, ANNU REV GENET, V7, P67, DOI 10.1146/annurev.ge.07.120173.000435; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; DOWER NA, 1981, P NATL ACAD SCI-BIOL, V78, P7033, DOI 10.1073/pnas.78.11.7033; DYKSTRA CC, 1984, COLD SPRING HARB SYM, V49, P463, DOI 10.1101/SQB.1984.049.01.052; EICHLER DC, 1977, J BIOL CHEM, V252, P499; FINCH PW, 1986, NUCLEIC ACIDS RES, V14, P8583, DOI 10.1093/nar/14.21.8583; FINCH PW, 1986, NUCLEIC ACIDS RES, V14, P4437, DOI 10.1093/nar/14.11.4437; FINCH PW, 1986, NUCLEIC ACIDS RES, V14, P8573, DOI 10.1093/nar/14.21.8573; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GOLDMARK PJ, 1972, J BIOL CHEM, V247, P1849; HICKSON ID, 1984, NUCLEIC ACIDS RES, V12, P3807, DOI 10.1093/nar/12.9.3807; HICKSON ID, 1985, J BIOL CHEM, V260, P1224; JULIN DA, 1987, J BIOL CHEM, V262, P9044; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBERMAN RP, 1974, P NATL ACAD SCI USA, V71, P4816, DOI 10.1073/pnas.71.12.4816; LLOYD RG, 1988, MOL GEN GENET, V212, P317, DOI 10.1007/BF00334702; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; MACKAY V, 1974, J BIOL CHEM, V249, P4286; OISHI M, 1969, P NATL ACAD SCI USA, V64, P1292, DOI 10.1073/pnas.64.4.1292; PAI EF, 1977, J MOL BIOL, V114, P37, DOI 10.1016/0022-2836(77)90281-9; PALAS KM, 1990, J BIOL CHEM, V265, P3447; PARSONAGE D, 1987, J BIOL CHEM, V262, P8022; PONTICELLI AS, 1985, CELL, V41, P145, DOI 10.1016/0092-8674(85)90069-8; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2873, DOI 10.1021/bi00433a019; ROSAMOND J, 1979, J BIOL CHEM, V254, P8646; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH GR, 1988, MICROBIOL REV, V52, P1; TAYLOR A, 1980, CELL, V22, P447, DOI 10.1016/0092-8674(80)90355-4; TAYLOR AF, 1985, CELL, V41, P153, DOI 10.1016/0092-8674(85)90070-4; TAYLOR AF, 1988, GENETIC RECOMBINATIO, P231; TELANDERMUSKAVI.KM, 1981, ENZYMES, V14, P233; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; WRIGHT M, 1971, J BIOL CHEM, V246, P6543	46	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13564	13572						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618858				2022-12-25	WOS:A1992JB74600074
J	SHINKI, T; JIN, CH; NISHIMURA, A; NAGAI, Y; OHYAMA, Y; NOSHIRO, M; OKUDA, K; SUDA, T				SHINKI, T; JIN, CH; NISHIMURA, A; NAGAI, Y; OHYAMA, Y; NOSHIRO, M; OKUDA, K; SUDA, T			PARATHYROID-HORMONE INHIBITS 25-HYDROXYVITAMIN-D(3)-24-HYDROXYLASE MESSENGER-RNA EXPRESSION STIMULATED BY 1-ALPHA,25-DIHYDROXYVITAMIN-D(3) IN RAT-KIDNEY BUT NOT IN INTESTINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							25-HYDROXYVITAMIN D3 24-HYDROXYLASE; VITAMIN-D; 1,25-DIHYDROXYVITAMIN D3; INVITRO METABOLISM; 25-HYDROXYCHOLECALCIFEROL; RECEPTORS; ACID; ADENOSINE-3',5'-MONOPHOSPHATE; MITOCHONDRIA; CATABOLISM	Using a cDNA probe for rat renal 24-hydroxylase, expression of its mRNA was compared in the rat kidney and intestine. Vitamin D-deficient rats received a single injection of 1-alpha,25-dihydroxyvitamin D3. Expression of 24-hydroxylase mRNA was first detected in the kidney at 3-h post-injection and increased thereafter. Similarly, 24-hydroxylase mRNA was expressed in the intestine after 1-alpha,25-dihydroxyvitamin D3 injection. However, the dose level of 1-alpha,25-dihydroxyvitamin D3 required to induce the intestinal 24-hydroxylase mRNA expression was only 1/100 the amount required to induce renal 24-hydroxylase mRNA. Induction of intestinal 24-hydroxylase mRNA expression by 1-alpha,25-dihydroxyvitamin D3 was far more rapid than that of renal 24-hydroxylase mRNA. Thyroparathyroidectomy shortened the time required to induce expression of renal, but not intestinal, 24-hydroxylase mRNA. Administration of either parathyroid hormone or cAMP to vitamin D-deficient rats greatly reduced the expression of 24-hydroxylase mRNA in the kidney but not in the intestine. When rats were fed a vitamin D-repleted diet containing 0.7% (adequate) or 0.03% (low) calcium for 2 weeks, intestinal expression of 24-hydroxylase mRNA could be induced only in the low calcium group. In contrast, renal mRNA expression was preferentially stimulated in the adequate calcium group. These results clearly demonstrate that the expression of 24-hydroxylase mRNA is down-regulated by parathyroid hormone in the kidney but not in the intestine.	SHOWA UNIV, SCH DENT,DEPT BIOCHEM,1-5-8 HATANODAI,SHINAGAWA KU, TOKYO 142, JAPAN; HIROSHIMA UNIV, SCH DENT, DEPT BIOCHEM, MINATO KU, HIROSHIMA 734, JAPAN	Showa University; Hiroshima University								ARMBRECHT HJ, 1981, ENDOCRINOLOGY, V109, P218, DOI 10.1210/endo-109-1-218; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOTHAM KM, 1976, BIOCHEMISTRY-US, V15, P2130, DOI 10.1021/bi00655a016; BURGOSTRINIDAD M, 1991, BIOCHIM BIOPHYS ACTA, V1078, P226, DOI 10.1016/0167-4838(91)90562-E; CHANDLER JS, 1984, J BIOL CHEM, V259, P2214; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELUCA HF, 1988, FASEB J, V2, P224, DOI 10.1096/fasebj.2.3.3280376; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRASER DR, 1973, NATURE-NEW BIOL, V241, P163, DOI 10.1038/newbio241163a0; FROLIK CA, 1971, ARCH BIOCHEM BIOPHYS, V147, P143, DOI 10.1016/0003-9861(71)90320-1; GARABEDIAN M, 1972, P NATL ACAD SCI USA, V69, P1673, DOI 10.1073/pnas.69.7.1673; GARABEDIAN M, 1978, ENDOCRINOLOGY, V102, P1262, DOI 10.1210/endo-102-4-1262; HARRISON B, 1986, ANAL BIOCHEM, V158, P307, DOI 10.1016/0003-2697(86)90555-5; HAUSSLER MR, 1988, RECENT PROG HORM RES, V44, P263; HAUSSLER MR, 1986, ANNU REV NUTR, V6, P527, DOI 10.1146/annurev.nu.06.070186.002523; HOLICK MF, 1987, KIDNEY INT, V32, P912, DOI 10.1038/ki.1987.295; HORIUCHI N, 1984, BIOCHEM BIOPH RES CO, V121, P174, DOI 10.1016/0006-291X(84)90703-4; HORIUCHI N, 1977, ENDOCRINOLOGY, V101, P969, DOI 10.1210/endo-101-3-969; INABA M, 1991, ARCH BIOCHEM BIOPHYS, V284, P257, DOI 10.1016/0003-9861(91)90293-R; JONGEN MJ, 1987, HORM METAB RES, V19, P481, DOI 10.1055/s-2007-1011858; KAWASHIMA H, 1981, P NATL ACAD SCI-BIOL, V78, P1199, DOI 10.1073/pnas.78.2.1199; KISSMEYER AM, 1991, BIOCHEM PHARMACOL, V41, P1601, DOI 10.1016/0006-2952(91)90160-7; KUMAR R, 1984, PHYSIOL REV, V64, P478, DOI 10.1152/physrev.1984.64.2.478; KUMAR R, 1978, J BIOL CHEM, V253, P3804; KURIBAYASHI K, 1988, NUCLEIC ACIDS RES S, V19, P61; MANGELSDORF DJ, 1987, P NATL ACAD SCI USA, V84, P354, DOI 10.1073/pnas.84.2.354; MCDONNELL DP, 1987, SCIENCE, V235, P1214, DOI 10.1126/science.3029866; MINGHETTI PP, 1988, FASEB J, V2, P3043, DOI 10.1096/fasebj.2.15.2847948; OHYAMA Y, 1991, FEBS LETT, V278, P195, DOI 10.1016/0014-5793(91)80115-J; OHYAMA Y, 1989, FEBS LETT, V255, P405, DOI 10.1016/0014-5793(89)81133-0; OHYAMA Y, 1991, J BIOL CHEM, V266, P8690; OHYAMA Y, 1990, DRUG METABOLIZING EN, P114; REINHARDT TA, 1990, ENDOCRINOLOGY, V127, P942, DOI 10.1210/endo-127-2-942; ROST CR, 1981, ENDOCRINOLOGY, V108, P1002, DOI 10.1210/endo-108-3-1002; SHIGEMATSU T, 1986, ENDOCRINOLOGY, V118, P1583, DOI 10.1210/endo-118-4-1583; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TANAKA Y, 1981, P NATL ACAD SCI-BIOL, V78, P196, DOI 10.1073/pnas.78.1.196; TANAKA Y, 1974, P NATL ACAD SCI USA, V71, P1040, DOI 10.1073/pnas.71.4.1040; TANAKA Y, 1975, ARCH BIOCHEM BIOPHYS, V171, P521, DOI 10.1016/0003-9861(75)90061-2; TENENHOUSE HS, 1988, J CLIN INVEST, V81, P461, DOI 10.1172/JCI113342; TOMON M, 1990, AM J PHYSIOL, V258, pG557, DOI 10.1152/ajpgi.1990.258.4.G557; TURNER RT, 1980, P NATL ACAD SCI-BIOL, V77, P1537, DOI 10.1073/pnas.77.3.1537; VIETH R, 1979, J BIOL CHEM, V254, P2455; WALTERS MR, 1983, J STEROID BIOCHEM, V19, P913, DOI 10.1016/0022-4731(83)90034-1; WASSERMAN RH, 1968, J BIOL CHEM, V243, P3978; YAMATO H, 1989, ENDOCRINOLOGY, V124, P511, DOI 10.1210/endo-124-1-511	46	159	159	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13757	13762						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618870				2022-12-25	WOS:A1992JB74600103
J	ARDUINI, A; MANCINELLI, G; RADATTI, GL; DOTTORI, S; MOLAJONI, F; RAMSAY, RR				ARDUINI, A; MANCINELLI, G; RADATTI, GL; DOTTORI, S; MOLAJONI, F; RAMSAY, RR			ROLE OF CARNITINE AND CARNITINE PALMITOYLTRANSFERASE AS INTEGRAL COMPONENTS OF THE PATHWAY FOR MEMBRANE PHOSPHOLIPID FATTY-ACID TURNOVER IN INTACT HUMAN ERYTHROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALONYL-COA; ACYLTRANSFERASE; MICROSOMES; BLOOD	The deacylation and reacylation process of phospholipids is the major pathway of turnover and repair in erythrocyte membranes. In this paper, we have investigated the role of carnitine palmitoyltransferase in erythrocyte membrane phospholipid fatty acid turnover. The role of acyl-L-carnitine as a reservoir of activated acyl groups, the buffer function of carnitine, and the importance of the acyl-CoA/free CoA ratio in t he reacylation process of erythrocyte membrane phospholipids have also been addressed. In intact erythrocytes, the incorporation of [1-C-14]palmitic acid into acyl-L-carnitine, phosphatidylcholine, and phosphatidylethanolamine was linear with time for at least 3 h. The greatest proportion of the radioactivity was found in acyl-L-carnitine. Competition experiments using [1-C-14]palmitic and [9,10-H-3]oleic acid demonstrated that [9,10-H-3]oleic acid was incorporated preferentially into the phospholipids and less into acyl-L-carnitine. When an erythrocyte suspension was incubated with [1-C-14]palmitoyl-L-carnitine, radiolabeled palmitate was recovered in the phospholipid fraction, and the carnitine palmitoyltransferase inhibitor, 2-tetradecylglycidic acid, completely abolished the incorporation. ATP depletion decreased incorporation of [1-C-14]palmitic and/or [9,10-H-3]oleic acid into acyl-L-carnitine, but the incorporation into phosphatidylcholine and phosphatidylethanolamine was unaffected. In contrast, ATP depletion enhanced the incorporation into phosphatidylcholine and phosphatidylethanolamine of the radiolabeled fatty acid from [1-C-14]palmitoyl-L-carnitine. These data are suggestive of the existence of an acyl-L-carnitine pool, in equilibrium with the acyl-CoA pool, which serves as a reservoir of activated acyl groups. The carnitine palmitoyltransferase inhibition by 2-tetradecylglycidic acid or palmitoyl-D-carnitine caused a significant reduction of radiolabeled fatty acid incorporation into membrane phospholipids, only when intact erythrocytes were incubated with [9,10-H-3]oleic acid. These latter data may be explained by the differences in rates and substrates specificities between acyl-CoA synthetase and the reacylating enzymes for palmitate and oleate, which support the importance of carnitine palmitoyltransferase in modulating the optimal acyl-CoA/free CoA ratio for the physiological expression of the membrane phospholipids fatty acid turnover.	SIGMA TAU PHARMACEUT CO,DIPARTIMENTO RIC & SVILUPPO,POMEZIA,ITALY; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; VET ADM MED CTR,DIV MOLEC BIOL,SAN FRANCISCO,CA 94121	Leadiant Biosciences; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	ARDUINI, A (corresponding author), UNIV G DANNUNZIO,IST SCI BIOCHIM,VIA VESTINI,I-66100 CHIETI,ITALY.		Arduini, Arduino/ABH-5284-2020; Ramsay, Rona/A-4065-2009; Ramsay, Rona R./A-6681-2008	Ramsay, Rona R./0000-0003-1535-4904	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041572] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-41572] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams H., 1963, METHOD ENZYMAT AN, P539; ARDUINI A, 1992, AM HEART J, V123, P1726, DOI 10.1016/0002-8703(92)90850-U; ARDUINI A, 1990, BIOCHEM BIOPH RES CO, V173, P212, DOI 10.1016/S0006-291X(05)81043-5; BEUTLER E, 1976, J LAB CLIN MED, V88, P328; BIEBER LL, 1988, ANNU REV BIOCHEM, V57, P261, DOI 10.1146/annurev.bi.57.070188.001401; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREMER J, 1983, PHYSIOL REV, V63, P1420, DOI 10.1152/physrev.1983.63.4.1420; BRORING K, 1989, BIOCHIM BIOPHYS ACTA, V986, P321, DOI 10.1016/0005-2736(89)90484-7; CLASSEN J, 1989, J MEMBRANE BIOL, V111, P169, DOI 10.1007/BF01871780; COOPER MB, 1988, BIOCHIM BIOPHYS ACTA, V959, P100, DOI 10.1016/0005-2760(88)90020-3; DAVIDSON BC, 1985, FEBS LETT, V193, P69, DOI 10.1016/0014-5793(85)80081-8; DERRICK JP, 1989, BIOCHEM J, V262, P801, DOI 10.1042/bj2620801; DISE CA, 1980, J LIPID RES, V21, P292; FRITZ IB, 1963, J BIOL CHEM, V238, P2509; KUNIMOTO M, 1988, LIPIDS, V19, P443; Lands W., 1976, ENZYMES BIOL MEMBRAN, V2, P3; LILLY K, 1990, ARCH BIOCHEM BIOPHYS, V280, P167, DOI 10.1016/0003-9861(90)90532-4; MACDONALD JIS, 1991, BIOCHIM BIOPHYS ACTA, V1084, P105, DOI 10.1016/0005-2760(91)90209-Z; MCLEOD ME, 1967, BIOCHIM BIOPHYS ACTA, V144, P391, DOI 10.1016/0005-2760(67)90168-3; MOK AYP, 1990, BIOCHEM CELL BIOL, V68, P1380, DOI 10.1139/o90-201; MOMCHILOVAPANKOVA AB, 1990, BIOCHIMIE, V72, P863, DOI 10.1016/0300-9084(90)90003-Y; MULDER E, 1965, BIOCHIM BIOPHYS ACTA, V106, P106, DOI 10.1016/0005-2760(65)90099-8; MULDER E, 1965, BIOCHIM BIOPHYS ACTA, V106, P348, DOI 10.1016/0005-2760(65)90043-3; OLIVEIRA MM, 1964, J LIPID RES, V5, P156; Pennell RB, 1964, RED BLOOD CELL, P29; RAMSAY RR, 1991, BIOCHEM J, V275, P685, DOI 10.1042/bj2750685; RENOOIJ W, 1974, BIOCHIM BIOPHYS ACTA, V363, P287, DOI 10.1016/0005-2736(74)90069-8; ROBERTSON AF, 1964, J LIPID RES, V5, P88; ROSE HG, 1965, J LIPID RES, V6, P428; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; ROUSER G, 1969, METHOD ENZYMOL, V14, P272; SHOHET SB, 1968, J CLIN INVEST, V47, P1096, DOI 10.1172/JCI105799; Tanaka T, 1981, Methods Enzymol, V71 Pt C, P334; THOMPSON GA, 1984, PHYSL MEMBRANE FLUID, V1, P99; Tutwiler G F, 1981, Methods Enzymol, V72, P533; WAKU K, 1968, J LIPID RES, V9, P12; WITTELS B, 1967, J BIOL CHEM, V242, P126; Yonetani T, 1967, METHODS ENZYMOL, V10, P332	39	109	110	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12673	12681						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618773				2022-12-25	WOS:A1992HZ48300047
J	DING, RC; POMMIER, Y; KANG, VH; SMULSON, M				DING, RC; POMMIER, Y; KANG, VH; SMULSON, M			DEPLETION OF POLY(ADP-RIBOSE) POLYMERASE BY ANTISENSE RNA EXPRESSION RESULTS IN A DELAY IN DNA STRAND BREAK REJOINING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-SENSE RNA; POLY(ADENOSINE DIPHOSPHATE RIBOSE); NUCLEAR-PROTEIN MODIFICATION; MAMMALIAN-CELLS; EXCISION REPAIR; GENE-EXPRESSION; CHROMATIN; GROWTH; DIFFERENTIATION; ONCOGENE	The effects of inducible expression of poly(ADP-ribose) polymerase (PADPRP) antisense RNA in HeLa cells were determined in order to gain further insight into the biological roles of the poly(ADP-ribosyl)ation modification of nuclear proteins. A recombinant expression plasmid was prepared with the mouse mammary tumor virus (MMTV) promoter upstream of the antisense-oriented PADPRP cDNA. Expression of the antisense RNA was under strict control, with negligible effects on cell growth being apparent in the absence of inducer. Consistent with the previously described stability of PADPRP (half-life of at least 2 days, in vivo), 48-72 h were required after induction of antisense RNA expression by dexamethasone for the abundant concentration of PADPRP, normally present in HeLa cells, to be reduced by greater than 80%. The depletion of endogenous PADPRP as mediated by induced antisense RNA expression was established by: (i) a progressive synthesis of antisense transcripts in cells as assessed by Northern analysis; (ii) an 80% decrease in activity of the enzyme; and (iii) a greater than 90% reduction in the cellular content of PADPRP protein, as demonstrated by both immunoblotting and immunohistochemical analysis in intact cells. Several biological parameters were monitored in cells depleted of PADPRP. The chromatin of PADPRP-depleted cells was shown to have an altered structure as assessed by deoxyribonuclease I susceptibility. Cell morphology was also altered, with multinucleated aggregates being evident 72 h after induction of antisense RNA expression. Cells depleted of PADPRP were not able to commence DNA strand break joining of damaged DNA. However, DNA repair capacity was re-established at later time periods, indicating that PADPRP may contribute to alterations in chromatin structure that occur initially in DNA strand break rejoining and that the concentration of the enzyme in nuclei exceeds the requirement for DNA repair/replication.	GEORGETOWN UNIV, DEPT BIOCHEM & MOLEC BIOL, 3900 RESERVOIR RD NW, WASHINGTON, DC 20007 USA; NCI, MOLEC PHARMACOL LAB, BALTIMORE, MD 21201 USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NATIONAL CANCER INSTITUTE [R01CA025344] Funding Source: NIH RePORTER; NCI NIH HHS [CA25344] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKHATIB HM, 1987, P NATL ACAD SCI USA, V84, P1224, DOI 10.1073/pnas.84.5.1224; ALTHAUS FR, 1985, ADP RIBOSYLATION PRO; BENJAMIN RC, 1980, J BIOL CHEM, V255, P502; BERGER NA, 1980, BIOCHEMISTRY-US, V19, P289, DOI 10.1021/bi00543a006; BHATIA K, 1990, CARCINOGENESIS, V11, P123, DOI 10.1093/carcin/11.1.123; BHATIA K, 1990, J CELL PHYSIOL, V144, P345, DOI 10.1002/jcp.1041440221; BOORSTEIN RJ, 1984, J CELL PHYSIOL, V120, P335, DOI 10.1002/jcp.1041200312; BUTT TR, 1978, NUCLEIC ACIDS RES, V5, P2775, DOI 10.1093/nar/5.8.2775; BUTT TR, 1979, P NATL ACAD SCI USA, V76, P1628, DOI 10.1073/pnas.76.4.1628; CHATTERJEE S, 1989, EXP CELL RES, V184, P1, DOI 10.1016/0014-4827(89)90358-3; CHERNEY BW, 1985, DEV BIOL, V112, P115, DOI 10.1016/0012-1606(85)90125-3; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DING R, 1985, MOL CELL BIOL, V5, P3293, DOI 10.1128/MCB.5.11.3293; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; FARZANEH F, 1982, NATURE, V300, P362, DOI 10.1038/300362a0; FERRO AM, 1984, J BIOL CHEM, V259, P547; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FRIEDMAN HM, 1989, MOL CELL BIOL, V9, P2303, DOI 10.1128/MCB.9.6.2303; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; IZANT JG, 1985, SCIENCE, V229, P345, DOI 10.1126/science.2990048; IZANT JG, 1984, CELL, V36, P1007, DOI 10.1016/0092-8674(84)90050-3; JACOBSON EL, 1979, J CELL PHYSIOL, V99, P417, DOI 10.1002/jcp.1040990316; JACOBSON MK, 1989, ADP RIBOSE TRANSFER; JAUREZSALINAS H, 1979, NATURE, V282, P740; JUMP DB, 1980, BIOCHEMISTRY-US, V19, P1031, DOI 10.1021/bi00546a031; JUMP DB, 1979, BIOCHEMISTRY-US, V18, P983, DOI 10.1021/bi00573a008; JUMP DB, 1980, BIOCHEMISTRY-US, V19, P1024, DOI 10.1021/bi00546a030; KIM SK, 1985, CELL, V42, P129, DOI 10.1016/S0092-8674(85)80108-2; KOHN KW, 1981, DNA REPAIR LABORATOR, P379; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; LUDWIG A, 1988, J BIOL CHEM, V263, P6993; MALIK N, 1983, P NATL ACAD SCI-BIOL, V80, P2554, DOI 10.1073/pnas.80.9.2554; MATHIS G, 1990, CARCINOGENESIS, V11, P1237, DOI 10.1093/carcin/11.7.1237; MILAM KM, 1984, SCIENCE, V223, P589, DOI 10.1126/science.6420886; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; ROSOLEN A, 1990, CANCER RES, V50, P6316; SAMBROOK J, 1989, MOL CLONING LABORATO, V2; SLATTERY E, 1983, J BIOL CHEM, V258, P5955; SMERDON MJ, 1989, NATO ADV SCI I A-LIF, V182, P271; SMULSON ME, 1977, CANCER RES, V37, P3006; TAN KB, 1987, NATL CANCER I MONOGR, V4, P95; THRAVES PJ, 1985, CANCER RES, V45, P386; UEDA K, 1982, ADP RIBOSYLATION REA, P561; YAMAGOE S, 1991, MOL CELL BIOL, V11, P3522, DOI 10.1128/MCB.11.7.3522; YUH YS, 1989, J BIOL CHEM, V264, P10904	49	151	163	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12804	12812						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618781				2022-12-25	WOS:A1992HZ48300064
J	FURUTA, T; TAKAHASHI, H; SHIBASAKI, H; KASUYA, Y				FURUTA, T; TAKAHASHI, H; SHIBASAKI, H; KASUYA, Y			REVERSIBLE STEPWISE MECHANISM INVOLVING A CARBANION INTERMEDIATE IN THE ELIMINATION OF AMMONIA FROM L-HISTIDINE CATALYZED BY HISTIDINE AMMONIA-LYASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRY; ACID; ASPARTASE	L-Histidine labeled with deuterium at the C-5' position of the imidazole ring, L-[5'-H-2]histidine (His-5'-D), was used as a probe for investigating a stepwise reversible mechanism via a carbanion intermediate in the elimination of ammonia catalyzed by histidine ammonia-lyase (EC 4.3.1.3). The labeled L-histidine (His-5'-D) (2.45 mM) was incubated with histidine ammonia-lyase (200 units) from Pseudomonas fluorescens at pH 7.0 or 9.0 at 25.0-degrees-C for 24 h. The time course of the reaction was examined to determine the rates of enzyme-catalyzed hydrogen exchange at C-5' of L-histidine and urocanic acid. The finding of the enzyme-catalyzed hydrogen exchange at C-5' of both L-histidine and urocanic acid in the presence Of L-histidine provided a rational explanation for a stepwise reversible mechanism via a carbanion intermediate in the elimination reaction. The rate of increase in the concentration of urocanic acid exchanged with hydrogen (UA-5'-H) did not depend on the formation rate of urocanic acid and UA-5'-H was continuously formed at a constant rate (25.6-mu-M/h) even after the completion of urocanic acid formation. These observations suggested the presence of the reversible reaction of urocanic acid and a carbanion intermediate. Since there was only a minor contribution for the formation of UA-5'-H from L-histidine exchanged with solvent hydrogen (His-5'-H), the main pathway in the enzymatic reaction of His-5'-D must be the formation of UA-5'-D via a carbanion intermediate (carbanion-D). Regeneration of the carbanion-D from UA-5'-D by its reverse reaction and subsequent hydrogen incorporation at C-5' would contribute to a large extent for the formation of UA-5'-H. The stability of carbanion was also demonstrated to be approximately three times higher at pH 7.0 than at pH 9.0.			FURUTA, T (corresponding author), TOKYO COLL PHARM,DEPT MED CHEM & CLIN PHARM,1432-1 HORINOUCHI,HACHIOJI,TOKYO 19203,JAPAN.							AKHTAR M, 1986, J CHEM SOC CHEM COMM, P1290, DOI 10.1039/c39860001290; BOTTING NP, 1988, BIOCHEMISTRY-US, V27, P2956, DOI 10.1021/bi00408a043; BOTTING NP, 1987, J CHEM SOC CHEM COMM, P1371, DOI 10.1039/c39870001371; BOTTING NP, 1988, BIOCHEMISTRY-US, V27, P2953, DOI 10.1021/bi00408a042; FURUTA T, 1987, J CHEM RES-S, P86; FURUTA T, 1988, BIOMED ENVIRON MASS, V16, P313, DOI 10.1002/bms.1200160160; FURUTA T, 1987, J CHROMATOGR-BIOMED, V413, P1, DOI 10.1016/0378-4347(87)80207-4; FURUTA T, 1992, J CHROMATOGR-BIOMED, V576, P213, DOI 10.1016/0378-4347(92)80195-V; FURUTA T, 1990, J AM CHEM SOC, V112, P3633, DOI 10.1021/ja00165a058; FURUTA T, 1991, J CHROMATOGR-BIOMED, V562, P363, DOI 10.1016/0378-4347(91)80591-Y; FURUTA T, 1989, 3RD P INT S SYNTH AP, P747; FURUTA T, 1992, IN PRESS J LABELLED; GIVOT IL, 1969, J BIOL CHEM, V244, P6341; HANSON KR, 1979, BIOCHEMISTRY-US, V18, P1431, DOI 10.1021/bi00575a007; Hanson KR, 1972, ENZYMES, P75; HERMES JD, 1985, BIOCHEMISTRY-US, V24, P2959, DOI 10.1021/bi00333a023; KLEE CB, 1974, FED PROC, V33, P1318; KLEE CB, 1979, BIOCHEM BIOPH RES CO, V87, P343, DOI 10.1016/0006-291X(79)91685-1; KLEE CB, 1975, J BIOL CHEM, V250, P5033; KLEE CB, 1972, J BIOL CHEM, V247, P1398; KURODA Y, 1979, CLIN CHIM ACTA, V96, P139; La Du BN, 1978, METABOLIC BASIS INHE, P317; MATSUDA I, 1982, LANCET, V1, P162; MATSUDA I, 1982, CLIN CHIM ACTA, V119, P319, DOI 10.1016/0009-8981(82)90345-X; NUIRY II, 1984, BIOCHEMISTRY-US, V23, P5168, DOI 10.1021/bi00317a013; PETERKOFSKY A, 1962, J BIOL CHEM, V237, P787; PORTER DJT, 1980, J BIOL CHEM, V255, P4772; RETEY J, 1970, FEBS LETT, V6, P203, DOI 10.1016/0014-5793(70)80057-6; SAWADA S, 1974, BIOCHIM BIOPHYS ACTA, V350, P354, DOI 10.1016/0005-2744(74)90509-9; TAKAHASHI H, 1990, Journal of Pharmacobio-Dynamics, V13, pS59	30	16	16	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12600	12605						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618765				2022-12-25	WOS:A1992HZ48300036
J	OHASHI, N; NASHIMOTO, H; IKEDA, H; TAMURA, A				OHASHI, N; NASHIMOTO, H; IKEDA, H; TAMURA, A			DIVERSITY OF IMMUNODOMINANT 56-KDA TYPE-SPECIFIC ANTIGEN (TSA) OF RICKETTSIA-TSUTSUGAMUSHI - SEQUENCE AND COMPARATIVE ANALYSES OF THE GENES ENCODING TSA HOMOLOGS FROM 4 ANTIGENIC VARIANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PROTEIN GENE; ESCHERICHIA-COLI; TANDEM PROMOTERS; STRAIN; PURIFICATION; PATIENT; CLONING	There are several antigenic variants in Rickettsia tsutsugamushi, and a type-specific antigen (TSA) of 56-kilodaltons located on the rickettsial surface is responsible for the variation. The primary structures of the protein in two variants, Gilliam and Karp, have been reported independently by us and Stover et al. by cloning and sequencing the corresponding genes (Ohashi, N., Nashimoto, H., Ikeda, H., and Tamura, A. (1990) Gene (Amst.) 91, 119-122; Stover, C. K., Marana, D. P., Carter, J. M., Roe, B. A., Mardis, E., and Oaks, E. V. (1990) Infect. Immun. 58, 2076-2084). In the present study, genes encoding the TSA homologues of the other four variants, Kato, Kawasaki, Kuroki, and Shimokoshi, which are all distinguishable serologically, were cloned and sequenced, and consequently, it became possible to compare the primary structures of the six antigenic variants. The sequence analyses revealed a complete open reading frame encoding 55,308-56,745-dalton proteins with 521-532 amino acids, in which a putative signal peptide consisting of 22 amino acids was recognized at the NH2-terminal end. Transcription of the gene is regulated by several tandem promoters. All TSA molecules have the characteristics of transmembrane proteins with alternating hydrophobic and hydrophilic regions, and contain four variable domains with spans of 16-40 amino acids which are located in the hydrophilic regions in the molecule and show different amino acid sequences among the strains. Phylogenetic classification among the R. tsutsugamushi strains based on TSA homologues supports the antigenic relationships known in the closely and distantly related strains.	UNIV TOKYO, INST MED SCI, DEPT MOLEC BIOL, TOKYO 108, JAPAN; TEIKYO UNIV, DEPT BIOSCI, UTSUNOMIYA 320, JAPAN; NIIGATA COLL PHARM, DEPT MICROBIOL, NIIGATA 95021, JAPAN	University of Tokyo; Teikyo University								CHIBA M, 1989, J BIOL CHEM, V264, P12785; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; GOTOH J, 1968, JPN J BACTERIOL, V23, P437; HAAS R, 1986, CELL, V44, P107, DOI 10.1016/0092-8674(86)90489-7; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; KUMURA K, 1991, INT J SYST BACTERIOL, V41, P247, DOI 10.1099/00207713-41-2-247; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Maniatis T., 1982, MOL CLONING; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MURATA M, 1986, MICROBIOL IMMUNOL, V30, P599, DOI 10.1111/j.1348-0421.1986.tb02987.x; MYERS WF, 1980, INT J SYST BACTERIOL, V30, P143, DOI 10.1099/00207713-30-1-143; Nei M., 1987, MOL EVOLUT GENET, P293; OHASHI N, 1990, J CLIN MICROBIOL, V28, P2111, DOI 10.1128/JCM.28.9.2111-2113.1990; OHASHI N, 1990, GENE, V91, P119, DOI 10.1016/0378-1119(90)90171-M; OHASHI N, 1989, INFECT IMMUN, V57, P1427, DOI 10.1128/IAI.57.5.1427-1431.1989; OLIVER D, 1985, ANNU REV MICROBIOL, V39, P615; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHE JX, 1991, P NATL ACAD SCI USA, V88, P453, DOI 10.1073/pnas.88.2.453; SHISHIDO A, 1962, JPN J MED SCI BIOL, V15, P308; STEPHENS RS, 1988, J BACTERIOL, V170, P744, DOI 10.1128/jb.170.2.744-750.1988; STEPHENS RS, 1989, INTRACELLULAR PARASI, P51; STOVER CK, 1990, INFECT IMMUN, V58, P2076, DOI 10.1128/IAI.58.7.2076-2084.1990; TAMURA A, 1988, Japanese Journal of Bacteriology, V43, P629, DOI 10.3412/jsb.43.629; TAMURA A, 1982, MICROBIOL IMMUNOL, V26, P321, DOI 10.1111/j.1348-0421.1982.tb00181.x; TAMURA A, 1984, MICROBIOL IMMUNOL, V28, P873, DOI 10.1111/j.1348-0421.1984.tb00743.x; TAMURA A, 1985, INFECT IMMUN, V48, P671, DOI 10.1128/IAI.48.3.671-675.1985; TAMURA A, 1988, MICROBIOL SCI, V5, P228; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; Weiss E., 1984, BERGEYS MANUAL SYSTE, VI, P688; WINKLER HH, 1988, BIOCHIMIE, V70, P977, DOI 10.1016/0300-9084(88)90262-3; YAMAMOTO S, 1986, MICROBIOL IMMUNOL, V30, P611, DOI 10.1111/j.1348-0421.1986.tb02988.x; YAMAMOTO S, 1989, J JPN ASS INFECT DIS, V63, P109; YUAN Y, 1990, INFECT IMMUN, V58, P2850, DOI 10.1128/IAI.58.9.2850-2855.1990	34	88	108	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12728	12735						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618776				2022-12-25	WOS:A1992HZ48300054
J	VELLEMAN, M; HEINZEL, T; SCHUSTER, H				VELLEMAN, M; HEINZEL, T; SCHUSTER, H			THE BOF PROTEIN OF BACTERIOPHAGE-P1 EXERTS ITS MODULATING FUNCTION BY FORMATION OF A TERNARY COMPLEX WITH OPERATOR DNA AND C1 REPRESSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BINDING-SITES; GEL-ELECTROPHORESIS; LAC REPRESSOR; P1; GENE; SEQUENCE; RECOMBINATION; EXPRESSION; MUTATION	Bacteriophage P1 encodes several regulatory elements for the lytic or lysogenic response, which are located in the immC, immI, and immT regions. Their products are the C1 repressor of lytic functions with the C1 inactivator protein Coi, the C4 repressor of antirepressor synthesis and the modulator protein Bof, respectively. We have studied in vitro the interaction of the components of the immC and immT regions with C1-controlled operators using highly purified Bof, C1, and Coi proteins. Bof protein (M(r) = 9,800) does not interact with C1 repressor alone, but as shown by DNA mobility shift experiments, in the presence of C1 repressor Bof binds to all operators tested by forming a C1.Bof.operator DNA ternary complex. The effect of this complex formation was studied in more detail with the operator of the c1 gene. Here, Bof only marginally alters the C1 repressor footprint at Op99a,b, but nevertheless considerably influences the repressibility of the operator.promoter element: (i) the autoregulated c1 mRNA synthesis is further down-regulated and (ii) the ability of Coi protein to dissociate the C1.operator DNA complex is strongly inhibited. We suggest that Bof protein functions by modulating C1 repression of many widely dispersed operators on the prophage genome.			VELLEMAN, M (corresponding author), MAX PLANCK INST MOLEC GENET,IHNESTR 73,W-1000 BERLIN 33,GERMANY.		Heinzel, Thorsten/B-1013-2015					BAUMSTARK BR, 1987, VIROLOGY, V156, P404, DOI 10.1016/0042-6822(87)90420-X; BAUMSTARK BR, 1990, VIROLOGY, V179, P217, DOI 10.1016/0042-6822(90)90291-X; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CITRON M, 1990, CELL, V62, P591, DOI 10.1016/0092-8674(90)90023-8; CITRON M, 1989, J BIOL CHEM, V264, P3611; CLEWELL DB, 1969, P NATL ACAD SCI USA, V62, P1159, DOI 10.1073/pnas.62.4.1159; COHN EJ, 1965, PROTEINS AMINO ACIDS, P370; DARI R, 1975, J MOL BIOL, V94, P341, DOI 10.1016/0022-2836(75)90207-7; DREISEIKELMANN B, 1988, J BIOL CHEM, V263, P1391; ELIASON JL, 1987, J MOL BIOL, V198, P281, DOI 10.1016/0022-2836(87)90313-5; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; HEINZEL T, 1990, J BIOL CHEM, V265, P17928; HEINZEL T, 1989, J MOL BIOL, V205, P127, DOI 10.1016/0022-2836(89)90370-7; HEINZEL T, 1992, J BIOL CHEM, V267, P4183; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HUDSON JM, 1990, J MOL BIOL, V214, P381, DOI 10.1016/0022-2836(90)90188-R; JOHNSON BF, 1982, MOL GEN GENET, V186, P122, DOI 10.1007/BF00422923; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAEFER TS, 1991, J BACTERIOL, V173, P6469, DOI 10.1128/jb.173.20.6469-6474.1991; SCHAEFER TS, 1990, J BACTERIOL, V172, P3269, DOI 10.1128/jb.172.6.3269-3277.1990; Scott J R, 1980, Curr Top Microbiol Immunol, V90, P49; SCOTT JR, 1977, VIROLOGY, V76, P39, DOI 10.1016/0042-6822(77)90279-3; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STERNBERG N, 1978, P NATL ACAD SCI USA, V75, P5594, DOI 10.1073/pnas.75.11.5594; STOFFLER G, 1971, P NATL ACAD SCI USA, V68, P2283, DOI 10.1073/pnas.68.9.2283; TOUATISCHWARTZ D, 1979, MOL GEN GENET, V174, P189, DOI 10.1007/BF00268355; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VELLEMAN M, 1990, J BIOL CHEM, V265, P18511; VELLEMAN M, 1987, P NATL ACAD SCI USA, V84, P5570, DOI 10.1073/pnas.84.16.5570; WINDLE BE, 1986, P NATL ACAD SCI USA, V83, P3885, DOI 10.1073/pnas.83.11.3885; WINDLE BE, 1988, J BACTERIOL, V170, P4881, DOI 10.1128/jb.170.10.4881-4889.1988; WINDLE BE, 1986, THESIS U MARYLAND CA; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YARMOLINSKY M, 1990, GENETIC MAPS, P52; YARMOLINSKY MB, 1988, BACTERIOPHAGES, V1, P291	40	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12174	12181						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601883				2022-12-25	WOS:A1992HY94700078
J	BENJANNET, S; REUDELHUBER, T; MERCURE, C; RONDEAU, N; CHRETIEN, M; SEIDAH, NG				BENJANNET, S; REUDELHUBER, T; MERCURE, C; RONDEAU, N; CHRETIEN, M; SEIDAH, NG			PROPROTEIN CONVERSION IS DETERMINED BY A MULTIPLICITY OF FACTORS INCLUDING CONVERTASE PROCESSING, SUBSTRATE-SPECIFICITY, AND INTRACELLULAR ENVIRONMENT - CELL TYPE-SPECIFIC PROCESSING OF HUMAN PRORENIN BY THE CONVERTASE PC1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ENDORPHIN; HUMAN RENIN; GENE; CDNA; SEQUENCE; PROTEINS; KEX2; SUBTILISIN; EXPRESSION; SECRETION	Proprotein and prohormone processing at pairs of basic residues is generally thought to be both tissue- and precursor-specific and to be developmentally regulated. Furin, PC1 (also called PC3), and PC2 represent three recently discovered subtilisin-like proteinases which cleave a number of precursors at the same pairs of basic residues normally processed in vivo. Using human prorenin as a model, we show that PC1 can process it to active renin in cells containing secretory granules, such as the somatomammotroph cell line GH4, but not in cells which lack granules, such as the Chinese hamster ovary or African green monkey kidney epithelial (BSC-40) cell lines. In contrast, in both cell types, human prorenin is not activated by either PC2 or furin. Using the vaccinia virus expression system, biosynthetic labeling experiments demonstrated that PC1 and PC2 are themselves cleaved intracellularly at pairs of basic residues and that these two proenzymes are processed to different extents independent of whether the cell line contains dense core secretory granules. Furthermore, we also show that the cells mostly secrete the cleaved forms of PC1 and PC2, and that intracellularly the pro- form of PC2 predominates. Our data demonstrate that propeptide removal from these enzymes, possibly leading to their activation, is not the only criterion which governs precursor processing.	UNIV MONTREAL, CLIN RES INST, JA DESEVE LAB BIOCHEM NEUROENDOCRINOL, 110 PINE AVE W, MONTREAL H2W 1R7, QUEBEC, CANADA; UNIV MONTREAL, CLIN RES INST, JA DESEVE LAB MOLEC NEUROENDOCRINOL, MONTREAL H2W 1RF, QUEBEC, CANADA; UNIV MONTREAL, CLIN RES INST, MOLEC BIOCHEM HYPERTENS LAB, MONTREAL H2W 1RF, QUEBEC, CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal			Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342; CHRETIEN, Michel/0000-0002-8588-4460				BARR PJ, 1991, DNA CELL BIOL, V10, P319, DOI 10.1089/dna.1991.10.319; BAXTER JD, 1987, ENDOCRINOL METAB, P693; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; BURNHAM CE, 1987, P NATL ACAD SCI USA, V84, P5605, DOI 10.1073/pnas.84.16.5605; CHRISTIE DL, 1991, J BIOL CHEM, V266, P15679; CHU WN, 1990, MOL ENDOCRINOL, V4, P1905, DOI 10.1210/mend-4-12-1905; DO YS, 1987, J BIOL CHEM, V262, P1037; FRITZ LC, 1987, J BIOL CHEM, V262, P12409; HACKENTHAL E, 1990, PHYSIOL REV, V70, P1067, DOI 10.1152/physrev.1990.70.4.1067; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; IMAI T, 1983, P NATL ACAD SCI-BIOL, V80, P7405, DOI 10.1073/pnas.80.24.7405; KIM SK, 1991, J BIOL CHEM, V266, P7044; LADENHEIM RG, 1991, EUR J BIOCHEM, V198, P535, DOI 10.1111/j.1432-1033.1991.tb16047.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZURE C, 1983, CAN J BIOCHEM CELL B, V61, P501, DOI 10.1139/o83-066; MACKIN RB, 1991, ENDOCRINOLOGY, V129, P2263, DOI 10.1210/endo-129-4-2263; MAINS RE, 1990, FRONT NEUROENDOCRIN, V11, P52; MATSUUCHI L, 1991, J CELL BIOL, V112, P843, DOI 10.1083/jcb.112.5.843; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; NAGAHAMA M, 1991, EUR J BIOCHEM, V197, P135, DOI 10.1111/j.1432-1033.1991.tb15891.x; OHTA Y, 1991, MOL MICROBIOL, V5, P1507, DOI 10.1111/j.1365-2958.1991.tb00797.x; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; RE RN, 1984, ARCH INTERN MED, V144, P2037, DOI 10.1001/archinte.144.10.2037; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; SAINTANDRE JP, 1989, HISTOCHEMISTRY, V91, P291, DOI 10.1007/BF00493003; SAWYER N, 1991, DNA CELL BIOL, V10, P259, DOI 10.1089/dna.1991.10.259; SCHALKEN JA, 1987, J CLIN INVEST, V80, P1545, DOI 10.1172/JCI113240; SEIDAH NG, 1978, P NATL ACAD SCI USA, V75, P3153, DOI 10.1073/pnas.75.7.3153; SEIDAH NG, 1991, GENOMICS, V11, P103, DOI 10.1016/0888-7543(91)90106-O; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SEIDAH NG, 1992, IN PRESS TRENDS ENDO; SHENNAN KIJ, 1991, J BIOL CHEM, V266, P24011; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAUGNER R, 1987, HISTOCHEMISTRY, V86, P249; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; THORNE BA, 1989, J BIOL CHEM, V264, P3545; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	45	160	161	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11417	11423						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597471				2022-12-25	WOS:A1992HX16900074
J	FORD, DA; ROSENBLOOM, KB; GROSS, RW				FORD, DA; ROSENBLOOM, KB; GROSS, RW			THE PRIMARY DETERMINANT OF RABBIT MYOCARDIAL ETHANOLAMINE PHOSPHOTRANSFERASE SUBSTRATE SELECTIVITY IS THE COVALENT NATURE OF THE SN-1 ALIPHATIC GROUP OF DIRADYL GLYCEROL ACCEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; HUMAN-PLATELETS; KIDNEY-CELLS; IDENTIFICATION; PLASMENYLETHANOLAMINE; PHOSPHOGLYCERIDES; PHOSPHOLIPASE-A2; PLASMALOGENS; METABOLISM	Plasmenylethanolamines represent the major endogenous phospholipid storage depot of arachidonic acid in many mammalian cells. To elucidate the biochemical mechanisms contributing to the high plasmalogen content and arachidonic acid enrichment present in myocardial ethanolamine glycerophospholipids, the substrate specificity of rabbit myocardial ethanolamine phosphotransferase (EPT) was quantified utilizing multiple molecular species of each subclass of diradyl glycerol substrate. Myocardial EPT demonstrated over a 16-fold selectivity for 1-O-alk-1'-enyl-2-acyl-sn-glycerol (AAG) compared to 1,2-diacyl-sn-glycerol (DAG) substrate utilizing individual molecular species of each subclass dispersed in Tween 20. The selective utilization of AAG by EPT was substantiated utilizing two independent assay systems which employed either the presentation of substrate to enzyme as a substitutional impurity in Triton X-100 mixed micelles or the obligatory utilization of endogenously generated diradyl glycerol substrates. Although rabbit myocardial microsomes contained over a 20-fold molar excess of endogenous DAG to AAG mass, incubation of rabbit myocardial microsomes with CDP-ethanolamine resulted in the highly selective synthesis of plasmenylethanolamines which were predominantly comprised of molecular species containing arachidonic acid at the sn-2 position (>75%). Endogenous AAG molecular species in rabbit myocardial microsomes were similarly enriched in arachidonic acid, and the distribution of AAG molecular species closely paralleled the distribution of plasmenylethanolamine (but not plasmenylcholine) molecular species. Thus, the subclass and molecular species distribution of the ethanolamine glycerophospholipids synthesized by rabbit myocardial EPT reflects independent contributions from the subclass selectivity of EPT for AAG substrate in conjunction with the enrichment of arachidonic acid in microsomal AAG molecular species.	WASHINGTON UNIV,SCH MED,DEPT CHEM,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	FORD, DA (corresponding author), WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,DIV BIOORGAN CHEM & MOLEC PHARMACOL,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.		Ford, David/D-1819-2018	Ford, David/0000-0002-0029-1560	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042665, R29HL042665] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42665] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHILTON FH, 1988, J BIOL CHEM, V263, P5260; DANIEL LW, 1981, J BIOL CHEM, V256, P2830; FORD DA, 1988, J BIOL CHEM, V263, P2644; FORD DA, 1989, P NATL ACAD SCI USA, V86, P3479, DOI 10.1073/pnas.86.10.3479; FORD DA, 1990, J BIOL CHEM, V265, P12280; GROSS RW, 1984, BIOCHEMISTRY-US, V23, P158, DOI 10.1021/bi00296a026; HAN XL, 1990, BIOCHEMISTRY-US, V29, P4992, DOI 10.1021/bi00472a032; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P4357; Kanoh H, 1981, Methods Enzymol, V71 Pt C, P536; KENNERLY DA, 1987, J BIOL CHEM, V262, P16305; LOEB LA, 1986, J BIOL CHEM, V261, P467; MUELLER HW, 1983, LIPIDS, V18, P814, DOI 10.1007/BF02534641; NIETO ML, 1991, J BIOL CHEM, V266, P18699; PALTAUF F, 1973, J BIOL CHEM, V248, P1609; PREISS J, 1986, J BIOL CHEM, V261, P8597; SHELTAWY A, 1968, J NEUROCHEM, V15, P144, DOI 10.1111/j.1471-4159.1968.tb06186.x; TAKAMURA H, 1989, J BIOCHEM-TOKYO, V105, P168, DOI 10.1093/oxfordjournals.jbchem.a122634; UEMURA Y, 1991, J BIOL CHEM, V266, P8268; VENABLE ME, 1991, J BIOL CHEM, V266, P18691; WEISS SB, 1958, J BIOL CHEM, V231, P53; WOLF RA, 1985, J LIPID RES, V26, P629; WOLF RA, 1985, J BIOL CHEM, V260, P7295; WYKLE RL, 1972, J BIOL CHEM, V247, P5442	24	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11222	11228						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597457				2022-12-25	WOS:A1992HX16900047
J	HAUSSER, H; OBER, B; QUENTINHOFFMANN, E; SCHMIDT, B; KRESSE, H				HAUSSER, H; OBER, B; QUENTINHOFFMANN, E; SCHMIDT, B; KRESSE, H			ENDOCYTOSIS OF DIFFERENT MEMBERS OF THE SMALL CHONDROITIN DERMATAN SULFATE PROTEOGLYCAN FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ARTICULAR-CARTILAGE; GROWTH-FACTOR-BETA; HUMAN-FIBROBLASTS; CORE PROTEIN; PROTEODERMATAN SULFATE; COLLAGEN; DECORIN; BIOSYNTHESIS; LOCALIZATION; CHONDROCYTES	The family of small interstitial chondroitin/dermatan sulfate proteoglycans consists of at least three different molecular species: biglycan (proteoglycan I), decorin (proteoglycan II), and proteoglycan-100, which has a glycosylated core protein of about 100 kDa. The core protein of decorin has been shown to be responsible for receptor-mediated endocytosis of this proteoglycan species by a variety of mesenchymal cells. It is now demonstrated that skin fibroblasts and articular chondrocytes endocytose biglycan with an efficiency similar to that of decorin. Uptake of biglycan is also mediated by its core protein and can be inhibited by decorin in a partially competitive manner. In human fibroblasts, endosomal proteins of 51 and 26 kDa, which are known to bind decorin core protein, also interact with biglycan. This interaction can be inhibited by decorin. Bovine articular chondrocytes contained binding proteins of 48 and 25 kDa. Proteoglycan-100 can be distinguished from biglycan and decorin by its low clearance rate, which however, exceeds the rate of fluid phase endocytosis.	UNIV GOTTINGEN,INST BIOCHEM 2,W-3400 GOTTINGEN,GERMANY	University of Gottingen	HAUSSER, H (corresponding author), UNIV MUNSTER,INST PHYSIOL CHEM & PATHOBIOCHEM,W-4400 MUNSTER,GERMANY.							AYDELOTTE MB, 1988, CONNECT TISSUE RES, V18, P205, DOI 10.3109/03008208809016808; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BREUER B, 1990, BIOCHEM J, V269, P551, DOI 10.1042/bj2690551; Cantz M, 1972, METHOD ENZYMOL, V28, P884; CHOI HU, 1989, J BIOL CHEM, V264, P2876; COSTE J, 1990, TETRAHEDRON LETT, V31, P205, DOI 10.1016/S0040-4039(00)94371-5; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; FISHER LW, 1989, J BIOL CHEM, V264, P4571; GLOSSL J, 1983, BIOCHEM J, V215, P295; GLOSSL J, 1984, J BIOL CHEM, V259, P4144; GUO JF, 1989, CONNECT TISSUE RES, V19, P277, DOI 10.3109/03008208909043901; HAUSSER H, 1991, J CELL BIOL, V114, P45, DOI 10.1083/jcb.114.1.45; HAUSSER H, 1989, BIOCHEM J, V263, P137, DOI 10.1042/bj2630137; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWANDOWSKA K, 1987, J CELL BIOL, V105, P1443, DOI 10.1083/jcb.105.3.1443; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCKINLEY DN, 1988, J CELL PHYSIOL, V136, P389, DOI 10.1002/jcp.1041360302; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; Neufeld EF, 1989, METABOLIC BASIS INHE, P1565; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; PRINZ R, 1978, BIOCHEM J, V176, P671, DOI 10.1042/bj1760671; ROMARIS M, 1991, BIOCHIM BIOPHYS ACTA, V1093, P229, DOI 10.1016/0167-4889(91)90127-J; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; SAMPAIO LD, 1988, BIOCHEM J, V254, P757; SCHMIDT G, 1987, J CELL BIOL, V104, P1683, DOI 10.1083/jcb.104.6.1683; SCHMIDT G, 1990, BIOCHEM J, V266, P591; SCHWARZ K, 1990, J BIOL CHEM, V265, P22023; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; SCOTT PG, 1986, BIOCHEM BIOPH RES CO, V138, P1348, DOI 10.1016/S0006-291X(86)80431-4; SMEDSROD B, 1990, BIOCHEM J, V266, P313, DOI 10.1042/bj2660313; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; VONFIGURA K, 1980, BIOL ARTICULAR CARTI, P189; VOSS B, 1986, J HISTOCHEM CYTOCHEM, V34, P1013, DOI 10.1177/34.8.2426331; WINNEMOLLER M, 1991, EUR J CELL BIOL, V54, P10; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YAMAGUCHI Y, 1988, NATURE, V336, P281; YANAGISHITA M, 1984, J BIOL CHEM, V259, P270	41	61	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11559	11564						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597483				2022-12-25	WOS:A1992HX16900095
J	SCHMIDT, RP; KREUZER, KN				SCHMIDT, RP; KREUZER, KN			PURIFIED MOTA PROTEIN BINDS THE -30 REGION OF A BACTERIOPHAGE-T4 MIDDLE-MODE PROMOTER AND ACTIVATES TRANSCRIPTION INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; RNA-POLYMERASE; REPLICATION ORIGIN; DNA-REPLICATION; T4 RNA; INITIATION; SEQUENCES; SYSTEM; GENE; RECOMBINATION	The bacteriophage T4-encoded MotA protein is critical for transcription from T4 middle-mode promoters. However, a direct interaction of this protein with a middle-mode promoter has not previously been demonstrated. We have cloned the motA gene and overexpressed the gene product using the T7 expression system. A simple procedure was then developed to purify the MotA protein to homogeneity. Using the purified protein we have demonstrated that MotA protein binds to the -30 region of the middle-mode promoter P(uvsY). This promoter has previously been shown to be a necessary component of a T4 replication origin, and thus MotA is also a T4 origin-binding protein. Modified RNA polymerase purified from T4-infected cells was used to establish middle-mode transcription in vitro. Transcription from P(uvsY) was markedly enhanced by the addition of MotA protein, whether or not the template contained the cytosine modifications characteristic of T4 DNA. However, transcription from P(uvsY) was apparently independent of the MotA protein when unmodified RNA polymerase from uninfected cells was used.	DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,PROGRAM CELL & MOLEC BIOL,DURHAM,NC 27710	Duke University; Duke University					NIGMS NIH HHS [GM34622, 5-T32-GM07184] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034622, T32GM007184, R37GM034622] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; BAKER TA, 1987, J BIOL CHEM, V262, P6877; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BRODY E, 1983, BACTERIOPHAGE T4, P174; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; CHAMBERLIN M, 1983, METHOD ENZYMOL, V101, P540; CHRISTENSEN AC, 1983, BACTERIOPHAGE T, V4, P184; DASGUPTA S, 1987, CELL, V51, P1113, DOI 10.1016/0092-8674(87)90597-6; DEFRANCISCIS V, 1982, J BIOL CHEM, V257, P4097; DEFRANCISCIS V, 1982, J BIOL CHEM, V257, P4087; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; GEIDUSCHEK EP, 1988, BACTERIOPHAGES, V1, P93; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GUILD N, 1988, J MOL BIOL, V199, P241, DOI 10.1016/0022-2836(88)90311-7; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HERENDEEN DR, 1990, SCIENCE, V248, P573, DOI 10.1126/science.2185541; HINTON DM, 1989, J BIOL CHEM, V264, P14432; HINTON DM, 1991, J BIOL CHEM, V266, P18034; HO YS, 1988, BACTERIOPHAGES, V2, P725; INOUE N, 1991, J BACTERIOL, V173, P1208, DOI 10.1128/jb.173.3.1208-1214.1991; KASSAVETIS GA, 1984, P NATL ACAD SCI-BIOL, V81, P5101, DOI 10.1073/pnas.81.16.5101; KOWALSKI D, 1988, P NATL ACAD SCI USA, V85, P9464, DOI 10.1073/pnas.85.24.9464; KOWALSKI D, 1989, EMBO J, V8, P4335, DOI 10.1002/j.1460-2075.1989.tb08620.x; KREUZER KN, 1985, P NATL ACAD SCI USA, V82, P3345, DOI 10.1073/pnas.82.10.3345; KREUZER KN, 1988, J BIOL CHEM, V263, P11348; KUTTER EM, 1990, GENETIC MAPS; LIEBIG HD, 1989, J MOL BIOL, V208, P517, DOI 10.1016/0022-2836(89)90145-9; LUDER A, 1982, P NATL ACAD SCI-BIOL, V79, P1101, DOI 10.1073/pnas.79.4.1101; MALIK S, 1984, J BIOL CHEM, V259, P3292; Maniatis T., 1982, MOL CLONING; MASUKATA H, 1987, CELL, V51, P1123, DOI 10.1016/0092-8674(87)90598-8; MASUKATA H, 1990, CELL, V62, P331, DOI 10.1016/0092-8674(90)90370-T; MATTSON T, 1978, J MOL BIOL, V126, P551, DOI 10.1016/0022-2836(78)90058-X; MATTSON T, 1974, NATURE, V250, P48, DOI 10.1038/250048a0; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCONNELL DJ, 1978, NUCLEIC ACIDS RES, V5, P1729, DOI 10.1093/nar/5.6.1729; MENKENS AE, 1988, J BIOL CHEM, V263, P11358; MOSIG G, 1988, BACTERIOPHAGES, V2, P521; NELSON MA, 1982, MOL GEN GENET, V188, P60, DOI 10.1007/BF00332996; NOSSAL NG, 1983, BACTERIOPHAGE T, V4, P71; OHMORI H, 1987, J MOL BIOL, V198, P223, DOI 10.1016/0022-2836(87)90308-1; ORSINI G, 1988, VIROLOGY, V162, P397, DOI 10.1016/0042-6822(88)90480-1; PULITZER JF, 1985, J MOL BIOL, V182, P249, DOI 10.1016/0022-2836(85)90343-2; PULITZER JF, 1979, J MOL BIOL, V135, P979, DOI 10.1016/0022-2836(79)90523-0; Rabussay D., 1983, BACTERIOPHAGE T4, P167; SCHULZ W, 1981, NUCLEIC ACIDS RES, V9, P6889, DOI 10.1093/nar/9.24.6889; SELICK HE, 1988, J BIOL CHEM, V263, P11336; SHINEDLING S, 1986, J VIROL, V60, P787, DOI 10.1128/JVI.60.2.787-792.1986; SNUSTAD DP, 1983, BACTERIOPHAGE T, V4, P40; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TSENG MJ, 1990, J BACTERIOL, V172, P6323, DOI 10.1128/jb.172.11.6323-6332.1990; UMEK RM, 1988, CELL, V52, P559, DOI 10.1016/0092-8674(88)90469-2; UZAN M, 1983, EMBO J, V2, P1207, DOI 10.1002/j.1460-2075.1983.tb01568.x; UZAN M, 1990, MOL MICROBIOL, V4, P1487, DOI 10.1111/j.1365-2958.1990.tb02059.x; UZAN M, 1985, J BIOL CHEM, V260, P633; WILLIAMS KP, 1987, J BIOL CHEM, V262, P12365	58	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11399	11407						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597469				2022-12-25	WOS:A1992HX16900072
J	KITAGAWA, M; SAITOH, S; OGINO, H; OKABE, T; MATSUMOTO, H; OKUYAMA, A; TAMAI, K; OHBA, Y; YASUDA, H; NISHIMURA, S; TAYA, Y				KITAGAWA, M; SAITOH, S; OGINO, H; OKABE, T; MATSUMOTO, H; OKUYAMA, A; TAMAI, K; OHBA, Y; YASUDA, H; NISHIMURA, S; TAYA, Y			CDC2-LIKE KINASE IS ASSOCIATED WITH THE RETINOBLASTOMA PROTEIN	ONCOGENE			English	Article							LARGE-T-ANTIGEN; ADENOVIRUS E1A PROTEINS; DNA-BINDING ACTIVITY; CELL-CYCLE; GENE-PRODUCT; SUSCEPTIBILITY GENE; RB GENE; TERMINAL REGION; OSTEO-SARCOMA; PHOSPHORYLATION	The growth-suppressive activity of the retinoblastoma (RB) protein is suggested to be regulated by phosphorylation. In studies on the kinase that phosphorylates the RB proteins, we have previously found that RB proteins can be phosphorylated by purified cdc2 kinase. In this study, we noted that RB proteins immunoprecipitated from human cell lysates are weakly phosphorylated in the absence of purified cdc2 kinase. Immunoblot analysis showed the presence of p34cdc2 in the immunoprecipitates with anti-RB monoclonal antibody. In addition, the coprecipitated kinase was found to have the same substrate specificity as cdc2 kinase. The associated kinase activity was particularly high in cells arrested in G1/S and S phase by aphidicolin. Furthermore, RB proteins were shown to be phosphorylated in nuclear extracts by some endogenous cdc2-like kinase(s). These results suggest that cdc2-like kinase is the main kinase for phosphorylation of RB proteins in vivo.	NATL CANC CTR, RES INST, DIV BIOL, TOKYO 104, JAPAN; MBL CO LTD, INA LABS, INA, NAGANO 396, JAPAN; KANAZAWA UNIV, FAC PHARMACEUT SCI, DIV BIOL, KANAZAWA, ISHIKAWA 920, JAPAN	National Cancer Center - Japan; Kanazawa University	KITAGAWA, M (corresponding author), BANYU PHARMACEUT CO LTD, TSUKUBA RES INST, OKUBO 3, TSUKUBA 30033, JAPAN.		Tamai, Katsuyuki/F-4743-2013	Tamai, Katsuyuki/0000-0003-4094-3911				BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BENEDICT WF, 1983, SCIENCE, V219, P973, DOI 10.1126/science.6336308; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHERINGTON V, 1988, MOL CELL BIOL, V8, P1380, DOI 10.1128/MCB.8.3.1380; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DRYJA TP, 1986, P NATL ACAD SCI USA, V83, P7391, DOI 10.1073/pnas.83.19.7391; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; HUNT T, 1991, NATURE, V349, P100, DOI 10.1038/349100a0; IOANNIDES CG, 1987, P NATL ACAD SCI USA, V84, P4244, DOI 10.1073/pnas.84.12.4244; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TAYA Y, 1986, EMBO J, V5, P1215, DOI 10.1002/j.1460-2075.1986.tb04349.x; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; TAYA Y, 1990, GENETIC BASIS FOR CARCINOGENESIS, P171; TOGUCHIDA J, 1989, NATURE, V338, P156, DOI 10.1038/338156a0; WANG NP, 1990, CELL GROWTH DIFFER, V1, P233; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YASUDA H, 1981, BIOCHEMISTRY-US, V20, P4414, DOI 10.1021/bi00518a028; YASUDA H, 1990, BIOCHEM BIOPH RES CO, V172, P371, DOI 10.1016/0006-291X(90)90682-D; YOKOTA J, 1988, ONCOGENE, V3, P471; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	69	47	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1992	7	6					1067	1074						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594240				2022-12-25	WOS:A1992HU64200003
J	BODDUPALLI, SS; OSTER, T; ESTABROOK, RW; PETERSON, JA				BODDUPALLI, SS; OSTER, T; ESTABROOK, RW; PETERSON, JA			RECONSTITUTION OF THE FATTY-ACID HYDROXYLATION FUNCTION OF CYTOCHROME-P-450BM-3 UTILIZING ITS INDIVIDUAL RECOMBINANT HEMOPROTEIN AND FLAVOPROTEIN DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-MEGATERIUM; MONOOXYGENASE; INDUCTION; BINDING; OMEGA-2; SYSTEM	Cytochrome P-450BM-3 is a catalytically self-sufficient fatty acid omega-hydroxylase with two domains. Functional and primary structure analyses of the hemo- and flavoprotein domains of cytochrome P-450BM-3 and the corresponding microsomal cytochrome P-450 system have shown that these proteins are highly homologous. Prior attempts to reconstitute the fatty acid hydroxylation function of cytochrome P-450BM-3, utilizing the two domains, obtained either by trypsinolysis or by recombinant methods, were unsuccessful. In this paper, we describe the reconstitution of the fatty acid hydroxylation activity of cytochrome P-450BM-3 UtiliZing the recombinantly produced flavoprotein domain (Oster, T., Boddupalli, S. S., and Peterson, J. A. (1991) J. Biol. Chem. 266, 22718-22725) and its hemoprotein counterpart. The rate of fatty acid-dependent oxygen consumption was shown to be linear when increasing concentrations of the hemoprotein domain are added to a fixed concentration of the flavoprotein domain and vice versa. The combination of the hemo- and flavoprotein domains in a ratio of 20:1 respectively, in the reaction mixture, results in the transfer of 80% of the reducing equivalents from NADPH for the hydroxylation of palmitate at 25-degrees-C. The ratio of the regioisomeric products obtained for lauric, myristic, and palmitic acids was similar to that obtained with the holoenzyme form of cytochrome P-450BM-3. The reconstitution of the fatty acid omega-hydroxylase activity, using the soluble domains of cytochrome P-450BM-3, without added factors such as lipids, may be useful for structure/function comparisons to their eukaryotic counterparts.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,5323 HARRY HINES BLVD,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043479] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43479] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN JE, 1991, P ROY SOC B-BIOL SCI, V245, P43, DOI 10.1098/rspb.1991.0086; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BODDUPALLI SS, 1992, ARCH BIOCHEM BIOPHYS, V292, P20, DOI 10.1016/0003-9861(92)90045-X; BODDUPALLI SS, 1990, J BIOL CHEM, V265, P4233; FULCO AJ, 1991, ANNU REV PHARMACOL, V31, P177; FULCO AJ, 1983, MOL CELL BIOCHEM, V53-4, P155; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; Gunsalus I.C., 1974, MOL MECHANISMS OXYGE, P559; GUNSALUS IC, 1985, CURR TOP CELL REGUL, V26, P295; HARE RS, 1975, BIOCHEM BIOPH RES CO, V65, P665, DOI 10.1016/S0006-291X(75)80198-7; HORLE S, 1978, CYTOCHROME P450, P73; KIM BH, 1983, BIOCHEM BIOPH RES CO, V116, P843, DOI 10.1016/S0006-291X(83)80219-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI HY, 1991, J BIOL CHEM, V266, P11909; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIURA Y, 1975, BIOCHIM BIOPHYS ACTA, V388, P305, DOI 10.1016/0005-2760(75)90089-2; MIURA Y, 1974, J BIOL CHEM, V249, P1880; MORELLE G, 1990, FOCUS, V11, P7; NARHI LO, 1982, J BIOL CHEM, V257, P2147; NARHI LO, 1986, J BIOL CHEM, V261, P7160; NARHI LO, 1987, J BIOL CHEM, V262, P6683; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; Ortiz de Montellano P.R., 2015, CYTOCHROME P450 STRU, P912; OSTER T, 1991, J BIOL CHEM, V266, P22718; PETERSON JA, 1971, ARCH BIOCHEM BIOPHYS, V144, P678, DOI 10.1016/0003-9861(71)90375-4; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RUETTINGER RT, 1989, J BIOL CHEM, V264, P10987; Sambrook J, 1989, MOL CLONING LABORATO; Warburg O., 1942, BIOCHEM Z, V310, P384	31	68	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10375	10380						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587824				2022-12-25	WOS:A1992HV09000029
J	ESTEBAN, LM; RODRIGUEZCOUSINO, N; ESTEBAN, R				ESTEBAN, LM; RODRIGUEZCOUSINO, N; ESTEBAN, R			T-DOUBLE-STRANDED RNA (DSRNA) SEQUENCE REVEALS THAT T-DSRNAS AND W-DSRNAS FORM A NEW RNA FAMILY IN SACCHAROMYCES-CEREVISIAE - IDENTIFICATION OF 23-S-RNA AS THE SINGLE-STRANDED FORM OF T-DSRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; GENETIC ELEMENT; YEAST VIRUS; POLYMERASE; SPORULATION; EVOLUTION; PLASMID; MUTANT; MOTIF	Some strains of the yeast Saccharomyces cerevisiae harbor a double-stranded RNA (dsRNA) molecule, called T. We obtained T cDNA clones by random priming of denatured T dsRNA followed by reverse transcription. Sequence data of T show that only one strand ((+)-strand) has coding capacity for a protein with 940 amino acids which spans almost the entire length of the molecule (2.9 kilobases). Within this protein we found a sequence pattern characteristic of RNA-dependent RNA polymerases of (+)-strand and double-stranded RNA viruses. Although T has no homology with other dsRNAs found in S. cerevisiae, such as L-A, L-BC, M1, or W, the T-encoded protein shows a high degree of conservation with the W-encoded protein. This conservation extends beyond a region that contains the consensus sequences for RNA-dependent RNA polymerases, suggesting that both T and W are evolutionarily related. With a (+)-strand-specific probe for T we identified 23 S RNA, a new single-stranded RNA (ssRNA) species with a sedimentation coefficient of 23 S. T and 23 S RNA have the same mobility under denaturing conditions with glyoxal, suggesting that 23 S RNA is, in fact, the (+)-single-stranded RNA form of T dsRNA. 23 S RNA synthesis is induced under stress conditions such as heat shock and starvation. The relationship between T and 23 S RNA clearly resembles the one between W and its single-stranded derivative form, 20 S RNA. Thus T and W dsRNAs (and their respective single-stranded species) constitute a new RNA family in S. cerevisiae.	UNIV SALAMANCA,INST MICROBIOL BIOQUIM,CSIC,E-37071 SALAMANCA,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca			Esteban, Rosa/K-4356-2014; Rodríguez-Cousiño, Nieves/K-6465-2014	Esteban, Rosa/0000-0001-6804-7209; Rodríguez-Cousiño, Nieves/0000-0002-6458-3677				ARGOS P, 1988, NUCLEIC ACIDS RES, V16, P9909, DOI 10.1093/nar/16.21.9909; BRUENN JA, 1991, NUCLEIC ACIDS RES, V19, P217, DOI 10.1093/nar/19.2.217; BUSSEY H, 1988, YEAST, V4, P17, DOI 10.1002/yea.320040103; CONDE J, 1976, P NATL ACAD SCI USA, V73, P3651, DOI 10.1073/pnas.73.10.3651; DIAMOND ME, 1989, J VIROL, V63, P3983, DOI 10.1128/JVI.63.9.3983-3990.1989; ESTEBAN R, 1987, GENETICS, V117, P399; ESTEBAN R, 1988, J VIROL, V62, P1278, DOI 10.1128/JVI.62.4.1278-1285.1988; FRIED HM, 1978, P NATL ACAD SCI USA, V75, P4224, DOI 10.1073/pnas.75.9.4224; FUJIMURA T, 1990, CELL, V62, P819, DOI 10.1016/0092-8674(90)90125-X; GARVIK B, 1978, J BACTERIOL, V134, P261, DOI 10.1128/JB.134.1.261-269.1978; GEORGOPOULOS DE, 1986, EXTRACHROMOSOMAL ELE, P203; HANSEN DR, 1985, J GEN VIROL, V66, P2605, DOI 10.1099/0022-1317-66-12-2605; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; ICHO T, 1989, J BIOL CHEM, V264, P6716; INOKUCHI Y, 1988, NUCLEIC ACIDS RES, V16, P6205, DOI 10.1093/nar/16.13.6205; INOKUCHI Y, 1986, J BIOCHEM-TOKYO, V99, P1169, DOI 10.1093/oxfordjournals.jbchem.a135580; KADOWAKI K, 1971, J BACTERIOL, V105, P831, DOI 10.1128/JB.105.3.831-836.1971; KADOWAKI K, 1971, J BACTERIOL, V105, P826, DOI 10.1128/JB.105.3.826-830.1971; KAMER G, 1984, NUCLEIC ACIDS RES, V12, P7269, DOI 10.1093/nar/12.18.7269; KOONIN EV, 1991, J GEN VIROL, V72, P2197, DOI 10.1099/0022-1317-72-9-2197; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LEE M, 1986, J VIROL, V58, P402, DOI 10.1128/JVI.58.2.402-407.1986; LEFEBRE A, 1990, PLANT MOL BIOL, V14, P447; Maniatis T., 1982, MOL CLONING; MATSUMOTO Y, 1990, P NATL ACAD SCI USA, V87, P7628, DOI 10.1073/pnas.87.19.7628; MATSUMOTO Y, 1991, J BIOL CHEM, V266, P12779; Mortimer R K, 1975, Methods Cell Biol, V11, P221, DOI 10.1016/S0091-679X(08)60325-8; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; PRIANO C, 1987, COLD SPRING HARB SYM, V52, P321, DOI 10.1101/SQB.1987.052.01.037; RODRIGUEZCOUSINO N, 1991, J BIOL CHEM, V266, P12772; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKIPPER N, 1984, EMBO J, V3, P107, DOI 10.1002/j.1460-2075.1984.tb01769.x; SOMMER SS, 1982, CELL, V31, P429, DOI 10.1016/0092-8674(82)90136-2; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; THIELE DJ, 1982, NUCLEIC ACIDS RES, V10, P6903, DOI 10.1093/nar/10.21.6903; TOHE A, 1978, J BACTERIOL, V136, P1002, DOI 10.1128/JB.136.3.1002-1007.1978; TOHE A, 1980, J BACTERIOL, V141, P413, DOI 10.1128/JB.141.1.413-416.1980; WEJKSNORA PJ, 1978, J BACTERIOL, V134, P246, DOI 10.1128/JB.134.1.246-260.1978; WESOLOWSKI M, 1984, MOL CELL BIOL, V4, P181, DOI 10.1128/MCB.4.1.181; WICKNER RB, 1978, GENETICS, V88, P419; WICKNER RB, 1989, FASEB J, V3, P2257, DOI 10.1096/fasebj.3.11.2550303; WIDNER WR, 1991, MOL CELL BIOL, V11, P2905, DOI 10.1128/MCB.11.5.2905; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x	43	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10874	10881						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587863				2022-12-25	WOS:A1992HV09000099
J	DAS, AK; HAJRA, AK				DAS, AK; HAJRA, AK			CRITICAL MICELLAR CONCENTRATIONS OF PALMITOYL DIHYDROXYACETONE PHOSPHATE AND 1-PALMITOYL-RAC-GLYCEROL 3-PHOSPHATE - APPENDIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								By fluorescent titration method, the critical micellar concentrations of palmitoyl CoA, palmitoyl dihydroxyacetone-P, and 1-palmitoyl-rac-glycerol-3-P in 75 mm Tris-HCl, pH 7.5, were determined to be 41, 58, and 70-mu-M, respectively.	UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48104	University of Michigan System; University of Michigan	DAS, AK (corresponding author), UNIV MICHIGAN,MENTAL HLTH RES INST,NEUROSCI LAB,ANN ARBOR,MI 48104, USA.			Das, Arun/0000-0002-0883-1816				CONSTANTINIDES PP, 1985, J BIOL CHEM, V260, P7573; HOROWITZ P, 1977, J COLLOID INTERF SCI, V61, P197, DOI 10.1016/0021-9797(77)90428-3; Mukerjee P., 1971, NSRDSNBS36; SMITH RH, 1986, ARCH BIOCHEM BIOPHYS, V244, P357, DOI 10.1016/0003-9861(86)90124-4	4	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9731	9731						1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577809				2022-12-25	WOS:A1992HT96500045
J	TRAXINGER, RR; MARSHALL, S				TRAXINGER, RR; MARSHALL, S			INSULIN REGULATION OF PYRUVATE-KINASE ACTIVITY IN ISOLATED ADIPOCYTES - CRUCIAL ROLE OF GLUCOSE AND THE HEXOSAMINE BIOSYNTHESIS PATHWAY IN THE EXPRESSION OF INSULIN ACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY CULTURED ADIPOCYTES; TRANSPORT SYSTEM; GENE-EXPRESSION; MESSENGER-RNAS; PROTEIN-KINASE; RAT; RECEPTOR; LIVER; 5,6-DICHLORO-1-BETA-D-RIBOFURANOSYLBENZIMIDAZOLE; MECHANISM	We recently identified glutamine:fructose-6-phosphate amidotransferase (GFAT) as an insulin-regulated enzyme in adipocytes. Moreover, we found that loss of GFAT activity is not due to a direct action of insulin but rather is mediated by enhanced glucose uptake and the subsequent routing of glucose through the hexosamine biosynthesis pathway. To assess whether other cytosolic enzymes are controlled through formation of hexosamine products, we treated adipocytes for 5 h with physiological concentrations of insulin (ED50 = 0.33 ng/ml), glucose (ED50 = 4.5 mM), and glutamine (ED50 = 4.4 mM) and then measured pyruvate kinase (PK) activity. Combined treatment resulted in a progressive (t1/2 of 2.5 h) and marked (3-fold) increase in PK activity, whereas omission of one or more of these components failed to alter enzyme activity. Several lines of additional evidence implicated the hexosamine biosynthesis pathway in PK regulation; therefore, it appears that the M2 isoform of pyruvate kinase represents another enzyme regulated by insulin through stimulation of glucose uptake and formation of hexosamine products. Related studies revealed that enhancement of PK activity is dependent upon ongoing mRNA synthesis and de novo protein synthesis and is mediated by an increase in enzyme content. Considered together, these findings provide new insights into the cascade of metabolic events triggered by insulin and implicate a novel metabolic pathway in the pretranslational control of enzyme function.	UNIV TENNESSEE CTR HLTH SCI,DEPT BIOCHEM,800 MADISON AVE,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008206] Funding Source: NIH RePORTER; NCRR NIH HHS [RR05-5423] Funding Source: Medline; NIDDK NIH HHS [DK08206] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEKESI JG, 1969, J BIOL CHEM, V244, P5663; BUCHER T, 1955, METHOD ENZYMOL, V63, P441; CIFUENTES ME, 1991, J BIOL CHEM, V266, P1557; CIMBALA MA, 1985, MOL BASIS INSULIN AC, P385; CLADARAS C, 1980, ARCH BIOCHEM BIOPHYS, V200, P426, DOI 10.1016/0003-9861(80)90373-2; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DELGIACCO R, 1964, J BIOL CHEM, V239, P2400; ENGSTROM L, 1987, ENZYMES, V18, P47; GARVEY WT, 1987, J BIOL CHEM, V262, P189; GARVEY WT, 1986, DIABETES, V35, P258, DOI 10.2337/diabetes.35.3.258; HARADA K, 1978, BIOCHIM BIOPHYS ACTA, V524, P327, DOI 10.1016/0005-2744(78)90169-9; HASSELL JR, 1986, ANNU REV BIOCHEM, V55, P539, DOI 10.1146/annurev.bi.55.070186.002543; HERN EP, 1978, P SOC EXP BIOL MED, V158, P255; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; IMAMURA K, 1982, METHOD ENZYMOL, V90, P150; IMAMURA K, 1972, J BIOCHEM-TOKYO, V71, P1043, DOI 10.1093/oxfordjournals.jbchem.a129852; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KAHN A, 1982, METHOD ENZYMOL, V90, P131; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KLETZIEN RF, 1975, ANAL BIOCHEM, V68, P537, DOI 10.1016/0003-2697(75)90649-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN MJ, 1982, BIOCHIM BIOPHYS ACTA, V699, P77, DOI 10.1016/0167-4781(82)90140-3; MAHER F, 1989, MOL ENDOCRINOL, V3, P2128, DOI 10.1210/mend-3-12-2128; MARSHALL S, 1984, J BIOL CHEM, V259, P6376; MARSHALL S, 1991, J BIOL CHEM, V266, P10155; MARSHALL S, 1989, J BIOL CHEM, V264, P2029; MARSHALL S, 1983, DIABETES, V32, P319, DOI 10.2337/diab.32.4.319; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; MEDDIO F, 1990, EUR J BIOCHEM, V187, P89; MOLNAR J, 1964, J BIOL CHEM, V239, P3157; MUNNICH A, 1984, J BIOL CHEM, V259, P228; NNOGUCHI T, 1983, J BIOL CHEM, V258, P15220; NOGUCHI T, 1985, J BIOL CHEM, V260, P4393; OREVI M, 1972, EUR J BIOCHEM, V30, P418, DOI 10.1111/j.1432-1033.1972.tb02113.x; POGSON CI, 1967, NATURE, V216, P156, DOI 10.1038/216156a0; RODBELL M, 1964, J BIOL CHEM, V239, P375; Schauer R., 1982, ADV CARBOHYD CHEM BI, V40, P132; SCHWARTZ NB, 1986, TXB BIOCH CLIN CORRE, P329; SHOELSON SE, 1989, MOL CELLULAR BIOL DI, P23; STEVENS A, 1989, BIOCHEM BIOPH RES CO, V159, P508, DOI 10.1016/0006-291X(89)90022-3; TAMM I, 1976, J CELL BIOL, V69, P229, DOI 10.1083/jcb.69.2.229; TRAXINGER RR, 1989, J BIOL CHEM, V264, P8156; TRAXINGER RR, 1991, J BIOL CHEM, V266, P10148; TRAXINGER RR, 1989, J BIOL CHEM, V264, P20910; WEBER A, 1984, J BIOL CHEM, V259, P1798; YUTEH B, 1982, ADV CARBOHY CHEM BIO, V40, P235; ZANDOMENI R, 1984, J BIOL CHEM, V259, P4804; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414; Zubay G., 1988, BIOCHEMISTRY	49	47	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9718	9723						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577807				2022-12-25	WOS:A1992HT96500043
J	MILLER, AF; ORMEJOHNSON, WH				MILLER, AF; ORMEJOHNSON, WH			THE DEPENDENCE ON IRON AVAILABILITY OF ALLOCATION OF IRON TO NITROGENASE COMPONENTS IN KLEBSIELLA-PNEUMONIAE AND ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM COFACTOR; AZOTOBACTER-VINELANDII; GENE-PRODUCT; FIXATION GENES; MOFE PROTEIN; FE-PROTEIN; NUCLEOTIDE-SEQUENCE; FOREIGN HOSTS; BIOSYNTHESIS; PURIFICATION	Nitrogenase contains approximately 38 iron ions/complete unit. Therefore, we sought to identify steps and genes involved in nitrogenase production that are responsive to iron availability. We have characterized nitrogenase production in Klebsiella pneumoniae grown in a range of different iron concentrations. We find significant accumulation (50-75%) and normal synthesis rates of the structural polypeptides, even under conditions in which the observed nitrogenase activities are only 14-28% of those observed in iron-sufficient conditions. Thus, maturation instead of synthesis of the structural polypeptides is primarily responsible for the iron dependence of nitrogenase activity. We have also used a binary plasmid system in Escherichia coli to investigate the contributions of various nitrogen fixation (nif) genes to the iron dependence of nitrogenase production. At least one of the nif genes DKTYENXUSVW can modulate synthesis of the structural polypeptide NIF H in response to iron availability. We speculate that an iron-deficient complex of the product(s) of at least one of these genes may repress structural polypeptide synthesis in iron-depleted K. pneumoniae. Such a system would compensate for the inactivity of NIF L in iron-depleted cultures and ensure balanced production of the structural polypeptides of nitrogenase in accordance with the iron available for their maturation.	MIT, DEPT CHEM, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)			Miller, Anne-Frances/M-7703-2017					ARNOLD W, 1988, J MOL BIOL, V203, P715, DOI 10.1016/0022-2836(88)90205-7; AUSTIN S, 1990, EUR J BIOCHEM, V187, P353, DOI 10.1111/j.1432-1033.1990.tb15312.x; BACHMANN BJ, 1972, BACTERIOL REV, V36, P525, DOI 10.1128/MMBR.36.4.525-557.1972; BERMAN J, 1985, J BIOL CHEM, V260, P5240; BULEN WA, 1966, P NATL ACAD SCI USA, V56, P979, DOI 10.1073/pnas.56.3.979; BURGESS BK, 1990, CHEM REV, V90, P1377, DOI 10.1021/cr00106a002; CARNAHAN JE, 1958, J BACTERIOL, V75, P121, DOI 10.1128/JB.75.2.121-124.1958; CARTER P, 1971, ANAL BIOCHEM, V40, P450, DOI 10.1016/0003-2697(71)90405-2; COLLINS JJ, 1986, J BACTERIOL, V168, P173, DOI 10.1128/jb.168.1.173-178.1986; DIXON RA, 1972, NATURE, V237, P102, DOI 10.1038/237102a0; Eady R. R., 1980, Methods for evaluating biological nitrogen fixation., P213; ESPOSITO RG, 1956, P SOC EXP BIOL MED, V93, P564; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; GEORGIADIS MM, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P111; GILL PR, 1991, PLANT SOIL, V130, P211, DOI 10.1007/BF00011875; GOSINK MM, 1990, J BACTERIOL, V172, P1441, DOI 10.1128/jb.172.3.1441-1447.1990; GUERINOT ML, 1991, PLANT SOIL, V130, P199, DOI 10.1007/BF00011874; HARRIS GS, 1990, J BIOL CHEM, V265, P15909; HAUSINGER RP, 1983, J BIOL CHEM, V258, P3486; HAWKES TR, 1984, BIOCHEM J, V217, P317, DOI 10.1042/bj2170317; HENDERSON N, 1989, MOL GEN GENET, V216, P484, DOI 10.1007/BF00334394; HOLLAND D, 1987, J BIOL CHEM, V262, P8814; HOOVER T R, 1988, Biofactors, V1, P199; HOOVER TR, 1989, BIOCHEMISTRY-US, V28, P2768, DOI 10.1021/bi00433a004; HOOVER TR, 1987, NATURE, V329, P855, DOI 10.1038/329855a0; HOWARD JB, 1989, J BIOL CHEM, V264, P11270; HOWARD KS, 1986, J BIOL CHEM, V261, P772; JOERGER RD, 1991, J BACTERIOL, V173, P4440, DOI 10.1128/JB.173.14.4440-4446.1991; JOERGER RD, 1988, J BACTERIOL, V170, P1475, DOI 10.1128/jb.170.4.1475-1487.1988; KUO CF, 1988, ANAL BIOCHEM, V170, P183, DOI 10.1016/0003-2697(88)90106-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMLEY PV, 1986, THESIS MIT CAMBRIDGE; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACNEIL T, 1978, J BACTERIOL, V136, P253, DOI 10.1128/JB.136.1.253-266.1978; MAHASNEH IA, 1991, MICROBIOS, V65, P31; MARTIN JH, 1988, NATURE, V331, P341, DOI 10.1038/331341a0; MCLEAN PA, 1987, J BIOL CHEM, V262, P12900; MORENOVIVIAN C, 1989, MOL GEN GENET, V216, P353, DOI 10.1007/BF00334376; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NEILANDS JB, 1989, METAL IONS BACTERIA, P141; NELSON MJ, 1983, P NATL ACAD SCI-BIOL, V80, P147, DOI 10.1073/pnas.80.1.147; OHARA GW, 1988, NEW PHYTOL, V108, P51, DOI 10.1111/j.1469-8137.1988.tb00203.x; ORMEJOHNSON WH, 1985, ANNU REV BIOPHYS BIO, V14, P419, DOI 10.1146/annurev.biophys.14.1.419; PAERL HW, 1990, ADV MICROB ECOL, V11, P305; PAUL W, 1989, EUR J BIOCHEM, V178, P675, DOI 10.1111/j.1432-1033.1989.tb14497.x; PAUSTIAN TD, 1989, P NATL ACAD SCI USA, V86, P6082, DOI 10.1073/pnas.86.16.6082; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; POSTLE K, 1990, J BACTERIOL, V172, P2287, DOI 10.1128/jb.172.5.2287-2293.1990; ROBERTS GP, 1978, J BACTERIOL, V136, P267, DOI 10.1128/JB.136.1.267-279.1978; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; SANDMANN G, 1990, PHOTOSYNTH RES, V26, P119, DOI 10.1007/BF00047083; SHAH VK, 1983, J BIOL CHEM, V258, P2064; STIEFEL EI, 1988, METAL CLUSTERS PROTE, P372; STJOHN RT, 1975, J BACTERIOL, V121, P759, DOI 10.1128/JB.121.3.759-765.1975; TANG CX, 1990, NEW PHYTOL, V114, P173, DOI 10.1111/j.1469-8137.1990.tb00388.x; UGALDE RA, 1985, J BACTERIOL, V164, P1081, DOI 10.1128/JB.164.3.1081-1087.1985; WAHL RC, 1987, J BIOL CHEM, V262, P10489; WHITE TC, 1990, NITROGEN FIXATION AC, P174; YAKUNIN AF, 1990, MICROBIOLOGY+, V59, P524; ZUMFT WG, 1974, EUR J BIOCHEM, V46, P525, DOI 10.1111/j.1432-1033.1974.tb03646.x	61	6	7	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9398	9408						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577767				2022-12-25	WOS:A1992HR85400105
J	SCHALKWIJK, C; PFEILSCHIFTER, J; MARKI, F; VANDENBOSCH, H				SCHALKWIJK, C; PFEILSCHIFTER, J; MARKI, F; VANDENBOSCH, H			INTERLEUKIN-1-BETA-INDUCED AND FORSKOLIN-INDUCED SYNTHESIS AND SECRETION OF GROUP-II PHOSPHOLIPASE-A(2) AND PROSTAGLANDIN-E(2) IN RAT MESANGIAL CELLS IS PREVENTED BY TRANSFORMING GROWTH-FACTOR-BETA-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MESSENGER-RNA SYNTHESIS; FACTOR-BETA; SIGNAL TRANSDUCTION; PURIFICATION; RELEASE; CHONDROCYTES; STIMULATION; EXPRESSION; INHIBITOR	Interleukin-1-beta and forskolin induce prostaglandin E2 release as well as 14-kDa group II phospholipase A2 gene expression and secretion of the enzyme from rat glomerular mesangial cells. We now report that pretreatment of mesangial cells with transforming growth factor-beta-2 prior to stimulation with interleukin-1-beta or forskolin inhibits the induced release of prostaglandin E2. At the same time the secretion of group II phospholipase A2, measured both as enzyme activity with sn-2-labeled phosphatidylethanolamine as substrate and as enzyme protein in immunoblot experiments, is dose-dependently inhibited by pretreatment of the cells with transforming growth factor-beta-2. Analyses of enzyme activity and enzyme protein levels in the cells indicated that this is not due to inhibition of enzyme secretion with a concomitant increase in cellular levels of the enzyme. Rather, pretreatment of the cells with transforming growth factor-beta-2 largely prevented both the interleukin-1-beta- and the forskolin-induced synthesis of phospholipase A2. This is the first report indicating an inhibition of group II phospholipase A2 gene expression by transforming growth factor-beta-2. In line with those results, transforming growth factor-beta-2 did not induce the synthesis and secretion of group II phospholipase A2. However, under conditions where the interleukin-1-beta-induced expression of group II phospholipase A2 is fully suppressed by transforming growth factor-beta-2, the growth factor itself stimulated prostaglandin E2 synthesis by a mechanism apparently not involving group II phospholipase A2. The immunochemical identification of the inducible and secretable phospholipase A2 from rat mesangial cells as a group II enzyme was confirmed by purification and N-terminal amino acid sequence determination.	CTR BIOMEMBRANES & LIPID ENZYMOL,PADUALAAN 8,3584 CH UTRECHT,NETHERLANDS; CIBA GEIGY AG,DIV PHARMACEUT,RES DEPT,CH-4002 BASEL,SWITZERLAND	Novartis								AARSMAN AJ, 1989, J BIOL CHEM, V264, P10008; BONVENTRE JV, 1990, J BIOL CHEM, V265, P4934; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL IK, 1990, BIOCHIM BIOPHYS ACTA, V1051, P310, DOI 10.1016/0167-4889(90)90140-9; COYNE DW, 1990, BIOCHEM BIOPH RES CO, V173, P718, DOI 10.1016/S0006-291X(05)80094-4; CROWL RM, 1991, J BIOL CHEM, V266, P2647; DEJONG JGN, 1987, EUR J BIOCHEM, V164, P129; DIAZ A, 1989, J BIOL CHEM, V264, P11554; DIGIOVINE FS, 1990, IMMUNOL TODAY, V11, P13; DINARELLO CA, 1989, CRIT REV IMMUNOL, V9, P1; DUBOIS CM, 1990, J EXP MED, V172, P737, DOI 10.1084/jem.172.3.737; GODFREY RW, 1987, BIOCHEM BIOPH RES CO, V142, P235, DOI 10.1016/0006-291X(87)90476-1; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; HAWKINS NJ, 1990, PATHOLOGY, V22, P24, DOI 10.3109/00313029009061422; HAYAKAWA M, 1988, J BIOCHEM-TOKYO, V104, P767, DOI 10.1093/oxfordjournals.jbchem.a122547; HEINRIKSON RL, 1977, J BIOL CHEM, V252, P4913; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYONSGIORDANO B, 1989, BIOCHEM BIOPH RES CO, V164, P488, DOI 10.1016/0006-291X(89)91746-4; MACKAY K, 1989, J CLIN INVEST, V83, P1160, DOI 10.1172/JCI113996; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MIZEL SB, 1990, IMMUNOL TODAY, V11, P390, DOI 10.1016/0167-5699(90)90154-2; MUHL H, 1991, FEBS LETT, V291, P249, DOI 10.1016/0014-5793(91)81295-J; NAKANO T, 1990, FEBS LETT, V261, P171, DOI 10.1016/0014-5793(90)80663-4; NAKANO T, 1990, J BIOL CHEM, V265, P12745; NAKAZATO Y, 1991, J BIOL CHEM, V266, P14119; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; ONEILL LAJ, 1990, IMMUNOL TODAY, V11, P392, DOI 10.1016/0167-5699(90)90155-3; ONO T, 1988, J BIOL CHEM, V263, P5732; PFEILSCHIFTER J, 1989, BIOCHEM BIOPH RES CO, V159, P385, DOI 10.1016/0006-291X(89)90003-X; PFEILSCHIFTER J, 1990, BIOCHEM BIOPH RES CO, V169, P585, DOI 10.1016/0006-291X(90)90371-S; PFEILSCHIFTER J, 1990, BIOCHEM J, V270, P269, DOI 10.1042/bj2700269; PFEILSCHIFTER J, 1989, BIOCHEM SOC T, V17, P916, DOI 10.1042/bst0170916; PFEILSCHIFTER J, 1984, BIOCHEM J, V223, P855, DOI 10.1042/bj2230855; PRUZANSKI W, 1991, IMMUNOL TODAY, V12, P143, DOI 10.1016/0167-5699(91)90077-7; RAZ A, 1988, J BIOL CHEM, V263, P3022; ROBERTS AB, 1983, BIOCHEMISTRY-US, V22, P5692, DOI 10.1021/bi00294a002; SCHALKWIJK C, 1991, BIOCHEM BIOPH RES CO, V174, P268, DOI 10.1016/0006-291X(91)90515-9; SCHALKWIJK C, 1991, BIOCHEM BIOPH RES CO, V180, P46, DOI 10.1016/S0006-291X(05)81252-5; SUFFYS P, 1988, FEBS LETT, V232, P24, DOI 10.1016/0014-5793(88)80379-X; TOJO H, 1988, BIOCHEM BIOPH RES CO, V151, P1188, DOI 10.1016/S0006-291X(88)80491-1; TOJO H, 1988, J BIOL CHEM, V263, P5724; TOPLEY N, 1989, J IMMUNOL, V143, P1989; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDENBOSCH H, 1979, AGENTS ACTIONS, V9, P382; VANDENBOSCH H, 1974, BIOCHIM BIOPHYS ACTA, V348, P197, DOI 10.1016/0005-2760(74)90231-8; VILCEK J, 1991, J BIOL CHEM, V266, P7313	46	84	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8846	8851						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577722				2022-12-25	WOS:A1992HR85400025
J	DONG, XR; LI, SF; DEMOSS, JA				DONG, XR; LI, SF; DEMOSS, JA			UPSTREAM SEQUENCE ELEMENTS REQUIRED FOR NARL-MEDIATED ACTIVATION OF TRANSCRIPTION FROM THE NARGHJI PROMOTER OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRATE REDUCTASE; NUCLEOTIDE-SEQUENCE; STRUCTURAL GENES; OPERON; REGION; K-12; DNA; FNR; CHLC	Transcription of the narGHJI operon (encoding nitrate reductase) in Escherichia coli is primarily dependent on the activation of the pleiotropic transacting factor Fnr, which interacts with the promoter through a cis element (Fnr box) located near the transcription start site. Further stimulation of transcription occurs in the presence of nitrate and is dependent on activation of the transacting factor NarL and a cis-acting sequence (NarL box) located approximately 200 base pairs upstream from the transcription start site. To define the structure of the NarL box, alterations in the NarL box region, generated by saturation mutagenesis of the sequence from positions -184 to -202 in the narGHJI promoter of a narG::lacZ fusion-bearing plasmid, were analyzed for their effects on NarL-mediated stimulation of transcription. Single base substitutions that significantly reduced the NarL-mediated stimulation were restricted to a 6-base sequence, TACTCC, located at positions -193 to -198 in the narGHJI promoter. When 2 bases were modified, NarL-mediated stimulation was severely reduced when one or both alterations were located within the 6-base sequence. Attempts to restore NarL-mediated stimulation with an inverted NarL box were not successful. Although previous studies suggested that NarL-mediated stimulation of transcription may occur by a DNA looping mechanism, the results presented here demonstrate that it does not involve the passive formation of a simple DNA loop. Replacement of 94 or 108 bases of the approximately 150 base sequence between the Fnr box and the NarL box with an unrelated sequence resulted in elimination of NarL-mediated stimulation of transcription. Furthermore, shifting of most of the intervening sequence or defined segments of the sequence by 4 bases while maintaining the position of the NarL box relative to sequences required for Fnr-dependent, anaerobic transcription also eliminated the NarL-mediated stimulation. We conclude that in addition to the 6-base NarL box located on a specific face of the promoter DNA, the stimulation of transcription by NarL requires some specific sequences and/or higher order structure specified by the DNA that separates the NarL box from the Fnr box.	UNIV TEXAS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Texas System					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019511] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19511] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG BL, 1990, GENETICS, V125, P691; BERG BL, 1991, J BIOL CHEM, V266, P22380; BLASCO F, 1989, MOL GEN GENET, V218, P249, DOI 10.1007/BF00331275; BONNEFOY V, 1986, MOL GEN GENET, V204, P180, DOI 10.1007/BF00330207; CHIPPAUX M, 1981, J BACTERIOL, V151, P1320; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; EDWARDS ES, 1983, J BACTERIOL, V153, P1513, DOI 10.1128/JB.153.3.1513-1520.1983; EIGLMEIER K, 1989, MOL MICROBIOL, V3, P869, DOI 10.1111/j.1365-2958.1989.tb00236.x; GUNSALUS RP, 1989, NUCLEIC ACIDS RES, V17, P1965, DOI 10.1093/nar/17.5.1965; HIDAKA M, 1991, J BACTERIOL, V173, P391, DOI 10.1128/jb.173.1.391-393.1991; HILL DE, 1987, METHOD ENZYMOL, V155, P558; IUCHI S, 1987, P NATL ACAD SCI USA, V84, P3901, DOI 10.1073/pnas.84.11.3901; LENNOX ES, 1955, VIROLOGY, V1, P190, DOI 10.1016/0042-6822(55)90016-7; LI S, 1985, J BACTERIOL, V164, P25, DOI 10.1128/JB.164.1.25-32.1985; LI SF, 1988, J BIOL CHEM, V263, P13700; LI SF, 1987, J BACTERIOL, V169, P4614, DOI 10.1128/jb.169.10.4614-4620.1987; LUI J, 1989, J BACTERIOL, V171, P1254; MANIATIS T, 1982, MOL CLONING LABORATO, P365; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; Miller JH., 1972, EXPT MOL GENETICS; NOHNO T, 1989, NUCLEIC ACIDS RES, V17, P2947, DOI 10.1093/nar/17.8.2947; NOJI S, 1989, FEBS LETT, V252, P139, DOI 10.1016/0014-5793(89)80906-8; ROBERTSON CA, 1988, J BIOL CHEM, V263, P3554; SHOWE MK, 1968, J BACTERIOL, V95, P1305, DOI 10.1128/JB.95.4.1305-1313.1968; SODERGREN EJ, 1988, J BACTERIOL, V170, P1721, DOI 10.1128/jb.170.4.1721-1729.1988; STEWART V, 1989, J BACTERIOL, V171, P2229, DOI 10.1128/jb.171.4.2229-2234.1989; STEWART V, 1982, J BACTERIOL, V151, P788, DOI 10.1128/JB.151.2.788-799.1982; STEWART V, 1982, J BACTERIOL, V151, P1320, DOI 10.1128/JB.151.3.1320-1325.1982; UNDEN G, 1990, MOL MICROBIOL, V4, P315, DOI 10.1111/j.1365-2958.1990.tb00598.x; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALKER MS, 1992, J BACTERIOL, V174, P1119, DOI 10.1128/jb.174.4.1119-1123.1992; WALKER MS, 1991, MOL MICROBIOL, V5, P353, DOI 10.1111/j.1365-2958.1991.tb02116.x	32	45	46	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14122	14128						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629213				2022-12-25	WOS:A1992JD32500054
J	HUTCHISON, KA; CZAR, MJ; SCHERRER, LC; PRATT, WB				HUTCHISON, KA; CZAR, MJ; SCHERRER, LC; PRATT, WB			MONOVALENT CATION SELECTIVITY FOR ATP-DEPENDENT ASSOCIATION OF THE GLUCOCORTICOID RECEPTOR WITH HSP70 AND HSP90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; STEROID-BINDING DOMAIN; PROGESTERONE-RECEPTOR; DNA-BINDING; UNCOATING ATPASE; TRANSFORMATION; RECONSTITUTION; COMPLEX; PURIFICATION; TRANSLATION	We have reported previously that incubation of the immunopurified transformed hormone-free glucocorticoid receptor with rabbit reticulocyte lysate reconstitutes the receptor complex with hsp90 and that reconstitution is accompanied by concomitant repression of DNA binding activity and regeneration of the steroid binding conformation (Scherrer, L. C., Dalman, F. C., Massa, E., Meshinchi, S., and Pratt, W. B. (1990) J. Biol. Chem. 265, 21397-21400). In this work we further characterize this system by defining the small M(r) components of reticulocyte lysate required for both structural and functional reconstitution of the receptor-hsp90 complex. Reconstitution is ATP-dependent and there is a direct relationship between the extent of hsp90 binding to the receptor and the number of specific steroid binding sites that are generated. Dialysis of reticulocyte lysate inactivates its reconstituting activity. Addition of an ATP-regenerating system or readdition of small M(r) lysate components (in the form of a Centricon C30 filtrate) has little effect, but the ' presence of both restores full reconstituting activity to dialyzed lysate, as assayed by steroid binding activity and by the binding of hsp90 and hsp70 to the receptor. The small M(r) activity is heat-stable, and it can be completely replaced by NH4+, K+, and Rb+, with K+ producing a maximal effect at the concentration normally present in undialyzed lysate. Na+ and Li+ have no reconstituting activity. This ion selectivity demonstrates that a monovalent cation binding site is involved in receptor heterocomplex reconstitution. It is intriguing that the protein unfoldase (e.g. clathrin uncoating ATPase) activity of hsp70 is known to have a similar monovalent cation dependence, and that under all conditions where hsp90 becomes bound to the receptor, we find that hsp70 is also bound.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,6448 MED SCI BLDG 1,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NCI NIH HHS [CA28010] Funding Source: Medline; NIDDK NIH HHS [DK31573] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031573, R01DK031573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CADEPOND F, 1991, J BIOL CHEM, V266, P5384; CHAKRABORTI PK, 1991, BIOCHEM BIOPH RES CO, V176, P1338, DOI 10.1016/0006-291X(91)90433-8; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DENIS M, 1988, J BIOL CHEM, V263, P18520; DENIS M, 1989, J BIOL CHEM, V264, P6005; ERHART JC, 1988, ONCOGENE, V3, P595; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; HUTCHISON KA, 1992, J BIOL CHEM, V267, P2902; JOVE R, 1986, J VIROL, V60, P840, DOI 10.1128/JVI.60.3.840-848.1986; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; MENDEL DB, 1988, J BIOL CHEM, V263, P6695; MESHINCHI S, 1990, J BIOL CHEM, V265, P4863; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PRATT WB, 1987, J CELL BIOCHEM, V35, P51, DOI 10.1002/jcb.240350105; PRATT WB, 1990, MOL CELL ENDOCRINOL, V74, pC69, DOI 10.1016/0303-7207(90)90198-H; PRATT WB, 1988, J BIOL CHEM, V263, P267; PRATT WB, 1992, J STEROID BIOCHEM, V41, P223, DOI 10.1016/0960-0760(92)90348-M; REXIN M, 1991, J BIOL CHEM, V266, P24601; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1987, J BIOL CHEM, V262, P6986; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHLATTER LK, 1992, MOL ENDOCRINOL, V6, P132, DOI 10.1210/me.6.1.132; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1990, J BIOL CHEM, V265, P3996	32	92	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14047	14053						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629204				2022-12-25	WOS:A1992JD32500043
J	MARKWELL, J; BRUCE, BD; KEEGSTRA, K				MARKWELL, J; BRUCE, BD; KEEGSTRA, K			ISOLATION OF A CAROTENOID-CONTAINING SUB-MEMBRANE PARTICLE FROM THE CHLOROPLASTIC ENVELOPE OUTER-MEMBRANE OF PEA (PISUM-SATIVUM)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANACYSTIS-NIDULANS; PROTEIN; ZEAXANTHIN; DNA	Chloroplastic envelope membranes isolated from pea (Pisum sativum) leaves are rich in carotenoids, containing approximately 2-mu-g of carotenoid mg-1 protein. We report here that envelopes can be surfactant-solubilized while maintaining association of carotenoids with protein components of the membrane. Treatment of isolated chloroplastic envelope membranes with 0.5% Deriphat 160 (N-lauryl-beta-imminodipropionate) causes general solubilization but preserves an envelope sub-membrane fragment which is fractionated by centrifugation in a sucrose gradient and by chromatography on a column of DEAE-Sephacel. The isolated submembrane complex contained five major proteins with M(r) values equivalent to 75,000, 36,000, 34,000 17,500, and 14,500. Spectroscopic and chromatographic analyses revealed that the complex contains violaxanthin and at least one other carotenoid. Carotenoid content of the fractionated complex was estimated as 4.8-mu-g mg-1 protein. Immunoblot analysis reveals that the constituent proteins of this complex are derived from the chloroplastic outer envelope membrane. These data suggest that at least some of the carotenoids of the chloroplastic envelope may be organized by apoproteins.	UNIV WISCONSIN,DEPT BOT,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison								ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; CERVANTESCERVANTES M, 1990, PLANT PHYSIOL, V92, P1241, DOI 10.1104/pp.92.4.1241; CLINE K, 1986, J BIOL CHEM, V261, P4804; COSTES C, 1979, FEBS LETT, V103, P17, DOI 10.1016/0014-5793(79)81241-7; Davies B., 1976, CAROTENOIDS CHEM BIO, P38, DOI [DOI 10.1590/S0101-20612001000200017, 10.1007/978-3-642-66632-2_11, DOI 10.1007/978-3-642-66632-2_11]; DEMMIGADAMS B, 1990, BIOCHIM BIOPHYS ACTA, V1020, P1, DOI 10.1016/0005-2728(90)90088-L; DIVERSEPIERLUISSI M, 1988, BIOCHIM BIOPHYS ACTA, V933, P372, DOI 10.1016/0005-2728(88)90045-X; DOUCE R, 1990, ANNU REV CELL BIOL, V6, P173, DOI 10.1146/annurev.cb.06.110190.001133; ENGLE JM, 1991, ARCH MICROBIOL, V155, P453, DOI 10.1007/BF00244961; FOOTE CS, 1970, J AM CHEM SOC, V92, P5216, DOI 10.1021/ja00720a036; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; JEFFREY SW, 1974, P NATL ACAD SCI USA, V71, P807, DOI 10.1073/pnas.71.3.807; JOYARD J, 1991, EUR J BIOCHEM, V199, P489, DOI 10.1111/j.1432-1033.1991.tb16148.x; JOYARD J, 1976, PHYSIOL VEG, V14, P31; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; KLAUER SF, 1991, PLANT PHYSIOL, V97, P1306, DOI 10.1104/pp.97.4.1306; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; LI HM, 1991, PLANT CELL, V3, P709, DOI 10.1105/tpc.3.7.709; MAKINO A, 1991, PHOTOSYNTH RES, V29, P79, DOI 10.1007/BF00035378; MARKWELL JP, 1979, P NATL ACAD SCI USA, V76, P1233, DOI 10.1073/pnas.76.3.1233; MARKWELL JP, 1986, PLANT PHYSIOL, V81, P329, DOI 10.1104/pp.81.2.329; MASAMOTO K, 1987, PLANT PHYSIOL, V84, P633, DOI 10.1104/pp.84.3.633; Moss G.P., 1976, CHEMISTRY BIOCHEMIST, P149; NOCTOR G, 1991, BIOCHIM BIOPHYS ACTA, V1057, P320, DOI 10.1016/S0005-2728(05)80143-4; POWLS R, 1976, BIOCHIM BIOPHYS ACTA, V453, P270, DOI 10.1016/0005-2795(76)90273-7; REDDY KJ, 1989, J BACTERIOL, V171, P3486, DOI 10.1128/jb.171.6.3486-3493.1989; SCHMIDT W, 1984, BLUE LIGHT EFFECTS B, P81; SIEFERMANNHARMS D, 1978, PLANT PHYSIOL, V61, P530, DOI 10.1104/pp.61.4.530; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEINHARDT J, 1969, MULTIPLE EQUILIBRIA, P85; WHATLEY JM, 1987, NEW PHYTOL, V106, P667, DOI 10.1111/j.1469-8137.1987.tb00167.x	32	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13933	13937						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629191				2022-12-25	WOS:A1992JD32500026
J	YANG, W; ABERNETHY, JL; ECKHARDT, AE; HILL, RL				YANG, W; ABERNETHY, JL; ECKHARDT, AE; HILL, RL			PURIFICATION AND CHARACTERIZATION OF A UDP-GALNAC-POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE SPECIFIC FOR GLYCOSYLATION OF THREONINE RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBMAXILLARY-GLAND APOMUCIN; TRANSFERASE; ACETYLGLUCOSAMINE; MUCIN	A UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase from porcine submaxillary glands was purified to electrophoretic homogeneity. IgG prepared from antisera against the pure enzyme immunoprecipitated the transferase in Triton X-100 extracts of submaxillary glands. The submaxillary transferase is a membrane-bound enzyme in contrast to the pure bovine colostrum enzyme, which is soluble in the absence of detergents. Both transferases have similar properties but also differ significantly. Examination of the acceptor substrate specificity of the submaxillary gland transferase showed that it specifically transferred N-acetylgalactosamine from UDP-GalNAc to the hydroxyl group of threonine and was devoid of transferase activity toward serine-containing peptides. These results imply that more than one transferase is involved in forming the GalNAc-threonine and the GalNAc-serine linkages found in O-linked oligosaccharides in glycoproteins. The amino acid sequence adjacent to glycosylated threonine residues may influence the rate of glycosylation by the pure transferase. For example, the second threonine residue in the sequence, Thr-Thr, appears to be glycosylated about twice as fast as the first and more rapidly than single, isolated threonine residues. However, no unique consensus sequence for glycosylation of threonine residues is evident, and any accessible threonine residue appears to be a potential acceptor substrate.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University					NIGMS NIH HHS [GM25766] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025766, R01GM025766] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERNATHY JL, 1992, TECHNIQUES PROTEIN C, V3, P277; AUBERT JP, 1976, ARCH BIOCHEM BIOPHYS, V175, P410, DOI 10.1016/0003-9861(76)90528-2; BARKER R, 1972, J BIOL CHEM, V247, P7135; BENDIAK B, 1987, J BIOL CHEM, V262, P5775; Beyer T A, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P23; BRIAND JP, 1981, J BIOL CHEM, V256, P2205; BRUCKNER H, 1989, J CHROMATOGR, V476, P73, DOI 10.1016/S0021-9673(01)93857-9; BRUCKNER H, 1991, CHROMATOGRAPHIA, V32, P383, DOI 10.1007/BF02321438; DALE RMK, 1975, BIOCHEMISTRY-US, V14, P2447, DOI 10.1021/bi00682a027; DESALEGUI M, 1969, ARCH BIOCHEM BIOPHYS, V129, P49, DOI 10.1016/0003-9861(69)90148-9; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; ECKHARDT AE, 1987, J BIOL CHEM, V262, P11339; ELHAMMER A, 1986, J BIOL CHEM, V261, P5249; HAGOPIAN A, 1969, ARCH BIOCHEM BIOPHYS, V129, P515, DOI 10.1016/0003-9861(69)90209-4; HAGOPIAN A, 1968, ARCH BIOCHEM BIOPHYS, V128, P122; HALTIWANGER RS, 1986, J BIOL CHEM, V261, P7440; HILL HD, 1977, J BIOL CHEM, V252, P3799; HILL HD, 1977, J BIOL CHEM, V252, P3791; HUGHES RC, 1988, CARBOHYD RES, V178, P259, DOI 10.1016/0008-6215(88)80117-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGUIRE EJ, 1967, J BIOL CHEM, V242, P3745; Sadler J. E., 1984, BIOL CARBOHYDRATES, V2, P199; SADLER JE, 1979, J BIOL CHEM, V254, P4434; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SUGIURA M, 1982, J BIOL CHEM, V257, P9501; TIMPTE CS, 1988, J BIOL CHEM, V263, P1081; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529	28	1	1	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12709	12716						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618775				2022-12-25	WOS:A1992HZ48300051
J	CAIN, CC; TRIMBLE, WS; LIENHARD, GE				CAIN, CC; TRIMBLE, WS; LIENHARD, GE			MEMBERS OF THE VAMP FAMILY OF SYNAPTIC VESICLE PROTEINS ARE COMPONENTS OF GLUCOSE TRANSPORTER-CONTAINING VESICLES FROM RAT ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INTEGRAL MEMBRANE-PROTEIN; ENDOCRINE-CELLS; 3T3-L1 ADIPOCYTES; ADIPOSE-CELLS; GENES; NEURONS; BRAIN	Existing data support the hypothesis that insulin triggers the exocytosis of small vesicles containing the GluT4 isoform of the glucose transporter. The data also suggest that these vesicles reform through endocytosis of GluT4. These processes resemble those described for synaptic vesicles after depolarization of nerve cells. To determine whether GluT4 vesicles are related to synaptic vesicles, rat adipocyte low density microsomes (LDM), which are rich in GluT4 vesicles, were screened for the synaptic vesicle proteins synaptotagmin, synaptophysin, SV2, p29, rab3, and VAMP (synaptobrevin) by immunoblotting. Two polypeptides that reacted with antibodies against the VAMPs were identified, one with the same apparent size as the two isoforms of VAMP in the brain (18 kDa) and one that was slightly smaller (17 kDa). These members of the VAMP family were highly enriched in GluT4 vesicles isolated by immunoadsorption and translocated from the LDM to the plasma membrane in response to insulin. With the exception of rab3, which was observed in the LDM but was not localized in the GluT4 vesicles, the other synaptic vesicle proteins were not detected. The presence of the VAMPs in both GluT4 and synaptic vesicles suggests that the genesis and/or exocytosis of these two types of vesicles involve shared processes.	DARTMOUTH COLL,DEPT BIOCHEM,HANOVER,NH 03755; UNIV TORONTO,CTR RES NEURODEGENERAT DIS,TORONTO M5S 1A8,ONTARIO,CANADA	Dartmouth College; University of Toronto			Mastick, Cynthia/G-9841-2017	Mastick, Cynthia/0000-0003-4769-5412	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025336, R55DK025336] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 25336] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARCHER BT, 1990, J BIOL CHEM, V265, P17267; BALDINI G, 1991, J BIOL CHEM, V266, P4037; BAUMERT M, 1990, J CELL BIOL, V110, P1285, DOI 10.1083/jcb.110.4.1285; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BROWN SJ, 1988, BIOCHIM BIOPHYS ACTA, V971, P339, DOI 10.1016/S0005-2728(88)80049-5; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CORREAROTTER R, 1992, BIOTECHNIQUES, V12, P154; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; DELVECCHIO RL, 1991, J BIOL CHEM, V266, P13278; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; GROESCH M E, 1991, Journal of Cell Biology, V115, p62A; HEUSER J, 1989, CELL BIOL INT REP, V13, P1063, DOI 10.1016/0309-1651(89)90020-9; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; JOOST HG, 1988, BIOCHEM J, V249, P155, DOI 10.1042/bj2490155; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIENHARD GE, 1984, BIOCHIM BIOPHYS ACTA, V769, P404, DOI 10.1016/0005-2736(84)90324-9; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; OSSIG R, 1991, MOL CELL BIOL, V11, P2980, DOI 10.1128/MCB.11.6.2980; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TRIMBLE WS, 1990, J NEUROSCI, V10, P1380; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; WEBER TM, 1988, RECEPTOR BIOCH METHO, P171; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	33	262	267	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11681	11684						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601842				2022-12-25	WOS:A1992HY94700006
J	TANG, DC; STULL, JT; KUBOTA, Y; KAMM, KE				TANG, DC; STULL, JT; KUBOTA, Y; KAMM, KE			REGULATION OF THE CA2+ DEPENDENCE OF SMOOTH-MUSCLE CONTRACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN KINASE; BETA-ADRENERGIC RELAXATION; PROTEIN-KINASE; MYOSIN PHOSPHORYLATION; CATALYTIC SUBUNIT; FREE-CALCIUM; INTRACELLULAR CALCIUM; CYTOSOLIC CA-2+; CELLS; CAMP	Cellular mechanisms for the regulation of Ca2+-dependent myosin light chain phosphorylation were investigated in bovine tracheal smooth muscle. Increases in the free intracellular Ca2+ concentration ([Ca2+]i), light chain phosphorylation, and force were proportional to carbachol concentration. K(CaM), the concentration of Ca2+/calmodulin required for half-maximal activation of myosin light chain kinase, also increased proportionally, presumably due to Ca2+-dependent phosphorylation of the kinase. Isoproterenol treatment inhibited agonist-induced contraction by decreasing [Ca2+]i and thereby light chain phosphorylation. Depolarization by increasing concentrations of KCl also resulted in proportional increases in [Ca2+]i, K(CaM), light chain phosphorylation, and force. However, the [Ca2+]i required to obtain a given value of either light chain phosphorylation or K(CaM) was greater in KCl-depolarized tissues compared to carbachol-treated tissues. In muscles contracted with KCl, isoproterenol treatment resulted in diminished light chain phosphorylation and force without alterations in [Ca2+]i or K(CaM). Thus, isoproterenol inhibition of KCl-induced contraction results from a cellular mechanism different from that found in agonist-induced contraction. In neither case does isoproterenol produce relaxation by altering the calmodulin activation properties of myosin light chain kinase.	UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NHLBI NIH HHS [HL32607, HL26043] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032607, R01HL026043, R23HL032607, R37HL026043] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABE A, 1989, J PHARMACOL EXP THER, V249, P895; ADELSTEIN RS, 1978, J BIOL CHEM, V253, P8347; AHMAD Z, 1989, J BIOL CHEM, V264, P3859; BECKER PL, 1987, AM J PHYSIOL, V253, pC613, DOI 10.1152/ajpcell.1987.253.4.C613; BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CONTI MA, 1981, J BIOL CHEM, V256, P3178; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; FELBEL J, 1988, J BIOL CHEM, V263, P16764; FRANCIS SH, 1988, MOL PHARMACOL, V34, P506; FUJIWARA T, 1989, J PHYSIOL-LONDON, V408, P535, DOI 10.1113/jphysiol.1989.sp017474; GERTHOFFER WT, 1991, AM J PHYSIOL, V261, pL15, DOI 10.1152/ajplung.1991.261.2.L15; GERTHOFFER WT, 1989, AM J PHYSIOL, V257, pC1062, DOI 10.1152/ajpcell.1989.257.6.C1062; GILBERT EK, 1991, FASEB J, V5, P2593, DOI 10.1096/fasebj.5.11.1868983; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUTH K, 1986, PFLUG ARCH EUR J PHY, V407, P552, DOI 10.1007/BF00657515; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HIMPENS B, 1988, J PHYSIOL-LONDON, V395, P507, DOI 10.1113/jphysiol.1988.sp016932; HIMPENS B, 1988, J GEN PHYSIOL, V92, P713, DOI 10.1085/jgp.92.6.713; JOHNSON EM, 1991, J BIOL CHEM, V266, P12618; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KARAKI H, 1989, TRENDS PHARMACOL SCI, V10, P320; KARGACIN G, 1991, BIOPHYS J, V60, P1088, DOI 10.1016/S0006-3495(91)82145-2; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; KITAZAWA T, 1991, J BIOL CHEM, V266, P1708; KONISHI M, 1988, BIOPHYS J, V54, P1089, DOI 10.1016/S0006-3495(88)83045-5; KUBOTA Y, 1992, AM J PHYSIOL, V262, pC405, DOI 10.1152/ajpcell.1992.262.2.C405; LINCOLN TM, 1990, AM J PHYSIOL, V258, pC399, DOI 10.1152/ajpcell.1990.258.3.C399; LINCOLN TM, 1991, BLOOD VESSELS, V28, P129; LOW AM, 1991, J PHARMACOL EXP THER, V258, P1105; MCDANIEL NL, 1991, J PHYSIOL-LONDON, V439, P147, DOI 10.1113/jphysiol.1991.sp018661; MEISHERI KD, 1982, J PHYSL, V331, P420; MILLER JR, 1983, MOL PHARMACOL, V24, P235; MITSUI M, 1990, AM J PHYSIOL, V258, pC787, DOI 10.1152/ajpcell.1990.258.5.C787; MORGAN JP, 1984, J PHYSIOL-LONDON, V357, P539, DOI 10.1113/jphysiol.1984.sp015516; MORGAN JP, 1991, AM  HEART J, V121; NEYLON CB, 1990, AM J PHYSIOL, V259, pC675, DOI 10.1152/ajpcell.1990.259.4.C675; NISHIKAWA M, 1984, J BIOL CHEM, V259, P8429; OZAKI H, 1990, PFLUG ARCH EUR J PHY, V416, P351, DOI 10.1007/BF00370740; PERSECHINI A, 1986, J BIOL CHEM, V261, P6293; REMBOLD CM, 1990, J PHYSIOL-LONDON, V429, P77, DOI 10.1113/jphysiol.1990.sp018245; REMBOLD CM, 1988, CIRC RES, V63, P593, DOI 10.1161/01.RES.63.3.593; REMBOLD CM, 1989, J PHYSIOL-LONDON, V416, P273, DOI 10.1113/jphysiol.1989.sp017760; ROE MW, 1990, CELL CALCIUM, V11, P63, DOI 10.1016/0143-4160(90)90060-8; SATO K, 1988, N-S ARCH PHARMACOL, V338, P443; SCHEID CR, 1979, NATURE, V277, P32, DOI 10.1038/277032a0; SHENOLIKAR S, 1991, ADV 2ND MESSENGER PH, V23, P1; STULL JT, 1990, J BIOL CHEM, V265, P16683; STULL JT, 1991, HYPERTENSION, V17, P723, DOI 10.1161/01.HYP.17.6.723; SUEMATSU E, 1991, J PHYSIOL-LONDON, V440, P85, DOI 10.1113/jphysiol.1991.sp018697; TANSEY MG, 1990, FEBS LETT, V270, P219, DOI 10.1016/0014-5793(90)81272-P; TANSEY MG, 1992, IN PRESS J BIOL CHEM, V266; TAYLOR DA, 1988, J BIOL CHEM, V263, P14456; TAYLOR DA, 1989, J BIOL CHEM, V264, P6207; TAYLOR SS, 1988, FASEB J, V2, P2677, DOI 10.1096/fasebj.2.11.3294077; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435	57	89	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11839	11845						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601855				2022-12-25	WOS:A1992HY94700033
J	MCFARLAN, SC; TERRELL, CA; HOGENKAMP, HPC				MCFARLAN, SC; TERRELL, CA; HOGENKAMP, HPC			THE PURIFICATION, CHARACTERIZATION, AND PRIMARY STRUCTURE OF A SMALL REDOX PROTEIN FROM METHANOBACTERIUM-THERMOAUTOTROPHICUM, AN ARCHAEBACTERIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; GLUTATHIONE-DEPENDENT SYNTHESIS; ESCHERICHIA-COLI GLUTAREDOXIN; CALF THYMUS GLUTAREDOXIN; MOLECULAR-WEIGHT THIOLS; CELL-EXTRACTS; CORYNEBACTERIUM-NEPHRIDII; THIOREDOXIN REDUCTASE; METHANOGENIC BACTERIA; DEOXYRIBONUCLEOTIDES	A small redox-active protein has been purified to homogeneity from cell-free extracts of the strictly anaerobic thermophilic methanogen, Methanobacterium thermoautotrophicum (strain Marburg). The purification consisted of streptomycin sulfate and acid treatments and three chromatographic steps using Sephadex G-75, Mono Q HR 10/10, and Superose 12 HR 10/30 columns. When these procedures were carried out under strictly anaerobic conditions, approximately 3 mg of this protein could be isolated from 45 g of wet cell paste. Like the thioredoxins and glutaredoxins, it is a small acidic protein (pI = 4.2) consisting of 83 amino acids (M(r) = 9136). In the presence of dithiothreitol or dihydrolipoate, the protein serves as a hydrogen donor for the ribonucleotide reductase from Escherichia coli, and it catalyzes the reduction of insulin. However, it does not interact with the thioredoxin reductases from E. coli or Corynebacterium nephridii and does not function as a hydrogen donor for the ribonucleotide reductase of C. nephridii. The amino acid sequences determined by automated Edman degradation of the C-14-carboxymethylated protein and of peptides derived from trypsin and chymotrypsin digestions show a redox-active site -Cys-Pro-Tyr-Cys-, typical of the glutaredoxins. Its amino acid sequence shows moderate identity with the known glutaredoxins (E. coli, yeast, rabbit bone marrow, calf thymus, and pig liver) when the proteins are aligned at the active site. The secondary structure of the glutaredoxin-like protein predicted by the Chou-Fasman procedure shows that it is similar to the known glutaredoxins. However, surprisingly, the protein does not function as a glutathione-disulfide oxidoreductase in the presence of glutathione and glutathione reductase. This glutaredoxin-like protein may be a component of a ribonucleotide-reducing system distinct from the previously described systems utilizing thioredoxin or glutaredoxin.	UNIV MINNESOTA, SCH MED,DEPT BIOCHEM,4-225 MILLARD HALL, 435 DELAWARE ST SE, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033776] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33776] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTHONY C, 1982, BIOCH METHYLOTROPHS, P296; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; EJIRI SI, 1980, ANAL BIOCHEM, V102, P393, DOI 10.1016/0003-2697(80)90173-6; EKLUND H, 1984, EMBO J, V3, P1443, DOI 10.1002/j.1460-2075.1984.tb01994.x; FAHEY RC, 1987, METHOD ENZYMOL, V143, P85; FISCHER R, 1990, FEBS LETT, V269, P368, DOI 10.1016/0014-5793(90)81195-T; FUCHS J, 1977, J BACTERIOL, V129, P967, DOI 10.1128/JB.129.2.967-972.1977; FUCHS JA, 1989, GLUTATHIONE CHEM B B, P551; GAN ZR, 1990, BIOCHEM BIOPH RES CO, V168, P944, DOI 10.1016/0006-291X(90)91120-H; GAN ZR, 1987, J BIOL CHEM, V262, P6699; GASSMANN M, 1990, FASEB J, V4, P2528, DOI 10.1096/fasebj.4.8.1970792; GLEASON FK, 1990, BIOCHEMISTRY-US, V29, P3701, DOI 10.1021/bi00467a016; GLEASON FK, 1988, FEMS MICROBIOL LETT, V54, P271, DOI 10.1111/j.1574-6968.1988.tb02747.x; GOSWAMI A, 1985, J BIOL CHEM, V260, P6012; GREENE RC, 1973, J BACTERIOL, V116, P230, DOI 10.1128/JB.116.1.230-234.1973; HAMMEL KE, 1983, P NATL ACAD SCI-BIOL, V80, P3681, DOI 10.1073/pnas.80.12.3681; HOGENKAMP HPC, 1987, FEBS LETT, V219, P197, DOI 10.1016/0014-5793(87)81215-2; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1968, EUR J BIOCHEM, V6, P475, DOI 10.1111/j.1432-1033.1968.tb00470.x; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HOLMGREN A, 1979, J BIOL CHEM, V254, P3664; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOOG JO, 1983, EUR J BIOCHEM, V136, P223, DOI 10.1111/j.1432-1033.1983.tb07730.x; HOPPER S, 1989, J BIOL CHEM, V264, P20438; KELTJENS JT, 1986, FEMS MICROBIOL LETT, V39, P259, DOI 10.1111/j.1574-6968.1986.tb01862.x; KLINTROT IM, 1984, EUR J BIOCHEM, V144, P417, DOI 10.1111/j.1432-1033.1984.tb08481.x; LIPMAN DJ, 1989, P NATL ACAD SCI USA, V86, P4412, DOI 10.1073/pnas.86.12.4412; LUNDELL DJ, 1978, J BIOL CHEM, V253, P3422; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCFARLAN SC, 1989, EUR J BIOCHEM, V179, P389, DOI 10.1111/j.1432-1033.1989.tb14565.x; MENG M, 1981, THESIS U MINNESOTA M; MOORE EC, 1964, J BIOL CHEM, V239, P3453; NEWTON GL, 1985, J BACTERIOL, V161, P438, DOI 10.1128/JB.161.1.438-441.1985; NIKKOLA M, 1991, J BIOL CHEM, V266, P16105; PAPAYANNOPOULOS IA, 1989, BIOCHEM BIOPH RES CO, V159, P1448, DOI 10.1016/0006-291X(89)92272-9; POLSON A, 1980, IMMUNOL COMMUN, V9, P495, DOI 10.3109/08820138009066011; RUSSEL M, 1990, J BACTERIOL, V172, P1923, DOI 10.1128/jb.172.4.1923-1929.1990; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLICHT F, 1985, NATURWISSENSCHAFTEN, V72, P328, DOI 10.1007/BF00454779; SCHONHEIT P, 1979, ARCH MICROBIOL, V123, P105, DOI 10.1007/BF00403508; SJOBERG BM, 1972, J BIOL CHEM, V247, P8063; STEEPER JR, 1970, ANAL BIOCHEM, V34, P123, DOI 10.1016/0003-2697(70)90092-8; STRUMEYER D, 1962, BIOCHEM PREP, V9, P52; THAUER RK, 1990, BIOCHIM BIOPHYS ACTA, V1018, P256, DOI 10.1016/0005-2728(90)90261-2; TSAI PK, 1980, J BIOL CHEM, V255, P1273; TSANG MLS, 1981, P NATL ACAD SCI-BIOL, V78, P7478, DOI 10.1073/pnas.78.12.7478; WOLFE RS, 1985, TRENDS BIOCHEM SCI, V10, P396, DOI 10.1016/0968-0004(85)90068-4; ZEIKUS JG, 1972, J BACTERIOL, V109, P707, DOI 10.1128/JB.109.2.707-713.1972	52	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10561	10569						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587836				2022-12-25	WOS:A1992HV09000053
J	POLAKIS, P; RUBINFELD, B; MCCORMICK, F				POLAKIS, P; RUBINFELD, B; MCCORMICK, F			PHOSPHORYLATION OF RAP1GAP INVIVO AND BY CAMP-DEPENDENT KINASE AND THE CELL-CYCLE P34CDC2 KINASE INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; GEL-ELECTROPHORESIS; EFFECTOR DOMAIN; RAS-P21 GTPASE; CDC2 KINASE; PROTEIN; BINDING; SEPARATION; INHIBITION; SEQUENCE	rap1GAP is a GTPase activating protein that specifically stimulates the GTP hydrolytic rate of the ras-related protein p21rap1. rap1GAP undergoes posttranslational modification that causes a substantial change in its mobility on sodium dodecyl sulfate-polyacrylamide gels. At least part of this modification is due to the phosphorylation. Expression of a rap1GAP cDNA in insect cells labeled with P-32(i) resulted in high level incorporation of radioactivity into serine residues of the expressed protein. Purified raplGAP was phosphorylated in vitro by cAMP-dependent kinase and the cell cycle p34cdc2 kinase. The molar ratio of incorporated phosphate/rap1GAP was approximately 3 by cAMP-dependent kinase and 2 by p34cdc2. The sites of phosphorylation by both kinases were localized to a 100-residue segment contained in the carboxyl-terminal region of the predicted primary structure of rap1GAP. Highly favorable recognition sequences for the two kinases are contained within this fragment and are proposed as the sites of phosphorylation. Treatment of SK-MEL-3 cells with dibutyryl cAMP promoted phosphorylation of rap1GAP in vivo. Based on the results of comparative phosphopeptide mapping the sites of phosphorylation in vivo and in vitro are identical.			POLAKIS, P (corresponding author), CETUS CORP,DEPT MOLEC BIOL,EMERYVILLE,CA 94608, USA.			Rubinfeld, Bonnee/0000-0001-9861-6775	NATIONAL CANCER INSTITUTE [U01CA051992] Funding Source: NIH RePORTER; NCI NIH HHS [CA51992-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLY E, 1991, NATURE, V350, P715, DOI 10.1038/350715a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HATA Y, 1990, J BIOL CHEM, V265, P7104; HILDEBRANDT E, 1989, ANAL BIOCHEM, V177, P407, DOI 10.1016/0003-2697(89)90075-4; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LAMB NJC, 1991, EMBO J, V10, P1523, DOI 10.1002/j.1460-2075.1991.tb07672.x; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUNOZ G, 1990, ANAL BIOCHEM, V190, P233, DOI 10.1016/0003-2697(90)90185-C; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; TOURNIER S, 1991, J BIOL CHEM, V266, P19018	28	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10780	10785						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587853				2022-12-25	WOS:A1992HV09000086
J	WALKER, B; KRISHNASASTRY, M; ZORN, L; KASIANOWICZ, J; BAYLEY, H				WALKER, B; KRISHNASASTRY, M; ZORN, L; KASIANOWICZ, J; BAYLEY, H			FUNCTIONAL EXPRESSION OF THE ALPHA-HEMOLYSIN OF STAPHYLOCOCCUS-AUREUS IN INTACT ESCHERICHIA-COLI AND IN CELL LYSATES - DELETION OF 5 C-TERMINAL AMINO-ACIDS SELECTIVELY IMPAIRS HEMOLYTIC-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; MEMBRANE DAMAGE; REGULATORY SUBUNIT; TOXIN; BINDING; SITE; MECHANISM; CHANNEL; GENE; MUTAGENESIS	The alpha-hemolysin gene from Staphylococcus aureus, excluding the 5' region encoding the hydrophobic leader sequence, was amplified from genomic DNA. The identity of the disputed C terminus has been confirmed and revisions made to the internal sequence. The hemolysin is expressed at high levels in Escherichia coli and has been purified to homogeneity from this source. In addition, active [S-35-Met]alpha-hemolysin of high specific radioactivity can be generated in an E. coli transcription-translation system. By criteria based on protein chemistry, and biological and electrophysiological assays, the recombinant polypeptide is closely similar to the staphylococcal polypeptide ruling out the possibility of functionally important posttranslational modifications in S. aureus. Convenient new assays utilizing the S-35-labeled polypeptide to measure erythrocyte binding, oligomer formation in detergent and on target cells, and hemolysis have been developed. They have been used to demonstrate that a deletion mutant of alpha-hemolysin, in which five C-terminal amino acids are absent, is severely compromised in its ability both to oligomerize and to lyse rabbit erythrocytes. The mutant polypeptide nevertheless binds tightly to erythrocytes as a monomer, strengthening the idea that oligomerization is required for cell lysis.	UNIV MASSACHUSETTS,CTR MED,GRAD SCH BIOMED SCI,WORCESTER,MA 01655; NIDDKD,BIOCHEM & METAB LAB,BETHESDA,MD 20892	University of Massachusetts System; University of Massachusetts Worcester; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	WALKER, B (corresponding author), WORCESTER FDN EXPTL BIOL INC,SHREWSBURY,MA 01545, USA.			Bayley, Hagan/0000-0003-2499-6116				ARBUTHNOTT JP, 1967, J BACTERIOL, V94, P1170, DOI 10.1128/JB.94.4.1170-1177.1967; BASHFORD CL, 1986, J BIOL CHEM, V261, P9300; BAYLEY H, 1991, MATER RES SOC SYMP P, V218, P69; BHAKDI S, 1983, TRENDS BIOCHEM SCI, V8, P134, DOI 10.1016/0968-0004(83)90237-2; BHAKDI S, 1991, IMMUNOL TODAY, V12, P318, DOI 10.1016/0167-5699(91)90007-G; BHAKDI S, 1981, P NATL ACAD SCI-BIOL, V78, P5475, DOI 10.1073/pnas.78.9.5475; BHAKDI S, 1984, INFECT IMMUN, V46, P318, DOI 10.1128/IAI.46.2.318-323.1984; BLOCH W, 1991, BIOCHEMISTRY-US, V30, P2735, DOI 10.1021/bi00225a001; CASSIDY P, 1976, BIOCHEMISTRY-US, V15, P2348, DOI 10.1021/bi00656a016; CASSIDY P, 1976, BIOCHEMISTRY-US, V15, P2342, DOI 10.1021/bi00656a015; CESCATTI L, 1991, J MEMBRANE BIOL, V119, P53, DOI 10.1007/BF01868540; CHRISTIE GE, 1981, P NATL ACAD SCI-BIOL, V78, P4180, DOI 10.1073/pnas.78.7.4180; COHEN SA, 1988, ANAL BIOCHEM, V174, P1, DOI 10.1016/0003-2697(88)90512-X; COOPER LZ, 1966, J BACTERIOL, V91, P1686, DOI 10.1128/JB.91.5.1686-1692.1966; ESSER AF, 1991, IMMUNOL TODAY, V12, P316, DOI 10.1016/0167-5699(91)90006-F; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; GRAY GS, 1984, INFECT IMMUN, V46, P615, DOI 10.1128/IAI.46.2.615-618.1984; HILDEBRAND A, 1991, J BIOL CHEM, V266, P17195; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; IKIGAI H, 1985, BIOCHEM BIOPH RES CO, V130, P175, DOI 10.1016/0006-291X(85)90398-5; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; JOHNSON KE, 1987, J BIOL CHEM, V262, P8636; KASIANOWICZ J J, 1991, Biophysical Journal, V59, p458A; KATO I, 1980, TOXICON, V18, P361, DOI 10.1016/0041-0101(80)90018-5; KEHOE M, 1983, INFECT IMMUN, V41, P1105, DOI 10.1128/IAI.41.3.1105-1111.1983; KRASILNIKOV OV, 1988, GEN PHYSIOL BIOPHYS, V7, P467; KRASILNIKOV OV, 1989, GEN PHYSIOL BIOPHYS, V8, P213; KURET J, 1988, J BIOL CHEM, V263, P9149; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESLEY SA, 1991, J BIOL CHEM, V266, P2632; MAKOFF AJ, 1989, NUCLEIC ACIDS RES, V17, P10191, DOI 10.1093/nar/17.24.10191; MENESTRINA G, 1986, J MEMBRANE BIOL, V90, P177, DOI 10.1007/BF01869935; Montal M, 1974, Methods Enzymol, V32, P545; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; OLINS PO, 1988, GENE, V73, P227, DOI 10.1016/0378-1119(88)90329-0; OLOFSSON A, 1990, J MOL BIOL, V214, P299, DOI 10.1016/0022-2836(90)90162-F; OREILLY M, 1986, MICROB PATHOGENESIS, V1, P125, DOI 10.1016/0882-4010(86)90015-X; PEDERZOLLI C, 1991, J MEMBRANE BIOL, V119, P41, DOI 10.1007/BF01868539; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SIX HR, 1973, BIOCHEMISTRY-US, V12, P2672, DOI 10.1021/bi00738a019; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THELESTAM M, 1988, TOXICON, V26, P51, DOI 10.1016/0041-0101(88)90137-7; THELESTAM M, 1991, BIOCHIM BIOPHYS ACTA, V1062, P245, DOI 10.1016/0005-2736(91)90399-S; TOBKES N, 1985, BIOCHEMISTRY-US, V24, P1915, DOI 10.1021/bi00329a017	45	88	94	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10902	10909						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587866				2022-12-25	WOS:A1992HV09000103
J	BURKE, CJ; SANYAL, G; BRUNER, MW; RYAN, JA; LAFEMINA, RL; ROBBINS, HL; ZEFT, AS; MIDDAUGH, CR; CORDINGLEY, MG				BURKE, CJ; SANYAL, G; BRUNER, MW; RYAN, JA; LAFEMINA, RL; ROBBINS, HL; ZEFT, AS; MIDDAUGH, CR; CORDINGLEY, MG			STRUCTURAL IMPLICATIONS OF SPECTROSCOPIC CHARACTERIZATION OF A PUTATIVE ZINC FINGER PEPTIDE FROM HIV-1 INTEGRASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; PROTEIN; PREDICTION; DOMAIN; POL; RECOGNITION; MUTAGENESIS; SELECTION	The N-terminal domain of human immunodeficiency virus (HIV-1) integrase (IN) contains the sequence motif His-Xaa3-His-Xaa23-Cys-Xaa2-Cys, which is strongly conserved in all retroviral and retrotransposon IN proteins. This structural motif constitutes a putative zinc finger in which a metal ion may be coordinately bound by the His and Cys residues. A recombinant peptide, IN(1-55), composed of the N-terminal 55 amino acids of HIV-1 IN was expressed in Escherichia coli and purified. Utilizing a combination of techniques including UV-visible absorption, circular dichroism, Fourier transform infrared, and fluorescence spectroscopies, we have demonstrated that metal ions (Zn2+, Co2+, and Cd2+) are bound with equimolar stoichiometry by IN(1-55). The liganded peptide assumes a highly ordered structure with increased alpha-helical content and exhibits remarkable, thermal stability. UV-visible difference spectra of the peptide-Co2+ complexes directly implicate thiols in metal coordination, and Co2+ d-d transitions in the visible range indicate that Co2+ is tetrahedrally coordinated. Mutant peptides containing conservative substitutions of one of the conserved His or either of the Cys residues displayed no significant Zn2+-induced conformational changes as monitored by CD and fluorescence spectra. We conclude that the N terminus of HIV-1 IN contains a metal-binding domain whose structure is stabilized by tetrahedral coordination of metal by histidines 12 and 16 and cysteines 40 and 43. A preliminary structural model for this zinc finger is presented.	MERCK SHARP & DOHME LTD,DEPT PHARMACEUT RES,W POINT,PA 19486; MERCK SHARP & DOHME LTD,DEPT VIRUS & CELL BIOL,W POINT,PA 19486	Merck & Company; Merck & Company								BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; Bertini I, 1984, Adv Inorg Biochem, V6, P71; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COPELAND RA, 1991, ARCH BIOCHEM BIOPHYS, V289, P53, DOI 10.1016/0003-9861(91)90441-K; Cotton F.A., 1980, ADV INORG CHEM, P768; CUNNINGHAM BC, 1991, SCIENCE, V253, P545, DOI 10.1126/science.1907025; DEVEREUX J, 1989, GCG SEQUENCE ANAL SO; DONEHOWER LA, 1984, P NATL ACAD SCI-BIOL, V81, P6461, DOI 10.1073/pnas.81.20.6461; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; FUJIWRA T, 1987, CELL, V54, P497; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GREEN LM, 1989, P NATL ACAD SCI USA, V86, P4047, DOI 10.1073/pnas.86.11.4047; HIPPENMEYER PJ, 1984, VIROLOGY, V137, P358, DOI 10.1016/0042-6822(84)90228-9; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; Kaptein R, 1991, CURR OPIN STRUC BIOL, V1, P63, DOI 10.1016/0959-440X(91)90013-J; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KAUPPINEN JK, 1981, APPL SPECTROSC, V35, P271, DOI 10.1366/0003702814732634; KHAN E, 1991, NUCLEIC ACIDS RES, V19, P851, DOI 10.1093/nar/19.4.851; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LEFEMINA RL, 1991, J VIROL, V65, P5624; LIN TH, 1989, PROTEINS, V5, P156, DOI 10.1002/prot.340050210; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MILLER WT, 1991, BIOCHEMISTRY-US, V30, P6970, DOI 10.1021/bi00242a023; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SCHWARTZBERG P, 1984, CELL, V37, P1043, DOI 10.1016/0092-8674(84)90439-2; SOUTH TL, 1990, BIOCHEM PHARMACOL, V40, P123, DOI 10.1016/0006-2952(90)90187-P; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P9808, DOI 10.1021/bi00494a008	34	155	157	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9639	9644						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577801				2022-12-25	WOS:A1992HT96500031
J	FLINK, IL; EDWARDS, JG; BAHL, JJ; LIEW, CC; SOLE, M; MORKIN, E				FLINK, IL; EDWARDS, JG; BAHL, JJ; LIEW, CC; SOLE, M; MORKIN, E			CHARACTERIZATION OF A STRONG POSITIVE CIS-ACTING ELEMENT OF THE HUMAN BETA-MYOSIN HEAVY-CHAIN GENE IN FETAL-RAT HEART-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; CREATINE-KINASE GENE; THYROID-HORMONE; SKELETAL-MUSCLE; ALPHA-MYOSIN; TRANSCRIPTIONAL CONTROL; VENTRICULAR MYOCARDIUM; REGULATED EXPRESSION; MOLECULAR-CLONING; COMPLETE SEQUENCE	A strong positive element within the proximal promoter region of the human beta-myosin heavy chain (beta-MHC) gene that is required for high level expression in primary cultures of fetal rat heart cells was localized by transient assays and DNase I footprinting to positions-277/-298. Using gel shift studies, this sequence was found to bind specifically at high affinity (K(d) almost-equal-to 4 X 10(-9) M) to a transcriptional factor (beta-F1) found in nuclear extracts from rabbit heart. Dimethyl sulfate interference studies suggested that beta-F1 may bind as a dimer to two hexameric imperfect direct repeats containing the consensus sequence 5'-(C/G)-T-G-(T/A)-G-G-3". Gel shift analyses suggested that beta-F1 is related to the M-CAT factor, which is known to control muscle-specific expression of the cardiac troponin T gene. A clustered mutation of the region between the putative binding half-sites and within the "M-CAT"-like domain abolished beta-MHC promoter activity. The sequence of the Positive element also contains binding motifs for several transcriptional factors that regulate viral and cellular genes, including AP4, AP5, TEF-1, and MyoD-like proteins. When multiple copies of the beta-MHC element were inserted downstream from the transcriptional initiation site of the thymidine kinase gene, it did not act as a classical enhancer, showing some dependence upon orientation.	UNIV ARIZONA,HLTH SCI CTR,CTR HEART,TUCSON,AZ 85724; UNIV ARIZONA,HLTH SCI CTR,DEPT INTERNAL MED,TUCSON,AZ 85724; UNIV ARIZONA,HLTH SCI CTR,DEPT PHYSIOL & PHARMACOL,TUCSON,AZ 85724; UNIV TORONTO,CTR CARDIOVASC RES,TORONTO M5G 1L5,ONTARIO,CANADA	University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona Health Sciences; University of Toronto					NHLBI NIH HHS [P01HL20984] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020984] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERGMAN Y, 1988, J IMMUNOL, V140, P2073; BERGSMA DJ, 1986, MOL CELL BIOL, V6, P2462, DOI 10.1128/MCB.6.7.2462; BOUVAGNET P, 1984, CIRC RES, V55, P794, DOI 10.1161/01.RES.55.6.794; BOUVAGNET PF, 1987, MOL CELL BIOL, V7, P4377, DOI 10.1128/MCB.7.12.4377; BRIGGS MM, 1990, DEV BIOL, V140, P253, DOI 10.1016/0012-1606(90)90075-T; CHANG KS, 1984, MOL CELL BIOL, V4, P2498, DOI 10.1128/MCB.4.11.2498; COOPER TA, 1984, SCIENCE, V226, P979, DOI 10.1126/science.6095446; CRIBBS LL, 1989, J BIOL CHEM, V264, P10672; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EMERSON CP, 1987, ANNU REV BIOCHEM, V56, P695, DOI 10.1146/annurev.bi.56.070187.003403; FLINK IL, 1990, J BIOL CHEM, V265, P11233; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GORZA L, 1984, CIRC RES, V54, P694, DOI 10.1161/01.RES.54.6.694; GUSTAFSON TA, 1986, CIRC RES, V59, P194, DOI 10.1161/01.RES.59.2.194; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; JAENICKE T, 1990, GENOMICS, V8, P194, DOI 10.1016/0888-7543(90)90272-V; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; JAYNES JB, 1986, MOL CELL BIOL, V6, P2855, DOI 10.1128/MCB.6.8.2855; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KOMURO I, 1988, CIRC RES, V62, P1075, DOI 10.1161/01.RES.62.6.1075; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LIEW CC, 1990, NUCLEIC ACIDS RES, V18, P3647, DOI 10.1093/nar/18.12.3647; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MATSUOKA R, 1988, AM J MED GENET, V29, P369, DOI 10.1002/ajmg.1320290217; MATSUOKA R, 1991, AM J MED GENET, V41, P537, DOI 10.1002/ajmg.1320410435; MEINNEL T, 1989, DEV BIOL, V131, P430, DOI 10.1016/S0012-1606(89)80015-6; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; MINTY A, 1986, MOL CELL BIOL, V6, P2137, DOI 10.1128/MCB.6.6.2137; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MIWA T, 1987, MOL CELL BIOL, V7, P2803, DOI 10.1128/MCB.7.8.2803; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; PARMACEK MS, 1989, J BIOL CHEM, V264, P13217; PERIASAMY M, 1984, J BIOL CHEM, V259, P3573; ROSENTHAL N, 1989, P NATL ACAD SCI USA, V86, P7780, DOI 10.1073/pnas.86.20.7780; SAUER RT, 1979, NATURE, V279, P396, DOI 10.1038/279396a0; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SINHA AM, 1982, P NATL ACAD SCI-BIOL, V79, P5847, DOI 10.1073/pnas.79.19.5847; TANIGAWA G, 1990, CELL, V62, P991, DOI 10.1016/0092-8674(90)90273-H; TAPSCOTT SJ, 1991, J CLIN INVEST, V87, P1133, DOI 10.1172/JCI115109; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; TSIKA RW, 1990, P NATL ACAD SCI USA, V87, P379, DOI 10.1073/pnas.87.1.379; TSONIS PA, 1988, NUCLEIC ACIDS RES, V16, P7745, DOI 10.1093/nar/16.15.7745; UETSUKI T, 1990, MOL CELL BIOL, V10, P2562, DOI 10.1128/MCB.10.6.2562; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YAMAUCHITAKIHARA K, 1989, P NATL ACAD SCI USA, V86, P3504, DOI 10.1073/pnas.86.10.3504; YU YT, 1989, MOL CELL BIOL, V9, P1839, DOI 10.1128/MCB.9.5.1839; YUTZEY KE, 1989, MOL CELL BIOL, V9, P1397, DOI 10.1128/MCB.9.4.1397	51	87	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9917	9924						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577822				2022-12-25	WOS:A1992HT96500073
J	REESE, JC; KATZENELLENBOGEN, BS				REESE, JC; KATZENELLENBOGEN, BS			CHARACTERIZATION OF A TEMPERATURE-SENSITIVE MUTATION IN THE HORMONE BINDING DOMAIN OF THE HUMAN ESTROGEN-RECEPTOR - STUDIES IN CELL-EXTRACTS AND INTACT-CELLS AND THEIR IMPLICATIONS FOR HORMONE-DEPENDENT TRANSCRIPTIONAL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROGESTERONE-RECEPTOR; GLUCOCORTICOID RECEPTOR; STEROID-BINDING; MAMMALIAN-CELLS; DNA; TRANSACTIVATION; IDENTIFICATION; PHARMACOLOGY; SEQUENCE; PROMOTER	A previous report from this laboratory (Reese, J. C., and Katzenellenbogen, B. S. (1991) J. Biol. Chem. 266, 10880-10887) identified an estrogen receptor (ER) mutant which had a similar binding affinity for estradiol as wild-type ER but displayed a dose-response shift for estradiol in transactivation studies. In this study, we have utilized hormone binding, DNA binding, and gene transfer experiments to further characterize this mutant, which contains an alanine substitution for a cysteine at amino acid 447 in the hormone binding domain of the receptor. Hormone binding studies indicate that the C447A receptor is a temperature-sensitive mutant, whose instability is only apparent at elevated temperatures, and that ligand can stabilize the mutant receptor. Western blot analysis reveals that the temperature-sensitive lose of hormone binding is not attributable to a degradation of receptor protein, but rather is an inactivation of the receptor's hormone binding ability. In addition to the loss in the hormone binding capacitY of the C447A mutant, this mutant shows a temperature-sensitive loss in the DNA binding ability of the receptor. Transactivation profiles of the mutant and wild-type receptors demonstrate that incubation of transfected cells with increasing concentrations of estradiol at more ambient temperatures shifts the mutant receptor's dose-response curves to the left, converging on the wild-type curve. Hence, these transactivation studies reveal that the dose-response shift observed for this mutant in cells reflects the measured instability of the hormone binding and DNA interaction of the C447A mutant that can be demonstrated in vitro. In addition, this temperature-sensitive ER mutant is of interest in that its DNA binding is now ligand-dependent with the result that transcriptional activation now parallels receptor occupancy by ligand, which is similar to other steroid hormone receptors.	UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,524 BURRILL HALL,407 S GOODWIN AVE,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign				reese, joseph/0000-0003-3578-4266	NCI NIH HHS [CA18119] Funding Source: Medline; NIGMS NIH HHS [GM07283] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA018119, R01CA018119] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGCHI MK, 1990, NATURE, V345, P547, DOI 10.1038/345547a0; BAGCHI MK, 1988, MOL ENDOCRINOL, V2, P1221, DOI 10.1210/mend-2-12-1221; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BROWN M, 1990, J BIOL CHEM, V265, P11238; BYRAVAN S, 1991, MOL ENDOCRINOL, V5, P752, DOI 10.1210/mend-5-6-752; CAIRNS W, 1991, J BIOL CHEM, V266, P11221; CHANG TC, 1990, J BIOL CHEM, V265, P8176; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEMARZO AM, 1991, P NATL ACAD SCI USA, V88, P72, DOI 10.1073/pnas.88.1.72; DENIS M, 1988, NATURE, V333, P686, DOI 10.1038/333686a0; DENIS M, 1989, J BIOL CHEM, V264, P6005; EDWARDS DP, 1989, MOL ENDOCRINOL, V3, P381, DOI 10.1210/mend-3-2-381; ELASHRY D, 1989, MOL ENDOCRINOL, V3, P1545, DOI 10.1210/mend-3-10-1545; FAWELL SE, 1989, MOL ENDOCRINOL, V3, P1002, DOI 10.1210/mend-3-6-1002; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOVINDAN MV, 1990, MOL ENDOCRINOL, V4, P417, DOI 10.1210/mend-4-3-417; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; GREENE GL, 1984, J STEROID BIOCHEM, V20, P51, DOI 10.1016/0022-4731(84)90188-2; HEINEMAN.SF, 1970, P NATL ACAD SCI USA, V67, P1122, DOI 10.1073/pnas.67.3.1122; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; JORDAN VC, 1984, PHARMACOL REV, V36, P245; KATZENELLENBOGEN BS, 1983, J STEROID BIOCHEM, V19, P59, DOI 10.1016/S0022-4731(83)80007-7; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; NORTHROP JP, 1985, J BIOL CHEM, V260, P6398; PAKDEL F, 1992, J BIOL CHEM, V267, P3429; PHAM TA, 1991, P NATL ACAD SCI USA, V88, P3125, DOI 10.1073/pnas.88.8.3125; PIKE JW, 1984, SCIENCE, V224, P879, DOI 10.1126/science.6326262; REESE JC, 1991, NUCLEIC ACIDS RES, V19, P6595, DOI 10.1093/nar/19.23.6595; REESE JC, 1991, J BIOL CHEM, V266, P10880; Sambrook J, 1989, MOL CLONING LABORATO; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SUZUKI DT, 1970, SCIENCE, V170, P695, DOI 10.1126/science.170.3959.695; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TZUKERMAN M, 1990, New Biologist, V2, P613; VANDERBILT JN, 1987, MOL ENDOCRINOL, V1, P68, DOI 10.1210/mend-1-1-68; WRENN CK, 1990, MOL ENDOCRINOL, V4, P1647, DOI 10.1210/mend-4-11-1647	41	43	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9868	9873						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577818				2022-12-25	WOS:A1992HT96500067
J	TSUNEOKA, M; MEKADA, E				TSUNEOKA, M; MEKADA, E			DEGRADATION OF A NUCLEAR-LOCALIZED PROTEIN IN MAMMALIAN COS CELLS, USING ESCHERICHIA-COLI BETA-GALACTOSIDASE AS A MODEL PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC ONCOGENE; GENE-PRODUCT; EXPRESSION; YEAST; PHOSPHORYLATION; SEQUENCE; SIGNAL; CYCLE	To investigate the mechanism of degradation of proteins localized in the nucleus, we constructed genes encoding modified Escherichia coli beta-galactosidases and expressed them in mammalian COS cells. When the beta-galactosidase with a nuclear localization signal from SV 40 T antigen was expressed in COS cells, the beta-galactosidase polypeptide was localized in the nuclei and was stable for at least 4 h. When 16 amino acid residues were deleted from the C-terminal end, the beta-galactosidase polypeptide was also observed in the nuclei but it was degraded rapidly, with a half-life of 1.6 h. When the nuclear localizing signal was replaced with a mutant sequence, which lacks nuclear targeting activity, the beta-galactosidase polypeptides were present throughout the cells rather than in the nuclei. The beta-galactosidase polypeptide with the complete C terminus was stable and the cytoplasmic truncated polypeptide was degraded at the same rate as the nuclear C terminus truncated polypeptide. The beta-galactosidase polypeptides with the complete C terminus were present as a tetramer as reported previously and had beta-galactosidase activity, but the C terminus truncated polypeptides were present as monomer and had no enzyme activity, indicating that C terminus truncated beta-galactosidase is malfolded. Together, the results suggest that a nuclear-localized malfolded protein is degraded as rapidly as a cytoplasmic malfolded protein.			TSUNEOKA, M (corresponding author), KURUME UNIV,INST LIFE SCI,2432-3 AIKAWA,KURUME,FUKUOKA 830,JAPAN.			Mekada, Eisuke/0000-0001-8858-4781				BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BEGUM N, 1990, J BIOL CHEM, V265, P11936; BEIMLING P, 1985, BIOCHEMISTRY-US, V24, P6349, DOI 10.1021/bi00344a005; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; FOWLER AV, 1966, SCIENCE, V154, P1027, DOI 10.1126/science.154.3752.1027; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KATZNELSON R, 1985, EUR J BIOCHEM, V146, P437, DOI 10.1111/j.1432-1033.1985.tb08670.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MCKNIGHT JL, 1981, J BIOL CHEM, V256, P9652; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; RECHSTEINER M, 1987, TRENDS BIOCHEM SCI, V12, P390; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SIMON R, 1990, MOL CELL BIOL, V10, P5609, DOI 10.1128/MCB.10.11.5609; SLAVICEK JM, 1988, EMBO J, V7, P3171, DOI 10.1002/j.1460-2075.1988.tb03184.x; TANAKA K, 1989, J CELL PHYSIOL, V139, P34, DOI 10.1002/jcp.1041390107; WANG S S, 1987, Journal of Biological Chemistry, V262, P6357	31	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9107	9111						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577746				2022-12-25	WOS:A1992HR85400063
J	WU, L; VERTINO, A; KOUDELKA, GB				WU, L; VERTINO, A; KOUDELKA, GB			NONCONTACTED BASES AFFECT THE AFFINITY OF SYNTHETIC P22-OPERATORS FOR P22-REPRESSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SPECIFICITY; LAC REPRESSOR; ALPHA-HELIX; DNA; OPERATOR; RESOLUTION	The affinity of synthetic P22 operators for P22 repressor varies with the base sequence at the operator's center. At 100 mm KCl, the affinity of these operators for P22 repressor varies over a 10-fold range. Dimethylsulfate protection experiments indicate that the central bases of the P22 operator are not contacted by the repressor. The K(D) for the complex of P22 repressor with an operator bearing central T-A bases (9T) increases less than 2-fold between 50 and 200 mm KCl, whereas the K(D) for the complex of repressor with an operator bearing central C-G bases (9C) increases 10-fold in the same salt range. The DNase I cleavage patterns of both bound and unbound P22 operators also vary with central base sequence. The DNase I pattern of the repressor-9C operator complex changes markedly with salt concentration, whereas that of the 9T operator-repressor complex does not. These changes in nuclease digestion pattern thereby mirror the salt-dependent changes in the P22 operator's affinity for repressor. P22 repressor protects the central base pair of the 9T operator from cleavage by the intercalative cleavage reagent Cu(I)-phenanthroline, while repressor does not protect the central bases of the 9C operator. Together these data indicate that central base pairs affect P22 operator strength by altering the structure of the unbound operator and the repressor-operator complex.	SUNY BUFFALO,DEPT BIOL SCI,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo			Koudelka, Gerald B./AAI-3738-2020	Koudelka, Gerald B./0000-0001-6280-0837	NIGMS NIH HHS [GM42138] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM042138, R01GM042138] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; ANDERSON JE, 1987, NATURE, V326, P888; BARKLEY MD, 1979, J CHEM PHYS, V70, P2991, DOI 10.1063/1.437838; CARLSON P, 1992, NATURE, V355, P89; CHEN CH, 1990, ANN REV BIOCH, V59, P7; DEANDA J, 1983, J BIOL CHEM, V258, P536; DEHASETH PL, 1977, BIOCHEMISTRY-US, V16, P4783, DOI 10.1021/bi00641a004; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; HOCHSCHILD A, 1983, CELL, V32, P319, DOI 10.1016/0092-8674(83)90451-8; JOHNSON AD, 1979, P NATL ACAD SCI USA, V76, P5061, DOI 10.1073/pnas.76.10.5061; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KOUDELKA GB, 1987, NATURE, V326, P886, DOI 10.1038/326886a0; KOUDELKA GB, 1988, P NATL ACAD SCI USA, V85, P4633, DOI 10.1073/pnas.85.13.4633; LIN S, 1972, J MOL BIOL, V72, P671, DOI 10.1016/0022-2836(72)90184-2; LOMONOSSOFF GP, 1981, J MOL BIOL, V149, P745, DOI 10.1016/0022-2836(81)90356-9; Maniatis T., 1982, MOL CLONING; MESSING J, 1983, METHOD ENZYMOL, V101, P29; POTEETE AR, 1980, J MOL BIOL, V137, P81, DOI 10.1016/0022-2836(80)90158-8; POTEETE AR, 1982, J MOL BIOL, V157, P21, DOI 10.1016/0022-2836(82)90511-3; Ptashne M., 1986, A GENETIC SWITCH; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SAUER RT, 1982, NATURE, V298, P447, DOI 10.1038/298447a0; SENN H, 1987, EUR BIOPHYS J BIOPHY, V14, P301, DOI 10.1007/BF00254895; SPASSKY A, 1985, BIOCHEMISTRY-US, V24, P8050, DOI 10.1021/bi00348a032; VEAL JM, 1991, BIOCHEMISTRY-US, V30, P1132, DOI 10.1021/bi00218a035; WHARTON RP, 1986, TRENDS BIOCHEM SCI, V11, P71, DOI 10.1016/0968-0004(86)90268-9; WHARTON RP, 1985, NATURE, V316, P601, DOI 10.1038/316601a0; WHARTON RP, 1984, CELL, V38, P361, DOI 10.1016/0092-8674(84)90491-4	29	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9134	9139						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577749				2022-12-25	WOS:A1992HR85400067
J	YADA, T; ARAI, M; SUZUKI, S; KIMATA, K				YADA, T; ARAI, M; SUZUKI, S; KIMATA, K			OCCURRENCE OF COLLAGEN AND PROTEOGLYCAN FORMS OF TYPE-IX COLLAGEN IN CHICK-EMBRYO CARTILAGE - PRODUCTION AND CHARACTERIZATION OF A COLLAGEN FORM-SPECIFIC ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE CHAIN(S); HUMAN-MELANOMA CELLS; MONOCLONAL-ANTIBODY; II COLLAGEN; POLYPEPTIDE; PROTEINS; CONTAINS; FIBRILS; DOMAIN; GLYCOSAMINOGLYCANS	Type IX collagen from chick embryonic cartilage is a proteoglycan bearing a single chondroitin sulfate chain covalently linked to the alpha-2(IX) polypeptide chain. We have isolated type IX collagen metabolically labeled with [H-3]proline using an antibody to type IX collagen and have found that the molecule is synthesized in two forms, a collagen form (COLIX) and a proteoglycan form (PGIX). In cultured chondrocytes, the two forms of type IX collagen showed a different ability to be deposited in the matrix. We have suggested the possibility that both forms may arise from an alternative substitution of a chondroitin sulfate chain to the NC3 domain of the alpha-2(IX) chain. Based on the reported amino acid sequence at the NC3 domain of alpha-2(IX), we have synthesized undecapeptides containing the sequence around the glycosaminoglycan attachment site of the alpha-2(IX) chain. Antibody against the peptide, which was raised in rabbit, only recognized COLIX and made it possible to distinguish COLIX from PGIX. Evidence shows that this could be due to a difference in antigenicity of the NC3 domain of the alpha-2(IX) chain between COLIX and PGIX caused by the substitution of a chondroitin sulfate chain to the serine residue in this domain. Therefore, this antibody may be useful as a probe for studies on the functions of glycosaminoglycan substitution in type IX collagen.	AICHI MED UNIV,INST MOLEC SCI MED,NAGAKUTE,AICHI 48011,JAPAN; SEIKAGAKU CORP,TOKYO RES INST,HIGASHIYAMATO 189,JAPAN	Aichi Medical University; Seikagaku Corporation								AYAD S, 1989, BIOCHEM J, V262, P753, DOI 10.1042/bj2620753; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; BOURIN MC, 1986, P NATL ACAD SCI USA, V83, P5924, DOI 10.1073/pnas.83.16.5924; BRUCKNER P, 1985, P NATL ACAD SCI USA, V82, P2608, DOI 10.1073/pnas.82.9.2608; BRUCKNER P, 1988, J BIOL CHEM, V263, P16911; BUMOL TF, 1984, J BIOL CHEM, V259, P2733; BUMOL TF, 1982, P NATL ACAD SCI-BIOL, V79, P1245, DOI 10.1073/pnas.79.4.1245; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; DUANCE VC, 1984, BIOCHEM J, V221, P885, DOI 10.1042/bj2210885; EYRE DR, 1987, FEBS LETT, V220, P337, DOI 10.1016/0014-5793(87)80842-6; FITCH JM, 1988, DEV BIOL, V128, P396, DOI 10.1016/0012-1606(88)90301-6; FITCH JM, 1989, DEVELOPMENT, V105, P85; Gordon MK, 1990, CURR OPIN CELL BIOL, V2, P833, DOI 10.1016/0955-0674(90)90080-X; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; HARPER JR, 1986, J BIOL CHEM, V261, P3600; HUBER S, 1986, J BIOL CHEM, V261, P5965; HUBER S, 1988, J BIOL CHEM, V263, P752; IRWIN MH, 1986, J BIOL CHEM, V261, P6281; JALKANEN S, 1988, J IMMUNOL, V141, P1615; KATO Y, 1978, J BIOL CHEM, V253, P2784; KIMATA K, 1978, BIOCHEM BIOPH RES CO, V85, P1431, DOI 10.1016/0006-291X(78)91163-4; KONOMI H, 1986, J BIOL CHEM, V261, P6742; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; LOHMANDER LS, 1979, J BIOL CHEM, V254, P551; MANN DM, 1990, J BIOL CHEM, V265, P5317; MCCORMICK D, 1987, P NATL ACAD SCI USA, V84, P4044, DOI 10.1073/pnas.84.12.4044; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MULLERGLAUSER W, 1986, J CELL BIOL, V102, P1931, DOI 10.1083/jcb.102.5.1931; NISHIMURA I, 1989, J BIOL CHEM, V264, P20033; NORO A, 1983, J BIOL CHEM, V258, P9323; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; RENNARD SI, 1981, ARCH BIOCHEM BIOPHYS, V207, P399, DOI 10.1016/0003-9861(81)90047-3; RODEN L, 1985, FED PROC, V44, P373; SHIMOKOMAKI M, 1990, ANN NY ACAD SCI, V580, P1, DOI 10.1111/j.1749-6632.1990.tb17912.x; TAKAGAKI K, 1990, J BIOL CHEM, V265, P854; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; VASIOS G, 1988, J BIOL CHEM, V263, P2324; VAUGHAN L, 1985, J BIOL CHEM, V260, P4758; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; YADA T, 1990, J BIOL CHEM, V265, P6992; YAMAGATA M, 1989, J BIOL CHEM, V264, P8012; YASUMOTO S, 1980, DEV GROWTH DIFFER, V22, P445	43	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9391	9397						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577766				2022-12-25	WOS:A1992HR85400104
J	KELLY, K; DAVIS, P; MITSUYA, H; IRVING, S; WRIGHT, J; GRASSMANN, R; FLECKENSTEIN, B; WANO, Y; GREENE, W; SIEBENLIST, U				KELLY, K; DAVIS, P; MITSUYA, H; IRVING, S; WRIGHT, J; GRASSMANN, R; FLECKENSTEIN, B; WANO, Y; GREENE, W; SIEBENLIST, U			A HIGH PROPORTION OF EARLY RESPONSE GENES ARE CONSTITUTIVELY ACTIVATED IN T-CELLS BY HTLV-I	ONCOGENE			English	Article							VIRUS TYPE-I; COLONY-STIMULATING FACTOR; LEUKEMIA-LYMPHOMA VIRUS; GROWTH-FACTORS ENCODES; DNA-BINDING PROTEINS; LONG TERMINAL REPEAT; ZINC FINGER PROTEIN; INTERLEUKIN-2 RECEPTOR; TRANS-ACTIVATION; TAX GENE	Immortalization of T cells by HTLV-I is mediated by the X region of the virus and probably involves transactivation of cellular genes. We show that T cells transformed by HTLV-I constitutively express a high proportion of early response genes that are normally transiently induced following antigenic or mitogenic activation of T cells. Thus, HTLV-I-infected T cells display an `early activation' phenotype that is distinct from the gene expression pattern of continuously dividing T cells. Ten early response genes representing a diverse array of functional categories were assayed. Four DNA-binding proteins/transcription factors including the p50 subunit of NF-kappa-B were evaluated. A protein(s) encoded by the X region of HTLV-I appeared to contribute to up-regulated expression of most, if not all, of the early response genes. For those genes that could be assayed, increased transcriptional rates, but not substantial changes in mRNA half-life, were demonstrated in the presence of pX-encoded proteins, suggesting that the transcriptional transactivator, Tax, affects the induction or maintenance of transcription for these mitogen-inducible genes. Therefore, Tax may mimic or interact with a component(s) of the signal transduction pathway activated by antigen or mitogen treatment. These data demonstrate that early response genes, some of which probably play roles in initiating or maintaining cellular proliferation, are frequent targets of HTLV-I activation.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; NCI,CLIN ONCOL PROGRAM,BETHESDA,MD 20892; NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892; UNIV ERLANGEN NURNBERG,INST KLIN & MOLEK VIROL,W-8520 ERLANGEN,GERMANY; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Erlangen Nuremberg; Duke University; Duke University	KELLY, K (corresponding author), NCI,PATHOL LAB,BETHESDA,MD 20892, USA.							BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BOHNLEIN E, 1989, J VIROL, V63, P1578; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHAN JY, 1986, P NATL ACAD SCI USA, V83, P8669, DOI 10.1073/pnas.83.22.8669; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GREEN JE, 1989, MOL CELL BIOL, V9, P4731, DOI 10.1128/MCB.9.11.4731; HATTORI T, 1981, BLOOD, V58, P645; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; INOUE J, 1987, P NATL ACAD SCI USA, V84, P3653, DOI 10.1073/pnas.84.11.3653; IRVING SG, 1989, MOL CELL BIOL, V9, P1034, DOI 10.1128/MCB.9.3.1034; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KELLY K, 1988, J BIOL CHEM, V263, P4828; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LILIENBAUM A, 1990, J VIROL, V64, P256, DOI 10.1128/JVI.64.1.256-263.1990; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MITSUYA H, 1984, SCIENCE, V225, P1484, DOI 10.1126/science.6206569; MIYATAKE S, 1988, MOL CELL BIOL, V8, P5581, DOI 10.1128/MCB.8.12.5581; MIYOSHI I, 1981, NATURE, V299, P640; MONTAGNE J, 1990, EMBO J, V9, P957, DOI 10.1002/j.1460-2075.1990.tb08194.x; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NYBORG JK, 1988, P NATL ACAD SCI USA, V85, P1457, DOI 10.1073/pnas.85.5.1457; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POPOVIC M, 1983, P NATL ACAD SCI-BIOL, V80, P5402, DOI 10.1073/pnas.80.17.5402; POTEAT HT, 1989, J VIROL, V63, P1604, DOI 10.1128/JVI.63.4.1604-1611.1989; RANGNEKAR VM, 1990, NUCLEIC ACIDS RES, V18, P2749, DOI 10.1093/nar/18.9.2749; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5489; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; SOOD AK, 1981, P NATL ACAD SCI-BIOL, V78, P616, DOI 10.1073/pnas.78.1.616; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TAN TH, 1989, J VIROL, V63, P3761, DOI 10.1128/JVI.63.9.3761-3768.1989; VARNUM BC, 1989, MOL CELL BIOL, V9, P3580, DOI 10.1128/MCB.9.8.3580; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOSHIDA M, 1987, ANNU REV IMMUNOL, V5, P541, DOI 10.1146/annurev.iy.05.040187.002545; ZANDOMENI R, 1982, P NATL ACAD SCI-BIOL, V79, P3167, DOI 10.1073/pnas.79.10.3167; ZIPFEL PF, 1989, J IMMUNOL, V142, P1582; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1034	61	43	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1463	1470						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630809				2022-12-25	WOS:A1992JE81300001
J	GOUT, E; BLIGNY, R; DOUCE, R				GOUT, E; BLIGNY, R; DOUCE, R			REGULATION OF INTRACELLULAR PH VALUES IN HIGHER-PLANT CELLS - C-13 AND P-31 NUCLEAR-MAGNETIC-RESONANCE STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACER-PSEUDOPLATANUS CELLS; EXTERNAL PH; P-31 NMR; PROTON TRANSPORT; PLASMA-MEMBRANE; CYTOPLASMIC PH; VACUOLAR PH; METABOLISM; NEUROSPORA	The regulation of the cytoplasmic and vacuolar pH values (pH(c) and pH(v)) in sycamore (Acer pseudoplatanus L.) cells was analyzed using P-31 and C-13 nuclear magnetic resonance spectroscopy. Suspension-cultured cells were compressed in the NMR tube and perfused with the help of an original arrangement enabling a tight control of the pH (external pH, pH(e)) of the carefully oxygenated circulating nutrient medium. Intracellular pH values were measured from the chemical shifts of: CH2-linked carboxyl groups of citric acid below pH 5.7; orthophosphate between pH 5.7 and 8.0; C-13-enriched bicarbonate over pH 8.0. pH(c) and pH(v) were independent of pH(e) over the range 4.5-7.5. In contrast intracellular pH values decreased rapidly below pH(e) 4.5 and increased progressively at pH(e) over 7.5. There was an acceleration in the rate of O2 consumption accompanied with a decrease in cytoplasmic ATP concentration as pH(e) decreased. When the rate of O2 consumption was approaching the uncoupled O2 uptake rate, a loss of pH(c) control was observed. It is concluded that as pH(e) decreased, the plasma membrane ATPase consumed more and more ATP to reject the invading H+ ions in order to maintain pH(c) at a constant value. Below pH(e) 4.5 the efficiency of the H+ pump to react to back leakage of H+ ions became insufficient, leading to an acidification of pH(c) and to an alkalinization of pH(e). On the other hand, over pH(e) 7.5 a passive influx of OH- ions was observed, and pH(c) increased proportionally to the increase of pH(e). Simultaneously appreciable amounts of organic acids (malate and citrate) were synthesized by cells during the course of the alkalinization of the cytoplasmic compartment. The synthesis of organic acids which partially counteract the alkalinization of the cytoplasmic compartment may result from a marked activation of the cytoplasmic phosphoenolpyruvate carboxylase induced by an increase in cytoplasmic bicarbonate concentration. The fluctuations of pH(v) followed a similar course to that of pH(c). It is concluded that the vacuole, which represents a potentially large H+ ions reservoir, can counteract H+ (or OH-) ion invasion observed at acidic (or alkaline) pH(e) contributing to the homeostasis of pH(c).	CEN,RESONANCE MAGNET BIOL & MED LAB,F-38041 GRENOBLE,FRANCE; UNIV GRENOBLE 1,F-38041 GRENOBLE,FRANCE; CEN,DEPT BIOL MOLEC & STRUCT,PHYSIOL CELLULAIRE VEGETALE LAB,F-38041 GRENOBLE,FRANCE	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)								BLIGNY R, 1976, PHYSIOL VEG, V14, P499; BLIGNY R, 1977, PLANT PHYSIOL, V59, P502, DOI 10.1104/pp.59.3.502; BLIGNY R, 1989, J BIOL CHEM, V264, P4888; BLIGNY R, 1989, NUCL MAGN RESON, P71; BUSH DR, 1989, PLANT PHYSIOL, V89, P1318, DOI 10.1104/pp.89.4.1318; DAVIES DD, 1986, PHYSIOL PLANTARUM, V67, P702, DOI 10.1111/j.1399-3054.1986.tb05081.x; DEAMER DW, 1987, J BIOENERG BIOMEMBR, V19, P457; EVANS FE, 1977, P NATL ACAD SCI USA, V74, P4909, DOI 10.1073/pnas.74.11.4909; FELLE H, 1987, J EXP BOT, V38, P340, DOI 10.1093/jxb/38.2.340; FOX GG, 1990, PLANT PHYSIOL, V93, P512, DOI 10.1104/pp.93.2.512; GADIAN DG, 1979, BIOL APPLICATIONS MA, P463; GENIX P, 1990, PLANT PHYSIOL, V94, P717, DOI 10.1104/pp.94.2.717; Gutmann I, 1974, METHOD ENZYMAT AN, P1585; KURKDJIAN A, 1989, ANNU REV PLANT PHYS, V40, P271, DOI 10.1146/annurev.pp.40.060189.001415; MARTIN JB, 1982, PLANT PHYSIOL, V70, P1156, DOI 10.1104/pp.70.4.1156; MATHIEU Y, 1986, PLANT PHYSIOL, V82, P846, DOI 10.1104/pp.82.3.846; NAVON G, 1979, BIOCHEMISTRY-US, V18, P4487, DOI 10.1021/bi00588a006; PFEFFER PE, 1986, PLANT PHYSIOL, V80, P77, DOI 10.1104/pp.80.1.77; PRADET A, 1983, ANNU REV PLANT PHYS, V34, P199, DOI 10.1146/annurev.pp.34.060183.001215; RAVEN JA, 1978, J EXP BOT, V29, P853, DOI 10.1093/jxb/29.4.853; RAVEN JA, 1988, NEW PHYTOL, V109, P1, DOI 10.1111/j.1469-8137.1988.tb00212.x; REBEILLE F, 1983, ARCH BIOCHEM BIOPHYS, V225, P143, DOI 10.1016/0003-9861(83)90017-6; REBEILLE F, 1982, ARCH BIOCHEM BIOPHYS, V219, P371, DOI 10.1016/0003-9861(82)90168-0; ROBERTS JKM, 1980, NATURE, V283, P870, DOI 10.1038/283870a0; ROBERTS JKM, 1981, BIOCHEMISTRY-US, V20, P5389, DOI 10.1021/bi00522a006; ROBERTS JKM, 1982, PLANT PHYSIOL, V69, P1344, DOI 10.1104/pp.69.6.1344; ROBERTS JKM, 1981, BIOCHIM BIOPHYS ACTA, V639, P53, DOI 10.1016/0304-4173(81)90005-7; ROBY C, 1987, J BIOL CHEM, V262, P5000; ROSSIGNOL M, 1982, BIOCHIM BIOPHYS ACTA, V684, P195, DOI 10.1016/0005-2736(82)90005-0; SANDERS D, 1982, J GEN PHYSIOL, V80, P377, DOI 10.1085/jgp.80.3.377; SLAYMAN CL, 1987, J BIOENERG BIOMEMBR, V19, P1; SZE H, 1984, PHYSIOL PLANTARUM, V61, P683, DOI 10.1111/j.1399-3054.1984.tb05191.x; TORIMITSU K, 1984, PLANT CELL PHYSIOL, V25, P1403, DOI 10.1093/oxfordjournals.pcp.a076851	33	131	136	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13903	13909						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629190				2022-12-25	WOS:A1992JD32500021
J	NAKANISHI, T; NAKANO, A; NOMURA, K; SEKIMIZU, K; NATORI, S				NAKANISHI, T; NAKANO, A; NOMURA, K; SEKIMIZU, K; NATORI, S			PURIFICATION, GENE CLONING, AND GENE DISRUPTION OF THE TRANSCRIPTION ELONGATION-FACTOR S-II IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ASCITES TUMOR-CELLS; FACTOR-SII; STIMULATORY FACTORS; YEAST; DNA; SEQUENCE; SIMILARITY; ANTIBODY	Saccharomyces cerevisiae S-II was purified to near homogeneity as a protein stimulating RNA polymerase II. Four of seven lysyl endopeptidase-digested fragments of S-II were located in the PPR2 sequence reported previously. Analysis of a genomic clone of S-II revealed that S-II and PPR2 are the same protein consisting of 309 amino acid residues, and frame shifts were found in the sequence of PPR2 gene reported previously. Yeast S-II and mouse S-II showed high similarity in their amino acid sequences, especially in their amino-terminal and carboxyl-terminal regions. A gene disruption experiment showed that an S-II null mutant was not lethal under usual growth conditions, indicating that S-II is not essential for the growth of yeast.	UNIV TOKYO,FAC PHARMACEUT SCI,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC SCI,DEPT BIOL,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo; University of Tokyo			Nakano, Akihiko/A-6420-2016; Nakano, Akihiko/G-4942-2014; Nakano, Akihiko/C-6185-2009	Nakano, Akihiko/0000-0003-3635-548X; Nakano, Akihiko/0000-0003-3635-548X; 				AHN BY, 1990, MOL CELL BIOL, V10, P5433, DOI 10.1128/MCB.10.10.5433; ANDREADIS A, 1982, CELL, V31, P319, DOI 10.1016/0092-8674(82)90125-8; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BITTER GA, 1983, ANAL BIOCHEM, V128, P294, DOI 10.1016/0003-2697(83)90378-0; DAVIES CJ, 1990, NATURE, V345, P298, DOI 10.1038/345298a0; HIRASHIMA S, 1988, J BIOL CHEM, V263, P3858; HORIKOSHI M, 1985, J BIOL CHEM, V260, P5739; HUBERT JC, 1983, EMBO J, V2, P2071, DOI 10.1002/j.1460-2075.1983.tb01702.x; KANAI A, 1991, J BIOCHEM-TOKYO, V109, P674, DOI 10.1093/oxfordjournals.jbchem.a123439; KESZENMANPEREYRA D, 1988, CURR GENET, V13, P21, DOI 10.1007/BF00365751; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MARSHALL TK, 1990, NUCLEIC ACIDS RES, V18, P6293, DOI 10.1093/nar/18.21.6293; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; NATORI S, 1982, MOL CELL BIOCHEM, V46, P173; RAPPAPORT J, 1987, J BIOL CHEM, V262, P5227; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1989, J BIOL CHEM, V264, P10799; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADOGO M, 1980, J BIOL CHEM, V255, P12; SEKIMIZU K, 1979, BIOCHEMISTRY-US, V18, P1582, DOI 10.1021/bi00575a031; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; UENO K, 1979, NATURE, V277, P145, DOI 10.1038/277145a0; VALENZUELA P, 1978, METHOD CELL BIOL, V19, P11; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; YOO OJ, 1991, NUCLEIC ACIDS RES, V19, P1073, DOI 10.1093/nar/19.5.1073	29	87	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13200	13204						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618824				2022-12-25	WOS:A1992JB74600019
J	TOMITA, T; WATANABE, M; YASUDA, T				TOMITA, T; WATANABE, M; YASUDA, T			INFLUENCE OF MEMBRANE FLUIDITY ON THE ASSEMBLY OF STAPHYLOCOCCUS-AUREUS ALPHA-TOXIN, A CHANNEL-FORMING PROTEIN, IN LIPOSOME MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							Y1 TUMOR-CELLS; PLASMA-MEMBRANE; PORE FORMATION; EARLY EVENTS; CHOLESTEROL; DAMAGE; MECHANISM; BILAYERS; BINDING	By use of multilamellar phosphatidylcholine (PC) liposomes of different acyl composition and cholesterol content as model membranes, we studied whether or not membrane fluidity affects the assembly process of Staphylococcus aureus alpha-toxin. Under conditions using fluid and solid membranes, we assayed accessibility (or hemolytic activity) of liposome-bound alpha-toxin to rabbit erythrocytes added, hexamerization of membrane-bound toxin using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under nondenaturating conditions, and susceptibility of liposome-bound toxin to trypsin digestion. Our data indicated 1) that alpha-toxin bound to PC membrane as a hemolytically active monomer (or reversibly bound state); 2) that when the membrane was fluidized either by phase transition of PC or by inclusion of cholesterol over 20 mol %, the hemolytically active monomer of the toxin was irreversibly converted to nonhemolytic monomer (and/or unstable oligomer) in a first-order kinetics with a t1/2 of about 1 min, and thereafter hexamerization of the toxin gradually proceeded in the following 60-90 min; 3) that alpha-toxin might have different topology and/or conformation in PC membrane, depending on the presence or absence of cholesterol in the PC membrane; and 4) that coexistence of unsaturated acyl chain-carrying PC and cholesterol was a prerequisite for efficient hexamerization of alpha-toxin in membrane. Thus, increase in membrane fluidity promoted the assembly process of S. aureus alpha-toxin.	OKAYAMA UNIV, SCH MED, OKAYAMA 700, JAPAN	Okayama University	TOMITA, T (corresponding author), UNIV TOKYO, INST MED SCI, 4-6-1 SHIROKANEDAI, MINATO KU, TOKYO 108, JAPAN.							BASHFORD CL, 1986, J BIOL CHEM, V261, P9300; BELMONTE G, 1987, EUR BIOPHYS J BIOPHY, V14, P349; BERNHEIMER AW, 1965, ANN NY ACAD SCI, V128, P112, DOI 10.1111/j.1749-6632.1965.tb11633.x; BHAKDI S, 1984, INFECT IMMUN, V46, P318, DOI 10.1128/IAI.46.2.318-323.1984; BHAKDI S, 1987, REV PHYSIOL BIOCH P, V107, P147, DOI 10.1007/BFb0027646; BHAKDI S, 1988, J EXP MED, V168, P527, DOI 10.1084/jem.168.2.527; BLOMQVIST L, 1986, INFECT IMMUN, V53, P636, DOI 10.1128/IAI.53.3.636-640.1986; Chapman D., 1973, FORM FUNCTION PHOSPH, P117; DAVIS PJ, 1981, BIOCHEMISTRY-US, V20, P3633, DOI 10.1021/bi00515a051; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FORTI S, 1989, EUR J BIOCHEM, V181, P767, DOI 10.1111/j.1432-1033.1989.tb14790.x; FREER JH, 1982, PHARMACOL THERAPEUT, V19, P55, DOI 10.1016/0163-7258(82)90042-0; FREER JH, 1968, J BACTERIOL, V95, P1153, DOI 10.1128/JB.95.3.1153-1168.1968; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; GERLACH E, 1963, BIOCHEM Z, V337, P477; HARSHMAN S, 1989, J BIOL CHEM, V264, P14978; IKIGAI H, 1987, J BIOL CHEM, V262, P2156; IKIGAI H, 1987, J BIOL CHEM, V262, P2150; IKIGAI H, 1985, BIOCHEM BIOPH RES CO, V130, P175, DOI 10.1016/0006-291X(85)90398-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGEE MP, 1983, INFECT IMMUN, V39, P439, DOI 10.1128/IAI.39.1.439-444.1983; MOELLBY, 1983, STAPHYLOCOCCI STAPHY, V2, P619; REICHWEIN J, 1987, INFECT IMMUN, V55, P2940, DOI 10.1128/IAI.55.12.2940-2944.1987; THELESTAM M, 1988, TOXICON, V26, P51, DOI 10.1016/0041-0101(88)90137-7; TOBKES N, 1985, BIOCHEMISTRY-US, V24, P1915, DOI 10.1021/bi00329a017; VANDIJCK PWM, 1976, BIOCHIM BIOPHYS ACTA, V455, P576, DOI 10.1016/0005-2736(76)90326-6; VERMA SP, 1976, BIOCHIM BIOPHYS ACTA, V436, P307, DOI 10.1016/0005-2736(76)90196-6; WATANABE M, 1987, BIOCHIM BIOPHYS ACTA, V898, P257, DOI 10.1016/0005-2736(87)90065-4	30	68	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13391	13397						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618841				2022-12-25	WOS:A1992JB74600048
J	ALBAGLI, O; FLOURENS, A; CREPIEUX, P; BEGUE, A; STEHELIN, D; LEPRINCE, D				ALBAGLI, O; FLOURENS, A; CREPIEUX, P; BEGUE, A; STEHELIN, D; LEPRINCE, D			PHYLOGENY OF THE P68C-ETS-1 AMINO-TERMINAL TRANSACTIVATING DOMAIN REVEALS SOME HIGHLY CONSERVED STRUCTURAL FEATURES	ONCOGENE			English	Note								The chicken c-ets-1 locus gives rise to two distinct transcription factors differing only in their structurally and functionally unrelated N-termini. One of these transcription factors, p54c-ets-1, contains a specific, short (27 amino acids), hydrophilic N-terminus encoded by a single exon, I54, that is widely conserved among vertebrates. The other one, p68c-ets-1, the cellular counterpart of the viral ets oncogene product, differs in the replacement of the I54 by two exons, termed alpha and beta encoding a larger (71 amino acids), hydrophobic N-terminus which, in contrast to I54, exhibits properties of a transactivating domain. To date the alpha and beta exons have only been found in chicken. Here, we demonstrate the existence of the alpha and beta-exons in other avian species (quail and duck) and the existence of the alpha exon in reptiles (turtle). However, none of them could be detected in mammals. Our results strongly suggest that, in contrast to the phylogenetically well-conserved I54 exon, the alpha-exon is restricted to reptilian species (birds and 'true' reptiles), whereas the beta-exon is detectable so far only in birds. Comparison of their amino acid sequences reveals that the alpha-exon and to a much greater extent the beta-exon have diverged faster than the I54 exon. In addition, we show that the N- and C-terminal thirds of the alpha-exon and the highly hydrophobic nature of the alpha-beta-encoded sequence are heavily conserved features and thus likely to be required for function as a transactivating domain in p68c-ets-1 and possibly in the viral P135gag-myb-ets transforming protein.	INST PASTEUR, CNRS, URA 1160, 1 RUE CALMETTE, F-59019 LILLE, FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			Crepieux, Pascale/X-3217-2019	Leprince, Dominique/0000-0002-1999-0775				BEVERLEY SM, 1984, J MOL EVOL, V21, P1, DOI 10.1007/BF02100622; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CHEN JH, 1990, ONCOGENE RES, V5, P277; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FRASER N, 1991, NATURE, V349, P278, DOI 10.1038/349278a0; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; GEGONNE A, 1987, MOL CELL BIOL, V7, P806, DOI 10.1128/MCB.7.2.806; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HOPP TP, 1983, MOL IMMUNOL, V20, P483, DOI 10.1016/0161-5890(83)90029-9; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1990, ONCOGENE RES, V5, P255; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; RAULF F, 1989, J NEUROSCI RES, V24, P81, DOI 10.1002/jnr.490240112; REISZ RR, 1991, NATURE, V349, P324, DOI 10.1038/349324a0; SCHNEIKERT J, 1992, IN PRESS ONCOGENE; SEEGER MA, 1990, EMBO J, V9, P2977, DOI 10.1002/j.1460-2075.1990.tb07490.x; STIEGLER P, 1990, NUCLEIC ACIDS RES, V18, P5298, DOI 10.1093/nar/18.17.5298; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; VANDENBUNDER B, 1989, DEVELOPMENT, V107, P265; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WOOD WM, 1991, MOL ENDOCRINOL, V5, P1049, DOI 10.1210/mend-5-8-1049	27	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1992	7	7					1435	1439						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620554				2022-12-25	WOS:A1992HZ97100024
J	HATCH, GM; VANCE, DE				HATCH, GM; VANCE, DE			STIMULATION OF SPHINGOMYELIN BIOSYNTHESIS BY BREFELDIN-A AND SPHINGOMYELIN BREAKDOWN BY OKADAIC ACID TREATMENT OF RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GH3 PITUITARY-CELLS; PROTEIN KINASE-C; PHORBOL ESTERS; LIPOPROTEIN SECRETION; FATTY-ACIDS; HL-60 CELLS; PHOSPHATIDYLCHOLINE; GOLGI; DIFFERENTIATION; SPHINGOLIPIDS	Studies on sphingomyelin metabolism in rat hepatocytes were facilitated by the use of choline-deficient cells which allowed for the rapid labeling of phosphatidylcholine and as a result sphingomyelin. Pulse and pulse-chase studies with [methyl-H-3]choline and [methyl-H-3]methionine demonstrated that both compounds were effectively used for sphingomyelin biosynthesis and that newly made and pre-existing phosphatidylcholine could be used for sphingomyelin biosynthesis. When hepatocytes were incubated with brefeldin A, there was a 2.4-fold stimulation of the conversion of phosphatidylcholine into sphingomyelin. Since brefeldin A causes collapse of the cis/medial Golgi into the endoplasmic reticulum the stimulation of sphingomyelin biosynthesis could be due to more rapid access of the labeled phosphatidylcholine in the endoplasmic reticulum to sphingomyelin synthase in the collapsed Golgi. Forskolin inhibited the brefeldin A-induced stimulation of sphingomyelin biosynthesis. To investigate whether or not phosphorylation reactions regulate sphingomyelin metabolism, hepatocytes were incubated with okadaic acid, a potent inhibitor of protein phosphatases 1 and 2A. Rather than stimulating sphingomyelin biosynthesis, okadaic acid enhanced the catabolism of sphingomyelin. In contrast, a cyclic AMP analogue and forskolin had no effect on sphingomyelin biosynthesis or catabolism. Surprisingly, other pulse-chase studies demonstrated that okadaic acid stimulated the catabolism of only newly made sphingomyelin. The brefeldin A and okadaic acid effects were independent of lysosomal involvement. Subcellular fractionation studies revealed that brefeldin A and okadaic acid effects were generalized in all sphingomyelin containing membranes. The brefeldin A studies suggest that the rate of transfer of phosphatidylcholine from the endoplasmic reticulum to the Golgi might be limiting for sphingomyelin biosynthesis. The okadaic acid studies indicate that the catabolism of sphingomyelin by a sphingomyelinase is regulated by an unidentified protein kinase and by either protein phosphatase 1 and/or 2A activity in hepatocytes.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2S2,ALBERTA,CANADA	University of Alberta	HATCH, GM (corresponding author), UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON T6G 2S2,ALBERTA,CANADA.							BAISTED DJ, 1988, BIOCHEM J, V253, P693, DOI 10.1042/bj2530693; BARENHOLZ Y, 1982, PHOSPHOLIPIDS, P129; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; ESKO JD, 1981, J BIOL CHEM, V256, P7388; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HATCH GM, 1991, BIOCHIM BIOPHYS ACTA, V1081, P25, DOI 10.1016/0005-2760(91)90245-D; JECKEL D, 1990, FEBS LETT, V261, P155, DOI 10.1016/0014-5793(90)80659-7; KIM MY, 1991, J BIOL CHEM, V266, P484; KISS Z, 1988, FEBS LETT, V240, P221, DOI 10.1016/0014-5793(88)80372-7; KOLESNICK RN, 1990, J BIOL CHEM, V265, P18803; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; KOLESNICK RN, 1989, J BIOL CHEM, V264, P11688; KOLESNICK RN, 1988, J BIOL CHEM, V263, P6534; KOVAL M, 1991, BIOCHIM BIOPHYS ACTA, V1082, P113, DOI 10.1016/0005-2760(91)90184-J; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPPINCOTTSCHWARTZ J, 1991, J CELL BIOL, V112, P567, DOI 10.1083/jcb.112.4.567; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MERRILL AH, 1988, BIOCHEMISTRY-US, V27, P340, DOI 10.1021/bi00401a051; MESSMER TO, 1989, J NUTR, V119, P534, DOI 10.1093/jn/119.4.534; NELSON DH, 1982, P NATL ACAD SCI-BIOL, V79, P6690, DOI 10.1073/pnas.79.21.6690; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PELECH SL, 1983, J BIOL CHEM, V258, P6782; PELECH SL, 1981, J BIOL CHEM, V256, P8283; PELECH SL, 1983, BIOCHEM J, V216, P729; SAMBORSKI RW, 1990, J BIOL CHEM, V265, P18322; SPENCE MW, 1989, PHOSPHATIDYLCHOLINE, P185; TOKMAKJIAN S, 1979, CAN J BIOCHEM CELL B, V57, P566, DOI 10.1139/o79-071; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; VANCE JE, 1986, J BIOL CHEM, V261, P4486; VANCE JE, 1988, J BIOL CHEM, V263, P5898; White D.A., 1973, FORM FUNCTION PHOSPH; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374; YAO ZM, 1988, J BIOL CHEM, V263, P2998	40	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12443	12451						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618752				2022-12-25	WOS:A1992HZ48300014
J	PACCAUD, JP; SIDDLE, K; CARPENTIER, JL				PACCAUD, JP; SIDDLE, K; CARPENTIER, JL			INTERNALIZATION OF THE HUMAN INSULIN-RECEPTOR - THE INSULIN-INDEPENDENT PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; CYTOPLASMIC DOMAIN; MEDIATED INTERNALIZATION; ULTRASTRUCTURAL ANALYSIS; 3T3-L1 ADIPOCYTES; KINASE-ACTIVITY; DOWN-REGULATION; PROTEIN-KINASE; OWN RECEPTOR; COATED PITS	Internalization of the human insulin receptor requires the activation by insulin of the intrinsic kinase of the receptor. However, even in the absence of kinase activation, insulin receptors slowly enter the cells. In the present study, we adressed the question of this insulin-independent pathway of internalization. To that end, we traced insulin receptor internalization with a monoclonal antibody (mAb 83-14) directed against the alpha-subunit of the human insulin receptor. Internalization of this antibody was followed in Chinese hamster ovary (CHO) cells transfected with either normal (CHO.HIRC2) or kinase-deficient (CHO.A1018) human insulin receptors. The internalization rate of I-125-mAb 83-14 was comparable in CHO cells expressing kinase-active or kinase-inactive receptors and was similar to that observed for I-125-insulin in CHO.A1018 cells. Moreover, in CHO.HIRC2 cells, the internalization of I-125-mAb 83-14 was identical with that of its I-125-Fab fragments. Thus, mAb 83-14 represents an appropriate tool to study the constitutive internalization of the insulin receptor. Internalization of insulin receptors tagged with I-125-mAb 83-14 was unaffected by cytochalasin B, which excluded a macropinocytotic process. By contrast, internalization was sensitive to hypertonia, which abrogates clathrin-coated pits-mediated endocytosis. The implication of clathrin-coated pits in this internalization process was directly demonstrated by quantitative electron microscopic autoradiography, which showed that I-125-mAb 83-14 present on the nonvillous domain of the cell surface preferentially associate with clathrin-coated pits at all time points.	UNIV CAMBRIDGE, DEPT CLIN BIOCHEM, CAMBRIDGE CB2 2QR, ENGLAND	University of Cambridge	PACCAUD, JP (corresponding author), UNIV GENEVA, UNIV MED CTR, DEPT MORPHOL, CH-1211 GENEVA, SWITZERLAND.							BACKER JM, 1990, J BIOL CHEM, V265, P16450; BRINDLE NPJ, 1990, BIOCHEM J, V268, P615, DOI 10.1042/bj2680615; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CARPENTIER JL, 1991, CELL REGUL, V2, P41, DOI 10.1091/mbc.2.1.41; CARPENTIER JL, 1989, DIABETOLOGIA, V32, P627; CARPENTIER JL, 1992, P NATL ACAD SCI USA, V89, P162, DOI 10.1073/pnas.89.1.162; CARPENTIER JL, 1982, J CELL BIOL, V95, P73, DOI 10.1083/jcb.95.1.73; CARPENTIER JL, 1981, J CELL BIOL, V91, P17, DOI 10.1083/jcb.91.1.17; CARPENTIER JL, 1985, DIABETES, V34, P1002, DOI 10.2337/diabetes.34.10.1002; CARPENTIER JL, 1989, CELL REGUL, V138, P519; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COBB MH, 1983, BIOCHIM BIOPHYS ACTA, V738, P1; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; FAN JY, 1983, J HISTOCHEM CYTOCHEM, V31, P859, DOI 10.1177/31.7.6343480; FREYCHET P, 1971, P NATL ACAD SCI USA, V68, P1833, DOI 10.1073/pnas.68.8.1833; GEIGER D, 1989, EXP CELL RES, V185, P33, DOI 10.1016/0014-4827(89)90034-7; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HEUSER JE, 1987, J CELL BIOL, V105, P1999, DOI 10.1083/jcb.105.5.1999; ILONDO MM, 1986, P NATL ACAD SCI USA, V83, P6460, DOI 10.1073/pnas.83.17.6460; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LARKIN JM, 1986, J CELL BIOL, V103, P2619, DOI 10.1083/jcb.103.6.2619; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LYEN KR, 1983, DIABETES, V32, P648, DOI 10.2337/diab.32.7.648; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; PARHAM P, 1986, HDB EXPT IMMUNOLOGY; PRIGENT SA, 1990, J BIOL CHEM, V265, P9970; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; ROTHENBERG P, 1990, HDB EXPT PHARM INSUL, V92, P209; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; ROTHENBERGER S, 1987, CELL, V49, P423, DOI 10.1016/0092-8674(87)90295-9; SALISBURY JL, 1983, METHOD ENZYMOL, V98, P368; SMITH RM, 1991, J BIOL CHEM, V266, P17522; SMITH RM, 1983, J CELL PHYSIOL, V115, P199, DOI 10.1002/jcp.1041150215; SMITH RM, 1985, J CELL PHYSIOL, V123, P167, DOI 10.1002/jcp.1041230204; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; SOOS MA, 1989, P NATL ACAD SCI USA, V86, P5217, DOI 10.1073/pnas.86.14.5217; STEELEPERKINS G, 1990, J BIOL CHEM, V265, P9458; THIES RS, 1990, J BIOL CHEM, V265, P10132; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; VANDEURS B, 1989, INT REV CYTOL, V117, P131; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WILLINGHAM MC, 1978, J CELL BIOL, V78, P480, DOI 10.1083/jcb.78.2.480; ZICK Y, 1983, J BIOL CHEM, V258, P3431	51	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					13101	13106						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618809				2022-12-25	WOS:A1992HZ48300103
J	PAN, GH; SADOWSKI, PD				PAN, GH; SADOWSKI, PD			LIGATION ACTIVITY OF FLP RECOMBINASE - THE STRAND LIGATION ACTIVITY OF A SITE-SPECIFIC RECOMBINASE USING AN ACTIVATED DNA SUBSTRATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MECHANISM; MUTANTS	The FLP protein of the 2-mu-m plasmid of yeast belongs to the integrase family of site-specific recombinases whose members form a covalent bond between a conserved tyrosine of the recombinase and the 3'-phosphoryl group at the site of cleavage. We have made an activated DNA substrate and have shown that FLP can promote efficient strand ligation without forming a covalent intermediate with the DNA substrate. The strand ligation activity of FLP is independent of its ability to cleave DNA. Since site-specific recombinases are members of the larger class of topoisomerases, these findings may be generally applicable to other members of this class of enzymes.	UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto								ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; AMIN A, 1991, MOL CELL BIOL, V11, P4497, DOI 10.1128/MCB.11.9.4497; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; Cox M. M., 1989, MOBILE DNA, P661; CRAIG NL, 1988, ANNU REV GENET, V22, P77; EVANS BR, 1990, J BIOL CHEM, V265, P18504; FRIESEN H, 1992, IN PRESS J MOL BIOL, V224; PARSONS RL, 1988, MOL CELL BIOL, V8, P3303, DOI 10.1128/MCB.8.8.3303; PARSONS RL, 1990, J BIOL CHEM, V265, P4527; PRASAD PV, 1987, P NATL ACAD SCI USA, V84, P2189, DOI 10.1073/pnas.84.8.2189; PROTEAU G, 1986, NUCLEIC ACIDS RES, V14, P4787, DOI 10.1093/nar/14.12.4787	12	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12397	12399						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618744				2022-12-25	WOS:A1992HZ48300002
J	KIKUCHI, Y; SASAKI, N				KIKUCHI, Y; SASAKI, N			HYPERPROCESSING OF TRANSFER-RNA BY THE CATALYTIC RNA OF RNASE-P - CLEAVAGE OF A NATURAL TRANSFER-RNA WITHIN THE MATURE TRANSFER-RNA SEQUENCE AND EVIDENCE FOR AN ALTERED CONFORMATION OF THE SUBSTRATE TRANSFER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETROVIRUS-LIKE PARTICLES; COPIA; DROSOPHILA; ENZYME	In the transposon copia-related retrovirus-like particles of Drosophila, a 39-nucleotide-long fragment from the 5'-region of Drosophila initiator methionine tRNA (tRNA(i)Met) is used as the primer for copia minus-strand reverse transcription. This primer tRNA(i)Met fragment is thought to be produced by cleavage within the mature tRNA(i)Met sequence. We call this cleavage hyperprocessing. We have previously reported that catalytic RNA of RNase P from Escherichia coli (M1RNA) cleaves the synthetic tRNA(i)Met precursor in vitro at several sites within the mature tRNA sequence. Based on this result, we proposed a model for formation of the primer tRNA fragment involving RNase P. Here we show that natural tRNA(i)Met prepared from Drosophila adult flies can be cleaved by M1RNA. Using mutant tRNA(i)Met substrates, we also show that these cleavages are dependent on the occurrence of an altered conformation of the tRNA substrate. This is evidence that a tRNA can exist in aqueous solution at least in part in an altered conformation.			KIKUCHI, Y (corresponding author), MITSUBISHI KASEI INST LIFE SCI, DEPT MOLEC BIOL, 11 MINAMIOOYA, MACHIDA, TOKYO 194, JAPAN.							ABELSON J, 1979, ANNU REV BIOCHEM, V48, P1035, DOI 10.1146/annurev.bi.48.070179.005131; ALTMAN S, 1989, ADV ENZYMOL RAMB, V62, P1; AMEMIYA Y, 1988, NATURE, V336, P89, DOI 10.1038/336089a0; BEIER H, 1984, EMBO J, V3, P351, DOI 10.1002/j.1460-2075.1984.tb01810.x; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HALL KB, 1989, BIOCHEMISTRY-US, V28, P5794, DOI 10.1021/bi00440a014; Jowett T., 1986, DROSOPHILA, P275; KIKUCHI Y, 1986, NATURE, V323, P824, DOI 10.1038/323824a0; KIKUCHI Y, 1989, AGR BIOL CHEM TOKYO, V53, P2005, DOI 10.1080/00021369.1989.10869574; KIKUCHI Y, 1990, P NATL ACAD SCI USA, V87, P8105, DOI 10.1073/pnas.87.20.8105; Krupp G., 1983, MODIFIED NUCLEOSIDES, VII, P11; Maniatis T., 1982, MOL CLONING; MCCLAIN WH, 1987, SCIENCE, V238, P527, DOI 10.1126/science.2443980; SHIBA T, 1983, NATURE, V302, P119, DOI 10.1038/302119a0; SILVERMAN S, 1979, NUCLEIC ACIDS RES, V6, P421, DOI 10.1093/nar/6.2.421	15	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11972	11976						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601867				2022-12-25	WOS:A1992HY94700050
J	TAKI, T; ROKUKAWA, C; KASAMA, T; KON, K; ANDO, S; ABE, T; HANDA, S				TAKI, T; ROKUKAWA, C; KASAMA, T; KON, K; ANDO, S; ABE, T; HANDA, S			HUMAN MECONIUM GANGLIOSIDES - CHARACTERIZATION OF A NOVEL I-TYPE GANGLIOSIDE WITH THE NEUAC-ALPHA-2-6GAL STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-MILK; ERYTHROCYTE-MEMBRANES; GLYCOSPHINGOLIPIDS; OLIGOSACCHARIDES; HEXASACCHARIDE	Three monosialogangliosides containing the NeuAc-alpha-2-6Gal structure have been detected in human meconium by immunological analysis using a monoclonal antibody, MSG-15, and purified by repeated silica beads column chromatography. One was previously shown to be NeuAc-alpha-2-6Gal-beta-1-4GlcNAc-beta-1-3Gal-beta-1-4Glc-beta-1-1Cer. The remaining two were characterized by proton NMR, fast atom bombardment mass spectrometry, methylation analysis by gas chromatography-mass spectrometry, and immunological studies, and their structures were concluded to be as follows. [GRAPHICS] The second ganglioside has the same structure that was isolated from bovine buttermilk (Takamizawa, K., Iwamori, M., Mutai, M., and Nagai, Y. (1986) J. Biol. Chem. 261, 5625-5630), and this is the first description of the occurrence of the ganglioside with the branched structure with two N-acetyllactosamines linked to lactosylceramide via beta-1-6 and beta-1-3 in human tissues. The third ganglioside is a novel ganglioside with blood group I-type and a NeuAc-alpha-2-6Gal structure.	TOKYO MED & DENT UNIV,BIOMED ANAL LAB,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,DEPT BIOCHEM,ITABASHI KU,TOKYO 173,JAPAN; KOSEI HOSP,DEPT OBSTET & GYNECOL,SHIZUOKA 420,JAPAN	Tokyo Medical & Dental University (TMDU)	TAKI, T (corresponding author), TOKYO MED & DENT UNIV,FAC MED,DEPT BIOCHEM,1-5-45 YUSHIMA,BUNKYO KU,TOKYO 113,JAPAN.							CHIEN JL, 1978, J BIOL CHEM, V253, P4031; HAKOMORI S, 1983, BIOCHEM BIOPH RES CO, V113, P791, DOI 10.1016/0006-291X(83)91069-0; IWAMORI M, 1988, FEBS LETT, V233, P134, DOI 10.1016/0014-5793(88)81370-X; KARLSSON KA, 1979, J BIOL CHEM, V254, P9311; KARLSSON KA, 1981, J BIOL CHEM, V256, P3512; KOBATA A, 1972, J BIOL CHEM, V247, P1525; KOBATA A, 1972, ARCH BIOCHEM BIOPHYS, V150, P273, DOI 10.1016/0003-9861(72)90036-7; MANSSON JE, 1986, FEBS LETT, V196, P259, DOI 10.1016/0014-5793(86)80259-9; MYOGA A, 1988, CANCER RES, V48, P1512; NILSSON O, 1985, BIOCHIM BIOPHYS ACTA, V835, P577, DOI 10.1016/0005-2760(85)90127-4; NILSSON O, 1981, FEBS LETT, V133, P197, DOI 10.1016/0014-5793(81)80504-2; SLOMIANY BL, 1977, CHEM PHYS LIPIDS, V20, P57, DOI 10.1016/0009-3084(77)90055-X; SVENNERHOLM L, 1973, J BIOL CHEM, V248, P740; TAKAMIZAWA K, 1986, J BIOL CHEM, V261, P5625; TAKI T, 1988, LIPIDS, V23, P192, DOI 10.1007/BF02535457; TAKI T, 1990, CANCER RES, V50, P1284; TARRAGO MT, 1988, ARCH BIOCHEM BIOPHYS, V267, P353, DOI 10.1016/0003-9861(88)90041-0; UENO K, 1982, BIOCHEM BIOPH RES CO, V105, P681, DOI 10.1016/0006-291X(82)91488-7; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; WATANABE K, 1979, J BIOL CHEM, V254, P8223; WIEGANDT H, 1973, H-S Z PHYSIOL CHEM, V354, P1049, DOI 10.1515/bchm2.1973.354.2.1049; YAMASHITA K, 1977, ARCH BIOCHEM BIOPHYS, V182, P546, DOI 10.1016/0003-9861(77)90536-7	22	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11811	11817						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601853				2022-12-25	WOS:A1992HY94700029
J	WANG, YC; RUBENSTEIN, PA				WANG, YC; RUBENSTEIN, PA			SPLICING OF 2 ALTERNATIVE EXON PAIRS IN BETA-TROPOMYOSIN PRE-MESSENGER-RNA IS INDEPENDENTLY CONTROLLED DURING MYOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE; ALPHA-TROPOMYOSIN; STRIATED-MUSCLE; SINGLE GENE; CELL LINE; ISOFORMS; CHICKEN; MOUSE; IDENTIFICATION; NONMUSCLE	Two known tissue-specific tropomyosin (TM) isoforms are produced from the rodent beta-TM gene. Skeletal muscle beta-TM uses the alternative exons 6b and 9a and the exon 9a-associated poly(A) site. Fibroblast and smooth muscle TM-1 use exons 6a and 9b and the exon-9b associated poly(A) site. We have identified a new skeletal muscle, beta-TM isoform, beta-TM2. Beta-TM2 contains exon 6b (muscle) and exon 9b (nonmuscle). Full-length beta-TM2 cDNA clones were isolated from a cDNA library of mouse muscle BC3H1 cells. Its mRNA was also found in mouse skeletal muscle tissue but not in other tissues. Beta-TM2 mRNA level and protein synthesis are differentiation-dependent, with a transient high level in the early stages of myogenesis both in BC3H1 cells and in mouse embryo limbs. Trace amounts of beta-TM3 mRNA, the other hybrid form (exons 6a + 9a), were found in less differentiated BC3H1 cells, mouse uterus, heart, and 3T3 fibroblasts but not skeletal muscle tissue. Thus, the selection of the two alternative exons appears to be controlled independently. Furthermore, during myogenesis, there is a sequential switch in the internal alternative exon, the terminal exon, and the poly(A) site from the nonmuscle to the muscle type.	UNIV IOWA,COLL MED,DEPT BIOCHEM,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,CTR CARDIOVASC RES,IOWA CITY,IA 52242	University of Iowa; University of Iowa				Rubenstein, Peter/0000-0003-1225-4414	NHLBI NIH HHS [HL-14388] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; CAPLAN AI, 1983, SCIENCE, V221, P921, DOI 10.1126/science.6348946; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUMMINS P, 1974, BIOCHEM J, V141, P43, DOI 10.1042/bj1410043; DAVIS LG, 1986, BASIC METHODS MOL BI, P143; DORVAL BC, 1991, SCIENCE, V252, P1823, DOI 10.1126/science.2063195; DORVAL BC, 1991, J MOL BIOL, V221, P837, DOI 10.1016/0022-2836(91)80179-X; EPSTEIN HF, 1991, SCIENCE, V251, P1039, DOI 10.1126/science.1998120; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORRYSCHAUDIES S, 1991, J BIOL CHEM, V266, P13821; FORRYSCHAUDIES S, 1990, J MOL BIOL, V211, P321, DOI 10.1016/0022-2836(90)90354-O; GOUXPELLETAN M, 1990, EMBO J, V9, P241, DOI 10.1002/j.1460-2075.1990.tb08101.x; GUO W, 1991, GENE DEV, V5, P2096, DOI 10.1101/gad.5.11.2096; HELFMAN DM, 1990, GENE DEV, V4, P98, DOI 10.1101/gad.4.1.98; HELFMAN DM, 1989, NUCLEIC ACIDS RES, V17, P5633, DOI 10.1093/nar/17.14.5633; HELFMAN DM, 1984, J BIOL CHEM, V259, P4136; HELFMAN DM, 1986, MOL CELL BIOL, V6, P3582, DOI 10.1128/MCB.6.11.3582; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LIBRI D, 1989, J BIOL CHEM, V264, P2935; LIBRI D, 1991, SCIENCE, V252, P1842, DOI 10.1126/science.2063196; MANIATIS T, 1982, MOL CLONING LABORATO, P458; MCINNES C, 1988, BIOCHIM BIOPHYS ACTA, V951, P117, DOI 10.1016/0167-4781(88)90031-0; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ONTELL M, 1984, AM J ANAT, V171, P133, DOI 10.1002/aja.1001710202; RICHARDSON CC, ENZYMES, V2, P299; RUIZOPAZO N, 1987, J BIOL CHEM, V262, P4755; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUBERT D, 1974, J CELL BIOL, V61, P398, DOI 10.1083/jcb.61.2.398; WANG YC, 1992, J BIOL CHEM, V267, P2728; WANG YC, 1988, J CELL BIOL, V106, P797, DOI 10.1083/jcb.106.3.797; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAMAWAKIKATAOKA Y, 1985, J BIOL CHEM, V260, P4440; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	34	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12004	12010						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601870				2022-12-25	WOS:A1992HY94700055
J	YAFFE, MB; BEEGEN, H; ECKERT, RL				YAFFE, MB; BEEGEN, H; ECKERT, RL			BIOPHYSICAL CHARACTERIZATION OF INVOLUCRIN REVEALS A MOLECULE IDEALLY SUITED TO FUNCTION AS AN INTERMOLECULAR CROSS-BRIDGE OF THE KERATINOCYTE CORNIFIED ENVELOPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL-CELLS; CIRCULAR-DICHROISM; LINKED ENVELOPE; BETA-TURNS; PROTEINS; TRANSGLUTAMINASE; PEPTIDES; LINKING; GENE; DIFFERENTIATION	Involucrin is a 68-kDa precursor of the keratinocyte cornified envelope. During keratinocyte terminal differentiation glutamine residues of involucrin become covalently cross-linked to other envelope precursors via covalent epsilon-(gamma-glutamyl)lysine bonds. In the present study we examine the secondary and tertiary structure of human involucrin using computer algorithms, circular dichroism, and electron microscopy. Our results indicate that involucrin is an extended, flexible, rod-shaped molecule that has a length of 460 angstrom, an axial ratio of 30:1 and possesses between 50 and 75% alpha-helical content. Glutamine residues are circumferentially distributed along the length of the alpha-helical segments of the molecule, a distribution that is conserved in all species. We hypothesize that this distribution of glutamine residues together with the elongated shape of the molecule permits optimal interaction of involucrin glutamyl side chains with the lysine residues of other para-membranous proteins during transglutaminase-mediated cross-linking. Moreover, its long length allows involucrin to cross-link molecules that are separated by substantial distances in the cornified envelope. These properties allow a single involucrin molecule to form multiple cross-links, in multiple spatial planes, with other envelope precursors. Thus, the structure of involucrin is that of an ideal intermolecular cross-bridge.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT DERMATOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT REPROD BIOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043751] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07653] Funding Source: Medline; NIAMS NIH HHS [AR39750] Funding Source: Medline; NIGMS NIH HHS [GM43751] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDER AJ, 1973, METHOD ENZYMOL, V27, P675; BLANK GS, 1986, ANN NY ACAD SCI, V466, P467, DOI 10.1111/j.1749-6632.1986.tb38425.x; BRADLEY EK, 1990, J MOL BIOL, V215, P607, DOI 10.1016/S0022-2836(05)80172-X; BUXMAN MM, 1976, BIOCHIM BIOPHYS ACTA, V452, P356, DOI 10.1016/0005-2744(76)90185-6; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P554; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHEN GC, 1977, ANAL LETT, V10, P1195, DOI 10.1080/00032717708067855; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; ECKERT RL, 1984, P NATL ACAD SCI-BIOL, V81, P4321, DOI 10.1073/pnas.81.14.4321; ETOH Y, 1986, BIOCHEM BIOPH RES CO, V136, P51, DOI 10.1016/0006-291X(86)90875-2; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GORODESKI GI, 1989, ENDOCRINOLOGY, V126, P399; Green H, 1980, Harvey Lect, V74, P101; GREEN NM, 1972, J BIOL CHEM, V247, P6284; HENNESSEY JP, 1981, BIOCHEMISTRY-US, V20, P1085, DOI 10.1021/bi00508a007; HOLZWARTH G, 1965, J AM CHEM SOC, V87, P218, DOI 10.1021/ja01080a015; KIM PS, 1984, NATURE, V307, P329, DOI 10.1038/307329a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANNING MC, 1988, BIOPHYS CHEM, V31, P77, DOI 10.1016/0301-4622(88)80011-5; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; MATOLTSY AG, 1966, J INVEST DERMATOL, V46, P127, DOI 10.1038/jid.1966.19; MAYS C, 1981, BIOCHEMISTRY-US, V20, P2810, DOI 10.1021/bi00513a016; MCLACHLAN AD, 1983, J MOL BIOL, V164, P605, DOI 10.1016/0022-2836(83)90053-0; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; NAGASAWA M, 1964, J AM CHEM SOC, V86, P538, DOI 10.1021/ja01058a002; ODERMATT E, 1982, J MOL BIOL, V159, P109, DOI 10.1016/0022-2836(82)90034-1; OGAWA H, 1976, J BIOL CHEM, V251, P7281; PHILLIPS M, 1990, J BIOL CHEM, V265, P7804; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; RORKE EA, 1991, J INVEST DERMATOL, V97, P543, DOI 10.1111/1523-1747.ep12481579; SAXENA VP, 1971, P NATL ACAD SCI USA, V68, P969, DOI 10.1073/pnas.68.5.969; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SIMON M, 1988, J BIOL CHEM, V263, P18093; SIMON M, 1985, CELL, V40, P677, DOI 10.1016/0092-8674(85)90216-8; SIMON M, 1984, CELL, V36, P827, DOI 10.1016/0092-8674(84)90032-1; SUN TT, 1976, CELL, V9, P511, DOI 10.1016/0092-8674(76)90033-7; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; TSENG H, 1990, MOL BIOL EVOL, V7, P293; TSENG H, 1988, CELL, V54, P491, DOI 10.1016/0092-8674(88)90070-0; WOOLFSON DN, 1990, FEBS LETT, V277, P185, DOI 10.1016/0014-5793(90)80839-B; WRIGLEY NG, 1968, J ULTRA MOL STRUCT R, V24, P454, DOI 10.1016/S0022-5320(68)80048-6; YANG JT, 1982, MICRODOMAINS POLYM S, P311	46	63	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12233	12238						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601889				2022-12-25	WOS:A1992HY94700087
J	PIERCE, RA; KOLODZIEJ, ME; PARKS, WC				PIERCE, RA; KOLODZIEJ, ME; PARKS, WC			1,25-DIHYDROXYVITAMIN-D(3) REPRESSES TROPOELASTIN EXPRESSION BY A POSTTRANSCRIPTIONAL MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; ELASTIN GENE-EXPRESSION; MESSENGER-RNA STABILITY; GROWTH-FACTOR-BETA; 5'-FLANKING REGION; DEVELOPMENTAL REGULATION; FUNCTIONAL PROMOTER; RAT TROPOELASTIN; HETEROGENEITY; INDUCTION	Tropoelastin expression is down-regulated by exposure to 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), and we present data indicating that this repression is primarily controlled by a posttranscriptional mechanism. Steady-state and functional levels of tropoelastin mRNA were coordinately repressed by 10(-7) M 1,25 (OH)2D3 in fetal bovine chondrocytes, but transcription, as determined by nuclear runoff assay, was not appreciably influenced in fetal bovine chondrocytes or in rat lung fibroblasts. Similarly, exposure to 1,25(OH)2D3 did not influence chloramphenicol acetyltransferase activity expressed by a human tropoelastin promoter-expression construct in either cell type. Exposure to cycloheximide had little effect on tropoelastin mRNA levels in control cells but partially restored tropoelastin mRNA levels in cells pretreated with 1,25(OH)2D3 and prevented repression when added together with 1,25(OH)2D3. Similarly, simultaneous exposure to actinomycin D and 1,25(OH)2D3 attenuated the down-regulation of tropoelastin. These data indicate that repression of tropoelastin steady-state mRNA levels by 1,25(OH)2D3 is primarily mediated by a posttranscriptional mechanism that requires both transcription and protein synthesis for full effect.	WASHINGTON UNIV, JEWISH HOSP ST LOUIS,MED CTR,DIV DERMATOL, 216 S KINGSHIGHWAY BLVD, ST LOUIS, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL)			Parks, William C./AAH-6786-2021		NHLBI NIH HHS [HL-41040] Funding Source: Medline; NIAMS NIH HHS [AR-07824] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL041040] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BADESCH DB, 1989, BIOCHEM BIOPH RES CO, V160, P382, DOI 10.1016/0006-291X(89)91667-7; BARSHAVIT Z, 1983, P NATL ACAD SCI-BIOL, V80, P5907, DOI 10.1073/pnas.80.19.5907; BASHIR MM, 1989, J BIOL CHEM, V264, P8887; BERK JL, 1991, J BIOL CHEM, V266, P3192; Bittar, 1993, ADV MOL CELL BIOL, P133, DOI [10.1016/S1569-2558(08)60201-5, DOI 10.1016/S1569-2558(08)60201-5]; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHEN YQ, 1992, IN PRESS J INVEST DE; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIDSON JM, 1986, REGULATION MATRIX AC, P177; DEAK SB, 1988, J BIOL CHEM, V263, P13504; DUPRET JM, 1987, J BIOL CHEM, V262, P16553; FAZIO MJ, 1990, J INVEST DERMATOL, V94, P191, DOI 10.1111/1523-1747.ep12874495; FOSTER JA, 1990, J GERONTOL, V45, pB113, DOI 10.1093/geronj/45.4.B113; FRANCESCHI RT, 1988, J BIOL CHEM, V263, P18938; FROMAN G, 1987, J BIOL CHEM, V262, P6564; GERSTENFELD LC, 1990, ENDOCRINOLOGY, V126, P1599, DOI 10.1210/endo-126-3-1599; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARRISON JR, 1989, ENDOCRINOLOGY, V125, P327, DOI 10.1210/endo-125-1-327; HINEK A, 1991, CONNECT TISSUE RES, V26, P155, DOI 10.3109/03008209109152434; ICHIRO T, 1990, BIOCHEM BIOPH RES CO, V168, P850, DOI 10.1016/0006-291X(90)92399-K; INDIK Z, 1990, EXTRACELLULAR MATRIX, P221; KAHARI VM, 1990, J BIOL CHEM, V265, P9485; KATO Y, 1990, P NATL ACAD SCI USA, V87, P6522, DOI 10.1073/pnas.87.17.6522; KUHN C, 1976, LAB INVEST, V34, P372; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; LICHTLER A, 1989, J BIOL CHEM, V264, P3072; LIU JM, 1988, BIOCHEM BIOPH RES CO, V154, P895, DOI 10.1016/0006-291X(88)90224-0; MAYELAFSHAR S, 1988, J BIOL CHEM, V263, P4355; MCGOWAN SE, 1990, AM J RESP CELL MOL, V3, P369, DOI 10.1165/ajrcmb/3.4.369; MECHAM RP, 1987, METHOD ENZYMOL, V144, P232; MINGHETTI PP, 1988, FASEB J, V2, P3043, DOI 10.1096/fasebj.2.15.2847948; NOGUCHI A, 1990, PEDIATR RES, V28, P379, DOI 10.1203/00006450-199010000-00015; PARKS WC, 1988, J BIOL CHEM, V263, P4416; PARKS WC, 1990, AM J RESP CELL MOL, V2, P399, DOI 10.1165/ajrcmb/2.5.399; PARKS WC, 1989, ELASTIN ELASTASES, V1, P213; PARKS WC, 1992, IN PRESS MATRIX, V12; PIERCE RA, 1990, BIOCHEMISTRY-US, V29, P9677, DOI 10.1021/bi00493a024; PROSSER IW, 1991, CONNECT TISSUE RES, V25, P265, DOI 10.3109/03008209109029162; PROSSER IW, 1989, AM J PATHOL, V135, P1073; RAVID A, 1984, BIOCHEM BIOPH RES CO, V123, P163, DOI 10.1016/0006-291X(84)90394-2; RUSSELL J, 1986, ENDOCRINOLOGY, V119, P2864, DOI 10.1210/endo-119-6-2864; Sachs A, 1990, CURR OPIN CELL BIOL, V2, P1092, DOI 10.1016/0955-0674(90)90161-7; SCHWARTZ Z, 1989, J BONE MINER RES, V4, P199; SHAPIRO DJ, 1987, BIOESSAYS, V6, P221, DOI 10.1002/bies.950060507; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TOBLER A, 1988, J CLIN INVEST, V81, P1819, DOI 10.1172/JCI113525; WRENN DS, 1987, J BIOL CHEM, V262, P2244; YEH H, 1989, BIOCHEMISTRY-US, V28, P2365, DOI 10.1021/bi00432a003	51	72	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11593	11599						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597486				2022-12-25	WOS:A1992HX16900100
J	SWAROOP, M; BRADLEY, K; OHURA, T; TAHARA, T; ROPER, MD; ROSENBERG, LE; KRAUS, JP				SWAROOP, M; BRADLEY, K; OHURA, T; TAHARA, T; ROPER, MD; ROSENBERG, LE; KRAUS, JP			RAT CYSTATHIONINE BETA-SYNTHASE GENE ORGANIZATION AND ALTERNATIVE SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPIONYL-COA CARBOXYLASE; SULFUR AMINO-ACIDS; ESCHERICHIA-COLI; S-ADENOSYLMETHIONINE; NUCLEOTIDE-SEQUENCE; CDNA CLONING; HUMAN-LIVER; DNA; BIOSYNTHESIS; SUBUNIT	We elucidated the structure and alternative splicing patterns of the rat cystathionine beta-synthase gene. The gene is 20-25 kilobase pairs long, and its coding region is divided into 17 exons. These are alternatively spliced, forming four distinct mRNAs (types I through IV). The predicted open reading frames encode proteins of 61.5, 39, 60, and 52.5 kDa, respectively. Exons 13 and 16 are used alternatively and mutually exclusively. Exon 13 includes a stop codon and encodes the unique carboxyl-terminal sequence found in types II and IV. Exon 16 is present only in type I. Types I and III, which differ by 42 nucleotides (exon 16), are the predominant synthase mRNA forms in rat liver. Seventeen arginine peptides from pure liver synthase matched the deduced amino acid sequences of types I matched III. These two polypeptides are detectable in liver extracts; each exhibits enzymatic activity when expressed in transfected Chinese hamster cells. Synthase shows substantial sequence similarity with pyridoxal 5'-phosphate dependent enzymes from lower organisms. Similarity of synthase to Escherichia coli O-acetylserine (thiol)-lyase (cysK) is 52%; E. coli tryptophan synthase beta-chain (trpB), 36%; yeast serine deaminase, 33%. Lysine 116 in synthase aligns with the established pyridoxyllysine residue of these enzymes suggesting that it is the pyridoxal 5'-phosphate binding residue.	UNIV COLORADO,SCH MED,DEPT PEDIAT C233,DENVER,CO 80262; YALE UNIV,SCH MED,DEPT HUMAN GENET,NEW HAVEN,CT 06510	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Yale University				Swaroop, Manju/0000-0002-0576-1664	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026651] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009527] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 26651] Funding Source: Medline; NIDDK NIH HHS [DK 09527] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELFAIZA J, 1986, P NATL ACAD SCI USA, V83, P867, DOI 10.1073/pnas.83.4.867; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; BYRNE CR, 1988, J BACTERIOL, V170, P3150, DOI 10.1128/jb.170.7.3150-3157.1988; ERICKSON PF, 1990, BIOCHEM J, V269, P335, DOI 10.1042/bj2690335; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINKELSTEIN JD, 1984, J BIOL CHEM, V259, P9508; FINKELSTEIN JD, 1984, BIOCHEM BIOPH RES CO, V118, P14, DOI 10.1016/0006-291X(84)91060-X; FINKELSTEIN JD, 1975, BIOCHEM BIOPH RES CO, V66, P81, DOI 10.1016/S0006-291X(75)80297-X; FINKELSTEIN JD, 1983, FED PROC, V42, pA2789; GIOVANELLI J, 1987, METHOD ENZYMOL, V143, P419; GOSS SJ, 1986, J CELL SCI, V82, P309; HORWICH AL, 1984, SCIENCE, V224, P1068, DOI 10.1126/science.6372096; KIELLANDBRANDT MC, 1984, CARLSBERG RES COMMUN, V49, P567, DOI 10.1007/BF02908685; KONDO K, 1987, J BIOL CHEM, V262, P8648; KORACEVIC D, 1977, EXPERIENTIA, V33, P1010; KRAUS JP, 1983, J BIOL CHEM, V258, P7245; KRAUS JP, 1986, P NATL ACAD SCI USA, V83, P8049, DOI 10.1073/pnas.83.21.8049; KRAUS JP, 1986, P NATL ACAD SCI USA, V83, P2047, DOI 10.1073/pnas.83.7.2047; KRAUS JP, 1983, ARCH BIOCHEM BIOPHYS, V222, P44, DOI 10.1016/0003-9861(83)90500-3; KUTZBACH C, 1971, BIOCHIM BIOPHYS ACTA, V250, P459, DOI 10.1016/0005-2744(71)90247-6; Mudd Sh, 1989, METABOLIC BASIS INHE, V1, P693; MUNKE M, 1988, AM J HUM GENET, V42, P550; OGAWA H, 1989, J BIOL CHEM, V264, P15818; Sambrook J., 1982, MOL CLONING LAB MANU, V1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKOVBY F, 1984, J BIOL CHEM, V259, P588; SODA K, 1987, METHOD ENZYMOL, V143, P453; YANOFSKY C, 1981, NUCLEIC ACIDS RES, V9, P6647, DOI 10.1093/nar/9.24.6647	28	142	148	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11455	11461						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597473				2022-12-25	WOS:A1992HX16900079
J	LI, HH; MERCHANT, S				LI, HH; MERCHANT, S			2 METAL-DEPENDENT STEPS IN THE BIOSYNTHESIS OF SCENEDESMUS-OBLIQUUS PLASTOCYANIN - DIFFERENTIAL MESSENGER-RNA ACCUMULATION AND HOLOPROTEIN FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASTIDIC CYTOCHROME-C; RECIPROCAL FORMATION; COMPLEMENTARY-DNA; CRYSTAL-STRUCTURE; GREEN-ALGA; COPPER; APOPLASTOCYANIN; CHLAMYDOMONAS; PROTEINS; CHLOROPLASTS	The accumulation of the interchangeable electron transfer catalysts plastocyanin and cytochrome c6 (cyt c6) in Scenedesmus obliquus is reciprocally regulated by the amount of copper ions in the medium. In copper-deficient cells, plastocyanin levels are severely reduced, whereas cyt c6 levels are high. Western blot analysis indicates that neither pre-apoplastocyanin nor apoplastocyanin accumulate to significant extents in copper-deficient Scenedesmus cells, and time course studies indicate that upon provision of copper salts to copper-deficient cells, the accumulation of plastocyanin to the levels maintained in copper-sufficient cells takes about 12-24 h. By 1) Northern hybridization analysis of Scenedesmus obliquus mRNA and 2) in vitro translation of polyadenylylated mRNA followed by immunoprecipitation of a 19.2-kilodalton precursor to plastocyanin, we demonstrate that the regulation of plastocyanin synthesis by copper must occur primarily at the level of mRNA accumulation. These results suggest that copper-dependent stimulation of holoplastocyanin accumulation requires de novo synthesis of the pre-apoprotein and contradict the conclusion of Bohner, H., Bohme, H., and Boger, P. (1981) FEBS Lett. 131, 386-388 that high levels of apoplastocyanin and a precursor to plastocyanin accumulate in copper-deficient Scenedesmus cells. We note also that although metal ions other than copper (e.g. silver) insert into Scenedesmus obliquus plastocyanin in vitro, synthesis of holoplastocyanin in vivo is specific for copper versus silver or mercury as it is in Chlamydomonas reinhardtii. Finally, the very different electrophoretic mobility and immunoreactivity of apoplastocyanin compared with holoplastocyanin suggests rather significant differences in structure between the copper-protein and the metal-free protein.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,405 HILGARD AVE,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles								BISHOP N, 1971, METHOD ENZYMOL, V53, P53; BOHNER H, 1981, BIOCHIM BIOPHYS ACTA, V636, P65, DOI 10.1016/0005-2728(81)90076-1; BOHNER H, 1978, FEBS LETT, V85, P337, DOI 10.1016/0014-5793(78)80486-4; BOHNER H, 1980, BIOCHIM BIOPHYS ACTA, V592, P103, DOI 10.1016/0005-2728(80)90117-6; BOHNER H, 1981, FEBS LETT, V131, P386, DOI 10.1016/0014-5793(81)80410-3; BOULTER D, 1977, INT REV BIOCHEM, V13, P3; BRIGGS LM, 1990, PLANT MOL BIOL, V15, P633, DOI 10.1007/BF00017837; BRUTSCH S, 1984, INORG CHIM A-BIOINOR, V92, P147, DOI 10.1016/S0020-1693(00)80012-2; CHAZIN WJ, 1988, J MOL BIOL, V202, P623, DOI 10.1016/0022-2836(88)90291-4; COLLYER CA, 1990, J MOL BIOL, V211, P617, DOI 10.1016/0022-2836(90)90269-R; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DAVIS DJ, 1980, PLANT PHYSIOL, V65, P697, DOI 10.1104/pp.65.4.697; GARRETT TPJ, 1984, J BIOL CHEM, V259, P2822; GUSS JM, 1983, J MOL BIOL, V169, P521; HARRIS EH, 1989, CHLAMDYDOMONAS SOUCE; HIBINO T, 1991, BIOCHIM BIOPHYS ACTA, V1058, P107, DOI 10.1016/S0005-2728(05)80226-9; HILL KL, 1991, J BIOL CHEM, V266, P15060; HO KK, 1984, BIOCHIM BIOPHYS ACTA, V766, P310, DOI 10.1016/0005-2728(84)90246-9; HOWE G, 1992, PLANT PHYSIOL, V98, P127, DOI 10.1104/pp.98.1.127; KATOH S, 1964, J BIOCHEM-TOKYO, V55, P378, DOI 10.1093/oxfordjournals.jbchem.a127898; LAUDENBACH DE, 1990, PLANT CELL, V2, P913, DOI 10.1105/tpc.2.9.913; LI HM, 1990, P NATL ACAD SCI USA, V87, P6748, DOI 10.1073/pnas.87.17.6748; Maniatis T., 1982, MOL CLONING; MATHEWS FS, 1985, PROG BIOPHYS MOL BIO, V45, P1, DOI 10.1016/0079-6107(85)90004-5; MCMILLIN DR, 1974, P NATL ACAD SCI USA, V71, P4760, DOI 10.1073/pnas.71.12.4760; MERCHANT S, 1986, MOL CELL BIOL, V6, P462, DOI 10.1128/MCB.6.2.462; MERCHANT S, 1991, EMBO J, V10, P1383, DOI 10.1002/j.1460-2075.1991.tb07658.x; MERCHANT S, 1990, J BIOL CHEM, V265, P12372; MERCHANT S, 1987, J BIOL CHEM, V262, P9062; MERCHANT S, 1986, J BIOL CHEM, V261, P5850; MOORE JM, 1988, SCIENCE, V240, P314, DOI 10.1126/science.3353725; SANDMANN G, 1980, PLANTA, V147, P330, DOI 10.1007/BF00379841; SANDMANN G, 1983, ARCH MICROBIOL, V134, P23, DOI 10.1007/BF00429401; SATO M, 1991, J BIOL CHEM, V266, P5128; SCHMIDT GW, 1986, ANNU REV BIOCHEM, V55, P879; SCHMIDT RJ, 1984, J CELL BIOL, V98, P2011, DOI 10.1083/jcb.98.6.2011; SYKES AG, 1985, CHEM SOC REV, V14, P283, DOI 10.1039/cs9851400283; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; VANDERPLAS J, 1989, MOL MICROBIOL, V3, P275; WEEKS DP, 1986, ANAL BIOCHEM, V152, P376, DOI 10.1016/0003-2697(86)90423-9; WILDNER GF, 1974, ARCH BIOCHEM BIOPHYS, V164, P136, DOI 10.1016/0003-9861(74)90015-0; WOOD PM, 1978, EUR J BIOCHEM, V87, P9, DOI 10.1111/j.1432-1033.1978.tb12346.x	42	22	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9368	9375						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577764				2022-12-25	WOS:A1992HR85400101
J	ORLOWSKI, J; KANDASAMY, RA; SHULL, GE				ORLOWSKI, J; KANDASAMY, RA; SHULL, GE			MOLECULAR-CLONING OF PUTATIVE MEMBERS OF THE NA/H EXCHANGER GENE FAMILY - CDNA CLONING, DEDUCED AMINO-ACID-SEQUENCE, AND MESSENGER-RNA TISSUE EXPRESSION OF THE RAT NA/H EXCHANGER NHE-1 AND 2 STRUCTURALLY RELATED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; NA+-H+ EXCHANGER; INTRACELLULAR PH REGULATION; SODIUM-HYDROGEN; GROWTH-FACTORS; CA-2+ PUMP; ANTIPORTER; BRAIN; IDENTIFICATION; ACTIVATION	Biochemical and pharmacological data support the existence of multiple forms of the Na/H exchanger (NHE). Two isoforms, termed NHE-1 and NHE-2, have recently been isolated from rabbit ileal villus epithelial cells (Tse, C. M., Ma, A. I., Yang, V. W., Watson, A. J. M., Levine, S., Montrose, M. H., Potter, J., Sardet, C., Pouyssegur, J., and Donowitz, M. (1 99 1) EMBO J. 10, 1957-1967; Tse, C. M., Watson, A. J. M., Ma, A. I., Pouyssegur, J., and Donowitz, M. (1991) Gastroenterology 100, A258). To identify additional molecular forms of the exchanger, rat brain, heart, kidney, stomach, and spleen cDNA libraries were screened for their presence using an NHE-1 cDNA probe under low stringency hybridization conditions. cDNAs encoding rat NHE-1 and two structurally related proteins, designated NHE-3 and NHE-4, have been isolated. Based on the deduced amino acid sequences, NHE-1, -3, and -4 are similar in size, having relative molecular masses of 91,506, 92,997, and 81,427, respectively. Overall, the proteins exhibit approximately 40% amino acid identity to each other and have similar hydropathy profiles, suggesting that they have the same transmembrane organization. The predicted N-terminal transmembrane regions of the three proteins, which span between 453 and 503 amino acids, exhibit the highest degree of identity (45-49%). In contrast, the C-terminal cytoplasmic regions, which span between 247 and 378 amino acids, exhibit very low amino acid identity (24-31%). Tissue distribution studies reveal that the NHE-1 mRNA is present at varying levels in all tissues examined, whereas NHE-3 and NHE-4 mRNAs exhibit a more limited distribution. NHE-3 mRNA is expressed at high levels in colon and small intestine, with significant levels also present in kidney and stomach. NHE-4 mRNA is most abundant in stomach, followed by intermediate levels in small intestine and colon and lesser amounts in kidney, brain, uterus, and skeletal muscle. These data suggest that the molecular basis for, the functional diversity of the Na/H exchanger in mammals is based, at least in part, on expression of multiple members of a gene family.	UNIV CINCINNATI,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati	ORLOWSKI, J (corresponding author), MCGILL UNIV,DEPT PHYSIOL,MCINTYRE MED SCI BLDG,3655 DRUMMOND ST,MONTREAL H3G 1Y6,QUEBEC,CANADA.				NHLBI NIH HHS [HL41496] Funding Source: Medline; NIDDK NIH HHS [DK39626] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039626] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; BOGART RB, 1989, P NATL ACAD SCI USA, V86, P8170; BORON WF, 1986, ANNU REV PHYSIOL, V48, P377; BURK SE, 1989, J BIOL CHEM, V264, P18561; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COHEN ME, 1990, P NATL ACAD SCI USA, V87, P8990, DOI 10.1073/pnas.87.22.8990; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FRIEDRICH T, 1986, J MEMBRANE BIOL, V94, P253, DOI 10.1007/BF01869721; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GREEB J, 1989, J BIOL CHEM, V264, P18569; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; GRINSTEIN S, 1985, P NATL ACAD SCI USA, V82, P1429, DOI 10.1073/pnas.82.5.1429; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; GRINSTEIN S, 1985, J CELL BIOL, V101, P269, DOI 10.1083/jcb.101.1.269; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; HAGGERTY JG, 1988, P NATL ACAD SCI USA, V85, P6797, DOI 10.1073/pnas.85.18.6797; HUOT SJ, 1989, J BIOL CHEM, V264, P683; IKEDA U, 1988, J MOL CELL CARDIOL, V20, P493, DOI 10.1016/S0022-2828(88)80076-2; KNICKELBEIN RG, 1988, J CLIN INVEST, V82, P2158, DOI 10.1172/JCI113838; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAPF R, 1991, J CLIN INVEST, V88, P783, DOI 10.1172/JCI115377; KUDRYCKI KE, 1990, J BIOL CHEM, V265, P462; KULANTHAIVEL P, 1990, J BIOL CHEM, V265, P1249; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MAHNENSMITH RL, 1985, CIRC RES, V56, P773, DOI 10.1161/01.RES.56.6.773; MOOLENAAR WH, 1986, ANNU REV PHYSIOL, V48, P363; PERIYASAMY SM, 1990, J BIOL CHEM, V265, P6035; PREISIG PA, 1987, J CLIN INVEST, V80, P970, DOI 10.1172/JCI113190; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RAJENDRAN VM, 1990, J BIOL CHEM, V265, P8408; RALEYSUSMAN KM, 1991, J BIOL CHEM, V266, P2739; RAMASWAMY K, 1989, BIOCHIM BIOPHYS ACTA, V981, P193, DOI 10.1016/0005-2736(89)90028-X; ROSS W, 1990, J BIOL CHEM, V265, P5341; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; TSE C M, 1991, Gastroenterology, V100, pA258; TSE CM, 1991, EMBO J, V10, P1957, DOI 10.1002/j.1460-2075.1991.tb07725.x; WATSON AJM, 1991, AM J PHYSIOL, V261, pG229, DOI 10.1152/ajpgi.1991.261.2.G229; WEINMAN EJ, 1987, AM J PHYSIOL, V252, pF19, DOI 10.1152/ajprenal.1987.252.1.F19; WEINMAN EJ, 1986, J MEMBRANE BIOL, V93, P133, DOI 10.1007/BF01870805; WERNKE G R, 1989, Biophysical Journal, V55, p390A; WU JSR, 1989, BIOCHEMISTRY-US, V28, P2980, DOI 10.1021/bi00433a036; YUSUFI ANK, 1988, J BIOL CHEM, V263, P13683	54	632	643	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9331	9339						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577762				2022-12-25	WOS:A1992HR85400096
J	RUTESHOUSER, EC; DECROMBRUGGHE, B				RUTESHOUSER, EC; DECROMBRUGGHE, B			PURIFICATION OF BBF, A DNA-BINDING PROTEIN RECOGNIZING A POSITIVE CIS-ACTING ELEMENT IN THE MOUSE ALPHA-1(III) COLLAGEN PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROLOGOUS SUBUNITS; TRANSCRIPTION FACTOR; RNA-POLYMERASE; YEAST HAP2; IDENTIFICATION; GENE; UPSTREAM; ACTIVATION; INTERACT; NUCLEI	A positive cis-acting element, the B element, located between -83 and -61 in the mouse alpha-1(III) collagen promoter, binds a factor present in nuclear extracts of NIH 3T3 fibroblasts and HeLa cells. We have purified this factor using ion exchange chromatography, sequence-specific DNA affinity chromatography, and sodium dodecyl sulfate-polyacrylamide gel fractionation. The DNA sequence used for the affinity chromatography was a single-base substitution in the B element that increased the stability of the B element-protein complex by 50%. Purification of the B element-binding factor (BBF) by DNA affinity chromatography resulted in the apparent loss of most or all of the DNA-binding activity of this factor. The DNA-binding activity could, however, be reconstituted by combining two chromatographic fractions: the high-salt eluate and the column flow-through. When the partially purified high-salt eluate was size-fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis with subsequent renaturation of gel fractions from guanidine HCl, the purified BBF (apparent molecular weight of about 95,000) bound to the B element with high affinity. These results suggest that during DNA affinity purification of BBF a factor that inhibits BBF DNA binding was co-eluted with BBF. This inhibition of BBF DNA binding was reversed by the addition of the DNA affinity column flow-through. The binding of BBF to the B element of the mouse alpha-1(III) collagen promoter is therefore an apparently complex process involving interactions between BBF and other protein factors.			RUTESHOUSER, EC (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030, USA.				NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CELADA A, 1989, MOL CELL BIOL, V9, P3097, DOI 10.1128/MCB.9.7.3097; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FESSLER JH, 1978, ANNU REV BIOCHEM, V47, P129, DOI 10.1146/annurev.bi.47.070178.001021; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAHN S, 1988, SCIENCE, V240, P317, DOI 10.1126/science.2832951; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; KARSENTY G, 1988, J BIOL CHEM, V263, P13909; KARSENTY G, 1990, J BIOL CHEM, V265, P9934; KELLER AD, 1988, P NATL ACAD SCI USA, V85, P3309, DOI 10.1073/pnas.85.10.3309; KUHN K, 1982, IMMUNOCHEMISTRY EXTR, V1, P1; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MANDEL G, 1986, P NATL ACAD SCI USA, V83, P6682; MERCURIO F, 1989, EMBO J, V8, P1455, DOI 10.1002/j.1460-2075.1989.tb03528.x; OIKARINEN J, 1987, J BIOL CHEM, V262, P11064; OLESEN J, 1987, CELL, V51, P953, DOI 10.1016/0092-8674(87)90582-4; RUTESHOUSER EC, 1989, J BIOL CHEM, V264, P13740; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; VUORIO T, 1990, J BIOL CHEM, V265, P22480	24	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14398	14404						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629225				2022-12-25	WOS:A1992JD32500092
J	VANCURA, A; HALDAR, D				VANCURA, A; HALDAR, D			REGULATION OF MITOCHONDRIAL AND MICROSOMAL PHOSPHOLIPID-SYNTHESIS BY LIVER FATTY ACID-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SN-GLYCEROL 3-PHOSPHATE; RAT-LIVER; PHOSPHATIDIC-ACID; LYSOPHOSPHATIDIC ACID; ARACHIDONIC-ACID; GLYCEROPHOSPHATE ACYLTRANSFERASE; SIGNAL TRANSDUCTION; QUANTIFICATION; TRANSLOCATION; BIOSYNTHESIS	Recently we have detected and partially purified a 15-kDa cytosolic L-alpha-lysophosphatidic acid (LPA)-binding protein (LPABP), which stimulates export of LPA from mitochondria (Vancura, A., Carroll, M. A., and Haldar, D. (1991) Biochem. Biophys. Res. Commun. 175, 339-343). Now we have purified this protein to homogeneity. By Western immunoblot analysis, amino acid sequence analysis, and binding characteristics we have shown that LPABP is identical with liver fatty acid-binding protein (L-FABP). This protein binds LPA, and stimulates mitochondrial and microsomal glycerophosphate acyltransferase (GAT) and the export of LPA from both the organelles. The mitochondrially synthesized LPA exported by L-FABP can be converted to phosphatidic acid by microsomes. L-FABP also stimulates microsomal conversion of LPA to phosphatidic acid but strongly inhibits this reaction in mitochondria. However, in the absence of L-FABP mitochondria predominantly synthesize PA. Taken together, these findings are suggestive that L-FABP plays a major role in mitochondrial and microsomal phospholipid metabolism by regulating both the synthesis and utilization of LPA.	ST JOHNS UNIV, DEPT BIOL SCI, JAMAICA, NY 11439 USA	Saint John's University				Vancura, Ales/0000-0002-5895-1218				BANSAL MP, 1989, J BIOL CHEM, V264, P13780; BASS NM, 1985, CHEM PHYS LIPIDS, V38, P95, DOI 10.1016/0009-3084(85)90060-X; BASSUK JA, 1987, P NATL ACAD SCI USA, V84, P7547, DOI 10.1073/pnas.84.21.7547; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BERNIER M, 1988, J BIOL CHEM, V263, P13626; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BILLAH MM, 1981, J BIOL CHEM, V256, P5399; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; BORDEWICK U, 1989, BIOL CHEM H-S, V370, P229, DOI 10.1515/bchm3.1989.370.1.229; BUELT MK, 1991, J BIOL CHEM, V266, P12266; BURNETT DA, 1979, GASTROENTEROLOGY, V77, P241; BURRIER RE, 1986, BIOCHIM BIOPHYS ACTA, V879, P229; CARROLL MA, 1982, ARCH BIOCHEM BIOPHYS, V214, P17, DOI 10.1016/0003-9861(82)90003-0; DAAE LNW, 1973, BIOCHIM BIOPHYS ACTA, V306, P186, DOI 10.1016/0005-2760(73)90224-5; DAHLBERG E, 1980, ANAL BIOCHEM, V106, P380, DOI 10.1016/0003-2697(80)90537-0; DAS AK, 1989, LIPIDS, V24, P329, DOI 10.1007/BF02535172; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; FREEMAN M, 1989, BIOCHEM J, V263, P589, DOI 10.1042/bj2630589; GLATZ JFC, 1989, MOL CELL BIOCHEM, V88, P37, DOI 10.1007/BF00223421; GLATZ JFC, 1985, BIOCHIM BIOPHYS ACTA, V837, P57, DOI 10.1016/0005-2760(85)90085-2; GLATZ JFC, 1983, ANAL BIOCHEM, V132, P89, DOI 10.1016/0003-2697(83)90429-3; HAJRA AK, 1986, ENZYMES LIPID METABO, V2, P199; Haldar D, 1983, Trans N Y Acad Sci, V41, P173; HALDAR D, 1979, J BIOL CHEM, V254, P4502; HALDAR D, 1990, J BIOL CHEM, V265, P11014; HESLER CB, 1985, J BIOL CHEM, V260, P7452; HOSTETLER KY, 1982, PHOSPHOLIPIDS, P481; JALINK K, 1990, J BIOL CHEM, V265, P12232; KAIKAUS RM, 1990, EXPERIENTIA, V46, P617, DOI 10.1007/BF01939701; KHAN SH, 1990, P NATL ACAD SCI USA, V87, P9401, DOI 10.1073/pnas.87.23.9401; KRAGHHANSEN U, 1981, PHARMACOL REV, V33, P17; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1981, NATURE, V292, P367, DOI 10.1038/292367a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MAYOREK N, 1989, J BIOL CHEM, V264, P4450; MISHKIN S, 1974, BIOCHEM BIOPH RES CO, V60, P376; MONROY G, 1972, J BIOL CHEM, V247, P6884; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; NACHBAUR J, 1968, BIOCHEM BIOPH RES CO, V33, P315, DOI 10.1016/0006-291X(68)90786-9; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; OCKNER RK, 1982, J BIOL CHEM, V257, P7872; OCKNER RK, 1976, J CLIN INVEST, V58, P632, DOI 10.1172/JCI108510; ODOHERTY PJA, 1975, FEBS LETT, V60, P256, DOI 10.1016/0014-5793(75)80725-3; RASMUSSEN JT, 1990, BIOCHEM J, V265, P849, DOI 10.1042/bj2650849; RAZA H, 1989, BIOCHEM BIOPH RES CO, V161, P448, DOI 10.1016/0006-291X(89)92619-3; SALMON DM, 1980, NATURE, V284, P344, DOI 10.1038/284344a0; SCALLEN TJ, 1985, J BIOL CHEM, V260, P4733; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHLAME M, 1990, BIOCHEM J, V272, P589, DOI 10.1042/bj2720589; SMITH ME, 1967, EUR J BIOCHEM, V3, P70, DOI 10.1111/j.1432-1033.1967.tb19499.x; SPECTOR AA, 1968, ANN NY ACAD SCI, V149, P768, DOI 10.1111/j.1749-6632.1968.tb53834.x; STERN W, 1978, J BIOL CHEM, V253, P8047; SWEETSER DA, 1987, ANNU REV NUTR, V7, P337, DOI 10.1146/annurev.nu.07.070187.002005; TAKAHASHI K, 1983, EUR J BIOCHEM, V136, P589, DOI 10.1111/j.1432-1033.1983.tb07781.x; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANCURA A, 1991, BIOCHEM BIOPH RES CO, V175, P339, DOI 10.1016/S0006-291X(05)81240-9; WHITAKER JR, 1980, ANAL BIOCHEM, V109, P156, DOI 10.1016/0003-2697(80)90024-X; WOOD R, 1969, ARCH BIOCHEM BIOPHYS, V131, P478, DOI 10.1016/0003-9861(69)90420-2	59	62	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14353	14359						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629224				2022-12-25	WOS:A1992JD32500086
J	MIROUX, B; CASTEILLA, L; KLAUS, S; RAIMBAULT, S; GRANDIN, S; CLEMENT, JM; RICQUIER, D; BOUILLAUD, F				MIROUX, B; CASTEILLA, L; KLAUS, S; RAIMBAULT, S; GRANDIN, S; CLEMENT, JM; RICQUIER, D; BOUILLAUD, F			ANTIBODIES SELECTED FROM WHOLE ANTISERUM BY FUSION PROTEINS AS TOOLS FOR THE STUDY OF THE TOPOLOGY OF MITOCHONDRIAL-MEMBRANE PROTEINS - EVIDENCE THAT THE N-TERMINAL EXTREMITY OF THE 6TH ALPHA-HELIX OF THE UNCOUPLING PROTEIN IS FACING THE MATRIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN-ADIPOSE-TISSUE; ADP ATP CARRIER; MALTOSE-BINDING-PROTEIN; BEEF-HEART MITOCHONDRIA; ONE-STEP PURIFICATION; AMINO-ACID-SEQUENCE; NUCLEOTIDE-BINDING; FAT MITOCHONDRIA; ESCHERICHIA-COLI; STRUCTURAL RELATIONSHIP	The reactivity to freeze-thawed mitochondria or sub-mitochondrial particles of a whole antiserum raised against the uncoupling protein has been investigated. Incubation with freeze-thawed brown adipose tissue mitochondria trapped antibodies reactive toward accessible parts of the uncoupling protein. One-third to one-half of antibodies against uncoupling protein which were present in the serum remained free. These antibodies were highly reactive with the vesicles obtained by sonication of mitochondria, in which the matricial side of the inner membrane was made accessible. To define epitopes recognized by the antiserum, different fusion proteins made up of MalE protein and uncoupling protein fragments were used. Immunoaffinity chromatography, using an immobilized purified fusion protein containing amino acids 253 to 290 of uncoupling protein, selected antibodies specifically directed against this part of the protein. A more precise localization of the main epitope recognized by these antibodies is proposed. These purified antibodies reacted with the protein only in submitochondrial particles, indicating a matricial orientation of this epitope. This result, associated with other data concerning uncoupling protein or related mitochondrial carriers such as the ADP/ATP translocator and the phosphate carrier, allowed us to determine the orientation of the sixth alpha-helix of the uncoupling protein.	CNRS,UPR 1151,CTR RECH ENDOCRINOL MOLEC & DEV,9 RUE JULES HETZEL,F-92190 MEUDON,FRANCE; INST PASTEUR,CNRS,URA 144,UNITE PROGRAMMAT MOLEC TOXICOL GENET,DEPT BIOTECHNOL,F-75724 PARIS 15,FRANCE	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Klaus, Susanne/P-9299-2018; Bouillaud, Frédéric R/L-3238-2017; Miroux, Bruno/E-9267-2017	Klaus, Susanne/0000-0001-8726-185X; Bouillaud, Frédéric R/0000-0002-7518-9237; Miroux, Bruno/0000-0002-3066-4700; Casteilla, Louis/0000-0001-9647-3248				AQUILA H, 1982, H-S Z PHYSIOL CHEM, V363, P345; AQUILA H, 1985, EMBO J, V4, P2369, DOI 10.1002/j.1460-2075.1985.tb03941.x; AQUILA H, 1987, FEBS LETT, V212, P1, DOI 10.1016/0014-5793(87)81546-6; ARENDS H, 1984, EMBO J, V3, P377, DOI 10.1002/j.1460-2075.1984.tb01815.x; BEDOUELLE H, 1988, EUR J BIOCHEM, V171, P541, DOI 10.1111/j.1432-1033.1988.tb13823.x; BOUILLAUD F, 1986, J BIOL CHEM, V261, P1487; BRANDOLIN G, 1989, BIOCHEMISTRY-US, V28, P1093, DOI 10.1021/bi00429a025; CAPOBIANCO L, 1991, BIOCHEMISTRY-US, V30, P4963, DOI 10.1021/bi00234a018; CASSARD AM, 1990, J CELL BIOCHEM, V43, P255, DOI 10.1002/jcb.240430306; CASTEILLA L, 1990, P NATL ACAD SCI USA, V87, P5124, DOI 10.1073/pnas.87.13.5124; CASTEILLA L, 1989, NUCLEIC ACIDS RES, V17, P2131, DOI 10.1093/nar/17.5.2131; DALBON P, 1988, BIOCHEMISTRY-US, V27, P5141, DOI 10.1021/bi00414a029; DUPLAY P, 1987, J MOL BIOL, V194, P663, DOI 10.1016/0022-2836(87)90243-9; DUPLAY P, 1984, J BIOL CHEM, V259, P606; ECKERSKORN C, 1987, FEBS LETT, V226, P166, DOI 10.1016/0014-5793(87)80572-0; FASMAN GD, 1990, TRENDS BIOCHEM SCI, V15, P89, DOI 10.1016/0968-0004(90)90187-G; FERENCI T, 1978, FEBS LETT, V94, P213, DOI 10.1016/0014-5793(78)80940-5; FERNANDEZ M, 1987, EUR J BIOCHEM, V164, P675, DOI 10.1111/j.1432-1033.1987.tb11179.x; FERREIRA GC, 1990, J BIOL CHEM, V265, P21202; FERREIRA GC, 1989, J BIOL CHEM, V264, P15628; GEYSEN HM, 1987, SCIENCE, V235, P1184, DOI 10.1126/science.3823878; HARLOW E, 1988, ANTIBODIES LABORATOR; JAHNIG F, 1990, TRENDS BIOCHEM SCI, V15, P93, DOI 10.1016/0968-0004(90)90188-H; JEZEK P, 1989, EUR J BIOCHEM, V183, P89, DOI 10.1111/j.1432-1033.1989.tb14900.x; JEZEK P, 1990, J BIOL CHEM, V265, P19303; KATIYAR SS, 1991, BIOCHEM BIOPH RES CO, V175, P1104, DOI 10.1016/0006-291X(91)91679-7; KATIYAR SS, 1989, P NATL ACAD SCI USA, V86, P2559, DOI 10.1073/pnas.86.8.2559; KLAUS S, 1991, INT J BIOCHEM, V23, P791, DOI 10.1016/0020-711X(91)90062-R; KLAUS S, 1990, BIOCHEM BIOPH RES CO, V167, P784, DOI 10.1016/0006-291X(90)92094-G; KLINGENBERG M, 1989, EUR J BIOCHEM, V180, P123, DOI 10.1111/j.1432-1033.1989.tb14622.x; KLINGENBERG M, 1990, TRENDS BIOCHEM SCI, V15, P108, DOI 10.1016/0968-0004(90)90194-G; LAUQUIN GJM, 1977, BIOCHIM BIOPHYS ACTA, V460, P331, DOI 10.1016/0005-2728(77)90219-5; LECLERC C, 1990, J IMMUNOL, V144, P3174; LIN CS, 1980, FEBS LETT, V113, P299, DOI 10.1016/0014-5793(80)80613-2; MARTINEAU P, 1991, BIO-TECHNOL, V9, P170, DOI 10.1038/nbt0291-170; MAYINGER P, 1990, EUR BIOENEGETICS C R, V6, P64; MURDZAINGLIS DL, 1991, J BIOL CHEM, V266, P11871; OCALLAGHAN D, 1990, RES MICROBIOL, V141, P963, DOI 10.1016/0923-2508(90)90136-E; PHELPS A, 1991, BIOCHEMISTRY-US, V30, P248, DOI 10.1021/bi00215a035; RIAL E, 1989, EUR J BIOCHEM, V182, P187, DOI 10.1111/j.1432-1033.1989.tb14816.x; RIAL E, 1983, EUR J BIOCHEM, V137, P197, DOI 10.1111/j.1432-1033.1983.tb07815.x; RICQUIER D, 1991, FASEB J, V5, P2237, DOI 10.1096/fasebj.5.9.1860614; RICQUIER D, 1983, BIOCHEM J, V210, P859, DOI 10.1042/bj2100859; RODSETH LE, 1990, J MOL BIOL, V213, P607, DOI 10.1016/S0022-2836(05)80246-3; RUNSWICK MJ, 1987, EMBO J, V6, P1367, DOI 10.1002/j.1460-2075.1987.tb02377.x; RUNSWICK MJ, 1990, BIOCHEMISTRY-US, V29, P11033, DOI 10.1021/bi00502a004; SARASTE M, 1982, FEBS LETT, V144, P250, DOI 10.1016/0014-5793(82)80648-0; SZMELCMAN S, 1990, J ACQ IMMUN DEF SYND, V3, P859; TUNWELL REA, 1991, BIOCHIM BIOPHYS ACTA, V1073, P585, DOI 10.1016/0304-4165(91)90234-8; WIESENBERGER G, 1991, J MOL BIOL, V217, P23, DOI 10.1016/0022-2836(91)90608-9; ZARRILLI R, 1989, MOL ENDOCRINOL, V3, P1498, DOI 10.1210/mend-3-9-1498	51	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13603	13609						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618863				2022-12-25	WOS:A1992JB74600080
J	MORRIS, SM; KEPKALENHART, D; MCGILL, RL; CURTHOYS, NP; ADLER, S				MORRIS, SM; KEPKALENHART, D; MCGILL, RL; CURTHOYS, NP; ADLER, S			SPECIFIC DISRUPTION OF RENAL-FUNCTION AND GENE-TRANSCRIPTION BY CYCLOSPORINE-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; UREA-CYCLE ENZYMES; MESSENGER-RNA; RAT-KIDNEY; EXPRESSION; CELLS; LIVER; TRANSPEPTIDASE; GLUTAMINASE; ACTIVATION	The effects of cyclosporin A (CsA) are cell-specific, ranging from its immunosuppressive action on cells of the immune system to a variety of nonimmunologic toxic side effects. The predominant undesirable side effects of CsA occur in the kidney. Although many toxic renal effects of CsA have been described, the molecular basis of the nephrotoxicity is unknown. Elucidation of the molecular basis for the renal action of CsA may shed light on the function of cyclophilin in nonimmune cell types. The present study demonstrates that CsA selectively reduces the gluconeogenic capacity of rat proximal tubules via a decrease in activity of phosphoenolpyruvate carboxykinase (GTP:oxaloacetate carboxy-lyase (transphosphorylating), E.C. 4.1.1.32; PEPCK). The decrease in renal PEPCK activity occurs within 3 days and reflects a corresponding reduction in renal PEPCK mRNA abundance. This, in turn, is due to a selective inhibition of renal PEPCK gene transcription. Expression of several other renal genes is unaffected by CsA, as is expression of the PEPCK gene in liver. Thus, the effects of CsA are organ-specific and do not represent a general cytotoxic effect on proximal tubule cells. These results suggest that selective inhibition of the activity of a transcription factor(s) required for expression of specific genes in renal tubules may play a role in CsA-induced nephrotoxicity.	MONTEFIORE UNIV HOSP,DIV NEPHROL,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian	MORRIS, SM (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261, USA.		Morris, Sidney M/I-3440-2015		NIDDK NIH HHS [DK 37124, DK 33144] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033144, R01DK037124] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAGCHI S, 1987, J BIOL CHEM, V262, P1558; BANNER C, 1988, MOL BRAIN RES, V3, P247, DOI 10.1016/0169-328X(88)90047-2; BERTY RM, 1991, J LAB CLIN MED, V118, P17; BURCH HB, 1984, J HISTOCHEM CYTOCHEM, V32, P731, DOI 10.1177/32.7.6588129; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIMBALA MA, 1982, J BIOL CHEM, V257, P7629; CURTHOYS NP, 1974, J BIOL CHEM, V249, P3261; ELLIOTT JF, 1984, SCIENCE, V226, P1439, DOI 10.1126/science.6334364; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HWANG JJ, 1991, J BIOL CHEM, V266, P9392; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KAISER S, 1991, J BIOL CHEM, V266, P9397; KOLETSKY AJ, 1986, J IMMUNOL, V137, P1054; KOPP JB, 1990, J AM SOC NEPHROL, V1, P162; KOSAKA T, 1989, FEBS LETT, V249, P42, DOI 10.1016/0014-5793(89)80011-0; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; LAPERCHE Y, 1986, P NATL ACAD SCI USA, V83, P937, DOI 10.1073/pnas.83.4.937; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEISNER H, 1985, BIOCHEMISTRY-US, V24, P421, DOI 10.1021/bi00323a027; MORRIS SM, 1989, ARCH BIOCHEM BIOPHYS, V273, P230, DOI 10.1016/0003-9861(89)90183-5; MORRIS SM, 1988, BIOCHEM GENET, V26, P769, DOI 10.1007/BF02395522; MORRIS SM, 1991, PEDIATR RES, V29, P151, DOI 10.1203/00006450-199102000-00010; MORRIS SM, 1987, ARCH BIOCHEM BIOPHYS, V256, P343, DOI 10.1016/0003-9861(87)90455-3; MORRIS SM, 1991, TRANSPLANT P, V23, P3116; NAST CC, 1991, KIDNEY INT, V39, P631, DOI 10.1038/ki.1991.75; NEBES VL, 1990, BIOCHEM BIOPH RES CO, V166, P133, DOI 10.1016/0006-291X(90)91921-E; POGSON CI, 1975, BIOCHEM J, V152, P401, DOI 10.1042/bj1520401; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1990, J BIOL CHEM, V265, P21011; SIGAL NH, 1990, BIOCHEM PHARMACOL, V40, P2201, DOI 10.1016/0006-2952(90)90712-T; TANNEN RL, 1984, KIDNEY INT, V25, P1, DOI 10.1038/ki.1984.1; TATE SS, 1974, J BIOL CHEM, V249, P7593; UCHIDA S, 1990, KIDNEY INT, V37, P380; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; VINAY P, 1981, AM J PHYSIOL, V241, pF403, DOI 10.1152/ajprenal.1981.241.4.F403; WOLF G, 1990, J AM SOC NEPHROL, V1, P918	42	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13768	13771						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618871				2022-12-25	WOS:A1992JB74600105
J	OHKI, R; KAWAMATA, T; KATOH, Y; HOSODA, F; OHKI, M				OHKI, R; KAWAMATA, T; KATOH, Y; HOSODA, F; OHKI, M			ESCHERICHIA-COLI DNAJ DELETION MUTATION RESULTS IN LOSS OF STABILITY OF A POSITIVE REGULATOR, CRP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-MONOPHOSPHATE RECEPTOR; BACTERIOPHAGE-LAMBDA; HEAT-SHOCK; PROTEINS; REPLICATION; GENE; CLONING; PROTEOLYSIS; INITIATION; MUTANTS	The dnaJ deletion mutant K7052(lambda-dnaK) has a temperature-sensitive defect in the synthesis of beta-galactosidase. We confirmed this operon-specific and temperature-sensitive defect in cell-free extracts prepared from the mutant cells and found that the missing factor was CRP. In the mutant, the cellular concentration of CRP was too low to allow the expression of the lac operon at a nonpermissive temperature. Introduction of a CRP over-producing plasmid into the dnaJ deletion mutant suppressed the defect of beta-galactosidase synthesis. The lower content of CRP in the mutant was found to result from extreme instability of the protein. These results strongly suggested that the heat shock protein dnaJ is involved in the stabilization (or degradation) of CRP.	SAITAMA CANC CTR,RES INST,INA,SAITAMA 362,JAPAN		OHKI, R (corresponding author), KYORIN UNIV,SCH HLTH SCI,DEPT MOLEC BIOL,476 MIYASHITA,MITAKA,TOKYO 181,JAPAN.							AIBA H, 1982, NUCLEIC ACIDS RES, V10, P1345, DOI 10.1093/nar/10.4.1345; AMES GFL, 1974, J BIOL CHEM, V249, P634; BUKAU B, 1989, J BACTERIOL, V171, P6030, DOI 10.1128/jb.171.11.6030-6038.1989; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; DYK TKV, 1989, NATURE, V342, P451; EILEN E, 1978, BIOCHEMISTRY-US, V17, P2469, DOI 10.1021/bi00606a001; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; HOPKINS AS, 1976, J MOL BIOL, V107, P549, DOI 10.1016/S0022-2836(76)80082-4; KELLER JA, 1988, MOL MICROBIOL, V2, P31, DOI 10.1111/j.1365-2958.1988.tb00004.x; KRAKOW JS, 1973, P NATL ACAD SCI USA, V70, P2529, DOI 10.1073/pnas.70.9.2529; KUNG HF, 1974, ARCH BIOCHEM BIOPHYS, V160, P168, DOI 10.1016/S0003-9861(74)80023-8; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; MAKI S, 1983, MOL GEN GENET, V191, P231, DOI 10.1007/BF00334819; Maniatis T., 1982, MOL CLONING LABORATO, P76; MILLER JH, 1972, EXPT MOL GENETICS, P419; MIZUSAWA S, 1982, GENE, V20, P317, DOI 10.1016/0378-1119(82)90200-1; OHKI M, 1987, J BACTERIOL, V169, P1917, DOI 10.1128/jb.169.5.1917-1922.1987; OHKI M, 1979, BACTERIAL OUTER MEMB, P293; OHKI R, 1989, BIOCHIM BIOPHYS ACTA, V1009, P94, DOI 10.1016/0167-4781(89)90085-7; OHKI R, 1975, J BACTERIOL, V123, P815, DOI 10.1128/JB.123.3.815-823.1975; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PHILLIPS GJ, 1990, NATURE, V344, P882, DOI 10.1038/344882a0; SABOURIN D, 1975, J BACTERIOL, V122, P338, DOI 10.1128/JB.122.1.338-340.1975; SAITO H, 1977, J MOL BIOL, V113, P1, DOI 10.1016/0022-2836(77)90038-9; SAITO H, 1978, MOL GEN GENET, V164, P1, DOI 10.1007/BF00267592; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; SUNSHINE M, 1977, MOL GEN GENET, V151, P27, DOI 10.1007/BF00446909; TILLY K, 1989, J BACTERIOL, V171, P6025, DOI 10.1128/jb.171.11.6025-6029.1989; YOCHEM J, 1978, MOL GEN GENET, V164, P9, DOI 10.1007/BF00267593; ZUBAY G, 1973, ANNU REV GENET, V7, P267, DOI 10.1146/annurev.ge.07.120173.001411	30	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13180	13184						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618821				2022-12-25	WOS:A1992JB74600016
J	PAI, SB; PAI, RB; JOHNSTON, RN				PAI, SB; PAI, RB; JOHNSTON, RN			OVEREXPRESSION OF C-MYC BY AMPLIFICATION OF NEGATIVE PROMOTER DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MODULATE EXPRESSION; GENE-EXPRESSION; PROTO-ONCOGENE; CELLS; ELEMENT; DNA; FOS; AUTOREGULATION; TRANSCRIPTION; UPSTREAM	Amplification of myc proto-oncogenes has been reported in many human malignancies, but whether the amplified genes are properly regulated has not been well studied. Transcription factors that control gene expression are of limited abundance, and we have previously shown (Johnston, R. N., and Kucey, B. L. (1988) Science 242, 1551-1554) that amplified heat shock promoter sequences can compete with natural heat shock genes for these factors, resulting in heat shock gene disregulation. To establish whether proto-oncogenes may also be disregulated in this manner, a previously identified negative regulatory domain from the human c-myc promoter was amplified by up to 800-fold in Chinese hamster ovary cells. The amplified cells showed up to a 14-fold increase in hamster c-myc transcript abundance when compared with controls and also displayed reduced doubling times, enhanced incorporation of tritiated thymidine, elevated growth in soft agar, and a fusiform morphology, consistent with an elevation in the degree of cellular transformation. We infer that overexpression of endogenous hamster c-myc genes in the experimental cells was elicited in trans by sequestration of an inhibitory factor or complex that bound to excess nonfunctional human c-myc promoter domains. The transcriptional inhibitory activity we detect is consistent with anti-oncogene function.	UNIV CALGARY, DEPT MED BIOCHEM, CALGARY T2N 4N1, ALBERTA, CANADA	University of Calgary			Johnston, Randal/B-9247-2009					BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; FU LN, 1991, SCIENCE, V251, P807, DOI 10.1126/science.1990443; GASSER CS, 1986, J BIOL CHEM, V261, P6938; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; JOHNSTON RN, 1983, P NATL ACAD SCI-BIOL, V80, P3711, DOI 10.1073/pnas.80.12.3711; JOHNSTON RN, 1988, SCIENCE, V242, P1551, DOI 10.1126/science.3201244; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; LANG JC, 1988, BRIT J CANCER, V58, P62; LANG JC, 1991, ONCOGENE, V6, P2067; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; REMMERS EF, 1986, EMBO J, V5, P899, DOI 10.1002/j.1460-2075.1986.tb04301.x; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHIMKE RT, 1986, P NATL ACAD SCI USA, V83, P2157, DOI 10.1073/pnas.83.7.2157; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; URLAUB G, 1983, CELL, V33, P405, DOI 10.1016/0092-8674(83)90422-1	31	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12428	12431						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618750				2022-12-25	WOS:A1992HZ48300010
J	SKELTON, TP; KUMAR, S; SMITH, PL; BERANEK, MC; BAENZIGER, JU				SKELTON, TP; KUMAR, S; SMITH, PL; BERANEK, MC; BAENZIGER, JU			PROOPIOMELANOCORTIN SYNTHESIZED BY CORTICOTROPHS BEARS ASPARAGINE-LINKED OLIGOSACCHARIDES TERMINATING WITH SO4-4GALNAC-BETA-1,4GLCNAC-BETA-1,2MAN-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; PITUITARY GLYCOPROTEIN HORMONES; LIPOTROPIN PRECURSOR GENE; N-GLYCOSIDASE-F; SIALYLATED OLIGOSACCHARIDES; ANIONIC OLIGOSACCHARIDES; STRUCTURAL ELUCIDATION; BOVINE LUTROPIN; PEPTIDE; FOLLITROPIN	We have determined that greater-than-or-equal-to 80% of the Asn-linked oligosaccharides on the glycosylated form of mouse adrenocorticotropin (15-kDa adrenocorticotropin (ACTH)) bear one or more branches terminating with the sequence SO4-4GalNAc-beta-21,4GlcNAc-beta-1, 2Man-alpha (S4GGnM). Proopiomelanocortin (POMC), the precursor of ACTH, is the first example of a glycoprotein that is not a member of the glycoprotein hormone family to bear such sulfated structures. Like lutropin and thyrotropin, 15-kDa ACTH bears dibranched oligosaccharides terminating with SO4-4-GalNAc; however, at least half of the oligosaccharides on 15-kDa ACTH terminating with SO4-4-GalNAc consist of more highly branched structures that have not previously been described. Both the GalNAc-beta-1,4GlcNAc-beta-1, 2Man-4-sulfotransferase and the glycoprotein hormone-specific GalNAc-transferase are expressed in the corticotroph-derived AtT-20 cell line. A tripeptide recognition sequence, Pro-Val-Lys, similar to the Pro-Leu-Arg sequence required for recognition of glycoprotein hormone alpha- and beta-subunits by the glycoprotein hormone-specific GalNAc-transferase, is present 8 residues amino-terminal to the glycosylated Asn of 15-kDa ACTH. Thus, POMC has the features expected for specific addition of the S4GGnM sequence to its oligosaccharides. The recent discovery of a receptor in hepatic endothelial cells that recognizes oligosaccharides terminating with S4GGnM suggests these sulfated oligosaccharides will regulate the circulatory half-life of glycosylated POMC cleavage products.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Baenziger, Jacques U/E-9430-2012		NIDDK NIH HHS [R01-DK-41738] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041738] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; BAENZIGER JU, 1988, BIOCHIM BIOPHYS ACTA, V947, P287, DOI 10.1016/0304-4157(88)90012-3; BAENZIGER JU, 1991, BIOL CARBOHYDRATES, V3, P1; BOURBONNAIS Y, 1985, J BIOL CHEM, V260, P5832; BUDARF ML, 1982, J BIOL CHEM, V257, P128; CHANG ACY, 1980, P NATL ACAD SCI-BIOL, V77, P4890, DOI 10.1073/pnas.77.8.4890; DROUIN J, 1985, FEBS LETT, V193, P54, DOI 10.1016/0014-5793(85)80078-8; Eipper B A, 1980, Endocr Rev, V1, P1; EVANS CJ, 1983, SCIENCE, V221, P957, DOI 10.1126/science.6308766; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; GREEN ED, 1985, J BIOL CHEM, V260, P5623; GREEN ED, 1988, J BIOL CHEM, V263, P25; GREEN ED, 1988, J BIOL CHEM, V263, P36; GREEN ED, 1985, P NATL ACAD SCI USA, V82, P7850, DOI 10.1073/pnas.82.23.7850; GREEN ED, 1984, P NATL ACAD SCI-BIOL, V81, P5320, DOI 10.1073/pnas.81.17.5320; GREEN ED, 1986, ANAL BIOCHEM, V158, P42, DOI 10.1016/0003-2697(86)90585-3; HOSHINA H, 1982, SCIENCE, V217, P63, DOI 10.1126/science.6283633; MAINS RE, 1981, J CELL BIOL, V89, P21, DOI 10.1083/jcb.89.1.21; MELLIS SJ, 1983, ANAL BIOCHEM, V134, P442, DOI 10.1016/0003-2697(83)90320-2; MENGELING BJ, 1991, ANAL BIOCHEM, V199, P286, DOI 10.1016/0003-2697(91)90103-Z; NAKANISHI S, 1981, EUR J BIOCHEM, V115, P429; NOTAKE M, 1983, FEBS LETT, V156, P67, DOI 10.1016/0014-5793(83)80250-6; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SKELTON TP, 1991, J BIOL CHEM, V266, P17142; SMITH AI, 1988, ENDOCR REV, V9, P159, DOI 10.1210/edrv-9-1-159; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; SMITH PL, 1990, J BIOL CHEM, V265, P874; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; SMITH PL, 1990, P NATL ACAD SCI USA, V87, P7275, DOI 10.1073/pnas.87.18.7275; SRIVASTAVA V, 1989, CARBOHYD RES, V185, P163, DOI 10.1016/0008-6215(89)84031-5; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; THOMAS LJ, 1991, J BIOL CHEM, V266, P23175; UHLER M, 1983, J BIOL CHEM, V258, P9444; VANDANA HO, 1987, CAN J CHEM, V65, P1645	37	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12998	13006						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618797				2022-12-25	WOS:A1992HZ48300090
J	LEE, SW; ROBB, J; NAZAR, RN				LEE, SW; ROBB, J; NAZAR, RN			TRUNCATED PHENYLALANINE AMMONIA-LYASE EXPRESSION IN TOMATO (LYCOPERSICON-ESCULENTUM)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; PLANT DEVELOPMENT; GENE; INDUCTION; ELICITOR; SEQUENCES; INVITRO; POTATO	Southern blot analyses of genomic DNA fragments suggest there are five different classes of phenylalanine ammonia-lyase (PAL, EC 4.3.1.5) genomic sequence in tomato (Lycopersicon esculentum). Isolation and subsequent sequence analysis of three examples from genomic libraries reveal highly homologous coding sequences but also a surprisingly high frequency of single point mutations which would truncate protein synthesis. The nucleotide sequence for one of the genes (PAL5) encodes a normal polypeptide of 721 amino acids, interrupted by a 710-base pair intron in the codon for amino acid 139. In contrast, premature stop codons, 363 triplets from the end in PAL1 and 304 triplets from the end in PAL3 would result in substantially (51-43%) shorter polypeptides that are consistent with the protein polymorphism, recently reported in alfalfa (Jorrin, J., and Dixon, R. A. (1990) Plant Physiol. 92, 447-445) but ascribed to protein degradation. S1 mapping of the mRNA termini and polymerase chain reaction analysis of cDNA transcripts indicate that at least one of these truncated coding sequences is expressed, strongly suggesting that at least some of the shorter polypeptides constitute original gene products with a potentially important function.			LEE, SW (corresponding author), UNIV GUELPH,DEPT MOLEC BIOL & GENET,GUELPH N1G 2W1,ONTARIO,CANADA.							BITTNER M, 1980, ANAL BIOCHEM, V102, P459, DOI 10.1016/0003-2697(80)90182-7; BOLWELL GP, 1986, BIOCHIM BIOPHYS ACTA, V881, P210; CRAMER CL, 1989, PLANT MOL BIOL, V12, P367, DOI 10.1007/BF00017577; DIXON RA, 1983, ADV ENZYMOLOGY RELAT, V53, P1; EDWARDS K, 1985, P NATL ACAD SCI USA, V82, P6731, DOI 10.1073/pnas.82.20.6731; GERARD GF, 1987, FOCUS, V9, P5; HAHLBROCK K, 1979, ANNU REV PLANT PHYS, V30, P105, DOI 10.1146/annurev.pp.30.060179.000541; JONES DH, 1984, PHYTOCHEMISTRY, V23, P1349, DOI 10.1016/S0031-9422(00)80465-3; JORRIN J, 1990, PLANT PHYSIOL, V92, P447, DOI 10.1104/pp.92.2.447; LEE SW, 1992, PLANT MOL BIOL, V18, P345, DOI 10.1007/BF00034961; LIANG X, 1989, P NATL ACAD SCI USA, V86, P9284, DOI 10.1073/pnas.86.23.9284; LIANG XW, 1989, J BIOL CHEM, V264, P14486; LOIS R, 1989, EMBO J, V8, P1641, DOI 10.1002/j.1460-2075.1989.tb03554.x; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MINAMI E, 1989, EUR J BIOCHEM, V185, P19, DOI 10.1111/j.1432-1033.1989.tb15075.x; OHL S, 1990, PLANT CELL, V2, P237; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO T, 1980, PLANT CELL PHYSIOL, V21, P137; SHARROCKS AD, 1991, BIOTECHNIQUES, V10, P426; TANAKA Y, 1989, PLANT PHYSIOL, V90, P1403, DOI 10.1104/pp.90.4.1403; VALLEJOS CE, 1986, GENETICS, V112, P93; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WILLIAMS BG, 1979, J VIROL, V29, P555, DOI 10.1128/JVI.29.2.555-575.1979	26	53	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11824	11830						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601854				2022-12-25	WOS:A1992HY94700031
J	NAGATA, Y; YAMASHIRO, S; YODOI, J; LLOYD, KO; SHIKU, H; FURUKAWA, K				NAGATA, Y; YAMASHIRO, S; YODOI, J; LLOYD, KO; SHIKU, H; FURUKAWA, K			EXPRESSION CLONING OF BETA-1,4 N-ACETYLGALACTOSAMINYLTRANSFERASE CDNAS THAT DETERMINE THE EXPRESSION OF GM2 AND GD2 GANGLIOSIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURO-BLASTOMA CELLS; PROTEIN KINASE-C; HUMAN-MELANOMA; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; PROMINENT GANGLIOSIDE; MEDIATED MODULATION; GENE-TRANSFER; SIALYL-LEX	G(M2) and G(D2) gangliosides are sialic acid-containing glycosphingolipids expressed in some normal tissues such as brain and in various tumors such as neuroblastomas, astrocytomas, and malignant melanomas. We used a eukaryotic cell transient expression system to isolate cDNA clones that determine G(M2) expression. We developed a new cell line from murine melanoma line B16 by transfecting with the polyoma T antigen gene that was suitable for this purpose. Two cDNA clones, both of which have a continuous open reading frame of 1683 base pairs, were isolated. Although the cloned cDNAs had no primary sequence similarity to reported glycosyltransferases, the deduced amino acid sequence predicted a type II transmembrane protein with an overall structure similar to other glycosyltransferases. The cDNA clones, when stably transfected, determined the expression of G(M2) in B16 cells and G(M2) and G(D2) in the human melanoma line MeWo. Northern blot analysis revealed two transcripts in all cells that expressed either G(M2) or G(D2) or both. These findings indicate that the cDNAs catalyze the transfer of GalNAc onto G(M3) and G(D2) by a beta-1,4 linkage, resulting in the synthesis of G(M2) and G(D2), respectively. Namely they suggest that these cDNAs derive from the UDP-GalNAc: G(M3)/B(D3) beta-1,4 N-acetylgalactosaminyltransferase (EC 2.4.1.92) gene.	NAGASAKI UNIV,SCH MED,DEPT ONCOL,NAGASAKI 852,JAPAN; KYOTO UNIV,INST VIRUS RES,KYOTO 606,JAPAN; SLOAN KETTERING MEM CANC CTR,NEW YORK,NY 10021	Nagasaki University; Kyoto University; Memorial Sloan Kettering Cancer Center					NCI NIH HHS [CA 21445, CA 08478] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA021445] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; CHERESH DA, 1984, P NATL ACAD SCI-BIOL, V81, P5767, DOI 10.1073/pnas.81.18.5767; CHERESH DA, 1986, J CELL BIOL, V102, P688, DOI 10.1083/jcb.102.3.688; CHEUNG NKV, 1985, CANCER RES, V45, P2642; CUMAR FA, 1972, J BIOL CHEM, V247, P2322; DAILEY L, 1985, J VIROL, V54, P739, DOI 10.1128/JVI.54.3.739-749.1985; DAVIS LG, 1986, BASIC METHODS MOL BI, P285; DAVIS LG, 1986, BASIC METHODS MOL BI, P290; EGGENS I, 1989, J BIOL CHEM, V264, P9476; ERNST LK, 1989, J BIOL CHEM, V264, P3436; FURUKAWA K, 1985, BIOCHEMISTRY-US, V24, P7820, DOI 10.1021/bi00347a047; Furukawa K., 1990, HUMAN MELANOMA BASIC, P15; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; HIRABAYASHI Y, 1985, J BIOL CHEM, V260, P3328; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; KLEINMAN HK, 1979, P NATL ACAD SCI USA, V76, P3367, DOI 10.1073/pnas.76.7.3367; KOJIMA H, 1987, BIOCHEM BIOPH RES CO, V143, P716, DOI 10.1016/0006-291X(87)91413-6; KOJIMA N, 1989, J BIOL CHEM, V264, P20159; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P3873, DOI 10.1093/nar/12.9.3873; KREUTTER D, 1987, J BIOL CHEM, V262, P1633; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; Maniatis T., 1982, MOL CLONING LABORATO, P86; Maniatis T., 1982, MOL CLONING LABORATO, P76; NARIMATSU H, 1986, P NATL ACAD SCI USA, V83, P4720, DOI 10.1073/pnas.83.13.4720; NATOLI EJ, 1986, CANCER RES, V46, P4116; PACUSZKA T, 1978, J BIOL CHEM, V253, P5839; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; PUKEL CS, 1982, J EXP MED, V155, P1133, DOI 10.1084/jem.155.4.1133; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; THURIN J, 1986, FEBS LETT, V208, P17, DOI 10.1016/0014-5793(86)81522-8; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; Wiegandt H, 1985, GLYCOLIPIDS, V10, P199, DOI DOI 10.1016/S0167-7306(08)60022-8; WYSOCKI LJ, 1978, P NATL ACAD SCI USA, V75, P2844, DOI 10.1073/pnas.75.6.2844; YAMAMOTO F, 1990, J BIOL CHEM, V265, P1146; YODOI J, 1985, J IMMUNOL, V134, P1623	62	182	189	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12082	12089						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601877				2022-12-25	WOS:A1992HY94700067
J	RABOUDI, N; JULIAN, J; ROHDE, LH; CARSON, DD				RABOUDI, N; JULIAN, J; ROHDE, LH; CARSON, DD			IDENTIFICATION OF CELL-SURFACE HEPARIN HEPARAN SULFATE-BINDING PROTEINS OF A HUMAN UTERINE EPITHELIAL-CELL LINE (RL95)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; SEQUENCE-ANALYSIS; EXPRESSION; PROTEOGLYCAN; GENE; CLONING; PURIFICATION; FIBRONECTIN; ENDOCYTOSIS; AFFINITY	The interaction of heparin (HP) with the cell-surface components of a human uterine epithelial carcinoma cell line (RL95) was studied. Binding of [H-3]HP to cell surfaces was saturable in a dose- and time-dependent manner. HP and certain forms of heparan sulfate (HS) efficiently compete for [H-2]HP binding. In contrast, other glycosaminoglycans, such as chondroitin sulfate, keratan sulfate, hyaluronic acid, and dermatan sulfate, do not compete for binding to these sites. Scatchard analysis revealed that [H-3]HP bound to these sites with an apparent K(D) of 0.7-0.9-mu-M and a binding capacity of 9 x 10(6) sites/cell to attached cells. EDTA-detached cells displayed a similar apparent K(D), but an approximately 2-fold increase in binding capacity. Protease digestion of cells on ice markedly reduced [H-3]HP binding, indicating that these binding sites were associated with proteins. In contrast, heparinase treatment of cells stimulated binding by approximately 2-fold, indicating that a large fraction of these binding sites were occupied with endogenous ligand. We examined the structural features of HP/HS required for HP/HS binding. O-Sulfation, substitution of amino groups, and, to a lesser extent, the presence of carboxyl groups were important recognition features of HP/HS by cell-surface HP/HS-binding sites. N-Sulfation was not required. Photoaffinity labeling with I-125-sulfosuccinimidyl 2-(p-azidosalicylamido)ethyl-1,3-dithiopropionate-HP was used to identify HP/HS-binding proteins on RL95 cell surfaces. Proteins with M(r) values of 14,000-18,500 and 31,000 were photolabeled at the surfaces of attached cells. Photolabeling was blocked by the addition of excess HP, but not chondroitin sulfate. Additional proteins with M(r) values >31,000 were photolabeled specifically on EDTA-detached cells. Moreover, the M(r) 14,00018, 500 and 31,000 proteins were retained on the EDTA-detached cells. These observations indicated that certain cell-surface HP/HS-binding proteins were not exposed when cells were attached to substrata. Proteins of similar M(r) values as the photolabeled components as well as many additional proteins were identified by heparin-agarose chromatographic selection of extracts of cells labeled metabolically with [S-35]methionine or vectorially with (NaI)-I-125 at the cell surface. Fragments of cell-surface HP/HS-binding proteins were released from intact RL95 and mouse uterine epithelial cells by mild trypsinization and isolated by heparin-agarose affinity chromatography. Three peptides with M(r) values between 6000 and 14,000 required > 0.5 M salt for elution from heparin-agarose, retained HP binding activity in a I-125-HP gel overlay assay, and selectively bound [H-2]HP in a solid-phase binding assay. Microsequencing demonstrated single unique amino-terminal sequences for each of the three peptides. Furthermore, these sequences each had similarities to other carbohydrate-binding proteins. Collectively, these studies indicate the presence of multiple HP/HS-binding proteins at the cell surface of human uterine cells. A role for some of these proteins in binding HP and certain forms of HS present in basal laminae and on peri-implantation-stage embryos is suggested by analogy with the indicated role for HS-binding proteins in mouse embryo implantation.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025235, R37HD025235] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-25235] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ATHA DH, 1984, BIOCHEMISTRY-US, V23, P5801, DOI 10.1021/bi00319a020; BARZU T, 1985, BIOCHIM BIOPHYS ACTA, V845, P196, DOI 10.1016/0167-4889(85)90177-6; BISWAS C, 1988, J CELL PHYSIOL, V136, P147, DOI 10.1002/jcp.1041360119; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CERI H, 1990, BIOCHEM CELL BIOL, V68, P790, DOI 10.1139/o90-113; DEPAGTERHOLTHUIZEN P, 1988, BIOCHIM BIOPHYS ACTA, V950, P282, DOI 10.1016/0167-4781(88)90124-8; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUTT A, 1986, ENDOCRINOLOGY, V118, P661, DOI 10.1210/endo-118-2-661; EBBOLE DJ, 1987, J BIOL CHEM, V262, P8274; FARACH MC, 1988, BIOL REPROD, V39, P443, DOI 10.1095/biolreprod39.2.443; FARACH MC, 1987, DEV BIOL, V123, P401, DOI 10.1016/0012-1606(87)90398-8; FEDARKO NS, 1989, J CELL PHYSIOL, V139, P287, DOI 10.1002/jcp.1041390210; FRANSSON LA, 1983, J BIOL CHEM, V258, P4342; FRITZE LMS, 1985, J CELL BIOL, V100, P1041, DOI 10.1083/jcb.100.4.1041; FUJISAWASEHARA A, 1990, J BIOL CHEM, V265, P15219; FURUKAWA T, 1990, J BIOCHEM-TOKYO, V108, P297, DOI 10.1093/oxfordjournals.jbchem.a123197; GALLAGHER JT, 1985, BIOCHEM J, V230, P665, DOI 10.1042/bj2300665; IOZZO RV, 1988, J CELL BIOCHEM, V37, P61, DOI 10.1002/jcb.240370107; IRIMURA T, 1986, BIOCHEMISTRY-US, V25, P5322, DOI 10.1021/bi00366a050; JALKANEN M, 1987, MED BIOL, V65, P41; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KJELLEN L, 1980, J BIOL CHEM, V255, P407; KOHNKEGODT B, 1991, BIOCHEMISTRY-US, V30, P55, DOI 10.1021/bi00215a009; KURAMOTO H, 1972, Acta Obstetrica et Gynaecologica Japonica (English Edition), V19, P47; LANKES W, 1988, BIOCHEM J, V251, P831, DOI 10.1042/bj2510831; LEUNG PSC, 1987, J BACTERIOL, V169, P4355, DOI 10.1128/jb.169.9.4355-4360.1987; LINDAHL U, 1987, BIOL PROTEOGLYCANS, P59; LIPKE PN, 1989, MOL CELL BIOL, V9, P3155, DOI 10.1128/MCB.9.8.3155; LOBB R, 1986, J BIOL CHEM, V261, P1924; MARASHI F, 1986, BIOCHEM CELL BIOL, V64, P277, DOI 10.1139/o86-039; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MILLIS AJT, 1985, J BIOL CHEM, V260, P3754; MORAD N, 1984, BIOCHIM BIOPHYS ACTA, V801, P117, DOI 10.1016/0304-4165(84)90219-8; MURPHY PR, 1990, ANAL BIOCHEM, V187, P197, DOI 10.1016/0003-2697(90)90440-K; NYBROE O, 1989, J NEUROCHEM, V52, P1947, DOI 10.1111/j.1471-4159.1989.tb07283.x; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; RUOSLAHTI E, 1981, COLLAGEN REL RES, V1, P95; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SORENSEN P, 1986, J BIOL CHEM, V261, P9094; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WAY DL, 1983, IN VITRO CELL DEV B, V19, P147; WILSON O, 1990, J CELL PHYSIOL, V143, P60, DOI 10.1002/jcp.1041430108; WOLLENWEBER HW, 1985, J BIOL CHEM, V260, P5068; WRIGHT TC, 1987, J CELL PHYSIOL, V132, P255, DOI 10.1002/jcp.1041320209; YAMADA KM, 1980, J BIOL CHEM, V255, P6055	47	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11930	11939						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601862				2022-12-25	WOS:A1992HY94700044
J	SCHROTH, GP; CHOU, PJ; HO, PS				SCHROTH, GP; CHOU, PJ; HO, PS			MAPPING Z-DNA IN THE HUMAN GENOME - COMPUTER-AIDED MAPPING REVEALS A NONRANDOM DISTRIBUTION OF POTENTIAL Z-DNA-FORMING SEQUENCES IN HUMAN GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURINE-PYRIMIDINE SEQUENCES; HANDED Z-DNA; MOLECULAR-STRUCTURE; ESCHERICHIA-COLI; Z TRANSITION; TRANSCRIPTION; TEMPLATE; INVITRO; INVIVO; TRACTS	In this work, we have predicted and mapped the potential Z-DNA-forming sequences in over one million base pairs of human DNA, containing 137 complete genes. The computer program (Z-Hunt-II) developed for this study uses a rigorous thermodynamic search strategy to map the occurrence of left-handed Z-DNA in genomic sequences. The search algorithm has been optimized to search large sequences for the potential occurrence of Z-DNA, taking into account sequence type, length, and cooperativity for a given stretch of potential Z-DNA-forming nucleotides. In this extensive data set we have identified 329 potential Z-DNA-forming sequences. The exact locations of the potential Z-DNA-forming sequences in the data set have been mapped with respect to the location of structural features of the genes. This analysis reveals a distinctly nonrandom distribution of potential Z-DNA-forming sequences across human genes and, most notably, that strong Z-DNA-forming sequences are more commonly found near the 5' ends of genes. We find that 35% of the Z-DNA-forming sequences are located upstream of the first expressed exon, while only 3% of the sequences are located downstream of the last expressed exon. The remaining 62% of the Z-DNA-forming sequences, which are located either in introns (47.1%) or exons (14.9%), are also nonrandomly distributed, with a strong bias toward locations near the site of transcription initiation. We interpret this distribution of potential Z-DNA-forming sequences toward the 5' end of human genes in terms of the well established "twin-domain model" of transcription-induced supercoiling and the effect of this topological strain on Z-DNA formation in eukaryotic cells.	OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,535 WENIGER HALL,CORVALLIS,OR 97331	Oregon State University			Ho, Pui/AAF-8838-2020; Ho, Pui S/F-6186-2014	Ho, Pui/0000-0002-8082-4311; Ho, Pui S/0000-0002-8082-4311	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043133] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-43133] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAATEN DC, 1988, NUCLEIC ACIDS RES, V16, P865, DOI 10.1093/nar/16.3.865; BRILL SJ, 1988, CELL, V54, P403, DOI 10.1016/0092-8674(88)90203-6; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; DROGE P, 1991, NUCLEIC ACIDS RES, V19, P2941, DOI 10.1093/nar/19.11.2941; ELLISON MJ, 1985, P NATL ACAD SCI USA, V82, P8320, DOI 10.1073/pnas.82.24.8320; FIGUEROA N, 1988, P NATL ACAD SCI USA, V85, P9416, DOI 10.1073/pnas.85.24.9416; GIAVER GN, 1988, CELL, V55, P849; GILBERT W, 1991, NATURE, V349, P99, DOI 10.1038/349099a0; GROSS DS, 1986, MOL CELL BIOL, V6, P3010, DOI 10.1128/MCB.6.8.3010; HAMADA H, 1982, NATURE, V298, P396, DOI 10.1038/298396a0; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; HANIFORD DB, 1983, NATURE, V302, P632, DOI 10.1038/302632a0; HAYES TE, 1985, J BIOL CHEM, V260, P8145; HO PS, 1986, EMBO J, V5, P2737, DOI 10.1002/j.1460-2075.1986.tb04558.x; HOHEISEL JD, 1987, J MOL BIOL, V193, P447, DOI 10.1016/0022-2836(87)90259-2; JAWORSKI A, 1987, SCIENCE, V238, P773, DOI 10.1126/science.3313728; JIMENEZRUIZ A, 1991, P NATL ACAD SCI USA, V88, P31, DOI 10.1073/pnas.88.1.31; JOVIN TM, 1987, ANNU REV PHYS CHEM, V38, P521, DOI 10.1146/annurev.physchem.38.1.521; KAGAWA TF, 1989, BIOCHEMISTRY-US, V28, P6642, DOI 10.1021/bi00442a017; KENNARD O, 1989, Q REV BIOPHYS, V22, P327, DOI 10.1017/S0033583500002997; KONOPKA AK, 1985, NUCLEIC ACIDS RES, V13, P1683, DOI 10.1093/nar/13.5.1683; LANCILLOTTI F, 1987, P NATL ACAD SCI USA, V84, P1560, DOI 10.1073/pnas.84.6.1560; LEE MS, 1991, P NATL ACAD SCI USA, V88, P9675, DOI 10.1073/pnas.88.21.9675; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; MADDOX J, 1991, NATURE, V352, P11, DOI 10.1038/352011a0; MCCLELLAN JA, 1986, NUCLEIC ACIDS RES, V14, P9291, DOI 10.1093/nar/14.23.9291; MCLEAN MJ, 1988, J BIOL CHEM, V263, P7378; MCLEAN MJ, 1988, BIOCHIM BIOPHYS ACTA, V950, P243, DOI 10.1016/0167-4781(88)90120-0; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; NAYLOR LH, 1990, NUCLEIC ACIDS RES, V18, P1595, DOI 10.1093/nar/18.6.1595; NORDHEIM A, 1983, NATURE, V303, P674, DOI 10.1038/303674a0; NORDHEIM A, 1983, P NATL ACAD SCI-BIOL, V80, P1821, DOI 10.1073/pnas.80.7.1821; PANYUTIN I, 1985, J BIOMOL STRUCT DYN, V2, P1221, DOI 10.1080/07391102.1985.10507634; PECK LJ, 1983, P NATL ACAD SCI-BIOL, V80, P6206, DOI 10.1073/pnas.80.20.6206; PFAFFLE P, 1990, J BIOL CHEM, V265, P16830; RAHMOUNI AR, 1989, SCIENCE, V246, P358, DOI 10.1126/science.2678475; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; ROLLO F, 1989, J MOL EVOL, V28, P225, DOI 10.1007/BF02102480; TRIFONOV EN, 1985, FEBS LETT, V185, P197, DOI 10.1016/0014-5793(85)80769-9; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; WANG AHJ, 1979, NATURE, V282, P680, DOI 10.1038/282680a0; WANG JC, 1988, SCIENCE, V240, P300, DOI 10.1126/science.3281259; WELLS RD, 1988, J BIOL CHEM, V263, P1095; WITTIG B, 1989, J CELL BIOL, V108, P755, DOI 10.1083/jcb.108.3.755; WITTIG B, 1991, P NATL ACAD SCI USA, V88, P2259, DOI 10.1073/pnas.88.6.2259; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8	46	181	189	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11846	11855						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601856				2022-12-25	WOS:A1992HY94700034
J	PORTLOCK, SH; LEE, Y; TOMICH, JM; TAMM, LK				PORTLOCK, SH; LEE, Y; TOMICH, JM; TAMM, LK			INSERTION AND FOLDING OF THE AMINO-TERMINAL AMPHIPHILIC SIGNAL SEQUENCES OF THE MANNITOL AND GLUCITOL PERMEASES OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOLAYERS; PROTEINS; MEMBRANE; BILAYERS; AREA	Peptides which correspond to the NH2-terminal 23 or 22 residues of the mannitol and glucitol permeases (enzymes II(mtl) and II(gut) of the bacterial phosphotransferase system; mtl-23 and gut-22) and which are believed to function in envelope targeting were synthesized chemically, and their interactions with lipid model membranes were studied. Both wild-type peptides penetrated phospholipid monolayers up to high surface pressures, and partition constants of 8.0 x 10(4) M-1 and 4.2 x 10(4) M-1, respectively, were derived from the incorporation isotherms of mtl-23 and gut-22 with monolayers of 1-palmitoyl-2-oleoyl-3-sn-phosphatidylcholine at 32 mN/m or bilayers of the same lipid. The mtl-23 peptide was highly alpha-helical in trifluoroethanol, sodium dodecyl sulfate, lysolecithin, or vesicles of 1-palmitoyl-2-oleoyl-3-sn-phosphatidylglycerol, with estimated percentages of alpha-helix ranging between 60 and 85%. The interactions with model membranes of several single site mutants (S3P, D4P, and D4K) of mtl-23 which were defective in properly assembling the mannitol permease in the cytoplasmic membrane of Escherichia coli were also studied. The contents of alpha-helix of these peptides in detergent micelles or phospholipid bilayers were not significantly changed compared with those of the wild type, suggesting that the amphiphilic NH2-terminal membrane-targeting domain could still be formed in these mutants. However, the mutants which contained a proline in positions 3 or 4, i.e. NH2-terminal to the proposed amphiphilic alpha-helix, partitioned into phospholipid monolayers with partition constants that were 2 or 4 times smaller than those of the wild type. Based on these data, a model of the amphiphilic structure of the NH2-terminal domain of the mannitol permease is discussed. This domain may interact physiologically with amphiphilic interfaces of lipids and/or proteins during membrane insertion.	CHILDRENS HOSP LOS ANGELES,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT BIOCHEM,LOS ANGELES,CA 90033	Children's Hospital Los Angeles; University of Southern California; University of Southern California	PORTLOCK, SH (corresponding author), UNIV VIRGINIA,SCH MED,DEPT PHYSIOL,CHARLOTTESVILLE,VA 22908, USA.			TOMICH, JOHN/0000-0001-7848-8307	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030557, R37AI030557] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 30557, R37 AI030557] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARNI B, 1986, J BIOL CHEM, V261, P16398; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FREY S, 1990, BIOCHEM J, V272, P713, DOI 10.1042/bj2720713; GROVE A, 1992, METHOD ENZYMOL, V207, P510; LEWIS BA, 1983, J MOL BIOL, V166, P211, DOI 10.1016/S0022-2836(83)80007-2; REYNOLDS JA, 1974, P NATL ACAD SCI USA, V71, P2925, DOI 10.1073/pnas.71.8.2925; ROISE D, 1988, J BIOL CHEM, V263, P4509; SAIER MH, 1988, BIOCHIMIE, V70, P1743, DOI 10.1016/0300-9084(88)90033-8; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SEELIG A, 1987, BIOCHIM BIOPHYS ACTA, V899, P196, DOI 10.1016/0005-2736(87)90400-7; TAMM LK, 1991, BIOCHIM BIOPHYS ACTA, V1071, P123, DOI 10.1016/0304-4157(91)90021-N; TAMM LK, 1986, BIOCHEMISTRY-US, V25, P7470, DOI 10.1021/bi00371a032; TAMM LK, 1989, J BIOL CHEM, V264, P2587; VOGEL H, 1987, BIOCHEMISTRY-US, V26, P4562, DOI 10.1021/bi00388a060; WHITE SH, 1985, P NATL ACAD SCI USA, V82, P6532, DOI 10.1073/pnas.82.19.6532; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; YAMADA Y, 1991, J BIOL CHEM, V266, P17863	18	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11017	11022						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597443				2022-12-25	WOS:A1992HX16900016
J	WRIGHT, APH; GUSTAFSSON, JA				WRIGHT, APH; GUSTAFSSON, JA			GLUCOCORTICOID-SPECIFIC GENE ACTIVATION BY THE INTACT HUMAN GLUCOCORTICOID RECEPTOR EXPRESSED IN YEAST - GLUCOCORTICOID SPECIFICITY DEPENDS ON LOW-LEVEL RECEPTOR EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION; HORMONE	In the presence of appropriate reporter genes mammalian nuclear receptors are competent to transactivate gene expression when expressed in yeast cells. Thus yeast genetics could be used to identify determinants of steroid specificity for these mammalian proteins. However, unlike the estrogen, progesterone, vitamin D3, and thyroid hormone receptors, the glucocorticoid receptor shows an apparently abnormal steroid specificity in yeast (Schena, M., and Yamamoto, K. (1988) Science 241, 965-967), suggesting that the expressed protein might be incorrectly folded. We show here that the glucocorticoid receptor does exhibit a normal steroid specificity in yeast cells, but only at low levels of expressed receptor protein. Thus, at least under these conditions, genetic studies on steroid specificity are possible. At least part of the abnormal specificity that is sometimes observed for the glucocorticoid receptor in yeast appears to result from an artifact of the assay system and is not due to an abnormal receptor structure. This mechanism could account for all our data and so could provide the sole explanation of the abnormal specificity observed. However, it is also possible that part of the abnormal specificity could result from structural or other changes in receptor function, which occur when the receptor expression level is increased.	KAROLINSKA INST,NOVUM,HUDDINGE UNIV HOSP,DEPT MED NUTR,S-14157 HUDDINGE,SWEDEN	Karolinska Institutet	WRIGHT, APH (corresponding author), KAROLINSKA INST,NOVUM,HUDDINGE UNIV HOSP,CTR BIOTECHNOL,S-14157 HUDDINGE,SWEDEN.		Wright, Anthony PH/J-8187-2015					ALKSNIS M, 1991, J BIOL CHEM, V266, P10078; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; MAK P, 1989, J BIOL CHEM, V264, P21613; MCDONNELL DP, 1989, MOL CELL BIOL, V9, P3517, DOI 10.1128/MCB.9.8.3517; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; NEMOTO T, 1990, BIOCHEMISTRY-US, V29, P1880, DOI 10.1021/bi00459a031; OHARANEMOTO Y, 1990, J STEROID BIOCHEM, V37, P481, DOI 10.1016/0960-0760(90)90391-W; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; WRIGHT APH, 1991, P NATL ACAD SCI USA, V88, P8283, DOI 10.1073/pnas.88.19.8283; WRIGHT APH, 1990, J BIOL CHEM, V265, P14763; WRIGHT APH, 1991, MOL ENDOCRINOL, V5, P1366, DOI 10.1210/mend-5-10-1366	18	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11191	11195						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597454				2022-12-25	WOS:A1992HX16900042
J	MORRISON, LE; BOEHMELT, G; ENRIETTO, PJ				MORRISON, LE; BOEHMELT, G; ENRIETTO, PJ			MUTATIONS IN THE REL-HOMOLOGY DOMAIN ALTER THE BIOCHEMICAL-PROPERTIES OF V-REL AND RENDER IT TRANSFORMATION DEFECTIVE IN CHICKEN-EMBRYO FIBROBLASTS	ONCOGENE			English	Article							NF-KAPPA-B; DNA-BINDING SUBUNIT; VIRUS STRAIN-T; RETICULOENDOTHELIOSIS VIRUS; LYMPHOID-CELLS; TRANSCRIPTION FACTOR; PROTO-ONCOGENE; SPLEEN-CELLS; C-REL; ACTIVATION	Sequential deletions of approximately 100 base pairs were made in the rel-homology domain of the viral rel protein. Each deletion mutant was cloned into a replication-competent viral vector and assayed in chicken embryo fibroblasts (CEFs). The deleted v-rel proteins were analysed for localization, complex formation and ability to induce transformation. In vitro-translated mutant proteins were assayed for binding to a NF-kappa-B consensus sequence. All the deletion mutants between nucleotides 37 and 798 in v-rel were transformation defective. Each of the mutants localized predominantly in the cytoplasm, whereas wild-type v-rel localizes predominantly in the nucleus of CEFs. Any disruption of the rel-homology domain reduced binding of the mutant v-rel proteins to the cellular protein, p36, while the requirements for binding to p68c-rel, p115 and p124 appeared to be more complicated. The binding of these three proteins to v-rel appeared to be linked and mediated through c-rel, suggesting that v-rel disrupts normal c-rel function. None of the deletion mutants in this region were able to bind to the NF-kappa-B site. However, mutants which lie outside the rel-homology domain retained the ability to transform CEFs, localize to the nucleus, complex with p36, p115, p124 and p68c-rel and bind to the NK-kappa-B site. These results suggest that transformation by v-rel requires an intact rel-homology domain and that the biochemical properties of v-rel are linked and dependent upon higher order protein structure for full function.	SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794; RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)					NCI NIH HHS [2T32CA09176, R0I CA51792] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009176, R01CA051792] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BHAT GV, 1990, ONCOGENE, V5, P625; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN ISY, 1981, J VIROL, V40, P800, DOI 10.1128/JVI.40.3.800-811.1981; COHEN RS, 1981, VIROLOGY, V113, P672, DOI 10.1016/0042-6822(81)90196-3; DAVEY J, 1985, CELL, V40, P667, DOI 10.1016/0092-8674(85)90215-6; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; GARSON K, 1990, VIROLOGY, V177, P106, DOI 10.1016/0042-6822(90)90464-3; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HOELZER JD, 1979, VIROLOGY, V93, P20, DOI 10.1016/0042-6822(79)90272-1; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; IP YT, 1991, CELL, V64, P439; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MORRISON LE, 1991, ONCOGENE, V6, P1657; MORRISON LE, 1989, ONCOGENE, V4, P667; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PURCHASE HG, 1975, RETICULOENDOTHELIOSI; RICE NR, 1982, J VIROL, V42, P237, DOI 10.1128/JVI.42.1.237-252.1982; RICHARDSON PM, 1991, IN PRESS J VIROL, V65; SCHWARTZ RC, 1988, VIROLOGY, V165, P182, DOI 10.1016/0042-6822(88)90671-X; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SIMEK S, 1988, ONCOGENE RES, V2, P102; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198	44	35	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1137	1147						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594245				2022-12-25	WOS:A1992HU64200011
J	MURPHY, JE; KEEN, JH				MURPHY, JE; KEEN, JH			RECOGNITION SITES FOR CLATHRIN-ASSOCIATED PROTEIN-AP-2 AND PROTEIN-AP-3 ON CLATHRIN TRISKELIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLES; ASSEMBLY PROTEIN; MONOCLONAL-ANTIBODIES; PLASMA-MEMBRANE; HEAVY-CHAIN; BINDING; IDENTIFICATION; PURIFICATION; POLYPEPTIDES; RECEPTORS	AP-2 and AP-3 are cellular proteins that drive the in vitro polymerization of clathrin triskelia into cage structures. The interaction of these two types of assembly proteins (APs) with preassembled clathrin cages has been studied in order to identify the sites on the triskelia required for binding. Comparing binding of the APs to intact or to proteolytically clipped cages, we attempted to distinguish between binding to the terminal domain, the globular end of the heavy chain, and binding to the hub of the clathrin triskelia, the portion that remains assembled after trypsin treatment. AP-3 binds to intact clathrin cages but not to those that were treated with trypsin. AP-3 also bound to cages consisting solely of clathrin heavy chains; proteolysis of these cages also eliminated AP-3 binding. In addition, AP-3 did not bind to either isolated hubs or terminal domains that had been immobilized on Sepharose. These data indicate that clathrin light chains are not required for binding of AP-3, and that neither terminal domain nor hubs alone will suffice. However, an intact heavy chain is both necessary and sufficient for the binding of AP-3. Previous work has demonstrated one binding site for AP-2 on proteolyzed cages containing only clathrin hubs; the existence of a second binding site associated with the terminal domain was hypothesized. Here we provide direct evidence for recognition by AP-2 of isolated terminal domains immobilized on Sepharose and show that the core of the AP-2 molecule is responsible for this interaction. These results provide the first demonstration of a functional role for the conserved terminal domain of the clathrin heavy chain.	THOMAS JEFFERSON UNIV,SCH MED,DEPT PHARMACOL,BLSB RM 915,233 S 10TH ST,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140	Jefferson University; Jefferson University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NIGMS NIH HHS [GM-28526] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028526] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLE S, 1989, J BIOL CHEM, V264, P20089; AHLE S, 1986, EMBO J, V5, P3143, DOI 10.1002/j.1460-2075.1986.tb04621.x; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; BECK KA, 1991, J BIOL CHEM, V266, P4442; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; CAVANNI P, 1989, BIOCHEM BIOPH RES CO, V160, P174, DOI 10.1016/0006-291X(89)91637-9; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; HANSPAL M, 1984, J BIOL CHEM, V259, P1075; HEUSER JE, 1988, J CELL BIOL, V107, P877, DOI 10.1083/jcb.107.3.877; KEEN JH, 1986, J CELL BIOL, V102, P1325, DOI 10.1083/jcb.102.4.1325; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KEEN JH, 1989, BIOCHEM BIOPH RES CO, V158, P17, DOI 10.1016/S0006-291X(89)80170-6; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; KEEN JH, 1991, J BIOL CHEM, V266, P7950; KEEN JH, 1990, ADV CELL BIOL, V3, P153; KIRCHHAUSEN T, 1986, J ULTRA MOL STRUCT R, V94, P199, DOI 10.1016/0889-1605(86)90067-4; KIRCHHAUSEN T, 1984, J CELL BIOL, V99, P1725, DOI 10.1083/jcb.99.5.1725; KIRCHHAUSEN T, 1987, P NATL ACAD SCI USA, V84, P8805, DOI 10.1073/pnas.84.24.8805; KOHTZ DS, 1988, J BIOL CHEM, V263, P7418; LEMMON SK, 1991, J CELL BIOL, V112, P65, DOI 10.1083/jcb.112.1.65; LIN HC, 1991, J CELL BIOL, V114, P881, DOI 10.1083/jcb.114.5.881; MATSUI W, 1990, BIOCHEMISTRY-US, V29, P10791, DOI 10.1021/bi00500a011; MUELLER SC, 1984, J CELL BIOL, V98, P341, DOI 10.1083/jcb.98.1.341; MURPHY J, 1991, J CELL BIOL, V115, P186; MURPHY JE, 1991, J BIOL CHEM, V266, P4401; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PRASAD K, 1988, BIOCHEMISTRY-US, V27, P6098, DOI 10.1021/bi00416a040; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; UNANUE ER, 1981, CELL, V26, P439, DOI 10.1016/0092-8674(81)90213-0; UNGEWICKELL E, 1983, EMBO J, V2, P1401, DOI 10.1002/j.1460-2075.1983.tb01598.x; VIGERS GPA, 1986, EMBO J, V5, P2079, DOI 10.1002/j.1460-2075.1986.tb04469.x; VIGERS GPA, 1986, EMBO J, V5, P529, DOI 10.1002/j.1460-2075.1986.tb04242.x; WINKLER FK, 1983, EMBO J, V2, P1393, DOI 10.1002/j.1460-2075.1983.tb01597.x; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339; ZAREMBA S, 1985, J CELL BIOCHEM, V28, P47, DOI 10.1002/jcb.240280108	36	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10850	10855						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587861				2022-12-25	WOS:A1992HV09000096
J	SHAKINESHLEMAN, SH; REMALEY, AT; ESHLEMAN, JR; WUNNER, WH; SPITALNIK, SL				SHAKINESHLEMAN, SH; REMALEY, AT; ESHLEMAN, JR; WUNNER, WH; SPITALNIK, SL			N-LINKED GLYCOSYLATION OF RABIES VIRUS GLYCOPROTEIN - INDIVIDUAL SEQUONS DIFFER IN THEIR GLYCOSYLATION EFFICIENCIES AND INFLUENCE ON CELL-SURFACE EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; SITE-DIRECTED MUTAGENESIS; HUMAN CHORIONIC-GONADOTROPIN; G-PROTEIN; OLIGOSACCHARIDE CHAINS; STRUCTURAL REQUIREMENTS; ENZYMATIC CONVERSION; VACCINIA VIRUS; ALPHA-SUBUNIT; TRANSPORT	Many eukaryotic proteins are modified by N-linked glycosylation, a process in which oligosaccharides are added to asparagine residues in the sequon Asn-X-Ser/Thr. However, not all such sequons are glycosylated. For example, rabies virus glycoprotein (RGP) contains three sequons, only two of which appear to be glycosylated in virions. To examine further the signals in proteins which regulate N-linked core glycosylation, the glycosylation efficiencies of each of the three sequons in the antigenic domain of RGP were compared. For these studies, mutants were generated in which one or more sequons were deleted by site-directed mutagenesis. Core glycosylation of these mutants was studied using two independent systems: 1) in vitro translation in rabbit reticulocyte lysate supplemented with dog pancreatic microsomes, and 2) transfection into glycosylation-deficient Chinese hamster ovary cells. Parallel results were obtained with both systems, demonstrating that the sequon at Asn37 is inefficiently glycosylated, the sequons at Asn247 and Asn319 are efficiently glycosylated, and the glycosylation efficiency of each sequon is not influenced by glycosylation at other sequons in this protein. High levels of cell surface expression of RGP in Chinese hamster ovary cells are seen with any mutant containing an intact sequon at Asn247 or Asn319, whereas low levels of cell surface expression are seen when the sequon at Asn37 is present alone; deletion of all three sequons completely blocks RGP cell surface expression. Thus, although core glycosylation at Asn37 is inefficient, it is still sufficient to support a biological function, cell surface expression. Future studies using mutagenesis of this model protein and its expression in these two well defined systems will aim to begin to unravel the rules governing core glycosylation of glycoproteins.	UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,220 JOHN MORGAN BLDG,36TH ST & HAMILTON WALK,PHILADELPHIA,PA 19104; WISTAR INST,PHILADELPHIA,PA 19104	University of Pennsylvania; The Wistar Institute				Spitalnik, Steven/0000-0002-8528-4561	NATIONAL CANCER INSTITUTE [T32CA009140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014373] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA09140-15] Funding Source: Medline; NIGMS NIH HHS [1 F32 GM 14373-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS D, 1989, BIOTECHNIQUES, V7, P960; ANDREWS DW, 1988, J BIOL CHEM, V263, P15791; BURGER SR, 1991, J GEN VIROL, V72, P359, DOI 10.1099/0022-1317-72-2-359; BURKE B, 1984, EMBO J, V3, P551, DOI 10.1002/j.1460-2075.1984.tb01845.x; DUBE S, 1988, J BIOL CHEM, V263, P17516; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; GIBSON R, 1981, J BIOL CHEM, V256, P456; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GUAN JL, 1985, CELL, V42, P489, DOI 10.1016/0092-8674(85)90106-0; GUAN JL, 1988, J BIOL CHEM, V263, P5306; HICKMAN S, 1978, J IMMUNOL, V121, P990; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOBMAN TC, 1991, VIROLOGY, V181, P768, DOI 10.1016/0042-6822(91)90915-X; KIENY MP, 1984, NATURE, V312, P163, DOI 10.1038/312163a0; KLENK HD, 1990, IMMUNOCHEMISTRY VIRU, V2, P25; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOTWAL GJ, 1986, J BIOL CHEM, V261, P8936; KRONQUIST KE, 1978, J SUPRAMOL STR CELL, V8, P51, DOI 10.1002/jss.400080105; LAFON M, 1983, J GEN VIROL, V64, P843, DOI 10.1099/0022-1317-64-4-843; LEAVITT R, 1977, J BIOL CHEM, V252, P9018; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MACHAMER CE, 1985, MOL CELL BIOL, V5, P3074, DOI 10.1128/MCB.5.11.3074; MACHAMER CE, 1988, J BIOL CHEM, V263, P5948; Marshall R D, 1974, Biochem Soc Symp, P17; MATZUK MM, 1989, J BIOL CHEM, V264, P2409; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; MIZRAHI A, 1978, J BIOL CHEM, V253, P7612; MONONEN I, 1984, BIOCHIM BIOPHYS ACTA, V788, P364, DOI 10.1016/0167-4838(84)90050-5; NAKAI K, 1988, J BIOCHEM-TOKYO, V104, P693, DOI 10.1093/oxfordjournals.jbchem.a122535; NG DTW, 1990, MOL CELL BIOL, V10, P1989, DOI 10.1128/MCB.10.5.1989; NIELSEN DA, 1986, NUCLEIC ACIDS RES, V14, P5936, DOI 10.1093/nar/14.14.5936; NORRILD B, 1982, J VIROL, V43, P395, DOI 10.1128/JVI.43.2.395-402.1982; NOTHWEHR SF, 1989, J BIOL CHEM, V264, P3979; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PERARA E, 1986, SCIENCE, V232, P348, DOI 10.1126/science.3961485; PITTA AM, 1989, J VIROL, V63, P3801, DOI 10.1128/JVI.63.9.3801-3809.1989; PIZER LI, 1980, J VIROL, V34, P142, DOI 10.1128/JVI.34.1.142-153.1980; PLESS DD, 1977, P NATL ACAD SCI USA, V74, P134, DOI 10.1073/pnas.74.1.134; ROITSCH T, 1989, EUR J BIOCHEM, V181, P525, DOI 10.1111/j.1432-1033.1989.tb14755.x; Sambrook J, 1989, MOL CLONING LABORATO; SANTOSAGUADO J, 1987, MOL CELL BIOL, V7, P982, DOI 10.1128/MCB.7.3.982; SEMENKOVICH CF, 1990, J BIOL CHEM, V265, P5429; SHEARES BT, 1988, J BIOL CHEM, V263, P12778; SMITH JS, 1984, J CLIN MICROBIOL, V19, P267, DOI 10.1128/JCM.19.2.267-272.1984; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; STRUCK DK, 1978, J BIOL CHEM, V253, P5786; STRUCK DK, 1978, J BIOL CHEM, V253, P5332; SZCZESNASKORUPA E, 1989, J CELL BIOL, V108, P1237, DOI 10.1083/jcb.108.4.1237; TAI T, 1977, BIOCHEM BIOPH RES CO, V78, P434, DOI 10.1016/0006-291X(77)91273-6; TAO MH, 1989, J IMMUNOL, V143, P2595; VIDAL S, 1989, J VIROL, V63, P892, DOI 10.1128/JVI.63.2.892-900.1989; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WIKTOR TJ, 1984, P NATL ACAD SCI-BIOL, V81, P7194, DOI 10.1073/pnas.81.22.7194; WRIGHT KE, 1989, VIROLOGY, V171, P417, DOI 10.1016/0042-6822(89)90610-7; WUNNER WH, 1983, J GEN VIROL, V64, P1649, DOI 10.1099/0022-1317-64-8-1649; WUNNER WH, 1985, VIROLOGY, V140, P1, DOI 10.1016/0042-6822(85)90440-4; WUNNER WH, 1988, REV INFECT DIS, V10, P771; YELVERTON E, 1983, SCIENCE, V219, P614, DOI 10.1126/science.6297004	60	91	97	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10690	10698						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587845				2022-12-25	WOS:A1992HV09000073
J	KAN, CC; KOLESNICK, RN				KAN, CC; KOLESNICK, RN			A SYNTHETIC CERAMIDE ANALOG, D-THREO-1-PHENYL-2-DECANOYLAMINO-3-MORPHOLINO-1-PROPANOL, SELECTIVELY INHIBITS ADHERENCE DURING MACROPHAGE DIFFERENTIATION OF HUMAN LEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MONOCYTIC DIFFERENTIATION; LINE HL-60; MELANOMA-CELLS; PROTO-ONCOGENE; EXPRESSION; GLYCOLIPIDS; GANGLIOSIDES; FIBRONECTIN; RECOGNITION; CARCINOMA	Prior studies have demonstrated that sphingomyelin synthesis is involved in adherence during macrophage differentiation of HL-60 cells (Dressler, K. A., Kan, C.-C., and Kolesnick, R. N. (1991) J. Biol Chem 266, 11522-11527). The present studies show that glycosphingolipid synthesis is also involved. Initial studies demonstrated that the potent phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) stimulates a 6- and 12-fold increase in the levels of sialosyllactosylceramide (G(M3)) and glucosylceramide (GlcCer), respectively, during development of an adherent macrophage population. In contrast, the level of lactosylceramide (LacCer) decreased to 20% of unstimulated controls. These effects were specific to adherent macrophages as nonadherent cells had minimal alteration in the glycosphingolipid profile. D-Threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP), a competitive inhibitor of UDP-glucose:ceramide glucosyltransferase (EC 2.4.1.80), selectively blocked adherence during macrophage differentiation. PDMP markedly reduced basal levels of GlcCer, LacCer, and G(M3) and prevented TPA-stimulated effects. PDMP (0.03-10-mu-M) reduced adherence after TPA from 30 to 6% of the total population. PDMP did not block other aspects of phorbol ester-induced macrophage differentiation including growth inhibition, expression of mRNA transcripts for the proto-oncogenes c-fos and c-myc, development of the specific enzyme markers alpha-naphthyl acetate esterase and acid phosphatase, and the gross morphologic changes associated with macrophage differentiation. PDMP appeared to have no short term or prolonged toxic effect on HL-60 cells. These studies show that PDMP selectively blocked adherence of HL-60 cells during phorbol ester-induced macrophage differentiation and suggest that this compound may be useful in the description of the biologic roles of glycosphingolipids.	CORNELL UNIV,MED CTR,COLL MED,SLOAN KETTERING INST,PROGRAM MOLEC PHARMACOL & THERAPEUT,NEW YORK,NY 10021	Cornell University; Memorial Sloan Kettering Cancer Center					NCI NIH HHS [R01-CA-42385] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042385] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLACKBURN CC, 1986, J BIOL CHEM, V261, P2873; DRESSLER KA, 1991, J BIOL CHEM, V266, P11522; EGGENS I, 1989, J BIOL CHEM, V264, P9476; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HUANG RTC, 1978, NATURE, V276, P624, DOI 10.1038/276624a0; INOKUCHI J, 1990, CANCER RES, V50, P6731; INOKUCHI JI, 1989, J CELL PHYSIOL, V141, P573, DOI 10.1002/jcp.1041410316; KOJIMA N, 1989, J BIOL CHEM, V264, P20159; KOLESNICK RN, 1989, J BIOL CHEM, V264, P7617; MacNeal WJ, 1922, JAMA-J AM MED ASSOC, V78, P1122, DOI 10.1001/JAMA.1922.26410680001011; MILLER LJ, 1986, J IMMUNOL, V137, P2891; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; MOMOI T, 1983, J NATL CANCER I, V70, P229; MUELLER J, 1975, EUR J IMMUNOL, V5, P270, DOI 10.1002/eji.1830050411; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NOJIRI H, 1986, P NATL ACAD SCI USA, V83, P782, DOI 10.1073/pnas.83.3.782; NOJIRI H, 1984, BLOOD, V64, P534; OKADA Y, 1988, FEBS LETT, V235, P25, DOI 10.1016/0014-5793(88)81227-4; PERKINS RM, 1982, EXP CELL RES, V141, P231, DOI 10.1016/0014-4827(82)90211-7; Radin N S, 1981, Methods Enzymol, V72, P673; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SAITO M, 1985, BIOCHEM BIOPH RES CO, V132, P223, DOI 10.1016/0006-291X(85)91011-3; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; SCHNYDER J, 1978, J EXP MED, V148, P435, DOI 10.1084/jem.148.2.435; SHAYMAN JA, 1990, J BIOL CHEM, V265, P12135; SINGER MS, 1990, J CELL BIOL, V111, P1225; VUNNAM RR, 1980, CHEM PHYS LIPIDS, V26, P265; YAM LT, 1971, AM J CLIN PATHOL, V21, P1; YAMADA KM, 1981, J CELL PHYSIOL, V109, P343, DOI 10.1002/jcp.1041090218	29	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9663	9667						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577803				2022-12-25	WOS:A1992HT96500034
J	NGUYEN, TD; WOLFE, MS; HEINTZ, GG; WHITCOMB, DC; TAYLOR, IL				NGUYEN, TD; WOLFE, MS; HEINTZ, GG; WHITCOMB, DC; TAYLOR, IL			HIGH-AFFINITY BINDING-PROTEINS FOR PANCREATIC-POLYPEPTIDE ON RAT-LIVER MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-YY; RECEPTORS; CELLS; HORMONE; CHICKEN	We report here the identification on rat liver plasma membranes and microsomes of proteins that bind pancreatic polypeptide (PP) with high affinity and specificity (plasma membranes: K(D) = 4.6 nm, B(max) = 3.28 pmol/mg protein; microsomes: K(D) = 3.45 nm, B(max) = 18.7 pmol/mg protein). These binding proteins appeared coupled to a G-protein, since 0.1 mm guanosine 5'-O-(3-thiotriphosphate) decreased the affinity by half. When I-125-labeled PP-binding protein complexes covalently cross-linked with disuccinimido suberate were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, two radioactive bands with M(r) values of 52,000 and 38,000 were demonstrated. Both bands were inhibited by unlabeled PP with an IC50 of approximately 5 nM (but not by neuropeptide Y or peptide YY). After the cross-linked complexes were solubilized from liver microsomes with 0.2% Triton X-100 and gel-filtered, they did not interact with the lectins wheat germ agglutinin, Ulex europaeus agglutinin, Ricinus communis agglutinin, and soy bean agglutinin. That these binding proteins may not be glycosylated was further supported by the failure of either peptide N-glycosidase F and endo-beta-N-acetylglucosaminidase F to alter the size of the PP-binding protein complexes on gel electrophoresis. These PP-binding proteins may serve as receptors and mediate a hepatic effect of PP.	DUKE UNIV,MED CTR,DIV GASTROENTEROL,DURHAM,NC 27710	Duke University	NGUYEN, TD (corresponding author), VET ADM MED CTR,EG-018,508 FULTON ST,DURHAM,NC 27705, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040506, R01DK044072] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 40506, DK 44072] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMO ML, 1983, ENDOCRINOLOGY, V113, P508, DOI 10.1210/endo-113-2-508; ADRIAN TE, 1982, AM J PHYSIOL, V243, pG204, DOI 10.1152/ajpgi.1982.243.3.G204; AMARCOSTESEC A, 1974, J CELL BIOL, V61, P201, DOI 10.1083/jcb.61.1.201; BEGLINGER C, 1984, AM J PHYSIOL, V246, pG286, DOI 10.1152/ajpgi.1984.246.3.G286; BONNEVIENIELSEN V, 1982, P NATL ACAD SCI-BIOL, V79, P2167, DOI 10.1073/pnas.79.7.2167; ELDER JH, 1982, P NATL ACAD SCI-BIOL, V79, P4540, DOI 10.1073/pnas.79.15.4540; GETTYS TW, 1991, PANCREAS, V6, P46, DOI 10.1097/00006676-199101000-00007; GILBERT WR, 1986, ENDOCRINOLOGY, V118, P2495, DOI 10.1210/endo-118-6-2495; GILBERT WR, 1988, P NATL ACAD SCI USA, V85, P4745, DOI 10.1073/pnas.85.13.4745; INUI A, 1990, ENDOCRINOLOGY, V127, P934, DOI 10.1210/endo-127-2-934; KIMMEL JR, 1968, ENDOCRINOLOGY, V83, P1323, DOI 10.1210/endo-83-6-1323; KIMMEL JR, 1981, ENDOCRINOLOGY, V109, P1693, DOI 10.1210/endo-109-5-1693; KIMMEL JR, 1975, J BIOL CHEM, V250, P9369; Lin T M, 1974, Gastroenterology, V67, P737; NATA K, 1990, BIOCHEM BIOPH RES CO, V171, P330, DOI 10.1016/0006-291X(90)91397-B; NEVILLE DM, 1968, BIOCHIM BIOPHYS ACTA, V154, P540, DOI 10.1016/0005-2795(68)90014-7; NGUYEN TD, 1986, BIOCHEMISTRY-US, V25, P361, DOI 10.1021/bi00350a013; NGUYEN TD, 1987, J MEMBRANE BIOL, V98, P197, DOI 10.1007/BF01871183; OSWALD B, 1987, J LIPID RES, V28, P798; SCHWARTZ SS, 1980, ENDOCRINOLOGY, V106, P1178, DOI 10.1210/endo-106-4-1178; SCHWARTZ TW, 1987, FEBS LETT, V225, P209, DOI 10.1016/0014-5793(87)81159-6; SUN YS, 1986, AM J SURG, V151, P130, DOI 10.1016/0002-9610(86)90023-1; WHITCOMB DC, 1990, AM J PHYSIOL, V259, pG687, DOI 10.1152/ajpgi.1990.259.4.G687	23	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9416	9421						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577769				2022-12-25	WOS:A1992HR85400107
J	REIZER, J; SUTRINA, SL; WU, LF; DEUTSCHER, J; REDDY, P; SAIER, MH				REIZER, J; SUTRINA, SL; WU, LF; DEUTSCHER, J; REDDY, P; SAIER, MH			FUNCTIONAL INTERACTIONS BETWEEN PROTEINS OF THE PHOSPHOENOLPYRUVATE-SUGAR PHOSPHOTRANSFERASE SYSTEMS OF BACILLUS-SUBTILIS AND ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; PHOSPHO-CARRIER PROTEIN; SALMONELLA-TYPHIMURIUM; INDUCER EXCLUSION; ENZYME-I; STAPHYLOCOCCUS-AUREUS; NUCLEOTIDE-SEQUENCE; LACTOSE TRANSPORT; CRR GENES; IIIGLC	Proteins of the phosphoenolpyruvate:sugar phosphotransferase system (PTS) of Bacillus subtilis were overexpressed, purified to near homogeneity, and characterized. The proteins isolated include Enzyme I, HPr, the glucose-specific IIA domain of the glucose-specific Enzyme II (IIA(glc)), and the mannitol-specific IIA protein, IIA(mtl). Site specific mutant proteins of IIA(glc) and HPr were also overexpressed and purified, and their properties were compared with those of the wild type proteins. These proteins and their phosphorylated derivatives were characterized with respect to their immunological cross-reactivities employing the Western blot technique and in terms of their migratory behavior during sodium dodecyl sulfate-gel electrophoresis, nondenaturing gel electrophoresis, and isoelectric focusing. The interactions between homologous and heterologous Enzymes I and HPrs, between homologous and heterologous HPrs and the IIA(glc) proteins, and between homologous and heterologous IIAg(glc) proteins and IIBC(scr) of B. subtilis as well as IICB(glc) of Escherichia coli were defined and compared kinetically. The mutant HPrs and IIA(glc) proteins were also characterized kinetically as PTS phosphocarrier proteins and/or as inhibitors of the phosphotransferase reactions of the PTS. These studies revealed that complexation of IIA(glc) with the mutant form of HPr in which serine 46 was replaced by aspartate (S46D) did not increase the rate of phosphoryl transfer from phospho Enzyme I to S46D HPr more than when IIA(mtl) was complexed to S46D HPr. These findings do not support a role for HPr(Ser-P) in the preferential utilization of one PTS carbohydrate relative to another. Functional analyses in E. coli established that IIA(glc) of B. subtilis can replace IIA(glc) of E. coli with respect both to sugar transport and to regulation of non-PTS permeases, catabolic enzymes, and adenylate cyclase. Site-specific mutations in histidyl residues 68 and 83 (H68A and H83A) inactivated IIA(glc) of B. subtilis with respect to phosphoryl transfer and its various regulatory roles.	NATL INST STANDARDS & TECHNOL,CTR ADV RES BIOTECHNOL,ROCKVILLE,MD 20850	National Institute of Standards & Technology (NIST) - USA	REIZER, J (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014176, R01AI021702] Funding Source: NIH RePORTER; NIAID NIH HHS [5R01 AI 21702, 2R01 AI 14176] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CRUTZ AM, 1990, J BACTERIOL, V172, P1043, DOI 10.1128/jb.172.2.1043-1050.1990; DEAN DA, 1990, J BIOL CHEM, V265, P21005; DEREUSE H, 1988, J BACTERIOL, V170, P3827, DOI 10.1128/jb.170.9.3827-3837.1988; DEREUSE H, 1985, GENE, V35, P199; DEUTSCHER J, 1984, BIOCHEMISTRY-US, V23, P4455, DOI 10.1021/bi00314a033; DEUTSCHER J, 1982, BIOCHEMISTRY-US, V21, P4867, DOI 10.1021/bi00263a006; DORSCHUG M, 1984, EUR J BIOCHEM, V144, P113, DOI 10.1111/j.1432-1033.1984.tb08438.x; FAIRBROTHER WJ, 1991, BIOCHEMISTRY-US, V30, P6896, DOI 10.1021/bi00242a013; GONZYTREBOUL G, 1987, J BACTERIOL, V169, P2287, DOI 10.1128/jb.169.5.2287-2290.1987; GONZYTREBOUL G, 1989, MOL MICROBIOL, V3, P103, DOI 10.1111/j.1365-2958.1989.tb00109.x; GRENIER FC, 1986, J CELL BIOCHEM, V31, P97, DOI 10.1002/jcb.240310203; HENGSTENBERG W, 1969, J BACTERIOL, V99, P383, DOI 10.1128/JB.99.2.383-388.1969; KAPADIA G, 1991, J MOL BIOL, V221, P1079; KUKURUZINSKA MA, 1984, J BIOL CHEM, V259, P1679; KUKURUZINSKA MA, 1982, J BIOL CHEM, V257, P4470; KUNDIG W, 1971, J BIOL CHEM, V246, P1393; LECOO D, 1990, GENETIC TRANSFORMATION AND EXPRESSION, P447; LIAO DI, 1991, BIOCHEMISTRY-US, V30, P9583, DOI 10.1021/bi00104a004; LONDON J, 1983, J BACTERIOL, V156, P611, DOI 10.1128/JB.156.2.611-619.1983; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEADOW ND, 1982, J BIOL CHEM, V257, P4526; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MEADOW ND, 1986, J BIOL CHEM, V261, P3504; MISKO TP, 1987, J BIOL CHEM, V262, P16261; MITCHELL WJ, 1987, J BIOL CHEM, V262, P16254; NELSON SO, 1986, EUR J BIOCHEM, V154, P337, DOI 10.1111/j.1432-1033.1986.tb09402.x; NOEL D, 1979, BIOCHEMISTRY-US, V18, P4159, DOI 10.1021/bi00586a017; PELTON JG, 1991, P NATL ACAD SCI USA, V88, P3479, DOI 10.1073/pnas.88.8.3479; PEREGO M, 1989, J BACTERIOL, V171, P6187, DOI 10.1128/jb.171.11.6187-6196.1989; PRESPER KA, 1989, P NATL ACAD SCI USA, V86, P4052, DOI 10.1073/pnas.86.11.4052; REIZER J, 1989, BIOCHIMIE, V71, P989, DOI 10.1016/0300-9084(89)90102-8; REIZER J, 1989, EMBO J, V8, P2111, DOI 10.1002/j.1460-2075.1989.tb03620.x; REIZER J, 1988, P NATL ACAD SCI USA, V85, P2041, DOI 10.1073/pnas.85.7.2041; REIZER J, 1984, J BACTERIOL, V160, P333, DOI 10.1128/JB.160.1.333-340.1984; REIZER J, 1988, CRC CR REV MICROBIOL, V15, P297, DOI 10.3109/10408418809104461; REIZER J, 1984, J BACTERIOL, V159, P243, DOI 10.1128/JB.159.1.243-250.1984; REIZER J, 1987, SUGAR TRANSPORT META, P333; REIZER J, 1989, FEMS MICROBIOL REV, V63, P149; ROMANO AH, 1990, J BACTERIOL, V172, P6741, DOI 10.1128/jb.172.12.6741-6748.1990; SAFFEN DW, 1987, J BIOL CHEM, V262, P16241; SAIER MH, 1990, RES MICROBIOL, V141, P1033, DOI 10.1016/0923-2508(90)90077-4; SAIER MH, 1989, MICROBIOL REV, V53, P109, DOI 10.1128/MMBR.53.1.109-120.1989; SAIER MH, 1976, J BIOL CHEM, V251, P6606; SAIER MH, 1975, J BIOL CHEM, V250, P7078; SAIER MH, 1985, MECHANISMS REGULATIO; Sambrook J, 1989, MOL CLONING LABORATO; SIMONI RD, 1973, J BIOL CHEM, V248, P932; STEINMETZ M, 1990, GENETICS BIOTECHNOLO, V3, P303; SUTRINA SL, 1990, J BIOL CHEM, V265, P18581; VOGLER AP, 1988, MOL GEN GENET, V213, P175, DOI 10.1007/BF00333417; WAYGOOD EB, 1980, CAN J BIOCHEM CELL B, V58, P40, DOI 10.1139/o80-006; WEIGEL N, 1982, J BIOL CHEM, V257, P4461; ZUBER M, 1987, P NATL ACAD SCI USA, V84, P4514, DOI 10.1073/pnas.84.13.4514	53	112	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9158	9169						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577753				2022-12-25	WOS:A1992HR85400071
J	CARVER, TE; BRANTLEY, RE; SINGLETON, EW; ARDUINI, RM; QUILLIN, ML; PHILLIPS, GN; OLSON, JS				CARVER, TE; BRANTLEY, RE; SINGLETON, EW; ARDUINI, RM; QUILLIN, ML; PHILLIPS, GN; OLSON, JS			A NOVEL SITE-DIRECTED MUTANT OF MYOGLOBIN WITH AN UNUSUALLY HIGH O-2 AFFINITY AND LOW AUTOOXIDATION RATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; LIGAND-BINDING; CARBON-MONOXIDE; CRYSTALLOGRAPHIC REFINEMENT; SYNTHETIC GENE; MUTAGENESIS; OXYGEN; MECHANISM; KINETICS; OXYMYOGLOBIN	Mutants of sperm whale myoglobin were constructed at position 29 (B10 in helix notation) to examine the effects of distal pocket size on the rates of ligand binding and autooxidation. Leu29 was replaced with Ala, Val, and Phe using the synthetic gene and Escherichia coli expression system of Springer and Sligar (Springer, B. A., and Sligar, S. G. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 8961-8965). Structures of the ferric forms of Val29 and Phe29, and the oxy form of Phe29 myoglobin were determined to 1.7 angstrom by x-ray crystallography. The ferric mutant proteins are remarkably isomorphous with the wild type protein except in the immediate vicinity of residue 29. Thus, the protein structure in the distal pocket of myoglobin can accommodate either a large "hole" (i.e. Ala or Val) or a large side chain (i.e. Phe) at position 29 without perturbation of tertiary structure. Phe29 oxymyoglobin is also identical to the native oxy protein in terms of overall structure and interactions between the bound O2 and His64, Val68, Phe43, and Ile107. The distance between the nearest side chain atom of residue 29 and the second atom of the bound oxygen molecule is 3.2 angstrom in the Phe29 protein and 4.9 angstrom in native myoglobin. The equilibrium constants for O2 binding to Ala29, Val29, and Leu29 (native) myoglobin are the same, approximately 1.0 x 10(6) m-1 at 20-degrees-C, whereas that for the Phe29 protein is markedly greater, 15 x 10(6) M-1. This increase in affinity is due primarily to a 10-fold decrease in the O2 dissociation rate constant for the Phe29 mutant and appears to be the result of stabilizing interactions between the negative portion of the bound O2 dipole and the partially positive edge of the phenyl ring. Increasing the size of residue 29 causes large decreases in the rate of autooxidation of myoglobin: k(ox) = 0.24, 0.23, 0.055, and 0.005 h-1 for Ala29, Val29, Leu29 (native), and Phe29 myoglobin, respectively, in air at 37-degrees-C. Thus, the Leu29 --> Phe mutation produces a reduced protein that is remarkably stable and is expressed in E. coli as 100% MbO2. The selective pressure to conserve LeU29 at the B10 position probably represents a compromise between reducing the rate of autooxidation and maintaining a large enough O2 dissociation rate constant to allow rapid oxygen release during respiration.	RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251	Rice University	CARVER, TE (corresponding author), RICE UNIV,WM KECK CTR COMPUTAT BIOL,HOUSTON,TX 77251, USA.			Olson, John/0000-0002-0760-5403	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040252] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008280] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40252] Funding Source: Medline; NIGMS NIH HHS [GM-08280, T32 GM008280, GM-07933] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRANTLEY RE, 1992, BIOPHYS J, V61, P298; BRANTLEY RE, 1992, THESIS WM RICE U HOU; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; CARVER TE, 1990, J BIOL CHEM, V265, P20007; EGEBERG KD, 1990, J BIOL CHEM, V265, P11788; ELBER R, 1990, J AM CHEM SOC, V112, P9161, DOI 10.1021/ja00181a020; FERMI G, 1981, HAEMOGLOBIN MYOGLOBI, P26; FINSEL BC, 1987, J APPL CRYSTALLOGR, V20, P53; GIBSON QH, 1989, J BIOL CHEM, V264, P100; GREENWOO.C, 1967, J BIOL CHEM, V242, P1782; JOHNSON KA, 1989, J MOL BIOL, V207, P459, DOI 10.1016/0022-2836(89)90269-6; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KOTTALAM J, 1988, J AM CHEM SOC, V110, P7690, DOI 10.1021/ja00231a018; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MATHEWS AJ, 1989, J BIOL CHEM, V264, P16573; NAGAI K, 1987, NATURE, V329, P858, DOI 10.1038/329858a0; PHILLIPS GN, 1990, PROTEINS, V7, P358, DOI 10.1002/prot.340070407; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; Sack J. S., 1988, J MOL GRAPHICS, V6, P244; Sambrook J, 1989, MOL CLONING LABORATO; SASSAROLI M, 1986, J BIOL CHEM, V261, P6292; SHIKAMA K, 1984, BIOCHEM J, V223, P279, DOI 10.1042/bj2230279; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; THOMAS KA, 1982, P NATL ACAD SCI-BIOL, V79, P4843, DOI 10.1073/pnas.79.16.4843; Vainshtein B. K., 1978, Soviet Physics - Crystallography, V23, P287; WALLACE WJ, 1982, J BIOL CHEM, V257, P4966; WEISS JJ, 1964, NATURE, V202, P83, DOI 10.1038/202083b0; WITTENBERG JB, 1986, J BIOL CHEM, V261, P3624	34	200	201	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14443	14450						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629229				2022-12-25	WOS:A1992JD32500099
J	FOURNIER, D; BRIDE, JM; HOFFMANN, F; KARCH, F				FOURNIER, D; BRIDE, JM; HOFFMANN, F; KARCH, F			ACETYLCHOLINESTERASE - 2 TYPES OF MODIFICATIONS CONFER RESISTANCE TO INSECTICIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-MELANOGASTER; ESTERASE GENE; AMPLIFICATION; MALATHION; FLIES	Quantitative and qualitative changes in acetylcholinesterase confer resistance to insecticides. We have constructed several Drosophila melanogaster strains producing various amounts of enzyme by P-mediated transformation. Toxicological analysis of these strains demonstrates that resistance to organophosphorus insecticides is correlated with the amount of acetylcholinesterase in the central nervous system. Resistance may also be qualitatively determined. Comparison of the Drosophila acetylcholinesterase gene between a resistant strain caught in the wild and a wild type susceptible strain only revealed one nucleotide transition resulting in the replacement of a phenylalanine by a tyrosine. Flies mutant for acetylcholinesterase and rescued with a minigene mutagenized for this same transition produced an altered enzyme which renders flies resistant to pesticides.	UNIV GENEVA,DEPT ZOOL & ANIM BIOL,CH-1224 CHEONE BOUGERIES,SWITZERLAND	University of Geneva	FOURNIER, D (corresponding author), INRA,CTR RECH ANTIBES,BIOL INVERTEBRES LAB,F-06606 ANTIBES,FRANCE.							ALDRIDGE WN, 1950, BIOCHEM J, V46, P451, DOI 10.1042/bj0460451; DEVONSHIRE AL, 1984, PESTIC BIOCHEM PHYS, V21, P336, DOI 10.1016/0048-3575(84)90101-9; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FIELD LM, 1988, BIOCHEM J, V251, P309, DOI 10.1042/bj2510309; FOURNIER D, 1992, J BIOL CHEM, V267, P1840; FOURNIER D, 1989, J MOL BIOL, V210, P15, DOI 10.1016/0022-2836(89)90287-8; FOURNIER D, 1988, FEBS LETT, V238, P233; HALL JC, 1976, GENETICS, V83, P517; HALL LMC, 1986, EMBO J, V5, P2949, DOI 10.1002/j.1460-2075.1986.tb04591.x; HOFFMANN F, 1992, J MOL BIOL, V223, P17, DOI 10.1016/0022-2836(92)90710-2; KREJCI E, 1991, P NATL ACAD SCI USA, V88, P6647, DOI 10.1073/pnas.88.15.6647; MORTON RA, 1982, BIOCHEM GENET, V20, P179, DOI 10.1007/BF00484945; MORTON RA, 1985, PESTIC BIOCHEM PHYS, V24, P19, DOI 10.1016/0048-3575(85)90109-9; MOUCHES C, 1986, SCIENCE, V233, P778, DOI 10.1126/science.3755546; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; PAURON D, 1989, BIOCHEMISTRY-US, V28, P1673, DOI 10.1021/bi00430a037; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SMISSAERT HR, 1964, SCIENCE, V143, P129, DOI 10.1126/science.143.3602.129; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899	21	176	191	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14270	14274						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629220				2022-12-25	WOS:A1992JD32500075
J	KU, G; THOMAS, CE; AKESON, AL; JACKSON, RL				KU, G; THOMAS, CE; AKESON, AL; JACKSON, RL			INDUCTION OF INTERLEUKIN-1-BETA EXPRESSION FROM HUMAN PERIPHERAL-BLOOD MONOCYTE-DERIVED MACROPHAGES BY 9-HYDROXYOCTADECADIENOIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE CELLS; HUMAN-ENDOTHELIAL-CELLS; CHOLESTEROL DEPOSITION; HUMAN ATHEROMA; LINOLEIC-ACID; MESSENGER-RNA; CYTO-TOXICITY; BINDING-SITE; DERIVATIVES	Oxidatively modified low density lipoproteins (LDL) have recently been proposed to play a role in atherogenesis by promoting foam cell formation and endothelial cell toxicity. The purpose of the present study was to determine whether modified LDL could also induce macrophage release of interleukin 1-beta (IL-1-beta), a cytokine which enhances vascular smooth muscle cell proliferation, another feature of the atherosclerotic process. LDL were oxidatively modified by incubation with either Cu2+ (Cu2+-LDL) or human peripheral blood monocyte-derived macrophages (M-LDL). Incubation of these modified LDL with macrophages (6 x 10(6) cells/culture) resulted in a dose-dependent induction of IL-1-beta release. At 300-mu-g protein/ml, Cu2+-LDL and M-LDL induced 422 and 333 pg of IL-1-beta/culture, respectively. Saponified Cu2+-LDL and M-LDL were shown to contain 9- and 13-hydroxyoctadecadienoic acid (HODE), lipid oxidation products of linoleate. When tested for activity in macrophage culture (3 x 10(6) cells/culture), it was found that 9-HODE and 13-HODE (final concentration 33-mu-M) induced the release of 122 and 43 pg of IL-1-beta/culture, respectively, whereas untreated cells released only 4 pg of IL-1-beta/culture. Incubation of macrophages with cholesteryl-9-HODE also induced IL-1-beta release; however, the degree of induction of IL-1-beta release by 9-HODE or its cholesteryl ester relative to modified LDL suggests that other components in oxidized LDL may also contribute to IL-1-beta induction. 9-HODE was rapidly taken up by macrophages, and the kinetics were similar to IL-1-beta release. A 1.5- to 6-fold increase in the level of IL-1-beta mRNA was detected as little as 3-h post-9-HODE treatment. The induction of IL-1-beta release from human monocyte-derived macrophages by 9-HODE and cholesteryl-9-HODE suggests a role for modified LDL, and its associated linoleate oxidation products, in vascular smooth muscle cell proliferation.			KU, G (corresponding author), MARION MERRELL DOW RES INST, 2110 E GALBRAITH RD, CINCINNATI, OH 45215 USA.							BROOKS CJW, 1971, ATHEROSCLEROSIS, V13, P223, DOI 10.1016/0021-9150(71)90025-6; BROOKS JCW, 1970, BIOCHIM BIOPHYS ACTA, V202, P563; BROWN MS, 1980, J SUPRAMOL STR CELL, V13, P67, DOI 10.1002/jss.400130107; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CARDIN AD, 1984, METHOD PHARMACOL, V5, P141; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; EVENSEN SA, 1983, ATHEROSCLEROSIS, V49, P23, DOI 10.1016/0021-9150(83)90004-7; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOURNEY RM, 1988, FOCUS, V10, P1; FRAENKELCONRAT H, 1957, METHOD ENZYMOL, V4, P247, DOI 10.1016/0076-6879(57)04059-8; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARLAND WA, 1973, BIOCHIM BIOPHYS ACTA, V316, P378, DOI 10.1016/0005-2760(73)90076-3; HASKILL S, 1988, J IMMUNOL, V140, P1690; IKEDA U, 1990, ATHEROSCLEROSIS, V84, P183, DOI 10.1016/0021-9150(90)90089-2; KADUCE TL, 1989, J BIOL CHEM, V264, P6823; KU G, 1990, FASEB J, V4, P1645, DOI 10.1096/fasebj.4.6.2318380; KU G, 1988, AM J CARDIOL, V62, P778; LENZ ML, 1990, J LIPID RES, V31, P1043; LIBBY P, 1988, J CLIN INVEST, V81, P487, DOI 10.1172/JCI113346; MCNALLY AK, 1990, J IMMUNOL, V145, P254; MOREL DW, 1983, J LIPID RES, V24, P1070; OBRIAN CA, 1988, BIOCHEM BIOPH RES CO, V155, P1374, DOI 10.1016/S0006-291X(88)81293-2; PARTHASARATHY S, 1985, P NATL ACAD SCI USA, V82, P3000, DOI 10.1073/pnas.82.9.3000; PEERS KE, 1983, CHEM PHYS LIPIDS, V32, P49, DOI 10.1016/0009-3084(83)90069-5; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; RANKIN SM, 1990, ARTERIOSCLEROSIS, V10, pA828; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; SCHADE UF, 1990, ADV EXP MED BIOL, V256, P361; SCHADE UF, 1987, BIOCHEM BIOPH RES CO, V147, P695, DOI 10.1016/0006-291X(87)90986-7; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TENG JI, 1985, J CHROMATOGR, V350, P445, DOI 10.1016/S0021-9673(01)93550-2; UNANUE ER, 1987, SCIENCE, V236, P551, DOI 10.1126/science.2437650; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717	36	137	141	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14183	14188						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629217				2022-12-25	WOS:A1992JD32500062
J	BORA, PS; WU, XL; SPILBURG, CA; LANGE, LG				BORA, PS; WU, XL; SPILBURG, CA; LANGE, LG			PURIFICATION AND CHARACTERIZATION OF FATTY-ACID ETHYL-ESTER SYNTHASE-II FROM HUMAN MYOCARDIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONOXIDATIVE ETHANOL-METABOLISM; GLUTATHIONE-S-TRANSFERASE; PROTEINS; IDENTIFICATION; HOMOGENEITY; SEQUENCE	Fatty acid ethyl ester synthases metabolize ethanol nonoxidatively in those extrahepatic organs most commonly damaged by alcohol abuse. This study was designed to isolate and purify human myocardial synthase-II, one of the enzymes responsible for catalyzing the formation of fatty acid ethyl esters. DEAE-cellulose chromatography of human myocardial cytosol at pH 8.0 separated synthase-I, synthase-II, and synthase-III activities, eluting at conductivities of 5, 7, and 11 mS, respectively. From this elution profile, fatty acid ethyl ester synthase-II accounts for up to 50% of total synthesis in the human heart. This enzyme species was purified over 2200-fold to homogeneity after chromatography over hydroxylapatite, CM-cellulose, and hydroxylapatite. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of this homogeneous species showed a single band at 65 kDa which corresponded to its molecular weight determined by gel filtration. This molecular weight and its lack of glutathione transferase activity indicate that this species is not related to synthase-I and -III. Homogeneous synthase-II has a V(max) for palmitate, stearate, oleate, and linoleate of 70, 80, 140, and 120 nmol/mg/h, respectively. The K(m) for palmitate, stearate, oleate, and linoleate is 0.19, 0.12, 0.10, and 0.18 mM, respectively. The substrate specificity with respect to alcohol chain length was also investigated in the presence of 0.65 mM [C-14] oleic acid. The V(max) for methanol, ethanol, propanol, and butanol was 180, 100, 280, and 410 nmol/mg/h, respectively. The K(m) for methanol, ethanol, propanol, and butanol was 1.16, 1.04, 0.58, and 0.33 M, respectively. The N-terminal 17-amino acid sequence of human synthase-II does not correspond to any known N-terminal amino acid sequence, indicating that this may be a novel protein. However, it has over 70% homology to a sequence close to the C terminus of rabbit cytochrome P-450IIC1 and over 50% homology to a sequence of human hemopexin starting at residue 16. Synthase-II does not cross-react with human hemopexin antibody and rat cytochrome P-450C antibody. Thus, this study provides evidence that synthase-II is a novel protein, distinct from synthase-I and -III, and it also provides a foundation for subsequent cloning and genetic studies of fatty acid ethyl ester synthase-II in man.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT MED,DIV CARDIOL,STEINBURG 4,216 S KINGSHIGHWAY,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL)				Bora, Puran/0000-0003-4781-1217	NIAAA NIH HHS [R01-AA08247-02, KO5-AA00139, R01-AA06989] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [K05AA000139, R01AA006989, R01AA008247] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BORA PS, 1989, J CLIN INVEST, V84, P1942, DOI 10.1172/JCI114382; BORA PS, 1989, FEBS LETT, V258, P236, DOI 10.1016/0014-5793(89)81662-X; BORA PS, 1989, P NATL ACAD SCI USA, V86, P4470, DOI 10.1073/pnas.86.12.4470; BORA PS, 1991, ANN NY ACAD SCI, V625, P827, DOI 10.1111/j.1749-6632.1991.tb33927.x; BORA PS, 1990, ALCOHOL HLTH RES WOR, V14, P85; BORA PS, 1991, ALCOHOL DRUG ABUSE R, V2, P241; BORA PS, 1991, J BIOL CHEM, V266, P12670; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; HABIG WH, 1974, J BIOL CHEM, V249, P7130; KYGER EM, 1990, BIOCHEMISTRY-US, V29, P3853, DOI 10.1021/bi00468a008; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGE LG, 1983, J CLIN INVEST, V72, P724, DOI 10.1172/JCI111022; LANGE LG, 1983, CIRC RES, V52, P479, DOI 10.1161/01.RES.52.4.479; LANGE LG, 1981, J BIOL CHEM, V256, P2968; LEIGHTON JK, 1984, BIOCHEMISTRY-US, V23, P204, DOI 10.1021/bi00297a005; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MOGELSON S, 1984, BIOCHEMISTRY-US, V23, P4075, DOI 10.1021/bi00313a010; MOSCOW JA, 1989, CANCER RES, V49, P1422; SEGAL LD, 1979, CARDIOVASC RES, V13, P136; SHIMADA T, 1986, J BIOL CHEM, V261, P909; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P73, DOI 10.1073/pnas.82.1.73; WRIGHT M, 1987, BIOCHEM BIOPH RES CO, V142, P979, DOI 10.1016/0006-291X(87)91510-5	23	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13217	13221						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618826				2022-12-25	WOS:A1992JB74600022
J	CHUANG, WJ; VANWART, HE				CHUANG, WJ; VANWART, HE			RESONANCE RAMAN-SPECTRA OF HORSERADISH-PEROXIDASE AND BOVINE LIVER CATALASE COMPOUND-I SPECIES - EVIDENCE FOR PREDOMINANT (2)A(2U) PI-CATION RADICAL GROUND-STATE CONFIGURATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; HEME-LINKED IONIZATION; ELECTRONIC-STRUCTURE; STRETCHING VIBRATION; ABSORPTION-SPECTRA; ENZYMIC CATALYSIS; SPECTROSCOPY; PORPHYRINS; OXIDATION; METALLOPORPHYRINS	The nature of the porphyrin-pi-cation radicals in the horseradish peroxidase and bovine liver catalase (BLC) compound I species have been investigated by studying their resonance Raman spectra. A variety of laser excitation and sample interrogation procedures have been employed in order to minimize previously documented problems arising from photoinduced conversions. With Soret band excitation, the spectra obtained for both species resemble that of a compound II-like photoproduct unless the samples are excited with residence times in the microsecond regime with very low (approximately 1 milliwatt) powers. When these precautions are taken, spectra attributable to the compound I species themselves are obtained. The spectrum for horseradish peroxidase compound I is similar to that reported by Paeng and Kincaid (Paeng, K.-J., and Kincaid, J. R. (1988) Am. Chem. Soc. 110, 7913-7915) using a similar approach. Both horseradish peroxidase and BLC compound I exhibit frequency shifts relative to their compound II species that are in the direction observed for model-pi-cation radicals with predominant 2A2u character. The magnitudes of these shifts are smaller than those observed for heme models that lack aromatic axial ligands, but agree well with those observed on formation of the compound I analog of N(alpha)-acetyl microperoxidase-8 that has His as a proximal ligand. This observation is consistent with partial delocalization of the radical density onto the proximal His-170 and Tyr-357 ligands in horseradish peroxidase and BLC, respectively. The strong ligand field provided by these ligands on the proximal side and oxo ligand on the distal side of the heme group is apparently sufficient to reverse the 2A1u radical ground state preference observed for heme-like porphyrin species (e.g. octaethylporphyrins) with weak axial fields. Enhancement of several bands assigned to the Tyr-357 ligand has also been observed for BLC compound I with 406.7-nm excitation. This is attributed either to resonance with a tyrosinate --> Fe(IV) charge transfer band or to the coupling provided by radical spin delocalization onto the tyrosinate ligand.	FLORIDA STATE UNIV,DEPT CHEM,TALLAHASSEE,FL 32306; FLORIDA STATE UNIV,INST MOLEC BIOPHYS,TALLAHASSEE,FL 32306	State University System of Florida; Florida State University; State University System of Florida; Florida State University					NIGMS NIH HHS [GM27276] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027276] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE M, 1978, J CHEM PHYS, V69, P4526, DOI 10.1063/1.436450; BROWETT WR, 1988, J AM CHEM SOC, V110, P3633, DOI 10.1021/ja00219a044; CHUANG WJ, 1988, J INORG BIOCHEM, V34, P201, DOI 10.1016/0162-0134(88)85030-X; CHUANG WJ, 1989, J BIOL CHEM, V264, P14209; CZERNUSZEWICZ RS, 1989, J AM CHEM SOC, V111, P3860, DOI 10.1021/ja00193a017; DOLPHIN D, 1979, INT J QUANTUM CHEM, V16, P311, DOI 10.1002/qua.560160213; DOLPHIN D, 1971, P NATL ACAD SCI USA, V68, P614, DOI 10.1073/pnas.68.3.614; DOLPHIN D, 1973, ANN NY ACAD SCI, V206, P177, DOI 10.1111/j.1749-6632.1973.tb43211.x; DOLPHIN D, 1974, ACCOUNTS CHEM RES, V7, P26, DOI 10.1021/ar50073a005; DOLPHIN D, 1981, ISRAEL J CHEM, V21, P67, DOI 10.1002/ijch.198100017; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; FAJER J, 1970, J AM CHEM SOC, V92, P3451, DOI 10.1021/ja00714a038; FAJER J, 1973, ANN NY ACAD SCI, V206, P349, DOI 10.1111/j.1749-6632.1973.tb43221.x; FELTON RH, 1976, BIOCHIM BIOPHYS ACTA, V434, P82, DOI 10.1016/0005-2795(76)90037-4; FELTON RH, 1973, ANN NY ACAD SCI, V206, P504, DOI 10.1111/j.1749-6632.1973.tb43233.x; FITA I, 1986, ACTA CRYSTALLOGR B, V42, P497, DOI 10.1107/S0108768186097835; FITA I, 1985, J MOL BIOL, V185, P21, DOI 10.1016/0022-2836(85)90180-9; FOOTE N, 1987, BIOCHEM J, V246, P659, DOI 10.1042/bj2460659; Frew J. E., 1984, ADV INORG BIOINORG M, V3, P175; FUJITA I, 1983, J AM CHEM SOC, V105, P3296, DOI 10.1021/ja00348a056; HANSON LK, 1981, J AM CHEM SOC, V103, P663, DOI 10.1021/ja00393a028; HASHIMOTO S, 1986, P NATL ACAD SCI USA, V83, P2417, DOI 10.1073/pnas.83.8.2417; HASHIMOTO S, 1991, J AM CHEM SOC, V113, P6542, DOI 10.1021/ja00017a027; HASHIMOTO S, 1987, J AM CHEM SOC, V109, P8096, DOI 10.1021/ja00260a030; JONGEWARD KA, 1988, J BIOL CHEM, V263, P6027; KIM D, 1986, J PHYS CHEM-US, V90, P3320, DOI 10.1021/j100406a005; KINCAID JR, 1989, J AM CHEM SOC, V111, P735, DOI 10.1021/ja00184a054; LAMAR GN, 1981, J BIOL CHEM, V256, P237; LI XY, 1990, J PHYS CHEM-US, V94, P47, DOI 10.1021/j100364a008; LOEW GH, 1980, J AM CHEM SOC, V102, P6173, DOI 10.1021/ja00539a047; MAGGIORA GM, 1973, J AM CHEM SOC, V95, P6555, DOI 10.1021/ja00801a005; MORISHIMA I, 1986, BIOCHEMISTRY-US, V25, P3576, DOI 10.1021/bi00360a016; MOSS TH, 1969, BIOCHEMISTRY-US, V8, P4159, DOI 10.1021/bi00838a037; NAGAI K, 1983, BIOCHEMISTRY-US, V22, P1305, DOI 10.1021/bi00274a048; OERTLING WA, 1987, J PHYS CHEM-US, V91, P3114, DOI 10.1021/j100295a095; OERTLING WA, 1985, J AM CHEM SOC, V107, P6406, DOI 10.1021/ja00308a050; OERTLING WA, 1988, BIOCHEMISTRY-US, V27, P3331, DOI 10.1021/bi00409a032; OERTLING WA, 1987, J PHYS CHEM-US, V91, P5887, DOI 10.1021/j100307a016; OERTLING WA, 1989, J PHYS CHEM-US, V93, P1311, DOI 10.1021/j100341a028; OGURA T, 1988, REV SCI INSTRUM, V59, P1316, DOI 10.1063/1.1139716; OGURA T, 1987, J AM CHEM SOC, V109, P2177, DOI 10.1021/ja00241a044; PAENG KJ, 1988, J AM CHEM SOC, V110, P7913, DOI 10.1021/ja00231a073; PALANIAPPAN V, 1989, J BIOL CHEM, V264, P16046; Que L, 1988, BIOL APPLICATIONS RA, P491; REID TJ, 1981, P NATL ACAD SCI-BIOL, V78, P4767, DOI 10.1073/pnas.78.8.4767; ROBERTS JE, 1981, J AM CHEM SOC, V103, P7654, DOI 10.1021/ja00415a044; ROBERTS JE, 1981, J BIOL CHEM, V256, P2118; RUTTER R, 1983, BIOCHEMISTRY-US, V22, P4769, DOI 10.1021/bi00289a024; SALEHI A, 1987, INORG CHEM, V26, P4296, DOI 10.1021/ic00272a033; SALEHI A, 1986, J AM CHEM SOC, V108, P5630, DOI 10.1021/ja00278a047; SANDUSKY PO, 1989, J AM CHEM SOC, V111, P6437, DOI 10.1021/ja00198a074; SCHUMB WC, 1955, HYDROGEN PEROXIDE, P278; SEYMOUR RJ, 1983, APPL SPECTROSC, V37, P375, DOI 10.1366/0003702834634424; SHARMA KD, 1989, J BIOL CHEM, V264, P12772; SIMPSON SF, 1986, ANAL CHEM, V58, P3163, DOI 10.1021/ac00127a054; SIMPSON SF, 1983, ANAL CHEM, V55, P1420, DOI 10.1021/ac00259a054; SITTER AJ, 1985, J BIOL CHEM, V260, P7515; SITTER AJ, 1984, J LABELLED COMPD RAD, V22, P461; SMULEVICH G, 1989, BIOCHEMISTRY-US, V28, P9905, DOI 10.1021/bi00452a004; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; SPIRO TG, 1983, IRON PORPHYRINS 2, P91; STILLMAN JS, 1975, BIOCHEMISTRY-US, V14, P3183, DOI 10.1021/bi00685a023; STILLMAN JS, 1975, BIOCHEM BIOPH RES CO, V63, P32, DOI 10.1016/S0006-291X(75)80006-4; TERAOKA J, 1982, J AM CHEM SOC, V104, P7354, DOI 10.1021/ja00389a094; TERNER J, 1985, BIOCHIM BIOPHYS ACTA, V828, P73, DOI 10.1016/0167-4838(85)90011-1; TERNER J, 1984, BIOCHIM BIOPHYS ACTA, V789, P80, DOI 10.1016/0167-4838(84)90064-5; THANABAL V, 1987, J AM CHEM SOC, V109, P7516, DOI 10.1021/ja00258a043; THANABAL V, 1988, BIOCHEMISTRY-US, V27, P5400, DOI 10.1021/bi00415a003; VANWART HE, 1985, J AM CHEM SOC, V107, P3379, DOI 10.1021/ja00297a072; Varsanyi G., 1969, VIBRATIONAL SPECTRA, P141, DOI [DOI 10.1016/B978-0-12-714950-9.50007-7, 10.1016/B978-0-12-714950-9.50007-7]; WANG JS, 1991, BIOCHEM BIOPH RES CO, V179, P1320, DOI 10.1016/0006-291X(91)91717-Q; WOODRUFF WH, 1974, APPL SPECTROSC, V28, P576, DOI 10.1366/000370274774331886; YAMAGUCHI H, 1982, CHEM LETT, P1397, DOI 10.1246/cl.1982.1397	73	71	72	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13293	13301						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618830				2022-12-25	WOS:A1992JB74600034
J	FAY, PJ; SMUDZIN, TM				FAY, PJ; SMUDZIN, TM			CHARACTERIZATION OF THE INTERACTION BETWEEN THE A2-SUBUNIT AND A1/A3-C1-C2 DIMER IN HUMAN FACTOR-VIII(A)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FACTOR-VIII; PORCINE FACTOR-VIII; THROMBIN; PROTEIN; INACTIVATION; ACTIVATION; COAGULANT; FORMS	Factor VIII(a) is a heterotrimer of the factor VIII heavy chain-derived A1 and A2 subunits plus the factor VIII light chain-derived A3-C1-C2 subunit. While the A1 and A3-C1-C2 subunits can be isolated as a stable dimer, the A2 subunit is weakly associated with the dimer. In the human protein, the association of A2 with dimer is reversible and governed by a pH-dependent dissociation constant. Using the specific activity of factor VIII(a) as an indicator of trimer concentration, the K(d) (pH 6.0) was determined to be 28 nM whereas at the more physiologic pH (pH 7.4) this value was approximately 260 nM. Results from pH shift experiments confirmed the reversible binding of A2 to dimer as did- the capacity for high levels of exogenous A2 subunit to inhibit the spontaneous decay of factor VIII(a) activity. A2 subunit associated with the A1 subunit in the A1/A3-C1-C2 dimer based upon the capacity for free A1 subunit to inhibit the reconstitution of factor VIII(a) from A2 subunit and dimer. These results indicate that the primary mechanism for the spontaneous decay of human factor VIII(a) is the reversible dissociation of A2 subunit from the A1 subunit of the A1/A3-C1-C2 dimer.	UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642	University of Rochester	FAY, PJ (corresponding author), UNIV ROCHESTER,SCH MED & DENT,MED CTR,DEPT MED,HEMATOL UNIT,POB 610,ROCHESTER,NY 14642, USA.				NHLBI NIH HHS [HL-38199] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038199] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON LO, 1986, P NATL ACAD SCI USA, V83, P2979, DOI 10.1073/pnas.83.9.2979; BIHOREAU N, 1989, EUR J BIOCHEM, V185, P111, DOI 10.1111/j.1432-1033.1989.tb15089.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FASS DN, 1982, BLOOD, V59, P594; FAY PJ, 1989, J BIOL CHEM, V264, P14005; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FAY PJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P525, DOI 10.1016/0003-9861(88)90404-3; FENTON JW, 1977, J BIOL CHEM, V252, P3587; FULCHER CA, 1982, P NATL ACAD SCI-BIOL, V79, P1648, DOI 10.1073/pnas.79.5.1648; HULTIN MB, 1981, BLOOD, V57, P476; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1992, J BIOL CHEM, V267, P3725; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1984, ARCH BIOCHEM BIOPHYS, V233, P438, DOI 10.1016/0003-9861(84)90465-X; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	24	104	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13246	13250						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618828				2022-12-25	WOS:A1992JB74600026
J	HAUSMAN, SZ; BURNS, DL				HAUSMAN, SZ; BURNS, DL			INTERACTION OF PERTUSSIS TOXIN WITH CELLS AND MODEL MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISLET-ACTIVATING PROTEIN; DIPHTHERIA-TOXIN; CHOLERA-TOXIN; BORDETELLA-PERTUSSIS; A-SUBUNIT; ADP-RIBOSYLTRANSFERASE; ADENINE-NUCLEOTIDES; NAD GLYCOHYDROLASE; ADENYLATE-CYCLASE; BINDING	The interaction of pertussis toxin (PT) with cells and model membranes was investigated by examining PT-induced intoxication of Chinese hamster ovary cells and by studying the binding of PT and its subunits to phospholipid vesicles. Since certain bacterial toxins require an acidic environment for efficient interaction with membranes and subsequent entry into the cell, the requirement for an acidic environment for PT action was examined. PT, unlike bacterial toxins such as diphtheria toxin, did not require an acidic environment for efficient intoxication of Chinese hamster ovary cells. Potential modes by which PT might interact with biological membranes were studied by examining the binding of PT to a model membrane system. PT was found to be capable of interacting with phospholipid vesicles, however, efficient binding of the toxin to the vesicles occurred only in the presence of both ATP and reducing agent. The A subunit portion of the toxin bound preferentially to the vesicles while little binding of the B oligomer portion of PT to the model membranes was observed. Isolated A subunit, in the absence of the B oligomer, also bound to the vesicles with optimal binding occurring in the presence of reducing agent. After cleavage of the A subunit by trypsin, probably at Arg-181, Arg-182, and/or Arg-193, large fragments which lacked the C-terminal portion of the A subunit of PT no longer associated with the lipid vesicles. These results suggest that the A subunit of PT can interact directly with a lipid matrix and, if freed from the constraints imposed by the B oligomer, may be capable of interacting with cellular membranes.	CTR BIOL EVALUAT & RES,DIV BACTERIAL PROD,BLDG 29,RM 418,8800 ROCKVILLE PIKE,BETHESDA,MD 20892	US Food & Drug Administration (FDA)								BLEWITT MG, 1985, BIOCHEMISTRY-US, V24, P5458, DOI 10.1021/bi00341a027; BONVENTRE PF, 1975, INFECT IMMUN, V11, P675, DOI 10.1128/IAI.11.4.675-684.1975; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN MJ, 1988, J BIOL CHEM, V263, P4895; BURNS DL, 1987, J BIOL CHEM, V262, P17677; BURNS DL, 1987, INFECT IMMUN, V55, P24, DOI 10.1128/IAI.55.1.24-28.1987; BURNS DL, 1986, J BIOL CHEM, V261, P4324; BURNS DL, 1989, J BIOL CHEM, V264, P564; COLLIER RJ, 1975, BACTERIOL REV, V39, P54, DOI 10.1128/MMBR.39.1.54-85.1975; DONOVAN JJ, 1985, J BIOL CHEM, V260, P8817; DUMONT ME, 1988, J BIOL CHEM, V263, P2087; FISHMAN PH, 1990, ADP RIBOSYLATING TOX, P127; GILL DM, 1976, BIOCHEMISTRY-US, V15, P1242, DOI 10.1021/bi00651a011; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GUERRANT RL, 1974, INFECT IMMUN, V10, P320, DOI 10.1128/IAI.10.2.320-327.1974; HAUSMAN SZ, 1990, BIOCHEMISTRY-US, V29, P6128, DOI 10.1021/bi00478a003; HEWLETT EL, 1983, INFECT IMMUN, V40, P1198, DOI 10.1128/IAI.40.3.1198-1203.1983; IVINS B, 1975, INFECT IMMUN, V11, P665, DOI 10.1128/IAI.11.4.665-674.1975; JANICOT M, 1991, J BIOL CHEM, V266, P12858; JOSEPH KC, 1978, P NATL ACAD SCI USA, V75, P2815, DOI 10.1073/pnas.75.6.2815; KATADA T, 1982, P NATL ACAD SCI-BIOL, V79, P3129, DOI 10.1073/pnas.79.10.3129; KIM K, 1965, J BACTERIOL, V90, P1557, DOI 10.1128/JB.90.6.1557-1562.1965; KIM K, 1965, J BACTERIOL, V90, P1552, DOI 10.1128/JB.90.6.1552-1556.1965; KRUEGER KM, 1991, J BIOL CHEM, V266, P8122; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEADE BD, 1984, INFECT IMMUN, V46, P733, DOI 10.1128/IAI.46.3.733-739.1984; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MONTECUCCO C, 1986, FEBS LETT, V194, P301, DOI 10.1016/0014-5793(86)80105-3; MOSS J, 1977, J BIOL CHEM, V252, P797; MOSS J, 1983, J BIOL CHEM, V258, P1879; MOSS J, 1986, BIOCHEMISTRY-US, V25, P2720, DOI 10.1021/bi00357a066; MURPHY JR, 1978, J CLIN MICROBIOL, V7, P91; RIBI HO, 1988, SCIENCE, V239, P1272, DOI 10.1126/science.3344432; ROBBINS AR, 1984, J CELL BIOL, V99, P1296, DOI 10.1083/jcb.99.4.1296; SAELINGER CB, 1990, TRAFFICKING BACTERIA, P26; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; TAMURA M, 1982, BIOCHEMISTRY-US, V21, P5516, DOI 10.1021/bi00265a021; TOMASI M, 1981, J BIOL CHEM, V256, P1177; TUOMANEN E, 1988, J EXP MED, V168, P267, DOI 10.1084/jem.168.1.267; Ui M, 1988, PATHOGENESIS IMMUNIT, P121; WISNIESKI BJ, 1981, NATURE, V289, P319, DOI 10.1038/289319a0; WITVLIET MH, 1989, INFECT IMMUN, V57, P3324, DOI 10.1128/IAI.57.11.3324-3330.1989	43	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13735	13739						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618869				2022-12-25	WOS:A1992JB74600100
J	TUCK, SF; AOYAMA, Y; YOSHIDA, Y; DEMONTELLANO, PRO				TUCK, SF; AOYAMA, Y; YOSHIDA, Y; DEMONTELLANO, PRO			ACTIVE-SITE TOPOLOGY OF SACCHAROMYCES-CEREVISIAE LANOSTEROL 14-ALPHA-DEMETHYLASE (CYP51) AND ITS G310D MUTANT (CYTOCHROME-P-450SG1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFIED CYTOCHROME-P-45014DM; ALTERED CYTOCHROME-P-450; CANDIDA-ALBICANS; YEAST; PURIFICATION; BIOSYNTHESIS; INTERMEDIATE; DEMETHYLASE; MICROSOMES; MODEL	Incubation of phenyldiazene (PhN = NH) with lanosterol 14-alpha-demethylase, a cytochrome P-450 enzyme (CYP51) that oxidatively removes the 14-alpha-methyl group of lanosterol, results in the appearance of a 478nm band indicative of phenyl-iron complex formation. In situ oxidation of the phenyl-iron complex by ferricyanide yields exclusively the N-phenylprotoporphyrin IX regioisomer with the phenyl group on the nitrogen of pyrrole ring C (N(C)). The biphenyl-iron complex formed in the analogous reaction of the enzyme with biphenyldiazene similarly rearranges on treatment with ferricyanide to the Nc regioisomer of N-biphenylprotoporphyrin IX. The active site cavity must therefore be at least 10 angstrom high directly above the iron atom and pyrrole ring C of the heme group, and lanosterol binds to the enzyme in the region above pyrrole ring C. Phenyl-iron complex formation is not detected spectroscopically with cytochrome P-450SG1, a catalytically inactive G310D mutant of lanosterol 14-alpha-demethylase in which the sixth iron coordination site is thought to be occupied by an imidazole ligand. Nevertheless, oxidation of the phenyldiazene-treated enzyme with ferricyanide provides the N(A) and N(C) regioisomers of N-phenylprotoporphyrin IX in a 40:60 ratio. The single amino acid substitution in cytochrome P-450SG1 thus causes a conformational change that retracts the amino acid residues that cover pyrrole ring A and moves an imidazole ligand into the active site.	UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR LIVER,SAN FRANCISCO,CA 94143; MUKOGAWA WOMENS UNIV,FAC PHARMACEUT SCI,NISHINOMIYA,HYOGO 663,JAPAN	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Mukogawa Women's University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025515, R01GM025515] Funding Source: NIH RePORTER; NIDDK NIH HHS [5 P30 DK26743] Funding Source: Medline; NIGMS NIH HHS [GM25515] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDE.K, 1972, J CHEM SOC CHEM COMM, P383, DOI 10.1039/c39720000383; AOYAMA Y, 1991, BIOCHEM BIOPH RES CO, V178, P1064, DOI 10.1016/0006-291X(91)91000-3; AOYAMA Y, 1987, J BIOL CHEM, V262, P14260; AOYAMA Y, 1991, BIOCHIM BIOPHYS ACTA, V1081, P262, DOI 10.1016/0005-2760(91)90280-U; AOYAMA Y, 1983, J BIOL CHEM, V258, P9040; AOYAMA Y, 1989, BIOCHIM BIOPHYS ACTA, V1006, P209, DOI 10.1016/0005-2760(89)90198-7; AOYAMA Y, 1987, J BIOL CHEM, V262, P1239; AOYAMA Y, 1989, J BIOL CHEM, V264, P18502; ATKINS WM, 1989, J AM CHEM SOC, V111, P2715, DOI 10.1021/ja00189a057; AUGUSTO O, 1982, J BIOL CHEM, V257, P6231; Berg D., 1988, STEROL BIOSYNTHESIS; CANONICA L, 1968, J AM CHEM SOC, V90, P3597, DOI 10.1021/ja01015a074; CHEN C, 1988, DNA-J MOLEC CELL BIO, V7, P617, DOI 10.1089/dna.1988.7.617; CORREIA MA, 1992, FRONTIERS BIOTRANSFO, V8; FISCHER RT, 1991, J BIOL CHEM, V266, P6124; HITCHCOCK CA, 1989, BIOCHEM J, V263, P573, DOI 10.1042/bj2630573; HUNSBERGER IM, 1956, J ORG CHEM, V21, P394, DOI 10.1021/jo01110a004; ISHIDA N, 1988, BIOCHEM BIOPH RES CO, P317; KALB VF, 1987, DNA-J MOLEC CELL BIO, V6, P529, DOI 10.1089/dna.1987.6.529; LAI MH, 1989, NUCLEIC ACIDS RES, V17, P804, DOI 10.1093/nar/17.2.804; MORRIS GM, 1991, BIOCHEM SOC T, V19, P793, DOI 10.1042/bst0190793; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; RAAG R, 1990, BIOCHEMISTRY-US, V29, P8119, DOI 10.1021/bi00487a019; SANTEN RJ, 1983, J CLIN ENDOCR METAB, V57, P732, DOI 10.1210/jcem-57-4-732; SONO H, 1991, BIOCHIM BIOPHYS ACTA, V1078, P388, DOI 10.1016/0167-4838(91)90161-R; STEVENSON DE, 1988, J CHEM SOC PERK T 1, P2043, DOI 10.1039/p19880002043; SWANSON BA, 1991, J AM CHEM SOC, V113, P8146, DOI 10.1021/ja00021a046; SWANSON BA, 1991, J BIOL CHEM, V266, P19258; SWANSON BA, 1992, ARCH BOCH BIOPHYS, V29, P42; TRZASKOS J, 1986, J BIOL CHEM, V261, P4651; TRZASKOS JM, 1986, J BIOL CHEM, V261, P6937; TUCK SF, 1992, J BIOL CHEM, V267, P5614; VANDENBOSSCHE H, 1990, BIOCHEM SOC T, V18, P56; WATANABE Y, 1989, J AM CHEM SOC, V111, P8047, DOI 10.1021/ja00202a073; YOSHIDA Y, 1984, J BIOL CHEM, V259, P1655; YOSHIDA Y, 1987, BIOCHEM PHARMACOL, V36, P229, DOI 10.1016/0006-2952(87)90694-0; YOSHIDA Y, 1990, CHIRALITY, V2, P10, DOI 10.1002/chir.530020103; Yoshida Y, 1988, Curr Top Med Mycol, V2, P388; YOSHIDA Y, 1991, BIOCHEM SOC T, V19, P778, DOI 10.1042/bst0190778	39	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13175	13179						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618820				2022-12-25	WOS:A1992JB74600015
J	ISHIZAKA, Y; SHIMA, H; SUGIMURA, T; NAGAO, M				ISHIZAKA, Y; SHIMA, H; SUGIMURA, T; NAGAO, M			DETECTION OF PHOSPHORYLATED RETTPC ONCOGENE PRODUCT IN CYTOPLASM	ONCOGENE			English	Note							THYROID PAPILLARY CARCINOMAS; HUMAN TRK ONCOGENE; PROTO-ONCOGENE; CELL-LINE; TYROSINE KINASE; EXPRESSION; TRANSFORMATION; CLEAVAGE; ANTIGENS; CLONING	The product of the ret(TPC) oncogene, an activated form of the ret proto-oncogene found in human papillary thyroid carcinomas, was identified as a 57-kDa protein (p57retTPC) by Western blotting with a polyclonal antibody raised by an oligopeptide corresponding to the carboxy-terminal region of the ret proto-oncogene product. Subcellular fractionation experiments using NIH3T3 cell transformants induced by the ret(TPC) cDNA showed that p57retTPC was localized in a soluble cytoplasmic fraction, whereas the ret proto-oncogene products expressed in a neuroblastoma cell line were present in a membrane fraction. Immunostaining also demonstrated that p57retTPC is localized in the cytoplasm. Immunoprecipitation with antiphosphotyrosine antibody followed by Western blotting revealed that p57retTPC is constitutively phosphorylated, whereas the ret proto-oncogene products are not. These findings suggest that p57retTPC has an abererant tyrosine kinase activity resulting in autophosphorylation associated with change in its location.	NATL CANC CTR,RES INST,DIV CARCINOGENESIS,TSUKIJI 5,CHUO KU,TOKYO 104,JAPAN	National Cancer Center - Japan								BARBACID M, 1981, J VIROL, V40, P812, DOI 10.1128/JVI.40.3.812-821.1981; COULIER F, 1989, MOL CELL BIOL, V9, P15, DOI 10.1128/MCB.9.1.15; DEGRAAF FK, 1978, BIOCHEMISTRY-US, V17, P1137, DOI 10.1021/bi00599a031; DONGHI R, 1989, ONCOGENE, V4, P521; EMORI Y, 1986, J BIOL CHEM, V261, P9472; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HARLOW E, 1988, ANTIBODIES LABORATOR; IKEDA I, 1990, ONCOGENE, V5, P1291; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P297, DOI 10.1111/j.1432-1033.1983.tb07362.x; ISHIZAKA Y, 1987, CARCINOGENESIS, V8, P1575, DOI 10.1093/carcin/8.11.1575; ISHIZAKA Y, 1989, ONCOGENE, V4, P1519; ISHIZAKA Y, 1991, ONCOGENE, V6, P1667; ISHIZAKA Y, 1991, BIOCHEM BIOPH RES CO, V179, P1331, DOI 10.1016/0006-291X(91)91719-S; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; ISHIZAKA Y, 1989, JPN J CANCER RES, V80, P1149, DOI 10.1111/j.1349-7006.1989.tb01645.x; ITOH F, 1989, Tumor Research, V24, P1; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MASAKI H, 1985, J MOL BIOL, V182, P217, DOI 10.1016/0022-2836(85)90340-7; MITRA G, 1987, P NATL ACAD SCI USA, V84, P6707, DOI 10.1073/pnas.84.19.6707; MONDINO A, 1991, MOL CELL BIOL, V11, P6084, DOI 10.1128/MCB.11.12.6084; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; NODA T, 1987, J VIROL, V61, P2253, DOI 10.1128/JVI.61.7.2253-2263.1987; SASAKI K, 1990, JPN J CANCER RES, V81, P1272, DOI 10.1111/j.1349-7006.1990.tb02690.x; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SOZZI G, 1991, ONCOGENE, V6, P339; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TANIGUCHI M, 1991, BIOCHEM BIOPH RES CO, V181, P416, DOI 10.1016/S0006-291X(05)81435-4	32	50	51	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1441	1444						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620555				2022-12-25	WOS:A1992HZ97100025
J	SLADEK, TL; JACOBBERGER, JW				SLADEK, TL; JACOBBERGER, JW			DEPENDENCE OF SV40 LARGE T-ANTIGEN CELL-CYCLE REGULATION ON T-ANTIGEN EXPRESSION LEVELS	ONCOGENE			English	Article							ANCHORAGE-INDEPENDENT GROWTH; SIMIAN VIRUS-40; FLOW-CYTOMETRY; RECOMBINANT RETROVIRUSES; INTRACELLULAR ANTIGENS; MOUSE FIBROBLASTS; TUMOR-ANTIGEN; P53; TRANSFORMATION; GENE	Simian virus 40 (SV40) large T antigen (Tag) expression results in reduced percentages of G1-phase cells and increased percentages of S- and G2 + M-phase cells in exponentially growing fibroblast populations as compared with identical cell populations not expressing Tag. This effect is the result of reduced G1 and increased G2 + M cell cycle phase durations caused by Tag [Sladek, T.L. & Jacobberger, J.W. (1992). J. Virol., 66, 1059-1065]. Using recombinant retroviruses to manipulate Tag expression over a 25-fold range, it is shown here that the magnitude of this cell cycle phenotype increases as a function of increasing intracellular Tag concentration. This effect of Tag on the cell cycle is not independent of negative regulation by cellular mechanisms since exponentially growing cell populations producing high and increasing levels of Tag, increase the fraction of cells residing in G1 and decrease the fraction in S and G2 + M as a function of cell density. Therefore, the data in this paper show, first, that Tag is a concentration-dependent, positive cell cycle regulator in exponentially proliferating cells and, second, that endogenous cellular mechanisms negatively regulating the cell cycle in response to cell density override the effect of Tag.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT GENET,2109 ADELBERT RD,CLEVELAND,OH 44106	Case Western Reserve University			Jacobberger, James/P-9183-2014	Jacobberger, James/0000-0002-3092-5157	NCI NIH HHS [CA43703] Funding Source: Medline; NHLBI NIH HHS [HL41945] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041945] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BAISCH H, 1988, CYTOMETRY, V9, P325, DOI 10.1002/cyto.990090409; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BROWN M, 1986, J VIROL, V60, P290, DOI 10.1128/JVI.60.1.290-293.1986; BUTEL JS, 1986, BIOCHIM BIOPHYS ACTA, V865, P171, DOI 10.1016/0304-419X(86)90027-2; CHANG SMW, 1987, MOL CELL BIOL, V7, P854, DOI 10.1128/MCB.7.2.854; COSENZA SC, 1991, J CELL PHYSIOL, V147, P231, DOI 10.1002/jcp.1041470207; CRAWFORD L, 1982, J VIROL, V41, P709, DOI 10.1128/JVI.41.2.709-709.1982; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DEAN PN, 1987, CYCLE ANAL, P207; DEAN PN, 1990, FLOW CYTOMETRY SORTI, P415; DEPAMPHILIS ML, 1986, PAPOVAVIRIDAE, V1, P99; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAYLES J, 1986, J CELL SCI S, V4, P155; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; JACOBBERGER JW, 1986, CYTOMETRY, V7, P356, DOI 10.1002/cyto.990070410; JACOBBERGER JW, 1989, FLOW CYTOMETRY ADV R, P305; JAT PS, 1986, MOL CELL BIOL, V6, P1204, DOI 10.1128/MCB.6.4.1204; LAFFIN J, 1989, CYTOMETRY, V10, P205, DOI 10.1002/cyto.990100212; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEHMAN JM, 1988, CYTOMETRY, V9, P52, DOI 10.1002/cyto.990090109; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LINNEY E, 1987, J VIROL, V61, P3248, DOI 10.1128/JVI.61.10.3248-3253.1987; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MILLER AD, 1986, SOMAT CELL MOLEC GEN, V12, P175, DOI 10.1007/BF01560664; MILNER J, 1986, VIROLOGY, V154, P21, DOI 10.1016/0042-6822(86)90426-5; MILNER J, 1986, VIROLOGY, V147, P206; RISSER R, 1974, VIROLOGY, V59, P477, DOI 10.1016/0042-6822(74)90457-7; SCHIMENTI KJ, 1992, CYTOMETRY, V13, P48, DOI 10.1002/cyto.990130109; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SLADEK TL, 1990, J VIROL, V64, P3135, DOI 10.1128/JVI.64.6.3135-3138.1990; SLADEK TL, 1992, J VIROL, V66, P1059, DOI 10.1128/JVI.66.2.1059-1065.1992; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; XU L, 1989, VIROLOGY, V171, P331, DOI 10.1016/0042-6822(89)90600-4	38	39	39	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1305	1313						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620545				2022-12-25	WOS:A1992HZ97100008
J	ADACHI, S; SUNOHARA, N; ISHIMORI, K; MORISHIMA, I				ADACHI, S; SUNOHARA, N; ISHIMORI, K; MORISHIMA, I			STRUCTURE AND LIGAND-BINDING PROPERTIES OF LEUCINE-29(B10) MUTANTS OF HUMAN MYOGLOBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; SITE-DIRECTED MUTAGENESIS; NUCLEAR MAGNETIC-RESONANCE; DYNAMIC PROTEIN STRUCTURES; BOVINE HEART MYOGLOBIN; NORMAL MODE ANALYSIS; CARBON-MONOXIDE; DISTAL HISTIDINE; ESCHERICHIA-COLI; HIGH-PRESSURE	Site-specific mutants of human myoglobin (Mb) have been prepared, in which Leu29(B10) is replaced by Ala(L29A) or Ile(L29I), in order to examine the influence of this highly conserved residue in the hydrophobic clusters of the heme distal site on the heme environmental structure and ligand binding properties of Mb. Structural characterizations of these recombinant Mbs are studied by electronic absorption, infrared (IR), one- and two-dimensional proton nuclear magnetic resonance spectroscopies, and ligand-binding kinetics by laser photolysis measurements under ambient and high pressures (up to 2000 bar). Multiple split carbon monoxide (CO) stretch bands in the IR spectra of mutant Mbs exhibit a relative decrease of the 1945 cm-1 band (approximately 50%) which is associated with an upright binding geometry of CO, accompanied by an increase of the tilted CO conformer at 1932 cm-1. On the basis of these results, replacement of Leu29(B10) by Ala or Ile appears to allow bound CO to rotate from a conformation pointing toward the beta-meso carbon of the heme group to the one pointing toward the alpha-meso carbon atom, presumably filling the space left by removal of the delta-2 carbon atom of Leu29(B10). These substitutions cause the rate constants for CO and O2 association to decrease almost 3-5-fold. Present results show that CO and O2 bindings to the heme iron of Mb are controlled by Leu29(B10) by influencing the structure of close vicinity of the heme and the geometry of iron-bound ligand. Further, mutant Mbs (Leu72(E15)-->Ala and Leu104 (G5)-->Ala) which have altered residues in another hydrophobic clusters around proximal and distal site are also examined.	KYOTO UNIV,GRAD SCH ENGN,DIV MOLEC ENGN,KYOTO 606,JAPAN	Kyoto University			Ishimori, Koichiro/S-1247-2016; Ishimori, Koichiro/AAQ-4434-2021	Ishimori, Koichiro/0000-0002-5868-0462; Ishimori, Koichiro/0000-0002-5868-0462; Adachi, Shin-ichi/0000-0002-3676-1165				ADACHI S, 1989, J BIOL CHEM, V264, P18896; ANSARI A, 1987, BIOPHYS CHEM, V26, P337, DOI 10.1016/0301-4622(87)80034-0; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BODENHAUSEN G, 1984, J MAGN RESON, V58, P370, DOI 10.1016/0022-2364(84)90142-2; BRAUNSTEIN D, 1988, P NATL ACAD SCI USA, V85, P8497, DOI 10.1073/pnas.85.22.8497; BROWN WE, 1983, BIOCHEMISTRY-US, V22, P2914, DOI 10.1021/bi00281a021; CARVER TE, 1991, BIOCHEMISTRY-US, V30, P4697, DOI 10.1021/bi00233a009; CARVER TE, 1990, J BIOL CHEM, V265, P20007; CAUGHEY WS, 1981, P NATL ACAD SCI-BIOL, V78, P2903, DOI 10.1073/pnas.78.5.2903; CHANCE MR, 1987, J BIOL CHEM, V262, P6959; COLLMAN JP, 1983, J AM CHEM SOC, V105, P3052, DOI 10.1021/ja00348a019; CUTNELL JD, 1981, J AM CHEM SOC, V103, P3567, DOI 10.1021/ja00402a053; DALVIT C, 1987, J MOL BIOL, V194, P313, DOI 10.1016/0022-2836(87)90378-0; Dickerson R.E., 1983, HEMOGLOBIN STRUCTURE; EGEBERG KD, 1990, J BIOL CHEM, V265, P11788; EMERSON SD, 1990, BIOCHEMISTRY-US, V29, P1545, DOI 10.1021/bi00458a028; EMERSON SD, 1990, BIOCHEMISTRY-US, V29, P1556, DOI 10.1021/bi00458a029; HASINOFF BB, 1974, BIOCHEMISTRY-US, V13, P3111, DOI 10.1021/bi00712a017; HUBBARD SR, 1990, J MOL BIOL, V213, P215, DOI 10.1016/S0022-2836(05)80181-0; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LACOMTE JTJ, 1985, BIOCHEMISTRY-US, V24, P7388; LAMAR GN, 1983, BIOPHYS J, V44, P177, DOI 10.1016/S0006-3495(83)84289-1; LAMBRIGHT DG, 1989, J MOL BIOL, V207, P289, DOI 10.1016/0022-2836(89)90456-7; MAYER A, 1974, J MOL BIOL, V86, P746; MOORE JN, 1988, P NATL ACAD SCI USA, V85, P5062, DOI 10.1073/pnas.85.14.5062; MORIKIS D, 1989, BIOCHEMISTRY-US, V28, P4791, DOI 10.1021/bi00437a041; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; ORMOS P, 1988, P NATL ACAD SCI USA, V85, P8492, DOI 10.1073/pnas.85.22.8492; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; PROJAHN HD, 1991, INORG CHEM, V30, P3288, DOI 10.1021/ic00017a014; PROJAHN HD, 1990, J AM CHEM SOC, V112, P17, DOI 10.1021/ja00157a005; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; SENO Y, 1990, J MOL BIOL, V216, P111, DOI 10.1016/S0022-2836(05)80064-6; SENO Y, 1990, J MOL BIOL, V216, P95, DOI 10.1016/S0022-2836(05)80063-4; SHEARD B, 1970, J MOL BIOL, V53, P35, DOI 10.1016/0022-2836(70)90044-6; SHIMADA H, 1989, BIOCHEM BIOPH RES CO, V158, P110, DOI 10.1016/S0006-291X(89)80184-6; SHIMADA H, 1982, J BIOL CHEM, V257, P1893; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; TAKANO T, 1977, J MOL BIOL, V110, P537, DOI 10.1016/S0022-2836(77)80111-3; TAUBE DJ, 1990, J AM CHEM SOC, V112, P6880, DOI 10.1021/ja00175a023; TRAYLOR TG, 1985, J AM CHEM SOC, V107, P604, DOI 10.1021/ja00289a012; UNNO M, 1991, BIOCHEMISTRY-US, V30, P10679, DOI 10.1021/bi00108a011; UNNO M, 1990, BIOCHEMISTRY-US, V29, P10199, DOI 10.1021/bi00496a007; VARADARAJAN R, 1989, BIOCHEMISTRY-US, V28, P3771, DOI 10.1021/bi00435a022; VARADARAJAN R, 1985, P NATL ACAD SCI USA, V82, P5681, DOI 10.1073/pnas.82.17.5681	48	38	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12614	12621						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618766				2022-12-25	WOS:A1992HZ48300038
J	GEBLER, J; GILKES, NR; CLAEYSSENS, M; WILSON, DB; BEGUIN, P; WAKARCHUK, WW; KILBURN, DG; MILLER, RC; WARREN, RAJ; WITHERS, SG				GEBLER, J; GILKES, NR; CLAEYSSENS, M; WILSON, DB; BEGUIN, P; WAKARCHUK, WW; KILBURN, DG; MILLER, RC; WARREN, RAJ; WITHERS, SG			STEREOSELECTIVE HYDROLYSIS CATALYZED BY RELATED BETA-1,4-GLUCANASES AND BETA-1,4-XYLANASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSTRIDIUM-THERMOCELLUM; NUCLEOTIDE-SEQUENCE; TRICHODERMA-REESEI; ESCHERICHIA-COLI; XYLANASE GENE; CELLOBIOHYDROLASE-II; MOLECULAR-CLONING; BACILLUS-SUBTILIS; CELLULOMONAS-FIMI; DELETION ANALYSIS	Over 80 beta-1,4-glucanases and beta-1,4-xylanases can be classified into one of eight families on the basis of amino acid sequence similarities in their catalytic domains (Gilkes, N. R., Henrissat, B., Kilburn, D. G., Miller, R. C., Jr., and Warren, R. A. J. (1991) Microbiol. Rev. 55, 303-315). As a test of this classification, the stereochemical course of hydrolysis of 10 enzymes representative of five families has been determined using proton NMR. These data, together with published data for six additional enzymes, show that representatives of a given enzyme family have the same stereoselectivity: four families catalyze hydrolysis with retention of anomeric configuration, two with inversion. The results support the hypothesis that family members share a common general fold, active site topology, and catalytic mechanism.	UNIV BRITISH COLUMBIA, DEPT MICROBIOL, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT CHEM, VANCOUVER V6T 1Z3, BC, CANADA; STATE UNIV GHENT, BIOCHEM LAB, B-9000 GHENT, BELGIUM; CORNELL UNIV, BIOCHEM MOLEC & CELL BIOL SECT, ITHACA, NY 14853 USA; INST PASTEUR, DEPT BIOTECHNOL, UNITE PHYSIOL CELLULAIRE, F-75724 PARIS 15, FRANCE; NATL RES COUNCIL CANADA, INST BIOL SCI, PROT STRUCT & DESIGN SECT, OTTAWA K1A 0R6, ONTARIO, CANADA	University of British Columbia; University of British Columbia; Ghent University; Cornell University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; National Research Council Canada			Gebler, John/F-7114-2011; Wakarchuk, Warren/AAO-2774-2020; Wakarchuk, Warren/Q-9514-2017; Withers, Stephen G/I-7229-2019	Wakarchuk, Warren/0000-0002-1539-1679; Wakarchuk, Warren/0000-0002-1539-1679; Withers, Stephen G/0000-0002-6722-5701; Gebler, John/0000-0003-0372-3725; Beguin, Pierre/0000-0002-5372-6281				BALLARDIE F, 1973, J CHEM SOC PERK T 1, P2418, DOI 10.1039/p19730002418; BEGUIN P, 1990, ANNU REV MICROBIOL, V44, P219, DOI 10.1146/annurev.mi.44.100190.001251; BEGUIN P, 1988, METHOD ENZYMOL, V160, P355; BERNIER R, 1983, GENE, V26, P59, DOI 10.1016/0378-1119(83)90036-7; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CLAEYSSENS M, 1990, BIOCHEM J, V270, P251, DOI 10.1042/bj2700251; EXCOFFIER G, 1975, CARBOHYD RES, V39, P368, DOI 10.1016/S0008-6215(00)86150-9; GILKES NR, 1991, MICROBIOL REV, V55, P303, DOI 10.1128/MMBR.55.2.303-315.1991; GILKES NR, 1991, EUR J BIOCHEM, V202, P367, DOI 10.1111/j.1432-1033.1991.tb16384.x; GREPINET O, 1988, J BACTERIOL, V170, P4582, DOI 10.1128/jb.170.10.4582-4588.1988; GREPINET O, 1988, J BACTERIOL, V170, P4576, DOI 10.1128/jb.170.10.4576-4581.1988; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1989, GENE, V81, P83, DOI 10.1016/0378-1119(89)90339-9; JOLIFF G, 1986, NUCLEIC ACIDS RES, V14, P8605, DOI 10.1093/nar/14.21.8605; KNOWLES JKC, 1988, J CHEM SOC CHEM COMM, P1401, DOI 10.1039/c39880001401; KOENERS HJ, 1980, TRAV CHIM PAY BAS, V11, P355; LAO G, 1991, J BACTERIOL, V173, P3397, DOI 10.1128/jb.173.11.3397-3407.1991; MEAGHER MM, 1988, CARBOHYD RES, V173, P273, DOI 10.1016/S0008-6215(00)90823-1; MEINKE A, 1991, J BACTERIOL, V173, P7126, DOI 10.1128/jb.173.22.7126-7135.1991; MEINKE A, 1991, J BACTERIOL, V173, P308, DOI 10.1128/jb.173.1.308-314.1991; ONEILL G, 1986, GENE, V44, P325, DOI 10.1016/0378-1119(86)90197-6; PAICE MG, 1978, APPL ENVIRON MICROB, V36, P802, DOI 10.1128/AEM.36.6.802-808.1978; PAICE MG, 1986, ARCH MICROBIOL, V144, P201, DOI 10.1007/BF00410947; PENTTILA M, 1986, GENE, V45, P253, DOI 10.1016/0378-1119(86)90023-5; ROUVINEN J, 1990, SCIENCE, V249, P380, DOI 10.1126/science.2377893; SALOHEIMO M, 1988, GENE, V63, P11, DOI 10.1016/0378-1119(88)90541-0; SCHWARZ WH, 1988, APPL MICROBIOL BIOT, V29, P25, DOI 10.1007/BF00258346; SCHWARZ WH, 1988, GENE, V63, P23, DOI 10.1016/0378-1119(88)90542-2; SHOEMAKER S, 1983, BIO-TECHNOL, V1, P691, DOI 10.1038/nbt1083-691; SINNOTT ML, 1988, ENZYME MECHANISMS, P259; TEERI TT, 1987, GENE, V51, P43, DOI 10.1016/0378-1119(87)90472-0; TOKATLIDIS K, 1991, FEBS LETT, V291, P185, DOI 10.1016/0014-5793(91)81279-H; WILSON DB, 1992, CRIT REV BIOTECHNOL, V12, P45, DOI 10.3109/07388559209069187; WITHERS SG, 1986, BIOCHEM BIOPH RES CO, V139, P487, DOI 10.1016/S0006-291X(86)80017-1; WONG WKR, 1986, GENE, V44, P315; Woodward J, 1984, TOP ENZYME FERMENT B, V8, P9; YAGUE E, 1990, GENE, V89, P61, DOI 10.1016/0378-1119(90)90206-7; ZVELEBIL MJJM, 1988, PROTEIN ENG, V2, P127, DOI 10.1093/protein/2.2.127	38	215	217	2	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12559	12561						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618761				2022-12-25	WOS:A1992HZ48300030
J	JANSEN, FK; JANSEN, A; DEROCQ, JM; CARRIERE, D; CARAYON, P; VEAS, F; JAFFREZOU, JP				JANSEN, FK; JANSEN, A; DEROCQ, JM; CARRIERE, D; CARAYON, P; VEAS, F; JAFFREZOU, JP			GOLGI VACUOLIZATION AND IMMUNOTOXIN ENHANCEMENT BY MONENSIN AND PERHEXILINE DEPEND ON A SERUM-PROTEIN - IMPLICATIONS FOR INTRACELLULAR TRAFFICKING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL MEMBRANE GLYCOPROTEIN; RECEPTOR-MEDIATED ENDOCYTOSIS; CARBOXYLIC IONOPHORES; HUMAN-FIBROBLASTS; HYBRID MOLECULES; COLLOIDAL GOLD; CYTO-TOXICITY; CELLS; RICIN; VESICLES	Vacuole formation around the Golgi and immunotoxin enhancement induced by low doses of the ionophore monensin were inhibited by 50% human plasma (final concentration), whereas the lysosomal pH increase remained unaffected. Immunotoxin enhancement by the Ca2+ antagonist perhexiline was also inhibited by plasma. The inhibiting factor was present in different species and highly concentration-dependent. After purification on DEAE- and CM-Sepharose it showed a heterogeneous distribution between 45 and 50 kDa, in sodium dodecyl sulfate-polyacrylamide gel electrophoresis, an extreme isoelectric point near 3.5, and binding to wheat germ agglutinin-Sepharose. Maximum inhibition was found in the lower molecular mass fraction of 45 kDa. The 50-kDa fraction, although showing immunological identity reactions, remained almost inactive. The simultaneous inhibition of morphological alterations and the enhancement of immunotoxin activity by the highly enriched protein provides a first direct link between both events. Apart from a role of this serum glycoprotein on in vivo inhibition of immunotoxin enhancement, its ability to maintain normal intracellular trafficking in the presence of blocking agents, such as monensin and perhexiline, suggests a more fundamental role in the regulation of these mechanisms.	SANOFI RECH,F-34184 MONTPELLIER,FRANCE; CNRS,PHARMACOL LAB,F-31077 TOULOUSE,FRANCE	Sanofi-Aventis; Sanofi France; Centre National de la Recherche Scientifique (CNRS)	JANSEN, FK (corresponding author), INST FRANCAIS RECH SCI DEV COOPERAT,PROJET SIDA,IMMUNOCIBLAGE LAB,911 AVE AGOPOLIS,BP 5045,F-34032 MONTPELLIER,FRANCE.							AKIYAMA S, 1985, CANCER RES, V45, P1005; BLYTHMAN HE, 1981, NATURE, V290, P145, DOI 10.1038/290145a0; CARRIERE D, 1985, EXP CELL RES, V156, P327; CASELLAS P, 1984, J BIOL CHEM, V259, P9359; COLOMBATTI M, 1990, CANCER RES, V50, P1385; EINSTEIN R, 1989, J CELL BIOL, V109, P1037, DOI 10.1083/jcb.109.3.1037; GRIFFIN TW, 1987, CANCER RES, V47, P4266; GROS O, 1985, J IMMUNOL METHODS, V81, P283, DOI 10.1016/0022-1759(85)90213-3; HARFORD J, 1983, J CELL BIOL, V96, P1824, DOI 10.1083/jcb.96.6.1824; HEDIN U, 1985, EUR J CELL BIOL, V39, P130; HOWE CL, 1988, P NATL ACAD SCI USA, V85, P7577, DOI 10.1073/pnas.85.20.7577; JAFFREZOU JP, 1990, CANCER RES, V50, P5558; JANSEN FK, 1982, IMMUNOL REV, V62, P185, DOI 10.1111/j.1600-065X.1982.tb00394.x; JANSEN FK, 1987, MEMBRANE MEDIATED CY, P167; LEDGER PW, 1980, J CELL BIOL, V87, P663, DOI 10.1083/jcb.87.3.663; LININGTON C, 1983, J NEUROCHEM, V41, P426, DOI 10.1111/j.1471-4159.1983.tb04759.x; MARSH M, 1982, P NATL ACAD SCI-BIOL, V79, P5297, DOI 10.1073/pnas.79.17.5297; MAXFIELD FR, 1982, J CELL BIOL, V95, P676, DOI 10.1083/jcb.95.2.676; MERION M, 1983, J CELL BIOL, V96, P644, DOI 10.1083/jcb.96.3.644; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; PIRKER R, 1989, CANCER RES, V49, P4791; POHLMANN R, 1984, BIOCHEM J, V217, P649, DOI 10.1042/bj2170649; PRESSMAN BC, 1968, FED PROC, V27, P1283; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; RASO V, 1984, J EXP MED, V160, P1234, DOI 10.1084/jem.160.4.1234; SANDVIG K, 1982, J BIOL CHEM, V257, P7504; VIDAL H, 1985, INT J CANCER, V36, P705, DOI 10.1002/ijc.2910360615; VIITALA J, 1988, P NATL ACAD SCI USA, V85, P3743, DOI 10.1073/pnas.85.11.3743; YANAGISHITA M, 1985, J BIOL CHEM, V260, P5445	29	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12577	12582						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618762				2022-12-25	WOS:A1992HZ48300033
J	KATSUYA, Y; SATO, M; KATSUBE, Y; MATSUURA, Y; TOMODA, K				KATSUYA, Y; SATO, M; KATSUBE, Y; MATSUURA, Y; TOMODA, K			SMALL-ANGLE X-RAY-SCATTERING STUDY OF METAL ION-INDUCED CONFORMATIONAL-CHANGES IN SERRATIA PROTEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOSAIC-VIRUS PROTEIN; SYNCHROTRON RADIATION; IMMUNOGLOBULIN	Metal ion-induced conformational changes in Serratia protease which contains one zinc ion per molecule were investigated by the small-angle x-ray scattering method. The molecule is an elongated ellipsoid of approximately 110 x 40 x 40 angstrom with a large cleft in its central region. Comparisons of the native (zinc-enzyme) with the zinc-free (apoenzyme) enzyme and with the zinc-replated metalloenzyme show small but significant differences in their radii of gyration, maximum particle dimensions, and intraparticle pair-distance distributions. The radius of gyration and maximum particle dimension of the native enzyme are almost the same as those of the cobalt-enzyme but are shorter and longer, respectively, than those of the apo- and cadmium-enzymes. Simulation analysis based on the intraparticle pair-distribution function showed that these modified enzymes are comparable with the native enzyme in overall structure, and, except for the cobalt-enzyme, differ in cleft size. The residual enzymatic activity of the cobalt-enzyme is the same as that of the native enzyme, but the apo- and cadmium-enzymes have considerably less activity. The size of the cleft therefore is strictly controlled to ensure optimal enzyme activity, and the position and coordination behavior of the zinc ion in the cleft appears to be essential both for biological functioning and for the maintenance of the gross tertiary structure.	OSAKA UNIV,INST PROT RES,SUITA,OSAKA 565,JAPAN; HYOGO PREFECTURAL INST IND RES,SUMA KU,KOBE 654,JAPAN; TAKEDA CHEM IND LTD,DIV RES & DEV,MICROBIOL RES LABS,YODOGAWA KU,OSAKA 532,JAPAN	Osaka University; Takeda Chemical Industries								GLATTER O, 1979, J APPL CRYSTALLOGR, V12, P166, DOI 10.1107/S0021889879012139; GLATTER O, 1974, J APPL CRYSTALLOGR, V7, P147, DOI 10.1107/S0021889874008983; GLATTER O, 1977, ACTA PHYS AUSTRIACA, V47, P83; Glatter O., 1982, SMALL ANGLE XRAY SCA, P119; GLATTER O, 1982, SMALL ANGLE XRAY SCA, P243; Guinier A., 1955, SMALL ANGLE SCATTERI, P126; HIRAGI Y, 1988, J MOL BIOL, V204, P129, DOI 10.1016/0022-2836(88)90604-3; HIRAGI Y, 1990, J MOL BIOL, V213, P495, DOI 10.1016/S0022-2836(05)80210-4; HOZAKI T, 1986, B CHEM SOC JPN, V59, P3747, DOI 10.1246/bcsj.59.3747; KATAGIRI C, 1987, J BIOL CHEM, V262, P15857; MIYATA K, 1970, AGR BIOL CHEM TOKYO, V34, P310, DOI 10.1080/00021369.1970.10859598; MIYATA K, 1971, AGR BIOL CHEM TOKYO, V35, P460, DOI 10.1080/00021369.1971.10859949; NAKAHAMA K, 1986, NUCLEIC ACIDS RES, V14, P5843, DOI 10.1093/nar/14.14.5843; PILZ I, 1970, BIOCHEMISTRY-US, V9, P211, DOI 10.1021/bi00804a004; PILZ I, 1977, EUR J BIOCHEM, V75, P195, DOI 10.1111/j.1432-1033.1977.tb11517.x; PILZ I, 1982, SMALL ANGLE XRAY SCA, P250; POROD G, 1951, KOLLOID Z Z POLYM, V124, P83, DOI 10.1007/BF01512792; SATO M, 1982, BIOCHEM INT, V5, P595; TURUTA H, 1990, FEBS LETT, V263, P66; UEKI T, 1985, BIOPHYS CHEM, V23, P115, DOI 10.1016/0301-4622(85)80069-7	20	3	3	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12668	12672						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618772				2022-12-25	WOS:A1992HZ48300046
J	PANICKER, MM; MINKLEY, EG				PANICKER, MM; MINKLEY, EG			PURIFICATION AND PROPERTIES OF THE F-SEX FACTOR TRAD PROTEIN, AN INNER MEMBRANE CONJUGAL TRANSFER PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; PROMOTER-DISTAL REGION; BACTERIOPHAGE-LAMBDA; NUCLEOTIDE-SEQUENCE; BACTERIAL CONJUGATION; DNA TRANSFER; OVERPRODUCTION; SYSTEM; OPERON	Using a traD overexpression plasmid, we purified the F sex factor TraD protein in milligram quantities. The purified protein has an apparent molecular weight of 82,000 and an amino acid composition rich in acidic residues. Using specific antibodies, TraD was localized to the inner membrane of F+ cells under conditions where it is produced in physiologically normal amounts. Furthermore, the protein was soluble only in the presence of detergents, but there is evidence that the carboxyl terminus is water-soluble. The purified protein shows pH-sensitive binding to DNA cellulose columns.	CARNEGIE MELLON UNIV,RES INST,CTR BIOTECHNOL,4400 5TH AVE,PITTSBURGH,PA 15213; CARNEGIE MELLON UNIV,RES INST,DEPT BIOL SCI,PITTSBURGH,PA 15213	Carnegie Mellon University; Carnegie Mellon University				Panicker, Mitradas/0000-0002-0782-6222	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028925] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28925] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELMONEM M, 1976, EUR J BIOCHEM, V65, P431, DOI 10.1111/j.1432-1033.1976.tb10358.x; ACHTMAN M, 1979, P NATL ACAD SCI USA, V76, P4837, DOI 10.1073/pnas.76.10.4837; ACHTMAN M, 1971, J BACTERIOL, V106, P529, DOI 10.1128/JB.106.2.529-538.1971; BERNARD HU, 1979, GENE, V5, P59, DOI 10.1016/0378-1119(79)90092-1; CAPALDI RA, 1972, P NATL ACAD SCI USA, V69, P930, DOI 10.1073/pnas.69.4.930; CUOZZO M, 1986, J BIOL CHEM, V261, P5175; CUOZZO M, 1984, J BIOL CHEM, V259, P6659; DATE T, 1977, BIOCHEMISTRY-US, V16, P5579, DOI 10.1021/bi00644a030; EVERETT R, 1980, J MOL BIOL, V136, P129, DOI 10.1016/0022-2836(80)90309-5; FRANKLIN NC, 1979, GENE, V8, P107, DOI 10.1016/0378-1119(79)90011-8; GARVEY JS, 1977, METHOD IMMUNOL, P218; GOTTESMAN ME, 1980, J MOL BIOL, V140, P57, DOI 10.1016/0022-2836(80)90356-3; IPPENIHLER KA, 1986, ANNU REV GENET, V20, P593, DOI 10.1146/annurev.ge.20.120186.003113; JALAJAKUMARI MB, 1987, J MOL BIOL, V198, P1, DOI 10.1016/0022-2836(87)90452-9; JALAJAKUMARI MB, 1989, GENE, V81, P195, DOI 10.1016/0378-1119(89)90179-0; KENNEDY N, 1977, NATURE, V270, P580, DOI 10.1038/270580a0; KINGSMAN A, 1978, J MOL BIOL, V122, P287, DOI 10.1016/0022-2836(78)90191-2; MANNING PA, 1981, P NATL ACAD SCI-BIOL, V78, P7487, DOI 10.1073/pnas.78.12.7487; MANNING PA, 1982, J BACTERIOL, V150, P76, DOI 10.1128/JB.150.1.76-88.1982; MINKLEY EG, 1984, J BACTERIOL, V158, P464, DOI 10.1128/JB.158.2.464-473.1984; MINKLEY EG, 1984, MOL GEN GENET, V196, P225, DOI 10.1007/BF00328054; Neidhardt FC., 1987, ESCHERICHIA COLI SAL, V2nd ed, P3; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PANICKER MM, 1985, J BACTERIOL, V162, P584, DOI 10.1128/JB.162.2.584-590.1985; PERUMAL NB, 1985, THESIS CARNEGIE MELL; WILLETTS N, 1984, MICROBIOL REV, V48, P24, DOI 10.1128/MMBR.48.1.24-41.1984; WILLETTS N, 1980, ANNU REV GENET, V14, P41, DOI 10.1146/annurev.ge.14.120180.000353; YOSHIOKA Y, 1990, J MOL BIOL, V214, P39, DOI 10.1016/0022-2836(90)90145-C	28	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12761	12766						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618779				2022-12-25	WOS:A1992HZ48300058
J	CASEY, JR; PIRRAGLIA, CA; REITHMEIER, RAF				CASEY, JR; PIRRAGLIA, CA; REITHMEIER, RAF			ENZYMATIC DEGLYCOSYLATION OF HUMAN BAND-3, THE ANION TRANSPORT PROTEIN OF THE ERYTHROCYTE-MEMBRANE - EFFECT ON PROTEIN-STRUCTURE AND TRANSPORT-PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-GLYCOSIDASE-F; CARBOHYDRATE MOIETY; TRANSMEMBRANE POLYPEPTIDE; LINKED OLIGOSACCHARIDES; EXCHANGE PROTEIN; CELL-LINE; GLYCOPROTEIN; CDNA; CLONING; SYSTEM	The structural and functional roles of the single asparagine (N)-linked oligosaccharide chain of Band 3 (AE1), the anion transport protein of the human erythrocyte membrane, were examined. Purified Band 3 (M(r) = 95,000) in 0.1% octaethylene glycol mono n-dodecyl ether (C12E8) detergent solution was deglycosylated using N-glycosidase F. This treatment sharpened the protein band on sodium dodecyl sulfate gel electrophoresis and decreased its apparent molecular weight by 5,000. The purified membrane domain could be deglycosylated under similar conditions, causing a shift from a broad band centered at 55 kDa to a sharp 46-kDa band. Band 3 was shown to bind tomato lectin, and loss of lectin binding on blots provided a sensitive assay for deglycosylation. Carbohydrate analysis revealed that greater than 80% of the oligosaccharide could be removed from Band 3 by N-glycosidase F digestion. The deglycosylated protein maintained its dimeric structure and level of detergent binding but had a smaller Stokes radius (R(S) = 72 angstrom) than native Band 3 (R(S) = 75 Angstrom). The Stokes radius of the membrane domain (R(S)60 angstrom) also decreased upon deglycosylation (R(S) = 58 angstrom). Circular dichroism studies showed that deglycosylation did not change the secondary structure of Band 3 or the membrane domain. The sensitivity of Band 3 or the membrane domain to proteolytic digestion by trypsin or proteinase K was also unaffected by deglycosylation. The deglycosylated protein aggregated more rapidly and was much more readily precipitable by ammonium sulfate. The deglycosylated protein bound the anion transport inhibitor 4-benzamido-4'-aminostilbene-2,2'-disulfonate with the same affinity (K(d) = 1-mu-M) as the native protein. Transport studies using reconstituted Band 3 and resealed ghosts showed that deglycosylated Band 3 retained its ability to transport anions. We conclude that removal of the oligosaccharide chain from Band 3 and any resultant structural changes had no effect on the transport function of this protein.	UNIV TORONTO, DEPT MED,MRC,MEMBRANE BIOL GRP,RM 7307, MED SCI BLDG, TORONTO M5S 1A8, ONTARIO, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO M5S 1A8, ONTARIO, CANADA	University of Toronto; University of Toronto			Casey, Joseph/A-8888-2013	Casey, Joseph/0000-0002-9890-5056				ALPER SL, 1988, J BIOL CHEM, V263, P17092; ALPER SL, 1991, ANNU REV PHYSIOL, V53, P549, DOI 10.1146/annurev.physiol.53.1.549; ASANO T, 1991, J BIOL CHEM, V266, P24632; BECK WS, 1977, HEMATOLOGY, P265; BIRNIR B, 1990, BIOCHIM BIOPHYS ACTA, V1048, P100, DOI 10.1016/0167-4781(90)90028-Z; BOODHOO A, 1984, J BIOL CHEM, V259, P785; CASEY JR, 1991, J BIOL CHEM, V266, P15726; CASEY JR, 1989, METHOD ENZYMOL, V173, P494; CHILDS RA, 1978, BIOCHEM J, V173, P333, DOI 10.1042/bj1730333; COX JV, 1988, MOL CELL BIOL, V8, P1327, DOI 10.1128/MCB.8.3.1327; DEMUTH DR, 1986, EMBO J, V5, P1205, DOI 10.1002/j.1460-2075.1986.tb04348.x; DRICKAMER LK, 1976, J BIOL CHEM, V251, P5115; DRICKAMER LK, 1978, J BIOL CHEM, V253, P7242; FEUGEAS JP, 1990, BIOCHIM BIOPHYS ACTA, V1030, P60, DOI 10.1016/0005-2736(90)90238-J; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; FUKUDA M, 1979, J BIOL CHEM, V254, P3700; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; HO MK, 1975, J BIOL CHEM, V250, P675; HOGUE DL, 1990, BIOCHEM CELL BIOL, V68, P199, DOI 10.1139/o90-026; ILLSLEY NP, 1987, BIOCHEMISTRY-US, V26, P1215, DOI 10.1021/bi00379a002; JENNINGS ML, 1984, J BIOL CHEM, V259, P4652; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; KUDRYCKI KE, 1990, J BIOL CHEM, V265, P462; KUDRYCKI KE, 1989, J BIOL CHEM, V264, P8185; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE BS, 1991, J BIOL CHEM, V266, P11448; LIBERMAN DM, 1983, BIOCHEMISTRY-US, V22, P4023; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERKLE RK, 1987, J BIOL CHEM, V262, P8179; MUELLER TJ, 1979, J BIOL CHEM, V254, P8103; OIKAWA K, 1985, BIOCHEMISTRY-US, V24, P2843, DOI 10.1021/bi00333a005; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; OTT RJ, 1982, J BIOL CHEM, V267, P133; PAPPERT G, 1983, BIOCHIM BIOPHYS ACTA, V730, P32, DOI 10.1016/0005-2736(83)90313-9; PASSOW H, 1986, REV PHYSIOL BIOCH P, V103, P61; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; RAO A, 1979, BIOCHEMISTRY-US, V18, P4505, DOI 10.1021/bi00588a008; Reithmeier R.A.F., 1989, ANION TRANSPORT PROT, P213; RESTREPO D, 1989, AM J PHYSIOL, V257, pC520, DOI 10.1152/ajpcell.1989.257.3.C520; SABBAN E, 1982, J CELL BIOL, V91, P637; SCHEURING U, 1986, J MEMBRANE BIOL, V90, P123, DOI 10.1007/BF01869930; STECK TL, 1976, BIOCHEMISTRY-US, V15, P1154, DOI 10.1021/bi00650a030; TAKEDA K, 1988, FEBS LETT, V238, P201, DOI 10.1016/0014-5793(88)80256-4; TANNER MJA, 1988, CARBOHYD RES, V178, P203, DOI 10.1016/0008-6215(88)80112-5; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TSUJI T, 1980, BIOCHEM J, V187, P677, DOI 10.1042/bj1870677; TSUJI T, 1981, J BIOL CHEM, V256, P497; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WOHLFART P, 1989, J BIOL CHEM, V264, P20934; WOLOSIN JM, 1980, BIOCHEM J, V189, P35, DOI 10.1042/bj1890035; YANG JT, 1986, METHOD ENZYMOL, V130, P208; YUSUFI ANK, 1988, J BIOL CHEM, V263, P13683	55	63	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11940	11948						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601863				2022-12-25	WOS:A1992HY94700045
J	DECLERCK, PJ; DEMOL, M; VAUGHAN, DE; COLLEN, D				DECLERCK, PJ; DEMOL, M; VAUGHAN, DE; COLLEN, D			IDENTIFICATION OF A CONFORMATIONALLY DISTINCT FORM OF PLASMINOGEN-ACTIVATOR INHIBITOR-1, ACTING AS A NONINHIBITORY SUBSTRATE FOR TISSUE-TYPE PLASMINOGEN-ACTIVATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LINKED IMMUNOSORBENT-ASSAY; FIBRO-SARCOMA CELLS; ENDOTHELIAL-CELLS; MONOCLONAL-ANTIBODIES; REACTIVE CENTER; HUMAN-PLASMA; PURIFICATION; PROTEIN; GENE	Plasminogen activator inhibitor-1 (PAI-1), the primary physiological inhibitor of tissue-type plasminogen activator (t-PA) in plasma, is a serine proteinase inhibitor (serpin) that forms a 1:1 stoichiometric complex with its target proteinase leading to the formation of a stable inactive complex. The active, inhibitory form of PAI-1 spontaneously converts to a latent form that can be reactivated by protein denaturants. In the present study we have isolated another molecular form of intact PAI-1 that, in contrast with active PAI-1, does not form stable complexes with t-PA but is cleaved at the P1-P1' bond (Arg346-Met347). Other serine proteinases, e.g. urokinase-type plasminogen activator and thrombin, also cleaved this "substrate" form of PAI-1. Fluorescence spectroscopy revealed conformational differences between the latent, active, and substrate forms of PAI-1. This observation confirms our hypothesis that the three functionally different forms of PAI-1 are the consequence of conformational transitions. Thus PAI-1 may occur in three interconvertible conformations: latent, inhibitor, and substrate PAI-1. The identification of two distinct conformations of PAI-1 which interact with their target protease either as an inhibitor or as a substrate is a previously unrecognized phenomenon among the serpins. Conversion of substrate PAI-1 to its inactive degradation product may constitute a pathway for the physiological regulation of PAI-1 activity.	VET ADM MED CTR W ROXBURY, DIV CARDIOL, BOSTON, MA 02132 USA		DECLERCK, PJ (corresponding author), CATHOLIC UNIV LEUVEN, CTR THROMBOSIS & VASC RES, CAMPUS GASTHUISBERG, O & N, HERESTR 49, B-3000 LOUVAIN, BELGIUM.		Declerck, Paul J/A-2330-2017	Declerck, Paul J/0000-0003-1259-9105				ALESSI MC, 1988, EUR J BIOCHEM, V175, P531, DOI 10.1111/j.1432-1033.1988.tb14225.x; ANDREASEN PA, 1986, FEBS LETT, V209, P213, DOI 10.1016/0014-5793(86)81113-9; BARTHA K, 1991, J BIOL CHEM, V266, P792; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CHMIELEWSKA J, 1988, BIOCHEM J, V251, P327, DOI 10.1042/bj2510327; DECLERCK PJ, 1988, BLOOD, V71, P220; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; DECLERCK PJ, 1982, FIBRINOLYSIS S2, V2, P77; GINSBURG D, 1986, J CLIN INVEST, V78, P1673, DOI 10.1172/JCI112761; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HOLMES WE, 1987, SCIENCE, V238, P209, DOI 10.1126/science.2958938; HOLVOET P, 1985, THROMB HAEMOSTASIS, V54, P684; KNUDSEN BS, 1988, J BIOL CHEM, V263, P9476; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LEVY NJ, 1990, P NATL ACAD SCI USA, V87, P265, DOI 10.1073/pnas.87.1.265; LOSKUTOFF DJ, 1977, P NATL ACAD SCI USA, V74, P3903, DOI 10.1073/pnas.74.9.3903; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; NIELSEN LS, 1986, FEBS LETT, V196, P269, DOI 10.1016/0014-5793(86)80261-7; NIELSEN LS, 1986, THROMB HAEMOSTASIS, V55, P206; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; PANNEKOEK H, 1986, EMBO J, V5, P2539, DOI 10.1002/j.1460-2075.1986.tb04532.x; PARKER CA, 1960, ANALYST, V85, P587, DOI 10.1039/an9608500587; PERRY DJ, 1989, MOL BIOL MED, V6, P239; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; VANMOURIK JA, 1984, J BIOL CHEM, V259, P14914; VERHEIJEN JH, 1982, THROMB HAEMOSTASIS, V48, P266	28	140	142	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11693	11696						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601844				2022-12-25	WOS:A1992HY94700009
J	NEWMAN, CMH; GIANNAKOUROS, T; HANCOCK, JF; FAWELL, EH; ARMSTRONG, J; MAGEE, AI				NEWMAN, CMH; GIANNAKOUROS, T; HANCOCK, JF; FAWELL, EH; ARMSTRONG, J; MAGEE, AI			POSTTRANSLATIONAL PROCESSING OF SCHIZOSACCHAROMYCES-POMBE YPT PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-METHYLATION; TERMINAL CYSTEINE; PLASMA-MEMBRANE; RAS PROTEINS; YEAST; GENE; SEQUENCE; P21RAS; BINDING; RESIDUE	ras proteins are post-translationally processed at their carboxyl-terminal CAAX motif by a triplet of modifications: prenylation of C with farnesyl, proteolytic trimming of AAX, and carboxyl-methylation. These modifications co-operate with palmitoylation of nearby sites or a polybasic region to target plasma membrane localization. The related YPT/rab proteins in contrast are localized to compartments of the endomembrane system and may be involved in directing membrane traffic. These proteins end in XCC or CXC motifs. We have analyzed the processing of members of this subfamily from the fission yeast Schizosaccharomyces pombe. We find using in vitro translation in reticulocyte lysates that YPT1, -3, and -5 are prenylated with geranylgeranyl and that they incorporate label from [H-3]mevalonic acid when expressed in transfected COS cells in vivo. Furthermore, prenylation was necessary for membrane binding in vivo. The CXC protein YPT5, but neither of the two XCC proteins YPT1 and YPT3, was carboxyl-methylated in S. pombe and in COS cells in vivo. However, YPT5 was not carboxyl-methylated in vitro in lysates which were able to methylate ras protein. YPT3 was detectably palmitoylated when expressed in COS cells, though at a much lower level than ras.	NATL INST MED RES, MILL HILL, LONDON NW7 1AA, ENGLAND; ROYAL FREE HOSP, SCH MED, LONDON NW3 2QG, ENGLAND; IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	MRC National Institute for Medical Research; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Cancer Research UK			Magee, Anthony/V-8345-2019; GIANNAKOUROS, THOMAS/R-3204-2019	Hancock, John/0000-0003-0542-4710				BAILLY E, 1991, NATURE, V350, P715, DOI 10.1038/350715a0; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FAWELL E, 1989, NUCLEIC ACIDS RES, V17, P4373, DOI 10.1093/nar/17.11.4373; FAWELL E, 1990, NUCLEIC ACIDS RES, V18, P4264, DOI 10.1093/nar/18.14.4264; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; GIANNAKOUROS T, 1992, FEBS LETT, V297, P103, DOI 10.1016/0014-5793(92)80337-G; GOODMAN LE, 1990, P NATL ACAD SCI USA, V87, P9665, DOI 10.1073/pnas.87.24.9665; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; Gutz H., 1974, HDB GENETICS, V1, P395; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HORIUCHI H, 1991, J BIOL CHEM, V266, P16981; JOHNSTON PA, 1991, NEURON, V7, P101, DOI 10.1016/0896-6273(91)90078-E; KAMIYA Y, 1979, AGR BIOL CHEM TOKYO, V43, P1049, DOI 10.1080/00021369.1979.10863559; KAUFER NF, 1985, NATURE, V318, P78, DOI 10.1038/318078a0; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KINSELLA BT, 1991, J BIOL CHEM, V266, P8540; KITA T, 1980, J CLIN INVEST, V66, P1094, DOI 10.1172/JCI109938; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MIYAKE S, 1990, EMBO J, V9, P1417, DOI 10.1002/j.1460-2075.1990.tb08257.x; MOLENAAR CMT, 1988, EMBO J, V7, P971, DOI 10.1002/j.1460-2075.1988.tb02903.x; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; ROSSI G, 1991, NATURE, V351, P158, DOI 10.1038/351158a0; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; TAKAI Y, 1992, IN PRESS INT REV CYT; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; VOLKER C, 1991, FEBS LETT, V295, P189, DOI 10.1016/0014-5793(91)81415-5; VORBURGER K, 1989, EMBO J, V8, P4007, DOI 10.1002/j.1460-2075.1989.tb08583.x; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; YOSHIDA Y, 1991, BIOCHEM BIOPH RES CO, V175, P720, DOI 10.1016/0006-291X(91)91625-M	51	55	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11329	11336						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597466				2022-12-25	WOS:A1992HX16900062
J	SEGUCHI, T; GOTO, Y; ONO, M; FUJIWARA, T; SHIMADA, T; KUNG, HF; NISHIOKA, M; IKEHARA, Y; KUWANO, M				SEGUCHI, T; GOTO, Y; ONO, M; FUJIWARA, T; SHIMADA, T; KUNG, HF; NISHIOKA, M; IKEHARA, Y; KUWANO, M			BREFELDIN-A-RESISTANT MUTANTS OF HUMAN EPIDERMOID CARCINOMA CELL-LINE WITH STRUCTURAL-CHANGES OF THE GOLGI-APPARATUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; CULTURED RAT HEPATOCYTES; SECRETORY PROTEINS; INTRACELLULAR-TRANSPORT; VARIANTS RESISTANT; MONENSIN; ACCUMULATION; PATHWAY; ER	We have isolated brefeldin A (BFA)-resistant cell lines, KB/BF-1 and KB/BF-2, from the human epidermoid carcinoma KB cell line. The BFA-resistant phenotypes have been stably maintained for more than 3 months in the absence of BFA. KB/BF-1 and KB/BF-2 showed 10-30-fold higher resistance to cytotoxicity of BFA but were 2-3-fold more sensitive to monensin and nigericin, than KB cells. KB/BF-1 showed aberrant structures of the Golgi complex with poorly developed cisternae surrounded by many small vesicles. Immunocytochemical studies were done with antibodies against a Golgi-specific antigen (chronic rheumatoid arthritis antigen) and a coatomer subunit (beta-subunit for coat proteins of non-clathrin-coated vesicles). Golgi-specific markers were distributed into the small vesicles which were localized diffusely in cytoplasm of KB/BF-1 cells. Such Golgi markers were observed in a strictly confined perinuclear region of the parental KB cells, whereas in the mutant cells the markers were distributed more diffusely in dot-like structures at perinuclear regions. In addition, when exposed to BFA, the mutant and parental cells showed a different distribution of these markers. Synthesis and maturation of low density lipoprotein receptor showed apparently slower rates in processing of low density lipoprotein receptor in KB/BF-1 and KB/BF-2 cells than those observed in their parental KB cells. Protein secretion in KB/BF-1 and KB/BF-2 cells was about 30% less than that in KB cells. Much less inhibition by BFA on the secretion was observed in KB/BF-1 and KB/BF-2 cells. A BFA-resistant mutation in BFA-resistant KB cell lines appears to affect assembly of the Golgi apparatus as well as some Golgi-specific functions.	OITA MED UNIV, DEPT ANAT, OITA 87955, JAPAN; NCI, FREDERICK CANC RES & DEV CTR, BIOL RESPONSE MODIFIERS PROGRAM, BIOCHEM PHYSIOL LAB, FREDERICK, MD 21702 USA; FUKUOKA UNIV, SCH MED, DEPT BIOCHEM, FUKUOKA 81401, JAPAN; KAGAWA MED SCH, DEPT INTERNAL MED, KAGAWA 76107, JAPAN	Oita University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Fukuoka University; Kagawa University	SEGUCHI, T (corresponding author), OITA MED UNIV, DEPT BIOCHEM, OITA 87955, JAPAN.							DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; Duden R, 1991, Trends Cell Biol, V1, P14, DOI 10.1016/0962-8924(91)90064-G; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FUJIWARA T, 1989, CELL STRUCT FUNCT, V14, P605, DOI 10.1247/csf.14.605; HAGINO Y, 1988, JPN J CANCER RES, V79, P74, DOI 10.1111/j.1349-7006.1988.tb00013.x; KUWANO M, 1991, J CELL SCI, V98, P131; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MATSUO K, 1990, CANCER RES, V50, P5819; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MIZOGUCHI H, 1990, BIOCHIM BIOPHYS ACTA, V1052, P475, DOI 10.1016/0167-4889(90)90158-A; NAKANO A, 1985, BIOCHIM BIOPHYS ACTA, V845, P324, DOI 10.1016/0167-4889(85)90195-8; ODA K, 1983, EUR J BIOCHEM, V135, P209, DOI 10.1111/j.1432-1033.1983.tb07639.x; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; ONO M, 1988, MOL CELL BIOL, V8, P4190, DOI 10.1128/MCB.8.10.4190; ONO M, 1985, J CELL BIOL, V101, P60, DOI 10.1083/jcb.101.1.60; ONO M, 1984, J CELL PHYSIOL, V119, P198, DOI 10.1002/jcp.1041190209; ONO M, 1991, CELL GROWTH DIFFER, V2, P317; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1991, CELL, V64, P1183; SCHEKMAN R, 1985, ANNU REV CELL BIOL, V1, P115, DOI 10.1146/annurev.cellbio.1.1.115; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SHITE S, 1988, J BIOL CHEM, V263, P19286; SHITE S, 1990, EUR J BIOCHEM, V191, P491, DOI 10.1111/j.1432-1033.1990.tb19148.x; SHITE S, 1990, J BIOL CHEM, V265, P17385; SHITE S, 1991, ARCH BIOCHEM BIOPHYS, V284, P245; TAKANO H, 1991, CANCER RES, V51, P3951; TANAKA S, 1989, J CLIN ELECT MISCROS, V22, P5; TARTAKOFF A, 1978, J CELL BIOL, V79, P694, DOI 10.1083/jcb.79.3.694; TARTAKOFF AM, 1977, J EXP MED, V146, P1332, DOI 10.1084/jem.146.5.1332; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; YOSHIMURA A, 1987, J BIOL CHEM, V262, P13299; ZUBER C, 1991, P NATL ACAD SCI USA, V88, P9818, DOI 10.1073/pnas.88.21.9818	35	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11626	11630						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597488				2022-12-25	WOS:A1992HX16900105
J	WILSON, JM; GROSSMAN, M; CABRERA, JA; WU, CH; WU, GY				WILSON, JM; GROSSMAN, M; CABRERA, JA; WU, CH; WU, GY			A NOVEL MECHANISM FOR ACHIEVING TRANSGENE PERSISTENCE INVIVO AFTER SOMATIC GENE-TRANSFER INTO HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-BIOLOGY; CELLS; EXPRESSION; DNA; REPLICATION; DELIVERY; VIRUS; MICE	Infusion of hepatocyte-specific DNA-protein complexes into rats leads to transient recombinant gene expression in liver. The eventual deterioration of gene expression is due in part to instability of the targeted DNA. In a previous report, we noted retention of transgene sequences in liver and persistent recombinant gene expression when the animals were subjected to partial hepatectomy following in vivo gene transfer. In an attempt to define the mechanism(s) responsible for persistent gene expression following partial hepatectomy, we characterized the molecular state of the retained, liver-associated transgenes. Southern blot analysis of DNA from liver tissues harvested various times after in vivo gene transfer and partial hepatectomy (10 min to 11 weeks) demonstrated high levels of transgene DNA (100-10,000 copies/cell). The predominant form of this DNA appeared to be episomal based on analyses of uncut DNA or DNA restricted by an endonuclease with one site in the plasmid. Livers from several animals contained a small proportion of transgene sequences of unknown structure. The existence of episomal DNA in liver was confirmed in experiments in which intact plasmid was rescued from total hepatocyte DNA by transformation of bacteria. Both strands of DNA in the liver-associated plasmid retained a bacterial pattern of methylation suggesting that the plasmid had not replicated in the eukaryotic cell. These results are consistent with the hypothesis that the majority of transgene sequences are retained as stabilized plasmids. The specific form of DNA which is transcriptionally active was not identified in these studies. This represents a new mechanism for retaining foreign DNA in eukaryotic cells in vivo and has implications both for the development of somatic gene therapies and the pathogenesis of viral diseases.	UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV CONNECTICUT,SCH MED,DEPT INTERNAL MED,FARMINGTON,CT 06030	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Connecticut	WILSON, JM (corresponding author), UNIV MICHIGAN,SCH MED,HOWARD HUGHES MED INST,RM 4554,MSRB II,ANN ARBOR,MI 48109, USA.		Wilson, James M/F-9220-2011	Wilson, James M/0000-0002-9630-3131				BISHOP JO, 1989, MOL BIOL MED, V6, P283; BLUM HE, 1989, TRENDS GENET, V5, P154, DOI 10.1016/0168-9525(89)90057-7; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; FRIEDMANN T, 1989, SCIENCE, V244, P1275, DOI 10.1126/science.2660259; GEIER GE, 1979, J BIOL CHEM, V254, P1408; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; PUGH JC, 1990, BRIT MED BULL, V46, P329, DOI 10.1093/oxfordjournals.bmb.a072402; Roth D., 1988, GENETIC RECOMBINATIO, P621; ROTH DB, 1985, MOL CELL BIOL, V5, P2599, DOI 10.1128/MCB.5.10.2599; SELL S, 1990, CANCER RES, V50, P3811; WAGNER E, 1991, P NATL ACAD SCI USA, V88, P4255, DOI 10.1073/pnas.88.10.4255; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410; WILKIE TM, 1987, MOL CELL BIOL, V7, P1646, DOI 10.1128/MCB.7.5.1646; WILSON JM, 1990, P NATL ACAD SCI USA, V87, P439, DOI 10.1073/pnas.87.1.439; WILSON JM, 1992, J BIOL CHEM, V267, P963; WU CH, 1989, J BIOL CHEM, V264, P16985; WU GY, 1987, J BIOL CHEM, V262, P4429; WU GY, 1988, J BIOL CHEM, V263, P14621; WU GY, 1991, J BIOL CHEM, V266, P14338; ZENKE M, 1990, P NATL ACAD SCI USA, V87, P3655, DOI 10.1073/pnas.87.10.3655	20	97	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11483	11489						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597475				2022-12-25	WOS:A1992HX16900083
J	FRADKIN, LG; KORNBERG, A				FRADKIN, LG; KORNBERG, A			PREREPLICATIVE COMPLEXES OF COMPONENTS OF DNA POLYMERASE-III HOLOENZYME OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCESSIVE SYNTHESIS; INITIATION COMPLEX; PRIMED DNA; REPLICATION; SUBUNIT; ATP; PURIFICATION; PROTEIN; BINDING; FORM	Stepwise reconstitution of the subunits of DNA polymerase III holoenzyme of Escherichia coli offers insights into the organization and function of this multisubunit assembly. A highly processive, holoenzyme-like activity can be generated when the gamma-complex, in the presence of ATP and a primed template, activates the beta-subunit to form a preinitiation complex, and this is then followed by addition of the core polymerase. Further analysis of early replicative complexes has now revealed: 1) that the gamma-complex can stably bind a single-stranded DNA binding protein (SSB)-coated template, 2) that neither SSB coating of the template nor a proper primer terminus is required to form the preinitiation complex, and 3) that the gamma-complex stabilizes the preinitiation complex in the presence of ATP and destabilizes it in the presence of adenosine 5'-O-(thiotriphosphate). Based on these findings, a sequence of stages can be formulated for an activation of the beta-subunit that enables it to bind the template-primer and thereby interact with the core to create a processive polymerase.	STANFORD UNIV,MED CTR,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM007581, R37GM007581] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG002908] Funding Source: NIH RePORTER; NIA NIH HHS [AGO2908] Funding Source: Medline; NIGMS NIH HHS [GM07581] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BISWAS SB, 1984, J BIOL CHEM, V259, P7990; BURGERS PMJ, 1983, J BIOL CHEM, V258, P7669; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1474; CRUTE JJ, 1983, J BIOL CHEM, V258, P1344; JOHANSON KO, 1984, J BIOL CHEM, V259, P4589; KWONSHIN O, 1987, J BIOL CHEM, V262, P2121; LADUCA RJ, 1983, BIOCHEMISTRY-US, V22, P5177, DOI 10.1021/bi00291a018; LOW RL, 1982, J BIOL CHEM, V257, P6242; MAKI H, 1985, J BIOL CHEM, V260, P2987; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6555; MAKI S, 1988, J BIOL CHEM, V263, P6561; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MCHENRY CS, 1988, BIOCHIM BIOPHYS ACTA, V951, P240, DOI 10.1016/0167-4781(88)90092-9; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; SCOTT JF, 1977, P NATL ACAD SCI USA, V74, P193, DOI 10.1073/pnas.74.1.193; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; WICKNER W, 1974, J BIOL CHEM, V249, P6244	23	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10318	10322						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587819				2022-12-25	WOS:A1992HV09000020
J	HILTON, DJ; NICOLA, NA				HILTON, DJ; NICOLA, NA			KINETIC ANALYSES OF THE BINDING OF LEUKEMIA INHIBITORY FACTOR TO RECEPTORS ON CELLS AND MEMBRANES AND IN DETERGENT SOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; EMBRYONIC STEM-CELLS; MOLECULAR-CLONING; HIGH-AFFINITY; HEMATOPOIETIC-CELLS; FATAL SYNDROME; FACTOR LIF; T-CELLS; GM-CSF; EXPRESSION	The equilibrium and kinetic properties of leukemia inhibitory factor (LIF) binding to a range of cell types have been compared. When binding was examined at 4-degrees-C, the majority of cells were found to express a single class of high affinity LIF receptor (K(D) = 20-100 pM; k(a) = 2-8 x 10(8) min-1 M-1; k(d) = 0.0004-0.0011 min-1). In contrast, certain activated macrophage populations expressed apparently independent classes of high and low affinity LIF receptor. The low affinity receptors differed from the high affinity receptors in terms of the dissociation rate of the receptor-ligand complex (K(D) = 1-2 nM; k(a) = 3-7 x 10(8) min-1 M-1; k(d) = 0.30-0.67 min-1). At 37-degrees-C, the interaction of LIF with its high affinity receptor was more complicated, since occupied LIF receptors were internalized more rapidly than unoccupied receptors, internalized LIF was hydrolyzed and released from the cell, and new receptors were synthesized and expressed on the cell surface. Interestingly, when membranes were prepared from cells that expressed only high affinity receptors, both high and low affinity receptors were detected, while after detergent solubilization of membranes only low affinity receptors were apparent. These results are discussed in terms of a structural model for the LIF receptor in which interaction of a low affinity binding subunit and a second nonbinding subunit is required for the generation of the high affinity receptor.	WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3054, AUSTRALIA	Walter & Eliza Hall Institute			Hilton, Douglas J/C-7250-2013; Nicola, Nicos/D-2989-2011	Hilton, Douglas J/0000-0002-7698-2392; Nicola, Nicos/0000-0003-1054-7889	NATIONAL CANCER INSTITUTE [R01CA022556, R37CA022556] Funding Source: NIH RePORTER; NCI NIH HHS [CA-22556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE T, 1989, J BIOL CHEM, V264, P8941; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BERNARD O, 1989, J NEUROSCI RES, V24, P9, DOI 10.1002/jnr.490240104; BERNSTINE EG, 1973, P NATL ACAD SCI USA, V70, P3899, DOI 10.1073/pnas.70.12.3899; CALVO JC, 1983, BIOCHEM J, V212, P259, DOI 10.1042/bj2120259; CONTRERAS MA, 1983, METHOD ENZYMOL, V92, P277; COULIE PG, 1989, EUR J IMMUNOL, V19, P2107, DOI 10.1002/eji.1830191121; CUATRECASAS P, 1972, P NATL ACAD SCI USA, V69, P318, DOI 10.1073/pnas.69.2.318; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DEMEYTS P, 1973, BIOCHEM BIOPH RES CO, V55, P154, DOI 10.1016/S0006-291X(73)80072-5; DEVOS R, 1991, EMBO J, V10, P2133, DOI 10.1002/j.1460-2075.1991.tb07747.x; DEWEY MJ, 1977, P NATL ACAD SCI USA, V74, P5564, DOI 10.1073/pnas.74.12.5564; Frost A.A., 1971, KINETICS MECH, P7; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GEARING DP, 1989, BIO-TECHNOL, V7, P1157; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GOUGH NM, 1988, P NATL ACAD SCI USA, V85, P2623, DOI 10.1073/pnas.85.8.2623; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GUILBERT LJ, 1986, J BIOL CHEM, V261, P4024; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HEATH JK, 1989, ENDOCRINOLOGY, V124, P3060; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1988, ANAL BIOCHEM, V173, P359, DOI 10.1016/0003-2697(88)90200-X; HILTON DJ, 1991, J CELL PHYSIOL, V146, P207, DOI 10.1002/jcp.1041460204; HILTON DJ, 1992, TRENDS BIOCHEM SCI, V17, P72, DOI 10.1016/0968-0004(92)90505-4; HILTON DJ, 1988, P NATL ACAD SCI USA, V85, P5971, DOI 10.1073/pnas.85.16.5971; ICHIKAWA Y, 1969, J CELL PHYSIOL, V74, P223, DOI 10.1002/jcp.1040740303; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; LANG RA, 1987, CELL, V51, P675, DOI 10.1016/0092-8674(87)90136-X; LIMBIRD LE, 1987, CELL SURFACE RECEPTO; LOPEZ AF, 1990, J CELL PHYSIOL, V145, P69, DOI 10.1002/jcp.1041450111; LOWE DG, 1989, DNA-J MOLEC CELL BIO, V8, P351, DOI 10.1089/dna.1.1989.8.351; LOWENTHAL JW, 1986, J EXP MED, V164, P1060, DOI 10.1084/jem.164.4.1060; MAYO KH, 1989, J BIOL CHEM, V264, P17838; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; METCALF D, 1991, BLOOD, V77, P2150; METCALF D, 1989, P NATL ACAD SCI USA, V86, P5948, DOI 10.1073/pnas.86.15.5948; METCALF D, 1990, BLOOD, V76, P50; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NICOLA NA, 1986, J CELL PHYSIOL, V128, P180, DOI 10.1002/jcp.1041280207; NICOLA NA, 1985, J CELL PHYSIOL, V124, P313, DOI 10.1002/jcp.1041240222; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; NICOLA NA, 1992, IN PRESS GROWTH FACT; Nicola NA, 1988, GROWTH FACTORS, V1, P29, DOI 10.3109/08977198809000244; Nicola NA, 1988, GROWTH FACTORS, V1, P41, DOI 10.3109/08977198809000245; PEASE S, 1990, EXP CELL RES, V190, P209, DOI 10.1016/0014-4827(90)90187-F; PEASE S, 1990, DEV BIOL, V141, P344, DOI 10.1016/0012-1606(90)90390-5; SAWYER ST, 1987, J BIOL CHEM, V262, P5554; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; STANLEY ER, 1981, J IMMUNOL METHODS, V42, P253, DOI 10.1016/0022-1759(81)90156-3; STEVENS LC, 1970, DEV BIOL, V21, P364, DOI 10.1016/0012-1606(70)90130-2; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; TOMIDA M, 1984, J BIOL CHEM, V259, P978; WALKER F, 1985, EMBO J, V4, P933, DOI 10.1002/j.1460-2075.1985.tb03721.x; WILEY HS, 1981, CELL, V25, P433, DOI 10.1016/0092-8674(81)90061-1; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0	61	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10238	10247						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587813				2022-12-25	WOS:A1992HV09000009
J	INOUE, A; OBATA, K; AKAGAWA, K				INOUE, A; OBATA, K; AKAGAWA, K			CLONING AND SEQUENCE-ANALYSIS OF CDNA FOR A NEURONAL CELL-MEMBRANE ANTIGEN, HPC-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MONOCLONAL-ANTIBODIES; NEURITE OUTGROWTH; RAT RETINA; SYNTHETIC PEPTIDE; CLEAVAGE SITES; A-CHAIN; LAMININ; PROTEINS; IDENTIFICATION	A monoclonal antibody (mAb), HPC-1, labels the plasma membrane of the amacrine cell soma and inner plexiform layer in rat retina and other central neurons. HPC-1 antigen recognizes several proteins of about 35 kDa. In this study, an HPC-1 positive cDNA, HPC-113, was isolated from a lambda-gt11 cDNA library of the rat hippocampus. HPC-113 had the 894-base pair nucleotide sequence in an open reading frame and the calculated molecular mass of the deduced amino acid sequence (298 residues) was 33,989 Da, implying that HPC-113 contains almost the full-length coding region of HPC-1 antigen mRNA. Sequence analysis suggested that HPC-1 antigen is an integrated membrane protein revealing the characteristic alpha-helical structure with periodical heptad repeats usually seen in proteins with coiled-coil structures. Although the entire amino acid sequence did not show significant homology to any proteins so far known, a few local sequences in the possible extracellular domain of the HPC-1 antigen molecule had notable homology to some partial sequences in the laminin B1 chain. These sequences of laminin are included in the portion which has neurite outgrowth and/or survival promoting activity. The HPC-1 gene was transcribed in nerve tissues much more predominantly than in non-neuronal tissues. Thus, HPC-1 antigen(s) was confined to be a newly identified neuronal cell membrane protein(s) localized in a subpopulation of neurons.	NATL INST PHYSIOL SCI,DEPT MOLEC PHYSIOL,NEUROCHEM LAB,OKAZAKI,AICHI 444,JAPAN; GRAD UNIV ADV STUDIES OKAZAKI,SCH LIFE SCI,DEPT PHYSIOL SCI,OKAZAKI,AICHI,JAPAN	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Graduate University for Advanced Studies - Japan								AKAGAWA K, 1987, DEV BRAIN RES, V31, P124, DOI 10.1016/0165-3806(87)90089-7; AKAGAWA K, 1986, BRAIN RES, V383, P110, DOI 10.1016/0006-8993(86)90012-0; AKAGAWA K, 1987, BRAIN RES, V437, P298, DOI 10.1016/0006-8993(87)91644-1; AKAGAWA K, 1990, BRAIN RES, V518, P1, DOI 10.1016/0006-8993(90)90945-8; AKAGAWA K, 1987, BRAIN RES, V408, P154, DOI 10.1016/0006-8993(87)90367-2; BARNSTABLE CJ, 1983, COLD SPRING HARB SYM, V48, P863, DOI 10.1101/SQB.1983.048.01.089; BARNSTABLE CJ, 1980, NATURE, V286, P231, DOI 10.1038/286231a0; BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BARNSTABLE CJ, 1984, NEUROSCIENCE, V11, P847, DOI 10.1016/0306-4522(84)90195-7; BASSELDUBY R, 1985, NATURE, V315, P421, DOI 10.1038/315421a0; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; CASHDOLLAR LW, 1985, P NATL ACAD SCI USA, V82, P24, DOI 10.1073/pnas.82.1.24; CHOMCZYNSKI P, 1984, BIOCHEM BIOPH RES CO, V122, P340, DOI 10.1016/0006-291X(84)90480-7; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COLE GJ, 1986, DEV BRAIN RES, V26, P133, DOI 10.1016/0165-3806(86)90015-5; DRAGER UC, 1984, J NEUROSCI, V4, P2025; EDGAR D, 1988, J CELL BIOL, V106, P1299, DOI 10.1083/jcb.106.4.1299; EDGAR D, 1984, EMBO J, V3, P1463, DOI 10.1002/j.1460-2075.1984.tb01997.x; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FEKETE DM, 1983, J NEUROCYTOL, V12, P785, DOI 10.1007/BF01258151; FRANZ JK, 1986, P NATL ACAD SCI USA, V83, P6475, DOI 10.1073/pnas.83.17.6475; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GELLEBTER J, 1987, FOCUS, V9, P5; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HUNTER DD, 1989, CELL, V59, P905, DOI 10.1016/0092-8674(89)90613-2; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; INOUE A, 1989, EUR J BIOCHEM, V183, P645, DOI 10.1111/j.1432-1033.1989.tb21094.x; JANIG F, 1990, TRENDS BIOCHEM SCI, V15, P93; KANEKO A, 1979, ANNU REV NEUROSCI, V2, P169, DOI 10.1146/annurev.ne.02.030179.001125; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMMON V, 1982, J NEUROSCI, V2, P531; LIESI P, 1989, FEBS LETT, V244, P141, DOI 10.1016/0014-5793(89)81180-9; Maniatis T, 1989, DECONTAMINATION DILU; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MCLACHLAN AD, 1983, J MOL BIOL, V164, P605, DOI 10.1016/0022-2836(83)90053-0; MESSING J, 1983, METHOD ENZYMOL, V101, P20; PARRY DAD, 1987, FIBROUS PROTEIN STRU, P141; PETER M, 1989, J MOL BIOL, V208, P393, DOI 10.1016/0022-2836(89)90504-4; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SANES JR, 1989, ANNU REV NEUROSCI, V12, P491, DOI 10.1146/annurev.ne.12.030189.002423; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SEPHEL GC, 1989, BIOCHEM BIOPH RES CO, V162, P821, DOI 10.1016/0006-291X(89)92384-X; SHIRAO T, 1986, DEV BRAIN RES, V29, P233, DOI 10.1016/0165-3806(86)90099-4; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; YOUNG LHY, 1984, P NATL ACAD SCI-BIOL, V81, P6255, DOI 10.1073/pnas.81.19.6255; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	54	271	277	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10613	10619						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587842				2022-12-25	WOS:A1992HV09000061
J	ROSENBERG, A; SAUER, A; NOBLE, EP; GROSS, HJ; CHANG, R; BROSSMER, R				ROSENBERG, A; SAUER, A; NOBLE, EP; GROSS, HJ; CHANG, R; BROSSMER, R			DEVELOPMENTAL PATTERNS OF GANGLIOSIDE SIALOSYLATION COINCIDENT WITH NEURITOGENESIS IN CULTURED EMBRYONIC CHICK BRAIN NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; INTRACELLULAR-TRANSPORT; BREFELDIN-A; CNS NEURONS; RAT-BRAIN; BIOSYNTHESIS; PROTEINS; GLYCOSPHINGOLIPIDS; SIALIDASE; MEMBRANE	Chick brain precursor neurons were observed to introduce sialic acid biosynthetically into only three specific gangliosides: monosialosyl lactosyl ceramide (G(M3)), disialosyl lactosyl ceramide (G(D3)), and disialosyl gangliotrihexosyl ceramide (G(D2)), when sialic acid was labeled metabolically by its obligate precursor, [H-3] ManNAc. Sialosyl donor CMP-[H-3]NeuAc supplied in the culture medium gave rise uniquely to surface-labeled G(D3). Thus sialosyl transferase/G(D3) synthase activity is expressed both intraneuronally and in the neuronal exofacial surface. Upon epidermal growth factor-induced onset of neurite outgrowth, labeled complex sialosyl gangliotetrahexosyl ceramide species of gangliosides began to appear in the embryonic neuronal plasma membrane. However, intraneuronal and exofacial sialosyl transferase/G(D3) synthase activities remained constant, with or without neurite outgrowth. Moreover, simpler species of gangliosides maintained a steady quantitative sialosyl level (1.6 +/- 0.2-mu-g of sialic acid/mg of protein), whereas more complex species completely absent before neurite outgrowth accrued and reached 4.8 +/- 0.9-mu-g of sialic acid/mg of protein with full neurite development. This analysis of developmental patterns of ganglioside sialosylation has provided evidence that stable neurite outgrowth depends upon generation by the neuron of special plasma membrane with a massive content of complex higher species of gangliosides.	UNIV CALIF LOS ANGELES,BRAIN RES INST,ALCOHOL RES CTR,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST NEUROPSYCHIAT,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	ROSENBERG, A (corresponding author), UNIV HEIDELBERG,INST BIOCHIM,W-6900 HEIDELBERG 1,GERMANY.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024488] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA007653] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA07653] Funding Source: Medline; NINDS NIH HHS [NS 24488] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARTON NW, 1973, J BIOL CHEM, V248, P7353; BASU M, 1987, METHOD ENZYMOL, V138, P575; BREEN KC, 1986, J NEUROCHEM, V47, P1176; Corfield A.P., 1981, PERSPECTIVES INHERIT, V4, P3; DAILEY ME, 1991, J NEUROSCI RES, V30, P242, DOI 10.1002/jnr.490300125; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DURRIE R, 1989, J LIPID RES, V30, P1259; DURRIE R, 1987, J NEUROSCI RES, V18, P456, DOI 10.1002/jnr.490180312; FISCHER S, 1970, Z ZELLFORSCH MIKROSK, V104, P165; GAMMON CM, 1985, J NEUROCHEM, V44, P376, DOI 10.1111/j.1471-4159.1985.tb05427.x; HANNEMAAIJER R, 1991, J NEUROSCI RES, V30, P163; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HESS HH, 1978, ANAL BIOCHEM, V85, P295, DOI 10.1016/0003-2697(78)90304-4; HOGAN MV, 1988, J NEUROSCI RES, V20, P390, DOI 10.1002/jnr.490200313; KINOSHITA A, 1990, J NEUROSCI RES, V25, P324, DOI 10.1002/jnr.490250308; LESKAWA KC, 1981, CELL MOL NEUROBIOL, V1, P373, DOI 10.1007/BF00716272; MASSERINI M, 1988, BIOCHEMISTRY-US, V27, P7973, DOI 10.1021/bi00420a057; MILLERPODRAZA H, 1982, BIOCHEMISTRY-US, V21, P3265, DOI 10.1021/bi00257a003; MILLERPRODRAZA H, 1984, BIOCHIM BIOPHYS ACTA, V804, P44, DOI 10.1016/0167-4889(84)90097-1; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MOMOI T, 1976, BIOCHIM BIOPHYS ACTA, V441, P488; MORRISON RS, 1988, J NEUROSCI RES, V21, P71, DOI 10.1002/jnr.490210111; PFENNINGER KH, 1982, AXOPLASMIC TRANSPORT, P52; PRETI A, 1980, J NEUROCHEM, V35, P281, DOI 10.1111/j.1471-4159.1980.tb06263.x; QUARLES RH, 1971, J NEUROCHEM, V18, P1809, DOI 10.1111/j.1471-4159.1971.tb09586.x; RIBCHESTER RR, 1986, MOL NERVE EMBRYO, P105; ROSENBERG A, 1966, J LIPID RES, V7, P122; ROSENBERG A, 1989, J NEUROSCI RES, V24, P531, DOI 10.1002/jnr.490240411; ROSENBERG A, 1956, NATURE, V177, P234, DOI 10.1038/177234a0; ROSENBERG A, 1992, IN PRESS BRAIN DIFFE; SAITO M, 1985, BIOCHEMISTRY-US, V24, P3054, DOI 10.1021/bi00333a038; SAITO M, 1984, BIOCHEMISTRY-US, V23, P3784, DOI 10.1021/bi00311a034; SCHWARZMANN G, 1990, BIOCHEMISTRY-US, V29, P10865, DOI 10.1021/bi00501a001; SEYFRIED TN, 1985, MOL CELL BIOCHEM, V68, P3; Svennerholm L, 1980, Adv Exp Med Biol, V125, P11; THAMPY KG, 1983, DEV BRAIN RES, V8, P101, DOI 10.1016/0165-3806(83)90161-X; VANECHTEN G, 1989, J NEUROCHEM, V52, P207; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; VANECHTEN G, 1990, J BIOL CHEM, V265, P9333	39	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10607	10612						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587841				2022-12-25	WOS:A1992HV09000060
J	PASCALE, MC; MALAGOLINI, N; SERAFINICESSI, F; MIGLIACCIO, G; LEONE, A; BONATTI, S				PASCALE, MC; MALAGOLINI, N; SERAFINICESSI, F; MIGLIACCIO, G; LEONE, A; BONATTI, S			BIOSYNTHESIS AND OLIGOSACCHARIDE STRUCTURE OF HUMAN CD8 GLYCOPROTEIN EXPRESSED IN A RAT EPITHELIAL-CELL LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAMM-HORSFALL GLYCOPROTEIN; O-LINKED OLIGOSACCHARIDES; SIMPLEX VIRUS TYPE-1; SURFACE-ANTIGEN T8; ENDOPLASMIC-RETICULUM; MEMBRANE-GLYCOPROTEINS; CARBOHYDRATE UNITS; LYMPHOCYTES-T; SIALIC-ACID; SEQUENCE	The biosynthesis, post-translational modifications, and oligosaccharide structure of human CD8 glycoprotein have been studied in transfected rat epithelial cells. These cells synthesized and expressed on the plasma membrane high amounts of CD8 in a homodimeric form stabilized by a disulfide bridge. Three different CD8 forms were detected by sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis after metabolic labeling and immunoprecipitation: a newly synthesized, unglycosylated 27-kDa (CD8u), a palmitylated and initially O-glycosylated 29-kDa (CD8i), and the mature, terminally glycosylated 32-34-kDa doublet (CD8m). CD8i is a transient intermediate form between CD8u and CD8m: characterization of carbohydrate moiety of [H-3]glucosamine-labeled CD8i showed that it comprises for the vast majority non-elongated O-linked GalNAc closely spaced on the peptide backbone. Structural analysis of oligosaccharides released by mild alkaline borohydride treatment from the [H-3]glucosamine-labeled CD8 34-kDa form showed that the neutral tetrasaccharide Gal-beta-1,4GlcNAc-beta-1,6(Gal-beta-1,3)GalNAcOH, and an homologous monosialylated pentasaccharide, predominate; the disialylated NeuAc2,3Gal-beta-1,3(NeuAc-alpha-2,6) GalNAcOH tetrasaccharide appeared to be poorly present. In the CD8 32-kDa form the neutral tetrasaccharide was by far the prominent O-linked chain, and no disialyloligosaccharides were identified. These results indicate that the maturation of CD8 glycoprotein in transfected rat epithelial cells results in the formation of branched O-linked oligosaccharides and that a higher degree of sialylation is responsible for the production of the heavier 34-kDa form.	NAPLES UNIV,DEPT BIOCHEM & MED BIOTECHNOL,VIA S PANSINI 5,I-80131 NAPLES,ITALY; UNIV BOLOGNA,DEPT EXPTL PATHOL,I-40126 BOLOGNA,ITALY	University of Naples Federico II; University of Bologna			Pascale, Maria/B-4273-2012					BALCH WE, 1986, J BIOL CHEM, V261, P4681; BERGH MLE, 1981, CARBOHYD RES, V94, P225, DOI 10.1016/S0008-6215(00)80720-X; BONATTI S, 1989, J BIOL CHEM, V264, P12590; BRIAND JP, 1981, J BIOL CHEM, V256, P2205; BROCKHAUSEN I, 1985, BIOCHEMISTRY-US, V24, P1866, DOI 10.1021/bi00329a010; CARLSSON SR, 1986, J BIOL CHEM, V261, P2787; CRIMMIN WRC, 1957, J CHEM SOC, P2838; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; DALLOLIO F, 1985, J VIROL, V56, P127, DOI 10.1128/JVI.56.1.127-134.1985; EDGE ASB, 1984, J BIOL CHEM, V259, P4710; FUKUDA M, 1991, Glycobiology, V1, P347, DOI 10.1093/glycob/1.4.347; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRIES TE, 1986, EMBO J, V5, P931; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; MIGLIACCIO G, 1989, EXP CELL RES, V185, P203, DOI 10.1016/0014-4827(89)90049-9; MIGLIACCIO G, 1990, EUR J CELL BIOL, V52, P291; NEIMANN H, 1984, EMBO J, V3, P665; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NITSCH L, 1985, EUR J CELL BIOL, V38, P57; PARNES JR, 1989, ADV IMMUNOL, V44, P265; PILLER F, 1991, J EXP MED, V173, P1501, DOI 10.1084/jem.173.6.1501; PILLER F, 1988, J BIOL CHEM, V263, P15146; RALSTON E, 1989, J CELL BIOL, V109, P2345, DOI 10.1083/jcb.109.5.2345; Sadler J. E., 1984, BIOL CARBOHYDRATES, V2, P199; SAITOH O, 1991, BLOOD, V77, P1491; SERAFINICESSI F, 1989, BIOCHEM J, V262, P479, DOI 10.1042/bj2620479; SERAFINICESSI F, 1986, CARBOHYD RES, V151, P65, DOI 10.1016/S0008-6215(00)90330-6; SERAFINICESSI F, 1985, ARCH BIOCHEM BIOPHYS, V240, P866, DOI 10.1016/0003-9861(85)90097-9; SERAFINICESSI F, 1983, BIOCHEM J, V215, P483, DOI 10.1042/bj2150483; SNOW PM, 1984, J IMMUNOL, V133, P2058; SNOW PM, 1985, J BIOL CHEM, V260, P2700; SNOW PM, 1983, J BIOL CHEM, V258, P4675; SPIRO RG, 1974, J BIOL CHEM, V249, P5704; TAKAHASHI N, 1984, P NATL ACAD SCI-BIOL, V81, P2021, DOI 10.1073/pnas.81.7.2021; TAMAIODA S, 1991, BIOCHEM J, V280, P179; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529	37	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9940	9947						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577825				2022-12-25	WOS:A1992HT96500076
J	RAE, C; BUBB, WA; KUCHEL, PW				RAE, C; BUBB, WA; KUCHEL, PW			ALDOLASE-CATALYZED DIKETONE PHOSPHATE FORMATION FROM OXOALDEHYDES - NMR-STUDIES AND METABOLIC SIGNIFICANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIOSEPHOSPHATE ISOMERASE; MAGNETIC-RESONANCE; HUMAN-ERYTHROCYTE; METHYLGLYOXAL; GLYCERALDEHYDE; H-1-NMR; PATHWAY	NMR spectroscopy showed fructose-1,6-bisphosphate aldolase from rabbit muscle accepts as substrates, in lieu of glyceraldehyde 3-phosphate, the oxoaldehydes methylglyoxal and phenylglyoxal but not hydroxymethylglyoxal. The enzyme catalyzed an aldol condensation between the oxoaldehyde and dihydroxyacetone phosphate to form a monophosphorylated diketone and was inactivated in the process. Circumvention of this reaction, by metabolism of oxoaldehydes to hydroxy acids, may be a metabolic role for the glyoxalase enzyme system. Transketolase and transaldolase were found not to accept oxoaldehydes as substrates in place of glyceraldehyde 3-phosphate.	UNIV SYDNEY,DEPT BIOCHEM,SYDNEY,NSW 2006,AUSTRALIA	University of Sydney			Rae, Caroline/B-7537-2008	Rae, Caroline/0000-0003-0673-8084; Kuchel, Philip/0000-0003-4100-7332				ARORA KK, 1988, BIOL CHEM H-S, V369, P549, DOI 10.1515/bchm3.1988.369.2.549; BEUTLER E, 1984, RED BLOOD CELL METAB, P47; BRANDT RB, 1979, CIBA F S, V67, P211; BRINDLE KM, 1982, BIOCHEM J, V208, P583, DOI 10.1042/bj2080583; BROWNE CA, 1976, J MOL BIOL, V100, P319, DOI 10.1016/S0022-2836(76)80066-6; CHRISTEN P, 1976, EUR J BIOCHEM, V63, P223, DOI 10.1111/j.1432-1033.1976.tb10224.x; CHRISTEN P, 1976, J BIOL CHEM, V251, P4220; Dakin HD, 1913, J BIOL CHEM, V14, P423; FURNISS BS, 1978, VOGELS TXB PRACTICAL, P917; GRAZI E, 1978, BIOCHEM J, V175, P361, DOI 10.1042/bj1750361; HEALY MJ, 1972, J AM CHEM SOC, V94, P7911, DOI 10.1021/ja00777a039; HOBERMAN HD, 1979, BIOCHEM BIOPH RES CO, V90, P757, DOI 10.1016/0006-291X(79)91892-8; IYENGAR R, 1981, BIOCHEMISTRY-US, V20, P1223, DOI 10.1021/bi00508a026; KELLUM MW, 1978, ANAL BIOCHEM, V85, P586, DOI 10.1016/0003-2697(78)90258-0; KUCHEL PW, 1988, J MAGN RESON, V76, P136, DOI 10.1016/0022-2364(88)90207-7; KUCHEL PW, 1990, BIOMED BIOCHIM ACTA, V49, pS105; LEONCINI G, 1980, FEBS LETT, V117, P17, DOI 10.1016/0014-5793(80)80903-3; LEONCINI G, 1989, CELL BIOCHEM FUNCT, V7, P65, DOI 10.1002/cbf.290070111; MEHLER AH, 1967, SCIENCE, V155, P1101, DOI 10.1126/science.155.3766.1101; Meyerhof O, 1936, BIOCHEM Z, V286, P301; PATTHY L, 1978, EUR J BIOCHEM, V88, P191, DOI 10.1111/j.1432-1033.1978.tb12437.x; RAE C, 1991, ARCH BIOCHEM BIOPHYS, V291, P291, DOI 10.1016/0003-9861(91)90137-8; RAE C, 1990, EUR J BIOCHEM, V193, P83, DOI 10.1111/j.1432-1033.1990.tb19307.x; REEVES HC, 1965, J BIOL CHEM, V240, P569; RICHARD JP, 1991, BIOCHEMISTRY-US, V30, P4581, DOI 10.1021/bi00232a031; WEBB MR, 1977, BIOCHEMISTRY-US, V16, P2738, DOI 10.1021/bi00631a023; WOLFF SP, 1984, EXPERIENTIA, V40, P244, DOI 10.1007/BF01947562	27	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9713	9717						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577806				2022-12-25	WOS:A1992HT96500042
J	OZAKI, K; II, M; ITOH, N; KAWASAKI, T				OZAKI, K; II, M; ITOH, N; KAWASAKI, T			EXPRESSION OF A FUNCTIONAL ASIALOGLYCOPROTEIN RECEPTOR THROUGH TRANSFECTION OF A CLONED CDNA THAT ENCODES A MACROPHAGE LECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PERITONEAL-MACROPHAGES; HUMAN HEPATOMA-CELLS; N-ACETYLGALACTOSAMINE; BINDING PROTEINS; RABBIT LIVER; GALACTOSE; HEPATOCYTES; OLIGOSACCHARIDES; IDENTIFICATION; TRANSFORMATION	The Gal/GalNAc-specific lectin on rat peritoneal macrophages (macrophage asialoglycoprotein binding protein, M-ASGP-BP) is structurally similar to rat hepatic asialoglycoprotein-binding protein (ASGP-BP) or rat hepatic lectin (RHL) and is highly homologous with the major component of RHL, RHL-1 (Ii, M, Kurata, H., Itoh, N., Yamashina, I., and Kawasaki, T. (1990) J. Biol. Chem. 265, 11295-11298). We found in this study that transfection with a cDNA clone that encodes a single polypeptide, M-ASGP-BP, was sufficient for the expression of an endocytic receptor for asialoorosomucoid (ASOR) on the COS-1 cell surface. The K(uptake) value for ASOR for the transfected cells was 12.5 nm, which is similar to that for peritoneal macrophages (23 nM), and the number of ASOR bound on the cell surface was 1-8 x 10(5)/cell, this value being hundreds of times larger than that for peritoneal macrophages. I-125-ASOR bound on the surfaces of the transfected cells was rapidly internalized on incubation at 37-degrees-C, and after 90 min of incubation, most of the radioactivity was recovered in acid-soluble degraded products from the medium. These results confirmed that the cDNA cloned in our previous study does in fact encode M-ASGP-BP and also that the single polypeptide chain can form a homooligomeric receptor (probably a hexamer or octamer) exhibiting high affinity for ASOR. The latter property was distinct from that of the hepatic ASGP-BP in that simultaneous transfection of two cloned cDNAs that encode RHL- 1 and RHL- 2/3 was required to produce an active ASOR receptor (McPhaul, M., and Berg, P. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 8863-8867). This M-ASGP-BP expression system may serve as a simple model with which to investigate the molecular mechanisms underlying carbohydrate-mediated endocytosis.	KYOTO UNIV, FAC PHARMACEUT SCI, DEPT BIOL CHEM, SAKYO KU, KYOTO 606, JAPAN	Kyoto University								ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BAENZIGER JU, 1980, CELL, V22, P611, DOI 10.1016/0092-8674(80)90371-2; BISCHOFF J, 1988, J CELL BIOL, V106, P1067, DOI 10.1083/jcb.106.4.1067; BISCHOFF J, 1987, J BIOL CHEM, V262, P11825; BRAITERMAN LT, 1989, J BIOL CHEM, V264, P1682; BREITFELD PP, 1984, J BIOL CHEM, V259, P414; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1984, J BIOL CHEM, V259, P770; FUKUNAGA R, 1984, P NATL ACAD SCI-BIOL, V81, P5086, DOI 10.1073/pnas.81.16.5086; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; HARFORD J, 1983, J BIOL CHEM, V258, P3191; HELENIUS A, 1975, BIOCHIM BIOPHYS ACTA, V415, P29, DOI 10.1016/0304-4157(75)90016-7; HONG WJ, 1988, HEPATOLOGY, V8, P553, DOI 10.1002/hep.1840080320; II M, 1988, J BIOCHEM-TOKYO, V104, P587; II M, 1990, J BIOL CHEM, V265, P11295; II M, 1988, BIOCHEM BIOPH RES CO, V155, P720; KAWASAKI T, 1978, BIOCHEM BIOPH RES CO, V81, P1018, DOI 10.1016/0006-291X(78)91452-3; KAWASAKI T, 1986, CARBOHYD RES, V151, P197, DOI 10.1016/S0008-6215(00)90340-9; KAWASAKI T, 1976, J BIOL CHEM, V251, P1296; KAWASAKI T, 1990, 15TH P INT CARB S YO; KELM S, 1988, BIOL CHEM H-S, V369, P693, DOI 10.1515/bchm3.1988.369.2.693; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE RT, 1982, BIOCHEMISTRY-US, V21, P1045, DOI 10.1021/bi00534a034; LEE YC, 1983, J BIOL CHEM, V258, P199; MACKETT M, 1985, DNA CLONING, V2, P209; MCPHAUL M, 1986, P NATL ACAD SCI USA, V83, P8863, DOI 10.1073/pnas.83.23.8863; OHARE K, 1981, P NATL ACAD SCI-BIOL, V78, P1527, DOI 10.1073/pnas.78.3.1527; RICE KG, 1990, J BIOL CHEM, V265, P18429; SAWYER JT, 1988, J BIOL CHEM, V263, P10534; Schauer R., 1988, SIALIC ACIDS REGULAT, P5; SCHWARTZ AL, 1980, J BIOL CHEM, V255, P9033; SCHWARTZ AL, 1981, J BIOL CHEM, V256, P8878; SCHWARTZ AL, 1982, J BIOL CHEM, V257, P4230; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P1158, DOI 10.1073/pnas.86.4.1158; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; WONG TC, 1987, CARBOHYD RES, V170, P27, DOI 10.1016/0008-6215(87)85003-6	40	44	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9229	9235						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577757				2022-12-25	WOS:A1992HR85400080
J	POOLMAN, B; MODDERMAN, R; REIZER, J				POOLMAN, B; MODDERMAN, R; REIZER, J			LACTOSE TRANSPORT-SYSTEM OF STREPTOCOCCUS-THERMOPHILUS - THE ROLE OF HISTIDINE-RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR PHOSPHOTRANSFERASE SYSTEM; DEPENDENT PROTON TRANSPORT; SITE-DIRECTED MUTANTS; ESCHERICHIA-COLI; LAC PERMEASE; NUCLEOTIDE-SEQUENCES; BACILLUS-SUBTILIS; MELIBIOSE CARRIER; ENHANCED RECOGNITION; PHOSPHOENOLPYRUVATE	The lactose transport protein (LacS) of Streptococcus thermophilus is a chimeric protein consisting of an amino-terminal carrier domain and a carboxyl-terminal phosphoenolpyruvate:sugar phosphotransferase system (PTS) IIA protein domain. The histidine residues of LacS were changed individually into glutamine or arginine residues. Of the 11 histidine residues present in LacS, only the His-376 substitution in the carrier domain significantly affected sugar transport. The region around His-376 was found to exhibit sequence similarity to the region around His-322 of the lactose transport protein (LacY) of Escherichia coli, which has been implicated in sugar binding and in coupling of sugar and H+ transport. The H376Q mutation resulted in a reduced rate of uptake and altered affinity for lactose (beta-galactoside), melibiose (alpha-galactoside), and the lactose analog methyl-beta-D-thiogalactopyranoside. Similarly, the extent of accumulation of the galactosides by cells expressing LacS(H376Q) was highly reduced in comparison to cells bearing the wild-type protein. Nonequilibrium exchange of lactose and methyl-beta-D-thiogalactopyranoside by the H376Q mutant was approximately 2-fold reduced in comparison to the activity of the wild-type transport protein. The data indicate that His-376 is involved in sugar recognition and is important, but not essential, for the cotransport of protons and galactosides. The carboxyl-terminal domain of LacS contains 2 histidine residues (His-537 and His-552) that are conserved in seven homologous IIA protein(s) (domains) of PTSs. P-enolpyruvate-dependent phosphorylation of wild-type LacS, but not of the mutant H552Q, was demonstrated using purified Enzyme I and HPr, the general energy coupling proteins of the PTS, and inside-out membrane vesicles isolated from E. coli in which the lactose transport gene was expressed. The His-537 and His-552 mutations did not affect transport activity when the corresponding genes were expressed in E. coli.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego	POOLMAN, B (corresponding author), UNIV GRONINGEN,DEPT MICROBIOL,KERKLAAN 30,9751 NN HAREN,NETHERLANDS.		Poolman, Bert/D-1882-2012					ASLANIDIS C, 1989, J BACTERIOL, V171, P6753, DOI 10.1128/jb.171.12.6753-6763.1989; BASSILANA M, 1987, J BIOL CHEM, V262, P16865; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BUCHEL DE, 1980, NATURE, V283, P541, DOI 10.1038/283541a0; CARRASCO N, 1989, BIOCHEMISTRY-US, V28, P2533, DOI 10.1021/bi00432a028; CARRASCO N, 1986, BIOCHEMISTRY-US, V25, P4486, DOI 10.1021/bi00364a004; COLLINS JC, 1989, J BIOL CHEM, V264, P14698; DORSCHUG M, 1984, EUR J BIOCHEM, V144, P113, DOI 10.1111/j.1432-1033.1984.tb08438.x; FRANCO PJ, 1989, J BIOL CHEM, V264, P15988; FRANCO PJ, 1991, J BIOL CHEM, V266, P6693; GONZYTREBOUL G, 1989, MOL MICROBIOL, V3, P103, DOI 10.1111/j.1365-2958.1989.tb00109.x; KING SC, 1989, J BIOL CHEM, V264, P7390; KING SC, 1990, J BIOL CHEM, V265, P3153; KING SC, 1989, BIOCHIM BIOPHYS ACTA, V982, P253, DOI 10.1016/0005-2736(89)90062-X; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JA, 1989, BIOCHEMISTRY-US, V28, P2540, DOI 10.1021/bi00432a029; LIAU DI, 1991, BIOCHEMISTRY-US, V30, P9583; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MCMORROW I, 1988, BIOCHIM BIOPHYS ACTA, V945, P315, DOI 10.1016/0005-2736(88)90494-4; MENICK DR, 1987, BIOCHEMISTRY-US, V26, P6638, DOI 10.1021/bi00395a012; NELSON SO, 1986, EUR J BIOCHEM, V154, P337, DOI 10.1111/j.1432-1033.1986.tb09402.x; NELSON SO, 1983, EMBO J, V3, P1587; NIEFIND K, 1991, J MOL BIOL, V219, P481, DOI 10.1016/0022-2836(91)90188-C; POOLMAN B, 1989, J BACTERIOL, V171, P244, DOI 10.1128/jb.171.1.244-253.1989; POOLMAN B, 1990, J BACTERIOL, V172, P4037, DOI 10.1128/jb.172.7.4037-4047.1990; POOLMAN B, 1983, EUR J BIOCHEM, V135, P41, DOI 10.1111/j.1432-1033.1983.tb07615.x; POOLMAN B, 1990, MOL MICROBIOL, V4, P1629, DOI 10.1111/j.1365-2958.1990.tb00539.x; POURCHER T, 1990, PHILOS T ROY SOC B, V326, P411, DOI 10.1098/rstb.1990.0021; POURCHER T, 1990, P NATL ACAD SCI USA, V87, P468, DOI 10.1073/pnas.87.1.468; PUTTNER IB, 1986, BIOCHEMISTRY-US, V25, P4483; PUTTNER IB, 1989, BIOCHEMISTRY-US, V28, P2525, DOI 10.1021/bi00432a027; REIZER J, 1992, J BIOL CHEM, V267, P9158; REIZER J, 1989, EMBO J, V8, P2111, DOI 10.1002/j.1460-2075.1989.tb03620.x; REIZER J, 1984, J BACTERIOL, V160, P333, DOI 10.1128/JB.160.1.333-340.1984; ROGERS MJ, 1988, GENE, V62, P197; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR HK, 1988, P NATL ACAD SCI USA, V85, P5463, DOI 10.1073/pnas.85.15.5463; SATO Y, 1989, J BACTERIOL, V171, P263, DOI 10.1128/jb.171.1.263-271.1989; SCHNETZ K, 1987, J BACTERIOL, V169, P2579, DOI 10.1128/jb.169.6.2579-2590.1987; SUTRINA SL, 1990, J BIOL CHEM, V265, P18581; TEATHER RM, 1980, EUR J BIOCHEM, V108, P223, DOI 10.1111/j.1432-1033.1980.tb04715.x; VOGLER AP, 1988, MOL MICROBIOL, V2, P719, DOI 10.1111/j.1365-2958.1988.tb00082.x; WILSON DM, 1987, BIOCHIM BIOPHYS ACTA, V904, P191, DOI 10.1016/0005-2736(87)90368-3; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YAZYU H, 1984, J BIOL CHEM, V259, P4320	49	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9150	9157						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577752				2022-12-25	WOS:A1992HR85400070
J	TERLECKY, SR; CHIANG, HL; OLSON, TS; DICE, JF				TERLECKY, SR; CHIANG, HL; OLSON, TS; DICE, JF			PROTEIN AND PEPTIDE BINDING AND STIMULATION OF INVITRO LYSOSOMAL PROTEOLYSIS BY THE 73-KDA HEAT-SHOCK COGNATE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROINJECTED RIBONUCLEASE-A; MAMMALIAN STRESS PROTEINS; SACCHAROMYCES-CEREVISIAE; HSP70-LIKE PROTEIN; UNCOATING PROTEIN; SERUM WITHDRAWAL; GENE FAMILY; HUMAN-CELLS; EXPRESSION; MEMBER	Lysosomal degradation of intracellular proteins during serum withdrawal is stimulated by a member of the 70-kDa heat shock protein (hsp70) family (Chiang, H.-L., Terlecky, S. R., Plant, C. P., and Dice, J. F. (1989) Science 246, 382-385). This hsp70, isolated by affinity chromatography with RNase S-peptide-Sepharose, is referred to as the 73-kDa peptide recognition protein (prp73). We now report that prp73 binds to several proteins and peptides whose degradative rates are increased during serum withdrawal. prp73 also binds to the pentapeptide, KFERQ, and more weakly to most modified RNase S-peptide derivatives with a single amino acid substitution within the KFERQ sequence. Taken together, these results suggest that prp73 binds to a variety of proteins at peptide regions biochemically related to KFERQ. Three lines of evidence indicate that prp73 is the heat shock cognate protein of 73 kDa (hsc73): (a) among five hsp70s tested, hsc73 binds to RNase S-peptide most avidly, (b) both prp73 and hsc73 also bind to RNase A and aspartate aminotransferase but not to ovalbumin, lysozyme, or ubiquitin, and (c) both prp73 and hsc73 promote uptake and degradation of [H-3] RNase S-peptide by lysosomes in vitro, while three other hsp70s are without activity in this assay.			TERLECKY, SR (corresponding author), TUFTS UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02111, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG006116, R01AG006116] Funding Source: NIH RePORTER; NIA NIH HHS [AG06116] Funding Source: Medline; NIDDK NIH HHS [DK07542] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVARES K, 1990, P NATL ACAD SCI USA, V87, P5293, DOI 10.1073/pnas.87.14.5293; BACKER JM, 1983, P NATL ACAD SCI-BIOL, V80, P2166, DOI 10.1073/pnas.80.8.2166; BACKER JM, 1986, P NATL ACAD SCI USA, V83, P5830, DOI 10.1073/pnas.83.16.5830; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; CAIRO G, 1989, HEPATOLOGY, V9, P740, DOI 10.1002/hep.1840090514; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CHIANG HL, 1988, J BIOL CHEM, V263, P6797; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CRAIG EA, 1987, P NATL ACAD SCI USA, V84, P4156, DOI 10.1073/pnas.84.12.4156; DANA RC, 1990, ENDOCRINOLOGY, V126, P672, DOI 10.1210/endo-126-1-672; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; DICE JF, 1987, FASEB J, V1, P349, DOI 10.1096/fasebj.1.5.2824267; DICE JF, 1989, BIOCHEM SOC SYMP, V55, P45; DICE JF, 1986, J BIOL CHEM, V261, P6853; ELLWOOD MS, 1984, MOL CELL BIOL, V4, P1454, DOI 10.1128/MCB.4.8.1454; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GAO BC, 1991, J BIOL CHEM, V266, P19565; GIEBEL LB, 1988, DEV BIOL, V125, P200, DOI 10.1016/0012-1606(88)90073-5; GOFF SA, 1987, DNA-J MOLEC CELL BIO, V6, P381, DOI 10.1089/dna.1987.6.381; GREEN LAD, 1989, J BIOL CHEM, V264, P15210; GUIDON PT, 1986, J CELL PHYSIOL, V128, P239, DOI 10.1002/jcp.1041280215; HIGHTOWER LE, 1989, J CELL PHYSIOL, V138, P257, DOI 10.1002/jcp.1041380206; HIGHTOWER LE, 1981, J CELL PHYSIOL, V108, P261, DOI 10.1002/jcp.1041080216; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; KURTZ S, 1986, SCIENCE, V231, P1154, DOI 10.1126/science.3511530; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEUNG TKC, 1990, BIOCHEM J, V267, P125, DOI 10.1042/bj2670125; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LOWE DG, 1986, J BIOL CHEM, V261, P2102; LOWE DG, 1984, P NATL ACAD SCI-BIOL, V81, P2317, DOI 10.1073/pnas.81.8.2317; MAEKAWA M, 1989, BIOL REPROD, V40, P843, DOI 10.1095/biolreprod40.4.843; MARGULIS BA, 1991, J BIOL CHEM, V266, P9295; MCELLIGOTT MA, 1985, J BIOL CHEM, V260, P1986; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; MIZZEN LA, 1989, J BIOL CHEM, V264, P20664; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NAPOLITANO EW, 1987, J BIOL CHEM, V262, P1493; NEFF NT, 1981, J CELL BIOL, V91, P184, DOI 10.1083/jcb.91.1.184; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PARDUE M, 1989, STRESS IND PROTEINS; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; RIABOWOL KT, 1988, SCIENCE, V242, P433, DOI 10.1126/science.3175665; RIPPMANN F, 1991, EMBO J, V10, P1053, DOI 10.1002/j.1460-2075.1991.tb08044.x; SADIS S, 1990, CURRENT RES PROTEIN, P339; SANTORO MG, 1989, P NATL ACAD SCI USA, V86, P8407, DOI 10.1073/pnas.86.21.8407; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SCHREIER AA, 1977, BIOCHEMISTRY-US, V16, P4203, DOI 10.1021/bi00638a012; SHEFFIELD WP, 1990, J BIOL CHEM, V265, P11069; SHERWOOD LM, 1965, J BIOL CHEM, V240, P3799; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SORGER PK, 1987, EMBO J, V6, P993, DOI 10.1002/j.1460-2075.1987.tb04850.x; STEVENSON MA, 1990, MOL CELL BIOL, V10, P1234, DOI 10.1128/MCB.10.3.1234; ULLMANN A, 1984, GENE, V29, P27, DOI 10.1016/0378-1119(84)90162-8; UNGEWICKELL E, 1985, EMBO J, V4, P3385, DOI 10.1002/j.1460-2075.1985.tb04094.x; VANBUSKIRK A, 1989, J EXP MED, V170, P1799, DOI 10.1084/jem.170.6.1799; WATOWICH SS, 1988, MOL CELL BIOL, V8, P393, DOI 10.1128/MCB.8.1.393; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; WING SS, 1991, BIOCHEM J, V275, P165, DOI 10.1042/bj2750165; ZAKERI ZF, 1988, MOL CELL BIOL, V8, P2925, DOI 10.1128/MCB.8.7.2925	67	172	177	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9202	9209						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577755				2022-12-25	WOS:A1992HR85400076
J	WETTENHALL, REH; ERIKSON, E; MALLER, JL				WETTENHALL, REH; ERIKSON, E; MALLER, JL			ORDERED MULTISITE PHOSPHORYLATION OF XENOPUS RIBOSOMAL PROTEIN-S6 BY S6 KINASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; RAT-LIVER; SUBSTRATE-SPECIFICITY; PEPTIDE ANALOG; INSULIN; PURIFICATION; SUBUNITS; INITIATION; GROWTH; SERUM	Phosphorylated ribosomal proteins were isolated from Xenopus 40 S ribosomal subunits by reversed-phase high performance liquid chromatography (HPLC) to enable direct analysis of the phosphorylation sites in ribosomal protein S6. Xenopus S6 closely resembled mammalian S6 with respect to the following properties: (i) reversed-phase HPLC elution behavior, (ii) amino-terminal sequence (96% identity in the first 37 residues), and (iii) an identical sequence within the region of its phosphorylation sites. Whereas S6 was the only ribosomal protein phosphorylated in vitro by Xenopus S6 kinase II, ribosomes phosphorylated in vivo were found to be associated with an additional phosphoprotein having an amino-terminal sequence identical to that of the ubiquitin carboxyl-terminal extension protein CEP 80. S6 kinase II phosphorylated at least four sites (serines 1-3 and 5) in the sequence Arg-Arg-Leu-Ser(1)-Ser(2)-Leu-Arg-Ala-Ser(3)-Thr-Ser(4)-Lys-Ser(5)-, which correspond to the residues known to be phosphorylated in the carboxyl-terminal region of mammalian S6. The in vivo S6 phosphorylation sites in maturing Xenopus oocytes were shown to be located within the same cluster of serine residues, although individual sites were not identified. Kinetic analysis of S6 kinase II-catalyzed phosphorylation events indicated a simple sequential mechanism of multisite phosphorylation initiating at either serine 2 (preferred) or serine 1, with the rates of phosphorylation of individual sites occurring in the order serine 2 > serine 1 > serine 3 > serine 5.	LA TROBE UNIV, CTR PROT & ENZYME TECHNOL, BUNDOORA, VIC 3083, AUSTRALIA; UNIV COLORADO, SCH MED, DEPT PHARMACOL, HOWARD HUGHES MED INST, DENVER, CO 80262 USA	La Trobe University; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	WETTENHALL, REH (corresponding author), UNIV MELBOURNE, DEPT BIOCHEM, PARKVILLE, VIC 3052, AUSTRALIA.				NIDDK NIH HHS [DK28353] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028353] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEBERSOLD R, 1990, ANAL BIOCHEM, V187, P56, DOI 10.1016/0003-2697(90)90417-8; ANDRES JL, 1989, J BIOL CHEM, V264, P151; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BRANDON SD, 1991, J BIOL CHEM, V266, P380; CHAN YL, 1988, J BIOL CHEM, V263, P2891; DELGRANDE RW, 1982, EUR J BIOCHEM, V123, P421; DUNCAN R, 1982, EUR J BIOCHEM, V123, P535; ECKOLS TK, 1983, EUR J BIOCHEM, V134, P249, DOI 10.1111/j.1432-1033.1983.tb07558.x; ERIKSON E, 1988, SEC MESS PHOSPHOPROT, V12, P135; ERIKSON E, 1985, P NATL ACAD SCI USA, V82, P742, DOI 10.1073/pnas.82.3.742; ERIKSON E, 1986, J BIOL CHEM, V261, P350; ERIKSON E, 1991, J BIOL CHEM, V266, P5249; ERIKSON E, 1991, METHOD ENZYMOL, V200, P252; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; GABRIELLI B, 1984, FEBS LETT, V175, P219, DOI 10.1016/0014-5793(84)80740-1; GORDON J, 1982, CURR TOP CELL REGUL, V21, P89; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; HEINZE H, 1988, J BIOL CHEM, V263, P4139; HOUSE C, 1987, J BIOL CHEM, V262, P772; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KRIEG J, 1988, J BIOL CHEM, V263, P11473; KRUSE C, 1985, P NATL ACAD SCI USA, V82, P7515, DOI 10.1073/pnas.82.22.7515; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; LEPEUCH CJ, 1983, P NATL ACAD SCI-BIOL, V80, P6858; LUBBEN TH, 1983, J BIOL CHEM, V258, P3992; MARTINPEREZ J, 1983, P NATL ACAD SCI-BIOL, V80, P926, DOI 10.1073/pnas.80.4.926; MONIA BP, 1989, J BIOL CHEM, V264, P4093; NICK HP, 1985, ANAL BIOCHEM, V148, P93, DOI 10.1016/0003-2697(85)90632-3; NIELSEN PJ, 1982, P NATL ACAD SCI-BIOL, V79, P2937, DOI 10.1073/pnas.79.9.2937; NOVAKHOFER I, 1984, J BIOL CHEM, V259, P5995; PADEL U, 1985, EUR J BIOCHEM, V151, P1, DOI 10.1111/j.1432-1033.1985.tb09061.x; PARKER PJ, 1985, EUR J BIOCHEM, V148, P579, DOI 10.1111/j.1432-1033.1985.tb08879.x; PELECH SL, 1987, J BIOL CHEM, V262, P11598; PELECH SL, 1986, P NATL ACAD SCI USA, V83, P5968, DOI 10.1073/pnas.83.16.5968; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; SAKANOUE Y, 1987, EUR J BIOCHEM, V168, P669, DOI 10.1111/j.1432-1033.1987.tb13468.x; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS G, 1982, CELL, V30, P235, DOI 10.1016/0092-8674(82)90029-0; WETTENHALL R E H, 1991, Peptide Research, V4, P158; WETTENHALL REH, 1986, J BIOL CHEM, V261, P2444; WETTENHALL REH, 1982, FEBS LETT, V148, P207, DOI 10.1016/0014-5793(82)80809-0; WETTENHALL REH, 1984, J BIOL CHEM, V259, P2084; WETTENHALL REH, 1988, BIOCHEMISTRY-US, V27, P170, DOI 10.1021/bi00401a026; WETTENHALL REH, 1982, FEBS LETT, V140, P263, DOI 10.1016/0014-5793(82)80910-1; WETTENHALL REH, 1991, METHOD ENZYMOL, V201, P186; WOOL IG, 1979, ANNU REV BIOCHEM, V48, P719, DOI 10.1146/annurev.bi.48.070179.003443	48	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9021	9027						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577739				2022-12-25	WOS:A1992HR85400050
J	ZEROVNIK, E; JERALA, R; KROONZITKO, L; PAIN, RH; TURK, V				ZEROVNIK, E; JERALA, R; KROONZITKO, L; PAIN, RH; TURK, V			INTERMEDIATES IN DENATURATION OF A SMALL GLOBULAR PROTEIN, RECOMBINANT HUMAN STEFIN-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBONIC-ANHYDRASE-B; RAY CRYSTAL-STRUCTURE; MOLTEN-GLOBULE; ALPHA-LACTALBUMIN; FOLDING INTERMEDIATE; CONFORMATIONAL TRANSITIONS; EQUILIBRIUM DENATURATION; CHICKEN CYSTATIN; GROWTH-HORMONE; STATE	Guanidinium HCl (GdmHCl), pH, and heat denaturation of the recombinant human stefin B, a low molecular weight protein inhibitor of cysteine proteinases, has been followed by circular dichroism. From the noncoincidence of the transitions in the near and far UV, the existence of stable intermediate states possessing few persistent tertiary interactions but most of the native-like secondary structure, was inferred. These intermediate states exist at equilibrium under various conditions, namely, state G at 1.7 M GdmHCl (pH 8, 25-degrees-C), state A at pH 4 (0.6 M GdmHCl, 25-degrees-C) and state T above 68-degrees-C. By size exclusion chromatography, their apparent compactness was determined. The intermediate states A, T, and G were compact and are therefore classified as "molten globule" states.	UNIV NEWCASTLE UPON TYNE, SCH MED, DEPT BIOCHEM & GENET, Newcastle Upon Tyne NE2 4HH, ENGLAND	Newcastle University - UK	ZEROVNIK, E (corresponding author), EDVARD KARDELJ UNIV, INST J STEFAN, DEPT BIOCHEM, JAMOVA 39, YU-61000 LJUBLJANA, SLOVENIA.		Zerovnik, Eva/AAB-6498-2022; Jerala, Roman/H-9850-2015	Jerala, Roman/0000-0002-6337-5251				BARRETT AJ, 1986, BIOCHEM J, V236, P312, DOI 10.1042/bj2360312; BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; BRAZHNIKOV EV, 1985, BIOPOLYMERS, V24, P1899, DOI 10.1002/bip.360241005; BREMS DN, 1985, BIOCHEMISTRY-US, V24, P7662, DOI 10.1021/bi00347a025; BREMS DN, 1990, J BIOL CHEM, V265, P5504; BYCROFT M, 1990, NATURE, V346, P488, DOI 10.1038/346488a0; CHRISTENSEN H, 1991, EUR BIOPHYS J, V19, P221, DOI 10.1007/BF00183530; CLELAND JL, 1990, BIOCHEMISTRY-US, V29, P11072, DOI 10.1021/bi00502a009; DAVIS LC, 1983, J CHROMATOGR SCI, V21, P214, DOI 10.1093/chromsci/21.5.214; DOLGIKH DA, 1984, FEBS LETT, V165, P88, DOI 10.1016/0014-5793(84)80020-4; ENDO S, 1983, ANAL BIOCHEM, V131, P108, DOI 10.1016/0003-2697(83)90141-0; GOLDBERG ME, 1990, FEBS LETT, V263, P51, DOI 10.1016/0014-5793(90)80703-L; GOTO Y, 1989, BIOCHEMISTRY-US, V28, P945, DOI 10.1021/bi00429a004; IKEGUCHI M, 1986, BIOCHEMISTRY-US, V25, P6965, DOI 10.1021/bi00370a034; JAGANNADHAM MV, 1985, FEBS LETT, V188, P326, DOI 10.1016/0014-5793(85)80396-3; JERALA R, 1988, FEBS LETT, V239, P41, DOI 10.1016/0014-5793(88)80541-6; JERALA R, 1990, BIOL CHEM H-S, V371, P157; KRIVACIC JR, 1971, ANAL CHEM, V43, P1508, DOI 10.1021/ac60305a031; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; Lenarcic B., 1986, CYSTEINE PROTEINASES, P473; MATTHEWS CR, 1981, BIOCHEMISTRY-US, V20, P784, DOI 10.1021/bi00507a021; MITCHINSON C, 1985, J MOL BIOL, V184, P331, DOI 10.1016/0022-2836(85)90384-5; NOZAKA M, 1978, BIOCHEMISTRY-US, V17, P3753, DOI 10.1021/bi00611a013; OHGUSHI M, 1983, FEBS LETT, V164, P21, DOI 10.1016/0014-5793(83)80010-6; PFEIL W, 1987, BIOCHIM BIOPHYS ACTA, V911, P114, DOI 10.1016/0167-4838(87)90277-9; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; RITONJA A, 1985, BIOCHEM BIOPH RES CO, V131, P1187, DOI 10.1016/0006-291X(85)90216-5; ROBSON B, 1976, BIOCHEM J, V155, P331, DOI 10.1042/bj1550331; SAITO Y, 1983, BIOPOLYMERS, V22, P2123, DOI 10.1002/bip.360220910; SHALONGO W, 1989, BIOCHEMISTRY-US, V28, P4820, DOI 10.1021/bi00437a045; SHALONGO W, 1987, BIOCHEMISTRY-US, V26, P3135, DOI 10.1021/bi00385a029; STUBBS MT, 1990, EMBO J, V9, P1939, DOI 10.1002/j.1460-2075.1990.tb08321.x; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; WEDLER FC, 1991, BIOCHIM BIOPHYS ACTA, V1076, P161, DOI 10.1016/0167-4838(91)90235-R; WONG KP, 1973, J BIOL CHEM, V248, P8518; ZEROVNIK E, 1990, BIOL CHEM H-S, V371, P151; ZEROVNIK E, 1991, BIOCHIM BIOPHYS ACTA, V1078, P313, DOI 10.1016/0167-4838(91)90149-T	40	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9041	9046						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577741				2022-12-25	WOS:A1992HR85400053
J	LEDUC, R; MOLLOY, SS; THORNE, BA; THOMAS, G				LEDUC, R; MOLLOY, SS; THORNE, BA; THOMAS, G			ACTIVATION OF HUMAN FURIN PRECURSOR PROCESSING ENDOPROTEASE OCCURS BY AN INTRAMOLECULAR AUTOPROTEOLYTIC CLEAVAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBTILISIN; ENZYME; KEX2; SITE; EXPRESSION; PROHORMONE; SEQUENCE; INVIVO	Human furin is a calcium-dependent serine endoprotease that can efficiently cleave many precursor proteins on the carboxyl side of the consensus cleavage sequence, -Arg-X-Lys/Arg-Arg-, both in vivo and in vitro. Analysis of furin proteins in extracts of cells infected with a vaccinia recombinant expressing human furin show that the enzyme is present as two prominent forms of 90 and 96 kDa. Because the structurally related bacterial subtilisins require endoproteolytic removal of the NH2-terminal pro-region by an autocatalytic intramolecular cleavage, we speculated that the size heterogeneity in the furin doublet similarly may result from a proteolytic removal of an NH2-terminal pro-region. Here we report identification of the 90-kDa furin NH2 terminus and, based on the reported sequence of the furin cDNA, demonstrate that this furin protein is derived from a larger precursor by an endoproteolytic cleavage on the COOH-terminal side of a consensus furin cleavage site, -Arg-Thr-Lys-Arg107-. Expression of mutant furin molecules containing an altered cleavage site (Arg104 --> Ala or Arg107 --> Gly) resulted in the production of only the 96-kDa furin protein. Assays of furin-dependent cleavage of a protein substrate in vitro showed that proteolytic activity was associated with the 90-kDa and not the 96-kDa furin protein, demonstrating that removal of the NH2-terminal pro-region is required for furin activity. Expression of a third furin construct containing a mutation of the active site aspartate (Asp153 --> Asn) similarly resulted in the expression of only the 96-kDa protein, suggesting that furin activation occurs by an autoproteolytic cleavage. Finally, the production of 90-kDa furin from either site-directed furin mutant could not be potentiated by overexpressing active furin, suggesting that the autoproteolytic activation was an intramolecular event.	OREGON HLTH SCI UNIV,INST VOLLUM,PORTLAND,OR 97201	Oregon Health & Science University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044629, R01DK037274] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-44629, DK-37274] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATHAUDA SBP, 1991, BIOCHEM BIOPH RES CO, V175, P152, DOI 10.1016/S0006-291X(05)81213-6; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BRENNER C, 1992, P NATL ACAD SCI USA, V89, P922, DOI 10.1073/pnas.89.3.922; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BRESNAHAN PA, 1992, IN PRESS MECHANISM I; CHANCE RE, 1968, SCIENCE, V161, P165, DOI 10.1126/science.161.3837.165; CONNER GE, 1989, BIOCHEM J, V263, P601, DOI 10.1042/bj2630601; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; HAYFLICK JS, 1992, J NEUROSCI, V12, P705; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; Hruby D E, 1986, Methods Enzymol, V124, P295; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; OHTA Y, 1991, MOL MICROBIOL, V5, P1507, DOI 10.1111/j.1365-2958.1991.tb00797.x; POWER SD, 1986, P NATL ACAD SCI USA, V83, P3096, DOI 10.1073/pnas.83.10.3096; ROEBROEK AJM, 1991, FEBS LETT, V289, P133, DOI 10.1016/0014-5793(91)81052-A; SANSEGUNDO B, 1982, BIOCHIM BIOPHYS ACTA, V707, P74, DOI 10.1016/0167-4838(82)90398-3; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHENNAN KIJ, 1991, J BIOL CHEM, V266, P24011; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; SOSSIN WS, 1989, NEURON, V2, P1407, DOI 10.1016/0896-6273(89)90186-4; STEINER DF, 1967, SCIENCE, V157, P697, DOI 10.1126/science.157.3789.697; THOMAS G, 1988, SCIENCE, V241, P226, DOI 10.1126/science.3291117; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; THORNE BA, 1990, J BIOL CHEM, V265, P8436; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; WILCOX CA, 1991, J CELL BIOL, V115, P297, DOI 10.1083/jcb.115.2.297; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	39	146	152	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14304	14308						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629222				2022-12-25	WOS:A1992JD32500079
J	YULE, DI; WILLIAMS, JA				YULE, DI; WILLIAMS, JA			U73122 INHIBITS CA2+ OSCILLATIONS IN RESPONSE TO CHOLECYSTOKININ AND CARBACHOL BUT NOT TO JMV-180 IN RAT PANCREATIC ACINAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-DEPENDENT PROCESSES; INOSITOL TRISPHOSPHATE; PHOSPHOLIPASE-C; POLYMORPHONUCLEAR NEUTROPHILS; CYTOSOLIC CALCIUM; AMYLASE SECRETION; TUMOR PROMOTER; G-PROTEINS; RECEPTORS; HYDROLYSIS	Stimulation of rat pancreatic acinar cells with low concentrations of phosphatidylinositol (PI)-linked secretagogues induces [Ca2+]i oscillations, without measurable changes in the formation of inositol 1,4,5-trisphosphate. Therefore, we tested U73122 a new phospholipase C inhibitor to determine if PI turnover is necessary for the generation of [Ca2+]i oscillations. In acini prelabeled with [H-3]inositol, PI hydrolysis on stimulation with either cholecystokinin or carbachol was inhibited dose-dependently by U73122, with a maximal effect seen at 10-mu-M; the formation of inositol 1,4,5-trisphosphate, measured using a radioreceptor assay, was also similarly inhibited. By contrast secretin- or vasoactive intestinal peptide-stimulated production of cAMP was unaffected by 10-mu-M U73122. These studies indicate that U73122 is a relatively specific inhibitor of G-protein-mediated phospholipase C activation in pancreatic acini. In fura-2-loaded acini, U73122 inhibited the increases in [Ca2+]i stimulated by these high concentrations of secretagogues which can be demonstrated to elicit PI turnover. The [Ca2+]i signal generated by directly stimulating G-proteins with sodium fluoride was also inhibited by U73122; however, the [Ca2+]i rise induced by thapsigargin was unaffected. These data indicate that the mechanism of inhibition was distal to the occupation of cell surface receptors but did not involve an interference of Ca2+ metabolism in general. When [Ca2+]i oscillations were elicited by low concentrations of cholecystokinin or carbachol, U73122 rapidly inhibited the oscillating [Ca2+]i signal. In contrast, oscillations induced by an analogue of cholecystokinin, JMV-180, which does not stimulate changes in PI metabolism at any concentration, were unaffected. This indicates that cholecystokinin- and carbachol-induced oscillations are probably initiated by small, localized changes in PI metabolism, which are not readily detectable. However, the inability of U73 122 to inhibit JMV-180-induced oscillations indicates that PI metabolism may not necessarily be a prerequisite for the generation of [Ca2+]i oscillations.			YULE, DI (corresponding author), UNIV MICHIGAN,DEPT PHYSIOL,7744 MED SCI 2,ANN ARBOR,MI 48109, USA.			Williams, John/0000-0002-6063-7615	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041225] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41225] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; BREDT DS, 1989, BIOCHEM BIOPH RES CO, V159, P976, DOI 10.1016/0006-291X(89)92204-3; FOSKETT JK, 1991, J BIOL CHEM, V266, P2778; GAISANO HY, 1989, J CLIN INVEST, V83, P321, DOI 10.1172/JCI113877; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; HOOTMAN SR, 1987, PHYSL GASTROINTESTIN, P1129; KORMAN LY, 1980, AM J PHYSIOL, V239, pG324, DOI 10.1152/ajpgi.1980.239.4.G324; MATOZAKI T, 1988, AM J PHYSIOL, V255, pE652, DOI 10.1152/ajpendo.1988.255.5.E652; MATOZAKI T, 1989, AM J PHYSIOL, V257, pG594, DOI 10.1152/ajpgi.1989.257.4.G594; MATOZAKI T, 1989, J BIOL CHEM, V264, P14729; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; MOLERO X, 1990, MOL PHARMACOL, V39, P150; MUALLEM S, 1989, ANNU REV PHYSIOL, V51, P83; PETERSEN OH, 1990, J MEMBRANE BIOL, V118, P93, DOI 10.1007/BF01868467; ROBBERECHT P, 1976, J BIOL CHEM, V251, P4635; ROWLEY WH, 1990, AM J PHYSIOL, V259, pG655, DOI 10.1152/ajpgi.1990.259.4.G655; SALUJA A, 1991, J CELL BIOL, V115, P272; SALUJA AK, 1989, BIOCHEM BIOPH RES CO, V164, P8, DOI 10.1016/0006-291X(89)91675-6; SCHNEFEL S, 1990, BIOCHEM J, V269, P483, DOI 10.1042/bj2690483; SCHNEFEL S, 1988, FEBS LETT, V230, P125, DOI 10.1016/0014-5793(88)80655-0; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SOMOGYI R, 1991, J BIOL CHEM, V266, P11068; SUGIYA H, 1991, FEBS LETT, V286, P113, DOI 10.1016/0014-5793(91)80953-Z; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; TSUNODA Y, 1990, AM J PHYSIOL, V259, pG792, DOI 10.1152/ajpgi.1990.259.5.G792; TSUNODA Y, 1990, AM J PHYSIOL, V258, pC147, DOI 10.1152/ajpcell.1990.258.1.C147; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WILLIAMS JA, 1987, REGUL PEPTIDES, V18, P109, DOI 10.1016/0167-0115(87)90041-3; WILLIAMS JA, 1978, AM J PHYSIOL, V235, pE517, DOI 10.1152/ajpendo.1978.235.5.E517; YULE DI, 1988, FEBS LETT, V239, P358, DOI 10.1016/0014-5793(88)80951-7; YULE DI, 1991, BIOCHEM BIOPH RES CO, V177, P159, DOI 10.1016/0006-291X(91)91962-C; YULE DI, 1991, CELL CALCIUM, V12, P145, DOI 10.1016/0143-4160(91)90016-8	45	340	340	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13830	13835						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629184				2022-12-25	WOS:A1992JD32500010
J	ZOVICH, DC; OROLOGA, A; OKUNO, M; KONG, LWY; TALMAGE, DA; PIANTEDOSI, R; GOODMAN, DS; BLANER, WS				ZOVICH, DC; OROLOGA, A; OKUNO, M; KONG, LWY; TALMAGE, DA; PIANTEDOSI, R; GOODMAN, DS; BLANER, WS			DIFFERENTIATION-DEPENDENT EXPRESSION OF RETINOID-BINDING PROTEINS IN BFC-1-BETA ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA LEVELS; EMBRYONAL CARCINOMA-CELLS; PREADIPOCYTE CLONAL LINE; VISCERAL YOLK-SAC; VITAMIN-A STATUS; ACID RECEPTOR; ADIPOSE CONVERSION; RAT-LIVER; GENE; INSULIN	Recently, we demonstrated that adipose tissue plays an important role in retinol storage and retinol-binding protein (RBP) synthesis. Our data suggested that RBP expression in adipose tissue is dependent on the state of adipocyte differentiation. To examine this possibility, we explored the differentiation-dependent expression of RBP using BFC-1-beta preadipocytes, which can be stimulated to undergo adipose differentiation. Total RNA was isolated from undifferentiated (preadipocytes) and differentiated (adipocytes) BFC-1-beta cells and analyzed by Northern blotting. RBP mRNA was not detected in the preadipocytes, but considerable RBP mRNA was present in differentiated BFC-1-beta cells. In BFC-1-beta cells, induced to differentiate with insulin and thyroid hormone, RBP mRNA was first detected after 4 days, reached a maximum level by day 10, and remained at this maximum level for at least 2 more days. Cellular retinol-binding protein was expressed at low levels in the BFC-1-beta preadipocytes and the level of expression increased for 6 days after induction to differentiate and slowly declined on later days. Neither the maximum level of RBP expression nor the day on which this level was reached was influenced by the level of retinol provided in the BFC-1-beta culture medium. BFC-1-beta cells secreted newly synthesized RBP into the culture medium at a rate of 43 +/- 14 ng RBP/24 h/10(6) adipocytes. When the BFC-1-beta adipocytes were provided 1.0-mu-M retinol in the medium, they accumulated the retinol and synthesized retinyl esters. These studies with BFC-1-beta cells confirm that RBP synthesis and secretion and retinol accumulation are intrinsic properties of differentiated adipocytes. Furthermore, they suggest that RBP and cellular retinol-binding protein gene expression are regulated as part of a package of genes which are modulated during adipocyte differentiation.	COLUMBIA UNIV, INST HUMAN NUTR, 630 W 168TH ST, NEW YORK, NY 10032 USA	Columbia University				Talmage, David/0000-0003-4627-3007	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD026854] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK005968, R37DK005968, R01DK043097] Funding Source: NIH RePORTER; NICHD NIH HHS [HD26854] Funding Source: Medline; NIDDK NIH HHS [DK 43097, DK 05968] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUMRAD NA, 1991, P NATL ACAD SCI USA, V88, P6008, DOI 10.1073/pnas.88.14.6008; ABUMRAD NA, 1991, AM J PHYSIOL, V261, pE76, DOI 10.1152/ajpendo.1991.261.1.E76; ANTRAS J, 1991, J BIOL CHEM, V266, P1157; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BLANER WS, 1989, ENDOCR REV, V10, P308, DOI 10.1210/edrv-10-3-308; BLANER WS, 1990, METHOD ENZYMOL, V189, P270; BLANER WS, 1986, J LIPID RES, V27, P1084; BLANER WS, 1990, METHOD ENZYMOL, V189, P193; BLANER WS, 1987, EUR J BIOCHEM, V164, P301, DOI 10.1111/j.1432-1033.1987.tb11058.x; BLANER WS, 1985, J LIPID RES, V26, P1241; BLOMHOFF R, 1982, P NATL ACAD SCI-BIOL, V79, P7326, DOI 10.1073/pnas.79.23.7326; BRIDGES CDB, 1982, METHOD ENZYMOL, V81, P463; BROUWER A, 1988, CHEM-BIOL INTERACT, V68, P203, DOI 10.1016/0009-2797(88)90017-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DONOFRIO C, 1985, EMBO J, V4, P1981, DOI 10.1002/j.1460-2075.1985.tb03881.x; ESPESETH AS, 1989, GENE DEV, V3, P1647, DOI 10.1101/gad.3.11.1647; FOREST C, 1987, EXP CELL RES, V168, P218, DOI 10.1016/0014-4827(87)90430-7; FOREST C, 1987, EXP CELL RES, V168, P233, DOI 10.1016/0014-4827(87)90431-9; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; Goodman DS, 1984, RETINOIDS, P41, DOI DOI 10.1016/B978-0-12-658102-7.50008-7; GOODMAN DS, 1984, RETINOIDS, V2, P1; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; HERBERT J, 1991, INVEST OPHTH VIS SCI, V32, P302; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT BC, 1985, J BIOL CHEM, V260, P1476; LEWIS KC, 1990, J LIPID RES, V31, P1535; MAKOVER A, 1989, J LIPID RES, V30, P171; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Maniatis T, 1982, MOL CLONING LABORATO, P312; MARTONE RL, 1988, BIOCHEM BIOPH RES CO, V157, P1078, DOI 10.1016/S0006-291X(88)80984-7; MUTO Y, 1972, J BIOL CHEM, V247, P2542; NEGREL R, 1978, P NATL ACAD SCI USA, V75, P6054, DOI 10.1073/pnas.75.12.6054; NOY N, 1991, BIOCHEMISTRY-US, V30, P6380, DOI 10.1021/bi00240a005; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; RAJAN N, 1990, J LIPID RES, V31, P821; RIAZULHAQ, 1991, BIOCHEM BIOPH RES CO, V176, P1539, DOI 10.1016/0006-291X(91)90462-G; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; SEMENKOVICH CF, 1989, J BIOL CHEM, V264, P9030; SOPRANO DR, 1986, P NATL ACAD SCI USA, V83, P7330, DOI 10.1073/pnas.83.19.7330; SOPRANO DR, 1986, J LIPID RES, V27, P166; SOPRANO DR, 1988, J BIOL CHEM, V263, P17897; SOPRANO DR, 1988, J BIOL CHEM, V263, P2934; TSUTSUMI C, 1992, J BIOL CHEM, V267, P1805; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644	47	62	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13884	13889						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629187				2022-12-25	WOS:A1992JD32500018
J	GRABER, SG; FIGLER, RA; KALMANMALTESE, VK; ROBISHAW, JD; GARRISON, JC				GRABER, SG; FIGLER, RA; KALMANMALTESE, VK; ROBISHAW, JD; GARRISON, JC			EXPRESSION OF FUNCTIONAL G-PROTEIN BETA-GAMMA DIMERS OF DEFINED SUBUNIT COMPOSITION USING A BACULOVIRUS EXPRESSION SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MUSCARINIC K+-CHANNEL; C-TERMINAL CYSTEINE; ADENYLATE-CYCLASE; INSECT CELLS; BRAIN; TRANSDUCIN; PURIFICATION; ACTIVATE; HOMOLOGY; CONTAIN	The 36-kDa-beta-1, 35-kDa-beta-2, and 6.5-kDa-gamma-2 subunits of the heterotrimeric guanine nucleotide-binding proteins have been overexpressed in Sf9 cells using a baculovirus expression system. The gamma-2 subunit expressed in Sf9 cells incorporated label derived from [H-3]mevalonate and is therefore likely to be isoprenylated, as is its mammalian counterpart. Extracts of Sf9 cells doubly infected with viruses encoding a beta-subunit and viruses encoding a gamma-subunit are active in promoting the pertussis toxin-catalyzed ADP-ribosylation of a G protein alpha-subunit. However, extracts from Sf9 cells singly infected with viruses encoding either a beta or gamma-subunit are not active in this assay. Results demonstrate utility of the insect/baculovirus system for expressing G protein beta-gamma-subunits of defined composition.	UNIV VIRGINIA,SCH MED,DEPT PHYSIOL,CHARLOTTESVILLE,VA 22908; GEISINGER MED CTR,WEISS CTR RES,DANVILLE,PA 17822	University of Virginia; Geisinger Medical Center	GRABER, SG (corresponding author), UNIV VIRGINIA,SCH MED,HLTH SCI CTR,DEPT PHARMACOL,BOX 448,CHARLOTTESVILLE,VA 22908, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019952] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039867, R01GM039867] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-19952] Funding Source: Medline; NIGMS NIH HHS [GM-39867] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGELO CS, 1987, J VIROL, V61, P361; BLUMER KJ, 1991, ANNU REV PHYSIOL, V53, P37; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CERIONE RA, 1987, BIOCHEMISTRY-US, V26, P1485, DOI 10.1021/bi00379a041; CODINA J, 1986, FEBS LETT, V207, P187, DOI 10.1016/0014-5793(86)81486-7; DODSON MS, 1989, J BIOL CHEM, V264, P20835; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FONG HKW, 1987, P NATL ACAD SCI USA, V84, P3792, DOI 10.1073/pnas.84.11.3792; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; FOSTER KA, 1990, AM J PHYSIOL, V259, P1271; FUNG BKK, 1990, FEBS LETT, V260, P313, DOI 10.1016/0014-5793(90)80132-3; GAO B, 1987, P NATL ACAD SCI USA, V84, P6122, DOI 10.1073/pnas.84.17.6122; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GRABER SG, 1992, J BIOL CHEM, V267, P1271; HASEMANN CA, 1990, P NATL ACAD SCI USA, V87, P3942, DOI 10.1073/pnas.87.10.3942; HEKMAN M, 1987, EUR J BIOCHEM, V169, P431, DOI 10.1111/j.1432-1033.1987.tb13630.x; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KURACHI Y, 1989, NATURE, V337, P555, DOI 10.1038/337555a0; LINDER ME, 1990, J BIOL CHEM, V265, P8243; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LOWE PN, 1990, ONCOGENE, V5, P1045; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; NEER EJ, 1984, J BIOL CHEM, V259, P4222; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; ROOF DJ, 1985, J BIOL CHEM, V260, P6242; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; SIMON MI, 1991, SCIENCE, V252, P804; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; SMITH GE, 1983, J VIROL, V46, P584, DOI 10.1128/JVI.46.2.584-593.1983; SUGIMOTO K, 1985, FEBS LETT, V191, P235, DOI 10.1016/0014-5793(85)80015-6; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TAMIR H, 1991, BIOCHEMISTRY-US, V30, P3929, DOI 10.1021/bi00230a018; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868	40	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13123	13126						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618813				2022-12-25	WOS:A1992JB74600003
J	HAMANAKA, R; KOHNO, K; SEGUCHI, T; OKAMURA, K; MORIMOTO, A; ONO, M; OGATA, J; KUWANO, M				HAMANAKA, R; KOHNO, K; SEGUCHI, T; OKAMURA, K; MORIMOTO, A; ONO, M; OGATA, J; KUWANO, M			INDUCTION OF LOW-DENSITY-LIPOPROTEIN RECEPTOR AND A TRANSCRIPTION FACTOR SP-1 BY TUMOR-NECROSIS-FACTOR IN HUMAN MICROVASCULAR ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; HUMAN-SKIN FIBROBLASTS; MONOCYTE-MACROPHAGES; FACTOR CACHECTIN; LDL RECEPTOR; FACTOR-ALPHA; KAPPA-B; GENE; INTERLEUKIN-1; EXPRESSION	We have previously reported that tumor necrosis factor-alpha (TNF-alpha) enhances expression of interleukin-6, collagenase, plasminogen activator inhibitor-1, and basic fibroblast growth factor genes in human omental microvascular endothelial (HOME) cells in culture. In this study, we found that treatment of HOME cells with TNF-alpha or interleukin-1 (IL-1) caused enhanced expression of low density lipoprotein (LDL) receptor. A few-fold increase in both LDL binding activity and the receptor mRNA levels was observed when HOME cells were treated with either TNF-alpha or IL-1. Northern blot analysis showed that cellular expression of LDL receptor gene was significantly increased 12-24 h after exposure to TNF-alpha. No significant changes in the life-span of LDL receptor mRNA were observed in untreated and TNF-alpha-treated cells. Scatchard analysis showed-an increased receptor number for LDL in TNF-alpha-treated cells. Parallel to increased LDL binding activity, internalization and degradation of LDL were also increased in HOME cells treated with TNF-alpha or IL-1. TNF-alpha-induced enhancement of LDL receptor gene expression was not observed when cycloheximide was present. Cellular mRNA level of SP-1 gene was increased about 3-4-fold at 12 h after treatment with TNF-alpha. Nuclear run-on assays showed increased transcription of LDL receptor gene as well as SP-1 gene by TNF-alpha. Gel retardation assay with the SP-1 consensus fragment showed that SP-1 binding activity was increased about 4-5-fold 12-24 h after treatment with TNF-alpha. NF-kB binding activity was also dramatically increased, but there is no NF-kB motif on the promoter for LDL receptor gene. The induction of LDL receptor by TNF might be mediated through a transcription factor, SP-1.	OITA MED UNIV,DEPT BIOCHEM,OITA 87955,JAPAN; OITA MED UNIV,DEPT UROL,OITA 87955,JAPAN	Oita University; Oita University								ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BEUTLER B, 1985, NATURE, V316, P552, DOI 10.1038/316552a0; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CHAIT A, 1979, J CLIN INVEST, V64, P1309, DOI 10.1172/JCI109587; CHIAT A, 1980, P NATL ACAD SCI USA, V77, P4084; COLLINS T, 1986, P NATL ACAD SCI USA, V83, P446, DOI 10.1073/pnas.83.2.446; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; FISHER R, 1985, J BIOL CHEM, V260, P1223; FOGELMAN AM, 1980, P NATL ACAD SCI-BIOL, V77, P2214, DOI 10.1073/pnas.77.4.2214; GERRITY RG, 1979, AM J PATHOL, V95, P775; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HARADA K, 1990, BIOCHEM BIOPH RES CO, V172, P1022, DOI 10.1016/0006-291X(90)91548-7; HIRAMATSU K, 1987, ARTERIOSCLEROSIS, V7, P55, DOI 10.1161/01.ATV.7.1.55; ISHIBASHI S, 1990, J BIOL CHEM, V265, P14109; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KESANIEMI YA, 1983, J CLIN INVEST, V71, P950, DOI 10.1172/JCI110849; KOHNO K, 1990, J BIOL CHEM, V265, P19690; LIBBY P, 1986, AM J PATHOL, V124, P179; LOWENTHAL JW, 1989, J IMMUNOL, V142, P3121; MATSUDA T, 1992, J CELL PHYSIOL, V150, P510, DOI 10.1002/jcp.1041500311; MAWATARI M, 1991, EXP CELL RES, V192, P574, DOI 10.1016/0014-4827(91)90078-9; MAWATARI M, 1989, J IMMUNOL, V143, P1619; MORIMOTO A, 1991, BIOCHEM BIOPH RES CO, V179, P1042, DOI 10.1016/0006-291X(91)91924-2; NAWROTH PP, 1986, J EXP MED, V163, P1363, DOI 10.1084/jem.163.6.1363; OKAMURA K, 1991, J BIOL CHEM, V266, P19162; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PARTHASARATHY S, 1989, P NATL ACAD SCI USA, V86, P1046, DOI 10.1073/pnas.86.3.1046; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; SATO Y, 1991, BIOCHEM BIOPH RES CO, V174, P1260, DOI 10.1016/0006-291X(91)91557-S; SHITE S, 1988, J BIOL CHEM, V263, P19286; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; TOMITA K, 1987, J BIOL CHEM, V262, P1398; YOSHIMURA A, 1987, J BIOL CHEM, V262, P13299	37	98	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13160	13165						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618817				2022-12-25	WOS:A1992JB74600012
J	VERGERES, G; WASKELL, L				VERGERES, G; WASKELL, L			EXPRESSION OF CYTOCHROME-B(5) IN YEAST AND CHARACTERIZATION OF MUTANTS OF THE MEMBRANE-ANCHORING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; PHOTOACTIVATABLE PHOSPHOLIPIDS; EMBEDDED SEGMENT; CROSS-LINKING; REDUCTASE; PROTEINS; BINDING; PURIFICATION; MUTAGENESIS; INSERTION	The soluble and membrane-bound forms of the synthetic rat cytochrome b5 gene have been expressed in Saccharomyces cerevisiae. In order to examine the topology and function of the COOH-terminal membrane binding domain of cytochrome b5, mutants have been constructed, expressed, purified, and partially characterized. Pro-115 is located in the middle of the putative alpha-helical membrane-anchoring domain of cytochrome b5 and has been hypothesized to give rise to either a hairpin-like loop or congruent-to 26-degrees kink in the helix, depending on whether it exists, respectively, in the cis or trans configuration. The Pro-115 --> Ala mutant, which is expected to have a straight transmembrane helix, inserted normally into the endoplasmic reticulum and exhibited wild type levels of activity in yeast microsomes and in vitro in the cytochrome P-450 mixed function oxidation system. Since a hairpin structure does not appear to be essential, it is likely that the membrane binding domain of cytochrome b5 spans the membrane. Characterization of the truncated cytochrome b5 molecule, Pro-115 --> Stop, lacking 19 amino acids at the COOH terminus indicates that the distal part of the membrane binding domain of cytochrome b5 is necessary for in vivo binding to the endoplasmic reticulum and for functioning with its membrane-associated electron transfer partners. Replacement of Ser-104 to Met-125, the putative membrane-anchoring domain of cytochrome b5, with 22 leucine residues results in a protein which targets to the endoplasmic reticulum but the extent of its reduction is only 50% of that of the wild type in yeast microsomes. In vitro, the polyleucine mutant is unable to support substrate oxidation by cytochrome P-450. The mutation of Ala-131 and Glu-132, amino acids flanking the transmembrane domain, to lysines resulted in a protein with normal membrane topology and function.	UNIV CALIF SAN FRANCISCO, VET ADM MED CTR, DEPT ANESTHESIA, SAN FRANCISCO, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NIGMS NIH HHS [GM 35333] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON DJ, 1983, P NATL ACAD SCI-BIOL, V80, P7249, DOI 10.1073/pnas.80.23.7249; AOYAMA T, 1990, P NATL ACAD SCI USA, V87, P5425, DOI 10.1073/pnas.87.14.5425; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; BELTZER JP, 1991, J BIOL CHEM, V266, P973; BENDZKO P, 1982, EUR J BIOCHEM, V123, P121, DOI 10.1111/j.1432-1033.1982.tb06507.x; BENNETT WS, 1980, J MOL BIOL, V140, P211, DOI 10.1016/0022-2836(80)90103-5; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; BERNSTEIN HD, 1989, CELL, V58, P1017, DOI 10.1016/0092-8674(89)90497-2; BUTT TR, 1987, MICROBIOL REV, V51, P351, DOI 10.1128/MMBR.51.3.351-364.1987; CANOVADAVIS E, 1985, BIOCHEM PHARMACOL, V34, P1907, DOI 10.1016/0006-2952(85)90307-7; CANOVADAVIS E, 1984, J BIOL CHEM, V259, P2541; CARLSEN J, 1988, BIOCHEM J, V256, P1051, DOI 10.1042/bj2561051; CHOU MM, 1990, J BIOL CHEM, V265, P2873; Coon M J, 1978, Methods Enzymol, V52, P109; DAILEY HA, 1981, J BIOL CHEM, V256, P1677; DAILEY HA, 1979, J BIOL CHEM, V254, P5388; DAILEY HA, 1978, J BIOL CHEM, V253, P8203; DEISENHOFER J, 1989, SCIENCE, V245, P1463, DOI 10.1126/science.245.4925.1463; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ENOCH HG, 1977, J BIOL CHEM, V252, P5656; ENOCH HG, 1979, J BIOL CHEM, V254, P6483; ETCHEVERRY T, 1986, BIO-TECHNOL, V4, P726, DOI 10.1038/nbt0886-726; ETCHEVERRY T, 1990, METHOD ENZYMOL, V185, P319; FRENCH JS, 1979, ARCH BIOCHEM BIOPHYS, V195, P565, DOI 10.1016/0003-9861(79)90383-7; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GEORGE SK, 1989, J BACTERIOL, V171, P4569, DOI 10.1128/jb.171.9.4569-4576.1989; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HAUGEN DA, 1976, J BIOL CHEM, V251, P7929; HEGESH E, 1986, NEW ENGL J MED, V314, P757, DOI 10.1056/NEJM198603203141206; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; HOLLOWAY PW, 1990, BIOCHEMISTRY-US, V29, P9631, DOI 10.1021/bi00493a018; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; ISHIDATE K, 1969, J BIOCHEM, V65, P375, DOI 10.1093/oxfordjournals.jbchem.a129024; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAP BK, 1989, J MOL BIOL, V205, P407, DOI 10.1016/0022-2836(89)90351-3; KONOPKA K, 1988, BIOCHIM BIOPHYS ACTA, V954, P189, DOI 10.1016/0167-4838(88)90071-4; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OKADA Y, 1982, EUR J BIOCHEM, V122, P393, DOI 10.1111/j.1432-1033.1982.tb05894.x; OSHINO N, 1982, HEPATIC CYTOCHROME P, P407; OZOLS J, 1989, BIOCHIM BIOPHYS ACTA, V997, P121, DOI 10.1016/0167-4838(89)90143-X; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.biochem.59.1.331; RACHUBINSKI RA, 1980, J CELL BIOL, V84, P705, DOI 10.1083/jcb.84.3.705; RAPOPORT TA, 1991, FASEB J, V5, P2792, DOI 10.1096/fasebj.5.13.1916103; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; ROBINSON NC, 1975, BIOCHEMISTRY-US, V14, P369, DOI 10.1021/bi00673a025; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Singer S. J., 1971, STRUCTURE FUNCTION B, P145; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SPIESS M, 1987, EMBO J, V6, P2683, DOI 10.1002/j.1460-2075.1987.tb02560.x; STRITTMATTER P, 1974, P NATL ACAD SCI USA, V71, P4565, DOI 10.1073/pnas.71.11.4565; TAKAGAKI Y, 1983, J BIOL CHEM, V258, P9128; TAKAGAKI Y, 1983, J BIOL CHEM, V258, P9136; VATSIS KP, 1982, J BIOL CHEM, V257, P1221; VONBODMAN SB, 1986, P NATL ACAD SCI USA, V83, P9443; WASKELL LA, 1991, METHOD ENZYMOL, V206, P523; WEISS MS, 1990, FEBS LETT, V267, P268, DOI 10.1016/0014-5793(90)80942-C; WILLIAMS KA, 1991, BIOCHEMISTRY-US, V30, P8919, DOI 10.1021/bi00101a001; YEATES TO, 1987, P NATL ACAD SCI USA, V84, P6438, DOI 10.1073/pnas.84.18.6438; YOSHIDA Y, 1983, ARCH BIOCHEM BIOPHYS, V220, P467, DOI 10.1016/0003-9861(83)90437-X; YOSHIDA Y, 1974, BIOCHEMISTRY-US, V75, P1211; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	65	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12583	12591						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618763				2022-12-25	WOS:A1992HZ48300034
J	WU, GY; WU, CH				WU, GY; WU, CH			SPECIFIC-INHIBITION OF HEPATITIS-B VIRAL GENE-EXPRESSION INVITRO BY TARGETED ANTISENSE OLIGONUCLEOTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN IMMUNODEFICIENCY VIRUS; CELLS; OLIGODEOXYNUCLEOTIDES; DNA; TRANSPORT; RECEPTOR	A 21-mer oligodeoxynucleotide complementary to the polyadenylation signal for human hepatitis B virus (HBV) was complexed to a soluble DNA-carrier system that is targetable to hepatocytes via asialoglycoprotein receptors present on those cells. A cell line, HepG2 (2.2.15) that possesses asialoglycoprotein receptors and is permanently transfected with hepatitis B virus (ayw subtype) was exposed to complexed antisense DNA or controls. In the presence of complexed anti-sense DNA, the concentration of hepatitis B surface antigen in medium was 80% lower than controls after 24 h. Furthermore, during the next 6 days, there was no significant increase in surface antigen concentration in the presence of complexed antisense DNA. The inhibition could be effectively blocked by competition with an excess of free asialoglycoprotein. Total protein synthesis remained unchanged by exposure to complexed antisense sequences under identical conditions. In addition, HBV DNA in the medium and cell layers after 24-h exposure to complexed antisense sequences was 80% lower than in controls. The data indicate that antisense oligonucleotides complexed by a soluble DNA-carrier system can be targeted to cells via asialoglycoprotein receptors resulting in specific inhibition of hepatitis B viral gene expression and replication.			WU, GY (corresponding author), UNIV CONNECTICUT,SCH MED,DEPT MED,DIV GASTROENTEROL HEPATOL,263 FARMINGTON AVE,FARMINGTON,CT 06030, USA.				NCI NIH HHS [CA-01110] Funding Source: Medline; NIDDK NIH HHS [DK-42182] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K04CA001110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042182] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRAWAL S, 1989, P NATL ACAD SCI USA, V86, P7790, DOI 10.1073/pnas.86.20.7790; ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; BEVILACQUA A, 1988, P NATL ACAD SCI USA, V85, P831, DOI 10.1073/pnas.85.3.831; GANEM D, 1982, REV INFECT DIS, V4, P1026; GOODCHILD J, 1988, P NATL ACAD SCI USA, V85, P5507, DOI 10.1073/pnas.85.15.5507; HIRSCHMAN SZ, 1980, P NATL ACAD SCI-BIOL, V77, P5507, DOI 10.1073/pnas.77.9.5507; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; LEMAITRE M, 1987, P NATL ACAD SCI USA, V84, P648, DOI 10.1073/pnas.84.3.648; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; MATSUKURA M, 1987, P NATL ACAD SCI USA, V84, P7705; MILLER JM, 1985, J AM COLL CARDIOL, V6, P769, DOI 10.1016/S0735-1097(85)80480-0; SAMBROOK J, 1989, MOL CLONING LABORATO, V2; SCHWARTZ AL, 1981, J BIOL CHEM, V256, P8878; SELLS MA, 1987, P NATL ACAD SCI USA, V84, P1005, DOI 10.1073/pnas.84.4.1005; SHAFRITZ DA, 1981, NEW ENGL J MED, V305, P1067, DOI 10.1056/NEJM198110293051807; STEIN CA, 1988, CANCER RES, V48, P2659; WU GY, 1987, J BIOL CHEM, V262, P4429; WU GY, 1988, J BIOL CHEM, V263, P14261	18	183	233	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12436	12439						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618751				2022-12-25	WOS:A1992HZ48300012
J	ZIERE, GJ; VANDIJK, MCM; BIJSTERBOSCH, MK; VANBERKEL, TJC				ZIERE, GJ; VANDIJK, MCM; BIJSTERBOSCH, MK; VANBERKEL, TJC			LACTOFERRIN UPTAKE BY THE RAT-LIVER - CHARACTERIZATION OF THE RECOGNITION SITE AND EFFECT OF SELECTIVE MODIFICATION OF ARGININE RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; BINDING; CELLS; INVIVO; GLYCOPROTEINS; RECEPTOR; LIGAND; LOCALIZATION; ENDOCYTOSIS; DEGRADATION	Recently it was found that lactoferrin, an iron-binding glycoprotein with a molecular weight of 76,500, inhibits the remnant receptor-mediated uptake of apo-lipoprotein E (apoE)-bearing lipoproteins by the liver. In the present study we characterized the hepatic recognition of lactoferrin. Intravenously injected I-125-lactoferrin was cleared rapidly from the circulation by the liver (92.8 +/- 9.5% of the dose at 5 min after injection). Parenchymal cells contained 97.1 +/- 1.5% of the hepatic radioactivity. Internalization, monitored by measuring the release of liver-associated radioactivity by the polysaccharide fucoidin, occurred slowly. Only about 40% of the liver-associated lactoferrin was internalized at 10 min after injection, and it took 180 min to internalize 90%. Subcellular fractionation indicated that internalized lactoferrin is transported to the lysosomes. Binding of lactoferrin to isolated parenchymal liver cells was saturable with a dissociation constant of 10-mu-M (20 x 10(6) binding sites/cell). The role of arginine residues on lactoferrin was studied by modifying these residues with 1,2-cyclohexanedione. The modification resulted in a strongly reduced liver association (15.9 +/- 1.6% of the dose at 5 min after injection). Furthermore, unlabeled 1,2-cyclohexanedione-modified lactoferrin did not inhibit the binding of I-125-lactoferrin to isolated parenchymal cells. Arginine residues on lactoferrin thus appear to be essential for its specific recognition by parenchymal liver cells. In particular the clustered N-terminal arginine residues, which resemble the arginine-rich receptor binding sequence in apoE, may be responsible for both the interaction of lactoferrin with its recognition site and the inhibition of the hepatic uptake of apoE-bearing lipoproteins.	LEIDEN UNIV, SYLVIUS LAB,CTR BIOPHARMACEUT SCI, DIV BIOPHARMACEUT,POB 9503, 2300 RA LEIDEN, NETHERLANDS	Leiden University; Leiden University - Excl LUMC			Van Berkel, Theo/ABD-7677-2021					ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; BENNETT RM, 1979, CLIN SCI, V57, P453, DOI 10.1042/cs0570453; BIJSTERBOSCH MK, 1989, MOL PHARMACOL, V36, P484; BLOUIN A, 1977, J CELL BIOL, V72, P441, DOI 10.1083/jcb.72.2.441; BLUARDDECONINCK JM, 1978, BIOCHEM J, V171, P321, DOI 10.1042/bj1710321; CAMPBELL EJ, 1982, P NATL ACAD SCI-BIOL, V79, P6941, DOI 10.1073/pnas.79.22.6941; CASTELEIJN E, 1986, FEBS LETT, V201, P193, DOI 10.1016/0014-5793(86)80607-X; CASTER WO, 1955, AM J PHYSIOL, V183, P317, DOI 10.1152/ajplegacy.1955.183.2.317; COURTOY PJ, 1984, LAB INVEST, V50, P329; DORLAND L, 1977, FEBS LETT, V77, P15, DOI 10.1016/0014-5793(77)80183-X; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; GORIUS JB, 1980, AM J PATHOL, V99, P413; GUTTERIDGE JMC, 1981, BIOCHEM J, V199, P259, DOI 10.1042/bj1990259; HALTIWANGER RS, 1986, J BIOL CHEM, V261, P5696; HALTIWANGER RS, 1986, J BIOL CHEM, V261, P7433; HOEG JM, 1985, SCIENCE, V227, P759, DOI 10.1126/science.2982214; HUETTINGER M, 1988, CLIN BIOCHEM, V21, P87, DOI 10.1016/S0009-9120(88)80093-6; IMBER MJ, 1982, J BIOL CHEM, V257, P5129; IMBER MJ, 1983, BIOCHEM J, V212, P249, DOI 10.1042/bj2120249; KARLE H, 1979, SCAND J HAEMATOL, V23, P303; KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P3623, DOI 10.1073/pnas.79.11.3623; LEE BR, 1991, J LIPID RES, V32, P165; LEGER D, 1977, ANN BIOL ANIM BIOCH, V17, P737, DOI 10.1051/rnd:19770609; Masson P. L., 1966, PROTIDES BIOL FLUIDS, V14, P115; MASSON PL, 1969, J EXP MED, V130, P643, DOI 10.1084/jem.130.3.643; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; METZBOUTIGUE MH, 1984, EUR J BIOCHEM, V145, P659, DOI 10.1111/j.1432-1033.1984.tb08607.x; MOGUILEVSKY N, 1984, LAB INVEST, V50, P335; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P2221; PATTHY L, 1975, J BIOL CHEM, V250, P557; PITTMAN RC, 1983, BIOCHEM J, V212, P791, DOI 10.1042/bj2120791; PIZZO SV, 1981, BIOCHEM BIOPH RES CO, V101, P704, DOI 10.1016/0006-291X(81)91315-2; PRIEELS JP, 1978, P NATL ACAD SCI USA, V75, P2215, DOI 10.1073/pnas.75.5.2215; QUERINJE.P, 1971, EUR J BIOCHEM, V20, P420, DOI 10.1111/j.1432-1033.1971.tb01408.x; RECOECZI E, 1985, AM J PHYSIOL, V248, pG8; RETEGUI LA, 1984, LAB INVEST, V50, P323; SCHLEPPERSCHAFER J, 1986, EXP CELL RES, V165, P494, DOI 10.1016/0014-4827(86)90602-6; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SPIK G, 1966, CR ACAD SCI D NAT, V263, P893; SPITZNAGEL JK, 1972, J CLIN INVEST, V51, pA93; VANBERKEL TJC, 1987, BIOCHEM J, V243, P715, DOI 10.1042/bj2430715; VANDIJK MCM, 1991, BIOCHEM J, V279, P863, DOI 10.1042/bj2790863; VANDIJK MCM, 1992, IN PRESS EUR J BIOCH; VANSNICK JL, 1976, J EXP MED, V144, P1568, DOI 10.1084/jem.144.6.1568; VANTOL A, 1978, ATHEROSCLEROSIS, V29, P449, DOI 10.1016/0021-9150(78)90173-9	45	84	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11229	11235						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597458				2022-12-25	WOS:A1992HX16900048
J	MIURA, M; ASOU, H; KOBAYASHI, M; UYEMURA, K				MIURA, M; ASOU, H; KOBAYASHI, M; UYEMURA, K			FUNCTIONAL EXPRESSION OF A FULL-LENGTH CDNA CODING FOR RAT NEURAL CELL-ADHESION MOLECULE-L1 MEDIATES HOMOPHILIC INTERCELLULAR-ADHESION AND MIGRATION OF CEREBELLAR NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-CAM; IMMUNOGLOBULIN SUPERFAMILY; MICROEXPLANT CULTURES; POSTNATAL-DEVELOPMENT; MOUSE CEREBELLUM; L1; BINDING; PROTEIN; GLIA; GLYCOPROTEINS	Neural cell adhesion molecule L1 is postulated to be involved in cell-cell interaction, neurite elongation, fasciculation of axons, cell migration, and myelination. To determine the function of L1 directly, we have transfected rat L1 cDNA into mouse fibroblast L cells. Stable transformants expressing L1 showed uniform surface expression of the molecule without phenotypic changes. Dispersed L1-expressing transfectants aggregated with faster kinetics than control cells in a homophilic manner. Divalent cations were not required for this cell aggregation. L1-transfected cells markedly enhanced neuronal cell adhesion and migration in co-culture with rat cerebellar neurons. These results indicate that L1 is involved in a determinant step of neural development through molecular interactions.			MIURA, M (corresponding author), KEIO UNIV,SCH MED,DEPT PHYSIOL,35 SHINANOMACHI,SHINJUKU KU,TOKYO 160,JAPAN.							ALTMAN J, 1969, J COMP NEUROL, V136, P269, DOI 10.1002/cne.901360303; ALTMAN J, 1972, J COMP NEUROL, V145, P353, DOI 10.1002/cne.901450305; BOCK E, 1985, EMBO J, V4, P2765, DOI 10.1002/j.1460-2075.1985.tb04001.x; BURGOON MP, 1991, J CELL BIOL, V112, P1017, DOI 10.1083/jcb.112.5.1017; CHANG S, 1987, J CELL BIOL, V104, P355, DOI 10.1083/jcb.104.2.355; CHUONG CM, 1987, J CELL BIOL, V104, P331, DOI 10.1083/jcb.104.2.331; CHUONG CM, 1984, J NEUROSCI, V4, P2354; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; EDELMAN GM, 1985, ANNU REV BIOCHEM, V54, P135, DOI 10.1146/annurev.bi.54.070185.001031; EDELMAN GM, 1987, P NATL ACAD SCI USA, V84, P8502, DOI 10.1073/pnas.84.23.8502; FAISSNER A, 1985, EMBO J, V4, P3105, DOI 10.1002/j.1460-2075.1985.tb04052.x; FAISSNER A, 1984, EMBO J, V3, P733, DOI 10.1002/j.1460-2075.1984.tb01876.x; FILBIN MT, 1990, NATURE, V344, P871, DOI 10.1038/344871a0; FISCHER G, 1986, J NEUROSCI, V6, P605; FUSHIKI S, 1986, DEV BRAIN RES, V24, P153, DOI 10.1016/0165-3806(86)90183-5; GENNARINI G, 1991, NEURON, V6, P595, DOI 10.1016/0896-6273(91)90062-5; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRUMET M, 1984, P NATL ACAD SCI-BIOL, V81, P7989, DOI 10.1073/pnas.81.24.7989; GRUMET M, 1984, J CELL BIOL, V98, P1746, DOI 10.1083/jcb.98.5.1746; GRUMET M, 1988, J CELL BIOL, V106, P487, DOI 10.1083/jcb.106.2.487; GRUMET M, 1984, P NATL ACAD SCI-BIOL, V81, P267, DOI 10.1073/pnas.81.1.267; GUAN C, 1988, GENE, V67, P21; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; HAVLIN ML, 1991, GENOMICS, V11, P416; HONIG MG, 1986, J CELL BIOL, V103, P171, DOI 10.1083/jcb.103.1.171; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; KELLERMANN OK, 1982, METHOD ENZYMOL, V90, P459; KOBAYASHI M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P238, DOI 10.1016/0167-4781(91)90108-X; KUHN TB, 1991, J CELL BIOL, V115, P1113, DOI 10.1083/jcb.115.4.1113; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; LEMMON V, 1986, J NEUROSCI, V6, P2987; LETOURNEAU PC, 1989, DEVELOPMENT, V105, P505; LINDNER J, 1983, NATURE, V305, P427, DOI 10.1038/305427a0; LINDNER J, 1986, BRAIN RES, V377, P298, DOI 10.1016/0006-8993(86)90872-3; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MCGUIRE JC, 1978, CELL, V15, P357, DOI 10.1016/0092-8674(78)90004-1; MEGE RM, 1988, P NATL ACAD SCI USA, V85, P7274, DOI 10.1073/pnas.85.19.7274; MIRAGALL F, 1988, DEV BIOL, V129, P516, DOI 10.1016/0012-1606(88)90397-1; MIRSKY R, 1986, J NEUROCYTOL, V15, P799, DOI 10.1007/BF01625196; MIURA M, 1991, FEBS LETT, V289, P91, DOI 10.1016/0014-5793(91)80915-P; MIURA M, 1990, J NEUROCHEM, V55, P1180, DOI 10.1111/j.1471-4159.1990.tb03123.x; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NAGATA I, 1990, DEV BRAIN RES, V52, P63, DOI 10.1016/0165-3806(90)90222-K; NAKATSUJI N, 1989, DEVELOPMENT, V106, P441; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; PERSOHN E, 1987, J CELL BIOL, V105, P569, DOI 10.1083/jcb.105.1.569; PIGOTT R, 1986, DEV BRAIN RES, V29, P111, DOI 10.1016/0165-3806(86)90087-8; PRINCE JT, 1991, J NEUROSCI RES, V30, P567, DOI 10.1002/jnr.490300315; RATHJEN FG, 1984, EMBO J, V3, P461, DOI 10.1002/j.1460-2075.1984.tb01828.x; RATHJEN FG, 1984, EMBO J, V3, P1; RATHJEN FG, 1987, J CELL BIOL, V104, P343, DOI 10.1083/jcb.104.2.343; SADOUL R, 1989, J NEUROCHEM, V53, P1471, DOI 10.1111/j.1471-4159.1989.tb08540.x; SIDMAN RL, 1973, BRAIN RES, V62, P1, DOI 10.1016/0006-8993(73)90617-3; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; STALLCUP WB, 1983, J NEUROSCI, V3, P53; STALLCUP WB, 1985, BRAIN RES, V346, P287, DOI 10.1016/0006-8993(85)90862-5; SWEADNER KJ, 1983, J NEUROSCI, V3, P2504; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TANAKA H, 1991, NEURON, V7, P535, DOI 10.1016/0896-6273(91)90366-8; THOR G, 1987, EMBO J, V6, P2581, DOI 10.1002/j.1460-2075.1987.tb02548.x; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; ZUELLIG RA, 1991, SOC NEUR ABSTR, V17	65	119	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10752	10758						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587850				2022-12-25	WOS:A1992HV09000082
J	WOOD, ER; MCDONALD, OB; SAHYOUN, N				WOOD, ER; MCDONALD, OB; SAHYOUN, N			QUANTITATIVE-ANALYSIS OF SH2 DOMAIN BINDING - EVIDENCE FOR SPECIFICITY AND COMPETITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; GROWTH-FACTOR RECEPTORS; EGF RECEPTOR; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE-C; SIGNAL TRANSDUCTION; VIRAL ONCOGENE; PDGF RECEPTOR; PROTEIN; GAP	We report the development of a quantitative assay for measuring SH2 domain binding in vitro. Using this assay we have analyzed the binding of purified recombinant SH2 domains from ras GTPase activating protein (GAP) and the 85-kDa subunit of phosphatidylinositol 3-kinase (p85) to proteins from epidermal growth factor-stimulated and v-src-transformed cells. The purified recombinant SH2 domains from GAP and p85 bind to the tyrosine phosphorylated epidermal growth factor receptor with nanomolar affinities. Moreover, competition studies suggest that these two proteins bind to equivalent or overlapping sites on this receptor. In v-src-transformed cells the purified recombinant SH2 domains from GAP and p85 bind to distinct but overlapping sets of proteins.			WOOD, ER (corresponding author), BURROUGHS WELLCOME CO,DIV CELL BIOL,RES TRIANGLE PK,NC 27709, USA.							ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; HAIGLER H, 1978, P NATL ACAD SCI USA, V75, P3317, DOI 10.1073/pnas.75.7.3317; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P362; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LIU XQ, 1991, MOL CELL BIOL, V11, P2511, DOI 10.1128/MCB.11.5.2511; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; Sambrook J, 1989, MOL CLONING LABORATO; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH DB, 1986, P NATL ACAD SCI USA, V83, P8703, DOI 10.1073/pnas.83.22.8703; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SUGIMOTO Y, 1985, MOL CELL BIOL, V5, P3194, DOI 10.1128/MCB.5.11.3194; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P543; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; Warren L, 1974, Methods Enzymol, V31, P156; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YAMAMOTO K, 1992, J BIOL CHEM, V267, P11337	54	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14138	14144						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629214				2022-12-25	WOS:A1992JD32500056
J	SCHWENK, U; MORITA, E; ENGEL, R; SCHRODER, JM				SCHWENK, U; MORITA, E; ENGEL, R; SCHRODER, JM			IDENTIFICATION OF 5-OXO-15-HYDROXY-6,8,11,13-EICOSATETRAENOIC ACID AS A NOVEL AND POTENT HUMAN EOSINOPHIL CHEMOTACTIC EICOSANOID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL-ACTIVATING PEPTIDE; ARACHIDONIC-ACID; POLYMORPHONUCLEAR LEUKOCYTES; 15-LIPOXYGENASE PRODUCTS; SOYBEAN LIPOXYGENASE-1; LEUKOTRIENE FORMATION; DOUBLE DIOXYGENATION; PORCINE LEUKOCYTES; BIOSYNTHESIS; PATHWAY	Incubation of human eosinophils with arachidonic acid led to the formation of a novel and potent eosinophil chemotactic lipid (ECL) (Morita, E., Schroder, J.-M., and Christophers, E. (1990) J. Immunol. 144, 1893-1900). To test the working hypothesis of whether ECL could have been formed via eosinophil-arachidonic acid 15-lipoxygenase we investigated whether other arachidonic acid 15-lipoxygenases such as soybean lipoxygenase I catalyze formation of a similar ECL. In the presence of hemoproteins and soybean lipoxygenase I arachidonic acid is converted to an ECL, which has physicochemical properties similar to those found for the eosinophil-derived ECL. Purification of this ECL by high performance liquid chromatography revealed that ECL is structurally different from well known eosinophil chemotactic eicosanoids such as leukotriene B4, 5,15-(6E,8Z,11Z,13E)-dihydroxyeicosatetraenoic acid (5,15-diHETE), and (8S,15S)-(5Z,9E, 11Z,13E)-dihydroxyeicosatetraenoic acid ((8S,15S)-diHETE). UV spectra of this ECL with absorbance maxima at 230 and 278 nm revealed the presence of two independent chromophores such as a conjugated oxodiene and a conjugated diene. Catalytic hydrogenation of ECL methyl ester led to the formation of 5,15-dihydroxyarachidic acid methyl ester. Reduction of ECL with sodium borohydride produced a product which is identical with authentic (5S,15S)-(6E,8Z,11Z,13E)-diHETE. Formation of an ECL monomethoxime derivative supports the conclusion that this highly potent eosinophil chemotactic eicosanoid is structurally identical with 5-oxo-15-hydroxy-6,8,11,13-eicosatetraenoic acid.	UNIV KIEL,DEPT DERMATOL,SCHITTENHELMSTR 7,W-2300 KIEL 1,GERMANY; FORSCHUNGSINST BORSTEL,W-2061 BORSTEL,GERMANY	University of Kiel; Forschungszentrum Borstel			Schroeder, Jens M/B-3994-2009					BILD GS, 1977, BIOCHEM BIOPH RES CO, V74, P949, DOI 10.1016/0006-291X(77)91610-2; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; CREAMER HR, 1983, INFLAMMATION, V7, P321, DOI 10.1007/BF00916296; DELACLOS BF, 1988, BIOCHIM BIOPHYS ACTA, V958, P424, DOI 10.1016/0005-2760(88)90228-7; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; GLASGOW WC, 1986, J BIOL CHEM, V261, P200; LEVINE JD, 1986, P NATL ACAD SCI USA, V83, P5331, DOI 10.1073/pnas.83.14.5331; MAAS RL, 1981, P NATL ACAD SCI-BIOL, V78, P5523, DOI 10.1073/pnas.78.9.5523; MORITA E, 1990, J IMMUNOL, V144, P1893; NAGY L, 1982, CLIN EXP IMMUNOL, V47, P541; RADMARK O, 1984, BIOCHIM BIOPHYS ACTA, V792, P324, DOI 10.1016/0005-2760(84)90200-5; RYHAGE R, 1960, ARK KEMI, V15, P545; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCHRODER JM, 1989, J EXP MED, V170, P847, DOI 10.1084/jem.170.3.847; SCHRODER JM, 1987, J IMMUNOL, V139, P3474; SEHMI R, 1991, J IMMUNOL, V147, P2276; SHAK S, 1983, J BIOL CHEM, V258, P4948; SOK DE, 1983, BIOCHEM BIOPH RES CO, V110, P273, DOI 10.1016/0006-291X(83)91291-3; TAO CNR, 1975, ULTRAVIOLET VISIBLE, P42; TURK J, 1982, J BIOL CHEM, V257, P7068; VANDERHOEK JY, 1985, J BIOL CHEM, V260, P5482; VANOS CPA, 1981, BIOCHIM BIOPHYS ACTA, V663, P177, DOI 10.1016/0005-2760(81)90204-6; VIOQUE E, 1962, ARCH BIOCHEM BIOPHYS, V99, P522, DOI 10.1016/0003-9861(62)90301-6	23	85	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12482	12488						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618754				2022-12-25	WOS:A1992HZ48300019
J	TAKAHASHI, T; SUCHI, M; DESNICK, RJ; TAKADA, G; SCHUCHMAN, EH				TAKAHASHI, T; SUCHI, M; DESNICK, RJ; TAKADA, G; SCHUCHMAN, EH			IDENTIFICATION AND EXPRESSION OF 5 MUTATIONS IN THE HUMAN ACID SPHINGOMYELINASE GENE CAUSING TYPE-A AND TYPE-B NIEMANN-PICK DISEASE - MOLECULAR EVIDENCE FOR GENETIC-HETEROGENEITY IN THE NEURONOPATHIC AND NON-NEURONOPATHIC FORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-GALACTOSIDASE; OVERLAP EXTENSION; POLYMERASE; DIAGNOSIS; SPLEEN; DNA	The deficient activity of the human lysosomal hydrolase, acid sphingomyelinase (ASM, EC 3.1.4.12), results in the neuronopathic (Type A) and non-neuronopathic (Type B) forms of Niemann-Pick disease (NPD). To investigate the genetic basis of the phenotypic heterogeneity in NPD, the molecular lesions in the ASM gene were determined from three unrelated NPD patients and evaluated by transient expression in COS-1 cells. A Type A NPD patient of Asian Indian ancestry (proband 1) was homoallelic for a T to A transversion in exon 2 of the ASM gene which predicted a premature stop at codon 261 of the ASM polypeptide (designated L261X). In contrast, an unrelated Type A patient of European ancestry (proband 2) was heteroallelic for a two-base (TT) deletion in exon 2 which caused a frame-shift mutation at ASM codon 178 (designated fsL178), leading to a premature stop at codon 190, and a G to A transition in exon 3 which caused a methionine to isoleucine substitution at codon 382 (designated M382I). Transient expression of the fsL178, L261X, and M382I mutations in COS-1 cells demonstrated that these lesions did not produce catalytically active ASM, consistent with the severe neuronopathic Type A NPD phenotype. In contrast, an unrelated Type B patient of European descent (proband 3) was heteroallelic for two missense mutations, a G to A transition in exon 2 which predicted a glycine to arginine substitution at ASM codon 242 (designated G242R), and an A to G transition in exon 3 which resulted in an asparagine to serine substitution at codon 383 (designated N383S). Interestingly, the G242R allele produced ASM activity in COS-1 cells at levels about 40% of that expressed by the normal allele, thereby explaining the mild Type B phenotype of proband 3 and the high residual activity (i.e. approximately 15% of normal) in cultured lymphoblasts. In contrast, the N383S allele did not produce catalytically active enzyme. None of these five ASM mutations was detected in over 60 other unrelated NPD patients analyzed, nor were these mutations found in over 100 normal ASM alleles. Thus, small deletions or nonsense mutations which trunctated the ASM polypeptide, or missense mutations that rendered the enzyme noncatalytic, resulted in Type A NPD disease, whereas a missense mutation that produced a defective enzyme with residual catalytic activity caused the milder non-neuronopathic Type B phenotype. These findings have facilitated genotype/phenotype correlations for this lysosomal storage disease and provided insights into the functional organization of the ASM polypeptide.	CUNY MT SINAI SCH MED,DIV MED & MOLEC GENET,100TH ST & 5TH AVE,NEW YORK,NY 10029; AKITA UNIV,SCH MED,DEPT PEDIAT,AKITA 010,JAPAN	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Akita University					NCRR NIH HHS [5 MO1 RR0071] Funding Source: Medline; NICHD NIH HHS [1 RO1 HD28607] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028607] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BERNSTEIN HS, 1989, J CLIN INVEST, V83, P1390, DOI 10.1172/JCI114027; BISHOP DF, 1981, J BIOL CHEM, V256, P1307; BRADY RO, 1966, P NATL ACAD SCI USA, V55, P366, DOI 10.1073/pnas.55.2.366; CHAN WC, 1977, J PATHOL, V121, P177, DOI 10.1002/path.1711210308; CHEN C, 1987, MOL CELL BIOL, V7, P2747; COULONDRE C, 1978, NATURE, V274, P775, DOI 10.1038/274775a0; DAWSON PJ, 1982, HUM PATHOL, V13, P1115, DOI 10.1016/S0046-8177(82)80249-9; FERLINZ K, 1991, BIOCHEM BIOPH RES CO, V179, P1187, DOI 10.1016/0006-291X(91)91697-B; FREDRICKSON DONALD S., 1966, P586; GAL AE, 1975, NEW ENGL J MED, V293, P632, DOI 10.1056/NEJM197509252931304; Gatt S, 1981, Methods Enzymol, V72, P351; GATT S, 1980, CLIN CHEM, V26, P93; GOODMAN RM, 1979, GENETIC DISORDERS JE, P96; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; ITAKURA K, 1984, ANNU REV BIOCHEM, V53, P323; JOBB E, 1987, J INHERIT METAB DIS, V10, P326, DOI 10.1007/BF01811441; KAUFMAN RJ, 1982, MOL CELL BIOL, V2, P1304, DOI 10.1128/MCB.2.11.1304; KLAR R, 1988, CLIN CHIM ACTA, V176, P259, DOI 10.1016/0009-8981(88)90185-4; LEVADE T, 1986, PEDIATR RES, V19, P153; LEVRAN O, 1991, P NATL ACAD SCI USA, V88, P3748, DOI 10.1073/pnas.88.9.3748; LEVRAN O, 1991, J CLIN INVEST, V88, P806, DOI 10.1172/JCI115380; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; QUINTERN LE, 1989, EMBO J, V8, P2469, DOI 10.1002/j.1460-2075.1989.tb08382.x; ROUSSON R, 1986, ENZYMES LIPID METABO, V2, P273; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER PB, 1967, J LIPID RES, V8, P202; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; SCHUCHMAN EH, 1991, NUCLEIC ACIDS RES, V19, P3160, DOI 10.1093/nar/19.11.3160; SOGAWA H, 1978, EUR J PEDIATR, V128, P235, DOI 10.1007/BF00445608; SPENCE MW, 1989, METABOLIC BASIS INHE, P1655; TAKAHASHI T, 1992, IN PRESS HUM MUT; VANIER MT, 1985, CLIN GENET, V27, P20	35	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12552	12558						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618760				2022-12-25	WOS:A1992HZ48300029
J	KALINSKI, A; MELROY, DL; DWIVEDI, RS; HERMAN, EM				KALINSKI, A; MELROY, DL; DWIVEDI, RS; HERMAN, EM			A SOYBEAN VACUOLAR PROTEIN (P34) RELATED TO THIOL PROTEASES IS SYNTHESIZED AS A GLYCOPROTEIN PRECURSOR DURING SEED MATURATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIGNA-MUNGO SEEDS; REGULATED CYSTEINE PROTEINASE; BARLEY ALEURONE LAYERS; RAT CATHEPSIN-L; DICTYOSTELIUM-DISCOIDEUM; CONCANAVALIN-A; OIL-BODIES; SULFHYDRYL-ENDOPEPTIDASE; VICILIN PEPTIDOHYDROLASE; GLYCOSYLATED PRECURSOR	We have examined the synthesis, posttranslational processing, and localization of soybean P34, a member of the papain superfamily. P34 has been identified as a constituent of oil storage organelles or oil bodies isolated from seed lysates and has been assumed to be one of the oil body proteins. Electron microscopic immunocytochemistry with a monoclonal antibody demonstrated that P34 is localized in the protein storage vacuoles but not in the oil bodies. Immunocytochemical observations of partially disrupted seed cells showed that the association of P34 with oil bodies appears to occur as a consequence of cell lysis. In vitro synthesis of P34 results in the formation of a 46-kDa polypeptide that increases to 47 kDa due to core glycosylation by canine microsomes. In vivo synthesis studies in the presence and absence of tunicamycin, an inhibitor of N-linked glycosylation, indicate that pro-P34 is 47 kDa. Since the cDNA sequence of prepro-P34 contains a single putative glycosylation site in the precursor domain, we conclude that P34, like a few other vacuolar proteins, is synthesized as a glycoprotein precursor. Pulse-chase experiments showed that the processing of pro-P34 to mature P34 occurs in a single step and that this posttranslational cleavage occurs on the carboxyl side of an Asn, which is typical of seed vacuolar proteins. Pro-P34 (47 kDa) is detected in immunoblots of maturing seeds. Analysis of RNA indicates that the P34 genes are expressed only during seed maturation and that the P34 mRNA is related to other thiol protease mRNAs detectable in other organs and plants. Unlike other seed thiol proteases that are synthesized only after seed germination, P34 accumulates during seed maturation.	USDA ARS,BELTSVILLE AGR RES CTR,PLANT MOLEC BIOL LAB,BELTSVILLE,MD 20705; HOWARD UNIV,DEPT BOT,WASHINGTON,DC 20059	United States Department of Agriculture (USDA); Howard University								AKASOFU H, 1989, NUCLEIC ACIDS RES, V17, P6733, DOI 10.1093/nar/17.16.6733; BAUMGARTNER B, 1978, J CELL BIOL, V79, P10, DOI 10.1083/jcb.79.1.10; BAUMGARTNER B, 1977, EUR J BIOCHEM, V77, P223, DOI 10.1111/j.1432-1033.1977.tb11661.x; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; BOWLES DJ, 1986, J CELL BIOL, V102, P1284, DOI 10.1083/jcb.102.4.1284; CHAN SJ, 1986, P NATL ACAD SCI USA, V83, P7721, DOI 10.1073/pnas.83.20.7721; COHEN LW, 1986, GENE, V48, P219, DOI 10.1016/0378-1119(86)90080-6; DATTA S, 1987, MOL CELL BIOL, V7, P149, DOI 10.1128/MCB.7.1.149; DIETRICH RA, 1989, PLANT CELL, V1, P73, DOI 10.1105/tpc.1.1.73; ERICKSON AH, 1989, J CELL BIOCHEM, V40, P31, DOI 10.1002/jcb.240400104; FAYE L, 1987, PLANTA, V170, P217, DOI 10.1007/BF00397891; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GUERRERO FD, 1990, PLANT MOL BIOL, V15, P11, DOI 10.1007/BF00017720; HERMAN EM, 1990, PLANT PHYSIOL, V94, P341, DOI 10.1104/pp.94.1.341; HERMAN EM, 1987, PLANTA, V172, P336, DOI 10.1007/BF00398662; HERMAN EM, 1985, PLANT PHYSIOL, V77, P886, DOI 10.1104/pp.77.4.886; HERMAN EM, 1985, PLANTA, V165, P23, DOI 10.1007/BF00392207; HERMAN EM, 1988, ANNU REV PLANT PHYS, V39, P139, DOI 10.1146/annurev.arplant.39.1.139; HERMAN EM, 1992, IN PRESS ADV STRUCTU; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HOLWERDA BC, 1990, PLANT CELL, V2, P1091, DOI 10.1105/tpc.2.11.1091; ISHIDOH K, 1987, FEBS LETT, V223, P69, DOI 10.1016/0014-5793(87)80511-2; ISHIDOH K, 1989, FEBS LETT, V259, P71, DOI 10.1016/0014-5793(89)81497-8; KALINSKI A, 1990, J BIOL CHEM, V265, P13843; KALINSKI A, 1991, PLANT MOL BIOL, V17, P1095, DOI 10.1007/BF00037150; KOEHLER S, 1988, PLANT PHYSIOL, V87, P95, DOI 10.1104/pp.87.1.95; KOEHLER SM, 1990, PLANT CELL, V2, P769, DOI 10.1105/tpc.2.8.769; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MANSFIELD MA, 1988, PLANTA, V173, P482, DOI 10.1007/BF00958961; MITSUHASHI W, 1986, PLANT PHYSIOL, V80, P628, DOI 10.1104/pp.80.3.628; MITSUHASHI W, 1989, PLANT PHYSIOL, V89, P274, DOI 10.1104/pp.89.1.274; MURPHY DJ, 1989, PHYTOCHEMISTRY, V28, P2063, DOI 10.1016/S0031-9422(00)97921-4; NORTH MJ, 1986, BIOCHEM J, V238, P623, DOI 10.1042/bj2380623; PAPASTOITSIS G, 1991, PLANT PHYSIOL, V96, P1086, DOI 10.1104/pp.96.4.1086; PEARS CJ, 1985, NUCLEIC ACIDS RES, V13, P8853, DOI 10.1093/nar/13.24.8853; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PODIVINSKY E, 1989, NUCLEIC ACIDS RES, V17, P8363, DOI 10.1093/nar/17.20.8363; PREAKELT UA, 1988, PLANT MOL BIOL, V10, P193; ROGERS JC, 1985, P NATL ACAD SCI USA, V82, P6512, DOI 10.1073/pnas.82.19.6512; Sambrook J, 1989, MOL CLONING LABORATO; SCHAFFER MA, 1988, PLANT PHYSIOL, V87, P431, DOI 10.1104/pp.87.2.431; SCOTT MP, 1992, P NATL ACAD SCI USA, V89, P658, DOI 10.1073/pnas.89.2.658; SHINSHI H, 1988, P NATL ACAD SCI USA, V85, P5541, DOI 10.1073/pnas.85.15.5541; TAHIO K, 1983, P NATL ACAD SCI USA, V80, P3666; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; TZEN JTC, 1990, PLANT PHYSIOL, V94, P1282, DOI 10.1104/pp.94.3.1282; VERNET T, 1990, J BIOL CHEM, V265, P16661; WATANABE H, 1991, J BIOL CHEM, V266, P16897; WILLIAMS JG, 1985, EMBO J, V4, P999, DOI 10.1002/j.1460-2075.1985.tb03730.x; WILSON KA, 1988, PLANT PHYSIOL, V88, P355, DOI 10.1104/pp.88.2.355	52	95	104	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12068	12076						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601876				2022-12-25	WOS:A1992HY94700065
J	GAUGITSCH, HW; PRIESCHL, EE; KALTHOFF, F; HUBER, NE; BAUMRUKER, T				GAUGITSCH, HW; PRIESCHL, EE; KALTHOFF, F; HUBER, NE; BAUMRUKER, T			A NOVEL TRANSIENTLY EXPRESSED, INTEGRAL MEMBRANE-PROTEIN LINKED TO CELL ACTIVATION - MOLECULAR-CLONING VIA THE RAPID DEGRADATION SIGNAL AUUUA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN T-CELLS; MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; GROWTH-FACTOR; HUMAN INTERLEUKIN; GM-CSF; MITOGENIC ACTIVATION; COMPLEMENTARY-DNA; GENETIC RESPONSE; CDNA	A novel cDNA clone termed E16 which codes for an integral membrane protein of 241 amino acids with six transmembrane domains was isolated from peripheral blood lymphocytes. The cDNA clone is 4000 base pairs in length and exhibits an unusually long 3'-untranslated region of about 3000 nucleotides. Its expression at the mRNA level is closely linked to cellular activation and division. In all myeloid and lymphoid cells, as well as in primary lymphocytes from peripheral blood, E16 transcripts are rapidly induced and rapidly degraded after stimulation. This pattern of expression is unusual for an integral membrane protein and resembles more closely the kinetic seen for protooncogenes and lymphokines in the T cell system. Its isolation was made possible by a novel approach especially designed to selectively clone cDNAs which exhibit such an expression kinetic. It is based on a combination of the differential screening of a subtracted cDNA library and the subsequent hybridization of the resulting phages to a short oligonucleotide (5'-TAAATAAA-TAAATA-3'). This oligonucleotide is complementary to a trimer of the rapid degradation signal (AUUUA) which is present as a single or reiterated motif in the 3'-untranslated region of many short-lived transcripts.	SANDOZ GMBH,DEPT IMMUNOPHARMACOL,BRUNNERSTR 59,A-1235 VIENNA,AUSTRIA	Novartis; Sandoz								ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BETZ H, 1990, BIOCHEMISTRY-US, V29, P3591, DOI 10.1021/bi00467a001; CAMPBELL HD, 1987, P NATL ACAD SCI USA, V84, P6629, DOI 10.1073/pnas.84.19.6629; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GAUGITSCH HW, 1991, EUR J IMMUNOL, V21, P377, DOI 10.1002/eji.1830210219; GOEDDEL DV, 1981, NATURE, V290, P20, DOI 10.1038/290020a0; GOODWIN RG, 1989, P NATL ACAD SCI USA, V86, P302, DOI 10.1073/pnas.86.1.302; GRAY PW, 1982, NATURE, V295, P503, DOI 10.1038/295503a0; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; KALTHOFF FS, 1991, IMMUNOL LETT, V27, P141, DOI 10.1016/0165-2478(91)90142-W; KOWALSKI J, 1989, MOL CELL BIOL, V9, P1946, DOI 10.1128/MCB.9.5.1946; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEBEAU MM, 1986, COLD SPRING HARB SYM, V51, P899, DOI 10.1101/SQB.1986.051.01.103; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MCCORMACK K, 1989, NATURE, V340, P103, DOI 10.1038/340103a0; MINNA JD, 1986, COLD SPRING HARB SYM, V51, P843, DOI 10.1101/SQB.1986.051.01.098; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; MOREAU JF, 1988, NATURE, V336, P690, DOI 10.1038/336690a0; NAGATA S, 1986, NATURE, V319, P415, DOI 10.1038/319415a0; NEDWIN GE, 1985, NUCLEIC ACIDS RES, V13, P6361, DOI 10.1093/nar/13.17.6361; OTSUKA T, 1988, J IMMUNOL, V140, P2288; RATNER L, 1985, NUCLEIC ACIDS RES, V13, P5007, DOI 10.1093/nar/13.14.5007; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; Sambrook J, 1989, MOL CLONING LABORATO; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TANIGUCHI T, 1983, NATURE, V302, P305, DOI 10.1038/302305a0; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WHITE MK, 1989, NATURE, V340, P103, DOI 10.1038/340103b0; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; YOKOTA T, 1986, P NATL ACAD SCI USA, V83, P5894, DOI 10.1073/pnas.83.16.5894; ZIPFEL PF, 1989, J IMMUNOL, V142, P1582; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1041, DOI 10.1128/MCB.9.3.1041	41	61	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11267	11273						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597461				2022-12-25	WOS:A1992HX16900054
J	RATAJCZAK, T; WILLIAMS, PM; DILORENZO, D; RINGOLD, GM				RATAJCZAK, T; WILLIAMS, PM; DILORENZO, D; RINGOLD, GM			MULTIPLE ELEMENTS WITHIN THE GLUCOCORTICOID REGULATORY UNIT OF THE RAT ALPHA-1-ACID GLYCOPROTEIN GENE ARE RECOGNITION SITES FOR C/EBP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING-PROTEIN; ACUTE-PHASE RESPONSE; ENRICHED TRANSCRIPTIONAL ACTIVATOR; HEPATOCYTE-STIMULATING FACTOR; STEROID-HORMONE RECEPTORS; COLI RNA-POLYMERASE; DNA-BINDING; POLYACRYLAMIDE GELS; LEUCINE ZIPPER; EXPRESSION	Sequences between -106 and -42, located immediately downstream of the glucocorticoid response element, are essential for efficient glucocorticoid-stimulated expression of the alpha-1-acid glycoprotein (AGP) gene. We have used mobility shift assays with oligonucleotides bearing wild type and mutated sequences from segmented portions of this region to characterize the specific interaction of similar binding factors from rat liver and HTC rat hepatoma cell nuclear extracts. One of these factors, AGP nuclear factor 2 (ANF-2), appears capable of dual interaction with the homologous recognition sites, HA (-133 to -104) and HB (-81 to -72), which overlap and are located downstream of the glucocorticoid response element, respectively. Using an affinity matrix containing the HB sequence we have isolated ANF-2 from rat liver nuclear extracts. On the basis of immunological evidence rat liver ANF-2 was confirmed to be highly related and probably identical to CCAAT/enhancer-binding protein (C/EBP). Methylation protection analyses with partially purified, rat liver ANF-2 confirmed HA and HB as recognition sites for C/EBP-related factors and are consistent with the location of a third interaction site for these transactivating proteins at HX (-102 to -93). We propose that the sequences HA, HX, and HB, spanning residues -113 to -72 of the AGP promoter, might serve as recognition sites for a family of C/EBP-like nuclear factors that coordinate the glucocorticoid-mediated induction of the AGP gene.	SYNTEX INC,INST CANC & DEV BIOL,PALO ALTO,CA 94304	Syntex Corporation					NIGMS NIH HHS [GM25821] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025821] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDISON WR, 1986, MOL CELL BIOL, V6, P2334, DOI 10.1128/MCB.6.7.2334; AKURA S, 1990, EMBO J, V9, P1897; BAUMANN H, 1981, J BIOL CHEM, V256, P145; BAUMANN H, 1987, J IMMUNOL, V139, P4122; BAUMANN H, 1983, J BIOL CHEM, V258, P563; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BAUMANN H, 1986, MOL CELL BIOL, V6, P2551, DOI 10.1128/MCB.6.7.2551; BENNETT M, 1980, P NATL ACAD SCI-BIOL, V77, P6109, DOI 10.1073/pnas.77.10.6109; BETHELL GS, 1981, J CHROMATOGR, V219, P361; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BRASIER AR, 1990, MOL ENDOCRINOL, V4, P1921, DOI 10.1210/mend-4-12-1921; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; DANESCH U, 1987, EMBO J, V6, P625, DOI 10.1002/j.1460-2075.1987.tb04800.x; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DILORENZO D, 1991, BIOCHEM BIOPH RES CO, V176, P1326, DOI 10.1016/0006-291X(91)90431-6; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KLEIN ES, 1987, J BIOL CHEM, V262, P520; KLEIN ES, 1988, MOL ENDOCRINOL, V2, P1343, DOI 10.1210/mend-2-12-1343; KULKARNI AB, 1985, J BIOL CHEM, V260, P5386; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MORTENSEN RF, 1988, J IMMUNOL, V140, P2260; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; PROWSE KR, 1988, MOL CELL BIOL, V8, P42, DOI 10.1128/MCB.8.1.42; REINKE R, 1985, J BIOL CHEM, V260, P4397; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUSS M, 1990, P NATL ACAD SCI USA, V87, P7180, DOI 10.1073/pnas.87.18.7180; VANNICE JL, 1983, DNA-J MOLEC CELL BIO, V2, P205, DOI 10.1089/dna.1983.2.205; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WILLIAMS PM, 1991, MOL CELL BIOL, V11, P4959, DOI 10.1128/MCB.11.10.4959	45	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11111	11119						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597449				2022-12-25	WOS:A1992HX16900030
J	LARSEN, JL				LARSEN, JL			HUMAN GROWTH-HORMONE ENHANCES PERTUSSIS TOXIN-STIMULATED ADP-RIBOSYLATION OF GI IN NB2 CELL-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; LYMPHOMA-CELLS; PROLACTIN RECEPTOR; COMPLEMENTARY-DNA; ADENYLYL CYCLASE; CHOLERA-TOXIN; IDENTIFICATION; SUBUNITS; MITOGENESIS; EXPRESSION	he Nb2 node lymphoma cell line has been widely used as a model for investigating lactogen cellular actions. Both pertussis (PTX) and cholera (CTX) toxins modulate lactogen-stimulated Nb2 cell mitogenesis, suggesting G protein involvement in lactogen signal transduction. The following studies were performed to further investigate this possibility. Both PTX-sensitive (41 kDa) and CTX-sensitive substrates (42 and 45 kDa) were identified in Nb2 cell membrane and recognized by specific anti-G(i) and anti-G(s) antibodies, respectively. Equal numbers of Nb2 cells were then incubated with the lactogen human growth hormone (hGH, 10 ng/ml) for 0-72 h. Membrane protein prepared from each time point (50-mu-g) was compared in toxin-stimulated ADP-ribosylation studies. CTX-stimulated ADP-ribosylation was unaffected by prior hGH incubation. PTX-stimulated ADP-ribosylation increased 237 +/- 69% (X +/- S.E.) compared with 0-h controls (n = 11; p < 0.01) after 4-7 h of hGH incubation then decreased toward 0-h samples by 24 and 72 h. No change in G(i-alpha). concentration was observed, but beta-subunit concentration increased (145 +/- 14% at 7 h; p < 0.01; n = 3) in a time course that paralleled the changes in PTX-stimulated ADP-ribosylation. In summary, 1) both G(i) and G(s) were present in Nb2 cell membrane, 2) incubation of cells with a lactogen, hGH, for 4-7 h markedly enhanced PTX-stimulated ADP-ribosylation of G(i-alpha) in vitro, whereas CTX-stimulated ADP-ribosylation of G(s-alpha) was unchanged, and 3) although no change in G(i-alpha) concentration was observed, beta-subunit concentration increased in parallel with the increase in PTX-stimulated ADP-ribosylation of G(i-alpha). These results suggest that hGH may modify PTX-stimulated ADP-ribosylation of G(i) not by changing G(i-alpha) concentration, perhaps by increasing beta-subunit concentration, enhancing association of G(i-alpha) by beta-gamma-subunits, which, in turn, is preferentially ADP-ribosylated. This may represent a late signal transduction event and may also have implications for other effectors dependent on G(i)-mediated events.			LARSEN, JL (corresponding author), UNIV NEBRASKA,MED CTR,DEPT INTERNAL MED,42ND & DEWEY,OMAHA,NE 68198, USA.				PHS HHS [REN 5 R29 DL40752-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARKEY RJ, 1988, BIOCHEM BIOPH RES CO, V156, P776, DOI 10.1016/S0006-291X(88)80911-2; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; CORDA D, 1987, EUR J BIOCHEM, V166, P475, DOI 10.1111/j.1432-1033.1987.tb13540.x; EDERY M, 1989, P NATL ACAD SCI USA, V86, P2112, DOI 10.1073/pnas.86.6.2112; ELSHOLTZ HP, 1986, BIOCHEM CELL BIOL, V64, P381, DOI 10.1139/o86-053; FLEMING WH, 1985, ENDOCRINOLOGY, V117, P2547, DOI 10.1210/endo-117-6-2547; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDSMITH P, 1988, J BIOL CHEM, V263, P6476; KLAINER LM, 1962, J BIOL CHEM, V237, P1239; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN JL, 1988, ENDOCRINOLOGY, V123, P438, DOI 10.1210/endo-123-1-438; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLIGAN G, 1988, BIOCHEM J, V252, P369, DOI 10.1042/bj2520369; MOSS J, 1983, J BIOL CHEM, V258, P1879; MUMBY S, 1988, J BIOL CHEM, V263, P2020; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NOBLE RL, 1980, CANCER RES, V40, P2437; REPIEJKO PJ, 1989, J BIOL CHEM, V264, P16183; RICH KA, 1984, J BIOL CHEM, V259, P7893; ROTHENBERG PL, 1988, J BIOL CHEM, V263, P15546; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; SHIU RPC, 1983, ENDOCRINOLOGY, V113, P159, DOI 10.1210/endo-113-1-159; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; TANAKA T, 1980, J CLIN ENDOCR METAB, V51, P1058, DOI 10.1210/jcem-51-5-1058; TOO CKL, 1989, ENDOCRINOLOGY, V124, P2185, DOI 10.1210/endo-124-5-2185; TOO CKL, 1990, BIOCHEM BIOPH RES CO, V173, P48, DOI 10.1016/S0006-291X(05)81019-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATKINS DC, 1989, J BIOL CHEM, V264, P4186	31	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10583	10587						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587839				2022-12-25	WOS:A1992HV09000056
J	RUAN, ZS; ANANTHARAM, V; CRAWFORD, IT; AMBUDKAR, SV; RHEE, SY; ALLISON, MJ; MALONEY, PC				RUAN, ZS; ANANTHARAM, V; CRAWFORD, IT; AMBUDKAR, SV; RHEE, SY; ALLISON, MJ; MALONEY, PC			IDENTIFICATION, PURIFICATION, AND RECONSTITUTION OF OXLT, THE OXALATE - FORMATE ANTIPORT PROTEIN OF OXALOBACTER-FORMIGENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; TRANSPORT-SYSTEM; DNA-SEQUENCE; CARRIER PROTEIN; DILUTE-SOLUTION; PROTON SYMPORT; GENE; MEMBRANE	We had proposed earlier that the anaerobe Oxalobacter formigenes sustains a proton-motive force by exploiting a secondary carrier rather than a primary proton pump. In this view, a carrier protein would catalyze the exchange of extracellular oxalate, a divalent anion, and intracellular formate, the monovalent product of oxalate decarboxylation. Such an electrogenic exchange develops an internally negative membrane potential, and since the decarboxylation reaction consumes an internal proton, the combined activity of the carrier and the soluble decarboxylase would constitute an "indirect" proton pump with a stoichiometry of 1H+ per turnover. This model is now verified by identification and purification of OxlT, the protein responsible for the anion exchange reaction. Membranes of O. formigenes were solubilized at pH 7 with 1.25% octyl glucoside in 20 mm 3-(N-morpholino)propanesulfonic acid/K, in the presence of 0.4% Escherichia coli phospholipids and with 20% glycerol present as the osmolyte stabilant. Rapid methods for reconstitution were developed to monitor the distribution of OxlT during biochemical fractionation, allowing its purification by sequential anion and cation exchange chromatography. OxlT proved to be a single hydrophobic polypeptide, of 38 kDa mobility during sodium dodecyl sulfate-polyacrylamide gel electrophoresis, with a turnover number estimated as at least 1000/s. The properties of OxlT point to an indirect proton pump as the mechanism by which a proton-motive force arises in O. formigenes, and one may reasonably argue that indirect proton pumps take part in bacterial events such as acetogenesis, malolactate fermentation, and perhaps methanogenesis.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV NEPHROL,BALTIMORE,MD 21205; USDA ARS,NATL ANIM DIS CTR,AMES,IA 50010	Johns Hopkins University; United States Department of Agriculture (USDA)	RUAN, ZS (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205, USA.		Ambudkar, Suresh V/L-1317-2016; Ambudkar, Suresh V/B-5964-2008		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024195, R56GM024195] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24195] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON MJ, 1985, ARCH MICROBIOL, V141, P1, DOI 10.1007/BF00446731; AMBUDKAR SV, 1990, J BIOL CHEM, V265, P12287; AMBUDKAR SV, 1986, J BIOL CHEM, V261, P79; ANANTHARAM V, 1989, J BIOL CHEM, V264, P7244; BAETZ AL, 1989, J BACTERIOL, V171, P2605, DOI 10.1128/jb.171.5.2605-2608.1989; BERG HC, 1983, RANDOM WALKS BIOL, P17; BISACCIA F, 1988, BIOCHIM BIOPHYS ACTA, V933, P229, DOI 10.1016/0005-2728(88)90030-8; Bjerrum OJ, 1986, ANAL ELECTROPHORESIS, P315; BUCHEL DE, 1980, NATURE, V283, P541, DOI 10.1038/283541a0; COOK NJ, 1988, J BIOL CHEM, V263, P11382; COSTELLO MJ, 1987, J BIOL CHEM, V262, P17072; COX DJ, 1989, J BACTERIOL, V171, P5750, DOI 10.1128/jb.171.10.5750-5752.1989; DAVIS EO, 1987, J BIOL CHEM, V262, P13928; ECKERT B, 1989, J BIOL CHEM, V264, P11663; EIGLMEIER K, 1987, MOL MICROBIOL, V1, P251, DOI 10.1111/j.1365-2958.1987.tb01931.x; FLUGGE UI, 1981, BIOCHIM BIOPHYS ACTA, V638, P296, DOI 10.1016/0005-2728(81)90240-1; GOLDRICK D, 1988, J BACTERIOL, V170, P3421, DOI 10.1128/jb.170.8.3421-3426.1988; HANADA K, 1988, J BIOL CHEM, V263, P7181; JANSSEN PH, 1990, J GEN MICROBIOL, V136, P1037, DOI 10.1099/00221287-136-6-1037; JONES WJ, 1987, MICROBIOL REV, V51, P135, DOI 10.1128/MMBR.51.1.135-177.1987; KAPLAN RS, 1986, J BIOL CHEM, V261, P2767; KARPEL R, 1988, J BIOL CHEM, V263, P10408; KRAMER R, 1989, BIOCHIM BIOPHYS ACTA, V974, P1, DOI 10.1016/S0005-2728(89)80160-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGE AJ, 1986, J BIOL CHEM, V261, P101; LUKACOVIC MF, 1981, BIOCHEMISTRY-US, V20, P3145, DOI 10.1021/bi00514a025; MAIDEN MCJ, 1988, J BIOL CHEM, V263, P8003; MALONEY PC, 1989, ARCH BIOCHEM BIOPHYS, V269, P1, DOI 10.1016/0003-9861(89)90080-5; MALONEY PC, 1992, J BIOL CHEM, V267, P10531; MALONEY PC, 1987, ESCHERICHIA COLI SAL, P222; MERRIL CR, 1984, METHOD ENZYMOL, V104, P441; NAKAO T, 1987, MOL GEN GENET, V208, P70, DOI 10.1007/BF00330424; OLSEN EB, 1991, J BACTERIOL, V173, P6199, DOI 10.1128/jb.173.19.6199-6206.1991; PEERCE BE, 1990, J BIOL CHEM, V265, P1731; QUAYLE JR, 1961, BIOCHEM J, V78, P225, DOI 10.1042/bj0780225; SASATSU M, 1985, J BACTERIOL, V164, P983, DOI 10.1128/JB.164.3.983-993.1985; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHEURING U, 1986, J MEMBRANE BIOL, V90, P123, DOI 10.1007/BF01869930; Smith B J, 1984, Methods Mol Biol, V1, P41, DOI 10.1385/0-89603-062-8:41; STERNBACH Y, 1990, J BIOL CHEM, V265, P3961; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; VIITANEN P, 1984, P NATL ACAD SCI-BIOL, V81, P1629, DOI 10.1073/pnas.81.6.1629; Walsh C., 1979, ENZYMATIC REACTION M, P24; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WESTON LA, 1987, J BACTERIOL, V169, P3546, DOI 10.1128/jb.169.8.3546-3555.1987; WHEELER TJ, 1985, ANNU REV PHYSIOL, V47, P503, DOI 10.1146/annurev.ph.47.030185.002443; WOHLRAB H, 1984, BIOCHEMISTRY-US, V23, P1057, DOI 10.1021/bi00301a004; YAZYU H, 1984, J BIOL CHEM, V259, P4320	48	83	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10537	10543						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587834				2022-12-25	WOS:A1992HV09000050
J	DESNOYERS, L; MANJUNATH, P				DESNOYERS, L; MANJUNATH, P			MAJOR PROTEINS OF BOVINE SEMINAL PLASMA EXHIBIT NOVEL INTERACTIONS WITH PHOSPHOLIPID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; MANNOSE 6-PHOSPHATE RECEPTOR; PLATELET-ACTIVATING-FACTOR; LIPID TRANSFER PROTEINS; APOLIPOPROTEIN-A-I; HUMAN FACTOR-VIII; BINDING-PROTEINS; POLYACRYLAMIDE GELS; SPERM CAPACITATION; GENOMIC STRUCTURE	A group of similar proteins, namely BSP-A1, BSP-A2, BSP-A3, and BSP-30-kDa (collectively called BSP proteins), are the major proteins found in bovine seminal fluid. These proteins are secretory products of seminal vesicles, and they bind to spermatozoa upon ejaculation, suggesting that there are binding sites for these proteins on the spermatozoa. It was of interest to characterize these binding sites on spermatozoa which may help in the elucidation of the biological function of BSP proteins. The binding sites on spermatozoa are resistant to protease or acid treatment and are heat-stable but extractable with organic solvents. The solvent-extractable material, when coated on plastic microtitration wells, binds radiolabeled BSP proteins thus indicating the lipid nature of the BSP binding sites on spermatozoa. We investigated the specificity of interaction of BSP proteins with lipids using liposomes of phospholipids, solid-phase, and thin-layer chromatography-overlay techniques. Results showed that BSP-A1, -A2, and -A3 proteins bound specifically to those phospholipids which contain the phosphorylcholine group. In contrast, BSP-30-kDa protein preferentially bound to phospholipids containing the phosphorylcholine moiety but also interacted with phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, and cardiolipin. Furthermore, of those lipids that were extracted from spermatozoa, only phospholipids which contain the phosphorylcholine moiety bound radiolabeled BSP proteins. These data suggest that the BSP protein binding sites on spermatozoa are phospholipids. We propose that this specific interaction plays an important role in the membrane modification of spermatozoa that occurs during capacitation and/or acrosome reaction.	HOP MAISON NEUVE ROSEMONT, CTR RECH, ENDOCRINE LAB, 5415 BLVD ASSOMPT, MONTREAL H1T 2M4, QUEBEC, CANADA; UNIV MONTREAL, DEPT MED, MONTREAL H3C 3J7, QUEBEC, CANADA	Universite de Montreal; Universite de Montreal								BAKER ME, 1985, BIOCHEM BIOPH RES CO, V130, P1010, DOI 10.1016/0006-291X(85)91715-2; BELLESISLES M, 1986, BIOCHEM J, V240, P863, DOI 10.1042/bj2400863; BLOOM JW, 1989, THROMB RES, V54, P261, DOI 10.1016/0049-3848(89)90084-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWER HB, 1986, METHOD ENZYMOL, V128, P223; BURK RR, 1983, METHOD ENZYMOL, V91, P247; BURNS AL, 1989, P NATL ACAD SCI USA, V86, P3798, DOI 10.1073/pnas.86.10.3798; CHANDONNET L, 1990, MOL REPROD DEV, V26, P313, DOI 10.1002/mrd.1080260404; CLEGG ED, 1973, J REPROD FERTIL, V34, P379, DOI 10.1530/jrf.0.0340379; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; DUCKCHONG CG, 1979, LIPIDS, V14, P492, DOI 10.1007/BF02533467; ESCH FS, 1983, BIOCHEM BIOPH RES CO, V113, P861, DOI 10.1016/0006-291X(83)91078-1; FOLCH J, 1957, J BIOL CHEM, V226, P497; GEISOW MJ, 1987, BIOSCIENCE REP, V7, P289, DOI 10.1007/BF01121450; GEISOW MJ, 1986, FEBS LETT, V203, P99, DOI 10.1016/0014-5793(86)81445-4; GENGE BR, 1989, J BIOL CHEM, V264, P10917; GILBERT GE, 1990, J BIOL CHEM, V265, P815; GLENNEY J, 1986, J BIOL CHEM, V261, P7247; GO KJ, 1983, ADV LIPID RES, V20, P317; HAWGOOD S, 1989, AM J PHYSIOL, V257, pL13, DOI 10.1152/ajplung.1989.257.2.L13; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; JI I, 1981, BIOL REPROD, V24, P617, DOI 10.1095/biolreprod24.3.617; JOHNSTON PA, 1990, BIOCHEM SOC T, V18, P1097, DOI 10.1042/bst0181097; KEMME M, 1988, DNA-J MOLEC CELL BIO, V7, P595, DOI 10.1089/dna.1988.7.595; KUZAN FB, 1990, PROSTAGLANDINS, V39, P61, DOI 10.1016/0090-6980(90)90095-D; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGLAIS J, 1985, GAMETE RES, V12, P183, DOI 10.1002/mrd.1120120209; LICHTENHELD MG, 1988, NATURE, V335, P448, DOI 10.1038/335448a0; LIU TY, 1987, J PROTEIN CHEM, V6, P263; LOBEL P, 1988, J BIOL CHEM, V263, P2563; MAGNANI JL, 1982, J BIOL CHEM, V257, P4365; MANJUNATH P, 1987, BIOSCIENCE REP, V7, P231, DOI 10.1007/BF01124794; MANJUNATH P, 1982, J BIOL CHEM, V257, P7109; MANJUNATH P, 1989, J BIOL CHEM, V264, P16853; MANJUNATH P, 1987, BIOCHEM J, V241, P685, DOI 10.1042/bj2410685; Manjunath P, 1984, GONADAL PROTEINS PEP, P49; Manjunath P, 1988, MOL BIOL BRAIN ENDOC, P259; MCMULLEN BA, 1985, J BIOL CHEM, V260, P5328; MILLER DJ, 1990, MOL REPROD DEV, V26, P184, DOI 10.1002/mrd.1080260213; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; NAGPURKAR A, 1983, J BIOL CHEM, V258, P518; OHNISHI S, 1974, BIOCHEMISTRY-US, V13, P881, DOI 10.1021/bi00702a008; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; PARKS JE, 1990, BIOL REPROD, V43, P806, DOI 10.1095/biolreprod43.5.806; PEPINSKY RB, 1988, J BIOL CHEM, V263, P10799; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PFAFFLE M, 1988, EMBO J, V7, P2335, DOI 10.1002/j.1460-2075.1988.tb03077.x; PURSEL VG, 1967, J REPROD FERTIL, V14, P203, DOI 10.1530/jrf.0.0140203; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; SEIDAH NG, 1987, BIOCHEM J, V243, P195, DOI 10.1042/bj2430195; SIDHU KS, 1989, INT REV CYTOL, V118, P231; SPIEGEL S, 1985, SCIENCE, V230, P1285, DOI 10.1126/science.2999979; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; USUI T, 1963, J BIOCHEM-TOKYO, V54, P283, DOI 10.1093/oxfordjournals.jbchem.a127785; VAHOUNY GV, 1987, ADV LIPID RES, V22, P83; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WAGNER H, 1961, BIOCHEM Z, V334, P175; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; WIRTZ KWA, 1982, LIPID PROTEIN INTERA, P151; Yanagimachi R., 1988, P135; ZILVERSMIT DB, 1983, METHOD ENZYMOL, V98, P565	62	247	249	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10149	10155						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577785				2022-12-25	WOS:A1992HT96500105
J	KILLEEN, M; COULOMBE, B; GREENBLATT, J				KILLEEN, M; COULOMBE, B; GREENBLATT, J			RECOMBINANT TBP, TRANSCRIPTION FACTOR-IIB, AND RAP30 ARE SUFFICIENT FOR PROMOTER RECOGNITION BY MAMMALIAN RNA POLYMERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INITIATION-FACTOR; BINDING-PROTEIN; PURIFICATION; SPECIFICITY; REQUIREMENT; COMPLEXES; ELEMENT; REGION	Initiation of transcription by RNA polymerase II is a complex, multistep process which requires several accessory factors in addition to the polymerase itself. A critical event in transcription initiation is the specific association of RNA polymerase II with promoter DNA. In this report we show that three eukaryotic polypeptides, produced in Escherichia coli and purified to near homogeneity, constitute a minimal set of general transcription factors both necessary and sufficient for specific and stable promoter binding by RNA polymerase II. These polypeptides are the yeast TATA box binding protein TBP, the human general initiation factor TFIIB, and human RAP30, the small subunit of RAP30/74 (or transcription factor IIF). Formation of the polymerase-containing complex required only the TATA box, and not the initiator element (Inr), of the adenovirus major late promoter which was used in these experiments.	BANTING & BEST DEPT MED RES,112 COLL ST,TORONTO M5G 1L6,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5G 1L6,ONTARIO,CANADA	University of Toronto; University of Toronto			Killeen, Marie/C-1131-2012	Killeen, Marie/0000-0001-9404-4845				AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, P1222; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; COULOMBE B, IN PRESS GENE EXPRES, V2; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; KILLEEN MT, 1992, MOL CELL BIOL, V12, P30, DOI 10.1128/MCB.12.1.30; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; MERMELSTEIN FH, 1989, BIOCHIM BIOPHYS ACTA, V1009, P1, DOI 10.1016/0167-4781(89)90071-7; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PETERSON MG, 1991, NATURE, V354, P369; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SAFER B, 1991, J BIOL CHEM, V266, P10989; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOPTA M, 1985, J BIOL CHEM, V260, P353; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495	37	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9463	9466						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577790				2022-12-25	WOS:A1992HT96500004
J	HSU, DK; ZUBERI, RI; LIU, FT				HSU, DK; ZUBERI, RI; LIU, FT			BIOCHEMICAL AND BIOPHYSICAL CHARACTERIZATION OF HUMAN RECOMBINANT IGE-BINDING PROTEIN, AN S-TYPE ANIMAL LECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING; ENDOGENOUS LECTINS; SELF-ASSOCIATION; 3T3 FIBROBLASTS; CULTURED-CELLS; IDENTIFICATION; LOCALIZATION; EXPRESSION; SEQUENCE; HOMOLOGY	IgE-binding protein (epsilon-BP) was originally identified by virtue of its affinity for IgE. It is now known to be a beta-galactoside-binding lectin with the characteristic of an S-type carbohydrate recognition domain. The protein is composed of two domains: the amino-terminal domain consisting of tandem repeats and the carboxyl-terminal domain containing sequences shared by other S-type carbohydrate recognition domains. The amino-terminal domain also contains a number of potential recognition sites for collagenase cleavage. In this study, human epsilon-BP was first expressed in Escherichia coli, and the carboxyl-terminal domain (epsilon-BP-C) was then generated by collagenase digestion of epsilon-BP. By equilibrium dialysis, the association constants of epsilon-BP and epsilon-BP-C for lactose were found to be similar (6.0 +/- 0.70) x 10(4) M-1 and (4.7 +/- 0.27) x 10(4) M-1, respectively. Both polypeptides contain only one lactose-binding site/molecule. By an assay involving binding of I-125-labeled epsilon-BP or epsilon-BP-C to solid phase IgE, and inhibition of this binding by saccharides, it was determined that epsilon-BP-C retains the saccharide specificity of epsilon-BP. Importantly, although unlabeled epsilon-BP-C inhibited the binding of the radiolabeled epsilon-BP to IgE, unlabeled epsilon-BP caused increased binding to IgE, suggesting self-association among epsilon-BP molecules. Oligomeric structures resulting from self-association of epsilon-BP were confirmed by chemical cross-linking studies. Furthermore, epsilon-BP possesses hemagglutination activity on rabbit erythrocytes, whereas epsilon-BP-C lacks such activity. Based on these results, we propose a structural model for multivalency of epsilon-BP: dimerization or oligomerization of epsilon-BP occurs through intermolecular interaction involving the amino-terminal domain.			HSU, DK (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Liu, FU-TONG/A-5749-2019	Liu, FU-TONG/0000-0002-3354-1001	NIAID NIH HHS [AI19747, AI32834, AI20958] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019747, U01AI032834, R01AI020958] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABBOTT WM, 1991, J BIOL CHEM, V266, P5552; ALBRANDT K, 1987, P NATL ACAD SCI USA, V84, P6859, DOI 10.1073/pnas.84.19.6859; BARONDES SH, 1984, SCIENCE, V223, P1259, DOI 10.1126/science.6367039; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; CHIPMAN DM, 1967, J BIOL CHEM, V242, P4388; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FINEL M, 1987, BIOCHIM BIOPHYS ACTA, V894, P174, DOI 10.1016/0005-2728(87)90187-3; FRIGERI LG, 1990, J BIOL CHEM, V265, P20763; FRIGERI LG, 1992, J IMMUNOL, V148, P861; GRITZMACHER CA, 1988, J IMMUNOL, V141, P2801; HANAHAN D, 1980, GENE, V10, P63, DOI 10.1016/0378-1119(80)90144-4; JIA SH, 1988, J BIOL CHEM, V263, P6009; KORNBLATT JA, 1980, CAN J BIOCHEM CELL B, V58, P219, DOI 10.1139/o80-030; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAING JG, 1988, BIOCHEMISTRY-US, V27, P5329, DOI 10.1021/bi00414a057; LAING JG, 1989, J BIOL CHEM, V264, P1907; LEFFLER H, 1989, BIOCHEMISTRY-US, V28, P9222, DOI 10.1021/bi00449a039; LEVI G, 1981, J BIOL CHEM, V256, P5735; LIU FT, 1990, CRIT REV IMMUNOL, V10, P289; LIU FT, 1980, J IMMUNOL, V124, P2728; LIU FT, 1985, P NATL ACAD SCI USA, V82, P4100, DOI 10.1073/pnas.82.12.4100; MCCONAHEY PJ, 1966, INT ARCH ALLER A IMM, V29, P185, DOI 10.1159/000229699; MOUTSATSOS IK, 1986, J CELL BIOL, V102, P477, DOI 10.1083/jcb.102.2.477; MOUTSATSOS IK, 1987, P NATL ACAD SCI USA, V84, P6452, DOI 10.1073/pnas.84.18.6452; ODA Y, 1991, GENE, V99, P279; PINCKARD RN, 1978, HDB EXPT IMMUNOLOGY; RAZ A, 1990, INT J CANCER, V46, P871, DOI 10.1002/ijc.2910460520; RAZ A, 1989, CANCER RES, V49, P3489; ROBERTSON MW, 1991, J IMMUNOL, V147, P3024; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; SWANEY JB, 1978, J BIOL CHEM, V253, P7069; TARVERS RC, 1982, J BIOL CHEM, V257, P708; TEALE FWJ, 1960, BIOCHEM J, V76, P381, DOI 10.1042/bj0760381; WOO HJ, 1990, J BIOL CHEM, V265, P7097; WOO HJ, 1991, J BIOL CHEM, V266, P18419	40	245	251	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14167	14174						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629216				2022-12-25	WOS:A1992JD32500060
J	GRUBER, JR; OHNO, S; NILES, RM				GRUBER, JR; OHNO, S; NILES, RM			INCREASED EXPRESSION OF PROTEIN KINASE-C-ALPHA PLAYS A KEY ROLE IN RETINOIC ACID-INDUCED MELANOMA DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIRSTEN SARCOMA-VIRUSES; PHORBOL ESTER; RECEPTOR PROTEIN; DOWN-REGULATION; CELL-LINE; TRANSFORMATION; KERATINOCYTES; INDUCTION; ISOZYMES; LEUKEMIA	Differentiation of B16 mouse melanoma cells induced by retinoic acid (RA) is preceded by a large increase in protein kinase C(alpha) (PKC(alpha)) mRNA and protein. To determine the-role of PKC(alpha) in the differentiation program, we stably transfected B16-F1 cells with a plasmid containing the full length PKC(alpha) cDNA driven by an SV40 promoter. Two out of thirty-two colonies screened were determined to overexpress PKC by 2-4-fold according to Western blot analysis and PKC enzyme activity. When compared to control cells (wild-type cells and cells transfected only with the neomycin resistance gene), PKC(alpha) overexpressing clones displayed longer doubling times, diminished anchorage-independent growth, and increased melanin production. RA treatment of control cells mimicked these phenotypic characteristics. When injected subcutaneously into syngeneic mice, PKC(alpha) overexpressing clones produced smaller tumors and had longer latencies than control cells. These findings, combined with the fact that phorbol esters down-regulate PKC and antagonize RA action suggest that PKC(alpha) plays a key role in the RA-induced melanoma differentiation.	BOSTON UNIV, MED CTR, DEPT BIOCHEM, BOSTON, MA 02118 USA; BOSTON UNIV, MED CTR, DEPT PATHOL, BOSTON, MA 02118 USA; YOKOHAMA CITY UNIV, SCH MED, DEPT MOLEC BIOL, KANAZAWA KU, YOKOHAMA 236, JAPAN	Boston University; Boston University; Yokohama City University			Ohno, Shigeo/B-1768-2010	Ohno, Shigeo/0000-0002-1294-5269	NATIONAL CANCER INSTITUTE [R01CA032543] Funding Source: NIH RePORTER; NCI NIH HHS [CA32543] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASE K, 1988, FEBS LETT, V236, P396, DOI 10.1016/0014-5793(88)80064-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIDA K, 1986, J BIOL CHEM, V261, P3013; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; FOURNIER A, 1987, NATURE, V330, P767, DOI 10.1038/330767a0; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUANG FL, 1989, J BIOL CHEM, V264, P4238; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; KRAFT AS, 1983, J BIOL CHEM, V258, P9178; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MELLONI E, 1990, P NATL ACAD SCI USA, V87, P4417, DOI 10.1073/pnas.87.12.4417; MUFSON RA, 1979, CANCER RES, V39, P3915; MURRAY AW, 1987, TRENDS BIOCHEM SCI, V12, P53, DOI 10.1016/0968-0004(87)90026-0; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; NILES R, 1992, CANCER RES, V294, P123; NILES RM, 1989, CANCER RES, V49, P4483; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; ROSENBAUM SE, 1992, ARCH BIOCHEM BIOPHYS, V294, P123, DOI 10.1016/0003-9861(92)90145-M; Sambrook J, 1989, MOL CLONING LABORATO; SCHER CD, 1975, NATURE, V256, P225, DOI 10.1038/256225a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; YOAKUM GH, 1985, SCIENCE, V227, P1174, DOI 10.1126/science.3975607; Zar J. H., 2009, BIOSTATISTICAL ANAL	28	121	124	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13356	13360						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618838				2022-12-25	WOS:A1992JB74600043
J	NGUYEN, T; PICKETT, CB				NGUYEN, T; PICKETT, CB			REGULATION OF RAT GLUTATHIONE S-TRANSFERASE-YA SUBUNIT GENE-EXPRESSION - DNA-PROTEIN INTERACTION AT THE ANTIOXIDANT RESPONSIVE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLLING INDUCIBLE EXPRESSION; TRANSCRIPTION FACTOR; RNA-POLYMERASE; BINDING; JUN; FOS; IDENTIFICATION; PURIFICATION; CONTACTS; COMPLEX	We have characterized the interaction of the antioxidant responsive element (ARE) in the 5'-flanking region of the rat glutathione S-transferase Ya subunit gene with its trans-acting factor. The ARE core sequence, 5'-ggTGACaaaGC-3', previously identified as the cis-acting element required for activation of the Ya subunit gene by planar aromatic compounds and phenolic antioxidants, is shown to be the high affinity recognition motif for a trans-acting factor(s) as determined by gel mobility shift assays as well as methylation interference and protection studies. The DNA-protein interaction appears to occur in the major groove and involves the GpG dinucleotide preceding and the G residue within the TGAC tetramer on the coding strand of the core sequence. In addition, DNase I protection analysis maps an extended region 5' from the core recognition motif, which was shown previously to be essential for basal activity of the ARE. The trans-acting factor is present in nuclear extracts from untreated and tert-butylhydroquinone-treated cells as determined by photochemical cross-linking experiments. The cross-linked protein appears to be a heterodimer with subunit molecular weights of approximately 28,000 and approximately 45,000.			NGUYEN, T (corresponding author), MERCK FROSST CTR THERAPEUT RES,POB 1005,POINTE CLAIRE H9R 4P8,QUEBEC,CANADA.							ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HENDRICKSON W, 1985, P NATL ACAD SCI USA, V82, P3129, DOI 10.1073/pnas.82.10.3129; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JAKOBY WB, 1984, BIOCHEM PHARMACOL, V33, P2539, DOI 10.1016/0006-2952(84)90621-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maxam A M, 1980, Methods Enzymol, V65, P499; PAULSON KE, 1990, MOL CELL BIOL, V10, P1841, DOI 10.1128/MCB.10.5.1841; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SHEN ES, 1989, J BIOL CHEM, V264, P17754; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TARTAGLIA LA, 1989, J MOL BIOL, V210, P709, DOI 10.1016/0022-2836(89)90104-6; TELAKOWSKIHOPKINS CA, 1988, P NATL ACAD SCI USA, V85, P1000, DOI 10.1073/pnas.85.4.1000; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975	29	93	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13535	13539						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618854				2022-12-25	WOS:A1992JB74600069
J	SAKAMOTO, H; BELLALOU, J; SEBO, P; LADANT, D				SAKAMOTO, H; BELLALOU, J; SEBO, P; LADANT, D			BORDETELLA-PERTUSSIS ADENYLATE-CYCLASE TOXIN - STRUCTURAL AND FUNCTIONAL INDEPENDENCE OF THE CATALYTIC AND HEMOLYTIC ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; VIRULENCE FACTORS; CALMODULIN; BINDING; IDENTIFICATION; PROTEIN; CLONING	The Bordetella pertussis calmodulin-dependent adenylate cyclase (CyaA) is a 1706-residue-long toxin, endowed with hemolytic activity. We have constructed B. pertussis mutant strains producing modified CyaAs devoid of adenylate cyclase activity. Our results show that such modified CyaAs display hemolytic activity identical to the wild-type toxin, thus demonstrating that the hemolytic activity is independent of the adenylate cyclase activity. Furthermore, B. pertussis and Escherichia coli strains producing CyaA lacking the catalytic domain (residues 1-373) were constructed. The truncated protein exhibits hemolytic activity comparable to the wild-type toxin, thus establishing that the carboxyl-terminal 1332 residues alone are endowed with hemolytic activity. Together, these findings show that adenylate cyclase and hemolytic activities are located in two distinct regions of the molecule (respectively, approximately amino acids 1-400 and 401-1706) and that the two regions of CyaA are functionally independent.			SAKAMOTO, H (corresponding author), INST PASTEUR,UNITE BIOCHIM REGULAT CELLULAIRES,F-75724 PARIS 15,FRANCE.		SEBO, Peter/F-7423-2011; SEBO, Peter/N-2043-2019	SEBO, Peter/0000-0002-9755-7715; SEBO, Peter/0000-0002-9755-7715; LADANT, Daniel/0000-0003-1955-548X; Sakamoto, Hiroshi/0000-0002-8767-2111				AU DC, 1989, BIOCHEMISTRY-US, V28, P2772, DOI 10.1021/bi00433a005; BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; BELLALOU J, 1990, INFECT IMMUN, V58, P3242, DOI 10.1128/IAI.58.10.3242-3247.1990; BHAKDI S, 1991, INFECT IMMUN, V59, P2955, DOI 10.1128/IAI.59.9.2955-2962.1991; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; CZUPRYNSKI CJ, 1991, INFECT IMMUN, V59, P3126, DOI 10.1128/IAI.59.9.3126-3133.1991; EHRMANN I, 1990, 1990 AM SOC MICR ANN; GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x; GLASER P, 1989, EMBO J, V8, P967, DOI 10.1002/j.1460-2075.1989.tb03459.x; GLASER P, 1988, MOL MICROBIOL, V2, P19, DOI 10.1111/j.1365-2958.1988.tb00003.x; GLASER P, 1991, EMBO J, V10, P1683, DOI 10.1002/j.1460-2075.1991.tb07692.x; GORDON VM, 1989, J BIOL CHEM, V264, P14792; HANSKI E, 1989, TRENDS BIOCHEM SCI, V14, P459, DOI 10.1016/0968-0004(89)90106-0; HANSKI E, 1985, J BIOL CHEM, V260, P5526; HEWLETT EL, 1991, J BIOL CHEM, V266, P17503; KHELEF N, 1992, IN PRESS MICROBIOL P; LADANT D, 1988, J BIOL CHEM, V263, P2612; LADANT D, 1986, J BIOL CHEM, V261, P6264; LADANT D, 1992, IN PRESS J BIOL CHEM, V267; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MONNERON A, 1988, BIOCHEMISTRY-US, V27, P536, DOI 10.1021/bi00402a005; MORALES VM, 1991, GENE, V97, P39, DOI 10.1016/0378-1119(91)90007-X; Pittman M., 1984, BERGEYS MANUAL SYSTE, V1, P388; ROGEL A, 1991, J BIOL CHEM, V266, P3154; Sambrook J, 1989, MOL CLONING LABORATO; SEBO P, 1991, GENE, V104, P19, DOI 10.1016/0378-1119(91)90459-O; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; STIBITZ S, 1986, GENE, V50, P133, DOI 10.1016/0378-1119(86)90318-5; WEISS AA, 1986, ANNU REV MICROBIOL, V40, P661, DOI 10.1146/annurev.micro.40.1.661; WEISS AA, 1983, INFECT IMMUN, V42, P33, DOI 10.1128/IAI.42.1.33-41.1983; WELSH RA, 1991, MOL MICROBIOL, V5, P521; Wolff J, 1980, P NATL ACAD SCI USA, V77, P3840; ZEALEY G, 1988, FEMS MICROBIOL LETT, V56, P123, DOI 10.1016/S0378-1097(97)00413-8	34	89	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13598	13602						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618862				2022-12-25	WOS:A1992JB74600079
J	HERRLER, G; GROSS, HJ; IMHOF, A; BROSSMER, R; MILKS, G; PAULSON, JC				HERRLER, G; GROSS, HJ; IMHOF, A; BROSSMER, R; MILKS, G; PAULSON, JC			A SYNTHETIC SIALIC-ACID ANALOG IS RECOGNIZED BY INFLUENZA-C VIRUS AS A RECEPTOR DETERMINANT BUT IS RESISTANT TO THE RECEPTOR-DESTROYING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYL-9-O-ACETYLNEURAMINIC ACID; BOVINE CORONAVIRUS; ERYTHROCYTES; ACETYLESTERASE; GLYCOPROTEIN; ESTERASE; FUSION; SPECIFICITY; RETROVIRUS; ACTIVATION	Synthetic sialic acid analogues varying in the substituents at position C-9 were analyzed for their ability to replace the natural receptor determinant for influenza C virus, N-acetyl-9-O-acetylneuraminic acid (Neu-5,9Ac-2). By incubation of erythrocytes with sialyltransferase and the CMP-activated analogues, the cell surface was modified to contain sialic acid with one of the following C-9 substituents: an azido, an amino, an acetamido, or a hexanoylamido group. Among these, only 9-acetamido-N-acetylneuraminic acid (9-acetamido-Neu5Ac) was able to function as a receptor determinant for influenza C virus as indicated by the ability of the virus to agglutinate the modified red blood cells. In contrast to the natural receptors, 9-acetamido-Neu5Ac-containing receptors were found to be resistant against the action of sialate 9-O-acetylesterase, the viral receptor-destroying enzyme. No difference in the hemolytic activity of influenza C virus was detected when analyzed with erythrocytes containing either Neu5,9Ac-2 or 9-acetamido-Neu5Ac on their surface. This finding indicates that cleavage of the receptor is not required for the viral fusion activity. The sialic acid analogues should be useful for analyzing not only the importance of the receptor-destroying enzyme of influenza C virus, but also other biological processes involving sialic acid.	UNIV HEIDELBERG,INST BIOCHEM 2,W-6900 HEIDELBERG,GERMANY; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024	Ruprecht Karls University Heidelberg; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	HERRLER, G (corresponding author), UNIV MARBURG,INST VIROL,W-3550 MARBURG,GERMANY.		Paulson, James/AAG-3565-2019					DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; GROSS HJ, 1990, ANAL BIOCHEM, V186, P127, DOI 10.1016/0003-2697(90)90585-W; GROSS HJ, 1989, BIOCHEMISTRY-US, V28, P7386, DOI 10.1021/bi00444a036; GROSS HJ, 1987, EUR J BIOCHEM, V168, P595, DOI 10.1111/j.1432-1033.1987.tb13458.x; GROSS HJ, 1988, EUR J BIOCHEM, V177, P583, DOI 10.1111/j.1432-1033.1988.tb14410.x; GROSS HJ, 1991, CLIN CHIM ACTA, V197, P237, DOI 10.1016/0009-8981(91)90144-2; HERRLER G, 1987, VIROLOGY, V159, P102, DOI 10.1016/0042-6822(87)90352-7; HERRLER G, 1985, EMBO J, V4, P1503, DOI 10.1002/j.1460-2075.1985.tb03809.x; HERRLER G, 1988, J GEN VIROL, V69, P839, DOI 10.1099/0022-1317-69-4-839; HERRLER G, 1988, ARCH VIROL, V102, P269, DOI 10.1007/BF01310831; HERRLER G, 1985, VIRUS RES, V2, P183, DOI 10.1016/0168-1702(85)90248-5; HERRLER G, 1985, VIROLOGY, V141, P144, DOI 10.1016/0042-6822(85)90190-4; HERRLER G, 1987, BIOL CHEM H-S, V368, P451, DOI 10.1515/bchm3.1987.368.1.451; KITAME F, 1985, VIRUS RES, V3, P231; KITAME F, 1982, ARCH VIROL, V73, P357, DOI 10.1007/BF01318090; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; LENTZ TL, 1990, J GEN VIROL, V71, P751, DOI 10.1099/0022-1317-71-4-751; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MUCHMORE EA, 1987, SCIENCE, V236, P1293, DOI 10.1126/science.3589663; OHUCHI M, 1982, J VIROL, V42, P1076, DOI 10.1128/JVI.42.3.1076-1079.1982; Paulson J, 1985, THE RECEPTORS, V2, P131; PAULSON JC, 1987, METHOD ENZYMOL, V138, P162; ROGERS GN, 1986, J BIOL CHEM, V261, P5947; ROGERS GN, 1983, VIROLOGY, V127, P361, DOI 10.1016/0042-6822(83)90150-2; SCHULTZE B, 1991, VIROLOGY, V180, P221, DOI 10.1016/0042-6822(91)90026-8; SCHULTZE B, 1990, VIRUS RES, V16, P185, DOI 10.1016/0168-1702(90)90022-4; VLASAK R, 1989, J VIROL, V63, P2056, DOI 10.1128/JVI.63.5.2056-2062.1989; VLASAK R, 1988, P NATL ACAD SCI USA, V85, P4526, DOI 10.1073/pnas.85.12.4526; VLASAK R, 1988, J VIROL, V62, P4686, DOI 10.1128/JVI.62.12.4686-4690.1988	30	49	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12501	12505						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618756				2022-12-25	WOS:A1992HZ48300022
J	BOURGOIN, S; GRINSTEIN, S				BOURGOIN, S; GRINSTEIN, S			PEROXIDES OF VANADATE INDUCE ACTIVATION OF PHOSPHOLIPASE-D IN HL-60 CELLS - ROLE OF TYROSINE PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; COLONY-STIMULATING FACTOR; HUMAN-NEUTROPHILS; PHOSPHATIDIC-ACID; NADPH-OXIDASE; PHOSPHATIDYLCHOLINE HYDROLYSIS; SIGNAL TRANSDUCTION; CHEMOTACTIC PEPTIDE; PHORBOL ESTERS; MECHANISMS	To determine the role of protein tyrosine phosphorylation in the activation of phospholipase D (PLD), electropermeabilized HL-60 cells labeled in [H-3]alkylphosphatidylcholine were treated with vanadate derivatives. Micromolar concentrations of vanadyl hydroperoxide (V4+-OOH) induced accumulation of tyrosine-phosphorylated proteins. Concomitantly, V4+-OOH or a combination of vanadate and NADPH elicited a concentration- and time-dependent accumulation of phosphatidic acid (PtdOH). In the presence of ethanol a sustained formation of phosphatidylethanol was observed, indicating that a type D phospholipase was activated. A good correlation was found to exist between the accumulation of tyrosine-phosphorylated proteins and activation of PLD. The V4+-OOH concentration dependence of the two responses was nearly identical, and the time course of activation was similar, with tyrosine phosphorylation preceding PLD activation by almost-equal-to 1 min. The ability of V4+-OOH to induce both responses was found to be strictly dependent on the presence of ATP and/or Mg2+, suggesting that PLD activation involves phosphotransferase reactions. Accordingly, ST638, a tyrosine kinase inhibitor, reduced concomitantly tyrosine phosphorylation and PLD activation elicited by V4+-OOH. The mechanism of action of V4+-OOH was investigated. The diacylglycerol kinase inhibitors, dioctanoylethylene glycol and R59022 potentiated PLD stimulation by exogenous diacylglycerol but not by V4+-OOH. Moreover, stimulation by V4+-OOH and by phorbol esters was synergystic. Therefore, diacylglycerol-induced activation of protein kinase C is unlikely to mediate the effects of V4+-OOH. The response of PLD to V4+-OOH was larger than that to guanosine 5'-(gamma-thio)triphosphate. Moreover, the effects of GTP-gamma-S and V4+-OOH were additive. Hence, activation of G proteins cannot account for the stimulation of PLD by V4+-OOH. V4+-OOH also triggers a burst of O2 consumption by the NADPH oxidase. Inhibition of PtdOH accumulation by addition of ethanol or by ST638 abolished this respiratory burst. Together, the results establish a strong correlation between tyrosine phosphorylation, PLD activation, and stimulation of the NADPH oxidase in HL-60 cells, suggesting a causal relationship.	HOSP SICK CHILDREN,RES INST,DIV CELL BIOL,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)				Bourgoin, Sylvain/0000-0001-9779-0368				AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; AGWU DE, 1989, J BIOL CHEM, V264, P1405; BABIOR BM, 1988, ARCH BIOCHEM BIOPHYS, V264, P361, DOI 10.1016/0003-9861(88)90300-1; BENAV P, 1989, FEBS LETT, V259, P64, DOI 10.1016/0014-5793(89)81495-4; BERKOW RL, 1989, BIOCHIM BIOPHYS ACTA, V997, P292, DOI 10.1016/0167-4838(89)90200-8; BERRIDGE MJ, 1984, NATURE, V312, P312; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; BOURGOIN S, 1990, J EXP MED, V172, P767, DOI 10.1084/jem.172.3.767; BOURGOIN S, 1991, J LEUKOCYTE BIOL S, V2, P79; ENGLISH D, 1991, BLOOD, V77, P2746; FABIATO A, 1989, J PHYSL, V75, P464; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FISHER GJ, 1991, J CELL PHYSIOL, V146, P309, DOI 10.1002/jcp.1041460216; GALLIN JI, 1982, FED PROC, V42, P2851; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOMEZCAMBRONERO J, 1989, P NATL ACAD SCI USA, V86, P3569, DOI 10.1073/pnas.86.10.3569; GRINSTEIN S, 1988, J BIOL CHEM, V263, P1779; GRINSTEIN S, 1990, J BIOL CHEM, V265, P318; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HEYWORTH PG, 1990, J BIOENERG BIOMEMBR, V22, P1, DOI 10.1007/BF00762842; HUANG CK, 1988, BIOCHEM BIOPH RES CO, V151, P794, DOI 10.1016/S0006-291X(88)80351-6; HUANG CK, 1989, MEMBRANE BIOCHEM, V8, P61, DOI 10.3109/09687688909082261; KAMPS MP, 1988, ONCOGENE, V2, P305; NACCACHE PH, 1990, BIOL CHEMOTACTIC RES, V24, P347; NAKAMURA K, 1984, ANAL BIOCHEM, V142, P406, DOI 10.1016/0003-2697(84)90484-6; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PAI JK, 1988, BIOCHEM BIOPH RES CO, V150, P355, DOI 10.1016/0006-291X(88)90528-1; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; SMITH CD, 1986, SCIENCE, V232, P97, DOI 10.1126/science.3006254; SMITH GA, 1978, LIPIDS, V13, P92, DOI 10.1007/BF02533373; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; TAUBER AI, 1987, BLOOD, V69, P711; TETTENBORN CS, 1987, BIOCHIM BIOPHYS ACTA, V931, P242, DOI 10.1016/0167-4889(87)90212-6; TETTENBORN CS, 1988, BIOCHEM BIOPH RES CO, V155, P249, DOI 10.1016/S0006-291X(88)81076-3; TRUDEL S, 1991, BIOCHEM J, V276, P611, DOI 10.1042/bj2760611; TRUDEL S, 1990, BIOCHEM J, V269, P127, DOI 10.1042/bj2690127; WANG P, 1991, J BIOL CHEM, V266, P14877; XIE MS, 1991, BIOCHEM J, V278, P81, DOI 10.1042/bj2780081	46	149	149	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11908	11916						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601860				2022-12-25	WOS:A1992HY94700041
J	HANLON, DW; MARQUEZMAGANA, LM; CARPENTER, PB; CHAMBERLIN, MJ; ORDAL, GW				HANLON, DW; MARQUEZMAGANA, LM; CARPENTER, PB; CHAMBERLIN, MJ; ORDAL, GW			SEQUENCE AND CHARACTERIZATION OF BACILLUS-SUBTILIS CHEW	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCEPTING CHEMOTAXIS PROTEINS; BACTERIAL CHEMOTAXIS; ESCHERICHIA-COLI; SIGNAL TRANSDUCTION; GENE-EXPRESSION; PHOSPHORYLATION; SYSTEM; METHYLESTERASE; METHYLATION; MUTATIONS	A Bacillus subtilis open reading frame (ORF) encoding a predicted polypeptide of 156 amino acids was subcloned and sequenced. The polypeptide was found to be homologous to CheW of Escherichia coli, sharing 28.6% amino acid identity. The ORF was verified by using a bacteriophage T7 expression system in E. coli. The gene was inactivated by insertion of a nonpolor chloramphenicol acetyltransferase cassette in its N-terminal region. In the absence of chemoeffectors, the mutant displayed a smooth swimming bias, with some tumbling. The CheW- mutant was defective on swarm plates but was complemented by a plasmid that expressed wild type CheW. Addition of attractant or repellent to the CheW- mutant resulted in transient smooth swimming or tumbling, respectively. However, capillary assays revealed that chemotaxis was substantially impaired in the mutant strain.	UNIV ILLINOIS,COLL MED,DEPT BIOCHEM,URBANA,IL 61801; UNIV ILLINOIS,COLL LIBERAL ARTS & SCI,URBANA,IL 61801; UNIV CALIF BERKELEY,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of California System; University of California Berkeley					NIAID NIH HHS [AI20336] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020336] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALAM M, 1991, J BACTERIOL, V173, P5837, DOI 10.1128/jb.173.18.5837-5842.1991; BAND L, 1984, DNA-J MOLEC CELL BIO, V3, P17, DOI 10.1089/dna.1.1984.3.17; BEDALE WA, 1988, J BACTERIOL, V170, P223, DOI 10.1128/jb.170.1.223-227.1988; BISCHOFF DS, 1991, J BIOL CHEM, V266, P12301; BISCHOFF DS, 1992, MOL MICROBIOL, V6, P23, DOI 10.1111/j.1365-2958.1992.tb00833.x; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BORKOVICH KA, 1990, CELL, V63, P1339, DOI 10.1016/0092-8674(90)90429-I; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; FUHRER DK, 1991, J BACTERIOL, V173, P7443, DOI 10.1128/jb.173.23.7443-7448.1991; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LEONHARDT H, 1988, J GEN MICROBIOL, V134, P605; LIU JD, 1991, J BACTERIOL, V173, P4941, DOI 10.1128/jb.173.16.4941-4951.1991; LIU JD, 1989, P NATL ACAD SCI USA, V86, P8703, DOI 10.1073/pnas.86.22.8703; LUPAS A, 1989, J BIOL CHEM, V264, P17337; MCBRIDE MJ, 1989, P NATL ACAD SCI USA, V86, P424, DOI 10.1073/pnas.86.2.424; MCNALLY DF, 1991, P NATL ACAD SCI USA, V88, P6269, DOI 10.1073/pnas.88.14.6269; MUTOH N, 1986, J BACTERIOL, V165, P161, DOI 10.1128/jb.165.1.161-166.1986; ORDAL GW, 1983, J BACTERIOL, V154, P1088, DOI 10.1128/JB.154.3.1088-1097.1983; ORDAL GW, 1975, SCIENCE, V189, P802, DOI 10.1126/science.808854; PARKINSON JS, 1978, CELL, V15, P1221, DOI 10.1016/0092-8674(78)90048-X; PARKINSON JS, 1978, J BACTERIOL, V135, P45, DOI 10.1128/JB.135.1.45-53.1978; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEWART RC, 1990, J BACTERIOL, V172, P3388, DOI 10.1128/jb.172.6.3388-3399.1990; STOCK A, 1987, J BIOL CHEM, V262, P535; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; THOELKE MS, 1990, J BIOL CHEM, V265, P1928; THOELKE MS, 1988, BIOCHEMISTRY-US, V27, P8453, DOI 10.1021/bi00422a024; THOELKE MS, 1987, J BIOL CHEM, V262, P2811; THOELKE MS, 1989, BIOCHEMISTRY-US, V28, P5585, DOI 10.1021/bi00439a037; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; ULLAH AHJ, 1981, J BACTERIOL, V145, P958, DOI 10.1128/JB.145.2.958-965.1981; WOLFE AJ, 1987, J BACTERIOL, V169, P1878, DOI 10.1128/jb.169.5.1878-1885.1987; ZUBERI AR, 1990, J BACTERIOL, V172, P1870, DOI 10.1128/jb.172.4.1870-1876.1990	37	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12055	12060						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601874				2022-12-25	WOS:A1992HY94700063
J	SCHWARTZ, HL; STRAIT, KA; LING, NC; OPPENHEIMER, JH				SCHWARTZ, HL; STRAIT, KA; LING, NC; OPPENHEIMER, JH			QUANTITATION OF RAT-TISSUE THYROID-HORMONE BINDING-RECEPTOR ISOFORMS BY IMMUNOPRECIPITATION OF NUCLEAR TRIIODOTHYRONINE BINDING-CAPACITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER NUCLEI; HUMAN TESTIS; CDNA CLONE; PROTEIN; PHOSPHORYLATION; IDENTIFICATION; AFFINITY; ENCODES; INVITRO; SITES	A panel of anti-thyroid hormone receptor (TR) antisera were generated to allow direct assay of the concentrations of the alpha-1 and,beta-1 receptor isoforms in nuclear extracts from adult rat liver, kidney, brain and heart, and fetal brain. An antiserum, immunoglobulin G (IgG)-beta-1, raised against amino acid sequence 62-92 of the rat TR-beta-1 specifically precipitated only TR-beta-1 in vitro translation products. A second antiserum, IgG-alpha-1/8, generated against a sequence that is identical in the ligand binding region of rat TR-alpha-1 and TR-beta isoforms immunoprecipitated both TR-alpha-1 and -beta-1 translation products. These IgG preparations were used to specifically immunoprecipitate thyroid hormone receptor binding activity from nuclear extracts. IgG-beta-1 cleared almost 80%, and the IgG-alpha-1/beta-immunoprecipitated nearly all binding from hepatic nuclear extracts. This distribution of TR protein, 80% beta-1 and 20%-alpha-1, is the same as previously reported for their respective mRNAs in liver. In heart, kidney, and brain IgG-beta-1 cleared 45, 43, and 28% of total binding, respectively, and IgG-alpha-1/beta-cleared all T3 binding activity from these tissues. In agreement with an earlier study, marked variations in specific protein/mRNA ratios were noted among these tissues. Consistent with our earlier report of the presence of only very low levels of TR-beta-1 mRNA in fetal brain, IgG-beta-1 cleared just 5% of binding in this tissue. Studies using an antiserum (IgG-ch) generated against homologous segments of the hinge region in both TR-alpha-1 and -beta-1 yielded results which contrasted sharply with those of IgG-alpha-1/beta. Whereas IgG-ch could also immunoprecipitate virtually all binding from hepatic extracts it cleared only 40-50% of binding from the other tissues, including fetal brain in which TR-alpha-1 accounts for >90% of binding protein. The data suggest the presence of posttranslational modification of the TR-alpha-1 protein in the hinge region, consistent with the presence in this segment of potential phosphorylation sites.	UNIV MINNESOTA,DEPT MED,ENDOCRINOL & METAB SECT,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT CELL BIOL & NEUROANAT,MINNEAPOLIS,MN 55455; WHITTIER INST,LA JOLLA,CA 92073	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NIDDK NIH HHS [DK-19812] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019812] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENBROOK D, 1987, SCIENCE, V238, P788, DOI 10.1126/science.3672126; BIGLER J, 1988, MOL CELL BIOL, V8, P4155, DOI 10.1128/MCB.8.10.4155; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BROWN TA, 1990, J BIOL CHEM, V265, P10025; Chin W.W., 1991, NUCL HORMONE RECEPTO, P79; GLINEUR C, 1989, ONCOGENE, V4, P1247; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; LATHAM KR, 1976, J BIOL CHEM, V251, P7388; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P893, DOI 10.1210/mend-2-10-893; LING N, 1984, P NATL ACAD SCI-BIOL, V81, P4302, DOI 10.1073/pnas.81.14.4302; MIGLIACCIO A, 1981, J STEROID BIOCHEM, V15, P369, DOI 10.1016/0022-4731(81)90299-5; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; MURRAY MB, 1988, J BIOL CHEM, V263, P12770; Oppenheimer J., 1983, MOL BASS THYROID HOR, P1; SAMUELS HH, 1973, SCIENCE, V181, P1253, DOI 10.1126/science.181.4106.1253; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHUELER PA, 1990, MOL ENDOCRINOL, V4, P227, DOI 10.1210/mend-4-2-227; SILVA ES, 1977, J BIOL CHEM, V252, P6799; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; SULLIVAN WP, 1988, J BIOL CHEM, V263, P14717; SURKS MI, 1973, J BIOL CHEM, V248, P7066; THOMPSON CC, 1987, SCIENCE, V237, P1610, DOI 10.1126/science.3629259; TORRESANI J, 1975, ENDOCRINOLOGY, V96, P1201, DOI 10.1210/endo-96-5-1201; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0	28	156	159	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11794	11799						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601852				2022-12-25	WOS:A1992HY94700026
J	SUBRAMANIAM, VN; YUSOFF, ARB; WONG, SH; LIM, GB; CHEW, M; HONG, WJ				SUBRAMANIAM, VN; YUSOFF, ARB; WONG, SH; LIM, GB; CHEW, M; HONG, WJ			BIOCHEMICAL FRACTIONATION AND CHARACTERIZATION OF PROTEINS FROM GOLGI-ENRICHED MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; ENDOPLASMIC-RETICULUM; BINDING-PROTEIN; CDNA CLONING; APPARATUS; IDENTIFICATION; PURIFICATION; EXPRESSION; SEQUENCE; OLIGOSACCHARIDES	Fractions enriched in Golgi membranes were prepared from rat liver by sucrose gradient ultracentrifugation. These enriched membranes were further subfractionated on the basis of their solubilities in EGTA, 150 mM sodium carbonate, pH 11.5, sodium deoxycholate, Triton X-100, or sodium dodecyl sulfate. This led to isolation of peripheral, luminal, and integral membrane proteins of the Golgi-enriched membranes. Luminal and membrane proteins were further purified by wheat germ agglutinin and concanavalin A lectin affinity chromatographies. Some proteins from these lectin columns were resolved by preparative gel electrophoresis and microsequenced. Subsequently, antibodies were produced for two proteins by immunization of either mice or rabbits. Immunofluorescence microscopy suggests that these proteins are confined to Golgi apparatus-like structures. The protocol described is well suited for the study of organelle structure and function.			SUBRAMANIAM, VN (corresponding author), NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, MOLEC & CELL BIOL MEMBRANES LAB, SINGAPORE 0511, SINGAPORE.		HONG, Wanjin/E-9927-2010; Subramaniam, V. Nathan/A-1901-2010	Subramaniam, V. Nathan/0000-0002-4583-7790				BERGERON JJM, 1979, BIOCHIM BIOPHYS ACTA, V555, P493, DOI 10.1016/0005-2736(79)90402-4; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; BRADA D, 1990, J CELL BIOL, V110, P309, DOI 10.1083/jcb.110.2.309; BRANDLI AW, 1991, BIOCHEM J, V276, P1; CLARY DO, 1990, J BIOL CHEM, V265, P10109; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; EHRENREICH JH, 1973, J CELL BIOL, V59, P45, DOI 10.1083/jcb.59.1.45; FARQUHAR MG, 1981, J CELL BIOL, V91, pS77, DOI 10.1083/jcb.91.3.77s; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; FLEISCHER B, 1983, METHOD ENZYMOL, V98, P60; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GONATAS JO, 1989, J BIOL CHEM, V264, P646; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GRAHAM JM, 1990, ANAL BIOCHEM, V187, P318, DOI 10.1016/0003-2697(90)90463-J; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HARTMANN E, 1989, EMBO J, V8, P2225, DOI 10.1002/j.1460-2075.1989.tb08346.x; HOLLAND EC, 1984, P NATL ACAD SCI-BIOL, V81, P7338, DOI 10.1073/pnas.81.23.7338; HONG WJ, 1987, P NATL ACAD SCI USA, V84, P7962, DOI 10.1073/pnas.84.22.7962; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONG RM, 1988, BIOCHEM BIOPH RES CO, V156, P866, DOI 10.1016/S0006-291X(88)80924-0; LOW SH, 1991, J BIOL CHEM, V266, P13391; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; Machamer C E, 1991, Trends Cell Biol, V1, P141, DOI 10.1016/0962-8924(91)90001-P; MACKENZIE PI, 1986, J BIOL CHEM, V261, P14112; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NIEHRS C, 1990, EMBO J, V9, P35, DOI 10.1002/j.1460-2075.1990.tb08077.x; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; SARASTE J, 1987, J CELL BIOL, V105, P2021, DOI 10.1083/jcb.105.5.2021; SCHREIBER G, 1979, J BIOL CHEM, V254, P2013; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; STOORVOGEL W, 1991, J BIOL CHEM, V266, P5438; STROUS GJ, 1986, CRC CR REV BIOCH MOL, V21, P119, DOI 10.3109/10409238609113610; SUGUMARAN G, 1991, J BIOL CHEM, V266, P9565; TAKAGI Y, 1988, J BIOCHEM-TOKYO, V104, P801, DOI 10.1093/oxfordjournals.jbchem.a122553; TARTAKOFF AM, 1983, J CELL BIOL, V97, P1243, DOI 10.1083/jcb.97.4.1243; THOMAS TC, 1990, METHOD ENZYMOL, V182, P499; TRINCHERA M, 1989, J BIOL CHEM, V264, P15766; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; WELLNER D, 1988, BIOCHEM BIOPH RES CO, V155, P622, DOI 10.1016/S0006-291X(88)80540-0; YUAN L, 1987, J CELL BIOL, V105, P215, DOI 10.1083/jcb.105.1.215	47	27	27	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12016	12021						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601872				2022-12-25	WOS:A1992HY94700057
J	MACKAY, K; DANIELPOUR, D; MILLER, D; BORDER, WA; ROBBINS, AR				MACKAY, K; DANIELPOUR, D; MILLER, D; BORDER, WA; ROBBINS, AR			THE 260-KDA TRANSFORMING GROWTH-FACTOR (TGF)-BETA BINDING-PROTEIN IN RAT GLOMERULI IS A COMPLEX COMPRISED OF 170-KDA AND 85-KDA TGF-BETA BINDING-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR; CELLS	In a previous study (MacKay, K., Robbins, A. R., Bruce, M. D., and Danielpour, D. (1990) J. Biol. Chem. 265, 9351-9356) we showed that rat glomeruli contain transforming growth factor (TGF)-beta-1 binding proteins with apparent molecular masses of 260, 170, and 85 kDa (Gl-260, Gl-170, Gl-85) as determined by electrophoresis under nonreducing conditions. We demonstrate here that Gl-260 is a complex of 170- and 85-kDa TGF-beta binding proteins. Under denaturing conditions the integrity of Gl-260 is maintained through the cross-linking of one monomer of the disulfide-linked TGF-beta-1 homodimer to Gl-85 and of the other monomer to the 100-kDa subunit of Gl-170. In addition, some Gl-260 complexes are maintained by direct cross-linking of Gl-85 to the 100-kDa subunit of Gl-170. One-dimensional peptide maps of Gl-85 and the 100-kDa subunit of Gl-170 indicate that they have distinctly different ligand binding domains. In contrast, peptide maps of Gl-85 and the type II receptor of normal rat kidney fibroblasts are similar. The biological responses of isolated glomeruli to TGF-beta appear to parallel those of cultured glomerular cells which are without detectable Gl-170 and Gl-260 binding proteins.	NIDDKD,BIOCHEM & METAB LAB,BETHESDA,MD 20892; NCI,CHEMOPREVENT LAB,BETHESDA,MD 20892; UNIV UTAH,SCH MED,DIV NEPHROL,SALT LAKE CITY,UT 84132	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Utah System of Higher Education; University of Utah	MACKAY, K (corresponding author), NIDDKD,METAB DIS BRANCH,KIDNEY DIS SECT,BETHESDA,MD 20892, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043609, R37DK043609] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43609] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BORDER WA, 1990, KIDNEY INT, V37, P689, DOI 10.1038/ki.1990.35; BORDER WA, 1990, NATURE, V346, P371, DOI 10.1038/346371a0; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COIMBRA T, 1991, AM J PATHOL, V138, P223; DESJARDINS M, 1991, J CELL BIOL, V113, P689, DOI 10.1083/jcb.113.3.689; FROLIK CA, 1984, J BIOL CHEM, V259, P995; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACKAY K, 1989, J CLIN INVEST, V83, P1160, DOI 10.1172/JCI113996; MACKAY K, 1990, J BIOL CHEM, V265, P9351; MACKAY K, 1988, KIDNEY INT, V33, P677, DOI 10.1038/ki.1988.53; MACKAY K, 1991, J BIOL CHEM, V266, P9907; MACKAY K, 1990, KIDNEY INT, V38, P1095, DOI 10.1038/ki.1990.318; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; OKUDA S, 1990, J CLIN INVEST, V86, P453, DOI 10.1172/JCI114731; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SMITH RJ, 1978, BIOCHEMISTRY-US, V17, P3719, DOI 10.1021/bi00611a007; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965	20	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11449	11454						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597472				2022-12-25	WOS:A1992HX16900078
J	NISHIMOTO, SK; ARAKI, N; ROBINSON, FD; WAITE, JH				NISHIMOTO, SK; ARAKI, N; ROBINSON, FD; WAITE, JH			DISCOVERY OF BONE GAMMA-CARBOXYGLUTAMIC ACID PROTEIN IN MINERALIZED SCALES - THE ABUNDANCE AND STRUCTURE OF LEPOMIS-MACROCHIRUS BONE GAMMA-CARBOXYGLUTAMIC ACID PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL TISSUE RESORPTION; K-DEPENDENT PROTEIN; MATRIX GLA PROTEIN; FUNDULUS-HETEROCLITUS; CALCIUM HOMEOSTASIS; CARASSIUS-AURATUS; ESTRADIOL; KILLIFISH; GOLDFISH; SEQUENCE	The mineralized scale of the freshwater sunfish Lepomis macrochirus (bluegill) contains a Gla protein. The protein was identified in extracts of scale by a new colorimetric assay for Gla-containing proteins. The protein was purified by gel filtration chromatography followed by reversed phase high performance liquid chromatography (HPLC). Several tests establish the identity of scale Gla protein and bone Gla protein (BGP). First, the proteins exhibit identical mobilities on electrophoresis and by reversed phase HPLC. Second, they have identical amino-terminal amino acid sequences. Finally, identical peptides are generated by proteolytic digestion. The 45-residue amino acid sequence of the bone Gla protein from L. macrochirus has a high sequence homology with swordfish, as well as homology to mammalian bone Gla protein. The BGP of bluegill shares with swordfish BGP a truncated NH2 terminus and an extended COOH terminus. These features may be unique to fish, as they have not been observed in terrestrial vertebrates. The bluegill BGP is the first vitamin K-dependent protein to contain a non-gamma-carboxylated residue to the NH2-terminal side of all of its Gla residues. In all other vitamin K-dependent proteins, Gla always appears to the NH2-terminal side of the first Glu. The implications of this result are discussed. The bluegill rib bone is curiously enriched in BGP, as are other mineralized tissues of this species. One hypothesis is that this may be due to the acellular nature of the bone in this species. The abundance of BGP in the bones of this fish may provide clues to the unknown function of this bone protein.	UNIV DELAWARE,COLL MARINE STUDIES,LEWES,DE 19958	University of Delaware	NISHIMOTO, SK (corresponding author), UNIV TENNESSEE CTR HLTH SCI,DEPT BIOCHEM,858 MADISON ST,SUITE G01,MEMPHIS,TN 38163, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035056] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR35056] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALLEN G, SEQUENCING PROTEINS, P90; HAUSCHKA PV, 1975, P NATL ACAD SCI USA, V72, P3925, DOI 10.1073/pnas.72.10.3925; JARRETT HW, 1986, ANAL BIOCHEM, V153, P189, DOI 10.1016/0003-2697(86)90079-5; KLARSKOV K, 1989, ANAL BIOCHEM, V180, P28; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY RJ, 1979, BIOCHEM BIOPH RES CO, V91, P41, DOI 10.1016/0006-291X(79)90580-1; LIAN JB, 1984, J CLIN INVEST, V73, P1223, DOI 10.1172/JCI111308; LIAN JB, 1977, J CLIN INVEST, V59, P1151, DOI 10.1172/JCI108739; LINDE A, 1980, J BIOL CHEM, V255, P5931; MOSS ML, 1962, ACTA ANAT, V48, P46; MOSS ML, 1965, ACTA ANAT, V60, P262; MUGIYA Y, 1977, COMP BIOCHEM PHYS A, V57, P197, DOI 10.1016/0300-9629(77)90455-8; NISHIMOTO SK, 1990, ANAL BIOCHEM, V186, P273, DOI 10.1016/0003-2697(90)90079-O; OTSUKA AS, 1978, THESIS U CALIFORNIA; POSER JW, 1980, J BIOL CHEM, V255, P8685; PRICE PA, 1980, P NATL ACAD SCI-BIOL, V77, P2234, DOI 10.1073/pnas.77.4.2234; PRICE PA, 1976, P NATL ACAD SCI USA, V73, P1447, DOI 10.1073/pnas.73.5.1447; PRICE PA, 1985, J BIOL CHEM, V260, P4971; PRICE PA, 1983, BIOCHEM BIOPH RES CO, V117, P765, DOI 10.1016/0006-291X(83)91663-7; PRICE PA, 1977, CALCIUM BINDING PROT, P333; SAUK JJ, 1984, BIOCHIM BIOPHYS ACTA, V798, P199, DOI 10.1016/0304-4165(84)90304-0; SUGITA A, 1987, J BIOCHEM-TOKYO, V101, P1593; WAITE JH, 1991, ANAL BIOCHEM, V192, P429, DOI 10.1016/0003-2697(91)90560-G; WEISS RE, 1978, COMP BIOCHEM PHYS A, V60, P207, DOI 10.1016/0300-9629(78)90233-5; YAMADA J, 1979, J MORPHOL, V159, P49, DOI 10.1002/jmor.1051590105	25	49	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11600	11605						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597487				2022-12-25	WOS:A1992HX16900101
J	TAKAHASHI, N; HIROSE, M				TAKAHASHI, N; HIROSE, M			REVERSIBLE DENATURATION OF DISULFIDE-REDUCED OVALBUMIN AND ITS REOXIDATION GENERATING THE NATIVE CYSTINE CROSS-LINK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEN OVALBUMIN; PROTEINS; RENATURATION; INHIBITOR; SEQUENCE; BRIDGES; FORM; GEL	The authors in a previous report (Klausner, R. D., Kempf, C., Weinstein, J. N., Blumenthal, R., and van Renswoude, J. (1983) Biochem. J. 212, 801-810) have argued that native folding of ovalbumin occurs during translation, but not in a renaturation system of the denatured form. To re-examine the possibility, we searched for the conditions of correct oxidative refolding of denatured disulfide-reduced ovalbumin. Data of trypsin resistance, CD-spectrum, and selective reactivity of cysteine sulfhydryls revealed that the fully denatured protein can refold into the native conformation under disulfide-reduced conditions. The interconversion between the native and denatured forms was fully reversible with a free energy change for unfolding of 6.6 kcal/mol at 25-degrees-C. Subsequent reoxidation under a variety of redox conditions generated only one disulfide bond in the reduced refolded protein with six cysteine sulfhydryls. Furthermore, the regenerated disulfide was found by peptide analyses to correspond to the native disulfide pairing, Cys73-Cys120. We, therefore, concluded that co-translational folding, if any, is not requisite for the correct oxidative folding of ovalbumin.	KYOTO UNIV,FOOD SCI RES INST,UJI,KYOTO 611,JAPAN	Kyoto University								AHMAD F, 1976, BIOCHEMISTRY-US, V15, P5168, DOI 10.1021/bi00668a034; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Creighton T E, 1986, Methods Enzymol, V131, P83; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; FOSTER JF, 1952, ARCH BIOCHEM BIOPHYS, V40, P437, DOI 10.1016/0003-9861(52)90131-8; GOTO Y, 1981, J MOL BIOL, V146, P321, DOI 10.1016/0022-2836(81)90391-0; HIRANO H, 1989, J PROTEIN CHEM, V8, P115, DOI 10.1007/BF01025083; HIROSE M, 1991, J BIOL CHEM, V266, P1463; HIROSE M, 1989, J BIOL CHEM, V264, P16867; HOLT JC, 1972, BIOCHEM J, V129, P665, DOI 10.1042/bj1290665; IMAHORI K, 1960, BIOCHIM BIOPHYS ACTA, V37, P336, DOI 10.1016/0006-3002(60)90242-0; KITABATAKE N, 1988, AGR BIOL CHEM TOKYO, V52, P967; KLAUSNER RD, 1983, BIOCHEM J, V212, P801, DOI 10.1042/bj2120801; KOSEKI T, 1988, J BIOCHEM-TOKYO, V103, P425, DOI 10.1093/oxfordjournals.jbchem.a122286; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MOORE S, 1963, J BIOL CHEM, V238, P235; NISBET AD, 1981, EUR J BIOCHEM, V115, P335, DOI 10.1111/j.1432-1033.1981.tb05243.x; ODANI S, 1973, J BIOCHEM-TOKYO, V74, P697, DOI 10.1093/oxfordjournals.jbchem.a130295; OTTESEN M, 1968, BIOCHIM BIOPHYS ACTA, V160, P262, DOI 10.1016/0005-2795(68)90098-6; OTTESEN M, 1958, C R Trav Lab Carlsberg Chim, V30, P211; Sambrook J, 1989, MOL CLONING LABORATO; SIMPSON RB, 1953, J AM CHEM SOC, V75, P5139, DOI 10.1021/ja01117a001; TABE L, 1984, J MOL BIOL, V180, P645, DOI 10.1016/0022-2836(84)90031-7; TAKAHASHI N, 1990, ANAL BIOCHEM, V188, P359, DOI 10.1016/0003-2697(90)90621-F; TAKAHASHI N, 1991, J BIOCHEM-TOKYO, V109, P846, DOI 10.1093/oxfordjournals.jbchem.a123469; Tanford C, 1970, Adv Protein Chem, V24, P1, DOI 10.1016/S0065-3233(08)60241-7; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; WRIGHT HT, 1990, J MOL BIOL, V213, P513	29	36	36	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11565	11572						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597484				2022-12-25	WOS:A1992HX16900096
J	MAESTRO, R; DOLCETTI, R; GASPAROTTO, D; DOGLIONI, C; PELUCCHI, S; BARZAN, L; GRANDI, E; BOIOCCHI, M				MAESTRO, R; DOLCETTI, R; GASPAROTTO, D; DOGLIONI, C; PELUCCHI, S; BARZAN, L; GRANDI, E; BOIOCCHI, M			HIGH-FREQUENCY OF P53-GENE ALTERATIONS ASSOCIATED WITH PROTEIN OVEREXPRESSION IN HUMAN SQUAMOUS-CELL CARCINOMA OF THE LARYNX	ONCOGENE			English	Article							HUMAN P53 GENE; LUNG-CANCER; BREAST-CANCER; BLAST CRISIS; ALLELE LOSS; MUTANT P53; EXPRESSION; MUTATIONS; ONCOGENE; REARRANGEMENT	A series of 58 primary human squamous cell carcinomas of the larynx (LSCCs) was examined for the expression of the p53 tumor-suppressor gene by a combined immunohistochemical and molecular approach. About 60% of the cases displayed nuclear p53 overexpression as revealed by immunostaining with PAb1801, PAb122 and PAb240 monoclonal antibodies. This phenomenon was associated with the presence of structural and/or transcriptional alterations of the p53 gene. Our results provide evidence that p53 abnormalities constitute the most frequent genetic alteration identified so far in LSCC and indicate that the abnormal accumulation of the protein correlates with the presence of p53-mutated versions. These findings, taken together with the peculiar biochemical properties of p53, support the hypothesis of a possible pathogenetic relationship between smoke carcinogen exposure and p53 inactivation in the development of this tumor type.	CTR RIFERIMENTO ONCOL,DIV EXPTL ONCOL 1,VIA PEDEMONTANA OCCIDENTALE,I-33081 AVIANO,ITALY; OSPED FELTRE,DIV PATHOL,FELTRE,ITALY; UNIV FERRARA,DEPT OTORHINOLARYNGOL,I-44100 FERRARA,ITALY; OSPED CIVILE,DIV OTORHINOLARYNGOL,PORDENONE,ITALY; UNIV FERRARA,DEPT PATHOL,I-44100 FERRARA,ITALY	IRCCS Aviano (CRO); ULSS 1 Dolomiti; Ospedale di Feltre; University of Ferrara; University of Ferrara			Maestro, Roberta/M-1846-2015; Dolcetti, Riccardo/O-3832-2015; Maestro, Roberta/P-9748-2019; Gasparotto, Daniela/Y-2351-2019	Maestro, Roberta/0000-0002-6642-5592; Dolcetti, Riccardo/0000-0003-1625-9853; Maestro, Roberta/0000-0002-6642-5592; Gasparotto, Daniela/0000-0003-0914-1654; DOGLIONI, Claudio/0000-0002-4969-5216				AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1990, ONCOGENE, V5, P893; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; BENDAVID Y, 1988, ONCOGENE, V3, P179; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CHEN YM, 1991, ONCOGENE, V6, P1799; CHIBA I, 1990, ONCOGENE, V5, P1603; DOLCETTI R, 1988, EUR J CANCER CLIN ON, V24, P1321, DOI 10.1016/0277-5379(88)90223-4; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; EISENSTADT E, 1982, P NATL ACAD SCI-BIOL, V79, P1945, DOI 10.1073/pnas.79.6.1945; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FLANDERS WD, 1982, AM J EPIDEMIOL, V115, P371, DOI 10.1093/oxfordjournals.aje.a113315; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KELMAN Z, 1989, BLOOD, V74, P2318; KNUDSON AG, 1985, CANCER RES, V45, P1437; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; Kriek E, 1984, Biochim Biophys Acta, V738, P181; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MACKAY J, 1988, LANCET, V2, P1384; Maniatis T, 1989, DECONTAMINATION DILU; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MASHAL R, 1990, BLOOD, V75, P180; MASHARANI U, 1988, NUCLEIC ACIDS RES, V16, P7757, DOI 10.1093/nar/16.15.7757; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MEIER R, 1988, NUCLEIC ACIDS RES, V16, P2340, DOI 10.1093/nar/16.5.2340; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5707, DOI 10.1093/nar/16.12.5707; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROMANO JW, 1989, ONCOGENE, V4, P1483; SAFFHILL R, 1985, BIOCHIM BIOPHYS ACTA, V823, P111, DOI 10.1016/0304-419X(85)90009-5; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUSSI T, 1990, ONCOGENE, V5, P945; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STELL PM, 1972, LANCET, V1, P617; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; THOMPSON AM, 1990, BRIT J CANCER, V61, P74, DOI 10.1038/bjc.1990.17; TUYNS AJ, 1982, INT J CANCER, V30, P9, DOI 10.1002/ijc.2910300103; VERONESI U, 1979, TUMORI TESTA COLLO; WOLF D, 1985, MOL CELL BIOL, V5, P1887, DOI 10.1128/MCB.5.8.1887; WOLF D, 1984, CELL, V38, P453; 1986, MONOGRAPHS EVALUATIO, V38	57	222	226	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1159	1166						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594246				2022-12-25	WOS:A1992HU64200013
J	KONIG, G; MONNING, U; CZECH, C; PRIOR, R; BANATI, R; SCHREITERGASSER, U; BAUER, J; MASTERS, CL; BEYREUTHER, K				KONIG, G; MONNING, U; CZECH, C; PRIOR, R; BANATI, R; SCHREITERGASSER, U; BAUER, J; MASTERS, CL; BEYREUTHER, K			IDENTIFICATION AND DIFFERENTIAL EXPRESSION OF A NOVEL ALTERNATIVE SPLICE ISOFORM OF THE BETA-A4 AMYLOID PRECURSOR PROTEIN (APP) MESSENGER-RNA IN LEUKOCYTES AND BRAIN MICROGLIAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; DNA-POLYMERASE; GENE; ACID; LOCALIZATION; MACROPHAGES; RECEPTOR; ADHESION; SYSTEM; CDNA	The gene for the beta-A4-amyloid precursor protein (APP) consists of 19 exons which code for a typical N- and O-glycosylated transmembrane protein with four extracellular domains followed by the transmembrane domain and a short cytoplasmic domain. The beta-A4-amyloid sequence is part of exons 16 and 17. Several APP isoforms can be generated by alternative splicing of exons 7 and 8, encoding domains with homologies to Kunitz-type protease inhibitors and the MRC OX-2 antigen, respectively. The mechanism by which the pathological beta-A4 is generated is unknown, it is however a critical event in Alzheimer's disease and is distinct from the normally occurring cleavage and secretion of APPs within the beta-A4 sequence. We report here for the first time considerable APP mRNA expression by rat brain microglial cells. In addition we showed by S1 nuclease protection and polymerase chain reaction analysis of reverse transcribed RNA (RT-PCR(TM)) that T-lymphocytes, macrophages, and microglial cells expressed a new APP isoform by selection of a novel alternative splice site and exclusion of exon 15 of the APP gene. This leads to a transmembrane, beta-A4 sequence containing APP variant, lacking 18 amino acid residues close to the amyloidogenic region. The use of this novel alternative splice site alters the structure of APP in close proximity to the beta-A4 region and thus may determine a variant, potentially pathogenic processing of leukocyte-derived APP in brain.	CENT INST MENTAL HLTH, W-6800 MANNHEIM, GERMANY; MAX PLANCK INST PSYCHIAT, W-8033 MARTINSRIED, GERMANY; UNIV HOSP FREIBURG, DEPT PSYCHIAT, W-7800 FREIBURG, GERMANY; UNIV MELBOURNE, DEPT PATHOL, PARKVILLE, VIC 3052, AUSTRALIA	Central Institute of Mental Health; Max Planck Society; University of Freiburg; University of Melbourne	KONIG, G (corresponding author), UNIV HEIDELBERG, ZENTRUM MOLEK BIOL, INF 282, W-6900 HEIDELBERG, GERMANY.			Czech, Christian/0000-0001-7746-0134				AUSBUBEL FM, 1989, CURRENT PROTOCOLS MO; BANATI RB, 1991, NEUROPATH APPL NEURO, V17, P223, DOI 10.1111/j.1365-2990.1991.tb00718.x; BAUER J, 1989, J EXP MED, V170, P1537, DOI 10.1084/jem.170.5.1537; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P31; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARKE L, 1976, CELL, V9, P91, DOI 10.1016/0092-8674(76)90055-6; DESAUVAGE F, 1989, SCIENCE, V245, P651, DOI 10.1126/science.2569763; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GIULIAN D, 1986, J NEUROSCI, V6, P2163; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; ITAGAKI S, 1989, J NEUROIMMUNOL, V24, P173, DOI 10.1016/0165-5728(89)90115-X; JOHNSON SA, 1989, NEUROBIOL AGING, V10, P267, DOI 10.1016/0197-4580(89)90061-4; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KONIG G, 1991, MOL BRAIN RES, V9, P259, DOI 10.1016/0169-328X(91)90010-U; KONIG G, 1990, FEBS LETT, V269, P305, DOI 10.1016/0014-5793(90)81181-M; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MONNING U, 1990, FEBS LETT, V277, P261, DOI 10.1016/0014-5793(90)80861-C; MULLERHILL B, 1989, ANNU REV BIOCHEM, V58, P287; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; PALMERT MR, 1988, SCIENCE, V241, P1080, DOI 10.1126/science.2457949; PERRY VH, 1988, TRENDS NEUROSCI, V11, P273, DOI 10.1016/0166-2236(88)90110-5; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROZEMULLER JM, 1989, J NEUROPATH EXP NEUR, V48, P674, DOI 10.1097/00005072-198911000-00009; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TANAKA S, 1988, BIOCHEM BIOPH RES CO, V157, P472, DOI 10.1016/S0006-291X(88)80273-0; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N; [No title captured]	41	220	230	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10804	10809						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587857				2022-12-25	WOS:A1992HV09000090
J	SHIBANUMA, M; KUROKI, T; NOSE, K				SHIBANUMA, M; KUROKI, T; NOSE, K			ISOLATION OF A GENE ENCODING A PUTATIVE LEUCINE ZIPPER STRUCTURE THAT IS INDUCED BY TRANSFORMING GROWTH FACTOR-BETA-1 AND OTHER GROWTH-FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; HUMAN-LUNG FIBROBLASTS; FACTOR-BETA; MESSENGER-RNA; EXTRACELLULAR-MATRIX; C-MYC; CELL PROLIFERATION; PROTO-ONCOGENE; EXPRESSION; BINDING	A gene sequence (TSC-22) that is induced by transforming growth factor (TGF) beta-1 was isolated by differential screening of a lambda-gt10 cDNA library constructed from poly(A)+ RNA of mouse osteoblastic cells treated with TGF-beta-1 for 2 h. TSC-22 gene expression was transcriptionally activated by TGF-beta-1. It was also induced by phorbol 12-myristate 13-acetate, serum, cholera toxin, or dexamethasone, but not appreciably by epidermal growth factor. Its induction was rapid and transient, reaching a peak 2 h after TGF-beta-1 treatment, and was resistant to cycloheximide like that of c-jun. The nucleotide sequences of TSC-22 cDNA showed no homology with any known gene sequence. The open reading frame and in vitro translation product indicated that the gene encodes a polypeptide of 143 amino acids with a molecular mass of 18 kDa that contains a putative leucine zipper structure. Polyclonal antibody was raised against TSC-22 protein expressed in Escherichia coli cells, and the antibody detected a 18-kDa protein in both the cytoplasmic and nuclear fractions of [S-35]Met-labeled cells. These results indicate that the TSC-22 gene is a new member of the family of early response genes, and encodes a small polypeptide that is a putative transcriptional regulator.	UNIV TOKYO, INST MED SCI,DEPT CANC CELL RES, SHIROKANEDAI 4-6-1,MINATO KU, TOKYO 108, JAPAN	University of Tokyo			Kuroki, Toshio/A-9500-2011	Kuroki, Toshio/0000-0001-6369-4351				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; BASSOLS A, 1988, J BIOL CHEM, V263, P3039; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOYD FT, 1989, J BIOL CHEM, V264, P2272; BRAVO R, 1990, CELL GROWTH DIFFER, V1, P305; CHIANG CP, 1986, J BIOL CHEM, V261, P478; CHILDS CB, 1982, P NATL ACAD SCI-BIOL, V79, P5312, DOI 10.1073/pnas.79.17.5312; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HOWE PH, 1990, J CELL PHYSIOL, V142, P39, DOI 10.1002/jcp.1041420106; HOWE PH, 1989, BIOCHEM J, V261, P879, DOI 10.1042/bj2610879; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KERR LD, 1988, J BIOL CHEM, V263, P16999; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KIM SJ, 1989, J BIOL CHEM, V264, P402; KRAMER IM, 1991, EMBO J, V10, P1083, DOI 10.1002/j.1460-2075.1991.tb08048.x; KURIHARA N, 1986, ENDOCRINOLOGY, V118, P940, DOI 10.1210/endo-118-3-940; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAIHO M, 1986, J CELL BIOL, V103, P2403, DOI 10.1083/jcb.103.6.2403; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LEOF EB, 1986, J CELL PHYSIOL, V127, P83, DOI 10.1002/jcp.1041270111; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; LEWIS SA, 1985, J CELL BIOL, V101, P852, DOI 10.1083/jcb.101.3.852; LUND LR, 1987, EMBO J, V6, P1281, DOI 10.1002/j.1460-2075.1987.tb02365.x; Maniatis T., 1982, MOL CLONING; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NODA M, 1988, J BIOL CHEM, V263, P13916; NOSE K, 1990, CELL GROWTH DIFFER, V1, P511; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; RICCIO A, 1988, NUCLEIC ACIDS RES, V16, P2805, DOI 10.1093/nar/16.7.2805; ROBERTS AB, 1988, ADV CANCER RES, V51, P107, DOI 10.1016/S0065-230X(08)60221-3; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; ROBEY PG, 1987, J CELL BIOL, V105, P457, DOI 10.1083/jcb.105.1.457; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; ROSA F, 1988, SCIENCE, V239, P783, DOI 10.1126/science.3422517; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SAKAI M, 1989, CANCER RES, V49, P5633; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEYEDIN SM, 1987, J BIOL CHEM, V262, P1946; SHIBANUMA M, 1987, EUR J BIOCHEM, V164, P15, DOI 10.1111/j.1432-1033.1987.tb10985.x; SHIBANUMA M, 1991, CELL GROWTH DIFFER, V2, P583; SPORN MB, 1989, JAMA-J AM MED ASSOC, V262, P938, DOI 10.1001/jama.262.7.938; SPORN MB, 1987, J CELL BIOL, V105, P1039, DOI 10.1083/jcb.105.3.1039; TAKEHARA K, 1987, CELL, V49, P415, DOI 10.1016/0092-8674(87)90294-7; THOMPSON KL, 1988, J BIOL CHEM, V263, P19519; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	61	141	154	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10219	10224						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587811				2022-12-25	WOS:A1992HV09000006
J	RICHARDSON, RM; PTASIENSKI, J; HOSEY, MM				RICHARDSON, RM; PTASIENSKI, J; HOSEY, MM			FUNCTIONAL-EFFECTS OF PROTEIN KINASE-C-MEDIATED PHOSPHORYLATION OF CHICK HEART MUSCARINIC CHOLINERGIC RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURO-BLASTOMA CELLS; AGONIST-INDUCED PHOSPHORYLATION; GTP-BINDING PROTEINS; ACETYLCHOLINE-RECEPTOR; PHOSPHOINOSITIDE HYDROLYSIS; BETA-2-ADRENERGIC RECEPTOR; RECONSTITUTION SYSTEM; GUANINE-NUCLEOTIDES; HIGH-AFFINITY; EXPRESSION	Muscarinic cholinergic receptors (mAChR) purified from chick heart were phosphorylated by protein kinase C (PKC) and reconstituted with the purified GTP-binding regulatory protein G(o). The effects of PKC phosphorylation on the interaction of mAChR with G(o) were assessed by monitoring for agonist-stimulated guanosine-5'-O-(3-thiotriphosphate) (GTP-gamma-S) binding to G(o), agonist-stimulated GTPase activity of G(o), and the capability of G(o) to induce high affinity agonist binding to mAChR. Both the receptor-stimulated GTP-gamma-S binding and GTPase activity of G(o) were markedly diminished as a result of PKC-mediated phosphorylation of the mAChR, whereas the ability of G(o) to induce high affinity agonist binding to the receptors was unaffected. When mAChR were first reconstituted with G(o) and then subjected to phosphorylation with PKC, a complete inhibition of the phosphorylation of mAChR by PKC was observed. The inhibitory effect of G(o) on mAChR phosphorylation was concentration-dependent and was prevented by the presence of GTP-gamma-S in the reaction mixtures. Taken together, these results indicate that the phosphorylation of mAChR by PKC modulates receptor/G-protein interactions and that the ability of the receptors to act as substrates for PKC may be regulated by receptor/G-protein interactions.	NORTHWESTERN UNIV,SCH MED,DEPT PHARMACOL,303 E CHICAGO AVE,CHICAGO,IL 60611	Northwestern University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031601] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007140] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 31601] Funding Source: Medline; NINDS NIH HHS [5T32-NS07140-80] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1989, TRENDS NEUROSCI, V12, P148, DOI 10.1016/0166-2236(89)90054-4; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; BROWN AM, 1988, AM J PHYSIOL, V254, pH401, DOI 10.1152/ajpheart.1988.254.3.H401; BROWN JH, 1984, J BIOL CHEM, V259, P3777; BURGOYNE RD, 1983, J NEUROCHEM, V40, P324, DOI 10.1111/j.1471-4159.1983.tb11286.x; BURGOYNE RD, 1981, FEBS LETT, V127, P144, DOI 10.1016/0014-5793(81)80361-4; BURGOYNE RD, 1980, FEBS LETT, V122, P288, DOI 10.1016/0014-5793(80)80458-3; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; CONKLIN BR, 1988, P NATL ACAD SCI USA, V85, P8698, DOI 10.1073/pnas.85.22.8698; ELFAKAHANY EE, 1988, FASEB J, V2, P2575, DOI 10.1096/fasebj.2.10.2838363; FEIGENBAUM P, 1985, J PHARMACOL EXP THER, V233, P134; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FUKUDA K, 1988, NATURE, V335, P355, DOI 10.1038/335355a0; GEORGE WJ, 1970, P NATL ACAD SCI USA, V66, P398, DOI 10.1073/pnas.66.2.398; GILES W, 1976, J PHYSIOL-LONDON, V261, P103, DOI 10.1113/jphysiol.1976.sp011550; HAGA K, 1990, J NEUROCHEM, V54, P1639, DOI 10.1111/j.1471-4159.1990.tb01216.x; HAGA K, 1989, MOL PHARMACOL, V35, P286; HAGA K, 1989, BIOMED RES-TOKYO, V10, P293, DOI 10.2220/biomedres.10.293; HAGA K, 1986, J BIOL CHEM, V261, P133; HAGA K, 1983, J BIOL CHEM, V258, P3575; HO AKS, 1985, BIOCHEM BIOPH RES CO, V133, P1193, DOI 10.1016/0006-291X(85)91263-X; JACOBS KH, 1979, N-S ARCH PHARMACOL, V310, P113; KATADA T, 1987, FEBS LETT, V213, P353, DOI 10.1016/0014-5793(87)81521-1; KEENAN AK, 1987, FEBS LETT, V217, P287, DOI 10.1016/0014-5793(87)80680-4; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KUBO T, 1986, FEBS LETT, V209, P367, DOI 10.1016/0014-5793(86)81144-9; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; KWATRA MM, 1986, J BIOL CHEM, V261, P2429; KWATRA MM, 1987, J BIOL CHEM, V262, P16314; KWATRA MM, 1989, MOL PHARMACOL, V35, P553; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LAI WS, 1987, J PHARMACOL EXP THER, V241, P366; LIAO CF, 1989, J BIOL CHEM, V264, P7328; LILES WC, 1986, J BIOL CHEM, V261, P5307; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MARTINSON EA, 1989, J BIOL CHEM, V264, P14748; MURAD F, 1962, J BIOL CHEM, V237, P1233; NATHANSON NM, 1987, ANNU REV NEUROSCI, V10, P195, DOI 10.1146/annurev.ne.10.030187.001211; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; ORELLANA SA, 1985, J BIOL CHEM, V260, P5236; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; RICHARDSON MR, 1992, MOL PHARMACOL, V40, P908; RICHARDSON RM, 1990, BIOCHEMISTRY-US, V29, P8555, DOI 10.1021/bi00489a008; ROSENBAUM LC, 1987, BIOCHEMISTRY-US, V26, P8183, DOI 10.1021/bi00399a024; SERRA M, 1986, BIOCHEM BIOPH RES CO, V140, P160, DOI 10.1016/0006-291X(86)91071-5; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TIETJE KM, 1991, J BIOL CHEM, V266, P17382; TIETJE KM, 1990, J BIOL CHEM, V265, P2828; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836	53	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10127	10132						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577782				2022-12-25	WOS:A1992HT96500102
J	GUPTA, D; RAO, NVSAVP; PURI, KD; MATTA, KL; SUROLIA, A				GUPTA, D; RAO, NVSAVP; PURI, KD; MATTA, KL; SUROLIA, A			THERMODYNAMIC AND KINETIC-STUDIES ON THE MECHANISM OF BINDING OF METHYLUMBELLIFERYL GLYCOSIDES TO JACALIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTOCARPUS-INTEGRIFOLIA AGGLUTININ; BEAN PSOPHOCARPUS-TETRAGONOLOBUS; ALPHA-D-MANNOPYRANOSIDE; DIMERIC CONCANAVALIN-A; SACCHARIDE BINDING; LIGAND-BINDING; LECTIN; JACKFRUIT; REVEALS	The binding of Artocarpus integrifolia lectin (jacalin) to 4-methylumbelliferyl (Meumb)-glycosides, Gal-alpha-Meumb, Gal-beta-Meumb, GalNAc-alpha-Meumb, GalNAc-beta-Meumb, and Gal-beta-3GalNAc-beta-Meumb was examined by extrinsic fluorescence quenching titration and stopped flow spectrofluorimetry. The binding was characterized by 100% quenching of fluorescence of Meumb-glycosides. Their association constants range from 2.0 x 10(4) to 1.58 x 10(6) M-1 at 15-degrees-C. Entropic contribution is the major stabilizing force for avid binding of Meumb-glycosides indicating the existence of a hydrophobic site that is complementary to their methylumbelliferyl group. The second order association rate constants for interaction of these sugars with lectin at 15-degrees-C vary from 8.8 x 10(5) to 3.24 x 10(6) M-1 s-1, at pH 7.2. The first order dissociation rate constants range from 2.30 to 43.0 s-1 at 15-degrees-C. Despite the differences in their association rate constants, the overall values of association constants for these saccharides are determined by their dissociation rate constants. The second order rate constant for the association of Meumb-glycosides follows a pattern consistent with the magnitude of the activation energies involved therein. Activation parameters for association of all ligands illustrate that the origin of the barrier between binding of jacalin to Meumb-glycosides is entropic, and the enthalpic contribution is small. A correlation between these parameters and the structure of the ligands on the association rates underscores the importance of steric factors in determining protein saccharide recognitions.	ROSEWELL PK MEM INST,NEW YORK,NY 10018		GUPTA, D (corresponding author), INDIAN INST SCI,MOLEC BIOPHYS UNIT,BANGALORE 560012,KARNATAKA,INDIA.		SUROLIA, AVADESHA/C-5442-2009					ACHARYA S, 1990, J BIOL CHEM, V265, P11586; APPUKUTTAN PS, 1977, INDIAN J BIOCHEM BIO, V14, P382; BANERJEE R, 1991, IN PRESS J MOL BIOL; BESSLER W, 1974, ARCH BIOCHEM BIOPHYS, V165, P444, DOI 10.1016/0003-9861(74)90184-2; BUNNMORENO MM, 1981, J IMMUNOL, V127, P427; CHIPMAN DM, 1967, J BIOL CHEM, V242, P4388; CLEGG RM, 1977, BIOCHEMISTRY-US, V16, P167, DOI 10.1021/bi00621a002; CRAMER F, 1967, J AM CHEM SOC, V89, P14, DOI 10.1021/ja00977a003; DEBOECK H, 1983, EUR J BIOCHEM, V131, P453; FARINA RD, 1980, BIOCHIM BIOPHYS ACTA, V631, P428, DOI 10.1016/0304-4165(80)90019-7; FLOWERS HM, 1965, J ORG CHEM, V30, P2041, DOI 10.1021/jo01017a078; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; KHAN MI, 1986, J BIOL CHEM, V261, P3013; KONDOH H, 1986, J IMMUNOL METHODS, V88, P171; LEWIS SD, 1976, ARCH BIOCHEM BIOPHYS, V172, P689, DOI 10.1016/0003-9861(76)90125-9; LOONTIENS FG, 1977, BIOCHEMISTRY-US, V16, P159, DOI 10.1021/bi00621a001; MAHANTA SK, 1990, BIOCHEM J, V265, P831, DOI 10.1042/bj2650831; NEUBERGER A, 1971, CARBOHYD RES, V17, P81; PAYNE NR, 1990, INFECT IMMUN, V58, P3663, DOI 10.1128/IAI.58.11.3663-3670.1990; ROQUEBARREIRA MC, 1985, J IMMUNOL, V134, P1740; SASTRY MVK, 1986, J BIOL CHEM, V261, P1726; SASTRY MVK, 1988, J BIOL CHEM, V263, P14826; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SWAMY MJ, 1986, BIOCHEM J, V234, P515, DOI 10.1042/bj2340515	24	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8909	8918						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577729				2022-12-25	WOS:A1992HR85400034
J	MATSUI, T; TITANI, K; MIZUOCHI, T				MATSUI, T; TITANI, K; MIZUOCHI, T			STRUCTURES OF THE ASPARAGINE-LINKED OLIGOSACCHARIDE CHAINS OF HUMAN VONWILLEBRAND-FACTOR - OCCURRENCE OF BLOOD GROUP-A, GROUP-B, AND GROUP-H(O) STRUCTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON WILLEBRAND FACTOR; HUMAN FACTOR-VIII; COMPLEX-TYPE OLIGOSACCHARIDES; HUMAN CHORIONIC-GONADOTROPIN; SUGAR CHAINS; CARBOHYDRATE MOIETY; ASPERGILLUS-SAITOI; ALPHA-MANNOSIDASE; IMMUNOGLOBULIN-G; BINDING DOMAIN	The asparagine-linked oligosaccharide chains of human von Willebrand factor (vWF) purified from pooled plasma were quantitatively liberated from the polypeptide moiety by hydrazinolysis. After N-acetylation, these were fractionated by paper electrophoresis and sequential chromatography on lectin-affinity columns of concanavalin A, Phaseolus vulgaris erythrophyto-hemagglutinin, Datura stramonium agglutinin, Ricinus communis agglutinin 120, and Ulex europaeus agglutinin I and on a Bio-Gel P-4 column. Their structures were investigated by sequential exoglycosidase digestion in conjunction with methylation analysis. The glycoprotein was shown to be unique in its great diversity of oligosaccharide structures. Another note-worthy finding which had not been reported previously was the occurrence of asparagine-linked oligosaccharide chains with blood group A, B, and H(O) structures. In the present study, this glycoprotein was shown to contain mono- (0.4% of the total oligosaccharides), bi- (78.2%), tri- (12.3%), and tetraantennary (2.3%) complex type oligosaccharides in addition to a series of high mannose type oligosaccharides, Man6-9GleNAC2 (0.8%). Biantennary complex type oligosaccharide chains were those with (8.2%) and without (70.0%) a bisecting GlcNAc residue and approximately 13.2%, 2.2%, and 0.4% of these contained blood group H(O), A, and B structures, respectively. The tri- and tetraantennary complex type chains were those with and without N-acetyllactosamine repeats, and about 13.0% of the triantennary chains without the N-acetyllactosamine repeat contained the blood group H(O) structure. Occurrence of these asparagine-linked oligosaccharides with blood group A and B structures suggest that the repeated use of factor VIII/vWF pooled concentrate for the treatment of hemophiliacs could result in the production of antibodies against vWF with a different blood group from that of the patient, and this development may be pathogenic.	FUJITA HLTH UNIV,SCH MED,INST COMPREHENS MED SCI,DIV BIOMED POLYMER SCI,TOYOAKE,AICHI 47011,JAPAN	Fujita Health University								AMANO J, 1986, J BIOCHEM-TOKYO, V99, P1645, DOI 10.1093/oxfordjournals.jbchem.a135639; ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8326, DOI 10.1021/bi00447a010; CAEKEBEKEPEERLINCK KMJ, 1989, BRIT J HAEMATOL, V73, P217, DOI 10.1111/j.1365-2141.1989.tb00255.x; CHOPEK MW, 1986, BIOCHEMISTRY-US, V25, P3146, DOI 10.1021/bi00359a012; CLAUSEN H, 1989, VOX SANG, V56, P1, DOI 10.1111/j.1423-0410.1989.tb03040.x; DEBEIRE P, 1983, FEBS LETT, V151, P22, DOI 10.1016/0014-5793(83)80334-2; DEMARCO L, 1981, J CLIN INVEST, V68, P321, DOI 10.1172/JCI110259; ENDO Y, 1979, J BIOCHEM-TOKYO, V85, P669; FEDERICI AB, 1988, BLOOD, V71, P947; FEDERICI AB, 1984, J CLIN INVEST, V74, P2049, DOI 10.1172/JCI111628; FINNE J, 1989, J BIOL CHEM, V264, P5720; FOSTER PA, 1987, J BIOL CHEM, V262, P8443; FUJIMURA Y, 1987, J BIOL CHEM, V262, P1734; GILL JC, 1987, BLOOD, V69, P1691; GIRMA JP, 1987, BLOOD, V70, P605; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; GOUDEMAND J, 1985, THROMB HAEMOSTASIS, V53, P390; GRALNICK HR, 1976, SCIENCE, V192, P56, DOI 10.1126/science.1083071; HINDSGAUL O, 1985, CAN J CHEM, V63, P2653, DOI 10.1139/v85-440; HORMIA M, 1983, CELL BIOL INT REP, V7, P467, DOI 10.1016/0309-1651(83)90136-4; ICHISHIMA E, 1981, BIOCHIM BIOPHYS ACTA, V658, P45, DOI 10.1016/0005-2744(81)90248-5; KESSLER CM, 1990, THROMB RES, V57, P59, DOI 10.1016/0049-3848(90)90195-I; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; MATSUI T, 1991, BIOCHEM BIOPH RES CO, V178, P1253, DOI 10.1016/0006-291X(91)91028-B; MIZUOCHI T, 1982, J IMMUNOL, V129, P2016; MIZUOCHI T, 1990, J BIOL CHEM, V265, P8519; MIZUOCHI T, 1987, ARCH BIOCHEM BIOPHYS, V257, P387, DOI 10.1016/0003-9861(87)90581-9; MIZUOCHI T, 1983, J BIOL CHEM, V258, P4126; Mizuochi T, 1988, Biomed Chromatogr, V2, P260; MIZUOCHI T, 1992, IN PRESS METHODS MOL; NARASIMHAN S, 1986, CARBOHYD RES, V149, P65, DOI 10.1016/S0008-6215(00)90370-7; OGATA S, 1975, J BIOCHEM, V78, P687, DOI 10.1093/oxfordjournals.jbchem.a130956; ORDONEZ NG, 1984, ARCH PATHOL LAB MED, V108, P129; PAULSON JC, 1978, J BIOL CHEM, V253, P5617; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; RENWICK AGC, 1987, J BIOCHEM-TOKYO, V101, P1209, DOI 10.1093/oxfordjournals.jbchem.a121985; SAMOR B, 1989, GLYCOCONJUGATE J, V6, P263, DOI 10.1007/BF01047846; SAMOR B, 1986, EUR J BIOCHEM, V158, P295, DOI 10.1111/j.1432-1033.1986.tb09750.x; SANO M, 1989, SEIKAGAKU, V61, P1109; SODETZ JM, 1979, J BIOL CHEM, V254, P754; SODETZ JM, 1978, J BIOL CHEM, V253, P7202; TAKAGI J, 1989, J BIOL CHEM, V264, P6017; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; TITANI K, 1988, TRENDS BIOCHEM SCI, V13, P94, DOI 10.1016/0968-0004(88)90048-5; WAGNER DD, 1986, J CELL BIOL, V102, P1320, DOI 10.1083/jcb.102.4.1320; WALKER RA, 1985, J PATHOL, V146, P123, DOI 10.1002/path.1711460207; YAMASHITA K, 1980, J BIOL CHEM, V255, P5635; YAMASHITA K, 1980, BIOCHEM BIOPH RES CO, V96, P1335, DOI 10.1016/0006-291X(80)90097-2; YAMASHITA K, 1987, J BIOL CHEM, V262, P1602; YAMASHITA K, 1981, BIOCHEM BIOPH RES CO, V100, P226, DOI 10.1016/S0006-291X(81)80086-1; YAMASHITA K, 1982, METHOD ENZYMOL, V83, P105; YAMASHITA K, 1983, J BIOL CHEM, V258, P4753	52	153	159	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8723	8731						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577715				2022-12-25	WOS:A1992HR85400006
J	JOHNSON, E; HENZEL, W; DEISSEROTH, A				JOHNSON, E; HENZEL, W; DEISSEROTH, A			AN ISOFORM OF PROTEIN DISULFIDE ISOMERASE ISOLATED FROM CHRONIC MYELOGENOUS LEUKEMIA-CELLS ALTERS COMPLEX-FORMATION BETWEEN NUCLEAR PROTEINS AND REGULATORY REGIONS OF INTERFERON-INDUCIBLE GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATL-DERIVED FACTOR; PHOSPHOLIPASE-C; TRANSCRIPTIONAL REGULATOR; SYNTHETASE GENE; THIOREDOXIN; PROMOTER; PURIFICATION; ACTIVATION; SEQUENCE; BINDING	We have previously shown that the electrophoretic mobility of complexes formed in vitro between nuclear proteins and the regulatory domains of interferon-inducible genes is altered by an extranuclear protein present in elevated levels in the myeloid cells of chronic myelogenous leukemia patients. Interferon-alpha reduces the level of this activity only in the cells of patients who are clinically sensitive to the antiproliferative effects of interferon-alpha. We have purified this protein to homogeneity and found it to be a 57-kDa protein which corresponds to an isoform of protein disulfide isomerase. Protein disulfide isomerase is an oxidoreductase which catalyzes the interconversion between the reduced and oxidized states of proteins which contain multiple sulfhydryl groups and disulfide bonds. These studies suggest that this protein may play an important role in the transcriptional activation of interferon-inducible genes, perhaps through redox mechanisms.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT HEMATOL, HOUSTON, TX 77030 USA; GENENTECH INC, S SAN FRANCISCO, CA 94080 USA	University of Texas System; UTMD Anderson Cancer Center; Roche Holding; Genentech				Henzel, William/0000-0003-2940-3797	NATIONAL CANCER INSTITUTE [P01CA049639] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA49639-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; BENNETT CF, 1988, NATURE, V334, P268, DOI 10.1038/334268a0; BENNETT CF, 1987, J BIOL CHEM, V262, P13789; CROOKE ST, 1989, CELL CALCIUM, V10, P309, DOI 10.1016/0143-4160(89)90057-2; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; ERICKSON RR, 1987, J PHARMACOL EXP THER, V242, P472; FLEGEL L, 1990, J BIOL CHEM, V265, P15496; HAUGEJORDEN SM, 1991, J BIOL CHEM, V266, P6015; HEMPEL WM, 1991, J IMMUNOL, V146, P3713; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOWARD OMZ, 1990, BLOOD, V76, P1117; IMAM AMA, 1990, NUCLEIC ACIDS RES, V18, P6573, DOI 10.1093/nar/18.22.6573; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MARTIN JL, 1991, BIOCHEM BIOPH RES CO, V178, P679, DOI 10.1016/0006-291X(91)90161-Y; MCCONKEY DJ, 1986, LIFE SCI, V38, P2139, DOI 10.1016/0024-3205(86)90213-4; MCMAHON M, 1986, J VIROL, V57, P362, DOI 10.1128/JVI.57.1.362-366.1986; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; SEONG DC, 1990, J CLIN INVEST, V86, P1664, DOI 10.1172/JCI114889; SHARROCKS AD, 1990, FEBS LETT, V270, P119, DOI 10.1016/0014-5793(90)81248-M; SHRINER CL, 1984, J BIOL CHEM, V259, P1383; SIPES NJ, 1990, CELL GROWTH DIFFER, V1, P241; SRIVASTAVA SP, 1991, J BIOL CHEM, V266, P20337; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; STRIFE A, 1990, CHRONIC MYELOGENOUS, P1; SUGITA K, 1987, MOL CELL BIOL, V7, P2625, DOI 10.1128/MCB.7.7.2625; TAGAYA Y, 1988, J IMMUNOL, V140, P2614; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; TALPAZ M, 1986, NEW ENGL J MED, V314, P1065, DOI 10.1056/NEJM198604243141701; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; YAMAMOTO S, 1986, BLOOD, V67, P1714; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	43	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14412	14417						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629227				2022-12-25	WOS:A1992JD32500094
J	PAYNE, DW; PACKMAN, JN; ADASHI, EY				PAYNE, DW; PACKMAN, JN; ADASHI, EY			FOLLICLE-STIMULATING-HORMONE INHIBITS GRANULOSA-CELL 5-ALPHA-REDUCTASE ACTIVITY - POSSIBLE ROLE OF 5-ALPHA-REDUCTASE AS A STEROIDOGENIC PUBERTAL SWITCH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; 1ST OVULATION; IMMATURE RAT; PROLACTIN; DIFFERENTIATION; EXPRESSION; OVARIES; GROWTH	In order to elucidate the role of 5-alpha-reductase in the ovarian pubertal transition from 5-alpha-reduced to non-5-alpha-reduced steroids, we examined the characteristics and regulation of granulosa cell (GC) 5-alpha-reductase activity. Maximum activity was observed at 37-degrees-C and at a pH of 6.5-8.0. Synthetic 4-aza-3-oxosteroids proved to be potent inhibitors (76% inhibition at 0.1-mu-M) of ovarian 5-alpha-reductase activity, and 20-alpha-DHP was a better substrate than either progesterone or testosterone (4- or 7-fold higher affinity constants, respectively). The K(m) (20-alpha-DHP) of the enzyme was 0.50 +/- 0.03-mu-M and 0.75 +/- 0.20-mu-M in homogenates of whole ovaries and GC, respectively. 17-beta-Estradiol was a non-competitive inhibitor (K(I) = 6.97-mu-M). 5-alpha-Reductase activity was 22-fold (immature) to 68-fold (mature) higher in liver than ovary and 4-fold higher in thecainterstitial shells than in isolated GC. Ovarian 5-alpha-reductase activity decreased markedly with age (>60% inhibition in mature, randomly cycling rats as compared to immature rats). In vivo administration of follicle-stimulating hormone (FSH) to immature rats produced a dose-dependent decrease in GC 5-alpha-reductase activity (36 +/- 1.1% and 46 +/- 5.9% inhibition following 12-mu-g and 24-mu-g FSH, respectively). Similarly, the in vitro provision of FSH (100 ng/ml) to cultured GC from immature rats resulted in (36-59%) inhibition in 5-alpha-reduced steroids. Inasmuch as FSH promotes GC development and the advancement of puberty, its ability to "switch-off" ovarian 5-alpha-reductase activity may enhance the formation of biologically potent (i.e. non-5-alpha-reduced) progestins as well as the availability of aromatizable androgens, in the best interests of pubertal steroidogenesis.			PAYNE, DW (corresponding author), UNIV MARYLAND,SCH MED,DEPT OBSTET & GYNECOL,DIV REPROD ENDOCRINOL,BRESSLER RES BLDG 11-011,BALTIMORE,MD 21201, USA.				NICHD NIH HHS [HD-00697, HD-19998] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD019998] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSSON S, 1990, P NATL ACAD SCI USA, V87, P3640, DOI 10.1073/pnas.87.10.3640; ANDERSSON S, 1989, J BIOL CHEM, V264, P16249; ANDERSSON S, 1991, NATURE, V354, P159, DOI 10.1038/354159a0; ANDREANI CL, 1991, J BIOL CHEM, V266, P6761; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHASE DJ, 1985, BIOL REPROD, V33, P637, DOI 10.1095/biolreprod33.3.637; ECKSTEIN B, 1977, BIOCHIM BIOPHYS ACTA, V499, P1, DOI 10.1016/0304-4165(77)90222-7; ECKSTEIN B, 1977, BIOCHIM BIOPHYS ACTA, V489, P143, DOI 10.1016/0005-2760(77)90240-5; FARKASH Y, 1988, P NATL ACAD SCI USA, V85, P5824, DOI 10.1073/pnas.85.16.5824; FREDERIKSEN DW, 1971, J BIOL CHEM, V246, P2584; FUKUDA S, 1979, J STEROID BIOCHEM, V11, P1421, DOI 10.1016/0022-4731(79)90116-X; GOLDRING NB, 1985, J BIOL CHEM, V260, P913; HERNANDEZ ER, 1988, ENDOCRINOLOGY, V122, P1603, DOI 10.1210/endo-122-4-1603; HSUEH AJW, 1984, ENDOCR REV, V5, P76, DOI 10.1210/edrv-5-1-76; JENKINS EP, 1992, J CLIN INVEST, V89, P293, DOI 10.1172/JCI115574; KARAKAWA T, 1976, ENDOCRINOLOGY, V98, P571, DOI 10.1210/endo-98-3-571; LERNER N, 1976, ENDOCRINOLOGY, V98, P179, DOI 10.1210/endo-98-1-179; LERNER N, 1978, ENDOCRINOLOGY, V103, P1039, DOI 10.1210/endo-103-4-1039; LIANG T, 1983, J STEROID BIOCHEM, V19, P385, DOI 10.1016/S0022-4731(83)80051-X; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MARTEL C, 1990, ENDOCRINOLOGY, V127, P2726, DOI 10.1210/endo-127-6-2726; MEIJSROELOFS HMA, 1975, J ENDOCRINOL, V67, P275, DOI 10.1677/joe.0.0670275; OJEDA SR, 1972, ENDOCRINOLOGY, V90, P466, DOI 10.1210/endo-90-2-466; OJEDA SR, 1976, ENDOCRINOLOGY, V98, P630, DOI 10.1210/endo-98-3-630; ORLY J, 1979, CELL, V17, P295, DOI 10.1016/0092-8674(79)90155-7; PAYNE DW, 1985, J BIOL CHEM, V260, P3648; PAYNE DW, 1988, BIOL REPROD, V39, P581, DOI 10.1095/biolreprod39.3.581; SUZUKI K, 1978, ENDOCRINOLOGY, V102, P1595, DOI 10.1210/endo-102-5-1595; TAKEYAMA M, 1986, ENDOCRINOLOGY, V118, P2268, DOI 10.1210/endo-118-6-2268; TOOROP AI, 1984, J ENDOCRINOL, V100, P281, DOI 10.1677/joe.0.1000281; UILENBROEK JTJ, 1985, J ENDOCRINOL, V107, P113, DOI 10.1677/joe.0.1070113	31	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13348	13355						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618837				2022-12-25	WOS:A1992JB74600042
J	BYRNE, BJ; KACZOROWSKI, YJ; COUTU, MD; CRAIG, SW				BYRNE, BJ; KACZOROWSKI, YJ; COUTU, MD; CRAIG, SW			CHICKEN VINCULIN AND META-VINCULIN ARE DERIVED FROM A SINGLE GENE BY ALTERNATIVE SPLICING OF A 207-BASE PAIR EXON UNIQUE TO META-VINCULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC VARIANTS; SMOOTH-MUSCLE; MICROFILAMENT BUNDLES; OVERLAY TECHNIQUE; MOLECULAR-WEIGHT; BINDING-PROTEINS; METAVINCULIN; ATTACHMENT; SARCOLEMMA; EXPRESSION	meta-Vinculin and vinculin are closely related proteins that are cytoplasmic components of microfilament-associated cell junctions. This report describes the structural relationship between these two proteins and the genetic basis for tissue-specific expression of meta-vinculin. Analysis of genomic DNA coding for amino acids 676-1066 of vinculin revealed 9 exons spanning an 11.7-kilobase pair region of the genome. In the 4 kilobase pairs of intervening sequence that separates vinculin exons E896-E915 and E916-E984, there is an open reading frame that predicts a sequence homologous to the 68-amino acid peptide specific to porcine meta-vinculin (Gimona, M., Small, J. V., Moeremans, M., Van Damme, J., Puype, M., and Vandekerckhove, J. (1988) EMBO J. 7, 2329-2334). Analysis of the corresponding cDNA established that chicken meta-vinculin contains a 69-amino acid insertion between residues 915 and 916 of vinculin and that there are no other amino acid sequence differences between chicken vinculin and meta-vinculin. Muscle-specific expression of meta-vinculin occurs by alternative splicing of a transcript produced from a single gene because: all 20 genomic isolates that contain the 3' vinculin exons, also contain the meta-vinculin-specific exon; Southern blots performed at high stringency with exon-specific probes indicate the presence of a single gene; and the 3'-untranslated sequences of vinculin and meta-vinculin cDNAs are identical.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD027799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM041605, R01GM041605] Funding Source: NIH RePORTER; NICHD NIH HHS [5 P30-HD27799-02] Funding Source: Medline; NIGMS NIH HHS [GM 41605] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BARSTEAD RJ, 1991, J CELL BIOL, V114, P715, DOI 10.1083/jcb.114.4.715; BELKIN AM, 1988, J CELL BIOL, V107, P545, DOI 10.1083/jcb.107.2.545; BELKIN AM, 1988, J BIOL CHEM, V263, P6631; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; BYRNE BJ, 1991, J CELL BIOL, V111, pA38; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; COUTU MD, 1987, BIOCHEM BIOPH RES CO, V147, P637, DOI 10.1016/0006-291X(87)90978-8; COUTU MD, 1988, P NATL ACAD SCI USA, V85, P8535, DOI 10.1073/pnas.85.22.8535; CRAIG SW, 1983, CELL MOTIL CYTOSKEL, V3, P449, DOI 10.1002/cm.970030513; DANOWSKI B A, 1991, Journal of Cell Biology, V115, p368A; ENDO T, 1982, BIOCHEM BIOPH RES CO, V107, P1467, DOI 10.1016/S0006-291X(82)80164-2; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERAMISCO JR, 1982, J BIOL CHEM, V257, P1024; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GEIGER B, 1982, J MOL BIOL, V159, P685, DOI 10.1016/0022-2836(82)90108-5; GEIGER B, 1980, P NATL ACAD SCI-BIOL, V77, P4127, DOI 10.1073/pnas.77.7.4127; GEIGER B, 1979, CELL, V18, P193, DOI 10.1016/0092-8674(79)90368-4; GIMONA M, 1988, EMBO J, V7, P2329, DOI 10.1002/j.1460-2075.1988.tb03076.x; GIMONA M, 1987, J MUSCLE RES CELL M, V8, P329, DOI 10.1007/BF01568889; GLUKHOVA MA, 1988, P NATL ACAD SCI USA, V85, P9542, DOI 10.1073/pnas.85.24.9542; ITO S, 1983, J BIOL CHEM, V258, P4626; JONES P, 1989, J CELL BIOL, V109, P2917, DOI 10.1083/jcb.109.6.2917; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOLONY L, 1985, J CELL BIOCHEM, V29, P3136; NIGGLI V, 1986, J BIOL CHEM, V261, P6912; OTTO JJ, 1983, J CELL BIOL, V97, P1283, DOI 10.1083/jcb.97.4.1283; PARDO JV, 1983, P NATL ACAD SCI-BIOL, V80, P1008, DOI 10.1073/pnas.80.4.1008; PARDO JV, 1983, J CELL BIOL, V97, P1081, DOI 10.1083/jcb.97.4.1081; PAVALKO FM, 1991, J CELL BIOL, V114, P481, DOI 10.1083/jcb.114.3.481; PRICE GJ, 1987, BIOCHEM J, V245, P595, DOI 10.1042/bj2450595; PRICE GJ, 1989, BIOCHEM J, V259, P453, DOI 10.1042/bj2590453; SAGA S, 1985, EXP CELL RES, V156, P45, DOI 10.1016/0014-4827(85)90260-5; Sambrook J, 1989, MOL CLONING LABORATO; SILICIANO JD, 1987, J CELL BIOL, V104, P473, DOI 10.1083/jcb.104.3.473; SILICIANO JD, 1982, NATURE, V300, P533, DOI 10.1038/300533a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1989, EUR J CELL BIOL, V49, P202; WESTMEYER A, 1990, EMBO J, V9, P2071, DOI 10.1002/j.1460-2075.1990.tb07374.x; WILKINS JA, 1983, BIOCHEM BIOPH RES CO, V116, P1026, DOI 10.1016/S0006-291X(83)80245-9	41	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12845	12850						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618784				2022-12-25	WOS:A1992HZ48300070
J	CHOY, LN; ROSEN, BS; SPIEGELMAN, BM				CHOY, LN; ROSEN, BS; SPIEGELMAN, BM			ADIPSIN AND AN ENDOGENOUS PATHWAY OF COMPLEMENT FROM ADIPOSE-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SERINE PROTEASE HOMOLOG; FACTOR-B; ALTERNATIVE PATHWAY; GENE-EXPRESSION; HORMONAL-REGULATION; HUMAN-FIBROBLASTS; HUMAN-MONOCYTES; MESSENGER-RNA; FACTOR-ALPHA	The alternative complement pathway is best known for its role in humoral suppression of infectious agents. We have previously shown that adipose cells synthesize adipsin, the mouse homolog of human complement factor D, and that the synthesis of this protein is reduced in several rodent models of obesity. We show here that adipose cells and adipose tissue also synthesize two other essential components of the alternative pathway of complement, factors C3 and B, and activate the proximal portion of this pathway. This activation occurs in the absence of infectious agents and without triggering the terminal, lytic part of this pathway. We demonstrate the production in vitro of several polypeptides characteristic of complement activation that are known to have potent biological activities, including the anaphylatoxin C3a. Cultured adipocytes require stimulation with cytokines to activate complement, while explanted adipose tissue has no such requirement. The adipose tissue from obese mice is deficient in this localized activation of the alternative pathway. These results indicate that complement activation occurs in a localized site, adipose tissue, in normal mice and is impaired in a state of metabolic dysfunction. This suggests a novel function for the proximal portion of this complement pathway related to adipose cell biology or energy balance.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	CHOY, LN (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA.							AMBRUS JL, 1990, J IMMUNOL, V144, P1549; AREND WP, 1989, J IMMUNOL, V142, P173; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BIANCO C, 1979, P NATL ACAD SCI USA, V76, P888, DOI 10.1073/pnas.76.2.888; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOK KS, 1987, SCIENCE, V237, P402, DOI 10.1126/science.3299705; COOK KS, 1985, P NATL ACAD SCI USA, V82, P6480, DOI 10.1073/pnas.82.19.6480; DANI C, 1989, MOL CELL ENDOCRINOL, V63, P199, DOI 10.1016/0303-7207(89)90096-8; DOBSON DE, 1987, J BIOL CHEM, V262, P1804; FALUS A, 1990, MOL IMMUNOL, V27, P197, DOI 10.1016/0161-5890(90)90115-G; FAUST IM, 1979, P SOC EXP BIOL MED, V161, P111, DOI 10.3181/00379727-161-40501; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FISHELSON Z, 1984, J IMMUNOL, V132, P1425; FLIER JS, 1987, SCIENCE, V237, P405, DOI 10.1126/science.3299706; FLIER JS, 1989, RECENT PROG HORM RES, V45, P567; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FOSTER DW, 1987, HARRISONS PRINCIPLES, P1677; HAEFFNERCAVAILLON N, 1987, J IMMUNOL, V139, P794; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HOURCADE D, 1989, ADV IMMUNOL, V45, P381, DOI 10.1016/S0065-2776(08)60697-5; HUGLI TE, 1990, CURR TOP MICROBIOL, V153, P181; Jarett L, 1974, Methods Enzymol, V31, P60; KAM CM, 1987, J BIOL CHEM, V262, P3444; KATZ Y, 1989, J IMMUNOL, V142, P3862; KATZ Y, 1989, EUR J IMMUNOL, V19, P983, DOI 10.1002/eji.1830190605; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPPIN DF, 1990, BIOCHEM J, V268, P387, DOI 10.1042/bj2680387; LAW SKA, 1988, COMPLEMENT; LESAVRE P, 1982, EUR J IMMUNOL, V12, P252, DOI 10.1002/eji.1830120317; LESAVRE PH, 1979, J IMMUNOL, V123, P529; LESAVRE PH, 1978, J EXP MED, V148, P1498, DOI 10.1084/jem.148.6.1498; LOWELL BB, 1990, ENDOCRINOLOGY, V126, P1514, DOI 10.1210/endo-126-3-1514; MAY LT, 1988, J BIOL CHEM, V263, P7760; MIN HY, 1986, NUCLEIC ACIDS RES, V14, P8879; PATTON JS, 1986, P NATL ACAD SCI USA, V83, P8313, DOI 10.1073/pnas.83.21.8313; PEKALA P, 1990, J BIOL CHEM, V265, P18051; PERLMUTTER DH, 1986, J CLIN INVEST, V78, P1349, DOI 10.1172/JCI112721; PRAZ F, 1986, J EXP MED, V163, P1349, DOI 10.1084/jem.163.5.1349; RAMADORI G, 1988, EUR J IMMUNOL, V18, P1259, DOI 10.1002/eji.1830180817; RIPOCHE J, 1988, J EXP MED, V168, P1917, DOI 10.1084/jem.168.5.1917; ROSEN BS, 1989, SCIENCE, V244, P1483, DOI 10.1126/science.2734615; SCHUPF N, 1983, J NEUROIMMUNOL, V5, P305, DOI 10.1016/0165-5728(83)90051-6; SPIEGELMAN BM, 1989, J BIOL CHEM, V264, P1811; SUNDSMO JS, 1981, J EXP MED, V154, P763, DOI 10.1084/jem.154.3.763; WHITE RT, 1991, IN PRESS MOL CELL BI; ZECHNER R, 1988, MOL CELL BIOL, V8, P2394, DOI 10.1128/MCB.8.6.2394	46	260	266	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12736	12741						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618777				2022-12-25	WOS:A1992HZ48300055
J	NAIR, S; DEY, R; SANFORD, JP; DOYLE, D				NAIR, S; DEY, R; SANFORD, JP; DOYLE, D			MOLECULAR-CLONING AND ANALYSIS OF AN EIF-4A-RELATED RAT-LIVER NUCLEAR-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC INITIATION FACTOR-4A; HEPATOCYTE BILE CANALICULUS; ATP-BINDING SITE; PLASMA-MEMBRANE; FACTOR EIF-4A; RNA HELICASE; ANTIGEN; EXPRESSION; GENES; LIBRARIES	In this paper, we report the cloning and analysis of a cDNA encoding a protein of M(r) congruent-to 47,000 (p47), which is localized to the nucleus of rat hepatocytes. The cDNA showed 37% overall sequence identity with a mouse translation initiation factor, eIF-4A, which belongs to a family of putative ATP-dependent RNA helicases. We raised polyclonal antibodies against the fusion protein and by indirect immunofluorescence on primary cultures of hepatocytes have demonstrated that p47 is located in the nucleus. Although only approximately 27% of hepatocytes showed this nuclear staining, most of the nuclei in proliferating transformed cell lines such as 3T3, PtK-1, and Hela were fluorescently labeled. Studies on serum-starved cells in culture indicated that p47 was expressed in a cell cycle-dependent manner. Northern analyses demonstrated that the levels of p47 mRNA were high in fetal liver and dropped significantly after birth to low levels in adult liver. Our data suggest that p47 is developmentally regulated in rat liver at the mRNA level.	SUNY BUFFALO,DEPT BIOL SCI,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL CANCER INSTITUTE [R01CA038773] Funding Source: NIH RePORTER; NCI NIH HHS [CA 38773] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMSON RD, 1987, J BIOL CHEM, V262, P3826; Aronson N N Jr, 1974, Methods Enzymol, V31, P90; BARTLES JR, 1985, J BIOL CHEM, V260, P2792; BENEDETTI AD, 1990, P NATL ACAD SCI USA, V87, P8212; CELIS JE, 1985, P NATL ACAD SCI USA, V82, P3262, DOI 10.1073/pnas.82.10.3262; CHING G, 1990, J CELL BIOL, V110, P255, DOI 10.1083/jcb.110.2.255; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; COOK J, 1983, J CELL BIOL, V97, P1823, DOI 10.1083/jcb.97.6.1823; CROY RG, 1983, P NATL ACAD SCI-BIOL, V80, P4699, DOI 10.1073/pnas.80.15.4699; DIAMOND M, 1987, J BIOL CHEM, V262, P14760; DOBBERSTEIN B, 1979, CELL, V17, P759, DOI 10.1016/0092-8674(79)90316-7; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GRIFO JA, 1984, J BIOL CHEM, V259, P8648; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; LIN SH, 1989, J BIOL CHEM, V264, P14408; LINDER P, 1989, P NATL ACAD SCI USA, V86, P2286, DOI 10.1073/pnas.86.7.2286; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MANIATIS T, 1982, MOL CLONING, V1; NAIR S, 1991, THESIS STATE U NEW Y; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; NIELSEN PJ, 1985, NUCLEIC ACIDS RES, V13, P6867, DOI 10.1093/nar/13.19.6867; NISHI K, 1988, NATURE, V336, P496, DOI 10.1038/336496a0; ODIN P, 1986, BIOCHEM J, V236, P559, DOI 10.1042/bj2360559; PETELL JK, 1987, J BIOL CHEM, V262, P14753; ROBINSON PA, 1988, J IMMUNOL METHODS, V108, P115, DOI 10.1016/0022-1759(88)90409-7; ROZEN F, 1989, MOL CELL BIOL, V9, P4061, DOI 10.1128/MCB.9.9.4061; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5453; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHMID SR, 1991, MOL CELL BIOL, V11, P3463, DOI 10.1128/MCB.11.7.3463; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SMITH HC, 1982, BIOCHEMISTRY-US, V21, P6751, DOI 10.1021/bi00269a021; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAVALI S, 1990, FASEB J, V4, P3209, DOI 10.1096/fasebj.4.14.2227212; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	47	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12928	12935						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618789				2022-12-25	WOS:A1992HZ48300080
J	BAXTER, A; FITZGERALD, BJ; HUTSON, JL; MCCARTHY, AD; MOTTERAM, JM; ROSS, BC; SAPRA, M; SNOWDEN, MA; WATSON, NS; WILLIAMS, RJ; WRIGHT, C				BAXTER, A; FITZGERALD, BJ; HUTSON, JL; MCCARTHY, AD; MOTTERAM, JM; ROSS, BC; SAPRA, M; SNOWDEN, MA; WATSON, NS; WILLIAMS, RJ; WRIGHT, C			SQUALESTATIN-1, A POTENT INHIBITOR OF SQUALENE SYNTHASE, WHICH LOWERS SERUM-CHOLESTEROL INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HMG COA REDUCTASE; ISOPRENOID SYNTHESIS; LIVER-MITOCHONDRIA; TISSUE; RAT; LOVASTATIN; CELLS	Squalestatin 1 is a member of a novel family of fermentation products isolated from a previously unknown Phoma species (Coelomycetes). Squalestatin 1 is a potent, selective inhibitor of squalene synthase, a key enzyme in cholesterol biosynthesis; in vitro, 50% inhibition of enzyme activity is observed at a concentration of 12 +/- 5 nM (range of 4-22 nM). Squalestatin 1 inhibits cholesterol biosynthesis from [C-14]acetate by isolated rat hepatocytes (50% inhibition at 39 nM) and by rat liver in vivo. In marmosets, a species with a lipoprotein profile similar to that of man, squalestatin 1 lowers serum cholesterol by up to 75%. This compound will allow further investigation of the control of the sterol biosynthesis pathway and could also lead to the development of new therapies for elevated serum cholesterol.	GLAXO GRP RES LTD,GREENFORD RD,GREENFORD UB6 0HE,MIDDX,ENGLAND; GLAXO GRP RES LTD,WARE SG12 OD5,HERTS,ENGLAND	GlaxoSmithKline; GlaxoSmithKline								BILLER SA, 1988, J MED CHEM, V31, P1869, DOI 10.1021/jm00118a001; BILLER SA, 1991, J MED CHEM, V34, P1912, DOI 10.1021/jm00110a024; BROWN MS, 1980, J LIPID RES, V21, P505; BRUENGER E, 1986, BIOCHIM BIOPHYS ACTA, V876, P500, DOI 10.1016/0005-2760(86)90037-8; CLAEYS D, 1989, J BIOL CHEM, V264, P14627; CROOK D, 1990, ARTERIOSCLEROSIS, V10, P625, DOI 10.1161/01.ATV.10.4.625; DAWSON MJ, 1992, J ANTIBIOT, V45, P614; FOLKERS K, 1990, P NATL ACAD SCI USA, V87, P8931, DOI 10.1073/pnas.87.22.8931; HARPER RD, 1975, BIOCHEM J, V152, P485, DOI 10.1042/bj1520485; MAHER VMG, 1990, Q J MED, V74, P165; ROBINSON BH, 1970, EUR J BIOCHEM, V15, P263, DOI 10.1111/j.1432-1033.1970.tb01003.x; SEGLEN PO, 1973, EXP CELL RES, V76, P25, DOI 10.1016/0014-4827(73)90414-X; SIDEBOTTOM PJ, 1992, J ANTIBIOT, V45, P623; TAIT RM, 1992, IN PRESS ANAL BIOCH; TSUJITA Y, 1986, BIOCHIM BIOPHYS ACTA, V877, P50, DOI 10.1016/0005-2760(86)90117-7; WATSON JA, 1969, ARCH BIOCHEM BIOPHYS, V135, P209, DOI 10.1016/0003-9861(69)90532-3; WATSON JA, 1985, J BIOL CHEM, V260, P4083; 1984, JAMA-J AM MED ASSOC, V251, P365; 1984, JAMA-J AM MED ASSOC, V251, P351	19	213	228	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11705	11708						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601846				2022-12-25	WOS:A1992HY94700012
J	JOHNSON, MR; BRUZDZINSKI, CJ; WINOGRAD, SS; GELEHRTER, TD				JOHNSON, MR; BRUZDZINSKI, CJ; WINOGRAD, SS; GELEHRTER, TD			REGULATORY SEQUENCES AND PROTEIN-BINDING SITES INVOLVED IN THE EXPRESSION OF THE RAT PLASMINOGEN-ACTIVATOR INHIBITOR-1 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE GENE; CYCLIC-NUCLEOTIDE REGULATION; RNA POLYMERASE-II; NUCLEAR FACTOR-I; HANDED Z-DNA; HEPATOMA-CELLS; TRANSCRIPTIONAL ACTIVATION; DEXAMETHASONE INHIBITION; EUKARYOTIC TRANSCRIPTION; ENZYMATIC AMPLIFICATION	Plasminogen activator inhibitor-1 (PAI-1) is a serine protease inhibitor that inhibits both tissue-type and urokinase-type plasminogen activators. Expression of PAI-1 is regulated-by growth factors, cytokines, and hormones. To determine the molecular mechanisms involved in the basal expression of the rat PAI-1 gene, we have analyzed the cis-acting sequences and the trans-acting factors involved in the transcription of this gene in the HTC rat hepatoma cell line. DNase I protection analyses revealed eight regions within the first 764 base pairs of 5'-flanking sequence that interact specifically with HTC cell nuclear proteins. The proteins that bind to five of the eight footprinted sites were identified as PEA3-, Sp1-, and CTF/NF-1-like proteins using competition electrophoretic mobility shift assays. The expression of fusion genes containing progressive 5' deletions of the rat PAI-1 promoter linked to the chloramphenicol acetyltransferase reporter gene were analyzed in transient transfection experiments in HTC cells. These studies demonstrated the Sp1 and CTF/NF-1 sites to be important for transcriptional activation. Two of the footprinted sites contain the sequence 5'-TTTGn(n)TCAAT-3' and were shown in competition electrophoretic mobility shift assays to bind the same or related protein(s). Sequences containing these sites, from -764 to -628 base pairs, and from -266 to -188 base pairs, were identified in functional studies as repressor elements of transcription.	UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL CANCER INSTITUTE [R01CA022729, R37CA022729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007544] Funding Source: NIH RePORTER; NCI NIH HHS [CA22729] Funding Source: Medline; NIGMS NIH HHS [T32GM07544] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; ANDREASEN PA, 1990, MOL CELL ENDOCRINOL, V68, P1, DOI 10.1016/0303-7207(90)90164-4; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BACHMANN F, 1987, THROMB DIATH HAEMO, P227; BAROUSKIMILLER PA, 1982, P NATL ACAD SCI-BIOL, V79, P2319, DOI 10.1073/pnas.79.7.2319; BOSMA PJ, 1988, J BIOL CHEM, V263, P9129; BRUZDZINSKI CJ, 1990, J BIOL CHEM, V265, P2078; BRUZDZINSKI CJ, 1989, DNA CELL BIOL, V9, P691; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHANG DJ, 1990, J BIOL CHEM, V265, P9496; COLEMAN PL, 1986, J BIOL CHEM, V261, P4352; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COURTOIS SJ, 1990, NUCLEIC ACIDS RES, V18, P57, DOI 10.1093/nar/18.1.57; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GELEHRTER TD, 1987, MOL ENDOCRINOL, V1, P97, DOI 10.1210/mend-1-1-97; GELEHRTER TD, 1986, J CLIN INVEST, V77, P165, DOI 10.1172/JCI112271; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P150; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAY T A, 1990, Technique (Philadelphia), V2, P147; GUMUCIO DL, 1988, MOL CELL BIOL, V8, P5310, DOI 10.1128/MCB.8.12.5310; GUSTAFSON TA, 1989, MOL CELL BIOL, V9, P3269, DOI 10.1128/MCB.9.8.3269; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAMILTON JA, 1985, ENDOCRINOLOGY, V116, P2186, DOI 10.1210/endo-116-6-2186; HEATON JH, 1990, MOL ENDOCRINOL, V4, P171, DOI 10.1210/mend-4-1-171; HEATON JH, 1989, MOL ENDOCRINOL, V3, P349, DOI 10.1210/mend-3-2-349; HEATON JH, 1992, MOL ENDOCRINOL, V6, P53, DOI 10.1210/me.6.1.53; HEATON JH, 1989, MOL ENDOCRINOL, V3, P185, DOI 10.1210/mend-3-1-185; HUBER P, 1987, NUCLEIC ACIDS RES, V15, P1615, DOI 10.1093/nar/15.4.1615; HUDSPETH MES, 1982, CELL, V30, P617, DOI 10.1016/0092-8674(82)90258-6; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; JANSON L, 1989, J MOL BIOL, V205, P387, DOI 10.1016/0022-2836(89)90349-5; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KRUITHOF EKO, 1988, ENZYME, V40, P113, DOI 10.1159/000469153; LEITH IR, 1988, NUCLEIC ACIDS RES, V16, P8277, DOI 10.1093/nar/16.17.8277; LEMAIGRE FP, 1990, MOL CELL BIOL, V10, P1811, DOI 10.1128/MCB.10.4.1811; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P6177, DOI 10.1073/pnas.80.20.6177; NORDHEIM A, 1982, P NATL ACAD SCI-BIOL, V79, P7729, DOI 10.1073/pnas.79.24.7729; OSSOWSKI L, 1979, CELL, V16, P929, DOI 10.1016/0092-8674(79)90108-9; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; RICCIO A, 1988, NUCLEIC ACIDS RES, V16, P2805, DOI 10.1093/nar/16.7.2805; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SEIFERT SC, 1978, P NATL ACAD SCI USA, V75, P6130, DOI 10.1073/pnas.75.12.6130; SERVENIUS B, 1987, J BIOL CHEM, V262, P8759; SPRENGERS ED, 1987, BLOOD, V69, P381; THOMAS MJ, 1990, MOL CELL BIOL, V10, P5378, DOI 10.1128/MCB.10.10.5378; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; VASSALLI JD, 1976, CELL, V8, P271, DOI 10.1016/0092-8674(76)90011-8; WANG AHJ, 1979, NATURE, V282, P680, DOI 10.1038/282680a0; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; YU CY, 1990, MOL CELL BIOL, V10, P282, DOI 10.1128/MCB.10.1.282	72	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12202	12210						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601887				2022-12-25	WOS:A1992HY94700083
J	NEGRI, A; CECILIANI, F; TEDESCHI, G; SIMONIC, T; RONCHI, S				NEGRI, A; CECILIANI, F; TEDESCHI, G; SIMONIC, T; RONCHI, S			THE PRIMARY STRUCTURE OF THE FLAVOPROTEIN D-ASPARTATE OXIDASE FROM BEEF KIDNEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID OXIDASE; MOLECULAR-CLONING; PIG-KIDNEY; SEQUENCE; PROTEINS; PEPTIDES; CDNA	The complete primary structure of the peroxisomal flavoenzyme D-aspartate oxidase from beef kidney has been determined by analyses of the peptides obtained through fragmentation of the carboxymethylated protein with trypsin, CNBr, heptafluorobutyric acid/CNBr and Staphylococcus aureus V8 protease. The protein consists of a single polypeptide of 338 residues, accounting for a M(r) of 37,305 for the apoprotein. A form of the enzyme lacking Lys-338 and therefore ending with Pro-337 has been detected. The N-terminal residue is blocked. Seven cysteines and no disulfide bridges are present. Residue 228 can be either Ile or Val. ThuS, D-aspartate oxidase presents two types of heterogeneity in the polypeptide chain in addition to the one already described concerning the possible content of FAD or 6-hydroxyflavin adenine dinucleotide. Comparison of the primary structure Of D-aspartate oxidase with other known sequences reveals that D-aspartate oxidase is homologous with D-amino acid oxidase (another flavo-oxidase) and does not present significant sequence similarities with any other protein, including flavoenzymes.	UNIV MILANO,IST FISIOL VET & BIOCHIM,VIA CELORIA 10,I-20133 MILAN,ITALY; CTR INTERUNIV MACROMOLEC INFORMAZ,I-20100 MILAN,ITALY	University of Milan			Negri, Armando/H-7914-2017; Tedeschi, Gabriella/I-6247-2017; Ceciliani, Fabrizio/Q-6551-2017	Negri, Armando/0000-0002-8401-7437; Tedeschi, Gabriella/0000-0003-2082-6443; Ceciliani, Fabrizio/0000-0002-9199-5757				CEDERLUND E, 1988, EUR J BIOCHEM, V173, P523, DOI 10.1111/j.1432-1033.1988.tb14029.x; CURTI B, 1991, CHEM BIOCH FLAVOENZY, V3, P69; DANIELLO A, 1972, COMP BIOCHEM PHYSIOL, V41, P625, DOI 10.1016/0305-0491(72)90124-1; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FLACHMANN R, 1988, EUR J BIOCHEM, V175, P221, DOI 10.1111/j.1432-1033.1988.tb14187.x; Fontana A, 1986, PRACTICAL PROTEIN CH, P67; FUJIWARA M, 1987, ANAL BIOCHEM, V166, P72, DOI 10.1016/0003-2697(87)90547-1; GEIGEL D, 1990, J BIOL CHEM, V265, P6626; GHISLA S, 1989, EUR J BIOCHEM, V181, P1, DOI 10.1111/j.1432-1033.1989.tb14688.x; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; ISOGAI T, 1990, J BIOCHEM-TOKYO, V108, P1063, DOI 10.1093/oxfordjournals.jbchem.a123306; JAKOBY WB, 1990, J BIOL CHEM, V265, P20715; KOMATSU K, 1988, CHEM ABSTR 49619S, V108; LEDERER F, 1985, EUR J BIOCHEM, V139, P59; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MIYAKE Y, 1991, FLAVINS AND FLAVOPROTEINS 1990, P135; MOMOI K, 1988, FEBS LETT, V238, P180, DOI 10.1016/0014-5793(88)80252-7; NEGRI A, 1988, J BIOL CHEM, V263, P13557; NIEDERMANN DM, 1990, J BIOL CHEM, V265, P17246; RONCHI S, 1982, J BIOL CHEM, V257, P8824; STILL JL, 1949, J BIOL CHEM, V179, P831; SWENSON RP, 1982, J BIOL CHEM, V257, P8817; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2	23	53	55	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11865	11871						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601857				2022-12-25	WOS:A1992HY94700036
J	MURGIA, M; PIZZO, P; SANDONA, D; ZANOVELLO, P; RIZZUTO, R; DIVIRGILIO, F				MURGIA, M; PIZZO, P; SANDONA, D; ZANOVELLO, P; RIZZUTO, R; DIVIRGILIO, F			MITOCHONDRIAL-DNA IS NOT FRAGMENTED DURING APOPTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELL; DEATH; LYMPHOCYTES; LYSIS	We have exposed mouse thymocytes and P-815 mastocytoma cells to four different conditions reported to cause apoptosis: 1) incubation in the absence of mitogenic factors; 2) incubation in the presence of dexamethasone; 3) stimulation with external ATP; 4) treatment with high concentrations of the K+ ionophore valinomycin. These treatments caused DNA fragmentation to a varying extent in the two cell types. High stringency hybridization with a cDNA probe specific to a mitochondrial DNA sequence revealed that during apoptosis induced by lack of mitogenic factors, dexamethasone, or extracellular ATP, mitochondrial DNA was not fragmented. On the contrary, valinomycin caused extensive degradation of mitochondrial DNA. These results support the notion that DNA fragmentation during apoptosis is a specific nuclear event and suggest that other agents, such as valinomycin, may act less selectively.	UNIV PADUA,CHAIR IMMUNOL,I-35100 PADUA,ITALY; UNIV PADUA,NATL RES COUNCIL STUDY PHYSIOL MITOCHONDRIA,I-35100 PADUA,ITALY; UNIV FERRARA,INST GEN PATHOL,I-44100 FERRARA,ITALY	University of Padua; University of Padua; University of Ferrara	MURGIA, M (corresponding author), UNIV PADUA,INST GEN PATHOL,VIA TRIESTE 75,I-35121 PADUA,ITALY.		Di Virgilio, Francesco/J-3754-2018; sandona, dorianna/AAB-9480-2020; DI VIRGILIO, Francesco/O-4634-2019; Pizzo, Paola/T-4874-2018; Rizzuto, Rosario/B-6312-2008	Di Virgilio, Francesco/0000-0003-3566-1362; DI VIRGILIO, Francesco/0000-0003-3566-1362; Pizzo, Paola/0000-0001-6077-3265; Zanovello, Paola/0000-0002-9996-2669; Rizzuto, Rosario/0000-0001-7044-5097				ALBRITTON NL, 1988, J EXP MED, V167, P514; BUSCH H, 1967, METHODS ENZYMOLOGY A, V12, P421; BUSCH W, 1990, BIOCH CELL BIOL, V68, P1071; COLLINS RJ, 1989, BRIT J HAEMATOL, V71, P343; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; GADALETA G, 1989, J MOL EVOL, V28, P497, DOI 10.1007/BF02602930; HALWELL B, 1991, FEBS LETT, V281, P9; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; LASTER SM, 1988, J IMMUNOL, V141, P2629; MARTZ E, 1989, IMMUNOL TODAY, V10, P79, DOI 10.1016/0167-5699(89)90231-4; PALVA TK, 1985, FEBS LETT, V192, P267, DOI 10.1016/0014-5793(85)80122-8; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; UCKER DS, 1987, NATURE, V327, P62, DOI 10.1038/327062a0; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIE AH, 1980, INT REV CYTOL, V68, P251; ZANOVELLO P, 1990, J IMMUNOL, V145, P1545; ZHENG LM, 1991, J CELL BIOL, V112, P279, DOI 10.1083/jcb.112.2.279	18	65	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					10939	10941						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597435				2022-12-25	WOS:A1992HX16900003
J	PAUL, HS; ADIBI, SA				PAUL, HS; ADIBI, SA			MECHANISM OF INCREASED CONVERSION OF BRANCHED-CHAIN KETO ACID DEHYDROGENASE FROM INACTIVE TO ACTIVE FORM BY A MEDIUM CHAIN FATTY-ACID (OCTANOATE) IN SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED RAT-HEART; AMINO-ACIDS; METABOLISM; LEUCINE; OXIDATION; ACTIVATION; INVIVO; HINDQUARTER; PHOSPHATASE; INHIBITION	We and others have previously shown that octanoate increases the oxidation of branched chain amino acids (BCAA) in skeletal muscle. The present study was designed to investigate the mechanism of this increased oxidation. Studies were performed with rat hind limbs perfused with 0.50 mM L-[1-C-14]leucine with or without octanoate. The flux through branched chain keto acid (BCKA) dehydrogenase was measured, and the basal and total activity of BCKA dehydrogenase in skeletal muscle was determined. The rate of flux through BCKA dehydrogenase increased by 37, 119, and 297% with 0.5, 1.0, and 2.0 mM octanoate, respectively. This increase in flux was not due to a change in BCAA aminotransferase activity but was due to an increase in the basal activity of BCKA dehydrogenase. There was a strong correlation (r = 0.96) between increases in flux through BCKA dehydrogenase and increases in the basal activities of BCKA dehydrogenase. Preincubation of BCKA dehydrogenase with Mg2+ caused full activation of this enzyme, but preincubation with octanoate did not activate this enzyme. On the other hand, octanoate completely prevented the ATP-dependent inactivation of fully activated BCKA dehydrogenase. We conclude that octanoate increases the oxidation of leucine in skeletal muscle by increasing the activation of BCKA dehydrogenase. The mechanism of this activation is the inhibition of BCKA dehydrogenase kinase rather than the stimulation of a specific or nonspecific protein phosphatase.	UNIV PITTSBURGH, SCH MED, DEPT MED, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, SCH MED, DEPT MOLEC GENET & BIOCHEM, PITTSBURGH, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM015855] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM-15855] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADIBI SA, 1971, AM J PHYSIOL, V221, P829; AFTRING RP, 1986, AM J PHYSIOL, V250, pE599, DOI 10.1152/ajpendo.1986.250.5.E599; BLOCK KP, 1987, AM J PHYSIOL, V252, pE396, DOI 10.1152/ajpendo.1987.252.3.E396; BUFFINGTON CK, 1979, J BIOL CHEM, V254, P453; BUSE MG, 1972, J BIOL CHEM, V247, P8085; BUXTON DB, 1984, BIOCHEM J, V221, P593, DOI 10.1042/bj2210593; DAMUNI Z, 1984, P NATL ACAD SCI-BIOL, V81, P4335, DOI 10.1073/pnas.81.14.4335; DAVIS EJ, 1988, METHOD ENZYMOL, V166, P476; GORSKI J, 1986, AM J PHYSIOL, V250, pE441, DOI 10.1152/ajpendo.1986.250.4.E441; HARPER AE, 1984, ANNU REV NUTR, V4, P409, DOI 10.1146/annurev.nu.04.070184.002205; HARRIS RA, 1982, BIOCHEM BIOPH RES CO, V107, P1497, DOI 10.1016/S0006-291X(82)80168-X; HARRIS RA, 1982, J BIOL CHEM, V257, P3915; HARRIS RA, 1986, ADV ENZYME REGUL, V25, P219, DOI 10.1016/0065-2571(86)90016-6; HOOD DA, 1987, AM J PHYSIOL, V253, pE636, DOI 10.1152/ajpendo.1987.253.6.E636; HUTSON SM, 1981, AM J CLIN NUTR, V34, P173, DOI 10.1093/ajcn/34.2.173; HUTSON SM, 1978, J BIOL CHEM, V253, P8126; Lamprecht W., 1974, METHOD ENZYMAT AN, V7, P1777; Lamprecht W, 1974, METHOD ENZYMAT AN, P2101; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAWABI MD, 1990, J CLIN INVEST, V85, P256, DOI 10.1172/JCI114421; NORDENSTROM J, 1991, EUR J CLIN INVEST, V21, P580, DOI 10.1111/j.1365-2362.1991.tb01412.x; ODESSEY R, 1972, AM J PHYSIOL, V223, P1376, DOI 10.1152/ajplegacy.1972.223.6.1376; ODLE J, 1991, J NUTR, V121, P605, DOI 10.1093/jn/121.5.605; PAUL HS, 1980, J CLIN INVEST, V65, P1285, DOI 10.1172/JCI109791; PAUL HS, 1982, J BIOL CHEM, V257, P2581; PAUL HS, 1976, J NUTR, V106, P1079, DOI 10.1093/jn/106.8.1079; PAUL HS, 1984, BRANCHED CHAIN AMINO, P182; PAXTON R, 1984, ARCH BIOCHEM BIOPHYS, V231, P48, DOI 10.1016/0003-9861(84)90361-8; PAXTON R, 1982, J BIOL CHEM, V257, P4433; RODRIGUEZ N, 1986, AM J PHYSIOL, V251, pE343, DOI 10.1152/ajpendo.1986.251.3.E343; RUDERMAN NB, 1980, BIOCHEM J, V190, P57, DOI 10.1042/bj1900057; RUDIGER HW, 1972, BIOCHEM J, V126, P445, DOI 10.1042/bj1260445; SHINNICK FL, 1976, BIOCHIM BIOPHYS ACTA, V437, P477, DOI 10.1016/0304-4165(76)90016-7; SHIOTA M, 1986, AM J PHYSIOL, V251, pC78, DOI 10.1152/ajpcell.1986.251.1.C78; SNEDECOR GW, 1955, STATISTICAL METHODS, P54; SPYDEVOLD O, 1981, BIOCHIM BIOPHYS ACTA, V676, P279, DOI 10.1016/0304-4165(81)90161-6; SPYDEVOLD O, 1979, EUR J BIOCHEM, V97, P389, DOI 10.1111/j.1432-1033.1979.tb13125.x; TREEM WR, 1989, J INHERIT METAB DIS, V12, P112, DOI 10.1007/BF01800712; VANTOL A, 1975, MOL CELL BIOCHEM, V7, P19, DOI 10.1007/BF01732160; VAZQUEZ JA, 1988, J CLIN INVEST, V82, P1606, DOI 10.1172/JCI113772; WAYMACK PP, 1980, J BIOL CHEM, V255, P9773	41	20	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11208	11214						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597456				2022-12-25	WOS:A1992HX16900045
J	CHILDS, RA; WRIGHT, JR; ROSS, GF; YUEN, CT; LAWSON, AM; CHAI, WG; DRICKAMER, K; FEIZI, T				CHILDS, RA; WRIGHT, JR; ROSS, GF; YUEN, CT; LAWSON, AM; CHAI, WG; DRICKAMER, K; FEIZI, T			SPECIFICITY OF LUNG SURFACTANT PROTEIN SP-A FOR BOTH THE CARBOHYDRATE AND THE LIPID MOIETIES OF CERTAIN NEUTRAL GLYCOLIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOSACCHARIDE PROBES NEOGLYCOLIPIDS; MANNOSE-BINDING PROTEINS; PULMONARY SURFACTANT; II CELLS; RECOGNITION DOMAINS; APOPROTEIN; RECOMBINANT; CDNA	Binding specificity of the major surfactant protein SP-A from human and dog lung has been investigated. Radiobinding experiments have shown that both proteins bind in a Ca2+-dependent manner to galactose, mannose, fucose, and glucose linked to bovine serum albumin. These results are in accord with a previous study in which monosaccharides were linked to agarose (Haagsman, H. P., Hawgood, S., Sargeant, T., Buckley, D., White, R. T., Drickamer, K., and Benson, B. J. (1987) J. Biol. Chem. 262, 13877-13880). Chromatogram overlays in conjunction with in situ liquid secondary ion mass spectrometry (TLC-LSIMS) of several purified glycosphingolipids and neoglycolipids as well as binding assays with glycolipids immobilized on plastic wells, demonstrate recognition of galactose (human and dog SP-A), glucose, and lactose (human SP-A) in association with specific lipids. In addition, the occurrence of several neutral and acidic glycosphingolipids in human and rat extracellular surfactants and rat alveolar type II cells is described. Selected components among the neutral glycolipids are bound by radiolabeled human SP-A; these are identified by TLC-LSIMS as predominantly ceramide mono- and disaccharides (human surfactant) and ceramide tri- and tetrasaccharides (rat surfactant and type II cells). A recombinant carbohydrate recognition domain (CRD) of human SP-A inhibits the binding of human SP-A to galactosyl ceramide and to galactose- and mannose- bovine serum albumin, indicating that the CRD is directly involved in the binding of SP-A to these ligands. These results provide evidence for a novel type of binding specificity for proteins that have Ca2+-dependent CRDs and raise the possibility that glycosphingolipids are endogenous ligands for SP-A.	MRC,CLIN RES CTR,GYCOCONJUGATES SECT,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND; MRC,CLIN RES CTR,CLIN MASS SPECTROMETRY SECT,HARROW HA1 3UJ,MIDDX,ENGLAND; UNIV CALIF SAN FRANCISCO,SCH MED,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CINCINNATI,MED CTR,DEPT PEDIAT,CINCINNATI,OH 45267; COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032	Medical Research Council Clinical Trials Unit; Medical Research Council Clinical Trials Unit; University of California System; University of California San Francisco; University System of Ohio; University of Cincinnati; Columbia University				Chai, Wengang/0000-0003-2977-5347; Feizi, Ten/0000-0001-6495-0329	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL030923, R01HL030923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042628] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30923] Funding Source: Medline; NIGMS NIH HHS [GM42628] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENSON B, 1985, P NATL ACAD SCI USA, V82, P6379, DOI 10.1073/pnas.82.19.6379; CHILDS RA, 1990, J BIOL CHEM, V265, P20770; CHILDS RA, 1989, BIOCHEM J, V262, P131, DOI 10.1042/bj2620131; CHILDS RA, 1983, BIOCHEM J, V215, P491, DOI 10.1042/bj2150491; COCKSHUTT AM, 1990, BIOCHEMISTRY-US, V29, P8424, DOI 10.1021/bi00488a032; DOBBS LG, 1986, AM REV RESPIR DIS, V134, P141; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1987, KIDNEY INT       S23, V32, P67; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FLOROS J, 1986, J BIOL CHEM, V261, P9029; HAAGSMAN HP, 1987, J BIOL CHEM, V262, P13877; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; KUROKI Y, 1991, J BIOL CHEM, V266, P3068; LAWSON AM, 1990, CARBOHYD RES, V200, P47, DOI 10.1016/0008-6215(90)84181-S; Maniatis T., 1982, MOL CLONING; MANZKEINKE H, 1991, EXP CELL RES, V192, P597, DOI 10.1016/0014-4827(91)90081-5; MIZUOCHI T, 1989, J BIOL CHEM, V264, P13834; PERSSON A, 1990, J BIOL CHEM, V265, P5755; POSSMAYER F, 1988, AM REV RESPIR DIS, V138, P990, DOI 10.1164/ajrccm/138.4.990; PRAKASH UBS, 1987, MAYO CLIN PROC, V62, P499, DOI 10.1016/S0025-6196(12)65477-9; ROSENBERG M, 1983, METHOD ENZYMOL, V101, P123; ROSENSTEIN IJ, 1988, LANCET, V2, P1327; ROSS GF, 1986, J BIOL CHEM, V261, P14283; SLOMIANY A, 1979, EUR J BIOCHEM, V98, P47, DOI 10.1111/j.1432-1033.1979.tb13158.x; STOLL MS, 1988, BIOCHEM J, V256, P661, DOI 10.1042/bj2560661; SUZUKI Y, 1989, AM REV RESPIR DIS, V140, P75, DOI 10.1164/ajrccm/140.1.75; VOORHOUT WF, 1991, J HISTOCHEM CYTOCHEM, V39, P1331, DOI 10.1177/39.10.1940306; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0; WRIGHT J R, 1990, American Review of Respiratory Disease, V141, pA694; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888; WRIGHT JR, 1989, P NATL ACAD SCI USA, V86, P5410, DOI 10.1073/pnas.86.14.5410; WRIGHT JR, 1987, AM REV RESPIR DIS, V135, P426	34	82	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9972	9979						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577827				2022-12-25	WOS:A1992HT96500080
J	KAUPPINEN, RA; NISSINEN, T; KARKKAINEN, AM; PIRTTILA, TRM; PALVIMO, J; KOKKO, H; WILLIAMS, SR				KAUPPINEN, RA; NISSINEN, T; KARKKAINEN, AM; PIRTTILA, TRM; PALVIMO, J; KOKKO, H; WILLIAMS, SR			DETECTION OF THYMOSIN BETA-4 INSITU IN A GUINEA-PIG CEREBRAL-CORTEX PREPARATION USING H-1-NMR SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; H-1-NMR SPECTROSCOPY; RAT-BRAIN; INVIVO; PEPTIDES; PROTEINS; HYPOXIA; BINDING; SPECTRA; HMG-14	In the present work we have investigated the macromolecules that contribute to the brain H-1 NMR spectrum. The cerebral cortex showed distinct resonances at the uncrowded methyl- and methylene chemical shift scale of the spin-echo H-1 NMR spectrum. The peaks at 1.22 and 1.40 ppm (relative to the methyl protons of N-acetyl aspartate at 2.02 ppm) arise from cerebral macromolecules without evidence for co-resonances from low molecular weight metabolites as shown by the spin-spin relaxation decays of these resonances. In addition to these NMR signals, peaks at 0.9 and 1.7 ppm from macromolecules were detected. These resonances are from proteins, and we have identified the polypeptides that contributed to the H-1 NMR peaks. Two proteins that were present at concentrations of 250 and 350-mu-g/g of dryed tissue showed H-1 NMR spectra that resembled the macromolecular pattern in the cerebral H-1 NMR spectrum. They were identified as thymosin beta-4 and histone H1, respectively. Thymosin beta-4 was present in soluble high speed cytoplasmic fraction and in P2 pellet, whereas histone H1 was detected in nuclear enriched fraction. A chemical shift-correlated two-dimensional H-1 NMR spectrum of thymosin beta-4 in vitro revealed a coupling pattern that matched the macromolecule in the cerebral cortex which we have previously noted (Kauppinen R. A., Kokko, H., and Williams, S. R. (1992) J. Neurochem. 58, 967-974). On the basis of both one- and two-dimensional NMR evidence, subcellular distribution and high concentration, we assign the H-1 NMR signals at 0.9, 1.22, 1.40, and 1.7 ppm in the cerebral cortex to thymosin beta-4.	UNIV KUOPIO,NMR,RES GRP,SF-70211 KUOPIO,FINLAND; ROYAL COLL SURG ENGLAND,DIV BIOPHYS,LONDON WC2A 3PN,ENGLAND	University of Eastern Finland; Royal College of Surgeons of England	KAUPPINEN, RA (corresponding author), UNIV KUOPIO,DEPT BIOCHEM & BIOTECHNOL,POB 1627,SF-70211 KUOPIO,FINLAND.		Kauppinen, Risto A/F-3274-2011; Williams, Steve C/D-6979-2011; kokko, Harri/C-4289-2011; Williams, Steve R/C-8945-2011	Williams, Steve C/0000-0003-4299-1941; Williams, Steve R/0000-0001-5940-1675; Palvimo, Jorma/0000-0003-2373-0578				ABERCROMBIE BD, 1978, EUR J BIOCHEM, V84, P173, DOI 10.1111/j.1432-1033.1978.tb12154.x; ARUS C, 1985, PHYSIOL CHEM PHYS, V17, P23; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BATES TE, 1989, J NEUROCHEM, V53, P102, DOI 10.1111/j.1471-4159.1989.tb07300.x; BEHAR KL, 1983, P NATL ACAD SCI-BIOL, V80, P4945, DOI 10.1073/pnas.80.16.4945; BEHAR KL, 1991, MAGNET RESON MED, V17, P285, DOI 10.1002/mrm.1910170202; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campbell I D, 1979, Methods Biochem Anal, V25, P1, DOI 10.1002/9780470110454.ch1; CARY PD, 1980, EUR J BIOCHEM, V112, P577; COOK GR, 1989, J BIOL CHEM, V264, P1799; DALAKAS MC, 1986, ANN NEUROL, V19, P349, DOI 10.1002/ana.410190407; DEGRAAF AA, 1990, MAGNET RESON MED, V15, P305, DOI 10.1002/mrm.1910150212; GOODWIN GH, 1977, FEBS LETT, V80, P413, DOI 10.1016/0014-5793(77)80488-2; HALL AK, 1991, MOL CELL ENDOCRINOL, V79, P37, DOI 10.1016/0303-7207(91)90093-8; HANNAPPEL E, 1986, ANAL BIOCHEM, V156, P390, DOI 10.1016/0003-2697(86)90270-8; HORE PJ, 1983, J MAGN RESON, V55, P283, DOI 10.1016/0022-2364(83)90240-8; JOHNS EW, 1976, SUBNUCLEAR COMPONENT, P187; KAUPPINEN RA, 1992, J NEUROCHEM, V58, P967, DOI 10.1111/j.1471-4159.1992.tb09350.x; KAUPPINEN RA, 1991, J NEUROCHEM, V57, P1136, DOI 10.1111/j.1471-4159.1991.tb08271.x; KAUPPINEN RA, 1990, J NEUROSCI RES, V26, P356, DOI 10.1002/jnr.490260313; KAUPPINEN RA, 1992, J NEUROCHEM, V58, P831, DOI 10.1111/j.1471-4159.1992.tb09332.x; LUGO DI, 1991, J NEUROCHEM, V56, P457, DOI 10.1111/j.1471-4159.1991.tb08172.x; MCEWEN BS, 1970, BRAIN RES, V17, P471, DOI 10.1016/0006-8993(70)90254-4; NAGAYAYAMA K, 1985, EUR J BIOCHEM, V114, P365; NICHOLLS DG, 1978, BIOCHEM J, V170, P511, DOI 10.1042/bj1700511; PALVIMO J, 1990, FEBS LETT, V277, P257, DOI 10.1016/0014-5793(90)80860-L; PARK IR, 1987, J NEUROCHEM, V49, P781; PETROFF OAC, 1988, COMP BIOCHEM PHYS B, V90, P249, DOI 10.1016/0305-0491(88)90069-7; REBAR RW, 1981, SCIENCE, V214, P669, DOI 10.1126/science.7027442; SAFER D, 1991, J BIOL CHEM, V266, P4029; WATTS JD, 1990, EUR J BIOCHEM, V192, P643, DOI 10.1111/j.1432-1033.1990.tb19271.x; WEISBROD S, 1982, NATURE, V297, P289, DOI 10.1038/297289a0; WELLNER D, 1990, P NATL ACAD SCI USA, V87, P1947, DOI 10.1073/pnas.87.5.1947; WILLIAMS SR, 1986, J MAGN RESON, V66, P562, DOI 10.1016/0022-2364(86)90203-9; Wuthrich K., 1986, NMR PROTEINS NUCL AC	35	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9905	9910						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577821				2022-12-25	WOS:A1992HT96500071
J	MASSIA, SP; HUBBELL, JA				MASSIA, SP; HUBBELL, JA			IMMOBILIZED AMINES AND BASIC-AMINO-ACIDS AS MIMETIC HEPARIN-BINDING DOMAINS FOR CELL-SURFACE PROTEOGLYCAN-MEDIATED ADHESION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; SUBSTRATUM ADHESION; DISSOCIATED NEURONS; FIBRONECTIN; FIBROBLASTS; RECEPTORS; INTEGRINS; ATTACHMENT; MOLECULES; FRAGMENTS	Diamines covalently coupled to glass substrates promoted human foreskin fibroblast adhesion in the absence of serum. These diamine-derivatized substrates were produced by coupling ethylene diamine, N-methylaminoethylamine, and N,N-dimethylaminoethylamine (NNDMAEA), to sulfonyl chloride-activated glass. Electron spectroscopy for chemical analysis demonstrated that the diamines were coupled via their primary amine ends to produce a surface-bound secondary amine linked to a free amino moiety via a two-carbon spacer. NNDMAEA-modified substrates containing free tertiary amines supported the highest degree of cell spreading (73 +/- 7% actively spreading cells) and the most extensive cytoskeletal organization. Both the free tertiary and surface-bound secondary amines were shown to be required for cell spreading. Lysine- and arginine-grafted substrates supported cell spreading and cytoskeletal organization similar to that on NNDMAEA-modified substrates. Although some stress fibers were observed within spread cells on these substrates, focal contacts did not form. Heparinase treatment did not inhibit cell attachment or spreading to the diamine-derivatized substrates, however chondroitinase ABC inhibited cell attachment and spreading on all substrates; heparinase inhibited spreading on lysine- and arginine-derivatized substrates to a lesser extent. These results imply that cell attachment to these substrates was mediated primarily by cell surface chondroitin sulfate proteoglycans. This study demonstrates that covalently grafted NNDMAEA, lysine, and arginine can mimic the adhesion-promoting activity of the glycosaminoglycan-binding domains of cell adhesion proteins. This study also demonstrates that the interaction with these proteoglycans depends in a very sensitive manner on the particular structure of the immobilized amine.	UNIV TEXAS,DEPT CHEM ENGN,AUSTIN,TX 78712; UNIV TEXAS,DEPT BIOL SCI,AUSTIN,TX 78712	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin			Hubbell, Jeffrey A/A-9266-2008	Hubbell, Jeffrey A/0000-0003-0276-5456				ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812; BRUNS RR, 1980, EXP CELL RES, V128, P1, DOI 10.1016/0014-4827(80)90379-1; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHARONIS AS, 1988, J CELL BIOL, V107, P1253, DOI 10.1083/jcb.107.3.1253; COSTELLO CA, 1987, MACROMOLECULES, V20, P2819, DOI 10.1021/ma00177a030; CULP LA, 1979, J SUPRAMOL STR CELL, V11, P401, DOI 10.1002/jss.400110314; CULP LA, 1978, J CELL BIOL, V78, P788; HAUGEN PK, 1990, J CELL BIOL, V111, P2733, DOI 10.1083/jcb.111.6.2733; HUMPHRIES MJ, 1990, J CELL SCI, V97, P585; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IZZARD CS, 1986, EXP CELL RES, V165, P320, DOI 10.1016/0014-4827(86)90586-0; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JULIANO RL, 1987, BIOCHIM BIOPHYS ACTA, V907, P261, DOI 10.1016/0304-419X(87)90009-6; KLEINFELD D, 1988, J NEUROSCI, V8, P4098; KOUZIKOLIAKOS K, 1989, J BIOL CHEM, V264, P17971; LARK MW, 1985, FED PROC, V44, P394; LATERRA J, 1983, J CELL BIOL, V96, P112, DOI 10.1083/jcb.96.1.112; LATERRA J, 1983, EXP CELL RES, V146, P15, DOI 10.1016/0014-4827(83)90320-8; LEBARON RG, 1988, J CELL BIOL, V106, P945, DOI 10.1083/jcb.106.3.945; LETOURNEAU PC, 1975, DEV BIOL, V44, P77, DOI 10.1016/0012-1606(75)90378-4; MASSIA SP, 1990, ANAL BIOCHEM, V187, P292, DOI 10.1016/0003-2697(90)90459-M; MASSIA SP, 1991, J CELL BIOL, V114, P1089, DOI 10.1083/jcb.114.5.1089; MCCARTHY JB, 1990, J CELL BIOL, V110, P777, DOI 10.1083/jcb.110.3.777; MCKEEHAN WL, 1976, J CELL BIOL, V71, P727, DOI 10.1083/jcb.71.3.727; NILSSON K, 1981, BIOCHEM BIOPH RES CO, V102, P449, DOI 10.1016/0006-291X(81)91541-2; PIEPKORN MW, 1985, LAB INVEST, V53, P22; RATNR BD, 1987, J BIOMED MATER RES-A, V21, P59; RUEGG UT, 1984, NEUROSCI LETT, V49, P319, DOI 10.1016/0304-3940(84)90309-4; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; YAVIN E, 1974, J CELL BIOL, V62, P540, DOI 10.1083/jcb.62.2.540	37	83	92	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10133	10141						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577783				2022-12-25	WOS:A1992HT96500103
J	RODRIGUEZAPARICIO, LB; LUENGO, JM; GONZALEZCLEMENTE, C; REGLERO, A				RODRIGUEZAPARICIO, LB; LUENGO, JM; GONZALEZCLEMENTE, C; REGLERO, A			PURIFICATION AND CHARACTERIZATION OF THE NUCLEAR CYTIDINE 5'-MONOPHOSPHATE N-ACETYLNEURAMINIC ACID SYNTHETASE FROM RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; 2-ACETYLAMINOFLUORENE-INDUCED HEPATOCARCINOGENESIS; SIALOGLYCOCONJUGATE CHANGES; COLOMINIC ACID; BIOSYNTHESIS; METABOLISM; GLUTAMATE; LOCATION; BINDING	N-Acetylneuraminic acid cytidylyltransferase (EC 2.7.7.43) (CMP-NeuAc synthetase) from rat liver catalyzes the formation of cytidine monophosphate N-acetylneuraminic acid from CTP and NeuAc. We have purified this enzyme to apparent homogeneity (241-fold) using gel filtration on Sephacryl S-200 and two types of affinity chromatographies (Reactive Brown-10 Agarose and Blue Sepharose CL-6B columns). The pure enzyme, whose amino acid composition and NH2-terminal amino acid sequence are also established, migrates as a single protein band on non-denaturing polyacrylamide gel electrophoresis. The molecular mass of the native enzyme, estimated by gel filtration, was 116 +/- 2 kDa whereas its M(r) in sodium dodecyl sulfate-polyacrylamide gel electrophoresis was 58 +/- 1 kDa. CMP-NeuAc synthetase requires Mg2+ for catalysis although this ion can be replaced by Mn2+, Ca2+, or Co2+. The optimal pH was 8.0 in the presence of 10 mM Mg2+ and 5 mm dithiothreitol. The apparent K(m) for CTP and NeuAc are 1.5 and 1.3 mM, respectively. The enzyme also converts N-glycolylneuraminic acid to its corresponding CMP-sialic acid (K(m), 2.6 mM), whereas CMP-NeuAc, high CTP concentrations, and other nucleotides (CDP, CMP, ATP, UTP, GTP, and TTP) inhibited the enzyme to different extents.	UNIV LEON,DEPT BIOQUIM & BIOL MOLEC,E-24007 LEON,SPAIN	Universidad de Leon			Luengo, Jose M./E-1935-2016	Luengo, Jose M./0000-0002-4984-6256; Rodriguez-Aparicio, Leandro B./0000-0002-0372-2055				BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BLACKLOW RS, 1962, J BIOL CHEM, V237, P3520; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COATES SW, 1980, J BIOL CHEM, V255, P9225; Corfield A. P., 1982, CELL BIOL MONOGR, V10, P195; CORFIELD AP, 1985, BIOCHEM J, V226, P163, DOI 10.1042/bj2260163; CREEK KE, 1984, BIOCHIM BIOPHYS ACTA, V793, P133, DOI 10.1016/0005-2760(84)90314-X; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; ELLIOTT WL, 1984, BIOCHIM BIOPHYS ACTA, V800, P194, DOI 10.1016/0304-4165(84)90060-6; ELLIS DB, 1972, BIOCHIM BIOPHYS ACTA, V289, P108, DOI 10.1016/0005-2744(72)90113-1; GIELEN W, 1974, H-S Z PHYSIOL CHEM, V355, P895, DOI 10.1515/bchm2.1974.355.2.895; GONZALEZCLEMENTE C, 1989, FEBS LETT, V250, P429, DOI 10.1016/0014-5793(89)80770-7; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HIGA HH, 1985, J BIOL CHEM, V260, P8838; KEAN EL, 1970, J BIOL CHEM, V245, P2301; KEAN EL, 1966, J BIOL CHEM, V241, P5643; KIRSCHBAUM BB, 1974, CHEM-BIOL INTERACT, V8, P207, DOI 10.1016/0009-2797(74)90029-5; KISHORE GS, 1981, CANCER LETT, V13, P281, DOI 10.1016/0304-3835(81)90055-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; McGuire E. J., 1976, BIOL ROLES SIALIC AC, P123; OZTURK DH, 1990, BIOCHEMISTRY-US, V29, P7112, DOI 10.1021/bi00482a024; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PEREZ M, 1982, FED PROC, V41, P662; RODRIGUEZAPARICIO LB, 1989, BIOCHEMISTRY-US, V28, P3070, DOI 10.1021/bi00433a050; RODRIGUEZAPARICIO LB, 1988, APPL MICROBIOL BIOT, V27, P474, DOI 10.1007/BF00451616; SCHAUER R, 1980, H-S Z PHYSIOL CHEM, V361, P641, DOI 10.1515/bchm2.1980.361.1.641; SCHAUER R, 1972, H-S Z PHYSIOL CHEM, V353, P883, DOI 10.1515/bchm2.1972.353.1.883; SHAILUBHAI K, 1990, J BIOL CHEM, V265, P14105; SLAMA JT, 1991, BIOCHEMISTRY-US, V30, P2527, DOI 10.1021/bi00223a033; Tuppy H., 1972, GLYCOPROTEINS THEIR, P403; VANDENEIJNDEN DH, 1973, J NEUROCHEM, V21, P949, DOI 10.1111/j.1471-4159.1973.tb07539.x; VANDENEIJNDEN DH, 1972, H-S Z PHYSIOL CHEM, V353, P1817, DOI 10.1515/bchm2.1972.353.2.1817; VANN WF, 1987, J BIOL CHEM, V262, P17556; VIMR ER, 1985, J BACTERIOL, V164, P854, DOI 10.1128/JB.164.2.854-860.1985; WARREN L, 1962, J BIOL CHEM, V237, P3527; ZAPATA G, 1989, J BIOL CHEM, V264, P14769	36	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9257	9263						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577759				2022-12-25	WOS:A1992HR85400084
J	USHA, R; SAVITHRI, HS; RAO, NA				USHA, R; SAVITHRI, HS; RAO, NA			ARGININE RESIDUES INVOLVED IN BINDING OF TETRAHYDROFOLATE TO SHEEP LIVER SERINE HYDROXYMETHYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT LIVER; ESCHERICHIA-COLI; ACTIVE-SITE; SEQUENCE; ACID; IDENTIFICATION; MECHANISM	The arginine residue(s) necessary for tetrahydrofolate binding to sheep liver serine hydroxymethyltransferase were located by phenylglyoxal modification. The incorporation of [7-C-14]phenylglyoxal indicated that 2 arginine residues were modified per subunit of the enzyme and the modification of these residues was prevented by tetrahydrofolate. In order to locate the sites of phenylglyoxal modification, the enzyme was reacted in the presence and absence of tetrahydrofolate using unlabeled and radioactive phenylglyoxal, respectively. The labeled phenylglyoxal-treated enzyme was digested with trypsin, and the radiolabeled peptides were purified by high-performance liquid chromatography on reversed-phase columns. Sequencing the tryptic peptides indicated that Arg-269 and Arg-462 were the sites of phenylglyoxal modification. Neither a spectrally discernible 495-nm intermediate (characteristic of the native enzyme when substrates are added) nor its enhancement by the addition of tetrahydrofolate, was observed with the phenylglyoxal-modified enzyme. There was no enhancement of the rate of the exchange of the alpha-proton of glycine upon addition of tetrahydrofolate to the modified enzyme as was observed with the native enzyme. These results demonstrate the requirement of specific arginine residues for the interaction of tetrahydrofolate with sheep liver serine hydroxymethyltransferase.	INDIAN INST SCI,DEPT BIOCHEM,BANGALORE 560012,KARNATAKA,INDIA	Indian Institute of Science (IISC) - Bangalore								ACHARYA JK, 1991, INDIAN J BIOCHEM BIO, V28, P381; BASKARAN N, 1989, BIOCHEMISTRY-US, V28, P9613, DOI 10.1021/bi00451a010; BASKARAN N, 1989, BIOCHEMISTRY-US, V28, P9607, DOI 10.1021/bi00451a009; CHANG JY, 1978, FEBS LETT, V93, P205, DOI 10.1016/0014-5793(78)81105-3; CHEN MS, 1973, J BIOL CHEM, V248, P3631; CHOI JD, 1981, BIOCHEMISTRY-US, V20, P5722, DOI 10.1021/bi00523a014; HATEFI Y, 1960, BIOCHEM PREP, V7, P89; Hirs C. H. W, 1967, METHODS ENZYMOL, V11, P197; JORDAN PM, 1970, BIOCHEM J, V116, P277, DOI 10.1042/bj1160277; KAZARINOFF MN, 1977, J BIOL CHEM, V252, P7598; KAZARINOFF MN, 1976, J BIOL CHEM, V251, P6179; MALEY GF, 1980, ARCH BIOCHEM BIOPHYS, V216, P551; MANOHAR R, 1984, BIOCHEM J, V224, P703, DOI 10.1042/bj2240703; MARTINI F, 1987, J BIOL CHEM, V262, P5499; MARTINI F, 1989, J BIOL CHEM, V264, P8509; MCGUIRE JJ, 1984, FOLATES PTERINS, V1, P135; PALEKAR AG, 1973, J BIOL CHEM, V248, P1158; PLAMANN MD, 1983, NUCLEIC ACIDS RES, V11, P2065, DOI 10.1093/nar/11.7.2065; RAO DN, 1983, INDIAN J BIOCHEM BIO, V20, P362; RUNSWICK MJ, 1983, J BIOL CHEM, V258, P3081; SCHIRCH L, 1964, J BIOL CHEM, V239, P3801; SCHIRCH L, 1982, ADV ENZYMOL RAMB, V53, P83; SCHIRCH L, 1984, FOLATES PTERINS, V1, P135; SNELL K, 1984, ADV ENZYME REGUL, V22, P325, DOI 10.1016/0065-2571(84)90021-9; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; THOMPSON PD, 1991, BIOCHEMISTRY-US, V30, P8124, DOI 10.1021/bi00247a005; VIJAYALAKSHMI D, 1989, BIOCHEM INT, V19, P625	27	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9289	9293						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577761				2022-12-25	WOS:A1992HR85400089
J	MARCOTTE, PA; KOZAN, IM; DORWIN, SA; RYAN, JM				MARCOTTE, PA; KOZAN, IM; DORWIN, SA; RYAN, JM			THE MATRIX METALLOPROTEINASE PUMP-1 CATALYZES FORMATION OF LOW-MOLECULAR-WEIGHT (PRO)UROKINASE IN CULTURES OF NORMAL HUMAN KIDNEY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PLASMINOGEN-ACTIVATOR; EXTRACELLULAR-MATRIX; PURIFICATION; UROKINASE; RECEPTOR; SEQUENCE; INVASION; BINDING	The enzyme responsible for the metalloproteinase activity which cleaves the Glu143-Leu144 bond of (pro)urokinase has been isolated from the conditioned medium of cultured normal human kidney cells. Using S-Sepharose and Cibacron Blue-agarose chromatography, then C-4 reversed phase high pressure liquid chromatography, a protein of about 20,000 Da was isolated. Through an identical amino-terminal sequence, the protein was shown to be the matrix metalloproteinase previously referred to in the literature as " pump-1" (putative metalloproteinase). When aprotinin was added during the course of the purification, the major species isolated was the zymogen form (28,000 Da) of pump-1. Pump-1 has been shown to efficiently cleave the susceptible bond of both pro-urokinase (single-chain) and active (two-chain) urokinase and thereby produce the corresponding low molecular weight forms. The amino-terminal sequences of the A and B chains of low molecular weight urokinase prepared by action of pump-1 on recombinant high molecular weight urokinase are identical to those of the low molecular weight urokinase isolated from human kidney cell culture. Since the reaction of urokinase with this metalloproteinase results in separation of its serine proteinase region from the domain which mediates binding to the urokinase receptor, it may be of importance in the regulation of the functional activity of the plasminogen activator in cellular processes.	ABBOTT LABS, DEPT BIOL DEV, DIV CHEM & AGR PROD, N CHICAGO, IL 60064 USA	Abbott Laboratories	MARCOTTE, PA (corresponding author), ABBOTT LABS, CORP MOLEC BIOL, DIV PHARMACEUT PROD, THROMBOLYT VENTURE, DEPT 48R, N CHICAGO, IL 60064 USA.							APPELLA E, 1987, J BIOL CHEM, V262, P4437; BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; Blasi F, 1990, Semin Cancer Biol, V1, P117; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EMONARD H, 1990, CELL MOL BIOL, V36, P131; HOMANDBERG GA, 1990, BIOCHIM BIOPHYS ACTA, V1038, P209, DOI 10.1016/0167-4838(90)90207-V; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LO KM, 1991, BIOCHIM BIOPHYS ACTA, V1088, P217; MARCOTTE PA, 1992, FIBRINOLYSIS, V6, P57, DOI 10.1016/0268-9499(92)90095-Y; MARCOTTE PA, 1992, FIBRINOLYSIS, V6, P69, DOI 10.1016/0268-9499(92)90063-N; Matrisian L M, 1990, Semin Cancer Biol, V1, P107; MATRISIAN LM, 1991, AM J MED SCI, V302, P157, DOI 10.1097/00000441-199109000-00008; MCDONNELL S, 1991, MOL CARCINOGEN, V4, P527, DOI 10.1002/mc.2940040617; MIYAZAKI K, 1990, CANCER RES, V50, P7758; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MULLER D, 1991, INT J CANCER, V48, P550, DOI 10.1002/ijc.2910480412; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; PAJOUH MS, 1991, J CANCER RES CLIN, V117, P144, DOI 10.1007/BF01613138; POLLANEN J, 1991, ADV CANCER RES, V57, P273; QUANTIN B, 1989, BIOCHEMISTRY-US, V28, P5327, DOI 10.1021/bi00439a004; RABBANI SA, 1990, BIOCHEM BIOPH RES CO, V173, P1058, DOI 10.1016/S0006-291X(05)80893-9; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STUMP DC, 1986, J BIOL CHEM, V261, P7120; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOESSNER JF, 1988, J BIOL CHEM, V263, P16918; 1992, ENZYME NOMENCLATURE, P412	30	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13803	13806						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629180				2022-12-25	WOS:A1992JD32500004
J	LEW, J; BEAUDETTE, K; LITWIN, CME; WANG, JH				LEW, J; BEAUDETTE, K; LITWIN, CME; WANG, JH			PURIFICATION AND CHARACTERIZATION OF A NOVEL PROLINE-DIRECTED PROTEIN-KINASE FROM BOVINE BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CONTROL; HUMAN CDC2 PROTEIN; FISSION YEAST; POLYACRYLAMIDE GELS; M-PHASE; TYROSINE PHOSPHORYLATION; P34CDC2 KINASE; NUCLEAR LAMINA; MITOSIS; ACTIVATION	A novel protein kinase which phosphorylates a synthetic peptide substrate (RRPDAHRTPNRAF) has been purified approximately 200,000-fold from bovine brain. This peptide contains the consensus sequence for phosphorylation by the p34cdc2 kinase. The purification procedure took advantage of the phenomenon that this novel brain kinase, in partially purified extracts, chromatographed on a gel filtration column as a high molecular weight complex which dissociated in buffer containing 1 M NaCl. The purified native enzyme was estimated to be approximately 63,000, and displayed two bands of M(r) = 33,000 and 25,000 on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. On Western immunoblot, the M(r) = 33,000 peptide reacted strongly with antibodies specific for a conserved amino-terminal sequence, weakly with antibodies to the conserved PSTAIRE sequence, and not at all with antibodies to the carboxyl terminus, of HeLa cell p34cdc2. The brain kinase and p34cdc2 were similar in displaying good activity toward the parent peptide substrate, but no activity toward peptide analogues in which the -T-P- motif was substituted with either -T-G- or -T-A-. Both kinases showed marked preference in phosphorylating a peptide derived from H1 histone (KTPKKAKKPKTPKKAKKL), and both kinases could be phosphorylated by the src-family tyrosine kinase, p56lyn, purified from bovine spleen. However, the brain kinase did not co-purify with a subunit having a molecular weight corresponding to known cyclins, nor did it undergo specific interaction with p13suc1 beads, suggesting that this enzyme is distinct from p34cdc2.	UNIV CALGARY,FAC MED,DEPT MED BIOCHEM,MRC,SIGNAL TRANSDUCT GRP,CALGARY T2N 4N1,ALBERTA,CANADA	University of Calgary								BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN RK, 1991, ARCH BIOCHEM BIOPHYS, V28, P187; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; CHENG HC, 1992, J BIOL CHEM, V267, P9248; CHOU YH, 1991, J BIOL CHEM, V266, P7325; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; DRAETTA G, 1988, ONCOGENE, V2, P553; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ENOCH T, 1991, J CELL BIOL, V112, P797, DOI 10.1083/jcb.112.5.797; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; FENNER C, 1975, ANAL BIOCHEM, V63, P595, DOI 10.1016/0003-2697(75)90386-3; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JESSUS C, 1990, FEBS LETT, V266, P4, DOI 10.1016/0014-5793(90)90002-C; JIMENEZ J, 1990, EMBO J, V9, P3565, DOI 10.1002/j.1460-2075.1990.tb07567.x; JOHNSON KW, 1991, J BIOL CHEM, V266, P3402; KREK W, 1989, EMBO J, V8, P3071, DOI 10.1002/j.1460-2075.1989.tb08458.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB NJC, 1990, CELL, V60, P151, DOI 10.1016/0092-8674(90)90725-T; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; LITWIN CME, 1991, J BIOL CHEM, V266, P2557; LUSCHER B, 1991, EMBO J, V10, P865, DOI 10.1002/j.1460-2075.1991.tb08019.x; MAK AS, 1991, J BIOL CHEM, V266, P6678; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MATSUSHIME H, 1990, MOL CELL BIOL, V10, P2261, DOI 10.1128/MCB.10.5.2261; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NORBURY CJ, 1989, BIOCHIM BIOPHYS ACTA, V989, P85, DOI 10.1016/0304-419X(89)90036-X; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PERLMAN R, 1989, J BIOL CHEM, V264, P8946; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PINES J, 1990, New Biologist, V2, P389; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; RATTNER JB, 1990, CELL MOTIL CYTOSKEL, V17, P227, DOI 10.1002/cm.970170309; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SIMON M, 1986, EMBO J, V5, P2697, DOI 10.1002/j.1460-2075.1986.tb04553.x; TOH A, 1988, MOL GEN GENET, V214, P162; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	65	219	226	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13383	13390						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618840				2022-12-25	WOS:A1992JB74600047
J	SWEENY, DJ; NELLANS, HN				SWEENY, DJ; NELLANS, HN			ENANTIOMERIC ACTIVATION OF GLUCURONIDATION IN DOG HEPATIC MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEREOSELECTIVITY; SUBSTRATE; PROPRANOLOL	Isomer-specific mechanisms of conjugation were investigated by evaluating the hepatic glucuronidation of the enantiomers of the 5-lipoxygenase inhibitor zileuton. The glucuronidation of the individual isomers was stereoselective, as dog hepatic microsomes glucuronidated the S-isomer but failed to generate a glucuronide conjugate of the R-isomer. In combination, the nonglucuronidated R-isomer caused a concentration-dependent increase in the rate of glucuronidation of its enantiomorph. Kinetic analysis of this interaction indicated that the R-isomer affected rates of glucuronidation by decreasing the K(m) of the S-isomer for this process. This effect appeared enantioselective as the achiral analogue A-65838 had no effect on the V(max) and K(m) of S-isomer glucuronidation. The data were modeled using Michaelis-Menten kinetics in which the K(m) of S-isomer glucuronidation was reduced in a saturable manner by the concentration of the R-isomer. These data indicate that the nonconjugated R-isomer competitively activates the glucuronidation of its enantiomorph. To our knowledge, these data represent the first demonstration of enantiomeric activation of an enzyme involved in hepatic drug metabolism.			SWEENY, DJ (corresponding author), ABBOTT LABS,DEPT GEN PHARMACOL,N CHICAGO,IL 60064, USA.							AMES MM, 1982, BIOCHEM PHARMACOL, V31, P5, DOI 10.1016/0006-2952(82)90228-3; BOCK KW, 1983, BIOCHEM PHARMACOL, V32, P953, DOI 10.1016/0006-2952(83)90610-X; BRAECKMAN RA, 1989, J CLIN PHARMACOL, V29, P22; CARTER GW, 1991, J PHARMACOL EXP THER, V256, P929; CUNDY KC, 1985, BIOCHEM BIOPH RES CO, V128, P312, DOI 10.1016/0006-291X(85)91680-8; OKAZAKI O, 1991, DRUG METAB DISPOS, V19, P376; SISENWINE SF, 1982, DRUG METAB DISPOS, V10, P605; STEVENSON T, 1968, BIOCHEM BIOPH RES CO, V32, P866; SWEENY DJ, 1992, DRUG METAB DISPOS, V20, P328; TESTA B, 1988, BIOCHEM PHARMACOL, V37, P85, DOI 10.1016/0006-2952(88)90757-5; THOMPSON JA, 1981, DRUG METAB DISPOS, V9, P466; VESSEY DA, 1971, J BIOL CHEM, V246, P4649; WILSON BK, 1984, DRUG METAB DISPOS, V12, P161; WINSNES A, 1969, BIOCHIM BIOPHYS ACTA, V191, P279, DOI 10.1016/0005-2744(69)90247-2; ZAKIM D, 1973, BIOCHEMISTRY-US, V12, P4068, DOI 10.1021/bi00745a007	15	10	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13171	13174						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618819				2022-12-25	WOS:A1992JB74600014
J	CASTLE, AM; STAHL, LE; CASTLE, JD				CASTLE, AM; STAHL, LE; CASTLE, JD			A 13-AMINO ACID N-TERMINAL DOMAIN OF A BASIC PROLINE-RICH PROTEIN IS NECESSARY FOR STORAGE IN SECRETORY GRANULES AND FACILITATES EXIT FROM THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; PITUITARY CELL-LINE; PAROTID-GLANDS; ANTERIOR-PITUITARY; MULTIGENE FAMILIES; GROWTH-HORMONE; MESSENGER-RNAS; PATHWAYS; CDNA; GENE	We have investigated the role of different domains of a salivary basic proline-rich protein in intracellular transport and sorting of proline-rich proteins to the secretory granules. We have cloned a full-length cDNA of a basic proline-rich protein from the rat parotid and expressed it in AtT-20 cells. It was correctly sorted into secretory granules as shown by EM immunolocalization and by its presence in 8-bromocyclic AMP-stimulated secretion. Deletion of the N-terminal thirteen amino acid domain upstream from the proline-rich domain eliminated storage whereas deletion of the C-terminal 20-amino acid domain downstream from the proline-rich domain had no effect. Intracellular transport of full-length and mutant proline-rich proteins was unusually slow due to slow exit from the endoplasmic reticulum. However, the rate of transport increased with increasing level of expression for the full-length protein and the C-terminal deletion mutant. In contrast, the rate of transport of the N-terminal deletion mutant was independent of the level of expression. These results imply that the N-terminal domain is necessary for both storage and efficient intracellular transport. Moreover, interactions (self-aggregation?) that mediate sorting may begin as early as the endoplasmic reticulum.	UNIV VIRGINIA, HLTH SCI CTR, DEPT ANAT & CELL BIOL, BOX 439, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, INST MOLEC BIOL, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [F32DE005529, R01DE008941] Funding Source: NIH RePORTER; NIDCR NIH HHS [F32 DE05529, DE08941] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANN DK, 1987, J BIOL CHEM, V262, P899; ANN DK, 1985, J BIOL CHEM, V260, P5863; ARVAN P, 1986, J CELL BIOL, V103, P1257, DOI 10.1083/jcb.103.4.1257; BERRYMAN MA, 1990, J HISTOCHEM CYTOCHEM, V38, P159, DOI 10.1177/38.2.1688894; BLAIR EA, 1991, AM J PHYSIOL, V261, pC897, DOI 10.1152/ajpcell.1991.261.5.C897; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; BURGESS TL, 1985, J CELL BIOL, V101, P639, DOI 10.1083/jcb.101.2.639; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHUNG KN, 1989, SCIENCE, V243, P192, DOI 10.1126/science.2911732; CLEMENTS S, 1985, J BIOL CHEM, V260, P3471; DICKERSON IM, 1987, J BIOL CHEM, V262, P13646; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FISHER JM, 1988, CELL, V54, P813, DOI 10.1016/S0092-8674(88)91131-2; FUMAGALLI G, 1985, J CELL BIOL, V100, P2019, DOI 10.1083/jcb.100.6.2019; GERDES HH, 1989, J BIOL CHEM, V264, P12009; GUMBINER B, 1981, P NATL ACAD SCI-BIOL, V78, P318, DOI 10.1073/pnas.78.1.318; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KIRSHMEIER PI, 1988, DNA CELL BIOL, V1, P219; KIZER JS, 1991, BIOCHEM BIOPH RES CO, V174, P586, DOI 10.1016/0006-291X(91)91457-N; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOH Y P, 1990, Journal of Cell Biology, V111, p319A; MAEDA N, 1985, J BIOL CHEM, V260, P1123; MAINS RE, 1983, ENDOCRINOLOGY, V112, P1986, DOI 10.1210/endo-112-6-1986; MAINS RE, 1981, J CELL BIOL, V89, P21, DOI 10.1083/jcb.89.1.21; MATSUUCHI L, 1991, J CELL BIOL, V112, P843, DOI 10.1083/jcb.112.5.843; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MOORE HPH, 1986, NATURE, V321, P443, DOI 10.1038/321443a0; MOORE HPH, 1985, J CELL BIOL, V101, P1773, DOI 10.1083/jcb.101.5.1773; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; MUENZER J, 1979, J BIOL CHEM, V254, P5629; NEUFELD G, 1988, J CELL BIOL, V106, P1385, DOI 10.1083/jcb.106.4.1385; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUER M K, 1990, Journal of Cell Biology, V111, p313A; SOSSIN WS, 1990, J CELL BIOL, V110, P1, DOI 10.1083/jcb.110.1.1; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; TOOZE J, 1987, J CELL BIOL, V105, P1215, DOI 10.1083/jcb.105.3.1215; TOOZE J, 1989, J CELL BIOL, V109, P35, DOI 10.1083/jcb.109.1.35; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONZASTROW M, 1987, J CELL BIOL, V105, P2675, DOI 10.1083/jcb.105.6.2675; WAGNER DD, 1991, CELL, V64, P403, DOI 10.1016/0092-8674(91)90648-I; WALTER P, 1983, METHOD ENZYMOL, V96, P84; ZIEMER MA, 1982, J BIOL CHEM, V257, P1176	46	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					13093	13100						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618808				2022-12-25	WOS:A1992HZ48300102
J	LARSEN, IK; CORNETT, C; KARLSSON, M; SAHLIN, M; SJOBERG, BM				LARSEN, IK; CORNETT, C; KARLSSON, M; SAHLIN, M; SJOBERG, BM			CARACEMIDE, A SITE-SPECIFIC IRREVERSIBLE INHIBITOR OF PROTEIN-R1 OF ESCHERICHIA-COLI RIBONUCLEOTIDE REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTITUMOR AGENT CARACEMIDE; CHOLINE-ACETYLTRANSFERASE; ACTIVE-SITE; TRIPHOSPHATE REDUCTASE; DIPHOSPHATE REDUCTASE; PHASE-I; INACTIVATION; MECHANISM; HYDROXYUREA; CISPLATIN	The anticancer drug caracemide, N-acetyl-N,O-di(methylcarbamoyl)hydroxylamine, and one of its degradation products, N-acetyl-O-methylcarbamoyl-hydroxylamine, were found to inhibit the enzyme ribonucleotide reductase of Escherichia coli by specific interaction with its larger component protein R1. No effect on the smaller protein R2 was observed. The effect of the degradation product was about 30 times lower than that of caracemide itself. The caracemide inactivation of R1 is irreversible, with an apparent second-order rate constant of 150 M-1 s-1. The R1R2 holoenzyme was approximately 30 times more sensitive to caracemide inactivation than the isolated R1 protein. The ribonucleotide reductase substrates were potent competitors of the caracemide inhibition, with a K(diss) for GDP binding to R1 of 80-mu-M. The reducing agent dithiothreitol was also found to be a potent competitor of caracemide inactivation. These results indicate that caracemide inactivates R1 by covalent modification at the substrate-binding site. By analogy with the known interaction between caracemide and acetylcholinesterase or choline acetyltransferase, we propose that the modification of R1 occurs at an activated cysteine or serine residue in the active site of the enzyme.	ROYAL DANISH SCH PHARM, DEPT ORGAN CHEM, DK-2100 COPENHAGEN, DENMARK; UNIV STOCKHOLM, ARRHENIUS LABS NAT SCI, DEPT MOLEC BIOL, S-10691 STOCKHOLM, SWEDEN	Royal Danish School of Pharmacy; Stockholm University			Cornett, Claus/B-8893-2009	Cornett, Claus/0000-0001-6991-5362; Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1989, J BIOL CHEM, V264, P12249; ATOR MA, 1985, BIOCHEMISTRY-US, V24, P7214, DOI 10.1021/bi00346a029; BUCCAFUSCO JJ, 1990, RES COMMUN CHEM PATH, V67, P219; CANTWELL BMJ, 1989, CANCER CHEMOTH PHARM, V23, P252, DOI 10.1007/BF00451651; CARBINI L, 1990, BRAIN RES BULL, V24, P119, DOI 10.1016/0361-9230(90)90295-B; CLIMENT I, 1991, BIOCHEMISTRY-US, V30, P5164, DOI 10.1021/bi00235a008; COHEN EA, 1986, NATURE, V321, P441, DOI 10.1038/321441a0; DIXON M, 1979, ENZYMES, P369; DOBELN UV, 1976, J BIOL CHEM, V251, P3616; DUTIA BM, 1986, NATURE, V321, P439, DOI 10.1038/321439a0; ELIASSON R, 1990, P NATL ACAD SCI USA, V87, P3314, DOI 10.1073/pnas.87.9.3314; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; FONTECAVE M, 1992, ADV ENZYMOL RAMB, V65, P147; FONTECAVE M, 1989, P NATL ACAD SCI USA, V86, P2147, DOI 10.1073/pnas.86.7.2147; HERSH LB, 1979, J BIOL CHEM, V254, P1988; HO BT, 1988, J NEUROSCI RES, V19, P119, DOI 10.1002/jnr.490190116; KARLSSON M, 1992, J BIOL CHEM, V267, P12622; LAM KY, 1990, J CHEM SOC CHEM COMM, P658, DOI 10.1039/c39900000658; LAMMERS M, 1983, STRUCT BOND, V54, P27; LARSEN IK, 1990, ACTA CRYSTALLOGR C, V46, P600, DOI 10.1107/S010827018900836X; LARSEN IK, 1982, EUR J BIOCHEM, V125, P75; LARSEN IK, 1990, ALFRED BENZON SYMP S, V28, P47; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; LEE MS, 1986, MUTAT RES, V172, P199, DOI 10.1016/0165-1218(86)90057-1; LIN ANI, 1987, BIOCHEMISTRY-US, V26, P6905, DOI 10.1021/bi00396a006; LURIA SE, 1957, J BACTERIOL, V74, P461, DOI 10.1002/path.1700740226; MAO SS, 1989, P NATL ACAD SCI USA, V86, P1485, DOI 10.1073/pnas.86.5.1485; MCKINNEY M, 1986, BIOCHEM PHARMACOL, V35, P2615, DOI 10.1016/0006-2952(86)90061-4; MILDVAN AS, 1964, BIOCHIM BIOPHYS ACTA, V89, P393, DOI 10.1016/0926-6569(64)90065-3; MOORE EC, 1984, CANCER TREAT REP, V68, P1293; NEWMAN RA, 1986, BIOCHEM PHARMACOL, V35, P2781, DOI 10.1016/0006-2952(86)90190-5; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; PAZDUR R, 1987, INVEST NEW DRUG, V5, P365; RABER MN, 1987, CANCER TREAT REP, V71, P349; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; SMITH SL, 1989, BIOCHEM BIOPH RES CO, V162, P715, DOI 10.1016/0006-291X(89)92369-3; STUBBE J, 1983, J BIOL CHEM, V258, P1625; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; Thelander L, 1978, Methods Enzymol, V51, P227; THELANDER L, 1976, J BIOL CHEM, V251, P1398	41	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12627	12631						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618768				2022-12-25	WOS:A1992HZ48300040
J	LIGHT, DR; DENNIS, MS; FORSYTHE, IJ; LIU, CC; GREEN, DW; KRATZER, DA; PLAPP, BV				LIGHT, DR; DENNIS, MS; FORSYTHE, IJ; LIU, CC; GREEN, DW; KRATZER, DA; PLAPP, BV			ALPHA-ISOENZYME OF ALCOHOL-DEHYDROGENASE FROM MONKEY LIVER - CLONING, EXPRESSION, MECHANISM, COENZYME, AND SUBSTRATE-SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE ADENINE-DINUCLEOTIDE; KINETIC CHARACTERIZATION; TERNARY COMPLEX; HORSE; YEAST; BINDING; ISOZYMES; ETHANOL; DNA; METABOLISM	The cDNA for the alpha-isoenzyme from rhesus monkey (Macaca mulatta) liver was cloned and expressed in yeast. The alpha-isoenzymes of human and monkey liver alcohol dehydrogenase differ from the other human and horse liver enzymes in having Met57, Ala93, and Val116 instead of Leu57, Phe93, and Leu116 in the substrate binding pocket and Gly47 instead of Arg47 near the pyrophosphate moiety of the coenzyme. The effects of these differences on the kinetic mechanism, substrate specificity, and coenzyme binding were studied with the purified, recombinant monkey alpha-isoenzyme (MmADH-alpha) and mutated enzymes with Gly47 substituted with His or Arg. The mechanism appears to be random for the binding of NAD+ and ethanol and ordered for NADH and acetaldehyde, with formation of a dead-end enzyme-NADH-ethanol complex. MmADH-alpha reacts 130-fold slower (V/K) with ethanol and 3-25-fold slower with 2-methyl alcohols but 20-fold faster with cyclohexanol, as compared with horse (Equus caballus) liver EE isoenzyme (EqADH). MmADH-alpha is stereoselective for the R isomer of 2-butanol, whereas EqADH favors the S isomer. Both enzymes have comparable reactivity with larger primary alcohols. MmADH-alpha is more reactive with secondary alcohols and has highest activity with cyclohexanol. However, it does not react with steroids such as 5-beta-androstane-17-beta-ol-3-one. Molecular modeling suggests that the differences between MmADH-alpha and EqADH are a result of the substitution of Ala for Phe93 and Thr for Ser48. MmADH-alpha binds NAD+ most rapidly when a group with a pK of 7.4 is unprotonated, implicating His51 in this reaction. The G47R substitution decreased the dissociation constants for NAD+ and NADH and turnover numbers only about 2-fold, whereas the G47H substitution increased dissociation constants 7-14-fold and turnover numbers 4-fold. A basic residue at position 47 is not crucial for activity, as multiple interactions determine coenzyme affinity.	UNIV IOWA,DEPT BIOCHEM,4-370 BOWEN SCI BLDG,IOWA CITY,IA 52242; GENENTECH INC,S SAN FRANCISCO,CA 94080	University of Iowa; Roche Holding; Genentech			Plapp, Bryce V/F-6353-2010		NIAAA NIH HHS [AA00279, AA06223] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006223] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AINSLIE GR, 1972, J BIOL CHEM, V247, P946; BOSRON WF, 1986, HEPATOLOGY, V6, P502, DOI 10.1002/hep.1840060330; BOSRON WF, 1983, BIOCHEMISTRY-US, V22, P1852, DOI 10.1021/bi00277a017; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Branden C.-I., 1975, ENZYMES, V11, P103; CHADHA VK, 1985, J MED CHEM, V28, P36, DOI 10.1021/jm00379a009; CHEN CY, 1984, NUCLEIC ACIDS RES, V12, P8951, DOI 10.1093/nar/12.23.8951; Cleland W W, 1979, Methods Enzymol, V63, P103; CORNELL NW, 1983, PHARMACOL BIOCHEM BE, V18, P215, DOI 10.1016/0091-3057(83)90174-0; CRONHOLM T, 1975, ACTA CHEM SCAND B, V29, P571, DOI 10.3891/acta.chem.scand.29b-0571; DAFELDECKER WP, 1981, BIOCHEMISTRY-US, V20, P6729, DOI 10.1021/bi00526a031; DAFELDECKER WP, 1981, BIOCHEMISTRY-US, V20, P856, DOI 10.1021/bi00507a031; DAFELDECKER WP, 1985, BIOCHEMISTRY-US, V24, P6474, DOI 10.1021/bi00344a025; DALZIEL K, 1966, BIOCHEM J, V100, P34, DOI 10.1042/bj1000034; DALZIEL K, 1966, BIOCHEM J, V100, P491, DOI 10.1042/bj1000491; DALZIEL K, 1963, J BIOL CHEM, V238, P2850; DENHOLLANDER JA, 1981, BIOCHEMISTRY-US, V20, P5871, DOI 10.1021/bi00523a034; DICKENSON CJ, 1978, BIOCHEM J, V171, P613, DOI 10.1042/bj1710613; DWORSCHACK RT, 1977, BIOCHEMISTRY-US, V16, P111, DOI 10.1021/bi00620a018; EKLUND H, 1987, EUR J BIOCHEM, V167, P185, DOI 10.1111/j.1432-1033.1987.tb13322.x; EKLUND H, 1982, J BIOL CHEM, V257, P4349; EKLUND H, 1984, BIOCHEMISTRY-US, V23, P5982, DOI 10.1021/bi00320a014; EKLUND H, 1981, J MOL BIOL, V146, P561, DOI 10.1016/0022-2836(81)90047-4; GANZHORN AJ, 1987, J BIOL CHEM, V262, P3754; GANZHORN AJ, 1988, J BIOL CHEM, V263, P5446; GOULD RM, 1990, BIOCHEMISTRY-US, V29, P5463, DOI 10.1021/bi00475a009; HURLEY TD, 1991, P NATL ACAD SCI USA, V88, P8149, DOI 10.1073/pnas.88.18.8149; HURLEY TD, 1990, J BIOL CHEM, V265, P16366; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MCEVILY AJ, 1988, BIOCHEMISTRY-US, V27, P4284, DOI 10.1021/bi00412a013; MELCHIOR WB, 1973, P NATL ACAD SCI USA, V70, P298, DOI 10.1073/pnas.70.2.298; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MOSER K, 1968, ENZYMOL BIOL CLIN, V9, P447, DOI 10.1159/000458284; PAPENBER.J, 1965, BIOCHEM Z, V342, P95; PARK DH, 1992, J BIOL CHEM, V267, P5527; PARK DH, 1991, J BIOL CHEM, V266, P13296; PETTERSSON G, 1987, CRIT REV BIOCHEM MOL, V21, P349, DOI 10.3109/10409238609113616; PLAPP BV, 1970, J BIOL CHEM, V245, P1727; RAO GSJ, 1987, J BIOL CHEM, V262, P14074; RICHARDS FM, 1974, J MOL BIOL, V82, P1, DOI 10.1016/0022-2836(74)90570-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKHAR VC, 1988, BIOCHEMISTRY-US, V27, P5082, DOI 10.1021/bi00414a020; STONE CL, 1989, J BIOL CHEM, V264, P11112; SUN HW, 1992, IN PRESS J MOL EVOL, V34; TOPHAM CM, 1986, EUR J BIOCHEM, V156, P555, DOI 10.1111/j.1432-1033.1986.tb09615.x; WILLS C, 1976, NATURE, V261, P26, DOI 10.1038/261026a0; WRATTEN CC, 1963, BIOCHEMISTRY-US, V2, P935, DOI 10.1021/bi00905a007; YIN SJ, 1984, BIOCHEMISTRY-US, V23, P5847, DOI 10.1021/bi00319a026; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	52	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12592	12599						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618764				2022-12-25	WOS:A1992HZ48300035
J	PANINI, SR; DELATE, TA; SINENSKY, M				PANINI, SR; DELATE, TA; SINENSKY, M			POSTTRANSCRIPTIONAL REGULATION OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A REDUCTASE BY 24(S),25-OXIDOLANOSTEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; HAMSTER OVARY CELLS; MEVALONATE-DERIVED PRODUCT; HMG-COA REDUCTASE; CULTURED FIBROBLASTS; NUCLEOTIDE-SEQUENCE; ALPHA-TUBULIN; EXPRESSION; 25-HYDROXYCHOLESTEROL; REPRESSION	We have examined the mechanism of regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase by 24(S),25-oxidolanosterol, a C30-sterol naturally occurring in mammalian tissues. In the absence of enzymatic demethylation to the C27-sterol, 24(S),25-epoxycholesterol, oxidolanosterol is shown to be a post-transcriptional regulator of reductase synthesis in both primary rat hepatocytes and Chinese hamster ovary cells. Under these conditions, oxidolanosterol also increases the rate of degradation of reductase protein in these cells. When demethylation is not inhibited, oxidolanosterol treatment produces transcriptional regulation of sterol-sensitive genes in Chinese hamster ovary cells. In contrast to previous findings with the oxygenated C27-sterol, 25-hydroxycholesterol, oxidolanosterol can act as a post-transcriptional regulator in cells starved for mevalonate. These findings are consistent with the hypothesis that oxidolanosterol down-regulates sterol synthesis in a fashion mechanistically distinct from that of C27-sterols.			PANINI, SR (corresponding author), ELEANOR ROOSEVELT INST,1899 GAYLORD ST,DENVER,CO 80206, USA.				NIDDK NIH HHS [DK 40804, DK 42270] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042270, R01DK040804] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASTIAN LS, 1991, MOL ENDOCRINOL, V5, P619, DOI 10.1210/mend-5-5-619; BLIGH EG, 1959, J BIOCH PHYSL, V32, P911; BROWN MS, 1980, J LIPID RES, V21, P505; CHAM BE, 1976, J LIPID RES, V17, P176; CHANG TY, 1981, ANAL BIOCHEM, V116, P298, DOI 10.1016/0003-2697(81)90360-2; CHANG TY, 1980, J BIOL CHEM, V255, P7787; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; CHIN DJ, 1985, MOL CELL BIOL, V5, P634, DOI 10.1128/MCB.5.4.634; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; Davis R A, 1986, Methods Enzymol, V129, P272; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; Dittmer J, 1969, METHOD ENZYMOL, V14, P482, DOI [DOI 10.1016/S0076-6879(69)14055-0, 10.1016/S0076-6879(69)14055-0]; DREVON CA, 1981, J LIPID RES, V22, P37; ELLIOTT EM, 1985, MOL CELL BIOL, V5, P236, DOI 10.1128/MCB.5.1.236; FAUST JR, 1982, P NATL ACAD SCI-BIOL, V79, P5205, DOI 10.1073/pnas.79.17.5205; FAVATA MF, 1987, J BIOL CHEM, V262, P12254; FAVATA MF, 1990, FASEB J, V4, pA1746; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1984, J LIPID RES, V25, P1450; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; KANDUTSCH AA, 1978, SCIENCE, V201, P498, DOI 10.1126/science.663671; KANDUTSCH AA, 1980, J BIOL CHEM, V256, P13068; LEE LY, 1989, NUCLEIC ACIDS RES, V17, P1259, DOI 10.1093/nar/17.3.1259; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; NELSON JA, 1981, J BIOL CHEM, V256, P1067; OSBORNE TF, 1991, J BIOL CHEM, V266, P13947; PANINI SR, 1986, J LIPID RES, V27, P1190; PANINI SR, 1989, J BIOL CHEM, V264, P11044; PANINI SR, 1990, J BIOL CHEM, V265, P14118; PEFFLEY D, 1988, SOMAT CELL MOLEC GEN, V14, P527, DOI 10.1007/BF01535308; PEFFLEY D, 1985, J BIOL CHEM, V260, P9949; SARRIA AJ, 1990, J CELL BIOL, V111, P553, DOI 10.1083/jcb.111.2.553; SAUCIER SE, 1985, J BIOL CHEM, V260, P4571; SCHACTERLE GR, 1973, ANAL BIOCHEM, V51, P654, DOI 10.1016/0003-2697(73)90523-X; SCHNITZERPOLOKOFF R, 1982, J BIOL CHEM, V257, P472; SCHNITZERPOLOKOFF R, 1983, ARCH BIOCHEM BIOPHYS, V227, P71, DOI 10.1016/0003-9861(83)90348-X; SINENSKY M, 1980, P NATL ACAD SCI-BIOL, V77, P6621, DOI 10.1073/pnas.77.11.6621; SINENSKY M, 1987, EXP CELL RES, V171, P492, DOI 10.1016/0014-4827(87)90180-7; SINENSKY M, 1981, J BIOL CHEM, V256, P1774; SPENCER TA, 1985, J BIOL CHEM, V260, P3391; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; TAYLOR FR, 1984, J BIOL CHEM, V259, P2382; TAYLOR FR, 1986, J BIOL CHEM, V261, P5039; TRZASKOS JM, 1987, J BIOL CHEM, V262, P12261; URLAUB G, 1986, SOMAT CELL MOLEC GEN, V12, P555, DOI 10.1007/BF01671941	47	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12647	12654						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618770				2022-12-25	WOS:A1992HZ48300043
J	TAKAHASHI, S; INOUE, H; MIYAKE, Y				TAKAHASHI, S; INOUE, H; MIYAKE, Y			THE HUMAN GENE FOR RENIN-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-ZIPPER; PORCINE KIDNEY; INSITU HYBRIDIZATION; NUCLEOTIDE-SEQUENCE; CDNA; PURIFICATION; EXPRESSION; CHROMOSOME; PROMOTER; CLONING	The human renin-binding protein (RnBP) gene was isolated from a human placental genomic library and characterized. The gene spans about 10 kilobases and consists of 11 exons separated by 10 introns. The 5'-flanking region and the exon-intron boundaries were sequenced. Residue G* in 5'-CGAG*TGG-3' was identified as the major transcription initiation site, and "GC" boxes were found in the vicinity of the cap site. No typical "TATA" or "CCAAT" box exists in the 5'-flanking region. The hydrophobic domain followed by a leucine-zipper motif in RnBP is encoded by the sixth exon. A fragment of the human RnBP gene (nucleotides -739 to +244) linked to the chloramphenicol acetyltransferase gene was transfected into human Wilms' tumor G401 and mouse L929 cells. The expression of this chimeric gene in G401 cells was 4-fold higher than that in L929 cells, the tissue-specific regulation of RnBP gene expression thus being suggested. The promoter for the RnBP gene was shown to be localized in nucleotides -35 to +244 on assaying of the promoter activity using deletion mutants of the chimeric constructs. The RnBP gene was found to be located in human chromosome X by means of polymerase chain reaction of hybrid DNAs from human and hamster somatic cells.	NATL CARDIOVASC CTR,RES INST,DEPT BIOCHEM,5-7-1 FUJISHIRO DAI,SUITA,OSAKA 565,JAPAN	National Cerebral & Cardiovascular Center - Japan								AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CALZONE FJ, 1987, METHOD ENZYMOL, V152, P611; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAWSON PA, 1989, J BIOL CHEM, V264, P16798; DODGSON JB, 1983, J BIOL CHEM, V258, P4623; DRAYNA D, 1985, SCIENCE, V230, P753, DOI 10.1126/science.4059909; DUSH MK, 1985, P NATL ACAD SCI USA, V82, P2731, DOI 10.1073/pnas.82.9.2731; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FUKUI K, 1989, BIOCHEM BIOPH RES CO, V164, P265, DOI 10.1016/0006-291X(89)91712-9; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HURBY DE, 1990, BIOTECHNIQUES, V8, P170; IMAI T, 1983, P NATL ACAD SCI-BIOL, V80, P7405, DOI 10.1073/pnas.80.24.7405; INOUE H, 1991, J BIOCHEM-TOKYO, V110, P493, DOI 10.1093/oxfordjournals.jbchem.a123609; INOUE H, 1990, J BIOL CHEM, V265, P6556; INOUE H, 1991, J BIOL CHEM, V266, P11896; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MCCORMACK K, 1989, NATURE, V340, P103, DOI 10.1038/340103a0; MCGILL JR, 1987, CYTOGENET CELL GENET, V45, P55, DOI 10.1159/000132425; MIYAZAKI H, 1984, P NATL ACAD SCI-BIOL, V81, P5999, DOI 10.1073/pnas.81.19.5999; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAKAI H, 1988, CYTOGENET CELL GENET, V47, P90, DOI 10.1159/000132515; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; TAKAHASHI S, 1983, J BIOCHEM, V93, P1583, DOI 10.1093/oxfordjournals.jbchem.a134297; TAKAHASHI S, 1983, J BIOCHEM-TOKYO, V93, P265, DOI 10.1093/oxfordjournals.jbchem.a134162; TAKAHASHI S, 1988, BIOCHEM INT, V16, P1053; TAKAHASHI S, 1985, J BIOCHEM-TOKYO, V97, P671, DOI 10.1093/oxfordjournals.jbchem.a135103; TAKENAKA M, 1989, J BIOL CHEM, V264, P2363; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VIBERT M, 1989, EUR J BIOCHEM, V181, P33, DOI 10.1111/j.1432-1033.1989.tb14690.x; WHITE MK, 1989, NATURE, V340, P103, DOI 10.1038/340103b0; WIERINGA B, 1983, NATURE, V301, P38, DOI 10.1038/301038a0; XIAO H, 1988, SCIENCE, V239, P1139, DOI 10.1126/science.3125608	42	38	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					13007	13013						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618798				2022-12-25	WOS:A1992HZ48300091
J	BARNETT, T; CLARK, GF				BARNETT, T; CLARK, GF			POLYGLYCOSYLCERAMIDES WITH BRANCHED N-ACETYLLACTOSAMINE SEQUENCES ARE SYNTHESIZED BY THE HUMAN PANCREATIC-CARCINOMA CELL-LINE PANC-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE MEMBRANES; HUMAN MONOCLONAL-ANTIBODY; WHEAT-GERM-AGGLUTININ; HUMAN-MILK; AFFINITY-CHROMATOGRAPHY; LINKED OLIGOSACCHARIDES; CARBOHYDRATE ANTIGENS; METHYLATION ANALYSIS; GLYCOLIPID ANTIGENS; MALIGNANT-MELANOMA	We have metabolically labeled the human pancreatic tumor cell line PANC-1 with high specific activity tritiated sugar precursors to study the expression of glycosphingolipids by this cell type. We have used a combination of detergent solubilization, exhaustive protease digestion, ceramide glycanase digestion, and reverse-phase chromatography to isolate glycosphingolipid-derived oligosaccharides specifically labeled in their component sugars. A significant proportion of the oligosaccharides derived from polar glycosphingolipids were of high molecular mass (>2000 Da). The results of compositional studies, lectin affinity chromatography, and methylation analysis suggested that this high molecular weight fraction consists of lactosaminoglycan type oligosaccharides derived from polyglycosylceramides. There are on average three beta-1-6 linked N-acetyllactosamine branches attached to the polylactosamine backbone in this type of glycosphingolipid-derived oligosaccharide. The majority of the oligosaccharides also contain 1-2 mol of sialic acid that are linked alpha-2-3 to penultimate galactose. The results indicate that PANC-1 cells, like human colorectal tumor cells, express highly extended neolacto type glycosphingolipids. However, the lactosaminoglycan sequences are highly branched, unlike those associated with colorectal tumor cells.	EASTERN VIRGINIA MED SCH, DEPT BIOCHEM, NORFOLK, VA 23501 USA	Eastern Virginia Medical School								ABRAMS PG, 1985, MONOCLONAL ANTIBODY, P103; ANET EFLJ, 1954, NATURE, V174, P930, DOI 10.1038/174930a0; BJORNDAL H, 1967, ACTA CHEM SCAND, V21, P1801, DOI 10.3891/acta.chem.scand.21-1801; BLANCHARD D, 1985, J BIOL CHEM, V260, P7813; BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; CHEUNG NKV, 1987, J CLIN ONCOL, V5, P1430, DOI 10.1200/JCO.1987.5.9.1430; CHING CK, 1988, J CLIN PATHOL, V41, P324, DOI 10.1136/jcp.41.3.324; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; CLARK GF, 1991, CARBOHYD RES, V213, P155, DOI 10.1016/S0008-6215(00)90606-2; CLARK GF, 1987, ARCH BIOCHEM BIOPHYS, V257, P217, DOI 10.1016/0003-9861(87)90561-3; CLAUSEN H, 1986, BIOCHEMISTRY-US, V25, P7075, DOI 10.1021/bi00370a048; COOPER CS, 1984, CANCER RES, V44, P1; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; DEIXONNE B, 1986, EXOCRINE PANCREATIC, P11; DENNIS JW, 1989, ONCOGENE, V4, P853; DIAZ S, 1985, ANAL BIOCHEM, V150, P32, DOI 10.1016/0003-2697(85)90438-5; DUTT A, 1988, J BIOL CHEM, V263, P2270; ESSELMAN WJ, 1972, METHOD ENZYMOL, V28, P140; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; GALLAGHER JT, 1985, BIOCHEM J, V231, P115, DOI 10.1042/bj2310115; GARDAS A, 1974, FEBS LETT, V42, P101, DOI 10.1016/0014-5793(74)80289-9; GARDAS A, 1973, EUR J BIOCHEM, V32, P178, DOI 10.1111/j.1432-1033.1973.tb02595.x; GUNNARSSON A, 1987, GLYCOCONJUGATE J, V4, P239, DOI 10.1007/BF01048429; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1986, CHEM PHYS LIPIDS, V42, P209, DOI 10.1016/0009-3084(86)90054-X; HAKOMORI SI, 1983, SPHINGOLIPID BIOCH, P1; HANFLAND P, 1981, BIOCHEMISTRY-US, V20, P5310, DOI 10.1021/bi00521a034; HANFLAND P, 1984, EUR J BIOCHEM, V145, P531, DOI 10.1111/j.1432-1033.1984.tb08589.x; HOLMES EH, 1987, J BIOL CHEM, V262, P15649; HOUGHTON AN, 1985, P NATL ACAD SCI USA, V82, P1242, DOI 10.1073/pnas.82.4.1242; IRIE RF, 1986, P NATL ACAD SCI USA, V83, P8694, DOI 10.1073/pnas.83.22.8694; IRIMURA T, 1983, CARBOHYD RES, V120, P187, DOI 10.1016/0008-6215(83)88016-1; KANFER JN, 1983, SPHINGOLIPID BIOCH; KANNAGI R, 1984, J BIOL CHEM, V259, P8444; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; Klenk E, 1941, H-S Z PHYSIOL CHEM, V270, P185, DOI 10.1515/bchm2.1941.270.3-4.185; KOSCIELAK J, 1976, EUR J BIOCHEM, V71, P9, DOI 10.1111/j.1432-1033.1976.tb11083.x; LEVERY SB, 1987, METHOD ENZYMOL, V138, P13, DOI 10.1016/0076-6879(87)38004-8; LEVERY SB, 1989, BIOCHEMISTRY-US, V28, P7772, DOI 10.1021/bi00445a037; LI E, 1978, J BIOL CHEM, V253, P7762; MAZZETTA C, 1975, INT J CANCER, V15, P741; MURAMATSU H, 1988, J BIOCHEM-TOKYO, V107, P629; MURAMATSU T, 1988, J CELL BIOCHEM, V36, P1, DOI 10.1002/jcb.240360102; NAKAISHI H, 1988, CANCER RES, V48, P1753; NOWACK WJ, 1984, FED PROC, V43, P926; NUDELMAN ED, 1989, J BIOL CHEM, V264, P18719; OKU N, 1983, J BIOL CHEM, V258, P8733; Schauer R, 1978, Methods Enzymol, V50, P64; SMITH DF, 1980, J BIOL CHEM, V255, P55; SMITH DF, 1987, J BIOL CHEM, V262, P12040; SMITH DF, 1978, ANAL BIOCHEM, V85, P602, DOI 10.1016/0003-2697(78)90261-0; STOFFYN P, 1971, J LIPID RES, V12, P318; SVENNERHOLM L, 1980, BIOCHIM BIOPHYS ACTA, V617, P97, DOI 10.1016/0005-2760(80)90227-1; TARRAGO MT, 1988, ARCH BIOCHEM BIOPHYS, V267, P353, DOI 10.1016/0003-9861(88)90041-0; TORRES BV, 1988, ARCH BIOCHEM BIOPHYS, V262, P1, DOI 10.1016/0003-9861(88)90161-0; TSUJI Y, 1988, J EXP MED, V168, P343, DOI 10.1084/jem.168.1.343; VANCE DE, 1967, J LIPID RES, V8, P621; VARKI A, 1991, FASEB J, V5, P226, DOI 10.1096/fasebj.5.2.2004668; VARKI A, 1980, J BIOL CHEM, V255, P847; WANG WC, 1988, ANAL BIOCHEM, V175, P390, DOI 10.1016/0003-2697(88)90562-3; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x; WOOD C, 1978, ANN INST PASTEUR IMM, VC129, P143; YAGEL S, 1989, INT J CANCER, V44, P685, DOI 10.1002/ijc.2910440422; YAMADA H, 1986, BIOCHEM BIOPH RES CO, V140, P167, DOI 10.1016/0006-291X(86)91072-7; Yurchenco P D, 1978, Methods Enzymol, V50, P175; ZHOU B, 1989, J BIOL CHEM, V264, P12272	67	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11760	11768						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601851				2022-12-25	WOS:A1992HY94700021
J	YOO, SH; LEWIS, MS				YOO, SH; LEWIS, MS			EFFECTS OF PH AND CA2+ ON MONOMER-DIMER AND MONOMER-TETRAMER EQUILIBRIA OF CHROMOGRANIN-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; RABBIT SKELETAL-MUSCLE; ADRENAL CHROMAFFIN GRANULES; PURIFIED RYANODINE RECEPTOR; AMINO-ACID SEQUENCE; SARCOPLASMIC-RETICULUM; HIGH-AFFINITY; TERMINAL CISTERNAE; MOLECULAR-CLONING; RELEASE CHANNEL	Chromogranin A is a high capacity, low affinity Ca2+ binding protein which undergoes Ca2+- and pH-dependent conformational changes, and has recently been suggested to play a Ca2+-buffering role in the secretory vesicle of adrenal medullary chromaffin cell, the major inositol 1,4,5-trisphosphate-sensitive intracellular Ca2+ store of chromaffin cell (Yoo, S. H., and Albanesi, J. P. (1990) J. Biol. Chem. 265, 13446-13448). In the present study, it is shown that chromogranin A exists in a monomer-dimer equilibrium at pH 7.5 and in a monomer-tetramer equilibrium at pH 5.5. The pH appears to be a necessary and sufficient factor determining the types of oligomers formed. Although Ca2+ did not change the type of oligomerization, it had a very significant effect on the values of the thermodynamic parameters characterizing the associations. The DELTA-G0 values for a monomer-dimer equilibrium were -7 to -8 kcal/mol, while those for a monomer-tetramer equilibrium were -20 to -23 kcal/mol. At pH 5.5, the values of DELTA-H0, DELTA-S0, and DELTA-C(p)0 were large and negative in the absence of Ca2+ and large and positive in the presence of 35 mM Ca2+, implying markedly different reaction mechanisms. Extrapolation of the results to 37-degrees-C and 1 mM chromogranin A suggests that chromogranin A is virtually 100% tetramer at pH 5.5 in the presence of 35 mM Ca2+ but is 96% dimer at pH 7.5 in the absence of Ca2+, the two conditions resembling those seen in vivo. These results suggest that chromogranin A is mostly dimer in the endoplasmic reticulum and cis-Golgi area and is essentially all tetramer in the vesicle.	NIH, NATL CTR RES RESOURCES, BIOMED ENGN & INSTRUMENTAT PROGRAM, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA	YOO, SH (corresponding author), NIDOCD, CELLULAR BIOL LAB, BETHESDA, MD 20892 USA.							ANDERSON RGW, 1984, P NATL ACAD SCI-BIOL, V81, P4838, DOI 10.1073/pnas.81.15.4838; BENEDUM UM, 1986, EMBO J, V5, P1495, DOI 10.1002/j.1460-2075.1986.tb04388.x; CLARKE ECW, 1966, T FARADAY SOC, V62, P539, DOI 10.1039/tf9666200539; COSTELLO B, 1986, J CELL BIOL, V103, P741, DOI 10.1083/jcb.103.3.741; COZENS B, 1984, J BIOL CHEM, V259, P6248; FLIEGEL L, 1987, P NATL ACAD SCI USA, V84, P1167, DOI 10.1073/pnas.84.5.1167; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; FRANZINIARMSTRONG C, 1987, J CELL BIOL, V105, P49, DOI 10.1083/jcb.105.1.49; HELMAN LJ, 1988, J BIOL CHEM, V263, P11559; IACANGELO A, 1986, NATURE, V323, P82, DOI 10.1038/323082a0; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; KNOTT GD, 1979, COMPUT PROG BIOMED, V10, P271, DOI 10.1016/0010-468X(79)90075-8; LAI FA, 1989, NATURE, V28, P315; MACLENNAN DH, 1973, COLD SPRING HARB SYM, V37, P469, DOI 10.1101/SQB.1973.037.01.058; MACLENNAN DH, 1971, P NATL ACAD SCI USA, V68, P1231, DOI 10.1073/pnas.68.6.1231; MILOS M, 1986, BIOCHEMISTRY-US, V25, P6279, DOI 10.1021/bi00368a067; MILOS M, 1987, J BIOL CHEM, V262, P2746; OSTWALD TJ, 1974, J BIOL CHEM, V249, P974; REITHMEIER RAF, 1987, CALCIUM BINDING PROT, P62; ROSS PD, 1981, BIOCHEMISTRY-US, V20, P3096, DOI 10.1021/bi00514a017; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SCHWARTZ AL, 1985, EMBO J, V4, P899, DOI 10.1002/j.1460-2075.1985.tb03716.x; SCOTT BT, 1988, J BIOL CHEM, V263, P8958; SELLERS P, 1991, BIOPHYS CHEM, V39, P199, DOI 10.1016/0301-4622(91)85022-I; SIMON JP, 1989, BIOCHEM J, V262, P1; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; SMITH MJ, 1989, EMBO J, V8, P3581, DOI 10.1002/j.1460-2075.1989.tb08530.x; TREVES S, 1990, BIOCHEM J, V271, P473, DOI 10.1042/bj2710473; VAN PN, 1989, J BIOL CHEM, V264, P17494; WAISMAN DM, 1985, J BIOL CHEM, V260, P1652; WINKLER H, 1986, NEUROSCIENCE, V18, P261, DOI 10.1016/0306-4522(86)90154-5; WINKLER H, 1980, NEUROSCIENCE, V5, P1803, DOI 10.1016/0306-4522(80)90031-7; WINKLER H, 1990, J BIOL CHEM, V265, P13446; YOO SH, 1990, J BIOL CHEM, V265, P14414; YOO SH, 1991, J BIOL CHEM, V266, P7740; ZAMYATNIN AA, 1984, ANNU REV BIOPHYS BIO, V13, P145, DOI 10.1146/annurev.bb.13.060184.001045	37	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11236	11241						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597459				2022-12-25	WOS:A1992HX16900049
J	ARAKI, N; UENO, N; CHAKRABARTI, B; MORINO, Y; HORIUCHI, S				ARAKI, N; UENO, N; CHAKRABARTI, B; MORINO, Y; HORIUCHI, S			IMMUNOCHEMICAL EVIDENCE FOR THE PRESENCE OF ADVANCED GLYCATION END-PRODUCTS IN HUMAN LENS PROTEINS AND ITS POSITIVE CORRELATION WITH AGING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NON-ENZYMATIC GLYCOSYLATION; GLUCOSE-MODIFIED PROTEINS; DIABETES-MELLITUS; STRUCTURAL PROTEINS; MAILLARD REACTION; HUMAN COLLAGEN; HUMAN-SERUM; RECEPTOR; INVIVO; AGE	Prolonged incubation of protein with reducing sugar proceeds through a series of reactions involving early stage products to the advanced glycation end products with fluorescence, brown color, and cross-linking. Known collectively as the Maillard reaction, these changes have been suggested as factors in diabetic complications and the aging process. The early stage products have been demonstrated in vivo, but evidence for the presence in vivo of the advanced glycation end products has been limited. We sought to provide immunochemical evidence by the preparation and use of polyclonal and monoclonal antibodies to these end products (Horiuchi, S., Araki, N., and Morino, Y. (1991) J. Biol. Chem. 266, 7329-7332) as probes to identify and quantitate such compounds in human lens crystallins. Neither of the antibodies reacted with extracts from infant lenses, but fractions from adult lenses showed a significant reactivity, correlating with lens age. Our findings provide the first immunochemical evidence that human lens crystallins contain advanced glycation end products and that these products increase with tissue age.	KUMAMOTO UNIV,SCH MED,DEPT BIOCHEM,KUMAMOTO 860,JAPAN; HARVARD UNIV,SCH MED,BOSTON,MA 02115; SCHEPENS EYE RES INST,BOSTON,MA 02114	Kumamoto University; Harvard University; Harvard Medical School; Harvard University; Schepens Eye Research Institute					NATIONAL EYE INSTITUTE [R01EY004161] Funding Source: NIH RePORTER; NEI NIH HHS [EY04161] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARAKI N, 1992, POSTTRANSLATIONAL MO, P253; BAILEY AJ, 1973, FRONTIERS MATRIX BIO, V1, P130; BANDYOPADHYAY S, 1992, PHOTOCHEM PHOTOBIOL, V55, P765; BUNN HF, 1978, SCIENCE, V200, P21, DOI 10.1126/science.635569; CHANG JCF, 1985, J BIOL CHEM, V260, P7970; DAY JF, 1979, J BIOL CHEM, V254, P595; DYER DG, 1991, J BIOL CHEM, V266, P11654; Finot P. A., 1982, Advances in Chemistry Series, V198, P91; GRANDHEE KS, 1991, J BIOL CHEM, V266, P11649; HARDING JJ, 1976, EXP EYE RES, V22, P1, DOI 10.1016/0014-4835(76)90033-6; HAYASE F, 1989, J BIOL CHEM, V264, P3758; HORIUCHI S, 1991, J BIOL CHEM, V266, P7329; HORIUCHI S, 1988, J BIOL CHEM, V263, P18821; KATO H, 1987, AGR BIOL CHEM TOKYO, V51, P683, DOI 10.1080/00021369.1987.10868106; KUCK JFR, 1970, BIOCH EYE, P183; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIANG JN, 1990, INT J BIOL MACROMOL, V12, P273, DOI 10.1016/0141-8130(90)90009-Y; LOW MF, 1967, BIOCHIM BIOPHYS ACTA, V141, P547; Maillard LC, 1912, CR HEBD ACAD SCI, V154, P66; MAKITA Z, 1991, NEW ENGL J MED, V325, P832; MILLER JA, 1980, J CLIN INVEST, V65, P896, DOI 10.1172/JCI109743; MONNIER VM, 1984, P NATL ACAD SCI-BIOL, V81, P583, DOI 10.1073/pnas.81.2.583; MONNIER VM, 1981, SCIENCE, V211, P491, DOI 10.1126/science.6779377; NAGARAJ RH, 1991, P NATL ACAD SCI USA, V88, P10257, DOI 10.1073/pnas.88.22.10257; NJOROGE FG, 1987, CARBOHYD RES, V167, P211; PONGOR S, 1984, P NATL ACAD SCI-BIOL, V81, P2684, DOI 10.1073/pnas.81.9.2684; RAHBAR S, 1968, CLIN CHIM ACTA, V22, P296, DOI 10.1016/0009-8981(68)90372-0; Reynolds T M, 1965, Adv Food Res, V14, P167; SCHLEICHER E, 1981, FEBS LETT, V129, P1, DOI 10.1016/0014-5793(81)80741-7; SCHNIDER SL, 1981, J CLIN INVEST, V67, P1630, DOI 10.1172/JCI110198; SELL DR, 1989, J BIOL CHEM, V264, P21597; SELL DR, 1990, J CLIN INVEST, V85, P380, DOI 10.1172/JCI114449; SEN AC, 1992, PHOTOCHEM PHOTOBIOL, V55, P753; SRIVASTAVA OP, 1988, EXP EYE RES, V47, P525, DOI 10.1016/0014-4835(88)90092-9; STEVENS VJ, 1978, P NATL ACAD SCI USA, V75, P2918, DOI 10.1073/pnas.75.6.2918; TAKATA K, 1988, J BIOL CHEM, V263, P14819; VLASSARA H, 1981, P NATL ACAD SCI-BIOL, V78, P5190, DOI 10.1073/pnas.78.8.5190; VLASSARA H, 1986, J EXP MED, V164, P1301, DOI 10.1084/jem.164.4.1301; VLASSARA H, 1985, P NATL ACAD SCI USA, V82, P5588, DOI 10.1073/pnas.82.17.5588	39	246	249	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10211	10214						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587810				2022-12-25	WOS:A1992HV09000004
J	ISHIMI, Y				ISHIMI, Y			PREINCUBATION OF T-ANTIGEN WITH DNA OVERCOMES REPRESSION OF SV40 DNA-REPLICATION BY NUCLEOSOME ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; INVITRO REPLICATION; PURIFICATION; ORIGIN; INITIATION; BINDING; PROTEIN; INVIVO; CELLS	Circular duplex DNA containing the SV40 replication origin was assembled into chromosomes in vitro with core histones and nucleosome assembly factor from HeLa cells. Their ability to serve as a template for replication was examined by incubating them with SV40 T antigen and HeLa cell extract. Nucleosome assembly of the template prevented DNA replication. Replication of chromosomes was severely inhibited at more than two-thirds of physiological nucleosome density. When the DNA was preincubated with T antigen and then assembled into chromosomes, however, inhibition of DNA replication was greatly reduced. These results suggest that nucleosome assembly of the template inhibits initiation of SV40 DNA replication and that the inhibition can be overcome by formation of an initiation complex before nucleosome assembly.			ISHIMI, Y (corresponding author), MITSUBISHI KASEI INST LIFE SCI,11 MINAMIOOYA,MACHIDA,TOKYO 194,JAPAN.							BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; DEPAMPHILIS ML, 1986, PAPOVAVIRIDAE, V1, P99; GOTTESFELD J, 1982, CELL, V28, P781, DOI 10.1016/0092-8674(82)90057-5; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; ISHIMI Y, 1991, J BIOL CHEM, V266, P16141; ISHIMI Y, 1985, CELL STRUCT FUNCT, V10, P373, DOI 10.1247/csf.10.373; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; ISHIMI Y, 1991, J BIOL CHEM, V266, P7025; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MURPHY CI, 1988, J VIROL, V62, P2951, DOI 10.1128/JVI.62.8.2951-2959.1988; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SIMPSON RT, 1990, NATURE, V343, P387, DOI 10.1038/343387a0; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SMITH S, 1991, J BIOL CHEM, V266, P12041; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9	21	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10910	10913						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587867				2022-12-25	WOS:A1992HV09000104
J	JAN, CR; SCHNEIDER, AS				JAN, CR; SCHNEIDER, AS			SODIUM-DEPENDENT CALCIUM EFFLUX FROM ADRENAL CHROMAFFIN CELLS FOLLOWING EXOCYTOSIS - POSSIBLE ROLE OF SECRETORY VESICLE MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATECHOLAMINE SECRETION; PERTUSSIS TOXIN; CA-2+; MEDULLA; RELEASE; GRANULES; NA+; MOBILIZATION; EXCHANGE; PROTEIN	Although cytosolic Ca2+ transients are known to influence the magnitude and duration of hormone and neurotransmitter release, the processes regulating the decay of such transients after cell stimulation are not well understood. Na2+-dependent Ca2+ efflux across the secretory vesicle membrane, following its incorporation into the plasma membrane, may play a significant role in Ca2+ efflux after stimulation of secretion. We have measured an enhanced Ca-45(2+) efflux from cultured bovine adrenal chromaffin cells following cell stimulation with depolarizing medium (75 mM K+) or nicotine (10-mu-M). Such stimulation also causes Ca2+ uptake via voltage-gated Ca2+ channels and secretion of catecholamines. Na+ replacement with any of several substitutes (N-methyl-glucamine, Li+, choline, or sucrose) during cell stimulation inhibited the enhanced Ca-45(2+) efflux, indicating an Na+-dependent Ca2+ efflux process. Na+ deprivation did not inhibit Ca-45(2+) uptake or catecholamine secretion evoked by elevated K+. Suppression of exocytotic incorporation of secretory vesicle membranes into the plasma membrane with hypertonic medium (620 mOsm) or by lowering temperature to 12-degrees-C inhibited K+-stimulated Ca-45(2+) efflux in Na+-containing medium but did not inhibit the stimulated Ca-45(2+) uptake. Enhancement of exocytotic secretion with pertussis toxin resulted in an enhanced Ca-45(2+) efflux without affecting calcium uptake. The combined results suggest that Na+-dependent Ca2+ efflux across secretory vesicle membranes, following their incorporation into the plasma membrane during exocytosis, plays a significant role in regulating calcium efflux and the decay of cytosolic Ca2+ in adrenal chromaffin cells and possibly in related secretory cells.	UNION UNIV,DEPT PHARMACOL & TOXICOL,ALBANY,NY 12208	Union College					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039220] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39220] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY CA, 1987, FASEB J, V46, P367; BROCKLEHURST KW, 1988, FEBS LETT, V234, P439, DOI 10.1016/0014-5793(88)80133-9; Carmichael S, 1987, STIMULUS SECRETION C, V1, P1; DOUGLAS WW, 1961, J PHYSIOL-LONDON, V159, P40, DOI 10.1113/jphysiol.1961.sp006791; GOH Y, 1990, BIOCHEM BIOPH RES CO, V166, P1346, DOI 10.1016/0006-291X(90)91014-J; HAMPTON RY, 1983, J CELL BIOL, V96, P1082, DOI 10.1083/jcb.96.4.1082; HIRAM Y, 1984, BIOPHYS J, V45, P651, DOI 10.1016/S0006-3495(84)84206-X; HOLZ RW, 1982, J NEUROCHEM, V39, P635, DOI 10.1111/j.1471-4159.1982.tb07940.x; JAN CR, 1990, J NEUROCHEM, V54, P355, DOI 10.1111/j.1471-4159.1990.tb13323.x; JAN CR, 1991, BIOPHYS J, V59, P449; KAO LS, 1985, J BIOL CHEM, V260, P2019; KAO LS, 1986, J BIOL CHEM, V261, P4881; KAO LS, 1984, J NEUROCHEM, V43, P590, DOI 10.1111/j.1471-4159.1984.tb00940.x; KAO LS, 1988, J NEUROCHEM, V51, P221, DOI 10.1111/j.1471-4159.1988.tb04859.x; KILPATRICK DL, 1982, J NEUROCHEM, V38, P427, DOI 10.1111/j.1471-4159.1982.tb08647.x; KRIEGERBRAUER H, 1981, FEBS LETT, V133, P244, DOI 10.1016/0014-5793(81)80515-7; KRIEGERBRAUER H, 1982, BIOCHIM BIOPHYS ACTA, V691, P61, DOI 10.1016/0005-2736(82)90214-0; KRIEGERBRAUER HI, 1983, J NEUROCHEM, V41, P1269, DOI 10.1111/j.1471-4159.1983.tb00821.x; LADONA MG, 1987, BIOCHIM BIOPHYS ACTA, V927, P18, DOI 10.1016/0167-4889(87)90061-9; MCKAY DB, 1984, J PHARMACOL EXP THER, V231, P102; MOHINDER KB, 1990, FEBS LETT, V276, P165; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; OHARAIMAIZUMI M, 1990, NEUROSCI LETT, V110, P167, DOI 10.1016/0304-3940(90)90806-K; ORNBERG RL, 1988, J BIOL CHEM, V263, P1488; OSULLIVAN AJ, 1988, BIOCHIM BIOPHYS ACTA, V969, P211, DOI 10.1016/0167-4889(88)90054-7; OSULLIVAN AJ, 1989, BIOSCIENCE REP, V9, P243, DOI 10.1007/BF01116001; PATZAK A, 1984, J CELL BIOL, V98, P1817, DOI 10.1083/jcb.98.5.1817; PHILIPSON KD, 1982, CIRC RES, V50, P287, DOI 10.1161/01.RES.50.2.287; PHILLIPS JH, 1983, J CELL BIOL, V97, P1906, DOI 10.1083/jcb.97.6.1906; PHILLIPS JH, 1981, BIOCHEM J, V200, P99, DOI 10.1042/bj2000099; SASAKAWA N, 1988, BIOCHEM PHARMACOL, V37, P2485; SERCKHAN.G, 1973, BIOCHIM BIOPHYS ACTA, V307, P404, DOI 10.1016/0005-2736(73)90106-5; SONTAG JM, 1991, BIOCHEM J, V274, P339, DOI 10.1042/bj2740339; STOEHR SJ, 1986, J NEUROCHEM, V46, P637, DOI 10.1111/j.1471-4159.1986.tb13014.x; TANAKA T, 1987, BIOCHEM BIOPH RES CO, V144, P907, DOI 10.1016/S0006-291X(87)80050-5; VONGRAFENSTEIN H, 1986, J CELL BIOL, V103, P2343, DOI 10.1083/jcb.103.6.2343; VONGRAFENSTEIN HRK, 1989, J NEUROCHEM, V53, P423	37	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9695	9700						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577804				2022-12-25	WOS:A1992HT96500039
J	GAO, EN; SHIER, P; SIU, CH				GAO, EN; SHIER, P; SIU, CH			PURIFICATION AND PARTIAL CHARACTERIZATION OF A CELL-ADHESION MOLECULE (GP150) INVOLVED IN POSTAGGREGATION STAGE CELL-CELL BINDING IN DICTYOSTELIUM-DISCOIDEUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-A GLYCOPROTEIN; PLASMA-MEMBRANE; SURFACE GLYCOPROTEIN; CONTACT SITE; MONOCLONAL-ANTIBODIES; BLOCKING FAB; GP80; AGGREGATION; COHESION; PROTEINS	A cell surface glycoprotein of apparent M(r) 150,000 (gp150) has been implicated in mediating EDTA-resistant cell-cell adhesion in Dictyostelium discoideum. A simple purification scheme making use of high-performance liquid chromatography has been devised to purify gp150 to near homogeneity. Purified gp150 was capable of neutralizing the effect of a rabbit antiserum raised against gel-purified gp150, which was previously reported to be a potent inhibitor of cell-cell adhesion (Geltosky, J. E., Weseman, J., Bakke, A., and Lerner, R. A. (1979) Cell 18, 391-398). The binding of I-125-labeled gp150 to intact cells was both dose-dependent and saturable, demonstrating the presence of specific cell surface binding sites for gp150. When reassociation of postaggregation stage cells was carried out in the presence of soluble gp150, aggregate formation was strongly inhibited. In contrast, gp150 failed to exert any effect on cells at the aggregation stage. The inhibitory effect of gp150 was sensitive to protease treatment, suggesting that the protein moiety is crucial to gp150 function. These results, taken together, provide direct evidence that gp150 is a cell-cell adhesion molecule involved in cell-cell binding in the postaggregation stage of Dictyostelium development.	UNIV TORONTO,DEPT BIOCHEM,TORONTO M5G 1L6,ONTARIO,CANADA; UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA	University of Toronto; University of Toronto								BEUG H, 1973, J CELL BIOL, V56, P647, DOI 10.1083/jcb.56.3.647; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; BONNER JT, 1959, P NATL ACAD SCI USA, V56, P379; BRODIE C, 1983, CELL, V32, P1115, DOI 10.1016/0092-8674(83)90295-7; CHOI AHC, 1987, J CELL BIOL, V104, P1375, DOI 10.1083/jcb.104.5.1375; DECHASTELLIER C, 1980, BIOL CELL, V38, P121; DESILVA NS, 1980, J BIOL CHEM, V255, P8489; DESILVA NS, 1981, J BIOL CHEM, V256, P5845; FEINBERG AP, 1979, P NATL ACAD SCI USA, V76, P3977, DOI 10.1073/pnas.76.8.3977; GARROD DR, 1972, EXP CELL RES, V72, P588, DOI 10.1016/0014-4827(72)90041-9; GELTOSKY JE, 1979, CELL, V18, P391, DOI 10.1016/0092-8674(79)90058-8; GELTOSKY JE, 1980, CELL, V21, P339, DOI 10.1016/0092-8674(80)90470-5; GELTOSKY JE, 1976, CELL, V8, P391, DOI 10.1016/0092-8674(76)90151-3; GERISCH G, 1961, EXP CELL RES, V25, P535, DOI 10.1016/0014-4827(61)90189-6; GERISCH G, 1980, CURR TOP DEV BIOL, V14, P234; GREEN AA, 1974, BIOCHEM J, V140, P313, DOI 10.1042/bj1400313; KAMBOJ RK, 1989, CELL, V59, P615, DOI 10.1016/0092-8674(89)90007-X; KAMBOJ RK, 1990, CELL REGUL, V1, P715, DOI 10.1091/mbc.1.10.715; KAMBOJ RK, 1988, J CELL BIOL, V107, P1835, DOI 10.1083/jcb.107.5.1835; KNECHT DA, 1987, DEV BIOL, V121, P277, DOI 10.1016/0012-1606(87)90160-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM TY, 1981, DIFFERENTIATION, V20, P22, DOI 10.1111/j.1432-0436.1981.tb01151.x; LOOMIS WF, 1983, EXP CELL RES, V147, P231, DOI 10.1016/0014-4827(83)90290-2; Loomis WF., 1975, DICTYOSTELIUM DISCOI; MA PCC, 1990, MOL CELL BIOL, V10, P3297, DOI 10.1128/MCB.10.7.3297; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MULLER K, 1978, NATURE, V274, P445, DOI 10.1038/274445a0; NELLEN W, 1987, METHOD CELL BIOL, V28, P209; NOEGEL A, 1986, EMBO J, V5, P1473, DOI 10.1002/j.1460-2075.1986.tb04384.x; SAXE CL, 1982, CELL, V29, P755, DOI 10.1016/0092-8674(82)90437-8; SIU CH, 1988, EXP CELL RES, V177, P338, DOI 10.1016/0014-4827(88)90467-3; SIU CH, 1990, DEV GENET, V11, P377, DOI 10.1002/dvg.1020110509; SIU CH, 1988, BIOCHEM CELL BIOL, V66, P1089, DOI 10.1139/o88-126; SIU CH, 1988, BIOCHIM BIOPHYS ACTA, V968, P283, DOI 10.1016/0167-4889(88)90019-5; SIU CH, 1987, J CELL BIOL, V105, P2523, DOI 10.1083/jcb.105.6.2523; SIU CH, 1983, P NATL ACAD SCI-BIOL, V80, P6596, DOI 10.1073/pnas.80.21.6596; SIU CH, 1977, J MOL BIOL, V116, P469, DOI 10.1016/0022-2836(77)90080-8; SIU CH, 1976, J MOL BIOL, V100, P157, DOI 10.1016/S0022-2836(76)80146-5; SIU CH, 1990, BIOESSAYS, V12, P357, DOI 10.1002/bies.950120802; SMART JE, 1974, NATURE, V251, P319, DOI 10.1038/251319a0; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SONNEBORN DR, 1964, J BACTERIOL, V87, P1312; STEINEMANN C, 1980, NATURE, V286, P621, DOI 10.1038/286621a0; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; Sussman M., 1966, METHOD CELL PHYSIOL, V2, P397; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; Takeuchi I., 1969, NUCL ACID METABOLISM, P297; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WONG LM, 1986, P NATL ACAD SCI USA, V83, P4248, DOI 10.1073/pnas.83.12.4248; ZISKA SE, 1988, P NATL ACAD SCI USA, V85, P817, DOI 10.1073/pnas.85.3.817	51	36	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9409	9415						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577768				2022-12-25	WOS:A1992HR85400106
J	GARFINKEL, MS; KATZE, MG				GARFINKEL, MS; KATZE, MG			TRANSLATIONAL CONTROL BY INFLUENZA-VIRUS - SELECTIVE AND CAP-DEPENDENT TRANSLATION OF VIRAL MESSENGER-RNAS IN INFECTED-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS TRIPARTITE LEADER; BINDING-PROTEIN COMPLEX; INITIATION FACTOR-II; POLIOVIRUS INFECTION; EUKARYOTIC RIBOSOMES; ALPHA-SUBUNIT; SHUT-OFF; EXPRESSION; KINASE; PHOSPHORYLATION	In cells infected by influenza virus type A, host protein synthesis undergoes a rapid and dramatic shutoff. To define the molecular mechanisms underlying this selective translation, a transfection/infection protocol was developed utilizing viral and cellular cDNA clones. When COS-1 cells were transfected with cDNAs encoding nonviral genes and subsequently infected with influenza virus, protein expression from the exogenous genes was diminished, similar to the endogenous cellular genes. However, when cells were transfected with a truncated influenza viral nucleocapsid protein (NP-S) gene, the NP-S protein was made as efficiently in influenza virus infected cells as in uninfected cells, showing that the NP-S mRNA, although expressed independently of the influenza virus replication machinery, was still recognized as a viral and not a cellular mRNA. Northern blot analysis demonstrated that the selective blocks to nonviral protein synthesis were at the level of translation. Moreover, polysome experiments revealed that the translational blocks occurred at both the initiation and elongation stages of cellular protein synthesis. Finally, we utilized this transfection/infection system as well as double infection experiments to demonstrate that the translation of influenza viral mRNAs probably occurred in a cap-dependent manner as poliovirus infection inhibited influenza viral mRNA translation.	UNIV WASHINGTON, SCH MED, DEPT MICROBIOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle					NCRR NIH HHS [RR-00166] Funding Source: Medline; NIAID NIH HHS [AI-22646] Funding Source: Medline; NIGMS NIH HHS [T32-GM07270] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSOCAPLEN FV, 1988, J VIROL, V62, P1606, DOI 10.1128/JVI.62.5.1606-1616.1988; BABICH A, 1983, MOL CELL BIOL, V3, P1212, DOI 10.1128/MCB.3.7.1212; BABLANIAN R, 1991, J VIROL, V65, P4449, DOI 10.1128/JVI.65.8.4449-4460.1991; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BLACK TL, 1989, J VIROL, V63, P2244, DOI 10.1128/JVI.63.5.2244-2251.1989; BLOBEL G, 1971, P NATL ACAD SCI USA, V68, P390, DOI 10.1073/pnas.68.2.390; CARRASCO L, 1977, FEBS LETT, V76, P11, DOI 10.1016/0014-5793(77)80110-5; CARRASCO L, 1983, PHARMACOL THERAPEUT, V23, P109, DOI 10.1016/0163-7258(83)90028-1; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DEBENEDETTI A, 1983, J BIOL CHEM, V258, P4556; DEBENEDETTI A, 1984, NATURE, V311, P79, DOI 10.1038/311079a0; DOLPH PJ, 1988, J VIROL, V62, P2059, DOI 10.1128/JVI.62.6.2059-2066.1988; DOLPH PJ, 1990, J VIROL, V64, P2669, DOI 10.1128/JVI.64.6.2669-2677.1990; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; ETKIND PR, 1975, J VIROL, V16, P1464, DOI 10.1128/JVI.16.6.1464-1475.1975; FALCONE D, 1991, MOL CELL BIOL, V11, P2656, DOI 10.1128/MCB.11.5.2656; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GALLIE DR, 1987, NUCLEIC ACIDS RES, V15, P8693, DOI 10.1093/nar/15.21.8693; GODCHAUX W, 1967, J MOL BIOL, V27, P57, DOI 10.1016/0022-2836(67)90351-8; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; KATZ RA, 1986, MOL CELL BIOL, V6, P372, DOI 10.1128/MCB.6.2.372; KATZE MG, 1988, J VIROL, V62, P3710, DOI 10.1128/JVI.62.10.3710-3717.1988; KATZE MG, 1984, MOL CELL BIOL, V4, P2198, DOI 10.1128/MCB.4.10.2198; KATZE MG, 1986, J VIROL, V60, P1027, DOI 10.1128/JVI.60.3.1027-1039.1986; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KATZE MG, 1984, CELL, V37, P483, DOI 10.1016/0092-8674(84)90378-7; KATZE MG, 1986, MOL CELL BIOL, V6, P1741, DOI 10.1128/MCB.6.5.1741; KATZE MG, 1991, IN PRESS TRANSLATION; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KOZAK M, 1986, ADV VIRUS RES, V31, P229, DOI 10.1016/S0065-3527(08)60265-1; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRUG RM, 1980, P NATL ACAD SCI-BIOL, V77, P5874, DOI 10.1073/pnas.77.10.5874; KRUG RM, 1989, INFLUENZA VIRUSES, P89; LAZAROWITZ SG, 1971, VIROLOGY, V46, P830, DOI 10.1016/0042-6822(71)90084-5; LEE KAW, 1982, P NATL ACAD SCI-BIOL, V79, P3447, DOI 10.1073/pnas.79.11.3447; LEE TG, 1990, P NATL ACAD SCI USA, V87, P6208, DOI 10.1073/pnas.87.16.6208; LENK R, 1979, CELL, V16, P289, DOI 10.1016/0092-8674(79)90006-0; LODISH HF, 1977, J BIOL CHEM, V252, P8804; LODISH HF, 1980, J VIROL, V36, P719, DOI 10.1128/JVI.36.3.719-733.1980; LODISH HF, 1976, ANNU REV BIOCHEM, V45, P39, DOI 10.1146/annurev.bi.45.070176.000351; OMALLEY RP, 1989, VIROLOGY, V168, P112, DOI 10.1016/0042-6822(89)90409-1; ONEILL RE, 1989, J VIROL, V63, P5069, DOI 10.1128/JVI.63.12.5069-5075.1989; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PENSIERO MN, 1985, J VIROL, V56, P161, DOI 10.1128/JVI.56.1.161-171.1985; RAGHOW R, 1983, J BIOL CHEM, V258, P571; SCHNEIDER RJ, 1987, ANNU REV BIOCHEM, V56, P317, DOI 10.1146/annurev.biochem.56.1.317; SKEHEL JJ, 1978, NUCLEIC ACIDS RES, V5, P1207, DOI 10.1093/nar/5.4.1207; SKEHEL JJ, 1972, VIROLOGY, V49, P23, DOI 10.1016/S0042-6822(72)80004-7; SONENBERG N, 1990, New Biologist, V2, P402; VASSALLI JD, 1989, GENE DEV, V3, P2163, DOI 10.1101/gad.3.12b.2163; WALDEN WE, 1981, J BIOL CHEM, V256, P1739	56	44	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9383	9390						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577765				2022-12-25	WOS:A1992HR85400103
J	GREGORY, RB; BERRY, MN				GREGORY, RB; BERRY, MN			STIMULATION BY THYROID-HORMONE OF COUPLED RESPIRATION AND OF RESPIRATION APPARENTLY NOT COUPLED TO THE SYNTHESIS OF ATP IN RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL OXIDATIVE-PHOSPHORYLATION; LIVER-MITOCHONDRIA; INNER MEMBRANE; METABOLISM; INVIVO; MECHANISM; POLYPEPTIDES; EFFICIENCY; TRANSPORT; INVITRO	Maximal rates of O2 uptake by hepatocytes from hypothyroid, euthyroid, and hyperthyroid rats, in the absence of uncoupling agents or ionophores, were achieved by simultaneously stimulating ureogenesis and gluconeogenesis. Rates were increased by pretreatment of the donor animals with thyroid hormone. Only a minor part of the increase could be attributed to stimulation of the activity of plasma membrane (Na+ + K+)-ATPase. No synthesis of glycogen occurred, nor was there any evidence of pyruvate cycling under the conditions used, thus ruling out these processes as potential sources of ATP turnover. Calculation of the O2 uptake necessary to satisfy the energy requirements of gluconeogenesis and ureogenesis, based on anticipated ATP demand and an assumed P:O ratio of 3:1, invariably yielded a theoretical quantity that was less than the experimentally measured increase in O2 uptake. The difference between measured and calculated rates of respiration, possibly representing noncoupled respiration, was related to the thyroid status of the animal, being greatest in cells from hyperthyroid rats. In another experimental approach the O2 uptake associated with ATP synthesis was inhibited by the addition of oligomycin to hepatocytes incubated in the presence of substrates, thus abolishing ATP-coupled respiration. The magnitude of the ATP-coupled as well as the residual respiration was increased in response to thyroid hormone. Thyroid hormone increased the turnover of intramitochondrial ATP. These results imply that a considerable portion of the thermogenic effect of thyroid hormone may be mediated by a stimulatory action on metabolism not directly associated with extramitochondrial ATP-dependent synthetic processes.			GREGORY, RB (corresponding author), FLINDERS UNIV,SCH MED,DEPT MED BIOCHEM,GPO BOX 2100,ADELAIDE,SA 5001,AUSTRALIA.							BARANYAI JM, 1989, BIOCHEM J, V258, P121, DOI 10.1042/bj2580121; BARKER SB, 1951, PHYSIOL REV, V31, P205, DOI 10.1152/physrev.1951.31.3.205; BERGMEYER HU, 1974, METHODS ENZYMATIC AN; BERRY MN, 1980, FEBS LETT, V117, pK106, DOI 10.1016/0014-5793(80)80575-8; BERRY MN, 1983, EUR J BIOCHEM, V131, P205, DOI 10.1111/j.1432-1033.1983.tb07251.x; BERRY MN, 1965, BIOCHEM J, V95, P587, DOI 10.1042/bj0950587; BERRY MN, 1991, ISOLATED HEPATOCYTES, P15, DOI DOI 10.1016/S0075-7535(08)70023-8; BERTINA RM, 1973, BIOCHIM BIOPHYS ACTA, V305, P503, DOI 10.1016/0005-2728(73)90072-8; BRONK JR, 1962, J BIOL CHEM, V237, P897; CAPALDI RA, 1982, BIOCHIM BIOPHYS ACTA, V694, P291, DOI 10.1016/0304-4157(82)90009-0; CHEN RF, 1967, J BIOL CHEM, V242, P173; CLARK DG, 1982, BIOCHEM J, V202, P661, DOI 10.1042/bj2020661; CORRIGALL J, 1984, EUR J BIOCHEM, V141, P435, DOI 10.1111/j.1432-1033.1984.tb08210.x; CRESPOARMAS A, 1987, BIOCHEM J, V241, P657, DOI 10.1042/bj2410657; DEBEER LJ, 1974, EUR J BIOCHEM, V47, P591, DOI 10.1111/j.1432-1033.1974.tb03730.x; FOLKE M, 1977, J PHYSIOL-LONDON, V269, P407, DOI 10.1113/jphysiol.1977.sp011909; FORMAN NG, 1983, J BIOL CHEM, V258, P8649; FREAKE HC, 1989, ENDOCRINOLOGY, V125, P2868, DOI 10.1210/endo-125-6-2868; Good CA, 1933, J BIOL CHEM, V100, P485; GREGORY RB, 1989, BIOCHEM PHARMACOL, V38, P2867, DOI 10.1016/0006-2952(89)90443-7; GREGORY RB, 1991, BIOCHIM BIOPHYS ACTA, V1098, P61; GREGORY RB, 1991, P AUST SOC BIOCH MOL, V23, P44; HAFNER RP, 1988, EUR J BIOCHEM, V178, P511, DOI 10.1111/j.1432-1033.1988.tb14477.x; HAFNER RP, 1988, BIOCHEM J, V250, P477, DOI 10.1042/bj2500477; HASSINEN I, 1990, BIOCHIM BIOPHYS ACTA, V1019, P73, DOI 10.1016/0005-2728(90)90126-O; HEMS R, 1966, BIOCHEM J, V101, P284, DOI 10.1042/bj1010284; HENKE W, 1991, BIOCHIM BIOPHYS ACTA, V1056, P71, DOI 10.1016/S0005-2728(05)80074-X; HOCH FL, 1968, ARCH BIOCHEM BIOPHYS, V124, P238, DOI 10.1016/0003-9861(68)90324-X; HORRUM MA, 1990, MOL CELL ENDOCRINOL, V68, P137, DOI 10.1016/0303-7207(90)90186-C; HORRUM MA, 1985, MOL CELL ENDOCRINOL, V41, P163, DOI 10.1016/0303-7207(85)90019-X; ISMAILBEIGI F, 1971, J GEN PHYSIOL, V57, P710, DOI 10.1085/jgp.57.6.710; JOSTE V, 1989, EUR J BIOCHEM, V184, P255, DOI 10.1111/j.1432-1033.1989.tb15015.x; Keogh J M, 1985, Adv Myocardiol, V6, P299; Keppler D., 1984, METHOD ENZYMAT AN, V6, P11; Krebs H.A., 1974, REGULATION HEPATIC M, P726; KREBS HA, 1964, BIOCHEM J, V93, P112, DOI 10.1042/bj0930112; KREBS HA, 1976, GLUCONEOGENESIS ITS, P269; LAHTELA JT, 1990, AM J PHYSIOL, V259, pE389, DOI 10.1152/ajpendo.1990.259.3.E389; LARDY HA, 1951, ANN NY ACAD SCI, V54, P636, DOI 10.1111/j.1749-6632.1951.tb54465.x; LEE YP, 1965, J BIOL CHEM, V240, P1427; MARTI J, 1988, ENDOCRINOLOGY, V123, P2167, DOI 10.1210/endo-123-5-2167; MARTIUS C, 1951, ARCH BIOCHEM BIOPHYS, V33, P486, DOI 10.1016/0003-9861(51)90137-3; MUTVEI A, 1989, ARCH BIOCHEM BIOPHYS, V268, P215, DOI 10.1016/0003-9861(89)90582-1; NOBES CD, 1989, BIOCHIM BIOPHYS ACTA, V976, P241, DOI 10.1016/S0005-2728(89)80236-1; PALACIOSROMERO R, 1979, BIOCHEM J, V184, P527, DOI 10.1042/bj1840527; SEITZ HJ, 1985, BIOCHEM J, V227, P149, DOI 10.1042/bj2270149; SESTOFT L, 1980, CLIN ENDOCRINOL, V13, P489, DOI 10.1111/j.1365-2265.1980.tb03415.x; SHEARS SB, 1981, FEBS LETT, V126, P9, DOI 10.1016/0014-5793(81)81020-4; SHEARS SB, 1979, BIOCHEM J, V178, P505, DOI 10.1042/bj1780505; TATA JR, 1963, BIOCHEM J, V86, P408, DOI 10.1042/bj0860408; THOMAS WE, 1987, BIOCHEM J, V247, P315, DOI 10.1042/bj2470315; VERHOEVEN AJ, 1985, BIOCHEM J, V226, P183, DOI 10.1042/bj2260183; VIGNAIS PV, 1973, BIOCHEMISTRY-US, V12, P1508, DOI 10.1021/bi00732a007; WALLICK ET, 1974, J PHARMACOL EXP THER, V189, P434; WILLIAMSON JR, 1969, J BIOL CHEM, V244, P5044; WILLIAMSON JR, 1969, ENERGY LEVEL METABOL, P385	56	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8903	8908						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577728				2022-12-25	WOS:A1992HR85400033
J	KATAYAMA, Y; NARAHARA, Y; INOUE, Y; AMANO, F; KANAGAWA, T; KURAISHI, H				KATAYAMA, Y; NARAHARA, Y; INOUE, Y; AMANO, F; KANAGAWA, T; KURAISHI, H			A THIOCYANATE HYDROLASE OF THIOBACILLUS-THIOPARUS - A NOVEL ENZYME CATALYZING THE FORMATION OF CARBONYL SULFIDE FROM THIOCYANATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE GELS; PROTEINS; OXIDATION; CYANIDE	A thiocyanate hydrolase that catalyzes the first step in thiocyanate degradation was purified to homogeneity from Thiobacillus thioparus, an obligate chemolithotrophic eubacterium metabolizing thiocyanate to sulfate as an energy source. The thiocyanate hydrolase was purified 52-fold by steps involving ammonium sulfate precipitation, DEAE-Sephacel column chromatography, and hydroxylapatite column chromatography. The enzyme hydrolyzed 1 mol of thiocyanate to form 1 mol of carbonyl sulfide and 1 mol of ammonia as follows: SCN- + 2H2O --> COS + NH3 + OH-. This is the first report describing the hydrolysis of thiocyanate to carbonyl sulfide by an enzyme. The enzyme had a molecular mass of 126 kDa and was composed of three different subunits: alpha (19 kDa), beta (23 kDa), and gamma (32 kDa). The enzyme exhibited optimal activities at pH 7.5-8.0 and at temperatures ranging from 30 to 40-degrees-C. The K(m) value for thiocyanate was approximately 11 mM. Immunoblot analysis with polyclonal antibodies against the purified enzyme suggested that it was induced in T. thioparus cells when the cells were grown with thiocyanate.	AGCY IND SCI & TECHNOL,FERMENTAT RES INST,TSUKUBA 305,JAPAN; NATL INST HLTH,DEPT CHEM,SINAGAWA KU,TOKYO 141,JAPAN	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Health Sciences - Japan	KATAYAMA, Y (corresponding author), TOKYO UNIV AGR & TECHNOL,FAC AGR,SAIWAICHO 3,FUCHU,TOKYO 183,JAPAN.		KATAYAMA, Yoko/G-1114-2013	Kanagawa, Takahiro/0000-0003-2476-6767				BETTS PM, 1979, CAN J MICROBIOL, V25, P1277, DOI 10.1139/m79-201; CERLETTI P, 1986, TRENDS BIOCHEM SCI, V129, P369; CHUNG J, 1970, ARCH BIOCHEM BIOPHYS, V141, P73, DOI 10.1016/0003-9861(70)90108-6; COVAL ML, 1967, J BIOL CHEM, V242, P5510; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DAVIS RE, 1962, J PHYS CHEM-US, V66, P956, DOI 10.1021/j100811a512; HAPPOLD FC, 1954, J GEN MICROBIOL, V10, P261, DOI 10.1099/00221287-10-2-261; HAPPOLD FC, 1958, NATURE, V182, P266, DOI 10.1038/182266a0; KATAYAMA Y, 1978, CAN J MICROBIOL, V24, P804, DOI 10.1139/m78-135; KATAYAMAFUJIMURA Y, 1982, J GEN MICROBIOL, V128, P1599; Kelly DP, 1989, BERGEYS MANUAL SYSTE, P1842; KNOWLES CJ, 1976, BACTERIOL REV, V40, P652, DOI 10.1128/MMBR.40.3.652-680.1976; KUNZ DA, 1989, APPL ENVIRON MICROB, V55, P256, DOI 10.1128/AEM.55.1.256-258.1989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; ORAM JD, 1966, BIOCHEM J, V100, P382, DOI 10.1042/bj1000382; PECK HD, 1968, ANNU REV MICROBIOL, V22, P489, DOI 10.1146/annurev.mi.22.100168.002421; PUTILINA NT, 1961, MIKROBIOLOGIYA, V30, P294; SORBO B, 1958, ACTA CHEM SCAND, V12, P470, DOI 10.3891/acta.chem.scand.12-0470; STAFFORD DA, 1969, J GEN MICROBIOL, V55, P285, DOI 10.1099/00221287-55-2-285; SUZUKI I, 1974, ANNU REV MICROBIOL, V28, P85, DOI 10.1146/annurev.mi.28.100174.000505; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WESTLEY J, 1973, ADV ENZYMOL RAMB, V39, P327; WOOD JL, 1975, CHEM BIOCH THIOCYANI, P156; YOUATT JB, 1954, J GEN MICROBIOL, V11, P139, DOI 10.1099/00221287-11-2-139; 1971, TESTING METHODS IND, P90	27	106	112	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9170	9175						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577754				2022-12-25	WOS:A1992HR85400072
J	YU, YT; NILSEN, TW				YU, YT; NILSEN, TW			SEQUENCE REQUIREMENTS FOR MATURATION OF THE 5' TERMINUS OF HUMAN 18-S RIBOSOMAL-RNA INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' END-FORMATION; RIBOSOMAL-RNA; MODIFICATION INTERFERENCE; CLEAVAGE SITE; TRANSCRIPTION; INITIATION; ELEMENTS; POLY(A)	Creation of the mature 5' terminus of human 18 S rRNA in vitro occurs via a two-step processing reaction. In the first step, an endonucleolytic activity found in HeLa cell nucleolar extract cleaves an rRNA precursor spanning the external transcribed spacer-18 S boundary at a position 3 bases upstream from the mature 18 S terminus leaving 2',3'-cyclic phosphate, 5' hydroxyl termini. In the second step, a nucleolytic activity(s) found in HeLa cell cytoplasmic extract removes the 3 extra bases and creates the authentic 5'-phosphorylated terminus of 18 S rRNA. Here we have examined the sequence requirements for the trimming reaction. The trimming activity(s), in addition to requiring a 5' hydroxyl terminus, prefers the naturally occurring adenosine as the 5'-terminal base. By a combination of deletion, site-directed mutagenesis, and chemical modification interference approaches we have also identified a region of 18 S rRNA spanning bases +6 to +25 (with respect to the mature 5' end) which comprises a critical recognition sequence for the trimming activity(s).	CASE WESTERN RESERVE UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,10900 EUCLID AVE,CLEVELAND,OH 44106	Case Western Reserve University					NIGMS NIH HHS [GM-31528] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031528] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AXELROD VD, 1985, BIOCHEMISTRY-US, V24, P5716, DOI 10.1021/bi00342a005; CONWAY L, 1987, EMBO J, V6, P4177, DOI 10.1002/j.1460-2075.1987.tb02764.x; CRAIG N, 1987, P NATL ACAD SCI USA, V84, P629, DOI 10.1073/pnas.84.3.629; CRAIG N, 1991, MOL CELL BIOL, V11, P458, DOI 10.1128/MCB.11.1.458; CROUCH R, 1984, PROCESSING RNA, P214; ENGLAND TE, 1978, NATURE, V275, P560, DOI 10.1038/275560a0; HANNON GJ, 1990, EMBO J, V9, P1915, DOI 10.1002/j.1460-2075.1990.tb08318.x; HANNON GJ, 1989, MOL CELL BIOL, V9, P4422, DOI 10.1128/MCB.9.10.4422; KASS S, 1987, MOL CELL BIOL, V7, P2891, DOI 10.1128/MCB.7.8.2891; KASS S, 1990, MOL CELL BIOL, V10, P4920, DOI 10.1128/MCB.10.9.4920; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANG KM, 1990, MOL CELL BIOL, V10, P4942, DOI 10.1128/MCB.10.9.4942; MILLER KG, 1981, CELL, V27, P165, DOI 10.1016/0092-8674(81)90370-6; MOWRY KL, 1989, MOL CELL BIOL, V9, P3105, DOI 10.1128/MCB.9.7.3105; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PERRY RP, 1976, ANNU REV BIOCHEM, V45, P605, DOI 10.1146/annurev.bi.45.070176.003133; RYMOND BC, 1988, GENE DEV, V2, P428, DOI 10.1101/gad.2.4.428; SHUMARD CM, 1990, MOL CELL BIOL, V10, P3868, DOI 10.1128/MCB.10.8.3868; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F	21	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9264	9268						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577760				2022-12-25	WOS:A1992HR85400085
J	TEAGUE, WE; DOBSON, GP				TEAGUE, WE; DOBSON, GP			EFFECT OF TEMPERATURE ON THE CREATINE-KINASE EQUILIBRIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SATURATION-TRANSFER; SKELETAL-MUSCLE; ATP SYNTHESIS; RAT-HEART	The effect of temperature on the apparent equilibrium constant of creatine kinase (ATP:creatine N-phosphotransferase (EC 2.7.3.2)) was determined. At equilibrium the apparent K' for the biochemical reaction was defined as K' = [SIGMA-ATP][Cr]/[SIGMA-ADP][SIGMA-PCr] The symbol SIGMA-denotes the sum of all the ionic and metal complex species of the reactant components in m. The K' at pH 7.0, 1.0 mM free Mg2+, and ionic strength of 0.25 M at experimental conditions was 177 +/- 7.0, 217 +/- 11, 255 +/- 10, and 307 +/- 13 (n = 8) at 38, 25, 15, and 5-degrees-C, respectively. The standard apparent enthalpy or heat of the reaction at the specified conditions (DELTA-H'degrees) was calculated from a van't Hoff plot of log10.K' versus 1/T, and found to be -11.93 kJ mol-1 (-2852 cal mol-1) in the direction of ATP formation. The corresponding standard apparent entropy of the reaction (DELTA-S'degrees) was +4.70 J K-1 mol-1. The linear function (r2 = 0.99) between log10 K' and 1/K demonstrates that both DELTA-H'degrees and DELTA-S'degrees are independent of temperature for the creatine kinase reaction, and that DELTA-C(p)'degrees, the standard apparent heat capacity of products minus reactants in their standard states, is negligible between 5 and 38-degrees-C. We further show from our data that the sign and magnitude of the standard apparent Gibbs energy (DELTA-G'degrees) of the creatine kinase reaction was comprised mostly of the enthalpy of the reaction, with 11% coming from the entropy T-DELTA-S'degrees term. The thermodynamic quantities for the following two reference reactions of creatine kinase were also determined. PCr2- + ADP3- + H+ = ATP4- + Cr (2) MgPCr + MgADP1- + H+ = MgATP2- + Cr + Mg2+ (3) The DELTA-H-degrees for Reaction 2 was -16.73 kJ mol-1 (-3998 cal mol-1) and for Reaction 3 was -23.23 kJ mol-1 (-5552 cal mol-1) over the temperature range 5-38-degrees-C. The corresponding DELTA-S-degrees values for the reactions were +110.43 and +83.49 J K-1 mol-1, respectively. Using the DELTA-H'degrees of -11.93 kJ mol-1, and one K' value at one temperature, a second K' at a second temperature can be calculated, thus permitting bioenergetic investigations of organs and tissues using the creatine kinase equilibria over the entire physiological temperature range.	NIAAA,12501 WASHINGTON AVE,ROCKVILLE,MD 20852	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)								ALBERTY RA, 1991, BIOPHYS CHEM, V4242, P117; ALBERTY RA, 1987, PHYSICAL CHEM, P934; BATES RG, 1964, DETERMINATION PH; BITTL JA, 1985, J BIOL CHEM, V260, P3512; CARLSON FD, 1959, J GEN PHYSIOL, V43, P301, DOI 10.1085/jgp.43.2.301; CHANCE B, 1955, J BIOL CHEM, V217, P383; CHANCE B, 1985, P NATL ACAD SCI USA, V82, P8384, DOI 10.1073/pnas.82.24.8384; CLARKE ECW, 1980, J CHEM SOC F1, V76, P1911; DANFORTH WILLIAM H., 1965, P287; DOBSON GP, 1991, NMR BIOMED, V5, P20; GADIAN DG, 1981, BIOCHEM J, V194, P215, DOI 10.1042/bj1940215; GELLERT M, 1960, J AM CHEM SOC, V82, P1497, DOI 10.1021/ja01491a053; HOHORST HJ, 1962, BIOCHEM BIOPH RES CO, V7, P142, DOI 10.1016/0006-291X(62)90163-8; KENYON GL, 1983, ADV ENZYMOL RAMB, V54, P367; KUBY S, 1962, ENZYMES, P515; KUBY SA, 1954, J BIOL CHEM, V210, P65; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; Lehmann H, 1936, BIOCHEM Z, V286, P336; Lohmann K, 1934, BIOCHEM Z, V271, P264; LOPRESTI P, 1989, BIOCHIM BIOPHYS ACTA, V998, P317, DOI 10.1016/0167-4838(89)90291-4; MATTHEWS PM, 1981, BIOCHEM BIOPH RES CO, V103, P1052, DOI 10.1016/0006-291X(81)90915-3; NODA L, 1954, J BIOL CHEM, V210, P83; OESPER P, 1951, PHOSPHORUS METABOL, P523; Passonneau J.V., 1972, FLEXIBLE SYSTEM ENZY; PODOLSKY RJ, 1955, J BIOL CHEM, V217, P603; VANTHOFF JH, 1898, LECTURES THEORETICAL; VEECH RL, 1979, J BIOL CHEM, V254, P6538; WATTS DC, 1973, ENZYMES, P384; WOLEDGE RC, 1972, COLD SPRING HARB SYM, V37, P629; [No title captured]	30	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14084	14093						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629208				2022-12-25	WOS:A1992JD32500049
J	BLACKSHEAR, PJ; VERGHESE, GM; JOHNSON, JD; HAUPT, DM; STUMPO, DJ				BLACKSHEAR, PJ; VERGHESE, GM; JOHNSON, JD; HAUPT, DM; STUMPO, DJ			CHARACTERISTICS OF THE F52 PROTEIN, A MARCKS HOMOLOG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMINENT CELLULAR SUBSTRATE; MANNOSE 6-PHOSPHATE RECEPTOR; C-KINASE SUBSTRATE; GROWTH FACTOR-II; PHORBOL ESTERS; PHOSPHORYLATION; CALMODULIN; INSULIN; EXPRESSION; BINDING	A recently cloned mouse cDNA designated F52 encodes a putative protein with striking sequence similarity to the MARCKS protein, a major cellular substrate for protein kinase C (PKC). Major regions of sequence similarity include the amino-terminal myristoylation consensus sequence and the central calmodulin-binding/PKC phosphorylation site domain. The F52 protein was expressed in Escherichia coli with apparent M(r) 50,000; it was a substrate for PKC and comigrated on two-dimensional electrophoresis with a myristoylated protein whose phosphorylation was stimulated by phorbol 12-myristate 13-acetate in mouse neuroblastoma cells. The F52 protein also was myristoylated in E. coli by co-expression with N-myristoyltransferase. A 24-amino acid peptide derived from the protein's phosphorylation site domain was a good substrate for PKC; like the cognate MARCKS peptide, it was phosphorylated with high affinity (S0.5 = 173 nM) and positive cooperativity (K(H) = 5.4). The F52 peptide also bound calmodulin with high affinity (K(d) = <3 nM); this binding could be disrupted by phosphorylation of the peptide with PKC, with a half-time of 8 min. The F52 protein is clearly a member of the MARCKS family as defined by primary sequence; in addition, the two proteins share several key attributes that may be functionally important.	DUKE UNIV, MED CTR,DEPT MED,DIV ENDOCRINOL METAB & NUTR, DIABET & METAB SECT, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA; OHIO STATE UNIV, COLL MED, DEPT MED BIOCHEM, COLUMBUS, OH 43210 USA	Duke University; Duke University; Ohio State University	BLACKSHEAR, PJ (corresponding author), DUKE UNIV, MED CTR, HOWARD HUGHES MED INST LABS, POB 3897, DURHAM, NC 27710 USA.		Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033727, R01DK040408] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-40408, DK-33727] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAGCHI IC, 1992, J BIOL CHEM, V267, P3024; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; DEGRADO WF, 1988, ADV PROTEIN CHEM, V39, P51; DURONIO R J, 1990, Methods (Orlando), V1, P253, DOI 10.1016/S1046-2023(05)80325-1; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; KATO K, 1990, EUR J NEUROSCI, V2, P704, DOI 10.1111/j.1460-9568.1990.tb00460.x; LOBEL P, 1987, P NATL ACAD SCI USA, V84, P2233, DOI 10.1073/pnas.84.8.2233; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; MOSIOR M, 1992, BIOCHEMISTRY-US, V31, P1767, DOI 10.1021/bi00121a026; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PERSECHINI A, 1988, J CARDIOVASC PHARM, V12, pS1; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; SPACH DH, 1986, J BIOL CHEM, V261, P2750; STRYNADKA NCJ, 1990, PROTEINS, V7, P234, DOI 10.1002/prot.340070305; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; UMEKAGE T, 1991, FEBS LETT, V286, P147, DOI 10.1016/0014-5793(91)80961-2	28	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13540	13546						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618855				2022-12-25	WOS:A1992JB74600070
J	TAYLOR, WR; EGAN, SE; MOWAT, M; GREENBERG, AH; WRIGHT, JA				TAYLOR, WR; EGAN, SE; MOWAT, M; GREENBERG, AH; WRIGHT, JA			EVIDENCE FOR SYNERGISTIC INTERACTIONS BETWEEN RAS, MYC AND A MUTANT FORM OF P53 IN CELLULAR-TRANSFORMATION AND TUMOR DISSEMINATION	ONCOGENE			English	Article							C-MYC; MURINE FIBROBLASTS; EMBRYO FIBROBLASTS; MULTISTAGE CARCINOGENESIS; METASTATIC PHENOTYPE; GENE-PRODUCT; ONCOGENES; CELLS; EXPRESSION; INHIBITION	Mouse 10T1/2 cells were transfected with combinations of F24 H-ras, human c-myc and the proline 193 mutant form of p53. The three-gene ras/myc/p53 combination was significantly more efficient than single genes or double gene combinations in inducing transformed foci in vitro. An analysis of cell lines isolated after transfections with ras, ras/myc, ras/p53 and ras/myc/p53 indicated that the last combination contained significantly higher levels of ras protein than the other combinations, produced tumors in syngeneic mice with a shorter latency period, and exhibted an increased ability to form lung tumors in an in vivo experimental metastasis assay. Synergistic interactions between ras, myc and mutant p53 genes were observed in focus formation and metastasis assays, suggesting that the action of the three oncogenes in malignant transformation occurs along separate but interactive pathways. These results support a working model of oncogene cooperativity in which alterations in myc and p53 permit elevated expression of ras, which is important in a mechanism affecting both cellular transformation in vitro and tumor dissemination in vivo.	UNIV MANITOBA,MANITOBA INST CELL BIOL,100 OLIVIA ST,WINNIPEG R3E 0V9,MANITOBA,CANADA	University of Manitoba								BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BICHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENEVIXTRENCH G, 1990, ONCOGENE, V5, P1187; CRAIG AM, 1990, INT J CANCER, V46, P133, DOI 10.1002/ijc.2910460124; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; DAMEN JE, 1989, J NATL CANCER I, V81, P628, DOI 10.1093/jnci/81.8.628; DENHARDT DT, 1987, ONCOGENE, V2, P55; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; EGAN SE, 1989, INT J CANCER, V43, P443, DOI 10.1002/ijc.2910430317; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; EGAN SE, 1989, J CELL BIOCH B, V13, P62; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GINGRAS MC, 1990, CANCER RES, V50, P4061; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HICKS GG, 1988, J VIROL, V62, P4752, DOI 10.1128/JVI.62.12.4752-4755.1988; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V80, P5602; HSIAO WLW, 1987, MOL CELL BIOL, V7, P3380, DOI 10.1128/MCB.7.10.3380; KOHL NE, 1987, ONCOGENE, V2, P41; KONIGSBERG WH, 1983, METHOD ENZYMOL, V91, P254; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PEACOCK JW, 1990, ONCOGENE, V5, P1769; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; ROVINSKI B, 1988, ONCOGENE, V2, P445; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; RULEY HE, 1987, ADV VIRAL ONCOL, V6, P1; SCHWARZ LC, 1988, CANCER RES, V48, P6999; Schwarz LC, 1990, GROWTH FACTORS, V3, P115, DOI 10.3109/08977199009108274; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STURZBECHER HW, 1990, ONCOGENE, V5, P795; SUGARBAKER EV, 1981, CANCER BIOL REV, V2, P235; TANIGUCHI S, 1989, CANCER RES, V49, P6738; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; WAITZ W, 1991, ONCOGENE, V6, P29; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; WRIGHT JA, 1990, ANTICANCER RES, V10, P1247; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	55	56	59	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1383	1390						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620551				2022-12-25	WOS:A1992HZ97100017
J	KASTERN, W; SJOBRING, U; BJORCK, L				KASTERN, W; SJOBRING, U; BJORCK, L			STRUCTURE OF PEPTOSTREPTOCOCCAL PROTEIN-L AND IDENTIFICATION OF A REPEATED IMMUNOGLOBULIN LIGHT CHAIN-BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGG-BINDING; ESCHERICHIA-COLI; BACTERIAL PROTEIN; FC-BINDING; STREPTOCOCCI; SEQUENCE; RECEPTOR; ALBUMIN; REGIONS; GENE	The gene for protein L, an immunoglobulin (Ig) light chain-binding protein expressed by some strains of the anaerobic bacterial species Peptostreptococcus magnus, was cloned and sequenced. The gene translates into a protein of 719 amino acid residues. Following a signal sequence of 18 amino acids and a NH2-terminal region ("A") of 79 residues, the molecule contains five homologous "B" repeats of 72-76 amino acids each. Further, toward the COOH terminus, two additional repeats ("C") were found. These are not related to the "B" repeats, but are highly homologous to each other. After the C repeats (52 amino acids each), a hydrophilic, proline-rich putative cell wall-spanning region ("W") was found, followed at the COOH-terminal end by a hydrophobic membrane anchor ("M"). Fragments of the gene were expressed, and the corresponding peptides were analyzed for Ig-binding activity. The B repeats were found to be responsible for the interaction with Ig light chains. An Escherichia coli high level expression system was adapted for the production of large amounts of two Ig-binding protein L fragments comprising one and four B repeats, respectively.	UNIV LUND,DEPT MED & PHYSIOL CHEM,S-22100 LUND,SWEDEN; UNIV LUND,DEPT MED MICROBIOL,S-22362 LUND,SWEDEN	Lund University; Lund University	KASTERN, W (corresponding author), UNIV FLORIDA,COLL MED,DEPT PATHOL,GAINESVILLE,FL 32610, USA.							AKERSTROM B, 1991, MOL IMMUNOL, V28, P349, DOI 10.1016/0161-5890(91)90147-C; AKERSTROM B, 1989, J BIOL CHEM, V264, P19740; AKERSTROM B, 1987, J BIOL CHEM, V262, P13388; AKERSTROM B, 1986, J BIOL CHEM, V261, P240; AKESSON P, 1990, MOL IMMUNOL, V27, P523, DOI 10.1016/0161-5890(90)90071-7; BJORCK L, 1988, J IMMUNOL, V140, P1194; BJORCK L, 1987, MOL IMMUNOL, V24, P1113, DOI 10.1016/0161-5890(87)90080-0; BJORCK L, 1989, NATURE, V337, P385, DOI 10.1038/337385a0; BJORCK L, 1984, J IMMUNOL, V133, P969; BJORCK L, 1990, MOL MICROBIOL, V4, P1439, DOI 10.1111/j.1365-2958.1990.tb02054.x; BJORCK L, 1990, P267; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; DALBOGE H, 1989, GENE, V79, P325, DOI 10.1016/0378-1119(89)90214-X; DAVIS NG, 1985, CELL, V41, P607, DOI 10.1016/S0092-8674(85)80033-7; FAHNESTOCK SR, 1986, J BACTERIOL, V167, P870, DOI 10.1128/jb.167.3.870-880.1986; FISCHETTI VA, 1990, MOL MICROBIOL, V4, P1603, DOI 10.1111/j.1365-2958.1990.tb02072.x; FISCHETTI VA, 1989, CLIN MICROBIOL REV, V2, P285, DOI 10.1128/CMR.2.3.285-314.1989; FORSGREN A, 1966, J IMMUNOL, V97, P822; GOMI H, 1990, J IMMUNOL, V144, P4046; GUSS B, 1986, EMBO J, V5, P1567, DOI 10.1002/j.1460-2075.1986.tb04398.x; HEDEN LO, 1991, EUR J IMMUNOL, V21, P1481, DOI 10.1002/eji.1830210623; JERLSTROM PG, 1991, MOL MICROBIOL, V5, P843, DOI 10.1111/j.1365-2958.1991.tb00757.x; KASTERN W, 1990, INFECT IMMUN, V58, P1217, DOI 10.1128/IAI.58.5.1217-1222.1990; LINDAHL G, 1989, MOL MICROBIOL, V3, P239, DOI 10.1111/j.1365-2958.1989.tb01813.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MYHRE EB, 1984, J MED MICROBIOL, V18, P189, DOI 10.1099/00222615-18-2-189; MYHRE EB, 1985, MOL IMMUNOL, V22, P879, DOI 10.1016/0161-5890(85)90073-2; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; NILSON BHK, 1992, J BIOL CHEM, V267, P2234; PATELLA V, 1990, J IMMUNOL, V145, P3054; PLUCKTHUN A, 1991, BIO-TECHNOL, V9, P545, DOI 10.1038/nbt0691-545; REIS KJ, 1984, J IMMUNOL, V132, P3091; RUAN M, 1990, J IMMUNOL, V145, P3379; RUSSELLJONES GJ, 1984, J EXP MED, V160, P1467, DOI 10.1084/jem.160.5.1467; SAIKI RK, 1988, SCIENCE, V239, P489; SJOBRING U, 1989, J IMMUNOL, V143, P2948; SJODAHL J, 1977, EUR J BIOCHEM, V73, P343, DOI 10.1111/j.1432-1033.1977.tb11324.x; STONE GC, 1989, J IMMUNOL, V143, P565; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	39	108	126	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12820	12825						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618782				2022-12-25	WOS:A1992HZ48300066
J	PLOWMAN, GD; GREEN, JM; NEUBAUER, MG; BUCKLEY, SD; MCDONALD, VL; TODARO, GJ; SHOYAB, M				PLOWMAN, GD; GREEN, JM; NEUBAUER, MG; BUCKLEY, SD; MCDONALD, VL; TODARO, GJ; SHOYAB, M			THE EPITHELIN PRECURSOR ENCODES 2 PROTEINS WITH OPPOSING ACTIVITIES ON EPITHELIAL-CELL GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1 RECEPTOR ANTAGONIST; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; GENE; DNA; AMPHIREGULIN; EXPRESSION; PITUITARY; INHIBIN; LENGTH	Epithelin 1 and 2 were originally purified from rat kidneys based on their ability to inhibit the growth of A-431 human epidermoid carcinoma cells (Shoyab, M., McDonald, V. L., Byles, C., Todaro, G. J., and Plowman, G. D. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 7912-7916). This study presents the complete amino acid sequence of these two growth factors and the cloning of their cDNAs from rat, mouse, and human sources. Epithelins 1 and 2 are 56- and 57-amino acid polypeptides, respectively, and share 47% amino acid sequence identity with the conserved spacing of 12 cysteine residues. Molecular cloning revealed that both proteins are encoded by a single precursor that contains 7 1/2 copies of this novel 12-cysteine motif, 2 of which represent the known active molecules. Recombinant expression in COS cells demonstrated that the epithelin 1 protein was mitogenic on rodent keratinocytes and fibroblasts. In contrast, epithelin 2 had no activity on these cells, but at high concentrations was capable of antagonizing the growth proliferative activities of epithelin 1. Northern analysis shows the epithelin mRNA to be expressed in many types of epithelial cells. The broad expression profile of epithelin transcripts, along with the opposing activities of the two mature protein products, implicates these factors as natural mediators of epithelial homeostasis.			PLOWMAN, GD (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, SEATTLE, WA 98121 USA.		PLOWMAN, Greg D/E-2012-2011					AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BERG JM, 1990, J BIOL CHEM, V265, P6513; BLUNDELL TL, 1980, NATURE, V287, P781, DOI 10.1038/287781a0; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; DUFTON MJ, 1984, J MOL EVOL, V20, P128, DOI 10.1007/BF02257373; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FERNIG DG, 1991, REGULATORY MECHANISM, P47; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOMEZ F, 1989, EUR J BIOCHEM, V186, P23, DOI 10.1111/j.1432-1033.1989.tb15172.x; GOSPODAROWICZ D, 1987, J CELL PHYSIOL, P15; HAN VKM, 1987, SCIENCE, V236, P193, DOI 10.1126/science.3563497; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; LING N, 1985, P NATL ACAD SCI USA, V82, P7217, DOI 10.1073/pnas.82.21.7217; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; RUGIN JS, 1989, P NATL ACAD SCI USA, V86, P802; SCHAFFER MA, 1988, PLANT PHYSIOL, V87, P431, DOI 10.1104/pp.87.2.431; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHARPLES K, 1987, DNA-J MOLEC CELL BIO, V6, P239, DOI 10.1089/dna.1987.6.239; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SHOYAB M, 1990, P NATL ACAD SCI USA, V87, P7912, DOI 10.1073/pnas.87.20.7912; SMITH AI, 1988, ENDOCR REV, V9, P159, DOI 10.1210/edrv-9-1-159; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258	29	167	181	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					13073	13078						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618805				2022-12-25	WOS:A1992HZ48300099
J	BRAY, KM; QUAST, U				BRAY, KM; QUAST, U			A SPECIFIC BINDING-SITE FOR K+ CHANNEL OPENERS IN RAT AORTA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SMOOTH-MUSCLE; PORTAL-VEIN; CROMAKALIM; CELLS; BRL-34915; DIAZOXIDE	The K+ channel openers, including cromakalim, pinacidil, minoxidil sulfate, diazoxide, and nicorandil, form a chemically heterogeneous group of compounds, which relax smooth muscle by opening plasmalemmal K+ channels. At present it is not known whether these drugs elicit their effects by binding to the same target, presumably the K+ channel. In order to address this question, a binding assay for K+ channel openers has been developed in vascular smooth muscle. The novel tritiated K+ channel opener, [H-3]P1075, an analogue of pinacidil, binds with high affinity (K(D) = 6 +/- 1 nM) to endothelium-denuded rings of rat aorta. Inhibition studies indicate that the different families of K+ channel openers bind to a common target. Evidence is presented to suggest that the binding site for the sulfonylurea, glibenclamide, the major blocker of the K+ channel openers, is coupled in a negative allosteric manner to the binding site(s) for the openers. The binding assay described here may open the way to the biochemical characterization of the drug receptor for the K+ channel openers.	SANDOZ PHARMA LTD,DEPT PRECLIN RES,CH-4002 BASEL,SWITZERLAND	Novartis; Sandoz								BEECH DJ, 1989, BRIT J PHARMACOL, V98, P851, DOI 10.1111/j.1476-5381.1989.tb14614.x; BRAY K, 1991, N-S ARCH PHARMACOL, V344, P351; COOK N S, 1989, British Journal of Pharmacology, V96, p181P; Cook NS, 1990, POTASSIUM CHANNELS S, P181; DRAPER NR, 1981, APPLIED REGRESSION A, P85; EDWARDS G, 1990, TRENDS PHARMACOL SCI, V11, P417, DOI 10.1016/0165-6147(90)90149-3; EDWARDS G, 1990, PHARMACOL THERAPEUT, V48, P237, DOI 10.1016/0163-7258(90)90082-D; FURUKAWA K, 1981, J PHARMACOL EXP THER, V218, P248; GARRINO MG, 1988, BRIT J PHARMACOL, V93, P61, DOI 10.1111/j.1476-5381.1988.tb11405.x; GELBAND CH, 1989, EUR J PHARMACOL, V167, P201, DOI 10.1016/0014-2999(89)90580-3; GOPALAKRISHNAN M, 1991, J PHARMACOL EXP THER, V257, P1162; HAMILTON TC, 1986, BRIT J PHARMACOL, V88, P103, DOI 10.1111/j.1476-5381.1986.tb09476.x; KITAMURA K, 1990, Japanese Journal of Pharmacology, V52, p36P; KLOCKNER U, 1989, ARZNEIMITTELFORSCH, V39-1, P120; NEWGREEN DT, 1990, BRIT J PHARMACOL, V100, P605, DOI 10.1111/j.1476-5381.1990.tb15854.x; POSTMA SW, 1984, MOL PHARMACOL, V25, P219; QUAST U, 1988, N-S ARCH PHARMACOL, V338, P319; QUAST U, 1989, TRENDS PHARMACOL SCI, V10, P431, DOI 10.1016/S0165-6147(89)80003-3; QUAST U, 1988, BRIT J PHARMACOL, V93, pP204; QUAST U, 1990, BRIT J PHARMACOL, V99, pP7; ROBERTSON DW, 1990, J MED CHEM, V33, P1529, DOI 10.1021/jm00168a001; STANDEN NB, 1989, SCIENCE, V245, P177, DOI 10.1126/science.2501869; STEINBERG MI, 1988, J CARDIOVASC PHARM, V12, pS30, DOI 10.1097/00005344-198812002-00007; STEINBERG MI, 1991, J PHARMACOL EXP THER, V256, P222; WILSON C, 1988, BRIT J PHARMACOL, V93, pP126; ZINI S, 1991, J PHARMACOL EXP THER, V259, P566; ZUNKLER BJ, 1988, N-S ARCH PHARMACOL, V337, P225	27	126	127	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11689	11692						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601843				2022-12-25	WOS:A1992HY94700008
J	KOSKI, P; SAARILAHTI, H; SUKUPOLVI, S; TAIRA, S; RIIKONEN, P; OSTERLUND, K; HURME, R; RHEN, M				KOSKI, P; SAARILAHTI, H; SUKUPOLVI, S; TAIRA, S; RIIKONEN, P; OSTERLUND, K; HURME, R; RHEN, M			A NEW ALPHA-HELICAL COILED COIL PROTEIN ENCODED BY THE SALMONELLA-TYPHIMURIUM VIRULENCE PLASMID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOCOCCAL M-PROTEIN; MYOSIN HEAVY-CHAIN; COMPLETE NUCLEOTIDE-SEQUENCE; GROUP-A STREPTOCOCCUS; AMINO-ACID-SEQUENCES; MONOCLONAL-ANTIBODIES; ESCHERICHIA-COLI; SECONDARY STRUCTURE; CLONING VEHICLES; M13 VECTORS	A new protein of Salmonella typhimurium was identified and characterized. The gene (tlpA) encoding this protein (TlpA) was isolated from the large virulence-associated plasmid of S. typhimurium and sequenced in order to predict the primary structure of TlpA. tlpA encodes a 371-amino acid soluble protein with a calculated M(r) of 41600 and pI of 4.63. Secondary structure predictions and sequence statistics of TlpA indicated a predominant alpha-helical configuration and presence of heptapeptide repeat motifs characteristic of coiled coil proteins. Purified TlpA was shown to have biochemical properties similar to those of coiled coil proteins, including adoption of an alpha-helical configuration and a tendency to form homodimers. Furthermore, TlpA possessed heat resistance, evidence for a chain register and altered mobility in urea/sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels which are characteristics of tropomyosins. TlpA shows 32% overall sequence similarity with rat cardiac myosin and 36% similarity with horse platelet-beta-tropomyosin over 226 residues, whereas selected regions possessed significant sequence identities with myosins, tropomyosins, and alpha-helical surface proteins of Streptococcus pyogenes. Our results indicate that TlpA represents a new member of prokaryotic coiled coil proteins.	UNIV HELSINKI,DEPT BIOCHEM,UNIONINKATU 35,SF-00170 HELSINKI 17,FINLAND; NATL PUBL HLTH INST,MOLEC BIOL UNIT,SF-00300 HELSINKI,FINLAND	Finland National Institute for Health & Welfare; University of Helsinki; Finland National Institute for Health & Welfare								BAUMANN M, 1990, ANAL BIOCHEM, V190, P198, DOI 10.1016/0003-2697(90)90181-8; BILLETER R, 1981, FEBS LETT, V132, P133, DOI 10.1016/0014-5793(81)80446-2; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASAREGOLA S, 1990, MOL MICROBIOL, V4, P505, DOI 10.1111/j.1365-2958.1990.tb00617.x; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CLEMENT RR, 1990, J BACTERIOL, V172, P6217; COHEN C, 1981, P NATL ACAD SCI-BIOL, V78, P5303, DOI 10.1073/pnas.78.9.5303; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CUNNINGHAM MW, 1986, J IMMUNOL, V136, P293; CUNNINGHAM MW, 1986, J EXP MED, V164, P998, DOI 10.1084/jem.164.4.998; CUNNINGHAM MW, 1988, J IMMUNOL, V141, P2760; DALE JB, 1986, J EXP MED, V164, P1785, DOI 10.1084/jem.164.5.1785; DEHOSTOS EL, 1991, EMBO J, V10, P4097, DOI 10.1002/j.1460-2075.1991.tb04986.x; DEISENHOFER J, 1978, H-S Z PHYSIOL CHEM, V359, P975, DOI 10.1515/bchm2.1978.359.2.975; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DOOLITTLE RF, 1981, SCIENCE, V214, P149, DOI 10.1126/science.7280687; ELLER M, 1982, NUCLEIC ACIDS RES, V17, P3591; FENDERSON PC, 1989, J IMMUNOL, V143, P2475; FENG DF, 1985, J MOL EVOL, V21, P112, DOI 10.1007/BF02100085; FINE RE, 1975, J MOL BIOL, V95, P447, DOI 10.1016/0022-2836(75)90202-8; FRITHZ E, 1989, MOL MICROBIOL, V3, P1111, DOI 10.1111/j.1365-2958.1989.tb00261.x; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GULIG PA, 1987, INFECT IMMUN, V55, P2891, DOI 10.1128/IAI.55.12.2891-2901.1987; HALLAUER PL, 1987, J BIOL CHEM, V262, P3590; HANSON J, 1963, J MOL BIOL, V6, P46, DOI 10.1016/S0022-2836(63)80081-9; HELANDER IM, 1989, EUR J BIOCHEM, V185, P541, DOI 10.1111/j.1432-1033.1989.tb15147.x; HELMUTH R, 1985, INFECT IMMUN, V48, P175, DOI 10.1128/IAI.48.1.175-182.1985; HITCHCOCKDEGREGORI SE, 1987, J BIOL CHEM, V262, P9730; HOLLINGSHEAD SK, 1986, J BIOL CHEM, V261, P1677; HOLTZER ME, 1990, BIOCHEM BIOPH RES CO, V166, P1279, DOI 10.1016/0006-291X(90)91004-C; HOSEIN B, 1979, P NATL ACAD SCI USA, V76, P3765, DOI 10.1073/pnas.76.8.3765; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; KRAFT R, 1989, NUCLEIC ACIDS RES, V17, P7529, DOI 10.1093/nar/17.18.7529; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANCEFIELD RC, 1962, J IMMUNOL, V89, P307; LEHRER SS, 1990, J BIOL CHEM, V265, P1134; LEHRER SS, 1975, P NATL ACAD SCI USA, V72, P3377, DOI 10.1073/pnas.72.9.3377; LEINONEN M, 1985, ENTEROBACTERIAL SURF, P179; LENNOX ES, 1955, VIROLOGY, V1, P190, DOI 10.1016/0042-6822(55)90016-7; LILJESTROM P, 1982, MOL GEN GENET, V188, P190, DOI 10.1007/BF00332674; MANJULA BN, 1985, P NATL ACAD SCI USA, V82, P1064, DOI 10.1073/pnas.82.4.1064; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; MCKEON FD, 1986, NATURE, V319, P463, DOI 10.1038/319463a0; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MOUW AR, 1988, J BACTERIOL, V170, P676, DOI 10.1128/jb.170.2.676-684.1988; NAKAMURA K, 1978, J BIOCHEM-TOKYO, V84, P1453, DOI 10.1093/oxfordjournals.jbchem.a132268; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NIKI H, 1991, EMBO J, V10, P183, DOI 10.1002/j.1460-2075.1991.tb07935.x; NOHMI T, 1991, J BACTERIOL, V173, P1051, DOI 10.1128/jb.173.3.1051-1063.1991; NOREL F, 1989, MOL MICROBIOL, V3, P733, DOI 10.1111/j.1365-2958.1989.tb00222.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEARSONWHITE SH, 1987, J BIOL CHEM, V262, P15998; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RHEN M, 1986, GENE, V49, P351, DOI 10.1016/0378-1119(86)90371-9; RHEN M, 1988, MICROB PATHOGENESIS, V5, P275, DOI 10.1016/0882-4010(88)90100-3; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHECHTER B, 1970, J BIOL CHEM, V245, P1438; SENDER PM, 1971, FEBS LETT, V17, P106, DOI 10.1016/0014-5793(71)80575-6; SUMMERS WC, 1970, ANAL BIOCHEM, V33, P495; TAIRA S, 1989, FEBS LETT, V257, P274, DOI 10.1016/0014-5793(89)81551-0; TAIRA S, 1991, FEMS MICROBIOL LETT, V77, P319, DOI 10.1016/S0378-1097(99)00333-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UBBEN D, 1986, GENE, V41, P145, DOI 10.1016/0378-1119(86)90093-4; VARTIAINEN J, 1964, ACTA MED SCAND, V175, P771; WARAVDEKAR VS, 1959, J BIOL CHEM, V234, P1945; WARREN CPW, 1970, ANN RHEUM DIS, V29, P483, DOI 10.1136/ard.29.5.483; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115	72	29	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12258	12265						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601892				2022-12-25	WOS:A1992HY94700091
J	ROSA, P; MANTOVANI, S; ROSBOCH, R; HUTTNER, WB				ROSA, P; MANTOVANI, S; ROSBOCH, R; HUTTNER, WB			MONENSIN AND BREFELDIN-A DIFFERENTIALLY AFFECT THE PHOSPHORYLATION AND SULFATION OF SECRETORY PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI CISTERNAE; TYROSYLPROTEIN SULFOTRANSFERASE; LINKED OLIGOSACCHARIDES; INTRACELLULAR-TRANSPORT; N-ACETYLGALACTOSAMINE; ENDOPLASMIC-RETICULUM; TYROSINE SULFATION; SECRETOGRANIN-I; MAMMARY-GLAND; RAT-LIVER	Chromogranin B and secretogranin II, two members of the granin family, are known to be post-translationally modified by the addition of O-linked carbohydrates to serine and/or threonine, phosphate to serine and threonine, and sulfate to carbohydrate and tyrosine residues. In the present study, chromogranin B and secretogranin II were used as model proteins to investigate in which subcompartment of the Golgi complex secretory proteins become phosphorylated. Monensin, a drug known to block the transport from the medial to the trans cisternae of the Golgi stack, inhibited the phosphorylation of the granins, indicating that this modification occurred distal to the medial Golgi. Monensin also blocked the addition of galactose to O-linked carbohydrates and the sulfation of the granins, confirming previous data that these modifications take place in the trans Golgi. To distinguish, within the trans Golgi, between the trans cisternae of the Golgi stack and the trans Golgi network, we made use of the previous observation that brefeldin A results in the redistribution to the endoplasmic reticulum of membrane-bound enzymes of the trans cisternae of the Golgi stack, but not of the trans Golgi network. Brefeldin A treatment abolished granin sulfation but resulted in the accumulation of phosphorylated and galactosylated granins. Differential effects of brefeldin A on membranes of the Golgi stack versus the trans Golgi network were also observed by immunofluorescence analysis of marker proteins specific for either compartment. Our results suggest that the phosphorylation of secretory proteins, like their galactosylation, largely occurs in the trans cisternae of the Golgi stack, whereas the sulfation of secretory proteins on both carbohydrate and tyrosine residues takes place selectively in the trans Golgi network.	UNIV HEIDELBERG, INST NEUROBIOL, W-6900 HEIDELBERG, GERMANY	Ruprecht Karls University Heidelberg	ROSA, P (corresponding author), CNR, CTR CYTOPHARMACOL, DEPT PHARMACOL, VIA VANVITELLI 32, I-20129 MILAN, ITALY.		Huttner, Wieland B./P-4080-2018	Rosa, Patrizia/0000-0002-2590-6955				ABEIJON C, 1987, J BIOL CHEM, V262, P4153; BAEUERLE PA, 1987, J CELL BIOL, V105, P2655, DOI 10.1083/jcb.105.6.2655; BRAULKE T, 1987, EUR J CELL BIOL, V43, P316; CAPASSO JM, 1989, J BIOL CHEM, V264, P5233; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; DESCHUYTENEER M, 1988, J BIOL CHEM, V263, P2452; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; EIPPER BA, 1982, J BIOL CHEM, V257, P4907; ELHAMMER A, 1984, J CELL BIOL, V99, P327, DOI 10.1083/jcb.99.1.327; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GLOSSL J, 1986, J BIOL CHEM, V261, P1920; GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835; HANOVER JA, 1980, J BIOL CHEM, V255, P6713; HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; HUTTNER WB, 1991, MARKERS NEURAL ENDOC, P93; KAARIAINEN L, 1980, J CELL BIOL, V87, P783, DOI 10.1083/jcb.87.3.783; KIMURA JH, 1984, J CELL BIOCHEM, V26, P261, DOI 10.1002/jcb.240260406; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEE RWH, 1985, P NATL ACAD SCI USA, V82, P6143, DOI 10.1073/pnas.82.18.6143; LEE RWH, 1983, J BIOL CHEM, V258, P1326; LIBERTI JP, 1985, BIOCHEM BIOPH RES CO, V128, P713, DOI 10.1016/0006-291X(85)90105-6; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; NIEHRS C, 1990, EMBO J, V9, P35, DOI 10.1002/j.1460-2075.1990.tb08077.x; NIEMANN H, 1982, EMBO J, V1, P1499, DOI 10.1002/j.1460-2075.1982.tb01346.x; OETTING WS, 1986, J BIOL CHEM, V261, P1649; PATHAK RK, 1988, J CELL BIOL, V106, P1831, DOI 10.1083/jcb.106.6.1831; PAUL JI, 1984, J BIOL CHEM, V259, P3477; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; ROSA P, 1989, J CELL BIOL, V109, P17, DOI 10.1083/jcb.109.1.17; ROSA P, 1985, J CELL BIOL, V101, P1999, DOI 10.1083/jcb.101.5.1999; ROSA P, 1985, J CELL BIOL, V100, P928, DOI 10.1083/jcb.100.3.928; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; SPIELMAN J, 1988, J BIOL CHEM, V263, P9621; STROUS JAM, 1980, CELL, V22, P709, DOI 10.1016/0092-8674(80)90547-4; TARTAKOFF A, 1978, J CELL BIOL, V79, P694, DOI 10.1083/jcb.79.3.694; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475; WANG SY, 1982, J BIOL CHEM, V257, P3837; WATKINSON A, 1989, J BIOL CHEM, V264, P3061; WEST DW, 1984, BIOCHEM J, V219, P181, DOI 10.1042/bj2190181; WHITSETT JA, 1985, J BIOL CHEM, V260, P5273; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5	51	80	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12227	12232						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601888				2022-12-25	WOS:A1992HY94700086
J	IKEDA, RA				IKEDA, RA			THE EFFICIENCY OF PROMOTER CLEARANCE DISTINGUISHES T7 CLASS-II AND CLASS-III PROMOTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; RIBONUCLEIC-ACID POLYMERASE; INVITRO TRANSCRIPTION PROPERTIES; LAC UV5 PROMOTER; NUCLEOTIDE-SEQUENCE; ENZYMATIC-REACTION; T7-RNA POLYMERASE; POINT MUTATIONS; INITIATION; DNA	Promoter strength has been defined as the relative production of transcripts from a promoter. For T7 transcription it has frequently been observed that T7 class III promoters are qualitatively stronger than T7 class II promoters. In previous work it was observed that the maximum rates of initiation of three class III and three class II promoters show no class distinctions (Ikeda, R. A., Lin, A. C., and Clarke, J. (1992) J. Biol. Chem. 267, 2640-2649). This suggests that the efficiency of the conversion of the polymerase initiation complex to a stable transcription complex contributes to the overall strength of T7 promoters. The class differences in the strengths of T7 class II and class III promoters are confirmed by measuring the relative synthesis of run-off transcripts. These results show that the relative strengths of the class III promoters, phi-6.5, phi-10, and phi-13, are all comparable ranging from 0.61 for phi-6.5 to 1.00 for phi-10, while the relative strengths of the T7 class II promoters, phi-1.1B, phi-1.3, and phi-3.8, vary widely. One T7 class II promoter, phi-1.1B (relative strength = 0.34), approaches the strength of the class III promoters, while the other T7 class II promoters, phi-1.3 (relative strength = 0.045) and phi-3.8 (relative strength = 0.070) are nearly inactive. The efficiency of promoter clearance is then determined by measuring the relative production of small transcription products in comparison with the production of run-off transcripts. These measurements clearly distinguish the T7 class III promoters from the T7 class II promoters. It is found that 68-75% of all initiations at the T7 class III promoters phi-6.5, phi-10, and phi-13 produce a run-off transcript, while only 16-36% of the initiations at the T7 class II promoters phi-1.1B, phi-1.3, and phi-3.8 produce a run-off transcript. Clearly, promoter clearance contributes to the difference in promoter strengths of the T7 class II and III promoters.			IKEDA, RA (corresponding author), GEORGIA INST TECHNOL,SCH CHEM & BIOCHEM,ATLANTA,GA 30332, USA.			Ikeda, Richard/0000-0003-4015-5528	NIAID NIH HHS [AI-24905] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI024905] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASU S, 1986, J MOL BIOL, V190, P425, DOI 10.1016/0022-2836(86)90013-6; BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; CARTER AD, 1981, J VIROL, V37, P636, DOI 10.1128/JVI.37.2.636-642.1981; CHAMBERL.M, 1973, J BIOL CHEM, V248, P2235; CHAMBERL.M, 1973, J BIOL CHEM, V248, P2245; CHAMBERLIN M, 1982, ENZYMES, V15, P92; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; CHAPMAN KA, 1982, NUCLEIC ACIDS RES, V10, P6331, DOI 10.1093/nar/10.20.6331; CHAPMAN KA, 1987, NUCLEIC ACIDS RES, V15, P5413, DOI 10.1093/nar/15.13.5413; CHAPMAN KA, 1988, NUCLEIC ACIDS RES, V16, P4511, DOI 10.1093/nar/16.10.4511; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; GOULOMB M, 1974, P NATL ACAD SCI USA, V71, P760; GUNDERSON SI, 1987, BIOCHEMISTRY-US, V26, P1539, DOI 10.1021/bi00380a007; IKEDA RA, 1987, J BIOL CHEM, V262, P3790; IKEDA RA, 1992, J BIOL CHEM, V267, P2640; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; JOLLIFFE LK, 1982, NATURE, V299, P653, DOI 10.1038/299653a0; LING ML, 1989, NUCLEIC ACIDS RES, V17, P1605, DOI 10.1093/nar/17.4.1605; Maniatis T., 1982, MOL CLONING; MARTIN CT, 1987, BIOCHEMISTRY-US, V26, P2690, DOI 10.1021/bi00384a006; MARTIN CT, 1989, BIOCHEMISTRY-US, V28, P2760, DOI 10.1021/bi00433a002; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MCALLISTER WT, 1978, P NATL ACAD SCI USA, V75, P804, DOI 10.1073/pnas.75.2.804; MCALLISTER WT, 1980, NUCLEIC ACIDS RES, V8, P4821, DOI 10.1093/nar/8.20.4821; MCALLISTER WT, 1981, J MOL BIOL, V153, P527, DOI 10.1016/0022-2836(81)90406-X; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MOFFATT BA, 1984, J MOL BIOL, V173, P265, DOI 10.1016/0022-2836(84)90194-3; MOOKHTIAR KA, 1991, BIOCHEMISTRY-US, V30, P6305, DOI 10.1021/bi00239a032; MULLER DK, 1988, BIOCHEMISTRY-US, V27, P5763, DOI 10.1021/bi00415a055; MULLER DK, 1989, BIOCHEMISTRY-US, V28, P3306, DOI 10.1021/bi00434a028; NILES EG, 1975, J MOL BIOL, V98, P57, DOI 10.1016/S0022-2836(75)80101-X; OAKLEY JL, 1979, BIOCHEMISTRY-US, V18, P528, DOI 10.1021/bi00570a023; RABKIN SD, 1988, J MOL BIOL, V204, P903, DOI 10.1016/0022-2836(88)90050-2; RANDERATH K, 1964, J CHROMATOGR, V16, P111, DOI 10.1016/S0021-9673(01)82445-6; RANDERATH K, 1967, METHODS ENZYMOLOGY A, V12, P323; SCHENBORN ET, 1985, NUCLEIC ACIDS RES, V13, P6223, DOI 10.1093/nar/13.17.6223; SMEEKENS SP, 1986, NUCLEIC ACIDS RES, V14, P2811, DOI 10.1093/nar/14.6.2811; STAHL SJ, 1981, J MOL BIOL, V148, P481, DOI 10.1016/0022-2836(81)90187-X; STRANEY DC, 1985, CELL, V43, P449, DOI 10.1016/0092-8674(85)90175-8; STROTHKAMP RE, 1980, BIOCHEMISTRY-US, V19, P1074, DOI 10.1021/bi00547a005; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074	42	26	29	3	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11322	11328						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597465				2022-12-25	WOS:A1992HX16900061
J	JUST, I; MOHR, C; SCHALLEHN, G; MENARD, L; DIDSBURY, JR; VANDEKERCKHOVE, J; VANDAMME, J; AKTORIES, K				JUST, I; MOHR, C; SCHALLEHN, G; MENARD, L; DIDSBURY, JR; VANDEKERCKHOVE, J; VANDAMME, J; AKTORIES, K			PURIFICATION AND CHARACTERIZATION OF AN ADP-RIBOSYLTRANSFERASE PRODUCED BY CLOSTRIDIUM-LIMOSUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-GENE-PRODUCT; PERFRINGENS IOTA TOXIN; GTP-BINDING PROTEINS; BOTULINUM ADP-RIBOSYLTRANSFERASE-C3; POLYACRYLAMIDE GELS; ESCHERICHIA-COLI; SKELETAL-MUSCLE; ACTIN; RIBOSYLATION; SUBSTRATE	We purified a novel ADP-ribosyltransferase produced by a Clostridium limosum strain isolated from a lung abscess and compared the exoenzyme with Clostridium botulinum ADP-ribosyltransferase C3. The C. limosum exoenzyme has a molecular weight of about 25,000 and a pl of 10.3. The specific activity of the ADP-ribosyltransferase is 3.1 nmol/mg/min with a K(m) for NAD of 0.3-mu-M. Partial amino acid sequence analysis of the tryptic peptides revealed about 70% homology with C3. The novel exoenzyme modifies selectively the small GTP-binding proteins of the rho family in human platelet membranes presumably at the same amino acid (asparagine 41) as known for C3. Recombinant rhoA and rhoB serve as substrates for C3 and the C. limosum exoenzyme. Whereas recombinant rac1 protein is only marginally ADP-ribosylated by C3 or by the C. limosum exoenzyme in the absence of detergent, in the presence of 0.01% sodium dodecyl sulfate rac1 is modified by C3 but not by the C. limosum exoenzyme. Recombinant CDC42Hs protein is a poor substrate for C. limosum exoenzyme and is even less modified by C3. The C. limosum exoenzyme is auto-ADP-ribosylated in the presence of 0.01% sodium dodecyl sulfate by forming an ADP-ribose protein bond highly stable toward hydroxylamine. The data indicate that ADP-ribosylation of small GTP-binding proteins of the rho family is not unique to C. botulinum C3 ADP-ribosyltransferase but is also catalyzed by a C3-related exoenzyme from C. limosum.	UNIV SAARLAND,INST PHARMACOL & TOXIKOL,W-6650 HOMBURG,GERMANY; UNIV BONN,INST MED MIKROBIOL & IMMUNOL,W-5300 BONN,GERMANY; LAB FYSIOL SCHEIKUNDE,B-9000 GHENT,BELGIUM; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710	Saarland University; University of Bonn; Duke University			Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436				AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; AKTORIES K, 1989, J CELL BIOL, V109, P1385, DOI 10.1083/jcb.109.4.1385; AKTORIES K, 1988, BIOCHEM BIOPH RES CO, V156, P361, DOI 10.1016/S0006-291X(88)80849-0; AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; BAUW G, 1987, P NATL ACAD SCI USA, V84, P4806, DOI 10.1073/pnas.84.14.4806; BAUW G, 1988, J PROTEIN CHEM, V7, P194; BOKOCH GM, 1983, J BIOL CHEM, V258, P2072; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P2669, DOI 10.1073/pnas.75.6.2669; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; COLLIER RJ, 1990, ADP RIBOSYLATING TOX, P3, DOI DOI 10.1126/SCIENCE.250.4982.841-A; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIDSBURY JR, 1990, BIOCHEM BIOPH RES CO, V171, P804, DOI 10.1016/0006-291X(90)91217-G; HABERMANN B, 1991, BIOCHIM BIOPHYS ACTA, V1077, P253, DOI 10.1016/0167-4838(91)90537-A; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HALL A, 1986, J BIOL CHEM, V261, P963; HONJO T, 1968, J BIOL CHEM, V243, P2553; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAEHAMA T, 1990, FEBS LETT, V263, P376, DOI 10.1016/0014-5793(90)81418-N; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PFEUFFER T, 1988, CURR TOP CELL REGUL, V29, P129; POPOFF M, 1990, NUCLEIC ACIDS RES, V18, P1291, DOI 10.1093/nar/18.5.1291; POPOFF MR, 1988, INFECT IMMUN, V56, P2299, DOI 10.1128/IAI.56.9.2299-2306.1988; POPOFF MR, 1988, BIOCHEM BIOPH RES CO, V152, P1361, DOI 10.1016/S0006-291X(88)80435-2; ROSENER S, 1987, FEBS LETT, V224, P38, DOI 10.1016/0014-5793(87)80418-0; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SCHERING B, 1988, EUR J BIOCHEM, V171, P225, DOI 10.1111/j.1432-1033.1988.tb13780.x; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SIMPSON LL, 1989, INFECT IMMUN, V57, P255, DOI 10.1128/IAI.57.1.255-261.1989; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDEKERCKHOVE J, 1987, FEBS LETT, V225, P48, DOI 10.1016/0014-5793(87)81129-8	39	141	143	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10274	10280						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587816				2022-12-25	WOS:A1992HV09000014
J	WO, YYP; MCCORMACK, AL; SHABANOWITZ, J; HUNT, DF; DAVIS, JP; MITCHELL, GL; VANETTEN, RI				WO, YYP; MCCORMACK, AL; SHABANOWITZ, J; HUNT, DF; DAVIS, JP; MITCHELL, GL; VANETTEN, RI			SEQUENCING, CLONING, AND EXPRESSION OF HUMAN RED CELL-TYPE ACID-PHOSPHATASE, A CYTOPLASMIC PHOSPHOTYROSYL PROTEIN PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRY; BOVINE HEART; PURIFICATION; POLYMERASE; ASSIGNMENT; LOCUS; ACP1; GELS; PCR	Low molecular weight phosphotyrosyl protein phosphatases of human placenta and human red cell were purified and sequenced by a combination of Edman degradation and tandem mass spectrometry. Screening of a human placental lambda-gt11 cDNA library yielded over-lapping cDNA clones coding for two distinct human cytoplasmic low molecular weight phosphotyrosyl protein phosphatases (HCPTPs). The two longest clones, designated HCPTP1-1 and HCPTP2-1, were found to have identical nucleotide sequences, with the exception of a 108-base pair segment in the middle of the open reading frame. Polymerase chain reaction studies with human genomic DNA suggest that the difference between HCPTP1-1 and HCPTP2-1 does not result from alternative RNA splicing. Studies with a human chromosome 2-specific library confirmed that these sequences are located on chromosome 2, which is known to be the location of red cell acid phosphatase locus ACP1. The coding sequences of HCPTP1-1 and HCPTP2-1 were placed downstream from a bacteriophage T7 promoter and the proteins were expressed in Escherichia coli. The resulting recombinant enzymes (designated HCPTP-A and HCPTP-B, respectively) showed molecular weights of 18,000 by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and both of them exhibited immunoreactivity with antisera raised against authentic human placental and bovine heart enzymes. The expressed proteins were highly active towards the phosphatase substrates p-nitrophenyl phosphate beta-naphthyl phosphate, and O-phospho-L-tyrosine, but not alpha-naphthyl phosphate, threonine phosphate, or O-phospho-L-serine. HCPTP-A and -B possessed effectively identical amino acid compositions, immunoreactivities, inhibition by formaldehyde, and kinetic properties when compared with two human red cell acid phosphatase isoenzymes. It is concluded that HCPTP-A and -B are the fast and slow forms of red cell acid phosphatase, respectively, and that this enzyme is not unique to the red cell but is instead expressed in all human tissues.	PURDUE UNIV, DEPT CHEM, W LAFAYETTE, IN 47907 USA; UNIV VIRGINIA, DEPT CHEM, CHARLOTTESVILLE, VA 22901 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Virginia			Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027003, R01GM037537] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 27713] Funding Source: Medline; NIGMS NIH HHS [GM 37537, GM 27003] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHMANN B, 1990, NUCLEIC ACIDS RES, V18, P1309, DOI 10.1093/nar/18.5.1309; BLACK MJ, 1983, ANAL BIOCHEM, V135, P233, DOI 10.1016/0003-2697(83)90756-X; BLAKE NM, 1973, JPN J HUM GENET, V18, P10; BOIVIN P, 1986, BIOCHEM BIOPH RES CO, V134, P557, DOI 10.1016/S0006-291X(86)80456-9; CAMICI G, 1989, J BIOL CHEM, V264, P2560; CHERNOFF J, 1985, ARCH BIOCHEM BIOPHYS, V240, P135, DOI 10.1016/0003-9861(85)90016-5; CHIEN A, 1976, J BACTERIOL, V127, P1550, DOI 10.1128/JB.127.3.1550-1557.1976; DIONNE CA, 1990, BIOTECHNIQUES, V8, P190; DISSING J, 1987, BIOCHEM GENET, V25, P919, DOI 10.1007/BF00502610; DISSING J, 1990, BIOCHIM BIOPHYS ACTA, V1041, P232, DOI 10.1016/0167-4838(90)90277-M; DISSING J, 1991, J BIOL CHEM, V266, P20619; DOOLITTLE RF, 1979, PROTEINS, V4, P1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENTON MR, 1971, ARCH BIOCHEM BIOPHYS, V142, P13, DOI 10.1016/0003-9861(71)90254-2; FERGUSONSMITH MA, 1973, NATURE-NEW BIOL, V243, P271, DOI 10.1038/newbio243271a0; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GILMAN JG, 1972, SCIENCE, V178, P873, DOI 10.1126/science.178.4063.873; HARRISON ML, 1991, J BIOL CHEM, V266, P4106; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HEINRIKSON RL, 1969, J BIOL CHEM, V244, P299; HOPKINSON DA, 1963, NATURE, V199, P969, DOI 10.1038/199969a0; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; HUNT DF, 1987, P NATL ACAD SCI USA, V84, P620, DOI 10.1073/pnas.84.3.620; HUNT DF, 1991, CURRENT RES PROTEIN, P441; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KLEPPE K, 1971, J MOL BIOL, V56, P341, DOI 10.1016/0022-2836(71)90469-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIDLER PM, 1982, ARCH BIOCHEM BIOPHYS, V216, P512, DOI 10.1016/0003-9861(82)90240-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MERCIER B, 1990, NUCLEIC ACIDS RES, V18, P5908, DOI 10.1093/nar/18.19.5908; MILLER SA, 1987, HUM HERED, V37, P371, DOI 10.1159/000153737; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR G, 1990, NUCLEIC ACIDS RES, V18, P7465, DOI 10.1093/nar/18.24.7465; SOKAL RR, 1991, NATURE, V351, P143, DOI 10.1038/351143a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SWALLOW DM, 1973, ANN HUM GENET, V37, P31, DOI 10.1111/j.1469-1809.1973.tb01812.x; TAGA EM, 1982, ARCH BIOCHEM BIOPHYS, V214, P505, DOI 10.1016/0003-9861(82)90054-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAO SGS, 1983, ANAL BIOCHEM, V131, P365, DOI 10.1016/0003-2697(83)90185-9; WAHEED A, 1988, BIOCHEMISTRY-US, V27, P4265, DOI 10.1021/bi00412a010; WILCOX AS, 1991, NUCLEIC ACIDS RES, V19, P1837, DOI 10.1093/nar/19.8.1837; ZHANG ZY, 1990, ARCH BIOCHEM BIOPHYS, V282, P39, DOI 10.1016/0003-9861(90)90084-C; ZHANG ZY, 1991, J BIOL CHEM, V266, P1516; ZHANG ZY, 1990, THESIS PURDUE U	46	108	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10856	10865						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587862				2022-12-25	WOS:A1992HV09000097
J	DAS, AK; HORIE, S; HAJRA, AK				DAS, AK; HORIE, S; HAJRA, AK			BIOSYNTHESIS OF GLYCEROLIPID PRECURSORS IN RAT-LIVER PEROXISOMES AND THEIR TRANSPORT AND CONVERSION TO PHOSPHATIDATE IN THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL DIHYDROXYACETONE PHOSPHATE; CRITICAL MICELLE CONCENTRATION; ACYL-COENZYME-A; LYSOPHOSPHATIDIC ACID; COA; ENZYMES; ACYLTRANSFERASE; LOCALIZATION; MICROBODIES; EXTRACTION	The transport of glycerolipid intermediates, viz. palmitoyl dihydroxyacetone phosphate (DHAP) and lysophosphatidate from peroxisomes and their conversion to phosphatidate in endoplasmic reticulum (microsomes) were studied in cell-free systems. The lipids were biosynthesized from [P-32]DHAP, palmitoyl-CoA, and freshly made rat liver peroxisomes and microsomes in the presence or absence of Mg2+, NADPH, and bovine serum albumin (BSA). After incubation, the soluble fraction and the membranes were separated, and the distribution of radioactive lipids in these fractions were determined. The results showed that palmitoyl-DHAP and lysophosphatidate were recovered in the supernatant when BSA was present or when BSA was absent, but Mg2+ was removed after incubation by chelation with EDTA (or ATP). At low optimum palmitoyl-CoA concentration or when palmitoyl-CoA was generated in peroxisomes, and in the absence of BSA, the biosynthesized keto ether and ester lipids and lysophosphatidate were similarly present in the supernatant. Phosphatidate, however, was always localized lin the membranes. Further fractionation showed that phosphatidate was associated with the microsomes. The critical micellar concentrations of palmitoyl-DHAP and 1-palmitoyl-rac-glycerol 3-phosphate, under the incubation conditions used, were determined to be 58 and 70-mu-M, respectively. These results suggest that at physiological concentrations the biosynthesized lysolipids are water soluble, and therefore, a carrier protein is unnecessary for their transport. These lipids freely diffuse from peroxisomes to endoplasmic reticulum where they are converted to membrane-bound phosphatidate.	UNIV MICHIGAN, MENTAL HLTH RES INST, NEUROSCI LAB, 1103 E HURON ST, ANN ARBOR, MI 48104 USA; UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48104 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan				Das, Arun/0000-0002-0883-1816	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015747, R01NS008841] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 08841, NS15747] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALLAS LM, 1984, BIOCHIM BIOPHYS ACTA, V795, P297, DOI 10.1016/0005-2760(84)90079-1; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BISHOP JE, 1982, ANN NY ACAD SCI, V386, P411, DOI 10.1111/j.1749-6632.1982.tb21437.x; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRANDES R, 1963, BIOCHEM J, V86, P244, DOI 10.1042/bj0860244; BURDETT K, 1991, J BIOL CHEM, V266, P12201; CONSTANTINIDES PP, 1985, J BIOL CHEM, V260, P7573; DAS AK, 1984, BIOCHIM BIOPHYS ACTA, V796, P178, DOI 10.1016/0005-2760(84)90346-1; DAS AK, 1989, LIPIDS, V24, P329, DOI 10.1007/BF02535172; DAVIS PA, 1981, ARCH BIOCHEM BIOPHYS, V211, P20, DOI 10.1016/0003-9861(81)90424-0; DECLERCQ PE, 1984, J BIOL CHEM, V259, P9064; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; GHOSH MK, 1986, ARCH BIOCHEM BIOPHYS, V245, P523, DOI 10.1016/0003-9861(86)90245-6; GHOSH MK, 1986, ANAL BIOCHEM, V159, P169, DOI 10.1016/0003-2697(86)90323-4; GLATZ JFC, 1989, MOL CELL BIOCHEM, V88, P37, DOI 10.1007/BF00223421; Hajra A K, 1988, Prog Clin Biol Res, V282, P99; HAJRA AK, 1968, BIOCHEM BIOPH RES CO, V33, P929, DOI 10.1016/0006-291X(68)90401-4; HAJRA AK, 1974, LIPIDS, V9, P502, DOI 10.1007/BF02532495; HAJRA AK, 1982, ANN NY ACAD SCI, V386, P170, DOI 10.1111/j.1749-6632.1982.tb21415.x; HAJRA AK, 1978, J NEUROCHEM, V31, P125, DOI 10.1111/j.1471-4159.1978.tb12440.x; HAJRA AK, 1983, CHEM PHYS LIPIDS, V33, P179, DOI 10.1016/0009-3084(83)90020-8; HAJRA AK, 1979, J BIOL CHEM, V254, P896; HAJRA AK, 1986, ENZYMES LIPID METABO, V2, P199; Haldar D, 1983, Trans N Y Acad Sci, V41, P173; HALDAR D, 1990, J BIOL CHEM, V265, P11014; HARDEMAN D, 1988, BIOCHIM BIOPHYS ACTA, V963, P1, DOI 10.1016/0005-2760(88)90331-1; HARDEMAN D, 1989, BIOCHIM BIOPHYS ACTA, V1006, P1, DOI 10.1016/0005-2760(89)90315-9; HORIE S, 1987, FASEB J, V46, P2287; HSU KHL, 1975, P NATL ACAD SCI USA, V72, P4729, DOI 10.1073/pnas.72.12.4729; JONES CL, 1980, J BIOL CHEM, V255, P8289; Kennedy E. P., 1986, LIPIDS MEMBRANES PRE, P171; KIYASU JY, 1963, J BIOL CHEM, V238, P2293; LABELLE EF, 1972, J BIOL CHEM, V247, P5835; LEHNINGER AL, 1982, PRINCIPLES BIOCH, P373; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNAERTS GP, 1982, BIOCHEM J, V204, P17, DOI 10.1042/bj2040017; NOVIKOFF AB, 1982, ANN NY ACAD SCI, V386, P138, DOI 10.1111/j.1749-6632.1982.tb21412.x; PETERS TJ, 1972, J EXP MED, V136, P1117, DOI 10.1084/jem.136.5.1117; POWELL GL, 1981, J BIOL CHEM, V256, P2740; RABERT U, 1986, BIOL CHEM H-S, V367, P215, DOI 10.1515/bchm3.1986.367.1.215; ROCK CO, 1977, J BIOL CHEM, V252, P6363; Schenkman J B, 1978, Methods Enzymol, V52, P83; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; Simoni R D, 1988, Prog Clin Biol Res, V282, P29; SMITH RH, 1986, ARCH BIOCHEM BIOPHYS, V244, P357, DOI 10.1016/0003-9861(86)90124-4; Tanford C., 1980, HYDROPHOBIC EFFECT F, P63; TIPPETT PS, 1982, J BIOL CHEM, V257, P2839; VANCURA A, 1991, BIOCHEM BIOPH RES CO, V175, P339, DOI 10.1016/S0006-291X(05)81240-9; VANDENBOSCH H, 1974, ANNU REV BIOCHEM, V43, P243; WILGRAM GF, 1963, J BIOL CHEM, V238, P2615; WILLIAMS CH, 1962, J BIOL CHEM, V237, P587; WOLDEGIORGIS G, 1985, ANAL BIOCHEM, V150, P8, DOI 10.1016/0003-2697(85)90434-8; ZAHLER WL, 1968, BIOCHIM BIOPHYS ACTA, V164, P1, DOI 10.1016/0005-2760(68)90065-9; ZAHLER WL, 1969, BIOCHIM BIOPHYS ACTA, V176, P699, DOI 10.1016/0005-2760(69)90250-1; ZILVERSMIT DB, 1984, J LIPID RES, V25, P1563	57	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9724	9730						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577808				2022-12-25	WOS:A1992HT96500044
J	BEDOWS, E; HUTH, JR; RUDDON, RW				BEDOWS, E; HUTH, JR; RUDDON, RW			KINETICS OF FOLDING AND ASSEMBLY OF THE HUMAN CHORIONIC GONADOTROPIN-BETA SUBUNIT IN TRANSFECTED CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHORIOCARCINOMA CELLS; DISULFIDE BONDS; ALPHA-SUBUNITS; SECRETION; PROTEIN; FORM; MUTAGENESIS; ISOMERASE; CULTURES; LUTROPIN	We have employed Chinese hamster ovary (CHO) cell lines transfected with either the wild type human chorionic gonadotropin-beta (hCG-beta) gene alone (CHO beta-cells) or in conjunction with the gene expressing the alpha-subunit (CHO alpha,beta-cells) to study the folding pathway of the hCG-beta subunit. In both CHO-beta and CHO alpha,beta-cells, the earliest detectable hCG-beta precursor, p-beta-1, which had two of six potential disulfide bonds (34-88 and 38-57) formed, was converted to p-beta-2, a form that, following the formation of disulfide bonds between cysteines 9-90 and 23-72, migrated more slowly than p-beta-1 by sodium dodecyl sulfate-polyacrylamide gel electrophoresis under nonreducing conditions. The t1/2 for the conversion of p-beta-1 to p-beta-2 in CHO-alpha,beta and CHO beta-cells was 5 min, demonstrating that the alpha-subunit had no effect on the rate of this conversion. Furthermore, the tryptic-releasable peptides generated from nonreduced p-beta-1 or p-beta-2 were the same in both CHO-alpha,beta and CHO-beta cells. Thus, both the rate and order of disulfide bond formation during the conversion of the folding intermediate p-beta-1 into p-beta-2 were the same whether or not the alpha-subunit was present. A comparison between cell types expressing different alpha/beta-subunit ratios revealed that the higher the glycoprotein hormone alpha-subunit to beta-subunit ratio, the greater the rate and extent of hCG heterodimer assembly.	UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT PHARMACOL,OMAHA,NE 68198; UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Michigan System; University of Michigan					NCI NIH HHS [CA32949] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA032949] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEEBE JS, 1990, J BIOL CHEM, V265, P312; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; COLE LA, 1983, ENDOCRINOLOGY, V113, P1176, DOI 10.1210/endo-113-3-1176; Creighton T E, 1986, Methods Enzymol, V131, P83; Ellis R J, 1990, Semin Cell Biol, V1, P1; HUTH JR, 1992, J BIOL CHEM, V267, P8870; KAETZEL DM, 1988, J BIOL CHEM, V263, P6344; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; MACRI JN, 1990, AM J OBSTET GYNECOL, V163, P1248, DOI 10.1016/0002-9378(90)90700-H; MATZUK MM, 1989, J CELL BIOL, V109, P1429, DOI 10.1083/jcb.109.4.1429; MATZUK MM, 1987, P NATL ACAD SCI USA, V84, P6354, DOI 10.1073/pnas.84.18.6354; MATZUK MM, 1988, J BIOL CHEM, V263, P17106; OZTURK M, 1987, ENDOCRINOLOGY, V120, P549, DOI 10.1210/endo-120-2-549; PATTILLO RA, 1979, IN VITRO, V6, P398; PETERS BP, 1984, J BIOL CHEM, V259, P5123; RUDDON RW, 1979, P NATL ACAD SCI USA, V76, P5143, DOI 10.1073/pnas.76.10.5143; RUDDON RW, 1989, ENDOCRINOLOGY, V124, P862, DOI 10.1210/endo-124-2-862; RUDDON RW, 1987, J BIOL CHEM, V262, P12533; RUDDON RW, 1981, J BIOL CHEM, V256, P1389; RYAN RJ, 1988, FASEB J, V2, P2661, DOI 10.1096/fasebj.2.11.2456242; STRICKLAND TW, 1982, J BIOL CHEM, V257, P2954; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; Vaitukaitis J L, 1976, Recent Prog Horm Res, V32, P289	25	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8880	8886						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577726				2022-12-25	WOS:A1992HR85400030
J	JOHNSON, CA; DENSEN, P; HURFORD, RK; COLTEN, HR; WETSEL, RA				JOHNSON, CA; DENSEN, P; HURFORD, RK; COLTEN, HR; WETSEL, RA			TYPE-I HUMAN-COMPLEMENT C2 DEFICIENCY - A 28-BASE PAIR GENE DELETION CAUSES SKIPPING OF EXON-6 DURING RNA SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE; CDNA CLONING; PLASMID DNA; FACTOR-B; SITE; COMPONENT; IDENTIFICATION; EXPRESSION; MUTATION; INVITRO	Two variants of a genetic deficiency of complement protein C2 (C2D) have been previously identified. No C2 protein translation is detected in type I deficiency, while type II deficiency is characterized by a selective block in C2 secretion. Type I C2 deficiency was described in a family in which the C2 null allele (C2Q0) is associated with the major histocompatibility haplotype/complotype HLA-A25,B18,C2Q0,BfS,C4A4, C4B2,Drw2; this extended haplotype occurs in over 90% of C2-deficient individuals (common complotype/haplotype). To determine the molecular basis of type I C2 deficiency, the C2 gene and cDNA were characterized from a homozygous type I C2-deficient individual with the common associated haplotype/complotype. We found a 28-base pair deletion in the type I C2Q0 gene, beginning 9 base pairs upstream of the 3'-end of exon 6, that generates a C2 transcript with a complete deletion of exon 6 (134 base pair) and a premature termination codon. In studies of eight kindred, the 28-base pair deletion was observed in all C2Q0 alleles associated with the common type I deficient complotype/haplotype; this deletion was not present in normal C2 nor in type II C2-deficient genes. These data demonstrate that: 1) type I human complement C2 deficiency is caused by a 28-base pair genomic deletion that causes skipping of exon 6 during RNA splicing, resulting in generation of a premature termination codon, 2) the 28-base pair deletion in the type I C2Q0 gene is strongly associated with the HLA haplotype/complo-type A25,B18,C2Q0,BfS,C4A4,C4B2,Drw2, suggesting that all C2-deficient individuals with this haplotype/complotype will harbor the 28-base pair C2 gene deletion, and 3) type II C2 deficiency is caused by a different, as yet uncharacterized, molecular genetic defect.	WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110; VET ADM MED CTR,DEPT INTERNAL MED,IOWA CITY,IA 52240; UNIV IOWA,COLL MED,IOWA CITY,IA 52242	Washington University (WUSTL); Washington University (WUSTL); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Iowa			Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024739, R55AI025011, R01AI024739, R01AI024836, R01AI025011] Funding Source: NIH RePORTER; NIAID NIH HHS [AI25011, AI24836, AI24739] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALPER CA, 1987, IMMUNOL LETT, V14, P175, DOI 10.1016/0165-2478(87)90098-8; AMOS DB, 1980, NIH83545 DHEW PUBL, P42; AWDEH ZL, 1981, J CLIN INVEST, V67, P581, DOI 10.1172/JCI110070; BIRNBOIM HC, 1983, METHOD ENZYMOL, V100, P243; CAPECCHI MR, 1989, TRENDS GENET, V5, P70, DOI 10.1016/0168-9525(89)90029-2; CARROLL MC, 1984, NATURE, V307, P237, DOI 10.1038/307237a0; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FIGUEROA JE, 1991, CLIN MICROBIOL REV, V4, P359, DOI 10.1128/CMR.4.3.359-395.1991; FU SM, 1974, J EXP MED, V140, P1108, DOI 10.1084/jem.140.4.1108; GLASS D, 1976, J CLIN INVEST, V58, P853, DOI 10.1172/JCI108538; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; HAYASHI SI, 1991, NUCLEIC ACIDS RES, V19, P1267, DOI 10.1093/nar/19.6.1267; HIDAKA Y, 1987, J CLIN INVEST, V80, P1409, DOI 10.1172/JCI113219; HORIUCHI T, 1989, J IMMUNOL, V142, P2105; ISHII Y, 1991, Complement and Inflammation, V8, P167; ISHIKAWA N, 1990, J BIOL CHEM, V265, P19040; JACOB M, 1989, NUCLEIC ACIDS RES, V17, P2159, DOI 10.1093/nar/17.6.2159; JOHNSON CA, 1992, IN PRESS N ENGL J ME; KINOSHITA T, 1991, IMMUNOL TODAY, V12, P291, DOI 10.1016/0167-5699(91)90001-A; KONTUSAARI S, 1990, AM J HUM GENET, V47, P112; MARVIT J, 1987, NUCLEIC ACIDS RES, V15, P5613, DOI 10.1093/nar/15.14.5613; MATSUO M, 1991, J CLIN INVEST, V87, P2127, DOI 10.1172/JCI115244; NELSON KK, 1988, GENE DEV, V2, P319, DOI 10.1101/gad.2.3.319; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; RYNES RI, 1982, ANN RHEUM DIS, V41, P93, DOI 10.1136/ard.41.1.93; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; TREISMAN R, 1982, CELL, V29, P903, DOI 10.1016/0092-8674(82)90452-4; VASAN NS, 1991, AM J HUM GENET, V48, P305; WEIL D, 1988, J BIOL CHEM, V263, P8561; WETSEL RA, 1990, J BIOL CHEM, V265, P2435; WOODS DE, 1984, J CLIN INVEST, V74, P634, DOI 10.1172/JCI111461; ZITNAN D, 1988, RHEUMATOLOGIA, V2, P15; [No title captured]	38	97	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9347	9353						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577763				2022-12-25	WOS:A1992HR85400098
J	SOBEL, M; SOLER, DF; KERMODE, JC; HARRIS, RB				SOBEL, M; SOLER, DF; KERMODE, JC; HARRIS, RB			LOCALIZATION AND CHARACTERIZATION OF A HEPARIN BINDING DOMAIN PEPTIDE OF HUMAN VONWILLEBRAND-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; COLLAGEN	Human von Willebrand factor, a plasma glycoprotein which plays a critical role in regulating hemostasis, binds heparin, but the physiological importance and mode of this interaction is poorly understood. Using the motif of an amino acid sequence of a consensus heparin binding synthetic peptide, a 23-residue sequence (Tyr565-Ala587) of human von Willebrand factor was identified that retains the consensus motif and binds heparin with affinity comparable with native von Willebrand factor and the consensus peptide. In a fluid phase binding assay, the Tyr566-Ala587 peptide competed effectively with von Willebrand factor for binding heparin. Synthesis and testing of peptides overlapping Tyr565-Ala587, as well as adjacent cationic regions, showed this core sequence to be the optimal linear binding domain. Far ultraviolet circular dichroism spectrometry of the Tyr566-Ala587 peptide suggested that the peptide undergoes conformational change upon binding heparin. The Tyr565-Ala587 peptide thus encompasses part (or all) of a functionally important heparin binding domain of von Willebrand factor. Further study of this and related peptides may be useful for exploring how heparin may influence von Willebrand factor-mediated platelet hemostasis.	VIRGINIA COMMONWEALTH UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, RICHMOND, VA 23298 USA	Virginia Commonwealth University	SOBEL, M (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA,DEPT SURG,DIV VASC SURG,BOX 108, MCV STN, RICHMOND, VA 23298 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039903, R29HL039903] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024933] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL39903] Funding Source: Medline; NINDS NIH HHS [NS 24933] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; FUJIMURA Y, 1987, J BIOL CHEM, V262, P1734; FURLAN M, 1986, BLUT, V52, P329, DOI 10.1007/BF00320779; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KUHN LA, 1990, P NATL ACAD SCI USA, V87, P8506, DOI 10.1073/pnas.87.21.8506; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MCCARTHY JB, 1989, Patent No. 4839464; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MOHRI H, 1989, J BIOL CHEM, V264, P17361; MOROOSE R, 1986, ANNU REV MED, V37, P157; RUGGERI ZM, 1987, BLOOD, V70, P895; SOBEL M, 1991, J CLIN INVEST, V87, P1787, DOI 10.1172/JCI115198; SOBEL M, 1988, CLIN RES, V36, pA420; SOBEL M, 1991, ACS SYM SER, V469, P60; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; VILLANUEVA GB, 1984, J BIOL CHEM, V259, P2531	17	166	169	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8857	8862						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577724				2022-12-25	WOS:A1992HR85400027
J	OBLONG, JE; LAMPPA, GK				OBLONG, JE; LAMPPA, GK			PRECURSOR FOR THE LIGHT-HARVESTING CHLOROPHYLL A/B-BINDING PROTEIN SYNTHESIZED IN ESCHERICHIA-COLI BLOCKS IMPORT OF THE SMALL SUBUNIT OF RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE OXYGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLAST IMPORT; TRANSLOCATION; MEMBRANE; RECEPTOR; ENZYME	When synthesized in Escherichia coli, the light-harvesting chlorophyll a/b-binding protein (LHCP) precursor accumulates in inclusion-like bodies (Abad, M. S., Oblong, J. E., and Lamppa, G. K. (1991) Plant Physiol. 96, 1220-1227). In this study we show that after solubilization in 6 M urea and dialysis into 20 mM Tris-HCl (pH 8.0) the recombinant LHCP precursor (preLHCP) was not found as a monomer (31 kDa), but instead produced a heterogeneous population of oligomeric complexes, ranging from 60-300 kDa as determined by gel filtration chromatography. Circular dichroism analysis indicated that the oligomers had folded structure, and that it was composed of both alpha-helix and beta-sheet. Approximately half of recombinant preLHCP found in these complexes was cleavable at the transit peptide-mature protein junction by a soluble chloroplast-processing enzyme in an organelle-free reaction. At 1.5-mu-M the recombinant precursor inhibited the import of radiolabeled preLHCP and the precursor of the small subunit of ribulose-1,5-bisphosphate carboxylase/oxygenase generated by reticulocyte lysate translations. When chloroplasts were preincubated with the precursor, followed by their reisolation, import was still blocked, providing evidence that competition between recombinant preLHCP and these substrates occurred at the chloroplast per se. Recombinant preLHCP was visualized on the envelope by immunofluorescence microscopy, and its presence there was mediated by a thermolysin-sensitive factor.	UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637	University of Chicago					NIGMS NIH HHS [GM36419] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036419] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABAD MS, 1989, PLANT PHYSIOL, V90, P117, DOI 10.1104/pp.90.1.117; ABADMS, 1991, PLANT PHYSIOL, V96, P1220; BARTLETT SG, 1982, METHODS CHLOROPLAST, P1081; BUVINGER WE, 1989, J BIOL CHEM, V264, P1195; Cantor C.R., 1980, BIOPHYSICAL CHEM 2; CLARK SE, 1989, J BIOL CHEM, V264, P17544; CLARK SE, 1991, J CELL BIOL, V114, P681, DOI 10.1083/jcb.114.4.681; CLARK SE, 1990, PLANT CELL, V2, P173, DOI 10.1105/tpc.2.2.173; CLINE K, 1985, J BIOL CHEM, V260, P3691; CORNWELL KL, 1987, PLANT PHYSIOL, V85, P780, DOI 10.1104/pp.85.3.780; FLUGGE UI, 1991, NATURE, V353, P364, DOI 10.1038/353364a0; HARLOW E, 1988, ANTIBODIES LABORATOR; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; KUHLBRANDT W, 1991, NATURE, V350, P130, DOI 10.1038/350130a0; LAMPPA GK, 1985, MOL CELL BIOL, V5, P1370, DOI 10.1128/MCB.5.6.1370; LAMPPA GK, 1987, J CELL BIOL, V105, P2641, DOI 10.1083/jcb.105.6.2641; PAIN D, 1988, NATURE, V331, P232, DOI 10.1038/331232a0; PERRY SE, 1991, J BIOL CHEM, V266, P11882; PICK U, 1982, METHODS CHLOROPLAST, P873; PILON M, 1990, J BIOL CHEM, V265, P3358; SCHNELL DJ, 1990, J CELL BIOL, V111, P1825, DOI 10.1083/jcb.111.5.1825; SCHNELL DJ, 1991, J BIOL CHEM, V266, P3335; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x; WAEGEMANN K, 1990, FEBS LETT, V261, P89, DOI 10.1016/0014-5793(90)80643-W	25	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14328	14334						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629223				2022-12-25	WOS:A1992JD32500083
J	YANAGAWA, H; OGAWA, Y; UENO, M				YANAGAWA, H; OGAWA, Y; UENO, M			REDOX RIBONUCLEOSIDES - ISOLATION AND CHARACTERIZATION OF 5-HYDROXYURIDINE, 8-HYDROXYGUANOSINE, AND 8-HYDROXYADENOSINE FROM TORULA YEAST RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE; OXYGEN RADICALS; DNA; EVOLUTION; ORIGIN; DAMAGE; LIFE; CATALYSIS; RADIATION; REPAIR	Three hydroxyribonucleosides catalyzing the oxido-reduction of NADH and K3Fe(CN)6 were purified from Torula yeast RNA by a series of steps including sodium dodecyl sulfate/phenol extraction, nuclease P1 digestion, alkaline phosphatase digestion, anion-exchange chromatography, and high performance liquid chromatography on an ODS column. Analysis by fast atom bombardment-mass spectrometry and H-1 and C-13 NMR spectroscopy led to identification of the redox ribonucleosides as 5-hydroxyuridine, 8-hydroxyguanosine, and 8-hydroxyadenosine. Their mass spectra, chromatographic behavior, UV spectra, NMR spectra, and IR spectra were identical to those from natural and synthetic sources. Oxidoreduction activities were specific for K3Fe(CN)6 as the oxidant and NADH as the reductant; and their magnitudes decreased in the order 5-hydroxycytidine, 5-hydroxyuridine, 8-hydroxyguanosine, and 8-hydroxyadenosine. The fact that these nucleosides have redox activities suggests new functional roles for RNAs as catalysts.	TOHOKU UNIV,FAC SCI,CTR INSTRUMENTAL ANAL,SENDAI,MIYAGI 980,JAPAN	Tohoku University	YANAGAWA, H (corresponding author), MITSUBISHI KASEI INST LIFE SCI,11 MINAMIOOYA,MACHIDA,TOKYO 194,JAPAN.							BECK MT, 1977, NATURWISSENSCHAFTEN, V64, P91, DOI 10.1007/BF00437354; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.biochem.55.1.599; CECH TR, 1981, CELL, V27, P487, DOI 10.1016/0092-8674(81)90390-1; CHILDERSPETERSON T, 1987, ANAL CHIM ACTA, V202, P167, DOI 10.1016/S0003-2670(00)85912-7; CROSS CE, 1987, ANN INTERN MED, V107, P526, DOI 10.7326/0003-4819-107-4-526; CUTLER RG, 1985, P NATL ACAD SCI USA, V82, P4798, DOI 10.1073/pnas.82.14.4798; DAVIES DB, 1974, BIOCHEMISTRY-US, V13, P4417, DOI 10.1021/bi00718a027; DIZDAROGLU M, 1985, ANAL BIOCHEM, V144, P593, DOI 10.1016/0003-2697(85)90158-7; DIZDAROGLU M, 1986, BIOCHEM J, V235, P531, DOI 10.1042/bj2350531; EGAMI F, 1974, J MOL EVOL, V4, P113, DOI 10.1007/BF01732017; FIALA ES, 1989, CANCER RES, V49, P5518; FLOYD RA, 1990, CARCINOGENESIS, V11, P1447, DOI 10.1093/carcin/11.9.1447; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; HAJDU J, 1977, BIOCHEMISTRY-US, V16, P2841, DOI 10.1021/bi00632a006; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HARTMAN H, 1975, J MOL EVOL, V4, P359, DOI 10.1007/BF01732537; IKEHARA M, 1968, CHEM PHARM BULL, V16, P1330; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; KAMALUDDIN MS, 1986, ORIGINS LIFE EVOL B, V17, P59, DOI 10.1007/BF01809813; KAPLAN F, 1969, ARCH BIOCHEM BIOPHYS, V132, P91, DOI 10.1016/0003-9861(69)90340-3; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; KASAI H, 1984, JPN J CANCER RES, V75, P1037; LIS AW, 1966, ARCH BIOCHEM BIOPHYS, V114, P593, DOI 10.1016/0003-9861(66)90384-5; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; Michaelis L, 1938, CHEM REV, V22, P437, DOI 10.1021/cr60073a003; OREILLY JE, 1973, BIOCHIM BIOPHYS ACTA, V292, P509, DOI 10.1016/0005-2728(73)90001-7; Orgel L. E., 1974, ORIGIN LIFE EVOLUTIO, P369; PACE NR, 1985, ORIGINS LIFE EVOL B, V16, P97, DOI 10.1007/BF01809465; RODKEY FL, 1955, J BIOL CHEM, V213, P777; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; STARK BC, 1978, P NATL ACAD SCI USA, V75, P3717, DOI 10.1073/pnas.75.8.3717; SYMONS RH, 1989, TRENDS BIOCHEM SCI, V14, P445, DOI 10.1016/0968-0004(89)90103-5; UHL W, 1983, NUCLEIC ACIDS RES, V11, P1167, DOI 10.1093/nar/11.4.1167; VISSER W, 1968, SYNTHETIC PROCEDURES, V1, P428; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; WHITE HB, 1976, J MOL EVOL, V7, P101, DOI 10.1007/BF01732468; YAMANO T, 1964, ARCH BIOCHEM BIOPHYS, V106, P360, DOI 10.1016/0003-9861(64)90201-2; YANAGAWA H, 1990, BIOCHEMISTRY-US, V29, P10585, DOI 10.1021/bi00499a002	39	115	115	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13320	13326						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618833				2022-12-25	WOS:A1992JB74600038
J	AKAKI, Y; HOTTA, Y; MASHIMA, Y; MURAKAMI, A; KENNAWAY, NG; WELEBER, RG; INANA, G				AKAKI, Y; HOTTA, Y; MASHIMA, Y; MURAKAMI, A; KENNAWAY, NG; WELEBER, RG; INANA, G			A DELETION IN THE ORNITHINE AMINOTRANSFERASE GENE IN GYRATE ATROPHY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; DELTA-AMINOTRANSFERASE; NONSENSE MUTATIONS; THALASSEMIA GENE; RETINA; FAMILY; DEFECT; DNA; BREAKPOINTS; DEFICIENCY	Gyrate atrophy (GA) is an autosomal recessive chorioretinal degenerative disease of the eye caused by an inborn defect of the nuclear encoded mitochondrial enzyme ornithine aminotransferase (OAT). We have described previously a GA patient with a 5.0-kilobase pair truncated EcoRI OAT gene fragment and the absence of OAT mRNA on Northern blot analysis. Cloning and sequencing analysis of the truncated gene fragment revealed a 1,072-base pair (bp) deletion including the entire exon 6, starting in intron 5, 172 bp upstream of exon 6 and ending in intron 6, 772 bp downstream of exon 6. A short direct repeat sequence (AGGAGC), resembling the sequence shown to cause DNA polymerase-alpha to pause, and sequences capable of forming hairpin loops were both present at the 5' and 3' break-points of the deletion. Reverse transcription-polymerase chain reaction amplification of the patient's RNA with OAT primers yielded DNA fragments of two different sizes, consistent with a low level expression of OAT mRNA. Direct sequencing of the smaller fragment demonstrated the complete absence of exon 6 sequence in the mRNA predicted from the deletion, causing a reading frame shift which results in a premature termination codon at position 192. The mutation in the other allele has been demonstrated by polymerase chain reaction, denaturing gradient gel electrophoresis, and direct sequencing also to be a premature termination codon in exon 6. The absence of detectable OAT mRNA in this patient is consistent with these premature termination mutations because they have been shown to decrease the level of mRNA, especially if present early in the coding sequence.	UNIV MIAMI, SCH MED, BASCOM PALMER EYE INST, 1638 NW 10TH AVE, MIAMI, FL 33136 USA; OREGON HLTH SCI UNIV, DEPT OPHTHALMOL, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT MOLEC & MED GENET, PORTLAND, OR 97201 USA	Bascom Palmer Eye Institute; University of Miami; Oregon Health & Science University; Oregon Health & Science University			Hotta, Yoshihiro/O-5115-2019	Hotta, Yoshihiro/0000-0003-4052-5066	NATIONAL EYE INSTITUTE [R01EY008904] Funding Source: NIH RePORTER; NEI NIH HHS [EY08904] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALBERTINI AM, 1982, CELL, V29, P319, DOI 10.1016/0092-8674(82)90148-9; ANAND R, 1988, BLOOD, V72, P636; BASERGA SJ, 1988, P NATL ACAD SCI USA, V85, P2056, DOI 10.1073/pnas.85.7.2056; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CANNING S, 1989, P NATL ACAD SCI USA, V86, P5044, DOI 10.1073/pnas.86.13.5044; CHALLBERG MD, 1979, J BIOL CHEM, V254, P7820; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAAR IO, 1988, MOL CELL BIOL, V8, P802, DOI 10.1128/MCB.8.2.802; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; HENTHORN PS, 1990, GENOMICS, V6, P226, DOI 10.1016/0888-7543(90)90561-8; HOTTA Y, 1989, AM J HUM GENET, V44, P353; HUMPHRIES RK, 1984, BLOOD, V64, P23; INANA G, 1988, INVEST OPHTH VIS SCI, V29, P1001; INANA G, 1986, P NATL ACAD SCI USA, V83, P1203, DOI 10.1073/pnas.83.5.1203; INANA G, 1989, J BIOL CHEM, V264, P17432; INANA G, 1983, NATURE, V302, P310, DOI 10.1038/302310a0; KADOWAKI T, 1990, P NATL ACAD SCI USA, V87, P658, DOI 10.1073/pnas.87.2.658; KENNAWAY NG, 1989, AM J HUM GENET, V44, P344; MCCLATCHEY AI, 1990, AM J HUM GENET, V47, P790; MITCHELL GA, 1988, J CLIN INVEST, V81, P630, DOI 10.1172/JCI113365; MITCHELL GA, 1988, J BIOL CHEM, V263, P14288; MITCHELL GA, 1989, P NATL ACAD SCI USA, V86, P197, DOI 10.1073/pnas.86.1.197; RAMESH V, 1988, P NATL ACAD SCI USA, V85, P3777, DOI 10.1073/pnas.85.11.3777; SPRITZ RA, 1982, NUCLEIC ACIDS RES, V10, P8025, DOI 10.1093/nar/10.24.8025; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; TAKKI KK, 1981, OPHTHALMOLOGY, V88, P292; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; VALLE D, 1989, METABOLIC BASIS INHE, P599; VANIN EF, 1983, CELL, V35, P701, DOI 10.1016/0092-8674(83)90103-4; WEAVER DT, 1982, J BIOL CHEM, V257, P2075; WELEBER RG, 1982, BIRTH DEFECTS-ORIG, V18, P219; WELEBER RG, 1988, RETINITIS PIGMENTOSA, P198; ZINTZ CB, 1990, EXP EYE RES, V50, P759, DOI 10.1016/0014-4835(90)90126-F	33	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12950	12954						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618792				2022-12-25	WOS:A1992HZ48300083
J	LUND, E; DICZFALUSY, U; BJORKHEM, I				LUND, E; DICZFALUSY, U; BJORKHEM, I			ON THE MECHANISM OF OXIDATION OF CHOLESTEROL AT C-7 IN A LIPOXYGENASE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOTOPE; ACID	Incubation of [7-H-2(2)]cholesterol with soybean lipoxygenase and linoleic acid in the presence of oxygen gave a mixture of 5-cholestene-3-beta,7-alpha-diol, 5-cholestene-3-beta, 7-beta-diol, 3-beta-hydroxy-5-cholesten-7-one,5-alpha,6-alpha-epoxy-cholestan-3-beta-ol, and 5-beta,6-beta-epoxycholestan-3-beta-ol. The conversion into the 7-oxygenated products was associated with a very high intermolecular isotope effect (K(H)/K(D) = 15-17), suggesting that the rate-limiting step in the overall conversion is likely to be the abstraction of hydrogen at C-7 in a radical reaction. Evidence that linoleic acid is to some extent directly involved was obtained with the use of [7-H-3]cholesterol. Incubation of [7-H-3]cholesterol resulted in a significant incorporation of H-3 in the reisolated linoleic acid fraction. The isotope effect associated with conversion of [7-alpha-H-2]cholesterol into 7-oxygenated products in the lipoxygenase system was 2-3, indicating that the extraction of hydrogen is nonstereospecific. Incubation of [7-H-2(2)]cholesterol with 13-hydroperoxy-9,11-octadecadienoic acid gave the above 7-oxygenated products with relatively small isotope effects (K(H)/K(D) = 3-4). It is concluded that the most important mechanism for oxidation of cholesterol at C-7 in the lipoxygenase system involves participation of radicals and that a carbon-centered linoleic acid radical can extract hydrogen directly from cholesterol. Fatty acid hydroperoxides and their secondary products seem to be less important as initiators in connection with oxidation of cholesterol.	KAROLINSKA INST,HUDDINGE HOSP,DEPT CLIN CHEM,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet			Diczfalusy, Ulf/A-5336-2008	Bjorkhem, Ingemar/0000-0001-6087-9190; Bjorkhem, Ingemar/0000-0002-0575-9425				ARINGER L, 1980, LIPIDS, V15, P563, DOI 10.1007/BF02534180; BIEMANN K, 1966, MASS SPECTROMETRY OR, P204; BJORKHEM I, 1988, J LIPID RES, V29, P136; BJORKHEM I, 1971, EUR J BIOCHEM, V18, P299; COREY EJ, 1958, J AM CHEM SOC, V81, P3127; EGMOND MR, 1973, BIOCHEM BIOPH RES CO, V54, P1178, DOI 10.1016/0006-291X(73)90816-4; GIROTTI AW, 1985, FREE RAD BIOL, V5, P1; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HAMBERG M, 1967, J BIOL CHEM, V242, P5329; HAMBERG M, 1984, BIOCHIM BIOPHYS ACTA, V793, P129, DOI 10.1016/0005-2760(84)90062-6; JOHANSSON G, 1971, EUR J BIOCHEM, V21, P68, DOI 10.1111/j.1432-1033.1971.tb01441.x; KALUZNY MA, 1985, J LIPID RES, V26, P135; MAKITA A, 1973, ANAL BIOCHEM, V5, P523; MELANDER L, 1960, ISOTOPE EFFECTS REAC, P65; NORTHROP DB, 1981, ANNU REV BIOCHEM, V50, P103, DOI 10.1146/annurev.bi.50.070181.000535; NORTHROP DB, 1975, BIOCHEMISTRY-US, V14, P2644, DOI 10.1021/bi00683a013; SCHENCK GO, 1957, LIEBIGS ANN CHEM, V603, P46; SMITH LL, 1981, CHOLESTEROL AUTOOXID, P214; TENG JI, 1973, J AM CHEM SOC, V95, P4060, DOI 10.1021/ja00793a045; TENG JI, 1976, BIOORG CHEM, V5, P99, DOI 10.1016/0045-2068(76)90017-1	20	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12462	12467						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618753				2022-12-25	WOS:A1992HZ48300016
J	REN, SL; SCARSDALE, JN; ARIGA, T; ZHANG, YJ; KLEIN, RA; HARTMANN, R; KUSHI, Y; EGGE, H; YU, RK				REN, SL; SCARSDALE, JN; ARIGA, T; ZHANG, YJ; KLEIN, RA; HARTMANN, R; KUSHI, Y; EGGE, H; YU, RK			O-ACETYLATED GANGLIOSIDES IN BOVINE BUTTERMILK - CHARACTERIZATION OF 7-O-ACETYL, 9-O-ACETYL, AND 7,9-DI-O-ACETYL G(D3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANOMA-ASSOCIATED GANGLIOSIDE; FAT GLOBULE-MEMBRANE; GERMINAL CELLS; PROTON NMR; ANTIBODY; MILK; ANTIGENS; RAT; DETERMINANT; ACID	Three O-acetylated gangliosides, G1, G2, and G3, were purified from bovine buttermilk by using chloroform/methanol methanol extraction, Folch partitioning, chromatography on DEAE-Sephadex A-25, and Iatrobeads columns. The final yields of gangliosides G1, G2, and G3 were 2 mg, 37 mg, and 40 mg per 1.7 kg of the buttermilk powder, respectively. On the basis of immunostaining on high performance thin layer chromatography with specific monoclonal antibodies, mild alkaline treatment, gas-liquid chromatographic analysis, fast atom bombardment mass spectrometry, and proton nuclear magnetic resonance studies, G1 and G2 are characterized as O-acetylated G(D3) and G3 as O-acetylated G(T3), and the structures of these gangliosides are as follows: [GRAPHICS] The major fatty acids of these gangliosides were C18:0, C22:0, C23:0, and C24:0, and the long chain base was C18-sphingosine.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT BIOCHEM & MOLEC BIOPHYS,RICHMOND,VA 23298; TOKYO MED & DENT UNIV,DEPT BIOCHEM,TOKYO 113,JAPAN; UNIV BONN,INST PHYSIOL CHEM,W-5300 BONN,GERMANY	Virginia Commonwealth University; Tokyo Medical & Dental University (TMDU); University of Bonn			Hartmann, Rudolf/H-9345-2017	Hartmann, Rudolf/0000-0001-7807-6273	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011853, R01NS023102, R01NS026994] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-11853, NS 26994, NS-23102] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDO S, 1989, J BIOL CHEM, V264, P3478; ARIGA T, 1988, BIOCHEMISTRY-US, V27, P52, DOI 10.1021/bi00401a010; BLUM AS, 1987, P NATL ACAD SCI USA, V84, P8716, DOI 10.1073/pnas.84.23.8716; BONAFEDE DM, 1989, LIPIDS, V24, P680, DOI 10.1007/BF02535204; CHERESH DA, 1984, SCIENCE, V225, P844, DOI 10.1126/science.6206564; CHERESH DA, 1984, J BIOL CHEM, V259, P7453; CHOU DKH, 1990, J NEUROCHEM, V54, P1598, DOI 10.1111/j.1471-4159.1990.tb01210.x; CONSTANTINEPATON M, 1986, NATURE, V324, P459, DOI 10.1038/324459a0; DRAZBA J, 1991, DEV BIOL, V145, P154, DOI 10.1016/0012-1606(91)90221-N; DUBOIS C, 1990, J BIOL CHEM, V265, P2797; FOLCH J, 1957, J BIOL CHEM, V226, P139; HIRABAYASHI Y, 1989, NEUROSCI LETT, V106, P193, DOI 10.1016/0304-3940(89)90225-5; HUANG RTC, 1973, BIOCHIM BIOPHYS ACTA, V306, P82, DOI 10.1016/0005-2760(73)90211-7; KASAI N, 1983, BRAIN RES, V277, P155, DOI 10.1016/0006-8993(83)90918-6; KASAI N, 1984, J BIOCHEM-TOKYO, V96, P261, DOI 10.1093/oxfordjournals.jbchem.a134821; KEENAN TW, 1974, BIOCHIM BIOPHYS ACTA, V337, P255, DOI 10.1016/0005-2760(74)90207-0; LEDEEN RW, 1982, METHOD ENZYMOL, V83, P139; LEVINE JM, 1984, J NEUROSCI, V4, P820; LEVINE JM, 1986, DEV BRAIN RES, V27, P211, DOI 10.1016/0165-3806(86)90247-6; MCPHERSON AV, 1983, J DAIRY RES, V50, P107, DOI 10.1017/S0022029900032581; MENDEZOTERO R, 1988, J NEUROSCI, V8, P564; MUCHMORE EA, 1987, SCIENCE, V236, P1293, DOI 10.1126/science.3589663; OSTRANDER GK, 1991, ARCH BIOCHEM BIOPHYS, V284, P413, DOI 10.1016/0003-9861(91)90317-C; PATTON S, 1975, BIOCHIM BIOPHYS ACTA, V415, P273, DOI 10.1016/0304-4157(75)90011-8; RAVINDRANATHS MH, 1988, J BIOL CHEM, V263, P2079; REID PE, 1984, HISTOCHEM J, V16, P235, DOI 10.1007/BF01003608; REN S, 1989, CANCER RES, V49, P7051; RITTER G, 1990, CANCER RES, V50, P1403; ROGERS GN, 1986, J BIOL CHEM, V261, P5947; Rosenberg Abraham, 1976, BIOL ROLES SIALIC AC; SCHAUER R, 1982, CELL BIOL MONOGR, V10, P32; SCHLOSSHAUER B, 1988, J NEUROSCI, V8, P580; SPARROW JR, 1988, J NEUROSCI, V8, P580; STALLCUP WB, 1989, DEV BIOL, V132, P212, DOI 10.1016/0012-1606(89)90218-2; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; TAKAMIZAWA K, 1986, J BIOL CHEM, V261, P5625; THURIN J, 1985, J BIOL CHEM, V260, P4556; VARKI A, 1991, CELL, V65, P65, DOI 10.1016/0092-8674(91)90408-Q; YU RK, 1986, CHEM PHYS LIPIDS, V42, P27, DOI 10.1016/0009-3084(86)90041-1; 1978, BIOCHEM J, V171, P21	41	60	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12632	12638						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618769				2022-12-25	WOS:A1992HZ48300041
J	REMACHA, M; SANTOS, C; BERMEJO, B; NARANDA, T; BALLESTA, JPG				REMACHA, M; SANTOS, C; BERMEJO, B; NARANDA, T; BALLESTA, JPG			STABLE BINDING OF THE EUKARYOTIC ACIDIC PHOSPHOPROTEINS TO THE RIBOSOME IS NOT AN ABSOLUTE REQUIREMENT FOR INVIVO PROTEIN-SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; IMMUNE ELECTRON-MICROSCOPY; ESCHERICHIA-COLI; LARGE SUBUNIT; ARTEMIA-SALINA; 60S RIBOSOMES; RAT-LIVER; GENES; TRANSFORMATION; FAMILY	The genes encoding the four acidic ribosomal phosphoproteins have been inactivated in Saccharomyces cerevisae by recombination with truncated genes carrying different genetic markers. By crossing single haploid disruptants, strains harboring two simultanously inactivated acidic protein genes were constructed. None of the six possible double disruptions was lethal, but the simultaneous inactivation of either YP1-alpha and YP1-beta(L44') or YP2-alpha(L44) and YP2-beta(L45) caused an important decrease in the cell growth rate. Ribosomes isolated from these slow-growing strains did not contain acidic proteins, not even the two polypeptides whose genes were still intact, although these proteins were present in the cell extracts and they seem to be able to form high-molecular weight protein complexes. Transformation of a slow-growing double transformant with a plasmid containing one of the disrupted genes restored the presence of the acidic proteins in the ribosomes and normal growth rates. The particles of the slow-growing strains were active in an in vitro amino acid polymerizing system, although their activity could be stimulated by the exogenous addition of the missing proteins. These results indicate that in the absence of either YP1-alpha and YP1-beta(L44') or YP2-alpha(L44) and YP2-beta(L45), the remaining acidic proteins are unable to interact with the ribosome in a stable manner, but that a strong interaction of these ribosomal components with the particle is not an absolute requirement for in vivo and in vitro protein synthesis.	UNIV AUTONOMA MADRID,E-28049 MADRID,SPAIN	Autonomous University of Madrid	REMACHA, M (corresponding author), CSIC,CTR BIOL MOLEC,MADRID 6,SPAIN.		Remacha, Miguel/G-1250-2016; Santos, Cruz/ABG-3054-2020	Santos, Cruz/0000-0001-5164-5050				BELTRAME M, 1990, MOL CELL BIOL, V10, P2341, DOI 10.1128/MCB.10.5.2341; BERNABEU C, 1976, EUR J BIOCHEM, V69, P233, DOI 10.1111/j.1432-1033.1976.tb10878.x; BURGERS PMJ, 1987, ANAL BIOCHEM, V163, P391, DOI 10.1016/0003-2697(87)90240-5; GUDKOV AT, 1980, FEBS LETT, V109, P34, DOI 10.1016/0014-5793(80)81305-6; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JUANVIDALES F, 1984, BIOCHEMISTRY-US, V23, P390; KOTELIANSKY VE, 1978, EUR J BIOCHEM, V90, P319, DOI 10.1111/j.1432-1033.1978.tb12607.x; LAVERGNE JP, 1987, FEBS LETT, V216, P83, DOI 10.1016/0014-5793(87)80761-5; MAASSEN JA, 1981, BIOCHEMISTRY-US, V20, P1020, DOI 10.1021/bi00507a057; MARQUIS DM, 1981, J MOL BIOL, V150, P121, DOI 10.1016/0022-2836(81)90327-2; MCCONNELL WP, 1982, J BIOL CHEM, V257, P5359; MITSUI K, 1989, BIOCHEM BIOPH RES CO, V161, P1001, DOI 10.1016/0006-291X(89)91342-9; MITSUI K, 1988, J BIOCHEM-TOKYO, V104, P908, DOI 10.1093/oxfordjournals.jbchem.a122581; MITSUI K, 1988, NUCLEIC ACIDS RES, V16, P3574, DOI 10.1093/nar/16.8.3574; MOLLER W, 1975, P NATL ACAD SCI USA, V72, P4744, DOI 10.1073/pnas.72.12.4744; Moller W., 1986, STRUCTURE FUNCTION G, P309; NARANDA T, 1991, P NATL ACAD SCI USA, V88, P10563, DOI 10.1073/pnas.88.23.10563; NEWTON CH, 1990, J BACTERIOL, V172, P579, DOI 10.1128/jb.172.2.579-588.1990; OLSON HM, 1986, J BIOL CHEM, V261, P6924; RADERMACHER M, 1987, EMBO J, V6, P1107, DOI 10.1002/j.1460-2075.1987.tb04865.x; REMACHA M, 1990, MOL CELL BIOL, V10, P2182, DOI 10.1128/MCB.10.5.2182; REMACHA M, 1988, J BIOL CHEM, V263, P9094; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAENZROBLES MT, 1990, BIOCHIM BIOPHYS ACTA, V1050, P51, DOI 10.1016/0167-4781(90)90140-W; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZMADRID F, 1979, EUR J BIOCHEM, V98, P409, DOI 10.1111/j.1432-1033.1979.tb13200.x; SANCHEZMADRID F, 1981, BIOCHEMISTRY-US, V20, P3263, DOI 10.1021/bi00514a043; SANCHEZMADRID F, 1981, EUR J BIOCHEM, V114, P609, DOI 10.1111/j.1432-1033.1981.tb05187.x; Sherman F., 1983, METHODS YEAST GENETI; SHIMMIN LC, 1989, J MOL EVOL, V29, P448, DOI 10.1007/BF02602915; STRYCHARZ WA, 1978, J MOL BIOL, V126, P123, DOI 10.1016/0022-2836(78)90355-8; SUBRAMANIAN AR, 1975, J MOL BIOL, V95, P1, DOI 10.1016/0022-2836(75)90330-7; TSURUGI K, 1985, J BIOCHEM-TOKYO, V98, P1427, DOI 10.1093/oxfordjournals.jbchem.a135410; VANAGTHOVEN A, 1978, EUR J BIOCHEM, V91, P553; VANAGTHOVEN AJ, 1977, BIOCHEM BIOPH RES CO, V77, P989, DOI 10.1016/S0006-291X(77)80075-2; VILELLA MD, 1991, EUR J BIOCHEM, V196, P407, DOI 10.1111/j.1432-1033.1991.tb15831.x; WOOL IG, 1991, BIOCHIMIE, V73, P861, DOI 10.1016/0300-9084(91)90127-M; WOOL IG, 1974, RIBOSOMES, P417; ZINKER S, 1980, BIOCHIM BIOPHYS ACTA, V606, P76, DOI 10.1016/0005-2787(80)90099-4; ZINKER S, 1976, J BIOL CHEM, V251, P1799	41	66	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12061	12067						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601875				2022-12-25	WOS:A1992HY94700064
J	SEN, AC; WALSH, MT; CHAKRABARTI, B				SEN, AC; WALSH, MT; CHAKRABARTI, B			AN INSIGHT INTO DOMAIN-STRUCTURES AND THERMAL-STABILITY OF GAMMA-CRYSTALLINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL SCANNING CALORIMETRY; BOVINE LENS CRYSTALLINS; X-RAY-ANALYSIS; EYE-LENS; MAMMALIAN LENS; II-CRYSTALLIN; PROTEINS; DENATURATION; CATARACT; THERMODYNAMICS	The thermal behavior of gamma-II, gamma-IIIA, gamma-IIIB, and gamma-IVA crystallin, from calorimetric and spectral studies, has been analyzed in terms of selective unfolding of domains, interdomain interactions, conformational stability, and the existence of intermediates in the order-disorder transition equilibrium. The major endothermic transition (T(m)) observed calorimetrically for all four fractions occurs between 67 and 78-degrees-C, with enthalpy change (DELTA-H) from 80 to 150 kcal/mol, values that agree reasonably well with those from spectroscopic measurements. Gamma-II and gamma-IIIB show a second thermal event at T < T(m) whereas gamma-IIIA and gamma-IVA showed no additional transition. Urea-induced equilibrium unfolding of gamma-II at acidic pH, unlike gamma-IVA, is biphasic as monitored by CD and fluorescence, indicating the existence of an intermediate. The absence of a cooperative transition in gamma-IVA in acidic urea and the appearance of a single endotherm in differential scanning calorimetry at low pH have been attributed to a structured intermediate that melts at low temperature. The difference in the folding/unfolding of gamma-II and gamma-IVA has been explained by subtle differences in the packing arrangement of their two domains and interactions between them. Thermal aggregation of gamma-crystallins could be prevented either by preincubation with ionic detergents or at low pH or in the presence of chemical denaturant, indicating that the protein surface charge and solvent polarity influence their stability. An increase in the 8-anilino-1-naphthalenesulfonate-bound fluorescence during heat denaturation also suggests that the thermal aggregation is governed by hydrophobic interactions.	EYE RES INST,20 STANIFORD ST,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT OPHTHALMOL,BOSTON,MA 02115; BOSTON UNIV,SCH MED,DEPT BIOPHYS,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Harvard University; Harvard Medical School; Boston University; Boston University					NEI NIH HHS [EY04161] Funding Source: Medline; NHLBI NIH HHS [HL26335] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY004161] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL026335] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDLEY UP, 1982, BIOCHEMISTRY-US, V21, P1853, DOI 10.1021/bi00537a023; AUGUSTEYN RC, 1981, MECHANISMS CATARACT, P71; BESSEMS GJH, 1983, EXP EYE RES, V37, P627, DOI 10.1016/0014-4835(83)90137-9; BJORK I, 1964, EXP EYE RES, V3, P254, DOI 10.1016/S0014-4835(64)80018-X; BLOEMENDAL H, 1982, CRC CR REV BIOCH MOL, V12, P1, DOI 10.3109/10409238209105849; BLUNDELL T, 1981, NATURE, V289, P771, DOI 10.1038/289771a0; BROIDE ML, 1991, P NATL ACAD SCI USA, V88, P5660, DOI 10.1073/pnas.88.13.5660; CHIRGADZE YN, 1986, DOKL AKAD NAUK SSSR, V209, P492; De Jong W.W., 1981, MOL CELLULAR BIOL EY, P221, DOI DOI 10.1146/ANNUREV.ECOLSYS.33.020602.095451; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; DRENTH J, 1970, PHILOS T R SOC B, V257, P231, DOI 10.1098/rstb.1970.0022; GERNER WH, 1981, BIOCHEM BIOPH RES CO, V98, P439; HARDING JJ, 1976, EXP EYE RES, V22, P1, DOI 10.1016/0014-4835(76)90033-6; HELENIUS A, 1975, BIOCHIM BIOPHYS ACTA, V415, P29, DOI 10.1016/0304-4157(75)90016-7; JACKSON WM, 1970, BIOCHEMISTRY-US, V9, P2294, DOI 10.1021/bi00813a011; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JONES MN, 1973, BIOCHEM J, V135, P231, DOI 10.1042/bj1350231; KONO M, 1988, PHOTOCHEM PHOTOBIOL, V47, P593, DOI 10.1111/j.1751-1097.1988.tb08849.x; KONO M, 1990, BIOCHEMISTRY-US, V29, P464, DOI 10.1021/bi00454a022; LOHNER K, 1991, BIOCHEMISTRY-US, V30, P6620, DOI 10.1021/bi00240a035; MACH H, 1990, J BIOL CHEM, V265, P4844; MANDAL K, 1985, BIOCHIM BIOPHYS ACTA, V832, P156, DOI 10.1016/0167-4838(85)90327-9; MANDAL K, 1987, BIOCHIM BIOPHYS ACTA, V911, P277, DOI 10.1016/0167-4838(87)90068-9; MANDAL K, 1987, J BIOL CHEM, V262, P8096; MANDAL K, 1988, PHOTOCHEM PHOTOBIOL, V47, P583, DOI 10.1111/j.1751-1097.1988.tb08848.x; MANDAL K, 1988, BIOCHEMISTRY-US, V27, P4564, DOI 10.1021/bi00412a051; NELSON CA, 1971, J BIOL CHEM, V246, P3895; PANDE A, 1987, INVEST OPHTH VIS SCI, V30, P266; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; RUDOLPH R, 1990, P NATL ACAD SCI USA, V87, P4625, DOI 10.1073/pnas.87.12.4625; SHOENMAKERS JGG, 1984, CIBA F S, V106, P208; SHRIVER JW, 1990, BIOCHEMISTRY-US, V29, P2556, DOI 10.1021/bi00462a018; SIEZEN RJ, 1985, P NATL ACAD SCI USA, V82, P1701, DOI 10.1073/pnas.82.6.1701; SLINGSBY C, 1983, EXP EYE RES, V37, P517, DOI 10.1016/0014-4835(83)90028-3; STEADMAN BL, 1989, BIOCHEMISTRY-US, V28, P9653, DOI 10.1021/bi00451a017; STURTEVANT JM, 1987, ANNU REV PHYS CHEM, V38, P463, DOI 10.1146/annurev.pc.38.100187.002335; TIKTOPULO EI, 1978, FEBS LETT, V91, P57, DOI 10.1016/0014-5793(78)80016-7; WALSH MT, 1991, J BIOL CHEM, V266, P20079; WALSH MT, 1990, J LIPID RES, V31, P1051; WHITE HE, 1989, J MOL BIOL, V207, P217, DOI 10.1016/0022-2836(89)90452-X; WISTOW G, 1983, J MOL BIOL, V170, P175, DOI 10.1016/S0022-2836(83)80232-0	41	21	21	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11898	11907						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601859				2022-12-25	WOS:A1992HY94700040
J	CARROLL, J; SWANN, K				CARROLL, J; SWANN, K			SPONTANEOUS CYTOSOLIC CALCIUM OSCILLATIONS DRIVEN BY INOSITOL TRISPHOSPHATE OCCUR DURING INVITRO MATURATION OF MOUSE OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERMINAL VESICLE BREAKDOWN; PROTEIN KINASE-C; INTRACELLULAR CALCIUM; MAMMALIAN OOCYTES; HAMSTER EGGS; CELL-CYCLE; CA-2+; FERTILIZATION; RELEASE; ACTIVATION	Immature mouse oocytes undergo spontaneous meiotic maturation when released from antral follicles into culture media. The first sign of meiotic resumption is germinal vesicle breakdown (GVB). Cytosolic free Ca2+ was measured in mouse oocytes during spontaneous maturation by monitoring fluorescence of indo-1 or fluo-3. The majority of oocytes showed a series of Ca2+ oscillations that continued for 1-3 h. Repetitive Ca2+ increases occurred every 1-3 min and lasted for 10-60 s. The Ca2+ oscillations appeared to be caused by an increase in inositol 1,4,5-trisphosphate (InsP3) because once they ceased, similar oscillations were triggered by injection of exogenous InsP3. Also, injection of the InsP3 receptor antagonist heparin (final concentration, 100-mu-g/ml) blocked the spontaneous Ca2+ oscillations. In contrast, Ca2+ oscillations induced by thimerosal were not inhibited by heparin. Treating oocytes with media containing 20-mu-M BAPTA/AM abolished Ca2+ oscillations in oocytes but did not affect the rate of GVB. The data show that cytosolic Ca2+ oscillations apparently caused by polyphosphoinositide turnover occur during mammalian oocyte maturation. However, the spontaneous oscillations do not appear to trigger GVB. Also, the data indicate that there are two separate Ca2+ release mechanisms in mouse oocytes, one sensitive to InsP3, the other to thimerosal.			CARROLL, J (corresponding author), ST GEORGE HOSP,SCH MED,MRC,EXPTL EMBRYOL & TERATOL UNIT,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.			Carroll, John/0000-0001-9644-5861; Swann, Karl/0000-0002-4355-1449				ALBERTINI DF, 1987, DEV BIOL, V120, P121, DOI 10.1016/0012-1606(87)90110-2; ANDERSON E, 1976, J CELL BIOL, V71, P680, DOI 10.1083/jcb.71.2.680; BERRIDGE MJ, 1988, J PHYSIOL-LONDON, V403, P589, DOI 10.1113/jphysiol.1988.sp017266; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BORNSLAEGER EA, 1986, EXP CELL RES, V165, P507, DOI 10.1016/0014-4827(86)90603-8; CHO WK, 1974, J EXP ZOOL, V187, P383, DOI 10.1002/jez.1401870307; CICIRELLI MF, 1987, DEV BIOL, V121, P48, DOI 10.1016/0012-1606(87)90137-0; CUTHBERTSON KSR, 1985, NATURE, V316, P541, DOI 10.1038/316541a0; DAVIS JS, 1987, J BIOL CHEM, V262, P8515; DEFELICI M, 1982, DEV BIOL, V92, P539, DOI 10.1016/0012-1606(82)90198-1; EDWARDS RG, 1965, NATURE, V208, P349, DOI 10.1038/208349a0; EUSEBI F, 1979, NATURE, V277, P651, DOI 10.1038/277651a0; FLORES JA, 1990, ENDOCRINOLOGY, V127, P3172, DOI 10.1210/endo-127-6-3172; FULTON BP, 1978, NATURE, V273, P149, DOI 10.1038/273149a0; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOLL RW, 1988, J BIOL CHEM, V263, P9682; HOMA ST, 1991, DEV BIOL, V146, P461, DOI 10.1016/0012-1606(91)90247-Z; HOMA ST, 1991, J EXP ZOOL, V258, P95, DOI 10.1002/jez.1402580111; IGUSA Y, 1983, J PHYSIOL-LONDON, V340, P611, DOI 10.1113/jphysiol.1983.sp014783; JACONI MEE, 1988, J BIOL CHEM, V263, P10557; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; LAWRENCE TS, 1978, NATURE, V272, P501, DOI 10.1038/272501a0; LINDEN J, 1989, TRENDS PHARMACOL SCI, V10, P114, DOI 10.1016/0165-6147(89)90209-5; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MINTA A, 1989, J BIOL CHEM, V264, P8171; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MIYAZAKI S, 1991, CELL CALCIUM, V12, P205, DOI 10.1016/0143-4160(91)90021-6; MIYAZAKI S, 1988, J CELL BIOL, V106, P345, DOI 10.1083/jcb.106.2.345; MIYAZAKI S, 1988, DEV GROWTH DIFFER, V30, P603; PERES A, 1990, FEBS LETT, V275, P213, DOI 10.1016/0014-5793(90)81474-3; PERES A, 1991, CELL CALCIUM, V12, P457, DOI 10.1016/0143-4160(91)90028-D; PETERSEN OH, 1990, J MEMBRANE BIOL, V118, P93, DOI 10.1007/BF01868467; Pincus G, 1935, J EXP MED, V62, P665, DOI 10.1084/jem.62.5.665; POENIE M, 1985, NATURE, V315, P147, DOI 10.1038/315147a0; POWERS RD, 1982, J REPROD FERTIL, V66, P1, DOI 10.1530/jrf.0.0660001; RACOWSKY C, 1986, J EXP ZOOL, V239, P263, DOI 10.1002/jez.1402390214; RAKOW TL, 1990, P NATL ACAD SCI USA, V87, P9285, DOI 10.1073/pnas.87.23.9285; SCHROEDER AC, 1984, DEV BIOL, V102, P493, DOI 10.1016/0012-1606(84)90215-X; SCHULTZ RM, 1988, MEIOTIC INHIBITION M, P137; SMITH LD, 1989, DEVELOPMENT, V107, P685; STAIGMILLER RB, 1984, GAMETE RES, V9, P221, DOI 10.1002/mrd.1120090211; SWANN K, 1989, EMBO J, V8, P3711, DOI 10.1002/j.1460-2075.1989.tb08546.x; SWANN K, 1990, DEVELOPMENT, V110, P1295; SWANN K, 1991, FEBS LETT, V278, P175, DOI 10.1016/0014-5793(91)80110-O; TAKUWA Y, 1986, J BIOL CHEM, V261, P4670; THIBAULT C, 1977, J REPROD FERTIL, V51, P1; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; URNER F, 1984, EXP CELL RES, V154, P600, DOI 10.1016/0014-4827(84)90184-8; WHITAKER M, 1990, DEVELOPMENT, V108, P525; Whittingham D.G., 1980, Oxford Reviews of Reproductive Biology, V2, P205; WITCHEL HJ, 1990, DEV BIOL, V141, P393, DOI 10.1016/0012-1606(90)90393-W	54	173	180	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11196	11201						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597455				2022-12-25	WOS:A1992HX16900043
J	LIM, HM; HUGHES, KT; SIMON, MI				LIM, HM; HUGHES, KT; SIMON, MI			THE EFFECTS OF SYMMETRICAL RECOMBINATION SITE HIXC ON HIN RECOMBINASE FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-DELTA-RESOLVASE; DNA INVERSION; CROSSOVER POINT; STRAND EXCHANGE; SUPERCOILED DNA; PHASE VARIATION; ENHANCER; PROTEIN; BINDING; INVIVO	An artificial recombination site hixC composed of two identical half-sites that bind the Hin recombinase served as a better operator in vivo than the wild type site hixL (Hughes, K. T., Youderian, P., and Simon, M. I (1988) Genes & Dev. 2, 937-948). In vitro binding assays such as gel retardation assay and methylation protection assay demonstrated that Hin binds to hixC as tightly as it binds to hixL, even when the sites are located in negatively supercoiled plasmids. However, hixC served as a poor recombination site when it was subjected to the standard inversion assay in vitro. hixC showed a 16-fold slower inversion rate than the wild type. A series of biochemical assays designed to probe different stages of the Hin-mediated inversion reaction, demonstrated that Hin dimers bound to hixC have difficulty in forming paired hix site intermediates. KMnO4 and S1 nuclease assays detected an anomalous structure of the center of hixC only when the site was in negatively supercoiled plasmids. Mutational analysis in the central region of hixC and assays of paired hix site formation with topoisomers of the hixC substrate plasmid suggested that Hin is not able to pair hixC sites because of the presence of the anomalous structure in the center of the site. The structure does not behave like a DNA "cruciform" since Hin dimers still bind efficiently to the site. It is thought to consist of a short denatured "bubble" encompassing 2 base pairs. During the study of mutations in the center of hixC, it was found that Hin is not able to cleave DNA if a guanine residue is one of the two central nucleotides close to the cleavage site. Furthermore, Hin acts in a concerted fashion and cannot cleave any DNA strand if one of the four strands in the inversion intermediate is not cleavable.	CALTECH,DIV BIOL 14775,PASADENA,CA 91125; UNIV WASHINGTON,DEPT MICROBIOL,SEATTLE,WA 98195	California Institute of Technology; University of Washington; University of Washington Seattle				Lim, Heon/0000-0003-1711-2589				AFFOLTER M, 1991, CELL, V64, P879, DOI 10.1016/0092-8674(91)90311-L; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWIEC JA, 1987, J MOL BIOL, V196, P101; BRUIST MF, 1987, GENE DEV, V1, P762, DOI 10.1101/gad.1.8.762; BRUIST MF, 1984, J BACTERIOL, V159, P71, DOI 10.1128/JB.159.1.71-79.1984; FALVEY E, 1988, NATURE, V332, P861, DOI 10.1038/332861a0; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GLASGOW AC, 1989, J BIOL CHEM, V264, P10072; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HATFULL GF, 1987, CELL, V49, P103, DOI 10.1016/0092-8674(87)90760-4; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; HEICHMAN KA, 1991, GENE DEV, V5, P1622, DOI 10.1101/gad.5.9.1622; HEICHMAN KA, 1990, SCIENCE, V249, P511, DOI 10.1126/science.2166334; HUGHES KT, 1988, GENE DEV, V2, P937, DOI 10.1101/gad.2.8.937; HUGHES KT, 1992, IN PRESS EMBO J; JOHNSON RC, 1985, CELL, V41, P781, DOI 10.1016/S0092-8674(85)80059-3; JOHNSON RC, 1986, CELL, V46, P531, DOI 10.1016/0092-8674(86)90878-0; JOHNSON RC, 1984, COLD SPRING HARB SYM, V49, P751, DOI 10.1101/SQB.1984.049.01.085; JOHNSON RC, 1989, EMBO J, V8, P1581, DOI 10.1002/j.1460-2075.1989.tb03542.x; KANAAR R, 1990, CELL, V62, P353, DOI 10.1016/0092-8674(90)90372-L; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOWALSKI D, 1988, P NATL ACAD SCI USA, V85, P9464, DOI 10.1073/pnas.85.24.9464; LATHE R, 1984, DNA-J MOLEC CELL BIO, V3, P173, DOI 10.1089/dna.1984.3.173; Lilley D.M.J., 1988, UNUSUAL DNA STRUCTUR, P55, DOI 10.1007/978-1-4612-3800-3_4; LIM HM, 1988, GENE ANAL TECH, V5, P32, DOI 10.1016/0735-0651(88)90024-6; LIM HM, 1992, J BIOL CHEM, V267, P11176; MERTENS G, 1988, EMBO J, V7, P1219, DOI 10.1002/j.1460-2075.1988.tb02934.x; MOSKOWITZ IPG, 1991, GENE DEV, V5, P1635, DOI 10.1101/gad.5.9.1635; MURCHIE AIH, 1987, NUCLEIC ACIDS RES, V15, P9641, DOI 10.1093/nar/15.23.9641; RICHET E, 1986, CELL, V46, P1011, DOI 10.1016/0092-8674(86)90700-2; Sambrook J, 1989, MOL CLONING LABORATO; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; ZIEG J, 1977, SCIENCE, V196, P170, DOI 10.1126/science.322276; ZIEG J, 1980, P NATL ACAD SCI-BIOL, V77, P4196, DOI 10.1073/pnas.77.7.4196	36	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11183	11190						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597453				2022-12-25	WOS:A1992HX16900041
J	MARSHALL, BC; XU, QP; RAO, NV; BROWN, BR; HOIDAL, JR				MARSHALL, BC; XU, QP; RAO, NV; BROWN, BR; HOIDAL, JR			PULMONARY EPITHELIAL-CELL UROKINASE-TYPE PLASMINOGEN-ACTIVATOR - INDUCTION BY INTERLEUKIN-1-BETA AND TUMOR-NECROSIS-FACTOR-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NF-KAPPA-B; RESPIRATORY-DISTRESS SYNDROME; PHORBOL-MYRISTATE ACETATE; HUMAN-LUNG CARCINOMA; SMOOTH-MUSCLE CELLS; GENE-EXPRESSION; ENDOTHELIAL-CELLS; TISSUE-TYPE; SIGNAL TRANSDUCTION	Diffuse alveolar damage, presenting clinically as adult respiratory distress syndrome, is characterized initially by widespread intra-alveolar fibrin deposition. Alveolar epithelial cells play a central role in the subsequent repair process. We have recently shown that alveolar epithelial cells have the capacity to promote fibrinolysis (Marshall, B. C., Sageser, D. S., Rao, N. V., Emi, M., and Hoidal, J. R. (1990) J. Biol. Chem. 265, 8198-8204) and may therefore directly participate in the extensive remodeling that follows acute lung injury. Because the tissue repair process occurs in an acute inflammatory setting, we investigated the effects of inflammatory mediators on urokinase-type plasminogen activator (u-PA) expression by pulmonary epithelial cells. We found that interleukin-1-beta (IL-1-beta) and tumor necrosis factor-alpha (TNF-alpha) upregulated PA activity in A549 human pulmonary epithelial cells. Biosynthetic labeling and immunoprecipitation showed that both cytokines caused marked accumulation of newly synthesized u-PA. Northern blot analyses demonstrated that both IL-1-beta and TNF-alpha induced relatively rapid accumulation of u-PA mRNA which did not require de novo protein synthesis and was substantially inhibited by glucocorticoids. Nuclear run-off transcription studies showed that both cytokines caused rapid transcriptional activation of the u-PA gene. While the effects of IL-1-beta and TNF-alpha were qualitatively similar, some differences emerged. Most notably, TNF-alpha led to a more sustained accumulation of u-PA mRNA than did IL-1-beta. In contrast to their effects on u-PA expression, IL-1-beta and TNF-alpha had minimal effect on PA inhibitor-1 expression. These effects of IL-1-beta and TNF-alpha, mediators known to play a key role in acute lung injury and inflammation, may promote lysis of alveolar fibrin by alveolar epithelium, thereby aiding in restoration of normal lung architecture.	UNIV UTAH, MED CTR, DEPT MED, DIV PULM, RM 4R240, SALT LAKE CITY, UT 84132 USA	Utah System of Higher Education; University of Utah					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002370] Funding Source: NIH RePORTER; NHLBI NIH HHS [1KO8HL02370] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMSON IYR, 1974, LAB INVEST, V30, P35; ALBERTS WM, 1983, CHEST, V84, P272, DOI 10.1378/chest.84.3.272; ALTUS MS, 1987, BIOCHEM J, V242, P387, DOI 10.1042/bj2420387; ANDREWS HJ, 1990, BIOCHIM BIOPHYS ACTA, V1051, P84, DOI 10.1016/0167-4889(90)90177-F; BACHOFEN M, 1977, AM REV RESPIR DIS, V116, P589, DOI 10.1164/arrd.1977.116.4.589; BERNARD GR, 1987, NEW ENGL J MED, V317, P1565, DOI 10.1056/NEJM198712173172504; BERTOZZI P, 1990, NEW ENGL J MED, V322, P890, DOI 10.1056/NEJM199003293221304; BIRD TA, 1989, J IMMUNOL, V142, P126; BLASI F, 1986, J CELL BIOCHEM, V32, P179, DOI 10.1002/jcb.240320303; BOMSZTYK K, 1990, J BIOL CHEM, V265, P9413; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSSO N, 1986, J BIOL CHEM, V261, P9309; CAMPBELL IK, 1988, BIOCHIM BIOPHYS ACTA, V967, P183, DOI 10.1016/0304-4165(88)90008-6; CHAPMAN HA, 1988, CHEST, V93, P1256, DOI 10.1378/chest.93.6.1256; CHEDID M, 1990, MOL CELL BIOL, V10, P3824, DOI 10.1128/MCB.10.7.3824; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEGEN JL, 1985, J BIOL CHEM, V260, P2426; DONATI D, 1990, J IMMUNOL, V145, P4115; ELLIOTT CG, 1981, AM REV RESPIR DIS, V123, P492; EVANS DB, 1990, BIOCHEM BIOPH RES CO, V166, P208, DOI 10.1016/0006-291X(90)91932-I; EVANS MJ, 1973, AM J PATHOL, V70, P175; GARVEY WT, 1989, MOL ENDOCRINOL, V3, P1132, DOI 10.1210/mend-3-7-1132; GERWIN BI, 1990, AM J PHYSIOL, V259, pL262, DOI 10.1152/ajplung.1990.259.4.L262; GINSBURG D, 1986, J CLIN INVEST, V78, P1673, DOI 10.1172/JCI112761; GRANELLIPIPERNO A, 1978, J EXP MED, V148, P223, DOI 10.1084/jem.148.1.223; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROSS TJ, 1991, AM J PHYSIOL, V260, pL286, DOI 10.1152/ajplung.1991.260.4.L286; GROSS TJ, 1990, AM J RESP CELL MOL, V3, P449, DOI 10.1165/ajrcmb/3.5.449; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HEATON JH, 1989, MOL ENDOCRINOL, V3, P185, DOI 10.1210/mend-3-1-185; IDELL S, 1989, J CLIN INVEST, V84, P181, DOI 10.1172/JCI114139; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; KATZ Y, 1989, J IMMUNOL, V142, P3862; KAUR P, 1989, FEBS LETT, V258, P269, DOI 10.1016/0014-5793(89)81671-0; KEHRER JP, 1984, AM REV RESPIR DIS, V130, P256; KESKIOJA J, 1988, J CELL BIOL, V106, P451, DOI 10.1083/jcb.106.2.451; LANE TA, 1990, BIOCHEM BIOPH RES CO, V172, P1273, DOI 10.1016/0006-291X(90)91587-I; LE JM, 1987, LAB INVEST, V56, P234; LEIZER T, 1989, J IMMUNOL, V143, P971; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; LUND LR, 1991, J BIOL CHEM, V266, P5177; MACCHIA G, 1990, MOL CELL BIOL, V10, P2731, DOI 10.1128/MCB.10.6.2731; MARSHALL BC, 1990, J BIOL CHEM, V265, P8198; MEDCALF RL, 1988, J CELL BIOL, V106, P971, DOI 10.1083/jcb.106.3.971; MOCHAN E, 1986, J RHEUMATOL, V13, P15; PERLMUTTER DH, 1989, J BIOL CHEM, V264, P7669; PICONE R, 1989, J CELL BIOL, V108, P693, DOI 10.1083/jcb.108.2.693; PRATT PC, 1979, AM J PATHOL, V95, P191; RON D, 1990, MOL CELL BIOL, V10, P1023, DOI 10.1128/MCB.10.3.1023; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SALONEN EM, 1985, J BIOL CHEM, V260, P2302; SALONEN EM, 1984, FEBS LETT, V172, P29, DOI 10.1016/0014-5793(84)80866-2; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; SHAPIRO DL, 1978, BIOCHIM BIOPHYS ACTA, V530, P197, DOI 10.1016/0005-2760(78)90005-X; SHIMADA H, 1981, THROMB HAEMOSTASIS, V46, P507; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; SMITH LJ, 1981, AM REV RESPIR DIS, V123, P459; SPRENGERS ED, 1987, BLOOD, V69, P381; STANDIFORD TJ, 1991, J BIOL CHEM, V266, P9912; STANDIFORD TJ, 1990, J CLIN INVEST, V86, P1945, DOI 10.1172/JCI114928; STOPPELLI MP, 1986, J CELL BIOL, V102, P1235, DOI 10.1083/jcb.102.4.1235; VANHINSBERGH VWM, 1990, BLOOD, V75, P1991; VERDE P, 1984, P NATL ACAD SCI-BIOL, V81, P4727, DOI 10.1073/pnas.81.15.4727; VERHEIJEN JH, 1984, THROMB HAEMOSTASIS, V51, P392; VISNER GA, 1990, J BIOL CHEM, V265, P2856; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WERB Z, 1977, NEW ENGL J MED, V296, P1017, DOI 10.1056/NEJM197705052961801; WISPE JR, 1990, J CLIN INVEST, V86, P1954, DOI 10.1172/JCI114929; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	76	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11462	11469						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597474				2022-12-25	WOS:A1992HX16900080
J	CHENEVIXTRENCH, G; LEARY, J; KERR, J; MICHEL, J; KEFFORD, R; HURST, T; PARSONS, PG; FRIEDLANDER, M; KHOO, SK				CHENEVIXTRENCH, G; LEARY, J; KERR, J; MICHEL, J; KEFFORD, R; HURST, T; PARSONS, PG; FRIEDLANDER, M; KHOO, SK			FREQUENT LOSS OF HETEROZYGOSITY ON CHROMOSOME-18 IN OVARIAN ADENOCARCINOMA WHICH DOES NOT ALWAYS INCLUDE THE DCC LOCUS	ONCOGENE			English	Article							COLORECTAL CARCINOMAS; LUNG-CANCER; ALLELE LOSS; DNA; GENE; REGION; MUTATIONS; TUMORS; P53	Inactivation of the DCC gene on chromosome 18 owing to loss of heterozygosity is a common finding in colorectal cancer. Because both ovarian and colon cancer are features of Lynch syndrome II, which has been provisionally mapped to chromosome 18, we hypothesized that loss of heterozygosity at the DCC locus may also occur in ovarian neoplasia. Fifty-two sporadic ovarian adenocarcinoma tumours were analysed by Southern blotting for loss of heterozygosity (LOH) at six chromosome 18 loci. Overall, tumours from 31 patients (60%) showed allelic loss at one or more of these loci. A similarly high level of LOH, 66%, was found at D17S5 (17p13.3). In contrast, moderate levels of LOH, of 31%, 39% and 33%, were found at MYCL1 (1p32), D1S57 (1p) and D14S20 (14q32.33) respectively. However, analysis of partial chromosome deletions in 11 patients indicates that the smallest region of overlap appears to exclude the DCC gene but to be between the D18S5 and D18S11 loci. This suggests that another locus, as well as or apart from DCC, may be involved.	QUEENSLAND INST MED RES,JOINT ONCOL PROGRAMME,RES UNIT,QUEENSLAND CANC FUND,BRISBANE,AUSTRALIA; UNIV QUEENSLAND,DEPT OBSTET & GYNAECOL,BRISBANE,QLD 4000,AUSTRALIA; UNIV SYDNEY,WESTMEAD HOSP,DEPT OBSTET & GYNAECOL,SYDNEY,NSW 2006,AUSTRALIA; UNIV SYDNEY,WESTMEAD HOSP,DEPT MED,SYDNEY,NSW 2006,AUSTRALIA; PRINCE WALES HOSP,DEPT MED ONCOL,SYDNEY,NSW,AUSTRALIA	Cancer Council Queensland; QIMR Berghofer Medical Research Institute; University of Queensland; University of Sydney; University of Sydney			Chenevix-Trench, Georgia/AAV-2014-2020; Parsons, Peter/J-4683-2013	Chenevix-Trench, Georgia/0000-0002-1878-2587; Kefford, Richard/0000-0001-9251-9229; Parsons, Peter/0000-0002-0473-3346				ATKIN NB, 1987, CANCER GENET CYTOGEN, V26, P355, DOI 10.1016/0165-4608(87)90070-7; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; BERTELSEN K, 1987, GYNECOL ONCOL, V28, P161, DOI 10.1016/0090-8258(87)90210-1; BOMAN BM, 1988, CANCER GENET CYTOGEN, V34, P153, DOI 10.1016/0165-4608(88)90182-3; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; DEVILEE P, 1991, ONCOGENE, V6, P311; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; ECCLES DM, 1990, ONCOGENE, V5, P1599; EHLEN T, 1990, ONCOGENE, V5, P219; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOULKES W, 1991, LANCET, V338, P444, DOI 10.1016/0140-6736(91)91065-3; GENDLER SJ, 1990, INT J CANCER, V45, P431, DOI 10.1002/ijc.2910450309; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEBEAU MM, 1989, CYTOGENET CELL GENET, V51, P338, DOI 10.1159/000132798; LEE JH, 1990, CANCER RES, V50, P2724; LEE JH, 1989, CANCER RES, V49, P1220; LI S, 1991, J NATL CANCER I, V83, P337; LYNCH HT, 1985, CANCER, V56, P934, DOI 10.1002/1097-0142(19850815)56:4<934::AID-CNCR2820560439>3.0.CO;2-I; MARHLENS F, 1987, NUCLEIC ACIDS RES, V15, P1348; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MITELMAN F, 1991, CATALOG CHROMOSOME A; MULERIS M, 1987, CANCER GENET CYTOGEN, V29, P289, DOI 10.1016/0165-4608(87)90239-1; MULLER U, 1987, CYTOGENET CELL GENET, V45, P16, DOI 10.1159/000132418; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5707, DOI 10.1093/nar/16.12.5707; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P4747, DOI 10.1093/nar/16.10.4747; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P6257, DOI 10.1093/nar/16.13.6257; NAROD SA, 1991, LANCET, V338, P82; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NISHISHO I, 1987, JPN J HUM GENET, V32, P1, DOI 10.1007/BF01876521; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OCONNELL P, 1988, GENOMICS, V3, P367, DOI 10.1016/0888-7543(88)90129-2; OKAMOTO A, 1991, CANCER RES, V51, P5171; PELTOMAKI P, 1991, CANCER RES, V51, P4135; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; SATO T, 1991, CANCER RES, V51, P5118; SILVERMAN GA, 1991, GENOMICS, V9, P219, DOI 10.1016/0888-7543(91)90245-A; TSUJIMOTO Y, 1987, P NATL ACAD SCI USA, V84, P1329, DOI 10.1073/pnas.84.5.1329; VIALLET J, 1990, AM J RESP CELL MOL, V2, P225, DOI 10.1165/ajrcmb/2.3.225; VIEL A, 1991, TUMORI, V77, P16, DOI 10.1177/030089169107700104; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; YOUNG J, 1990, NUCLEIC ACIDS RES, V18, P7196, DOI 10.1093/nar/18.23.7196; ZHENG JP, 1991, CANCER RES, V51, P4045	47	82	82	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1059	1065						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594239				2022-12-25	WOS:A1992HU64200002
J	AUCHINCLOSS, AH; ALEXANDER, A; KOHORN, BD				AUCHINCLOSS, AH; ALEXANDER, A; KOHORN, BD			REQUIREMENT FOR 3 MEMBRANE-SPANNING ALPHA-HELICES IN THE POSTTRANSLATIONAL INSERTION OF A THYLAKOID MEMBRANE-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPHYLL-A/B-PROTEIN; LIGHT-HARVESTING COMPLEX; CHARGED AMINO-ACIDS; PRECURSOR PROTEIN; TRANSIT PEPTIDE; ESCHERICHIA-COLI; CHLOROPLAST MEMBRANES; BINDING POLYPEPTIDES; POLYACRYLAMIDE GELS; IMPORT	The insertion of a protein into a lipid bilayer usually involves a short signal sequence and can occur either during or after translation. A light-harvesting chlorophyll a/b-binding protein (LHCP) is synthesized in the cytoplasm of plant cells as a precursor and is post-translationally imported into chloroplasts where it subsequently inserts into the thylakoid membrane. Only mature LHCP is required for insertion into the thylakoid. To define which sequences of the mature protein are necessary and sufficient for thylakoid integration, fusion and deletion proteins and proteins with internal rearrangements were synthesized and incubated with isolated thylakoids and stroma. No evidence is found for the existence of a short signal sequence within LHCP, and, with the exception of the amino terminus and a short lumenal loop, the entire mature protein with consecutively ordered alpha-helices is required for insertion into thylakoid membranes. The addition of positive charges into stromal but not lumenal segments permits the insertion of mutant LHCPs into isolated thylakoids. Replacement of the LHCP transit peptide with the transit peptide from plastocyanin has no effect on LHCP insertion and does not restore insertion of the lumenal charge addition mutants.	DUKE UNIV,DEPT BOT,139 BIOL SCI,DURHAM,NC 27706	Duke University				Auchincloss, Andrea/0000-0002-5297-5390	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039696] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39696-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUERLE C, 1991, J BIOL CHEM, V266, P5876; BELLEMARE G, 1982, J BIOL CHEM, V257, P7762; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; BUTLER PJG, 1988, P NATL ACAD SCI USA, V85, P3797, DOI 10.1073/pnas.85.11.3797; CASHMORE AR, 1984, P NATL ACAD SCI-BIOL, V81, P2960, DOI 10.1073/pnas.81.10.2960; CHUA NH, 1973, P NATL ACAD SCI USA, V70, P1554, DOI 10.1073/pnas.70.5.1554; CLARK SE, 1990, PLANT CELL, V2, P173, DOI 10.1105/tpc.2.2.173; CLINE K, 1988, PLANT PHYSIOL, V86, P1120, DOI 10.1104/pp.86.4.1120; CLINE K, 1985, J BIOL CHEM, V260, P3691; CLINE K, 1989, J BIOL CHEM, V264, P14225; CLINE K, 1986, J BIOL CHEM, V261, P4804; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; EVANS MCW, 1991, NATURE, V350, P109, DOI 10.1038/350109a0; FULSON DR, 1988, PLANT PHYSIOL, V88, P1146, DOI 10.1104/pp.88.4.1146; GAVEL Y, 1991, FEBS LETT, V282, P41, DOI 10.1016/0014-5793(91)80440-E; GELLER BL, 1985, J BIOL CHEM, V260, P3281; GREEN BR, 1991, TRENDS BIOCHEM SCI, V16, P181, DOI 10.1016/0968-0004(91)90072-4; HAND JM, 1989, EMBO J, V8, P3195, DOI 10.1002/j.1460-2075.1989.tb08478.x; HARLOW E, 1988, ANTIBODIES LAB MANUA, P493; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HOFFMAN NE, 1987, P NATL ACAD SCI USA, V84, P8844, DOI 10.1073/pnas.84.24.8844; KARLINNEUMANN GA, 1985, J MOL APPL GENET, V3, P45; KAVANAGH TA, 1988, MOL GEN GENET, V215, P38, DOI 10.1007/BF00331300; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KIRWIN PM, 1989, EMBO J, V8, P2251, DOI 10.1002/j.1460-2075.1989.tb08349.x; KOHORN BD, 1989, PLANT CELL, V1, P159; KOHORN BD, 1986, J CELL BIOL, V102, P972, DOI 10.1083/jcb.102.3.972; KOHORN BD, 1991, J BIOL CHEM, V266, P12048; KOHORN BD, 1987, J BIOL CHEM, V262, P12897; KUHLBRANDT W, 1984, NATURE, V307, P478, DOI 10.1038/307478a0; KUHLBRANDT W, 1991, NATURE, V350, P130, DOI 10.1038/350130a0; KUHLBRANDT W, 1989, J MOL BIOL, V207, P823, DOI 10.1016/0022-2836(89)90247-7; KUMAMOTO CA, 1989, P NATL ACAD SCI USA, V86, P5320, DOI 10.1073/pnas.86.14.5320; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPPA GK, 1988, J BIOL CHEM, V263, P14996; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; MULLET JE, 1983, J BIOL CHEM, V258, P9941; MURPHY DJ, 1986, BIOCHIM BIOPHYS ACTA, V864, P33, DOI 10.1016/0304-4157(86)90015-8; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; OHNOIWASHITA Y, 1983, J BIOL CHEM, V258, P1885; PAYAN LA, 1991, J CELL BIOL, V112, P603, DOI 10.1083/jcb.112.4.603; RANDALL LL, 1983, CELL, V33, P231, DOI 10.1016/0092-8674(83)90352-5; REED JE, 1990, EUR J BIOCHEM, V194, P33, DOI 10.1111/j.1432-1033.1990.tb19423.x; ROBINSON C, 1984, EUR J BIOCHEM, V142, P337, DOI 10.1111/j.1432-1033.1984.tb08291.x; SCHMIDT GW, 1981, J CELL BIOL, V91, P468, DOI 10.1083/jcb.91.2.468; SMEEKENS S, 1990, TRENDS BIOCHEM SCI, V15, P73, DOI 10.1016/0968-0004(90)90180-J; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; VIITANEN PV, 1988, J BIOL CHEM, V263, P15000; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; VORST O, 1988, GENE, V65, P59, DOI 10.1016/0378-1119(88)90417-9; WICKNER W, 1988, BIOCHEMISTRY-US, V27, P1081, DOI 10.1021/bi00404a001; WILLEY DL, 1984, CELL, V36, P555, DOI 10.1016/0092-8674(84)90248-4	58	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10439	10446						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587827				2022-12-25	WOS:A1992HV09000038
J	EVANS, AJ; SAWYEZ, CG; WOLFE, BM; HUFF, MW				EVANS, AJ; SAWYEZ, CG; WOLFE, BM; HUFF, MW			LIPOLYSIS IS A PREREQUISITE FOR LIPID-ACCUMULATION IN HEPG2 CELLS INDUCED BY LARGE HYPERTRIGLYCERIDEMIC VERY LOW-DENSITY LIPOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE-RICH LIPOPROTEINS; MOUSE PERITONEAL-MACROPHAGES; CORONARY-ARTERY DISEASE; HUMAN HEPATOMA HEP-G2; APOLIPOPROTEIN-E; RECEPTOR PATHWAY; HUMAN-PLASMA; CHOLESTEROL-METABOLISM; MONOCLONAL-ANTIBODIES; HUMAN-FIBROBLASTS	Lipoprotein kinetic studies have demonstrated that a large proportion of S(f) 60-400 very low density lipoprotein (VLDL) is cleared directly from the circulation in Type IV hypertriglyceridemic subjects, at an unknown tissue site. The present studies were designed to investigate the role of hepatocytes in this process and to define the conditions, whereby Type IV S(f) 60-400 VLDL would induce lipid accumulation in HepG2 cells. Type IV VLDL (S(f) 60-400) failed to augment the total cholesterol, esterified cholesterol, or triglyceride content of HepG2 cells following 24-h incubations. Coincubation of bovine milk lipoprotein lipase (LPL) and Type IV VLDL with HepG2 cells induced a 3-fold increment in cellular esterified cholesterol mass (p < 0.005) and a 7-fold increase in cellular triglyceride mass (p < 0.005), compared to VLDL alone. The increased cellular lipid mass was associated with increased oleate incorporation into cellular cholesterol esters and triglycerides. Exogenous LPL hydrolyzed 76% of the VLDL triglyceride over 24 h. LPL action on Type IV VLDL was sufficient to promote cellular uptake of these lipoproteins, while elevated media-free fatty acid levels were not. Although HepG2 cells secrete apolipoprotein (apo) E, we assessed the role of VLDL-associated apoE in the lipid accumulation induced by VLDL plus LPL. ApoE-rich and apoE-poor Type IV VLDL subfractions induced similar increments in cellular esterified cholesterol in the presence of LPL, despite a 4-fold difference in apoE content. S(f) 60-400 VLDL, from subjects homozygous for the defective apoE2, plus LPL, behaved identically to Type IV VLDL plus LPL. Type IV VLDL plus LPL, preincubated with anti-apoE (1D7) and apoB (5E11) monoclonal antibodies, known to block the binding of apoE and -B, respectively, to the LDL receptor failed to block lipid accumulation. In contrast, apoE-poor Type IV VLDL, apoE2 VLDL, and VLDL plus 1D7 were taken up poorly by J774 cells, cells that secrete LPL, but not apoE. These studies suggest that lipolytic remodeling of large Type IV VLDL by LPL is a prerequisite for their uptake by HepG2 cells and that HepG2 cell-secreted apoE rather than VLDL-associated apoE is the ligand involved in uptake.	UNIV WESTERN ONTARIO,ROBARTS RES INST,LONDON N6A 5K8,ONTARIO,CANADA; UNIV WESTERN ONTARIO,DEPT BIOCHEM,LONDON N6A 5K8,ONTARIO,CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario)	EVANS, AJ (corresponding author), UNIV WESTERN ONTARIO,DEPT MED,LONDON N6A 5K8,ONTARIO,CANADA.		Huff, Murray/G-3307-2011					BARBIR M, 1988, BRIT HEART J, V60, P397; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BLACHE D, 1983, CLIN CHEM, V29, P154; BRADLEY WA, 1984, J BIOL CHEM, V259, P4728; BROWN MS, 1980, J BIOL CHEM, V255, P9344; BURY J, 1985, CLIN CHEM, V31, P247; BUSCH SJ, 1989, LIFE SCI, V45, P615, DOI 10.1016/0024-3205(89)90047-7; CARLSON LA, 1985, ACTA MED SCAND, V218, P207; CRAIG WY, 1988, J BIOL CHEM, V263, P13880; CRAIG WY, 1988, J LIPID RES, V29, P299; DASHTI N, 1986, BIOCHIM BIOPHYS ACTA, V875, P473, DOI 10.1016/0005-2760(86)90067-6; EISENBERG S, 1988, ARTERIOSCLEROSIS, V8, P480, DOI 10.1161/01.ATV.8.5.480; ERICKSON SK, 1986, J LIPID RES, V27, P875; EVANS AJ, 1989, J LIPID RES, V30, P1691; FAUST RA, 1989, ATHEROSCLEROSIS, V77, P77, DOI 10.1016/0021-9150(89)90012-9; FREEDMAN DS, 1988, AM J EPIDEMIOL, V127, P1118, DOI 10.1093/oxfordjournals.aje.a114906; FRIEDMAN G, 1990, BIOCHIM BIOPHYS ACTA, V1044, P118, DOI 10.1016/0005-2760(90)90226-N; GIANTURCO SH, 1988, J CLIN INVEST, V82, P1633, DOI 10.1172/JCI113775; GIANTURCO SH, 1982, J CLIN INVEST, V70, P168, DOI 10.1172/JCI110590; GIANTURCO SH, 1983, J BIOL CHEM, V258, P4526; GIANTURCO SH, 1986, J LIPID RES, V27, P412; GUSTAFSON S, 1985, BIOCHIM BIOPHYS ACTA, V834, P308, DOI 10.1016/0005-2760(85)90003-7; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HUFF MW, 1988, ARTERIOSCLEROSIS, V8, P471, DOI 10.1161/01.ATV.8.5.471; HUFF MW, 1991, ARTERIOSCLER THROMB, V11, P221, DOI 10.1161/01.ATV.11.2.221; HUFF MW, 1990, J LIPID RES, V31, P385; HUFF MW, 1984, BIOCHIM BIOPHYS ACTA, V796, P251, DOI 10.1016/0005-2760(84)90125-5; INNERARITY TL, 1986, LIPOPROTEIN DEFICIEN, P273; JAVITT NB, 1990, FASEB J, V4, P161, DOI 10.1096/fasebj.4.2.2153592; KREMPLER F, 1987, J CLIN INVEST, V80, P401, DOI 10.1172/JCI113086; KRUL ES, 1984, J CLIN INVEST, V75, P361; KUO P, 1990, BIOCHEMISTRY-US, V29, P6626, DOI 10.1021/bi00480a011; Mahley R. W., 1991, CURR OPIN LIPIDOL, V2, P170; MAHLEY RW, 1989, ARTERIOSCLER, V9, P14; MARCEL YL, 1988, ARTERIOSCLEROSIS, V8, P832, DOI 10.1161/01.ATV.8.6.832; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MILNE RW, 1983, ARTERIOSCLEROSIS, V3, P23, DOI 10.1161/01.ATV.3.1.23; MILNE RW, 1983, FEBS LETT, V146, P97; MUDLER M, 1991, BIOCHIM BIOPHYS ACTA, V1081, P308; MUSLINER TA, 1979, BIOCHIM BIOPHYS ACTA, V575, P277, DOI 10.1016/0005-2760(79)90029-8; NERI BP, 1973, CLIN CHEM, V19, P1201; NOVAK M, 1965, J LIPID RES, V6, P431; ORDOVAS JM, 1987, J LIPID RES, V28, P1216; OSWALD B, 1987, J LIPID RES, V28, P798; PERSOON NLM, 1986, LIFE SCI, V38, P1029, DOI 10.1016/0024-3205(86)90237-7; RANGANATHAN S, 1989, HEPATOLOGY, V9, P547, DOI 10.1002/hep.1840090407; REARDON MF, 1978, J CLIN INVEST, V61, P850, DOI 10.1172/JCI108999; RUDLING MJ, 1985, BIOCHIM BIOPHYS ACTA, V833, P359, DOI 10.1016/0005-2760(85)90091-8; SACKS FM, 1987, ARTERIOSCLEROSIS, V7, P35, DOI 10.1161/01.ATV.7.1.35; SCHAEFER EJ, 1985, NEW ENGL J MED, V312, P1300, DOI 10.1056/NEJM198505163122007; SCHNEIDER WJ, 1981, J CLIN INVEST, V68, P1075, DOI 10.1172/JCI110330; SEHAYEK E, 1991, J CLIN INVEST, V88, P553, DOI 10.1172/JCI115339; SHELBURNE F, 1980, J CLIN INVEST, V65, P652, DOI 10.1172/JCI109710; SHEPHERD J, 1987, AM HEART J, V113, P503, DOI 10.1016/0002-8703(87)90621-1; SOCORRO L, 1985, J BIOL CHEM, V260, P6324; TABAS I, 1987, J CLIN INVEST, V79, P418, DOI 10.1172/JCI112828; WEISGRABER KH, 1983, J BIOL CHEM, V258, P2348; WINDLER E, 1980, J BIOL CHEM, V255, P5475; WINDLER E, 1985, J LIPID RES, V26, P556; YEN FT, 1989, CIRCULATION, V80, P487; ZANNIS VI, 1981, BIOCHEMISTRY-US, V20, P7089, DOI 10.1021/bi00528a006	62	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10743	10751						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587849				2022-12-25	WOS:A1992HV09000081
J	QUESENBERRY, MS; DRICKAMER, K				QUESENBERRY, MS; DRICKAMER, K			ROLE OF CONSERVED AND NONCONSERVED RESIDUES IN THE CA2+-DEPENDENT CARBOHYDRATE-RECOGNITION DOMAIN OF A RAT MANNOSE-BINDING PROTEIN - ANALYSIS BY RANDOM CASSETTE MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR; CONTAINS; LECTIN	The carbohydrate-recognition domain of rat serum mannose-binding protein A has been subjected to random cassette mutagenesis. Mutant domains, expressed in bacteria, were initially screened for binding to invertase-coated nitrocellulose and then analyzed further for Ca2+ affinity, saccharide binding, resistance to proteolysis, and oligomerization. The results are consistent with previous evolutionary and structural studies. Six out of seven completely inactive mutants have changes in residues directly involved in ligating Ca2+. Most changes in conserved residues which form part of the hydrophobic core characteristic of Ca2+-dependent (C-type) animal lectins result in decreased affinity for Ca2+, even though these residues are distant from the Ca2+ sites. Changes can be made in large portions of the surface without affecting saccharide binding. The results indicate that the precise arrangement of the regular portion of the domain containing the hydrophobic core is necessary for formation of a stable Ca2+-ligated structure under physiological conditions. The data also suggest that the saccharide-binding site is likely to be in close proximity to the bound Ca2+.	COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, 630 W 168TH ST, NEW YORK, NY 10032 USA	Columbia University					NIDDK NIH HHS [DK07328] Funding Source: Medline; NIGMS NIH HHS [GM42628] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042628] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATHERTON E, 1985, J CHEM SOC CHEM COMM, P165, DOI 10.1039/c39850000165; BEZOUSKA K, 1991, J BIOL CHEM, V266, P11604; CHILDS RA, 1990, J BIOL CHEM, V265, P20770; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1989, BIOCHEM SOC T, V17, P13, DOI 10.1042/bst0170013; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; GHRAYEB J, 1984, EMBO J, V3, P2437, DOI 10.1002/j.1460-2075.1984.tb02151.x; HARLOW E, 1988, ANTIBODIES LABORATOR; HOLLAND EC, 1986, J BIOL CHEM, V261, P1286; IKEDA K, 1987, J BIOL CHEM, V262, P7451; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; LEE RT, 1991, J BIOL CHEM, V266, P4810; LOEB JA, 1987, J BIOL CHEM, V262, P3022; Maniatis T., 1982, MOL CLONING; MURRAY R, 1988, P NATL ACAD SCI USA, V85, P3535, DOI 10.1073/pnas.85.10.3535; QUESENBERRY M S, 1991, Glycobiology, V1, P615, DOI 10.1093/glycob/1.6.615; REEKE GN, 1978, P NATL ACAD SCI USA, V75, P2286, DOI 10.1073/pnas.75.5.2286; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DH, 1981, J MOL BIOL, V145, P653, DOI 10.1016/0022-2836(81)90308-9; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241	26	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10831	10841						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587859				2022-12-25	WOS:A1992HV09000094
J	ZIEGELBAUER, K; OVERATH, P				ZIEGELBAUER, K; OVERATH, P			IDENTIFICATION OF INVARIANT SURFACE GLYCOPROTEINS IN THE BLOOD-STREAM STAGE OF TRYPANOSOMA-BRUCEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORMS; PLASMA-MEMBRANE; PROTEINS; TRANSPORT; ANTIGENS; PURIFICATION; RHODESIENSE; INVOLVEMENT; DOMAINS; COAT	Surface proteins of the mammalian stage of the parasitic protozoan, Trypanosoma brucei, were biotinylated with sulfosuccinimidyl 6-(biotinamido) hexanoate. Since the predominant protein labeled by this reagent is the membrane form of the variant surface glycoprotein (mfVSG), a procedure was developed to convert mfVSG to its soluble form by the endogenous glycosylphosphatidylinositol-specific phospholipase C while retaining other biotinylated surface proteins in a membrane-bound state. From these membranes, three novel glycoproteins of 60, 65, and 75 kDa could be isolated by a combination of Triton X-114 phase separation and precipitations by streptavidin and concanavalin A coupled to solid supports. These polypeptides were detected in trypanosomes expressing different mfVSGs and are thus considered to be invariant. In a variant clone in which the mfVSG is trypsin-sensitive, the invariant surface glycoproteins of 65 and 75 kDa, designated ISG65 and ISG75, respectively, were proteolytically degraded with similar kinetics as the mfVSG. Neither ISG65 nor ISG75 could be detected in procyclic trypanosomes, the stage of the parasite characteristic for the insect midgut. Gene cloning reported in the accompanying paper (Ziegelbauer, K., Multhaup, G., and Overath, P. (1992) J. Biol. Chem. 267, 10797-10803) suggests that ISG65 and ISG75 are transmembrane proteins.			ZIEGELBAUER, K (corresponding author), MAX PLANCK INST BIOL, MEMBRANE BIOCHEM ABT, CORRENSSTR 38, W-7400 TUBINGEN, GERMANY.							BARRY JD, 1979, J CELL SCI, V37, P287; BEAT DA, 1984, J PROTOZOOL, V31, P541, DOI 10.1111/j.1550-7408.1984.tb05499.x; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BORST P, 1991, IMMUNOPARASITOL TOD, pA29, DOI 10.1016/S0167-5699(05)80009-X; BORST P, 1991, TRENDS GENET, V7, P307, DOI 10.1016/0168-9525(91)90406-G; BOWLES DJ, 1982, FEBS LETT, V139, P17, DOI 10.1016/0014-5793(82)80477-8; BULOW R, 1989, J CELL SCI, V93, P233; BURGESS DE, 1985, INFECT IMMUN, V50, P893, DOI 10.1128/IAI.50.3.893-899.1985; COPPENS I, 1991, BIOCHEM BIOPH RES CO, V178, P185, DOI 10.1016/0006-291X(91)91797-G; COPPENS I, 1988, P NATL ACAD SCI USA, V85, P6753, DOI 10.1073/pnas.85.18.6753; COPPENS I, 1987, J PROTOZOOL, V34, P465, DOI 10.1111/j.1550-7408.1987.tb03216.x; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P83, DOI 10.1146/annurev.iy.08.040190.000503; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; DEALMEIDA MLC, 1983, NATURE, V302, P349, DOI 10.1038/302349a0; EISENTHAL R, 1989, BIOCHIM BIOPHYS ACTA, V985, P81, DOI 10.1016/0005-2736(89)90107-7; GAME S, 1986, FEBS LETT, V194, P126, DOI 10.1016/0014-5793(86)80063-1; GARDINER PR, 1987, SCIENCE, V235, P774, DOI 10.1126/science.3810164; GRUENBERG J, 1978, EUR J BIOCHEM, V89, P461, DOI 10.1111/j.1432-1033.1978.tb12549.x; Helenius A, 1979, Methods Enzymol, V56, P734; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HIRUMI H, 1980, PARASITOLOGY, V80, P371, DOI 10.1017/S0031182000000822; HURLEY WL, 1985, J IMMUNOL METHODS, V85, P195, DOI 10.1016/0022-1759(85)90287-X; INGALLS HM, 1986, P NATL ACAD SCI USA, V83, P4779, DOI 10.1073/pnas.83.13.4779; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; MANCINI PE, 1982, BIOCHIM BIOPHYS ACTA, V688, P399, DOI 10.1016/0005-2736(82)90351-0; MCLAUGHLIN J, 1982, J IMMUNOL, V128, P2656; Overath Peter, 1992, NATO ASI (Advanced Science Institute) Series Series H Cell Biology, V63, P333; PAYS E, 1989, CELL, V57, P835, DOI 10.1016/0092-8674(89)90798-8; RAUTENBERG P, 1981, MOL BIOCHEM PARASIT, V4, P129, DOI 10.1016/0166-6851(81)90012-8; ROLIN S, 1990, EXP PARASITOL, V71, P350, DOI 10.1016/0014-4894(90)90041-A; ROSS DT, 1991, EMBO J, V10, P2047, DOI 10.1002/j.1460-2075.1991.tb07735.x; ROVIS L, 1978, NATURE, V271, P654, DOI 10.1038/271654a0; RUSSELL DG, 1986, J IMMUNOL, V136, P2613; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; SCHELL D, 1991, EMBO J, V10, P1061, DOI 10.1002/j.1460-2075.1991.tb08045.x; SCHELL D, 1991, PARASITOL RES, V77, P558, DOI 10.1007/BF00931012; SHAPIRO S Z, 1986, P215; TERKUILE BH, 1991, J BIOL CHEM, V266, P857; van Meirvenne N., 1975, Annales Soc belge Med trop, V55, P1; ZIEGELBAUER K, 1992, J BIOL CHEM, V267, P10797	42	82	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10791	10796						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587855				2022-12-25	WOS:A1992HV09000088
J	LOPEZ, JA; LUDWIG, EH; MCCARTHY, BJ				LOPEZ, JA; LUDWIG, EH; MCCARTHY, BJ			POLYMORPHISM OF HUMAN GLYCOPROTEIN-IB-ALPHA RESULTS FROM A VARIABLE NUMBER OF TANDEM REPEATS OF A 13-AMINO ACID SEQUENCE IN THE MUCIN-LIKE MACROGLYCOPEPTIDE REGION - STRUCTURE-FUNCTION IMPLICATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVINE SUBMAXILLARY MUCIN; O-LINKED GLYCOPROTEINS; GENETIC-POLYMORPHISM; SHEAR RATE; PLATELET INTERACTION; HUMAN-BLOOD; SUBENDOTHELIUM; CLONING; PROTEIN; CHAIN	Four polymorphic variants of the platelet receptor for von Willebrand factor, glycoprotein Ib, have been described that differ in molecular weight on sodium dodecyl sulfate-polyacrylamide gels (Moroi, M., Jung, S. M., and Yoshida, N. (1984) Blood 64, 622-629). A recent report localized the polymorphic site to the heavily O-glycosylated region of the glycoprotein Ib alpha-chain known as the macroglycopeptide (Meyer, M., and Schellenberg, I. (1990) Thromb. Res. 58, 233-242). This region contains several tandem repeats of a mucin-like sequence, which appeared to be a likely site for polymorphic variation. We amplified genomic DNA corresponding to the macroglycopeptide from 206 individuals from four ethnic groups and identified three length variants based on the migration of the amplified DNA on denaturing polyacrylamide gels. DNA sequencing revealed that the three variants represented four alleles, two of which varied by only one base pair, a difference that did not result in an amino acid change. The three length variants differed in the number of tandem repeats of a 39-base pair sequence that results in perfect duplication of a 13-amino acid sequence that originated within a region flanked by Glu-396 and Thr-411. The smallest isoform contained one such sequence; the next largest, two repeats; and the largest, three repeats. The DNA sequence containing the tandem repeats was flanked by direct repeats typical of the target site duplications found flanking transposed DNA, suggesting a mechanism for acquisition of this region by the primordial glycoprotein Ib(alpha) precursor. The amino acid sequence of the repeated element that accounts for the polymorphism contained five sites for potential O-glycosylation, which together with the repeated amino acids would result in incremental differences in molecular weight of approximately 6,000 between the different isoforms. The addition of repeats to the macroglycopeptide is predicted to increase the length of this elongated glycosylated region and extend the distance between the ligand-binding domain of glycoprotein Ib and the platelet plasma membrane, an effect that would project the ligand-binding domain farther into the bloodstream. Such a change may alter the susceptibility of platelets to shear-induced activation, a process that requires an interaction between glycoprotein Ib and von Willebrand factor.	UNIV CALIF SAN FRANCISCO,DEPT MED,DIV HEMATOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	LOPEZ, JA (corresponding author), GLADSTONE INST CARDIOVASC DIS,CARDIOVASC RES INST,POB 19100,SAN FRANCISCO,CA 94141, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002463, R01HL038781] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38781, HL02463] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AARTS PAMM, 1988, ARTERIOSCLEROSIS, V8, P819, DOI 10.1161/01.ATV.8.6.819; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; COLMAN RW, 1989, HEMOSTASIS THROMBOSI, P3; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FOX JEB, 1988, J BIOL CHEM, V263, P4882; FOX JEB, 1985, J BIOL CHEM, V260, P1970; GENDLER S, 1988, J BIOL CHEM, V263, P12820; GERARD C, 1990, J CLIN INVEST, V86, P1921, DOI 10.1172/JCI114925; GERKEN TA, 1989, BIOCHEMISTRY-US, V28, P5536, DOI 10.1021/bi00439a030; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GUM JR, 1989, J BIOL CHEM, V264, P6480; HICKEY MJ, 1989, P NATL ACAD SCI USA, V86, P6773, DOI 10.1073/pnas.86.17.6773; HICKEY MJ, 1991, CLIN RES, V39, pA337; HIGUCHI R, 1989, AMPLIFICATIONS, V2, P3; HIGUCHI R, 1989, AMPLIFICATIONS, V2, P1; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; JUNG SM, 1986, THROMB RES, V42, P83, DOI 10.1016/0049-3848(86)90199-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAN MS, 1990, J BIOL CHEM, V265, P15294; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MEYER M, 1990, THROMB RES, V58, P233, DOI 10.1016/0049-3848(90)90093-R; MOAKE JL, 1988, BLOOD, V71, P1366; MOROI M, 1984, BLOOD, V64, P622; MURATA M, 1991, J BIOL CHEM, V266, P15474; MUSTARD JF, 1990, CIRCULATION S1, V81, P24; OKUMURA T, 1976, J BIOL CHEM, V251, P5950; OLSON JD, 1989, J LAB CLIN MED, V14, P6; PERUTZ MF, 1960, NATURE, V185, P416, DOI 10.1038/185416a0; PONCZ M, 1987, J BIOL CHEM, V262, P8476; PROBST JC, 1990, BIOCHEMISTRY-US, V29, P6240, DOI 10.1021/bi00478a018; ROTH GJ, 1991, BLOOD, V77, P5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP PA, 1983, NATURE, V301, P471, DOI 10.1038/301471a0; SHOGREN R, 1989, BIOCHEMISTRY-US, V28, P5525, DOI 10.1021/bi00439a029; SIMON M, 1991, GENOMICS, V9, P576, DOI 10.1016/0888-7543(91)90349-J; TIMPTE CS, 1988, J BIOL CHEM, V263, P1081; TURITTO VT, 1979, MICROVASC RES, V17, P38, DOI 10.1016/0026-2862(79)90006-2; TURITTO VT, 1980, MICROVASC RES, V19, P352, DOI 10.1016/0026-2862(80)90054-0; WEISS HJ, 1986, J CLIN INVEST, V78, P1072, DOI 10.1172/JCI112663; WELLER P, 1984, EMBO J, V3, P439, DOI 10.1002/j.1460-2075.1984.tb01825.x; WENGER RH, 1988, BIOCHEM BIOPH RES CO, V156, P389, DOI 10.1016/S0006-291X(88)80853-2	44	141	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10055	10061						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577776				2022-12-25	WOS:A1992HT96500092
J	LUO, GX; NISHIMURA, JS				LUO, GX; NISHIMURA, JS			ADENOSINE 5'-TETRAPHOSPHATE IS SYNTHESIZED BY THE HISTIDINE ALPHA-142-]ASPARAGINE MUTANT OF ESCHERICHIA-COLI SUCCINYL-COA SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; COENZYME; TETRAPHOSPHATE; MUTAGENESIS; RESIDUE	Recently, we described the properties of a mutant (H142N) of Escherichia coli succinyl coenzyme A (CoA) synthetase in which His-142 of the alpha-subunit was changed to Asn (Luo, G.-X., and Nishimura, J. S. (1991) J. Biol. Chem. 266, 20781-20785). The mutant enzyme was practically devoid of ability to catalyze the overall reaction but was able to catalyze half-reactions at significant rates. Thus, phosphorylation by ATP and dephosphorylation by ADP of the mutant enzyme occurred at rates that were at least 10 times greater than those with wild type enzyme, and dephosphorylation by succinate plus CoA (succinyl-CoA formation) proceeded with a V(max) of 10% that of wild type, with no change in K(m) for succinate and very little change in K(m) for CoA. In the present work, it has been shown that incubation of P-32-labeled H142N with ATP caused a rapid depletion of label from the enzyme and incorporation of radioactivity into a nucleotide species that was neither ATP nor ADP. This reaction was catalyzed at comparatively negligible rates by wild type enzyme. Analysis of the labeled product by high pressure liquid chromatography and P-31 NMR revealed that it was adenosine 5'-tetraphosphate (AP4). Incubation of labeled H142N with the ATP analog beta, gamma-methylene adenosine triphosphate also gave a product that appeared to be the corresponding tetraphosphate. The reaction in which AP4 was formed was greatly stimulated by the addition of phosphoenolpyruvate plus pyruvate kinase and strongly inhibited by ADP and by CoA plus succinate. The results are consistent with binding of ATP to, and reaction with, phosphorylated succinyl-CoA synthetase to form AP4. In this reaction, it was determined that the K(m) for ATP and the turnover number of phosphorylated enzyme were 14.5-mu-M and 0.024 s-1, respectively.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017534] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-17534] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atkinson T., 1984, OLIGONUCLEOTIDE SYNT, P35; BOWMAN CM, 1975, J BIOL CHEM, V250, P5609; Bridger W. A., 1974, ENZYMES, P581; BUCK D, 1985, BIOCHEMISTRY-US, V24, P6245, DOI 10.1021/bi00343a031; Cha S, 1969, METHOD ENZYMOL, V13, P62, DOI 10.1016/0076-6879(69)13017-7; COLLIER GE, 1978, J BIOL CHEM, V253, P4938; COLLIER GE, 1979, J BIOL CHEM, V254, P925; Fiske CH, 1925, J BIOL CHEM, V66, P375; GRINNELL FL, 1969, BIOCHEMISTRY-US, V8, P568, DOI 10.1021/bi00830a016; KAUFMAN S, 1955, J BIOL CHEM, V216, P153; KLAUS W, 1984, RES EXP MED, V185, P145; KREBS A, 1974, CAN J BIOCHEM CELL B, V52, P594, DOI 10.1139/o74-086; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUPRIYANOV VV, 1986, BIOCHIM BIOPHYS ACTA, V869, P107, DOI 10.1016/0167-4838(86)90316-X; LIEBERMAN I, 1955, J AM CHEM SOC, V77, P3373, DOI 10.1021/ja01617a064; LOBATON CD, 1975, EUR J BIOCHEM, V50, P495, DOI 10.1111/j.1432-1033.1975.tb09888.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUO GX, 1991, J BIOL CHEM, V266, P20781; MAJUMDAR R, 1991, BIOCHIM BIOPHYS ACTA, V1076, P86, DOI 10.1016/0167-4838(91)90223-M; MANN CJ, 1989, J BIOL CHEM, V264, P1457; MANN CJ, 1991, BIOCHEMISTRY-US, V30, P1497, DOI 10.1021/bi00220a008; MARRIAN DH, 1954, BIOCHIM BIOPHYS ACTA, V13, P278, DOI 10.1016/0006-3002(54)90314-5; MEJBAUM W, 1934, Z PHYSL CHEM, V258, P177; NISHIMURA JS, 1972, ADV ENZYMOL RAMB, V36, P183; NISHIMURA JS, 1986, ADV ENZYMOL, V58, P142; NISHIYAMA M, 1991, MOL GEN GENET, V226, P1, DOI 10.1007/BF00273580; PEARSON PH, 1975, J BIOL CHEM, V250, P8524; SACKS J, 1955, BIOCHIM BIOPHYS ACTA, V16, P436, DOI 10.1016/0006-3002(55)90253-5; SILVERMAN RH, 1979, MICROBIOL REV, V43, P27, DOI 10.1128/MMBR.43.1.27-41.1979; SMALL GD, 1966, BIOCHEMISTRY-US, V5, P14, DOI 10.1021/bi00865a003; SMALL GD, 1966, BIOCHEMISTRY-US, V5, P26, DOI 10.1021/bi00865a004; VOGEL HJ, 1982, J BIOL CHEM, V257, P4834; WANG T, 1972, BIOCHEMISTRY-US, V11, P2067, DOI 10.1021/bi00761a011	33	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9516	9520						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577794				2022-12-25	WOS:A1992HT96500014
J	BUTTKE, TM; FOLKS, TM				BUTTKE, TM; FOLKS, TM			COMPLETE REPLACEMENT OF MEMBRANE CHOLESTEROL WITH 4,4',14-TRIMETHYL STEROLS IN A HUMAN T-CELL LINE DEFECTIVE IN LANOSTEROL DEMETHYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST MUTANT STRAIN-GL7; METABOLISM; GROWTH; BIOSYNTHESIS; CYCLOARTENOL; REQUIREMENT; LYMPHOCYTES; INHIBITION; RETROVIRUS	A3.01 is a hypoxanthine/aminopterin/thymidine-sensitive, human immunodeficiency virus-susceptible, human T cell line derived by Folks et al. (Folks, T., Benn, S., Rabson, A., Theodore, T., Hoggan, M. D., Martin, M., Lightfoote, M., and Sell, K. (1985) Proc. Natl. Acad. Sci. U.S.A. 82, 4539-4543) following exposure of CEM cells to 8-azaguanine. In the present study, it is shown that A3.01 also contains a heretofore unrecognized mutation in cholesterol biosynthesis. A3.01 cells grown in the presence of 10% fetal bovine serum (FBS) contain primarily cholesterol in their membranes, but based on [C-14]acetate labeling, synthesize only lanosterol and 24,25-dihydrolanosterol. Reduction in the amount of FBS provided resulted in decreased cellular levels of cholesterol with corresponding increases in the two 4,4',14-trimethyl sterols. In A3.01 cells cultured in 1% FBS medium, lanosterol and 24,25-dihydrolanosterol accounted for 7 and 45%, respectively, of total cellular sterols. Following dilution of the 1% FBS-grown cells into serum-free media, the level of membrane cholesterol gradually declined, such that after three passages it became virtually undetectable, whereas the proportions of lanosterol and 24,25-dihydrolanosterol rose to 25 and 75%, respectively. Even after eight passages in the serum-free media, A3.01 cells displayed a complete absence of cholesterol with no obvious effect on cell growth. Membranes isolated from A3.01 cells grown in the presence or absence of 10-mu-g/ml of cholesterol displayed similar phospholipid:sterol ratios, but membranes from the unsupplemented cells contained only approximately 5% as much cholesterol as the supplemented cell membranes. Finally, A3.01 cells grown in the absence of cholesterol were extremely resistant to the cytotoxic effectS of amphotericin B, whereas cells cultured in the combined presence of 1% FCS and 10-mu-g/ml of cholesterol were sensitive to the drug. Collectively, these results demonstrate that 4,4', 14-trimethyl sterols can effectively replace cholesterol in a human T cell lineage, indicating that not all mammalian cells have a requirement for cholesterol, per se. The A3.01 T cell lineage should prove useful in defining the role of cholesterol in membrane fusion and human immunodeficiency virus-mediated syncitia formation and cytopathic effects.	CTR DIS CONTROL,RETROVIRUS DIS BRANCH,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	BUTTKE, TM (corresponding author), E CAROLINA UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,GREENVILLE,NC 27858, USA.							Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BERRY DJ, 1982, BIOCHEMISTRY-US, V21, P573, DOI 10.1021/bi00532a025; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLOCH KE, 1983, CRC CR REV BIOCH MOL, V14, P47, DOI 10.3109/10409238309102790; BOLARD J, 1986, BIOCHIM BIOPHYS ACTA, V864, P257, DOI 10.1016/0304-4157(86)90002-X; BROOKS CJW, 1968, LIPIDS, V3, P391, DOI 10.1007/BF02531277; BUTTKE TM, 1981, BIOCHEMISTRY-US, V20, P3267, DOI 10.1021/bi00514a044; BUTTKE TM, 1980, BIOCHEM BIOPH RES CO, V92, P229, DOI 10.1016/0006-291X(80)91543-0; BUTTKE TM, 1983, ANTIMICROB AGENTS CH, V24, P478, DOI 10.1128/AAC.24.4.478; BUTTKE TM, 1980, J BACTERIOL, V144, P124, DOI 10.1128/JB.144.1.124-130.1980; CHANG TY, 1977, P NATL ACAD SCI USA, V74, P832, DOI 10.1073/pnas.74.3.832; CHEN HW, 1988, J BIOL CHEM, V263, P1248; CUTHBERT JA, 1981, J IMMUNOL, V126, P2093; DAHL C, 1987, P NATL ACAD SCI USA, V84, P4012, DOI 10.1073/pnas.84.12.4012; DAHL CE, 1980, BIOCHEM BIOPH RES CO, V92, P221, DOI 10.1016/0006-291X(80)91542-9; DAHL CE, 1981, BIOCHEMISTRY-US, V20, P7158, DOI 10.1021/bi00528a016; DAHL JS, 1983, P NATL ACAD SCI-BIOL, V80, P692, DOI 10.1073/pnas.80.3.692; DAHL JS, 1980, BIOCHEMISTRY-US, V19, P1467, DOI 10.1021/bi00548a032; ESFAHANI M, 1984, J CELL BIOCHEM, V25, P87, DOI 10.1002/jcb.240250204; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; FOLKS T, 1985, P NATL ACAD SCI USA, V82, P4539, DOI 10.1073/pnas.82.13.4539; FOLKS TM, 1986, J EXP MED, V164, P280, DOI 10.1084/jem.164.1.280; FREEMAN CP, 1966, J LIPID RES, V7, P324; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HEINIGER HJ, 1978, P NATL ACAD SCI USA, V75, P5683, DOI 10.1073/pnas.75.11.5683; HIDAKA K, 1978, CELL, V14, P415, DOI 10.1016/0092-8674(78)90126-5; HOWELL DN, 1982, IMMUNOGENETICS, V15, P199, DOI 10.1007/BF00621951; KANDUTSCH AA, 1978, SCIENCE, V201, P498, DOI 10.1126/science.663671; LALA AK, 1978, BIOORG CHEM, V7, P437, DOI 10.1016/0045-2068(78)90034-2; LIMANEK JS, 1978, P NATL ACAD SCI USA, V75, P5452, DOI 10.1073/pnas.75.11.5452; LO SC, 1991, SCIENCE, V251, P1074, DOI 10.1126/science.1705362; MAEDA T, 1983, BIOCHIM BIOPHYS ACTA, V731, P115, DOI 10.1016/0005-2736(83)90404-2; MINOWADA J, 1972, J NATL CANCER I, V49, P891; PARKS LW, 1978, CRC CR REV MICROBIOL, V6, P301, DOI 10.3109/10408417809090625; RAMGOPAL M, 1983, P NATL ACAD SCI-BIOL, V80, P712, DOI 10.1073/pnas.80.3.712; RODRIGUEZ RJ, 1982, BIOCHEM BIOPH RES CO, V106, P435, DOI 10.1016/0006-291X(82)91129-9; RUJANAVECH C, 1986, J BIOL CHEM, V261, P7196; SAITO Y, 1977, P NATL ACAD SCI USA, V74, P3730, DOI 10.1073/pnas.74.9.3730; SCHULER I, 1991, P NATL ACAD SCI USA, V88, P6926, DOI 10.1073/pnas.88.16.6926; VINSON JA, 1977, J CHROMATOGR, V135, P226, DOI 10.1016/S0021-9673(00)86325-6; YEAGLE PL, 1977, P NATL ACAD SCI USA, V74, P4924, DOI 10.1073/pnas.74.11.4924	41	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8819	8826						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577721				2022-12-25	WOS:A1992HR85400021
J	KINDT, JT; WOODS, A; MARTIN, BM; COTTER, RJ; OSAWA, Y				KINDT, JT; WOODS, A; MARTIN, BM; COTTER, RJ; OSAWA, Y			COVALENT ALTERATION OF THE PROSTHETIC HEME OF HUMAN HEMOGLOBIN BY BRCCL3 - CROSS-LINKING OF HEME TO CYSTEINE RESIDUE-93	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADDUCT FORMATION; BINDING; BENZO<A>PYRENE; DENATURATION; RESOLUTION; MECHANISM; MYOGLOBIN; PROTEIN; MOUSE; RATS	Recent studies have shown that a protein-bound heme adduct formed from the reaction of BrCCl3 with myoglobin was due to bonding of the proximal histidine residue through the ring I vinyl of a heme-CCl2 moiety. The present study reveals that BrCCl3 also reacts with the heme of reduced human hemoglobin to form two protein-bound heme adducts. Edman degradation and mass spectrometry provided evidence that these protein-bound heme adducts were addition products in which heme-CCl2 or heme-CCl3 were bound to cysteine residue 93 of the beta-chain of hemoglobin. It appeared that the cysteine residue was bonded regiospecifically to the ring I vinyl group of the altered heme moiety, because the nonprotein-bound products of the reaction included the beta-carboxyvinyl and alpha-hydroxy-beta-trichloromethylethyl derivatives of the ring I vinyl moiety of heme. The absorption spectra of the protein-bound adducts in both the oxidized and reduced states were highly similar to those described for hemichromes, which are thought to be involved in the formation of Heinz bodies and subsequent red cell lysis.	NHLBI,CHEM PHARMACOL LAB,BETHESDA,MD 20892; NIMH,CLIN NEUROSCI BRANCH,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,SCH MED,MIDDLE ATLANTIC MASS SPECTROMETRY LAB,BALTIMORE,MD 21205	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Johns Hopkins University								AKHREM AA, 1989, BIOCHIM BIOPHYS ACTA, V992, P191, DOI 10.1016/0304-4165(89)90009-3; AXWORTHY DB, 1988, CHEM-BIOL INTERACT, V68, P99, DOI 10.1016/0009-2797(88)90009-9; BEAVEN GH, 1954, NATURE, V173, P389, DOI 10.1038/173389b0; BRYANT MS, 1987, CANCER RES, V47, P602; CATALANO CE, 1989, J BIOL CHEM, V264, P10534; Dayhoff MO, 1978, ATLAS PROTEIN SEQUEN, V5; FARMER PB, 1987, ARCH TOXICOL, V60, P251, DOI 10.1007/BF01234663; FERMI G, 1975, J MOL BIOL, V97, P237, DOI 10.1016/S0022-2836(75)80037-4; Gordon A. J., 1972, CHEM COMPANION; GORELICK NJ, 1989, CARCINOGENESIS, V10, P1579, DOI 10.1093/carcin/10.9.1579; HAUGEN DA, 1989, CHEM RES TOXICOL, V2, P379, DOI 10.1021/tx00012a005; HEBBEL RP, 1989, SEMIN HEMATOL, V26, P136; ITANO HA, 1975, NATURE, V256, P665, DOI 10.1038/256665a0; JANDL JH, 1960, J CLIN INVEST, V39, P1818, DOI 10.1172/JCI104206; KAUR S, 1989, J BIOL CHEM, V264, P16981; LADNER RC, 1977, J MOL BIOL, V114, P385, DOI 10.1016/0022-2836(77)90256-X; MATHEWS AJ, 1989, J BIOL CHEM, V264, P16573; NAYLOR S, 1990, CHEM RES TOXICOL, V3, P111, DOI 10.1021/tx00014a005; OLSON JS, 1987, J BIOL CHEM, V262, P12930; Orten JM, 1975, HUMAN BIOCH; OSAWA Y, 1990, J BIOL CHEM, V265, P10340; OSAWA Y, 1991, P NATL ACAD SCI USA, V88, P7081, DOI 10.1073/pnas.88.16.7081; OSAWA Y, 1991, J BIOL CHEM, V266, P3208; OSAWA Y, 1989, CHEM RES TOXICOL, V2, P131, DOI 10.1021/tx00009a001; OSAWA Y, 1989, J AM CHEM SOC, V111, P4462, DOI 10.1021/ja00194a048; PERUTZ MF, 1990, ANNU REV PHYSIOL, V52, P1; PERUTZ MF, 1968, NATURE, V219, P131, DOI 10.1038/219131a0; RACHMILEWITZ EA, 1974, SEMIN HEMATOL, V11, P441; SABBIONI G, 1990, ARCH TOXICOL, V64, P451, DOI 10.1007/BF01977626; SABBIONI G, 1990, CARCINOGENESIS, V11, P111, DOI 10.1093/carcin/11.1.111; SHELTON JB, 1984, J LIQ CHROMATOGR, V7, P1969, DOI 10.1080/01483918408068849; SKIPPER PL, 1989, CHEM RES TOXICOL, V2, P280, DOI 10.1021/tx00011a002; Stryer L., 1988, BIOCHEMISTRY-US; SUN JD, 1989, TOXICOL APPL PHARM, V100, P86, DOI 10.1016/0041-008X(89)90093-8; TEALE FWJ, 1959, BIOCHIM BIOPHYS ACTA, V35, P543, DOI 10.1016/0006-3002(59)90407-X; WINTERBOURN CC, 1990, SEMIN HEMATOL, V27, P41	36	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8739	8743						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577716				2022-12-25	WOS:A1992HR85400008
J	REDDY, MK; WEITZEL, SE; VONHIPPEL, PH				REDDY, MK; WEITZEL, SE; VONHIPPEL, PH			PROCESSIVE PROOFREADING IS INTRINSIC TO T4 DNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC ACID POLYMERASES; ESCHERICHIA-COLI; EXONUCLEASE ACTIVITY; SPONTANEOUS MUTATION; GEL-ELECTROPHORESIS; REPLICATION SYSTEM; III HOLOENZYME; AMBER MUTANT; SIZE CLASSES; PROTEIN	DNA replication occurs in vivo with very high processivity, meaning that the replication complex assembles at the origin(s) of replication and then performs template-directed synthesis of DNA over virtually the entire genome without dissociation. Such processivity also characterizes reconstituted replication holoenzyme complexes in vitro. However, the isolated DNA polymerases are much less processive, especially under physiological conditions. In this paper we monitor the degree of processivity displayed by the bacteriophage T4-coded DNA polymerase while in its proofreading mode by asking whether an isolated polymerase can "edit-out" the 3'-terminal nucleotide from the primer (using the 3'-->5'-exonuclease activity of the polymerase) and then switch into the synthesis mode without dissociating from the DNA template. This "switch experiment" is accomplished by using mismatched primer/template substrates as an experimental tool to mimic the situation that T4 DNA polymerase encounters after a misincorporation event has occurred. By performing experiments under single-turnover conditions (obtained using a heparin trap), we demonstrate that T4 DNA polymerase, upon encountering a misincorporated base, neither synthesizes the next base nor dissociates into solution. Instead, with a greater than 80% probability, it removes the misincorporated base and then continues synthesis in a fully processive manner. We also show that the removal of a doubly mispaired sequence from the 3'-terminus of the primer, followed by synthesis, is comparably processive. In contrast, the apparent processivity of removing a triply mispaired terminus is much reduced. Taken together, these observations are consistent with the notion that the "editing active site" of the T4 enzyme optimally accommodates only two unpaired nucleotide residues. Our results do not support the idea that the exonuclease activity of T4 DNA polymerase is highly selective for mismatched termini; they suggest instead that the dwell time at a misincorporated base determines overall editing efficiency. The integrated results of this study provide additional insight into the structure of the T4 DNA polymerase, as well as into the interactions between the polymerase and the polymerase accessory proteins that are required to provide the holoenzyme complex with full processivity.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon; University of Oregon				von Hippel, Peter H./0000-0003-2512-8097	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015792, R01GM029158, R37GM015792] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29158, GM-15792] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOULELA F, 1985, NUCLEIC ACIDS RES, V13, P4811, DOI 10.1093/nar/13.13.4811; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CATALANO CE, 1990, BIOCHEMISTRY-US, V29, P3612, DOI 10.1021/bi00467a004; CLAYTON LK, 1979, J BIOL CHEM, V254, P1902; COWART M, 1989, BIOCHEMISTRY-US, V28, P1975, DOI 10.1021/bi00431a004; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; DAS SK, 1980, J BIOL CHEM, V255, P7149; Der Garabedian P A, 1991, Biochemistry, V30, P9940, DOI 10.1021/bi00105a018; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; DOLEJSI MK, 1988, THESIS U OREGON; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; FAY PJ, 1981, J BIOL CHEM, V256, P976; FAY PJ, 1982, J BIOL CHEM, V257, P5692; FERSHT AR, 1982, J MOL BIOL, V156, P37, DOI 10.1016/0022-2836(82)90457-0; FERSHT AR, 1981, P NATL ACAD SCI-BIOL, V78, P4251, DOI 10.1073/pnas.78.7.4251; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOODMAN MF, 1983, J BIOL CHEM, V258, P3469; GOULIAN M, 1968, J BIOL CHEM, V243, P627; GREIP MA, 1989, J BIOL CHEM, V264, P11294; HERENDEEN DR, 1990, SCIENCE, V248, P573, DOI 10.1126/science.2185541; HUANG WM, 1972, J BIOL CHEM, V247, P3139; HUBER HE, 1987, J BIOL CHEM, V262, P16224; JARVIS TC, 1991, J BIOL CHEM, V266, P1830; JARVIS TC, 1990, UCLA SYM BI, V127, P261; JARVIS TC, 1990, J BIOL CHEM, V265, P15160; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; JOYCE CM, 1988, DNA REPLICATION MUTA, P220; Kornberg A., 1992, DNA REPLICATION; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; KUNKEL TA, 1988, CELL, V53, P837, DOI 10.1016/S0092-8674(88)90189-4; KUNKEL TA, 1981, J BIOL CHEM, V256, P9883; KUNKEL TA, 1984, J BIOL CHEM, V259, P1539; LEIRMO S, 1987, BIOCHEMISTRY-US, V26, P2095, DOI 10.1021/bi00382a006; LOEB LA, 1982, ANNU REV BIOCHEM, V52, P429; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCARTHY D, 1976, J MOL BIOL, V106, P963, DOI 10.1016/0022-2836(76)90346-6; MIZRAHI V, 1986, ADV ENZYMOL RELAT AR, V61, P437; MUZYCZKA N, 1972, J BIOL CHEM, V247, P7116; NEWPORT JW, 1980, MECHANISTIC STUDIES, V19, P485; NOSSAL NG, 1971, J BIOL CHEM, V246, P5414; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; OVERMAN LB, 1988, BIOCHEMISTRY-US, V34, P440; PETRUSKA J, 1986, P NATL ACAD SCI USA, V83, P1559, DOI 10.1073/pnas.83.6.1559; PETRUSKA J, 1988, P NATL ACAD SCI USA, V85, P6252, DOI 10.1073/pnas.85.17.6252; REHAKRANTZ LJ, 1991, P NATL ACAD SCI USA, V88, P2417, DOI 10.1073/pnas.88.6.2417; REHAKRANTZ LJ, 1988, J MOL BIOL, V202, P711, DOI 10.1016/0022-2836(88)90552-9; RUSH J, 1989, PREP BIOCHEM, V19, P329, DOI 10.1080/10826068908544921; SINHA NK, 1980, J BIOL CHEM, V255, P4290; SPICER EK, 1988, J BIOL CHEM, V263, P7478; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1989, J BIOL CHEM, V264, P6447; TOPAL MD, 1976, NATURE, V263, P285, DOI 10.1038/263285a0; VANDESAN.JH, 1973, BIOCHEMISTRY-US, V12, P5050, DOI 10.1021/bi00749a004; von Hippel P.H., 1975, PROTEIN LIGAND INTER, P270; WARSHAW MM, 1970, BIOPOLYMERS, V9, P1079, DOI 10.1002/bip.1970.360090910; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030	60	84	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14157	14166						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629215				2022-12-25	WOS:A1992JD32500059
J	SOBOTKABRINER, C; CHELSKY, D				SOBOTKABRINER, C; CHELSKY, D			COOH-TERMINAL METHYLATION OF LAMIN-B AND INHIBITION OF METHYLATION BY FARNESYLATED PEPTIDES CORRESPONDING TO LAMIN-B AND OTHER CAAX MOTIF PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT PROTEINS; SACCHAROMYCES-CEREVISIAE; CARBOXYL-METHYLATION; NUCLEAR-ENVELOPE; POSTTRANSLATIONAL MODIFICATION; ESTERIFIED PROTEINS; GAMMA-SUBUNIT; RAS2 PROTEIN; CDNA CLONES; CELL LINE	Previous reports from this laboratory have demonstrated that lamin B is reversibly methylesterified in a cell cycle-dependent manner. The site of this methylation, however, was not identified. In this report, we describe a single major methylated product obtained following reversed-phase high-performance liquid chromatographic analysis of peptides generated by proteolytic digestion of lamin B from rat liver nuclear envelopes. This peptide was retained on a lamin B COOH-terminal-specific antibody-affinity column, and COOH-terminal localization was confirmed by amino acid sequencing. Two other COOH-terminal peptides were found but were not methylated and differed in sequence by at least a single residue from the methylated peptide, indicating the existence of two lamin B gene products. Tetrapeptides, representing the putative mature COOH termini of lamin B, K-ras-2A, and unprocessed lamin A, were synthesized with or without farnesyl modification of the COOH-terminal cysteines. All three farnesylated peptides served as substrates for the partially purified lamin B methyltransferase with apparent K(m) values of 4.5, 0.69, and 21-mu-M, respectively. Nonfarnesylated peptides were not substrates for the enzyme. The three farnesylated peptides were also effective to varying degrees at inhibiting the methylation of lamin B and other cellular proteins in cell lysates.	DUPONT MERCK PHARMACEUT CO,CANC DISCOVERY RES,WILMINGTON,DE 19880	DuPont								ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; ATHERTON E, 1985, J CHEM SOC CHEM COMM, V3, P165; BACKLUND PS, 1990, J BIOL CHEM, V265, P15572; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CHELSKY D, 1985, BIOCHEMISTRY-US, V24, P6651, DOI 10.1021/bi00344a053; CHELSKY D, 1984, ANAL BIOCHEM, V141, P143, DOI 10.1016/0003-2697(84)90437-8; CHELSKY D, 1989, J BIOL CHEM, V264, P7637; CHELSKY D, 1987, J BIOL CHEM, V262, P4303; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DESCHENES RJ, 1989, J BIOL CHEM, V264, P11865; DWYER N, 1976, J CELL BIOL, V70, P581, DOI 10.1083/jcb.70.3.581; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; FUNG BKK, 1990, FEBS LETT, V260, P313, DOI 10.1016/0014-5793(90)80132-3; GEORGE DL, 1985, EMBO J, V4, P1199, DOI 10.1002/j.1460-2075.1985.tb03760.x; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOGER TH, 1990, CHROMOSOMA, V99, P379, DOI 10.1007/BF01726689; HOGER TH, 1988, EUR J CELL BIOL, V47, P283; KAUFMANN SH, 1983, J BIOL CHEM, V258, P2710; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KITTEN GT, 1991, J CELL BIOL, V113, P13, DOI 10.1083/jcb.113.1.13; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MCKEON FD, 1986, NATURE, V319, P463, DOI 10.1038/319463a0; MEIENHOFER J, 1979, INT J PEPT PROT RES, V13, P35; PETER M, 1989, J MOL BIOL, V208, P393, DOI 10.1016/0022-2836(89)90504-4; POLLARD KM, 1990, MOL CELL BIOL, V10, P2164, DOI 10.1128/MCB.10.5.2164; RUEGG R, 1959, HELV CHIM ACTA, V42, P2616, DOI 10.1002/hlca.19590420733; STIMMEL JB, 1990, BIOCHEMISTRY-US, V29, P9651, DOI 10.1021/bi00493a021; VORBURGER K, 1989, J MOL BIOL, V208, P405, DOI 10.1016/0022-2836(89)90505-6; WEBER K, 1989, FEBS LETT, V257, P411, DOI 10.1016/0014-5793(89)81584-4; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286	35	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12116	12122						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601879				2022-12-25	WOS:A1992HY94700071
J	XU, Q; LEIVA, MC; FISCHKOFF, SA; HANDSCHUMACHER, RE; LYTTLE, CR				XU, Q; LEIVA, MC; FISCHKOFF, SA; HANDSCHUMACHER, RE; LYTTLE, CR			LEUKOCYTE CHEMOTACTIC ACTIVITY OF CYCLOPHILIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMATURE RAT UTERUS; CIS-TRANS ISOMERASE; A-BINDING-PROTEIN; LEUKEMIA-CELLS; EOSINOPHIL; ESTROGEN; CYCLOSPORINE; PURIFICATION; INHIBITION; DISTINCT	During the purification of eosinophil chemotactic factors synthesized by the uterus in response to estrogen we isolated a protein having an N-terminal (15 amino acids) sequence identical to that of rat cyclophilin. Our data demonstrate that cyclophilin, a cytosolic protein isolated from bovine thymocytes, which specifically binds the immunosuppressive drug cyclosporin A, as well as recombinant human cyclophilin, displays eosinophil chemotactic activity. In addition to its chemotactic activity, cyclophilin stimulated the release of peroxidase activity from eosinophils. Maximal chemotactic activity of cyclophilin was achieved at a concentration of approximately 10 nM. At similar concentrations cyclophilin was also able to stimulate the migration of neutrophils. This chemotactic activity could be prevented by the addition of cyclosporin A, but not by a nonimmunosuppressive analog (1-fur-furyl-cyclosporin A) at similar concentrations. This chemotactic activity may represent an additional mechanism by which immunosuppressive drugs function to prevent tissue rejection.	UNIV PENN,SCH MED,DEPT OBSTET & GYNECOL,CLIN RES BLDG,422 CURIE BLVD,RM 778,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19104; YALE UNIV,DEPT PHARMACOL,NEW HAVEN,CT 06520	University of Pennsylvania; University of Pennsylvania; Yale University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020025, P01HD006274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM040660] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-20025, HD06274] Funding Source: Medline; NIGMS NIH HHS [GM-40660] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BJERSING L, 1964, ACTA PATHOL MIC SC, V60, P27, DOI 10.1111/apm.1964.60.1.27; CARONI P, 1991, J BIOL CHEM, V266, P10739; CORNER GW, 1969, J ENDOCRINOL, V131, P3; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DRATH DB, 1983, TRANSPLANT P, V15, P2367; DURETTE PL, 1988, TRANSPLANT P, V20, P51; ETIENNE A, 1989, INT ARCH ALLER A IMM, V88, P216, DOI 10.1159/000234790; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GOETZL EJ, 1975, P NATL ACAD SCI USA, V72, P4123, DOI 10.1073/pnas.72.10.4123; GOETZL EJ, 1980, EOSINOPHIL HLTH DISE, P158; GRANELLIPIPERNO A, 1984, J EXP MED, V160, P1792, DOI 10.1084/jem.160.6.1792; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HEROLD KC, 1986, J IMMUNOL, V136, P1315; HIRASAWA K, 1990, TRANSPLANTATION, V50, P637, DOI 10.1097/00007890-199010000-00022; HOWE RS, 1990, ENDOCRINOLOGY, V126, P3193, DOI 10.1210/endo-126-6-3193; HOWE RS, 1990, EXP HEMATOL, V18, P299; HULTSCH T, 1990, J IMMUNOL, V144, P2659; LEE YH, 1989, ENDOCRINOLOGY, V125, P3022, DOI 10.1210/endo-125-6-3022; LIMBERG MB, 1986, BRIT J OPHTHALMOL, V70, P343, DOI 10.1136/bjo.70.5.343; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; LYTTLE CR, 1977, P NATL ACAD SCI USA, V74, P3162, DOI 10.1073/pnas.74.8.3162; MAKI N, 1990, P NATL ACAD SCI USA, V87, P5440, DOI 10.1073/pnas.87.14.5440; Rytomaa T., 1960, ACTA PATHOL MIC S140, V50, P111; SCHLUTER E, 1975, VIRCHOWS ARCH A, V368, P191, DOI 10.1007/BF00432522; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, J IMMUNOL, V143, P1580; SPIK G, 1991, J BIOL CHEM, V266, P10735; STACK G, 1984, ENDOCRINOLOGY, V115, P1141, DOI 10.1210/endo-115-3-1141; TCHERNITCHIN A, 1974, NATURE, V248, P142, DOI 10.1038/248142a0; VENGE P, 1990, AGENTS ACTIONS, V29, P122, DOI 10.1007/BF01964739; ZHENG Y, 1988, J LEUKOCYTE BIOL, V44, P27, DOI 10.1002/jlb.44.1.27	34	162	175	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11968	11971						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601866				2022-12-25	WOS:A1992HY94700049
J	BEAUMELLE, B; BENSAMMAR, L; BIENVENUE, A				BEAUMELLE, B; BENSAMMAR, L; BIENVENUE, A			SELECTIVE TRANSLOCATION OF THE A-CHAIN OF DIPHTHERIA-TOXIN ACROSS THE MEMBRANE OF PURIFIED ENDOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; PLASMA-MEMBRANE; CELL-MEMBRANE; PROTEIN; PH; LYMPHOCYTES; ENTRY; REQUIREMENTS; FRAGMENT; BINDING	Translocation is a necessary and rate-limiting step for diphtheria toxin (DT) cytotoxicity. We have reconstituted DT translocation in a cell-free system using endosomes purified from lymphocytes and have demonstrated this using two different probe/cell systems, which provided identical results: I-125-DT/human CEM cells and I-125-transferrin-DT/mouse BW cells. The cell-free DT translocation process was found to be dependent on the presence of the pH gradient endosome (pH 5.3)/cytosol (pH 7). Among the pH equilibrating agents, nigericin (5-mu-M) was found to be the most effective, inhibiting DT translocation by 88%. An optimum pH value of 7 on the cytosolic side of the membrane (pH gradient almost-equal-to 1.7) was determined. ATP per se is not required for DT translocation. I-125-DT translocation was 3-fold more active from late than from early endosomes, probably because of their slightly more acidic pH. Only the A chain of the toxin was found to escape from either I-125-DT/CEM or I-125-transferrin-DT/BW endosomes. Translocation of control endosome labels (I-125-transferrin and I-125-horseradish peroxidase) was never observed. We also show that DT receptors present on resistant (mouse) cells block the translocation of the toxin and are responsible for the resistance of these cells to DT.			BEAUMELLE, B (corresponding author), UNIV MONTPELLIER 2, DEPT BIOL SANTE, CNRS, URA 530, CASE 107, F-34095 MONTPELLIER 5, FRANCE.			Beaumelle, Bruno/0000-0002-4912-9134				BEAUMELLE BD, 1990, J CELL BIOL, V111, P1811, DOI 10.1083/jcb.111.5.1811; BEAUMELLE BD, 1989, BIOCHEM J, V264, P137, DOI 10.1042/bj2640137; CARRIERE D, 1989, EXP CELL RES, V182, P114, DOI 10.1016/0014-4827(89)90284-X; DOMINGO DL, 1985, METHOD ENZYMOL, V112, P238; DONOVAN JJ, 1985, J BIOL CHEM, V260, P8817; DUMONT ME, 1988, J BIOL CHEM, V263, P2087; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; GONZALEZ JE, 1988, J BIOL CHEM, V263, P15257; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; HUDSON TH, 1988, J BIOL CHEM, V263, P4773; HUDSON TH, 1987, J BIOL CHEM, V262, P16484; JIANG JX, 1991, J BIOL CHEM, V266, P24003; JOHNSON VG, 1988, J BIOL CHEM, V263, P1295; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; KEEN JH, 1982, P NATL ACAD SCI-BIOL, V79, P2912, DOI 10.1073/pnas.79.9.2912; MADSHUS IH, 1988, BIOCHEM J, V250, P1, DOI 10.1042/bj2500001; MARSH JW, 1988, J BIOL CHEM, V263, P15993; MARSH M, 1984, BIOCHEM J, V218, P1; MEKADA E, 1991, J BIOL CHEM, V266, P20457; MEKADA E, 1988, J CELL BIOL, V107, P511, DOI 10.1083/jcb.107.2.511; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MOSKAUG JO, 1988, J BIOL CHEM, V263, P2518; MOSKAUG JO, 1987, J BIOL CHEM, V262, P10339; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; NAKAMURA LT, 1990, J BIOL CHEM, V265, P5237; OKEEFE DO, 1985, J BIOL CHEM, V260, P932; OLSNES S, 1988, TRENDS BIOCHEM SCI, V13, P348, DOI 10.1016/0968-0004(88)90105-3; Olsnes S., 1988, IMMUNOTOXINS, P39; RINK TJ, 1982, J CELL BIOL, V95, P189, DOI 10.1083/jcb.95.1.189; SAINTEMARIE J, 1989, BIOCHIM BIOPHYS ACTA, V982, P265, DOI 10.1016/0005-2736(89)90063-1; STENMARK H, 1988, J BIOL CHEM, V263, P13449; URADE R, 1988, BIOCHIM BIOPHYS ACTA, V946, P151, DOI 10.1016/0005-2736(88)90468-3; VANDEURS B, 1989, INT REV CYTOL, V117, P131; WILSON BA, 1990, SCIENCE, V250, P834, DOI 10.1126/science.250.4982.834	36	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11525	11531						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597480				2022-12-25	WOS:A1992HX16900090
J	NAKAGOSHI, H; KANEIISHII, C; SAWAZAKI, T; MIZUGUCHI, G; ISHII, S				NAKAGOSHI, H; KANEIISHII, C; SAWAZAKI, T; MIZUGUCHI, G; ISHII, S			TRANSCRIPTIONAL ACTIVATION OF THE C-MYC GENE BY THE C-MYB AND B-MYB GENE-PRODUCTS	ONCOGENE			English	Article							RNA INHIBITS PROLIFERATION; DNA-BINDING ACTIVITY; V-MYB; PROTO-ONCOGENE; OLIGOMER COMPLEMENTARY; NUCLEOTIDE-SEQUENCE; CELLULAR PROGENITOR; MYELOID-LEUKEMIA; EXPRESSION; CELLS	To identify the target genes modulated by the myb gene product (Myb), a co-transfection assay with a Myb expression plasmid was performed. Both c-Myb and B-Myb, another member of the myb gene family, trans-activated the human c-myc promoter. DNAase I footprint analysis using the bacterially expressed c-Myb, identified multiple c-Myb binding sites in the c-myc promoter region. Deletion analysis of the c-myc promoter suggested that some number of Myb binding sites, not a specific Myb binding site, is important for the c-Myb-induced trans-activation of the c-myc promoter. Using the c-myc-chloramphenicol acetyltransferase (CAT) construct as a reporter in a co-transfection assay, the domains of c-Myb required for trans-activation were examined. The functional domains of c-Myb identified using the c-myc promoter were almost the same as those identified previously with the artificial target gene containing Myb binding sites, but unlike the case with the artificial target gene the N-terminal half of the previously identified negative regulatory domains and the C-terminal 136 amino acids were required for the maximal trans-activation of the c-myc promoter. These results indicate that there are some differences in the regulation of Myb-dependent trans-activation in different target genes.	INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC GENET LAB,TSUKUBA,IBARAKI 305,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,SUITA,OSAKA 565,JAPAN; SCI UNIV TOKYO,DEPT PHARMACEUT SCI,SHINJUKU KU,TOKYO 162,JAPAN	RIKEN; Osaka University; Tokyo University of Science			NAKAGOSHI, Hideki/B-2145-2011; Ishii, Shunsuke/A-5271-2016	NAKAGOSHI, Hideki/0000-0003-0850-1814; Ishii, Shunsuke/0000-0002-6530-2478				ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; ANTON IA, 1988, NATURE, V336, P719, DOI 10.1038/336719a0; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BORTNER DM, 1991, NUCLEIC ACIDS RES, V19, P1533, DOI 10.1093/nar/19.7.1533; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; GEARWIRTZ AM, 1988, SCIENCE, V242, P1303; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HU YL, 1991, ONCOGENE, V6, P1549; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; NAGASE T, 1990, GENE, V94, P249, DOI 10.1016/0378-1119(90)90395-8; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; ONCLERCQ R, 1988, J VIROL, V62, P4533, DOI 10.1128/JVI.62.12.4533-4537.1988; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; RUSHLOW KE, 1982, SCIENCE, V216, P1421, DOI 10.1126/science.6283631; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sambrook J, 1989, MOL CLONING LABORATO; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; TAYA Y, 1984, EMBO J, V3, P2943, DOI 10.1002/j.1460-2075.1984.tb02236.x; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; YANG BS, 1991, MOL CELL BIOL, V11, P2291, DOI 10.1128/MCB.11.4.2291; ZOBEL A, 1991, ONCOGENE, V6, P1397	47	133	134	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1233	1240						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594249				2022-12-25	WOS:A1992HU64200022
J	TELLER, JK; FAHIEN, LA; DAVIS, JW				TELLER, JK; FAHIEN, LA; DAVIS, JW			KINETICS AND REGULATION OF HEPATOMA MITOCHONDRIAL NAD(P) MALIC ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRICARBOXYLIC-ACID CYCLE; RAT-LIVER MITOCHONDRIA; TUMOR MITOCHONDRIA; DEHYDROGENASE COMPLEX; MALATE-DEHYDROGENASE; ALPHA-KETOGLUTARATE; CITRATE SYNTHASE; CELLS; PURIFICATION; GLUTAMATE	Kinetic studies of Morris 7777 hepatoma mitochondrial NAD(P) malic enzyme were consistent with an ordered mechanism where NAD adds to the enzyme before malate and dissociation of NADH from the enzyme is rate-limiting. In addition to its active site, malate apparently also associates with a lower affinity with an activator site. The activator fumarate competes with malate at the activator site and facilitates dissociation of NADH from the enzyme. The ratio of NAD(P) malic enzyme to malate dehydrogenase activity in the hepatoma mitochondrial extract was found to be too low, even in the presence of known inhibitors of malate dehydrogenase, to account for the known ability of NAD(P) malic enzyme to intercept exogenous malate from malate dehydrogenase in intact tumor mitochondria (Moreadith, R. W., and Lehninger, A. L. (1984) J. Biol. Chem. 259, 6215-6221). However, NAD(P) malic enzyme may be able to intercept exogenous malate because according to the present results, it can associate with the pyruvate dehydrogenase complex, which could localize NAD(P) malic enzyme in the vicinity of the inner mitochondrial membrane. The activity levels of some key metabolic enzymes were found to be different in Morris 7777 mitochondria than in liver or mitochondria of other rapidly dividing tumors. These results are discussed in terms of differences among tumors in their ability to utilize malate, glutamate, and citrate as respiratory fuels.	UNIV WISCONSIN, SCH MED, DEPT PHARMACOL, 1300 UNIV AVE, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					NCI NIH HHS [CA 40445] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040445] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGGETTO LG, 1987, J BIOL CHEM, V262, P9535; Barritt G. J., 1976, GLUCONEOGENESIS ITS, P3; BOARD M, 1990, BIOCHEM J, V265, P503, DOI 10.1042/bj2650503; BURTON K, 1953, BIOCHEM J, V54, P86, DOI 10.1042/bj0540086; Cleland W W, 1979, Methods Enzymol, V63, P103; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P173, DOI 10.1016/0926-6569(63)90226-8; DENYER GS, 1986, BIOCHEM J, V239, P347, DOI 10.1042/bj2390347; DSOUZA SF, 1983, J BIOL CHEM, V258, P4706; FAHIEN LA, 1969, ARCH BIOCHEM BIOPHYS, V130, P478, DOI 10.1016/0003-9861(69)90060-5; FAHIEN LA, 1969, ARCH BIOCHEM BIOPHYS, V130, P449, DOI 10.1016/0003-9861(69)90057-5; FAHIEN LA, 1992, J BIOL CHEM, V267, P10411; FAHIEN LA, 1964, J BIOL CHEM, V239, P1925; FAHIEN LA, 1989, J BIOL CHEM, V264, P12303; FAHIEN LA, 1970, MOL PHARMACOL, V6, P156; FAHIEN LA, 1969, ARCH BIOCHEM BIOPHYS, V130, P468, DOI 10.1016/0003-9861(69)90059-9; FAHIEN LA, 1988, J BIOL CHEM, V263, P10687; FAHIEN LA, 1969, ARCH BIOCHEM BIOPHYS, V130, P456, DOI 10.1016/0003-9861(69)90058-7; FRIEDEN C, 1964, J BIOL CHEM, V239, P3522; FUKUSHIMA T, 1989, J BIOL CHEM, V264, P16483; HANSFORD RG, 1973, BIOCHEM BIOPH RES CO, V51, P480, DOI 10.1016/0006-291X(73)91282-5; HARARY I, 1953, J BIOL CHEM, V203, P595; HOEK JB, 1974, BIOCHIM BIOPHYS ACTA, V333, P546, DOI 10.1016/0005-2728(74)90138-8; HSU RY, 1967, J BIOL CHEM, V242, P5315; KEYS DA, 1990, J BACTERIOL, V172, P4280, DOI 10.1128/jb.172.8.4280-4287.1990; KOVACEVIC Z, 1971, BIOCHEM J, V125, P757, DOI 10.1042/bj1250757; KOVACEVIC Z, 1991, BIOCHEM J, V273, P271, DOI 10.1042/bj2730271; KOVACEVIC Z, 1972, CANCER RES, V32, P326; LAWSON D, 1975, CANCER RES, V35, P156; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; LAZO PA, 1981, EUR J BIOCHEM, V117, P19; LAZO PA, 1980, BIOCHEM J, V190, P705, DOI 10.1042/bj1900705; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; LENARTOWICZ E, 1979, BIOCHIM BIOPHYS ACTA, V586, P31, DOI 10.1016/0304-4165(79)90402-1; LINDERHOROWITZ M, 1969, CANCER RES, V29, P1195; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARESPERLMAN JA, 1988, CANCER RES, V48, P602; MOREADITH RW, 1984, J BIOL CHEM, V259, P6215; MOREADITH RW, 1984, J BIOL CHEM, V259, P6222; NAGEL WO, 1982, J BIOL CHEM, V257, P2405; PARLO RA, 1984, J BIOL CHEM, V259, P9997; Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190; REED LJ, 1981, COLD SPRING HARBOR C, V8, P701; REITZER LJ, 1979, J BIOL CHEM, V254, P2669; ROBINSON JB, 1987, J BIOL CHEM, V262, P1786; ROBINSON JB, 1985, J BIOL CHEM, V260, P800; SAUER LA, 1973, BIOCHEM BIOPH RES CO, V50, P524, DOI 10.1016/0006-291X(73)90871-1; SAUER LA, 1973, FEBS LETT, V33, P251, DOI 10.1016/0014-5793(73)80205-4; SAUER LA, 1980, J BIOL CHEM, V255, P3844; SCHIMERLIK MI, 1977, BIOCHEMISTRY-US, V16, P571, DOI 10.1021/bi00623a002; SIESS EA, 1976, CANCER RES, V36, P55; SILVERSTEIN E, 1969, BIOCHIM BIOPHYS ACTA, V185, P297, DOI 10.1016/0005-2744(69)90422-7; SILVERSTEIN E, 1969, BIOCHEMISTRY-US, V8, P2543, DOI 10.1021/bi00834a042; SMITH CM, 1979, EUR J BIOCHEM, V97, P283, DOI 10.1111/j.1432-1033.1979.tb13113.x; SRERE PA, 1976, GLUCONEOGENESIS ITS, P153; STANLEY CJ, 1980, BIOCHEM J, V191, P147, DOI 10.1042/bj1910147; SUMEGI B, 1980, BIOCHIM BIOPHYS ACTA, V616, P158, DOI 10.1016/0005-2744(80)90134-5; SUMEGI B, 1984, J BIOL CHEM, V259, P5040; SWICK RW, 1965, J BIOL CHEM, V240, P3334; Teller J K, 1990, Protein Expr Purif, V1, P151, DOI 10.1016/1046-5928(90)90009-N; TELLER JK, 1990, J BIOL CHEM, V265, P19486; TISCHLER ME, 1977, ARCH BIOCHEM BIOPHYS, V184, P222, DOI 10.1016/0003-9861(77)90346-0; WICE BM, 1981, J BIOL CHEM, V256, P7812; ZOLNIEROWICZ S, 1988, BIOCHEM MED METAB B, V39, P208, DOI 10.1016/0885-4505(88)90078-3	63	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10423	10432						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587826				2022-12-25	WOS:A1992HV09000036
J	IM, MJ; GRAY, C; RIM, AJ				IM, MJ; GRAY, C; RIM, AJ			CHARACTERIZATION OF A PHOSPHOLIPASE-C ACTIVITY REGULATED BY THE PURIFIED GH IN RECONSTITUTION SYSTEMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1-ADRENERGIC RECEPTOR SUBTYPES; LIVER PLASMA-MEMBRANES; GUANINE-NUCLEOTIDE; RAT-BRAIN; G-PROTEIN; INOSITOL TRISPHOSPHATE; ADENYLATE-CYCLASE; BINDING-PROTEINS; BOVINE BRAIN; PURIFICATION	Recently, we have reported that the isolated guanine nucleotide-binding regulatory protein, G(h), couples to the alpha-1-adrenergic receptor (Im, M.-J., and Graham, R. M. (1990) J. Biol. Chem. 265, 18944-18951 and Im, M.-J., Riek, R. P., and Graham, R. M. (1990) J. Biol. Chem. 265, 18952-18960) and has a molecular mass of approximately 74 kDa, and the approximately 50-kDa protein which is co-purified probably regulates guanine nucleotide binding of the 74-kDa GTP-binding protein. In this paper, we describe the role of purified G(h) in the regulation of phospholipase C in the reconstitution system. The stimulation of phospholipase C activity by G(h) effectively occurred at a low calcium concentration (less-than-or-equal-to 2-mu-M), but the phospholipase C (PLC) itself required at least 50-100 times more calcium to become fully activated. The characteristic nature of phospholipase C stimulation by G(h) is its response to the calcium concentration. Thus, the enzyme activity changes in narrow submicromolar ranges and reaches maximal stimulation, but it does not extend to the levels above those stimulated by calcium alone. The calcium concentrations for the maximal stimulation of phospholipase C activity were 10-20-mu-M with phospholipid vesicles and 100-200-mu-M with detergent solution. These calcium concentrations were further decreased when G(h) and phospholipase C were co-reconstituted into the phospholipid vesicles or in the detergent solution. The maximal stimulations of the PLC activity were reached at < 5-mu-M calcium in both the vesicles and the detergent solution. The changes of calcium concentration for the activation of PLC are quite different from those obtained by reconstituting PLC-beta-1 with G(q)-like G-proteins (Smarcka, A. V., Hepler, J. R., Brown, K. O., and Sternweis, P. C. (1991) Science 251, 804-807 and Taylor, S. J., Chae, H. Z., Rhee, S. G., and Exton, J. H. (1991) Nature 350, 516-518). The phospholipase C activity was stimulated in a G(h) concentration-dependent manner in the presence of GTP-gamma-S. The phospholipase C activity was activated by G(h-alpha) in the presence of aluminum fluoride, but not by G(h-beta). Furthermore, a G(h).PLC complex can be induced by incubation with aluminum fluoride in a detergent solution and partially purified without the dissociation of related proteins. Thus, our reconstitution studies show that the pattern of stimulation of PLC by AlF4--activated G(h) in the ternary complex is similar to the stimulation of PLC activated by G(h) in both detergent solution and phospholipid vesicles.			IM, MJ (corresponding author), CLEVELAND CLIN FDN,RES INST,DEPT HEART & HYPERTENS RES FFB37,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL033713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045985] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-33713-06] Funding Source: Medline; NIGMS NIH HHS [GM45985] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEHR W, 1982, J BIOL CHEM, V257, P6452; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; COCKCROFT S, 1987, TRENDS BIOCHEM SCI, V12, P75, DOI 10.1016/0968-0004(87)90035-1; DAWSON MC, 1980, EUR J BIOCHEM, V112, P33, DOI 10.1111/j.1432-1033.1980.tb04983.x; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; FEDER D, 1986, EMBO J, V5, P1509, DOI 10.1002/j.1460-2075.1986.tb04390.x; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GONZALES RA, 1985, BIOCHEM J, V232, P799, DOI 10.1042/bj2320799; HAN C, 1987, MOL PHARMACOL, V32, P505; HAN C, 1987, NATURE, V329, P333, DOI 10.1038/329333a0; HOFMANN SL, 1982, J BIOL CHEM, V257, P4359; IM MJ, 1990, J BIOL CHEM, V265, P18952; IM MJ, 1990, J BIOL CHEM, V265, P18944; IRVINE RF, 1984, BIOCHEM J, V218, P177, DOI 10.1042/bj2180177; IRVINE RF, 1978, BIOCHEM J, V176, P475, DOI 10.1042/bj1760475; JOHNSON RD, 1987, MOL PHARMACOL, V31, P239; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KIM UH, 1991, J BIOL CHEM, V266, P1359; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LEE CO, 1980, SCIENCE, V209, P699, DOI 10.1126/science.7394527; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; MINNEMAN KP, 1988, MOL PHARMACOL, V33, P509; MORRIS AJ, 1990, J BIOL CHEM, V265, P13508; MORROW AL, 1985, EUR J PHARMACOL, V109, P285, DOI 10.1016/0014-2999(85)90432-7; MORROW AL, 1986, MOL PHARMACOL, V29, P321; NEER EJ, 1988, NATURE, V333, P12; NIJJAR MS, 1977, BIOCHIM BIOPHYS ACTA, V480, P390, DOI 10.1016/0005-2744(77)90032-8; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PFEUFFER E, 1985, P NATL ACAD SCI USA, V82, P3086, DOI 10.1073/pnas.82.10.3086; PFEUFFER T, 1988, CURR TOP CELL REGUL, V29, P129; Razin S, 1974, Methods Enzymol, V32, P459; REBECCHI MJ, 1987, J BIOL CHEM, V262, P12526; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RYU SH, 1987, J BIOL CHEM, V262, P12511; SLIVKA SR, 1987, J BIOL CHEM, V262, P4200; SMITH GL, 1985, BIOCHIM BIOPHYS ACTA, V839, P287, DOI 10.1016/0304-4165(85)90011-X; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; TAKENAWA T, 1981, J BIOL CHEM, V256, P6769; TAYLOR SJ, 1987, BIOCHEM J, V248, P791, DOI 10.1042/bj2480791; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; TERMAN BI, 1990, MOL PHARMACOL, V37, P526; TSIEN RY, 1980, BIOCHIM BIOPHYS ACTA, V599, P623, DOI 10.1016/0005-2736(80)90205-9; TSUJIMOTO G, 1989, MOL PHARMACOL, V36, P166; UHING RJ, 1986, J BIOL CHEM, V261, P2140; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114	48	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8887	8894						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577727				2022-12-25	WOS:A1992HR85400031
J	PRIVALLE, CT; FRIDOVICH, I				PRIVALLE, CT; FRIDOVICH, I			TRANSCRIPTIONAL AND MATURATIONAL EFFECTS OF MANGANESE AND IRON ON THE BIOSYNTHESIS OF MANGANESE-SUPEROXIDE DISMUTASE IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAEROBIC BIOSYNTHESIS; INDUCTION; DIAMIDE; ENZYME; OPERON	Anaerobically grown Escherichia coli contain an enzymatically active iron superoxide dismutase (Fe2-FeSOD) and an inactive iron-substituted manganese superoxide dismutase (Fe2-MnSOD). The anaerobic electron sink, nitrate plus paraquat, enhanced biosynthesis of the MnSOD polypeptide, with accumulation of inactive Fe2-MnSOD. The oxidant, diamide, in contrast, allowed anaerobic production of the active forms of MnSOD, i.e. Mn2-MnSOD and Mn/Fe-MnSOD. Nutritional supplementation with Mn(II) favored occupancy of the MnSOD active site with manganese and allowed anaerobic accumulation of Mn2-MnSOD in the absence of diamide. Enrichment of the anaerobic growth medium with Fe(II) both suppressed biosynthesis of the MnSOD polypeptide and inhibited formation of the active manganese-containing forms. A tac-sodA operon fusion was used to examine the effects of chelating agents and metals on maturation of nascent MnSOD, independent from the transcriptional effects these agents impose. Isopropyl-1-thio-beta-D-galactopyranoside (IPTG) elicited anaerobic biosynthesis of MnSOD, which accumulated as the inactive Fe2-MnSOD. Diamide, with IPTG, allowed formation of active Mn/Fe-MnSOD while 1,10-phenanthroline with IPTG resulted in accumulation of Mn2-MnSOD. These results suggest that iron participates in the redox-sensitive control of the formation of active MnSOD at two levels, i.e. that of transcription as well as that of maturation. During maturation of the nascent MnSOD polypeptide, iron and manganese compete for the metal-binding site; anaerobic conditions favor iron-binding, whereas oxidants, such as dioxygen or diamide, favor binding of manganese.			PRIVALLE, CT (corresponding author), DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710, USA.							BAGG A, 1987, BIOCHEMISTRY-US, V26, P5471, DOI 10.1021/bi00391a039; BAGG A, 1987, MICROBIOL REV, V51, P509, DOI 10.1128/MMBR.51.4.509-518.1987; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; BEYER WF, 1991, J BIOL CHEM, V266, P303; BEYER WF, 1989, BIOCHEMISTRY-US, V28, P4403, DOI 10.1021/bi00436a042; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; GARDNER PR, 1987, J BIOL CHEM, V262, P17591; HASSAN HM, 1987, J BIOL CHEM, V262, P17173; KEELE BB, 1970, J BIOL CHEM, V245, P6176; KIRBY T, 1980, ARCH BIOCHEM BIOPHYS, V201, P551, DOI 10.1016/0003-9861(80)90544-5; KOSOWER EM, 1972, BIOCHIM BIOPHYS ACTA, V264, P39, DOI 10.1016/0304-4165(72)90114-6; KOSOWER NS, 1969, BIOCHEM BIOPH RES CO, V37, P593, DOI 10.1016/0006-291X(69)90850-X; LAWRENCE GD, 1979, BIOCHEMISTRY-US, V18, P3045, DOI 10.1021/bi00581a021; LEGENDRE N, 1988, BIOTECHNIQUES, V6, P154; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MIYAKE K, 1988, J GEN APPL MICROBIOL, V34, P105, DOI 10.2323/jgam.34.105; MOODY CS, 1984, J BIOL CHEM, V259, P2821; OSE DE, 1979, ARCH BIOCHEM BIOPHYS, V194, P360, DOI 10.1016/0003-9861(79)90628-3; PRIVALLE CT, 1991, FREE RADICAL RES COM, V12-3, P419, DOI 10.3109/10715769109145812; PRIVALLE CT, 1988, J BIOL CHEM, V263, P4274; PRIVALLE CT, 1989, J BIOL CHEM, V264, P2758; PRIVALLE CT, 1990, J BIOL CHEM, V265, P21966; PUGH SYR, 1985, J BACTERIOL, V162, P196, DOI 10.1128/JB.162.1.196-202.1985; SCHIAVONE JR, 1988, J BIOL CHEM, V263, P4269; TARDAT B, 1991, MOL MICROBIOL, V5, P455, DOI 10.1111/j.1365-2958.1991.tb02129.x; TOUATI D, 1989, FREE RADICAL RES COM, V8, P1, DOI 10.3109/10715768909087967; TOUATI D, 1988, J BACTERIOL, V170, P2511, DOI 10.1128/jb.170.6.2511-2520.1988; TOUATI D, 1988, OXYRADICALS MOL BIOL, P247	30	60	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9140	9145						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577750				2022-12-25	WOS:A1992HR85400068
J	NEUENSCHWANDER, PF; MORRISSEY, JH				NEUENSCHWANDER, PF; MORRISSEY, JH			DELETION OF THE MEMBRANE ANCHORING REGION OF TISSUE FACTOR ABOLISHES AUTOACTIVATION OF FACTOR-VII BUT NOT COFACTOR FUNCTION - ANALYSIS OF A MUTANT WITH A SELECTIVE DEFICIENCY IN ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-VII; ACTIVATED FACTOR-IX; BOVINE FACTOR-VII; FACTOR-X; BLOOD-COAGULATION; PROTEIN; MECHANISM; THROMBIN; CLEAVAGE; CALCIUM	The activation of human blood coagulation factor VII can occur by the feedback activity of either factor VIIa (autoactivation) or factor Xa. Both of these reactions are known to be enhanced by the presence of tissue factor, an integral membrane protein and the cofactor for factor VIIa. We examine here the activation of I-125-factor VII by both factor VIIa and factor Xa employing a mutant soluble form of tissue factor which has had its transmembrane and cytoplasmic domains deleted (sTF1-219). This mutant soluble tissue factor retains cofactor activity toward factor VIIa in a single-stage clotting assay but shows a strong dependence on initial plasma levels of factor VIIa (from 1 to 10,000 ng/ml) when compared to wild-type tissue factor. We show that this dependence is due to a deficiency of sTF1-219 in ability to both promote autoactivation and enhance the factor Xa-catalyzed activation of I-125-factor VII. sTF1-219 does not, however, inhibit the tissue factor-independent activation of I-125-factor VII by factor Xa. The results strongly suggest that the phospholipid anchoring region of tissue factor is essential for autoactivation and beneficial for factor Xa-catalyzed activation of I-125-factor VII. In addition, when taken together with the dependence of clotting times on initial factor VIIa levels observed with sTF1-219, these results indicate that factor VII autoactivation may be of greater importance in the initiation of blood coagulation via tissue factor than has been previously realized.	OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,825 NE 13TH ST,OKLAHOMA CITY,OK 73104	Oklahoma Medical Research Foundation			Morrissey, James H/H-4933-2011; Morrissey, James H./GLR-5645-2022	Morrissey, James H/0000-0002-1570-1569; 	NHLBI NIH HHS [HL-44225] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044225] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BACH R, 1990, P NATL ACAD SCI USA, V87, P6995, DOI 10.1073/pnas.87.18.6995; BAJAJ SP, 1981, J BIOL CHEM, V256, P253; Bevington P. R., 1969, DATA REDUCTION ERROR; BJORKLID E, 1977, BIOCHEM J, V165, P89, DOI 10.1042/bj1650089; COMP PC, 1984, BLOOD, V63, P15; GUHA A, 1992, FASEB J, V6, pA328; HAPAK RC, 1992, FASEB J, V6, pA330; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P4189, DOI 10.1021/bi00638a009; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4901, DOI 10.1021/bi00667a023; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MASYS DR, 1982, BLOOD, V60, P1143; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MORRISSEY JH, 1988, THROMB RES, V50, P481, DOI 10.1016/0049-3848(88)90197-1; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NELSESTUEN GL, 1984, MET IONS BIOL SYST, V17, P353; NEMERSON Y, 1973, P NATL ACAD SCI USA, V70, P310, DOI 10.1073/pnas.70.2.310; NEMERSON Y, 1985, THROMB RES, V40, P351, DOI 10.1016/0049-3848(85)90270-1; NEMERSON Y, 1988, BLOOD, V71, P1; NEUENSCHWANDER PF, 1991, ARTERIOSCL THROMB, V11, P1544; PABORSKY LR, 1991, J BIOL CHEM, V266, P21911; PEDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P9331, DOI 10.1021/bi00450a013; RADCLIFFE R, 1976, J BIOL CHEM, V251, P4797; RADCLIFFE R, 1975, J BIOL CHEM, V250, P388; RAO LVM, 1988, P NATL ACAD SCI USA, V85, P6687, DOI 10.1073/pnas.85.18.6687; RAO LVM, 1985, BLOOD, V65, P218; RAPAPORT SI, 1991, ANN NY ACAD SCI, V614, P51, DOI 10.1111/j.1749-6632.1991.tb43691.x; RUF W, 1991, J BIOL CHEM, V266, P2158; RUF W, 1991, J BIOL CHEM, V266, P15719; RUF W, 1991, J BIOL CHEM, V266, P16256; SELIGSOHN U, 1979, J CLIN INVEST, V64, P1056, DOI 10.1172/JCI109543	34	112	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14477	14482						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629232				2022-12-25	WOS:A1992JD32500104
J	SCHMIDT, CJ; THOMAS, TC; LEVINE, MA; NEER, EJ				SCHMIDT, CJ; THOMAS, TC; LEVINE, MA; NEER, EJ			SPECIFICITY OF G-PROTEIN-BETA-SUBUNIT AND GAMMA-SUBUNIT INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ROD OUTER SEGMENTS; MUSCARINIC K+-CHANNEL; LIMITED PROTEOLYSIS; RETINAL ROD; CDNA CLONE; TRANSDUCIN; PHOSPHOLIPASE-A2; IDENTIFICATION; HOMOLOGY; BRAIN	Multiple heterotrimeric guanine nucleotide binding protein (G protein) subunits have evolved to couple a large variety of receptors to intracellular effectors. G protein beta-gamma subunits are essential for efficient coupling of alpha-subunits to receptors, and they are also important for modulation of effectors. Several different beta and gamma-subunits exist, but it is not known whether all possible combinations of beta and gamma can form functional dimers. To answer this question, we have compared the ability of in vitro translated beta-1, beta-2, and beta-3 to form dimers with either gamma-1 or gamma-2. Dimerization was monitored by gel filtration, resistance to tryptic digestion, and chemical cross-linking. The results indicate that beta-1 binds both gamma-subunits, beta-2 binds only gamma-2, and beta-3 will bind neither gamma-1 or gamma-2. Hence, the occurrence of beta-gamma dimers may be partially regulated by the ability of the subunits to associate. Specificity of dimerization might allow cells to co-express multiple beta and gamma-subunits while maintaining efficient and specific signal transduction.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV ENDOCRINOL & METAB,BALTIMORE,MD 21205	Harvard University; Harvard Medical School; Johns Hopkins University	SCHMIDT, CJ (corresponding author), BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,75 FRANCIS ST,BOSTON,MA 02115, USA.			Levine, Michael/0000-0003-0036-7809; Schmidt, Carl/0000-0002-8386-4781	NIDDK NIH HHS [R01 DK34281, T32 DK07737] Funding Source: Medline; NIGMS NIH HHS [GM36295] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034281, T32DK007737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036295] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATRUDA TT, 1988, J BIOL CHEM, V263, P5008; CHRISTY KG, 1989, BIOTECHNIQUES, V7, P692; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GAO B, 1987, P NATL ACAD SCI USA, V84, P6122, DOI 10.1073/pnas.84.17.6122; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; HURWITZ RL, 1985, J BIOL CHEM, V260, P568; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEREA CL, 1986, SCIENCE, V234, P77, DOI 10.1126/science.3529395; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LOGOTHETIS DE, 1988, P NATL ACAD SCI USA, V85, P5814, DOI 10.1073/pnas.85.16.5814; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5983; NATHANS J, 1987, ANNU REV NEUROSCI, V10, P163; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F; WINSLOW JW, 1986, J BIOL CHEM, V261, P7571; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9316; YI F, 1991, J BIOL CHEM, V266, P3900	30	170	172	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13807	13810						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629181				2022-12-25	WOS:A1992JD32500005
J	WARD, CR; STOREY, BT; KOPF, GS				WARD, CR; STOREY, BT; KOPF, GS			ACTIVATION OF A GI PROTEIN IN MOUSE SPERM MEMBRANES BY SOLUBILIZED PROTEINS OF THE ZONA-PELLUCIDA, THE EGGS EXTRACELLULAR-MATRIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROINJECTED INOSITOL 1,4,5-TRISPHOSPHATE; NUCLEOTIDE REGULATORY PROTEINS; MANNOSE 6-PHOSPHATE RECEPTOR; INDUCED ACROSOME REACTION; PERTUSSIS TOXIN; MAMMALIAN SPERM; FERTILIZATION INVITRO; PHOSPHOLIPID-VESICLES; GAMETE INTERACTIONS; BINDING PROTEINS	Zona pellucida (ZP)-induced acrosomal exocytosis in mammalian spermatozoa is thought to be mediated by signal transduction cascades similar to those found in hormonally responsive cells. In order to characterize this process further, we have examined the role of GTP-binding regulatory proteins (G proteins) in coupling sperm-ZP interaction to intracellular second messenger systems in mouse sperm. An in vitro signal transduction assay was developed to assess ZP-G protein dynamics in sperm membrane preparations. Guanosine 5'-3-O-(thio)triphosphate (GTP-gamma-S), a poorly hydrolyzable analogue of GTP, bound to these membranes in a specific and concentration-dependent fashion which reached saturation at 100 nm. Incubation of the membrane preparations with heat-solubilized ZP resulted in a significant increase in specific GTP-gamma-S binding in a concentration-dependent fashion with a half-maximal response at 1.25-2 ZP/mu-l. Solubilized ZP also caused a significant increase in high affinity GTPase activity in the membranes over basal levels. Mastoparan increased specific GTP-gamma-S binding to the sperm membranes and stimulated high-affinity membrane GTPase activity to levels consistently greater than that seen with the solubilized ZP. Mastoparan, together with solubilized ZP, gave the same level of stimulation of GTP-gamma-S binding as mastoparan alone. Pertussis toxin completely inhibited the ZP-stimulated GTP-gamma-S binding, but only decreased mastoparan-stimulated GTP-gamma-S binding by 70-80%. Purified ZP3, the ZP component which possesses quantitatively all of the acrosomal exocytosis-inducing activity of the intact ZP, stimulated GTP-gamma-S binding to the same level as solubilized ZP; ZP1 and ZP2 did not stimulate GTP-gamma-S binding. ZP from fertilized eggs (ZP(f)), which does not possess acrosome reaction-inducing activity, also failed to stimulate GTP-gamma-S binding to sperm membranes. These data demonstrate the direct activation of a G(i) protein in sperm membrane preparations in response to the ZP glycoprotein, ZP3, that induces the acrosome reaction. These data imply that G(i) protein activation is an early event in the signal sequence leading to sperm acrosomal exocytosis.			WARD, CR (corresponding author), UNIV PENN, SCH MED, DEPT OBSTET & GYNECOL, DIV REPROD BIOL, PHILADELPHIA, PA 19104 USA.				NICHD NIH HHS [HD06274, HD07725, HD22732] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD022732] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD006274] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEDFORD JM, 1978, CELL SURF REV, V5, P65; BIRNBAUMER L, 1990, CRIT REV BIOCHEM MOL, V25, P225, DOI 10.3109/10409239009090610; BLEIL JD, 1988, DEV BIOL, V128, P376, DOI 10.1016/0012-1606(88)90299-0; BLEIL JD, 1990, P NATL ACAD SCI USA, V87, P5563, DOI 10.1073/pnas.87.14.5563; BLEIL JD, 1980, CELL, V20, P873, DOI 10.1016/0092-8674(80)90334-7; BLEIL JD, 1986, J CELL BIOL, V102, P1363, DOI 10.1083/jcb.102.4.1363; BLEIL JD, 1983, DEV BIOL, V95, P317, DOI 10.1016/0012-1606(83)90032-5; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CAMORATTO AM, 1985, ENDOCRINOLOGY, V116, P1506, DOI 10.1210/endo-116-4-1506; CASSEL D, 1976, BIOCHIM BIOPHYS ACTA, V452, P538, DOI 10.1016/0005-2744(76)90206-0; CERIONE RA, 1986, J BIOL CHEM, V261, P3901; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; ENDO Y, 1987, DEV BIOL, V119, P210, DOI 10.1016/0012-1606(87)90222-3; ENDO Y, 1988, DEV BIOL, V129, P12, DOI 10.1016/0012-1606(88)90157-1; FAUNDES DF, 1991, J CELL BIOL, V4115, pA141; FLORMAN HM, 1984, DEV BIOL, V106, P243, DOI 10.1016/0012-1606(84)90079-4; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; FLORMAN HM, 1982, DEV BIOL, V91, P121, DOI 10.1016/0012-1606(82)90015-X; FLORMAN HM, 1989, DEV BIOL, V135, P133, DOI 10.1016/0012-1606(89)90164-4; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLASSNER M, 1991, DEV BIOL, V146, P438, DOI 10.1016/0012-1606(91)90245-X; GREVE JM, 1985, J MOL BIOL, V181, P253, DOI 10.1016/0022-2836(85)90089-0; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HILF G, 1989, EUR J BIOCHEM, V186, P725, DOI 10.1111/j.1432-1033.1989.tb15266.x; HIRAI Y, 1979, CHEM PHARM BULL, V27, P1942; HUANG CL, 1989, J BIOL CHEM, V264, P4391; IMAMURA K, 1988, J BIOL CHEM, V263, P14093; KALAB P, 1991, BIOL REPROD, V45, P783, DOI 10.1095/biolreprod45.5.783; KARNIK NS, 1992, IN PRESS DEV BIOL; KINLOCH RA, 1991, J CELL BIOL, V115, P655, DOI 10.1083/jcb.115.3.655; KLIGMAN I, 1991, DEV BIOL, V145, P344, DOI 10.1016/0012-1606(91)90133-N; KOCH G, 1991, FEBS LETT, V291, P336, DOI 10.1016/0014-5793(91)81315-Y; KOPF GS, 1986, J BIOL CHEM, V261, P7327; KOPF GS, 1991, METHOD ENZYMOL, V195, P257; KURASAWA S, 1989, DEV BIOL, V133, P295, DOI 10.1016/0012-1606(89)90320-5; KURODA Y, 1980, P JPN ACAD B-PHYS, V56, P660, DOI 10.2183/pjab.56.660; KUROSE H, 1986, J BIOL CHEM, V261, P6423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MA, 1985, BIOL REPROD, V33, P235, DOI 10.1095/biolreprod33.1.235; LEE MA, 1992, MOL REPROD DEV, V31, P78, DOI 10.1002/mrd.1080310114; LEYTON L, 1989, J CELL BIOL, V108, P2163, DOI 10.1083/jcb.108.6.2163; LEYTON L, 1989, CELL, V57, P1123, DOI 10.1016/0092-8674(89)90049-4; LEYTON L, 1989, DEV BIOL, V132, P174, DOI 10.1016/0012-1606(89)90215-7; LIANG M, 1991, J BIOL CHEM, V266, P13342; LUTTRELL L, 1990, J BIOL CHEM, V265, P16873; MANEJWALA FM, 1991, DEV BIOL, V144, P301, DOI 10.1016/0012-1606(91)90423-Z; MEYERHOF W, 1991, FEBS LETT, V284, P155, DOI 10.1016/0014-5793(91)80674-R; MOUSLI M, 1990, FEBS LETT, V259, P260, DOI 10.1016/0014-5793(90)80023-C; MURAYAMA Y, 1990, J BIOL CHEM, V265, P17456; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; OBRIEN DA, 1989, ENDOCRINOLOGY, V125, P2973, DOI 10.1210/endo-125-6-2973; OKAJIMA F, 1985, J BIOL CHEM, V260, P6761; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; SALING PM, 1979, J CELL BIOL, V83, P544, DOI 10.1083/jcb.83.3.544; WASSARMAN PM, 1988, ANNU REV BIOCHEM, V57, P414; WILDE MW, 1992, MOL REPROD DEV, V31, P297, DOI 10.1002/mrd.1080310411; YANG LJ, 1991, J BIOL CHEM, V266, P22451; YOKOKAWA N, 1989, BIOCHEM BIOPH RES CO, V158, P712, DOI 10.1016/0006-291X(89)92779-4	60	93	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14061	14067						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629205				2022-12-25	WOS:A1992JD32500045
J	ALLEN, LAH; RAETZ, CRH				ALLEN, LAH; RAETZ, CRH			PARTIAL PHENOTYPIC SUPPRESSION OF A PEROXISOME-DEFICIENT ANIMAL-CELL MUTANT TREATED WITH AMINOGLYCOSIDE-G418	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-OXIDATION ENZYMES; HAMSTER OVARY CELLS; ZELLWEGER SYNDROME; MEMBRANE-PROTEINS; LIGNOCERIC ACID; BIOSYNTHESIS; FIBROBLASTS; LIVER; DISORDERS; PLASMALOGENS	Certain enzymes normally associated with peroxisomes, such as the dihydroxyacetone phosphate (DHAP) acyltransferase involved in plasmalogen biosynthesis, are present at low levels in peroxisomedeficient mutants of Chinese hamster ovary (CHO) cells. We now show that the aminoglycoside G418 increases the residual DHAP acyltransferase in mutant ZR-82 by 60-fold. This is accompanied by a dose- and time-dependent restoration of the plasmalogen content. G418 treatment of ZR-82 also increases residual peroxisomal beta-oxidation activity by 3.8-fold. G418 does not affect wild-type CHO cells (CHO-K1) or a different peroxisome-deficient mutant, ZR-78.1. The effects of G418 on ZR-82 are transient, since plasmalogens and DHAP-acyltransferase decline to basal levels 5 days after G418 withdrawal. Other aminoglycosides and lysosomotropic agents do not alter plasmalogen levels in ZR-82. The subcellular distribution of catalase (an enzyme of the peroxisomal matrix which is present in normal amounts in peroxisome-deficient mutants but is mislocalized in the cytosol) is unaffected by G418 treatment of ZR-82, demonstrating that G418 does not restore peroxisomes. Localization of catalase by immunofluorescence microscopy confirms a total absence of intact peroxisomes in ZR-82, either before or after exposure to G418. This study is the first to demonstrate that some peroxisome-deficient mutants can be induced to accumulate functional DHAP acyltransferase and other peroxisomal enzymes, usually missing in the absence of peroxisomes. G418 may have some theraputic value in selected patients with inborn errors of peroxisome assembly, such as Zellweger syndrome.	MERCK SHARP & DOHME LTD,DEPT BIOCHEM,POB 2000,RAHWAY,NJ 07065; UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53706	Merck & Company; University of Wisconsin System; University of Wisconsin Madison				Allen, Lee-Ann/0000-0001-8929-6968				ALLEN LAH, 1989, P NATL ACAD SCI USA, V86, P7012, DOI 10.1073/pnas.86.18.7012; ALLEN LAH, 1990, FASEB J, V4, P2246; AUBERTTULKENS G, 1979, LAB INVEST, V40, P481; BALLAS LM, 1984, BIOCHIM BIOPHYS ACTA, V795, P297, DOI 10.1016/0005-2760(84)90079-1; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORST P, 1986, BIOCHIM BIOPHYS ACTA, V866, P179, DOI 10.1016/0167-4781(86)90044-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHANAN JH, 1987, EUR J CELL BIOL, V43, P141; DANIELSON KG, 1989, IN VITRO CELL DEV B, V25, P535; DEDUVE C, 1966, PHYSIOL REV, V46, P323, DOI 10.1152/physrev.1966.46.2.323; ESKO JD, 1980, J BIOL CHEM, V255, P4474; EUSTICE DC, 1984, BIOCHEMISTRY-US, V23, P1462, DOI 10.1021/bi00302a019; EUSTICE DC, 1984, ANTIMICROB AGENTS CH, V26, P53, DOI 10.1128/AAC.26.1.53; GUPTA D, 1988, SCIENCE, V242, P1446, DOI 10.1126/science.2904699; HAJRA AK, 1982, ANN NY ACAD SCI, V386, P170, DOI 10.1111/j.1749-6632.1982.tb21415.x; HYMAN R, 1989, CELL SURFACE ANTIGEN, V1, P223; LAZAROW PB, 1987, J INHERIT METAB DIS, V10, P11, DOI 10.1007/BF01812843; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; MANNAERTS GP, 1979, J BIOL CHEM, V254, P4585; MINGEOTLECLERCQ MP, 1988, BIOCHEM PHARMACOL, V37, P591, DOI 10.1016/0006-2952(88)90130-X; MORAND OH, 1990, BIOCHIM BIOPHYS ACTA, V1034, P132, DOI 10.1016/0304-4165(90)90066-6; MORAND OH, 1988, J BIOL CHEM, V263, P11597; MOSER HW, 1987, DEV NEUROSCI-BASEL, V9, P1, DOI 10.1159/000111604; MOSLEY ST, 1981, P NATL ACAD SCI-BIOL, V78, P5717, DOI 10.1073/pnas.78.9.5717; PETERS TJ, 1972, J EXP MED, V136, P1117, DOI 10.1084/jem.136.5.1117; RAETZ CRH, 1982, P NATL ACAD SCI-BIOL, V79, P3223, DOI 10.1073/pnas.79.10.3223; SANTERRE RF, 1984, GENE, V30, P147, DOI 10.1016/0378-1119(84)90115-X; SANTOS MJ, 1988, J BIOL CHEM, V263, P10502; SANTOS MJ, 1988, SCIENCE, V239, P1536, DOI 10.1126/science.3281254; SCHLOSSMAN DM, 1976, J BIOL CHEM, V251, P5738; SCHRAM AW, 1986, P NATL ACAD SCI USA, V83, P6156, DOI 10.1073/pnas.83.16.6156; SCHUTGENS RBH, 1986, EUR J PEDIATR, V144, P430, DOI 10.1007/BF00441734; SINGH I, 1983, J LIPID RES, V24, P662; SINGH I, 1984, P NATL ACAD SCI-BIOL, V81, P4203, DOI 10.1073/pnas.81.13.4203; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; STEVENS VL, 1990, J BIOL CHEM, V265, P15653; SUZUKI Y, 1986, J INHERIT METAB DIS, V9, P292, DOI 10.1007/BF01799668; SUZUKI Y, 1987, J INHERIT METAB DIS, V10, P297, DOI 10.1007/BF01800086; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; VAZQUEZ D, 1978, INT REV BIOCH AMINO, V18, P169; WANDERS RJA, 1986, CLIN CHIM ACTA, V159, P1, DOI 10.1016/0009-8981(86)90160-9; WEBBER KO, 1987, ARCH BIOCHEM BIOPHYS, V254, P611, DOI 10.1016/0003-9861(87)90144-5; WIEMER EAC, 1989, EUR J CELL BIOL, V50, P407; ZOELLER RA, 1986, P NATL ACAD SCI USA, V83, P5170, DOI 10.1073/pnas.83.14.5170; ZOELLER RA, 1989, J BIOL CHEM, V264, P21872; ZOELLER RA, 1988, J BIOL CHEM, V263, P11590	47	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13191	13199						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618823				2022-12-25	WOS:A1992JB74600018
J	CLELAND, JL; HEDGEPETH, C; WANG, DIC				CLELAND, JL; HEDGEPETH, C; WANG, DIC			POLYETHYLENE-GLYCOL ENHANCED REFOLDING OF BOVINE CARBONIC ANHYDRASE-B - REACTION STOICHIOMETRY AND REFOLDING MODEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMER ADSORPTION; REARRANGEMENT; FLUORESCENCE	Polyethylene glycol (PEG) inhibited aggregation during refolding of bovine carbonic anhydrase B (CAB) through the formation of a nonassociating PEG-intermediate complex. Stoichiometric concentrations of PEG were required for complete recovery of active protein during refolding at aggregating conditions. For example, a PEG (M(r) = 3350) to CAB molar ratio ([PEG] /[CAB]) of 2 was sufficient to inhibit aggregation during refolding at 1.0 mg/ml (33.3-mu-M) protein and 0.5 M guanidine hydrochloride. In addition, the PEG concentration required for enhancement was dependent upon the molecular weight and only molecular weights between 1000 and 8000 were effective in inhibiting aggregation. In the presence of PEG, the rate of refolding was the same as that observed for refolding without the formation of associated species. Refolding in the presence of PEG resulted in the rapid formation of a PEG complex with the molten globule first intermediate, and this PEG-intermediate complex did not aggregate. The CAB refolding kinetics in the presence of PEG were determined and used to develop a model of the PEG enhanced refolding pathway. The mathematical model was validated by independent activity measurements of CAB refolding. This model predicted that PEG enhanced refolding of CAB occurred by a specific interaction of PEG with the molten globule first intermediate to form a nonassociating complex which continued to fold at the same rate as the first intermediate. The predicted pathway and binding properties of PEG indicate that PEG enhanced refolding may be analogous to chaperonin mediated protein folding.	MIT,DEPT CHEM ENGN,CTR BIOTECHNOL PROC ENGN,CAMBRIDGE,MA 02139; GENENTECH INC,PHARMACEUT RES & DEV,SAN FRANCISCO,CA 94080; UNIV MARYLAND,DEPT BIOL,CATONSVILLE,MD 21228	Massachusetts Institute of Technology (MIT); Roche Holding; Genentech								ARAWAKA T, 1985, BIOCHEMISTRY-US, V24, P6756; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHAR K, 1988, LANGMUIR, V4, P989, DOI 10.1021/la00082a034; CHAR K, 1989, LANGMUIR, V5, P1096, DOI 10.1021/la00088a038; CLELAND JL, 1992, J BIOL CHEM, V267, P3147; CLELAND JL, 1992, BIOTECHNOL PROGR, V8, P97, DOI 10.1021/bp00014a002; CLELAND JL, 1990, BIO-TECHNOL, V8, P1274, DOI 10.1038/nbt1290-1274; CLELAND JL, 1990, BIOCHEMISTRY-US, V29, P11072, DOI 10.1021/bi00502a009; CLELAND JL, 1991, ACS SYM SER, V470, P169; HUBBARD TJP, 1991, PROTEIN ENG, V4, P711, DOI 10.1093/protein/4.7.711; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; POCKER Y, 1967, BIOCHEMISTRY-US, V6, P668, DOI 10.1021/bi00855a005; SEMISOTNOV GV, 1990, J MOL BIOL, V213, P561, DOI 10.1016/S0022-2836(05)80215-3; WONG KP, 1973, J BIOL CHEM, V248, P8518	15	160	173	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13327	13334						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618834				2022-12-25	WOS:A1992JB74600039
J	KAISER, SM; LANEUVILLE, P; BERNIER, SM; RHIM, JS; KREMER, R; GOLTZMAN, D				KAISER, SM; LANEUVILLE, P; BERNIER, SM; RHIM, JS; KREMER, R; GOLTZMAN, D			ENHANCED GROWTH OF A HUMAN KERATINOCYTE CELL-LINE INDUCED BY ANTISENSE RNA FOR PARATHYROID HORMONE-RELATED PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETIC PEPTIDE; ADENYLATE-CYCLASE; BONE-RESORPTION; GENE-EXPRESSION; PROTEIN; MALIGNANCY; INVITRO; INVIVO; DIFFERENTIATION; HYPERCALCEMIA	We have used antisense RNA technology to inhibit endogenous parathyroid hormone-related peptide (PTHRP) production in the established human keratinocyte cell line, HPK1A, in order to assess the role of PTHRP as a potential modulator of cell growth. Rat PTHRP cDNA was cloned into the replication defective retroviral vector pYN in an antisense orientation and a stable cell line (HPK1A-AS) was generated after infection by amphotropic virus and selection by the neomycin derivative, G418. Expression of the transfected antisense sequence was confirmed with an RNA sense probe for PTHRP. The effect of the retrovirally mediated gene transfer on the endogenous PTHRP transcript was examined with an RNA antisense probe which demonstrated an absence of the endogenous transcript in HPK1A-AS cells. A 1.6-kilobase transcript was, however, present in equivalent quantities in both uninfected HPK1A and pYN-infected (HPK1A-pYN) cells. Immunocytochemistry and assessment of PTHRP secretion into the medium using an NH2-terminal radioimmunoassay and a UMR 106 adenylate cyclase bioassay confirmed the absence of PTHRP in HPK1A-AS cells. Examination of the inhibition of PTHRP production on cell growth demonstrated a reduction in doubling time and an increase in [H-3]thymidine incorporation. Cell cycle analysis showed an increase in the proportion of the cell population in the S phase (relative to G0/G1) in HPK1A-AS cells compared to HPK1A or HPK1A-pYN cells. These data, therefore, indicate that endogenous PTHRP acts as an effective inhibitor of cell growth in this keratinocyte model and that this action occurs, at least in part, by diminishing entry into the S phase of the cell cycle. Furthermore, the antisense RNA method is a potent one to evaluate the cellular actions of PTHRP.	ROYAL VICTORIA HOSP,CALCIUM RES LAB,RM H467,687 PINE AVE W,MONTREAL H3A 1A1,QUEBEC,CANADA; MCGILL UNIV,DEPT MED,MONTREAL H3A 1A1,QUEBEC,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL H3A 1A1,QUEBEC,CANADA; MCGILL UNIV,DEPT PHYSIOL,MONTREAL H3A 1A1,QUEBEC,CANADA; NCI,BETHESDA,MD 20892	McGill University; Royal Victoria Hospital; McGill University; McGill University; McGill University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Laneuville, Pierre/AAH-2293-2021	Kremer, Richard/0000-0002-7053-2139				ADACHI N, 1990, BIOCHEM BIOPH RES CO, V166, P1088, DOI 10.1016/0006-291X(90)90978-V; ASA SL, 1990, J CLIN ENDOCR METAB, V71, P1112, DOI 10.1210/jcem-71-5-1112; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BERNIER SM, 1991, ENDOCRINOLOGY, V128, P2752, DOI 10.1210/endo-128-6-2752; BRADY G, 1988, ONCOGENE, V3, P687; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; BURTON PBJ, 1990, BIOCHEM BIOPH RES CO, V167, P1134, DOI 10.1016/0006-291X(90)90641-Y; CHAN SDH, 1990, MOL ENDOCRINOL, V4, P638, DOI 10.1210/mend-4-4-638; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMENS MJ, 1987, CELL, V49, P157, DOI 10.1016/0092-8674(87)90553-8; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DAUGHERTY BL, 1989, GENE ANAL TECH, V6, P1, DOI 10.1016/0735-0651(89)90007-1; DEFTOS LJ, 1989, MOL ENDOCRINOL, V3, P503, DOI 10.1210/mend-3-3-503; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DRUCKER DJ, 1989, MOL ENDOCRINOL, V3, P1589, DOI 10.1210/mend-3-10-1589; DURST M, 1987, ONCOGENE, V1, P251; ERNST M, 1989, J BONE MINER RES, V3, pS309; FUKAYAMA S, 1988, ENDOCRINOLOGY, V123, P2841, DOI 10.1210/endo-123-6-2841; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HENDERSON J, 1991, CANCER RES, V51, P6521; HENDERSON JE, 1992, ENDOCRINOLOGY, V130, P449, DOI 10.1210/en.130.1.449; HENDERSON JE, 1990, J BONE MINER RES, V5, P105, DOI 10.1002/jbmr.5650050203; Holick M. F., 1988, J BONE MINERAL RES S, V3, pS214; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; HORIUCHI N, 1987, SCIENCE, V238, P1566, DOI 10.1126/science.3685994; IKEDA K, 1988, MOL ENDOCRINOL, V2, P1230, DOI 10.1210/mend-2-12-1230; IKEDA K, 1990, J BIOL CHEM, V265, P5398; JUPPNER H, 1988, J BIOL CHEM, V263, P8557; KEMP BE, 1987, SCIENCE, V238, P1568, DOI 10.1126/science.3685995; KIM SK, 1985, CELL, V42, P129, DOI 10.1016/S0092-8674(85)80108-2; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KREMER R, 1991, J CLIN INVEST, V87, P884, DOI 10.1172/JCI115094; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MCGARRY TJ, 1986, P NATL ACAD SCI USA, V83, P399, DOI 10.1073/pnas.83.2.399; MERENDINO JJ, 1986, SCIENCE, V231, P388, DOI 10.1126/science.2417317; MILSTONE L, 1988, Journal of Cell Biology, V107, p73A; NISSENSON RA, 1988, J BIOL CHEM, V263, P12866; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RABBANI SA, 1988, ENDOCRINOLOGY, V123, P2709; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STERNBER.LA, 1970, J HISTOCHEM CYTOCHEM, V18, P315, DOI 10.1177/18.5.315; STEWART AF, 1988, J CLIN INVEST, V81, P596, DOI 10.1172/JCI113358; STEWART AF, 1991, J BONE MINER RES, V6, P305; STRICKLAND S, 1988, SCIENCE, V241, P680, DOI 10.1126/science.2456615; THIEDE MA, 1988, SCIENCE, V242, P278, DOI 10.1126/science.3175653; VINDELOV LL, 1977, VIRCHOWS ARCH B, V24, P227; YASUDA T, 1989, J BIOL CHEM, V264, P7720; YASUDA T, 1989, MOL ENDOCRINOL, V3, P518, DOI 10.1210/mend-3-3-518; YATES AJP, 1988, J CLIN INVEST, V81, P932, DOI 10.1172/JCI113406	51	133	133	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13623	13628						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618864				2022-12-25	WOS:A1992JB74600083
J	YIP, CC; JACK, E				YIP, CC; JACK, E			INSULIN-RECEPTORS ARE BIVALENT AS DEMONSTRATED BY PHOTOAFFINITY-LABELING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GROWTH FACTOR-I; SITE-SITE INTERACTIONS; NEGATIVE COOPERATIVITY; BINDING; SPECIFICITY	Insulin receptors in human placental membranes were photoaffinity-labeled with a radioactive human insulin-like growth factor I (hIGF-I) photoprobe N(epsilon-B28)-monoazidobenzoyl I-125-hIGF-I either alone or together with a non-radioactive insulin photoprobe N(epsilon-B29)-monoazidobenzoyl insulin. Precipitation of the solubilized receptors with anti-insulin antibody showed that receptors labeled with the radioactive hIGF-I photoprobe were detected in the immunoprecipitate only when photolabeling was carried out in the presence of the non-radioactive insulin photoprobe. Comparable results were obtained in converse experiments using a radioactive insulin photoprobe N(epsilon-B29)-monoazidobenzoyl I-125-insulin, a non-radioactive hIGF-I photoprobe N(epsilon-B28)-monoazidobenzoyl hIGF-I, and an antibody to hIGF-I. The amount of radioactive receptors precipitated by either the anti-insulin antibody or the anti-hIGHF-I antibody was close to the expected amount. These observations demonstrate that the insulin receptor is bivalent being capable of binding two molecules of ligand.			YIP, CC (corresponding author), UNIV TORONTO,BANTING & BEST DEPT MED RES,112 COLL ST,TORONTO M5G 1L6,ONTARIO,CANADA.							ANDERSEN AS, 1990, BIOCHEMISTRY-US, V29, P7363, DOI 10.1021/bi00484a002; CZECH MP, 1985, ANN REV PHYSL, V47, P375; DEMEYTS P, 1976, J BIOL CHEM, V251, P1877; DEVRIES CP, 1991, ENDOCR RES, V17, P331, DOI 10.1080/07435809109106811; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; FUJITAYAMAGUCHI Y, 1983, J BIOL CHEM, V258, P5045; GOLDFINE ID, 1987, ENDOCR REV, V8, P235, DOI 10.1210/edrv-8-3-235; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; HELMERHORST E, 1987, BIOCHEM BIOPH RES CO, V147, P399, DOI 10.1016/S0006-291X(87)80135-3; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; MARKUSSEN J, 1991, J BIOL CHEM, V266, P18814; POLLET RJ, 1977, J BIOL CHEM, V252, P5828; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SOOS MA, 1989, BIOCHEM J, V263, P553, DOI 10.1042/bj2630553; YIP CC, 1992, J CELL BIOCHEM, V48, P19, DOI 10.1002/jcb.240480105; YIP CC, 1991, BIOCHEMISTRY-US, V30, P695, DOI 10.1021/bi00217a016; YIP CC, 1984, METHODS DIABETES RES, V1, P3; YIP CC, 1969, BIOCHEMISTRY-US, V62, P415; ZHANG B, 1991, BIOCHEMISTRY-US, V30, P5113, DOI 10.1021/bi00235a001	19	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13131	13134						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618814				2022-12-25	WOS:A1992JB74600005
J	APEL, TW; MAUTNER, J; POLACK, A; BORNKAMM, GW; EICK, D				APEL, TW; MAUTNER, J; POLACK, A; BORNKAMM, GW; EICK, D			2 ANTISENSE PROMOTERS IN THE IMMUNOGLOBULIN MU-SWITCH REGION DRIVE EXPRESSION OF C-MYC IN THE BURKITTS-LYMPHOMA CELL-LINE BL67	ONCOGENE			English	Article							HEAVY-CHAIN LOCUS; TRANSCRIPTIONAL ACTIVATION; EPSILON-TRANSCRIPTS; GENE; ENHANCER; INTERLEUKIN-4; SP1; TRANSFORMATION; TRANSLOCATION; MUTATIONS	In the Burkitt's lymphoma (BL) cell line BL67 the first exon of the c-myc gene is fused to the mu-switch region of the immunoglobulin heavy-chain gene (IgH). BL67 cells express IgH/c-myc hybrid RNAs which are initiated in the immunoglobulin locus, transcribed across the chromosomal breakpoint into the first exon of c-myc and spliced using the physiological splice donor and acceptor sites of the c-myc gene. We have isolated cDNAs of these hybrid RNAs and characterized the start points in the Ig heavy-chain gene. Two promoters were identified in the mu-switch region of BL67 cells which give rise to antisense transcription of the mu-gene. These promoters are also active in other BL cell lines, in B cells without Ig translocation and in a T-cell line. Both promoters co-localize with DNAase I-hypersensitive sites. HNF and HSW, in the mu-switch region. The structures of IgH/c-myc hybrid RNAs and of the corresponding promoters are described.	GSF MUNICH,FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT,INST KLIN MOLEK BIOL & TUMORGENET,W-8000 MUNICH,GERMANY; UNIV FREIBURG,INST MED MIKROBIOL & HYG,VIROL ABT,W-7800 FREIBURG,GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Freiburg								ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BORNKAMM GW, 1988, CELLULAR ONCOGENE AC, P223; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; FISCHER KD, 1990, NUCLEIC ACIDS RES, V18, P5685, DOI 10.1093/nar/18.19.5685; FRYKBERG L, 1987, ONCOGENE, V1, P415; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; GERONDAKIS S, 1990, P NATL ACAD SCI USA, V87, P1581, DOI 10.1073/pnas.87.4.1581; GUBLER U, 1983, GENE, V25, P262; HENNIGHAUSEN L, 1985, NATURE, V314, P289, DOI 10.1038/314289a0; JULIUS MA, 1988, ONCOGENE, V2, P469; KAKKIS E, 1988, NUCLEIC ACIDS RES, V16, P77, DOI 10.1093/nar/16.1.77; KEMP DJ, 1980, P NATL ACAD SCI-BIOL, V77, P7400, DOI 10.1073/pnas.77.12.7400; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LUTZKER S, 1988, MOL CELL BIOL, V8, P1849, DOI 10.1128/MCB.8.4.1849; MILLS FC, 1990, NUCLEIC ACIDS RES, V18, P7305, DOI 10.1093/nar/18.24.7305; PETTERSSON S, 1990, NATURE, V344, P165, DOI 10.1038/344165a0; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RABBITTS TH, 1983, NATURE, V306, P806, DOI 10.1038/306806a0; RADCLIFFE G, 1990, MOL CELL BIOL, V10, P382, DOI 10.1128/MCB.10.1.382; ROTHMAN P, 1990, MOL CELL BIOL, V10, P1672, DOI 10.1128/MCB.10.4.1672; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SPENCER CA, 1991, ADV CANCER RES, P1; SYMONDS G, 1989, ONCOGENE, V4, P285; WIMAN KG, 1984, P NATL ACAD SCI-BIOL, V81, P6798, DOI 10.1073/pnas.81.21.6798	29	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1267	1271						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620543				2022-12-25	WOS:A1992HZ97100003
J	BORNER, C; GUADAGNO, SN; FABBRO, D; WEINSTEIN, IB				BORNER, C; GUADAGNO, SN; FABBRO, D; WEINSTEIN, IB			EXPRESSION OF 4 PROTEIN-KINASE-C ISOFORMS IN RAT FIBROBLASTS - DISTINCT SUBCELLULAR-DISTRIBUTION AND REGULATION BY CALCIUM AND PHORBOL ESTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL DOWN-REGULATION; BREAST CANCER-CELLS; ALLOSTERIC REGULATION; SIGNAL TRANSDUCTION; LIMITED PROTEOLYSIS; KINETIC-ANALYSIS; GH4C1 CELLS; PKC-EPSILON; PURIFICATION; RECEPTOR	Protein kinase C (PKC), the major receptor for tumor-promoting phorbol esters, consists of a family of at least eight distinct lipid-regulated enzymes. How the various PKC isozymes are regulated in vivo and how they couple to particular cellular responses is largely unknown. We have examined the expression and regulation of PKC isoforms in R6 rat embryo fibroblasts. Northern and Western blot analyses indicate that these cells express four PKC isoforms, cPKC-alpha, nPKC-epsilon, nPKC-delta, and nPKC-zeta; of which nPKC-epsilon and nPKC-delta are the most abundant. In agreement with the simultaneous presence of cPKC and nPKC isozymes, both Ca2+-dependent and -independent PKC activities were detected in extracts of these cells. cPKC-alpha and nPKC-zeta were predominantly localized in the cytosol when subcellular fractionation was carried out in the presence of [ethylenebis(oxyethylenenitrilo)]tetraacetic acid. When cell lysis was carried out in the presence of Ca2+, >50% of cPKC-alpha redistributed to the particulate fraction, whereas nPKC-zeta remained in the cytosol. In contrast to cPKC-alpha and nPKC-zeta, 60-80% of nPKC-epsilon and nPKC-delta were located in a Ca2+-insensitive, membrane-bound form. Treatment of R6 cells with 12-O-tetradecanoyl phorbol 13-acetate (TPA), resulted in the translocation of all four PKC isozymes to the membrane fraction, and the subsequent down-regulation of cPKC-alpha, nPKC-zeta, and nPKC-delta, nPKC-epsilon, however, was only partially down-regulated in response to long-term TPA exposure. Overproduction of exogenous cPKC-beta-I in R6 cells conferred partial resistance of nPKC-delta to TPA-induced down-regulation and potentiated the resistance of nPKC-epsilon to down-regulation. These results demonstrate that the multiple isoforms of PKC which coexist within a single cell type are differentially regulated by extra- and intracellular stimuli and may thereby influence growth control and transformation via distinct mechanisms.	COLUMBIA UNIV, CTR COMPREHENS CANC, 701 W 168TH ST, NEW YORK, NY 10027 USA; COLUMBIA UNIV, INST CANC RES, NEW YORK, NY 10027 USA; COLUMBIA UNIV, DEPT PHARMACOL, NEW YORK, NY 10027 USA; CIBA GEIGY AG, DEPT PHARMACEUT RES, ONCOL K125, CH-4002 BASEL, SWITZERLAND	Columbia University; Columbia University; Columbia University; Novartis					NCI NIH HHS [CA 02656] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKITA Y, 1990, BIOCHEM BIOPH RES CO, V172, P184, DOI 10.1016/S0006-291X(05)80191-3; AKITA Y, 1990, J BIOL CHEM, V265, P354; ANDERSON WB, 1985, ADV CYCLIC NUCL PROT, V19, P287; ASE K, 1988, FEBS LETT, V236, P396, DOI 10.1016/0014-5793(88)80064-4; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BAZZI MD, 1988, BIOCHEMISTRY-US, V27, P7589, DOI 10.1021/bi00420a003; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; BORNER C, 1989, J BIOL CHEM, V264, P13902; BORNER C, 1990, CELL GROWTH DIFFER, V1, P653; BORNER C, 1992, IN PRESS PROTEIN KIN; BORNER C, 1991, J BIOL CHEM, V267, P12900; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER DR, 1989, BIOCHEM BIOPH RES CO, V161, P327, DOI 10.1016/0006-291X(89)91600-8; CRABOS M, 1991, BIOCHEM BIOPH RES CO, V178, P878, DOI 10.1016/0006-291X(91)90973-B; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; ELDAR H, 1990, J BIOL CHEM, V265, P13290; ELTOUNY S, 1990, J BIOL CHEM, V265, P16437; EXTON JH, 1990, J BIOL CHEM, V265, P1; FOURNIER A, 1989, BIOCHEM BIOPH RES CO, V161, P556, DOI 10.1016/0006-291X(89)92635-1; FREIREMOAR J, 1991, J IMMUNOL, V147, P405; FRY MJ, 1985, EMBO J, V4, P3173, DOI 10.1002/j.1460-2075.1985.tb04061.x; GODSON C, 1990, J BIOL CHEM, V265, P8369; GUADAGNO SN, 1992, IN PRESS J BIOL CHEM; HANNUN YA, 1990, J BIOL CHEM, V265, P2962; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HEIDENREICH KA, 1990, J BIOL CHEM, V265, P15076; HIDAKA H, 1988, J BIOL CHEM, V263, P4523; HOMAN EC, 1991, J BIOL CHEM, V266, P5676; HOSHINA S, 1990, J CELL PHYSIOL, V145, P262, DOI 10.1002/jcp.1041450210; HOUSEY GM, 1987, P NATL ACAD SCI USA, V84, P1065, DOI 10.1073/pnas.84.4.1065; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUANG KP, 1986, J BIOL CHEM, V261, P2134; HUANG KP, 1989, ACTA ENDOCRINOL-COP, V121, P307, DOI 10.1530/acta.0.1210307; HUWILER A, 1991, BIOCHEM J, V279, P441, DOI 10.1042/bj2790441; HYATT SL, 1990, MOL CARCINOGEN, V3, P45, DOI 10.1002/mc.2940030202; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KILEY S, 1990, J BIOL CHEM, V265, P15704; KILEY SC, 1990, MOL ENDOCRINOL, V4, P59, DOI 10.1210/mend-4-1-59; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LEACH KL, 1991, J BIOL CHEM, V266, P3215; LEIBERSPERGER H, 1990, J BIOL CHEM, V265, P16108; LEIBERSPERGER H, 1991, J BIOL CHEM, V266, P14778; MARAIS RM, 1989, EUR J BIOCHEM, V182, P129, DOI 10.1111/j.1432-1033.1989.tb14809.x; MARAIS RM, 1990, FEBS LETT, V277, P151, DOI 10.1016/0014-5793(90)80831-3; MCCAFFREY PG, 1987, BIOCHEM BIOPH RES CO, V146, P140, DOI 10.1016/0006-291X(87)90702-9; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; MISHAK H, 1991, BIOCHEMISTRY-US, V30, P7925; MISHAK H, 1991, J IMMUNOL, V147, P3981; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; NELSESTUEN GL, 1991, J BIOENERG BIOMEMBR, V23, P43; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1990, J BIOL CHEM, V265, P22434; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PATEL G, 1989, CELL SIGNAL, V1, P227, DOI 10.1016/0898-6568(89)90040-5; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P28, DOI 10.1016/0968-0004(89)90086-8; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PFEFFER LM, 1991, P NATL ACAD SCI USA, V88, P7988, DOI 10.1073/pnas.88.18.7988; REGAZZI R, 1986, INT J CANCER, V37, P731, DOI 10.1002/ijc.2910370514; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SCHAAP D, 1990, EUR J BIOCHEM, V191, P431, DOI 10.1111/j.1432-1033.1990.tb19139.x; STRULOVICI B, 1991, J BIOL CHEM, V266, P168; STRULOVICI B, 1989, BIOCHEMISTRY-US, V28, P3569, DOI 10.1021/bi00434a063; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UCHIDA T, 1984, J BIOL CHEM, V259, P2311; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WEYMAN CM, 1988, CANCER RES, V48, P6535; WOLF M, 1990, BIOCHEM J, V269, P723, DOI 10.1042/bj2690723; Woodgett JR., 1987, CELL MEMBRANES, P215, DOI [10.1007/978-1-4613-1915-3_6, DOI 10.1007/978-1-4613-1915-3_6]; YOUNG S, 1988, EUR J BIOCHEM, V173, P247, DOI 10.1111/j.1432-1033.1988.tb13991.x	82	186	188	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12892	12899						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618787				2022-12-25	WOS:A1992HZ48300076
J	GERTLER, A; HAUSER, SD; SAKAL, E; VASHDI, D; STATEN, N; FREEMAN, JJ; KRIVI, GG				GERTLER, A; HAUSER, SD; SAKAL, E; VASHDI, D; STATEN, N; FREEMAN, JJ; KRIVI, GG			PREPARATION, PURIFICATION, AND DETERMINATION OF THE BIOLOGICAL-ACTIVITIES OF 12-N TERMINUS-TRUNCATED RECOMBINANT ANALOGS OF BOVINE PLACENTAL-LACTOGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; SCANNING MUTAGENESIS; BINDING-PROPERTIES; MAMMARY-GLAND; PROLACTIN; RECEPTOR; OVINE; TECHNOLOGY; PROTEINS; CELLS	Removal of 13 to 15 amino acids from the N terminus of bovine placental lactogen (bPL), which according to the three-dimensional structure of pGH corresponds to a nonhelical part of bPL, did not effect its secondary structure or change the monomer content of the protein preparation. However, it remarkably decreased the binding to the prolactin (PRL) type of receptors on Nb2 cells with subsequent reduction in bioactivity. The binding to the growth hormone (somatogen) receptors either did not change or was increased, resulting in an increase of somatogen receptor-mediated bioactivity. Further truncation (17-18 amino acids) resulted in a decrease of alpha-helical content and loss of binding properties and biological activity mediated through interaction of the analogues with both somatogen (3T3-F442A cells) and lactogen (PRL) receptors (NB2-11C cells). Truncation of 19-27 amino acids caused additional loss in activity, without further change in the secondary structure. Replacement of Leu28 by a more hydrophobic Phe has only minor, if any, effect on the bioactivity of bPL. Occasional point mutations due to polymerase chain reaction errors in several analogues did not seem to have any major effect on the hormone properties. It can thus be suggested that the N-terminal part of the nonhelical portion of bPL, which corresponds to the portion of the molecule that does not exist in growth hormones, is required for efficient binding to the lactogen (PRL) but not to the somatogen or unique bPL receptors. Removal of the N-terminal part of bPL changed the specificity of bPL by decreasing its PRL receptor-mediated activities and increasing its somatogen receptor-mediated activities.	MONSANTO CO, DEPT BIOL SCI, ST LOUIS, MO 63198 USA	Monsanto	GERTLER, A (corresponding author), HEBREW UNIV JERUSALEM, FAC AGR, DEPT AGR BIOCHEM, IL-76100 REHOVOT, ISRAEL.							ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; ASHKENAZI A, 1987, ENDOCRINOLOGY, V121, P414, DOI 10.1210/endo-121-1-414; BINDER L, 1989, MOL ENDOCRINOL, V3, P923, DOI 10.1210/mend-3-6-923; BINDER L, 1990, MOL ENDOCRINOL, V4, P1060, DOI 10.1210/mend-4-7-1060; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BYATT JC, 1986, ENDOCRINOLOGY, V119, P1343, DOI 10.1210/endo-119-3-1343; BYATT JC, 1990, ENDOCRINOLOGY, V127, P1041, DOI 10.1210/endo-127-3-1041; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CORIN RE, 1990, P NATL ACAD SCI USA, V87, P7507, DOI 10.1073/pnas.87.19.7507; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DAVIS JA, 1989, MOL ENDOCRINOL, V3, P949, DOI 10.1210/mend-3-6-949; FORSYTH IA, 1986, J DAIRY SCI, V69, P866; GALOSY SS, 1991, MOL CELL ENDOCRINOL, V78, P229, DOI 10.1016/0303-7207(91)90127-E; GERARDOGETTENS T, 1989, AM J PHYSIOL, V256, pR276, DOI 10.1152/ajpregu.1989.256.1.R276; GERTLER A, 1984, MOL CELL ENDOCRINOL, V34, P51, DOI 10.1016/0303-7207(84)90158-8; GERTLER A, 1983, MOL CELL ENDOCRINOL, V33, P169, DOI 10.1016/0303-7207(83)90165-X; GERTLER A, 1986, ENDOCRINOLOGY, V118, P720, DOI 10.1210/endo-118-2-720; GERTLER A, 1985, ENDOCRINOLOGY, V116, P1636, DOI 10.1210/endo-116-4-1636; GERTLER A, 1991, 73RD P M END SOC BET, P216; GLENN KC, 1988, J CELL BIOCHEM, V37, P371, DOI 10.1002/jcb.240370405; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; KRIVI GG, 1989, 71ST P M END SOC BET, P403; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCK DN, 1989, MOL ENDOCRINOL, V3, P822, DOI 10.1210/mend-3-5-822; MOORE S, 1963, METHOD ENZYMOL, V6, P819, DOI 10.1016/0076-6879(63)06257-1; MUNSON PJ, 1987, USERS GUIDE LIGAND, P107; MURTHY GS, 1982, ENDOCRINOLOGY, V111, P2117, DOI 10.1210/endo-111-6-2117; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5464; SHAMAY A, 1989, THESIS HEBREW U JERU; SHIMOMURA K, 1988, MOL ENDOCRINOL, V2, P845, DOI 10.1210/mend-2-9-845; SOBER HA, 1978, CRC HDB BIOCH MOL BI, V1, P187; TALAMANTES F, 1988, PHYSL REPRODUCTION, P2053; TOWNS R, 1992, ENDOCRINOLOGY, V130, P1225, DOI 10.1210/en.130.3.1225; VASHDI D, 1991, P ANN M ISRAELI ENDO, P93; YANG JT, 1986, METHOD ENZYMOL, V130, P256	37	42	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12655	12659						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618771				2022-12-25	WOS:A1992HZ48300044
J	GEE, JE; BLUME, S; SNYDER, RC; RAY, R; MILLER, DM				GEE, JE; BLUME, S; SNYDER, RC; RAY, R; MILLER, DM			TRIPLEX FORMATION PREVENTS SP1 BINDING TO THE DIHYDROFOLATE-REDUCTASE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNUSUAL DNA STRUCTURES; GENE AMPLIFICATION; TRANSCRIPTION FACTOR; CELL-CYCLE; METHOTREXATE; RESISTANCE; EXPRESSION; SEQUENCES; ESTROGEN; LINE	The human dihydrofolate reductase (DHFR) promoter sequence contains two consensus binding sites for the Sp1 regulatory protein. We have determined the effect of intermolecular triplex DNA formation on Sp1 binding to the DHFR promoter. The DHFR Sp1 binding site I (-39 to -48 relative to the DHFR transcription start site) demonstrates concentration-dependent triplex formation with a 19-base pair G-rich oligonucleotide (GR19) which is complementary to the polypyrimidine strand. DNase I footprint analysis demonstrates that GR19 forms a DNA triplex structure with the DHFR promoter fragment in a sequence-specific manner. DNase I footprinting analysis also indicates that the orientation of binding of these G-rich oligonucleotides is antiparallel. CR19, a C-rich complementary oligonucleotide, on the other hand, does not form triplex. The DNase I protection pattern of DHFR promoter fragment incubated with both recombinant Sp1 and triplex-forming oligonucleotide suggests that triplex formation prevents Sp1 binding. This is confirmed by gel shift analysis which demonstrates that triplex formation by the Sp1 binding sequences of t he DHFR promoter prevents recombinant Sp1 binding in a concentration-dependent manner. These results demonstrate that intermolecular triplex formation prevents regulatory protein binding in a sequence-specific manner.	UNIV ALABAMA, DEPT INTERNAL MED, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, CTR COMPREHENS CANC, BIRMINGHAM, AL 35294 USA; VET ADM MED CTR, BIRMINGHAM, AL 35233 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)	GEE, JE (corresponding author), UNIV ALABAMA, DEPT BIOCHEM, BIRMINGHAM, AL 35294 USA.			Gee, Jay/0000-0003-4308-1659	NCI NIH HHS [CA 42337, CA 42664] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042664, R01CA042337] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CARMAN MD, 1984, J CLIN ONCOL, V2, P16, DOI 10.1200/JCO.1984.2.1.16; CHEN MJ, 1984, J BIOL CHEM, V259, P3933; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; COWAN KH, 1982, J BIOL CHEM, V257, P5079; DURLAND RH, 1990, JERUS SYM Q, V23, P565; FARNHAM PJ, 1985, J BIOL CHEM, V260, P7675; GOLDSMITH ME, 1986, MOL CELL BIOL, V6, P878, DOI 10.1128/MCB.6.3.878; HENDRICKSON SL, 1980, P NATL ACAD SCI-BIOL, V77, P5140, DOI 10.1073/pnas.77.9.5140; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; JOHNSTON BH, 1988, SCIENCE, V241, P1800, DOI 10.1126/science.2845572; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; LETAI AG, 1988, BIOCHEMISTRY-US, V27, P9108, DOI 10.1021/bi00426a007; LEVINE RM, 1985, CANCER RES, V45, P1644; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; SCHIMKE RT, 1986, CANCER, V57, P1912, DOI 10.1002/1097-0142(19860515)57:10<1912::AID-CNCR2820571004>3.0.CO;2-O; SRIMATKANDADA S, 1983, BIOCHEMISTRY-US, V22, P5774, DOI 10.1021/bi00294a015; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; WELLS RD, 1988, J BIOL CHEM, V263, P1095; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307	23	63	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11163	11167						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597451				2022-12-25	WOS:A1992HX16900038
J	RAULO, E; JULKUNEN, I; MERENMIES, J; PIHLASKARI, R; RAUVALA, H				RAULO, E; JULKUNEN, I; MERENMIES, J; PIHLASKARI, R; RAUVALA, H			SECRETION AND BIOLOGICAL-ACTIVITIES OF HEPARIN-BINDING GROWTH-ASSOCIATED MOLECULE - NEURITE OUTGROWTH-PROMOTING AND MITOGENIC ACTIONS OF THE RECOMBINANT AND TISSUE-DERIVED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; AMINO-ACID-SEQUENCE; MOUSE EMBRYOGENESIS; DEVELOPING BRAIN; CLONING; BOVINE; DIFFERENTIATION; PURIFICATION; EXPRESSION; PEPTIDES	The cDNA for the developmentally regulated, neurite outgrowth-promoting protein HB-GAM (heparin-binding growth-associated molecule) was recently cloned and shown to encode a novel lysine-rich sequence that is homologous with retinoic acid-induced sequences suggested to function in cell differentiation (Merenmies, J., and Rauvala, H. (1990) J. Biol. Chem. 265, 16721-16724). The same sequence was found for the mitogenic and neurite outgrowth-promoting protein pleiotrophin (Li, Y.-S., Milner, P. G., Chauhan, A. K., Watson, M. A., Hoffman, R. M., Kodner, C. M., Milbrandt, J., and Deuel, T. F. (1990) Science 250, 1690-1694). In this study, we have constructed a recombinant baculovirus using the cDNA that encodes the putative preprotein of HB-GAM. The putative secretion signal of HB-GAM is cleaved off in the baculovirus expression system, and the recombinant protein is rapidly secreted to the culture medium. Recombinant HB-GAM purified from the culture medium retains the biochemical characteristics and the neurite outgrowth-promoting activity found for the tissue-derived protein. Studies on the neurite outgrowth-promoting activity suggest that HB-GAM functions as an extracellular matrix-associated protein that enhances axonal growth in perinatal cerebral neurons of the rat. Since the same predicted amino acid sequence has been ascribed to a mitogenic protein, mitogenic activities of the recombinant HB-GAM and of tissue-derived HB-GAM fractions were also studied. Recombinant HB-GAM did not display any significant mitogenic activity, suggesting that tissue-derived HB-GAM preparations may contain other heparin-binding mitogenic factors. We identified in brain-derived HB-GAM fractions a 17-kDa protein (p17) that is detached from heparin by a slightly higher salt concentration as compared to HB-GAM. We suggest that p17 is structurally distinct from HB-GAM and responsible for the mitogenic actions of tissue-derived HB-GAM fractions.	NATL PUBL HLTH INST,SF-00300 HELSINKI,FINLAND; UNIV HELSINKI,NEUROBIOL RES UNIT,SF-00170 HELSINKI 17,FINLAND; UNIV HELSINKI,DEPT MED CHEM,SF-00170 HELSINKI 17,FINLAND	Finland National Institute for Health & Welfare; University of Helsinki; University of Helsinki	RAULO, E (corresponding author), UNIV HELSINKI,INST BIOTECHNOL,KARVAAMOKUJA 3,SF-00380 HELSINKI,FINLAND.			Rauvala, Heikki/0000-0001-7809-9811				BAUMANN M, 1990, ANAL BIOCHEM, V190, P198, DOI 10.1016/0003-2697(90)90181-8; CONTEAS CN, 1990, P NATL ACAD SCI USA, V87, P3269, DOI 10.1073/pnas.87.9.3269; Engvall E, 1980, Methods Enzymol, V70, P419; HUBER D, 1990, NEUROCHEM RES, V15, P435, DOI 10.1007/BF00969930; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; KLAGSBRUN M, 1985, P NATL ACAD SCI USA, V82, P805, DOI 10.1073/pnas.82.3.805; KLAGSBRUN M, 1987, METHOD ENZYMOL, V147, P95; KUNEMUND V, 1988, J CELL BIOL, V106, P213, DOI 10.1083/jcb.106.1.213; KUO MD, 1990, J BIOL CHEM, V265, P18749; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; LOCHTER A, 1991, J CELL BIOL, V113, P1159, DOI 10.1083/jcb.113.5.1159; MATSUBARA S, 1990, J BIOL CHEM, V265, P9441; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; MERENMIES J, 1991, J BIOL CHEM, V266, P16722; MILNER PG, 1989, BIOCHEM BIOPH RES CO, V165, P1096, DOI 10.1016/0006-291X(89)92715-0; MURAMATSU H, 1991, BIOCHEM BIOPH RES CO, V177, P652, DOI 10.1016/0006-291X(91)91838-4; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; RAUVALA H, 1988, J CELL BIOL, V107, P2293, DOI 10.1083/jcb.107.6.2293; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STOECKLI ET, 1991, J CELL BIOL, V112, P449, DOI 10.1083/jcb.112.3.449; SUMMERS M, 1986, TEXAS AGR EXPT STATI, V1555; TEZUKA K, 1990, BIOCHEM BIOPH RES CO, V173, P246, DOI 10.1016/S0006-291X(05)81048-4; THANNHAUSER TW, 1987, METHOD ENZYMOL, V143, P115; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URIOS P, 1991, BIOCHEM BIOPH RES CO, V175, P617, DOI 10.1016/0006-291X(91)91610-O; VIGNY M, 1989, EUR J BIOCHEM, V186, P733, DOI 10.1111/j.1432-1033.1989.tb15267.x; WATTS JD, 1989, FEBS LETT, V245, P17, DOI 10.1016/0014-5793(89)80182-6	29	116	118	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11408	11416						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597470				2022-12-25	WOS:A1992HX16900073
J	SIROIS, J; SIMMONS, DL; RICHARDS, JS				SIROIS, J; SIMMONS, DL; RICHARDS, JS			HORMONAL-REGULATION OF MESSENGER-RIBONUCLEIC-ACID ENCODING A NOVEL ISOFORM OF PROSTAGLANDIN ENDOPEROXIDE-H SYNTHASE IN RAT PREOVULATORY FOLLICLES - INDUCTION INVIVO AND INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GONADOTROPIN-RELEASING-HORMONE; GRANULOSA-CELLS; FOLLICULAR DEVELOPMENT; OVARIAN FOLLICLES; CORPORA-LUTEA; LUTEINIZING-HORMONE; GM-CSF; SEQUENCE; OVULATION; ESTRADIOL	Recent purification and amino-terminal analysis of t he isoform of prostaglandin endoperoxide H synthase (PGS) induced in rat preovulatory follicles by gonadotropins identified it as a novel distinct isoform of PGS (rPGS(i)) which exhibited a high degree of homology to the deduced sequence of PGS-related cDNAs recently cloned in chicken and mice. To further verify the similarities of these novel gene products and to examine the hormonal regulation of rPGS(i) mRNA in ovarian cells, three different in vivo and in vitro models were used. Northern blots using a cDNA encoding the mouse homologue of rPGS(i) detected a 4.4-kilobase transcript which was rapidly but transiently induced in granulosa cells of preovulatory follicles exposed in vivo to an ovulatory dose of human chorionic gonadotropin. The rPGS(i) mRNA was undetectable at 0 h, peaked 4 h after human chorionic gonadotropin, and had almost disappeared by 6 h. Increases in rPGS(i) protein (immunoblots) lagged by about 1 h, peaked at 5 h, and remained present at 11 h. PGS(i) mRNA and protein were also induced in a time- and dose-dependent manner when preovulatory follicles were isolated and incubated with elevated levels of follicle-stimulating hormone (500 ng/ml) or luteinizing hormone (500 ng/ml), or when differentiated granulosa cell cultures were stimulated with follicle-stimulating hormone, luteinizing hormone, or with gonadotropin-releasing hormone (10(-6) M). In both in vitro systems, rPGS(i) mRNA peaked at 4-5 h. When the same RNA samples were probed with the mouse cDNA encoding the other PGS isoform, no mRNA transcripts (2.8 kilobases) were observed. These results show for the first time that a rapid and transient induction of mRNA encoding a novel PGS enzyme occurs in granulosa cells of preovulatory follicles prior to ovulation and that results in vitro closely mimicked those in vivo and thereby provide models for studying the molecular mechanisms of rPGS(i) gene expression.	BAYLOR COLL MED, DEPT CELL BIOL, 1 BAYLOR PLAZA, HOUSTON, TX 77030 USA; BRIGHAM YOUNG UNIV, DEPT CHEM, PROVO, UT 84602 USA	Baylor College of Medicine; Brigham Young University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD016229] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD016229] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-16229] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARMSTRONG DT, 1981, J REPROD FERTIL, V62, P283; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CLARK MR, 1980, ENDOCRINOLOGY, V107, P17, DOI 10.1210/endo-107-1-17; CROMWELL O, 1988, EICOSANOIDS INFLAMMA, P21; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FITZPATRICK SL, 1991, ENDOCRINOLOGY, V129, P1452, DOI 10.1210/endo-129-3-1452; GADDYKURTEN D, 1989, ENDOCRINOLOGY, V125, P2985; GALWAY AB, 1989, ENDOCRINOLOGY, V125, P126, DOI 10.1210/endo-125-1-126; HEDIN L, 1987, ENDOCRINOLOGY, V121, P722, DOI 10.1210/endo-121-2-722; HICKEY GJ, 1988, ENDOCRINOLOGY, V122, P1426, DOI 10.1210/endo-122-4-1426; IWAI M, 1991, ENDOCRINOLOGY, V129, P1621, DOI 10.1210/endo-129-3-1621; KEIRSE MJN, 1990, EICOSANOIDS REPRODUC, P199; KOOS RD, 1985, ENDOCRINOLOGY, V116, P628, DOI 10.1210/endo-116-2-628; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1987, CRC HDB EICOSANOID A, V1, P163; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; MOORE PK, 1988, PROSTANOIDS PHARM PH, P173; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; Niswender G.D., 1988, P489; OIKAWA M, 1990, ENDOCRINOLOGY, V127, P2350, DOI 10.1210/endo-127-5-2350; OONK RB, 1989, J BIOL CHEM, V264, P21934; PELHAM HRB, 1982, CELL, V30, P517, DOI 10.1016/0092-8674(82)90249-5; PLESCIA OJ, 1988, PROG ALLERGY, V44, P153; QUILLEY J, 1988, EICOSANOIDS CARDIOVA, P16; RAISZ LG, 1988, NEW ENGL J MED, V318, P818; RATOOSH SL, 1985, ENDOCRINOLOGY, V117, P917, DOI 10.1210/endo-117-3-917; RICHARDS JS, 1988, ANNU REV PHYSIOL, V50, P441; RICHARDS JS, 1975, ENDOCRINOLOGY, V97, P1174, DOI 10.1210/endo-97-5-1174; RICHARDS JS, 1982, ENDOCRINOLOGY, V111, P1429, DOI 10.1210/endo-111-5-1429; ROSEN GD, 1989, BIOCHEM BIOPH RES CO, V164, P1358, DOI 10.1016/0006-291X(89)91819-6; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SEGALOFF DL, 1990, MOL ENDOCRINOL, V4, P1856, DOI 10.1210/mend-4-12-1856; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIGAL E, 1991, AM J PHYSIOL, V260, pL13, DOI 10.1152/ajplung.1991.260.2.L13; SIMMONS DL, 1992, PROSTAGLANDINS LEUKO, P67; SIROIS J, 1992, J BIOL CHEM, V267, P6382; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; WEKSLER BB, 1982, CARDIOVASCULAR PHARM, P137; WONG WYL, 1989, MOL ENDOCRINOL, V3, P1714, DOI 10.1210/mend-3-11-1714; WONG WYL, 1991, MOL ENDOCRINOL, V5, P1269, DOI 10.1210/mend-5-9-1269; WONG WYL, 1992, IN PRESS ENDOCRINOLO; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X; Zurier RB, 1988, PROSTAGLANDINS BIOL, P595	51	248	254	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11586	11592						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597485				2022-12-25	WOS:A1992HX16900099
J	BELUNIS, CJ; RAETZ, CRH				BELUNIS, CJ; RAETZ, CRH			BIOSYNTHESIS OF ENDOTOXINS - PURIFICATION AND CATALYTIC PROPERTIES OF 3-DEOXY-D-MANNO-OCTULOSONIC ACID TRANSFERASE FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-A PRECURSORS; PHOSPHATIDYLGLYCEROL-DEFICIENT MUTANT; POLYMERASE CHAIN-REACTION; SALMONELLA-TYPHIMURIUM; GLUCOSAMINE 1-PHOSPHATE; SYNTHETASE; SYNTHASE; CYTIDYLYLTRANSFERASE; PROTEINS; ENZYMES	The enzyme 3-deoxy-D-manno-octulosonic acid (Kdo) transferase is encoded by the kdtA gene of Escherichia coli and plays a key role in lipopolysaccharide biosynthesis. It transfers Kdo from CMP-Kdo to lipid A or its tetraacyldisaccharide-1,4'-bisphosphate precursor, lipid IV(A). Using a strain that overproduces the transferase approximately 500-fold, we have purified the enzyme to near homogeneity. The subunit molecular mass is approximately 43 kDa. Activity is stimulated by Triton X-100, is maximal at pH 7, but does not require Mg2+. The apparent K(m) values for lipid IV(A) and CMP-Kdo are 52 and 88-mu-M, respectively. V(max) is 15-18-mu-mol/min/mg when both substrates are added near saturation at pH 8. The purified enzyme transfers 2 Kdo residues to lipid A precursors or analogs bearing four to six fatty acyl chains and a 4'-monophosphate moiety. Activity is inhibited by polymixin B and Re endotoxin. At low Kdo concentrations small amounts of the intermediate, (Kdo)1-IV(A), accumulate. When this substance is isolated and incubated with purified enzyme in the presence of CMP-Kdo, it is converted to (Kdo)2-IV(A). Formation of (Kdo)1-IV(A) is also observed when purified enzyme is incubated with (Kdo)2-IV(A) and 5 mM CMP, demonstrating that Kdo transfer is reversible. In summary, Kdo transferase consists of a single bifunctional polypeptide that incorporates the 2 innermost Kdo residues common to all lipopolysaccharide molecules in E. coli.	MERCK SHARP & DOHME LTD, DEPT BIOCHEM, RAHWAY, NJ 07065 USA	Merck & Company								ANDERSON MS, 1987, J BIOL CHEM, V262, P5159; AUSUBEL FM, 1989, CURRENT PROTOLS MOL; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1990, J BIOL CHEM, V265, P15410; CARMAN GM, 1979, J BIOL CHEM, V254, P8391; CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; DOWHAN W, 1974, J BIOL CHEM, V249, P3079; DUTT A, 1985, BIOCHEMISTRY-US, V24, P1074, DOI 10.1021/bi00326a001; GHALAMBOR MA, 1966, J BIOL CHEM, V241, P3207; GHALAMBOR MA, 1963, BIOCHEM BIOPH RES CO, V10, P346, DOI 10.1016/0006-291X(63)90536-9; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HEATH EC, 1966, ANN NY ACAD SCI, V133, P315, DOI 10.1111/j.1749-6632.1966.tb52374.x; HJELMSTAD RH, 1991, BIOCHEMISTRY-US, V30, P1731, DOI 10.1021/bi00221a001; KADOWAKI H, 1989, GENE, V76, P161, DOI 10.1016/0378-1119(89)90018-8; KOHLBRENNER WE, 1985, J BIOL CHEM, V260, P4695; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMANN V, 1977, EUR J BIOCHEM, V81, P443, DOI 10.1111/j.1432-1033.1977.tb11969.x; MACFERRIN KD, 1990, P NATL ACAD SCI USA, V87, P1937, DOI 10.1073/pnas.87.5.1937; MUNSON RS, 1978, J BIOL CHEM, V253, P1503; NAKAMURA K, 1979, J BACTERIOL, V137, P595, DOI 10.1128/JB.137.1.595-604.1979; NISHIJIMA M, 1979, J BIOL CHEM, V254, P7837; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; RADIKA K, 1988, J BIOL CHEM, V263, P14859; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1986, ANNU REV GENET, V20, P253, DOI 10.1146/annurev.ge.20.120186.001345; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RAY PH, 1982, METHOD ENZYMOL, V83, P525; RAY PH, 1982, METHOD ENZYMOL, V83, P535; RICK PD, 1977, J BIOL CHEM, V252, P4895; Rietschel E. T., 1984, HDB ENDOTOXIN CHEM E, VI; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPARROW CP, 1985, J BIOL CHEM, V260, P2084; STRAIN SM, 1985, J BIOL CHEM, V260, P2974; STRAIN SM, 1985, J BIOL CHEM, V260, P6089; SUTCLIFFE J, 1985, FED PROC, V44, P652; TAKAYAMA K, 1983, J BIOL CHEM, V258, P4245; TAKAYAMA K, 1983, J BIOL CHEM, V258, P7379; WHITE A, 1978, PRINCIPLES BIOCH, P489; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	43	118	122	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9988	9997						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577828				2022-12-25	WOS:A1992HT96500082
J	OKAMOTO, CT; SHIA, SP; BIRD, C; MOSTOV, KE; ROTH, MG				OKAMOTO, CT; SHIA, SP; BIRD, C; MOSTOV, KE; ROTH, MG			THE CYTOPLASMIC DOMAIN OF THE POLYMERIC IMMUNOGLOBULIN RECEPTOR CONTAINS 2 INTERNALIZATION SIGNALS THAT ARE DISTINCT FROM ITS BASOLATERAL SORTING SIGNAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; INFLUENZA-VIRUS HEMAGGLUTININ; DENSITY-LIPOPROTEIN RECEPTOR; MEMBRANE-PROTEIN; LDL-RECEPTOR; ENDOCYTOSIS; EXPRESSION; IGA; SEQUENCE; TRANSCYTOSIS	The C-terminal cytoplasmic domain of the polymeric immunoglobulin receptor (pIgR) contains two tyrosine residues, Tyr668 and Tyr734. Previous work identifying Tyr734 as a critical residue in the endocytosis of the pIgR in Madin-Darby canine kidney (MDCK) cells also suggested that a second functional internalization signal was present (Breitfeld, P. P., Casanova, J. E., McKinnon, W. C., and Mostov, K. E. (1990) J. Biol. Chem. 265, 13750-13757). To test this hypothesis, Tyr668 and Tyr734 were mutated singly or together by oligonucleotide-directed mutagenesis of pIgR cDNA, and the mutants were expressed in MDCK cells. The amount of ligand internalized within 5 min from the basolateral membrane by the pIgR in which cytoplasmic tyrosines were mutated separately to Cys668 or Ser734 or together to Cys668, Ser734 Was 58, 39, and 20%, respectively, of that internalized by the wild-type pIgR. The cytoplasmic and transmembrane domain of the pIgR, when joined to the external domain of the influenza virus hemagglutinin, retained the capacity to mediate rapid internalization. As with the full-length pIgR, mutation of either tyrosine in the chimera resulted in impairment of endocytosis, with mutation of Tyr734 having a significantly greater effect than mutation on Tyr668 on the initial rate of endocytosis (3 and 44% of control values, respectively). However, unlike the full-length pIgR, mutation of both tyrosines together in the chimera did not reduce internalization further. The two tyrosines in the cytoplasmic sequence of the pIgR, although widely separated in the linear amino acid sequence, both contribute to internalization of the protein, suggesting that both can function as internalization signals. In addition, the correlation between endocytosis and basolateral targeting of the pIgR in MDCK cells was investigated. Neither tyrosine of the cytoplasmic domain was necessary for basolateral targeting of the pIgR.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	OKAMOTO, CT (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA.			Roth, Michael/0000-0002-9056-332X; mostov, keith/0000-0002-8123-6247	NHLBI NIH HHS [HL 07185] Funding Source: Medline; NIAID NIH HHS [R01 AI25144] Funding Source: Medline; NIGMS NIH HHS [GM37547] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025144] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037547] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ E, 1990, BIOCHEM J, V267, P31, DOI 10.1042/bj2670031; BANTING G, 1989, FEBS LETT, V254, P177, DOI 10.1016/0014-5793(89)81034-8; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; BREITFELD PP, 1989, J CELL BIOL, V109, P475, DOI 10.1083/jcb.109.2.475; BREITFELD PP, 1989, METHOD CELL BIOL, V32, P329; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; FUHRER C, 1991, J CELL BIOL, V114, P423, DOI 10.1083/jcb.114.3.423; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HARTER C, 1990, J CELL BIOL, V111, P66; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HOPPE CA, 1985, J CELL BIOL, V101, P2113, DOI 10.1083/jcb.101.6.2113; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; KRAJCI P, 1989, BIOCHEM BIOPH RES CO, V158, P783, DOI 10.1016/0006-291X(89)92790-3; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LAZAROVITS J, 1990, J BIOL CHEM, V265, P4760; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LIMET JN, 1985, EUR J BIOCHEM, V146, P539, DOI 10.1111/j.1432-1033.1985.tb08685.x; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MCGRAW TE, 1991, J CELL BIOL, V112, P853, DOI 10.1083/jcb.112.5.853; MOSTOV KE, 1985, CELL, V43, P389, DOI 10.1016/0092-8674(85)90166-7; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; MOSTOV KE, 1984, NATURE, V308, P37, DOI 10.1038/308037a0; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; Sambrook J, 1989, MOL CLONING LABORATO; SOLARI R, 1984, CELL, V36, P61, DOI 10.1016/0092-8674(84)90074-6; SZTUL ES, 1985, J CELL BIOL, V100, P1248, DOI 10.1083/jcb.100.4.1248; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955	44	84	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9925	9932						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577823				2022-12-25	WOS:A1992HT96500074
J	CHOW, KC; XUE, H; SHI, W; WONG, JT				CHOW, KC; XUE, H; SHI, W; WONG, JT			MUTATIONAL IDENTIFICATION OF AN ESSENTIAL TRYPTOPHAN IN TRYPTOPHANYL RNA-TRANSFER SYNTHETASE OF BACILLUS-SUBTILIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; STRUCTURAL GENE; CLONING; MUTAGENESIS; PROTEIN	The strongly conserved single tryptophan residue, Trp92, in Bacillus subtilis tryptophanyl-tRNA synthetase has been mutagenized via site direction singly into Gln, Ala, and Phe. All three mutant enzymes were inactive toward the catalysis of tRNA tryptophanylation. The Trp92 --> Phe mutant has been subcloned into the high expression plasmid pKK223-3 to yield the recombinant plasmid pKSW-F92. Growth of bacteria carrying the latter plasmid made possible the purification of the mutant TrpRS-F92 enzyme to homogeneity. This mutant enzyme was deficient in ultraviolet absorbance and fluorescence relative to the wild type enzyme and inactive in the partial reaction of Trp-activation as well as the overall reaction of tRNA tryptophanylation. Furthermore, unlike the wild type B. subtilis trpS gene, the mutant trpS-F92 gene upon transformation into Escherichia coli trpS 10343 failed to complement the temperature sensitive trpS mutation of the host cells. Trp92 therefore represents an essential residue both in vitro and in vivo for the function of the tryptophanyl-tRNA synthetase.			CHOW, KC (corresponding author), UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA.			Wong, J. Tze-Fei/0000-0001-8539-8537				BARSTOW DA, 1986, GENE, V46, P37, DOI 10.1016/0378-1119(86)90164-2; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; CHOW KC, 1988, GENE, V73, P537; DAVIE EW, 1962, METHOD ENZYMOL, V5, P718, DOI 10.1016/S0076-6879(62)05300-8; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DOOLITTLE WF, 1968, J BACTERIOL, V95, P1283, DOI 10.1128/JB.95.4.1283-1294.1968; HALL CV, 1982, J BIOL CHEM, V257, P6132; KHAMIS MI, 1987, J BIOL CHEM, V262, P10938; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P342; MYERS AM, 1985, J BIOL CHEM, V260, P5371; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; SHI W, 1989, BIOCH CELL BIOL, V68, P492; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; XU ZJ, 1989, J BIOL CHEM, V264, P4304; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	15	11	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9146	9149						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577751				2022-12-25	WOS:A1992HR85400069
J	PAN, YT; DEGESPARI, R; WARREN, CD; ELBEIN, AD				PAN, YT; DEGESPARI, R; WARREN, CD; ELBEIN, AD			FORMATION OF UNUSUAL MANNOSAMINE-CONTAINING LIPID-LINKED OLIGOSACCHARIDES IN MADIN-DARBY CANINE KIDNEY-CELL-CULTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GLCNAC; PROTEIN GLYCOSYLATION; PARTIAL-PURIFICATION; GLUCOSE STARVATION; BIOSYNTHESIS; MANNOSYLTRANSFERASE; PATHWAY; SACCHARIDES; TRANSFERASE; AMPHOMYCIN	Glc3Man9(GlcNAC)2-pyrophosphoryl-dolichol is the major lipid-linked oligosaccharide (LLO) produced by Madin-Darby canine kidney cells in culture. However, when these cells are incubated in the presence of millimolar concentrations of mannosamine and labeled with [2-H-3]mannose, they accumulate various LLO that have smaller-sized oligosaccharides with unusual structures and the GlC3Man9(GlcNAc)2-pyrophosphoryl-dolichol is not detected. Thus in the presence of 10 mm mannosamine, more than 80% of the oligosaccharides are eluted from concanavalin A-Sepharose with 10 mM alpha-methylglucoside, indicating that they no longer have the tight-binding characteristics of control oligosaccharides. In addition, 20-40% of these oligosaccharides bind to Dowex 50-H+, indicating the presence of mannosamine in these structures. Interestingly enough, these abnormal oligosaccharides are still transferred to protein. The mannosamine-induced oligosaccharides were separated into neutral and basic fractions on a cation exchange resin. The neutral oligosaccharides ranged in size from hexose3(GlcNAc)2 to hexose10(GlcNAc)2 with the major species being Man5(GlcNAC)2 to Man7(GlcNAC)2. These oligosaccharides were almost completely susceptible to digestion by alpha-mannosidase and by endoglucosaminidase H. The basic oligosaccharides showed anomolous behavior on the Bio-Gel P-4 columns and appeared to be of small size on the standard columns, ranging from hexose2 to hexose4. However, most of these oligosaccharides were susceptible to digestion by endoglucosaminidase H as well as by alpha-mannosidase, suggesting that they were of different size and structure than would be predicted from the gel filtration patterns. Significantly, when the basic oligosaccharides were subjected to chemical N-acetylation, or when the gel filtration columns were run at high pH rather than at the usual pH of 3.0, the basic oligosaccharides migrated like much larger oligosaccharides. These data provide strong evidence to indicate that some mannosamine can be incorporated into the LLO, and that these mannosamine-containing oligosaccharides exhibit unusual properties. Preliminary studies indicated that Madin-Darby canine kidney cells do incorporate label from [H-3]mannosamine into the LLO.	HARVARD UNIV,SCH MED,LOVETT LABS,CARBOHYDRATE UNIT,BOSTON,MA 02129; MASSACHUSETTS GEN HOSP E,BOSTON,MA 02129	Harvard University; Harvard Medical School	PAN, YT (corresponding author), UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOLEC BIOL,LITTLE ROCK,AR 72205, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040930, R01DK021800] Funding Source: NIH RePORTER; NCRR NIH HHS [SO7RR05486-28] Funding Source: Medline; NIDDK NIH HHS [DK-21800, DK-40930] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BODANSZKY M, 1973, J AM CHEM SOC, V95, P2352, DOI 10.1021/ja00788a040; CHAMBERS J, 1977, J BIOL CHEM, V252, P2498; COUTO JR, 1984, J BIOL CHEM, V259, P378; DATEMA R, 1980, EUR J BIOCHEM, V110, P355, DOI 10.1111/j.1432-1033.1980.tb04875.x; DEGESPARI R, 1991, J BIOL CHEM, V266, P16556; DISTLER JJ, 1958, J BIOL CHEM, V230, P497; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; ELBEIN AD, 1979, ANNU REV PLANT PHYS, V30, P239, DOI 10.1146/annurev.pp.30.060179.001323; GERSHMAN H, 1981, J BIOL CHEM, V256, P7774; HASELBECK A, 1982, P NATL ACAD SCI-BIOL, V79, P1520, DOI 10.1073/pnas.79.5.1520; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; JENSEN JW, 1981, J BIOL CHEM, V256, P2899; JENSEN JW, 1985, EUR J BIOCHEM, V153, P41, DOI 10.1111/j.1432-1033.1985.tb09264.x; KANG MS, 1978, BIOCHEM BIOPH RES CO, V82, P568, DOI 10.1016/0006-291X(78)90912-9; KANG MS, 1978, J BIOL CHEM, V253, P8860; KAUSHAL GP, 1986, PLANT PHYSIOL, V82, P748, DOI 10.1104/pp.82.3.748; KAUSHAL GP, 1985, J BIOL CHEM, V260, P6303; KAUSHAL GP, 1986, PLANT PHYSIOL, V81, P1086, DOI 10.1104/pp.81.4.1086; KAUSHAL GP, 1987, BIOCHEMISTRY-US, V26, P7953, DOI 10.1021/bi00398a061; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LISANTI MP, 1991, EMBO J, V10, P1969, DOI 10.1002/j.1460-2075.1991.tb07726.x; MATERN H, 1990, EUR J BIOCHEM, V190, P99, DOI 10.1111/j.1432-1033.1990.tb15551.x; MATSUMOTO A, 1983, BIOCHEMISTRY-US, V22, P188, DOI 10.1021/bi00270a028; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; PAN YT, 1983, BIOCHEMISTRY-US, V22, P3975, DOI 10.1021/bi00285a038; PAN YT, 1985, ARCH BIOCHEM BIOPHYS, V242, P447, DOI 10.1016/0003-9861(85)90229-2; PAN YT, 1979, J BACTERIOL, V139, P507, DOI 10.1128/JB.139.2.507-514.1979; PAN YT, 1982, J BIOL CHEM, V257, P2795; PLOUHAR PL, 1983, J BIOL CHEM, V258, P2988; REARICK JI, 1981, J BIOL CHEM, V256, P6255; SCHUTZBACH JS, 1980, J BIOL CHEM, V255, P4170; SCHWARZ RT, 1982, ADV CARBOHYD CHEM BI, V40, P287, DOI 10.1016/S0065-2318(08)60111-0; SHAILUBHAI K, 1988, J BIOL CHEM, V263, P15964; SHARMA CB, 1990, BIOCHEMISTRY-US, V29, P8901, DOI 10.1021/bi00490a004; SHARMA CB, 1982, EUR J BIOCHEM, V126, P319; TURCO SJ, 1980, ARCH BIOCHEM BIOPHYS, V205, P330, DOI 10.1016/0003-9861(80)90115-0; WAECHTER CJ, 1976, ANNU REV BIOCHEM, V45, P95, DOI 10.1146/annurev.bi.45.070176.000523; WARREN CD, 1983, CARBOHYD RES, V116, P171, DOI 10.1016/0008-6215(83)88107-5; [No title captured]	39	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8991	8999						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577737				2022-12-25	WOS:A1992HR85400046
J	HOLMES, WM; ANDRAOSSELIM, C; ROBERTS, I; WAHAB, SZ				HOLMES, WM; ANDRAOSSELIM, C; ROBERTS, I; WAHAB, SZ			STRUCTURAL REQUIREMENTS FOR TRANSFER-RNA METHYLATION - ACTION OF ESCHERICHIA-COLI TRANSFER RNA(GUANOSINE-1)METHYLTRANSFERASE ON TRANSFER RNA(1)LEU STRUCTURAL VARIANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA(M1G)METHYLTRANSFERASE; GENE TRMD; SEQUENCE; OPERON; K-12	The Escherichia coli enzyme tRNA(m1G)methyltransferase, one of a group of post-transcription tRNA-modifying enzymes, shows remarkable specificity in selecting the tRNA species and the specific guanosine base to be methylated. To examine the structural basis of this specificity, we synthesized a total of 15 modifications of tRNA1Leu and measured their methylation reaction kinetics in vitro. Elimination of any one of the three tRNA side loops, the V loop, the T loop, or the D loop, reduced the V(max) for methylation by about 1 order of magnitude. Elimination of all three side loops reduced V(max) by about 2 orders of magnitude. Clearly, gross tRNA structure is important for full enzyme activity. At the bottom of the stem proximal to the anticodon loop, in the pair at positions 31-39, substitution of a G-C for a C-G, a change that should not weaken the helical structure, had little effect on V(max) or K(m). However, substitution of a G for a C increased V(max) and K(m), whereas substitution of a C for G sharply reduced V(max) and, to a lesser extent, K(m). These results appear to be a consequence of the principle that purines are better than pyrimidines in the stacking of adjacent bases for stability. Stacking in the stem structure appears to be important for methylation enzyme activity. In the anticodon loop itself, changing a U to a C had little effect, but changing the G of the anticodon to a C reduced V(max) over 20-fold, demonstrating the importance of the presence of the anticodon G adjacent to the G being methylated for enzyme recognition.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,MASSEY CANC CTR,RICHMOND,VA 23298	Virginia Commonwealth University	HOLMES, WM (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MICROBIOL,RICHMOND,VA 23298, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025871] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM25871] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BJORK GR, 1989, SCIENCE, V244, P986, DOI 10.1126/science.2471265; BJORK GR, 1987, ANNU REV BIOCHEM, V56, P263, DOI 10.1146/annurev.bi.56.070187.001403; BYSTROM AS, 1982, MOL GEN GENET, V188, P447, DOI 10.1007/BF00330047; BYSTROM AS, 1982, MOL GEN GENET, V188, P440, DOI 10.1007/BF00330046; BYSTROM AS, 1983, EMBO J, V2, P899, DOI 10.1002/j.1460-2075.1983.tb01519.x; GROSJEAN H, 1990, BIOCHIM BIOPHYS ACTA, V1050, P267, DOI 10.1016/0167-4781(90)90179-6; HJALMARSSON KJ, 1983, J BIOL CHEM, V258, P1343; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; KOMINE Y, 1990, J MOL BIOL, V212, P579, DOI 10.1016/0022-2836(90)90224-A; NORMANLY J, 1989, ANNU REV BIOCHEM, V58, P1029, DOI 10.1146/annurev.bi.58.070189.005121; RAJBHANDARY UL, 1982, NUCLEASES; Roberts I, 1991, Protein Expr Purif, V2, P117, DOI 10.1016/1046-5928(91)90059-R; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SAENGER W, 1984, PRINCIPLES NUCLEIC A, V1, P34; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SCHULMAN LH, 1990, NUCLEIC ACIDS RES, V18, P285, DOI 10.1093/nar/18.2.285; VOLCKAERT G, 1977, ANAL BIOCHEM, V83, P228, DOI 10.1016/0003-2697(77)90531-0; VOLCKAERT G, 1976, ANAL BIOCHEM, V72, P433, DOI 10.1016/0003-2697(76)90551-0	18	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13440	13445						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618846				2022-12-25	WOS:A1992JB74600055
J	JOHNSON, MG; ESCALANTESEMERENA, JC				JOHNSON, MG; ESCALANTESEMERENA, JC			IDENTIFICATION OF 5,6-DIMETHYLBENZIMIDAZOLE AS THE CO-ALPHA LIGAND OF THE COBAMIDE SYNTHESIZED BY SALMONELLA-TYPHIMURIUM - NUTRITIONAL CHARACTERIZATION OF MUTANTS DEFECTIVE IN BIOSYNTHESIS OF THE IMIDAZOLE RING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; COBALAMIN; VITAMIN-B12; COENZYME-B12; CORRINOIDS; DENOVO	The Co-beta-cyano derivative of the cobamide isolated from Salmonella typhimurium was identified as Co-alpha-(alpha-5,6-dimethylbenzimidazolyl)-Co-beta-cyanocobamide, indicating that this bacterium synthesizes 5,6-dimethylbenzimidazole (DMB) de novo. We found that mutants deficient in the synthesis of DMB can incorporate benzimidazole without modification to form Co-alpha-(alpha-benzimidazolyl) cobamide, a cobamide that is physiologically active. The analysis of the nutritional requirements of mutants deficient in DMB synthesis identified 4,5-dimethylphenylenediamine as a putative intermediate in the synthesis of the imidazole ring of DMB. Our results suggest that the CobII region of the cob operon of S. typhimurium only encodes functions involved in the synthesis of the imidazole ring of DMB.	UNIV WISCONSIN,DEPT BACTERIOL,1550 LINDEN DR,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NCRR NIH HHS [RR02301, RR02781] Funding Source: Medline; NIGMS NIH HHS [GM40313, R01 GM040313] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002301, S10RR002781] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040313] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAX A, 1987, J AM CHEM SOC, V109, P566, DOI 10.1021/ja00236a040; BLANCHE F, 1990, ANAL BIOCHEM, V189, P24, DOI 10.1016/0003-2697(90)90038-B; CAUTHEN SE, 1966, BIOCHEM J, V98, P630, DOI 10.1042/bj0980630; DAWSON RMC, 1986, DATA BIOCH RES, P120; ESCALANTESEMERENA JC, 1992, J BACTERIOL, V174, P24, DOI 10.1128/jb.174.1.24-29.1992; ESCALANTESEMERENA JC, 1987, J BACTERIOL, V169, P2251, DOI 10.1128/jb.169.5.2251-2258.1987; ESCALANTESEMERENA JC, 1990, J BACTERIOL, V172, P273, DOI 10.1128/JB.172.1.273-280.1990; HALPERN J, 1985, SCIENCE, V227, P869, DOI 10.1126/science.2857503; HITCHMAN ML, 1978, MEASUREMENT DISSOLVE, V49, P7; HOGENKAMP HPC, 1971, METHODS ENZYMOL    C, V18, P57; JETER RM, 1984, J BACTERIOL, V159, P206, DOI 10.1128/JB.159.1.206-213.1984; RENZ P, 1987, EUR J BIOCHEM, V163, P175, DOI 10.1111/j.1432-1033.1987.tb10752.x; STUPPERICH E, 1986, ANAL BIOCHEM, V155, P365, DOI 10.1016/0003-2697(86)90447-1; STUPPERICH E, 1987, J BACTERIOL, V169, P3076, DOI 10.1128/jb.169.7.3076-3081.1987; STUPPERICH E, 1988, EUR J BIOCHEM, V172, P459, DOI 10.1111/j.1432-1033.1988.tb13910.x; STUPPERICH E, 1988, ADV SPACE SCI, V9, P117; TAYLOR RT, 1973, ENZYMES, V9, P121; VOGEL HJ, 1956, J BIOL CHEM, V218, P97	18	27	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13302	13305						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618831				2022-12-25	WOS:A1992JB74600035
J	KIM, SJ; PARK, K; KOELLER, D; KIM, KY; WAKEFIELD, LM; SPORN, MB; ROBERTS, AB				KIM, SJ; PARK, K; KOELLER, D; KIM, KY; WAKEFIELD, LM; SPORN, MB; ROBERTS, AB			POSTTRANSCRIPTIONAL REGULATION OF THE HUMAN TRANSFORMING GROWTH FACTOR-BETA-1 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCOMPANIES VIRAL TRANSFORMATION; IRON-RESPONSIVE ELEMENT; FERRITIN MESSENGER-RNA; FACTOR-BETA; TRANSLATIONAL REGULATION; MOUSE EPIDERMIS; AP-1 COMPLEX; CELL-LINE; EXPRESSION; PROMOTER	Since many lines of evidence suggest that expression of the transforming growth factor-beta-1 (TGF-beta-1) gene may be regulated post-transcriptionally, we examined the effect of the 5'-untranslated region (UTR) of this gene on TGF-beta-1 expression. For this purpose, fragments of the 840-nucleotide highly GC-rich TGF-beta-1 5'-UTR were inserted into the 5'-UTR of the structural gene for human growth hormone driven by the simian virus 40 early promoter. A portion of the 5'-UTR of TGF-beta-1 mRNA spanning the sequences from +11 to +147 was shown to inhibit growth hormone expression by as much as 22-fold. This effect was cell-specific; growth hormone production was inhibited in PC-3 human prostate adenocarcinoma and A-549 human lung adenocarcinoma cells, while no effect was seen in rat pheochromocytoma PC12 cells, which show efficient translation of endogenous TGF-beta-1 mRNA. Computer analysis showed that this region of the 5'-UTR contained a stable secondary stem-loop structure spanning sequences +49 to +76. This stem-loop region alone is sufficient to inhibit expression of the growth hormone gene, suggesting that it plays an important role in post-transcriptional regulation of TGF-beta-1 gene expression.	NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	KIM, SJ (corresponding author), NCI,CHEMOPREVENT LAB,BETHESDA,MD 20892, USA.		Wakefield, Lalage M/M-1963-2017	Wakefield, Lalage M/0000-0003-4124-5250				AKHURST RJ, 1988, NATURE, V331, P363, DOI 10.1038/331363a0; ANZANO MA, 1985, MOL CELL BIOL, V5, P242, DOI 10.1128/MCB.5.1.242; ARRICK BA, 1991, MOL CELL BIOL, V11, P4306, DOI 10.1128/MCB.11.9.4306; ASSOIAN RK, 1987, P NATL ACAD SCI USA, V84, P6020, DOI 10.1073/pnas.84.17.6020; BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CAUGHMAN SW, 1988, J BIOL CHEM, V263, P19048; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLETTA AA, 1990, BRIT J CANCER, V62, P405, DOI 10.1038/bjc.1990.307; Danielpour D, 1989, GROWTH FACTORS, V2, P61, DOI 10.3109/08977198909069082; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DICKEY LF, 1988, J BIOL CHEM, V263, P3071; GEISER AG, 1991, MOL CELL BIOL, V11, P84, DOI 10.1128/MCB.11.1.84; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HEINE UI, 1987, J CELL BIOL, V105, P2861, DOI 10.1083/jcb.105.6.2861; HENTZE MW, 1987, P NATL ACAD SCI USA, V84, P6730, DOI 10.1073/pnas.84.19.6730; IKEDA T, 1987, BIOCHEMISTRY-US, V26, P2406, DOI 10.1021/bi00383a002; JAKOWLEW SB, 1988, ONCOGENE RES, V2, P135; KAIGHN ME, 1979, INVEST UROL, V17, P16; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; KIM SJ, 1989, J BIOL CHEM, V264, P402; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KONDAIAH P, 1988, J BIOL CHEM, V263, P18313; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2580; LAFYATIS R, 1990, J BIOL CHEM, V265, P19128; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; Noma T, 1991, GROWTH FACTORS, V4, P247, DOI 10.3109/08977199109043910; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; RATNER L, 1987, NUCLEIC ACIDS RES, V15, P6017, DOI 10.1093/nar/15.15.6017; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; ROUAULT TA, 1989, P NATL ACAD SCI USA, V86, P5768, DOI 10.1073/pnas.86.15.5768; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; WALDEN WE, 1989, J BIOL CHEM, V264, P13765	38	177	180	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13702	13707						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618868				2022-12-25	WOS:A1992JB74600095
J	LAMEH, J; PHILIP, M; SHARMA, YK; MORO, O; RAMACHANDRAN, J; SADEE, W				LAMEH, J; PHILIP, M; SHARMA, YK; MORO, O; RAMACHANDRAN, J; SADEE, W			HM1 MUSCARINIC CHOLINERGIC RECEPTOR INTERNALIZATION REQUIRES A DOMAIN IN THE 3RD CYTOPLASMIC LOOP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; SITE-DIRECTED MUTAGENESIS; HUMAN ASTROCYTOMA-CELLS; ACETYLCHOLINE-RECEPTOR; DOWN-REGULATION; BETA-2-ADRENERGIC RECEPTOR; PHORBOL ESTERS; GROWTH-FACTOR; ENDOCYTOSIS; PHOSPHORYLATION	Selected regions of the Hm1 muscarinic cholinergic receptor were mutated to analyze the molecular mechanisms of agonist-induced receptor internalization (or sequestration). The wild-type and mutant Hm1 genes were expressed, using pSG5, in U293 human kidney cells. Whereas surface receptor density measured with the polar tracer N-[H-3]methylscopolamine was rapidly reduced by carbachol exposure, total receptor content measured with [H-3]quinuclidinyl benzilate did not decline for at least 24 h, indicating the absence of extensive receptor down-regulation in U293 cells. Carbachol stimulation of phosphatidylinositol turnover paralleled receptor internalization, both with EC50 values of 10-20-mu-M. Furthermore, a D71N point mutation that prevented receptor activation also abolished carbachol-induced receptor internalization, indicating that receptor activation (but not necessarily second messenger stimulation) was required for internalization. Truncation of the COOH-terminal tail (K447 trunc) and point mutations of several potential Ser and Thr phosphorylation sites to Ala failed to affect receptor activation and internalization. In contrast, partial deletions of the third intracellular loop (i3) (Tyr208-Thr366) resulted in receptor mutants deficient in agonist-induced receptor internalization/sequestration. Various deletions caused either complete loss of internalization (d 232-358) or impaired internalization, ranging from 10 to 30% over 2 h, whereas wild-type Hm1 internalized to approximately 50%. Whereas the reason for the observed differences among the deficient deletion mutants remains unclear, the initial rate of N-[H-3]methylscopolamine binding loss from the cell surface was much slower than that of wild-type Hm1 in each case. The deletion of only one single domain, 284-292 (SMESLTSSE), in the middle of i3 was consistently associated with impaired internalization. Domain 284-292 is partially conserved among closely related muscarinic receptors, whereas most of the remainder of i3 is not (except for the i3 membrane junctions), and similar Ser- and Thr-rich regions are present in many other G protein-coupled receptors. We propose that a small receptor domain in the middle of the i3 loop of Hm1 is involved in agonist-induced receptor internalization.	NEUREX CORP,MENLO PK,CA 94025; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	LAMEH, J (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHARM,SAN FRANCISCO,CA 94143, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004166] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 04166] Funding Source: Medline; NIGMS NIH HHS [GM 43102] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; CHEUNG AH, 1989, MOL PHARMACOL, V34, P132; CONE RI, 1991, LIFE SCI, V49, pPL147, DOI 10.1016/0024-3205(91)90396-S; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; FRASER CM, 1989, MOL PHARMACOL, V36, P840; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; HAGA K, 1990, J NEUROCHEM, V54, P1639, DOI 10.1111/j.1471-4159.1990.tb01216.x; HARDEN TK, 1985, J BIOL CHEM, V260, P3060; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HERTEL C, 1985, J BIOL CHEM, V260, P2547; HOOVER RK, 1990, J PHARMACOL EXP THER, V253, P185; HOOVER RK, 1989, J PHARMACOL EXP THER, V251, P63; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; LAI WS, 1990, BIOCHEM J, V267, P23, DOI 10.1042/bj2670023; LAMEH J, 1990, PHARMACEUT RES, V7, P1213, DOI 10.1023/A:1015969301407; LILES WC, 1986, J BIOL CHEM, V261, P5307; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MAEDA S, 1990, FEBS LETT, V269, P386, DOI 10.1016/0014-5793(90)81199-X; MAHAN LC, 1985, P NATL ACAD SCI USA, V82, P129, DOI 10.1073/pnas.82.1.129; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; ROTHENBERGER S, 1987, CELL, V49, P423, DOI 10.1016/0092-8674(87)90295-9; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SERRA M, 1986, BIOCHEM BIOPH RES CO, V140, P160, DOI 10.1016/0006-291X(86)91071-5; SHAPIRO RA, 1989, BIOCHEMISTRY-US, V28, P8946, DOI 10.1021/bi00448a039; SHAPIRO RA, 1989, P NATL ACAD SCI USA, V86, P9039, DOI 10.1073/pnas.86.22.9039; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; STRASSER RH, 1988, J CARDIOVASC PHARM, V12, pS15, DOI 10.1097/00005344-198806121-00004; THIES RS, 1990, J BIOL CHEM, V265, P10132; THOMPSON AK, 1990, J PHARMACOL EXP THER, V252, P744; VALIQUETTE M, 1990, P NATL ACAD SCI USA, V87, P5089, DOI 10.1073/pnas.87.13.5089	36	128	130	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13406	13412						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618842				2022-12-25	WOS:A1992JB74600050
J	MEIGS, TE; SIMONI, RD				MEIGS, TE; SIMONI, RD			REGULATED DEGRADATION OF 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE IN PERMEABILIZED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; STEROL-ENHANCED DEGRADATION; MEVALONATE-DERIVED PRODUCT; MEMBRANE-BOUND DOMAIN; HMG-COA REDUCTASE; ENDOPLASMIC-RETICULUM; RAT-LIVER; PROTEIN; ENZYME; 25-HYDROXYCHOLESTEROL	We have studied the regulated degradation of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase within the endoplasmic reticulum in cells permeabilized with digitonin. Using Chinese hamster ovary cells transfected with a plasmid encoding HMGal, a chimeric protein containing the membrane domain of HMG-CoA reductase coupled to beta-galactosidase, we have demonstrated mevalonate and sterol-stimulated loss of beta-galactosidase activity. In pulse-chase experiments we have demonstrated mevalonate-stimulated degradation of both HMGal and HMG-CoA reductase. The rate of mevalonate-stimulated degradation observed in permeabilized cells tends to be slightly slower than that observed in intact cells treated with mevalonate and is dependent upon incubation of cells with mevalonate prior to permeabilization. The degradation process measured in this report extends a previous report of HMG-CoA reductase degradation in digitonin-permeabilized cells (Leonard, D. A., and Chen, H. W. (1987) J. Biol. Chem. 262, 7914-7919) by mimicking key physiological features of the in vivo process, including: stimulation by regulatory molecules, specifically mevalonate and sterols; inhibition by cycloheximide; and inhibition by an inhibitor of neutral cysteine proteases.			MEIGS, TE (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.				NHLBI NIH HHS [HL26502] Funding Source: Medline; NIGMS NIH HHS [GM07276] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026502] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEAUFAY H, 1974, J CELL BIOL, V61, P213, DOI 10.1083/jcb.61.1.213; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; CHIN DJ, 1985, MOL CELL BIOL, V5, P634, DOI 10.1128/MCB.5.4.634; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CLARKE PR, 1990, EMBO J, V9, P2439, DOI 10.1002/j.1460-2075.1990.tb07420.x; EDWARDS PA, 1983, J BIOL CHEM, V258, P7272; FAUST JR, 1982, P NATL ACAD SCI-BIOL, V79, P5205, DOI 10.1073/pnas.79.17.5205; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HARDEMAN EC, 1984, ARCH BIOCHEM BIOPHYS, V232, P549, DOI 10.1016/0003-9861(84)90572-1; INOUE S, 1991, J BIOL CHEM, V266, P13311; JINGAMI H, 1987, J CELL BIOL, V104, P1693, DOI 10.1083/jcb.104.6.1693; KATZ J, 1985, J CELL BIOCHEM, V28, P207, DOI 10.1002/jcb.240280304; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LEONARD DA, 1987, J BIOL CHEM, V262, P7914; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; PARKER RA, 1989, J BIOL CHEM, V264, P4877; PEFFLEY D, 1985, J BIOL CHEM, V260, P9949; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROITELMAN J, 1992, IN PRESS J CELL BIOL; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; TANAKA RD, 1983, J BIOL CHEM, V258, P3331; WIKSTROM L, 1992, J BIOL CHEM, V267, P5	30	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13547	13552						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618856				2022-12-25	WOS:A1992JB74600071
J	URUSHIBARA, N; KUMAZAKI, T; ISHII, S				URUSHIBARA, N; KUMAZAKI, T; ISHII, S			HEMOGLOBIN-BINDING SITE ON HUMAN HAPTOGLOBIN - IDENTIFICATION OF LYSYL RESIDUES PARTICIPATING IN THE BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; BETA-CHAIN; CDNA; RESOLUTION; CLEAVAGE; PRODUCT; COMPLEX	The locus of human haptoglobin (Hp) molecules that interacts with human hemoglobin (Hb) was examined by the differential labeling technique. First, amino groups of Hp were extensively labeled with ethyl acetimidate (EAI) either in the free state (experiment A) or in the equimolar complex with Hb (experiment B). Each of the labeled Hp samples was reduced and S-carboxymethylated, and the remaining amino groups were then allowed to react with trinitrobenzenesulfonic acid (TNBS) under denatured conditions. Only 0.6 mol/mol of the trinitrophenyl (TNP) group was introduced into the heavy chain of Hp in experiment A, whereas 2.5 mol/mol of TNP groups were into the same chain in experiment B. The extent of TNP modification for the light chain was very low in either of the experiments. The amino acid residues carrying TNP groups in the heavy chain were identified by the peptide mapping procedure. They were Ile1, Lys136, and Lys218 in experiment B, and only Ile1 in experiment A. These findings suggest that epsilon-amino groups of Lys136 and Lys218 in the heavy chain are both situated within the Hb-binding locus of Hp, and that the alpha-amino group of Ile1 is buried inside the molecule either in the presence or absence of Hb.			URUSHIBARA, N (corresponding author), HOKKAIDO UNIV,FAC PHARMACEUT SCI,DEPT BIOCHEM,SAPPORO,HOKKAIDO 060,JAPAN.		Urushibara, Noriko/AAQ-9883-2021	Urushibara, Noriko/0000-0003-0363-567X				ARCOLEO JP, 1982, J BIOL CHEM, V257, P63; BENESCH RE, 1972, BIOCHEMISTRY-US, V11, P3576, DOI 10.1021/bi00769a013; BERNINI L F, 1970, Biochimica et Biophysica Acta, V200, P203, DOI 10.1016/0005-2795(70)90165-0; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BIRKTOFT JJ, 1969, BIOCHEM BIOPH RES CO, V36, P131, DOI 10.1016/0006-291X(69)90659-7; BOWMAN BH, 1982, ADV HUM GENET, V12, P189; CHANG JY, 1989, J BIOL CHEM, V264, P7141; CHIAO MT, 1972, BIOCHIM BIOPHYS ACTA, V263, P60, DOI 10.1016/0005-2795(72)90159-6; DICKERSON RE, 1983, HEMOGLOBIN STRUCTURE, P20; DOBRYSZYCKA W, 1969, BIOCHIM BIOPHYS ACTA, V175, P271, DOI 10.1016/0005-2795(69)90005-1; FEHLHAMMER H, 1975, J MOL BIOL, V98, P683, DOI 10.1016/S0022-2836(75)80004-0; FERRIS TG, 1966, AM J CLIN PATHOL, V46, P385, DOI 10.1093/ajcp/46.3_ts.385; GREER J, 1980, P NATL ACAD SCI-BIOL, V77, P3393, DOI 10.1073/pnas.77.6.3393; HIGA Y, 1981, J BIOL CHEM, V256, P2322; HIRS CHW, 1967, METHOD ENZYMOL, V11, P199; HUNTER MJ, 1962, J AM CHEM SOC, V84, P3491, DOI 10.1021/ja00877a016; KINO K, 1980, J BIOL CHEM, V255, P9616; KUMAZAKI T, 1979, J BIOCHEM, V85, P581, DOI 10.1093/oxfordjournals.jbchem.a132367; KUROSKY A, 1980, P NATL ACAD SCI-BIOL, V77, P3388, DOI 10.1073/pnas.77.6.3388; LADNER RC, 1977, J MOL BIOL, V114, P385, DOI 10.1016/0022-2836(77)90256-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUSTBADER JW, 1983, J BIOL CHEM, V258, P1227; MAKINEN MW, 1972, BIOCHEMISTRY-US, V11, P3851, DOI 10.1021/bi00771a004; MALCHY B, 1973, CAN J BIOCHEM CELL B, V51, P265, DOI 10.1139/o73-033; MALCHY B, 1973, CAN J BIOCHEM CELL B, V51, P249, DOI 10.1139/o73-032; MARINKOVIC S, 1990, MOL CELL BIOL, V10, P1573, DOI 10.1128/MCB.10.4.1573; MCCORMICK DJ, 1990, J PROTEIN CHEM, V9, P735, DOI 10.1007/BF01024768; NAGEL RL, 1971, J BIOL CHEM, V246, P69; NUREDDIN A, 1975, BIOCHEM J, V147, P71, DOI 10.1042/bj1470071; PERUTZ MF, 1965, J MOL BIOL, V13, P646, DOI 10.1016/S0022-2836(65)80133-4; PLAPP BV, 1974, ANAL BIOCHEM, V62, P291, DOI 10.1016/0003-2697(74)90390-X; PUTNAM FW, 1975, PLASMA PROTEIN STRUC, V2, P1; RAFELSON ME, 1961, NATURE, V191, P279, DOI 10.1038/191279b0; RAUGEI G, 1983, NUCLEIC ACIDS RES, V11, P5811, DOI 10.1093/nar/11.17.5811; RICHARDSON RH, 1980, J BIOL CHEM, V255, P3377; SATAKE K, 1960, J BIOCHEM-TOKYO, V47, P654, DOI 10.1093/oxfordjournals.jbchem.a127107; SHINODA T, 1965, J BIOCHEM-TOKYO, V57, P100, DOI 10.1093/oxfordjournals.jbchem.a128048; STROUD RM, 1971, S QUANTITATIVE BIOL, V36, P125; VALETTE I, 1981, J BIOL CHEM, V256, P672; VANDERSTRATEN A, 1984, FEBS LETT, V168, P103, DOI 10.1016/0014-5793(84)80215-X; VANDERSTRATEN A, 1983, EMBO J, V2, P1003, DOI 10.1002/j.1460-2075.1983.tb01534.x; WAKS M, 1966, ARCH BIOCHEM BIOPHYS, V113, P268; WEJMAN JC, 1984, J MOL BIOL, V174, P319, DOI 10.1016/0022-2836(84)90341-3; YANG FM, 1983, P NATL ACAD SCI-BIOL, V80, P5875, DOI 10.1073/pnas.80.19.5875; YOSHIOKA N, 1986, BIOCHEM J, V234, P453, DOI 10.1042/bj2340453	45	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13413	13417						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618843				2022-12-25	WOS:A1992JB74600051
J	WAN, JS; TAUB, ME; SHAH, D; SHEN, WC				WAN, JS; TAUB, ME; SHAH, D; SHEN, WC			BREFELDIN-A ENHANCES RECEPTOR-MEDIATED TRANSCYTOSIS OF TRANSFERRIN IN FILTER-GROWN MADIN-DARBY CANINE KIDNEY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COTURNIX-COTURNIX-JAPONICA; CULTURED OVIDUCT CELLS; BLOOD-BRAIN-BARRIER; EGG-WHITE PROTEINS; SECRETORY PROTEINS; INTRACELLULAR-TRANSPORT; ENDOPLASMIC-RETICULUM; RAT HEPATOCYTES; GOLGI-COMPLEX; MDCK CELLS	The effects of brefeldin A (BFA) on transferrin (Tf) transcellular transport, Tf receptor (TfR) distribution, and TfR-mediated endocytosis in filter-grown Madin-Darby canine kidney (MDCK) cells were studied. BFA (1.6-mu-g/ml) markedly enhanced the transcytosis of I-125-labeled Tf (I-125-Tf) in both apical-to-basal and basal-to-apical directions; yet, BFA did not enhance the transcytosis of either native horseradish peroxidase (HRP) or membrane-bound HRP-poly(L-lysine) conjugates. Furthermore, this enhanced transcytosis of I-125 Tf was abolished either by competition with excess unlabeled Tf or by incubation at temperatures less-than-or-equal-to 25-degrees-C. In addition, BFA treatment to MDCK cells: (a) increased I-125-Tf specific binding to the apical membrane and decreased I-125-Tf specific binding to the basal membrane; (b) decreased TfR recycling at the basolateral membrane; (c) altered the apical/basolateral distribution of TfRs in favor of the apical side; and (d) markedly increased Fe-59 extraction, but not transcytosis, from apically endocytosed Fe-59-loaded Tf. These effects are consistent with a model in which BFA alters the traffic pattern of internalized Tf by decreasing basolateral TfR recycling, while diverting the nonrecycled fraction to the apical side of the cell. Our results indicate that, unlike the reported inhibition of polymeric IgA transcytosis (Hunziker, W., Whitney, J. A., and Mellman, I. (1991) Cell 67, 617-627), BFA can enhance the transcytosis of Tf in MDCK cells. Thus, by altering the intracellular traffic of ligand-receptor complexes, BFA can elicit either a decrease or an increase in transcytosis depending on the nature of the intracellular receptor processing.	UNIV SO CALIF,SCH PHARM,DEPT PHARMACEUT SCI,1985 ZONAL AVE,RM 404B,LOS ANGELES,CA 90089	University of Southern California					NCI NIH HHS [CA-34798] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034798] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALCH WE, 1989, J BIOL CHEM, V264, P16965; BANERJEE D, 1986, GASTROENTEROLOGY, V91, P861, DOI 10.1016/0016-5085(86)90687-6; Breitfeld PP, 1989, CURR OPIN CELL BIOL, V1, P617, DOI 10.1016/0955-0674(89)90024-0; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CERNEUS DP, 1991, J CELL BIOL, V114, P1149, DOI 10.1083/jcb.114.6.1149; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; FISHMAN JB, 1987, J NEUROSCI RES, V18, P299, DOI 10.1002/jnr.490180206; FRIDEN PM, 1991, P NATL ACAD SCI USA, V88, P4771, DOI 10.1073/pnas.88.11.4771; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FULLER SD, 1986, J CELL BIOL, V103, P1767, DOI 10.1083/jcb.103.5.1767; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; JEFFERIES WA, 1984, NATURE, V312, P162, DOI 10.1038/312162a0; KATO S, 1989, BIOCHIM BIOPHYS ACTA, V991, P36, DOI 10.1016/0304-4165(89)90025-1; KLAUSNER RD, 1984, J CELL BIOL, V98, P1098, DOI 10.1083/jcb.98.3.1098; LARRICK JW, 1979, BIOCHIM BIOPHYS ACTA, V583, P483, DOI 10.1016/0304-4165(79)90065-5; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MOSTOV KE, 1985, CELL, V43, P389, DOI 10.1016/0092-8674(85)90166-7; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; PARDRIDGE WM, 1987, METABOLISM, V36, P892, DOI 10.1016/0026-0495(87)90099-0; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PERKEL VS, 1988, ENDOCRINOLOGY, V123, P310, DOI 10.1210/endo-123-1-310; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; Rodman JS, 1990, CURR OPIN CELL BIOL, V2, P664, DOI 10.1016/0955-0674(90)90108-Q; RODRIGUEZBOULAN E, 1989, ANNU REV PHYSIOL, V51, P741, DOI 10.1146/annurev.physiol.51.1.741; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; SHEN WC, 1990, BIOCHEM BIOPH RES CO, V166, P316, DOI 10.1016/0006-291X(90)91947-Q; SIMIONESCU M, 1989, ENDOTHELIAL CLEL BIO, P69; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; TAUB ME, 1992, J CELL PHYSIOL, V150, P283, DOI 10.1002/jcp.1041500210; TIMCHAK LM, 1986, J BIOL CHEM, V261, P14154; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992; ULMER JB, 1991, J BIOL CHEM, V266, P9173; WAN J, 1991, Pharmaceutical Research (New York), V8, pS4; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; 1972, WORTHINGTON ENZYME M, P43	41	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13446	13450						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618847				2022-12-25	WOS:A1992JB74600056
J	HARPUR, AG; ANDRES, AC; ZIEMIECKI, A; ASTON, RR; WILKS, AF				HARPUR, AG; ANDRES, AC; ZIEMIECKI, A; ASTON, RR; WILKS, AF			JAK2, A 3RD MEMBER OF THE JAK FAMILY OF PROTEIN TYROSINE KINASES	ONCOGENE			English	Article							MEMBRANE GUANYLATE-CYCLASE; POLYMERASE CHAIN-REACTION; CATALYTIC DOMAINS; RECEPTOR; GENE; SEQUENCE; PHOSPHATASES; EXPRESSION; DIVERSITY; CELLS	We have isolated cDNA clones encoding a third, widely expressed, member of the JAK family of protein tyrosine kinases (PTKs). The anticipated amino acid sequence of JAK2 predicts the presence of two kinase-related domains, a feature characteristic of this family of PTKs. The structural similarity of JAK2 to the other members of this family extends towards their N-termini, beyond the two kinase-related domains, and reveals five further domains of substantial amino acid similarity. The C-terminal portion of one of these domains, the JH4 domain, bears an intriguing, albeit tenuous, similarity to the core element of the SH2 domain, whereas the remaining JAK homology domains do not appear to be a feature of other known proteins.	LUDWIG INST CANC RES,MELBOURNE TUMOR BIOL BRANCH,MELBOURNE,VIC 3050,AUSTRALIA; UNIV BERN,INST CLIN & EXPTL CANC RES,CH-3004 BERN,SWITZERLAND	Ludwig Institute for Cancer Research; University of Bern			Wilks, Andrew F/R-5542-2019	Wilks, Andrew F/0000-0002-8554-2399				CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANSK SK, 1991, METHOD ENZYMOL, V200, P38; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOLTZMAN DA, 1987, P NATL ACAD SCI USA, V84, P8325, DOI 10.1073/pnas.84.23.8325; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; Maniatis T., 1982, MOL CLONING; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; NISHIZAWA M, 1986, MOL CELL BIOL, V6, P511, DOI 10.1128/MCB.6.2.511; PAWSON T, 1988, ONCOGENE, V3, P491; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SINGH S, 1988, NATURE, V334, P708, DOI 10.1038/334708a0; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; WILKS A F, 1990, Progress in Growth Factor Research, V2, P97, DOI 10.1016/0955-2235(90)90026-G; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237	35	289	298	0	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1347	1353						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620548				2022-12-25	WOS:A1992HZ97100013
J	BALCH, WE; KAHN, RA; SCHWANINGER, R				BALCH, WE; KAHN, RA; SCHWANINGER, R			ADP-RIBOSYLATION FACTOR IS REQUIRED FOR VESICULAR TRAFFICKING BETWEEN THE ENDOPLASMIC-RETICULUM AND THE CIS-GOLGI COMPARTMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; YPT1 GENE-PRODUCT; SECRETORY PATHWAY; EUKARYOTIC PROTEIN; ADENYLATE-CYCLASE; CHOLERA-TOXIN; BREFELDIN-A; YEAST YPT1; TRANSPORT; APPARATUS	We describe the potential role of ADP-ribosylation factor (ARF) in vesicular trafficking using an in vitro assay that efficiently reconstitutes transport between the endoplasmic reticulum (ER) and the cis-Golgi compartment in mammalian semi-intact cells, a population of cells in which the plasma membrane is physically perforated to reveal intact ER and Golgi compartments. We demonstrate that peptides identical to the amino-terminal domain of ARF, which inhibit ARF cofactor activity in cholera toxin-catalyzed ADP-ribosylation of G(alpha-s) (Kahn, R. A., Randazzo, P., Serafini, T., Weiss, O., Rulka, C., Clark, J., Amherdt, M., Roller, P., Orci, L., and Rothman, J. E. (1992) J. Biol. Chem. 267, 13039-13046), inhibit transport of the vesicular stomatitis virus G protein between the ER and cis-Golgi compartment. Inhibition of transport was rapid (t1/2 = 30-60 s) and irreversible. Half-maximal inhibition was observed at concentrations of 15 and 22-mu-M with peptides identical to the amino-terminal domain of the human ARF4 (hARF4) protein and the human ARF1 protein, respectively. Kinetic analysis of vesicular stomatitis virus G protein transport suggested that the hARF4 peptide inhibits a late vesicle fusion step. In addition, incubation of semi-intact cells in the presence of the myristoylated form human ARF1 (hARF1myr) protein, but not the nonmyristoylated form of ARF1, inhibited transport. In contrast to peptide, the hARF1myr blocked an early transport step, similar to that observed with guanosine 5'-3-O-(thio)triphosphate. These results suggest that ARF and components facilitating ARF function play an important role in the cyclical fission and fusion of transport vesicles mediating ER to Golgi trafficking.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; NCI, DIV CANC TREATMENT, BIOL CHEM LAB, BETHESDA, MD 20892 USA	Scripps Research Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	BALCH, WE (corresponding author), SCRIPPS RES INST, DEPT CELLULAR BIOL, LA JOLLA, CA 92037 USA.		Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601	NATIONAL CANCER INSTITUTE [P01CA027489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042336, R01GM033301] Funding Source: NIH RePORTER; NCI NIH HHS [CA 27489] Funding Source: Medline; NIGMS NIH HHS [GM 42336, GM33301] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BECKER J, 1991, EMBO J, V10, P785, DOI 10.1002/j.1460-2075.1991.tb08010.x; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BECKERS CJM, 1990, J BIOL CHEM, V265, P18298; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; DENFERT C, 1991, J CELL BIOL, V114, P663, DOI 10.1083/jcb.114.4.663; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1991, SCIENCE, V253, P451; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; GODA Y, 1991, J CELL BIOL, V112, P823, DOI 10.1083/jcb.112.5.823; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1991, Current Opinion in Cell Biology, V3, P626, DOI 10.1016/0955-0674(91)90033-U; GRAVOTTA D, 1990, J CELL BIOL, V111, P2893, DOI 10.1083/jcb.111.6.2893; HAUBRUCK H, 1989, EMBO J, V8, P1427, DOI 10.1002/j.1460-2075.1989.tb03524.x; HAUBRUCK H, 1987, EMBO J, V6, P4049, DOI 10.1002/j.1460-2075.1987.tb02750.x; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, 1989, G PROTEINS, P201; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; NISHIKAWA S, 1991, BIOCHIM BIOPHYS ACTA, V1093, P135, DOI 10.1016/0167-4889(91)90114-D; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OKA T, 1991, J CELL BIOL, V114, P671, DOI 10.1083/jcb.114.4.671; ORCI L, 1991, CELL, V64, P1183; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PFEFFER S, 1992, IN PRESS TRENDS CELL; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; RANDAZZO PA, 1991, SCIENCE, V254, P850, DOI 10.1126/science.1658935; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TABAS I, 1979, J BIOL CHEM, V254, P1655; TAYLOR R, 1992, IN PRESS J CELL BIOL; TOOZE SA, 1990, NATURE, V347, P207, DOI 10.1038/347207a0; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WILSON DW, 1991, TRENDS BIOCHEM SCI, V16, P334, DOI 10.1016/0968-0004(91)90138-L; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	66	204	205	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					13053	13061						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618803				2022-12-25	WOS:A1992HZ48300097
J	LODISH, HF; KONG, N; WIKSTROM, L				LODISH, HF; KONG, N; WIKSTROM, L			CALCIUM IS REQUIRED FOR FOLDING OF NEWLY MADE SUBUNITS OF THE ASIALOGLYCOPROTEIN RECEPTOR WITHIN THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DISULFIDE ISOMERASE; HUMAN HEPATOMA-CELLS; HAMSTER OVARY CELLS; SECRETORY PROTEINS; BINDING-PROTEINS; INTRACELLULAR DEGRADATION; EXOCRINE PANCREAS; GOLGI-COMPLEX; PRE-GOLGI; GLYCOPROTEINS	By resolving immunoprecipitates on nonreducing sodium dodecyl sulfate gels, we have detected several disulfide-bonded intermediates in folding within the endoplasmic reticulum of newly made H1 subunits of t he asialoglycoprotein receptor. H1 in the endoplasmic reticulum (ER) can be partially unfolded by treatment of cells with dithiothreitol, but H1 in Golgi or post-Golgi organelles is resistant to such unfolding. This defines a late step in H1 folding that occurs just prior to exit from the ER. Depletion of calcium from the endoplasmic reticulum, either by treatment with A23187 or thapsigargin, has no effect on folding or secretion of newly made albumin, but totally blocks H1 maturation from the ER. No ER intermediates in H1 folding are formed in cells treated with A23187 or thapsigargin, indicating that at least an early step in H1 folding requires a high Ca2+ concentration in the ER lumen. As judged by cross-linking experiments, formation of H1 dimers and trimers occurs immediately after biosynthesis of the peptide chain, before monomer folding, and occurs normally in cells in which ER Ca2+ is reduced and where the monomer never folds properly. Calcium is essential for the asialoglycoprotein receptor to bind galactose, and our results suggest that Ca2+ is also essential for the receptor polypeptides to fold in the ER.	LUDWIG INST CANC RES, S-10401 STOCKHOLM, SWEDEN; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Ludwig Institute for Cancer Research; Massachusetts Institute of Technology (MIT)	LODISH, HF (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035012] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35012] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; ANDREWS SB, 1988, P NATL ACAD SCI USA, V85, P1682, DOI 10.1073/pnas.85.5.1682; BISCHOFF J, 1988, J CELL BIOL, V106, P1067, DOI 10.1083/jcb.106.4.1067; BISCHOFF J, 1987, J BIOL CHEM, V262, P11825; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; COLLINS PL, 1991, J VIROL, V65, P2362, DOI 10.1128/JVI.65.5.2362-2371.1991; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; DORNER AJ, 1990, J BIOL CHEM, V265, P22029; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FREEDMAN R, 1987, NATURE, V329, P196, DOI 10.1038/329196a0; FREEDMAN RB, 1984, TRENDS BIOCHEM SCI, V9, P438, DOI 10.1016/0968-0004(84)90152-X; FRIES E, 1984, EMBO J, V3, P147, DOI 10.1002/j.1460-2075.1984.tb01775.x; GOTTLIEB C, 1975, J BIOL CHEM, V250, P3303; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; HASEL KW, 1991, MOL CELL BIOL, V11, P3484, DOI 10.1128/MCB.11.7.3484; HENIS YI, 1990, J CELL BIOL, V111, P1409, DOI 10.1083/jcb.111.4.1409; HILLE A, 1990, J CELL BIOL, V110, P963, DOI 10.1083/jcb.110.4.963; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LANG K, 1988, NATURE, V331, P453, DOI 10.1038/331453a0; LE A, 1990, J BIOL CHEM, V265, P14001; LEDFORD BE, 1983, J BIOL CHEM, V258, P3304; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LODISH HF, 1990, J BIOL CHEM, V265, P10893; LODISH HF, 1991, J BIOL CHEM, V266, P14835; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LODISH HF, 1991, TRENDS BIOCHEM SCI, V16, P374, DOI 10.1016/0968-0004(91)90154-N; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; MACER DRJ, 1988, J CELL SCI, V91, P61; MIZUOCHI T, 1984, J BIOCHEM-TOKYO, V95, P1209, DOI 10.1093/oxfordjournals.jbchem.a134711; OLSON TS, 1989, FASEB J, V3, P1618, DOI 10.1096/fasebj.3.5.2537774; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PERSSON R, 1991, J CELL BIOL, V112, P257, DOI 10.1083/jcb.112.2.257; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; ROOS N, 1988, SCANNING MICROSCOPY, V2, P323; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SCHEELE G, 1985, J BIOL CHEM, V260, P926; SCHWARTZ AL, 1983, J BIOL CHEM, V258, P1249; SCHWARTZ AL, 1982, J BIOL CHEM, V257, P4230; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P1158, DOI 10.1073/pnas.86.4.1158; SOMLYO AP, 1985, NATURE, V314, P622, DOI 10.1038/314622a0; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; Stamnes MA, 1990, CURR OPIN CELL BIOL, V2, P1104, DOI 10.1016/0955-0674(90)90163-9; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WATOWICH SS, 1988, MOL CELL BIOL, V8, P393, DOI 10.1128/MCB.8.1.393; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WIKSTROM L, 1992, J BIOL CHEM, V267, P5; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997; WILEMAN T, 1991, J BIOL CHEM, V266, P4500; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973	61	227	232	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12753	12760						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618778				2022-12-25	WOS:A1992HZ48300057
J	LONGO, N; SHUSTER, RC; GRIFFIN, LD; LANGLEY, SD; ELSAS, LJ				LONGO, N; SHUSTER, RC; GRIFFIN, LD; LANGLEY, SD; ELSAS, LJ			ACTIVATION OF INSULIN-RECEPTOR SIGNALING BY A SINGLE AMINO-ACID SUBSTITUTION IN THE TRANSMEMBRANE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GROWTH-FACTOR RECEPTOR; KINASE-ACTIVITY; HUMAN-FIBROBLASTS; POINT MUTATION; NEU ONCOGENE; PROTEIN; BINDING; 2-DEOXYGLUCOSE; REPLACEMENT; TRANSPORT	The insulin receptor is a ligand-activated tyrosine kinase composed of two alpha and two beta-subunits. A single transmembrane domain composed of 23 hydrophobic residues is contained in each beta-subunit. We examined the role of the transmembrane domain in regulating insulin receptor signaling by inserting a negatively charged amino acid (Asp) for Val938 (V938D). Chinese hamster ovary (CHO) cells were stably transfected with a plasmid containing both the neomycin-resistance gene and either the wild-type or the mutant (V938D) insulin receptor cDNA. Insulin binding increased similarly in CHO cells stably transfected with the wild-type and the V938D-mutant insulin receptor cDNA. Insulin stimulated glucose transport and cell growth in cells expressing the normal insulin receptor. By contrast, in the absence of insulin, glucose transport and cell growth in CHO-V938D cells were as high as in insulin-stimulated control cells and no longer responsive to insulin stimulation. Phosphorylation of the beta-subunit of the insulin receptor was also increased in CHO-V938D cells not exposed to insulin. These results support an essential role of the transmembrane domain of the insulin receptor in the transduction of insulin signaling.	EMORY UNIV,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University	LONGO, N (corresponding author), EMORY UNIV,DEPT PEDIAT,DIV MED GENET,2040 RIDGEWOOD DR,ATLANTA,GA 30322, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040362] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK 40362] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BRANDTRAUF PW, 1990, P NATL ACAD SCI USA, V87, P8660, DOI 10.1073/pnas.87.21.8660; CARPENTER CD, 1991, J BIOL CHEM, V266, P5750; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU CK, 1987, J BIOL CHEM, V262, P1842; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1987, MOL ENDOCRINOL, V1, P15, DOI 10.1210/mend-1-1-15; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FRATTALI AL, 1991, J BIOL CHEM, V266, P9829; KASHLES O, 1988, P NATL ACAD SCI USA, V85, P9567, DOI 10.1073/pnas.85.24.9567; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LONGO N, 1988, AM J PHYSIOL, V254, pC628, DOI 10.1152/ajpcell.1988.254.5.C628; LONGO N, 1985, BIOCHIM BIOPHYS ACTA, V844, P216, DOI 10.1016/0167-4889(85)90093-X; LONGO N, 1989, METABOLISM, V38, P690, DOI 10.1016/0026-0495(89)90109-1; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; SHOELSON SE, 1988, J BIOL CHEM, V263, P4852; STEELEPERKINS G, 1990, J BIOL CHEM, V265, P9458; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WANG CS, 1975, ANAL BIOCHEM, V63, P414, DOI 10.1016/0003-2697(75)90363-2; WELNER DB, 1989, NATURE, V339, P230	25	42	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12416	12419						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618747				2022-12-25	WOS:A1992HZ48300007
J	ARAKAWA, T; OSHIMA, T; KISHIMOTO, K; YOSHIMOTO, T; YAMAMOTO, S				ARAKAWA, T; OSHIMA, T; KISHIMOTO, K; YOSHIMOTO, T; YAMAMOTO, S			MOLECULAR-STRUCTURE AND FUNCTION OF THE PORCINE ARACHIDONATE 12-LIPOXYGENASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN 5-LIPOXYGENASE GENE; PROMOTER; CLONING; EXPRESSION; SEQUENCE; TRANSCRIPTION; LEUKOCYTES; CDNA; SP1	The gene encoding arachidonate 12-lipoxygenase was cloned from a porcine EMBL3 genomic library using a cDNA probe of the enzyme, and its nucleotide sequence was determined. The gene consists of 14 exons with 13 introns, and spans approximately 8 kilobases. Analysis of splice junctions indicated that all of the splice donor and acceptor sites conformed to the GT/AG rule. An approximately 1-kilobase region upstream of the coding sequence contains nine GC-boxes for potential Sp1-binding sites at positions -77, -135, -145, -165, -214, -636, -643, -684, and -813. There are two sets of AP-2 binding sequence at positions -234 and -402. Neither typical TATA box nor CCAAT box is found in this region. The transcriptional start site was determined by primer extension analysis, and was tentatively identified as a cytidine residue located 19 bases upstream from initiation codon. Southern blot analysis revealed the presence of one copy of 12-lipoxygenase gene per haploid genome. We found striking similarities in genomic organization as well as the promoter sequences between the porcine 12-lipoxygenase and the rabbit 15-lipoxygenase genes, suggesting that these genes are evolutionarily related.	UNIV TOKUSHIMA,SCH MED,DEPT BIOCHEM,KURAMOTO CHO,TOKUSHIMA 770,JAPAN	Tokushima University								BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2587, DOI 10.1073/pnas.86.8.2587; FUNK CD, 1990, P NATL ACAD SCI USA, V87, P5638, DOI 10.1073/pnas.87.15.5638; HADA T, 1991, BIOCHIM BIOPHYS ACTA, V1083, P89, DOI 10.1016/0005-2760(91)90128-5; HOSHIKO S, 1990, P NATL ACAD SCI USA, V87, P9073, DOI 10.1073/pnas.87.23.9073; IZUMI T, 1990, P NATL ACAD SCI USA, V87, P7477, DOI 10.1073/pnas.87.19.7477; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; OPREY J, 1989, GENE, V84, P493, DOI 10.1016/0378-1119(89)90526-X; RUSKIN B, 1985, NATURE, V317, P732, DOI 10.1038/317732a0; Sambrook J, 1989, MOL CLONING LABORATO; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINJO F, 1986, J BIOL CHEM, V261, P3377; TAKAHASHI Y, 1988, ARCH BIOCHEM BIOPHYS, V266, P613, DOI 10.1016/0003-9861(88)90294-9; YAMAMOTO S, 1991, FREE RADICAL BIO MED, V10, P149, DOI 10.1016/0891-5849(91)90008-Q; YAMAMOTO S, 1989, PROSTAG LEUKOTR ESS, V35, P219, DOI 10.1016/0952-3278(89)90005-7; YAMAMOTO S, 1988, PROSTAGLANDINS BIOL, P37; YOSHIMOTO T, 1990, P NATL ACAD SCI USA, V87, P2142, DOI 10.1073/pnas.87.6.2142; YOSHIMOTO T, 1990, BIOCHEM BIOPH RES CO, V172, P1230, DOI 10.1016/0006-291X(90)91580-L; YOSHIMOTO T, 1991, INT S OXYGENASES OXY, P59	22	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12188	12191						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601885				2022-12-25	WOS:A1992HY94700080
J	LANG, P; GUIZANI, L; VITTEMONY, I; STANCOU, R; DORSEUIL, O; GACON, G; BERTOGLIO, J				LANG, P; GUIZANI, L; VITTEMONY, I; STANCOU, R; DORSEUIL, O; GACON, G; BERTOGLIO, J			ADP-RIBOSYLATION OF THE RAS-RELATED, GTP-BINDING PROTEIN RHOA INHIBITS LYMPHOCYTE-MEDIATED CYTOTOXICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CLOSTRIDIUM-BOTULINUM; NATURAL-KILLER; CELLS; FAMILY	The Rho proteins are identified as a subgroup of the Ras superfamily of low molecular weight GTP-binding proteins. We have studied the expression of these proteins in human cytotoxic natural killer cells and found that RhoA is the most abundantly expressed member of the Rho family. The Rho proteins are specific substrates for ADP-ribosylation catalyzed by the C3 exoenzyme from Clostridium botulinum. We report here that introduction of recombinant C3 in electropermeabilized natural killer cells or in cytotoxic T lymphocytes resulted in a dose-dependent inhibition of their cytolytic function. Furthermore, a single substrate is efficiently ADP-ribosylated by C3 in extracts from cytotoxic cells. Biochemical analyses indicate that this substrate is RhoA, and subcellular fractionation experiments demonstrate that it is essentially present in the cytosol of the cells. Western blot analysis, however, revealed that a small proportion of the Rho protein can be found associated with the cell membrane as well as with the cytotoxic granules. These results indicate that the low molecular weight GTP-binding protein RhoA is present in cytotoxic lymphocytes and plays a critical role in cell-mediated cytotoxicity.	INST GUSTAVE ROUSSY,INSERM,U333,39 RUE CAMILLE DESMOULINS,F-94805 VILLEJUIF,FRANCE; INST COCHIN GENET MOLEC,INSERM,U257,F-75014 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm)								ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LENHARD JM, 1991, BIOCHEM BIOPH RES CO, V174, P197, DOI 10.1016/0006-291X(91)90505-2; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PHILIPS MR, 1991, J BIOL CHEM, V266, P1289; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; REIBEL L, 1991, BIOCHEM BIOPH RES CO, V175, P451, DOI 10.1016/0006-291X(91)91585-Z; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SEKINE A, 1989, J BIOL CHEM, V264, P8602; STASIA MJ, 1991, BIOCHEM BIOPH RES CO, V180, P615, DOI 10.1016/S0006-291X(05)81110-6; TIMONEN T, 1981, J EXP MED, V153, P569, DOI 10.1084/jem.153.3.569; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VITTEMONY I, 1990, J IMMUNOL, V145, P4272; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869; YODOI J, 1985, J IMMUNOL, V134, P1623; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	28	92	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11677	11680						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601841				2022-12-25	WOS:A1992HY94700005
J	TRUETT, AP; BOCCKINO, SB; MURRAY, JJ				TRUETT, AP; BOCCKINO, SB; MURRAY, JJ			REGULATION OF PHOSPHATIDIC-ACID PHOSPHOHYDROLASE ACTIVITY DURING STIMULATION OF HUMAN POLYMORPHONUCLEAR LEUKOCYTES	FASEB JOURNAL			English	Note						DIACYLGLYCEROL; PHOSPHOLIPASE-D; SUPEROXIDE ANION; NEUTROPHIL; SIGNAL TRANSDUCTION	PHOSPHOLIPASE-D ACTIVATION; ISOLATED RAT HEPATOCYTES; HUMAN NEUTROPHILS; DIACYLGLYCEROL PRODUCTION; SUPEROXIDE PRODUCTION; HUMAN-GRANULOCYTES; DIGLYCERIDES; CALCIUM; ASSAY; GLYCEROL	Phosphatidic acid phosphohydrolase (PPH) activity was determined in human polymorphonuclear leukocytes (PMNs) by measuring the hydrolysis of [P-32]phosphatidic acid (PA) added to cell sonicates. Enzyme activity was localized primarily to a soluble fraction. Soluble and particulate activities required magnesium and were inhibited by calcium, N-ethylmaleimide, sphingosine, and propranolol. The activity in unstimulated PMNs was 0.64 +/- 0.11 nmol of PA hydrolyzed.mg protein-1.min-1 in particulate and 4.20 +/- 0.42 in soluble fractions. Stimulation of PMNs with 1-mu-M f-Met-Leu-Phe (FMLP) for 10 min caused a slight decrease in soluble activity and a small increase in the activity of particulate fractions. Preincubation with 10-mu-M cytochalasin B for 5 min before FMLP stimulation markedly enhanced both of these changes. The effect of FMLP plus cytochalasin B was rapid (< 10 s), whereas the calcium ionophore A23187 (1-mu-M) and phorbol myristate acetate (100 ng/ml) caused slower and smaller changes in enzyme activity. These results indicate that after chemoattractant stimulation; PPH activity decreases in the soluble fraction and increases in the particulate fraction suggesting that PPH may participate in signal transduction in the PMN.	VANDERBILT UNIV,MED CTR,DEPT MED,ALLERGY LAB,843 LIGHT HALL,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,DEPT PHARMACOL,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University; Vanderbilt University					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR008130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, P50GM015431] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-05424] Funding Source: Medline; NIAMS NIH HHS [AR/AI-08130-01] Funding Source: Medline; NIGMS NIH HHS [GM-15431] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; AGWU DE, 1989, J BIOL CHEM, V264, P1405; BELLAVITE P, 1988, J BIOL CHEM, V263, P8210; BEVINGTON A, 1989, ANAL BIOCHEM, V181, P130, DOI 10.1016/0003-2697(89)90405-3; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1987, FEBS LETT, V225, P201, DOI 10.1016/0014-5793(87)81157-2; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BRINDLEY DN, 1987, CRC SERIES ENZYME BI, V1, P1; CASCALES C, 1984, BIOCHEM J, V219, P911, DOI 10.1042/bj2190911; COX CC, 1986, J IMMUNOL, V136, P4611; ENGLISH D, 1991, BIOCHEM BIOPH RES CO, V175, P423, DOI 10.1016/0006-291X(91)91581-V; GAY JC, 1990, BLOOD S, V76, pA180; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; JONES GS, 1981, J CELL PHYSIOL, V106, P75, DOI 10.1002/jcp.1041060109; KORCHAK HM, 1988, J BIOL CHEM, V263, P11098; MARTIN A, 1991, PHOSPHOLIPASES, V197, P553; MULLMANN TJ, 1990, J IMMUNOL, V144, P1901; MULLMANN TJ, 1990, BIOCHEM BIOPH RES CO, V170, P1197, DOI 10.1016/0006-291X(90)90520-W; MULLMANN TJ, 1991, J BIOL CHEM, V266, P2013; PITTNER RA, 1986, BIOCHEM J, V240, P253, DOI 10.1042/bj2400253; PITTNER RA, 1985, BIOCHEM J, V225, P455, DOI 10.1042/bj2250455; PREISS JE, 1987, J IMMUNOL, V138, P1542; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; SMITH RJ, 1988, J LEUKOCYTE BIOL, V43, P411, DOI 10.1002/jlb.43.5.411; STURTON RG, 1978, BIOCHEM J, V171, P263, DOI 10.1042/bj1710263; TAYLOR SJ, 1986, BIOCHEM J, V239, P275, DOI 10.1042/bj2390275; TRUETT AP, 1989, J ALLERGY CLIN IMMUN, V83, P311; TRUETT AP, 1989, BIOCHEM J, V260, P909, DOI 10.1042/bj2600909; TRUETT AP, 1988, P NATL ACAD SCI USA, V85, P1549, DOI 10.1073/pnas.85.5.1549; WALTON PA, 1985, ANAL BIOCHEM, V151, P479, DOI 10.1016/0003-2697(85)90208-8; WELLS GN, 1986, BIOCHIM BIOPHYS ACTA, V878, P225, DOI 10.1016/0005-2760(86)90150-5; WHITIN JC, 1985, J IMMUNOL, V134, P1206	33	23	23	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1992	6	9					2720	2725		10.1096/fasebj.6.9.1612297	http://dx.doi.org/10.1096/fasebj.6.9.1612297			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HZ481	1612297				2022-12-25	WOS:A1992HZ48100014
J	LEBARON, RG; ZIMMERMANN, DR; RUOSLAHTI, E				LEBARON, RG; ZIMMERMANN, DR; RUOSLAHTI, E			HYALURONATE BINDING-PROPERTIES OF VERSICAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCANS; LYMPHOCYTE HOMING RECEPTOR; LINK PROTEIN; CARTILAGE PROTEOGLYCAN; CELL-MIGRATION; CHICK-EMBRYO; CDNA CLONES; SEQUENCE; EXPRESSION; ADHESION	We have previously cloned a large chondroitin sulfate proteoglycan (versican) from human fibroblasts. The primary sequence shows that the N terminus contains sequence homology with known hyaluronate-binding molecules, suggesting that versican can bind hyaluronate. To test this hypothesis we have reconstructed a full-length versican cDNA and a versican cDNA fragment encoding the N terminus and have transfected Chinese hamster ovary cells and mouse 3T3 fibroblasts, respectively, with these constructs. The transfected Chinese hamster ovary cells make a proteoglycan shown to be versican by enzymatic and immunologic analysis. No corresponding proteoglycan was seen in the control cells. Using hyaluronate affinity chromatography, we show that recombinant versican specifically binds hyaluronate and does not bind to heparin or chondroitin sulfate. The transfected fibroblasts make a 78-kDa truncated form of versican that also binds hyaluronate and does not bind the related polysaccharides, showing that the hyaluronate binding activity resides at the N terminus of versican. The binding of versican to hyaluronate is substrate-concentration dependent and time dependent and can be competed with unlabeled versican. The dissociation constant for versican binding to hyaluronate was determined to be 4 x 10(-9)M.	UNIV ZURICH,INST CLIN PATHOL,DEPT PATHOL,CH-8091 ZURICH,SWITZERLAND	University of Zurich	LEBARON, RG (corresponding author), LA JOLLA CANC RES FDN,CANC RES CTR,LA JOLLA,CA 92037, USA.		Lebaron, Richard/K-4722-2013	Lebaron, Richard/0000-0002-7770-305X	NCI NIH HHS [CA30199, CA42507] Funding Source: Medline; NIAMS NIH HHS [AR08131] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042507, P30CA030199] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR008131] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ATHA DH, 1984, BIOCHEMISTRY-US, V23, P5801, DOI 10.1021/bi00319a020; BAKER JR, 1987, METHOD ENZYMOL, V144, P401; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BRAY B, 1989, BIOCHEM J, V262, P225, DOI 10.1042/bj2620225; BRENNAN MJ, 1983, CANCER RES, V43, P4302; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEAK F, 1986, P NATL ACAD SCI USA, V83, P3766, DOI 10.1073/pnas.83.11.3766; DOEGE K, 1986, P NATL ACAD SCI USA, V83, P3761, DOI 10.1073/pnas.83.11.3761; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FICHARD A, 1991, DEV BIOL, V148, P1, DOI 10.1016/0012-1606(91)90312-Q; FOSANG AJ, 1990, MATRIX, V10, P306, DOI 10.1016/S0934-8832(11)80186-1; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FROST E, 1978, VIROLOGY, V91, P39, DOI 10.1016/0042-6822(78)90353-7; FUNDERBURG FM, 1986, J CELL BIOL, V103, P2475, DOI 10.1083/jcb.103.6.2475; GOETINCK PF, 1987, J CELL BIOL, V105, P2403, DOI 10.1083/jcb.105.5.2403; GOLDBERG RL, 1984, J CELL BIOL, V99, P2114, DOI 10.1083/jcb.99.6.2114; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; Hascall V.C., 1981, CELL BIOL EXTRACELLU, P39; JOHANSSON S, 1985, BIOCHEM J, V232, P161, DOI 10.1042/bj2320161; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KAUFMAN RJ, 1982, J MOL BIOL, V159, P601, DOI 10.1016/0022-2836(82)90103-6; KIMATA K, 1986, J BIOL CHEM, V261, P3517; KIMURA JH, 1987, METHOD ENZYMOL, V144, P372; KISS I, 1987, P NATL ACAD SCI USA, V84, P6399, DOI 10.1073/pnas.84.18.6399; KRUSIUS T, 1987, J BIOL CHEM, V262, P13120; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LINDAHL U, 1978, ANNU REV BIOCHEM, V47, P385, DOI 10.1146/annurev.bi.47.070178.002125; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; MORGELIN M, 1988, BIOCHEM J, V253, P175; MUNAIM SI, 1991, DEV BIOL, V143, P297, DOI 10.1016/0012-1606(91)90080-M; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURAKAMI S, 1990, J IMMUNOL, V145, P3618; OAKLEY RA, 1991, DEV BIOL, V147, P187, DOI 10.1016/S0012-1606(05)80017-X; OOHIRA A, 1991, J NEUROSCI, V11, P822; ORKIN RW, 1985, DEV BIOL, V107, P527, DOI 10.1016/0012-1606(85)90333-1; PERIDES G, 1989, J BIOL CHEM, V264, P5981; PERRIS R, 1990, DEV BIOL, V137, P1, DOI 10.1016/0012-1606(90)90002-Z; RAPRAEGER A, 1985, J BIOL CHEM, V260, P1046; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; UNDERHILL CB, 1982, J CELL PHYSIOL, V110, P123, DOI 10.1002/jcp.1041100204; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; URLAUB G, 1986, SOMAT CELL MOLEC GEN, V12, P555, DOI 10.1007/BF01671941; VERNA JM, 1989, INT J DEV NEUROSCI, V7, P389, DOI 10.1016/0736-5748(89)90060-9; YAMAGATA M, 1989, J BIOL CHEM, V264, P8012; YAMAGATA M, 1986, J BIOL CHEM, V261, P3526; YAMAGUCHI Y, 1988, NATURE, V336, P244, DOI 10.1038/336244a0; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; ZABEAU M, 1982, EMBO J, V1, P1217, DOI 10.1002/j.1460-2075.1982.tb00016.x; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	59	284	285	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10003	10010						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577773				2022-12-25	WOS:A1992HT96500084
J	VENEMA, J; BARTOSOVA, Z; NATARAJAN, AT; VANZEELAND, AA; MULLENDERS, LHF				VENEMA, J; BARTOSOVA, Z; NATARAJAN, AT; VANZEELAND, AA; MULLENDERS, LHF			TRANSCRIPTION AFFECTS THE RATE BUT NOT THE EXTENT OF REPAIR OF CYCLOBUTANE PYRIMIDINE DIMERS IN THE HUMAN ADENOSINE-DEAMINASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FACTOR-IX; SACCHAROMYCES-CEREVISIAE; DIFFERENTIAL REPAIR; HEMOPHILIA-B; DNA-REPAIR; ACTIVE DNA; DHFR GENE; UV DAMAGE; FIBROBLASTS; DEFICIENCY	To study the relationship between transcription and strand-specific repair of UV-induced cyclobutane pyrimidine dimers, dimer removal was analyzed in a cell line containing two alleles of an inactivated adenosine deaminase (ADA) gene. The cell line was derived from a patient suffering from severe combined immunodeficiency. The disease was caused by a deletion of the complete promoter of the gene as well as the first exon of the ADA gene. This resulted in a true null allele without any detectable transcription (Berkvens, T. M., Gerritsen, E. J. A., Oldenburg, M., Breukel, C., Wijnen, J. T. H., Van Ormondt, H., Vossen, J. M., Van der Eb, A. J., and Meera Khan, P. (1987) Nucleic Acids Res. 15, 9365-9378). Despite this lack of transcription, repair of the ADA gene in this cell line was found to be very efficient with 80% of the dimers being removed within 24 h after UV irradiation. However, the initial rapid repair which is associated with the transcribed strand in normal cells is absent. Dimer removal from two inactive loci, 754 and coagulation factor IX, was much less efficient with only 40% dimers removed after 24 h. From this data, we conclude that transcription is not required for efficient repair of a gene, but forms an additional signal for accelerated repair of the transcribed strand. Furthermore, we suggest that different levels of repair exist between non-transcribed sequences in active genes and those in repressed loci. The results are discussed in terms of the current ideas about the mechanism of preferential DNA repair in human cells.	LEIDEN UNIV, DEPT RADIAT GENET & CHEM MUTAGENESIS, MGC, 2333 AL LEIDEN, NETHERLANDS; INTERUNIV RES INST RADIAT PROTECT & RADIOPATHOL, JA COHEN INST, LEIDEN, NETHERLANDS; SLOVAK ACAD SCI, CANC RES INST, CS-80936 BRATISLAVA, CZECHOSLOVAKIA	Leiden University; Leiden University - Excl LUMC; Slovak Academy of Sciences								ANSON DS, 1984, EMBO J, V3, P1053, DOI 10.1002/j.1460-2075.1984.tb01926.x; ANTONARAKIS SE, 1988, ADV HUM GENET, V17, P27; BERKVENS TM, 1990, GENOMICS, V7, P486, DOI 10.1016/0888-7543(90)90190-6; BERKVENS TM, 1987, NUCLEIC ACIDS RES, V15, P9365, DOI 10.1093/nar/15.22.9365; BIERNAT J, 1989, J BIOCHEM BIOPH METH, V19, P155, DOI 10.1016/0165-022X(89)90023-7; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; DECOCK JGR, 1991, NUCLEIC ACIDS RES, V19, P3289, DOI 10.1093/nar/19.12.3289; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HOFKER MH, 1986, HUM GENET, V74, P270, DOI 10.1007/BF00282547; KANTOR GJ, 1990, MUTAT RES, V235, P171, DOI 10.1016/0921-8777(90)90071-C; LATTIER DL, 1989, NUCLEIC ACIDS RES, V17, P1061, DOI 10.1093/nar/17.3.1061; LEADON SA, 1991, MUTAT RES, V255, P67, DOI 10.1016/0921-8777(91)90019-L; MADHANI HD, 1986, CELL, V45, P417, DOI 10.1016/0092-8674(86)90327-2; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MULLENDERS LHF, 1988, NUCLEIC ACIDS RES, V16, P10607, DOI 10.1093/nar/16.22.10607; NAKABEPPU Y, 1982, J BIOL CHEM, V257, P2556; PALMER TD, 1989, BLOOD, V73, P438; TERLETH C, 1990, EMBO J, V9, P2899, DOI 10.1002/j.1460-2075.1990.tb07480.x; TERLETH C, 1989, NUCLEIC ACIDS RES, V17, P4433, DOI 10.1093/nar/17.12.4433; TERLETH C, 1991, THESIS STATE U LEIDE; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; WILL CL, 1986, MOL PHARMACOL, V29, P643; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049	26	66	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8852	8856						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577723				2022-12-25	WOS:A1992HR85400026
J	BLACKLOCK, BJ; SMILLIE, M; RYAN, RO				BLACKLOCK, BJ; SMILLIE, M; RYAN, RO			INSECT LIPID TRANSFER PARTICLE CAN FACILITATE NET VECTORIAL LIPID TRANSFER VIA A CARRIER-MEDIATED MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY LIPOPROTEINS; HUMAN-PLASMA LOW; MANDUCA-SEXTA; TRANSFER PROTEIN; CHOLESTERYL ESTER; LIPOPHORIN; HEMOLYMPH; TRANSPORT; DIACYLGLYCEROL; EXCHANGE	The mechanism of facilitated lipid transfer by insect or mammalian plasma lipid transfer proteins has not been elucidated. Transfer catalysts may act as carriers of lipid between donor and acceptor lipoproteins or, alternatively, transfer may require formation of a ternary complex. This study was designed to determine if Manduca sexta hemolymph lipid transfer particle (LTP) can facilitate net vectorial transfer of lipid without concomitant contact between donor and acceptor lipoproteins and LTP. M. sexta [H-3]diacylglycerol-high density lipophorin-larval ([H-3]DAG-HDLp-L) and human low density lipoprotein (LDL) were covalently bound to Sepharose matrices and packed into separate columns. In incubations lacking LTP, greater than 98% of the recovered DAG remained associated with HDLp-L. An unrelated hemolymph storage protein, arylphorin, was unable to catalyze the transfer of DAG between solid-phase lipoproteins. Facilitated transfer of DAG from HDLp-L to LDL was observed when LTP was circulated between the columns. Under these conditions, facilitated transfer occurred at a rate of 2.24 ng of DAG/h (versus 0.16-mu-g of DAG/h in the control), and after 16 h greater than 26% of recovered labeled DAG was transferred to LDL. This corresponds to a 14-fold rate enhancement induced by LTP. The LTP-specific transfer of DAG between physically separated lipoproteins demonstrates the ability of LTP to facilitate net lipid transfer via a carrier-mediated mechanism in the absence of a ternary complex involving donor, acceptor, and catalyst. In experiments aimed at assessing the relative contribution of ternary complex formation to DAG transfer, acceptor LDL was circulated with HDLp-L remaining immobilized. Under these conditions, LTP induced a 13-fold rate enhancement from 1.3 to 16.3-mu-g of DAG/h. The similar rate enhancements observed with both lipoproteins bound and only donor bound suggest the overall contribution of ternary complex formation to facilitated lipid transfer is insignificant. The described system should prove useful in mechanistic studies of other transfer proteins as well as studies of transfer of other lipids.	UNIV ALBERTA,LIPID & LIPOPROT RES GRP,328 HERITAGE BLDG,EDMONTON T6G 2S2,ALBERTA,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2S2,ALBERTA,CANADA	University of Alberta; University of Alberta					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034786] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-34786] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDO S, 1990, BIOCHIM BIOPHYS ACTA, V1043, P289, DOI 10.1016/0005-2760(90)90029-W; BARTER PJ, 1980, J LIPID RES, V21, P238; CHARLTON SC, 1978, BIOCHEMISTRY-US, V17, P3301; CHINO H, 1985, COMPREHENSIVE INSECT, V10, P115; DOWNER RGH, 1985, INSECT BIOCHEM, V15, P62; HIRAYAMA Y, 1990, J LIPID RES, V31, P793; IHM J, 1982, J LIPID RES, V23, P1328; KAWOOYA JK, 1988, J BIOL CHEM, V263, P8748; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU H, 1991, BIOCHIM BIOPHYS ACTA, V1085, P112, DOI 10.1016/0005-2760(91)90238-D; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MORTON RE, 1985, J BIOL CHEM, V260, P2593; POWNALL HJ, 1983, J AM CHEM SOC, V105, P2440, DOI 10.1021/ja00346a055; PRASAD SV, 1986, J BIOL CHEM, V261, P558; RYAN RO, 1990, J BIOL CHEM, V265, P10551; RYAN RO, 1990, J LIPID RES, V31, P1725; RYAN RO, 1985, ARCH BIOCHEM BIOPHYS, V243, P115, DOI 10.1016/0003-9861(85)90779-9; RYAN RO, 1990, J BIOL CHEM, V265, P546; RYAN RO, 1988, BIOCHIM BIOPHYS ACTA, V962, P143, DOI 10.1016/0005-2760(88)90105-1; RYAN RO, 1986, J BIOL CHEM, V261, P563; RYAN RO, 1990, J LIPID RES, V31, P871; RYAN RO, 1986, BIOCHEM BIOPH RES CO, V136, P260, DOI 10.1016/0006-291X(86)90903-4; RYAN RO, 1992, J LIPID RES, V1, P55; SHAPIRO JP, 1988, ANNU REV ENTOMOL, V33, P297, DOI 10.1146/annurev.en.33.010188.001501; SHAPIRO JP, 1984, J BIOL CHEM, V259, P3680; SILVER ET, 1990, J BIOL CHEM, V265, P22487; SINGH TKA, 1991, ARCH BIOCHEM BIOPHYS, V286, P376, DOI 10.1016/0003-9861(91)90054-M; SWENSON TL, 1988, J BIOL CHEM, V263, P5150; TALL AR, 1986, J LIPID RES, V27, P361; VANHEUSDEN MC, 1989, J BIOL CHEM, V264, P17287; YAN RO, 1988, J BIOL CHEM, V263, P14140	31	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14033	14037						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629202				2022-12-25	WOS:A1992JD32500041
J	PONTIUS, BW; BERG, P				PONTIUS, BW; BERG, P			RAPID ASSEMBLY AND DISASSEMBLY OF COMPLEMENTARY-DNA STRANDS THROUGH AN EQUILIBRIUM INTERMEDIATE STATE MEDIATED BY A1 HNRNP PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; RNA-BINDING PROTEINS; COMPLEX PROTEIN-A1; CALF THYMUS; PARTICLES; PURIFICATION; DOMAIN; SEX	A1 hnRNP protein, which rapidly renatures complementary strands of nucleic acids in vitro, affects both the equilibrium and kinetic properties of the reaction (single-stranded DNA double-line arrow pointing left and right double-stranded DNA). Al lowers the melting transition of duplex DNA. However, at temperatures above this new T(m), both single- and double-stranded DNAs are present at equilibrium and are rapidly interconverting. Although the ratio of single and double strands under these conditions is a function of both the A1 protein and complementary DNA strand concentrations, it is not strongly affected by further increases in temperature. These surprising results demonstrate that A1 does not act as a simple catalyst in promoting renaturation and indicate how A1 and other proteins could act to speed the turnover of intermediate complexes in important biological processes.	STANFORD UNIV,MED CTR,BECKMAN CTR,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University					PHS HHS [13235] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAKER BS, 1989, GENOME, V31, P638, DOI 10.1139/g89-117; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BEYER AL, 1977, CELL, V11, P127, DOI 10.1016/0092-8674(77)90323-3; CHUNG S Y, 1986, Proteins Structure Function and Genetics, V1, P195, DOI 10.1002/prot.340010302; COBIANCHI F, 1988, J BIOL CHEM, V263, P1063; COBIANCHI F, 1986, J BIOL CHEM, V261, P3536; DOTY P., 1959, PROC NATL ACAD SCI, V45, P482, DOI 10.1073/pnas.45.4.482; DREYFUSS G, 1988, J CELL BIOL, V106, P1419, DOI 10.1083/jcb.106.5.1419; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HERRICK G, 1976, J BIOL CHEM, V251, P2133; KUMAR A, 1986, J BIOL CHEM, V261, P1266; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P10717, DOI 10.1021/bi00500a001; KUMAR A, 1990, J BIOL CHEM, V265, P17094; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; MARMUR J, 1961, J MOL BIOL, V3, P585, DOI 10.1016/S0022-2836(61)80023-5; MARMUR J, 1962, J MOL BIOL, V5, P109, DOI 10.1016/S0022-2836(62)80066-7; MATTAJ IW, 1989, CELL, V57, P1, DOI 10.1016/0092-8674(89)90164-5; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MERRILL BM, 1986, J BIOL CHEM, V261, P878; MERRILL BM, 1988, J BIOL CHEM, V263, P3307; MUKKUR TKS, 1980, TRENDS BIOCHEM SCI, V5, P72, DOI 10.1016/0968-0004(80)90072-9; MUNROE SH, 1992, P NATL ACAD SCI USA, V89, P895, DOI 10.1073/pnas.89.3.895; NADLER SG, 1991, BIOCHEMISTRY-US, V30, P2968, DOI 10.1021/bi00225a034; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHILDKRAUT C, 1965, BIOPOLYMERS, V3, P195, DOI 10.1002/bip.360030207; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; SWANSON MS, 1987, MOL CELL BIOL, V6, P2932; WETMUR JG, 1976, ANNU REV BIOPHYS BIO, V29, P336	31	55	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13815	13818						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629182				2022-12-25	WOS:A1992JD32500007
J	MORRISON, JR; MCPHERSON, GA; FIDGE, NH				MORRISON, JR; MCPHERSON, GA; FIDGE, NH			EVIDENCE FOR 2 SITES ON RAT-LIVER PLASMA-MEMBRANES WHICH INTERACT WITH HIGH-DENSITY LIPOPROTEIN(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; A-I; PURIFICATION; CHOLESTEROL; LIGAND; CELLS; IDENTIFICATION; FIBROBLASTS; RECEPTORS; HDL3	There is little dispute that high density lipoprotein (HDL) binds to cells, however, the nature of the interaction is not fully understood. We now present evidence for a new binding site of higher affinity but lower capacity than the sites previously described in the literature. This new site is characterized by high affinity/low capacity for HDL binding (K(d) = 0.94-mu-g/ml, B(max) = 36 ng/mg), while the low affinity site (K(d) = 36-mu-g/ml, B(max) almost-equal-to 700 ng/mg) appears to be consistent with the literature values for the interaction of HDL with cells and isolated membranes. Proteolysis of HDL with trypsin abolished its interaction with the high affinity site, suggesting an apolipoprotein requirement, while having no effect on binding to the lower affinity site. Kinetic rates of association/dissociation were determined in order to further characterize the high affinity site. At a concentration which favored the binding of HDL with the high affinity site (1-mu-g/ml, 37-degrees-C), the time course of association of HDL with rat liver plasma membranes, displayed a biphasic pattern, requiring 6-8 h to reach the level of binding predicted from the saturation studies. The second phase was highly sensitive to temperature, being considerably slower at 24-degrees-C and totally abolished at 0-degrees-C. A kinetic K(d), derived from the measured association and dissociation rate constants (K(d) = 0.31-mu-g/ml), was found to be of a similar magnitude to the K(d) calculated for the high affinity site by Scatchard analysis (K(d) = 0.94-mu-g/ml). In summary, the high affinity site on rat liver plasma membranes displays an apoprotein requirement and kinetic parameters, consistent with a ligand-receptor interaction.	BAKER MED RES INST,POB 348,PRAHRAN,VIC 3181,AUSTRALIA	Baker Heart and Diabetes Institute								BARBARAS R, 1990, BIOCHEM J, V269, P767, DOI 10.1042/bj2690767; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; CHACKO GK, 1982, BIOCHIM BIOPHYS ACTA, V712, P129, DOI 10.1016/0005-2760(82)90094-7; EISENBERG S, 1984, J LIPID RES, V25, P1017; FIDGE N, 1985, BIOCHEM BIOPH RES CO, V129, P759, DOI 10.1016/0006-291X(85)91957-6; FIDGE NH, 1974, CLIN CHIM ACTA, V52, P15, DOI 10.1016/0009-8981(74)90383-0; Fleischer S, 1974, Methods Enzymol, V31, P6; GLASS C, 1985, J BIOL CHEM, V260, P744; GRAHAM DL, 1987, J BIOL CHEM, V262, P7439; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOPKINS GJ, 1984, BIOCHIM BIOPHYS ACTA, V794, P31, DOI 10.1016/0005-2760(84)90294-7; KESO L, 1987, FEBS LETT, V215, P105, DOI 10.1016/0014-5793(87)80122-9; LEBLOND L, 1991, J BIOL CHEM, V266, P5058; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATHAI D, 1990, ARTERIOSCLEROSIS, V10, P1045, DOI 10.1161/01.ATV.10.6.1045; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MCPHERSON GA, 1985, KINETIC EBDA LIGAND; MENDEL CM, 1988, J BIOL CHEM, V263, P1314; MITCHEL YB, 1987, BIOCHIM BIOPHYS ACTA, V917, P324, DOI 10.1016/0005-2760(87)90137-8; MORRISON J, 1991, J BIOL CHEM, V266, P18780; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; ORAM JF, 1991, ARTERIOSCLER THROMB, V11, P403, DOI 10.1161/01.ATV.11.2.403; PITAS RE, 1979, P NATL ACAD SCI USA, V76, P2311, DOI 10.1073/pnas.76.5.2311; RAY TK, 1970, BIOCHIM BIOPHYS ACTA, V196, P1, DOI 10.1016/0005-2736(70)90159-8; SLOTTE JP, 1987, J BIOL CHEM, V262, P12904; TABAS I, 1984, J BIOL CHEM, V259, P3897; TILLEY L, 1988, J BIOL CHEM, V263, P17541; TOZUKA M, 1989, BIOCHEM J, V261, P239, DOI 10.1042/bj2610239; TULSIANI DRP, 1977, J BIOL CHEM, V252, P3227; POLYACRYLAMIDE GEL E, P26	30	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13205	13209						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618825				2022-12-25	WOS:A1992JB74600020
J	SINGH, I; LAZO, O; DHAUNSI, GS; CONTRERAS, M				SINGH, I; LAZO, O; DHAUNSI, GS; CONTRERAS, M			TRANSPORT OF FATTY-ACIDS INTO HUMAN AND RAT PEROXISOMES - DIFFERENTIAL TRANSPORT OF PALMITIC AND LIGNOCERIC ACIDS AND ITS IMPLICATION TO X-ADRENOLEUKODYSTROPHY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COA LIGASE DEFICIENCY; LIVER PEROXISOMES; BETA-OXIDATION; LONG-CHAIN; TOPOGRAPHICAL LOCALIZATION; BRAIN MICROSOMES; SYNTHETASE; MEMBRANE; PROTEIN; FRACTIONATION	The different topology of palmitoyl-CoA ligase (on the cytoplasmic surface) and of lignoceroyl-CoA ligase (on the luminal surface) in peroxisomal membranes suggests that these fatty acids may be transported in different form through the peroxisomal membrane (Lazo, O., Contreras, M., and Singh, I. (1990) Biochemistry 29, 3981-3986), and this differential transport may account for deficient oxidation of lignoceric acid in X-adrenoleukodystrophy (X-ALD) (Singh, I., Moser, A. B., Goldfisher, S., and Moser, H. W. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 4203-4207). To define the transport mechanism for these fatty acids through the peroxisomal membrane and its possible implication to lignoceric acid metabolism in X-ALD, we examined cofactors and energy requirements for the transport of palmitic and lignoceric acids in isolated peroxisomes from rat liver and peroxisomes isolated from X-ALD and control fibroblasts. The similar rates of transport of palmitoyl-CoA (87.6 +/- 6.3 nmol/h/mg protein) and palmitic acid in the fatty acid activating conditions (83.4 +/- 5.1 nmol/h/mg protein) and lack of transport of palmitic acid (4% of palmitoyl-CoA transport) when ATP and/or CoASH were removed or substituted by alpha,beta-methyleneadenosine-5'-triphosphate (AMPCPOP) and/or desulfoCo-Aagarose from assay medium clearly demonstrate that transport of palmitic acid requires prior synthesis of palmitoyl-CoA by palmitoyl-CoA ligase on the cytoplasmic surface of peroxisomes. The 10-fold higher rate of transport of lignoceric acid (5.3 +/- 0.6 nmol/h/mg protein) as compared with lignoceroyl-CoA (0.41 +/- 0.11 nmol/h/mg protein) and lack of inhibition of transport of lignoceric acid when ATP and/or CoASH were removed or substituted with AMPCPOP or desulfoCoA-agarose suggest that lignoceric acid is transported through the peroxisomal membrane as such. Moreover, the lack of effect of removal of ATP or substitution with AMPOPCP (a nonhydrolyzable substrate) demonstrates that the translocation of palmitoyl-CoA and lignoceric acid across peroxisomal membrane does not require energy. The transport, activation, and oxidation of palmitic acid are normal in peroxisomes from X-ALD. The deficient lignoceroyl-CoA ligase (13% of control) and oxidation of lignoceric acid (10% of control) as compared with normal transport of lignoceric acid into peroxisomes from X-ALD clearly demonstrates that pathognomonic accumulation of very long chain fatty acids (>C22) in X-ALD is due to the deficiency of peroxisomal lignoceroyl-CoA ligase activity.			SINGH, I (corresponding author), MED UNIV S CAROLINA,DEPT PEDIAT,171 ASHLEY AVE,CHARLESTON,SC 29425, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS022576, R01NS022576] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 22576] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKANUMA H, 1979, J BIOL CHEM, V254, P1050; APPELKVIST EL, 1980, BIOCHIM BIOPHYS ACTA, V617, P156, DOI 10.1016/0005-2760(80)90233-7; BAUDHUIN P, 1964, BIOCHEM J, V92, P179, DOI 10.1042/bj0920179; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BIEBER LL, 1982, ANN NY ACAD SCI, V386, P395, DOI 10.1111/j.1749-6632.1982.tb21431.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; CORNELL NW, 1980, ANAL BIOCHEM, V102, P326, DOI 10.1016/0003-2697(80)90162-1; DOLE VP, 1956, J CLIN INVEST, V35, P150, DOI 10.1172/JCI103259; FARRELL SO, 1983, ARCH BIOCHEM BIOPHYS, V222, P123, DOI 10.1016/0003-9861(83)90509-X; HASHIMOTO T, 1982, ANN NY ACAD SCI, V386, P5, DOI 10.1111/j.1749-6632.1982.tb21403.x; HASHMI M, 1986, FEBS LETT, V196, P247, DOI 10.1016/0014-5793(86)80256-3; HOSHI M, 1973, J BIOL CHEM, V248, P4123; IMANAKA T, 1987, J CELL BIOL, V105, P2915, DOI 10.1083/jcb.105.6.2915; KRISANS SK, 1980, J BIOL CHEM, V255, P9599; LAGEWEG W, 1991, BIOCHEM J, V276, P53, DOI 10.1042/bj2760053; LAZAROW PB, 1978, J BIOL CHEM, V253, P1522; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LAZO O, 1989, ARCH BIOCHEM BIOPHYS, V270, P722, DOI 10.1016/0003-9861(89)90555-9; LAZO O, 1990, J LIPID RES, V31, P583; LAZO O, 1988, P NATL ACAD SCI USA, V85, P7647, DOI 10.1073/pnas.85.20.7647; LAZO O, 1990, BIOCHEMISTRY-US, V29, P3981, DOI 10.1021/bi00468a027; LAZO O, 1981, MOL CELL BIOCHEM, V100, P159; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; LEIGHTON F, 1969, J CELL BIOL, V41, P521, DOI 10.1083/jcb.41.2.521; MANNAERTS GP, 1979, J BIOL CHEM, V254, P4585; MANNAERTS GP, 1982, ANN NY ACAD SCI, V386, P30, DOI 10.1111/j.1749-6632.1982.tb21405.x; MANNAERTS GP, 1982, BIOCHEM J, V204, P17, DOI 10.1042/bj2040017; MIYAZAWA S, 1985, J BIOCHEM, V98, P723, DOI 10.1093/oxfordjournals.jbchem.a135330; Osmundsen H., 1987, PEROXISOMES BIOL MED, P152; SELLINGER OZ, 1960, BIOCHEM J, V74, P450, DOI 10.1042/bj0740450; SINGH H, 1988, ARCH BIOCHEM BIOPHYS, V266, P486, DOI 10.1016/0003-9861(88)90281-0; SINGH I, 1985, ARCH BIOCHEM BIOPHYS, V236, P418, DOI 10.1016/0003-9861(85)90642-3; SINGH I, 1988, BIOCHIM BIOPHYS ACTA, V963, P509, DOI 10.1016/0005-2760(88)90319-0; SINGH I, 1984, P NATL ACAD SCI-BIOL, V81, P4203, DOI 10.1073/pnas.81.13.4203; THOMAS J, 1980, BIOCHEM J, V190, P485, DOI 10.1042/bj1900485; TOLBERT NE, 1981, ANNU REV BIOCHEM, V50, P133, DOI 10.1146/annurev.bi.50.070181.001025; VANVELDHOVEN P, 1983, BIOCHEM J, V210, P685, DOI 10.1042/bj2100685; VANVELDHOVEN PP, 1987, J BIOL CHEM, V262, P4310; WANDERS RJA, 1988, BIOCHEM BIOPH RES CO, V153, P618, DOI 10.1016/S0006-291X(88)81140-9	40	57	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13306	13313						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618832				2022-12-25	WOS:A1992JB74600036
J	CHAKRABARTI, A; MAITRA, U				CHAKRABARTI, A; MAITRA, U			RELEASE AND RECYCLING OF EUKARYOTIC INITIATION FACTOR-II IN THE FORMATION OF AN 80 S-RIBOSOMAL POLYPEPTIDE-CHAIN INITIATION COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS INITIATION; FACTOR-II; REVERSING FACTOR; ALPHA-SUBUNIT; RABBIT RETICULOCYTES; CALF LIVER; PHOSPHORYLATION; PURIFICATION; INHIBITION; MECHANISM	The eukaryotic initiation factor (eIF)-5 mediates hydrolysis of GTP bound to the 40 S initiation complex in the absence of 60 S ribosomal subunits. The eIF-2.GDP formed under these conditions is released from the 40 S ribosomal subunit while initiator Met-tRNA(f) remains bound. The released eIF-2.GDP can participate in an eIF-2B-catalyzed GDP/GTP exchange reaction to reform the Met-tRNA(f).eIF-2.GTP ternary complex. In contrast, when 60 S ribosomal subunits were also present in an eIF-5-catalyzed reaction, the eIF-2.GDP produced remained bound to the 60 S ribosomal subunit of the 80 S initiation complex. When such an 80 S initiation complex, containing bound eIF-2.GDP, was incubated with GTP and eIF-2B, GDP was released. However, eIF-2 still remained bound to the ribosomes and was unable to form a Met-tRNA(f).eIF-2.GTP ternary complex. In contrast, when 60 S ribosomal subunits were preincubated with either free eIF-2 or with eIF-2.eIF-2B complex and then added to a reaction containing both the 40 S initiation complex and eIF-5, the eIF-2.GDP produced did not bind to the 60 S ribosomal subunits but was released from the ribosomes. Thus, the 80 S initiation complex formed under these conditions did not contain bound eIF-2.GDP. Under similar experimental conditions, preincubation of 60 S ribosomal subunits with purified eIF-2B (free of eIF-2) failed to cause release of eIF-2.GDP from the ribosomal initiation complex. These results suggest that 60 S ribosome-bound eIF-2.GDP does not act as a direct substrate for eIF-2B-mediated release of eIF-2 from ribosomes. Rather, the affinity of 60 S ribosomal subunits for either eIF-2, or the eIF-2 moiety of the eIF-2.eIF-2B complex, prevents association of 60 S ribosomal subunits with eIF-2.GDP formed in the initiation reaction. This ensures release of eIF-2 from ribosomes following hydrolysis of GTP bound to the 40 S initiation complex.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT DEV BIOL & CANC,DIV BIOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NCI NIH HHS [P30CA13330] Funding Source: Medline; NIGMS NIH HHS [GM15399] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015399] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMESZ H, 1979, EUR J BIOCHEM, V98, P513, DOI 10.1111/j.1432-1033.1979.tb13212.x; CHAKRABARTI A, 1991, J BIOL CHEM, V266, P14039; CHAUDHURI A, 1981, J BIOL CHEM, V256, P3988; CLARK SJ, 1989, BIOCHIM BIOPHYS ACTA, V1010, P377, DOI 10.1016/0167-4889(89)90065-7; GHOSH S, 1989, J BIOL CHEM, V264, P5134; GROSS M, 1985, J BIOL CHEM, V260, P9491; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; KONIECZNY A, 1983, J BIOL CHEM, V258, P3402; MAITRA U, 1982, ANNU REV BIOCHEM, V51, P869, DOI 10.1146/annurev.bi.51.070182.004253; MATTS RL, 1983, P NATL ACAD SCI-BIOL, V80, P2559, DOI 10.1073/pnas.80.9.2559; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; PAIN VM, 1983, BIOCHEMISTRY-US, V22, P726, DOI 10.1021/bi00273a003; PANNIERS R, 1983, J BIOL CHEM, V258, P7928; PATHAK VK, 1988, MOL CELL BIOL, V8, P9930; RAYCHAUDHURI P, 1987, J BIOL CHEM, V262, P14222; RAYCHAUDHURI P, 1985, J BIOL CHEM, V260, P2132; RAYCHAUDHURI P, 1985, J BIOL CHEM, V260, P2140; SAFER B, 1982, FEBS LETT, V147, P1, DOI 10.1016/0014-5793(82)81000-4; SCHREIER MH, 1977, J MOL BIOL, V116, P727, DOI 10.1016/0022-2836(77)90268-6; SIEKIERKA J, 1982, P NATL ACAD SCI-BIOL, V79, P2537, DOI 10.1073/pnas.79.8.2537; SIEKIERKA J, 1984, P NATL ACAD SCI-BIOL, V81, P352, DOI 10.1073/pnas.81.2.352; STRINGER EA, 1979, J BIOL CHEM, V254, P6845; THOMAS NSB, 1985, J BIOL CHEM, V260, P9860; THOMAS NSB, 1984, P NATL ACAD SCI-BIOL, V81, P6998, DOI 10.1073/pnas.81.22.6998	25	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12964	12972						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618793				2022-12-25	WOS:A1992HZ48300085
J	MARSCHAL, P; HERRMANN, J; LEFFLER, H; BARONDES, SH; COOPER, DNW				MARSCHAL, P; HERRMANN, J; LEFFLER, H; BARONDES, SH; COOPER, DNW			SEQUENCE AND SPECIFICITY OF A SOLUBLE LACTOSE-BINDING LECTIN FROM XENOPUS-LAEVIS SKIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; FULL-LENGTH CDNA; S-TYPE LECTIN; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; ANIMAL LECTINS; PROTEIN; GENE; HEART; LUNG	A 16-kDa lactose-binding lectin comprises 5% or more of the soluble protein in Xenopus laevis skin. This lectin is mainly localized in the cytoplasm of granular gland cells. In response to stress, the lectin along with a variety of toxic and antibiotic peptides are released onto the skin surface by holocrine secretion. We have purified the lectin, sequenced tryptic peptides using tandem mass spectrometry and Edman degradation, and isolated full-length cDNA using a deduced oligonucleotide. Comparison of the cDNA and peptide sequences revealed expression of at least two isolectins, which differ in sequence at only two or three amino acids. Comparison of cDNA with complementary message by ribonuclease protection confirmed expression in approximately equal abundance of two nearly identical messages. The major soluble lactose-binding lectin expressed in Xenopus muscle is composed of these same isolectins, but at 100-fold lower levels. Similarities and distinctions in sequence and carbohydrate-binding specificity indicate that this lectin is a novel member of a family of soluble lactose-binding lectins expressed in a wide range of vertebrate tissues.	UNIV CALIF SAN FRANCISCO,LANGLEY PORTER PSYCHIAT INST,BOX F,401 PARNASSUS AVE,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Leffler, Hakon/A-2416-2019	Leffler, Hakon/0000-0003-4482-8945	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038627] Funding Source: NIH RePORTER; NCRR NIH HHS [DRR-RRO1614] Funding Source: Medline; NHLBI NIH HHS [1-RO1-HL38627] Funding Source: Medline; PHS HHS [2KT0032] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABBOTT WM, 1989, BIOCHEM J, V259, P283, DOI 10.1042/bj2590283; ABBOTT WM, 1989, BIOCHEM J, V259, P291, DOI 10.1042/bj2590291; ABBOTT WM, 1988, BIOCHEM J, V252, P283, DOI 10.1042/bj2520283; ABBOTT WM, 1991, J BIOL CHEM, V266, P5552; ALBRANDT K, 1987, P NATL ACAD SCI USA, V84, P6859, DOI 10.1073/pnas.84.19.6859; BARONDES SH, 1984, SCIENCE, V223, P1259, DOI 10.1126/science.6367039; BARONDES SH, 1988, TRENDS BIOCHEM SCI, V13, P480, DOI 10.1016/0968-0004(88)90235-6; BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.bi.59.070190.002143; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; BOLS NC, 1986, J CELL BIOL, V102, P492, DOI 10.1083/jcb.102.2.492; CATT JW, 1985, J CELL SCI, V73, P347; CERRA RF, 1985, J BIOL CHEM, V260, P10474; CHERAYIL BJ, 1990, P NATL ACAD SCI USA, V87, P7324, DOI 10.1073/pnas.87.18.7324; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISPEELS MJ, 1991, PLANT CELL, V3, P1, DOI 10.1105/tpc.3.1.1; CLERCH LB, 1988, BIOCHEMISTRY-US, V27, P692, DOI 10.1021/bi00402a030; CLOSE TJ, 1982, GENE, V20, P305, DOI 10.1016/0378-1119(82)90048-8; COOPER DNW, 1991, J CELL BIOL, V115, P1437, DOI 10.1083/jcb.115.5.1437; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; COURAUD PO, 1989, J BIOL CHEM, V264, P1310; DECABUTTI NEF, 1987, FEBS LETT, V223, P330, DOI 10.1016/0014-5793(87)80314-9; DOCKRAY GJ, 1975, J CELL BIOL, V64, P724, DOI 10.1083/jcb.64.3.724; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FRITZ AF, 1989, DEV BIOL, V131, P584, DOI 10.1016/S0012-1606(89)80029-6; GIOVANNINI MG, 1987, BIOCHEM J, V243, P113, DOI 10.1042/bj2430113; GITT MA, 1991, BIOCHEMISTRY-US, V30, P82, DOI 10.1021/bi00215a013; HARRISON FL, 1991, J CELL SCI, V100, P9; HIRABAYASHI J, 1991, J BIOL CHEM, V266, P23648; HIRABAYASHI J, 1991, J BIOL CHEM, V266, P2320; HIRABAYASHI J, 1989, BIOCHIM BIOPHYS ACTA, V1008, P85, DOI 10.1016/0167-4781(89)90173-5; HOLT G D, 1991, Glycobiology, V1, P329, DOI 10.1093/glycob/1.4.329; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; JEFFREYS AJ, 1980, CELL, V21, P555, DOI 10.1016/0092-8674(80)90493-6; JIA SH, 1988, J BIOL CHEM, V263, P6009; KOBEL HR, 1986, TRENDS GENET, V2, P310, DOI 10.1016/0168-9525(86)90286-6; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LEE RT, 1990, J BIOL CHEM, V265, P7864; LEFFLER H, 1986, J BIOL CHEM, V261, P119; LEFFLER H, 1989, BIOCHEMISTRY-US, V28, P9222, DOI 10.1021/bi00449a039; MATSUDAIRA PT, 1989, PRACTICAL GUIDE PROT, P33; MCCONAHEY PJ, 1966, INT ARCH ALLER A IMM, V29, P185, DOI 10.1159/000229699; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; MEDZIHRADSZKY KF, 1992, EUR J BIOCHEM, V203, P327, DOI 10.1111/j.1432-1033.1992.tb16553.x; MERKLE RK, 1988, J BIOL CHEM, V263, P16143; MERKLE RK, 1989, ARCH BIOCHEM BIOPHYS, V274, P404, DOI 10.1016/0003-9861(89)90453-0; ODA Y, 1991, GENE, V99, P279; OGILVIE ML, 1984, J HERPETOL, V18, P285, DOI 10.2307/1564082; OHYAMA Y, 1986, BIOCHEM BIOPH RES CO, V134, P51, DOI 10.1016/0006-291X(86)90525-5; OHYAMA Y, 1988, J BIOCHEM-TOKYO, V104, P173, DOI 10.1093/oxfordjournals.jbchem.a122436; OZEKI Y, 1991, BIOCHEM BIOPH RES CO, V178, P407, DOI 10.1016/0006-291X(91)91828-Z; PAROUTAUD P, 1987, P NATL ACAD SCI USA, V84, P6345, DOI 10.1073/pnas.84.18.6345; RAZ A, 1989, CANCER RES, V49, P3489; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; SAKAKURA Y, 1990, J BIOL CHEM, V265, P21573; Sambrook J, 1989, MOL CLONING LABORATO; SANFORD GL, 1990, FASEB J, V4, P2912, DOI 10.1096/fasebj.4.11.2379767; SHET MS, 1989, BIOCHIM BIOPHYS ACTA, V991, P465, DOI 10.1016/0304-4165(89)90074-3; SHULDINER AR, 1989, J BIOL CHEM, V264, P9428; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; STUTZ F, 1986, J MOL BIOL, V187, P349, DOI 10.1016/0022-2836(86)90438-9; SU MW, 1991, J CELL BIOL, V115, P565, DOI 10.1083/jcb.115.2.565; WALLS FC, 1990, BIOLOGICAL MASS SPECTROMETRY /, P197; WASANO K, 1990, CELL TISSUE RES, V259, P43, DOI 10.1007/BF00571428; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G; WHITNEY PL, 1986, BIOCHEM J, V238, P683, DOI 10.1042/bj2380683; WILSON TJG, 1989, BIOCHEM J, V261, P847, DOI 10.1042/bj2610847; YAMAOKA K, 1991, BIOCHEM BIOPH RES CO, V179, P272, DOI 10.1016/0006-291X(91)91365-J; ZHOU Q, 1990, ARCH BIOCHEM BIOPHYS, V281, P27, DOI 10.1016/0003-9861(90)90408-Q	69	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12942	12949						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618791				2022-12-25	WOS:A1992HZ48300082
J	GRIFF, IC; SCHEKMAN, R; ROTHMAN, JE; KAISER, CA				GRIFF, IC; SCHEKMAN, R; ROTHMAN, JE; KAISER, CA			THE YEAST SEC17 GENE-PRODUCT IS FUNCTIONALLY EQUIVALENT TO MAMMALIAN ALPHA-SNAP PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; SENSITIVE FUSION PROTEIN; VESICULAR TRANSPORT; SECRETORY PATHWAY; GOLGI STACK; SHUTTLE VECTORS; IDENTIFICATION; REQUIRES; COMPONENT; PURIFICATION	The SEC17 gene of Saccharomyces cerevisiae is required for vesicular transport between the endoplasmic reticulum and the Golgi apparatus. Here we report that the product of the SEC17 gene has the exact biochemical properties expected for a yeast homologue of the mammalian transport factor, alpha-SNAP. The DNA sequence of SEC17 codes for a protein of predicted molecular mass of 33 kDa. Immunoblotting indicates that Sec17p fractionates as a peripheral membrane protein and is mostly soluble when overexpressed, suggesting the presence of a saturable membrane receptor for Sec17p. Sec17p was purified from yeast cytosol using a SNAP-dependent in vitro mammalian Golgi transport assay. Kinetic analysis using this assay shows Sec17p acts temporally close to the fusion of transport vesicles with the medial Golgi compartment. In yeast extracts, Sec17p binds to Sec18p with a 1:1 stoichiometry. The interaction between Sec17p and Sec18p requires an activity provided by yeast membranes, and this putative membrane receptor activity is not extracted by high salt treatment of membranes.	MIT,DEPT BIOL,77 MASSACHUSETTS AVE,RM 56-534,CAMBRIDGE,MA 02139; SLOAN KETTERING MEM CANC CTR,PROGRAM CELLULAR BIOPHYS & BIOCHEM,NEW YORK,NY 10021; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544; UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	Massachusetts Institute of Technology (MIT); Memorial Sloan Kettering Cancer Center; Princeton University; Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley					NIDDK NIH HHS [DK27044] Funding Source: Medline; NIGMS NIH HHS [GM26755] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK027044, R01DK027044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026755] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCH WE, 1984, CELL, V39, P525, DOI 10.1016/0092-8674(84)90459-8; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; ESMON B, 1981, CELL, V25, P451, DOI 10.1016/0092-8674(81)90063-5; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LOWENADLER B, 1986, EMBO J, V5, P2393, DOI 10.1002/j.1460-2075.1986.tb04509.x; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; NASMYTH KA, 1980, CELL, V19, P753, DOI 10.1016/S0092-8674(80)80051-1; NEWMAN AJ, 1985, CELL, V42, P335, DOI 10.1016/S0092-8674(85)80129-X; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; SIKORSKI RS, 1989, GENETICS, V122, P19; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; WATTENBERG BW, 1986, J BIOL CHEM, V261, P2202; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	26	136	143	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12106	12115						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601878				2022-12-25	WOS:A1992HY94700070
J	KAWASAKI, Y; WADA, C; YURA, T				KAWASAKI, Y; WADA, C; YURA, T			BINDING OF REPE INITIATOR PROTEIN TO MINI-F DNA ORIGIN (ORI2) - ENHANCING EFFECTS OF REPE MUTATIONS AND DNAJ HEAT-SHOCK PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPY NUMBER CONTROL; P1 PLASMID REPLICATION; ESCHERICHIA-COLI; REPEATING SEQUENCES; AUTONOMOUS CONTROL; GENE-PRODUCT; PURIFICATION; REGION; INCOMPATIBILITY; EXPRESSION	Replication of mini-F plasmid in Escherichia coli requires the plasmid-encoded RepE initiator protein and a number of host factors and is regulated by interaction of RepE with specific sequences near the replication origin, ori2. We have examined DNA binding properties of several hyperactive mutant RepE proteins with single amino acid substitutions. Plasmids carrying these (repE) mutations, unlike the parental plasmid, can replicate in bacterial hosts lacking the heat shock sigma-factor (sigma-32) or deficient in the DnaK, DnaJ, or GrpE heat shock protein. Using gel-retardation assays, the mutant RepE proteins were shown to bind the ori2 repeated sequences with much increased affinities compared to the wild type RepE, whereas they bound to the repE operator with slightly reduced affinities. These results agreed well with the properties of mutant RepE proteins studied in vivo and accounted for the high RepE initiator activities and the high copy numbers of mutant plasmids. In addition, the DnaJ heat shock protein was found to markedly enhance the binding of wild type RepE to ori2 or the operator. DnaK protein with or without ATP failed to show such enhancements. Thus, among the heat shock proteins required for mini-F replication, DnaJ appears to play a major role in RepE binding to ori2 and the operator, perhaps accompanied by RepE activation.	KYOTO UNIV,INST VIRUS RES,KYOTO 60601,JAPAN	Kyoto University								ABELES AL, 1986, J BIOL CHEM, V261, P3548; BEX F, 1986, J MOL BIOL, V189, P293; CEGIELSKA A, 1989, J BIOL CHEM, V264, P21122; EZAKI B, 1989, MOL GEN GENET, V218, P183, DOI 10.1007/BF00331267; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; HELSBERG M, 1985, PLASMID, V14, P53, DOI 10.1016/0147-619X(85)90032-0; IMBER R, 1987, GENE, V52, P1, DOI 10.1016/0378-1119(87)90389-1; KAWASAKI Y, 1991, J BACTERIOL, V173, P1064, DOI 10.1128/jb.173.3.1064-1072.1991; KAWASAKI Y, 1990, MOL GEN GENET, V220, P277; KLINE BC, 1992, IN PRESS J BACTERIOL; MAKI S, 1983, MOL GEN GENET, V191, P231, DOI 10.1007/BF00334819; MASSON L, 1988, NUCLEIC ACIDS RES, V16, P413, DOI 10.1093/nar/16.2.413; MASSON L, 1986, NUCLEIC ACIDS RES, V14, P5693, DOI 10.1093/nar/14.14.5693; MUROTSU T, 1984, MOL GEN GENET, V196, P373, DOI 10.1007/BF00328075; MUROTSU T, 1981, GENE, V15, P257, DOI 10.1016/0378-1119(81)90135-9; OHKI M, 1986, J BIOL CHEM, V261, P1778; ROKEACH LA, 1985, J BACTERIOL, V164, P1262, DOI 10.1128/JB.164.3.1262-1270.1985; SEELKE RW, 1982, PLASMID, V7, P163, DOI 10.1016/0147-619X(82)90075-0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TILLY K, 1989, J BACTERIOL, V171, P6025, DOI 10.1128/jb.171.11.6025-6029.1989; TOKINO T, 1986, P NATL ACAD SCI USA, V83, P4109, DOI 10.1073/pnas.83.12.4109; TOLUN A, 1982, MOL GEN GENET, V186, P3072; TSUTSUI H, 1983, J BACTERIOL, V155, P337, DOI 10.1128/JB.155.1.337-344.1983; WADA C, 1986, MOL GEN GENET, V203, P208, DOI 10.1007/BF00333956; WADA C, 1987, P NATL ACAD SCI USA, V84, P8849, DOI 10.1073/pnas.84.24.8849; WATSON LA, 1982, GENE AMST, P173; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690; XIA GX, 1991, MOL MICROBIOL, V5, P631, DOI 10.1111/j.1365-2958.1991.tb00734.x	30	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11520	11524						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597479				2022-12-25	WOS:A1992HX16900089
J	TASANEN, K; OIKARINEN, J; KIVIRIKKO, KI; PIHLAJANIEMI, T				TASANEN, K; OIKARINEN, J; KIVIRIKKO, KI; PIHLAJANIEMI, T			PROMOTER OF THE GENE FOR THE MULTIFUNCTIONAL PROTEIN DISULFIDE ISOMERASE POLYPEPTIDE - FUNCTIONAL-SIGNIFICANCE OF THE 6 CCAAT BOXES AND OTHER PROMOTER ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-BINDING-PROTEIN; HUMAN GROWTH-HORMONE; NUCLEAR FACTOR-I; PROLYL 4-HYDROXYLASE; BETA-SUBUNIT; ENDOPLASMIC-RETICULUM; DISULPHIDE-ISOMERASE; SECRETORY PROTEINS; MOLECULAR-CLONING; COLLAGEN PROMOTER	Protein disulfide isomerase (PDI) is a highly unusual multifunctional polypeptide that is identical to the beta-subunit of prolyl 4-hydroxylase, a cellular thyroid hormone-binding protein and a subunit of the microsomal triglyceride transfer protein complex, and very similar to a polypeptide functioning in vitro as a glycosylation site binding protein of oligosaccharyl transferase. The human PDI gene possesses several putative transcriptional control elements, including the highly unusual presence of six CCAAT boxes between -108 and -378 of the 5'-flanking region. We report here on a promoter analysis of this gene. Eleven PDI promoter elements recognized by DNA-binding proteins present in HeLa cell and HT-1080 cell nuclear extracts were identified by DNase I footprinting analysis within the first 630 nucleotides of the 5'-flanking region. Interestingly, these included all six CCAAT elements. Functional 5' deletion analysis suggested that only two or three of the CCAAT elements may contribute significantly to the promoter activity in HeLa cells. Mutations introduced into each of the CCAAT boxes separately indicated, however, that all six appear to contribute to the promoter strength, the largest decreases (approximately 50%) being seen with mutations in the second or fifth CCAAT box. These data thus suggested that efficient expression of the multifunctional PDI polypeptide is secured by multiple CCAAT elements, some of which appear to be functionally redundant. The 5' deletion analysis further suggested that a region between -623 and -518 may contain additional positively and negatively acting elements.	UNIV OULU, DEPT MED BIOCHEM, KAJAANINTIE 52A, SF-90220 OULU, FINLAND; UNIV OULU, BIOCTR, COLLAGEN RES UNIT, SF-90220 OULU, FINLAND	University of Oulu; University of Oulu				Pihlajaniemi, Taina/0000-0002-1664-9045; Tasanen, Kaisa/0000-0001-8056-5949				Anfinsen C B, 1975, Adv Protein Chem, V29, P205, DOI 10.1016/S0065-3233(08)60413-1; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BULLEID NJ, 1990, EMBO J, V9, P3527, DOI 10.1002/j.1460-2075.1990.tb07561.x; CHANG SC, 1987, P NATL ACAD SCI USA, V84, P680, DOI 10.1073/pnas.84.3.680; CHENG SY, 1987, J BIOL CHEM, V262, P11221; CHENKIANG S, 1978, P NATL ACAD SCI USA, V75, P1379, DOI 10.1073/pnas.75.3.1379; DENOTO FM, 1981, NUCLEIC ACIDS RES, V9, P3719, DOI 10.1093/nar/9.15.3719; DORNER AJ, 1990, J BIOL CHEM, V265, P22029; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; FREEDMAN RB, 1988, BIOCHEM SOC T, V16, P96, DOI 10.1042/bst0160096; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GEETHAHABIB M, 1988, CELL, V54, P1053, DOI 10.1016/0092-8674(88)90120-1; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HELAAKOSKI T, 1990, J BIOL CHEM, V265, P11413; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; KIVIRIKKO KI, 1990, ANN NY ACAD SCI, V580, P132, DOI 10.1111/j.1749-6632.1990.tb17925.x; KOIVU J, 1987, J BIOL CHEM, V262, P6447; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MYLLYLA R, 1983, EUR J BIOCHEM, V134, P7, DOI 10.1111/j.1432-1033.1983.tb07523.x; NAKAZAWA M, 1988, GENE, V71, P451, DOI 10.1016/0378-1119(88)90062-5; NOIVA R, 1991, P NATL ACAD SCI USA, V88, P1986, DOI 10.1073/pnas.88.5.1986; OIKARINEN J, 1987, J BIOL CHEM, V262, P11064; PAJUNEN L, 1991, CYTOGENET CELL GENET, V56, P165, DOI 10.1159/000133078; PAJUNEN L, 1988, CYTOGENET CELL GENET, V42, P560; PARKKONEN T, 1988, BIOCHEM J, V256, P1005, DOI 10.1042/bj2561005; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; PIHLAJANIEMI T, 1987, METHOD ENZYMOL, V145, P213; PIHLAJANIEMI T, 1981, BIOCHEMISTRY-US, V20, P7409, DOI 10.1021/bi00529a014; POPESCU NC, 1988, AM J HUM GENET, V42, P560; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RISTINIEMI J, 1989, J BIOL CHEM, V264, P2164; ROGUSKA MA, 1985, J BIOL CHEM, V260, P3893; ROTH RA, 1981, BIOCHEMISTRY-US, V20, P6594, DOI 10.1021/bi00526a012; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; TASANEN K, 1988, J BIOL CHEM, V263, P16218; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; WOODEN SK, 1991, MOL CELL BIOL, V11, P5612, DOI 10.1128/MCB.11.11.5612; WU C, 1984, NATURE, V311, P81, DOI 10.1038/311081a0; YAMAUCHI K, 1987, BIOCHEM BIOPH RES CO, V146, P1485, DOI 10.1016/0006-291X(87)90817-5; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	48	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11513	11519						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597478				2022-12-25	WOS:A1992HX16900088
J	DIAZ, A; REGINATO, AM; JIMENEZ, SA				DIAZ, A; REGINATO, AM; JIMENEZ, SA			ALTERNATIVE SPLICING OF HUMAN PROSTAGLANDIN G/H SYNTHASE MESSENGER-RNA AND EVIDENCE OF DIFFERENTIAL REGULATION OF THE RESULTING TRANSCRIPTS BY TRANSFORMING GROWTH FACTOR-BETA-1, INTERLEUKIN-1-BETA, AND TUMOR-NECROSIS-FACTOR-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR GLAND MICROSOMES; ENDOPEROXIDE SYNTHASE; FACTOR-BETA; RECOMBINANT INTERLEUKIN-1; PEROXIDASE-ACTIVITIES; COMPLEMENTARY-DNA; H SYNTHASE; CYCLOOXYGENASE; CELLS; STIMULATION	Prostaglandin G/H synthase (PGG/HS) is the rate-limiting enzyme in the conversion of arachidonic acid to prostaglandins and thromboxanes. We screened a human lung fibroblast cDNA library with an ovine PGG/HS cDNA and isolated a 2.3-kilobase clone (HCO-T9). Sequence analysis of this clone showed that (a) it contained the entire translated region of PGG/HS and (b) it displayed an in-frame splicing of the last 111 base pairs encoded by exon 9, which resulted in the elimination of the N-glycosylation site at residue 409. Polymerase chain reaction amplification with specific oligonucleotides of reverse-transcribed mRNA from diverse human tissues and cultured cells yielded 400-and 300-base pair fragments that corresponded, respectively, to the intact and spliced transcripts. The expression of these two transcripts in cultured human lung fibroblasts was differentially regulated by serum, transforming growth factor beta-1, interleukin 1-beta, tumor necrosis factor-alpha, and phorbol 12-myristate 13-acetate, as each of these conditions stimulated preferentially the expression of the unspliced transcripts. The elimination of one of the four N-glycosylation sites by the alternative splicing of exon 9 and the differential regulation of this process by relevant cytokines and growth factors may represent a mechanism for the regulation of PGG/HS enzymatic activity under physiological or pathological conditions.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL,DEPT MED,DIV RHEUMATOL,RM 509, BLUEMLE LIFE SCI BLDG, PHILADELPHIA, PA 19107 USA	Jefferson University				Jimenez, Sergio/0000-0001-5213-1203	NHLBI NIH HHS [HL41214] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041214] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAILEY JM, 1985, J LIPID RES, V26, P54; BALDWIN CT, 1989, BIOCHEM J, V262, P521, DOI 10.1042/bj2620521; BASHEY RI, 1977, J MOL MED, V2, P153; DAYER JM, 1986, J CLIN INVEST, V77, P645, DOI 10.1172/JCI112350; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1989, ADV PROSTAG THROMB L, V19, P454; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DEWITT DL, 1990, ADV PROSTAGLANDIN TH, V21, P65; DIAZ A, 1990, ANN NY ACAD SCI, V593, P306, DOI 10.1111/j.1749-6632.1990.tb16126.x; DIAZ A, 1989, J BIOL CHEM, V264, P11554; DUNIEC ZM, 1991, MOL PHARMACOL, V39, P164; ELIAS JA, 1987, J IMMUNOL, V138, P3812; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FU JY, 1990, J BIOL CHEM, V265, P16737; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HLA T, 1991, J BIOL CHEM, V266, P24059; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1989, J BIOL CHEM, V264, P14136; LIN AH, 1989, J BIOL CHEM, V264, P17379; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MARNETT LJ, 1988, J BIOL CHEM, V263, P16532; MARUSIC A, 1991, J IMMUNOL, V146, P2633; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; OHKI S, 1979, J BIOL CHEM, V254, P829; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; RAZ A, 1990, BIOCHEM J, V269, P603, DOI 10.1042/bj2690603; RAZ A, 1988, J BIOL CHEM, V263, P3022; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROSEN GD, 1989, BIOCHEM BIOPH RES CO, V164, P1358, DOI 10.1016/0006-291X(89)91819-6; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SIONSON MS, 1990, ADV PROSTAGLANDIN TH, V21, P69; SMITH WL, 1991, PROSTAGLANDIN LEUKOT; SUMITANI K, 1989, ARCH BIOCHEM BIOPHYS, V270, P588, DOI 10.1016/0003-9861(89)90541-9; TSAI AL, 1990, ADV PROSTAGLANDIN TH, V21, P141; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; VARGA J, 1987, BIOCHEM BIOPH RES CO, V147, P1282, DOI 10.1016/S0006-291X(87)80209-7; WONG WYL, 1991, MOL ENDOCRINOL, V5, P1269, DOI 10.1210/mend-5-9-1269; WU KK, 1991, P NATL ACAD SCI USA, V88, P2384, DOI 10.1073/pnas.88.6.2384; WU KK, 1988, J BIOL CHEM, V263, P19043; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X; ZURIER RB, 1990, ADV PROSTAGLANDIN TH, V21, P947	49	101	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10816	10822						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587858				2022-12-25	WOS:A1992HV09000092
J	MORROW, CS; CHIU, J; COWAN, KH				MORROW, CS; CHIU, J; COWAN, KH			POSTTRANSCRIPTIONAL CONTROL OF GLUTATHIONE-S-TRANSFERASE-PI GENE-EXPRESSION IN HUMAN BREAST-CANCER CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR CONTENT; MESSENGER-RNA STABILITY; C-MYC ONCOGENE; DRUG-RESISTANCE; PLACENTAL FORM; STEM-LOOP; RAT; REGION; CDNA; HEPATOCARCINOGENESIS	The glutathione S-transferase pi-gene (GST-pi) is highly expressed in estrogen receptor negative (ER-) but not expressed in ER+ human breast cancer cell lines. To define regulatory mechanisms of GST-pi gene expression, we analyzed both the activity of the GST-pi promoter and the posttranscriptional fate of GST-pi RNA sequences in three ER+ and three ER- breast cancer cell lines. Expression of a transiently transfected CAT reporter gene driven by the GST-pi promoter and 2203 nucleotides of 5'-flanking sequences were similar in all six cell lines regardless of ER status. Endogenous GST-pi transcription rates in nuclei isolated from ER- cells were quite low despite high steady state levels of cytoplasmic mRNA. Furthermore, the endogenous GST-pi gene was transcribed in ER+ nuclei at rates similar to those obtained in ER- nuclei. We determined the stabilities of mRNAs transcribed from the endogenous GST-pi gene (ER- cells) and from a stably transfected GST-pi cDNA expression vector (ER+ and ER- cells). The endogenous GST-pi mRNA was extraordinarily stable in ER- cells. Comparisons between transfected ER+ and ER- cells revealed no significant differences in the stabilities of transfection-derived GST-pi mRNA sequences. We conclude that GST-pi mRNA stability contributes significantly to the high levels of cytoplasmic mRNA observed in ER-cells, but that the differential expression of GST-pi in ER+ versus ER- cells is governed by other posttranscriptional processes.			MORROW, CS (corresponding author), NCI,MED BRANCH,BLDG 10,RM 12N226,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							BATIST G, 1986, J BIOL CHEM, V261, P5544; Battey, 1986, BASIC METHODS MOL BI; BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; BURT RK, 1988, CARCINOGENESIS, V9, P2329, DOI 10.1093/carcin/9.12.2329; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHANG CD, 1991, J BIOL CHEM, V266, P8663; CLEVELAND D W, 1989, New Biologist, V1, P121; CLEVELAND DW, 1988, TRENDS BIOCHEM SCI, V13, P339, DOI 10.1016/0968-0004(88)90103-X; COWELL IG, 1988, BIOCHEM J, V255, P79, DOI 10.1042/bj2550079; DAVIDSON NE, 1987, MOL ENDOCRINOL, V1, P216, DOI 10.1210/mend-1-3-216; DIXON KH, 1989, BIOCHEM BIOPH RES CO, V163, P815, DOI 10.1016/0006-291X(89)92295-X; DUBIK D, 1988, J BIOL CHEM, V263, P12705; FAIRCHILD CR, 1990, MOL PHARMACOL, V37, P801; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1987, CURRENT PROTOCOLS MO; GUDAS JM, 1988, P NATL ACAD SCI USA, V85, P4705, DOI 10.1073/pnas.85.13.4705; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P5, DOI 10.1093/nar/19.1.5; KETTERER B, 1986, XENOBIOTICA, V16, P957, DOI 10.3109/00498258609038976; Lamond AI, 1991, CURR OPIN CELL BIOL, V3, P493, DOI 10.1016/0955-0674(91)90078-D; LIU JM, 1991, VIROLOGY, V182, P361, DOI 10.1016/0042-6822(91)90682-2; LIU TJ, 1989, MOL CELL BIOL, V9, P3499, DOI 10.1128/MCB.9.8.3499; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; Maniatis T., 1982, MOL CLONING; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MARZLUFF WF, 1988, TRENDS BIOCHEM SCI, V13, P49, DOI 10.1016/0968-0004(88)90027-8; MIYAZAKI M, 1990, BIOCHEM BIOPH RES CO, V166, P1368; MORROW CS, 1989, GENE, V75, P3, DOI 10.1016/0378-1119(89)90377-6; MORROW CS, 1990, CANCER CELL-MON REV, V2, P15; MORROW CS, 1990, GENE, V88, P215, DOI 10.1016/0378-1119(90)90034-O; MOSCOW JA, 1989, MOL PHARMACOL, V36, P22; MOSCOW JA, 1988, P NATL ACAD SCI USA, V85, P6518, DOI 10.1073/pnas.85.17.6518; MOSCOW JA, 1992, J BIOL CHEM, V267, P5949; MOSCOW JA, 1989, CANCER RES, V49, P1422; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; NAKAGAWA K, 1990, J BIOL CHEM, V265, P4296; PANDEY NB, 1987, MOL CELL BIOL, V7, P4557, DOI 10.1128/MCB.7.12.4557; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; PUCHALSKI RB, 1990, P NATL ACAD SCI USA, V87, P2443, DOI 10.1073/pnas.87.7.2443; SATO K, 1988, JPN J CANCER RES, V79, P556, DOI 10.1111/j.1349-7006.1988.tb00022.x; SATOH K, 1985, P NATL ACAD SCI USA, V82, P3964, DOI 10.1073/pnas.82.12.3964; SHIRATORI Y, 1987, CANCER RES, V47, P6806; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; TALBOT D, 1989, NATURE, V338, P352, DOI 10.1038/338352a0; TOWNES TM, 1990, TRENDS GENET, V6, P219, DOI 10.1016/0168-9525(90)90182-6; TOWNSEND A J, 1989, Cancer Bulletin (Houston), V41, P31; TOWNSEND AJ, 1991, CANC COMM, V3, P1; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; TSUTSUMI M, 1987, JPN J CANCER RES, V78, P631; VICKERS PJ, 1988, MOL ENDOCRINOL, V2, P886, DOI 10.1210/mend-2-10-886; VICKERS PJ, 1989, MOL ENDOCRINOL, V3, P157, DOI 10.1210/mend-3-1-157; XIA CL, 1991, BIOCHEM BIOPH RES CO, V176, P233, DOI 10.1016/0006-291X(91)90914-S; YEN TJ, 1988, MOL CELL BIOL, V8, P1224, DOI 10.1128/MCB.8.3.1224	54	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10544	10550						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587835				2022-12-25	WOS:A1992HV09000051
J	WEINBERG, RB; IBDAH, JA; PHILLIPS, MC				WEINBERG, RB; IBDAH, JA; PHILLIPS, MC			ADSORPTION OF APOLIPOPROTEIN-A-IV TO PHOSPHOLIPID MONOLAYERS SPREAD AT THE AIR-WATER-INTERFACE - A MODEL FOR ITS LABILE BINDING TO HIGH-DENSITY-LIPOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PROTEIN INTERACTIONS; ESTER TRANSFER PROTEIN; HUMAN-PLASMA; CHOLESTEROL ACYLTRANSFERASE; SURFACE-ACTIVITIES; PERIPHERAL LYMPH; HUMAN-SERUM; RAT PLASMA; C-II; ACTIVATION	The mechanisms that mediate the labile binding of apolipoprotein A-IV (apoA-IV) to high density lipoproteins (HDL) are not known. We therefore used a surface balance and surface radioactivity detector to investigate the adsorption of apoA-IV to egg phosphatidylcholine monolayers spread at the air/water interface. ApoA-IV bound rapidly and reversibly to phospholipid monolayers and generated a maximum increase in surface pressure of 19 millinewtons (mN)/m at a subphase concentration of 2 x 10(-5) g/dl. Binding decreased linearly with increasing initial surface pressure; at pressures > 28-29 mN/m, apoA-IV could no longer penetrate the lipid monolayer. The area occupied by the amino acid residues in apoA-IV reached an unusually low limiting molecular area of 10-12 angstrom2/residue at surface saturation. The surface pressure of native HDL3 was calculated to be 33 mN/m, and it rapidly decreased with the action of lecithin: cholesterol acyltransferase on the particle surface. We conclude that the surface activity of apoA-IV is lower than that of any other human apolipoprotein; its binding and surface conformation are particularly sensitive to pressure; and at saturation, a significant portion of the molecule is excluded from the interface. The exclusion pressure of apoA-IV may be only slightly lower than the surface pressure of HDL; in vivo, the action of lecithin:cholesterol acyltransferase and lipid transfer proteins may cause the HDL3 surface pressure to oscillate about a narrow range that spans the exclusion pressure of apoA-IV. The resultant labile association of apoA-IV and HDL may be of central importance to its role in lipoprotein metabolism.	MED COLL PENN,DEPT PHYSIOL & BIOCHEM,PHILADELPHIA,PA 19129; BOWMAN GRAY SCH MED,GASTROENTEROL SECT,WINSTON SALEM,NC 27157	Drexel University; Wake Forest University; Wake Forest Baptist Medical Center	WEINBERG, RB (corresponding author), BOWMAN GRAY SCH MED,DEPT MED,WINSTON SALEM,NC 27157, USA.			Ibdah, Jamal/0000-0002-5646-9014; Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030897, R23HL030897] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-30897] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATKINSON D, 1986, ANNU REV BIOPHYS BIO, V15, P403; BARTER PJ, 1988, BIOCHEM J, V254, P179, DOI 10.1042/bj2540179; BEISIEGEL U, 1979, EUR J BIOCHEM, V93, P601, DOI 10.1111/j.1432-1033.1979.tb12860.x; BISGAIER CL, 1985, J LIPID RES, V26, P11; BISGAIER CL, 1987, J LIPID RES, V28, P693; BISGAIER CL, 1989, J LIPID RES, V30, P1025; CHEN CH, 1985, BIOCHIM BIOPHYS ACTA, V836, P279, DOI 10.1016/0005-2760(85)90131-6; DELAMATRE JG, 1983, J LIPID RES, V24, P1578; EISENBERG D, 1982, NATURE, V299, P371, DOI 10.1038/299371a0; ELSHOURBAGY NA, 1987, J BIOL CHEM, V262, P7973; FIDGE NH, 1980, BIOCHIM BIOPHYS ACTA, V619, P129, DOI 10.1016/0005-2760(80)90249-0; GHISELLI G, 1986, BIOCHEM BIOPH RES CO, V139, P122, DOI 10.1016/S0006-291X(86)80088-2; GHISELLI G, 1986, J LIPID RES, V27, P813; GOLDBERG IJ, 1990, J BIOL CHEM, V265, P4266; GREEN PHR, 1979, J CLIN INVEST, V64, P233, DOI 10.1172/JCI109444; GREEN PHR, 1980, J CLIN INVEST, V65, P911, DOI 10.1172/JCI109745; IBDAH JA, 1989, BIOCHEMISTRY-US, V28, P1126, DOI 10.1021/bi00429a029; IBDAH JA, 1988, BIOCHEMISTRY-US, V27, P7155, DOI 10.1021/bi00418a073; IBDAH JA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P300, DOI 10.1016/0005-2760(89)90077-5; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; JONES MN, 1975, BIOL INTERFACES, pCH3; KREBS KE, 1983, BIOCHIM BIOPHYS ACTA, V754, P227, DOI 10.1016/0005-2760(83)90165-0; KREBS KE, 1984, FEBS LETT, V175, P263, DOI 10.1016/0014-5793(84)80748-6; KREBS KE, 1988, BIOCHIM BIOPHYS ACTA, V959, P229, DOI 10.1016/0005-2760(88)90195-6; KREBS KE, 1983, BIOCHIM BIOPHYS ACTA, V751, P470, DOI 10.1016/0005-2760(83)90308-9; LAGROST L, 1989, J LIPID RES, V30, P1525; LAGROST L, 1990, J LIPID RES, V31, P1569; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDKATZ S, 1984, BIOCHEMISTRY-US, V23, P1130, DOI 10.1021/bi00301a015; Macritchie F, 1978, Adv Protein Chem, V32, P283, DOI 10.1016/S0065-3233(08)60577-X; MALCOLM BR, 1973, PROGR SURFACE MEMBRA, V7, P183; MORRISETT JD, 1977, BIOCHIM BIOPHYS ACTA, V472, P93, DOI 10.1016/0304-4157(77)90015-6; NOWICKA G, 1990, J LIPID RES, V31, P1947; OHTA T, 1985, J CLIN INVEST, V76, P1252, DOI 10.1172/JCI112081; Osborne J C Jr, 1980, Ann N Y Acad Sci, V348, P104, DOI 10.1111/j.1749-6632.1980.tb21294.x; PHILLIPS MC, 1986, METHOD ENZYMOL, V128, P387; RIFICI VA, 1985, BIOCHIM BIOPHYS ACTA, V834, P205, DOI 10.1016/0005-2760(85)90157-2; SAVION N, 1988, ARTERIOSCLEROSIS, V8, P178, DOI 10.1161/01.ATV.8.2.178; SCANU A, 1969, BIOCHEMISTRY-US, V8, P3309, DOI 10.1021/bi00836a027; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; SHEN BW, 1977, P NATL ACAD SCI USA, V74, P837, DOI 10.1073/pnas.74.3.837; SLOOP CH, 1983, J LIPID RES, V24, P1429; SLOOP CH, 1983, ATHEROSCLEROSIS, V49, P9, DOI 10.1016/0021-9150(83)90003-5; SLOTTE JP, 1990, J LIPID RES, V31, P2235; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; STEIN O, 1986, BIOCHIM BIOPHYS ACTA, V878, P7, DOI 10.1016/0005-2760(86)90337-1; STEINMETZ A, 1989, J CHROMATOGR-BIOMED, V487, P154, DOI 10.1016/S0378-4347(00)83018-2; STEINMETZ A, 1985, EUR J BIOCHEM, V152, P747, DOI 10.1111/j.1432-1033.1985.tb09256.x; STEINMETZ A, 1990, J BIOL CHEM, V265, P7859; STEINMETZ A, 1985, J BIOL CHEM, V260, P2258; THUREN T, 1991, J BIOL CHEM, V266, P4853; UTERMANN G, 1979, EUR J BIOCHEM, V99, P333, DOI 10.1111/j.1432-1033.1979.tb13261.x; VAINIO P, 1983, BIOCHEMISTRY-US, V22, P2270, DOI 10.1021/bi00278a033; WEINBERG RB, 1985, BIOCHEM BIOPH RES CO, V129, P576, DOI 10.1016/0006-291X(85)90190-1; WEINBERG RB, 1983, J LIPID RES, V24, P52; WEINBERG RB, 1985, J LIPID RES, V26, P26; WEINBERG RB, 1986, BIOCHEM BIOPH RES CO, V135, P756, DOI 10.1016/0006-291X(86)90993-9; WEINBERG RB, 1985, J BIOL CHEM, V260, P4914; WEINBERG RB, 1985, J BIOL CHEM, V260, P4279; WEINBERG RB, 1990, J BIOL CHEM, V265, P8081; WEINBERG RB, 1987, BIOCHIM BIOPHYS ACTA, V918, P299, DOI 10.1016/0005-2760(87)90234-7; WEISGRABER KH, 1978, BIOCHEM BIOPH RES CO, V85, P287, DOI 10.1016/S0006-291X(78)80041-2	62	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8977	8983						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577735				2022-12-25	WOS:A1992HR85400044
J	LOCKER, JK; GRIFFITHS, G; HORZINEK, MC; ROTTIER, PJM				LOCKER, JK; GRIFFITHS, G; HORZINEK, MC; ROTTIER, PJM			O-GLYCOSYLATION OF THE CORONAVIRUS-M PROTEIN - DIFFERENTIAL LOCALIZATION OF SIALYLTRANSFERASES IN N-LINKED AND O-LINKED GLYCOSYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; DENSITY-LIPOPROTEIN RECEPTOR; TRANS-GOLGI NETWORK; BREFELDIN-A; ENDOPLASMIC-RETICULUM; E1 GLYCOPROTEIN; SUBCELLULAR ORGANIZATION; INTRACELLULAR-TRANSPORT; CELLULAR COMPARTMENTS; SECRETORY PROTEINS	It has previously been shown that the M (E1) glycoprotein of mouse hepatitis virus strain A59 (MHV-A59) contains only O-linked oligosaccharides and localizes to the Golgi region when expressed independently. A detailed pulse-chase analysis was made of the addition of O-linked sugars to the M protein; upon sodium dodecyl sulfate-polyacrylamide gel electrophoresis, three different electrophoretic forms could be distinguished that corresponded to the sequential acquisition of N-acetylgalactosamine (GalNAc), galactose (Gal), and sialic acid (SA). A fourth and fifth form could also be detected which we were unable to identify. Following Brefeldin A treatment, the M protein still acquired GalNAc, Gal, and SA, but the fourth and fifth forms were absent, suggesting that these modifications occur in the trans-Golgi network (TGN). In contrast, in the presence of BFA, the G protein of vesicular stomatitis virus (VSV), which contains N-linked oligosaccharides, acquired Gal and fucose but not SA. These results are consistent with earlier published data showing that Golgi compartments proximal to the TGN, but not the TGN itself, relocate to the endoplasmatic reticulum/intermediate compartment. More importantly, our data argue that, whereas addition of SA to N-linked sugars occurs in the TGN the acquisition of both SA on O-linked sugars and the addition of fucose to N-linked oligosaccharides must occur in Golgi compartments proximal to the TGN. The glycosylation of the M protein moreover indicates that it is transported to trans-Golgi and TGN. This was confirmed by electron microscopy immunocytochemistry, showing that the protein is targeted to cisternae on the trans side of the Golgi and co-localizes, at least in part, with TGN 38, a marker of the TGN, as well as with a lectin specific for sialic acid.	EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)	LOCKER, JK (corresponding author), UNIV UTRECHT,FAC VET MED,INST VIROL,UTRECHT,NETHERLANDS.		Locker, Jacomine Krijnse/E-1009-2016; Locker, Jacomine Krijnse/AAX-1185-2020					ABEIJON C, 1987, J BIOL CHEM, V262, P4153; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CHEN SSL, 1988, J VIROL, V62, P2552, DOI 10.1128/JVI.62.8.2552-2556.1988; CORFIELD AP, 1986, BIOL CHEM H-S, V367, P433, DOI 10.1515/bchm3.1986.367.1.433; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; DENBOON JA, 1991, VIROLOGY, V182, P655, DOI 10.1016/0042-6822(91)90606-C; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; ELHAMMER A, 1986, J BIOL CHEM, V261, P5249; ELHAMMER A, 1984, J CELL BIOL, V98, P327; ELLINGER A, 1988, EUR J CELL BIOL, V47, P62; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GABEL CA, 1985, J CELL BIOL, V101, P460, DOI 10.1083/jcb.101.2.460; GEUZE HJ, 1981, J CELL BIOL, V89, P653, DOI 10.1083/jcb.89.3.653; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; HOLMES KV, 1981, VIROLOGY, V115, P334, DOI 10.1016/0042-6822(81)90115-X; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LIPPINCOTTSCHWA.J, 1990, CELL, V60, P8221; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MACHAMER CE, 1990, P NATL ACAD SCI USA, V87, P6944, DOI 10.1073/pnas.87.18.6944; METSIKKO K, 1986, EMBO J, V5, P1913, DOI 10.1002/j.1460-2075.1986.tb04444.x; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; NIEMANN H, 1982, EMBO J, V1, P1499, DOI 10.1002/j.1460-2075.1982.tb01346.x; NIEMANN H, 1984, EMBO J, V3, P665, DOI 10.1002/j.1460-2075.1984.tb01864.x; NIEMANN H, 1981, J MOL BIOL, V153, P993, DOI 10.1016/0022-2836(81)90463-0; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; PATHAK RK, 1988, J CELL BIOL, V106, P1831, DOI 10.1083/jcb.106.6.1831; PATHAK RK, 1988, J CELL BIOL, V326, P191; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; ROTH J, 1984, J CELL BIOL, V98, P399, DOI 10.1083/jcb.98.2.399; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; ROTH J, 1984, J HISTOCHEM CYTOCHEM, V32, P1167, DOI 10.1177/32.11.6208237; ROTTIER PJM, 1987, J VIROL, V61, P2042, DOI 10.1128/JVI.61.6.2042-2045.1987; ROTTIER PJM, 1981, J VIROL, V40, P350, DOI 10.1128/JVI.40.2.350-357.1981; ROTTIER PJM, 1981, J VIROL, V38, P20, DOI 10.1128/JVI.38.1.20-26.1981; SHITE S, 1990, J BIOL CHEM, V265, P17385; SIMONS K, 1992, IN PRESS CELL; SPAAN WJM, 1981, VIROLOGY, V108, P424, DOI 10.1016/0042-6822(81)90449-9; STERN DF, 1982, J VIROL, V44, P804, DOI 10.1128/JVI.44.3.804-812.1982; STROUS GJA, 1979, P NATL ACAD SCI USA, V76, P2691; STURMAN LS, 1985, J VIROL, V56, P904, DOI 10.1128/JVI.56.3.904-911.1985; TOOZE J, 1984, EUR J CELL BIOL, V33, P281; TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475; ULMER JB, 1989, BIOCH BIPHYS ACTA, P6992; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; VENNEMA H, 1990, J VIROL, V64, P339, DOI 10.1128/JVI.64.1.339-346.1990; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838	49	66	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14094	14101						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629209				2022-12-25	WOS:A1992JD32500050
J	ZERRAHN, J; DEPPERT, W; WEIDEMANN, D; PATSCHINSKY, T; RICHARDS, F; MILNER, J				ZERRAHN, J; DEPPERT, W; WEIDEMANN, D; PATSCHINSKY, T; RICHARDS, F; MILNER, J			CORRELATION BETWEEN THE CONFORMATIONAL PHENOTYPE OF P53 AND ITS SUBCELLULAR LOCATION	ONCOGENE			English	Article							LARGE-T-ANTIGEN; CELLULAR TUMOR-ANTIGEN; SV40 LARGE-T; TRANSFORMATION-RELATED PROTEIN; AMINO-ACID-SEQUENCE; MONOCLONAL-ANTIBODIES; PLASMA-MEMBRANE; 3T3 CELLS; COMPLEX-FORMATION; NUCLEAR MATRIX	In order to obtain insight into the parameters determining the subcellular localization of mutant and wild-type forms of p53, we analysed the subcellular distribution of p53 in four Balb/c mouse-derived cell lines ranging in their cellular phenotypes from normal (3T3), via minimal transformant (T3T3), to maximally transformed (3T3tx, Meth A). Epitope mapping showed the p53 proteins in 3T3 and in T3T3 cells to be in a wild-type conformation, as they reacted with PAb246, whereas p53 in 3T3tx and in Meth A cells were PAb246 negative and thus displayed a mutant conformation. Despite its reactivity with PAb246, p53 in T3T3 cells had an extended half-life and accumulated to abnormally high levels. We show that the conformationally wild-type p53 in 3T3 and T3T3 cells predominantly localized to the cell nucleus, with about half of it being tightly associated with nuclear structures. In contrast, approximately 60% of mutant p53 in 3T3tx and Meth A cells localized to the cytoplasm, the rest residing in the cell nucleus, all the nuclear p53 in these cells appeared to be structurally bound. The cytoplasmic location of mutant p53 in 3T3tx and Meth A cells was not seen by immunofluorescence microscopic analysis, and required cell fractionation for its detection. Both cytoplasmic and nuclear p53 of the mutant phenotype bound to hsc proteins with a similar stoichiometry, suggesting that hsc binding is not directly related to the subcellular distribution of these proteins. We suggest that the conformational phenotype of p53 is a major determinant of its subcellular location.	UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,MARTINISTR 52,W-2000 HAMBURG 13,GERMANY; UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE,ENGLAND	Heinrich Pette Institute; University of Hamburg; University of Cambridge					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; BOONE C, 1965, J NATL CANCER I, V34, P725; BROWN M, 1986, J VIROL, V60, P290, DOI 10.1128/JVI.60.1.290-293.1986; COLLEDGE WH, 1986, MOL CELL BIOL, V6, P4136, DOI 10.1128/MCB.6.11.4136; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; CRAWFORD L, 1983, INT REV EXP PATHOL, V25, P1; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1988, VIROLOGY, V165, P457, DOI 10.1016/0042-6822(88)90589-2; DEPPERT W, 1989, NATO ASI SERIES H, V34, P4399; DEPPERT W, 1990, J VIROL, V2, P838; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1991, NATURE, V349, P802; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GURNEY EG, 1986, J VIROL, V57, P1168, DOI 10.1128/JVI.57.3.1168-1172.1986; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALEVY O, 1989, MOL CELL BIOL, V9, P3385, DOI 10.1128/MCB.9.8.3385; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINZPETER M, 1987, ONCOGENE, V1, P119; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JENKINS JR, 1988, ONCOGENE HDB, P403; KACZMAREK L, 1986, EXP CELL RES, V162, P268, DOI 10.1016/0014-4827(86)90445-3; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KIT S, 1969, INT J CANCER, V4, P384, DOI 10.1002/ijc.2910040403; KLOCKMANN U, 1983, EMBO J, V2, P1151, DOI 10.1002/j.1460-2075.1983.tb01560.x; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1986, VIROLOGY, V150, P265, DOI 10.1016/0042-6822(86)90286-2; MILNER J, 1986, VIROLOGY, V154, P21, DOI 10.1016/0042-6822(86)90426-5; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; PATSCHINSKY T, 1990, ONCOGENE, V5, P1071; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; RISSER R, 1974, VIROLOGY, V59, P477, DOI 10.1016/0042-6822(74)90457-7; ROTTER V, 1980, J VIROL, V36, P547, DOI 10.1128/JVI.36.2.547-555.1980; ROTTER V, 1985, ADV CANCER RES, V43, P113, DOI 10.1016/S0065-230X(08)60944-6; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; SCHIRMBECK R, 1987, J VIROL, V61, P3561, DOI 10.1128/JVI.61.11.3561-3569.1987; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SCHMIEG FI, 1984, J VIROL, V52, P350, DOI 10.1128/JVI.52.2.350-355.1984; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SHOHAT O, 1987, ONCOGENE, V1, P277; STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X; STAUFENBIEL M, 1984, J CELL BIOL, V98, P1886, DOI 10.1083/jcb.98.5.1886; STEINMEYER K, 1990, ONCOGENE, V5, P1691; STEINMEYER K, 1988, ONCOGENE, V3, P501; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; WALSER A, 1989, J VIROL, V63, P3926, DOI 10.1128/JVI.63.9.3926-3933.1989; WALSER A, 1986, EMBO J, V5, P883, DOI 10.1002/j.1460-2075.1986.tb04299.x; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	62	68	69	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1371	1381						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620550				2022-12-25	WOS:A1992HZ97100016
J	BORNER, C; GUADAGNO, SN; HSIAO, WWL; FABBRO, D; BARR, M; WEINSTEIN, IB				BORNER, C; GUADAGNO, SN; HSIAO, WWL; FABBRO, D; BARR, M; WEINSTEIN, IB			EXPRESSION OF 4 PROTEIN-KINASE-C ISOFORMS IN RAT FIBROBLASTS - DIFFERENTIAL ALTERATIONS IN RAS-TRANSFORMED, SRC-TRANSFORMED, AND FOS-TRANSFORMED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL PHOSPHOLIPID-METABOLISM; EPIDERMAL GROWTH-FACTOR; PHORBOL ESTER RECEPTOR; TRANSCRIPTIONAL ACTIVATION; TUMOR PROMOTERS; GENE-EXPRESSION; DOWN-REGULATION; NEU ONCOGENE; 3T3 CELLS; PURIFICATION	In the accompanying study (Borner, C. B., Guadagno, S. N., and Weinstein, 1. B. (1992) J. Biol. Chem. 267, 12892-12899) we found that R6 embryo fibroblasts express four isoforms of PKC, cPKC-alpha, nPKC-epsilon, nPKC-delta, and nPKC-zeta whose subcellular distribution, activation, and down-regulation are differentially regulated. Furthermore, we demonstrated that overproduction of an exogenous cPKC-beta-I isoform in these cells (R6-PKC3) altered the TPA-induced down-regulation of nPKC-delta and nPKC-epsilon. In this paper we show that transformation of R6 or R6-PKC3 cells with a variety of different oncogenes results in differential alterations in expression of individual PKC isoforms. R6 or R6-PKC3 cells transformed by an activated c-H-ras oncogene displayed a marked increase in the expression of both cPKC-alpha and nPKC-delta, decreased expression of nPKC-epsilon, and no change in the expression of nPKC-zeta. These alterations occurred at both the mRNA and protein levels but did not significantly affect the subcellular distribution of any of the four isoforms. Studies using actinomycin D and nuclear run-off assays indicated that the increased expression of cPKC-alpha in ras-transformed cells was due to increased de novo transcription rather than increased mRNA stability. Qualitatively similar, but less extensive changes in the expression of the four PKC isoforms were seen in v-fos-transformed R6-PKC3 cells. Decreased expression of nPKC-epsilon was also seen in the v-src-transformed R6- and R6-PKC3 lines; however, the cellular level of cPKC-beta-I appeared to be a limiting factor in mediating the effects of v-src on the increased expression of cPKC-alpha and nPKC-delta. Interestingly, no major changes in the levels of expression of any of the four PKC isoforms were found when R6 cells were transformed by myc, neu/erb-B2, or mos oncogenes. These results demonstrate that transformation of R6 cells by the oncogenes ras, src, and fos differentially alter the expression of three isoforms of PKC in the same host cell, and they suggest that individual isoforms may play distinct roles in mediating cellular transformation by specific oncogenes.	COLUMBIA UNIV, INST CANC RES, NEW YORK, NY 10027 USA; COLUMBIA UNIV, DEPT PHARMACOL, NEW YORK, NY 10027 USA; CIBA GEIGY AG, DEPT PHARMACEUT RES, ONCOL K125, CH-4002 BASEL, SWITZERLAND; UNIV CALIF IRVINE, DEPT BIOCHEM & MOLEC BIOL, IRVINE, CA 92717 USA; COLUMBIA UNIV, DEPT GENET & DEV, NEW YORK, NY 10027 USA	Columbia University; Columbia University; Novartis; University of California System; University of California Irvine; Columbia University	BORNER, C (corresponding author), COLUMBIA UNIV, CTR COMPREHENS CANC, 701 W 168TH ST, NEW YORK, NY 10027 USA.							AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; BORNER C, 1990, CELL GROWTH DIFFER, V1, P653; BORNER C, 1992, J BIOL CHEM, V267, P12892; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; CUADRADO A, 1990, FEBS LETT, V260, P281, DOI 10.1016/0014-5793(90)80123-Z; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; Curran T, 1988, ONCOGENE HDB, P307; DIAZLAVIADA I, 1990, EMBO J, V9, P3907, DOI 10.1002/j.1460-2075.1990.tb07611.x; DOTTO GP, 1985, NATURE, V318, P472; ELDAR H, 1990, J BIOL CHEM, V265, P13290; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANNUN YA, 1990, J BIOL CHEM, V265, P2962; HOROWITZ M, 1984, EMBO J, V3, P2937, DOI 10.1002/j.1460-2075.1984.tb02235.x; HOUSEY GM, 1987, P NATL ACAD SCI USA, V84, P1065, DOI 10.1073/pnas.84.4.1065; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; HSIAO WLW, 1986, MOL CELL BIOL, V6, P1943, DOI 10.1128/MCB.6.6.1943; HSIAO WLW, 1984, SCIENCE, V226, P552, DOI 10.1126/science.6436974; HUANG KP, 1989, ACTA ENDOCRINOL-COP, V121, P307, DOI 10.1530/acta.0.1210307; HUANG M, 1988, J BIOL CHEM, V263, P17975; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KATO M, 1987, J BIOL CHEM, V262, P5696; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KRAUSS RS, 1989, ONCOGENE, V4, P991; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MARAIS RM, 1989, EUR J BIOCHEM, V182, P129, DOI 10.1111/j.1432-1033.1989.tb14809.x; MARAIS RM, 1990, FEBS LETT, V277, P151, DOI 10.1016/0014-5793(90)80831-3; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MEYER T, 1989, INT J CANCER, V43, P851, DOI 10.1002/ijc.2910430519; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1986, FEBS LETT, V203, P111, DOI 10.1016/0014-5793(86)80724-4; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1988, J BIOL CHEM, V263, P6927; OSADA S, 1990, J BIOL CHEM, V265, P22434; OWEN RD, 1990, P NATL ACAD SCI USA, V87, P3866, DOI 10.1073/pnas.87.10.3866; PANDIELLA A, 1989, ONCOGENE, V4, P1299; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PATEL G, 1989, CELL SIGNAL, V1, P227, DOI 10.1016/0898-6568(89)90040-5; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PRIESS J, 1986, J BIOL CHEM, V261, P8597; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SLAGA TJ, 1984, MECHANISMS TUMOR PRO, V2, P1; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; STACEY DW, 1987, MOL CELL BIOL, V9, P3174; SUGIMOTO Y, 1984, P NATL ACAD SCI USA, V81, P16546; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WEYMAN CM, 1988, CANCER RES, V48, P6535; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; Woodgett JR., 1987, CELL MEMBRANES, P215, DOI [10.1007/978-1-4613-1915-3_6, DOI 10.1007/978-1-4613-1915-3_6]	76	76	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12900	12910						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618788				2022-12-25	WOS:A1992HZ48300077
J	KOUNNAS, MZ; MORRIS, RE; THOMPSON, MR; FITZGERALD, DJ; STRICKLAND, DK; SAELINGER, CB				KOUNNAS, MZ; MORRIS, RE; THOMPSON, MR; FITZGERALD, DJ; STRICKLAND, DK; SAELINGER, CB			THE ALPHA-2-MACROGLOBULIN RECEPTOR LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN BINDS AND INTERNALIZES PSEUDOMONAS EXOTOXIN-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LDL-RECEPTOR; CULTURED FIBROBLASTS; ESCHERICHIA-COLI; APOLIPOPROTEIN-E; PLASMA-MEMBRANE; MAMMALIAN-CELLS; DOMAIN-I; AERUGINOSA; TOXIN; SEQUENCE	The alpha-2-macroglobulin receptor/low density lipoprotein receptor-related protein (alpha-2MR/LRP) is a large cell-surface glycoprotein consisting of a 515-kDa and an 85-kDa polypeptide; this receptor is thought to be responsible for the binding and endocytosis of activated alpha-2-macroglobulin and apoE-enriched beta-very low density lipoprotein. A similar high molecular weight glycoprotein has been identified as a potential receptor for Pseudomonas exotoxin A (PE). We demonstrate that the alpha-2MR/LRP and the PE-binding glycoprotein have a similar mobility upon sodium dodecyl sulfate-polyacrylamide gel electrophoresis and are immunologically indistinguishable. Furthermore, affinity-purified alpha-2MR/LRP binds specifically to PE but not to a mutant toxin defective in its ability to bind cells. The 39-kDa receptor-associated protein, which blocks binding of ligands to alpha-2MR/LRP, also prevents binding and subsequent toxicity of PE for mouse fibroblasts. The concentration of receptor-associated protein that was required to reduce binding and toxicity to 50% was approximately 14 nM, a value virtually identical to the, K(D) measured for the interaction of receptor-associated protein with the purified receptor. Overall, the studies strongly suggest that the alpha-2MR/LRP is responsible for internalizing PE.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267; AMER RED CROSS,BIOCHEM LAB,ROCKVILLE,MD 20855; UNIV CINCINNATI,COLL MED,DEPT ANAT & CELL BIOL,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DIV DIGEST DIS,CINCINNATI,OH 45267; NCI,DIV CANC BIOL DIAG & CTR,MOLEC BIOL LAB,BETHESDA,MD 20892	University System of Ohio; University of Cincinnati; American Red Cross; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NHLBI NIH HHS [HL30200/ +] Funding Source: Medline; NIAID NIH HHS [AI17529] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017529] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BATRA JK, 1991, MOL CELL BIOL, V11, P2200, DOI 10.1128/MCB.11.4.2200; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; CHAUDRY GJ, 1989, J BIOL CHEM, V264, P15151; FELDMAN SR, 1985, BIOCHEM BIOPH RES CO, V128, P795, DOI 10.1016/0006-291X(85)90117-2; FITZGERALD D, 1980, CELL, V21, P867, DOI 10.1016/0092-8674(80)90450-X; FORRISTAL JJ, 1991, INFECT IMMUN, V59, P2880, DOI 10.1128/IAI.59.9.2880-2884.1991; GLIEMANN J, 1986, BIOCHIM BIOPHYS ACTA, V885, P49, DOI 10.1016/0167-4889(86)90037-6; GRAY GL, 1984, P NATL ACAD SCI-BIOL, V81, P2645, DOI 10.1073/pnas.81.9.2645; HANOVER JA, 1983, J BIOL CHEM, V258, P370; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HOLDER IA, 1989, J BURN CARE REHABIL, V9, P285; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; IGLEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284, DOI 10.1073/pnas.72.6.2284; IGLEWSKI BH, 1977, INFECT IMMUN, V15, P138, DOI 10.1128/IAI.15.1.138-144.1977; JINNO Y, 1988, J BIOL CHEM, V263, P13203; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LUND H, 1989, P NATL ACAD SCI USA, V86, P9318, DOI 10.1073/pnas.86.23.9318; MANHART MD, 1984, INFECT IMMUN, V45, P596, DOI 10.1128/IAI.45.3.596-603.1984; MIDDLEBROOK JL, 1977, CAN J MICROBIOL, V23, P183, DOI 10.1139/m77-026; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MORRIS RE, 1985, SURV SYN PATHOL RES, V4, P34; OGATA M, 1990, J BIOL CHEM, V265, P20678; PASTAN I, 1991, SCIENCE, V254, P1173, DOI 10.1126/science.1683495; PASTAN I, 1989, J BIOL CHEM, V264, P15157; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; SEETHARAM S, 1991, J BIOL CHEM, V266, P17376; SIEGALL CB, 1989, J BIOL CHEM, V264, P14256; SNELL K, 1978, INFECT IMMUN, V19, P839, DOI 10.1128/IAI.19.3.839-845.1978; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; THOMPSON MR, 1991, J BIOL CHEM, V266, P2390; VANDENPOL AN, 1984, Q J EXP PHYSIOL CMS, V69, P1; VANLEUVEN F, 1979, J BIOL CHEM, V254, P5155; VASIL ML, 1978, J GEN MICROBIOL, V108, P333, DOI 10.1099/00221287-108-2-333; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLINGHAM MC, 1979, J CELL BIOL, V82, P614, DOI 10.1083/jcb.82.3.614	47	413	432	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12420	12423						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618748				2022-12-25	WOS:A1992HZ48300008
J	NYHUS, KJ; IKEUCHI, M; INOUE, Y; WHITMARSH, J; PAKRASI, HB				NYHUS, KJ; IKEUCHI, M; INOUE, Y; WHITMARSH, J; PAKRASI, HB			PURIFICATION AND CHARACTERIZATION OF THE PHOTOSYSTEM-I COMPLEX FROM THE FILAMENTOUS CYANOBACTERIUM ANABAENA-VARIABILIS ATCC-29413	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTIRE PRECURSOR POLYPEPTIDES; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; SUBUNIT-II; SPINACH; CHLOROPHYLL; GENE; P700; PHOTOSYNTHESIS; IDENTIFICATION	A photoactive photosystem I complex has been purified from the filamentous, nitrogen-fixing cyanobacterium Anabaena variabilis ATCC 29413. Cells were broken using glass beads, and the membrane fraction was solubilized with beta-dodecyl maltoside followed by two rounds of fast protein liquid chromatography on anion exchange columns. The polypeptide composition of the isolated complex was determined by sodium dodecyl sulfate-urea-polyacrylamide gel electrophoresis and N-terminal amino acid sequencing of the fractionated proteins. The purified complex consists of at least 11 proteins, identified as the PsaA, PsaB, PsaC, PsaD, PsaE, PsaF, PsaI, PsaJ, PsaK, PsaL, and PsaN proteins. The spectrum of the flash-induced absorbance change measured between 670 and 830 nm shows that the purified complex contains 99 +/- 11 chlorophyll alpha-molecules per P700, the primary donor in photosystem I. The kinetics of the rereduction of oxidized P700 following an actinic flash indicate that forward electron transfer from P700 to the F(A)/F(B) iron-sulfur center acceptors is functional in the isolated complex.	WASHINGTON UNIV, DEPT BIOL, PLANT BIOL PROGRAM, ST LOUIS, MO 63130 USA; INST PHYS & CHEM RES, SOLAR ENERGY RES GRP, WAKO, SAITAMA 35101, JAPAN; UNIV ILLINOIS, USDA ARS, PHOTOSYNTH RES UNIT, URBANA, IL 61801 USA; UNIV ILLINOIS, DEPT PLANT BIOL, URBANA, IL 61801 USA; UNIV ILLINOIS, DEPT PHYSIOL & BIOPHYS, URBANA, IL 61801 USA	Washington University (WUSTL); RIKEN; United States Department of Agriculture (USDA); University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign					NIGMS NIH HHS [GM 41841] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRY BA, 1988, ISRAEL J CHEM, V28, P129; BENGIS C, 1977, J BIOL CHEM, V252, P4564; BOSE S, 1982, PHOTOCHEM PHOTOBIOL, V36, P725, DOI 10.1111/j.1751-1097.1982.tb09496.x; BRICKER TM, 1985, ARCH BIOCHEM BIOPHYS, V237, P170, DOI 10.1016/0003-9861(85)90266-8; BRYANT DA, 1992, IN PRESS CURRENT TOP, V11; BRYANT DA, 1990, CURRENT RES PHOTOSYN, V2, P1; CANTRELL A, 1987, PLANT MOL BIOL, V9, P453, DOI 10.1007/BF00015877; CHITNIS PR, 1991, J BIOL CHEM, V266, P20146; DEKKER JP, 1989, FEBS LETT, V254, P150, DOI 10.1016/0014-5793(89)81028-2; GOLBECK JH, 1986, BIOCHIM BIOPHYS ACTA, V849, P16, DOI 10.1016/0005-2728(86)90091-5; GOLBECK JH, 1991, CURR TOP BIOENERG, V16, P83; HIYAMA T, 1972, BIOCHIM BIOPHYS ACTA, V267, P160, DOI 10.1016/0005-2728(72)90147-8; IKEUCHI M, 1991, FEBS LETT, V280, P332, DOI 10.1016/0014-5793(91)80324-V; IKEUCHI M, 1988, PLANT CELL PHYSIOL, V29, P1233; IKEUCHI M, 1990, FEBS LETT, V263, P274, DOI 10.1016/0014-5793(90)81391-Z; IKEUCHI M, 1991, FEBS LETT, V287, P5, DOI 10.1016/0014-5793(91)80003-L; KIRSCH W, 1986, CURR GENET, V10, P843, DOI 10.1007/BF00418531; KOIKE H, 1989, FEBS LETT, V253, P257, DOI 10.1016/0014-5793(89)80971-8; LAGOUTTE B, 1989, PHOTOCHEM PHOTOBIOL, V49, P833, DOI 10.1111/j.1751-1097.1989.tb05580.x; LI N, 1991, BIOCHIM BIOPHYS ACTA, V1059, P215, DOI 10.1016/S0005-2728(05)80206-3; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; LOCKAU W, 1981, ARCH MICROBIOL, V128, P336, DOI 10.1007/BF00422541; LUNDELL DJ, 1985, J BIOL CHEM, V260, P646; MacKinney G, 1941, J BIOL CHEM, V140, P315; MALDENER I, 1991, MOL GEN GENET, V225, P113, DOI 10.1007/BF00282649; MANNAN RM, 1991, P NATL ACAD SCI USA, V88, P10168, DOI 10.1073/pnas.88.22.10168; MANNAN RM, 1992, PLANT PHYSIOL, V98, P798, DOI 10.1104/pp.98.2.798; MUNCH S, 1988, CURR GENET, V14, P511, DOI 10.1007/BF00521277; OGAWA T, 1969, BIOCHIM BIOPHYS ACTA, V172, P216, DOI 10.1016/0005-2728(69)90065-6; OKKELS JS, 1991, J BIOL CHEM, V266, P6767; REILLY P, 1988, J BIOL CHEM, V263, P17658; ROGNER M, 1990, J BIOL CHEM, V265, P6189; SCHAFFERNICHT H, 1981, PHOTOCHEM PHOTOBIOL, V34, P223; SCHELLER HV, 1990, PHYSIOL PLANTARUM, V78, P484, DOI 10.1034/j.1399-3054.1990.780326.x; SMART LB, 1991, PLANT MOL BIOL, V17, P959, DOI 10.1007/BF00037136; SMART LB, 1991, EMBO J, V10, P3289, DOI 10.1002/j.1460-2075.1991.tb04893.x; SONOIKE K, 1989, BIOCHIM BIOPHYS ACTA, V976, P210, DOI 10.1016/S0005-2728(89)80232-4; STEPPUHN J, 1988, FEBS LETT, V237, P218, DOI 10.1016/0014-5793(88)80205-9; STEPPUHN J, 1989, CURR GENET, V16, P99, DOI 10.1007/BF00393402; TAKAHASHI Y, 1991, EMBO J, V10, P2033, DOI 10.1002/j.1460-2075.1991.tb07733.x; TOELGE M, 1991, BIOCHIM BIOPHYS ACTA, V1060, P233, DOI 10.1016/S0005-2728(09)91011-8; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WHITMARSH J, 1984, ARCH BIOCHEM BIOPHYS, V231, P378, DOI 10.1016/0003-9861(84)90401-6; WOLK CP, 1976, ARCH MICROBIOL, V110, P145; WOLK CP, 1971, J PHYCOL, V7, P339, DOI 10.1111/j.0022-3646.1971.00339.x; WYNN RM, 1989, BIOCHEMISTRY-US, V28, P5554, DOI 10.1021/bi00439a032; Zieger R., 1965, BEITR BIOL PFLANZ, V41, P11	47	25	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12489	12495						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618755				2022-12-25	WOS:A1992HZ48300020
J	DUDLEY, B; HAMMOND, A; DEUTSCH, WA				DUDLEY, B; HAMMOND, A; DEUTSCH, WA			THE PRESENCE OF URACIL-DNA GLYCOSYLASE IN INSECTS IS DEPENDENT UPON DEVELOPMENTAL COMPLEXITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-MELANOGASTER; INHIBITOR; RESIDUES; REPAIR; ENZYME; AGE	The metamorphosis of insects can, in a general way, be divided between those organisms that undergo pupation accompanied by cellular histolysis and those that gradually develop into adults without an intervening pupal stage of development. In the former case, the death of a cell population is an integral part of development that is tightly associated with massive DNA degradation during pupation. In that regard, it has been suggested that uracil-containing DNA acts as a target for the nucleolytic breakdown of DNA during histolysis in insects (Deutsch, W. A. (1987) Mutat. Res. 184, 209-215), thus placing into question how compatible the existence of uracil-DNA glycosylases would be for this form of developmental signal. As a result, we tested for the presence of a uracil-DNA glycosylase in insects representative of those having an intervening pupal stage of development and those that do not. We show here that a nonpupating insect contains a uracil-DNA glycosylase activity. Conversely, crude extracts of Drosophila melanogaster, as well as of three other insect populations that undergo pupation similar to that found in Drosophila, do not contain detectable levels of this DNA repair activity. Thus, there appears to be a consistent correlation between cellular destruction during development and the absence of a uracil-DNA glycosylase, which supports the possibility that uracil-containing DNA may play an important role in those cells targeted for death.	LOUISIANA STATE UNIV, DEPT BIOCHEM, BATON ROUGE, LA 70803 USA; LOUISIANA STATE UNIV, DEPT ENTOMOL, BATON ROUGE, LA 70803 USA	Louisiana State University System; Louisiana State University; Louisiana State University System; Louisiana State University								BICKLE TA, 1982, NUCLEASES, P85; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREIMER LH, 1986, BIOCHEM BIOPH RES CO, V134, P201, DOI 10.1016/0006-291X(86)90547-4; BURTON WG, 1979, P NATL ACAD SCI USA, V76, P1390, DOI 10.1073/pnas.76.3.1390; CLIFFORD CW, 1977, ANN ENTOMOL SOC AM, V70, P69, DOI 10.1093/aesa/70.1.69; DEUTSCH WA, 1987, MUTAT RES, V184, P209, DOI 10.1016/0167-8817(87)90018-6; DEUTSCH WA, 1982, J BIOL CHEM, V257, P3366; DUNCAN BK, 1982, J BACTERIOL, V151, P750, DOI 10.1128/JB.151.2.750-755.1982; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; FESCEMYER HW, 1986, ENVIRON ENTOMOL, V15, P784, DOI 10.1093/ee/15.4.784; FRANKLIN WA, 1988, EMBO J, V7, P3617, DOI 10.1002/j.1460-2075.1988.tb03240.x; FRIEDBERG EC, 1978, DNA REPAIR MECHANISM, P163; GATES FT, 1977, J BIOL CHEM, V252, P1647; GIROIR IE, 1987, J BIOL CHEM, V262, P130; HENSLEY SD, 1968, J ECON ENTOMOL, V61, P1742, DOI 10.1093/jee/61.6.1742; JOHNSON AW, 1988, J BIOL CHEM, V263, P18009; MORGAN AR, 1989, J BIOL CHEM, V264, P9911; NATION MD, 1989, BIOCHEM J, V259, P593, DOI 10.1042/bj2590593; PRICE AR, 1975, J BIOL CHEM, V250, P8804; ROE RM, 1982, ANN ENTOMOL SOC AM, V75, P421, DOI 10.1093/aesa/75.4.421; SADOWSKI PD, 1969, J BIOL CHEM, V244, P6192; WITTWER CU, 1985, BIOCHIM BIOPHYS ACTA, V832, P308, DOI 10.1016/0167-4838(85)90264-X; WYLIE AH, 1980, NATURE, V284, P555	23	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11964	11967						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601865				2022-12-25	WOS:A1992HY94700048
J	MIYAMOTO, I; MIURA, N; NIWA, H; MIYAZAKI, J; TANAKA, K				MIYAMOTO, I; MIURA, N; NIWA, H; MIYAZAKI, J; TANAKA, K			MUTATIONAL ANALYSIS OF THE STRUCTURE AND FUNCTION OF THE XERODERMA-PIGMENTOSUM GROUP-A COMPLEMENTING PROTEIN - IDENTIFICATION OF ESSENTIAL DOMAINS FOR NUCLEAR-LOCALIZATION AND DNA EXCISION REPAIR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC FINGERS; MOLECULAR CHARACTERIZATION; CDNA CLONING; GENE; HOMOLOGY	We showed previously that the xeroderma pigmentosum group A complementing (XPAC) protein involved in the DNA excision repair pathway contains a zinc-finger motif and is localized in the nucleus of normal human cells. For detailed structural and functional analyses of the XPAC protein, we constructed various XPAC cDNAs by site-directed mutagenesis and isolated permanent cell lines expressing mutant proteins. Immunofluorescent analysis of these lines indicated that the nuclear localization signal is located in the region encoded by Exon 1, especially centered at amino acids 30-42. A UV survival study showed that regions from Exons 2 through 6 were essential for DNA repair function, but that Exon 1 was not. Interestingly, deletion of the glutamic acid cluster in the region encoded by Exon 2 resulted in a dramatic loss of DNA repair activity. Furthermore, replacements of each of the 4 cysteines supposed to form a zinc-finger structure in the region encoded by Exon 3 by serine or glycine resulted in similar levels of loss of repair activity. These results suggest that all 4 cysteines forming a zinc-finger structure and also the glutamic acid cluster are important for DNA repair function.	OSAKA UNIV,INST MOLEC & CELLULAR BIOL,1-3 YAMADA OKA,SUITA,OSAKA 565,JAPAN; HYOGO MED UNIV,DEPT UROL,NISHINOMIYA,HYOGO 663,JAPAN; KUMAMOTO UNIV,SCH MED,INST MED GENET,KUMAMOTO 862,JAPAN; UNIV TOKYO,FAC MED,DEPT DIS RELATED GENE REGULAT RES SANDOZ,TOKYO 113,JAPAN	Osaka University; Hyogo College of Medicine; University of Hyogo; Kumamoto University; Novartis; Sandoz; University of Tokyo			Miyazaki, Jun-ichi/N-1976-2015	Miyazaki, Jun-ichi/0000-0003-2475-589X				BERG JM, 1990, J BIOL CHEM, V265, P6513; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; EARNSHAW WC, 1987, J CELL BIOL, V105, P1479, DOI 10.1083/jcb.105.4.1479; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; HARLOW H, 1988, ANTIBODIES LABORATOR, P647; HOEIJMAKERS JHJ, 1990, CANCER CELL-MON REV, V2, P311; MIURA N, 1991, J BIOL CHEM, V266, P19786; MUDGETT JS, 1990, GENOMICS, V8, P623, DOI 10.1016/0888-7543(90)90248-S; NAVARATNAM S, 1989, J BIOL CHEM, V264, P16067; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOKATA I, 1990, P NATL ACAD SCI USA, V87, P9908, DOI 10.1073/pnas.87.24.9908; SATOKATA I, 1992, MUTAT RES, V273, P193, DOI 10.1016/0921-8777(92)90080-M; SATOKATA I, 1992, IN PRESS HUM GENET; SHIMAMOTO T, 1991, BIOCHEM BIOPH RES CO, V181, P1231, DOI 10.1016/0006-291X(91)92070-Z; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TANAKA K, 1989, P NATL ACAD SCI USA, V86, P5512, DOI 10.1073/pnas.86.14.5512; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TROELSTRA C, 1990, MOL CELL BIOL, V10, P5806, DOI 10.1128/MCB.10.11.5806; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U	26	119	123	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12182	12187						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601884				2022-12-25	WOS:A1992HY94700079
J	PITARRESI, TM; RUBATTU, S; HEINRIKSON, R; SEALEY, JE				PITARRESI, TM; RUBATTU, S; HEINRIKSON, R; SEALEY, JE			REVERSIBLE CRYOACTIVATION OF RECOMBINANT HUMAN PRORENIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INACTIVE RENIN; HUMAN-PLASMA; ASPARTIC PROTEINASES; BIG RENIN; ACTIVATION; MECHANISM; ANGIOTENSINOGEN; IDENTIFICATION; PREKALLIKREIN; ALDOSTERONE	Cleavage of prorenin's prosegment causes irreversible formation of renin. In contrast, renin activity is reversibly exposed when prorenin is acidified to pH 3.3. Nonetheless, acidification of plasma results in irreversible activation of prorenin, because endogenous proteases cleave the prosegment of acid-activated prorenin. Chilling of plasma results in irreversible cryoactivation of prorenin. In this study we investigated whether cryoactivation of purified prorenin is reversible. The intrinsic renin activity of recombinant human prorenin was measured by an enzyme kinetic assay using partially purified human angiotensinogen as substrate. Results are expressed as a percent (mean +/- S.E.) of the maximal activity exposed after limited proteolysis by trypsin. The intrinsic renin activity of two pools (0.3 and 0.06 Goldblatt units/ml) was 1.5% +/- 0.3 and 1.2% +/- 0.6 at 37-degrees-C. Activity increased to 19% +/- 0.3 and 26% +/- 0.5 after incubation at 0-degrees-C and to 5.4% +/- 0.5 and 2.1% +/- 1.2 at room temperature. Cryoactivation did not occur in buffers containing more than 1 M NaCl. It took 8 min at 37-degrees-C or 180 min at room temperature for cryoactivated prorenin to lose half of its intrinsic renin activity. It took 48 and 26 h, respectively, at 0-degrees-C for the two pools of prorenin at 37-degrees-C to regain half of their maximum intrinsic activity at 0-degrees-C. A direct immunoradiometric assay that detects active renin but not prorenin was able to detect cryoactivated prorenin. These results show that human prorenin can be reversibly cryoactivated in buffers of low ionic strength and has greater intrinsic activity at room temperature than at 37-degrees-C.	CORNELL UNIV, MED CTR, COLL MED, CTR CARDIOVASC, 525 E 68TH ST, NEW YORK, NY 10021 USA	Cornell University			Rubattu, S./K-4036-2016; Sealey, Jean/A-9562-2009	Rubattu, Speranza/0000-0002-9808-7970; RUBATTU, Speranza Donatella/0000-0001-5921-7368	NHLBI NIH HHS [HL 18323, HL 40152] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040152, P50HL018323] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATLAS SA, 1982, HYPERTENSION, V4, P86, DOI 10.1161/01.HYP.4.3_Pt_2.86; ATLAS SA, 1985, BIOCHEM BIOPH RES CO, V132, P1038, DOI 10.1016/0006-291X(85)91911-4; ATLAS SA, 1978, CIRC RES, V43, pI128; BOUHNIK J, 1985, J CLIN ENDOCR METAB, V60, P399, DOI 10.1210/jcem-60-2-399; CARILLI CT, 1988, HYPERTENSION, V11, P713, DOI 10.1161/01.HYP.11.6.713; COOPER JB, 1990, J MOL BIOL, V214, P199, DOI 10.1016/0022-2836(90)90156-G; DANSER AHJ, 1989, J CLIN ENDOCR METAB, V68, P160, DOI 10.1210/jcem-68-1-160; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; DAY RP, 1974, J CLIN ENDOCR METAB, V38, P923, DOI 10.1210/jcem-38-5-923; DELEIVA A, 1976, NEW ENGL J MED, V295, P639, DOI 10.1056/NEJM197609162951203; DERKX FHM, 1987, J BIOL CHEM, V262, P2472; DERKX FHM, 1979, NATURE, V280, P315, DOI 10.1038/280315a0; GALEN FX, 1984, J CLIN INVEST, V73, P1144, DOI 10.1172/JCI111300; HEINRIKSON RL, 1989, AM J HYPERTENS, V2, P367, DOI 10.1093/ajh/2.5.367; HOBART PM, 1987, DIURETICS, V2, P510; HSUEH WA, 1981, HYPERTENSION, V3, P22; HUI KY, 1985, PEPTIDES STRUCTURE F, P771; INAGAMI T, 1980, BIOMED RES-TOKYO, V1, P456, DOI 10.2220/biomedres.1.456; JAMES MNG, 1986, NATURE, V319, P33, DOI 10.1038/319033a0; KAGEYAMA T, 1987, EUR J BIOCHEM, V165, P483, DOI 10.1111/j.1432-1033.1987.tb11464.x; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; KIM SJ, 1985, BIOCHEM BIOPH RES CO, V126, P641, DOI 10.1016/0006-291X(85)90232-3; LARAGH JH, 1992, HDB RENAL PHYSL, P1409; LECKIE BJ, 1980, NATURE, V288, P702, DOI 10.1038/288702a0; LENZ T, 1990, AM J HYPERTENS, V3, P257, DOI 10.1093/ajh/3.4.257; LENZ T, 1989, J CLIN ENDOCR METAB, V69, P31, DOI 10.1210/jcem-69-1-31; LENZ T, 1990, HYPERTENSION PATHOPH, P1319; LUETSCHER JA, 1989, AM J HYPERTENS, V2, P382, DOI 10.1093/ajh/2.5.382; MCGIFF JC, 1970, NATURE, V227, P1255, DOI 10.1038/2271255b0; MCPHIE P, 1989, BIOCHEM BIOPH RES CO, V158, P115, DOI 10.1016/S0006-291X(89)80185-8; NARUSE M, 1983, J CLIN ENDOCR METAB, V57, P482, DOI 10.1210/jcem-57-3-482; NETER J, 1974, APPLIED LINEAR STATI; OSMOND DH, 1973, CAN J PHYSIOL PHARM, V51, P705, DOI 10.1139/y73-107; PREIBISZ JJ, 1982, CARDIOVASC REV REP, V3, P787; Sealey J E, 1980, Endocr Rev, V1, P365; SEALEY JE, 1991, AM J HYPERTENS, V4, P972, DOI 10.1093/ajh/4.12.972; SEALEY JE, 1976, AM J MED, V61, P731, DOI 10.1016/0002-9343(76)90154-6; SEALEY JE, 1979, P NATL ACAD SCI USA, V76, P5914, DOI 10.1073/pnas.76.11.5914; SEALEY JE, 1988, J CLIN ENDOCR METAB, V66, P974, DOI 10.1210/jcem-66-5-974; SEALEY JE, 1975, CIRC RES, V36, P10, DOI 10.1161/01.RES.36.6.10; SEALEY JE, 1990, FRONT NEUROENDOCRIN, V11, P213; SKINNER SL, 1975, AM J OBSTET GYNECOL, V121, P626, DOI 10.1016/0002-9378(75)90463-9	42	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11753	11759						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601850				2022-12-25	WOS:A1992HY94700020
J	VOS, HL; DEVARAYALU, S; DEVRIES, Y; BORNSTEIN, P				VOS, HL; DEVARAYALU, S; DEVRIES, Y; BORNSTEIN, P			THROMBOSPONDIN-3 (THBS3), A NEW MEMBER OF THE THROMBOSPONDIN GENE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESIVE GLYCOPROTEIN; SEQUENCE; ANGIOGENESIS; CHROMOSOME-1; PLATELETS; REGION; INTRON; SITES	A third member of the thrombospondin gene family (Thbs3) has been partially characterized in the mouse. In both the mouse and humans, the Thbs3/THBS3 gene is located immediately upstream from the Muc1/MUC1 (episialin) gene; <3 kilobases separate the polyadenylation signal of one gene from the start of transcription of the other. The available coding sequence in Thbs3 shows a high degree of amino acid sequence identity to Thbs1 and Thbs2 (58 and 59%, respectively, in exons 15 and 16), but the exon/intron organization of Thbs3 appears to be more disparate than that of the two previously described members of the family. The shorter length of the Thbs3 mRNA (3.5 kilobases) can be attributed largely to a shorter 3'-untranslated region. The Thbs3 gene is expressed in a distinctive pattern in mouse tissues, with the highest level of expression in lung. This pattern suggests a unique function for the translation product of the Thbs3 gene.	UNIV WASHINGTON, DEPT BIOCHEM, SJ-70, SEATTLE, WA 98195 USA; NETHERLANDS CANC INST, DIV TUMOR BIOL, 1066 CX AMSTERDAM, NETHERLANDS	University of Washington; University of Washington Seattle; Netherlands Cancer Institute					NHLBI NIH HHS [HL 18645] Funding Source: Medline; NIDCR NIH HHS [DE 08229] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE008229] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ASCH AS, 1989, PROG HEMOST THROMB, V9, P157; ASCH AS, 1991, J BIOL CHEM, V266, P1740; BAENZIGER NL, 1972, J BIOL CHEM, V247, P2723; BORNSTEIN P, 1990, J BIOL CHEM, V265, P16691; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; BORNSTEIN P, 1991, P NATL ACAD SCI USA, V88, P8636, DOI 10.1073/pnas.88.19.8636; BOUCK N, 1986, CANCER RES, V46, P5101; CASTLE V, 1991, J CLIN INVEST, V87, P1883, DOI 10.1172/JCI115212; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FRAZIER WA, 1987, J CELL BIOL, V105, P625, DOI 10.1083/jcb.105.2.625; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; GIL A, 1984, NATURE, V312, P473, DOI 10.1038/312473a0; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; HENNESSY SW, 1989, J CELL BIOL, V108, P729, DOI 10.1083/jcb.108.2.729; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; JAFFE E, 1990, GENOMICS, V7, P123, DOI 10.1016/0888-7543(90)90528-3; LABELL TL, 1992, GENOMICS, V12, P421, DOI 10.1016/0888-7543(92)90430-Z; LAHERTY CD, 1992, J BIOL CHEM, V267, P3274; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LAWLER J, 1991, GENOMICS, V11, P587, DOI 10.1016/0888-7543(91)90066-N; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; MAJACK RA, 1987, CELL MEMBRANES METHO, V3, P55; MANSFIELD PJ, 1990, J CELL BIOL, V111, P3077, DOI 10.1083/jcb.111.6.3077; PATTHY L, 1987, FEBS LETT, V214, P1, DOI 10.1016/0014-5793(87)80002-9; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SPICER AP, 1991, J BIOL CHEM, V266, P15099; SWALLOW DM, 1987, ANN HUM GENET, V51, P289, DOI 10.1111/j.1469-1809.1987.tb01063.x; VOS HL, 1991, BIOCHEM BIOPH RES CO, V181, P121, DOI 10.1016/S0006-291X(05)81390-7; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; WOLF FW, 1990, GENOMICS, V6, P685, DOI 10.1016/0888-7543(90)90505-O; WU H, 1990, MOL CELL BIOL, V10, P1452, DOI 10.1128/MCB.10.4.1452	32	101	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12192	12196						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601886				2022-12-25	WOS:A1992HY94700081
J	NUNEZ, MT; ESCOBAR, A; AHUMADA, A; GONZALEZSEPULVEDA, M				NUNEZ, MT; ESCOBAR, A; AHUMADA, A; GONZALEZSEPULVEDA, M			SEALED RETICULOCYTE GHOSTS - AN EXPERIMENTAL-MODEL FOR THE STUDY OF FE2+ TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERRIN-BOUND IRON; RAT-LIVER; MEMBRANE-VESICLES; CLEARANCE; MOUSE	Sealed right-side-out reticulocyte ghosts transported and accumulated iron offered as Fe-59(2+)-ascorbate (K(m) = 1.1-mu-M). The uptake of iron by ghosts presented the characteristics of a transporter-mediated process: it responded to osmotic challenge, the rate of transport increased when iron was present in the opposing side, and the transport rate showed the temperature dependence typical of membrane-mediated processes. The transport of iron was dependent on an associated influx of Cl- in order to keep electroneutrality. Other transition metals, such as Cu2+, Zn2+, and Co2+, inhibited the transport of Fe2+. The overall characteristics of the system make reticulocyte sealed ghosts a very useful model in determining the basic mechanisms of membrane iron transport.			NUNEZ, MT (corresponding author), UNIV CHILE,FAC CIENCIAS,DEPT BIOL,CASILLA 653,SANTIAGO,CHILE.		Nunez, Marco/H-6348-2014	Nunez, Marco/0000-0002-1967-8570				ANDERSON TF, 1951, T NEW YORK ACAD SCI, V13, P130, DOI 10.1111/j.2164-0947.1951.tb01007.x; BRISSOT P, 1985, J CLIN INVEST, V76, P1463, DOI 10.1172/JCI112125; CRAVEN CM, 1987, P NATL ACAD SCI USA, V84, P3457, DOI 10.1073/pnas.84.10.3457; DEVES R, 1979, BIOCHIM BIOPHYS ACTA, V556, P524, DOI 10.1016/0005-2736(79)90138-X; DEVES R, 1989, PROC R SOC SER B-BIO, V237, P85, DOI 10.1098/rspb.1989.0038; EGYED A, 1988, BRIT J HAEMATOL, V68, P483, DOI 10.1111/j.1365-2141.1988.tb04241.x; EVANS RM, 1982, BR J NUTR, V47, P353; HUEBERS H, 1975, IRON METABOLISM ITS, P13; JACQUEZ JA, 1980, MEMBRANE PHYSL, P147; KAPLAN J, 1991, J BIOL CHEM, V266, P2997; LODISH HF, 1975, J CELL BIOL, V65, P51, DOI 10.1083/jcb.65.1.51; MARX JJM, 1981, BIOCHIM BIOPHYS ACTA, V649, P297, DOI 10.1016/0005-2736(81)90418-1; MORGAN EH, 1988, BIOCHIM BIOPHYS ACTA, V943, P428, DOI 10.1016/0005-2736(88)90374-4; MUIR WA, 1984, J BIOL CHEM, V259, P4896; NUNEZ MT, 1990, J BIOL CHEM, V265, P6688; NUNEZ MT, 1983, J BIOL CHEM, V258, P1146; QUIAN ZM, 1991, BIOCHIM BIOPHYS ACTA, V1073, P456; SIMPSON RJ, 1984, BIOCHIM BIOPHYS ACTA, V772, P220, DOI 10.1016/0005-2736(84)90047-6; Steck T L, 1974, Methods Enzymol, V31, P172; STURROCK A, 1990, J BIOL CHEM, V265, P3139; WASHKO P, 1989, J BIOL CHEM, V264, P18996; WRIGHT TL, 1986, J BIOL CHEM, V261, P909; WRIGHT TL, 1988, J BIOL CHEM, V263, P1842; YOUNG SP, 1977, BIOCHIM BIOPHYS ACTA, V469, P281, DOI 10.1016/0005-2736(77)90164-X	24	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11490	11494						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597476				2022-12-25	WOS:A1992HX16900084
J	DELAROSA, J; LEGROS, HL; GELLER, AM; KOTB, M				DELAROSA, J; LEGROS, HL; GELLER, AM; KOTB, M			CHANGES IN THE RELATIVE AMOUNT OF SUBUNITS OF METHIONINE ADENOSYLTRANSFERASE IN HUMAN-LYMPHOCYTES UPON STIMULATION WITH A POLYCLONAL T-CELL MITOGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE SYNTHETASE; STREPTOCOCCAL-M-PROTEIN; GENE; METHYLATION	Activation of resting human peripheral blood T lymphocytes by the lectin phytohemagglutinin results in an increase in methionine adenosyltransferase (MAT) activity, accompanied by an increase in the amount of the alpha/alpha' catalytic subunits of the enzyme. In contrast, the amount of the noncatalytic beta-subunit remains constant throughout the course of the response. Using both polyclonal antibodies to the holoenzyme and monoclonal antibodies to the alpha/alpha' subunits, we detected a cross-reactive 68-kDa protein, which we refer to as lambda. This protein is present in high abundance in resting T cells but decreases upon cell stimulation, as both MAT activity and the amount of the catalytic alpha/alpha' subunits increase. The decrease in lambda and increase in alpha/alpha' occurs after interleukin-2 production and before DNA synthesis. Lambda virtually disappears when the cells are actively dividing. Several continuous T cell lines (HPB-ALL, MOLT-4, and Jurkat) as well as a freshly isolated T cell leukemia (ALL-2) had no detectable lambda. The K(m) for L-methionine for enzyme from resting peripheral blood mononuclear cells was 19-23-mu-M, which is 3-8-fold higher than purified MAT from fresh leukemic cells or enzyme from Jurkat cells, both of which have a K(m) of 3.5-3.8-mu-M. Kinetic analysis of enzyme activity from activated peripheral blood mononuclear cells suggested the presence of two forms of enzyme catalyzing the synthesis of AdoMet. After separation of lambda from the alpha and beta-subunits by hydrophobic chromatography, it was determined that lambda has MAT activity but that it is significantly less active than the form containing the alpha-subunit. It therefore appears that in resting T cells MAT is sequestered as a less active form. We hypothesize that lambda is a precursor to the catalytic subunits of human lymphocyte MAT and propose that the transition from lambda to alpha/alpha' may be important in the response of T cells to mitogenic signals.	VET ADM MED CTR,RES SERV,1030 JEFFERSON AVE,MEMPHIS,TN 38104; UNIV TENNESSEE CTR HLTH SCI,DEPT SURG,MEMPHIS,TN 38163; UNIV TENNESSEE CTR HLTH SCI,DEPT MICROBIOL & IMMUNOL,MEMPHIS,TN 38163; UNIV TENNESSEE CTR HLTH SCI,DEPT BIOCHEM,MEMPHIS,TN 38163	US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center								CARBONE AM, 1988, SCIENCE, V242, P1174, DOI 10.1126/science.2460926; CHOW O, 1972, BIOCHIM BIOPHYS ACTA, V276, P399; DELAROSA J, 1991, BIOCHIM BIOPHYS ACTA, V1077, P225, DOI 10.1016/0167-4838(91)90062-5; DOUCET JP, 1988, ANAL BIOCHEM, V168, P265, DOI 10.1016/0003-2697(88)90317-X; GERMAN DC, 1983, J BIOL CHEM, V258, P997; GILLIS S, 1978, J IMMUNOL, V120, P2027; HOFFMAN JL, 1983, METHOD ENZYMOL, V94, P223; KOTB M, 1990, J IMMUNOL, V145, P1332; KOTB M, 1985, J BIOL CHEM, V260, P3923; KOTB M, 1990, BIOCHIM BIOPHYS ACTA, V1039, P253, DOI 10.1016/0167-4838(90)90193-J; KOTB M, 1990, BIOCHIM BIOPHYS ACTA, V1040, P137, DOI 10.1016/0167-4838(90)90068-Q; KOTB M, 1987, J IMMUNOL, V139, P202; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAU MC, 1979, CANCER RES, V39, P2113; MUDD SH, 1975, METABOLISM, V24, P721, DOI 10.1016/0026-0495(75)90040-2; ODEN KL, 1983, BIOCHIM BIOPHYS ACTA, V760, P270, DOI 10.1016/0304-4165(83)90173-3; SAKAMOTO S, 1989, J BIOL CHEM, V264, P251; Segel I.H., 1975, ENZYME KINETICS; SEYFERT VL, 1990, SCIENCE, V250, P797, DOI 10.1126/science.2237429; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TABOR CW, 1976, ANNU REV BIOCHEM, V45, P285, DOI 10.1146/annurev.bi.45.070176.001441; TSUKADA K, 1980, BIOCHEM BIOPH RES CO, V94, P1078, DOI 10.1016/0006-291X(80)90529-X	22	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10699	10704						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587846				2022-12-25	WOS:A1992HV09000074
J	ISHIGURO, K; TAKAMATSU, M; TOMIZAWA, K; OMORI, A; TAKAHASHI, M; ARIOKA, M; UCHIDA, T; IMAHORI, K				ISHIGURO, K; TAKAMATSU, M; TOMIZAWA, K; OMORI, A; TAKAHASHI, M; ARIOKA, M; UCHIDA, T; IMAHORI, K			TAU PROTEIN KINASE-I CONVERTS NORMAL TAU PROTEIN INTO A68-LIKE COMPONENT OF PAIRED HELICAL FILAMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMER-DISEASE; DEPENDENT KINASE; SENSITIVE METHOD; PHOSPHORYLATION; IDENTIFICATION; BRAIN; NEUROFILAMENTS; TANGLES; BINDING; CORE	From bovine brain microtubules we purified tau protein kinase I (TPKI, M(r) 45,000 on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)) and tau protein kinase II (TPKII) whose activity was attributed to a 30-kDa protein on SDS-PAGE by affinity-labeling using an ATP analog. Both kinases were activated by tubulin. TPKII, but not TPKI, phosphorylated tau fragment peptides previously used for detection of a Ser/ThrPro kinase activity. Therefore, TPKII was considered to be the Ser/ThrPro kinase. TPKI was more effective than TPKII for producing the decrease of tau-1 immunoreactivity and mobility shift of tau on SDS-PAGE. Moreover, TPKI, but not TPKII nor other well-known protein kinases, generated an epitope present on paired helical filaments. These findings suggested that tau phosphorylated by TPKI resembled A-68, a component of paired helical filaments.			ISHIGURO, K (corresponding author), MITSUBISHI KASEI INST LIFE SCI,11 MINAMIOOYA,MACHIDA,TOKYO 194,JAPAN.							BAUDIER J, 1987, J BIOL CHEM, V262, P17577; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLEMAN MP, 1990, J NEUROCHEM, V54, P1548, DOI 10.1111/j.1471-4159.1990.tb01203.x; COLES LS, 1987, J BIOL CHEM, V262, P9656; FLAMENT S, 1989, J NEUROL SCI, V92, P133, DOI 10.1016/0022-510X(89)90131-7; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; IHARA Y, 1986, J BIOCHEM-TOKYO, V99, P1807, DOI 10.1093/oxfordjournals.jbchem.a135662; IHARA Y, 1988, BRAIN RES, V459, P138, DOI 10.1016/0006-8993(88)90293-4; IHARA Y, 1979, J BIOCHEM, V86, P587, DOI 10.1093/oxfordjournals.jbchem.a132560; IIMOTO DS, 1989, BRAIN RES, V507, P273; IQBAL K, 1989, P NATL ACAD SCI USA, V86, P5646, DOI 10.1073/pnas.86.14.5646; ISHIGURO K, 1991, NEUROSCI LETT, V128, P195, DOI 10.1016/0304-3940(91)90259-V; ISHIGURO K, 1988, J BIOCHEM-TOKYO, V104, P319, DOI 10.1093/oxfordjournals.jbchem.a122465; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KONDO J, 1988, NEURON, V1, P827, DOI 10.1016/0896-6273(88)90130-4; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P1998, DOI 10.1073/pnas.85.6.1998; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; TAKAHASHI M, 1991, FEBS LETT, V289, P37, DOI 10.1016/0014-5793(91)80903-G; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; WOODFORD TA, 1986, J BIOL CHEM, V261, P4669; YAMAMOTO H, 1983, J NEUROCHEM, V41, P1119, DOI 10.1111/j.1471-4159.1983.tb09060.x	27	249	271	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10897	10901						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587865				2022-12-25	WOS:A1992HV09000102
J	LEE, YC; ASA, SL; DRUCKER, DJ				LEE, YC; ASA, SL; DRUCKER, DJ			GLUCAGON GENE 5'-FLANKING SEQUENCES DIRECT EXPRESSION OF SIMIAN VIRUS-40 LARGE T-ANTIGEN TO THE INTESTINE, PRODUCING CARCINOMA OF THE LARGE-BOWEL IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREPROGLUCAGON CONTAINS; PRE-PROGLUCAGON; PANCREAS; PEPTIDES; BRAIN; ACID; RNA	Glucagon and the glucagon-like peptides play important roles in the regulation of glucose homeostasis. Previous studies have demonstrated that approximately 1300 base pairs of rat glucagon gene 5'-flanking sequences direct transgene expression to the pancreas and brain, but not to the intestine, of transgenic mice. These observations suggested that different tissue-specific enhancer elements mediate activation of glucagon gene transcription in the pancreas and intestine. We have now generated mice that express SV40 large T antigen under the control of approximately 2000 base pairs of glucagon gene 5'-flanking sequences. Transgene expression was observed in the brain and pancreas in association with the development of pancreatic endocrine tumors. In contrast to the mice described previously, we also detected transgene expression throughout the gastrointestinal tract in endocrine cells of the stomach and small and large intestine. Focal areas of enteroendocrine cell hyperplasia in the large bowel invariably progressed to invasive and metastasizing plurihormonal endocrine carcinoma, which was clinically and pathologically evident by 4 weeks of age. In contrast, transgene expression in the small bowel and stomach was not associated with progression to either hyperplasia or carcinoma. The results of these studies provide functional evidence for the existence of an upstream cis-acting regulatory domain that directs glucagon gene transcription to the endocrine cells of the intestine in transgenic mice.	UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO M5G 2C4,ONTARIO,CANADA; UNIV TORONTO,DEPT GENET,TORONTO M5G 2C4,ONTARIO,CANADA; UNIV TORONTO,DEPT PATHOL,TORONTO M5G 2C4,ONTARIO,CANADA; UNIV TORONTO,BANTING & BEST DIABET CTR,TORONTO M5G 2C4,ONTARIO,CANADA	University of Toronto; University of Toronto; University of Toronto; University of Toronto	LEE, YC (corresponding author), UNIV TORONTO,DEPT MED,TORONTO M5G 2C4,ONTARIO,CANADA.		Drucker, Daniel J/A-4092-2010	Asa, Sylvia/0000-0001-8418-5054				ASA SL, 1987, ACTA ENDOCRINOL-COP, V115, P331, DOI 10.1530/acta.0.1150331; BELL GI, 1983, NATURE, V302, P716, DOI 10.1038/302716a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DONG J, 1991, IN PRESS MOL ENDOCRI, V5; DRUCKER DJ, 1989, P NATL ACAD SCI USA, V86, P3953, DOI 10.1073/pnas.86.11.3953; DRUCKER DJ, 1987, J BIOL CHEM, V262, P15659; DRUCKER DJ, 1988, J BIOL CHEM, V263, P13475; EFRAT S, 1988, NEURON, V1, P605, DOI 10.1016/0896-6273(88)90110-9; HAN VKM, 1986, J NEUROSCI RES, V16, P97, DOI 10.1002/jnr.490160110; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HEINRICH G, 1984, J BIOL CHEM, V259, P4082; HEINRICH G, 1984, ENDOCRINOLOGY, V115, P2176, DOI 10.1210/endo-115-6-2176; HOGAN B, 1986, MANIPULATING MOUSE E, P1633; LEE YC, 1990, ENDOCRINOLOGY, V127, P2217, DOI 10.1210/endo-127-5-2217; LOPEZ LC, 1983, P NATL ACAD SCI-BIOL, V80, P5485, DOI 10.1073/pnas.80.18.5485; MOJSOV S, 1986, J BIOL CHEM, V261, P1880; NOVAK U, 1987, EUR J BIOCHEM, V164, P553, DOI 10.1111/j.1432-1033.1987.tb11162.x; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; SEINO S, 1986, FEBS LETT, V203, P25, DOI 10.1016/0014-5793(86)81429-6; UNGER RH, 1985, DIABETOLOGIA, V28, P574, DOI 10.1007/BF00281991	20	113	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10705	10708						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587847				2022-12-25	WOS:A1992HV09000075
J	SWERTS, JP; SOULA, C; SAGOT, Y; GUINAUDY, MJ; GUILLEMOT, JC; FERRARA, P; DUPRAT, AM; COCHARD, P				SWERTS, JP; SOULA, C; SAGOT, Y; GUINAUDY, MJ; GUILLEMOT, JC; FERRARA, P; DUPRAT, AM; COCHARD, P			HEMOPEXIN IS SYNTHESIZED IN PERIPHERAL-NERVES BUT NOT IN CENTRAL-NERVOUS-SYSTEM AND ACCUMULATES AFTER AXOTOMY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; RAT HEPATOCYTES; GENE-EXPRESSION; REGENERATION; HEME; GROWTH; CELLS; DIFFERENTIATION; MATURATION; RECEPTOR	In adult mammals, injured axons regrow over long distances in peripheral nerves but fail to do so in the central nervous system. Analysis of molecular components of tissue environments that allow axonal regrowth revealed a dramatic increase in the level of hemopexin, a heme-transporting protein, in long-term axotomized peripheral nerve. In contrast, hemopexin did not accumulate in lesioned optic nerve. Sciatic nerve and skeletal muscle, but not brain, were shown to be sites of synthesis of hemopexin. Thus, hemopexin expression, which can no longer be considered to be liver-specific, correlates with tissular permissivity for axonal regeneration.	SANOFI ELF BIORECH, UNITE BIOCHIM PROT, F-31328 LABEGE, FRANCE	Sanofi-Aventis	SWERTS, JP (corresponding author), UNIV TOULOUSE 3, INSERM,CNRS,URA 675,CTR BIOL DEV, 118 ROUTE NARBONNE, F-31062 TOULOUSE, FRANCE.			SOULA, Cathy/0000-0002-9027-9994				Aguayo A., 1979, ADV CELL NEUROBIOL, V3, P215; Aguayo A.J., 1985, SYNAPTIC PLASTICITY, P457; ALAM J, 1989, J BIOL CHEM, V264, P17637; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BERNARD N, 1983, BIOCHIMIE, V65, P185, DOI 10.1016/S0300-9084(83)80083-2; BERNARD N, 1980, EUR J BIOCHEM, V103, P271, DOI 10.1111/j.1432-1033.1980.tb04311.x; BONYHADY RE, 1982, DEV NEUROSCI-BASEL, V5, P125, DOI 10.1159/000112669; BOSCH EP, 1989, J NEUROSCI, V9, P3690; BUNGE RP, 1988, PROG BRAIN RES, V78, P321; CARBONETTO S, 1988, CURRENT ISSUES NEURA, P147; FAWCETT J W, 1991, Current Biology, V1, P55, DOI 10.1016/0960-9822(91)90129-K; FAWCETT JW, 1990, ANNU REV NEUROSCI, V13, P43, DOI 10.1146/annurev.neuro.13.1.43; FUNANAGE VL, 1989, J CELL PHYSIOL, V141, P591, DOI 10.1002/jcp.1041410318; GOLDFARB V, 1986, BIOCHEMISTRY-US, V25, P6555, DOI 10.1021/bi00369a033; GRIENINGER G, 1986, J BIOL CHEM, V261, P5719; GUILLOUZO A, 1984, BIOCHEM BIOPH RES CO, V120, P311, DOI 10.1016/0006-291X(84)91255-5; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; HEUMANN R, 1987, J CELL BIOL, V104, P1623, DOI 10.1083/jcb.104.6.1623; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; ISHII DN, 1978, NATURE, V274, P372, DOI 10.1038/274372a0; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; KATZ NR, 1985, EUR J BIOCHEM, V146, P155, DOI 10.1111/j.1432-1033.1985.tb08632.x; Lander AD, 1990, CURR OPIN CELL BIOL, V2, P907, DOI 10.1016/0955-0674(90)90091-R; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; LIN JJ, 1991, P NATL ACAD SCI USA, V88, P6068, DOI 10.1073/pnas.88.14.6068; LONDON IM, 1987, ENZYMES, V18, P359; LOWRY CV, 1988, MOL CELL BIOL, V8, P4651, DOI 10.1128/MCB.8.11.4651; LUTTON JD, 1991, P SOC EXP BIOL MED, V196, P260; MEIER R, 1989, NATURE, V342, P548, DOI 10.1038/342548a0; MULLER HW, 1985, SCIENCE, V228, P499, DOI 10.1126/science.3983637; MULLEREBERHARD U, 1988, METHOD ENZYMOL, V163, P536; NIKKILA H, 1991, BIOCHEMISTRY-US, V30, P823, DOI 10.1021/bi00217a036; PADMANABAN G, 1989, TRENDS BIOCHEM SCI, V14, P492, DOI 10.1016/0968-0004(89)90182-5; PATTERSON PH, 1988, NEURON, V1, P263, DOI 10.1016/0896-6273(88)90074-8; RANGARAJAN PN, 1989, P NATL ACAD SCI USA, V86, P3963, DOI 10.1073/pnas.86.11.3963; REICHARDT LF, 1988, CURRENT ISSUES NEURA, P119; SANES JR, 1989, ANNU REV NEUROSCI, V12, P491, DOI 10.1146/annurev.ne.12.030189.002423; SASSA S, 1988, SEMIN HEMATOL, V25, P312; SCHWAB ME, 1990, TRENDS NEUROSCI, V13, P452, DOI 10.1016/0166-2236(90)90098-U; SMITH GM, 1988, PROG BRAIN RES, V78, P353; SPREYER P, 1990, EMBO J, V9, P2479, DOI 10.1002/j.1460-2075.1990.tb07426.x; TAKETANI S, 1990, J BIOL CHEM, V265, P13981; TESSIERLAVIGNE M, 1991, TRENDS NEUROSCI, V14, P303, DOI 10.1016/0166-2236(91)90142-H; TRUEBLOOD CE, 1988, MOL CELL BIOL, V8, P4537, DOI 10.1128/MCB.8.10.4537; WALDMAN SA, 1984, J BIOL CHEM, V259, P4038; WELLNER D, 1988, BIOCHEM BIOPH RES CO, V155, P622, DOI 10.1016/S0006-291X(88)80540-0	46	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10596	10600						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587840				2022-12-25	WOS:A1992HV09000058
J	AGOSTINIS, P; VANLINT, J; SARNO, S; DEWITTE, P; VANDENHEEDE, JR; MERLEVEDE, W				AGOSTINIS, P; VANLINT, J; SARNO, S; DEWITTE, P; VANDENHEEDE, JR; MERLEVEDE, W			RAPID STIMULATION OF SER THR PROTEIN-KINASES FOLLOWING TREATMENT OF SWISS 3T3 CELLS WITH BOMBESIN - INVOLVEMENT OF CASEIN KINASE-2 IN THE SIGNALING PATHWAY OF BOMBESIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; GLYCOGEN-SYNTHASE KINASE-3; II ACTIVITY; SYNTHETIC PEPTIDES; TYROSINE KINASES; SKELETAL-MUSCLE; PHOSPHORYLATION; IDENTIFICATION; INSULIN; PURIFICATION	Treatment of quiescent Swiss 3T3 mouse fibroblasts with bombesin resulted in a rapid 6-8-fold stimulation of cytosolic Ser/Thr kinase activities toward the S6 Peptide (RRLSSLR), myelin basic protein (MBP), and the G peptide (SPQPSRRGSESSEE). Anion exchange Mono Q chromatography resolved multiple S6 peptide- and G peptide kinase activities and two MBP kinase peaks. Both MBP- and several S6 Peptide kinase peaks could be inactivated by PCS(L) (PP2A2) phosphatase action. This indicates that the bombesin-induced activation of these enzymes is mediated by a Ser/Thr phosPhorylation event. The S6 peptide kinases as well as the two MBP kinases stimulated in response to bombesin are similar to those activated by epidermal growth factor in Swiss 3T3 fibroblasts which suggests that the early events of the signal transduction pathway mediated by these growth factors in Swiss 3T3 cells may converge in the activation of common Ser/Thr kinases. Bombesin, which acts as a sole mitogen for Swiss 3T3 fibroblasts, also Produced a several-fold increase in the kinase activity toward the RRREEESEEE peptide, a specific substrate for CK-2. This kinase activity was heparin-sensitive and also measurable with the G peptide (SPQPSRRGSESSEE) and GS-1 peptide (YRRAAVPPSPSPSLSRHSSPHQSEDEE), which contain consensus sequences for phosphorylation by CK-2. The bombesin-stimulated CK-2 activity could not be measured in whole cytosols but was revealed by the anion exchange chromatography step. The activation of CK-2 was not reversed by PCSL phosphatase action. The implication of CK-2 in the signal transduction pathway of bombesin is discussed.	CATHOLIC UNIV LEUVEN,FAC GENEESKUNDE,AFDELING BIOCHEM,CAMPUS GASTHUISBERG,B-3000 LOUVAIN,BELGIUM; CATHOLIC UNIV LEUVEN,DEPT FARMACEUT WETENSCHAPPEN,B-3000 LOUVAIN,BELGIUM	KU Leuven; KU Leuven			Agostinis, Patrizia/ABI-1177-2020; Van Lint, Johan/P-9073-2019; Agostinis, Patrizia/AAO-2468-2020	Agostinis, Patrizia/0000-0003-1314-2115; 				ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; AHN NG, 1990, J BIOL CHEM, V265, P11495; BASERGA R, 1989, CELL GROWTH DIVISION; BATTEY YF, 1990, P NATL ACAD SCI USA, V88, P395; BRUNATI AM, 1986, FEBS LETT, V206, P59, DOI 10.1016/0014-5793(86)81340-0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHESSA G, 1983, EUR J BIOCHEM, V135, P609, DOI 10.1111/j.1432-1033.1983.tb07695.x; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; DENT P, 1989, FEBS LETT, V248, P67, DOI 10.1016/0014-5793(89)80433-8; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; FIOL CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P797, DOI 10.1016/0003-9861(88)90089-6; GAUTHIERROUVIERE C, 1991, EMBO J, V10, P2921, DOI 10.1002/j.1460-2075.1991.tb07842.x; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; HACCARD O, 1990, EUR J BIOCHEM, V192, P633, DOI 10.1111/j.1432-1033.1990.tb19270.x; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HONKANEN RE, 1990, J BIOL CHEM, V265, P19401; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRIEG J, 1988, J BIOL CHEM, V263, P11473; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MUNRO J, 1990, BIOCHIM BIOPHYS ACTA, V1054, P225, DOI 10.1016/0167-4889(90)90245-9; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; PELECH SL, 1987, BIOCHEMISTRY-US, V26, P7960, DOI 10.1021/bi00398a062; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; PEREZ M, 1987, EUR J BIOCHEM, V170, P493, DOI 10.1111/j.1432-1033.1987.tb13726.x; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1990, PHILOS T ROY SOC B, V327, P209, DOI 10.1098/rstb.1990.0055; SCHNEIDER HR, 1986, EUR J BIOCHEM, V161, P733, DOI 10.1111/j.1432-1033.1986.tb10501.x; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SEITZ G, 1989, BIOCHEM BIOPH RES CO, V163, P635, DOI 10.1016/0006-291X(89)92184-0; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SOMMERCORN J, 1987, J BIOL CHEM, V262, P3839; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TAKUWA N, 1991, J BIOL CHEM, V266, P14237; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WAELKENS E, 1987, J BIOL CHEM, V262, P1049; WILLEY JC, 1984, EXP CELL RES, V153, P245, DOI 10.1016/0014-4827(84)90466-X; WOODGETT JR, 1989, ANAL BIOCHEM, V180, P237, DOI 10.1016/0003-2697(89)90423-5; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YU IJ, 1991, J CELL BIOL, V114, P1217, DOI 10.1083/jcb.114.6.1217; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577	52	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9732	9737						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577810				2022-12-25	WOS:A1992HT96500046
J	ELSNER, RH; ZIEGLER, K				ELSNER, RH; ZIEGLER, K			RADIATION INACTIVATION OF MULTISPECIFIC TRANSPORT-SYSTEMS FOR BILE-ACIDS AND XENOBIOTICS IN BASOLATERAL RAT-LIVER PLASMA-MEMBRANE VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED HEPATOCYTES; CHOLIC-ACID; COMPETITIVE-INHIBITION; TAUROCHOLATE UPTAKE; NAK-ATPASE; BINDING; PHALLOIDIN; CHOLATE; PROTEINS; COTRANSPORTER	The functional molecular mass of the cholate, phallotoxin, iodipamide, and ouabain transport proteins in isolated basolateral plasma membrane vesicles was determined by radiation inactivation. Purified basolateral plasma membrane vesicles were irradiated (- 90 to - 120-degrees-C) with high energy electrons from a 10-MeV linear accelerator at doses from 0 to 30 megarads. After each dose, the initial uptake, the equilibrium binding, and the binding of the substrates at 4-degrees-C were checked. The size of the transporting function was, for cholate, 107 +/- 8.9 kDa; for phallotoxin, 104 +/- 7 kDa; and for ouabain, 120 +/- 4.7 kDa. The target size for the binding proteins was 56 +/- 4.2, 57 +/- 5, and 47.2 +/- 1.95 kDa for cholate, phallotoxin, and taurocholate, respectively. In the case of iodipamide, the functional molecular mass for both the transport and binding proteins was 54 +/- 4.8 kDa.	UNIV GIESSEN,INST PHARMACOL & TOXIKOL,FRANKFURTER STR 107,W-6300 GIESSEN,GERMANY	Justus Liebig University Giessen								AMES BN, 1960, J BIOL CHEM, V235, P769; ANANTHANARAYANAN M, 1988, J BIOL CHEM, V263, P8338; ANWER MS, 1977, H-S Z PHYSIOL CHEM, V358, P543, DOI 10.1515/bchm2.1977.358.1.543; ANWER MS, 1976, H-S Z PHYSIOL CHEM, V357, P1477, DOI 10.1515/bchm2.1976.357.2.1477; BELIVEAU R, 1988, BIOCHEM J, V252, P807, DOI 10.1042/bj2520807; BLITZER BL, 1985, AM J PHYSIOL, V249, pG120, DOI 10.1152/ajpgi.1985.249.1.G120; BLITZER BL, 1986, J BIOL CHEM, V261, P2042; BLITZER BL, 1984, J BIOL CHEM, V259, P9295; CAFLISCH C, 1990, BIOCHIM BIOPHYS ACTA, V1021, P70, DOI 10.1016/0005-2736(90)90386-3; DUFFY MC, 1983, J CLIN INVEST, V72, P1470, DOI 10.1172/JCI111103; ELSNER R, 1989, BIOCHIM BIOPHYS ACTA, V983, P113, DOI 10.1016/0005-2736(89)90387-8; ELSNER RH, 1989, N-S ARCH PHARMACOL, V340, pR69; Fricke H, 1927, AM J ROENTGENOL RADI, V18, P426; FRIMMER M, 1980, N-S ARCH PHARMACOL, V313, P85, DOI 10.1007/BF00505808; FRIMMER M, 1988, BIOCHIM BIOPHYS ACTA, V947, P75, DOI 10.1016/0304-4157(88)90020-2; HAGENBUCH B, 1990, J BIOL CHEM, V265, P5357; HARPER AE, 1962, METHODEN ENZYMATISCH, P788; INOUE M, 1982, HEPATOLOGY, V2, P572; JUNG CY, 1984, MOL CHEM CHARACTERIZ, P193; KEEFFE EB, 1979, J CLIN INVEST, V64, P1590, DOI 10.1172/JCI109620; KEMPNER ES, 1982, J BIOL CHEM, V257, P13297; KEPNER GR, 1968, BIOCHIM BIOPHYS ACTA, V163, P188, DOI 10.1016/0005-2736(68)90097-7; KRAMER W, 1982, EUR J BIOCHEM, V129, P13, DOI 10.1111/j.1432-1033.1982.tb07015.x; LUTZ F, 1972, N-S ARCH PHARMACOL, V273, P341, DOI 10.1007/BF00499668; MICHELL RH, 1965, BIOCHEM BIOPH RES CO, V21, P333, DOI 10.1016/0006-291X(65)90198-1; PETZINGER E, 1983, N-S ARCH PHARMACOL, V322, P174, DOI 10.1007/BF00512393; PETZINGER E, 1981, N-S ARCH PHARMACOL, V316, P345, DOI 10.1007/BF00501368; PETZINGER E, 1985, BIOCHIM BIOPHYS ACTA, V815, P334, DOI 10.1016/0005-2736(85)90359-1; PETZINGER E, 1986, CARDIAC GLYCOSIDES 1, P297; SCHARSCHMIDT BF, 1979, J LAB CLIN MED, V93, P790; SCHWENK M, 1981, N-S ARCH PHARMACOL, V316, P340, DOI 10.1007/BF00501367; STEVENS BR, 1990, P NATL ACAD SCI USA, V87, P1456, DOI 10.1073/pnas.87.4.1456; TAFLER M, 1986, BIOCHIM BIOPHYS ACTA, V855, P157, DOI 10.1016/0005-2736(86)90200-2; TAFLER M, 1988, N-S ARCH PHARMACOL, V337, P231; VONDIPPE P, 1983, J BIOL CHEM, V258, P8896; WIELAND T, 1984, P NATL ACAD SCI-BIOL, V81, P5232, DOI 10.1073/pnas.81.16.5232; ZIEGLER K, 1982, N-S ARCH PHARMACOL, V319, P254, DOI 10.1007/BF00495875; ZIEGLER K, 1984, BIOCHIM BIOPHYS ACTA, V773, P11, DOI 10.1016/0005-2736(84)90545-5; ZIEGLER K, 1988, BIOCHIM BIOPHYS ACTA, V945, P263, DOI 10.1016/0005-2736(88)90488-9; ZIEGLER K, 1989, BIOCHIM BIOPHYS ACTA, V980, P161, DOI 10.1016/0005-2736(89)90395-7; ZIEGLER K, 1985, BIOCHIM BIOPHYS ACTA, V845, P86, DOI 10.1016/0167-4889(85)90058-8; ZIMMERLI B, 1989, J PHARMACOL EXP THER, V250, P301	42	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9788	9793						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577813				2022-12-25	WOS:A1992HT96500055
J	QUEST, AFG; BLOOMENTHAL, J; BARDES, ESG; BELL, RM				QUEST, AFG; BLOOMENTHAL, J; BARDES, ESG; BELL, RM			THE REGULATORY DOMAIN OF PROTEIN-KINASE-C COORDINATES 4 ATOMS OF ZINC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER RECEPTOR; DILUTE-SOLUTION; ACTIVATION; PHOSPHATIDYLSERINE; PHOSPHOLIPIDS; BINDING; FAMILY	Protein kinase C (PKC) was found to be a zine metallo-enzyme. Atomic absorption measurements on the intact enzyme indicated that four zine atoms (4.2 +/- 0.5) were bound per PKC-alpha-molecule. Similar stoichiometric ratios were determined for PKC beta-II and PKC-gamma, other PKC isoforms individually expressed in the baculovirus-insect cell expression system, as well as for purified rat brain PKC. By trypsin treatment of PKC-alpha, a 32-kDa lipid binding regulatory and a 50-kDa catalytic domain were generated that were subsequently completely separated by gel filtration in the presence of Triton X-100/phosphatidylserine mixed micelles. Zinc was present at levels significantly above background in fractions that contained the 32-kDa fragment and displayed phorbol ester binding activity. Lipid association and phorbol ester binding did not lead to displacement of zinc from the protein. The stoichiometry determined for this fragment (4.7 +/- 0.9) suggested that zinc was bound exclusively within the lipid binding regulatory domain of intact PKC. Furthermore, this stoichiometry is consistent with zinc being coordinated between 6 cysteine residues in a structural motif related to the Zn(II)2Cys6 binuclear cluster identified in the GAL4 transcriptional factor (Pan, T., and Coleman, J. E. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 2077-2081).	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University					NIGMS NIH HHS [GM 38737] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038737] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; BELL RM, 1991, J BIOL CHEM, V266, P4661; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; EBELING JG, 1985, P NATL ACAD SCI USA, V82, P815, DOI 10.1073/pnas.82.3.815; FALCHUK KH, 1988, METHOD ENZYMOL, V158, P422, DOI 10.1016/0076-6879(88)58073-4; GESCHWENDT M, 1991, TRENDS BIOCHEM SCI, V16, P167; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MH, 1986, J BIOL CHEM, V261, P4867; MAKOWSKE M, 1989, J BIOL CHEM, V264, P16155; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; OSADA S, 1990, J BIOL CHEM, V265, P22434; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALLEE BL, 1991, P NATL ACAD SCI USA, V88, P999, DOI 10.1073/pnas.88.3.999; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	30	121	123	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10193	10197						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577787				2022-12-25	WOS:A1992HT96500111
J	VANDERREST, ME; SIEWE, RM; ABEE, T; SCHWARZ, E; OESTERHELT, D; KONINGS, WN				VANDERREST, ME; SIEWE, RM; ABEE, T; SCHWARZ, E; OESTERHELT, D; KONINGS, WN			NUCLEOTIDE-SEQUENCE AND FUNCTIONAL-PROPERTIES OF A SODIUM-DEPENDENT CITRATE TRANSPORT-SYSTEM FROM KLEBSIELLA-PNEUMONIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DNA-SEQUENCE; MEMBRANE; CLONING; GENE; EXPRESSION; BACTERIA	The gene of the sodium-dependent citrate transport system from Klebsiella pneumoniae (citS) is located on plasmid pES3 (Schwarz, E., and Oesterhelt, D. (1985) EMBO J. 4, 1599-1603) and encodes a 446-amino acid protein. Transport of citrate via this citrate transport protein (CitS) is dependent on the presence of sodium ions and is inhibited by magnesium ions. The DELTA-pH (pH gradient across the membrane) is the major driving force for uptake. It is postulated that, in analogy with the proton-dependent citrate carrier (CitH) of K. pneumoniae (van der Rest, M. E., Abee, T., Molenaar, D., and Konings, W. N. (1990) Eur. J. Biochem. 195, 71-77), only one of the protonated species of citrate is recognized by CitS and that citrate is translocated across the membrane in symport with protons and sodium ions. The hydrophobicity profile of CitS suggests that the protein is very hydrophobic and contains 12 membrane-spanning segments. These segments are not centered around a hydrophilic core as has been suggested for other transport proteins, but the protein is asymmetrical with seven transmembrane segments in front of a large hydrophilic loop and five after this loop. The amino acid sequence is highly similar to a citrate transport system of Lactococcus lactis subsp. lactis var. diacetylactis (CitP) (David, S., van der Rest, M. E., Driessen, A. J. M., Simons, G., and de Vos, W. M. (1990) J. Bacteriol. 172, 5789-5794) and less similar to CitH of K. pneumoniae. We conclude that the citS gene of K. pneumoniae encodes a sodium-dependent citrate transport system that belongs to a novel subclass of transport proteins.	UNIV GRONINGEN, CTR BIOL, MICROBIOL LAB, KERKLAAN 30, 9751 NN HAREN, NETHERLANDS; MAX PLANCK INST BIOCHEM, W-8033 MARTINSRIED, GERMANY	University of Groningen; Max Planck Society			Konings, Wilhelmus N./C-7063-2013					BALDWIN SA, 1989, ANNU REV PHYSIOL, V51, P459, DOI 10.1146/annurev.physiol.51.1.459; BERGSMA J, 1983, EUR J BIOCHEM, V134, P151, DOI 10.1111/j.1432-1033.1983.tb07545.x; DAIMON H, 1989, J BACTERIOL, V171, P620, DOI 10.1128/jb.171.1.620-623.1989; DAVID S, 1990, J BACTERIOL, V172, P5789, DOI 10.1128/jb.172.10.5789-5794.1990; DIMROTH P, 1990, J BIOL CHEM, V265, P7221; DIMROTH P, 1987, MICROBIOL REV, V51, P320, DOI 10.1128/MMBR.51.3.320-340.1987; DIMROTH P, 1986, BIOL CHEM HOPPESEYLE, V376, P813; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HIRATO T, 1986, J BACTERIOL, V165, P324, DOI 10.1128/jb.165.1.324-327.1986; INOUYE M, 1983, EXPT MANIPULATION GE; ISHIGURO N, 1985, J BACTERIOL, V164, P977, DOI 10.1128/JB.164.3.977-982.1985; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; Koser SA, 1924, J BACTERIOL, V9, P59, DOI 10.1128/JB.9.1.59-77.1924; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LARA FJS, 1952, J BACTERIOL, V63, P415, DOI 10.1128/JB.63.3.415-420.1952; LAUSSERMAIR E, 1989, J BIOL CHEM, V264, P14710; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; Maniatis T., 1982, MOL CLONING; Martin WJ, 1980, MANUAL CLIN MICROBIO, P195; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASATSU M, 1985, J BACTERIOL, V164, P983, DOI 10.1128/JB.164.3.983-993.1985; SATO G, 1978, MICROBIOL IMMUNOL, V22, P357, DOI 10.1111/j.1348-0421.1978.tb00380.x; SCHWARZ E, 1985, EMBO J, V4, P1599, DOI 10.1002/j.1460-2075.1985.tb03823.x; SCHWARZ E, 1986, THESIS LUDWIGMAXIMIL; SHIMAMOTO T, 1991, J BIOCHEM-TOKYO, V110, P22, DOI 10.1093/oxfordjournals.jbchem.a123537; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SMITH LM, 1987, METHOD ENZYMOL, V155, P260; VANDERREST ME, 1991, EUR J BIOCHEM, V195, P71; VANDERREST ME, 1990, EUR J BIOCHEM, V189, P401; VANSCHIE BJ, 1985, J BACTERIOL, V163, P493, DOI 10.1128/JB.163.2.493-499.1985; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	34	63	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8971	8976						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577734				2022-12-25	WOS:A1992HR85400043
J	WANG, ZY; LIN, XH; NOBYUOSHI, M; QIU, QQ; DEUEL, TF				WANG, ZY; LIN, XH; NOBYUOSHI, M; QIU, QQ; DEUEL, TF			BINDING OF SINGLE-STRANDED OLIGONUCLEOTIDES TO A NON-B-FORM DNA-STRUCTURE RESULTS IN LOSS OF PROMOTOR ACTIVITY OF THE PLATELET-DERIVED GROWTH FACTOR-A-CHAIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE-HELIX FORMATION; NUCLEASE; TRANSCRIPTION; SITE; CHROMATIN; REGIONS; CELLS; CONFORMATION; CLEAVAGE; CHICKEN	Levels of expression of the platelet-derived growth factor (PDGF) A-chain gene differ significantly in normal and transformed cells. We have identified an S1 nuclease-sensitive site in a GC box located at -55 to -72 in the PDGF A-chain promoter region. We now demonstrate that a 24-base, G-rich complementary oligonucleotide anneals specifically to the C-rich strand of the GC box and protects the GC box from nicking by S1 nuclease whereas the C-rich complementary oligonucleotide and its double-stranded counterpart do not. In transient transfection assays, expression of the PDGF A-chain gene is sharply reduced by deletions within the GC box or if the 24-base G-rich complementary oligonucleotide is preincubated with the promoter construct prior to transfection. The data suggest that the GC box of the PDGF A-chain gene may promote a non-B-form DNA structure, which is recognized by S1 nuclease and which anneals to a short complementary G-rich oligonucleotide. The data also suggest that this non-B-form DNA is important for efficient transcription of PDGF A-chain gene.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,DEPT BIOCHEM MOLEC BIOPHYS,216 S KINGSHIGHWAY,ST LOUIS,MO 63110; WASHINGTON UNIV,MED CTR,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031102, P50HL014147, R37HL031102] Funding Source: NIH RePORTER; NCI NIH HHS [CA49712] Funding Source: Medline; NHLBI NIH HHS [HL14147, HL31102] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEATTIE KL, 1977, J MOL BIOL, V116, P783, DOI 10.1016/0022-2836(77)90271-6; CHRISTY BA, 1988, P NATL ACAD SCI USA, V86, P8737; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; DYAN WS, 1985, NATURE, V316, P774; ELGIN SCR, 1981, CELL, V27, P413, DOI 10.1016/0092-8674(81)90381-0; EVANS T, 1984, NUCLEIC ACIDS RES, V12, P8043, DOI 10.1093/nar/12.21.8043; GAILLARD C, 1990, J MOL BIOL, V215, P245, DOI 10.1016/S0022-2836(05)80343-2; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; KOHWI Y, 1988, P NATL ACAD SCI USA, V84, P2223; LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LIM K, 1989, BIOTECHNIQUES, V7, P576; LYAMICHEV VI, 1988, NUCLEIC ACIDS RES, V16, P2165, DOI 10.1093/nar/16.5.2165; MACE HAF, 1983, NATURE, V304, P555, DOI 10.1038/304555a0; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MCKEON C, 1984, J BIOL CHEM, V259, P6636; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; NICKOL JM, 1983, CELL, V35, P467, DOI 10.1016/0092-8674(83)90180-0; SETA FD, 1988, J BIOL CHEM, V263, P15888; STROBEL SA, 1988, J AM CHEM SOC, V110, P7927, DOI 10.1021/ja00231a082; TAKIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P1686, DOI 10.1073/pnas.88.5.1686; WEINTRAUB H, 1983, CELL, V32, P1191, DOI 10.1016/0092-8674(83)90302-1; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; YU YT, 1986, CELL, V45, P743, DOI 10.1016/0092-8674(86)90788-9	30	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13669	13674						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618866				2022-12-25	WOS:A1992JB74600090
J	FATTAL, PG; SCHNEIDER, DJ; SOBEL, BE; BILLADELLO, JJ				FATTAL, PG; SCHNEIDER, DJ; SOBEL, BE; BILLADELLO, JJ			POSTTRANSCRIPTIONAL REGULATION OF EXPRESSION OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 MESSENGER-RNA BY INSULIN AND INSULIN-LIKE GROWTH FACTOR-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FACTOR-I; PLASMA-INSULIN; IGF-I; CELLS; GENE; RAT; SEQUENCES; HYPERINSULINEMIA; STIMULATION; TRANSLATION	In humans and non-human primates, alternative cleavage and polyadenylation of plasminogen activator inhibitor type-1 (PAI-1) pre-mRNA transcripts results in two forms of mature mRNA, an unstable 3.2-kilo-base (kb) form, and a relatively more stable 2.2-kb form. Insulin and insulin-like growth factor I (IGF-1) increase steady state levels of PAI-1 mRNA in Hep G2 cells independently and synergistically. In the present study we found that the rate of transcription of the PAI-1 gene is not affected by insulin, IGF-1, or both but that insulin prolongs the half-life of the 3.2-kb PAI-1 mRNA species 2.7-fold without affecting the half-life of the 2.2-kb species. In contrast IGF-1, alone or with insulin, markedly prolongs the half-lives of both species. Our results demonstrate a novel mechanism of regulation of expression of the PAI-I gene by insulin and IGF-1 operating at the post-transcriptional level.			FATTAL, PG (corresponding author), WASHINGTON UNIV, SCH MED, DIV CARDIOVASC, BOX 8086, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA.		Schneider, David/AAQ-4970-2021	Schneider, David/0000-0002-2751-6870	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL017646, R01HL038868, P50HL017646] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL17646, HL38868] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADASHI EY, 1985, ENDOCRINOLOGY, V116, P2135, DOI 10.1210/endo-116-6-2135; ALEMANY J, 1990, P NATL ACAD SCI USA, V87, P3353, DOI 10.1073/pnas.87.9.3353; ANDREASEN PA, 1990, MOL CELL ENDOCRINOL, V68, P1, DOI 10.1016/0303-7207(90)90164-4; BANDYOPADHYAY R, 1990, MOL CELL BIOL, V10, P2060, DOI 10.1128/MCB.10.5.2060; BEERS WH, 1975, CELL, V6, P387, DOI 10.1016/0092-8674(75)90188-9; BOSMA PJ, 1991, J BIOL CHEM, V266, P17845; BOSMA PJ, 1988, J BIOL CHEM, V263, P9129; BUONANNO A, 1986, J BIOL CHEM, V261, P1452; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; DAMANTE G, 1988, BIOCHEM BIOPH RES CO, V151, P1194, DOI 10.1016/S0006-291X(88)80492-3; DEUTSCH E, 1965, THROMBOSIS ANTICOAGU, P128; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJII S, 1990, THROMB HAEMOSTASIS, V64, P412; GRAVES RA, 1987, CELL, V48, P615, DOI 10.1016/0092-8674(87)90240-6; GROSS JL, 1983, P NATL ACAD SCI-BIOL, V80, P2623, DOI 10.1073/pnas.80.9.2623; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; HOPKINS WE, 1991, NUCLEIC ACIDS RES, V19, P163, DOI 10.1093/nar/19.1.163; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; JUHANVAGUE I, 1984, THROMB RES, V33, P523, DOI 10.1016/0049-3848(84)90018-5; JUHANVAGUE I, 1987, DIABETES METAB, V13, P331; JUHANVAGUE I, 1989, ARTERIOSCLEROSIS, V9, P362, DOI 10.1161/01.ATV.9.3.362; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LEE YL, 1988, MOL ENDOCRINOL, V2, P404, DOI 10.1210/mend-2-5-404; LOSKUTOFF DJ, 1991, FIBRINOLYSIS, V5, P197, DOI 10.1016/0268-9499(91)90001-K; LUCORE CL, 1988, CIRCULATION, V77, P660, DOI 10.1161/01.CIR.77.3.660; LUCORE CL, 1988, J BIOL CHEM, V263, P15845; Marzluff W. F., 1984, TRANSCRIPTION TRANSL, P89; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P301, DOI 10.1210/endo-124-1-301; MCQUILLAN DJ, 1986, BIOCHEM J, V240, P423, DOI 10.1042/bj2400423; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; OSBORN L, 1988, J BIOL CHEM, V263, P16519; PAN WH, 1986, AM J EPIDEMIOL, V123, P504, DOI 10.1093/oxfordjournals.aje.a114266; PANREKOEK H, 1986, EMBO J, V9, P2539; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; RAGHOW R, 1987, TRENDS BIOCHEM SCI, V12, P358, DOI 10.1016/0968-0004(87)90165-4; RASMUSSEN SM, 1975, DIABETOLOGIA, V11, P151; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SCHNEIDER DJ, 1991, P NATL ACAD SCI USA, V88, P9959, DOI 10.1073/pnas.88.22.9959; SPRENGERS ED, 1987, BLOOD, V69, P381; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; SWISLOCKI ALM, 1989, AM J HYPERTENS, V2, P419, DOI 10.1093/ajh/2.6.419; THIEBAUD D, 1990, J BONE MINER RES, V5, P761; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VAGUE P, 1986, METABOLISM, V35, P250, DOI 10.1016/0026-0495(86)90209-X; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909; WERNER H, 1991, INSULIN LIKE GROWTH, P17; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; WUN TC, 1987, FEBS LETT, V210, P11, DOI 10.1016/0014-5793(87)81288-7; YAMASHITA S, 1987, J CLIN INVEST, V79, P449, DOI 10.1172/JCI112832; ZAPF J, 1984, CLIN ENDOCRINOL META, V13, P3, DOI 10.1016/S0300-595X(84)80006-7	54	110	111	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12412	12415						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618746				2022-12-25	WOS:A1992HZ48300006
J	BHATTACHARJEE, H; BHADURI, A				BHATTACHARJEE, H; BHADURI, A			DISTINCT FUNCTIONAL ROLES OF 2 ACTIVE-SITE THIOLS IN UDPGLUCOSE 4-EPIMERASE FROM KLUYVEROMYCES-FRAGILIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHOSPHATE GALACTOSE 4-EPIMERASE; SUBSTRATE; MECHANISM; REDUCTION; REAGENT; ENZYME	UDPglucose 4-epimerase from Kluyveromyces fragilis was earlier shown to have two conformationally vicinal thiols at the active site. Upon treatment with diamide, these thiols form a disulfide linkage across the subunits that results in coordinated loss of catalytic activity and coenzyme fluorescence (Ray, M., and Bhaduri, A. (1980) J. Biol. Chem. 255, 10777-10786). Employing a number of thiol-specific reagents, we now suggest discriminatory and nonidentical roles for these two thiols. Kinetic and statistical analysis of 5,5'-dithiobis-(2-nitrobenzoic acid) and N-ethylmaleimide modification reaction of epimerase show that only one thiol is essential for activity. Consecutive modification experiments clearly show that the same active thiol is modified in both cases. However, significant differences are observed when the reactivity of these reagents is monitored in terms of coenzyme fluorescence. Treatment with N-ethylmaleimide leads to a form of inactive enzyme that fully retains its fluorescent properties whereas modification with 5,5'-dithiobis-(2-nitrobenzoic acid), on the other hand, results in the loss of both activity and fluorescence. The closely spaced nonessential second thiol, which is not modified by N-ethylmaleimide is therefore involved in generating and maintaining the coenzyme fluorescence. Modification studies with a series of spin-labeled maleimide shows that only 3-(maleimidomethyl)proxyl causes partial quenching of coenzyme fluorescence. This suggests that the active thiol is situated at a distance of 4.5 angstrom approximately from the coenzyme fluorophore.			BHATTACHARJEE, H (corresponding author), INDIAN INST CHEM BIOL,4 RAJA SC MULLICK RD,CALCUTTA 700032,W BENGAL,INDIA.							ADAIR WL, 1973, J BIOL CHEM, V248, P4635; ARABSHAHI A, 1988, J BIOL CHEM, V263, P2638; BAUER AJ, 1991, PROTEINS, V9, P135, DOI 10.1002/prot.340090207; Berliner L J, 1978, Methods Enzymol, V49, P418; BERTLAND AU, 1970, BIOCHEMISTRY-US, V9, P4649, DOI 10.1021/bi00826a005; BERTLAND LH, 1971, BIOCHEMISTRY-US, V10, P3145, DOI 10.1021/bi00792a025; Branden C.-I., 1975, ENZYMES, V11, P103; CARLSON GM, 1978, BIOCHEMISTRY-US, V17, P5329, DOI 10.1021/bi00618a002; CREVELING CR, 1965, BIOCHEM BIOPH RES CO, V21, P624, DOI 10.1016/0006-291X(65)90532-2; DARROW RA, 1968, BIOCHEMISTRY-US, V7, P1645, DOI 10.1021/bi00845a005; DARROW RA, 1966, P NATL ACAD SCI USA, V55, P205, DOI 10.1073/pnas.55.1.205; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FLENTKE GR, 1990, BIOCHEMISTRY-US, V29, P2430, DOI 10.1021/bi00461a029; FLUHARTY AL, 1961, J BIOL CHEM, V236, P2772; Frey P. A., 1987, PYRIDINE NUCLEOTID B, V2B, P462; GABRIEL O, 1978, INT REV BIOCHEM, V16, P1; GABRIEL O, 1975, SUBUNIT ENZYMES BIOC, P85; HANKER JS, 1957, ANAL CHEM, V29, P879, DOI 10.1021/ac60126a005; HARRIS JI, 1976, ENZYMES, V13, P1; Holbrook JJ., 1975, ENZYMES, P191; HORIIKE K, 1979, J THEOR BIOL, V79, P403, DOI 10.1016/0022-5193(79)90355-2; KAPLAN NO, 1951, J BIOL CHEM, V191, P461; LEVY HM, 1963, J BIOL CHEM, V238, P3654; MAITRA US, 1971, P NATL ACAD SCI USA, V68, P2660, DOI 10.1073/pnas.68.11.2660; MANIATIS T, 1982, MOL CLONING LABORATO, P466; MAXWELL ES, 1958, ARCH BIOCHEM BIOPHYS, V78, P407, DOI 10.1016/0003-9861(58)90366-7; MORRISETT JD, 1975, J BIOL CHEM, V250, P2487; MUKHERJI S, 1986, J BIOL CHEM, V261, P4519; MUKHERJI S, 1992, J BIOL CHEM, V267, P11709; NELSESTU.GL, 1971, J BIOL CHEM, V246, P7533; RAY M, 1980, J BIOL CHEM, V255, P777; RAY M, 1980, J BIOL CHEM, V255, P782; RAY M, 1978, BIOCHIM BIOPHYS ACTA, V526, P635, DOI 10.1016/0005-2744(78)90154-7; RAY WJ, 1962, J BIOL CHEM, V237, P2493; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; SAMANTA AK, 1982, BIOCHIM BIOPHYS ACTA, V707, P129, DOI 10.1016/0167-4838(82)90405-8; SMITH DJ, 1975, BIOCHEMISTRY-US, V14, P766, DOI 10.1021/bi00675a019; TSOU C, 1962, SCI SINICA, V11, P1535; UDENFRIEND S, 1962, FLUORESCENCE ASSAY B, V1, P249; UDENFRIEND S, 1969, FLUORESCENCE ASSAY B, V2, P253; WEE TG, 1973, J BIOL CHEM, V248, P33; WU CW, 1976, BIOCHEMISTRY-US, V15, P2863, DOI 10.1021/bi00658a025	42	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11714	11720						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601848				2022-12-25	WOS:A1992HY94700014
J	LIU, ML; OLSON, AL; MOYEROWLEY, WS; BUSE, JB; BELL, GI; PESSIN, JE				LIU, ML; OLSON, AL; MOYEROWLEY, WS; BUSE, JB; BELL, GI; PESSIN, JE			EXPRESSION AND REGULATION OF THE HUMAN GLUT4/MUSCLE-FAT FACILITATIVE GLUCOSE TRANSPORTER GENE IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INSULIN-RESPONSIVE TISSUES; ADIPOSE-CELLS; MESSENGER-RNA; PROTEIN; ENHANCER; EFFICIENT; PROMOTER; CLONING; MUSCLE; INVIVO	To study the molecular basis of tissue-specific expression of the GLUT4/muscle-fat facilitative glucose transporter gene, we generated lines of transgenic mice carrying 2.4 kilobases of the 5'-flanking region of the human GLUT4 gene fused to a chloramphenicol acetyltransferase (CAT) reporter gene (hGLUT4[2.4]-CAT). This reporter gene construct was specifically expressed in tissues that normally express GLUT4 mRNA, which include both brown and white adipose tissues as well as cardiac, skeletal, and smooth muscle. In contrast, CAT reporter activity was not detected in brain or liver, two tissues that do not express the GLUT4 gene. In addition, the relative levels of CAT mRNA driven by the human GLUT4 promoter in various tissues of these transgenic animals mirrored those of the endogenous mouse GLUT4 mRNA. Since previous studies have observed alterations in GLUT4 mRNA levels induced by fasting and refeeding (Sivitz, W. I., DeSautel, S. L., Kayano, T., Bell, G. I., and Pessin, J. E. (1989) Nature 340, 72-74), the regulated expression the hGLUT4[2.4]-CAT transgene was also assessed in these animals. Fasting was observed to decrease CAT activity in white adipose tissue which was super-induced upon refeeding. These alterations in CAT expression occurred in parallel to the changes in endogenous mouse GLUT4 mRNA levels. Although CAT expression in skeletal muscle and brown adipose tissue was unaffected, the endogenous mouse GLUT4 mRNA was also refractory to the effects of fasting/refeeding in these tissues. These data demonstrate that 2.4 kilobases of the 5'-flanking region of the human GLUT4 gene contain all the necessary sequence elements to confer tissue-specific expression and at least some of the sequence elements controlling the hormonal/metabolic regulation of this gene.	UNIV IOWA, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, DEPT BIOCHEM & MOLEC BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA	University of Iowa; Howard Hughes Medical Institute; University of Chicago; University of Chicago			Buse, John Bernard/J-9742-2019; Moye-Rowley, Scott/AFL-7135-2022	Buse, John Bernard/0000-0002-9723-3876; Moye-Rowley, Scott/0000-0002-7163-1120	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K04DK001822, R01DK042452] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25925, DK01822, DK42452] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGER J, 1989, NATURE, V340, P70, DOI 10.1038/340070a0; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BURANT CF, 1991, RECENT PROG HORM RES, V47, P349; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CHARRON MJ, 1990, J BIOL CHEM, V265, P7994; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; GARVEY WT, 1991, J CLIN INVEST, V87, P1072, DOI 10.1172/JCI115068; GARVEY WT, 1989, SCIENCE, V245, P60, DOI 10.1126/science.2662408; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAESTNER KH, 1991, P NATL ACAD SCI USA, V88, P1933, DOI 10.1073/pnas.88.5.1933; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KAHN BB, 1989, J CLIN INVEST, V84, P404, DOI 10.1172/JCI114180; LAWN RM, 1978, CELL, V15, P1157, DOI 10.1016/0092-8674(78)90043-0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; OLSON AL, 1990, PEDIATR RES, V28, P183, DOI 10.1203/00006450-199009000-00001; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; RICHARDSON JM, 1991, J BIOL CHEM, V266, P12690; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; Sambrook J, 1989, MOL CLONING LABORATO; SINHA MK, 1991, DIABETES, V40, P473; SIVITZ WI, 1989, NATURE, V340, P72, DOI 10.1038/340072a0	28	57	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11673	11676						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601840				2022-12-25	WOS:A1992HY94700004
J	MORRISON, BW; LEDER, P				MORRISON, BW; LEDER, P			A RECEPTOR-BINDING DOMAIN OF MOUSE INTERLEUKIN-4 DEFINED BY A SOLID-PHASE BINDING ASSAY AND INVITRO MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATORY FACTOR-I; EXPRESSES B-CELL; T-CELL; CDNA CLONE; PROTEINS; IL-4; SEQUENCE; INVIVO; LIGAND; MUTANT	Interleukin 4 (IL-4) is a Potent, pleiotropic lymphokine that affects a variety of cells, especially those of hematopoietic origin. Although murine and human IL-4 are homologous proteins, they display a species specificity in which murine IL-4 acts only upon mouse cells, and human IL-4 only upon human cells. We have used a mutagenesis strategy to define both the structural determinants of this specificity and a receptor binding domain of murine IL-4. To do this, we developed convenient solid-phase binding assays for mouse and for human IL-4, each utilizing receptor-immunoglobulin fusion proteins and alkaline phosphatase-tagged ligands. These were employed to assess the receptor binding activities of wild type and mutant forms of IL-4. In a separate biological assay, we measured the ability of each version of IL-4 to induce proliferation of a cultured mouse T-cell line. By replacing regions of mouse IL-4 with homologous segments of human IL-4, we found that the amino-terminal 16 residues and the carboxyl-terminal 20 residues of murine IL-4 are required for species-specific receptor binding as well as for T-cell proliferation. A major portion of the amino acid sequence between these regions can be substituted between mouse and human without loss of receptor binding or biological activity. Further, alanine-scanning mutagenesis revealed specific residues in the amino- and carboxyl-terminal regions (Glu-12, Ile-14, Leu-104, Asp-106, Phe-107, and Leu-111) that bear side chains critical for function. An analysis of the carboxyl-terminal region of murine IL-4 and its comparison with carboxyl-terminal regions of other related cytokines suggest an evolutionary conservation of structural and functional features.	HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED ONCOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NATIONAL CANCER INSTITUTE [T32CA009172] Funding Source: NIH RePORTER; NCI NIH HHS [CA 09172] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; CARR C, 1991, BIOCHEMISTRY-US, V30, P1515, DOI 10.1021/bi00220a011; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; CUNNINGHAM BC, 1990, SCIENCE, V247, P1461, DOI 10.1126/science.2321008; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; HARADA N, 1990, P NATL ACAD SCI USA, V87, P857, DOI 10.1073/pnas.87.3.857; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; HULI J, 1989, J IMMUNOL, V142, P800; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; KRUSE N, 1991, FEBS LETT, V286, P58, DOI 10.1016/0014-5793(91)80939-Z; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LE HV, 1991, BIOCHEMISTRY-US, V30, P9576, DOI 10.1021/bi00104a003; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; LOWENTHAL JW, 1988, J IMMUNOL, V140, P456; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MOSMANN TR, 1987, J IMMUNOL, V138, P1813; OHARA J, 1987, J IMMUNOL, V139, P1127; OHARA J, 1987, NATURE, V325, P537, DOI 10.1038/325537a0; OTSUKA T, 1987, NUCLEIC ACIDS RES, V15, P333, DOI 10.1093/nar/15.1.333; PARK LS, 1987, P NATL ACAD SCI USA, V84, P1669, DOI 10.1073/pnas.84.6.1669; PARK LS, 1987, J EXP MED, V166, P476, DOI 10.1084/jem.166.2.476; PAUL WE, 1991, BLOOD, V77, P1859; REDFIELD C, 1991, BIOCHEMISTRY-US, V30, P11029, DOI 10.1021/bi00110a004; ROSE GD, 1985, SCIENCE, V229, P834, DOI 10.1126/science.4023714; Sambrook J, 1989, MOL CLONING LABORATO; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; YOKOTA T, 1986, P NATL ACAD SCI USA, V83, P5894, DOI 10.1073/pnas.83.16.5894; ZETTLMEISSL G, 1990, DNA CELL BIOL, V9, P347, DOI 10.1089/dna.1990.9.347	39	50	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11957	11963						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601864				2022-12-25	WOS:A1992HY94700047
J	SHIRATAKI, H; KAIBUCHI, K; YAMAGUCHI, T; WADA, K; HORIUCHI, H; TAKAI, Y				SHIRATAKI, H; KAIBUCHI, K; YAMAGUCHI, T; WADA, K; HORIUCHI, H; TAKAI, Y			A POSSIBLE TARGET PROTEIN FOR SMG-25A/RAB3A SMALL GTP-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BOVINE BRAIN CYTOSOL; AFFECT ONCOGENIC MUTANTS; RAS P21 GTPASE; REGULATORY PROTEIN; SMG P25A; SUBSEQUENT BINDING; PURIFICATION; DISSOCIATION; GDP; MEMBRANES	The smg-25A/rab3A protein (smg p25A) is a small GTP-binding protein implicated in intracellular vesicle traffic, particularly in neurotransmitter release from the presynapse. In the present study, we attempted to identify a target protein in bovine brain crude membranes that might be interacted with the GTP-bound form of smg p25A. When the guanosine-5'-(3-O-thio)triphosphate (GTP-gamma-S)-bound form of radioiodinated smg p25A and the crude membrane fraction of bovine brain were incubated with a cross-linker, disuccinimidyl suberate, and the sample was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by autoradiography, one radioactive band with a M(r) of about 110,000 was detected. This radioactive band appeared to be composed of radioiodinated smg p25A and a molecule with a M(r) of about 86,000. This molecule, tentatively termed here smg p25A target, was extracted from the membranes by a detergent and highly purified by column chromatographies and sucrose density gradient ultracentrifugation. The purified smg p25A target was sensitive to heat boiling and tryptic digestion, indicating that smg p25A target is a protein molecule. The M(r) of the purified smg p25A target was estimated to be about 85,000-86,000 from SDS-PAGE and to be about 100,000 from the S value. The cross-linking of radioiodinated smg p25A with the purified smg p25A target was inhibited by the GTP-gamma-S-bound form of non-radioactive smg p25A with an IC50 of about 8 nm. The GDP-bound form of smg p25A was much less effective. Other small GTP-binding proteins, such as c-Ki-ras p21, rhoA p21, smg p21B, and rab11 p24 were ineffective. These results indicate that a protein with a M(r) of about 85,000-100,000 is a target for smg p25A.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN	Kobe University								ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; GARRETT MD, 1989, J BIOL CHEM, V264, P10; HART MJ, 1991, J BIOL CHEM, V266, P20840; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; SASAKI T, 1990, J BIOL CHEM, V265, P2333; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; UEDA T, 1990, J BIOL CHEM, V265, P9373; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626	22	113	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					10946	10949						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597436				2022-12-25	WOS:A1992HX16900005
J	GILLADOGA, AD; EDELHOFF, S; BLACKWOOD, EM; EISENMAN, RN; DISTECHE, CM				GILLADOGA, AD; EDELHOFF, S; BLACKWOOD, EM; EISENMAN, RN; DISTECHE, CM			MAPPING OF MAX TO HUMAN CHROMOSOME-14 AND MOUSE CHROMOSOME-12 BY INSITU HYBRIDIZATION	ONCOGENE			English	Note							GENE; ABNORMALITIES; LOCALIZATION	The protein encoded by the MAX gene is a member of the class of basic region-helix-loop-helix-zipper proteins and has been demonstrated to associate with N-, L-, and c-Myc proteins both in vitro and in vivo. Heterodimers formed between c-Myc and Max proteins have been shown to possess sequence-specific DNA-binding activity. Here we report the mapping of the MAX gene to a single region on human chromosome 14 (bands q22-q24) and to mouse chromosome 12 (region D). Chromosome abnormalities linked to several neoplasms have been previously associated with this region on human chromosome 14. The mapping results also confirm a region of homology between human chromosome 14q22-24 and mouse chromosome 12 region D.	FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,1124 COLUMBIA ST,SEATTLE,WA 98104; UNIV WASHINGTON,SCH MED,DEPT PATHOL,SEATTLE,WA 98195	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle					NATIONAL CANCER INSTITUTE [R01CA057138, T32CA009437] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA09437, R01CA57138] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERBERICH SJ, IN PRESS ONCOGENE; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLACKWOOD EM, 1992, IN PRESS CURR OPIN G; BLOOMFIELD CD, 1983, CANCER RES, V43, P2975; COLE MD, 1991, CELL, V65, P715, DOI 10.1016/0092-8674(91)90377-B; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; EISEMAN RN, ONCOGENES MOL ORIGIN, P175; GAHRTON G, 1980, BLOOD, V56, P640; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; MAGRATH I, 1990, ADV CANCER RES, V55, P137; MARTH JD, 1986, P NATL ACAD SCI USA, V83, P7400, DOI 10.1073/pnas.83.19.7400; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; TEDDER TF, 1988, J IMMUNOL, V141, P4388; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; 1990, CYTOGENET CELL GENET, V55, P1	16	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1249	1251						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594250				2022-12-25	WOS:A1992HU64200024
J	TAKAYAMA, H; SUZUKI, T; MUGISHIMA, H; FUJISAWA, T; OOKUNI, M; SCHWAB, M; GEHRING, M; NAKAMURA, Y; SUGIMURA, T; TERADA, M; YOKOTA, J				TAKAYAMA, H; SUZUKI, T; MUGISHIMA, H; FUJISAWA, T; OOKUNI, M; SCHWAB, M; GEHRING, M; NAKAMURA, Y; SUGIMURA, T; TERADA, M; YOKOTA, J			DELETION MAPPING OF CHROMOSOME-14Q AND CHROMOSOME-1P IN HUMAN NEUROBLASTOMA	ONCOGENE			English	Article							N-MYC AMPLIFICATION; NEURO-BLASTOMA; CELL CARCINOMA; HETEROZYGOSITY; CANCER; TUMOR; GENES; DNA; ADENOCARCINOMA; ABNORMALITIES	It has been suggested that loss of heterozygosity (LOH) on the short arm of chromosome 1 is a critical event for the development of neuroblastoma, and we have previously shown frequent LOH on chromosome 14 in neuroblastoma. To pursue these observations, especially to define further the regions which are commonly deleted in the tumor, we examined for allelic losses in 27 cases of neuroblastomas by using a number of polymorphic DNA markers for chromosomes 14q and 1p. LOH was observed in 10 out of the 25 informative cases (40%) on chromosome 14q and in eight out of the 21 informative cases (38%) on 1p. The commonly deleted regions were distal to the D14S13 locus (14q32-qter) on chromosome 14 and distal to the D1S112 locus (1p36.1-pter) on chromosome 1. These results strongly suggest that tumor-suppressor genes important in the pathogenesis of human neuroblastoma are located on the distal part of both chromosomes 14q and 1p.	NATL CANC CTR,RES INST,1-1 TSUKIJI,5-CHOME,TOKYO 104,JAPAN; NIHON UNIV,SCH MED,DEPT PEDIAT,ITABASHI KU,TOKYO 173,JAPAN; GERMAN CANC RES CTR,INST EXPTL PATHOL,W-6900 HEIDELBERG 1,GERMANY; JAPANESE FDN CANC RES,INST CANC,DEPT BIOCHEM,TOKYO 170,JAPAN	National Cancer Center - Japan; Nihon University; Helmholtz Association; German Cancer Research Center (DKFZ); Japanese Foundation for Cancer Research				Licka, Manuela/0000-0002-5270-5294				BRODEUR GM, 1981, CANCER RES, V41, P4678; DEVILEE P, 1991, CANCER RES, V51, P1020; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FLEJTER WL, 1989, GENE CHROMOSOME CANC, V1, P148, DOI 10.1002/gcc.2870010207; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; GENUARDI M, 1989, AM J HUM GENET, V45, P73; GILBERT F, 1984, CANCER RES, V44, P5444; HOFKER MH, 1990, GENOMICS, V6, P33, DOI 10.1016/0888-7543(90)90445-Z; KEATS BJB, 1990, CYTOGENET CELL GENET, V55, P387, DOI 10.1159/000133023; KIDD KK, 1989, CYTOGENET CELL GENET, V51, P622, DOI 10.1159/000132810; KOVACS G, 1989, CANCER RES, V49, P651; LEISTER I, 1990, CANCER RES, V50, P7232; MARTINSSON T, 1989, GENE CHROMOSOME CANC, V1, P67, DOI 10.1002/gcc.2870010111; MATHEW CGP, 1987, NATURE, V328, P524, DOI 10.1038/328524a0; NAKAMURA Y, 1989, GENOMICS, V4, P76, DOI 10.1016/0888-7543(89)90317-0; SASAKI M, 1989, CANCER RES, V49, P4402; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SIMON D, 1991, ONCOGENE, V6, P765; SUZUKI T, 1989, CANCER RES, V49, P1095; TSAI YC, 1990, CANCER RES, V50, P44; TSUDA T, 1987, CANCER, V60, P820, DOI 10.1002/1097-0142(19870815)60:4<820::AID-CNCR2820600418>3.0.CO;2-Y; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; YAMADA H, 1986, JPN J CANCER RES, V77, P370; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; ZHANG WD, 1990, JPN J CANCER RES, V81, P108, DOI 10.1111/j.1349-7006.1990.tb02534.x	29	95	95	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1185	1189						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594247				2022-12-25	WOS:A1992HU64200016
J	HRYCYNA, CA; CLARKE, S				HRYCYNA, CA; CLARKE, S			MATURATION OF ISOPRENYLATED PROTEINS IN SACCHAROMYCES-CEREVISIAE - MULTIPLE ACTIVITIES CATALYZE THE CLEAVAGE OF THE 3 CARBOXYL-TERMINAL AMINO-ACIDS FROM FARNESYLATED SUBSTRATES INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS PROTEINS; METHYL-ESTER; A-FACTOR; SEQUENCE DETERMINATION; CYSTEINE; YEAST; GENE; METHYLTRANSFERASE; IDENTIFICATION; PHEROMONE	Eukaryotic polypeptides containing COOH-terminal -CXXX sequences can be posttranslationally modified by isoprenylation of the cysteine residue via a thioether linkage, proteolytic removal of the three terminal amino acids, and alpha-carboxyl methylation of the cysteine residue. Through the development of an indirect coupled assay, we have identified three in vitro activities in the yeast Saccharomyces cerevisiae that can catalyze the proteolytic cleavage of the three COOH-terminal amino acids of the synthetic peptide substrate N-acetyl-KSKTK[S-farnesyl-Cys]VIM. One of these is the vacuolar protease carboxypeptidase Y. Using a mutant strain deficient in this enzyme, we find evidence for an additional soluble activity as well as for a membrane-associated activity. These latter activities are candidates for roles in the physiological processing of isoprenylated protein precursors. They are both insensitive to inhibitors of serine and aspartyl proteinases but are sensitive to sulfhydryl reagents and 0.5 mm ZnCl2. The soluble activity appears to be a metalloenzyme, inhibitable by 2 mm o-phenanthroline but not by 1 mm N-ethylmaleimide, whereas the membrane-associated enzyme is inhibitable by 1 mm N-ethylmaleimide but not 2 mm o-phenanthroline. We show that the membrane-bound protease is not an activity of the membrane-bound methyltransferase, because protease activity is observed in membrane preparations that lack the STE14-encoded methyltransferase. The soluble activity appears to be a novel carboxypeptidase of approximately 1 10 kDa that catalyzes a processive removal of amino acids from the COOH terminus from both the farnesylated and non-farnesylated substrate, but not from three other unrelated peptides. Finally, we find no evidence for non-vacuolar membrane or soluble activities that catalyze the ester hydrolysis of N-acetyl-S-farnesyl-L-cysteine methyl ester.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	HRYCYNA, CA (corresponding author), UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007185, R01GM026020, R37GM026020] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-07185, GM-26020] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; ASHBY MN, 1992, IN PRESS P NATL ACAD, V89; BERMINGHAMMCDONOGH O, 1988, P NATL ACAD SCI USA, V85, P4789, DOI 10.1073/pnas.85.13.4789; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.bi.54.070185.002403; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DER CJ, 1991, CANCER CELL, V3, P1; FAGAN JM, 1991, BIOCHEM J, V277, P779, DOI 10.1042/bj2770779; FINEGOLD AA, 1990, SCIENCE, V249, P165, DOI 10.1126/science.1695391; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; FOLK JE, 1960, J BIOL CHEM, V235, P2272; FUJIYAMA A, 1987, EMBO J, V6, P223, DOI 10.1002/j.1460-2075.1987.tb04742.x; FUJIYAMA A, 1990, J BIOL CHEM, V265, P3362; GILBERT JM, 1988, BIOCHEMISTRY-US, V27, P5227, DOI 10.1021/bi00414a042; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOODMAN LE, 1990, P NATL ACAD SCI USA, V87, P9665, DOI 10.1073/pnas.87.24.9665; GOODMAN LE, 1988, YEAST, V4, P271, DOI 10.1002/yea.320040405; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; HEIKKILA RE, 1976, ANAL BIOCHEM, V75, P356, DOI 10.1016/0003-2697(76)90089-0; HRYCYNA CA, 1990, MOL CELL BIOL, V10, P5071, DOI 10.1128/MCB.10.10.5071; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; JOHNSON DI, 1991, GENE, V98, P149, DOI 10.1016/0378-1119(91)90119-V; JOHNSON DI, 1991, GENE, V90, P93; JOLY A, 1991, J BIOL CHEM, V266, P13495; JONES BN, 1981, J LIQ CHROMATOGR, V4, P565, DOI 10.1080/01483918108059956; JONES EW, 1991, J BIOL CHEM, V266, P7963; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MARCUS S, 1991, MOL CELL BIOL, V11, P3603, DOI 10.1128/MCB.11.7.3603; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; MOORES SL, 1991, J BIOL CHEM, V266, P14603; NOGAE I, 1990, GENE, V96, P161, DOI 10.1016/0378-1119(90)90248-P; OHYA Y, 1991, J BIOL CHEM, V266, P12356; ONG OC, 1989, P NATL ACAD SCI USA, V86, P9238, DOI 10.1073/pnas.86.23.9238; OTA IM, 1989, J BIOL CHEM, V264, P12879; PEREZSALA D, 1991, P NATL ACAD SCI USA, V88, P3043, DOI 10.1073/pnas.88.8.3043; PFEIFER R, 1983, AM LAB, V15, P78; POLAKIS PG, 1988, J BIOL CHEM, V263, P4969; POWERS S, 1986, CELL, V47, P413, DOI 10.1016/0092-8674(86)90598-2; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RINE J, 1990, New Biologist, V2, P219; RUSSELL DW, 1983, J BIOL CHEM, V258, P2674; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; STACHELEK C, 1986, NUCLEIC ACIDS RES, V14, P945, DOI 10.1093/nar/14.2.945; STEPHENSON RC, 1990, J BIOL CHEM, V265, P16248; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; STEPHENSON RC, 1992, IN PRESS J BIOL CHEM, V267; STIMMEL JB, 1990, BIOCHEMISTRY-US, V29, P9651, DOI 10.1021/bi00493a021; VENKATASUBRAMANIAN K, 1980, MOL IMMUNOL, V17, P201, DOI 10.1016/0161-5890(80)90072-3; VOLKER C, 1991, J BIOL CHEM, V266, P21515; WOLF DH, 1986, MICROBIOL SCI, V3, P107; WORTHINGTON CC, 1988, WORTHINGTON MANUAL E; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286; YOKAYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302; YOSHIDA Y, 1991, BIOCHEM BIOPH RES CO, V175, P720, DOI 10.1016/0006-291X(91)91625-M; YUE RH, 1969, J BIOL CHEM, V244, P1353	63	67	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10457	10464						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587828				2022-12-25	WOS:A1992HV09000040
J	MALONEY, PC; ANANTHARAM, V; ALLISON, MJ				MALONEY, PC; ANANTHARAM, V; ALLISON, MJ			MEASUREMENT OF THE SUBSTRATE DISSOCIATION-CONSTANT OF A SOLUBILIZED MEMBRANE CARRIER - SUBSTRATE STABILIZATION OF OXLT, THE ANION-EXCHANGE PROTEIN OF OXALOBACTER-FORMIGENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RECONSTITUTION; TRANSPORT; PERMEASE	OxlT, a secondary carrier found in Oxalobacter formigenes, mediates the exchange of divalent oxalate and monovalent formate. Because OxlT has an unusually high turnover number (greater-than-or-equal-to 1000/s), and because formate, one its substrates, shows high passive membrane permeability as formic acid, it has been difficult to obtain information on protein-substrate interactions using traditional methods in membrane biology. For this reason, we devised a new way to measure substrate dissociation constants. Detergent-solubilized material was exposed to inactivating temperatures in the absence or presence of OxlT substrates, and periodic reconstitution was used to monitor the kinetics of thermal decay. The data were consistent with a simple scheme in which only unliganded OxlT was temperature-sensitive; this premise, along with the assumption of equilibrium between liganded and unliganded species, allowed calculation of substrate dissociation constants for oxalate (18 +/- 3-mu-M), malonate (1.2 +/- 0.2 mm), and formate (3.1 +/- 0.6 mM). Further analysis revealed that substrate binding energy contributed at least 3.5 kcal/mol to stabilization of solubilized OxlT. Accordingly, we suggest that substrate binding energy is directly involved in driving protein structure reorganization during membrane transport. This new approach to analyzing protein-substrate interactions may have wider application in the study of membrane carriers.	USDA ARS,NATL ANIM DIS CTR,AMES,IA 50010	United States Department of Agriculture (USDA)	MALONEY, PC (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205, USA.				NIGMS NIH HHS [GM 24195] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM024195, R01GM024195] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBUDKAR SV, 1990, J BIOL CHEM, V265, P12287; AMBUDKAR SV, 1986, J BIOL CHEM, V261, P79; ANANTHARAM V, 1989, J BIOL CHEM, V264, P7244; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; KABACK HR, 1986, ANNU REV BIOPHYS BIO, V15, P279; KENNEDY EP, 1970, LACTOSE OPERON, P49; Klingenberg M, 1980, Ann N Y Acad Sci, V358, P83, DOI 10.1111/j.1749-6632.1980.tb15388.x; LANCASTER JR, 1977, J BIOL CHEM, V252, P7657; MALONEY PC, 1989, ARCH BIOCHEM BIOPHYS, V269, P1, DOI 10.1016/0003-9861(89)90080-5; MALONEY PC, 1990, MICROBIOL REV, V54, P1; MOORE WT, 1963, PHYSICAL CHEM; OVERATH P, 1987, P NATL ACAD SCI USA, V84, P5535, DOI 10.1073/pnas.84.16.5535; PAGE MGP, 1981, BIOCHEM J, V196, P721, DOI 10.1042/bj1960721; ROTMAN B, 1961, P NATL ACAD SCI USA, V47, P1981, DOI 10.1073/pnas.47.12.1981; RUAN ZS, 1992, J BIOL CHEM, V267, P10537; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; TEATHER RM, 1977, BIOCHIM BIOPHYS ACTA, V467, P386, DOI 10.1016/0005-2736(77)90316-9; WEST IC, 1983, BIOCH MEMBRANE TRANS; WRIGHT JK, 1981, BIOCHEMISTRY-US, V20, P6404, DOI 10.1021/bi00525a019	19	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10531	10536						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587833				2022-12-25	WOS:A1992HV09000049
J	TRIMBUR, DE; WARREN, RAJ; WITHERS, SG				TRIMBUR, DE; WARREN, RAJ; WITHERS, SG			REGION-DIRECTED MUTAGENESIS OF RESIDUES SURROUNDING THE ACTIVE-SITE NUCLEOPHILE IN BETA-GLUCOSIDASE FROM AGROBACTERIUM-FAECALIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; GALACTOSIDASE GENE; ESCHERICHIA-COLI; EXPRESSION; CELLOBIASE; CELLULOSE; LYSOZYME; BINDING; INVITRO; CLONING	The active site nucleophile of the beta-glucosidase of Agrobacterium faecalis has recently been identified by the use of inhibitors. A combination of site-directed and in vitro enzymatic mutagenesis was carried out on the beta-glucosidase to probe the structure of the active site region. Forty-three point mutations were generated at 22 different residues in the region surrounding the active site nucleophile, Glu358. Only five positions were identified which affected enzyme activity indicating that only a few key residues are important to enzyme activity, thus the enzyme can tolerate a number of single residue changes and still function. The importance of Glu358 to enzymatic function has been confirmed and other residues important to enzyme structure or function have been identified.	UNIV BRITISH COLUMBIA, DEPT MICROBIOL, VANCOUVER V6T 1Y5, BC, CANADA	University of British Columbia	TRIMBUR, DE (corresponding author), UNIV BRITISH COLUMBIA, DEPT CHEM, VANCOUVER V6T 1Y5, BC, CANADA.		Withers, Stephen G/I-7229-2019	Withers, Stephen G/0000-0002-6722-5701				ANAND NN, 1988, BIOCHEM BIOPH RES CO, V153, P862, DOI 10.1016/S0006-291X(88)81175-6; BOIZET B, 1988, GENE, V62, P249, DOI 10.1016/0378-1119(88)90563-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREIDT F, 1987, APPL ENVIRON MICROB, V53, P969, DOI 10.1128/AEM.53.5.969-973.1987; DAY AG, 1986, BIOCHEM CELL BIOL, V64, P914, DOI 10.1139/o86-122; GERHARDT P, 1981, MANUAL METHODS GENER; GILKES NR, 1988, J BIOL CHEM, V263, P10401; GONZALEZCANDELAS L, 1990, GENE, V95, P31, DOI 10.1016/0378-1119(90)90410-S; GRABNITZ F, 1991, EUR J BIOCHEM, V200, P301, DOI 10.1111/j.1432-1033.1991.tb16186.x; GRUTTER MG, 1983, NATURE, V303, P828, DOI 10.1038/303828a0; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; Imoto T., 1972, ENZYMES, V7, P665; KRISTENSEN T, 1987, NUCLEIC ACIDS RES, V15, P5507, DOI 10.1093/nar/15.14.5507; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHTOVAARA PM, 1988, PROTEIN ENG, V2, P63, DOI 10.1093/protein/2.1.63; LITTLE S, 1989, NUCLEIC ACIDS RES, V17, P7980, DOI 10.1093/nar/17.19.7980; LOVE DR, 1988, MOL GEN GENET, V213, P84, DOI 10.1007/BF00333402; MALCOLM BA, 1989, P NATL ACAD SCI USA, V86, P133, DOI 10.1073/pnas.86.1.133; Maniatis T, 1989, MOL CLONING; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P282; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; Miller J.H., 1972, EXPT MOL GENETICS; PORTER EV, 1988, GENE, V62, P263; SCHNETZ K, 1987, J BACTERIOL, V169, P2579, DOI 10.1128/jb.169.6.2579-2590.1987; SHEWALE JG, 1982, INT J BIOCHEM, V14, P435, DOI 10.1016/0020-711X(82)90109-4; SINNOTT ML, 1990, CHEM REV, V90, P1173; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VIERA J, 1987, METHOD ENZYMOL, V153, P3; WAKARCHUK WW, 1986, MOL GEN GENET, V205, P146, DOI 10.1007/BF02428044; WAKARCHUK WW, 1988, J BACTERIOL, V170, P301, DOI 10.1128/jb.170.1.301-307.1988; WITHERS SG, 1988, J AM CHEM SOC, V110, P8551, DOI 10.1021/ja00233a045; WITHERS SG, 1990, J AM CHEM SOC, V112, P5887, DOI 10.1021/ja00171a043; 1990, GENE AMST, V94, P89	37	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10248	10251						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587814				2022-12-25	WOS:A1992HV09000010
J	TURNBULL, JE; FERNIG, DG; KE, YQ; WILKINSON, MC; GALLAGHER, JT				TURNBULL, JE; FERNIG, DG; KE, YQ; WILKINSON, MC; GALLAGHER, JT			IDENTIFICATION OF THE BASIC FIBROBLAST GROWTH-FACTOR BINDING SEQUENCE IN FIBROBLAST HEPARAN-SULFATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE; PROTEOLYTIC DEGRADATION; ANGIOGENIC PROTEIN; ESCHERICHIA-COLI; HIGH-AFFINITY; EHS TUMOR; CELLS; OLIGOSACCHARIDES; PROTEOGLYCANS; ORGANIZATION	The structural properties of fibroblast heparan sulfate (HS) that are necessary for it to bind strongly to basic fibroblast growth factor (bFGF) have been investigated using bFGF affinity chromatography. Specific enzymic and chemical scission of HS, together with chemical N-desulfation, revealed that N-sulfate groups and iduronate-2-sulfates (IdoA(2-OSO3)) were essential for the interaction. bFGF-affinity chromatography of sulfated oligosaccharides released from HS by treatment with heparitinase led to the identification of an oligosaccharide component (oligo-H), seven disaccharides in length, with a similar affinity for bFGF as the parent molecule. Heparinase treatment of this fraction abolished the high affinity binding to bFGF. Analysis of oligo-H indicated that 74% of the disaccharide units had the structure IdoA(2-OSO3)alpha-1,4GlCNSO3; the remainder comprised N-acetylated and N-sulfated units, the majority of which were devoid of O-sulfate groups. Oligo-H was fully degraded to disaccharides by treatment with nitrous acid. These results indicate that the sequence of oligo-H is as shown below. DELTA-GlcA-beta-1,4GlcNSO3-alpha-1,4[IdoA(2-OSO3)alpha-1,4GlcNSO3]5-alpha-1, 4IdoA-alpha-1,4GlcNAc Sulfated oligosaccharides of similar size but with a lower affinity for bFGF had a reduced concentration of IdoA(2-OSO3) but significant quantities of Glc-NSO3(6-OSO3) and GlcNAc(6-OSO3). The data indicate a primary role for contiguous sequences of IdoA(2-OSO3)alpha-1,4GlcNSO3 in mediating the high affinity binding between fibroblast HS and bFGF.	UNIV MANCHESTER,CHRISTIE HOSP,CANC RES CAMPAIGN,DEPT MED ONCOL,MANCHESTER M13 9PL,LANCS,ENGLAND; UNIV LIVERPOOL,DEPT BIOCHEM,CANC & POLIO RES FUND LAB,LIVERPOOL L69 3BX,ENGLAND	Christie NHS Foundation Trust; Christie Hospital; University of Manchester; University of Liverpool	TURNBULL, JE (corresponding author), UNIV MANCHESTER,CHRISTIE HOSP,CLIN RES DEPT,WILMSLOW RD,MANCHESTER M20 9BX,ENGLAND.		Fernig, David G/A-3590-2008	Fernig, David G/0000-0003-4875-4293; Wilkinson, Mark/0000-0003-3109-6888				ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; AMANN E, 1985, GENE, V40, P183, DOI 10.1016/0378-1119(85)90041-1; BARZU T, 1989, J CELL PHYSIOL, V140, P538, DOI 10.1002/jcp.1041400320; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; FOLKMAN J, 1988, AM J PATHOL, V130, P393; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; GALLAGHER JT, 1990, BIOCHEM SOC T, V18, P207, DOI 10.1042/bst0180207; GALLAGHER JT, 1985, BIOCHEM J, V230, P665, DOI 10.1042/bj2300665; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; GALLAGHER JT, 1989, HEPARIN, P135; INOUE Y, 1976, CARBOHYD RES, V46, P87, DOI 10.1016/S0008-6215(00)83533-8; KE YQ, 1990, BIOCHEM BIOPH RES CO, V171, P963, DOI 10.1016/0006-291X(90)90778-L; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5499; PEJLER G, 1987, BIOCHEM J, V248, P69, DOI 10.1042/bj2480069; PRESTA M, 1989, J CELL PHYSL, V140, P67; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SOMMER A, 1989, J CELL PHYSIOL, V138, P215, DOI 10.1002/jcp.1041380129; SUDHALTER J, 1989, J BIOL CHEM, V264, P6892; TRESCONY PV, 1989, CONNECT TISSUE RES, V19, P219, DOI 10.3109/03008208909043898; TURNBULL JE, 1990, BIOCHEM J, V265, P715, DOI 10.1042/bj2650715; TURNBULL JE, 1991, BIOCHEM J, V277, P297, DOI 10.1042/bj2770297; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; VIGNY M, 1988, J CELL PHYSIOL, V137, P321, DOI 10.1002/jcp.1041370216; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	32	504	516	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10337	10341						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587820				2022-12-25	WOS:A1992HV09000023
J	DENKER, BM; SCHMIDT, CJ; NEER, EJ				DENKER, BM; SCHMIDT, CJ; NEER, EJ			PROMOTION OF THE GTP-LIGANDED STATE OF THE G0-ALPHA PROTEIN BY DELETION OF THE C-TERMINUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEINS; H-RAS P21; MONOCLONAL-ANTIBODIES; CRYSTAL-STRUCTURE; PERTUSSIS TOXIN; ALPHA-SUBUNIT; ADP-RIBOSYLATION; TRANSDUCIN; SITE; IDENTIFICATION	G proteins are active as long as GTP is bound to the alpha-subunit. Activation ends when GTP is cleaved to GDP that then stays bound to the active site. Agonist-liganded receptors allow formation of the active state by decreasing the affinity of alpha-subunits for GDP allowing exchange of GDP for GTP. Since receptors interact with the C terminus of the alpha-subunits, we tested whether deletion of the C terminus could mimic activation by receptors. Three deletions and one point mutation at the C terminus of alpha(o) were engineered in alpha(o) cDNA by the polymerase chain reaction, transcribed into RNA, and translated in a rabbit reticulocyte lysate. The ability of in vitro synthesized protein to bind guanine nucleotide was inferred from analysis of native tryptic cleavage patterns, while the ability of the proteins to associate with beta-gamma was measured by sucrose density gradient centrifugation. Deletion of 14 amino acids, alpha(o)D[341], from the C terminus causes a large decrease in GDP affinity, with little or no change in guanosine 5'-3-O-(thio)triphosphate affinity. When GTP is present, alpha(o)D[341] remains in the activated conformation because exchange of GTP for GDP is rapid. Deletion of 10 amino acids, alpha(o)D[345], lowers GDP affinity, but less dramatically than in alpha(o)D[341]. Deletion of 5 amino acids, alpha(o)D[350], or mutation of Arg349 to proline alpha(o)R[349P] has no detectable effects on GDP affinity. Deletion of up to 10 amino acids from the C terminus does not prevent formation of alpha-beta-gamma heterotrimers. We propose that the C terminus of the alpha-subunit is a mobile region that blocks dissociation of GDP. Agonist-liganded receptors may move it aside to allow release of GDP, exchange for GTP, and activation of the alpha-subunit.	BRIGHAM & WOMENS HOSP, DIV CARDIOVASC, 75 FRANCIS ST, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV RENAL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School				Schmidt, Carl/0000-0002-8386-4781	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035417, R37GM036259, F32GM012578, R01GM036259] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36259, GM35417, GM12578] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRUNGER AT, 1990, P NATL ACAD SCI USA, V87, P4849, DOI 10.1073/pnas.87.12.4849; DENKER BM, 1992, J BIOL CHEM, V267, P6272; DERETIC D, 1987, J BIOL CHEM, V262, P10839; FANG BKK, 1983, J BIOL CHEM, V258, P10503; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HAMM HE, 1987, J BIOL CHEM, V262, P10831; HIRSCH JP, 1991, GENE DEV, V5, P467, DOI 10.1101/gad.5.3.467; HOLBROOK SR, 1989, P NATL ACAD SCI USA, V86, P1751, DOI 10.1073/pnas.86.6.1751; HUFF RM, 1986, J BIOL CHEM, V261, P1105; JONES DT, 1987, J BIOL CHEM, V262, P14241; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDIS CA, 1989, NATURE, V340, P695; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MARSHALL MS, 1987, MOL CELL BIOL, V7, P2309, DOI 10.1128/MCB.7.7.2309; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NAVON SE, 1988, J BIOL CHEM, V263, P489; NEER EJ, 1988, J BIOL CHEM, V263, P8996; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PENNEL RB, 1974, RED BLOOD CELL; RALL T, 1987, FEBS LETT, V224, P365, DOI 10.1016/0014-5793(87)80486-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; SPIEGEL AM, 1990, SOC GEN PHY, V45, P185; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; UI M, 1984, ADV CYCLIC NUCL PROT, V17, P145; VANDOP C, 1984, J BIOL CHEM, V259, P23; WEST RE, 1985, J BIOL CHEM, V260, P4428; WINSLOW JW, 1986, J BIOL CHEM, V261, P7571	35	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9998	10002						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577829				2022-12-25	WOS:A1992HT96500083
J	MATA, NL; TSIN, ATC; CHAMBERS, JP				MATA, NL; TSIN, ATC; CHAMBERS, JP			HYDROLYSIS OF 11-CIS-RETINYL AND ALL-TRANS-RETINYL PALMITATE BY RETINAL-PIGMENT EPITHELIUM MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-A; RAT-LIVER; EYE; RETINOIDS; ESTERIFICATION; ISOMERIZATION; REGENERATION; BIOSYNTHESIS; ISOMERASE; RHODOPSIN	A partial characterization of the enzymatic hydrolysis of 11-cis- and all-trans-retinyl palmitate by bovine retinal pigment epithelium microsomes was carried out using a micro-radiometric method to quantitate liberated palmitic acid. Retinyl ester hydrolase (REH) activity was examined in the absence of detergent. Hydrolysis of 11-cis- and all-trans-retinyl palmitate was protein- and time-dependent. Optimal enzyme activity occurred at slightly alkaline pH (8-9). Apparent kinetic constants (V(max) and K(m)) for the 11-cis-REH were 2.1 nmol/min/mg protein and 66-mu-M, respectively. All-trans-REH demonstrated a lower maximum velocity of 0.3 nmol/min/mg protein and a slightly higher substrate affinity of 27-mu-M. Further characterization of 11-cis-retinyl palmitate hydrolysis involved monitoring formation of reaction products, 11-cis retinol and palmitic acid, which were found to be released in essentially a 1:1 stoichiometry. Addition of all-trans retinyl bromoacetate, a known inhibitor of lecithin:retinol acyltransferase reduced both 11-cis and all-trans-REH activities but to significantly different degrees (50 and 76%, respectively). Although the microsomal preparation exhibited LRAT activity, acyl transfer was not readily reversible as labeled palmitic acid was not transferred to added acyl acceptor compounds. These findings suggest that hydrolysis of 11-cis-retinyl palmitate by bovine retinal pigment epithelium microsomes may occur at a catalytic site distinct from that for the all-trans isomer and that this hydrolysis is not representative of a reverse transesterification reaction.	UNIV TEXAS,DIV LIFE SCI,6900 LOOP 1604 NW,SAN ANTONIO,TX 78249	University of Texas System					NATIONAL EYE INSTITUTE [R01EY006438] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM008194] Funding Source: NIH RePORTER; NEI NIH HHS [EY06438] Funding Source: Medline; NIGMS NIH HHS [GM08194] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRY RJ, 1989, J BIOL CHEM, V264, P9231; BERMAN ER, 1980, BIOCHIM BIOPHYS ACTA, V630, P36, DOI 10.1016/0304-4165(80)90135-X; BERNSTEIN PS, 1987, J BIOL CHEM, V262, P16848; BERNSTEIN PS, 1987, P NATL ACAD SCI USA, V84, P1849, DOI 10.1073/pnas.84.7.1849; BLANER WS, 1987, J BIOL CHEM, V262, P53; BRIDGES CDB, 1976, EXP EYE RES, V22, P435, DOI 10.1016/0014-4835(76)90182-2; BRIDGES CDB, 1977, EXP EYE RES, V24, P571, DOI 10.1016/0014-4835(77)90114-2; BRIDGES CDB, 1984, VISION RES, V24, P1581, DOI 10.1016/0042-6989(84)90316-X; BRIDGES CDB, 1984, RETINOIDS, V2, P125; DEIGNER PS, 1989, SCIENCE, V244, P968, DOI 10.1126/science.2727688; DOWLING JE, 1960, NATURE, V188, P114, DOI 10.1038/188114a0; FULTON BS, 1987, BIOCHEMISTRY-US, V26, P7938, DOI 10.1021/bi00398a059; GAWINOWICZ MA, 1982, BIOCHEMISTRY-US, V21, P1899, DOI 10.1021/bi00537a030; GUELI MC, 1991, ARCH BIOCHEM BIOPHYS, V288, P572, DOI 10.1016/0003-9861(91)90238-E; HARRISON EH, 1989, J BIOL CHEM, V264, P17142; KRINSKY NI, 1958, J BIOL CHEM, V232, P881; LAI YL, 1985, BRAIN RES BULL, V15, P143, DOI 10.1016/0361-9230(85)90130-3; LAW WC, 1988, BIOCHEMISTRY-US, V27, P4147, DOI 10.1021/bi00411a037; LENTZ BR, 1975, CHEM PHYS LIPIDS, V15, P216, DOI 10.1016/0009-3084(75)90044-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PRYSTOWSKY JH, 1981, J BIOL CHEM, V256, P4498; RANDO RR, 1991, BIOCHEMISTRY-US, V30, P595, DOI 10.1021/bi00217a001; Saari J.C., 1990, Progress in Retinal Research, V9, P363, DOI 10.1016/0278-4327(90)90011-6; SAARI JC, 1989, J BIOL CHEM, V264, P8636; SAARI JC, 1988, J BIOL CHEM, V263, P8084; SANDERSSANCHEZ SR, 1990, EXPERIENTIA, V46, P498; SELINGER Z, 1966, J LIPID RES, V7, P174; SZUTS EZ, 1991, ARCH BIOCHEM BIOPHYS, V287, P297, DOI 10.1016/0003-9861(91)90482-X; TREHAN A, 1990, BIOCHEMISTRY-US, V29, P309, DOI 10.1021/bi00454a001; Wald G, 1936, J GEN PHYSIOL, V19, P781, DOI 10.1085/jgp.19.5.781; Wald G, 1934, NATURE, V134, P65, DOI 10.1038/134065a0; ZIMMERMAN WF, 1974, EXP EYE RES, V23, P159	32	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9794	9799						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577814				2022-12-25	WOS:A1992HT96500056
J	DENZIN, LK; VOSS, EW				DENZIN, LK; VOSS, EW			CONSTRUCTION, CHARACTERIZATION, AND MUTAGENESIS OF AN ANTIFLUORESCEIN SINGLE CHAIN ANTIBODY IDIOTYPE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; IGG ANTIBODIES; AFFINITY; BINDING; LIGAND; EXPRESSION; PROTEINS; DNA	In addition to crystallographic studies that determined antigen contact residues for monoclonal antifluorescein (Fl) antibody 4-4-20 (K(a) = 2.5 x 10(10) M-1), primary structure comparisons revealed idiotypically cross-reactive monoclonal antibodies (mAbs) 9-40 (K(a) = 4.4 x 10(7) M-1), 12-40 (K(a) = 4.0 x 10(8) M-1), and 5-14 (K(a) = 2.4 x 10(8) M-1) possessed identical Fl contact residues, with the exception of L34His for L34Arg. Site-specific mutagenesis of single chain antibody (SCA) 4-4-20 in which L34Arg was changed to L34His resulted in approximately 1000- and 3-fold decreases in binding affinity and Q(max) (maximum quenching of bound Fl), respectively, which suggested that L34Arg was directly involved in increased binding affinity and fluorescence quenching. Therefore, substitution of Arg for His at residue L34 in mAbs 9-40, 12-40, and 5-14 should result in increased binding affinity and Q(max). To facilitate site-specific mutagenesis studies, single chain derivatives of mAbs 9-40, 12-40, and 5-14 were constructed. Following expression in Escherichia coli, characterization of the SCAs demonstrated that when compared with the respective parental mAb, the SCAs possessed identical binding affinities and similar Q(max) and lambda(max) (absorption profiles of bound Fl) values. These results validated SCA 9-40, 12-40, and 5-14 for use in site-directed mutagenesis studies. Results of mutagenesis studies indicated that substitution of L34Arg into the active sites of 9-40, 12-40, and 5-14 was not enough to produce 4-4-20-like binding characteristics. Therefore, the following single chain mutants were constructed: 9-40L34Arg/L46Val, 12-40L34Arg/L46Val and 5-14L34Arg/L46Val, 9-40L34Arg/L46Val/H101Asp and 4-4-20H101Ala. Results demonstrated that these mutations were not able to render the mutant SCAs with increased binding affinity and fluorescence quenching values. Collectively, these results suggest that the combining sites of mAb 9-40, 12-40, and 5-14 may possess different active site structures than mAb 4-4-20.			DENZIN, LK (corresponding author), UNIV ILLINOIS,DEPT MICROBIOL,407 S GOODWIN AVE,URBANA,IL 61801, USA.							BATES RM, 1985, MOL IMMUNOL, V22, P871, DOI 10.1016/0161-5890(85)90072-0; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; BEDZYK WD, 1989, J BIOL CHEM, V264, P1565; BEDZYK WD, 1986, MOL IMMUNOL, V23, P1319, DOI 10.1016/0161-5890(86)90017-9; BEDZYK WD, 1990, J BIOL CHEM, V265, P133; BEDZYK WD, 1990, J BIOL CHEM, V265, P18615; BEDZYK WD, 1991, MOL IMMUNOL, V23, P27; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DENZIN LK, 1991, J BIOL CHEM, V266, P14095; GALFRE G, 1977, NATURE, V266, P550, DOI 10.1038/266550a0; GIBSON AL, 1988, PROTEINS, V3, P155, DOI 10.1002/prot.340030304; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; HERRON JN, 1984, FLUORESCEIN HAPTEN I, P49; KABAT EA, 1987, SEQUENCES PROTEINS I, P1; KAWASAKI E, 1989, AMPLIFICATIONS FORUM, V3, P4; KRANZ DM, 1983, MOL IMMUNOL, V20, P1313, DOI 10.1016/0161-5890(83)90162-1; KRANZ DM, 1982, J BIOL CHEM, V257, P6987; KRANZ DM, 1981, MOL IMMUNOL, V18, P889, DOI 10.1016/0161-5890(81)90012-2; KRANZ DM, 1984, FLUORESCEIN HAPTEN I, P121; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; Miller J. H., 1972, EXPT MOL GENETICS, P433; MORAHAN G, 1983, NATURE, V301, P720, DOI 10.1038/301720a0; NISHINARITA S, 1985, J IMMUNOL, V134, P2544; REINITZ DM, 1984, MOL IMMUNOL, V21, P775, DOI 10.1016/0161-5890(84)90164-0; REINITZ DM, 1985, J IMMUNOL, V135, P3365; RINFRET A, 1985, J IMMUNOL, V135, P2574; SCANDELLA D, 1985, J CELL BIOCH B, V9, P203; SEN J, 1986, Proteins Structure Function and Genetics, V1, P256, DOI 10.1002/prot.340010308; SMITH RA, 1983, APPL ENVIRON MICROB, V45, P586, DOI 10.1128/AEM.45.2.586-590.1983; SWINDLEHURST CA, 1991, BIOPHYS J, V59, P619, DOI 10.1016/S0006-3495(91)82277-9; TEMPLETON EFG, 1985, MOL IMMUNOL, V22, P45, DOI 10.1016/0161-5890(85)90033-1; WATT RM, 1977, IMMUNOCHEMISTRY, V14, P533, DOI 10.1016/0019-2791(77)90308-1; WATT RM, 1978, IMMUNOCHEMISTRY, V15, P875, DOI 10.1016/0161-5890(78)90121-9	38	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8925	8931						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577730				2022-12-25	WOS:A1992HR85400036
J	MYLES, ME; RUSSELL, JD; TRUPIN, JS; SMITH, JC; RUSSELL, SB				MYLES, ME; RUSSELL, JD; TRUPIN, JS; SMITH, JC; RUSSELL, SB			KELOID FIBROBLASTS ARE REFRACTORY TO INHIBITION OF DNA-SYNTHESIS BY PHORBOL ESTERS - ALTERED RESPONSE IS ACCOMPANIED BY REDUCED SENSITIVITY TO PROSTAGLANDIN-E2 AND ALTERED DOWN-REGULATION OF PHORBOL ESTER BINDING-SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; EPIDERMAL GROWTH-FACTOR; ARACHIDONIC-ACID RELEASE; TUMOR PROMOTERS; MESSENGER-RNA; CELL-LINES; STIMULATION; EXPRESSION; GENE; 12-O-TETRADECANOYLPHORBOL-13-ACETATE	To investigate abnormal growth regulation in keloid fibroblasts, responses to phorbol esters were examined. Treatment of quiescent cultures with phorbol 12-myristate 13-acetate (PMA) blocked a normally occurring (20-24 h) peak of serum-stimulated thymidine incorporation in normal and keloid cells. In keloid fibroblasts PMA induced a delayed peak of DNA synthesis. When indomethacin was added with PMA the delayed peak appeared in normal fibroblasts. The ED50 for inhibition of the 20-24-h peak was 1 nm, whereas the delayed peak required a 50-fold-higher PMA concentration. In both cell types PMA induced prostaglandin E2 (PGE2) synthesis, and exogenous PGE2 caused 50% inhibition of the 20-24-h peak. When PMA and indomethacin were added with PGE2 the delayed peak was inhibited 90% in normal fibroblasts, whereas inhibition of keloid cells was the same as with PGE2 alone. Normal and keloid fibroblasts had the same number of phorbol ester binding sites. However, in normal cells, phorbol 12,13-dibutyrate bound with greater affinity, and down-regulation of phorbol ester binding occurred to a greater extent. These findings suggest that altered expression of protein kinase C isozymes or another molecule that binds phorbol esters may play a role in abnormal growth regulation of keloid cells.	MEHARRY MED COLL,SCH GRAD STUDIES,DIV BIOMED SCI,NASHVILLE,TN 37208; MEHARRY MED COLL,SCH MED,DEPT MICROBIOL,NASHVILLE,TN 37208; MEHARRY MED COLL,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37208	Meharry Medical College; Meharry Medical College; Meharry Medical College					NATIONAL CANCER INSTITUTE [R01CA017229] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S06RR008037] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K14HL002332] Funding Source: NIH RePORTER; NCI NIH HHS [CA-17229] Funding Source: Medline; NCRR NIH HHS [RR-08037] Funding Source: Medline; NHLBI NIH HHS [HL-02332] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JC, 1989, BIOCHEM J, V257, P905, DOI 10.1042/bj2570905; ASE K, 1988, FEBS LETT, V236, P396, DOI 10.1016/0014-5793(88)80064-4; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BALLOU LR, 1990, J IMMUNOL, V145, P4245; BLUMBERG PM, 1988, CANCER RES, V48, P1; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BURCH RM, 1988, J BIOL CHEM, V263, P4764; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHABBOTT H, 1986, P NATL ACAD SCI USA, V83, P3126, DOI 10.1073/pnas.83.10.3126; CHIDA K, 1983, CANCER RES, V43, P3638; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DATUBOBROWN DD, 1990, BRIT J PLAST SURG, V43, P70, DOI 10.1016/0007-1226(90)90047-4; DECKER SJ, 1984, MOL CELL BIOL, V4, P1718, DOI 10.1128/MCB.4.9.1718; DIAMOND L, 1978, LIFE SCI, V23, P1979, DOI 10.1016/0024-3205(78)90229-1; DRIEDGER PE, 1980, P NATL ACAD SCI-BIOL, V77, P567, DOI 10.1073/pnas.77.1.567; FURSTENBERGER G, 1978, BIOCHEM BIOPH RES CO, V84, P1103, DOI 10.1016/0006-291X(78)91697-2; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HORI T, 1989, J CELL PHYSIOL, V141, P275, DOI 10.1002/jcp.1041410207; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HWONG CL, 1989, J BIOL CHEM, V264, P14923; ISAKOV N, 1990, J BIOL CHEM, V265, P2091; KO SD, 1977, P NATL ACAD SCI USA, V74, P3429, DOI 10.1073/pnas.74.8.3429; KORN JH, 1980, J CLIN INVEST, V65, P543, DOI 10.1172/JCI109698; LECHNER JF, 1980, CELL BIOL INT REP, V4, P23, DOI 10.1016/0309-1651(80)90005-3; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; MARAGANORE JM, 1987, TRENDS BIOCHEM SCI, V12, P176, DOI 10.1016/0968-0004(87)90082-X; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MAUVIEL A, 1988, FEBS LETT, V231, P125, DOI 10.1016/0014-5793(88)80715-4; MUIR IFK, 1990, BRIT J PLAST SURG, V43, P61, DOI 10.1016/0007-1226(90)90046-3; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PARKER J, 1987, J BIOL CHEM, V262, P5385; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; RAZ A, 1989, P NATL ACAD SCI USA, V86, P1657, DOI 10.1073/pnas.86.5.1657; RECHLER MM, 1976, J SUPRAMOL STR CELL, V4, P199, DOI 10.1002/jss.400040207; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; RUSSEL SB, 1988, COLLAGEN REL RES, V8, P537; RUSSELL JD, 1978, J CELL PHYSIOL, V97, P221, DOI 10.1002/jcp.1040970211; RUSSELL JD, 1976, PLAST RECONSTR SURG, V57, P207, DOI 10.1097/00006534-197602000-00014; RUSSELL SB, 1989, J BIOL CHEM, V264, P13730; RUSSELL SB, 1988, P NATL ACAD SCI USA, V85, P587, DOI 10.1073/pnas.85.2.587; SOLANKI V, 1981, P NATL ACAD SCI-BIOL, V78, P1722, DOI 10.1073/pnas.78.3.1722; STABEL S, 1987, J CELL PHYSIOL, V130, P111, DOI 10.1002/jcp.1041300116; TAKASU N, 1987, BIOCHEM BIOPH RES CO, V143, P880, DOI 10.1016/0006-291X(87)90331-7; TAO W, 1989, BIOCHEM J, V257, P633, DOI 10.1042/bj2570633; TASHJIAN AH, 1978, PROSTAGLANDINS, V16, P221, DOI 10.1016/0090-6980(78)90023-0; TAYLOR L, 1977, FEBS LETT, V79, P69, DOI 10.1016/0014-5793(77)80352-9; TAYLOR L, 1981, PROSTAGLANDINS, V22, P723, DOI 10.1016/0090-6980(81)90211-2; TRUPIN JS, 1983, COLLAGEN REL RES, V3, P13; VELDHUIS JD, 1987, MOL CELL ENDOCRINOL, V49, P249, DOI 10.1016/0303-7207(87)90219-X; VERMA AK, 1980, CANCER RES, V40, P308; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; YAMAGUCHI DT, 1988, J BIOL CHEM, V263, P10745; YAMASHITA T, 1987, J BIOL CHEM, V262, P5536; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775	55	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9014	9020						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577738				2022-12-25	WOS:A1992HR85400049
J	COMBEAU, C; DIDRY, D; CARLIER, MF				COMBEAU, C; DIDRY, D; CARLIER, MF			INTERACTION BETWEEN G-ACTIN AND MYOSIN SUBFRAGMENT-1 PROBED BY COVALENT CROSS-LINKING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; BINDING-SITES; HEAVY-CHAIN; NH2-TERMINAL SEGMENT; ATOMIC MODEL; POLYMERIZATION; PROTEINS; COMPLEX; STOICHIOMETRY; TROPOMYOSIN	The topography of rapid equilibrium complexes formed between G-actin and myosin subfragment-1, which are the first kinetic intermediates in the polymerization process into F-acto-S1 filaments, has been probed by chemical cross-linking. In the absence of ATP, cross-linking of G-actin-S1 complexes by 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) yielded a major 165-170-kDa and a fainter 200-205-kDa doublet polypeptide. The actin:S1 molar ratio was 1 in the EDC-cross-linked complexes, using either double labeling techniques or the method combining EDC + N-hydroxysuccinimide. Chemical cleavages of the covalently cross-linked complexes by formic acid and N-hydroxylamine (Sutoh, K. (1983) Biochemistry 22, 1579-1585) showed that in the main cross-linked 165-kDa polypeptide, the 1-12 acidic N-terminal region of actin was covalently linked to the lysine-rich region connecting the central 50-kDa domain to the C-terminal 20-kDa domain of S1, as in F-acto-S1 complexes. G-actin, but not F-actin, was covalently cross-linked to S1 by N,N'-paraphenylenedimaleimide (p-PDM). A major 195-kDa and a minor 165-kDa polypeptide were obtained, could be separated from actin and S1 by DEAE-cellulose chromatography, and did not exhibit actin-activated Mg-ATPase activity. Both EDC-cross-linked and p-PDM-cross-linked complexes between G-actin and S1 could be incorporated into F-acto-S1 decorated filaments. The C-terminal cysteine 374 of actin is involved in the p-PDM cross-linked 195-kDa complex. Accordingly, a covalent photocross-linked 200-kDa conjugate was formed between S1 heavy chain and benzophenone-G-actin, obtained by covalent modification of Cys374 by benzophenonemaleimide (Tao, T., Lamkin, M., and Scheiner, C. J. (1985) Arch. Biochem. Biophys. 240, 627-634). These results demonstrate that (i) G-actin-S1 and F-actin-S1 complexes display a large similarity in the EDC-cross-linked electrostatic close contacts and (ii) a change in the environment of Cys374 is linked to the polymerization into F-actin-S1 decorated filaments.	CNRS,ENZYMOL LAB,F-91198 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay								AUDEMARD E, 1988, J MUSCLE RES CELL M, V9, P197, DOI 10.1007/BF01773891; BERTRAND R, 1989, EUR J BIOCHEM, V181, P747, DOI 10.1111/j.1432-1033.1989.tb14787.x; BERTRAND R, 1988, BIOCHEMISTRY-US, V27, P5728, DOI 10.1021/bi00415a050; BETTACHE N, 1989, P NATL ACAD SCI USA, V86, P6028, DOI 10.1073/pnas.86.16.6028; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLIER MF, 1991, J BIOL CHEM, V266, P1; CHAUSSEPIED P, 1989, J BIOL CHEM, V264, P20752; CHAUSSEPIED P, 1989, NATURE, V342, P950, DOI 10.1038/342950a0; CHAUSSEPIED P, 1988, P NATL ACAD SCI USA, V85, P7471, DOI 10.1073/pnas.85.20.7471; CHEN T, 1985, BIOCHEMISTRY-US, V24, P137, DOI 10.1021/bi00322a019; CHEN T, 1991, BIOCHEMISTRY-US, V30, P4546, DOI 10.1021/bi00232a026; COMBEAU C, 1992, BIOCHEMISTRY-US, V31, P300, DOI 10.1021/bi00116a041; DASGUPTA G, 1990, BIOCHEMISTRY-US, V29, P8503, DOI 10.1021/bi00488a043; DETMERS P, 1981, J BIOL CHEM, V256, P99; DOI YK, 1991, BIOCHEMISTRY-US, V30, P5769, DOI 10.1021/bi00237a020; DUONG AM, 1989, BIOCHEMISTRY-US, V28, P3502, DOI 10.1021/bi00434a053; EISENBERG E, 1974, J BIOL CHEM, V249, P4742; ELZINGA M, 1984, P NATL ACAD SCI-BIOL, V81, P6599, DOI 10.1073/pnas.81.21.6599; ELZINGA M, 1991, BIOPHYS J, V59, P52; GEEVES MA, 1989, BIOCHEMISTRY-US, V28, P5864, DOI 10.1021/bi00440a024; GEEVES MA, 1986, BIOCHEMISTRY-US, V25, P8454, DOI 10.1021/bi00374a020; GRABAREK Z, 1990, ANAL BIOCHEM, V185, P131, DOI 10.1016/0003-2697(90)90267-D; GRAZI E, 1980, FEBS LETT, V12, P67; GREENE LE, 1984, J BIOL CHEM, V259, P7363; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HEAPHY S, 1984, BIOCHEMISTRY-US, V23, P2211, DOI 10.1021/bi00305a017; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Holmes KC, 1991, CURR OPIN STRUC BIOL, V1, P270, DOI 10.1016/0959-440X(91)90073-3; KEANE AM, 1990, NATURE, V344, P265, DOI 10.1038/344265a0; KNIGHT P, 1980, BIOCHEMISTRY-US, V19, P4682, DOI 10.1021/bi00561a022; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LU RC, 1991, BIOPHYS J, V59, P411; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; MILLER L, 1988, J BIOL CHEM, V263, P1996; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MOCKRIN S, 1980, BIOCHEMISTRY-US, V9, P5358; MORNET D, 1981, NATURE, V292, P301, DOI 10.1038/292301a0; OFFER G, 1973, J MOL BIOL, V74, P653, DOI 10.1016/0022-2836(73)90055-7; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; REISLER E, 1982, METHOD ENZYMOL, V85, P84; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P3654, DOI 10.1021/bi00258a020; SUTOH K, 1983, BIOCHEMISTRY-US, V22, P1579, DOI 10.1021/bi00276a009; TAO T, 1985, ARCH BIOCHEM BIOPHYS, V240, P627, DOI 10.1016/0003-9861(85)90070-0; TAO T, 1984, FEBS LETT, V168, P169, DOI 10.1016/0014-5793(84)80229-X; TAWADA K, 1969, BIOCHIM BIOPHYS ACTA, V180, P199, DOI 10.1016/0005-2728(69)90209-6; VALENTINRANC C, 1991, J BIOL CHEM, V266, P17872; VALENTINRANC C, 1989, J BIOL CHEM, V264, P20871; WEEDS A, 1991, Current Biology, V1, P307, DOI 10.1016/0960-9822(91)90093-C; WEEDS AG, 1977, J MOL BIOL, V111, P129, DOI 10.1016/S0022-2836(77)80119-8; YAMAMOTO K, 1989, BIOCHEMISTRY-US, V28, P5573, DOI 10.1021/bi00439a035	54	39	39	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14038	14046						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629203				2022-12-25	WOS:A1992JD32500042
J	MORGELIN, M; ENGEL, J; HEINEGARD, D; PAULSSON, M				MORGELIN, M; ENGEL, J; HEINEGARD, D; PAULSSON, M			PROTEOGLYCANS FROM THE SWARM RAT CHONDROSARCOMA - STRUCTURE OF THE AGGREGATES EXTRACTED WITH ASSOCIATIVE AND DISSOCIATIVE SOLVENTS AS REVEALED BY ELECTRON-MICROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE CARTILAGE PROTEOGLYCAN; LINK-PROTEIN; BINDING REGION; CORE PROTEIN; KERATAN SULFATE; HYALURONIC-ACID; NASAL CARTILAGE; PARTIAL CDNA; MOLECULES; SEQUENCE	Proteoglycan aggregates were extracted from Swarm rat chondrosarcoma tissue in the native state and compared with proteoglycan aggregates isolated dissociatively with 4 m guanidine HCl. Purified aggregates were examined with a variety of electron microscopic techniques. In some cases they showed a structure of the central filament identical to that of the link-stabilized central filament observed in earlier experiments where the separated constituents were allowed to reconstitute (Morgelin, M., Paulsson, M., Hardingham, T. E., Heinegard, D., and Engel, J. (1988) Biochem. J. 253, 175-185). The tight packing of proteoglycan monomers along the hyaluronate with a minimum distance of 12 nm between adjacent E1 strands also could thus be confirmed for never dissociated aggregates. The results therefore show that the organization of proteoglycan aggregates assembled in vitro from the participating molecules is representative for conditions in situ. An additional structural type of central filament was observed in the preparations. This contained long stretches of free hyaluronate interspaced by short stretches of central filament with condensed arrays of link protein-proteoglycan. Chemical cross-linking in combination with low shear electron microscopical techniques showed that this discontinuous central filament structure is not an artifact of specimen preparation. The addition of suprastoichiometric amounts of exogenous link protein did not affect the central filament structure with the low packing density. Densely and loosely packed types of central filament were isolated in varying relative amounts with different associative and dissociative solvents.	UNIV BASEL,BIOCTR,DEPT BIOPHYS CHEM,CH-4056 BASEL,SWITZERLAND; UNIV LUND,DEPT MED & PHYSIOL CHEM,S-22100 LUND,SWEDEN; UNIV BERN,ME MULLER INST BIOMECH,CH-3010 BERN,SWITZERLAND	University of Basel; Lund University; University of Bern	MORGELIN, M (corresponding author), UNIV BASEL,BIOCTR,ME MULLER INST HIGH RESOLUT ELECTRON MICROSCOPY,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.							ANTONSSON P, 1989, J BIOL CHEM, V264, P16170; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BONNET F, 1985, BIOCHEM J, V228, P77, DOI 10.1042/bj2280077; CHOI HU, 1971, P NATL ACAD SCI USA, V68, P877, DOI 10.1073/pnas.68.5.877; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOEGE K, 1990, BIOCHEM SOC T, V18, P200, DOI 10.1042/bst0180200; DOEGE K, 1986, J BIOL CHEM, V261, P8108; FALTZ LL, 1979, J BIOL CHEM, V254, P1381; FALTZ LL, 1979, J BIOL CHEM, V254, P1375; FRANZEN A, 1981, BIOCHEM J, V197, P669, DOI 10.1042/bj1970669; HALBERG DF, 1988, J BIOL CHEM, V263, P9486; HARDINGHAM TE, 1979, BIOCHEM J, V177, P237, DOI 10.1042/bj1770237; HARDINGHAM TE, 1986, RHEUMATOLOGY, V10, P143; HASCALL VC, 1972, J BIOL CHEM, V247, P4521; HASCALL VC, 1974, J BIOL CHEM, V249, P4242; HASCALL VC, 1970, J BIOL CHEM, V245, P4920; HEINEGARD D, 1985, BIOCHEM J, V225, P95, DOI 10.1042/bj2250095; HEINEGARD D, 1987, METHOD ENZYMOL, V144, P319; HEINEGARD D, 1977, J BIOL CHEM, V252, P1980; HEINEGARD D, 1977, J BIOL CHEM, V252, P1971; HEINEGARD D, 1974, J BIOL CHEM, V249, P4250; HEINEGARD D, 1984, EXTRACELLULAR MATRIX, P277; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORGELIN M, 1990, BIOCHEM SOC T, V18, P204; MORGELIN M, 1988, BIOCHEM J, V253, P175; MORGELIN M, 1989, J BIOL CHEM, V264, P12080; MOULD AP, 1985, J ULTRA MOL STRUCT R, V91, P66, DOI 10.1016/0889-1605(85)90077-1; NAVE R, 1989, J CELL BIOL, V109, P2177, DOI 10.1083/jcb.109.5.2177; OEGEMA TE, 1977, J BIOL CHEM, V25, P6470; OEGEMA TR, 1975, J BIOL CHEM, V250, P6151; OLDBERG A, 1987, BIOCHEM J, V243, P255, DOI 10.1042/bj2430255; PAULSSON M, 1987, BIOCHEM J, V245, P763, DOI 10.1042/bj2450763; Roden L., 1972, METHODS ENZYMOLOGY, V28, P73; SAI S, 1986, P NATL ACAD SCI USA, V83, P5081, DOI 10.1073/pnas.83.14.5081; SAJDERA S, 1969, J BIOL CHEM, V244, P77; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; TENGBLAD A, 1981, BIOCHEM J, V199, P297, DOI 10.1042/bj1990297; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; WIEDEMANN H, 1985, BIOCHEM J, V224, P331	39	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14275	14284						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629221				2022-12-25	WOS:A1992JD32500076
J	SENER, A; MALAISSE, WJ				SENER, A; MALAISSE, WJ			HEXOSE METABOLISM IN PANCREATIC-ISLETS - CA2+-DEPENDENT ACTIVATION OF THE GLYCEROL PHOSPHATE SHUTTLE BY NUTRIENT SECRETAGOGUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSE; PHOSPHORYLATION; DEHYDROGENASE; OXIDATION; EVENTS	A method is proposed for the measurement of the flux through the glycerol phosphate shuttle in pancreatic islets. Such a flux is taken as the ratio between the production of (HOH)-H-3 and the specific radioactivity of L-[2-H-3]glycerophosphate in islets exposed to [2-H-3] glycerol. D-Glucose and non-glucidic nutrient secretagogues, such as 2-ketoisocaproate and 2-aminobicyclo[2,2,1]heptane-2-carboxylate, stimulate, in a Ca2+-dependent manner, circulation in the glycerol phosphate shuttle. The shuttle flux is commensurate with the fraction of pyruvate generation which is not coupled with L-lactate production. These findings support the view that a rise in D-glucose concentration leads to activation of the FAD-linked mitochondrial glycerophosphate dehydrogenase through an increase in cytosolic Ca2+ concentration.			SENER, A (corresponding author), FREE UNIV BRUSSELS,EXPTL MED LAB,B-1070 BRUSSELS,BELGIUM.		SENER, Abdullah/A-1769-2008	SENER, Abdullah/0000-0003-2718-5423				CARPINELLI AR, 1987, MED SCI RES-BIOCHEM, V15, P481; CRONHOLM T, 1984, BIOCHEM J, V224, P731, DOI 10.1042/bj2240731; LOWRY OH, 1972, FLEXIBLE SYSTEM ENZY, P141; MACDONALD MJ, 1981, J BIOL CHEM, V256, P8287; MACDONALD MJ, 1982, HORM METAB RES, V14, P678, DOI 10.1055/s-2007-1019117; MALAISSE WJ, 1991, MOL CELL BIOCHEM, V107, P95; MALAISSE WJ, 1988, BIOCHIM BIOPHYS ACTA, V971, P246, DOI 10.1016/S0005-2728(88)80038-0; MALAISSE WJ, 1982, ENDOCRINOLOGY, V111, P392, DOI 10.1210/endo-111-2-392; MALAISSE WJ, 1991, INT J BIOCHEM, V23, P955, DOI 10.1016/0020-711X(91)90085-2; Malaisse WJ, 1984, METHODS DIABETES RES, V1, P147; OSTLUND AK, 1983, BIOCHEM MED METAB B, V30, P231, DOI 10.1016/0006-2944(83)90089-3; RASSCHAERT J, 1991, BIOCHEM J, V278, P335, DOI 10.1042/bj2780335; SENER A, 1988, INT J BIOCHEM, V20, P595, DOI 10.1016/0020-711X(88)90098-5; SENER A, 1990, ANAL BIOCHEM, V186, P236, DOI 10.1016/0003-2697(90)90073-I; SENER A, 1984, BIOCHEM J, V220, P433, DOI 10.1042/bj2200433; SENER A, 1991, BIOCHIMIE, V73, P1287, DOI 10.1016/0300-9084(91)90090-N; YILMAZ MT, 1987, MOL CELL ENDOCRINOL, V52, P251, DOI 10.1016/0303-7207(87)90051-7	17	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13251	13256						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618829				2022-12-25	WOS:A1992JB74600027
J	STEPHENS, JM; PEKALA, PH				STEPHENS, JM; PEKALA, PH			TRANSCRIPTIONAL REPRESSION OF THE C/EBP-ALPHA AND GLUT4 GENES IN 3T3-L1 ADIPOCYTES BY TUMOR-NECROSIS-FACTOR-ALPHA - REGULATION IS COORDINATE AND INDEPENDENT OF PROTEIN-SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER BINDING-PROTEIN; MESSENGER-RNA; GLUCOSE TRANSPORTER; EXPRESSION; DIFFERENTIATION; FAMILY; CELLS; PREADIPOCYTES; MEMBER; BETA	We have previously demonstrated the ability of tumor necrosis factor-alpha (TNF) to down-regulate the expression of GLUT4 (insulin-responsive glucose transporter) and C/EBP-alpha (CCAAT/enhancer-binding protein) (Stephens J. M., and Pekala, P. H. (1991) J. Biol. Chem. 266, 21839-21845). As C/EBP-alpha has been suggested to control GLUT4 expression, we have examined the time course for attenuation of transcription of these genes. Run-on transcription assays indicate a coordinate transcriptional repression of both GLUT4 and C/EBP-alpha-genes (as well as the 422/aP2 gene, the adipocyte lipid-binding protein, whose expression has also been proposed to be controlled by C/EBP-alpha). Inhibition of transcription was observed within 1 h of TNF addition, with maximal suppression observed after 4 h. The inhibition was not blocked by cycloheximide. Okadaic acid treatment (1 h, 0.5-mu-M) also resulted in the coordinate transcriptional repression of the C/EBP-alpha, GLUT4, and 422/aP2 genes, consistent with involvement of a kinase-phosphatase system in the regulation of these genes. The decrease in C/EBP-alpha-protein content was detectable 4 h after TNF addition and declined to 25% of controls within 24 h. A minor decrease in the protein content of GLUT4 was observed during the first 24 h of exposure to TNF; however, after 72 h of exposure GLUT4 protein was not detectable. The rapid coordinate transcriptional regulation of C/EBP-alpha, GLUT4, and 422/aP2 by TNF in the presence of cycloheximide suggests that the TNF-induced loss of GLUT4 protein may be mediated by a post-translational modification of an existing transcription factor. However, the rapid loss of C/EBP-alpha-protein may be a contributing factor to further transcriptional suppression of the GLUT4 gene at the later time points. In addition to the transcriptional effect, we report that TNF-induced destabilization of these mRNAs contributes to decreased expression of all three genes.	E CAROLINA UNIV,SCH MED,DEPT BIOCHEM,GREENVILLE,NC 27834	University of North Carolina; East Carolina University			Stephens, Jacqueline M/R-5217-2018		NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005812] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032892] Funding Source: NIH RePORTER; NCRR NIH HHS [2 S07 RR05812-12] Funding Source: Medline; NIGMS NIH HHS [GM32892] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5394; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; CORNELIUS P, 1991, J CELL PHYSIOL, V146, P298, DOI 10.1002/jcp.1041460215; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; CORNELIUS P, 1988, BIOCHEM J, V249, P765, DOI 10.1042/bj2490765; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; FROST SC, 1985, J BIOL CHEM, V260, P2646; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GRAVES RA, 1992, MOL CELL BIOL, V12, P1202, DOI 10.1128/MCB.12.3.1202; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; KAESTNER KH, 1991, P NATL ACAD SCI USA, V88, P1933, DOI 10.1073/pnas.88.5.1933; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; MCKEON C, 1991, BIOCHEM BIOPH RES CO, V174, P721, DOI 10.1016/0006-291X(91)91477-T; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; PEKALA P, 1983, J EXP MED, V157, P1360, DOI 10.1084/jem.157.4.1360; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; RON D, 1992, J CLIN INVEST, V89, P223, DOI 10.1172/JCI115566; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; SAMUELSSON L, 1991, EMBO J, V10, P3787, DOI 10.1002/j.1460-2075.1991.tb04948.x; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597; TORTI FM, 1989, J CELL BIOL, V108, P1105, DOI 10.1083/jcb.108.3.1105; WEINER FR, 1989, BIOCHEMISTRY-US, V28, P4094, DOI 10.1021/bi00435a070; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553	34	180	185	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13580	13584						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618860				2022-12-25	WOS:A1992JB74600076
J	DEARRUDA, MV; BAZARI, H; WALLEK, M; MATSUDAIRA, P				DEARRUDA, MV; BAZARI, H; WALLEK, M; MATSUDAIRA, P			AN ACTIN FOOTPRINT ON VILLIN - SINGLE SITE SUBSTITUTIONS IN A CLUSTER OF BASIC RESIDUES INHIBIT THE ACTIN SEVERING BUT NOT CAPPING ACTIVITY OF VILLIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; MICROVILLUS CYTOSKELETON; VISCERAL ENDODERM; ESCHERICHIA-COLI; CALCIUM CONTROL; BINDING DOMAIN; GELSOLIN; PROTEINS; SEQUENCE; EXPRESSION	Villin is a multidomain protein that severs, caps, and bundles actin filaments. We employed a chemical modification/cleavage strategy to identify residues whose chemical reactivities are reduced when villin is complexed with actin. We found that actin protects 3 methionine residues, Met125, Met379, and Met711 from oxidation by N-chlorosuccinimide. Because Met125 lies within the actin-severing domain of villin (44T), we probed this region for actin binding sites using a series of overlapping peptides each with an additional cysteine residue at their C terminus. Each peptide, as a disulfide-bonded dimer, was examined for actin cross-linking activity by electron microscopy and light scattering. Our results with M3R suggest this region contains an F-actin binding site and are consistent with proteolysis and deletion mutagenesis studies of gelsolin. Single substitution of the basic residues modulated actin severing but not capping activity of 44T. Circular dichroism and protease digestions did not detect alterations in secondary structure or conformational changes in the mutants, although some are cleaved more rapidly, thereby suggesting a change in the packing of the domains. Our results highlight that basic residues comprise part of the F-actin binding site that is involved in the actin severing activity of villin.	MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT)	DEARRUDA, MV (corresponding author), MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.		Matsudaira, Paul/H-1475-2012	Matsudaira, Paul/0000-0002-8399-3276	NIDDK NIH HHS [DK35306] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035306] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMPE C, 1987, EMBO J, V6, P4149, DOI 10.1002/j.1460-2075.1987.tb02761.x; ANDRE E, 1988, J BIOL CHEM, V263, P722; BAZARI WL, 1988, P NATL ACAD SCI USA, V85, P4986, DOI 10.1073/pnas.85.14.4986; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETSCHER A, 1980, CELL, V20, P839, DOI 10.1016/0092-8674(80)90330-X; BRYAN J, 1985, J CELL BIOL, V101, P1236, DOI 10.1083/jcb.101.4.1236; BRYAN J, 1988, J CELL BIOL, V106, P1553, DOI 10.1083/jcb.106.5.1553; CHAUSSEPIED P, 1988, P NATL ACAD SCI USA, V85, P7471, DOI 10.1073/pnas.85.20.7471; DOERING D, 1992, THESIS MIT; EICHINGER L, 1991, J CELL BIOL, V112, P665, DOI 10.1083/jcb.112.4.665; EZZELL RM, 1989, DEVELOPMENT, V106, P407; GLENNEY JR, 1980, P NATL ACAD SCI-BIOL, V77, P6458, DOI 10.1073/pnas.77.11.6458; GLENNEY JR, 1981, P NATL ACAD SCI-BIOL, V78, P2810, DOI 10.1073/pnas.78.5.2810; JANMEY PA, 1988, J BIOL CHEM, V263, P16738; JANMEY PA, 1986, J MUSCLE RES CELL M, V7, P446, DOI 10.1007/BF01753587; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JANMEY PA, 1992, J BIOL CHEM, P11818; JOHNSTON PA, 1990, J BIOL CHEM, V265, P17946; JOPPICHKUHN R, 1982, ANAL BIOCHEM, V119, P73, DOI 10.1016/0003-2697(82)90666-2; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; KWIATKOWSKI DJ, 1985, J BIOL CHEM, V260, P5232; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Louvard D, 1989, CURR OPIN CELL BIOL, V1, P51, DOI 10.1016/S0955-0674(89)80036-5; MATSUDAIRA P, 1985, P NATL ACAD SCI USA, V82, P6788, DOI 10.1073/pnas.82.20.6788; MATSUDAIRA P, 1985, NATURE, V315, P248, DOI 10.1038/315248a0; MATSUDAIRA P, 1992, P73; MATSUDAIRA P, 1983, NATURE, V301, P209, DOI 10.1038/301209a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATSUDAIRA PT, 1978, ANAL BIOCHEM, V87, P386, DOI 10.1016/0003-2697(78)90688-7; MATSUDAIRA PT, 1982, J CELL BIOL, V92, P657, DOI 10.1083/jcb.92.3.657; MAUNOURY R, 1988, EMBO J, V7, P3321, DOI 10.1002/j.1460-2075.1988.tb03203.x; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; PRENDERGAST GC, 1991, EMBO J, V10, P757, DOI 10.1002/j.1460-2075.1991.tb08007.x; Sambrook J, 1989, MOL CLONING LABORATO; SHECHTER Y, 1975, BIOCHEMISTRY-US, V14, P4497, DOI 10.1021/bi00691a025; SOUTHWICK FS, 1986, J BIOL CHEM, V261, P14191; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUTOH K, 1989, BIOCHEMISTRY-US, V28, P5269, DOI 10.1021/bi00438a052; SUZUKI R, 1987, J BIOL CHEM, V262, P11410; TAYLOR RS, 1976, BIOCHEM J, V159, P301, DOI 10.1042/bj1590301; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALSH TP, 1984, BIOCHEMISTRY-US, V23, P2613, DOI 10.1021/bi00307a012; WAY M, 1992, J CELL BIOL, V116, P1135, DOI 10.1083/jcb.116.5.1135; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x; YIN HL, 1990, FEBS LETT, V264, P78, DOI 10.1016/0014-5793(90)80769-F; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912	50	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					13079	13085						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618806				2022-12-25	WOS:A1992HZ48300100
J	CHATTOPADHYAY, A; JAMES, HL; FAIR, DS				CHATTOPADHYAY, A; JAMES, HL; FAIR, DS			MOLECULAR RECOGNITION SITES ON FACTOR-XA WHICH PARTICIPATE IN THE PROTHROMBINASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION; SERINE PROTEASES; FACTOR-V; ACTIVATION	Coagulation factor X, when activated to factor Xa by proteolytic cleavage, itself becomes an active serine protease which participates as a component of the macromolecular prothrombinase complex along with factor Va, phospholipid, and calcium ions. To identify specific structural regions on factor Xa responsible for mediating its function in activating prothrombin, we used 21 synthetic peptides corresponding to 65% of the primary structure of factor X as potential inhibitors of prothrombin activation. Using purified components, thrombin formation was inhibited by seven peptides in a dose-dependent noncompetitive manner. Antibodies to selected inhibitory peptides affinity purified on a factor Xa-agarose column inhibited thrombin formation in a dose-dependent manner, indicating that the corresponding regions on factor Xa are surface-exposed. Kinetic analyses varying the order of reagent addition suggested that peptides 211-222, 254-269, and 263-274 were highly effective in preventing the factor Xa-factor Va interaction. Peptides 275-287 and 415-425 were considered to derive from a distal region involved in substrate binding, based upon mixed inhibition kinetic analyses and assuming that inhibitory peptides not inhibitory in factor Va binding are related to a specific region of substrate interaction. Cross-linking studies confirmed that peptides 263-274 and 263-276 could bind specifically to the light chain of factor V/Va. These findings provide the basis for further pursuing the precise definition of interactive sites on factor Xa using site-directed mutagenesis and molecular modeling.	UNIV TEXAS, CTR HLTH, DEPT BIOCHEM, POB 2003, TYLER, TX 75710 USA	University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039040] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL39040] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRUNNER J, 1976, BIOCHIM BIOPHYS ACTA, V455, P322, DOI 10.1016/0005-2736(76)90308-4; CHATTOPADHYAY A, 1989, J BIOL CHEM, V264, P11035; DAHLBACK B, 1980, J CLIN INVEST, V66, P583, DOI 10.1172/JCI109890; FAIR DS, 1979, J CLIN INVEST, V64, P884, DOI 10.1172/JCI109554; FUNG MR, 1988, THESIS U BRIT COLUMB; FURIE B, 1982, J BIOL CHEM, V257, P3875; GREER J, 1981, J MOL BIOL, V153, P1027, DOI 10.1016/0022-2836(81)90465-4; Hartley BS, 1971, ENZYMES, V3, P323; Hewett-Emmett D, 1981, Ann N Y Acad Sci, V370, P511, DOI 10.1111/j.1749-6632.1981.tb29759.x; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; JACKSON CM, 1984, PROG HEMOST THROMB, V7, P55; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lundblad R L, 1976, Methods Enzymol, V45, P156; Mann K G, 1976, Methods Enzymol, V45, P123; NEMERSON Y, 1980, CRC CR REV BIOCH MOL, V9, P45, DOI 10.3109/10409238009105472; NESHEIM ME, 1979, J BIOL CHEM, V254, P508; NOSSEL HL, 1964, THROMB DIATH HAEMOST, V12, P505; SCHWARTZ BS, 1981, J CLIN INVEST, V67, P1650, DOI 10.1172/JCI110201; Segel I.H., 1975, ENZYME KINETICS; SEGERS WH, 1962, PROTHROMBIN, P213; SUTTIE JW, 1977, PHYSIOL REV, V57, P1, DOI 10.1152/physrev.1977.57.1.1	22	61	66	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12323	12329						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601896				2022-12-25	WOS:A1992HY94700100
J	ARNER, ESJ; VALENTIN, A; ERIKSSON, S				ARNER, ESJ; VALENTIN, A; ERIKSSON, S			THYMIDINE AND 3'-AZIDO-3'-DEOXYTHYMIDINE METABOLISM IN HUMAN PERIPHERAL-BLOOD LYMPHOCYTES AND MONOCYTE-DERIVED MACROPHAGES - A STUDY OF BOTH ANABOLIC AND CATABOLIC PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; HUMAN LYMPHOID-CELLS; PYRIMIDINE NUCLEOSIDES; ESCHERICHIA-COLI; DNA-SYNTHESIS; BRAIN-TISSUE; PHOSPHORYLASE; REPLICATION; INHIBITION; AIDS	3'-Azido-3'-deoxythymidine (AZT) is HIV-inhibitory in human macrophages, which is surprising in view of the low AZT phosphorylation reported in macrophage extracts. To elucidate the mechanism of AZT activation, we studied AZT anabolism as well as catabolism in human lymphocytes and macrophages, and compared it to that of thymidine. Thymidine kinase (TK)-specific activity in mitogen-stimulated lymphocytes was 15 times higher than in macrophages. However, the TK activity per cell was only 1.3 times higher, because of the large macrophage cell volume. Total cellular TK activity, but not specific activity, matched the level of intracellular AZT anabolism. The substrate specificity of TK in macrophages strongly suggests that mitochondrial TK2 was the enzyme phosphorylating thymidine and AZT in these cells, whereas it was cytosolic TK1 in stimulated lymphocytes. In vivo thymidine catabolism was extensive, forming thymine and dihydrothymine. In macrophages more than 95% of the added thymidine (0.5-mu-M) was degraded within 60 min. AZT, in contrast, was not catabolized, which explains the high AZT nucleotide accumulation, a process opposed only by AZTMP excretion. The lack of catabolism together with phosphorylation by TK2 clarifies how AZT can inhibit human immunodeficiency virus in macrophages. The fact that TK2 and not TK1 phosphorylates AZT in macrophages should have important implications for combination chemotherapy.	KAROLINSKA INST,DEPT VIROL,S-10521 STOCKHOLM,SWEDEN	Karolinska Institutet	ARNER, ESJ (corresponding author), KAROLINSKA INST,INST MED NOBEL,DEPT BIOCHEM 1,S-10401 STOCKHOLM 60,SWEDEN.		Arnér, Elias S.J./J-5832-2012; Arnér, Elias/K-6737-2019	Arnér, Elias S.J./0000-0002-4807-6114; Arnér, Elias/0000-0002-4807-6114				BALZARINI J, 1988, BIOCHEM PHARMACOL, V37, P897, DOI 10.1016/0006-2952(88)90178-5; BALZARINI J, 1987, MOL PHARMACOL, V32, P798; BODYCOTE J, 1986, P NATL ACAD SCI USA, V83, P4749, DOI 10.1073/pnas.83.13.4749; BOGENHAGEN D, 1976, J BIOL CHEM, V251, P2938; BOHMAN C, 1990, BIOCH LIFE SCI ADV, V9, P11; BOLS NC, 1980, ANAL BIOCHEM, V106, P230, DOI 10.1016/0003-2697(80)90142-6; BROWNE MJ, 1990, 6TH P INT C AIDS SAN, P200; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; COHEN A, 1983, J BIOL CHEM, V258, P2334; COHN ZA, 1965, J EXP MED, V121, P153, DOI 10.1084/jem.121.1.153; COHN ZA, 1965, J EXP MED, V121, P279, DOI 10.1084/jem.121.2.279; COOK WJ, 1987, J BIOL CHEM, V262, P3788; DESGRANGES C, 1982, BIOCHEM PHARMACOL, V31, P2755, DOI 10.1016/0006-2952(82)90129-0; DESGRANGES C, 1981, BIOCHIM BIOPHYS ACTA, V654, P211, DOI 10.1016/0005-2787(81)90174-X; ERIKSSON S, 1991, BIOCHEM BIOPH RES CO, V176, P586, DOI 10.1016/S0006-291X(05)80224-4; FINK RM, 1956, J BIOL CHEM, V218, P1; FRIDLAND A, 1990, MOL PHARMACOL, V37, P665; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GARTNER S, 1986, JAMA-J AM MED ASSOC, V256, P2365, DOI 10.1001/jama.256.17.2365; HAMAMOTO Y, 1987, ANTIMICROB AGENTS CH, V31, P907, DOI 10.1128/AAC.31.6.907; HAO Z, 1988, MOL PHARMACOL, V34, P431; HOLSTEGE A, 1986, CANCER RES, V46, P5576; Ives D H, 1978, Methods Enzymol, V51, P337; KARLSSON A, 1990, THESIS KAROLINSKA I, V2, P369; KIT S, 1985, MICROBIOL SCI, V2, P369; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; KRAJEWSKA E, 1978, BIOCHEM PHARMACOL, V27, P1421, DOI 10.1016/0006-2952(78)90095-3; MITSUYA H, 1991, FASEB J, V5, P2369, DOI 10.1096/fasebj.5.10.1712326; MOYER JD, 1985, J BIOL CHEM, V260, P2812; MUNCHPETERSEN B, 1991, J BIOL CHEM, V266, P9032; NIEMANN MA, 1981, BIOCHIM BIOPHYS ACTA, V652, P347, DOI 10.1016/0005-2787(81)90124-6; PERIGNON JL, 1987, BIOCHIM BIOPHYS ACTA, V928, P130, DOI 10.1016/0167-4889(87)90113-3; PERNO CF, 1988, J EXP MED, V168, P1111, DOI 10.1084/jem.168.3.1111; PERO RW, 1984, CANCER RES, V44, P4955; PETIT AJC, 1988, J IMMUNOL, V140, P1485; POGOLOTTI AL, 1981, ANAL BIOCHEM, V117, P178, DOI 10.1016/0003-2697(81)90708-9; POSAKONY JW, 1977, J CELL BIOL, V74, P468, DOI 10.1083/jcb.74.2.468; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; SPYROU G, 1987, J BIOL CHEM, V262, P16425; SUNDQVIST VA, 1989, J MED VIROL, V29, P170, DOI 10.1002/jmv.1890290305; SZEBENI J, 1991, ANTIMICROB AGENTS CH, V35, P198, DOI 10.1128/AAC.35.1.198; TERAI C, 1991, EXP CELL RES, V193, P375, DOI 10.1016/0014-4827(91)90110-G; TORNEVIK Y, 1991, AIDS RES HUM RETROV, V7, P751, DOI 10.1089/aid.1991.7.751; WALTER MR, 1990, J BIOL CHEM, V265, P14016; YARCHOAN R, 1989, NEW ENGL J MED, V321, P726, DOI 10.1056/NEJM198909143211106; YARCHOAN R, 1989, PHARMACOL THERAPEUT, V40, P329, DOI 10.1016/0163-7258(89)90083-1; ZHU Z, 1990, MOL PHARMACOL, V38, P929	48	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					10968	10975						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597439				2022-12-25	WOS:A1992HX16900009
J	LIM, HM; SIMON, MI				LIM, HM; SIMON, MI			THE ROLE OF NEGATIVE SUPERCOILING IN HIN-MEDIATED SITE-SPECIFIC RECOMBINATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA INVERSION; ENHANCER ACTIVITY; BACTERIOPHAGE-MU; STRAND EXCHANGE; PHASE VARIATION; FIS BINDING; PROTEIN; INVIVO; SYSTEM	A series of biochemical assays were developed and performed to monitor the molecular events that occur during the Hin-mediated DNA inversion reaction. These events can be divided into five different stages: 1) binding of proteins (Hin, Fis, and HU) to DNA; 2) pairing of Hin-binding sites; 3) invertasome formation; 4) DNA strand cleavage; 5) strand rotation and religation. A series of topoisomers of the wild type DNA substrate plasmid (ranging from fully relaxed molecules to those with more than the physiological superhelical density (the physiological superhelical density of pKH336 from Escherichia coli DH10B(TM) is -0.072 in this study)) was generated, and the role of negative supercoiling in each step of the inversion reaction was investigated. We found differences in the dependence of the formation of paired Hin-binding sites and of the invertasome formation on the superhelical density of the substrate plasmid. Pairing of Hin-binding sites occurs independently from invertasome formation, and a relatively low degree of negative supercoiling is enough to promote maximal pairing. However, efficient invertasome formation requires higher levels of negative supercoiling.	CALTECH,DIV BIOL 14775,PASADENA,CA 91125	California Institute of Technology								BENJAMIN HW, 1986, P RA WELCH F C CHEM, V29, P107; BOLES TC, 1990, J MOL BIOL, V213, P931, DOI 10.1016/S0022-2836(05)80272-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUIST MF, 1987, GENE DEV, V1, P762, DOI 10.1101/gad.1.8.762; BRUIST MF, 1984, J BACTERIOL, V159, P71, DOI 10.1128/JB.159.1.71-79.1984; GLASGOW AC, 1989, J BIOL CHEM, V264, P10072; GLASGOW AC, 1989, MOBILE DNA, P637; HEICHMAN KA, 1991, GENE DEV, V5, P1622, DOI 10.1101/gad.5.9.1622; HEICHMAN KA, 1990, SCIENCE, V249, P511, DOI 10.1126/science.2166334; HUBNER P, 1989, J MOL BIOL, V205, P493, DOI 10.1016/0022-2836(89)90220-9; HUGHES KT, 1988, GENE DEV, V2, P937, DOI 10.1101/gad.2.8.937; IIDA S, 1984, VIROLOGY, V134, P421, DOI 10.1016/0042-6822(84)90309-X; JOHNSON RC, 1985, CELL, V41, P781, DOI 10.1016/S0092-8674(85)80059-3; JOHNSON RC, 1987, NATURE, V329, P462, DOI 10.1038/329462a0; JOHNSON RC, 1986, CELL, V46, P531, DOI 10.1016/0092-8674(86)90878-0; JOHNSON RC, 1984, COLD SPRING HARB SYM, V49, P751, DOI 10.1101/SQB.1984.049.01.085; JOHNSON RC, 1989, EMBO J, V8, P1581, DOI 10.1002/j.1460-2075.1989.tb03542.x; KANAAR R, 1990, CELL, V62, P353, DOI 10.1016/0092-8674(90)90372-L; KANAAR R, 1989, CELL, V58, P147, DOI 10.1016/0092-8674(89)90411-X; KELLER W, 1975, P NATL ACAD SCI USA, V72, P4876, DOI 10.1073/pnas.72.12.4876; LEDERBERG J, 1956, GENETICS, V41, P743; LIM HM, 1992, J BIOL CHEM, V267, P11183; PLASTERK RHA, 1983, P NATL ACAD SCI-BIOL, V80, P5355, DOI 10.1073/pnas.80.17.5355; RHODES D, 1980, NATURE, V286, P573, DOI 10.1038/286573a0; SHURE M, 1977, NUCLEIC ACIDS RES, V4, P1183, DOI 10.1093/nar/4.5.1183; SINGLETON CK, 1982, ANAL BIOCHEM, V122, P253, DOI 10.1016/0003-2697(82)90277-9; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; VANDEPUTTE P, 1980, NATURE, V286, P218, DOI 10.1038/286218a0; ZIEG J, 1977, SCIENCE, V196, P170, DOI 10.1126/science.322276; ZIEG J, 1980, P NATL ACAD SCI-BIOL, V77, P4196, DOI 10.1073/pnas.77.7.4196	30	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11176	11182						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597452				2022-12-25	WOS:A1992HX16900040
J	READ, C; LAROSE, AM; LEBLANC, B; BANNISTER, AJ; FIREK, S; SMITH, DR; MOSS, T				READ, C; LAROSE, AM; LEBLANC, B; BANNISTER, AJ; FIREK, S; SMITH, DR; MOSS, T			HIGH-RESOLUTION STUDIES OF THE XENOPUS-LAEVIS RIBOSOMAL GENE PROMOTER INVIVO AND INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-I; TRANSCRIPTION FACTOR; BASE SUBSTITUTIONS; INITIATION-FACTOR; RDNA PROMOTER; CORE PROMOTER; UPSTREAM; DNA; MUTAGENESIS; SEQUENCES	The first high resolution maps of the Xenopus laevis ribosomal promoter and its flanking regions (-179 to +14) have been created by assaying point mutants both in oocyte and in vitro. Within the promoter boundaries (-141(-145) to +3(+4)), domains analogous to the Core Promoter and "Upstream Control Element" (UCE) were clearly detected. The base pairs at -133, within the UCE, and -20, -10, -7, and +3, within the Core, were all shown to be especially important for promotion. Between the Core and UCE, two central promoter elements (CPEs) were also resolved. Surprisingly, these CPEs did not correspond to the highly conserved enhancer homology (approximately -70 to -110), but to CCCGGCC motifs immediately flanking it. Although xUBF was shown to be a limiting component for in vitro transcription, none of the point mutations was found to affect the interaction of this factor with the promoter.	UNIV LAVAL,HOTEL DIEU QUEBEC,CTR RECH CANCEROL,QUEBEC CITY G1R 2J6,QUEBEC,CANADA	Laval University	READ, C (corresponding author), PORTSMOUTH POLYTECH,BIOPHYS LABS,PORTSMOUTH PO1 2DT,ENGLAND.			Bannister, Andrew/0000-0002-6312-4436; Moss, Thomas (Tom)/0000-0003-2047-4783				BATEMAN E, 1988, CELL, V54, P985, DOI 10.1016/0092-8674(88)90113-4; BELL SP, 1989, CELL, V59, P489, DOI 10.1016/0092-8674(89)90032-9; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BELL SP, 1990, GENE DEV, V4, P943, DOI 10.1101/gad.4.6.943; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BIRKENMEIER EH, 1978, CELL, V15, P1077, DOI 10.1016/0092-8674(78)90291-X; CASSIDY B, 1987, BIOCHIM BIOPHYS ACTA, V909, P133, DOI 10.1016/0167-4781(87)90035-2; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DEWINTER RFJ, 1986, NUCLEIC ACIDS RES, V14, P6041, DOI 10.1093/nar/14.15.6041; DUNAWAY M, 1989, GENE DEV, V3, P1768, DOI 10.1101/gad.3.11.1768; FIREK S, 1989, MOL CELL BIOL, V9, P3777, DOI 10.1128/MCB.9.9.3777; FIREK S, 1990, NUCLEIC ACIDS RES, V18, P105, DOI 10.1093/nar/18.1.105; GRUMMT I, 1982, P NATL ACAD SCI-BIOL, V79, P6908, DOI 10.1073/pnas.79.22.6908; GRUMMT I, 1982, NATURE, V296, P173, DOI 10.1038/296173a0; HALTINER MM, 1986, MOL CELL BIOL, V6, P227, DOI 10.1128/MCB.6.1.227; HENDERSON SL, 1990, MOL CELL BIOL, V10, P4970, DOI 10.1128/MCB.10.9.4970; HENDERSON SL, 1989, GENE DEV, V3, P12; JONES MH, 1988, P NATL ACAD SCI USA, V85, P669, DOI 10.1073/pnas.85.3.669; KEMPERSVEENSTRA AE, 1985, CURR GENET, V10, P253, DOI 10.1007/BF00365621; KOHORN BD, 1983, P NATL ACAD SCI-BIOL, V80, P3265, DOI 10.1073/pnas.80.11.3265; KOHORN BD, 1983, NATURE, V304, P179, DOI 10.1038/304179a0; KOWNIN P, 1985, NUCLEIC ACIDS RES, V13, P6237, DOI 10.1093/nar/13.17.6237; KOWNIN P, 1988, MOL CELL BIOL, V8, P747, DOI 10.1128/MCB.8.2.747; LEARNED RM, 1985, MOL CELL BIOL, V5, P1358, DOI 10.1128/MCB.5.6.1358; LEARNED RM, 1983, P NATL ACAD SCI-BIOL, V80, P3558, DOI 10.1073/pnas.80.12.3558; Maxam A M, 1980, Methods Enzymol, V65, P499; MCSTAY B, 1990, GENE DEV, V4, P1240, DOI 10.1101/gad.4.7.1240; MILLER KG, 1985, MOL CELL BIOL, V5, P554, DOI 10.1128/MCB.5.3.554; MISHIMA Y, 1982, NUCLEIC ACIDS RES, V10, P6659, DOI 10.1093/nar/10.21.6659; MITCHELSON K, 1987, NUCLEIC ACIDS RES, V15, P9577, DOI 10.1093/nar/15.22.9577; MOSS T, 1983, NATURE, V302, P223, DOI 10.1038/302223a0; Moss T, 1985, Oxf Surv Eukaryot Genes, V2, P207; MOSS T, 1982, CELL, V30, P835, DOI 10.1016/0092-8674(82)90288-4; MUSTERS W, 1989, NUCLEIC ACIDS RES, V17, P9661, DOI 10.1093/nar/17.23.9661; PAPE LK, 1990, GENE DEV, V4, P52, DOI 10.1101/gad.4.1.52; PIKAARD CS, 1990, MOL CELL BIOL, V10, P3810, DOI 10.1128/MCB.10.7.3810; PIKAARD CS, 1989, GENE DEV, V3, P1779, DOI 10.1101/gad.3.11.1779; REEDER RH, 1987, NUCLEIC ACIDS RES, V15, P7429, DOI 10.1093/nar/15.18.7429; SCHNAPP A, 1990, NUCLEIC ACIDS RES, V18, P1385, DOI 10.1093/nar/18.6.1385; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHORTLE D, 1978, P NATL ACAD SCI USA, V75, P2170, DOI 10.1073/pnas.75.5.2170; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; SOLLNERWEBB B, 1983, CELL, V35, P199, DOI 10.1016/0092-8674(83)90222-2; TANAKA N, 1990, J BIOL CHEM, V265, P13836; TOWER J, 1986, MOL CELL BIOL, V6, P3451, DOI 10.1128/MCB.6.10.3451; WALKER P, 1988, NUCLEIC ACIDS RES, V16, P10657, DOI 10.1093/nar/16.22.10657; WINDLE J, 1986, MOL CELL BIOL, V6, P1228, DOI 10.1128/MCB.6.4.1228; WINDLE JJ, 1986, MOL CELL BIOL, V6, P4585, DOI 10.1128/MCB.6.12.4585; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x; YAMAMOTO O, 1984, P NATL ACAD SCI-BIOL, V81, P299, DOI 10.1073/pnas.81.2.299	51	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					10961	10967						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597438				2022-12-25	WOS:A1992HX16900008
J	SANT, ME; LYONS, SD; PHILLIPS, L; CHRISTOPHERSON, RI				SANT, ME; LYONS, SD; PHILLIPS, L; CHRISTOPHERSON, RI			ANTIFOLATES INDUCE INHIBITION OF AMIDO PHOSPHORIBOSYLTRANSFERASE IN LEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE L1210 LEUKEMIA; DENOVO PURINE SYNTHESIS; DIHYDROFOLATE-REDUCTASE; METHOTREXATE; LYMPHOBLASTS; MECHANISMS; SYNERGISM; PATHWAY; LIVER	The pathway for de novo biosynthesis of purine, nucleotides contains two one-carbon transfer reactions catalyzed by glycinamide ribotide (GAR) and 5-aminoimidazole-4-carboxamide ribotide (AICAR) transformylases in which N-10-formyltetrahydrofolate is the one-carbon donor. We have found that the antifolates methotrexate (MTX) and piritrexim (PTX) completely block the de novo purine pathway in mouse L1210 leukemia cells growing in culture but with only minor accumulations of GAR and AICAR to less than 5% of the polyphosphate derivatives of N-formylglycinamide ribotide (FGAR) which accumulate when the pathway is blocked completely by azaserine. This azaserine-induced accumulation of FGAR polyphosphates is completely abolished by MTX, indicating that inhibition of the pathway is at or before GAR transformylase (reaction 3; Lyons, S. D., and Christopherson, R. I. (1991) Biochem. Int. 24, 187-197). Three h after the addition of MTX (0.1-mu-M), cellular 5-phosphoribosyl-1-pyrophosphate has accumulated 3.4-fold while 6-methylmercaptopurine riboside (25-mu-M) induces a 6.3-fold accumulation. These data suggest that amido phosphoribosyltransferase catalyzing reaction 1 of the pathway is the primary site of inhibition. In support of this conclusion, we have found that dihydrofolate-Glu5, which accumulates in MTX-treated cells, is a noncompetitive inhibitor of amido phosphoribosyltransferase with a dissociation constant of 3.41 +/- 0.08-mu-M for interaction with the enzyme-glutamine complex in vitro. Folate-Glu5, MTX-Glu5, PTX, dihydrotriazine benzenesulfonyl fluoride, and AICAR also inhibit amido phosphoribosyltransferase.	UNIV SYDNEY,DEPT BIOCHEM,SYDNEY,NSW 2006,AUSTRALIA	University of Sydney			Lyons, Stephen/AAH-2528-2020; Christopherson, Richard/AAM-3115-2020					ALLEGRA CJ, 1986, J BIOL CHEM, V261, P6478; ALLEGRA CJ, 1985, J BIOL CHEM, V260, P9720; ALLEGRA CJ, 1987, J BIOL CHEM, V262, P13520; BERTINO JR, 1965, BIOCHEMISTRY-US, V4, P839, DOI 10.1021/bi00881a007; BOKKERINK JPM, 1986, BIOCHEM PHARMACOL, V35, P3549, DOI 10.1016/0006-2952(86)90625-8; CHABNER BA, 1985, J CLIN INVEST, V76, P907, DOI 10.1172/JCI112088; COWARD JK, 1974, BIOCHEMISTRY-US, V13, P3899, DOI 10.1021/bi00716a013; DUCH DS, 1982, CANCER RES, V42, P3987; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; HILL DL, 1969, BIOCHEMISTRY-US, V8, P122, DOI 10.1021/bi00829a017; HOLMES EW, 1980, ADV ENZYME REGUL, V19, P215; ITAKURA M, 1979, J BIOL CHEM, V254, P333; KUMAR AA, 1981, J BIOL CHEM, V256, P8970; LYONS SD, 1990, J BIOL CHEM, V265, P11377; LYONS SD, 1991, BIOCHEM INT, V24, P187; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; NELSON JA, 1972, CANCER RES, V32, P2034; ROWE PB, 1978, J BIOL CHEM, V253, P7711; SANT ME, 1989, CANCER RES, V49, P2645; SANT ME, 1989, ANAL BIOCHEM, V182, P121, DOI 10.1016/0003-2697(89)90728-8; SCHENDEL FJ, 1988, BIOCHEMISTRY-US, V27, P2614, DOI 10.1021/bi00407a052; SEEGER DR, 1949, J AM CHEM SOC, V71, P1753, DOI 10.1021/ja01173a061; SEITHER RL, 1989, J BIOL CHEM, V264, P17016; THILLET J, 1988, J BIOL CHEM, V263, P12500; WALTHAM MC, 1989, P AUST BIOCHEM SOC, V21, pSP38; WERKHEISER W, 1961, J BIOL CHEM, V236, P888; WOOD AW, 1973, J BIOL CHEM, V248, P138	27	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11038	11045						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597445				2022-12-25	WOS:A1992HX16900020
J	WAN, J; XU, HX; GRUNSTEIN, M				WAN, J; XU, HX; GRUNSTEIN, M			CDC14 OF SACCHAROMYCES-CEREVISIAE - CLONING, SEQUENCE-ANALYSIS, AND TRANSCRIPTION DURING THE CELL-CYCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TYROSINE PHOSPHATASES; SINGLE-DIVISION MEIOSIS; HISTONE GENES; YEAST; SEGREGATION; DNA; MUTANTS; REPLICATION; NUCLEOSOME; PATHWAY	We have cloned, mapped and sequenced the complete CDC14 gene of Saccharomyces cerevisiae and characterized its transcription during the cell cycle. CDC14 was found within a 3.5-kilobase pair XhoI-XbaI fragment of chromosome VI. The DNA sequence reveals an open reading frame capable of encoding a 423-amino acid polypeptide. Protein sequence comparisons through the Prosite, GenBank and EMBL databases allowed us to identify a conserved protein tyrosine phosphatase active site in the encoded CDC14 protein beginning at amino acid 153. Disruption demonstrates that CDC14 is an essential gene. The level of the CDC14 transcript appears to be weakly cell cycle-regulated and has a periodicity which lags approximately 15 min behind histone HTB1 mRNA accumulation levels. DNA sequence analysis has identified a region within the CDC14 promoter which bears a striking resemblance (15 out of 21 base pairs identity) to the cell cycle regulation region of the promoter of the histone H2A1-H2B1 (HTA1-HTB1) gene pair. The cell cycle regulation sequence is responsible for the periodic accumulation and hydroxyurea sensitivity of the histone HTA1-HTB1 message. However, unlike histone mRNA, which is repressed upon hydroxyurea arrest, CDC14 mRNA appears to be unaffected. This suggests that CDC14 and histone genes are regulated by different mechanisms during the cell cycle. Furthermore, superhelical density measurements suggest that CDC14 is not involved in nucleosome assembly.	UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	WAN, J (corresponding author), UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023674, R01GM023674, T32GM007185] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23674, GM07185] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; GUAN K, 1991, J BIOL CHEM, V266, P12964; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HAN M, 1987, CELL, V48, P589, DOI 10.1016/0092-8674(87)90237-6; HARTWELL LH, 1973, GENETICS, V74, P267; HARTWELL LH, 1985, GENETICS, V110, P381; Hartwell LH, 1981, MOL BIOL YEAST SACCH, P97; HEREFORD L, 1979, CELL, V18, P1261, DOI 10.1016/0092-8674(79)90237-X; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; LYCAN DE, 1987, MOL CELL BIOL, V7, P614, DOI 10.1128/MCB.7.2.614; MOIR D, 1982, GENETICS, V100, P565; NASMYTH KA, 1980, P NATL ACAD SCI-BIOL, V77, P2119, DOI 10.1073/pnas.77.4.2119; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; OSLEY MA, 1986, CELL, V45, P537, DOI 10.1016/0092-8674(86)90285-0; OTTILIE S, 1991, P NATL ACAD SCI USA, V88, P3455, DOI 10.1073/pnas.88.8.3455; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SAMBROOK J, 1989, MOL CLONIGN LABORATO; SHARON G, 1990, GENETICS, V125, P487; SHARON G, 1990, GENETICS, V125, P475; SIKORSKI RS, 1989, GENETICS, V122, P19; STRABY KB, 1988, NUCLEIC ACIDS RES, V16, P2841, DOI 10.1093/nar/16.7.2841; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TSAI AYM, 1991, J BIOL CHEM, V266, P10534; WANG JC, 1982, CELL, V29, P724, DOI 10.1016/0092-8674(82)90433-0; WOOD JS, 1982, J CELL BIOL, V94, P718, DOI 10.1083/jcb.94.3.718; WORCEL A, 1981, P NATL ACAD SCI-BIOL, V78, P1461, DOI 10.1073/pnas.78.3.1461; XU HX, 1990, MOL CELL BIOL, V10, P2687, DOI 10.1128/MCB.10.6.2687	32	94	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11274	11280						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597462				2022-12-25	WOS:A1992HX16900055
J	DEKKER, EE; KITSON, RP				DEKKER, EE; KITSON, RP			2-KETO-4-HYDROXYGLUTARATE ALDOLASE - PURIFICATION AND CHARACTERIZATION OF THE HOMOGENEOUS ENZYME FROM BOVINE KIDNEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ACTIVE-SITE; BINDING	2-Keto-4-hydroxyglutarate aldolase, which catalyzes the reversible cleavage of 2-keto-4-hydroxyglutarate, yielding pyruvate plus glyoxylate, has been purified from extracts of bovine kidney to apparent homogeneity as judged by polyacrylamide gel electrophoresis, gel filtration chromatography, sucrose density gradient centrifugation, and meniscus depletion sedimentation equilibrium experiments. The enzyme from this source has a native and a subunit mass of 144 and 36 kDa, respectively; the pH-activity optimum is 8.8. Rather than being stimulated, aldolase activity is inhibited to varying degrees by added divalent metal ions, whereas a number of metal ion-chelating agents have no effect. An absolute requirement for added thiol compounds could not be shown, but 2-mercaptoethanol enhances activity 2-fold, and added Hg2+ as well as p-mercuribenzoate or dithiodipyridine markedly inhibit catalysis. Incubation of the enzyme with either pyruvate or glyoxylate in the presence of NaBH4 causes extensive loss of aldolase activity concomitant with stable binding of approximately 1.0-1.5 mol of C-14-labeled substrate/mol of enzyme. The circular dichroism spectrum for native aldolase is characteristic of an alpha-helix; incubation of the enzyme with glyoxylate has no effect on this spectrum, but it is considerably altered by pyruvate. Bovine kidney aldolase shows no stereospecificity in catalyzing the aldol cleavage of the two optical isomers of 2-keto-4-hydroxyglutarate, and although it also catalyzes the beta-decarboxylation of oxalacetate, its decarboxylase/aldolase activity ratio is lower than that seen with the pure enzyme from either bovine liver or Escherichia coli.			DEKKER, EE (corresponding author), UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109, USA.				NIDDK NIH HHS [DK-03718] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK003718] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLISON WS, 1966, METHOD ENZYMOL, V9, P212; ANDREWS P, 1965, BIOCHEM J, V96, P595, DOI 10.1042/bj0960595; BEERS RF, 1952, J BIOL CHEM, V195, P133; BOYER PD, 1954, J AM CHEM SOC, V76, P4331, DOI 10.1021/ja01646a025; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RK, 1957, METHOD ENZYMOL, V11, P917; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; Dekker E E, 1975, Methods Enzymol, V42, P285; Dekker E E, 1975, Methods Enzymol, V42, P280; DEKKER EE, 1962, J BIOL CHEM, V237, P2218; FRIDOVICH I, 1962, J AM CHEM SOC, V84, P3208, DOI 10.1021/ja00875a050; Friedemann TE, 1943, J BIOL CHEM, V147, P415; GOLDSTEIN IJ, 1965, ARCH BIOCHEM BIOPHYS, V111, P407, DOI 10.1016/0003-9861(65)90203-1; Goodwin T. W., 1946, BIOCHEM JOUR, V40, P628; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GUPTA SC, 1984, J BIOL CHEM, V259, P12; Harlow E, 1988, ANTIBODIES LABORATOR, P471; Horecker B. L, 1972, ENZYMES, P213, DOI DOI 10.1016/S1874-6047(08)60450-3; HORECKER BL, 1963, BIOCHEM Z, V338, P36; KOBES RD, 1969, J BIOL CHEM, V244, P1919; KOBES RD, 1971, BIOCHEMISTRY-US, V10, P388, DOI 10.1021/bi00779a005; KORNBERG A, 1955, METHOD ENZYMOL, V1, P441, DOI 10.1016/0076-6879(55)01072-0; LAI CY, 1965, J BIOL CHEM, V240, P1347; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; Liu T Y, 1972, Methods Enzymol, V25, P55, DOI 10.1016/S0076-6879(72)25007-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAITRA U, 1963, J BIOL CHEM, V238, P3660; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; NISHIHARA H, 1972, J BIOL CHEM, V247, P5079; Parikh I, 1974, Methods Enzymol, V34, P77; PATIL RV, 1992, J BACTERIOL, V174, P102, DOI 10.1128/jb.174.1.102-107.1992; RUTTER WJ, 1964, FED PROC, V23, P1248; TAKAHASHI K, 1973, J BIOCHEM, V74, P1083, DOI 10.1093/oxfordjournals.jbchem.a130335; VLAHOS CJ, 1990, J BIOL CHEM, V265, P20384; VLAHOS CJ, 1985, J BIOL CHEM, V260, P5480; VLAHOS CJ, 1988, J BIOL CHEM, V263, P11683; VLAHOS CJ, 1986, J BIOL CHEM, V261, P1049; WANG JK, 1981, J BIOL CHEM, V256, P1793; WEBER K, 1975, PROTEINS, V1, P180; WESTHEIMER FH, 1963, P CHEM SOC LONDON, P253; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	42	14	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10507	10514						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587831				2022-12-25	WOS:A1992HV09000046
J	FLACHMANN, R; BOHNERT, HJ				FLACHMANN, R; BOHNERT, HJ			REPLACEMENT OF A CONSERVED ARGININE IN THE ASSEMBLY DOMAIN OF RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE OXYGENASE SMALL SUBUNIT INTERFERES WITH HOLOENZYME FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-BISPHOSPHATE CARBOXYLASE; 1,5-BISPHOSPHATE CARBOXYLASE; 3-DIMENSIONAL STRUCTURE; NUCLEOTIDE-SEQUENCES; QUATERNARY STRUCTURE; PLANT RUBISCO; HYDROGEN-BOND; PROTEIN; MUTATIONS; SITE	In higher plants the small subunit (S) of ribulose-1,5-bisphosphate carboxylase/oxygenase (ribulose-P2 carboxylase, EC 4.1.1.39) contains a segment of 16 amino acids which is absent from cyanobacterial S. This segment connecting two beta-sheets has been shown, by crystallographic analysis, to form a hairpin loop. The quaternary structure of ribulose-P2 carboxylase indicates several S to large subunit (L) interactions. Eleven of 22 residues within the loop form the interface with 20 residues from two different L dimers. Eight of the loop residues are involved in hydrogen bonds, salt links, and hydrophobic interactions. To test the hypothesis, whether this loop had a function in the assembly of L and S into the hexadecameric enzyme, 6 amino acids within the loop were modified by site-directed mutagenesis of the pea rbcS-3A gene. All substituted S were imported by isolated chloroplasts from pea with wild type efficiency. Mutants E54-R, H55-A, P59-A, D63-G, D63-L, and Y66-A were assembly-competent, indicating that changes of side chains at these positions are tolerated. Replacement of arginine 53, whose side chain forms H-bonds with L residues Y226 and G261, with glutamate completely abolished assembly into holoenzyme. We suggest that arginine 53 in S is essential for ribulose-P2 carboxylase quaternary structure in higher plants.	UNIV ARIZONA,DEPT BIOCHEM,BIOSCI W,TUCSON,AZ 85721; UNIV ARIZONA,DEPT MOLEC & CELLULAR BIOL,TUCSON,AZ 85721; UNIV ARIZONA,DEPT PLANT SCI,TUCSON,AZ 85721	University of Arizona; University of Arizona; University of Arizona			Bohnert, Hans J/A-7104-2009					ALBER T, 1987, BIOCHEMISTRY-US, V26, P3754, DOI 10.1021/bi00387a002; ANDREWS TJ, 1988, J BIOL CHEM, V263, P12213; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; AVNI A, 1989, EMBO J, V8, P1915, DOI 10.1002/j.1460-2075.1989.tb03594.x; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P91; BARRACLOUGH R, 1980, BIOCHIM BIOPHYS ACTA, V608, P19, DOI 10.1016/0005-2787(80)90129-X; BARTLETT PA, 1987, SCIENCE, V235, P569, DOI 10.1126/science.3810155; BARTLETT SG, 1982, METHODS CHLOROPLAST, P1081; CHAPMAN MS, 1988, SCIENCE, V241, P71, DOI 10.1126/science.3133767; CHAPMAN MS, 1987, NATURE, V329, P354, DOI 10.1038/329354a0; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CORUZZI G, 1983, J BIOL CHEM, V258, P1399; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FERSHT AR, 1987, TRENDS BIOCHEM SCI, V12, P301, DOI 10.1016/0968-0004(87)90146-0; FITCHEN JH, 1990, P NATL ACAD SCI USA, V87, P5768, DOI 10.1073/pnas.87.15.5768; FLUHR R, 1986, EMBO J, V5, P2063, DOI 10.1002/j.1460-2075.1986.tb04467.x; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; KELLIS JT, 1988, NATURE, V333, P784, DOI 10.1038/333784a0; KNIGHT S, 1989, SCIENCE, V244, P702, DOI 10.1126/science.244.4905.702; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUNDQVIST T, 1988, J BIOL CHEM, V263, P3343; Maniatis T., 1982, MOL CLONING; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PAGE MI, 1984, CHEM ENZYME ACTION, P1; PAKULA AA, 1986, P NATL ACAD SCI USA, V83, P8829, DOI 10.1073/pnas.83.23.8829; PONGOR S, 1987, METHOD ENZYMOL, V154, P450; RAMAGE RT, 1989, TECHNIQUES NEW DEV P, P307; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROY H, 1989, PLANT CELL, V1, P1035, DOI 10.1105/tpc.1.11.1035; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER G, 1986, EMBO J, V5, P3409, DOI 10.1002/j.1460-2075.1986.tb04662.x; TRONRUD DE, 1987, SCIENCE, V235, P571, DOI 10.1126/science.3810156; WASMANN CC, 1988, J BIOL CHEM, V263, P617; WASMANN CC, 1989, P NATL ACAD SCI USA, V86, P1198, DOI 10.1073/pnas.86.4.1198; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	40	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10576	10582						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587838				2022-12-25	WOS:A1992HV09000055
J	PAPOULAS, O; WILLIAMS, NG; KINGSTON, RE				PAPOULAS, O; WILLIAMS, NG; KINGSTON, RE			DNA-BINDING ACTIVITIES OF C-MYC PURIFIED FROM EUKARYOTIC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AVIAN MYELOCYTOMATOSIS VIRUS; LOOP-HELIX PROTEINS; LEUCINE ZIPPER; NUCLEAR-LOCALIZATION; TRANSCRIPTION FACTOR; SEX DETERMINATION; GENE FAMILY; EXPRESSION; ONCOGENE; SEQUENCE	c-Myc is a nuclear phosphoprotein which contains both a leucine zipper and a helix-loop-helix dimerization motif. These are adjacent to a basic region believed to make specific contacts with DNA upon dimerization. We report the purification of full-length c-Myc to near homogeneity from two independent eukaryotic systems: the baculovirus overexpression system using an insect cell host, and Chinese hamster ovary cells containing heat-inducible c-myc genes. The DNA binding capabilities of these preparations were characterized. Both preparations contain two distinct activities that bind specifically to sequences with a core of CACGTG. The Myc protein is solely responsible for one of these binding activities. Specific sequences that bound to c-Myc were selected from a large pool of random DNA sequence. Sequencing of individual binding sites selected by this procedure yielded a 12-base consensus, PuACCACGTGCTC, for c-Myc binding. Both protein preparations additionally demonstrated a distinct complex, containing both c-Myc and a copurifying 26-29-kDa protein, that bound to DNA with higher affinity than Myc alone. Selection of specific DNA sequences by this complex revealed a consensus binding site similar to the 12-base consensus described above. These data demonstrate that c-Myc isolated from eukaryotic cells is capable of sequence-specific DNA binding and further refine the optimal sequence for c-Myc binding. These protein preparations should prove useful in further characterizing the biochemical properties of c-Myc.	MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,WELLMAN 10,FRUIT ST,BOSTON,MA 02114; HARVARD UNIV,SCH MED,PROGRAM CELL & DEV BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School								ABRAMS HD, 1982, CELL, V29, P427, DOI 10.1016/0092-8674(82)90159-3; ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; BAGCHI MK, 1987, MOL CELL BIOL, V7, P4151, DOI 10.1128/MCB.7.12.4151; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BREYER RM, 1989, J BIOL CHEM, V264, P13348; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CRONMILLER C, 1988, GENE DEV, V2, P1666, DOI 10.1101/gad.2.12a.1666; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DANG CV, 1988, ANAL BIOCHEM, V174, P313, DOI 10.1016/0003-2697(88)90551-9; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DONNER P, 1982, NATURE, V296, P262, DOI 10.1038/296262a0; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KERKHOFF E, 1991, ONCOGENE, V6, P93; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LUDWIG SR, 1990, CELL, V62, P849, DOI 10.1016/0092-8674(90)90259-H; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MIYAMOTO C, 1985, MOL CELL BIOL, V5, P2860, DOI 10.1128/MCB.5.10.2860; MIYAMOTO C, 1985, P NATL ACAD SCI USA, V82, P7232, DOI 10.1073/pnas.82.21.7232; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NILSSON B, 1985, EMBO J, V4, P1075, DOI 10.1002/j.1460-2075.1985.tb03741.x; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; Penn L J, 1990, Semin Cancer Biol, V1, P69; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; PINNEY DF, 1988, CELL, V53, P781, DOI 10.1016/0092-8674(88)90095-5; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SUMMERS MD, 1988, TEXAS AGR EXPT STATI, V1555, P12; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; WURM FM, 1986, P NATL ACAD SCI USA, V83, P5414, DOI 10.1073/pnas.83.15.5414; YANG BS, 1991, MOL CELL BIOL, V11, P2291, DOI 10.1128/MCB.11.4.2291	60	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10470	10480						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587829				2022-12-25	WOS:A1992HV09000042
J	SIERRA, F; COEYTAUX, S; JUILLERAT, M; RUFFIEUX, C; GAULDIE, J; GUIGOZ, Y				SIERRA, F; COEYTAUX, S; JUILLERAT, M; RUFFIEUX, C; GAULDIE, J; GUIGOZ, Y			SERUM T-KININOGEN LEVELS INCREASE 2 TO 4 MONTHS BEFORE DEATH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE PROTEIN; PHENOL-CHLOROFORM EXTRACTION; SINGLE-STEP METHOD; DIETARY RESTRICTION; GENE-EXPRESSION; RNA ISOLATION; POLYACRYLAMIDE; INFLAMMATION; INHIBITOR; CELLS	We have reported an accumulation of T-kininogen mRNA in the liver of aging Sprague-Dawley rats. T-kininogen is a cysteine proteinase inhibitor. Since a disruption of the intracellular protein degradation machinery is known to occur during senescence, we wished to further define the role of this protein in the aging process. As a first step, we have measured T-kininogen levels both in serum and within the liver. We have found that serum protein levels are indeed augmented during senescence, although not as dramatically as the mRNA (2.5-fold versus 8.3-fold). Immunocytochemistry, as well as Western blot analysis suggests that this is due to the presence of T-kininogen within hepatic cells in aged rats. Life-long dietary restriction, a known age-prolonging treatment, decreases the overexpression of the protein in 24-month-old rats. Later, diet-restricted animals still show an increased expression from the gene, the effect being delayed but not abolished by dietary manipulation. Interestingly, a longitudinal study indicated the existence of a positive correlation between the time of increase of serum T-kininogen and the time of death of the animal. Serum T-kininogen was found to increase 2.5-4 months before death.	MCMASTER UNIV,DEPT PATHOL,HAMILTON L8N 3Z5,ONTARIO,CANADA	McMaster University	SIERRA, F (corresponding author), NESTEC LTD,RES CTR,VERS CHEZ LES BLANC,POB 44,CH-1000 LAUSANNE 26,SWITZERLAND.							ANDERSON KP, 1985, J BIOL CHEM, V260, P2065; ANDERSON KP, 1984, ARCH BIOCHEM BIOPHYS, V233, P624, DOI 10.1016/0003-9861(84)90488-0; BAUMANN H, 1987, J BIOL CHEM, V262, P9756; BIRCH HE, 1986, J BIOL CHEM, V261, P8077; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHAO J, 1988, BIOCHIM BIOPHYS ACTA, V964, P329, DOI 10.1016/0304-4165(88)90033-5; CHATTERJEE B, 1989, FASEB J, V172, P169; CHEN JC, 1973, BIOCHIM BIOPHYS ACTA, V312, P598, DOI 10.1016/0005-2787(73)90458-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FERNANDES G, 1976, P NATL ACAD SCI USA, V73, P1279, DOI 10.1073/pnas.73.4.1279; FEY GH, 1990, PROGR LIVER DISEASE; FURUTOKATO S, 1985, J BIOL CHEM, V260, P2054; GLECKMAN R, 1982, JAMA-J AM MED ASSOC, V248, P1478, DOI 10.1001/jama.248.12.1478; GUIGOZ Y, 1985, HDB BIOL AGEING; IVY GO, 1989, BRAIN RES, V498, P360, DOI 10.1016/0006-8993(89)91117-7; IVY GO, 1984, SCIENCE, V226, P958; IVY GO, 1987, NEURAL PLASTICITY LE; IVY GO, 1990, LIPOFUSCIN CEROID PI; KATUNUMA N, 1983, CURR TOP CELL REGUL, V22, P71; KNOOK DL, 1989, IMMUNOL INVEST, V18, P339; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; LAURELL CB, 1981, METHOD ENZYMOL, V73, P339; LAVIE L, 1982, BIOCHEM J, V202, P47, DOI 10.1042/bj2020047; MARTIN LW, 1989, AM J PHYSIOL, V257, pR189, DOI 10.1152/ajpregu.1989.257.1.R189; MASORO EJ, 1982, P NATL ACAD SCI-BIOL, V79, P4239, DOI 10.1073/pnas.79.13.4239; MASORO EJ, 1989, LAB INVEST, V60, P165; MASORO EJ, 1988, J GERONTOL BIOL SCI, V43, P1359; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; OKAMOTO H, 1983, BIOCHEM BIOPH RES CO, V112, P701, DOI 10.1016/0006-291X(83)91519-X; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RICHARDSON A, 1987, J BIOL CHEM, V262, P12821; ROTHSTEIN M, 1985, MODIFICATION PROTEIN; SIERRA F, 1989, MOL CELL BIOL, V9, P5610, DOI 10.1128/MCB.9.12.5610; THOMAN ML, 1981, J IMMUNOL, V127, P2102; VANBEZOOIJEN CFA, 1984, MECH AGEING DEV, V25, P1, DOI 10.1016/0047-6374(84)90126-X; WARD WF, 1988, J GERONTOL B-PSYCHOL, V43, P50; WEINDRUCH RH, 1979, FED PROC, V38, P2007; YU BP, 1982, J GERONTOL, V37, P130, DOI 10.1093/geronj/37.2.130; YU BP, 1987, REV BIOL RES AGING, V3	40	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10665	10669						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587844				2022-12-25	WOS:A1992HV09000069
J	GONZALEZYANES, B; CICERO, JM; BROWN, RD; WEST, CM				GONZALEZYANES, B; CICERO, JM; BROWN, RD; WEST, CM			CHARACTERIZATION OF A CYTOSOLIC FUCOSYLATION PATHWAY IN DICTYOSTELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-BIOSYNTHESIS; DEVELOPMENTAL REGULATION; PLASMA-MEMBRANES; LINKED GLYCANS; DISCOIDIN-II; RAT-LIVER; PURIFICATION; GLYCOSYLATION; OLIGOSACCHARIDES; TRANSFERASE	FP21 is a 21-kDa fucoprotein which fractionates with the cytosol after high-speed centrifugation of gently lysed Dictyostelium cells. Less than 0.7% of FP21 is associated with vesicles. In proliferating cells, 4 x 10(5) fucosyl moieties/cell are associated with FP21 as anionic, possibly O-linked oligosaccharides equal in size to 4.8 glucose units. FP21 is underfucosylated in a mutant strain (HL250) that depends on extracellular fucose for synthesis of GDP-fucose. To determine the cellular site of FP21 fucosylation, cytosolic and vesicular preparations from strain HL250 were compared for their ability to transfer fucose from GDP-fucose to FP21. Cytosolic preparations fucosylate endogenous FP21 in a time-, concentration-, and divalent cation-dependent fashion, with a K(m) for GDP-fucose of 1.4-mu-M. Activity in normal cell cytosol is dependent on exogenous mutant FP21, demonstrating that FP21 is normally fully fucosylated. Both mutant and normal cytosols are also able to alpha-fucosylate a type 1 glycolipid substrate (8-methoxycarbonyloctyl-Gal-beta-1-3-beta-GlcNAc), but not related substrates, with K(m) values for the type 1 glycolipid of 0.99 mM and for GDP-fucose of 1.6-mu-M. Competitive inhibition between FP21 and the type 1 glycolipid shows that the same enzyme fucosylates both substrates. Intact and permeabilized vesicle preparations from wild-type cells are unable to fucosylate FP21 or the type 1 glycolipid by a divalent cation-dependent mechanism, and thus are devoid of FP-21-fucosyltransferase. Since control experiments showed that vesicle leakage is minimal during cytosol preparation, these results indicate that FP21 is synthesized and fucosylated in the cytosolic compartment, by an unusual soluble fucosyltransferase.	UNIV FLORIDA,COLL MED,DEPT ANAT & CELL BIOL,POB 100235,GAINESVILLE,FL 32610; UNIV FLORIDA,INST FOOD & AGR SCI,DEPT ENTOMOL,GAINESVILLE,FL 32610; UNIV FLORIDA,INST FOOD & AGR SCI,DEPT NEMATOL,GAINESVILLE,FL 32610; UNIV FLORIDA,INST FOOD & AGR SCI,DEPT FOOD SCI & NUTR,GAINESVILLE,FL 32610	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida					NIGMS NIH HHS [GM-37539] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037539] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1990, J BIOL CHEM, V265, P14691; BARONDES SH, 1983, J CELL BIOL, V96, P291, DOI 10.1083/jcb.96.1.291; BEYER TA, 1980, J BIOL CHEM, V255, P5364; DAS OP, 1983, BIOCHIM BIOPHYS ACTA, V736, P45; ERDOS GW, 1983, J CELL BIOL, V97, P993, DOI 10.1083/jcb.97.4.993; FOSTER CS, 1991, J BIOL CHEM, V266, P3526; FRANKE J, 1977, P NATL ACAD SCI USA, V74, P2157, DOI 10.1073/pnas.74.5.2157; FRAZIER WA, 1975, J BIOL CHEM, V250, P7714; FREEZE HH, 1983, J BIOL CHEM, V258, P4874; GONDA DK, 1989, J BIOL CHEM, V264, P16700; GONZALEZYANES B, 1989, DEV BIOL, V133, P576, DOI 10.1016/0012-1606(89)90060-2; GOODLOEHOLLAND CM, 1987, METHOD CELL BIOL, V28, P103; GREGG JH, 1978, EXP CELL RES, V112, P31, DOI 10.1016/0014-4827(78)90522-0; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HENDERSON PJF, 1985, TECHNIQUES LIF B 2 S, V1, P1; IVATT RJ, 1981, J SUPRAMOL STR CELL, V17, P359, DOI 10.1002/jsscb.380170407; IVATT RL, 1984, CELL, V38, P561, DOI 10.1016/0092-8674(84)90510-5; KEAN EL, 1991, J BIOL CHEM, V266, P942; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KYPRIANOU P, 1990, GLYCOCONJUGATE J, V7, P573, DOI 10.1007/BF01189078; LAM TY, 1981, DEV BIOL, V83, P127, DOI 10.1016/S0012-1606(81)80015-2; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MATSUDAIRE P, 1987, J BIOL CHEM, V262, P10135; MCMAHON D, 1977, BIOCHIM BIOPHYS ACTA, V465, P224, DOI 10.1016/0005-2736(77)90076-1; MURAMATSU H, 1986, EUR J BIOCHEM, V157, P71, DOI 10.1111/j.1432-1033.1986.tb09639.x; Opheim D J, 1978, Methods Enzymol, V50, P505; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PRIEELS JP, 1981, J BIOL CHEM, V256, P456; SARNESTO A, 1990, J BIOL CHEM, V265, P15067; SATIR BH, 1990, J CELL BIOL, V111, P901, DOI 10.1083/jcb.111.3.901; SOMMERS LW, 1982, J BIOL CHEM, V257, P811; SPUDICH JA, 1987, METHOD CELL BIOL, V28, P3; STONE DB, 1987, METHOD CELL BIOL, V28, P215; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TSCHURSIN E, 1989, DIFFERENTIATION, V40, P1, DOI 10.1111/j.1432-0436.1989.tb00807.x; WEST CM, 1988, EXP CELL RES, V175, P26, DOI 10.1016/0014-4827(88)90252-2; WEST CM, 1988, CELL DIFFER DEV, V23, P1, DOI 10.1016/0045-6039(88)90032-2; YAMASHITA K, 1982, METHOD ENZYMOL, V83, P105; ZINN AB, 1978, J BIOL CHEM, V253, P6761	41	23	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9595	9605						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577798				2022-12-25	WOS:A1992HT96500025
J	REXIN, M; BUSCH, W; SEGNITZ, B; GEHRING, U				REXIN, M; BUSCH, W; SEGNITZ, B; GEHRING, U			STRUCTURE OF THE GLUCOCORTICOID RECEPTOR IN INTACT-CELLS IN THE ABSENCE OF HORMONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; CHEMICAL CROSS-LINKING; MONOCLONAL-ANTIBODIES; 59-KILODALTON PROTEIN; RAT-LIVER; HSP90	The nonactivated glucocorticoid receptor (M(r) approximately 330,000, Stokes radius = 82 angstrom) contained in cell extracts and complexed with a steroidal ligand was previously investigated by chemical cross-linking. It was identified as a heterotetramer composed of one receptor polypeptide, two molecules of the 90-kDa heat shock protein hsp90, and one 59-kDa protein subunit (Rexin, M., Busch, W., and Gehring, U. (1991) J. Biol. Chem. 266, 24601-24605). We now have used the cross-linking technique to investigate the receptor structure in intact WEHI-7 mouse lymphoma cells at 37-degrees-C and under steroid-free conditions. Using immunochemical methods we show that the receptor present in whole cells likewise exists as a high molecular weight structure of Stokes radius 82 angstrom. It has a subunit composition identical to that of the nonactivated receptor-steroid complex in cell extracts. This is the first account of a steroid hormone receptor in its native state as it is contained in target cells under physiological conditions and before a hormonal signal is received.	UNIV HEIDELBERG,INST BIOL CHEM,NEUENHEIMER FELD 501,W-6900 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg								DANIEL V, 1991, J BIOL CHEM, V266, P1320; Danielson M, 1991, NUCLEAR HORMONE RECE, P39; DENIS M, 1988, J STEROID BIOCHEM, V30, P271, DOI 10.1016/0022-4731(88)90105-7; DENIS M, 1989, CANCER RES, V49, pS2275; FULLER PJ, 1991, FASEB J, V5, P3092, DOI 10.1096/fasebj.5.15.1743440; GEHRING U, 1987, MOL CELL ENDOCRINOL, V53, P33, DOI 10.1016/0303-7207(87)90189-4; GEHRING U, 1985, FEBS LETT, V179, P138, DOI 10.1016/0014-5793(85)80208-8; HARRIS AW, 1973, J IMMUNOL, V110, P431; LEFEBVRE P, 1989, BIOCHEM BIOPH RES CO, V159, P677, DOI 10.1016/0006-291X(89)90048-X; MENDEL DB, 1988, J BIOL CHEM, V263, P6695; OKRET S, 1985, BIOCHEMISTRY-US, V24, P6581, DOI 10.1021/bi00344a041; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PRATT WB, 1990, MOL CELL ENDOCRINOL, V74, pC69, DOI 10.1016/0303-7207(90)90198-H; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; REXIN M, 1988, BIOCHEMISTRY-US, V27, P5593, DOI 10.1021/bi00415a030; REXIN M, 1991, J BIOL CHEM, V266, P24601; REXIN M, 1988, FEBS LETT, V241, P234, DOI 10.1016/0014-5793(88)81068-8; REXIN M, 1991, J STEROID BIOCHEM, V40, P287, DOI 10.1016/0960-0760(91)90194-A; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SEGNITZ B, 1990, J BIOL CHEM, V265, P2789; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; WESTPHAL HM, 1982, EMBO J, V1, P1467, DOI 10.1002/j.1460-2075.1982.tb01339.x	23	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9619	9621						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577799				2022-12-25	WOS:A1992HT96500028
J	HIRATA, K; KIKUCHI, A; SASAKI, T; KURODA, S; KAIBUCHI, K; MATSUURA, Y; SEKI, H; SAIDA, K; TAKAI, Y				HIRATA, K; KIKUCHI, A; SASAKI, T; KURODA, S; KAIBUCHI, K; MATSUURA, Y; SEKI, H; SAIDA, K; TAKAI, Y			INVOLVEMENT OF RHO P21 IN THE GTP-ENHANCED CALCIUM-ION SENSITIVITY OF SMOOTH-MUSCLE CONTRACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BOTULINUM ADP-RIBOSYLTRANSFERASE; BOVINE BRAIN CYTOSOL; BINDING PROTEIN; GENE-PRODUCT; CLOSTRIDIUM-BOTULINUM; SIGNAL TRANSDUCTION; PURIFICATION; RAS; IDENTIFICATION; PHOSPHORYLATION	In the rabbit mesenteric arterial smooth muscle skinned by saponin, Ca2+ induced contraction in a concentration-dependent manner. Guanosine 5'-(3-O-thio)triphosphate (GTP-gamma-S), a non-hydrolyzable GTP analogue, lowered the Ca2+ concentrations required for this contraction and increased the Ca2+ sensitivity of the skinned smooth muscle contraction. GTP-gamma-S alone did not induce the contraction in the absence of Ca2+. This GTP-gamma-S-enhanced Ca2+ sensitivity was completely abolished by an exoenzyme of Staphylococcus aureus, named EDIN, and an exoenzyme of Clostridium botulinum, named C3, both of which are known to ADP-ribosylate the rho p21 family that belongs to the ras p21-like small GTP-binding protein superfamily. The GTP-gamma-S-bound form of rhoA p21 overcame the inhibitory action of EDIN. smg p21B, another small GTP-binding protein, was inactive. EDIN ADP-ribosylated a protein, which was most likely to be rho p21, in the skinned smooth muscle. The GTP-gamma-S-bound form of rhoA p21, but not the GDP-bound form, substituted for GTP-gamma-S and enhanced the Ca2+ sensitivity of the skinned smooth muscle contraction. smg p21B was inactive. These results indicate that rhoA p21 is involved in the GTP-gamma-S-enhanced Ca2+ sensitivity of the smooth muscle contraction.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN; NATL INST HLTH,DEPT VET SCI,TOKYO 208,JAPAN; BAYER YAKUHIN LTD,INST PHARMACOL,NISHI KU,KOBE 65123,JAPAN	Kobe University; National Institute of Health Sciences - Japan; Bayer AG			KURODA, SHINYA/G-4961-2014					BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIALOJAN C, 1988, J PHYSIOL-LONDON, V398, P81, DOI 10.1113/jphysiol.1988.sp017030; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY AB, 1987, J PHYSIOL-LONDON, V385, P437, DOI 10.1113/jphysiol.1987.sp016500; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; FUJIWARA T, 1989, J PHYSIOL-LONDON, V408, P535, DOI 10.1113/jphysiol.1989.sp017474; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; KAWAHARA Y, 1990, BIOCHEM BIOPH RES CO, V170, P673, DOI 10.1016/0006-291X(90)92144-O; KAWATA M, 1989, BIOCHEM BIOPH RES CO, V163, P1418, DOI 10.1016/0006-291X(89)91137-6; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; KITAZAWA T, 1991, J BIOL CHEM, V266, P1708; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MORII N, 1991, J BIOL CHEM, V266, P7646; MORIISHI K, 1990, J BIOL CHEM, V265, P16614; NISHIMURA J, 1988, BIOCHEM BIOPH RES CO, V157, P677, DOI 10.1016/S0006-291X(88)80303-6; OHMORI T, 1989, J BIOL CHEM, V264, P1877; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SAIDA K, 1978, J GEN PHYSIOL, V72, P1, DOI 10.1085/jgp.72.1.1; SAIDA K, 1992, IN PRESS J VASC MED; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SOMLYO AP, 1985, CIRC RES, V57, P497, DOI 10.1161/01.RES.57.4.497; SUGAI M, 1990, BIOCHEM BIOPH RES CO, V173, P92, DOI 10.1016/S0006-291X(05)81026-5; SUGAI M, 1992, J BIOL CHEM, V267, P2600; TAKAI Y, 1984, ADV CYCLIC NUCL PROT, V18, P119; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; UEDA T, 1990, J BIOL CHEM, V265, P9373; YAMAMOTO J, 1990, MOL BRAIN RES, V8, P105, DOI 10.1016/0169-328X(90)90054-H; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626	36	401	408	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8719	8722						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577714				2022-12-25	WOS:A1992HR85400005
J	PERRELLA, M; DAVIDS, N; ROSSIBERNARDI, L				PERRELLA, M; DAVIDS, N; ROSSIBERNARDI, L			THE ASSOCIATION REACTION BETWEEN HEMOGLOBIN AND CARBON-MONOXIDE AS STUDIED BY THE ISOLATION OF THE INTERMEDIATES - IMPLICATIONS ON THE MECHANISM OF COOPERATIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; CARBOXYHEMOGLOBIN; DISSOCIATION; EQUILIBRIUM; PROTEINS; KINETICS; STATES; MODEL; CO	The concentrations of the intermediates in the association reaction between human hemoglobin and CO at 20-degrees-C, pH 7, under conditions of negligible dissociation of the ligand, were measured by cryogenic techniques. The monoligated species were predominant at all values of overall ligand bound studied. The analysis of the experimental data assuming a scheme of four consecutive reactions indicated that the binding rates increased in a continuous fashion. A significant acceleration after the binding of the second molecule of ligand occurred in the presence of 0.1 M KCl, but not with the addition of an excess of inositol hexaphosphate, indicating that major functional, and possibly structural, transitions occur at the diligated state. Differences in the concentrations of the intermediates in the same state of ligation were observed under all conditions. The analyses of the data on the basis of schemes of multiple pathways of reaction indicated that the beta-subunits reacted about 1.5 times faster than the alpha-subunits in the first ligation reaction. After the addition of inositol hexaphosphate, the alpha-subunits reacted about 1.5 times faster than the beta-subunits in the first ligation step, but the overall rate of the first CO binding step was unchanged.	PENN STATE UNIV,UNIV PK,PA 16801	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University	PERRELLA, M (corresponding author), DIPARTIMENTO SCI & TECNOL BIOMED,VIA CELORIA 2,I-20133 MILAN,ITALY.							ACKERS GK, 1981, J MOL BIOL, V147, P559, DOI 10.1016/0022-2836(81)90400-9; ACKERS GK, 1990, BIOPHYS CHEM, V37, P371, DOI 10.1016/0301-4622(90)88036-R; ACKERS GK, 1987, ANNU REV BIOPHYS BIO, V16, P583; BALDWIN JM, 1979, J MOL BIOL, V129, P183; BENESCH R, 1968, P NATL ACAD SCI USA, V61, P1102, DOI 10.1073/pnas.61.3.1102; BRUNORI M, 1970, J MOL BIOL, V49, P461, DOI 10.1016/0022-2836(70)90257-3; COLETTA M, 1991, EUR J BIOCHEM, V196, P569, DOI 10.1111/j.1432-1033.1991.tb15851.x; DAVIDS N, 1964, COMMUN ACM, V7, P547, DOI 10.1145/364847.364873; Douzou P., 1977, CRYOBIOCHEMISTRY INT; Evelyn KA, 1938, J BIOL CHEM, V126, P655; GIBSON QH, 1973, J BIOL CHEM, V248, P1281; GIBSON QH, 1959, PROG BIOPHYS MOL BIO, V9, P1; GIBSON QH, 1957, PROC R SOC SER B-BIO, V146, P206, DOI 10.1098/rspb.1957.0005; GILL SJ, 1985, BIOPHYS CHEM, V21, P1, DOI 10.1016/0301-4622(85)85001-8; GRAY RD, 1971, J BIOL CHEM, V246, P5176; GRAY RD, 1971, J BIOL CHEM, V246, P7168; HOPFIELD JJ, 1971, J MOL BIOL, V61, P425, DOI 10.1016/0022-2836(71)90391-3; JOHNSON ME, 1974, BIOCHEMISTRY-US, V13, P3653, DOI 10.1021/bi00715a005; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P364; LEE AWM, 1988, BIOCHEMISTRY-US, V27, P1285, DOI 10.1021/bi00404a031; LIDDINGTON R, 1988, NATURE, V331, P725, DOI 10.1038/331725a0; MIURA S, 1987, BIOCHEMISTRY-US, V26, P2149, DOI 10.1021/bi00382a013; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PERRELLA M, 1983, J BIOCHEM BIOPH METH, V7, P187, DOI 10.1016/0165-022X(83)90028-3; PERRELLA M, 1990, BIOPHYS CHEM, V37, P211, DOI 10.1016/0301-4622(90)88020-S; PERRELLA M, 1990, BIOPHYS CHEM, V35, P97, DOI 10.1016/0301-4622(90)80064-E; PERRELLA M, 1983, J BIOL CHEM, V258, P4511; PERRELLA M, 1981, J BIOL CHEM, V256, P1098; PERRELLA M, 1986, J BIOL CHEM, V261, P8391; PERRELLA M, 1988, S OXYGEN BINDING HEM; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; SAMAJA M, 1987, J BIOL CHEM, V262, P4528; SHARMA VS, 1988, J BIOL CHEM, V263, P2292; SHARMA VS, 1976, J BIOL CHEM, V251, P4267; SHARMA VS, 1989, J BIOL CHEM, V264, P10582; SMITH FR, 1985, P NATL ACAD SCI USA, V82, P5347, DOI 10.1073/pnas.82.16.5347; SMITH FR, 1987, P NATL ACAD SCI USA, V84, P7089, DOI 10.1073/pnas.84.20.7089; VIGGIANO G, 1979, P NATL ACAD SCI USA, V76, P3673, DOI 10.1073/pnas.76.8.3673	39	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8744	8751						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577717				2022-12-25	WOS:A1992HR85400009
J	HUTCHISON, KA; STANCATO, LF; JOVE, R; PRATT, WB				HUTCHISON, KA; STANCATO, LF; JOVE, R; PRATT, WB			THE PROTEIN-PROTEIN COMPLEX BETWEEN PP60(V-SRC) AND HSP90 IS STABILIZED BY MOLYBDATE, VANADATE, TUNGSTATE, AND AN ENDOGENOUS CYTOSOLIC METAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; ROUS-SARCOMA VIRUS; CELL GLUCOCORTICOID RECEPTOR; STEROID-BINDING DOMAIN; TRANSFORMING PROTEIN; DNA-BINDING; PROGESTERONE-RECEPTOR; MONOCLONAL-ANTIBODY; PHOSPHOPROTEIN; RECONSTITUTION	In a recent study demonstrating the cell-free reconstitution of the pp60v-src-hsp90 complex, we found that the tyrosine kinase-hsp90 complex is stabilized by molybdate (Hutchison, K. A., Brott, B. K., De Leon, J. H., Perdew, G. H., Jove, R., and Pratt, W. B. (1992) J. Biol. Chem. 267, 2902-2908). In this paper, we examine in detail the stabilization of this protein-protein interaction by transition metal oxyanions. The pp60v-src-hsp90 complex is stabilized by sodium molybdate with the same concentration dependence as the glucocorticoid receptor-hsp90 complex. As with the steroid receptor heterocomplexes, vanadate and tungstate also stabilize the pp60v-src-hsp90 interaction. Passage of cytosol through a Chelex-100 metal-chelating resin destabilizes the native pp60v-src-hsp90 complex, suggesting that the complex is normally stabilized by an endogenous metal factor. Readdition of either the heat-stable components of cytosol or a partially purified endogenous metal factor stabilizes the metal-depleted complex. Molybdate also stabilizes the presence of p50, a known hsp90-associated protein, in the pp60v-src heterocomplex. Given the identical effects of transition metal oxyanions on both pp60v-src- and steroid receptor-hsp90 complexes and the lack of any sequence homology between pp60v-src and the receptors, it seems very likely that it is the common component, hsp90, that contains the site of the metal interaction.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,6322 MED SCI BLDG 1,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT MICROBIOL & IMMUNOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NCI NIH HHS [CA47809] Funding Source: Medline; NIDDK NIH HHS [DK31573] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA047809] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031573, R37DK031573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRESNICK EH, 1990, BIOCHEMISTRY-US, V29, P520, DOI 10.1021/bi00454a028; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; BRUGGE J, 1983, MOL CELL BIOL, V3, P9, DOI 10.1128/MCB.3.1.9; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; BRUGGE JS, 1981, CELL, V25, P3633; CADEPOND F, 1991, J BIOL CHEM, V266, P5834; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; CHAKRABORTI PK, 1991, BIOCHEM BIOPH RES CO, V176, P1338, DOI 10.1016/0006-291X(91)90433-8; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; DAHMER MK, 1981, J BIOL CHEM, V256, P9401; DAHMER MK, 1984, ANNU REV PHYSIOL, V46, P67; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DENIS M, 1988, J BIOL CHEM, V263, P18520; DIEMANN E, 1973, COORDIN CHEM REV, V10, P79, DOI 10.1016/S0010-8545(00)80232-5; ERHART JC, 1988, ONCOGENE, V3, P595; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GETHING M J, 1991, Current Opinion in Cell Biology, V3, P610, DOI 10.1016/0955-0674(91)90030-3; HIRST MA, 1990, MOL ENDOCRINOL, V4, P162, DOI 10.1210/mend-4-1-162; HOUSLEY PR, 1985, J BIOL CHEM, V260, P3810; JOVE R, 1986, J VIROL, V60, P849, DOI 10.1128/JVI.60.3.849-857.1986; JOVE R, 1986, J VIROL, V60, P840, DOI 10.1128/JVI.60.3.840-848.1986; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; LEACH KL, 1982, J BIOL CHEM, V257, P381; LEACH KL, 1979, J BIOL CHEM, V254, P1884; MARTINS VR, 1991, MOL ENDOCRINOL, V5, P217, DOI 10.1210/mend-5-2-217; MENDEL DB, 1986, J BIOL CHEM, V261, P3758; MESHINCHI S, 1988, J BIOL CHEM, V263, P16809; MESHINCHI S, 1990, J BIOL CHEM, V265, P4863; MESHINCHI S, 1991, BIOCHEMISTRY-US, V30, P8617, DOI 10.1021/bi00099a018; MESHINCHI S, 1990, J BIOL CHEM, V265, P11643; NIELSEN CJ, 1977, J BIOL CHEM, V252, P7568; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PRATT WB, 1987, J CELL BIOCHEM, V35, P51, DOI 10.1002/jcb.240350105; PRATT WB, 1990, MOL CELL ENDOCRINOL, V74, pC69, DOI 10.1016/0303-7207(90)90198-H; PRATT WB, 1988, J BIOL CHEM, V263, P267; REXIN M, 1991, J BIOL CHEM, V266, P24601; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SANCHEZ ER, 1987, J BIOL CHEM, V262, P6986; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SANDO JJ, 1979, J BIOL CHEM, V254, P4772; SATO B, 1980, ENDOCRINOLOGY, V106, P1142, DOI 10.1210/endo-106-4-1142; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHUH S, 1985, J BIOL CHEM, V260, P4292; SEFTON BM, 1982, J VIROL, V44, P467, DOI 10.1128/JVI.44.2.467-474.1982; SIMONS SS, 1989, J BIOL CHEM, V264, P14493; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1990, J BIOL CHEM, V265, P3996; TAMURA T, 1983, CELL, V34, P587, DOI 10.1016/0092-8674(83)90391-4; THUCHISON KA, 1992, J BIOL CHEM, V267, P2902; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436	55	48	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13952	13957						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629193				2022-12-25	WOS:A1992JD32500029
J	SOTERIADOU, KP; REMOUNDOS, MS; KATSIKAS, MC; TZINIA, AK; TSIKARIS, V; SAKARELLOS, C; TZARTOS, SJ				SOTERIADOU, KP; REMOUNDOS, MS; KATSIKAS, MC; TZINIA, AK; TSIKARIS, V; SAKARELLOS, C; TZARTOS, SJ			THE SER-ARG-TYR-ASP REGION OF THE MAJOR SURFACE GLYCOPROTEIN OF LEISHMANIA MIMICS THE ARG-GLY-ASP-SER CELL ATTACHMENT REGION OF FIBRONECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; PEPTIDE-SYNTHESIS; AMINO-ACID; MEMBRANE; PROMASTIGOTES; RECEPTOR; IDENTIFICATION; ANTIGEN; PROTEIN; MACROPHAGES	The major surface glycoprotein of Leishmania, gp63, a fibronectin-like molecule, plays a key role in parasite-macrophage interaction. Binding of gp63 to macrophage receptors is inhibited by Arg-Gly-Asp-Ser (RGDS)-containing synthetic peptides of fibronectin and by antibodies to these peptides. However, gp63 lacks an RGDS tetrapeptide. We sought to identify the region of gp63 that antigenically and functionally mimics the RGDS-containing region of fibronectin. We thus synthesized on polyethylene rods overlapping tetracosapeptides covering the whole sequence of Leishmania major gp63. gp63 affinity-purified antibodies raised against fibronectin and against the RGDS-containing fibronectin decapeptide RGDSPASSKP bound specifically to gp63 residues 241-264. Subsequently, by the use of smaller peptides, the gp63 tetrapeptide 252-255 (SRYD) was identified as the minimum antibody binding segment. Single residue substitution peptide analogues showed that indeed Tyr and Gly can be alternatively substituted in the SRYD- and RGDS-containing peptides of gp63 and fibronectin, respectively, without major effects on their antibody binding capacity. Subsequently, we investigated the effect of an SRYD peptide on promastigote-macrophage interaction in vitro; treatment of macrophages with an SRYD-containing gp63 octapeptide efficiently inhibited parasite attachment to macrophage receptors. Thus, the conserved among species sequence SRYD of gp63, with significant hydrophilicity, flexibility, and beta-turn propensity features, mimics antigenically and functionally the RGDS sequence of fibronectin. We suggest that this segment constitutes the putative gp63 adhesion site.	UNIV IOANNINA,DEPT CHEM,GR-45110 IOANNINA,GREECE	University of Ioannina	SOTERIADOU, KP (corresponding author), HELLEN INST PASTEUR,DEPT BIOCHEM,127 VAS SOFIAS AVE,GR-11521 ATHENS,GREECE.							AUFFRY C, 1986, HUMAN IMMUNOL, V5, P381; BOUVIER J, 1989, MOL BIOCHEM PARASIT, V37, P235, DOI 10.1016/0166-6851(89)90155-2; BOUVIER J, 1985, J BIOL CHEM, V260, P5504; BUTTON LL, 1990, J EXP MED, V171, P589; BUTTON LL, 1988, J EXP MED, V167, P724, DOI 10.1084/jem.167.2.724; CHANG CS, 1986, P NATL ACAD SCI USA, V83, P100, DOI 10.1073/pnas.83.1.100; CHANG KP, 1983, CIBA F SYMP, V99, P113; CHOU PY, 1979, BIOPHYS J, V26, P367, DOI 10.1016/S0006-3495(79)85259-5; GEYSEN HM, 1987, SCIENCE, V235, P1184, DOI 10.1126/science.3823878; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GISIN BF, 1972, ANAL CHIM ACTA, V58, P248, DOI 10.1016/S0003-2670(00)86882-8; GISIN BF, 1973, HELV CHIM ACTA, V56, P1476, DOI 10.1002/hlca.19730560503; HANDMAN E, 1985, EMBO J, V4, P329, DOI 10.1002/j.1460-2075.1985.tb03633.x; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; KARA U, 1989, J IMMUNOL, V143, P1334; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; KLEMPNER MS, 1983, J INFECT DIS, V148, P377, DOI 10.1093/infdis/148.3.377; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLER RA, 1990, MOL BIOCHEM PARASIT, V39, P267, DOI 10.1016/0166-6851(90)90065-T; PETERSON DS, 1986, NATURE, V322, P566, DOI 10.1038/322566a0; RIZVI FS, 1988, EUR J IMMUNOL, V18, P473, DOI 10.1002/eji.1830180323; RUSELL DG, 1989, INFECT IMMUN, V57, P630; RUSSELL DG, 1988, J IMMUNOL, V140, P1274; RUSSELL DG, 1988, J EXP MED, V168, P279, DOI 10.1084/jem.168.1.279; RUSSELL DG, 1986, J IMMUNOL, V136, P2613; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; SHUKLA DD, 1989, P NATL ACAD SCI USA, V86, P8192, DOI 10.1073/pnas.86.21.8192; SOTERIADOU KP, 1988, INFECT IMMUN, V56, P1180, DOI 10.1128/IAI.56.5.1180-1186.1988; TAUB R, 1989, J BIOL CHEM, V264, P259; TZARTOS SJ, 1990, J BIOL CHEM, V265, P21462; TZINIA AK, 1991, MOL BIOCHEM PARASIT, V47, P83, DOI 10.1016/0166-6851(91)90150-5; VOYIATZAKI CS, 1990, J BIOL CHEM, V265, P22380; WILSON ME, 1986, J IMMUNOL, V136, P4681	36	83	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13980	13985						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629196				2022-12-25	WOS:A1992JD32500033
J	MURAKAMI, Y; MATSUFUJI, S; MIYAZAKI, Y; HAYASHI, S				MURAKAMI, Y; MATSUFUJI, S; MIYAZAKI, Y; HAYASHI, S			DESTABILIZATION OF ORNITHINE DECARBOXYLASE BY TRANSFECTED ANTIZYME GENE-EXPRESSION IN HEPATOMA TISSUE-CULTURE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RAT-LIVER; MONOCLONAL-ANTIBODY; DEGRADATION; PUTRESCINE; PROTEIN; POLYAMINES; SPERMIDINE; INHIBITOR; ENZYME	The degradation of ornithine decarboxylase (ODC) is stimulated by polyamines in a protein synthesis-dependent manner. It has been suggested that antizyme, an ODC-inhibiting protein induced by polyamines, is involved in the process of polyamine-stimulated ODC decay. In this study, we investigated the direct effect of antizyme on ODC decay in hepatoma tissue culture (HTC) cells. A truncated rat antizyme cDNA, Z1, was inserted into an expression vector at a site under the control of a glucocorticoid-inducible promoter and transfected into HTC cells. In the transfected cells dexamethasone increased the amount of Z1 mRNA and induced active antizyme in the absence of exogenous polyamines. When dexamethasone was added to cells with a high level of ODC, rapid decays of ODC activity and protein were elicited after a lag time. Cycloheximide abolished the effect of dexamethasone. These effects of dexamethasone were not observed in control HTC cells transfected with the chloramphenicol acetyltransferase gene. This study indicated that, once induced, antizyme stimulated ODC degradation independently of polyamines and strongly supported our previous hypothesis that the ODC decay-accelerating action of polyamines is mediated by antizyme.			MURAKAMI, Y (corresponding author), JIKEI UNIV,DEPT NUTR,MINATO KU,TOKYO 105,JAPAN.							CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FONG WF, 1976, BIOCHIM BIOPHYS ACTA, V428, P456, DOI 10.1016/0304-4165(76)90054-4; GLASS JR, 1987, J CELL PHYSIOL, V130, P133, DOI 10.1002/jcp.1041300119; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAYASHI S, 1989, ORNITHINE DECARBOXYL, P47; HELLER JS, 1976, P NATL ACAD SCI USA, V73, P1858, DOI 10.1073/pnas.73.6.1858; HOLTTA E, 1986, J BIOL CHEM, V261, P9502; KANAMOTO R, 1986, EUR J BIOCHEM, V154, P539, DOI 10.1111/j.1432-1033.1986.tb09432.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUFUJI S, 1990, J BIOCHEM, V107, P87, DOI 10.1093/oxfordjournals.jbchem.a123018; MATSUFUJI S, 1990, J BIOCHEM-TOKYO, V108, P365, DOI 10.1093/oxfordjournals.jbchem.a123207; MATSUFUJI S, 1984, J BIOCHEM-TOKYO, V96, P1525, DOI 10.1093/oxfordjournals.jbchem.a134981; MCCANN PP, 1979, J CELL PHYSIOL, V99, P183, DOI 10.1002/jcp.1040990204; MITCHELL JLA, 1985, BIOCHIM BIOPHYS ACTA, V840, P309, DOI 10.1016/0304-4165(85)90210-7; MURAKAMI Y, 1989, BIOCHEM J, V259, P839, DOI 10.1042/bj2590839; MURAKAMI Y, 1985, BIOCHEM J, V225, P689, DOI 10.1042/bj2250689; MURAKAMI Y, 1985, BIOCHEM J, V226, P893, DOI 10.1042/bj2260893; MURAKAMI Y, 1988, BIOCHEM J, V254, P367, DOI 10.1042/bj2540367; NISHIYAMA M, 1988, PREP BIOCHEM, V18, P227, DOI 10.1080/00327488808062524; SEELY JE, 1983, BIOCHEM J, V216, P701, DOI 10.1042/bj2160701; UTSUNOMIYA K, 1985, Jikeikai Medical Journal, V32, P575	21	77	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13138	13141						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618815				2022-12-25	WOS:A1992JB74600007
J	KAHN, RA; RANDAZZO, P; SERAFINI, T; WEISS, O; RULKA, C; CLARK, J; AMHERDT, M; ROLLER, P; ORCI, L; ROTHMAN, JE				KAHN, RA; RANDAZZO, P; SERAFINI, T; WEISS, O; RULKA, C; CLARK, J; AMHERDT, M; ROLLER, P; ORCI, L; ROTHMAN, JE			THE AMINO TERMINUS OF ADP-RIBOSYLATION FACTOR (ARF) IS A CRITICAL DETERMINANT OF ARF ACTIVITIES AND IS A POTENT AND SPECIFIC INHIBITOR OF PROTEIN-TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI STACK; ADENYLATE-CYCLASE; CHOLERA-TOXIN; REGULATORY COMPONENT; VESICULAR TRANSPORT; RNA-POLYMERASE; BOVINE BRAIN; BINDING; PURIFICATION; EXPRESSION	Deletion of the amino-terminal 17 residues from human ADP-ribosylation factor (ARF) resulted in a protein ([DELTA-1-17]mARF1p) devoid of ARF activity but which retained the ability to bind guanine nucleotides with high affinity. Unlike the wild type, the binding of guanine nucleotides to this deletion mutant was found to be independent of added phospholipids. A chimeric protein was produced, consisting of 10% (the amino-terminal 17 amino acids) human ARF1p and 90% ARL1p, an ARF-like protein (55% identical protein sequence) from Drosophila. This chimera was found to have ARF activity, lacking in the parental ARL1 protein. Thus, the amino terminus of ARF1p was shown to be a critical component of ARF activity. A synthetic peptide, derived from the amino terminus of ARF1p, has no ARF activity. Rather, the peptide was found to be a specific inhibitor of ARF activities. This peptide was also found to be a potent and specific inhibitor of both an in vitro intra-Golgi transport assay and the guanosine 5'-3-O-(thio)triphosphate-stimulated accumulation of coated vesicles and buds from Golgi preparations. We conclude that ARF is required for the budding of coated vesicles from the Golgi stacks and serves a regulatory role in protein secretion through the Golgi in eukaryotic cells.	NCI, DIV CANC TREATMENT, MEDICINAL CHEM LAB, DEV THERAPEUT PROGRAM, BETHESDA, MD 20892 USA; PRINCETON UNIV, DEPT BIOL, PRINCETON, NJ 08544 USA; UNIV GENEVA, INST HISTOL & EMBRYOL, DEPT MORPHOL, CH-1211 GENEVA 4, SWITZERLAND	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Princeton University; University of Geneva	KAHN, RA (corresponding author), NCI, BIOL CHEM LAB, BETHESDA, MD 20892 USA.		Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601				BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1992, J BIOL CHEM, V267, P13053; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P12655; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1991, METHOD ENZYMOL, V195, P233; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, 1989, G PROTEINS, P201; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1991, CELL, V64, P1183; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SCHLEIFER LS, 1982, J BIOL CHEM, V257, P20; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; WEISS O, 1989, J BIOL CHEM, V264, P21066; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15	33	239	243	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					13039	13046						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618801				2022-12-25	WOS:A1992HZ48300095
J	LENHARD, JM; KAHN, RA; STAHL, PD				LENHARD, JM; KAHN, RA; STAHL, PD			EVIDENCE FOR ADP-RIBOSYLATION FACTOR (ARF) AS A REGULATOR OF INVITRO ENDOSOME-ENDOSOME FUSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; G-PROTEINS; BINDING; TRANSPORT	We have used an in vitro endosome fusion assay, recombinant ARF, synthetic peptides, and guanosine 5'-3-O-(thio)triphosphate (GTP-gamma-S) to study the role of ARF during endocytosis. Previous work has shown that GTP-gamma-S stimulates in vitro endosome fusion in dilute cytosol (<0.5 mg/ml) but inhibits fusion in concentrated cytosol (>1.0 mg/ml). Two peptides corresponding to the NH2-terminal 16 amino acids of human ARF1 and ARF4 blocked GTP-gamma-S stimulation of fusion in dilute cytosol and reversed GTP-gamma-S inhibition of fusion in concentrated cytosol. The addition of recombinant human ARF1 to endosomes in dilute or concentrated cytosol resulted in GTP-gamma-S-dependent inhibition of fusion. Only the myristoylated form of ARF inhibited fusion. The NH2-terminal ARF1 peptide reversed inhibition by recombinant ARF1. Preincubation experiments showed that endosomes could form an ARF-resistant intermediate during the fusion process. Western blot analysis revealed clathrin-coated vesicles extracted with detergent retained ARF. The results suggest that ARF is involved in both the stimulatory and inhibitory effects of GTP-gamma-S in dilute and concentrated cytosol, respectively. Furthermore, myristoylation, the NH2-terminal domain, and binding to GTP appear to be critical for ARF activity during an early prefusion step required for endocytosis.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,660 S EUCLID,ST LOUIS,MO 63110; NCI,DIV CANC TREATMENT,BIOL CHEM LAB,DEV THERAPEUT PROGRAM,BETHESDA,MD 20892	Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Kahn, Richard/ABD-2666-2020; Stahl, Philip/D-6315-2012	Kahn, Richard/0000-0002-0259-0601; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020015, R01AI020015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042259] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20015] Funding Source: Medline; NIGMS NIH HHS [GM42259] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1991, J BIOL CHEM, V266, P2606; LENHARD JM, 1991, BIOCHEM BIOPH RES CO, V174, P197, DOI 10.1016/0006-291X(91)90505-2; LENHARD JM, 1992, J BIOL CHEM, V267, P1896; MAYORGA LS, 1989, CELL REGUL, V1, P113, DOI 10.1091/mbc.1.1.113; MAYORGA LS, 1989, SCIENCE, V244, P1474; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; REGAZZI R, 1991, BIOCHEM J, V275, P639, DOI 10.1042/bj2750639; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; WEISS O, 1989, J BIOL CHEM, V264, P21066	25	179	179	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					13047	13052						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618802				2022-12-25	WOS:A1992HZ48300096
J	LUO, Y; NEET, KE				LUO, Y; NEET, KE			THE UNPROCESSED C-TERMINAL DIPEPTIDE OF RECOMBINANT BETA-NERVE GROWTH-FACTOR DETERMINES 3 STABLE FORMS WITH DISTINCT BIOLOGICAL-ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; NEUROTROPHIC FACTOR; MOLECULAR-CLONING; GAMMA-SUBUNIT; FACTOR RECEPTORS; PC12 CELLS; SUBMAXILLARY GLAND; FACTOR BINDING; ALPHA-SUBUNIT; FACTOR FAMILY	The processing of polypeptide neurotrophins in the nervous system is poorly understood. In this paper, we provide information on the effects of C-terminal processing of nerve growth factor. Three forms of recombinant mouse-beta-nerve growth factor (rNGF) were produced and isolated from insect cells infected with a recombinant baculovirus. The three purified forms of rNGF exhibited distinct biological activities and differed in their abilities to compete with high affinity binding of mouse-beta-nerve growth factor (mNGF). However, they were chemically and structurally indistinguishable from each other. All three forms of rNGF differed from mature mNGF from mouse submaxillary gland in that the C-terminal Arg-Gly dipeptide had not been proteolytically removed. Removal of the C-terminal dipeptide by gamma-NGF peptidase treatment converted the three forms into a single form identical with mature mNGF. The above results demonstrate that a single polypeptide of rNGF, due to the presence of a C-terminal dipeptide, exhibits three stable dimeric protein conformations with distinct biological activities. The apparent lack of gamma-NGF peptidase in the nervous system raises the possibility that the biologically significant form of NGF may differ from mature mNGF; such a difference may be of physiological relevance.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT BIOCHEM, CLEVELAND, OH 44106 USA; UNIV HLTH SCI CHICAGO MED SCH, DEPT BIOL CHEM, N CHICAGO, IL 60064 USA	Case Western Reserve University; Chicago Medical School					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024380] Funding Source: NIH RePORTER; NINDS NIH HHS [NS24380] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANGELETT.RH, 1971, P NATL ACAD SCI USA, V68, P2417, DOI 10.1073/pnas.68.10.2417; ANGELETT.RH, 1973, BIOCHEMISTRY-US, V12, P100, DOI 10.1021/bi00725a018; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BARNETT J, 1990, EXP NEUROL, V110, P11, DOI 10.1016/0014-4886(90)90047-V; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BERGER EA, 1977, P NATL ACAD SCI USA, V74, P3647, DOI 10.1073/pnas.74.9.3647; BOTHWELL MA, 1977, J BIOL CHEM, V252, P8532; BRADSHAW RA, 1978, ANNU REV BIOCHEM, V47, P191, DOI 10.1146/annurev.bi.47.070178.001203; BRADSHAW RA, 1983, NATURE, V303, P751, DOI 10.1038/303751a0; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BUXSER S, 1991, J NEUROCHEM, V56, P1012, DOI 10.1111/j.1471-4159.1991.tb02022.x; COHEN S, 1960, P NATL ACAD SCI USA, V46, P302, DOI 10.1073/pnas.46.3.302; EDWARDS RH, 1988, J BIOL CHEM, V263, P6810; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; FIELDS KL, 1978, CELL, V14, P43, DOI 10.1016/0092-8674(78)90299-4; GREENE L A, 1971, Neurobiology (Copenhagen), V1, P37; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; IBANEZ CF, 1991, EMBO J, V10, P2105, DOI 10.1002/j.1460-2075.1991.tb07743.x; IBANEZ CF, 1990, EMBO J, V9, P1477, DOI 10.1002/j.1460-2075.1990.tb08265.x; ISACKSON PJ, 1987, J CELL BIOCHEM, V33, P65, DOI 10.1002/jcb.240330107; ISACKSON PJ, 1984, BIOCHEMISTRY-US, V23, P5997, DOI 10.1021/bi00320a015; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; JONGSTRABILEN J, 1989, MOL BRAIN RES, V5, P159, DOI 10.1016/0169-328X(89)90007-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KASAIAN MT, 1988, J BIOL CHEM, V263, P5083; KIM IS, 1985, EXP CELL RES, V156, P391, DOI 10.1016/0014-4827(85)90546-4; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KNUSEL B, 1990, EXP NEUROL, V110, P274, DOI 10.1016/0014-4886(90)90039-U; LANDRETH GE, 1980, P NATL ACAD SCI-BIOL, V77, P4751, DOI 10.1073/pnas.77.8.4751; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MEIER R, 1986, EMBO J, V5, P1489, DOI 10.1002/j.1460-2075.1986.tb04387.x; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; MOORE JB, 1974, BIOCHEMISTRY-US, V13, P833, DOI 10.1021/bi00701a030; MOWRY MD, 1984, CELL TISSUE RES, V238, P627; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; MURPHY RA, 1989, J BIOL CHEM, V264, P12502; NEET KE, 1987, METHOD ENZYMOL, V147, P186; PALMER TE, 1980, ARCH BIOCHEM BIOPHYS, V205, P412, DOI 10.1016/0003-9861(80)90124-1; PANTAZIS NJ, 1983, BIOCHEMISTRY-US, V22, P4264, DOI 10.1021/bi00287a016; PHELPS CH, 1989, SCIENCE, V243, P1189; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; REINHOLD DS, 1989, J BIOL CHEM, V264, P3538; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SCHWARZ MA, 1989, J NEUROCHEM, V52, P1203, DOI 10.1111/j.1471-4159.1989.tb01867.x; SCOTT J, 1983, NATURE, V302, P538, DOI 10.1038/302538a0; SELBY MJ, 1987, J NEUROSCI RES, V18, P293, DOI 10.1002/jnr.490180205; SIMINOSKI K, 1987, BRAIN RES, V435, P273, DOI 10.1016/0006-8993(87)91610-6; SMITH AP, 1969, BIOCHEMISTRY-US, V8, P4918, DOI 10.1021/bi00840a040; SMITH AP, 1968, BIOCHEMISTRY-US, V7, P3259, DOI 10.1021/bi00849a032; SNYDER SH, 1991, NATURE, V350, P195, DOI 10.1038/350195a0; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; STACH RW, 1977, ANAL BIOCHEM, V83, P26, DOI 10.1016/0003-2697(77)90505-X; SUMMERS MD, 1987, MANUAL METHODS BACUL, P16; SUTER U, 1992, J NEUROSCI, V12, P306; SUTTER A, 1979, J BIOL CHEM, V254, P5972; THOENEN H, 1987, REV PHYSIOL BIOCH P, V109, P145, DOI 10.1007/BFb0031026; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; THOMAS KA, 1981, J BIOL CHEM, V256, P9156; ULLRICH A, 1983, NATURE, V303, P821, DOI 10.1038/303821a0; VARON S, 1967, BIOCHEMISTRY-US, V6, P2202, DOI 10.1021/bi00859a043; VARON S, 1967, P NATL ACAD SCI USA, V57, P1782, DOI 10.1073/pnas.57.6.1782; WHITTEMORE SR, 1988, J NEUROSCI RES, V20, P403, DOI 10.1002/jnr.490200402; WION D, 1986, FEBS LETT, V203, P82, DOI 10.1016/0014-5793(86)81441-7; WOODRUFF NR, 1986, BIOCHEMISTRY-US, V25, P7956, DOI 10.1021/bi00372a026; ZIMMERMANN A, 1978, J SUPRAMOL STR CELL, V9, P351, DOI 10.1002/jss.400090306	75	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12275	12283						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601893				2022-12-25	WOS:A1992HY94700093
J	NEWTON, DL; WALES, R; RICHARDSON, PT; WALBRIDGE, S; SAXENA, SK; ACKERMAN, EJ; ROBERTS, LM; LORD, JM; YOULE, RJ				NEWTON, DL; WALES, R; RICHARDSON, PT; WALBRIDGE, S; SAXENA, SK; ACKERMAN, EJ; ROBERTS, LM; LORD, JM; YOULE, RJ			CELL-SURFACE AND INTRACELLULAR FUNCTIONS FOR RICIN GALACTOSE BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS INACTIVATION; CHAIN-CONTAINING IMMUNOTOXINS; B-CHAIN; A-CHAIN; INTERNALIZED RICIN; GOLGI-APPARATUS; ANTIBODY; MACROPHAGES; SITE; RECEPTORS	The role of the two galactose binding sites of ricin B chain in ricin toxicity was evaluated by studying a series of ricin point mutants. Wild-type (WT) ricin and three ricin B chain point mutants having mutations in either 1) the first galactose binding domain (site 1 mutant, Met in place of Lys-40 and Gly in place of Asn-46), 2) the second galactose binding domain (site 2 mutant, Gly in place of Asn-255), or 3) both galactose binding domains (double site mutant containing all three amino acid replacements formerly stated) were expressed in Xenopus oocytes and then reassociated with recombinant ricin A chain. The different ricin B chains were mannosylated to the same extent. Cytotoxicity of these toxins was evaluated when cell entry was mediated either by galactose-containing receptors or through an alternate receptor, the mannose receptor of macrophages. WT ricin and each of the single domain mutants was able to kill Vero cells following uptake by galactose containing receptors. Lactose blocked the toxicity of each of these ricins. Site 1 and 2 mutants were 20-40 times less potent than WT ricin, and the double site mutant had no detectable cytotoxicity. WT ricin, the site 1 mutant, and the site 2 mutant also inhibited protein synthesis of mannose receptor-containing cells. Ricin can enter these cells through either a cell-surface galactose-containing receptor or through the mannose receptor. By including lactose in the cell medium, galactose-containing receptor-mediated uptake is blocked and cytotoxicity occurs solely via the mannose receptor. WT ricin, site 1, and site 2 mutants were cytotoxic to macrophages in the presence of lactose with the relative potency, WT > site 2 mutant> site 1 mutant. The double site mutant lacked cytotoxicity either in the absence or presence of lactose. Thus, even for mannose receptor-mediated toxicity of ricin, at least one galactose binding site remains necessary for cytotoxicity and two galactose binding sites further increases potency. These results are consistent with the model that the ricin B chain galactose binding activity plays a role not only in cell surface binding but also intracellularly for ricin cytotoxicity.	NIDDKD,GENET & BIOCHEM BRANCH,BETHESDA,MD 20892; UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Warwick	NEWTON, DL (corresponding author), NINCDS,SURG NEUROL BRANCH,BIOCHEM SECT,BETHESDA,MD 20892, USA.		Saxena, Shailendra K/ABK-6489-2022	Saxena, Shailendra K/0000-0003-2856-4185				ENDO Y, 1987, J BIOL CHEM, V262, P5908; FARQUHAR MG, 1981, J CELL BIOL, V91, pS77, DOI 10.1083/jcb.91.3.77s; GONATAS NK, 1975, EXP CELL RES, V94, P426, DOI 10.1016/0014-4827(75)90508-X; GREGG EO, 1987, J IMMUNOL, V138, P4502; Gurdon J.B., 1977, Methods Cell Biol, V16, P125; HATAKEYAMA T, 1986, J BIOCHEM-TOKYO, V100, P781, DOI 10.1093/oxfordjournals.jbchem.a121771; HUDSON TH, 1991, J BIOL CHEM, V266, P18586; JOHNSON VG, 1991, INTRACELLULAR TRAFFI, P183; KONISH M, 1983, METHOD ENZYMOL, V98, P301; KORNFELD SB, 1991, CANCER RES, V51, P1689; LAMBERT JM, 1991, CANCER RES, V51, P6236; LEONARD JE, 1985, CANCER RES, V45, P5263; MCINTOSH DP, 1983, FEBS LETT, V164, P17, DOI 10.1016/0014-5793(83)80009-X; MISE T, 1986, AGR BIOL CHEM TOKYO, V50, P151, DOI 10.1080/00021369.1986.10867335; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; NICOLSON GL, 1974, BIOCHEMISTRY-US, V13, P196, DOI 10.1021/bi00698a029; OLSNES S, 1973, BIOCHEMISTRY-US, V12, P3121, DOI 10.1021/bi00740a028; Olsnes S., 1982, MOL ACTION TOXINS VI, P51; RICHARDSON PT, 1988, BIO-TECHNOL, V6, P565, DOI 10.1038/nbt0588-565; ROTH J, 1982, J CELL BIOL, V92, P223; RUTENBER E, 1987, NATURE, V326, P624, DOI 10.1038/326624a0; RUTENBER E, 1991, PROTEINS, V10, P260, DOI 10.1002/prot.340100310; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; SIMMONS BM, 1986, J BIOL CHEM, V261, P7912; SKILLETER DN, 1981, BIOCHIM BIOPHYS ACTA, V677, P495, DOI 10.1016/0304-4165(81)90264-6; STAHL P, 1980, CELL, V19, P207, DOI 10.1016/0092-8674(80)90402-X; THORPE PE, 1984, EUR J BIOCHEM, V140, P63, DOI 10.1111/j.1432-1033.1984.tb08067.x; TIETZE C, 1982, J CELL BIOL, V92, P417, DOI 10.1083/jcb.92.2.417; TIMAR J, 1991, BRIT J CANCER, V64, P655, DOI 10.1038/bjc.1991.377; UCKUN FM, 1985, J IMMUNOL, V134, P3504; VANDEURS B, 1988, J CELL BIOL, V106, P253, DOI 10.1083/jcb.106.2.253; VANDEURS B, 1986, J CELL BIOL, V102, P37, DOI 10.1083/jcb.102.1.37; VITETTA ES, 1983, P NATL ACAD SCI-BIOL, V80, P6332, DOI 10.1073/pnas.80.20.6332; VITETTA ES, 1986, J IMMUNOL, V136, P1880; WALES R, 1991, J BIOL CHEM, V266, P19172; WAWRZYNCZAK EJ, 1991, CANCER IMMUNOL IMMUN, V32, P289, DOI 10.1007/BF01789046; WAWRZYNCZAK EJ, 1988, BIOCHIM BIOPHYS ACTA, V971, P55, DOI 10.1016/0167-4889(88)90161-9; WILEMAN T, 1984, BIOCHEM J, V220, P665, DOI 10.1042/bj2200665; YOKOYAMA M, 1980, EXP CELL RES, V125, P47, DOI 10.1016/0014-4827(80)90187-1; YOSHIDA T, 1991, EXP CELL RES, V192, P389, DOI 10.1016/0014-4827(91)90056-Z; YOULE RJ, 1982, J BIOL CHEM, V257, P1598; YOULE RJ, 1979, P NATL ACAD SCI USA, V76, P5559, DOI 10.1073/pnas.76.11.5559; YOULE RJ, 1987, J BIOL CHEM, V262, P4676; YOULE RJ, 1981, CELL, V23, P551, DOI 10.1016/0092-8674(81)90151-3; ZENTZ C, 1978, BIOCHIM BIOPHYS ACTA, V536, P18, DOI 10.1016/0005-2795(78)90047-8	45	80	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11917	11922						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601861				2022-12-25	WOS:A1992HY94700042
J	REZAIE, AR; ESMON, NL; ESMON, CT				REZAIE, AR; ESMON, NL; ESMON, CT			THE HIGH-AFFINITY CALCIUM-BINDING SITE INVOLVED IN PROTEIN-C ACTIVATION IS OUTSIDE THE 1ST EPIDERMAL GROWTH-FACTOR HOMOLOGY DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GAMMA-CARBOXYGLUTAMIC ACID; BETA-HYDROXYASPARTIC ACID; BOVINE FACTOR-X; PROTEOLYTIC FORMATION; BLOOD-COAGULATION; CA-2+ BINDING; REGION; THROMBOMODULIN; THROMBIN; ANTICOAGULANT	Binding Ca2+ to a high affinity site in protein C and 4-carboxyglutamic acid (Gla)-domainless protein C results in a conformational change that is required for activation by the thrombin-thrombomodulin complex, the natural activator of protein C. It has been hypothesized that this high affinity Ca2+-binding site is located in the NH2-terminal epidermal growth factor (EGF) homology region of protein C. We have expressed in human 293 cells a deletion mutant of protein C (E2-PD) which lacks the entire Gla region as well as the NH2-terminal EGF homology region of protein C. Ca2+ inhibits activation of E2-PD or Gla-domainless protein C by thrombin with half-maximal inhibition occurring at Ca2+ concentrations of 103 +/- 11 and 70 +/- 7-mu-M, respectively, but is required for both E2-PD and Gla-domainless protein C activation by the thrombin-thrombomodulin complex with half-maximal acceleration occurring at Ca2+ concentrations of 87 +/- 8 and 89 +/- 8-mu-M, respectively. Both E2-PD and Gla-domainless protein C exhibit a reversible, Ca2+- but not Mg2+-dependent decrease (6 +/- 1%) in fluorescence emission intensity with K(d) = 38 +/- 3-mu-M Ca2+. We conclude that the high affinity Ca2+-binding site important for the activation of protein C is located outside of the NH2-terminal EGF homology region and that the metal-binding site in the NH2-terminal EGF homology region may not be a high affinity site in intact protein C.	OKLAHOMA MED RES FDN,HOWARD HUGHES MED INST,825 NE 13,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT PATHOL,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM,OKLAHOMA CITY,OK 73104	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center					NHLBI NIH HHS [R01 HL-29807, R37 HL-30340] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030340, R01HL029807] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJAJ SP, 1992, P NATL ACAD SCI USA, V89, P152, DOI 10.1073/pnas.89.1.152; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; DANGELO SV, 1986, J CLIN INVEST, V77, P416, DOI 10.1172/JCI112319; DITTMAN WA, 1990, BLOOD, V75, P329; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON NL, 1982, J BIOL CHEM, V257, P859; ESMON NL, 1983, J BIOL CHEM, V258, P5548; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GALVIN JB, 1987, J BIOL CHEM, V262, P2199; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRINNELL BW, 1991, ADV APPL BIOTECHNOL, V11, P29; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; JOHNSON AE, 1983, J BIOL CHEM, V258, P5554; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANN KG, 1990, BLOOD, V76, P1; MILETICH JP, 1990, J BIOL CHEM, V265, P11397; MORITA T, 1985, BIOCHEM BIOPH RES CO, V130, P841, DOI 10.1016/0006-291X(85)90493-0; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; OHLIN AK, 1987, J BIOL CHEM, V262, P13798; OHLIN AK, 1988, J BIOL CHEM, V263, P7411; OHLIN AK, 1990, BIOCHEMISTRY-US, V29, P644; OHLIN AK, 1988, J BIOL CHEM, V263, P19240; OWEN WG, 1974, J BIOL CHEM, V249, P594; PERSSON E, 1989, J BIOL CHEM, V264, P16897; PERSSON E, 1991, J BIOL CHEM, V266, P2444; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUGO T, 1984, J BIOL CHEM, V259, P5705; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902	28	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11701	11704						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601845				2022-12-25	WOS:A1992HY94700011
J	MOHN, H; CHALIFA, V; LISCOVITCH, M				MOHN, H; CHALIFA, V; LISCOVITCH, M			SUBSTRATE-SPECIFICITY OF NEUTRAL PHOSPHOLIPASE-D FROM RAT-BRAIN STUDIED BY SELECTIVE LABELING OF ENDOGENOUS SYNAPTIC MEMBRANE PHOSPHOLIPIDS INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDATE PHOSPHATASE; MIXED MICELLES; HUMAN-PLASMA; PHOSPHATIDYLCHOLINE; PURIFICATION; HYDROLYSIS; DIACYLGLYCEROL; NEUTROPHILS; BREAKDOWN; PATHWAY	We have designed a novel approach for studying the specificity of neutral phospholipase D from rat brain synaptic plasma membranes for endogenous phospholipid substrates in native membranes. A procedure was established that provides synaptic membranes labeled in selected phospholipids. This labeling procedure exploits the presence of endogenous acyl-coenzyme A synthetase and acyl-coenzyme A:lysophospholipid acyltransferase in synaptosomes for acylating various lysophospholipid acceptors with radioactive fatty acid. With [H-3]arachidonate for acylation and optimal concentrations of the respective lysophospholipids, membranes were labeled in either of the following phospholipids: phosphatidylcholine (93% of total label in phospholipids), 1-O-alkyl-phosphatidylcholine (87%), phosphatidylinositol (90%), phosphatidylethanolamine (85%), phosphatidylethanolamine-plasmalogen (81%) or phosphatidylserine (59%). These membranes were employed to study the substrate specificity of the neutral, oleate-activated rat brain phospholipase D. This phospholipase exhibited almost absolute specificity for the choline-phospholipids phosphatidylcholine and 1-O-alkyl-phosphatidylcholine: 0.34% of the former labeled substrate were transphosphatidylated to phosphatidylpropanol during the assay and 0.28% of the latter. Activity toward other phospholipids was barely detectable and could largely be accounted for by utilization of residual labeled phosphatidylcholine present in those preparations. The phospholipase D exhibited some preference for fatty acids in the C-2 position of phosphatidylcholine in the following order: 2-oleoyl-phosphatidylcholine (0.67% of this labeled phosphatidylcholine were converted to phosphatidylpropanol), 2-myristoyl-phosphatidylcholine (0.60%), 2-palmitoyl-phosphatidylcholine (0.46%) and 2-arachidonoyl-phosphatidylcholine (0.34%). The present approach of labeling membrane phospholipids in vitro could be useful in studies of phospholipase specificity as an alternative to the use of sonicated vesicles or mixed detergent-phospholipid micellar systems.	WEIZMANN INST SCI,DEPT HORMONE RES,POB 26,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science				Welch, Heidi/0000-0001-7865-7000; Chalifa-Caspi, Vered/0000-0001-6030-5816				BALSINDE J, 1990, FEBS LETT, V259, P237, DOI 10.1016/0014-5793(90)80017-D; BALSINDE J, 1988, BIOCHEM BIOPH RES CO, V154, P502, DOI 10.1016/0006-291X(88)90168-4; BALSINDE J, 1989, EUR J BIOCHEM, V186, P717, DOI 10.1111/j.1432-1033.1989.tb15265.x; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHALIFA V, 1990, J BIOL CHEM, V265, P17512; CHALIFOUR RJ, 1980, CAN J BIOCHEM CELL B, V58, P1189, DOI 10.1139/o80-159; COCKCROFT S, 1985, FEBS LETT, V181, P259, DOI 10.1016/0014-5793(85)80271-4; DAVITZ MA, 1989, J BIOL CHEM, V264, P13760; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; Eibl H, 1981, Methods Enzymol, V72, P632; EXTON JH, 1990, J BIOL CHEM, V265, P1; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HUANG KS, 1990, J BIOL CHEM, V265, P17738; JONES DH, 1974, BIOCHIM BIOPHYS ACTA, V356, P276, DOI 10.1016/0005-2736(74)90268-5; KATER LA, 1976, J CLIN INVEST, V57, P1173, DOI 10.1172/JCI108385; KISS Z, 1990, J BIOL CHEM, V265, P7345; LIN YP, 1989, J BIOL CHEM, V264, P8641; LISCOVITCH M, 1991, BIOCHEM SOC T, V19, P402, DOI 10.1042/bst0190402; LOFFELHOLZ K, 1989, BIOCHEM PHARMACOL, V38, P1543, DOI 10.1016/0006-2952(89)90299-2; MACDONALD JIS, 1991, BIOCHIM BIOPHYS ACTA, V1084, P105, DOI 10.1016/0005-2760(91)90209-Z; MARTIN TW, 1988, BIOCHIM BIOPHYS ACTA, V962, P282, DOI 10.1016/0005-2760(88)90258-5; NATARAJAN V, 1984, J NEUROCHEM, V42, P1613, DOI 10.1111/j.1471-4159.1984.tb12750.x; PANAGIA V, 1991, BIOCHIM BIOPHYS ACTA, V1064, P242, DOI 10.1016/0005-2736(91)90308-U; QIAN Z, 1989, J BIOL CHEM, V264, P21720; SAITO M, 1975, ARCH BIOCHEM BIOPHYS, V169, P318, DOI 10.1016/0003-9861(75)90346-X; SCALLON BJ, 1991, SCIENCE, V252, P446, DOI 10.1126/science.2017684; SCHMID HHO, 1990, PROG LIPID RES, V29, P1, DOI 10.1016/0163-7827(90)90004-5; SHUKLA SD, 1991, LIFE SCI, V48, P851, DOI 10.1016/0024-3205(91)90031-6; STROSZNAJDER J, 1983, J NEUROCHEM, V40, P84, DOI 10.1111/j.1471-4159.1983.tb12656.x; TAKI T, 1979, J BIOL CHEM, V254, P9761; WANG P, 1991, J BIOL CHEM, V266, P14877; [No title captured]	34	34	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11131	11136						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597450				2022-12-25	WOS:A1992HX16900033
J	MUNFORD, RS; HUNTER, JP				MUNFORD, RS; HUNTER, JP			ACYLOXYACYL HYDROLASE, A LEUKOCYTE ENZYME THAT DEACYLATES BACTERIAL LIPOPOLYSACCHARIDES, HAS PHOSPHOLIPASE, LYSOPHOSPHOLIPASE, DIACYLGLYCEROLLIPASE, AND ACYLTRANSFERASE ACTIVITIES INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-NEUTROPHILS; FATTY-ACIDS; SUBSTRATE-SPECIFICITY; PURIFICATION; METABOLISM; PROTEINS; CALCIUM; FUSION; LIPASE; CELLS	Human acyloxyacyl hydrolase (AOAH) is a leukocyte enzyme that hydrolyzes acyloxyacyl bonds in the lipid A region of bacterial lipopolysaccharide (LPS), thereby detoxifying the LPS. We report here that the enzyme also acts in vitro on glycerophospholipids, lysophospholipids, and diacylglycerol. While AOAH preferentially removes palmitate or stearate from the sn-1 position of phospholipid and diacylglycerol substrates that have unsaturated acyl chains in the sn-2 position, it is able to cleave both palmitates from sn-1,2-dipalmitoylphosphatidylcholine and sn-1,2-dipalmitoylglycerol. This apparent preference for removing saturated (or shorter) acyl chains from glycerolipids is consistent with its ability to cleave laurate more rapidly than palmitoleate from lipopolysaccharide (Erwin, A. L., and Munford, R. S. (1990) J. Biol. Chem. 265, 16444-16449). AOAH also catalyzes acyl transfer from LPS and phosphatidylethanolamine to acceptor lipids; approximately equal amounts of laurate and myristate are transferred from LPS to monooleoylglyceryl ether, forming acyloleoylglyceryl ether. The demonstration that AOAH has phospholipase, lysophospholipase, diacylglycerol lipase, and acyltransferase activities in vitro suggests that the enzyme may have roles in addition to LPS deacylation (detoxification) in phagocytic cells.	UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	MUNFORD, RS (corresponding author), UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018188, R56AI018188, R37AI018188] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18188] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMES GF, 1968, J BACTERIOL, V95, P833, DOI 10.1128/JB.95.3.833-843.1968; BALSINDE J, 1991, J BIOL CHEM, V266, P15638; BALSINDE J, 1988, J BIOL CHEM, V263, P1929; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; ELSBACH P, 1963, AM J PHYSIOL, V205, P1154, DOI 10.1152/ajplegacy.1963.205.6.1154; ERWIN AL, 1990, J BIOL CHEM, V265, P16444; FRANSON R, 1974, J LIPID RES, V15, P380; HAGEN FS, 1991, BIOCHEMISTRY-US, V30, P8415, DOI 10.1021/bi00098a020; HALL CL, 1983, P NATL ACAD SCI-BIOL, V80, P6671, DOI 10.1073/pnas.80.21.6671; HOSTETLER KY, 1986, BIOCHEMISTRY-US, V25, P6456, DOI 10.1021/bi00369a017; KENNERLY DA, 1979, J EXP MED, V150, P1039, DOI 10.1084/jem.150.4.1039; KUCERA GL, 1988, J BIOL CHEM, V263, P1920; MACDONALD JIS, 1991, BIOCHIM BIOPHYS ACTA, V1084, P105, DOI 10.1016/0005-2760(91)90209-Z; MUNFORD RS, 1990, MICROBIAL DETERMINANTS OF VIRULENCE AND HOST RESPONSE, P271; MUNFORD RS, 1985, INFECT IMMUN, V48, P464, DOI 10.1128/IAI.48.2.464-473.1985; MUNFORD RS, 1986, SCIENCE, V234, P203, DOI 10.1126/science.3529396; MUNFORD RS, 1989, J BIOL CHEM, V264, P15613; MUNFORD RS, 1991, METHOD ENZYMOL, V209, P485; NACCACHE PH, 1984, J LEUKOCYTE BIOL, V36, P333, DOI 10.1002/jlb.36.3.333; PLUCKTHUN A, 1982, BIOCHEMISTRY-US, V21, P1743; RAO RH, 1981, EXP LUNG RES, V2, P9, DOI 10.3109/01902148109052298; SCHULTZ A, 1984, VIROLOGY, V133, P431, DOI 10.1016/0042-6822(84)90409-4; TANAKA T, 1988, J BIOL CHEM, V263, P13670; TRAYNOR JR, 1981, BIOCHIM BIOPHYS ACTA, V665, P571, DOI 10.1016/0005-2760(81)90272-1; VANDENBOSCH H, 1974, BIOCHIM BIOPHYS ACTA, V348, P197, DOI 10.1016/0005-2760(74)90231-8; VANDENBOSCH H, 1980, BIOCHIM BIOPHYS ACTA, V604, P191; WAITE M, 1985, J LIPID RES, V26, P1379; WAITE M, 1987, HDB LIPID RES, V5; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WRIGHT GW, 1990, J BIOL CHEM, V265, P6675; YAMAGUCHI T, 1986, BIOCHIM BIOPHYS ACTA, V861, P440, DOI 10.1016/0005-2736(86)90452-9	31	49	51	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10116	10121						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577781				2022-12-25	WOS:A1992HT96500100
J	TAKATA, Y; WEBSTER, NJG; OLEFSKY, JM				TAKATA, Y; WEBSTER, NJG; OLEFSKY, JM			INTRACELLULAR SIGNALING BY A MUTANT HUMAN INSULIN-RECEPTOR LACKING THE CARBOXYL-TERMINAL TYROSINE AUTOPHOSPHORYLATION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; V-ROS; KINASE; ACTIVATION; PROTEIN; FIBROBLASTS; MULTIPLE; SERUM; S6	We have recently characterized a mutant insulin receptor (Y/F2) in which the two tyrosines in the carboxyl terminus (Tyr1316, Tyr1322) were mutated to phenylalanine. Compared with wild type receptors, the Y/F2 receptor exhibited markedly enhanced sensitivity to insulin-stimulated DNA synthesis with normal insulin-stimulated glucose uptake (Takata, Y., Webster, N. J. G., and Olefsky, J. M. (1991) J. Biol. Chem. 266, 9135-9139). In this paper, we present further evidence for the divergence of the metabolic and mitogenic signaling pathways utilized by the insulin receptor. The mutant receptor showed normal sensitivity and responsiveness for insulin-stimulated glucose incorporation into glycogen. The insulin sensitivity for phosphorylation of two substrates (pp180 and pp220) was the same in both Y/F2 cells and HIRc cells. Phosphotyrosine content, however, was greater in Y/F2 cells than in HIRc cells, especially in the basal state. Insulin stimulated S6 kinase activity 2-6-fold, with an ED50 of -10 nm in Rat 1 cells and 0.5 nm in HIRc cells. The sensitivity to insulin was enhanced in Y/F2 cells with an ED50 of 0.1 nm. These effects were insulin-specific, since insulin-like growth factor (IGF)-I-stimulated mitogenesis was normal. In summary: 1) Y/F2 receptors exhibit normal metabolic and enhanced mitogenic signaling; 2) the enhanced mitogenic signaling is specific for the insulin receptor in the Y/F2 cells, since IGF-I-stimulated mitogenesis is normal; 3) Y/F2 cells display increased endogenous substrate phosphorylation and augmented insulin-stimulated S6 kinase activity placing these responses among insulin's mitogenic effects; and 4) these results are consistent with the concept that the COOH-terminal tyrosine residues of the insulin receptor are normally inhibitory to mitogenic signaling.	VET ADM MED CTR,MED RES SERV,SAN DIEGO,CA 92161	US Department of Veterans Affairs; Veterans Health Administration (VHA)	TAKATA, Y (corresponding author), UNIV CALIF SAN DIEGO,DEPT MED,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093, USA.		Webster, Nick/AAI-8410-2021		NIDDK NIH HHS [DK 33651, DK 33649] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033649, R37DK033649, R01DK033651, R37DK033651] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDO A, 1991, FOLIA ENDOCRINOL JPN, V67, P910; BARON V, 1990, BIOCHEMISTRY-US, V29, P4634, DOI 10.1021/bi00471a019; BOULTON TG, 1990, J BIOL CHEM, V265, P2713; CHIN JE, 1991, J BIOL CHEM, V266, P15587; CZECH MP, 1988, J BIOL CHEM, V263, P11017; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; GORDEN HJ, 1987, BIOCHEMISTRY-US, V26, P2374; HEIDENREICH KA, 1989, ENDOCRINOLOGY, V125, P1458, DOI 10.1210/endo-125-3-1458; HOFMANN C, 1989, ENDOCRINOLOGY, V124, P257, DOI 10.1210/endo-124-1-257; KAMPS MP, 1988, ONCOGENE, V2, P305; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE WL, 1990, ENDOCRINOLOGY, V127, P2854, DOI 10.1210/endo-127-6-2854; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MASSAGUE J, 1985, METHOD ENZYMOL, V109, P179; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MCCLAIN DM, 1986, J BIOL CHEM, V263, P8904; MYERS MG, 1991, J BIOL CHEM, V266, P10616; Ogata K, 1979, Methods Enzymol, V59, P502; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; SAKATA S, 1988, IMMUNOL INVEST, V17, P237, DOI 10.3109/08820138809052963; SOOS MA, 1990, J BIOCHEM-TOKYO, V270, P382; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; THIES RS, 1989, J BIOL CHEM, V264, P12820; TREADWAY JL, 1991, P NATL ACAD SCI USA, V88, P214, DOI 10.1073/pnas.88.1.214; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P765	28	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9065	9070						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577744				2022-12-25	WOS:A1992HR85400057
J	WRIGHT, JF; PERNOLLET, M; REBOUL, A; AUDE, C; COLOMB, MG				WRIGHT, JF; PERNOLLET, M; REBOUL, A; AUDE, C; COLOMB, MG			IDENTIFICATION AND PARTIAL CHARACTERIZATION OF A LOW AFFINITY METAL-BINDING SITE IN THE LIGHT CHAIN OF TETANUS TOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTOXIN TYPE-A; T-CELL EPITOPES; ESCHERICHIA-COLI; PROTEINS; SEQUENCE; OXIDATION	Tetanus toxin was shown to contain a metal-binding site for zinc and copper. Equilibrium dialysis binding experiments using Zn-65 indicated an association constant of 9-15-mu-M, with one zinc-binding site/toxin molecule. The zinc-binding site was localized to the toxin light chain as determined by binding of Zn-65 to the light chain but not to the heavy chain after separation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transfer to Immobilon membranes. Copper was an efficient inhibitor of Zn-65 binding to tetanus toxin and caused two peptide bond cleavages in the toxin light chain in the presence of ascorbate. These metal-catalyzed oxidative cleavages were inhibited by the presence of zinc. Partial characterization of metal-catalyzed oxidative modifications of a peptide based on a putative metal-binding site (HELIH) in the toxin light chain was used to map the metal-binding site in the protein.	CEN, DEPT BIOL MOLEC & STRUCT,INSERM,U238, IMMUNOCHIM LAB,85X, F-38041 GRENOBLE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)								AHNERTHILGER G, 1989, FEBS LETT, V242, P245, DOI 10.1016/0014-5793(89)80478-8; BINZ T, 1990, J BIOL CHEM, V265, P9153; CALABRESE L, 1989, J BIOL CHEM, V264, P6183; CORNETTE JL, 1989, METHOD ENZYMOL, V178, P611; DASGUPTA BR, 1984, ARCH BIOCHEM BIOPHYS, V232, P172, DOI 10.1016/0003-9861(84)90532-0; EISEL U, 1986, EMBO J, V5, P2495, DOI 10.1002/j.1460-2075.1986.tb04527.x; FAIRWEATHER NF, 1986, NUCLEIC ACIDS RES, V14, P7809, DOI 10.1093/nar/14.19.7809; FARBER JM, 1986, J BIOL CHEM, V261, P4574; JHON DY, 1991, BIOFACTORS, V3, P121; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; KORBASHI P, 1989, J BIOL CHEM, V264, P8479; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARX G, 1986, BIOCHEM J, V236, P397, DOI 10.1042/bj2360397; MASELLE SY, 1991, FEMS MICROBIOL IMMUN, V76, P171, DOI 10.1111/j.1574-6968.1991.tb04211.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAZEN A, 1988, ANAL BIOCHEM, V172, P39, DOI 10.1016/0003-2697(88)90408-3; MERRIFIELD RB, 1964, BIOCHEMISTRY-US, V3, P1385, DOI 10.1021/bi00897a032; MILLER DM, 1990, FREE RADICAL BIO MED, V8, P95, DOI 10.1016/0891-5849(90)90148-C; MOCHIDA S, 1989, FEBS LETT, V253, P47, DOI 10.1016/0014-5793(89)80926-3; OZUTSUMI K, 1985, APPL ENVIRON MICROB, V49, P939, DOI 10.1128/AEM.49.4.939-943.1985; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; ROTHBARD JB, 1988, EMBO J, V7, P93, DOI 10.1002/j.1460-2075.1988.tb02787.x; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCOTT RA, 1988, BIOCHEMISTRY-US, V27, P5411, DOI 10.1021/bi00415a005; SIGMAN DS, 1990, BIOCHEMISTRY-US, V29, P9097, DOI 10.1021/bi00491a001; SKOTLAND T, 1983, EUR J BIOCHEM, V132, P171, DOI 10.1111/j.1432-1033.1983.tb07343.x; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; STILLE CJ, 1987, MOL IMMUNOL, V24, P1021, DOI 10.1016/0161-5890(87)90068-X; THIELENS NM, 1990, J BIOL CHEM, V265, P14469; UCHIDA K, 1990, ARCH BIOCHEM BIOPHYS, V283, P20, DOI 10.1016/0003-9861(90)90606-Y; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VIJAYARAGHAVAN J, 1990, J BIOL CHEM, V265, P14150; VILLIERS MB, 1991, SCAND J IMMUNOL, V34, P585, DOI 10.1111/j.1365-3083.1991.tb01582.x; YAMASHITA MM, 1990, P NATL ACAD SCI USA, V87, P5648, DOI 10.1073/pnas.87.15.5648	34	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9053	9058						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577743				2022-12-25	WOS:A1992HR85400055
J	ZHENG, J; SCHODEL, F; PETERSON, DL				ZHENG, J; SCHODEL, F; PETERSON, DL			THE STRUCTURE OF HEPADNAVIRAL CORE ANTIGENS - IDENTIFICATION OF FREE THIOLS AND DETERMINATION OF THE DISULFIDE BONDING PATTERN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-B VIRUS; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; PROTEIN; ELECTROPHORESIS; PARTICLES; SERUM	A set of wild-type and mutant human, woodchuck, and duck hepatitis viral core proteins have been prepared and used to study the free thiol groups and the disulfide bonding pattern present within the core particle. Human (HBcAg) and woodchuck (WHcAg) core proteins contain 4 cysteine residues, whereas duck (DHcAg) core protein contains a single cysteine residue. Each of the cysteines of HBcAg has been eliminated, either singly or in combinations, by a two-step mutagenesis procedure. All of the proteins were shown to have very similar physical and immunochemical properties. All assemble into essentially identical core particle structures. Therefore disulfide bonds are not essential for core particle formation. No intra-chain disulfide bonds occur. Cys107 is a free thiol buried within the particle structure, whereas Cys48 is present partly as a free sulfhydryl which is exposed at the surface of the particle. Cys61 is always and Cys48 is partly involved in interchain disulfide bonds with the identical residues of another monomer, whereas Cys183 is always involved in a disulfide bond with the Cys183 of a different monomer. WHcAg has the same pattern of bonding, whereas DHcAg lacks any disulfide bonds, and the single free sulfhydryl, Cys153 which is equivalent to Cys107 of HBcAg, is buried.	VIRGINIA COMMONWEALTH UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,RICHMOND,VA 23298; MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY	Virginia Commonwealth University; Max Planck Society					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015955] Funding Source: NIH RePORTER; NIAID NIH HHS [AI15955] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARGOS P, 1988, EMBO J, V7, P819, DOI 10.1002/j.1460-2075.1988.tb02880.x; BIRNBAUM F, 1990, J VIROL, V64, P3319, DOI 10.1128/JVI.64.7.3319-3330.1990; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FEITELSON MA, 1982, J VIROL, V43, P687, DOI 10.1128/JVI.43.2.687-696.1982; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GALLINA A, 1989, J VIROL, V63, P4645, DOI 10.1128/JVI.63.11.4645-4652.1989; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GARCIA PD, 1988, J CELL BIOL, V106, P1093, DOI 10.1083/jcb.106.4.1093; GIRONES R, 1989, P NATL ACAD SCI USA, V86, P1846, DOI 10.1073/pnas.86.6.1846; JENKINS WT, 1962, BIOCHEM PREP, V9, P83; KANEKO S, 1989, J CLIN MICROBIOL, V27, P1930, DOI 10.1128/JCM.27.9.1930-1933.1989; LAYNE E, 1957, METHOD ENZYMOL, V3, P4447; MARION PL, 1983, CURR TOP MICROBIOL, V105, P99; MCKAY P, 1981, J MED VIROL, V8, P237; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OU JH, 1986, P NATL ACAD SCI USA, V83, P1578, DOI 10.1073/pnas.83.6.1578; PASEK M, 1979, NATURE, V282, P575, DOI 10.1038/282575a0; PUGH J, 1989, J VIROL, V63, P1371, DOI 10.1128/JVI.63.3.1371-1376.1989; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; SCHJEIDE OA, 1969, ANAL BIOCHEM, V27, P473; SUMMERS J, 1981, HEPATOLOGY, V2, P179; TAKAHASHI K, 1983, J IMMUNOL, V130, P2903	24	83	97	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9422	9429						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577770				2022-12-25	WOS:A1992HR85400108
J	CARR, DW; HAUSKEN, ZE; FRASER, IDC; STOFKOHAHN, RE; SCOTT, JD				CARR, DW; HAUSKEN, ZE; FRASER, IDC; STOFKOHAHN, RE; SCOTT, JD			ASSOCIATION OF THE TYPE-II CAMP-DEPENDENT PROTEIN-KINASE WITH A HUMAN THYROID RII-ANCHORING PROTEIN - CLONING AND CHARACTERIZATION OF THE RII-BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; REGULATORY SUBUNIT; BOVINE BRAIN; RAT-BRAIN; IDENTIFICATION; LOCALIZATION; EXPRESSION; COMPARTMENTALIZATION; ACCUMULATION	The type II cAMP-dependent protein kinase (PKA) is localized to specific subcellular environments through binding of the dimeric regulatory subunit (RII) to anchoring proteins. Subcellular localization is likely to influence which substrates are most accessible to the catalytic subunit upon activation. We have previously shown that the RII-binding domains of four anchoring proteins contain sequences which exhibit a high probability of amphipathic helix formation (Carr, D. W., Stofko-Hahn, R. E., Fraser, I. D. C., Bishop, S. M., Acott, T. E., Brennan, R. G., and Scott J. D. (1991) J. Biol. Chem. 266, 14188-14192). In the present study we describe the cloning of a cDNA which encodes a 1015-amino acid segment of Ht 31. A synthetic peptide (Asp-Leu-Ile-Glu-Glu-Ala-Ala-Ser-Arg-Ile-Val-Asp-Ala-Val-Ile-Glu-Gln-Val-Lys-Ala-Ala-Tyr) representing residues 493-515 encompasses the minimum region of Ht 31 required for RII binding and blocks anchoring protein interaction with RII as detected by band-shift analysis. Structural analysis by circular dichroism suggests that this peptide can adopt an alpha-helical conformation. Both Ht 31 (493-515) peptide and its parent protein bind RII-alpha or the type II PKA holoenzyme with high affinity. Equilibrium dialysis was used to calculate dissociation constants of 4.0 and 3.8 nM for Ht 31 peptide interaction with RII-alpha and the type II PKA, respectively. A survey of nine different bovine tissues was conducted to identify RII binding proteins. Several bands were detected in each tissues using a P-32-RII overlay method. Addition of 0.4-mu-M Ht 31 (493-515) peptide to the reaction mixture blocked all RII binding. These data suggest that all anchoring proteins bind RII-alpha at the same site as the Ht 31 peptide. The nanomolar affinity constant and the different patterns of RII-anchoring proteins in each tissue suggest that the type II-alpha PKA holoenzyme may be specifically targeted to different locations in each type of cell.	OREGON HLTH SCI UNIV, VOLLUM INST ADV BIOMED RES, 3181 SW SAM JACKSON PK RD, PORTLAND, OR 97201 USA	Oregon Health & Science University			Fraser, Iain DC/L-4735-2017	Fraser, Iain DC/0000-0003-2272-3907	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044239, F32DK008767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044427] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 08767, DK 44239] Funding Source: Medline; NIGMS NIH HHS [GM 44427] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARSONY J, 1990, P NATL ACAD SCI USA, V87, P1188, DOI 10.1073/pnas.87.3.1188; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CARR DW, 1991, J BIOL CHEM, V266, P14188; CORBIN JD, 1977, J BIOL CHEM, V252, P3854; DECAMILLI P, 1986, J CELL BIOL, V103, P189, DOI 10.1083/jcb.103.1.189; EARP HS, 1978, ANNU REV PHARMACOL, V18, P431, DOI 10.1146/annurev.pa.18.040178.002243; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P123; FRASER IDC, 1991, FED PROC, V75, P1530; HARPER JF, 1985, VITAM HORM, V42, P197; HELFMAN DM, 1983, P NATL ACAD SCI-BIOL, V80, P31, DOI 10.1073/pnas.80.1.31; HOFMANN F, 1977, J BIOL CHEM, V252, P1441; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KLOTZ IM, 1989, PROTEIN FUNCTION PRA, P25; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEISER M, 1986, J BIOL CHEM, V261, P1904; LOHMANN SM, 1984, P NATL ACAD SCI-BIOL, V81, P6723, DOI 10.1073/pnas.81.21.6723; LOHMANN SM, 1980, J BIOL CHEM, V255, P9985; LUDVIG N, 1990, BRAIN RES, V520, P90, DOI 10.1016/0006-8993(90)91694-C; LUO Z, 1991, J BIOL CHEM, V265, P21804; OBAR RA, 1989, NEURON, V3, P639, DOI 10.1016/0896-6273(89)90274-2; PARKER CW, 1990, METHOD ENZYMOL, V182, P721; RUBIN CS, 1979, J BIOL CHEM, V254, P797; RUBINO HM, 1989, NEURON, V3, P631, DOI 10.1016/0896-6273(89)90273-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR D, 1984, J BIOL CHEM, V259, P9840; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; SCOTT JD, 1992, IN PRESS NEWS PHYSL; SHARMA RK, 1983, METHOD ENZYMOL, V102, P210; STEIN JC, 1987, J BIOL CHEM, V262, P3002; STUDIER FW, 1990, GENE EXPRESSION TECH, V185, P60; SUTHERLAND E, 1969, CIRCULATION, V37, P279; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; THREURKAUF W, 1982, J BIOL CHEM, V257, P3284	37	293	306	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13376	13382						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618839				2022-12-25	WOS:A1992JB74600046
J	DESBOIS, C; CAPEAU, J; HAINAULT, I; WICEK, D; REYNET, C; VEISSIERE, D; CARON, M; PICARD, J; GUERREMILLO, M; CHERQUI, G				DESBOIS, C; CAPEAU, J; HAINAULT, I; WICEK, D; REYNET, C; VEISSIERE, D; CARON, M; PICARD, J; GUERREMILLO, M; CHERQUI, G			DIFFERENTIAL ROLE OF INSULIN-RECEPTOR AUTOPHOSPHORYLATION SITE-1162 AND SITE-1163 IN THE LONG-TERM INSULIN STIMULATION OF GLUCOSE-TRANSPORT, GLYCOGENESIS, AND PROTEIN-SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; PRIMARY CULTURED ADIPOCYTES; TYROSINE KINASE-ACTIVITY; SUBSTRATE PHOSPHORYLATION; HYBRID RECEPTORS; PLASMA-MEMBRANE; GENE-EXPRESSION; 3T3 ADIPOCYTES; CELLS; RESIDUE-1162	The long-term regulatory effect of insulin on glucose transport activity and glucose transporter expression was examined in Chinese hamster ovary (CHO) transfectants that overexpress either human insulin receptors of the wild type (CHO-R cells) or human insulin receptors mutated at two major autophosphorylation sites, Tyr1162 and Tyr1163 (CHO-Y2 cells). Previous studies showed that, when acutely stimulated by insulin, CHO-Y2 cells exhibit decreased receptor kinase activity along with decreased signaling of several pathways, including that for glucose transport, as compared with CHO-R cells. We now report the following. (i) When treated for 24 h with insulin (10(-10) to 10(-6) M), CHO-R and CHO-Y2 cells displayed closely similar concentration-dependent increases in 2-deoxyglucose uptake. In both transfectants, the maximal insulin-induced increase (approximately 3.5-fold) in uptake was cycloheximide-sensitive and was paralleled by equivalent increases in the levels of GLUT-1 immunoreactive protein and mRNA. (ii) By contrast, under similar conditions, CHO-Y2 cells exhibited a marked decrease in their response to insulin for [U-C-14]glucose incorporation into glycogen (decreased sensitivity and maximal responsiveness) and for [U-C-14]leucine incorporation into protein (decreased sensitivity) as compared with CHO-R cells. (iii) After a 24-h treatment with 10(-7) M insulin, CHO-R (but not CHO-Y2) cells showed a decreased ability to respond to a subsequent acute insulin stimulation of either receptor exogenous kinase activity or 2-deoxyglucose uptake as compared with respective untreated controls. These results indicate that (i) insulin receptors mutated at Tyr1162 and Tyr1163 retain normal signaling of the long-term stimulatory effect of insulin on glucose transport activity and GLUT-1 expression, but not on glycogenesis and overall protein synthesis; (ii) these three insulin signaling pathways may be triggered by distinct domains of the insulin receptor-beta-subunit; and (iii) wild-type (but not twin-tyrosine mutant) receptors undergo negative regulation by chronic insulin treatment for subsequent signaling of acute biological actions of insulin.	UNIV PARIS 06,BIOCHIM LAB,INSERM,U181,27 RUE CHALIGNY,F-75571 PARIS 12,FRANCE; INSERM,U177,INST BIOMED CORDELIERS,F-75006 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite			Desbois-Mouthon, Christele/M-7076-2017	Desbois-Mouthon, Christele/0000-0002-0772-1711				BERGER J, 1989, NATURE, V340, P70, DOI 10.1038/340070a0; BOULTON TG, 1990, J BIOL CHEM, V265, P2713; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPEAU J, 1984, ENDOCRINOLOGY, V115, P654, DOI 10.1210/endo-115-2-654; CARON M, 1989, HORM METAB RES, V21, P295, DOI 10.1055/s-2007-1009219; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHERQUI G, 1990, J BIOL CHEM, V265, P21254; CHIN JE, 1991, J BIOL CHEM, V266, P15587; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; DEHERREROS AG, 1989, J BIOL CHEM, V264, P9885; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GOTTSCHALK WK, 1991, J BIOL CHEM, V266, P8814; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HAINAULT I, 1991, J CLIN INVEST, V87, P1127, DOI 10.1172/JCI115077; HAINQUE B, 1990, J BIOL CHEM, V265, P7982; HARING H, 1989, DIABETES METAB REV, V5, P431; HARRISON SA, 1990, J BIOL CHEM, V265, P5793; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; KLIP A, 1989, J MEMBRANE BIOL, V111, P1, DOI 10.1007/BF01869205; KLIP A, 1990, DIABETES CARE, V13, P228, DOI 10.2337/diacare.13.3.228; KOIVISTO UM, 1991, J BIOL CHEM, V266, P2615; KOSAKI A, 1988, DIABETES, V37, P1583, DOI 10.2337/diabetes.37.11.1583; KOZKA IJ, 1991, J BIOL CHEM, V266, P11729; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADDUX BA, 1991, J BIOL CHEM, V266, P6731; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MOLLER DE, 1991, J BIOL CHEM, V266, P10995; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; MURUKAMI MS, 1991, J BIOL CHEM, V266, P22653; OKUBO M, 1991, ARCH BIOCHEM BIOPHYS, V288, P126, DOI 10.1016/0003-9861(91)90173-G; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; OLEFSKY JM, 1981, AM J MED, V70, P151, DOI 10.1016/0002-9343(81)90422-8; RAFAELOFF R, 1991, BIOCHEM BIOPH RES CO, V179, P912, DOI 10.1016/0006-291X(91)91905-R; REYNET C, 1990, MOL ENDOCRINOL, V4, P304, DOI 10.1210/mend-4-2-304; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SINHA MK, 1989, DIABETES, V38, P1217, DOI 10.2337/diabetes.38.10.1217; SOOS MA, 1990, BIOCHEM J, V270, P383, DOI 10.1042/bj2700383; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; THIES RS, 1989, J BIOL CHEM, V264, P12820; THIES RS, 1990, DIABETES, V39, P250, DOI 10.2337/diabetes.39.2.250; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; TRAXINGER RR, 1990, J BIOL CHEM, V265, P18879; TRAXINGER RR, 1989, J BIOL CHEM, V264, P8156; TREADWAY JL, 1989, J BIOL CHEM, V264, P15136; TREADWAY JL, 1989, J BIOL CHEM, V264, P21450; VANPUTTEN JPM, 1985, DIABETOLOGIA, V28, P51, DOI 10.1007/BF00277000; WALKER PS, 1989, J BIOL CHEM, V264, P6587; WALKER PS, 1990, J BIOL CHEM, V265, P1516; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1989, J CELL BIOCHEM, V39, P429, DOI 10.1002/jcb.240390409; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; YONEZAWA K, 1991, MOL ENDOCRINOL, V5, P194, DOI 10.1210/mend-5-2-194; ZHANG B, 1991, J BIOL CHEM, V266, P990	60	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13488	13497						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618850				2022-12-25	WOS:A1992JB74600063
J	KIDO, H; YOKOGOSHI, Y; SAKAI, K; TASHIRO, M; KISHINO, Y; FUKUTOMI, A; KATUNUMA, N				KIDO, H; YOKOGOSHI, Y; SAKAI, K; TASHIRO, M; KISHINO, Y; FUKUTOMI, A; KATUNUMA, N			ISOLATION AND CHARACTERIZATION OF A NOVEL TRYPSIN-LIKE PROTEASE FOUND IN RAT BRONCHIOLAR EPITHELIAL CLARA CELLS - A POSSIBLE ACTIVATOR OF THE VIRAL FUSION GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIC LYMPHOCYTES-T; SENDAI VIRUS; SERINE PROTEASES; MAST-CELLS; INFLUENZA-VIRUS; FACTOR-X; CLEAVAGE; PURIFICATION; ESTERASE; LOCALIZATION	A novel trypsin-like protease associated with rat bronchiolar epithelial Clara cells, named Tryptase Clara, was purified to homogeneity from rat lung by a series of standard chromatographic procedures. The enzyme has apparent molecular masses of 180 +/- 16 kDa on gel filtration and 30 +/- 1.5 kDa on sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing conditions. Its isoelectric point is pH 4.75. Studies with model peptide substrates showed that the enzyme preferentially recognizes a single arginine cleavage site, cleaving Boc-Gln-Ala-Arg-4-methylcoumaryl-7-amide most efficiently and having a pH optimum of 7.5 with this substrate. The enzyme is strongly inhibited by aprotinin, diisopropylfluorophosphate, antipain, leupeptin, and Kunitz-type soybean trypsin inhibitor, but inhibited only slightly by Bowman-Birk soybean trypsin inhibitor, benzamidine, and alpha-1-anti-trypsin. Immunohistochemical studies indicated that the enzyme is located exclusively in the bronchiolar epithelial Clara cells and colocalized with surfactant. An immunoreactive protein with a molecular mass of 28.5 kDa was also detected in airway secretions by Western blotting analyses, suggesting that the 30-kDa protease in Clara cells is processed before or after its secretion. Proteolytic cleavage of the hemagglutinin of influenza virus is a prerequisite for the virus to become infectious. Tryptase Clara was shown to cleave the hemagglutinin and activate infectivity of influenza A virus in a dose-dependent way. These results suggest that the enzyme is a possible activator of inactive viral fusion glycoprotein in the respiratory tract and thus responsible for pneumopathogenicity of the virus.	UNIV TOKUSHIMA, SCH MED, DEPT NUTR, TOKUSHIMA 770, JAPAN; JICHI MED SCH, DEPT VIROL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN	Tokushima University; Jichi Medical University	KIDO, H (corresponding author), UNIV TOKUSHIMA, INST ENZYME RES, DIV ENZYME CHEM, TOKUSHIMA 770, JAPAN.							BARBEYMOREL CL, 1987, J INFECT DIS, V155, P667, DOI 10.1093/infdis/155.4.667; FRUTH U, 1987, EUR J IMMUNOL, V17, P1625, DOI 10.1002/eji.1830171116; GETHING MJ, 1980, NATURE, V287, P301, DOI 10.1038/287301a0; GOTOH B, 1990, EMBO J, V9, P4189, DOI 10.1002/j.1460-2075.1990.tb07643.x; HAYASHI T, 1991, J GEN VIROL, V72, P979, DOI 10.1099/0022-1317-72-4-979; HOMMA M, 1973, J VIROL, V12, P1457, DOI 10.1128/JVI.12.6.1457-1465.1973; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HSU SM, 1981, AM J CLIN PATHOL, V75, P734, DOI 10.1093/ajcp/75.5.734; KASHIWAZ.H, 1965, P SOC EXP BIOL MED, V120, P134, DOI 10.3181/00379727-120-30467; KATUNUMA N, 1988, J CELL BIOCHEM, V38, P291, DOI 10.1002/jcb.240380408; KETTNER C, 1981, THROMB RES, V22, P645, DOI 10.1016/0049-3848(81)90062-1; KIDO H, 1990, J BIOL CHEM, V265, P21979; KIDO H, 1985, ARCH BIOCHEM BIOPHYS, V239, P436, DOI 10.1016/0003-9861(85)90709-X; Klenk H D, 1980, Curr Top Microbiol Immunol, V90, P19; Klenk H D, 1988, Adv Virus Res, V34, P247, DOI 10.1016/S0065-3527(08)60520-5; KRAHENBUHL O, 1988, J IMMUNOL, V141, P3471; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASSON D, 1978, CELL, V49, P769; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; OUCHTERLONY O, 1968, HDB IMMUNODIFFUSION; PASTERNACK MS, 1985, NATURE, V314, P743, DOI 10.1038/314743a0; RICE RH, 1971, J BIOL CHEM, V246, P831; Rott R., 1977, CELL SURF REV, V2, P47; SCHEID A, 1974, VIROLOGY, V57, P475, DOI 10.1016/0042-6822(74)90187-1; Schwartz L B, 1990, Monogr Allergy, V27, P90; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SINGH G, 1984, J HISTOCHEM CYTOCHEM, V32, P49, DOI 10.1177/32.1.6418790; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH TJ, 1984, J BIOL CHEM, V259, P1046; TASHIRO M, 1983, INFECT IMMUN, V39, P879, DOI 10.1128/IAI.39.2.879-888.1983; TASHIRO M, 1990, J VIROL, V64, P3627, DOI 10.1128/JVI.64.8.3627-3634.1990; TASHIRO M, 1987, VIROLOGY, V157, P421, DOI 10.1016/0042-6822(87)90284-4; TOYODA T, 1987, VIROLOGY, V158, P242, DOI 10.1016/0042-6822(87)90261-3; WALKER SR, 1986, J HISTOCHEM CYTOCHEM, V34, P1137, DOI 10.1177/34.9.2426341; WOODBURY RG, 1980, FEBS LETT, V114, P189, DOI 10.1016/0014-5793(80)81112-4; YOUNG JDE, 1986, CELL, V47, P183, DOI 10.1016/0092-8674(86)90441-1; [No title captured]	37	224	243	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13573	13579						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618859				2022-12-25	WOS:A1992JB74600075
J	TURNER, SR; IRELAND, R; MORGAN, C; RAWSTHORNE, S				TURNER, SR; IRELAND, R; MORGAN, C; RAWSTHORNE, S			IDENTIFICATION AND LOCALIZATION OF MULTIPLE FORMS OF SERINE HYDROXYMETHYLTRANSFERASE IN PEA (PISUM-SATIVUM) AND CHARACTERIZATION OF A CDNA-ENCODING A MITOCHONDRIAL ISOFORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE DECARBOXYLASE; ESCHERICHIA-COLI; LEAF MITOCHONDRIA; H-PROTEIN; PURIFICATION; GENE; EXPRESSION; HISTIDINE; COMPONENT; CLONING	Serine hydroxymethyltransferase (SHMT) has been purified from the mitochondria of green pea leaves. Activity can be fractionated into two distinct peaks by ion exchange chromatography. While these two forms of the enzyme are immunologically indistinguishable, immunoinhibition experiments show the presence of a distinct non-mitochondrial third form of the enzyme to also be present in green pea leaves. While this mitochondrial form of SHMT is abundant in leaves it is absent from roots, although the two tissues have comparable SHMT activity. An antibody raised to purified mitochondrial SHMT was used to screen a cDNA expression library. The sequence of one of the isolated positive clones contained an open reading frame, which encoded a sequence that matched the amino acid sequence determined from the N terminus of the mature protein. The open reading frame encodes a mature protein of 487 amino acids with a M(r) of 54,000, together with a 27-31 amino acid serine-rich leader sequence, presumably required for mitochondrial targeting. The cDNA hybridizes to a small multigene family of 2-3 genes, which appear to be expressed predominantly in leaves. Comparison of the deduced amino acid sequence with the amino acid sequences of the rabbit mitochondrial and cytoplasmic SHMT, show that pea mitochondrial SHMT is equally similar to both of these enzymes. In addition, the rabbit sequences are more like one another than they are to the pea sequence, suggesting an interesting evolutionary relationship for these proteins.	MT ALLISON UNIV,DEPT BIOL,SACKVILLE E0A 3C0,NB,CANADA	Mount Allison University	TURNER, SR (corresponding author), AFRC,INST PLANT SCI RES,JOHN INNES CTR,CAMBRIDGE LAB,COLNEY LANE,NORWICH NR4 7UA,NORFOLK,ENGLAND.		Turner, Simon/K-7580-2012	Turner, Simon/0000-0003-4859-1068				APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; ARTIGUES A, 1990, J BIOL CHEM, V265, P4853; BOURGUIGNON J, 1988, BIOCHEM J, V255, P169, DOI 10.1042/bj2550169; COMBETTE B, 1991, 3RD PLANT RESP M UTR; CYBULSKI RL, 1976, BIOCHEMISTRY-US, V15, P3183, DOI 10.1021/bi00660a004; FUJIOKA M, 1969, BIOCHIM BIOPHYS ACTA, V185, P338, DOI 10.1016/0005-2744(69)90427-6; GARDESTROM P, 1985, PHYSIOL PLANTARUM, V64, P29, DOI 10.1111/j.1399-3054.1985.tb01208.x; GRAY MW, 1989, P NATL ACAD SCI USA, V86, P2267, DOI 10.1073/pnas.86.7.2267; HENRICSON D, 1988, PHYSIOL PLANTARUM, V74, P602, DOI 10.1111/j.1399-3054.1988.tb02024.x; HOPKINS S, 1986, J BIOL CHEM, V261, P3363; KIM YH, 1990, J BIOL CHEM, V265, P848; KISAKI T, 1971, PLANT CELL PHYSIOL, V12, P267; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MACHEREL D, 1990, BIOCHEM J, V268, P783, DOI 10.1042/bj2680783; MARTINI F, 1987, J BIOL CHEM, V262, P5499; MARTINI F, 1989, J BIOL CHEM, V264, P8509; MCALISTERHENN L, 1988, TRENDS BIOCHEM SCI, V13, P178, DOI 10.1016/0968-0004(88)90146-6; MITCHELL MK, 1986, PLANT PHYSIOL, V81, P553, DOI 10.1104/pp.81.2.553; MOOS M, 1988, J BIOL CHEM, V263, P6005; MORRIS DR, 1983, METHOD ENZYMOL, V94, P125; OLIVER DJ, 1990, PLANT PHYSIOL, V94, P833, DOI 10.1104/pp.94.2.833; PALEKAR AG, 1973, J BIOL CHEM, V248, P1158; PIZER LI, 1965, J BACTERIOL, V89, P1145, DOI 10.1128/JB.89.4.1145-1150.1965; PLAMANN MD, 1983, NUCLEIC ACIDS RES, V11, P2065, DOI 10.1093/nar/11.7.2065; RAO DN, 1982, PLANT PHYSIOL, V69, P11, DOI 10.1104/pp.69.1.11; RAWSTHORNE S, 1988, PLANTA HEIDELB, V175, P452; SCHIRCH L, 1980, J BIOL CHEM, V255, P7801; SCHIRCH L, 1982, ADV ENZYMOL RAMB, V53, P83; SCHIRCH V, 1985, J BACTERIOL, V163, P1; SCHIRCH V, 1991, J BIOL CHEM, V266, P759; SCHIRCH V, 1984, CHEM BIOL ASPECTS A, P301; SHINGLES R, 1984, PLANT PHYSIOL, V74, P705, DOI 10.1104/pp.74.3.705; SOMERVILLE CR, 1981, PLANT PHYSIOL, V67, P666, DOI 10.1104/pp.67.4.666; STAUFFER GV, 1981, GENE, V14, P63, DOI 10.1016/0378-1119(81)90148-7; TURNER SR, 1992, J BIOL CHEM, V267, P7745; TURNER SR, 1992, J BIOL CHEM, V267, P5355; VAALER GL, 1989, BIOCHEMISTRY-US, V28, P7306, DOI 10.1021/bi00444a024; WALTON NJ, 1986, PLANTA, V167, P119, DOI 10.1007/BF00446378	38	60	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13528	13534						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618853				2022-12-25	WOS:A1992JB74600068
J	ANDO, A; MOMOMURA, K; TOBE, K; YAMAMOTOHONDA, R; SAKURA, H; TAMORI, Y; KABURAGI, Y; KOSHIO, O; AKANUMA, Y; YAZAKI, Y; KASUGA, M; KADOWAKI, T				ANDO, A; MOMOMURA, K; TOBE, K; YAMAMOTOHONDA, R; SAKURA, H; TAMORI, Y; KABURAGI, Y; KOSHIO, O; AKANUMA, Y; YAZAKI, Y; KASUGA, M; KADOWAKI, T			ENHANCED INSULIN-INDUCED MITOGENESIS AND MITOGEN-ACTIVATED PROTEIN-KINASE ACTIVITIES IN MUTANT INSULIN-RECEPTORS WITH SUBSTITUTION OF 2 COOH-TERMINAL TYROSINE AUTOPHOSPHORYLATION SITES BY PHENYLALANINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; PHOSPHORYLATION; CELLS; BINDING; SUBUNIT; IDENTIFICATION; MUTAGENESIS; ADIPOCYTES; PP60C-SRC; ANTIBODY	We have studied the function of a mutant human insulin receptor in which two COOH-terminal autophosphorylation sites (Tyr-1316 and -1322) were replaced by phenylalanine (F/Y COOH-terminal 2 tyrosines (CT2)). In addition, we have also constructed a mutant receptor in which Lys-1018 in the ATP-binding site was changed to arginine (R/K 1018). Both the wild type insulin receptor (HIR) and the mutant receptors were expressed in Chinese hamster ovary (CHO) cells by stable transfection. Autophosphorylation of solubilized and partially purified F/Y CT2 was decreased by approximately 30% compared with the HIR. Tyrosine kinase activities of F/Y CT2 and HIR toward exogenous substrates were almost equal. When CHO cells transfected with F/Y CT2 (CHO-F/Y CT2) were stimulated with insulin, autophosphorylation of the beta-subunit of the insulin receptor and the phosphorylation of an endogenous substrate (pp185) in the intact cell were normal compared with cells expressing HIR (CHO-HIR). CHO-F/Y CT2 exhibited the same insulin sensitivity as CHO-HIR with respect to 2-deoxyglucose uptake. However, the dose-response curve of insulin-stimulated thymidine incorporation in CHO-F/Y CT2 was shifted to the left (approximately 5-7-fold) compared with that in CHO-HIR. There was no significant difference in insulin-like growth factor 1-stimulated thymidine incorporation between CHO-F/Y CT2 and CHO-HIR. Furthermore, the dose-response curve of insulin-stimulated kinase activity toward myelin basic protein in CHO-F/Y CT2 was also shifted to the left (approximately 5-fold) compared with that in CHO-HIR. Kinase assays in myelin basic protein-containing gels revealed that both species of MAP kinases (M(r) 44,000, 42,000) were more sensitive to activation by insulin in CHO-F/Y CT2 than in CHO-HIR. This observation was confirmed in immune complex kinase assays toward microtubule-associated protein 2 (MAP2) using specific antibodies against mitogen-activated protein (MAP) kinase. R/K 1018 mutant insulin receptors showed an absence of insulin-stimulated kinase activity and CHO cells transfected with R/K 1018 (CHO-R/K 1018) failed to enhance 2-deoxyglucose uptake or thymidine incorporation in response to insulin. In addition, R/K 1018 kinase-defective insulin receptors were unable to mediate insulin-stimulated MAP kinase activation. These data suggest that: 1) tyrosine kinase activity of the insulin receptor is required for activation of insulin-stimulated MAP kinases and 2) phosphorylation of COOH-terminal tyrosine residues may play an inhibitory role in mitogenic signaling through regulation of MAP kinases.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN; ASAHI LIFE FDN,INST DIABET CARE & RES,CHIYUDA KU,TOKYO 100,JAPAN; KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,CHUO KU,KOBE 650,JAPAN	University of Tokyo; Asahi Life Foundation; Kobe University								AHN NG, 1991, J BIOL CHEM, V266, P4220; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; HARI J, 1987, J BIOL CHEM, V262, P15341; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOSHI M, 1989, EUR J BIOCHEM, V184, P477, DOI 10.1111/j.1432-1033.1989.tb15040.x; KADOWAKI H, 1989, GENE, V76, P161, DOI 10.1016/0378-1119(89)90018-8; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KADOWAKI T, 1990, J BIOL CHEM, V265, P19143; KASUGA M, 1983, P NATL ACAD SCI-BIOL, V80, P2137, DOI 10.1073/pnas.80.8.2137; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KASUGA M, 1982, J BIOL CHEM, V257, P392; KIM H, 1979, J CELL BIOL, V80, P266, DOI 10.1083/jcb.80.2.266; KULL FC, 1982, BIOCHEM BIOPH RES CO, V106, P1019, DOI 10.1016/0006-291X(82)91813-7; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MCCLAIN DA, 1990, J BIOL CHEM, V265, P1678; MOMOMURA K, 1988, BIOCHEM BIOPH RES CO, V155, P1181, DOI 10.1016/S0006-291X(88)81264-6; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROTH RA, 1983, SCIENCE, V219, P299, DOI 10.1126/science.6849137; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; TASHIROHASHIMOTO Y, 1989, J BIOL CHEM, V264, P6879; THIES RS, 1989, J BIOL CHEM, V264, P12820; TOBE K, 1991, J BIOL CHEM, V266, P24793; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; YAMAMOTOHONDA R, 1990, J BIOL CHEM, V265, P14777	47	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12788	12796						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618780				2022-12-25	WOS:A1992HZ48300062
J	HIRABAYASHI, Y; NAKAO, T; IRIE, F; WHITTAKER, VP; KON, K; ANDO, S				HIRABAYASHI, Y; NAKAO, T; IRIE, F; WHITTAKER, VP; KON, K; ANDO, S			STRUCTURAL CHARACTERIZATION OF A NOVEL CHOLINERGIC NEURON-SPECIFIC GANGLIOSIDE IN BOVINE BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-CONTAINING GLYCOSPHINGOLIPIDS; HANGANUTZIU-DEICHER ANTIGENS; CHROMATOGRAPHY; TRISIALOGANGLIOSIDE; CHOL-1	A new ganglioside antigen, termed Chol-1-alpha-b, recognized by cholinergic neuron-specific antibody, Cholla, was isolated from bovine brain ganglioside mixture using Q-Sepharose. The yield was approximately 1.3 mg from 5 g of the total ganglioside. The chemical structure was characterized as a novel ganglioside by means of gas-liquid chromatography, a permethylation study, mild acid hydrolysis, thin layer chromatography-enzyme immunostaining, fast atom bombardment mass spectrometry, and proton nuclear magnetic resonance spectroscopy. The ganglioside has the following unique structure. [GRAPHICS] When examined by thin layer chromatography immunostaining and enzyme-linked immunosorbant assays, this ganglioside has the most intense immunoreactivity with Chol-1-alpha antibody among bovine brain gangliosides. As combined with our previous results (Hirabayashi, Y., Hyogo, A., Nakao, T., Tsuchiya, K., Suzuki, Y., Matsumoto, M., Kon, K., and Ando, S. (1990) J. Biol. Chem. 265, 8144-8151; Ando, S., Hirabayashi, Y., Kon, K., Inagaki, F., Tate, S., and Whittaker, X. (1992) J. Biochem. (Tokyo), 111, 287-290), the present study indicates the occurrence of a new series of gangliosides containing N-acetylneuraminic acid residue attaching to N-acetylgalactosamine as cholinergic specific antigens.	UNIV SHIZUOKA, SCH PHARMACEUT SCI, DEPT BIOCHEM, OYA, SHIZUOKA 422, JAPAN; UNIV MAINZ, INST ANAT, ARBEITSGRP NEUROCHEM, W-6500 MAINZ, GERMANY; TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL, DEPT MEMBRANE BIOCHEM, ITABASHI KU, TOKYO 173, JAPAN	University of Shizuoka; Johannes Gutenberg University of Mainz				Hirabayashi, Yoshio/0000-0002-5774-7354				ANDO S, 1991, J BIOCHEM-TOKYO, V11, P287; BHATTI T, 1970, BIOCHIM BIOPHYS ACTA, V222, P339, DOI 10.1016/0304-4165(70)90122-4; FERRETTI P, 1986, J NEUROCHEM, V46, P1888; GIULIANI A, 1990, ARCH BIOCHEM BIOPHYS, V280, P211, DOI 10.1016/0003-9861(90)90538-A; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HIGASHI H, 1984, J BIOCHEM, V95, P785, DOI 10.1093/oxfordjournals.jbchem.a134670; HIGASHI H, 1984, J BIOCHEM-TOKYO, V95, P1517, DOI 10.1093/oxfordjournals.jbchem.a134760; HIRABAYASHI Y, 1988, J CHROMATOGR, V445, P377, DOI 10.1016/S0021-9673(01)84550-7; HIRABAYASHI Y, 1991, J BIOL CHEM, V266, P10268; HIRABAYASHI Y, 1990, J BIOL CHEM, V265, P8144; ISHIZUKA I, 1972, BIOCHIM BIOPHYS ACTA, V260, P279, DOI 10.1016/0005-2760(72)90039-2; JONES RT, 1981, CELL TISSUE RES, V218, P355; LEVERY SB, 1987, METHOD ENZYMOL, V138, P13, DOI 10.1016/0076-6879(87)38004-8; NAKAMURA K, 1988, J BIOL CHEM, V263, P9896; NAKAO T, 1991, BIOCHIM BIOPHYS ACTA, V1086, P305, DOI 10.1016/0005-2760(91)90174-G; OBROCKI J, 1988, EXP BRAIN RES, V72, P71, DOI 10.1007/BF00248502; RICHARDSON PJ, 1982, J NEUROCHEM, V38, P1605, DOI 10.1111/j.1471-4159.1982.tb06640.x; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P21, DOI 10.1515/bchm2.1973.354.1.21; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; TAKI T, 1986, J BIOL CHEM, V261, P3075; WALKER JH, 1982, CELL TISSUE RES, V223, P101; WU GS, 1988, ANAL BIOCHEM, V173, P368, DOI 10.1016/0003-2697(88)90201-1; YUKI N, 1991, IN PRESS NEUROLOGY	24	77	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12973	12978						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618794				2022-12-25	WOS:A1992HZ48300086
J	FOSTER, DN; MIN, BH; FOSTER, LK; STOFLET, ES; SUN, SQ; GETZ, MJ; STRAUCH, AR				FOSTER, DN; MIN, BH; FOSTER, LK; STOFLET, ES; SUN, SQ; GETZ, MJ; STRAUCH, AR			POSITIVE AND NEGATIVE CIS-ACTING REGULATORY ELEMENTS MEDIATE EXPRESSION OF THE MOUSE VASCULAR SMOOTH-MUSCLE ALPHA-ACTIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BC3H1 CELL-DIFFERENTIATION; SERUM RESPONSE ELEMENT; C-FOS; BINDING-FACTOR; PURIFICATION; PROMOTER; TRANSCRIPTION; POLYPEPTIDE; MODULATE; REGIONS	Segments of the 5'-flanking region of the mouse vascular smooth muscle a-actin gene were assayed for promoter activity in transfected mouse BC3H1 myogenic cells and AKR-2B embryonic fibroblasts. The region between -150 and -191 that functions as a positive transcriptional element in myogenic and fibroblastic cells contains a mammalian-specific inverted CC(A/T)6GG-type consensus sequence. Expression was restricted to fully differentiated myogenic cells when an additional sequence spanning -191 to -224 was included in reporter gene constructs. This 33-base pair (bp) negative regulatory element is 70% conserved between the mouse and human genes and contains a 10-bp motif at its 3' end that only partially resembles a CC(A/T)6GG element. Retention of a GGGA motif at the 3' boundary of the 33-bp region is sufficient to maintain full transcriptional repression in fibroblasts and is partly responsible for repression in undifferentiated myoblasts. Complete muscle tissue-restrictive expression requires an additional 8 bp from the CC(A/T)6GG-like element immediately 5' to the GGGA motif, since replacement of this region with an unrelated 10-bp sequence completely eliminated restrictive transcriptional behavior in undifferentiated myoblasts. The distal portion of the 5'-flanking region between -224 and -1074 contains six E-box motifs (CANNTG) and mediates high level transcription only in post-confluent BC3H1 myoblasts. Analysis of reporter gene constructs including either the proximal E-box at -240 or all six E-boxes indicate that the five distal E-boxes are not required for high level transcription. A 724-bp segment of the 5'-flanking region consisting of the proximal E-box flanked upstream by a mammalian-specific 352-bp region was sufficient for maximal transcriptional activation in postconfluent BC3H1 myoblasts. Deletion of the 352-bp region restricts the early transcriptional response to high cell density in temporal studies of promoter activity during BC3H1 myogenic cell differentiation.	OHIO STATE UNIV,COLL MED,DEPT CELL BIOL NEUROBIOL & ANAT,333 W 10TH AVE,COLUMBUS,OH 43210; OHIO STATE UNIV,COLL MED,OHIO STATE BIOCHEM PROGRAM,COLUMBUS,OH 43210; MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Mayo Clinic					NCI NIH HHS [CA 33643] Funding Source: Medline; NHLBI NIH HHS [HL 43370] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033643] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043370] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BLANK RS, 1992, J BIOL CHEM, V267, P984; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; CARROLL SL, 1988, MOL CELL BIOL, V8, P241, DOI 10.1128/MCB.8.1.241; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRICHNIK JM, 1986, NUCLEIC ACIDS RES, V14, P1683, DOI 10.1093/nar/14.4.1683; KEDES LH, 1989, CELLULAR MOL BIOL MU, P429; LIAU G, 1990, J CELL PHYSIOL, V142, P236, DOI 10.1002/jcp.1041420204; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MIN BH, 1990, J BIOL CHEM, V265, P16667; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; PRYWES R, 1987, MOL CELL BIOL, V7, P3482, DOI 10.1128/MCB.7.10.3482; RUZICKA DL, 1988, J CELL BIOL, V107, P2575, DOI 10.1083/jcb.107.6.2575; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SAWTELL NM, 1989, J CELL BIOL, V109, P2929, DOI 10.1083/jcb.109.6.2929; SCHROTER H, 1987, NUCLEIC ACIDS RES, V15, P10145, DOI 10.1093/nar/15.24.10145; SCHUBERT D, 1974, J CELL BIOL, V61, P398, DOI 10.1083/jcb.61.2.398; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; STRAUCH AR, 1984, J BIOL CHEM, V259, P3152; STRAUCH AR, 1989, J BIOL CHEM, V264, P8345; STRAUCH AR, 1991, J CELL PHYSIOL, V146, P337, DOI 10.1002/jcp.1041460302; STRAUCH AR, 1986, J BIOL CHEM, V261, P849; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; VANDEKERCKHOVE J, 1981, EUR J BIOCHEM, V113, P595, DOI 10.1111/j.1432-1033.1981.tb05104.x; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704	28	76	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11995	12003						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601869				2022-12-25	WOS:A1992HY94700054
J	SHIMOKAWA, T; SMITH, WL				SHIMOKAWA, T; SMITH, WL			PROSTAGLANDIN ENDOPEROXIDE SYNTHASE - THE ASPIRIN ACETYLATION REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-INFLAMMATORY DRUGS; VESICULAR GLAND MICROSOMES; HIGHER OXIDATION-STATES; H-SYNTHASE; PEROXIDASE REACTION; COMPLEMENTARY-DNA; BINDING-SITES; SYNTHETASE; SHEEP; CYCLOOXYGENASE	Aspirin selectively acetylates Ser-530 of prostaglandin endoperoxide (PGH) synthase-1. This causes inactivation of the cyclooxygenase activity of the enzyme, but does not appreciably affect its peroxidase activity. Although the aspirin-acetylated enzyme is inactive, we found that PGH synthase-1 in which Ser-530 had been replaced with an alanine was catalytically active; accordingly, we proposed that aspirin inhibits cyclooxygenase activity by placing a larger than normal side chain at position 530 thereby interfering with arachidonate binding (DeWitt, D. L., El-Harith, E. A., Kraemer, S. A., Andrews, M. J., Yao, E. F., Armstrong, R. L., and Smith, W. L. (1990) J. Biol. Chem. 265, 5192-5198). As a further test of this hypothesis we have used site-directed mutagenesis and transient expression in cos-1 cells to prepare and characterize five additional substitutions of Ser-530. Consistent with our proposal, the presence of amino acids with bulky side chains at position 530 inhibited cyclooxygenase activity and decreased the apparent affinity of the enzyme for arachidonate. In related work, we characterized a series of mutant PGH synthases-1 having substitutions at residues adjoining Ser-530, including Phe-529, Leu-531, Lys-532, and Gly-533, in order to evaluate the contributions of each residue to cyclooxygenase catalysis. The most significant conclusion of this part of the study is that residues 529-533 all are important for the peroxidase activity as well as the cyclooxygenase activity of PGH synthase-1. Phe-529, in particular, was found to be critical for PGH synthase-I structure and catalysis; some substitutions at this position led to the production of proteins lacking about 100 amino acids from their COOH termini.	MICHIGAN STATE UNIV,DEPT BIOCHEM,RM 510,BIOCHEM BLDG,E LANSING,MI 48824	Michigan State University			SHIMOKAWA, Teruhiko/GZA-4834-2022		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042509] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42509] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN YNP, 1987, J BIOL CHEM, V262, P16892; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; FERREIRA SH, 1971, NATURE-NEW BIOL, V231, P237, DOI 10.1038/newbio231237a0; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; GRENIER FC, 1978, PROSTAG OTH LIPID M, V16, P759, DOI 10.1016/0090-6980(78)90009-6; HEMLER ME, 1976, J BIOL CHEM, V250, P5575; HOLTZMAN MJ, 1991, CLIN RES, V39, P182; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1990, BIOCHEMISTRY-US, V29, P8760, DOI 10.1021/bi00489a037; KULMACZ RJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P502, DOI 10.1016/0003-9861(89)90317-2; KULMACZ RJ, 1982, BIOCHEM BIOPH RES CO, V104, P758, DOI 10.1016/0006-291X(82)90702-1; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LASSMANN G, 1991, J BIOL CHEM, V266, P20045; MARNETT JJ, 1990, PEROXIDASES CHEM BIO, P1; MARNETT LJ, 1988, J BIOL CHEM, V263, P16532; MARSHALL PJ, 1988, ARCH BIOCHEM BIOPHYS, V266, P162, DOI 10.1016/0003-9861(88)90246-9; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; MIZUNO K, 1982, PROSTAGLANDINS, V23, P743; MUTSAERS JHGM, 1985, EUR J BIOCHEM, V147, P569; OGINO N, 1978, J BIOL CHEM, V253, P5061; ROME LH, 1975, P NATL ACAD SCI USA, V72, P4863, DOI 10.1073/pnas.72.12.4863; ROTH GJ, 1983, BIOCHEMISTRY-US, V22, P4672, DOI 10.1021/bi00289a010; ROTH GJ, 1980, J BIOL CHEM, V255, P1301; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SMITH JB, 1971, NATURE-NEW BIOL, V231, P235, DOI 10.1038/newbio231235a0; SMITH WL, 1971, J BIOL CHEM, V246, P6700; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; SMITH WL, 1990, STROKE, V21, P24; VANDEROUDERAA FJ, 1980, EUR J BIOCHEM, V109, P1; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; VANE J, 1987, FASEB J, V1, P89, DOI 10.1096/fasebj.1.2.3111928; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X	42	119	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12387	12392						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601897				2022-12-25	WOS:A1992HY94700110
J	HOOPES, BC; LEBLANC, JF; HAWLEY, DK				HOOPES, BC; LEBLANC, JF; HAWLEY, DK			KINETIC-ANALYSIS OF YEAST TFIID-TATA BOX COMPLEX-FORMATION SUGGESTS A MULTISTEP PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TRANSCRIPTION INITIATION; BINDING-PROTEIN; FUNCTIONAL DOMAINS; PROMOTER; ACTIVATION; MECHANISM; ELEMENTS; SEQUENCES; INVITRO	The eukaryotic transcription factor TFIID recognizes and binds a promoter sequence element called the TATA box. We have analyzed the interaction of yeast TFIID with the consensus TATA box sequence of the adenovirus major late promoter. To facilitate this detailed characterization, we developed a method for obtaining quantitative information from a gel retardation (bandshift) assay, allowing measurement of the rate and extent of TFIID-TATA box complex formation. Using this assay and DNase I protection assays, we determined that the association rate constant for TFIID binding to the major late promoter was too low to be consistent with a simple diffusion-limited association, suggesting that the binding proceeds by a multi-step pathway. Furthermore, we found that the slow rate of TFIID binding reported by other research groups was not the consequence of a rate-limiting conformational change, as has been previously suggested. Instead, we observed that the formation of a stable TFIID-TATA box complex was relatively rapid (complete in less than 1 min) at saturating concentrations of TFIID. We have proposed a two-step pathway consistent with the observed kinetics and have considered the possible contributions of each step to the overall rate of TFIID binding. This study lays the groundwork for a systematic characterization of the interaction of TFIID with additional TATA box sequences, including an experimental test of the possibility that different steps in the binding reaction are rate-limiting for different promoters.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon; University of Oregon								BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; FIRE A, 1984, J BIOL CHEM, V259, P2509; GARNER MM, 1986, TRENDS BIOCHEM SCI, V11, P395, DOI 10.1016/0968-0004(86)90149-0; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1990, GENE DEV, V4, P1141, DOI 10.1101/gad.4.7.1141; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN PM, 1991, MOL CELL BIOL, V11, P63, DOI 10.1128/MCB.11.1.63; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; MALAN TP, 1984, J MOL BIOL, V180, P881, DOI 10.1016/0022-2836(84)90262-6; Maniatis T., 1982, MOL CLONING; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; Miller J.H., 1972, EXPT MOL GENETICS; MUHICH ML, 1990, P NATL ACAD SCI USA, V87, P9148, DOI 10.1073/pnas.87.23.9148; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; PENOTTI FE, 1990, J MOL BIOL, V213, P37, DOI 10.1016/S0022-2836(05)80120-2; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PONTICELLI AS, 1990, MOL CELL BIOL, V10, P2832, DOI 10.1128/MCB.10.6.2832; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHMIDT MC, 1989, MOL CELL BIOL, V9, P3299, DOI 10.1128/MCB.9.8.3299; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SHIH MC, 1984, J MOL BIOL, V172, P489, DOI 10.1016/S0022-2836(84)80019-4; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAMURA T, 1991, NUCLEIC ACIDS RES, V19, P3861, DOI 10.1093/nar/19.14.3861; TAYLOR ICA, 1990, MOL CELL BIOL, V10, P165, DOI 10.1128/MCB.10.1.165; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859	52	177	178	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11539	11547						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597482				2022-12-25	WOS:A1992HX16900092
J	MALHOTRA, KT; NICHOLAS, RA				MALHOTRA, KT; NICHOLAS, RA			SUBSTITUTION OF LYSINE-213 WITH ARGININE IN PENICILLIN-BINDING PROTEIN-5 OF ESCHERICHIA-COLI ABOLISHES D-ALANINE CARBOXYPEPTIDASE ACTIVITY WITHOUT AFFECTING PENICILLIN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL PEPTIDOGLYCAN; NUCLEOTIDE-SEQUENCE; BETA-LACTAMASE; ENZYME-ACTIVITIES; TRANSPEPTIDASE; PEPTIDASE; GENE; PURIFICATION; MEMBRANE; IA	All penicillin-binding proteins (PBPs) contain a conserved box of homology in the carboxyl-terminal half of their primary sequence that can be Lys-Thr-Gly, Lys-Ser-Gly, or His-Thr-Gly. Site-saturation mutagenesis was used to address the role of the lysine residue at this position (Lys213) in Escherichia coli PBP 5, a D-alanine carboxypeptidase enzyme. A soluble form of PBP 5 was used to replace Lys213 with 18 other amino acids, and the ability of these mutant proteins to bind [H-3]penicillin G was assessed. Only the substitution of lysine with arginine resulted in a protein that was capable of forming a stable covalent complex with antibiotic. The affinity of [C-14]penicillin G for the arginine mutant was 1.2-fold higher than for wild-type PBP 5 (4.4 versus 5.1-mu-g/ml for 20 min at 30-degrees-C), and both proteins showed identical rates of hydrolysis of the [C-14]penicilloyl-bound complex (t1/2 = 9.1 min). Surprisingly, the arginine-substituted protein was unable to catalyze D-alanine carboxypeptidase activity in vitro, which suggests that there is a substantial difference in the geometries of the peptide substrate and penicillin G within the active site of PBP 5.	UNIV N CAROLINA, DEPT PHARMACOL, CB 7365 FLOB, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill					NIAID NIH HHS [AI-27039] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027039] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMANUMA H, 1980, J BIOL CHEM, V255, P1173; AMANUMA H, 1984, J BIOL CHEM, V259, P1294; AMBLER RP, 1975, BIOCHEM J, V151, P197, DOI 10.1042/bj1510197; AMBLER RP, 1969, NATURE, V222, P24, DOI 10.1038/222024a0; ASOH S, 1986, EUR J BIOCHEM, V160, P231, DOI 10.1111/j.1432-1033.1986.tb09961.x; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BOISSINOT M, 1990, J BIOL CHEM, V265, P1225; BROOMESMITH J, 1983, TARGET PENICILLIN, P403; BROOMESMITH JK, 1985, EUR J BIOCHEM, V147, P437, DOI 10.1111/j.1432-1033.1985.tb08768.x; BROOMESMITH JK, 1988, NUCLEIC ACIDS RES, V16, P1617, DOI 10.1093/nar/16.4.1617; DEPEDRO MA, 1981, P NATL ACAD SCI-BIOL, V78, P5856; DUEZ C, 1987, EUR J BIOCHEM, V162, P509, DOI 10.1111/j.1432-1033.1987.tb10669.x; ELLERBY LM, 1990, BIOCHEMISTRY-US, V29, P5797, DOI 10.1021/bi00476a022; Frere J M, 1976, Methods Enzymol, V45, P610; GHUYSEN JM, 1986, BIOCHEM J, V235, P159, DOI 10.1042/bj2350159; HARLOW E, 1988, ANTIBODIES LABORATOR; ISHINO F, 1981, BIOCHEM BIOPH RES CO, V101, P905, DOI 10.1016/0006-291X(81)91835-0; ISHINO F, 1980, BIOCHEM BIOPH RES CO, V97, P287, DOI 10.1016/S0006-291X(80)80166-5; JORIS B, 1988, BIOCHEM J, V250, P313, DOI 10.1042/bj2500313; KELLY JA, 1986, SCIENCE, V231, P1429, DOI 10.1126/science.3082007; KELLY JA, 1985, J BIOL CHEM, V260, P6449; KELLY JA, 1989, J MOL BIOL, V209, P281, DOI 10.1016/0022-2836(89)90277-5; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUSTU SG, 1974, J BIOL CHEM, V249, P6976; LENFANT F, 1991, J BIOL CHEM, V266, P17187; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUHASHI M, 1978, P NATL ACAD SCI USA, V75, P2631, DOI 10.1073/pnas.75.6.2631; MATSUHASHI M, 1979, J BACTERIOL, V137, P644, DOI 10.1128/JB.137.1.644-647.1979; MEDEIROS AA, 1984, BRIT MED BULL, V40, P18, DOI 10.1093/oxfordjournals.bmb.a071942; NAKAGAWA J, 1984, J BIOL CHEM, V259, P3937; NAKAGAWA J, 1979, AGR BIOL CHEM TOKYO, V43, P1379, DOI 10.1080/00021369.1979.10863634; NAKAMURA M, 1983, MOL GEN GENET, V191, P1, DOI 10.1007/BF00330881; NICHOLAS RA, 1988, J BIOL CHEM, V263, P2034; PRATT JM, 1981, NATURE, V293, P307, DOI 10.1038/293307a0; PRATT JM, 1986, EMBO J, V5, P2399, DOI 10.1002/j.1460-2075.1986.tb04510.x; Sambrook J, 1989, MOL CLONING LABORATO; SAMRAOUI B, 1986, NATURE, V320, P378, DOI 10.1038/320378a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; SMITH JB, 1984, FEBS LETT, V165, P185, DOI 10.1016/0014-5793(84)80166-0; SPRATT BG, 1975, P NATL ACAD SCI USA, V72, P2999, DOI 10.1073/pnas.72.8.2999; SPRATT BG, 1976, J BACTERIOL, V127, P660, DOI 10.1128/JB.127.1.660-663.1976; SUTCLIFFE JG, 1978, P NATL ACAD SCI USA, V75, P3737, DOI 10.1073/pnas.75.8.3737; TAMURA T, 1976, J BIOL CHEM, V251, P414; TIPPER DJ, 1965, P NATL ACAD SCI USA, V54, P1133, DOI 10.1073/pnas.54.4.1133	45	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11386	11391						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597468				2022-12-25	WOS:A1992HX16900070
J	SAVAGE, B; SHATTIL, SJ; RUGGERI, ZM				SAVAGE, B; SHATTIL, SJ; RUGGERI, ZM			MODULATION OF PLATELET-FUNCTION THROUGH ADHESION RECEPTORS - A DUAL ROLE FOR GLYCOPROTEIN-IIB-IIIA (INTEGRIN-ALPHA(IIB)BETA(3) MEDIATED BY FIBRINOGEN AND GLYCOPROTEIN-IB-VON-WILLEBRAND FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR-BINDING; PROTEIN-KINASE-C; FACTOR-VIII; SPHINGOSINE INHIBITION; CYCLIC-AMP; AGGREGATION; ACTIVATION; SUBENDOTHELIUM; COMPLEX; FORSKOLIN	We have found that the form of glycoprotein (GP) IIb-IIIa (integrin-alpha(IIb)beta-3) expressed on nonstimulated platelets is a functional receptor that mediates selective and irreversible adhesion to immobilized fibrinogen. This occurs even in the presence of the elevated intracellular cAMP levels induced by prostaglandin E1 or after inhibition of protein kinase C activity by sphingosine. In the absence of inhibitors, platelets adhering to fibrinogen through GP IIb-IIIa become fully activated and aggregate with one another. Immobilized von Willebrand factor (vWF), in contrast, is recognized by nonstimulated platelets through another receptor, GP Ib. This interaction leads to a change in the ligand recognition specificity of GP IIb-IIIa that can then bind to immobilized vWF and mediate irreversible platelet adhesion and aggregation; this process, however, is inhibited by elevated intracellular cAMP levels or blockade of protein kinase C activity. Therefore, GP Ib and GP IIb-IIIa induce platelet activation through the selective recognition of immobilized vWF and fibrinogen, respectively, in the absence of exogenous agonists. Moreover, "nonactivated" and "activated" GP IIb-IIIa exhibits distinctly different reactivity toward surface-bound vWF, and the functional switch can be induced by the binding of vWF to GP Ib. These findings demonstrate the modulation of platelet function by two different adhesion receptors, GP Ib and GP IIb-IIIa, as well as the distinct dual role of the latter as the necessary common mediator of irreversible adhesion and aggregation on both fibrinogen and vWF.	SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA; UNIV PENN, SCH MED, DEPT MED, HEMATOL ONCOL SECT, PHILADELPHIA, PA 19104 USA	Scripps Research Institute; University of Pennsylvania	SAVAGE, B (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV EXPTL HEMOSTASIS & THROMBOSIS, LA JOLLA, CA 92037 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950, P01HL040387] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00833] Funding Source: Medline; NHLBI NIH HHS [HL-40387, HL-31950] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERLINER S, 1988, J BIOL CHEM, V263, P7500; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DAVIES MJ, 1986, CIRCULATION, V73, P418, DOI 10.1161/01.CIR.73.3.418; DECOURCELLES DD, 1987, BIOCHEM J, V244, P93, DOI 10.1042/bj2440093; DEMARCO L, 1987, J CLIN INVEST, V80, P475, DOI 10.1172/JCI113095; DEMARCO L, 1986, J CLIN INVEST, V77, P1272, DOI 10.1172/JCI112430; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FEINSTEIN MB, 1983, BIOCHEM BIOPH RES CO, V113, P598, DOI 10.1016/0006-291X(83)91768-0; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUSTER V, 1985, J AM COLL CARDIOL, V5, pB175, DOI 10.1016/S0735-1097(85)80552-0; HANDA M, 1986, J BIOL CHEM, V261, P2579; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1987, J BIOL CHEM, V262, P13620; HAVERSTICK DM, 1985, BLOOD, V66, P946; IKEDA Y, 1991, J CLIN INVEST, V87, P1234, DOI 10.1172/JCI115124; INSEL PA, 1982, J BIOL CHEM, V257, P7485; JEN CJ, 1987, AM J PHYSIOL, V253, pH745, DOI 10.1152/ajpheart.1987.253.4.H745; KAZAL LA, 1963, P SOC EXP BIOL MED, V113, P989; KIEFFER N, 1991, J CELL BIOL, V113, P451, DOI 10.1083/jcb.113.2.451; KUNICKI TJ, 1981, BLOOD, V58, P268; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDON JN, 1986, BLOOD, V68, P355; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MCKEE PA, 1966, ARCH BIOCHEM BIOPHYS, V116, P271, DOI 10.1016/0003-9861(66)90033-6; MUSTARD JF, 1978, BLOOD, V52, P453; NEWMAN J, 1971, BRIT J HAEMATOL, V21, P1, DOI 10.1111/j.1365-2141.1971.tb03413.x; NIEUWENHUIS HK, 1986, BLOOD, V68, P692; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; NIIYA K, 1987, BLOOD, V70, P475; PETERSON DM, 1987, BLOOD, V69, P625; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; SAKARIASSEN KS, 1979, NATURE, V279, P636, DOI 10.1038/279636a0; SALZMAN EW, 1972, NEW ENGL J MED, V286, P358; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SUGIMOTO M, 1991, BIOCHEMISTRY-US, V30, P5202, DOI 10.1021/bi00235a013; SWITZER ME, 1976, J CLIN INVEST, V57, P925, DOI 10.1172/JCI108369; WEISS HJ, 1975, NEW ENGL J MED, V293, P531, DOI 10.1056/NEJM197509112931105; WEISS HJ, 1975, NEW ENGL J MED, V293, P580, DOI 10.1056/NEJM197509182931204; WEISS HJ, 1989, J CLIN INVEST, V83, P288, DOI 10.1172/JCI113871; WEISS HJ, 1978, BLOOD, V51, P267; [No title captured]	44	304	312	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11300	11306						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597464				2022-12-25	WOS:A1992HX16900058
J	YANG, J; CLARK, AE; KOZKA, IJ; CUSHMAN, SW; HOLMAN, GD				YANG, J; CLARK, AE; KOZKA, IJ; CUSHMAN, SW; HOLMAN, GD			DEVELOPMENT OF AN INTRACELLULAR POOL OF GLUCOSE TRANSPORTERS IN 3T3-L1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-STIMULATED TRANSLOCATION; RAT SKELETAL-MUSCLE; HEXOSE-TRANSPORT; PLASMA-MEMBRANE; MURINE FIBROBLASTS; ADIPOSE-CELLS; MESSENGER-RNA; ADIPOCYTES; HEPG2; EXPRESSION	The membrane-impermeant bis-mannose photolabel 2-N-4-(1-azi-2,2,2-trifluoroethyl)benzoyl-1,3-bis-(D-mannos-4-yloxy)-2-propylamine (ATB-BMPA) has been used to study the development of an intracellular pool of glucose transporters in 3T3-L1 cells. The subcellular distributions of the transporter isoforms GLUT1 and GLUT4 were determined by comparing the labeling obtained in cells in which the impermeant reagent only had access to the cell surface and the labeling obtained in digitonin-permeabilized cells. ATB-BMPA labeling showed that only GLUT1 was present in preconfluent fibroblasts and that most of the transporters were distributed to the cell surface. In preconfluent fibroblasts, the 2-deoxy-D-glucose transport activity was almost-equal-to 5 times higher than in confluent fibroblasts. ATB-BMPA labeling showed that the decrease in transport as cells reached confluence was associated with a decrease in the proportion of GLUT1 distributed to the cell surface. The sequestration of these transporters was associated with the development of an insulin-responsive transport activity which increased by almost-equal-to 2.5-fold compared with unstimulated confluent cells. ATB-BMPA labeling showed that insulin stimulation resulted in an almost-equal-to 2-fold increase in surface GLUT1 so that about one-half of the available transporters became recruited to the cell surface. Measurements of the changes in the distribution of both GLUT1 and GLUT4 throughout the differentiation of confluent fibroblasts into adipocytes showed that both transporters were sequestered in parallel. Basal levels of transport and photolabeling remained low throughout the differentiation period when the total pool of transporters (GLUTI plus GLUT4) was increased by almost-equal-to 5-fold. These results suggest that the sequestration process was present before new transporters were synthesized. Thus, the sequestration mechanism develops in confluent growth-arrested fibroblasts although the capacity to sequester additional transporters may increase as differentiation proceeds.	NIDDKD,DIABET BRANCH,EXPTL DIABET METAB & NUTR SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	YANG, J (corresponding author), UNIV BATH,DEPT BIOCHEM,BATH BA2 7AY,AVON,ENGLAND.			Holman, Geoffrey/0000-0001-7045-1358				BLOK J, 1988, J CELL BIOL, V106, P69, DOI 10.1083/jcb.106.1.69; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CLANCY BM, 1991, J BIOL CHEM, V266, P10122; CLARK AE, 1991, BIOCHEM J, V278, P235, DOI 10.1042/bj2780235; CLARK AE, 1990, BIOCHEM J, V269, P615, DOI 10.1042/bj2690615; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; FROST SC, 1985, J BIOL CHEM, V260, P2646; GOULD GW, 1989, ARCH BIOCHEM BIOPHYS, V268, P264, DOI 10.1016/0003-9861(89)90588-2; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; GOULD GW, 1989, J BIOL CHEM, V264, P2180; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; HARRISON SA, 1991, P NATL ACAD SCI USA, V88, P7839, DOI 10.1073/pnas.88.17.7839; HARRISON SA, 1991, J BIOL CHEM, V266, P19438; HARRISON SA, 1990, J BIOL CHEM, V265, P20106; HASPEL HC, 1986, J BIOL CHEM, V261, P6778; HIRSHMAN MF, 1990, J BIOL CHEM, V265, P987; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KLIP A, 1990, BIOCHEM BIOPH RES CO, V172, P728, DOI 10.1016/0006-291X(90)90735-6; KLIP A, 1987, FEBS LETT, V224, P224, DOI 10.1016/0014-5793(87)80452-0; KOZKA IJ, 1991, J BIOL CHEM, V266, P11726; PALFREYMAN RW, 1992, IN PRESS BIOCH J; REED BC, 1990, ARCH BIOCHEM BIOPHYS, V279, P261, DOI 10.1016/0003-9861(90)90490-P; SATOH S, 1991, DIABETES S1, V40, pA85; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TORDJMAN KM, 1990, BIOCHEM J, V271, P201, DOI 10.1042/bj2710201; WARDZALA LJ, 1983, BIOCHIM BIOPHYS ACTA, V730, P49, DOI 10.1016/0005-2736(83)90315-2; WATANABE T, 1984, J BIOL CHEM, V259, P3117; WEILAND M, 1990, BIOCHEM J, V270, P331, DOI 10.1042/bj2700331; WIDNELL CC, 1990, FASEB J, V4, P1634, DOI 10.1096/fasebj.4.6.2156742; YANG J, 1992, BIOCHEM J, V281, P809, DOI 10.1042/bj2810809; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	37	85	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10393	10399						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587825				2022-12-25	WOS:A1992HV09000032
J	ZIEGELBAUER, K; MULTHAUP, G; OVERATH, P				ZIEGELBAUER, K; MULTHAUP, G; OVERATH, P			MOLECULAR CHARACTERIZATION OF 2 INVARIANT SURFACE GLYCOPROTEINS SPECIFIC FOR THE BLOOD-STREAM STAGE OF TRYPANOSOMA-BRUCEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; SEQUENCE-ANALYSIS; TUBULIN GENES; BLOOD-STREAM; PROTEIN; DNA; PURIFICATION; COAT; DIFFERENTIATION; ACTIVATION	In the accompanying paper (Ziegelbauer, K., and Overath, P. (1992) J. Biol. Chem. 267,10791-10796), two invariant surface glycoproteins, ISG65 and ISG75, were identified in the mammalian stage of the parasitic protozoan, Trypanosoma brucei. In this study, the genes coding for these proteins have been isolated. Their nucleotide sequence suggests no relationship to other known genes and predicts polypeptides with NH2-terminal signal sequences, hydrophilic extracellular domains, single trans-membrane alpha-helices, and short cytoplasmic domains. ISG65 and ISG75 are expressed in bloodstream forms (70,000 and 50,000 molecules/cell, respectively) but not in the insect midgut stage. They can be detected in all T. brucei brucei variant clones investigated. Both polypeptides are distributed over the entire surface of the parasite.	MAX PLANCK INST BIOL, MEMBRANE BIOCHEM ABT, CORRENSSTR 38, W-7400 TUBINGEN, GERMANY; UNIV HEIDELBERG, ZENTRUM MOLEK BIOL, W-6900 HEIDELBERG, GERMANY	Max Planck Society; Ruprecht Karls University Heidelberg								ALLINGTON WB, 1978, ANAL BIOCHEM, V85, P188, DOI 10.1016/0003-2697(78)90289-0; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BALBER AE, 1990, CRIT REV IMMUNOL, V10, P177; BERNARDS A, 1981, CELL, V27, P497, DOI 10.1016/0092-8674(81)90391-3; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BRUN R, 1979, ACTA TROP, V36, P289; BULOW R, 1989, MOL BIOCHEM PARASIT, V32, P85, DOI 10.1016/0166-6851(89)90132-1; BULOW R, 1988, BIOCHEMISTRY-US, V27, P2384; CLAYTON CE, 1992, IN PRESS PROG NUCLEI, V43; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EHLERS B, 1987, MOL CELL BIOL, V7, P1242, DOI 10.1128/MCB.7.3.1242; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREYMANN D, 1990, J MOL BIOL, V216, P141, DOI 10.1016/S0022-2836(05)80066-X; GLASS DJ, 1986, MOL CELL BIOL, V6, P4657, DOI 10.1128/MCB.6.12.4657; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; IMBODEN M, 1986, J MOL BIOL, V188, P393, DOI 10.1016/0022-2836(86)90163-4; KONIG E, 1989, NUCLEIC ACIDS RES, V17, P8727, DOI 10.1093/nar/17.21.8727; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEEFLANG P, 1976, INT J PARASITOL, V6, P413, DOI 10.1016/0020-7519(76)90027-8; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MICHELS PAM, 1983, J MOL BIOL, V166, P537, DOI 10.1016/S0022-2836(83)80283-6; MICHELS PAM, 1986, EMBO J, V5, P1049, DOI 10.1002/j.1460-2075.1986.tb04321.x; MOTTRAM JC, 1989, MOL BIOCHEM PARASIT, V37, P115, DOI 10.1016/0166-6851(89)90108-4; MOWATT MR, 1987, MOL CELL BIOL, V7, P2838, DOI 10.1128/MCB.7.8.2838; OVERATH P, 1983, EMBO J, V2, P1721, DOI 10.1002/j.1460-2075.1983.tb01648.x; REINWALD E, 1978, H-S Z PHYSIOL CHEM, V359, P939, DOI 10.1515/bchm2.1978.359.2.939; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHELL D, 1991, EMBO J, V10, P1061, DOI 10.1002/j.1460-2075.1991.tb08045.x; SCHELL D, 1990, FEBS LETT, V271, P67, DOI 10.1016/0014-5793(90)80373-Q; SEEBECK T, 1983, P NATL ACAD SCI-BIOL, V80, P4634, DOI 10.1073/pnas.80.15.4634; STEPHEN D, 1990, NUCLEIC ACIDS RES, V18, P7463, DOI 10.1093/nar/18.24.7463; THOMASHOW LS, 1983, CELL, V32, P35, DOI 10.1016/0092-8674(83)90494-4; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; TSCHUDI C, 1985, P NATL ACAD SCI USA, V82, P3998, DOI 10.1073/pnas.82.12.3998; VANDERPLOEG LHT, 1985, SCIENCE, V228, P1443, DOI 10.1126/science.4012301; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; ZIEGELBAUER K, 1992, J BIOL CHEM, V267, P10791	41	88	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10797	10803						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587856				2022-12-25	WOS:A1992HV09000089
J	PERSAT, F; BOUHOURS, JF; MOJON, M; PETAVY, AF				PERSAT, F; BOUHOURS, JF; MOJON, M; PETAVY, AF			GLYCOSPHINGOLIPIDS WITH GAL-BETA-1-6GAL SEQUENCES IN METACESTODES OF THE PARASITE ECHINOCOCCUS-MULTILOCULARIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTAL-CHANGES; TRYPANOSOMA-CRUZI; RAT STOMACH; GLYCOLIPIDS; ANTIGENS; IDENTIFICATION; GANGLIOSIDES; BIOSYNTHESIS; INFECTION; GENETICS	Neutral glycosphingolipids of the metacestodes of Echinococcus multilocularis, an animal and human parasite, were resolved by high performance thin layer chromatography into 12 fractions. Nine of these fractions were permethylated, analyzed by electron impact-mass spectrometry, and submitted to methylation analysis by gas chromatography-mass spectrometry. Native fractions were analyzed by liquid secondary ion-mass spectrometry and degraded sequentially by exoglycosidases. In addition to a previously described galactosylceramide, a di-, a tri-, and a tetragalactosylceramide having Gal-beta-1-6Gal internal linkages were characterized. This type of carbohydrate chain has been described in glycolipids of a marine mollusk, Turbo cornutus (Matsubara, T., and Hayashi, A. (1981) J. Biochem. (Tokyo), 89,645-650). In addition two novel fucolipids were found with the following structures: Fuc-alpha-1-3Gal-beta-1-6Gal-Cer and Gal-beta-1-6(Fuc-alpha-1-3)Gal-beta-1-6Gal-Cer. Ceramides contained sphinganine and either nonhydroxy fatty acids with 16, 18, 26, and 28 carbon atoms, or hydroxy fatty acids, with 16 and 18 carbon atoms. Di-, tri-, and tetragalactosylceramides containing the Gal-beta-1-6Gal disaccharide were found to be immunogenic in humans.	INSERM,U76,F-75005 PARIS,FRANCE; GOTHENBURG UNIV,DEPT MED BIOCHEM,S-41124 GOTHENBURG,SWEDEN	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Gothenburg	PERSAT, F (corresponding author), UNIV CLAUDE BERNARD,DEPT PARASITOL & PATHOL EXOT,8 AVE ROCKEFELLER,F-69373 LYONS 08,FRANCE.		Persat, Florence/AAW-5561-2021	Persat, Florence/0000-0002-3421-8177				Aspinall G. O., 1970, POLYSACCHARIDES; AVILA JL, 1990, AM J TROP MED HYG, V43, P52, DOI 10.4269/ajtmh.1990.43.52; BARRETOBERGTER E, 1985, COMP BIOCHEM PHYS B, V80, P543, DOI 10.1016/0305-0491(85)90287-1; BARRETT J, 1983, BIOL EUCESTODA, V2, P392; BOUHOURS D, 1985, J BIOL CHEM, V260, P2172; BOUHOURS JF, 1987, J BIOL CHEM, V262, P16370; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DISSOUS C, 1986, NATURE, V323, P443, DOI 10.1038/323443a0; FERGUSON MAJ, 1988, PARASITE IMMUNOL, V10, P465, DOI 10.1111/j.1365-3024.1988.tb00236.x; GLAUDEMANS CPJ, 1987, MOL IMMUNOL, V24, P371, DOI 10.1016/0161-5890(87)90179-9; HAKOMORI SE, 1974, METHOD ENZYMOL, V23, P345; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HOUNSELL EF, 1987, CHEM SOC REV, V16, P161, DOI 10.1039/cs9871600161; KARLSSON KA, 1982, BIOL MEMBR, V4, P1; KARLSSON KA, 1974, J BIOL CHEM, V249, P4819; KISHIMOTO Y, 1986, CHEM PHYS LIPIDS, V42, P117, DOI 10.1016/0009-3084(86)90047-2; KROEZE WK, 1987, INT J PARASITOL, V17, P873, DOI 10.1016/0020-7519(87)90003-8; Kundu S K, 1981, Methods Enzymol, V72, P185, DOI 10.1016/S0076-6879(81)72012-3; KUNZ J, 1991, PARASITOL RES, V77, P443, DOI 10.1007/BF00931642; MARCUS DM, 1976, ADV IMMUNOL, V23, P203, DOI 10.1016/S0065-2776(08)60321-1; MARCUS DM, 1981, SEMIN HEMATOL, V18, P63; MATSUBARA T, 1981, J BIOCHEM-TOKYO, V89, P645, DOI 10.1093/oxfordjournals.jbchem.a133241; MERILL AH, 1986, J BIOL CHEM, V261, P3764; NAOI M, 1974, ANAL BIOCHEM, V58, P571, DOI 10.1016/0003-2697(74)90226-7; NISHIMURA K, 1991, GLYCOCONJUGATE J, V8, P242; PERSAT F, 1988, COMP BIOCHEM PHYS B, V91, P133, DOI 10.1016/0305-0491(88)90124-1; PERSAT F, 1990, MOL BIOCHEM PARASIT, V38, P97, DOI 10.1016/0166-6851(90)90209-5; PERSAT F, 1990, MOL BIOCHEM PARASIT, V41, P1, DOI 10.1016/0166-6851(90)90090-9; PERSAT F, 1991, PARASITE IMMUNOL, V13, P379, DOI 10.1111/j.1365-3024.1991.tb00291.x; PETRY K, 1988, MOL BIOCHEM PARASIT, V30, P113, DOI 10.1016/0166-6851(88)90104-1; PILLER F, 1984, J BIOL CHEM, V259, P3385; POTTER M, 1972, METHOD ENZYMOL, V28, P388; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; RADIN NS, 1984, J LIPID RES, V25, P1536; SAITO T, 1971, J LIPID RES, V12, P257; SIDDIQUI B, 1971, J BIOL CHEM, V246, P5766; SINGH BN, 1987, J CELL BIOCHEM, V11, P493; STELLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P464, DOI 10.1016/0003-9861(73)90138-0; UENO K, 1978, J LIPID RES, V19, P863; VIEIRA RP, 1988, J BIOL CHEM, V263, P18176; Watkins W M, 1980, Adv Hum Genet, V10, P1; WEISS JB, 1986, J IMMUNOL, V136, P4275; 1977, LIPIDS, V12, P455	43	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8764	8769						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577719				2022-12-25	WOS:A1992HR85400012
J	KAM, M; PERLTREVES, D; CASPI, D; ADDADI, L				KAM, M; PERLTREVES, D; CASPI, D; ADDADI, L			ANTIBODIES AGAINST CRYSTALS	FASEB JOURNAL			English	Article						GOUT; ANTIGEN-ANTIBODY COMPLEX; CATALYTIC ANTIBODIES; IGG; CRYSTAL-NUCLEATION	MONOSODIUM URATE MONOHYDRATE; CALCIUM PYROPHOSPHATE DIHYDRATE; 3-DIMENSIONAL STRUCTURE; PROTEINS; CRYSTALLIZATION; RESOLUTION; NUCLEATION; MONOLAYERS; COMPLEX; BINDING	We suggest that crystals, when introduced into an organism, may behave as conventional antigens, mediating the production of specific antibodies. These antibodies would bear an imprint of the crystal surface and may consequently behave as a nucleating matrix in a new crystallization event. Thus, they would behave as catalytic antibodies. We show that IgG antibodies isolated from patients suffering from gout, a joint disease caused by crystals of monosodium urate monohydrate (MSUM), accelerate the appearance of new crystals of MSUM from a supersaturated solution of the salt in vitro. The same effect is not observed for IgG antibodies isolated from the joint fluids of patients with other joint diseases, such as pseudogout, rheumatoid arthritis, or osteoarthritis. Furthermore, IgG antibodies obtained from rabbits injected subcutaneously with crystals of MSUM, were also nucleating towards MSUM crystals.	WEIZMANN INST SCI,DEPT STRUCT BIOL,IL-76100 REHOVOT,ISRAEL; ICHILOV HOSP,DEPT RHEUMATOL,IL-64239 TEL AVIV,ISRAEL	Weizmann Institute of Science; Tel Aviv University				Perl-Treves, Daniele/0000-0001-6312-4092				ADDADI L, 1985, P NATL ACAD SCI USA, V82, P4110, DOI 10.1073/pnas.82.12.4110; AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BARDIN T, 1984, J RHEUMATOL, V11, P339; CHERIAN PV, 1986, ULTRASTRUCT PATHOL, V10, P209, DOI 10.3109/01913128609032219; COLMAN PM, 1987, IMMUNOL TODAY, V8, P323, DOI 10.1016/0167-5699(87)90004-1; DIEPPE PA, 1983, CRYSTALS JOINT DISEA; GINSBERG MH, 1978, ARTHRITIS RHEUM, V21, P896, DOI 10.1002/art.1780210805; HALL AP, 1967, AM J MED, V42, P27, DOI 10.1016/0002-9343(67)90004-6; HARVEY PRC, 1991, J BIOL CHEM, V266, P13996; HASSELBACHER P, 1979, J LAB CLIN MED, V94, P532; HASSELBACHER P, 1982, ADV INFLAMMAT RES, V4, P73; HOFFMAN WL, 1990, ARTHRITIS RHEUM, V33, P1196; HOLLANDER JL, 1965, ANN INTERN MED, V62, P271, DOI 10.7326/0003-4819-62-2-271; KOZIN F, 1977, J LAB CLIN MED, V89, P1314; KOZIN F, 1980, J LAB CLIN MED, V95, P49; LANDAU EM, 1985, NATURE, V318, P353, DOI 10.1038/318353a0; MANDEL NS, 1980, ARTHRITIS RHEUM, V23, P772, DOI 10.1002/art.1780230610; MANN S, 1989, P ROY SOC LOND A MAT, V423, P457, DOI 10.1098/rspa.1989.0065; MCCARTY DJ, 1976, ARTHRITIS RHEUM, V19, P275, DOI 10.1002/1529-0131(197605/06)19:3+<275::AID-ART1780190702>3.0.CO;2-0; PERLTREVES D, 1990, MOL CRYST LIQ CRYST, V187, P1, DOI 10.1080/00268949008036022; PERLTREVES D, 1988, PROC R SOC SER B-BIO, V235, P145, DOI 10.1098/rspb.1988.0069; SEEGMILLER JE, 1962, JAMA-J AM MED ASSOC, V180, P469; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SOHNEL O, 1988, J CRYST GROWTH, V89, P202, DOI 10.1016/0022-0248(88)90403-4; SWARTZ GM, 1988, P NATL ACAD SCI USA, V85, P1902, DOI 10.1073/pnas.85.6.1902; TAK HK, 1980, J COLLOID INTERF SCI, V772, P195; TAK HK, 1980, ARTHRITIS RHEUM, V23, P547; WEISSBUCH I, 1987, J AM CHEM SOC, V109, P1869, DOI 10.1021/ja00240a052; WEISSBUCH I, 1990, J AM CHEM SOC, V112, P7718, DOI 10.1021/ja00177a036; 1984, BIORAD B, V1152; 1988, PROTEIN G SEPHAROSE, P3	31	53	53	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1992	6	8					2608	2613		10.1096/fasebj.6.8.1592211	http://dx.doi.org/10.1096/fasebj.6.8.1592211			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HU423	1592211				2022-12-25	WOS:A1992HU42300014
J	OGAWA, Y; SCHMIDT, DK; NATHAN, RM; ARMSTRONG, RM; MILLER, KL; SAWAMURA, SJ; ZIMAN, JM; ERICKSON, KL; DELEON, ER; ROSEN, DM; SEYEDIN, SM; GLASER, CB; CHANG, RJ; CORRIGAN, AZ; VALE, W				OGAWA, Y; SCHMIDT, DK; NATHAN, RM; ARMSTRONG, RM; MILLER, KL; SAWAMURA, SJ; ZIMAN, JM; ERICKSON, KL; DELEON, ER; ROSEN, DM; SEYEDIN, SM; GLASER, CB; CHANG, RJ; CORRIGAN, AZ; VALE, W			BOVINE BONE ACTIVIN ENHANCES BONE MORPHOGENETIC PROTEIN-INDUCED ECTOPIC BONE-FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; PURIFICATION; INHIBIN; SUBUNITS; FSH	A 25-kDa homodimeric protein was purified from demineralized bovine bone extract and identified as activin A. The bovine bone activin enhanced formation of ectopic bone in rat subcutis when implanted in combination with partially purified bovine bone morphogenetic protein (BMP-2, BMP-3) in collagen/ceramic carrier. The implants, removed at 14 days, contained markedly elevated levels of alkaline phosphatase activity. Histological examination revealed an extensive formation of woven bone with very little cartilage. In contrast, a combination of transforming growth factor-beta-2 and BMP promoted formation of bone with an abundance of cartilage. The implants with BMP alone exhibited some osteoinductive activity, while the implants with activin alone showed no activity. These results demonstrate that bone is a rich source of activin and that activin plays an important role in modulating bone formation.	BERLEX BIOSCI, San Francisco, CA 94080 USA; CLAYTON FDN LABS PEPTIDE BIOL, LA JOLLA, CA 92037 USA; SALK INST BIOL STUDIES, LA JOLLA, CA 92037 USA	Salk Institute	OGAWA, Y (corresponding author), CELTRIX PHARMACEUT INC, 3055 PATRICK HENRY DR, SANTA CLARA, CA 95052 USA.			Sawamura, Steven/0000-0002-9018-6990				BENTZ H, 1989, J BIOL CHEM, V264, P20805; BENTZ H, 1991, MATRIX, V11, P269, DOI 10.1016/S0934-8832(11)80234-9; CENTRELLA M, 1991, MOL CELL BIOL, V11, P250, DOI 10.1128/MCB.11.1.250; CHARBONNEAU H, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P15; GOODMAN JW, 1985, P NATL ACAD SCI USA, V82, P3291, DOI 10.1073/pnas.82.10.3291; JOYCE ME, 1990, J CELL BIOL, V110, P2195, DOI 10.1083/jcb.110.6.2195; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LING N, 1986, BIOCHEM BIOPH RES CO, V138, P1129, DOI 10.1016/S0006-291X(86)80400-4; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; OGAWA Y, 1992, J BIOL CHEM, V267, P2325; OGAWA Y, 1991, METHOD ENZYMOL, V198, P317; REDDI AH, 1972, P NATL ACAD SCI USA, V69, P1601, DOI 10.1073/pnas.69.6.1601; Roberts AB, 1990, PEPTIDE GROWTH FACTO, P419; ROSEN DM, 1990, CALCIUM REGULATIO BO, V10, P344; SEYEDIN SM, 1987, J BIOL CHEM, V262, P1946; STEWART S, 1984, EXP HEMATOL, V12, P309; VALE W, 1988, RECENT PROG HORM RES, V44, P1; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; WANG EA, 1988, P NATL ACAD SCI USA, V85, P9484, DOI 10.1073/pnas.85.24.9484; Wozney J M, 1989, Prog Growth Factor Res, V1, P267, DOI 10.1016/0955-2235(89)90015-X	21	118	169	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14233	14237						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629219				2022-12-25	WOS:A1992JD32500069
J	BANERJEE, A; LUDUENA, RF				BANERJEE, A; LUDUENA, RF			KINETICS OF COLCHICINE BINDING TO PURIFIED BETA-TUBULIN ISOTYPES FROM BOVINE BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE; COMPLEX; DISSOCIATION; MICROTUBULES; LOCALIZATION; EXPRESSION; PROTEIN	Tubulin, the constituent protein of microtubules, is an alpha-beta-heterodimer; both alpha and beta exist in several isotypic forms whose functional significance is not precisely known. The antimitotic alkaloid colchicine binds to mammalian brain tubulin in a biphasic manner under pseudo-first-order conditions in the presence of a large excess of colchicine (Garland, D. L. (1978) Biochemistry 17, 4266-4272). We have studied the kinetics of colchicine binding to purified beta-tubulin isotypes and find that each of the purified beta-tubulin isotypes binds colchicine in a monophasic manner. The apparent onrate constants for the binding of colchicine to alpha-beta(II)-, alpha-beta(III)-, and alpha-beta(IV)-tubulin dimers are respectively 132 +/- 5, 30 +/- 2, and 236 +/- 7 m-1 s-1. When the isotypes are mixed, the kinetics become biphasic. Scatchard analysis revealed that the isotypes differ significantly in their affinity constants (K(alpha)) for binding colchicine. The affinity constants are 0.24 x 10(6), 0.12 x 10(6), and 3.31 x 10(6) M-1, respectively, for alpha-beta(II)-, alpha-beta(III)-, and alpha-beta(IV)-tubulin dimers. Our results are in agreement with the hypothesis that the beta-subunit of tubulin plays a major role in the interaction of colchicine with tubulin. Our binding data raise the possibility that the tubulin isotypes might play important regulatory roles by interacting differently with other non-tubulin proteins in vivo, which in turn, may regulate microtubule-based functions in living cells.			BANERJEE, A (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.				NATIONAL CANCER INSTITUTE [R01CA026376] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023476] Funding Source: NIH RePORTER; NCI NIH HHS [CA26376] Funding Source: Medline; NIGMS NIH HHS [GM23476] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI T, 1975, ANAL BIOCHEM, V69, P443, DOI 10.1016/0003-2697(75)90146-3; BANE S, 1984, J BIOL CHEM, V259, P7391; BANERJEE A, 1992, J BIOL CHEM, V267, P5625; BANERJEE A, 1987, FEBS LETT, V219, P103, DOI 10.1016/0014-5793(87)81199-7; BANERJEE A, 1990, J BIOL CHEM, V265, P1794; BANERJEE A, 1988, J BIOL CHEM, V263, P3029; BANERJEE A, 1991, J BIOL CHEM, V266, P1689; BHATTACH.B, 1974, P NATL ACAD SCI USA, V71, P2627, DOI 10.1073/pnas.71.7.2627; BORISY GG, 1967, J CELL BIOL, V34, P525, DOI 10.1083/jcb.34.2.525; DETRICH HW, 1981, BIOCHEMISTRY-US, V20, P5999, DOI 10.1021/bi00524a012; DIAZ JF, 1991, J BIOL CHEM, V266, P2890; Dustin P., 1978, MICROTUBULES; FELLOUS A, 1977, EUR J BIOCHEM, V78, P167, DOI 10.1111/j.1432-1033.1977.tb11726.x; FLOID LJ, 1989, BIOCHEMISTRY-US, V28, P8515; Fulton C., 1976, CELL MOTILITY, P987; GARLAND DL, 1978, BIOCHEMISTRY-US, V17, P4266, DOI 10.1021/bi00613a024; IDE G, 1981, J BIOL CHEM, V256, P1684; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P1; LAMBEIR A, 1981, J BIOL CHEM, V256, P3279; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LOPATA MA, 1987, J CELL BIOL, V105, P1707, DOI 10.1083/jcb.105.4.1707; LUDUENA RF, 1977, J BIOL CHEM, V252, P7006; MUKHOPADHYAY K, 1990, BIOCHEMISTRY-US, V29, P6845, DOI 10.1021/bi00481a013; OLMSTED JB, 1973, ANNU REV BIOCHEM, V42, P507, DOI 10.1146/annurev.bi.42.070173.002451; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SERRANO L, 1984, J BIOL CHEM, V259, P6607; SHERLINE P, 1975, J BIOL CHEM, V250, P5481; SULLIVAN KF, 1986, P NATL ACAD SCI USA, V83, P4327, DOI 10.1073/pnas.83.12.4327; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; VILLASANTE A, 1986, MOL CELL BIOL, V6, P2409, DOI 10.1128/MCB.6.7.2409; WANG D, 1986, J CELL BIOL, V103, P1903, DOI 10.1083/jcb.103.5.1903; WILLIAMS RF, 1985, J BIOL CHEM, V260, P3794; WOLFF J, 1991, P NATL ACAD SCI USA, V88, P2820, DOI 10.1073/pnas.88.7.2820	34	130	134	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13335	13339						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618835				2022-12-25	WOS:A1992JB74600040
J	CRISE, B; ROSE, JK				CRISE, B; ROSE, JK			IDENTIFICATION OF PALMITOYLATION SITES ON CD4, THE HUMAN-IMMUNODEFICIENCY-VIRUS RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PROTEIN-KINASE; AMINO-TERMINAL DOMAIN; VESICULAR STOMATITIS; ENDOPLASMIC-RETICULUM; CYTOPLASMIC DOMAINS; MEMBRANE-GLYCOPROTEINS; COVALENT MODIFICATION; POLYACRYLAMIDE GELS; VIRAL GLYCOPROTEIN; PLASMA-MEMBRANE	We report that the cell surface glycoprotein CD4 expressed in HeLa cells can be metabolically labeled with [H-3]palmitic acid. Analysis of the H-3-label after hydrolysis of the protein indicated that it was incorporated predominantly as palmitic acid. Comparison of the amount of [H-3]palmitate incorporated into CD4 with that incorporated into a protein known to contain one molecule of esterified palmitate suggested that one to two molecules of palmitate were added to CD4. The fatty acid was readily cleaved from CD4 by treatment with weak base suggesting a thioester linkage. Mutations of each of 2 cysteine residues, Cys394 and Cys397, in CD4 at the junction of the transmembrane and cytoplasmic domains reduced labeling with [H-3]palmitic acid, and mutation of both cysteines eliminated labeling. These results indicate that both cysteines are esterified to palmitate. Modification with palmitate was not required for expression of CD4 on the cell surface or for binding of p56lck to its cytoplasmic domain.	YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT BIOL, NEW HAVEN, CT 06510 USA	Yale University; Yale University; Yale University					NIAID NIH HHS [AI-30374, AI-07019, AI-24345] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030374, R37AI024345, T32AI007019, R01AI024345] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALVAREZ E, 1990, J BIOL CHEM, V265, P16644; BERGER M, 1985, FEBS LETT, V187, P289, DOI 10.1016/0014-5793(85)81261-8; BONATTI S, 1989, J BIOL CHEM, V264, P12590; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CRISE B, 1990, J VIROL, V64, P5585, DOI 10.1128/JVI.64.11.5585-5593.1990; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DIAMOND DC, 1990, P NATL ACAD SCI USA, V87, P5001, DOI 10.1073/pnas.87.13.5001; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; JABBAR MA, 1990, J VIROL, V64, P6297, DOI 10.1128/JVI.64.12.6297-6304.1990; JASIN M, 1991, J VIROL, V65, P440, DOI 10.1128/JVI.65.1.440-444.1991; KAUFMAN JF, 1984, J BIOL CHEM, V259, P7230; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITTMAN DR, 1988, CELL, V55, P541, DOI 10.1016/0092-8674(88)90211-5; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; ROJO JM, 1989, P NATL ACAD SCI USA, V86, P3311, DOI 10.1073/pnas.86.9.3311; ROSE JK, 1983, CELL, V34, P513, DOI 10.1016/0092-8674(83)90384-7; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; ROSE JK, 1984, P NATL ACAD SCI-BIOL, V81, P2050, DOI 10.1073/pnas.81.7.2050; ROSOFF PM, 1987, CELL, V49, P845, DOI 10.1016/0092-8674(87)90622-2; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATTENTAU QJ, 1988, CELL, V52, P631, DOI 10.1016/0092-8674(88)90397-2; SCHMIDT MFG, 1979, P NATL ACAD SCI USA, V76, P1687, DOI 10.1073/pnas.76.4.1687; SCHMIDT MFG, 1984, EMBO J, V3, P2295, DOI 10.1002/j.1460-2075.1984.tb02129.x; SCHMIDT MFG, 1979, CELL, V17, P813, DOI 10.1016/0092-8674(79)90321-0; SCHMIDT MFG, 1980, J BIOL CHEM, V255, P3334; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; SCULLION BF, 1987, J CELL BIOL, V105, P69, DOI 10.1083/jcb.105.1.69; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; STEWART SJ, 1986, J IMMUNOL, V136, P3773; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; THOMAS Y, 1983, IMMUNOL REV, V74, P113, DOI 10.1111/j.1600-065X.1983.tb01086.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; WHITT MA, 1991, VIROLOGY, V185, P875, DOI 10.1016/0042-6822(91)90563-Q	43	99	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13593	13597						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618861				2022-12-25	WOS:A1992JB74600078
J	MILNE, DM; PALMER, RH; CAMPBELL, DG; MEEK, DW				MILNE, DM; PALMER, RH; CAMPBELL, DG; MEEK, DW			PHOSPHORYLATION OF THE P53 TUMOR-SUPPRESSOR PROTEIN AT 3 N-TERMINAL SITES BY A NOVEL CASEIN KINASE I-LIKE ENZYME	ONCOGENE			English	Article							LARGE T-ANTIGEN; GLYCOGEN-SYNTHASE; DNA-REPLICATION; MOUSE P53; WILD-TYPE; SV40-TRANSFORMED CELLS; 3T3 CELLS; ONCOGENE; TRANSFORMATION; IDENTIFICATION	Wild-type mouse p53, expressed in Escherichia coli, was phosphorylated by highly purified casein kinase I (CKI) from rabbit muscle. The major site of phosphorylation in the p53 was identified as serine 6, which is known to be phosphorylated in vivo. Serines 4 and 9 were also phosphorylated. To determine whether CKI is likely to be a physiological p53 kinase, SV3T3 cell lysates were fractionated on a Mono Q column and assayed for p53 kinase and casein kinase activities. Four p53 kinase activities were detected, one of which co-purified with CKI activity. This p53 kinase (designated PK270) further co-purified with CKI on sucrose gradients and had a native molecular weight, like CKI, in the range of 35000-45000. However, PK270 was separated from the bulk of CKI activity on a phosvitin-Sepharose affinity column, and was therefore likely to be a CKI-related kinase. In support of these conclusions, phosphorylation of p53, by both CKI and PK270, was inhibited by a peptide corresponding to a consensus CKI target sequence, but not by a non-specific peptide. Moreover, phosphopeptide analyses of p53 phosphorylated by CKI or by PK270 gave similar results, indicating that these two kinases phosphorylate the same sites in p53.	UNIV DUNDEE,DEPT BIOCHEM,MRC,PROT PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND	University of Dundee			Campbell, David G/K-1874-2015	Campbell, David G/0000-0003-2278-2149				ADDISON C, 1990, ONCOGENE, V5, P423; AGOSTINIS P, 1989, FEBS LETT, V259, P75, DOI 10.1016/0014-5793(89)81498-X; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; COFFMAN RL, 1981, J EXP MED, V153, P269, DOI 10.1084/jem.153.2.269; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FLOTOW H, 1989, J BIOL CHEM, V264, P9126; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; FUKASAWA K, 1991, MOL CELL BIOL, V11, P3472, DOI 10.1128/MCB.11.7.3472; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GRAESSER FA, 1988, VIROLOGY, V165, P13; GREEN MR, 1989, CELL, V51, P1; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HERRMANN CPE, 1991, ONCOGENE, V6, P877; KURET J, 1985, EUR J BIOCHEM, V151, P39, DOI 10.1111/j.1432-1033.1985.tb09066.x; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MEEK DW, 1990, J VIROL, V64, P1734, DOI 10.1128/JVI.64.4.1734-1744.1990; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1990, ONCOGENE, V5, P973; MUNDAY MR, 1988, EUR J BIOCHEM, V175, P331, DOI 10.1111/j.1432-1033.1988.tb14201.x; NAKIELNY S, 1991, EUR J BIOCHEM, V199, P713, DOI 10.1111/j.1432-1033.1991.tb16175.x; OROURKE RW, 1990, ONCOGENE, V5, P1829; PATCHINSKY T, 1990, ONCOGENE, V5, P1071; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; POTTER V, 1980, J VIROL, V36, P547; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; SAMAD A, 1991, MOL CELL BIOL, V11, P1598, DOI 10.1128/MCB.11.3.1598; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1988, ONCOGENE, V3, P405; STURZBECHER HW, 1987, VIROLOGY, V160, P445; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG YH, 1986, J BIOL CHEM, V261, P6909; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988	57	164	165	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1361	1369						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620549				2022-12-25	WOS:A1992HZ97100015
J	SHARIFI, J; STGERMAIN, DL				SHARIFI, J; STGERMAIN, DL			THE CDNA FOR THE TYPE-I IODOTHYRONINE 5'-DEIODINASE ENCODES AN ENZYME MANIFESTING BOTH HIGH KM AND LOW KM ACTIVITY - EVIDENCE THAT RAT-LIVER AND KIDNEY CONTAIN A SINGLE ENZYME WHICH CONVERTS THYROXINE TO 3,5,3'-TRIIODOTHYRONINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS-OOCYTES; 5'-MONODEIODINASE; DIHYDROLIPOAMIDE; IDENTIFICATION; BINDING	The enzymatic conversion of thyroxine (T4) to 3,5,3'-triiodothyronine (T3) by iodothyronine 5'-deiodinase(s) is an obligate step in the physiologic action of thyroid hormones in most extrathyroidal tissues. In the rat liver and kidney, 5'-deiodinase processes having either high K(m) (micromolar range) or low K(m) (nanomolar range) values for thyroid hormone substrates have been described. The number of enzymes mediating these reactions, however, remains uncertain and controversial. To examine this question we have compared the 5'-deiodinase activity expressed in membrane preparations of Xenopus laevis oocytes after the injection of either rat liver poly(A)+ RNA or in vitro prepared RNA transcribed using the G21 full-length type I 5'-deiodinase cDNA. In oocytes injected with rat liver poly(A)+ RNA, high K(m) (i.e. type I) activity was observed when 20 mM dithiothreitol was used as the thiol cofactor, whereas K(m) values in the nanomolar range were noted with 0.5 mM dithiothreitol, glutathione, one, or a reconstituted thioredoxin cofactor system. This complex pattern of 5'-deiodinase activity, which mimics that found in homogenates and subcellular fractions of rat liver and kidney, was reproduced exactly in oocytes by the microinjection of G21-derived RNA transcripts. Furthermore, hybrid arrest of translation in oocytes using a partial type I 5'-deiodinase cDNA completely inhibited the expression of both high and low K(m) activity after the injection of rat liver poly(A)+ RNA. These findings demonstrate that rat liver and kidney contain only a single 5'-deiodinase which manifests either high or low K(m) activity depending on the reduced thiol cofactor utilized in the reaction.	DARTMOUTH COLL,DEPT MED,LEBANON,NH 03756; DARTMOUTH COLL,DEPT PHYSIOL,LEBANON,NH 03756	Dartmouth College; Dartmouth College					NCI NIH HHS [CA23108] Funding Source: Medline; NIDDK NIH HHS [DK-42271] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042271] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEHNE D, 1990, BIOCHEM BIOPH RES CO, V173, P1143, DOI 10.1016/S0006-291X(05)80905-2; BERRY MJ, 1991, ENDOCRINOLOGY, V129, P550, DOI 10.1210/endo-129-1-550; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BHAT GB, 1989, BIOCHEM J, V258, P785, DOI 10.1042/bj2580785; BOADO RJ, 1989, ENDOCRINOLOGY, V124, P2245, DOI 10.1210/endo-124-5-2245; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOPRA IJ, 1991, THYROID HORMONE META, P41; GALTON VA, 1987, ENDOCRINOLOGY, V120, P2604, DOI 10.1210/endo-120-6-2604; GOSWAMI A, 1988, ENDOCRINOLOGY, V123, P192, DOI 10.1210/endo-123-1-192; GOSWAMI A, 1987, ENDOCRINOLOGY, V121, P1937, DOI 10.1210/endo-121-6-1937; GOSWAMI A, 1984, J CLIN INVEST, V74, P2097, DOI 10.1172/JCI111634; GOSWAMI A, 1983, ENDOCRINOLOGY, V112, P1180, DOI 10.1210/endo-112-4-1180; GOSWAMI A, 1990, BIOCHEM BIOPH RES CO, V17, P6; KOHRLE J, 1990, J BIOL CHEM, V265, P6155; Leonard JL, 1986, THYROID HORMONE META, P189; ROSENBERG IN, 1991, THYROID HORMONE META, P29; SAFRAN M, 1991, J BIOL CHEM, V266, P13477; SAFRAN M, 1991, J BIOL CHEM, V266, P3233; SAKANE S, 1990, ENDOCRINOLOGY, V127, P2709, DOI 10.1210/endo-127-6-2709; SAWADA K, 1985, ENDOCRINOLOGY, V117, P1259, DOI 10.1210/endo-117-3-1259; SILVA JE, 1987, ENDOCRINOLOGY, V121, P650, DOI 10.1210/endo-121-2-650; STGERMAIN DL, 1989, J BIOL CHEM, V264, P3054; STGERMAIN DL, 1989, ENDOCRINOLOGY, V125, P2735; STGERMAIN DL, 1990, J BIOL CHEM, V265, P20087	24	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12539	12544						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618759				2022-12-25	WOS:A1992HZ48300027
J	PAIETTA, E; STOCKERT, RJ; RACEVSKIS, J				PAIETTA, E; STOCKERT, RJ; RACEVSKIS, J			ALTERNATIVELY SPLICED VARIANTS OF THE HUMAN HEPATIC ASIALOGLYCOPROTEIN RECEPTOR, H2, DIFFER IN CELLULAR TRAFFICKING AND REGULATION OF PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR; BETA-CHAIN; DEGRADATION; EXPRESSION; SUBUNITS; SEQUENCE; DOMAIN; DNA	The less abundant subunit of the asialoglycoprotein receptor, H2, may be encoded by at least four variant transcripts as a result of alternative mRNA splicing. We had cloned two H2-cDNAs that differed predominantly by the presence (clone H2') or absence (clone L-H2) of two presumed exons; one of 57 nucleotides was near the 5' end of the sequence, and the other was within the transmembrane region consisting of 15 nucleotides. The relevance of these two segments to H2 processing was studied after expression in rat-6 fibroblasts of these two isolates and of artificial constructs containing either only the 57-nucleotide (transfectant-57) or the 15-nucleotide (transfectant-15) region. H2 proteins encoded by cDNAs containing the 15-nucleotide region were intracellularly retained and degraded independently of the presence of the 57-nucleotide sequence. Of proteins derived from clones lacking the 15-nucleotide region, only a fraction was processed through the trans-Golgi, as evidenced by sensitivity to O-glycanase and neuraminidase, and reached the cell surface. The presence of the 57-nucleotide sequence was necessary for protein phosphorylation. Phosphorylation of serine residue(s) was detected in the endoglycosidase H-sensitive and mature forms of H2 protein encoded by transfectant-57. Since the 57-nucleotide region does not encode for serine residues, it per se cannot be the site of phosphorylation but rather constitutes a regulatory element for post-translational modification.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	PAIETTA, E (corresponding author), MONTEFIORE MED CTR,DEPT ONCOL,111 E 210TH ST,BRONX,NY 10467, USA.				NCI NIH HHS [P30CA13330] Funding Source: Medline; NIDDK NIH HHS [DK-17702, DK-32972] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032972, P50DK017702] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALCOVER A, 1990, J BIOL CHEM, V265, P4131; AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BISCHOFF J, 1987, J BIOL CHEM, V262, P11825; BRAITERMAN LT, 1989, J BIOL CHEM, V264, P1682; GEFFEN I, 1991, P NATL ACAD SCI USA, V88, P8425, DOI 10.1073/pnas.88.19.8425; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HEVEZI P, 1991, J VIROL, V65, P5333, DOI 10.1128/JVI.65.10.5333-5341.1991; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KLAUSNER R D, 1989, New Biologist, V1, P3; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MORLEY BJ, 1988, J EXP MED, V168, P1971, DOI 10.1084/jem.168.6.1971; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PAIETTA E, 1989, J IMMUNOL, V143, P2850; PAIETTA E, 1992, HEPATOLOGY, V15, P395, DOI 10.1002/hep.1840150307; PAIETTA E, 1990, CANCER RES, V50, P2049; PRICER WE, 1971, J BIOL CHEM, V246, P4825; Sambrook J, 1989, MOL CLONING LAB MANU, P121; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P1158, DOI 10.1073/pnas.86.4.1158; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; STOCKERT RJ, 1977, SCIENCE, V197, P667, DOI 10.1126/science.877581; STOCKERT RJ, 1990, J BIOL CHEM, V265, P1841; STOORVOGEL W, 1991, J BIOL CHEM, V266, P5438; WIKSTROM L, 1992, J BIOL CHEM, V267, P5	30	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11078	11084						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597447				2022-12-25	WOS:A1992HX16900025
J	OLAH, ME; REN, HZ; OSTROWSKI, J; JACOBSON, KA; STILES, GL				OLAH, ME; REN, HZ; OSTROWSKI, J; JACOBSON, KA; STILES, GL			CLONING, EXPRESSION, AND CHARACTERIZATION OF THE UNIQUE BOVINE-A1 ADENOSINE RECEPTOR - STUDIES ON THE LIGAND-BINDING SITE BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; ADENYLATE CYCLASE SYSTEM; MOLECULAR-CLONING; ALPHA-1-ADRENERGIC RECEPTOR; CEREBRAL-CORTEX; BRAIN MEMBRANES; CDNA; A1-ADENOSINE; ANTAGONIST; SUBTYPES	The bovine brain A1 adenosine receptor (A1AR) is distinct from other A1ARs in that it displays the unique agonist potency series of N6-R-phenylisopropyladenosine (R-PIA) > N6-S-phenylisopropyladenosine (S-PIA) > 5'-N-ethylcarboxamidoadenosine and has a 5-10-fold higher affinity for both agonists and antagonists. The cDNA for this receptor has been cloned from a size-selected (2-4-kb) bovine brain library and sequenced. The 2.0-kb cDNA encodes a protein of 326 amino acid residues with a molecular mass of 36,570 daltons. The amino acid sequence fits well into the seven-transmembrane domain motif typical of G protein-coupled receptors. Northern analysis in bovine tissue using the full length cDNA demonstrates mRNAs of 3.4 and 5.7 kb with a tissue distribution consistent with A1AR binding. Subcloning of the cDNA in a pCMV5 expression vector with subsequent transfection into both COS7 and Chinese hamster ovary cells revealed a fully functional A1AR which could inhibit adenylylcyclase and retained the unique pharmacologic properties of the bovine brain A1AR. The A1AR was found to have a single histidine residue in each of transmembrane domains 6 and 7. Histidine residues have been postulated by biochemical studies to be important for ligand binding. Mutation of His-278 to Leu-278 (seventh transmembrane domain) dramatically decreased both agonist and antagonist binding by > 90%. In contrast, mutation of His-251 to Leu-251 decreased antagonist affinity and the number of receptors recognized by an antagonist radioligand. In contrast, agonist affinity was not perturbed but the number of receptors detected by an agonist radioligand was also reduced. These data suggest that both histidines are important for both agonist and antagonist binding, but His-278 appears critical for ligand binding to occur.	DUKE UNIV,MED CTR,DEPT MED,BOX 3444,DURHAM,NC 27710; NIDDKD,CHEM LAB,BETHESDA,MD 20892; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710	Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Duke University; Duke University; Howard Hughes Medical Institute			Jacobson, Kenneth Alan/A-1530-2009	Jacobson, Kenneth Alan/0000-0001-8104-1493	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035134] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013713] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 DK031117-20, Z99 DK999999] Funding Source: Medline; NHLBI NIH HHS [R01-HL35134] Funding Source: Medline; NIGMS NIH HHS [1F32-GM-13713-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN PH, 1990, TRENDS PHARMACOL SCI, V11, P231, DOI 10.1016/0165-6147(90)90249-8; BARRINGTON WW, 1989, J BIOL CHEM, V264, P13157; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DALY JW, 1985, ADV CYCLIC NUCL PROT, V19, P29; DELEAN A, 1982, MOL PHARMACOL, V21, P5; FARGIN A, 1988, NATURE, V335, P358, DOI 10.1038/335358a0; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KLOTZ KN, 1988, J BIOL CHEM, V263, P17522; KUBO T, 1986, FEBS LETT, V209, P367, DOI 10.1016/0014-5793(86)81144-9; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; LIAO CF, 1989, J BIOL CHEM, V264, P7328; LIBERT F, 1991, EMBO J, V10, P1677, DOI 10.1002/j.1460-2075.1991.tb07691.x; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; LONGABAUGH JP, 1989, MOL PHARMACOL, V36, P681; LORENZ W, 1990, MOL PHARMACOL, V38, P599; MAHAN LC, 1991, MOL PHARMACOL, V40, P1; Maniatis T, 1989, DECONTAMINATION DILU; MURPHY KMM, 1982, MOL PHARMACOL, V22, P250; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; OLAH ME, 1990, ARCH BIOCHEM BIOPHYS, V283, P440, DOI 10.1016/0003-9861(90)90665-L; OLSSON RA, 1990, PHYSIOL REV, V70, P761, DOI 10.1152/physrev.1990.70.3.761; PARSONS WJ, 1987, J BIOL CHEM, V262, P841; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PRITCHETT DB, 1988, EMBO J, V7, P4135, DOI 10.1002/j.1460-2075.1988.tb03308.x; RAMKUMAR V, 1990, MOL PHARMACOL, V37, P149; RAMKUMAR V, 1991, MOL PHARMACOL, V40, P639; RAMKUMAR V, 1988, J CLIN INVEST, V82, P242, DOI 10.1172/JCI113577; RAPIEJKO PJ, 1987, BIOCHEM J, V241, P765, DOI 10.1042/bj2410765; REPPERT SM, 1991, MOL ENDOCRINOL, V5, P1037, DOI 10.1210/mend-5-8-1037; SCHWINN DA, 1990, J BIOL CHEM, V265, P8183; STILES GL, 1990, CLIN RES, V38, P10; STILES GL, 1986, J BIOL CHEM, V261, P839; STILES GL, 1985, J BIOL CHEM, V260, P806; STILES GL, 1988, J NEUROCHEM, V51, P1592, DOI 10.1111/j.1471-4159.1988.tb01129.x; STILES GL, 1991, NEWS PHYSIOL SCI, V6, P161; STILES GL, 1987, MOL PHARMACOL, V32, P184; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; STROSBERG AD, 1991, EUR J BIOCHEM, V196, P1, DOI 10.1111/j.1432-1033.1991.tb15778.x; SURYANARAYANA S, 1991, J BIOL CHEM, V266, P15488; UKENA D, 1986, FEBS LETT, V209, P122, DOI 10.1016/0014-5793(86)81096-1; YEUNG SMH, 1983, J BIOL CHEM, V258, P2334	46	157	175	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10764	10770						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587851				2022-12-25	WOS:A1992HV09000084
J	PEDERSEN, SE; SHARP, SD; LIU, WS; COHEN, JB				PEDERSEN, SE; SHARP, SD; LIU, WS; COHEN, JB			STRUCTURE OF THE NONCOMPETITIVE ANTAGONIST-BINDING SITE OF THE TORPEDO NICOTINIC ACETYLCHOLINE-RECEPTOR - [H-3] MEPROADIFEN MUSTARD REACTS SELECTIVELY WITH ALPHA-SUBUNIT-GLU-262	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; ALPHA-SUBUNIT; AMINO-ACIDS; ION CHANNEL; POSTSYNAPTIC MEMBRANES; PROTEINS; IDENTIFICATION; MARMORATA; LIGAND; CALIFORNICA	[H-3]Meproadifen mustard, an affinity label for the noncompetitive antagonist site of the nicotinic acetylcholine receptor (AChR), specifically alkylates the AChR alpha-subunit when the acetylcholine-binding sites are occupied by agonist (Dreyer, E. B., Hasan, F., Cohen, S. G., and Cohen, J. B. (1986) J. Biol. Chem. 261, 13727-13734). In this report, we identify the site of alkylation within the alpha-subunit as Glu-262. AChR-rich membranes from Torpedo californica electric organ were reacted with [H-3]meproadifen mustard in the presence of carbamylcholine and in the absence or presence of nonradioactive meproadifen to define specific alkylation of the noncompetitive antagonist site. Alkylated alpha-subunits were isolated and subjected to chemical or enzymatic cleavage. When digests with CNBr in 70% trifluoroacetic acid or 70% formic acid were fractionated by gel filtration high performance liquid chromatography (HPLC), specifically labeled material was recovered in the void volume fractions. Based upon NH2-terminal sequence analysis, for both digests, the void volume fractions contained a fragment beginning at Gln-208 before the M1 hydrophobic sequence, whereas the sample from the digest in trifluoroacetic acid also contained as a primary sequence a fragment beginning at Thr-244 and extending through the M2 hydrophobic sequence. Sequence analysis revealed no release of H-3 for the sample from digestion in formic acid, whereas for the trifluoroacetic acid digest, there was specific release of H-3 in cycle 19, which would correspond to Glu-262. This site of alkylation was confirmed by isolation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and reversed-phase HPLC of a specifically labeled fragment from an endoproteinase Lys-C digest of the alkylated alpha-subunit. NH2-terminal amino acid sequencing revealed release of H-3 at cycle 20 from a fragment beginning at Met-243 and extending into the M3 hydrophobic sequence. Because [H-3]meproadifen mustard contains, as its reactive group, a positively charged quaternary aziridinium ion, Glu-262 of the alpha-subunit is identified as a contributor to the cation-binding domain of the noncompetitive antagonist-binding site and thus of the ion channel.	WASHINGTON UNIV, SCH MED, DEPT ANAT & NEUROBIOL, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA	Washington University (WUSTL)				Pedersen, Steen E./0000-0001-8755-8899	NINDS NIH HHS [NS 19522, NS 22828] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS022828, R01NS019522] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLEN G, 1989, SEQUENCING PROTEINS; ARAMSON SN, 1989, J BIOL CHEM, V264, P12666; BLANTON MP, 1992, IN PRESS BIOCHEMISTR; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; CHARNET P, 1990, NEURON, V4, P87, DOI 10.1016/0896-6273(90)90445-L; Cohen J. B., 1986, MOL CELLULAR MECHANI, P111; COHEN JB, 1991, J BIOL CHEM, V266, P23354; COHEN JB, 1985, EFFECTS ANESTHESIA, P53; COLQUHOUN D, 1986, HDB EXPT PHARM, V79, P59; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DERMER OC, 1969, ETHYLENIMINE OTHER A, P205; DIPAOLA M, 1990, J BIOL CHEM, V265, P11017; DREYER EB, 1986, J BIOL CHEM, V261, P3727; Fontana A, 1986, PRACTICAL PROTEIN CH, P67; FORMAN SA, 1989, TRENDS PHARMACOL SCI, V10, P447, DOI 10.1016/S0165-6147(89)80009-4; GALZI JL, 1990, J BIOL CHEM, V265, P10430; GERBER GE, 1979, P NATL ACAD SCI USA, V76, P227, DOI 10.1073/pnas.76.1.227; GIRAUDAT J, 1987, BIOCHEMISTRY-US, V26, P2410, DOI 10.1021/bi00383a003; GIRAUDAT J, 1989, FEBS LETT, V253, P190, DOI 10.1016/0014-5793(89)80957-3; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HEIDMANN T, 1983, BIOCHEMISTRY-US, V22, P3112, DOI 10.1021/bi00282a014; HERZ JM, 1987, J BIOL CHEM, V262, P7238; HUCHO F, 1986, FEBS LETT, V205, P137, DOI 10.1016/0014-5793(86)80881-X; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; KAO PN, 1984, J BIOL CHEM, V259, P1662; KRODEL EK, 1979, MOL PHARMACOL, V15, P294; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIDDLETON RE, 1991, BIOCHEMISTRY-US, V30, P6987, DOI 10.1021/bi00242a026; MITRA AK, 1989, J CELL BIOL, V109, P755, DOI 10.1083/jcb.109.2.755; NEHER E, 1978, J PHYSIOL-LONDON, V277, P153, DOI 10.1113/jphysiol.1978.sp012267; NEHER E, 1983, J PHYSIOL-LONDON, V335, P123; NEUBIG RR, 1979, BIOCHEMISTRY-US, V18, P5464, DOI 10.1021/bi00591a032; NEUBIG RR, 1980, BIOCHEMISTRY-US, V19, P2770, DOI 10.1021/bi00553a036; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; OGDEN DC, 1981, NATURE, V289, P596, DOI 10.1038/289596a0; PEDERSEN SE, 1986, J BIOL CHEM, V261, P3735; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; PEDERSEN SE, 1990, J BIOL CHEM, V265, P569; PEPER K, 1982, PHYSIOL REV, V62, P1271, DOI 10.1152/physrev.1982.62.4.1271; PORTER S, 1983, J BIOL CHEM, V258, P34; RAFTERY MA, 1980, SCIENCE, V208, P1454, DOI 10.1126/science.7384786; REVAH F, 1990, P NATL ACAD SCI USA, V87, P4675, DOI 10.1073/pnas.87.12.4675; REYNOLDS JA, 1978, BIOCHEMISTRY-US, V17, P2035, DOI 10.1021/bi00604a001; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHROEDER WA, 1969, ARCH BIOCHEM BIOPHYS, V130, P551, DOI 10.1016/0003-9861(69)90069-1; SOBEL A, 1977, EUR J BIOCHEM, V80, P215, DOI 10.1111/j.1432-1033.1977.tb11874.x; STEFFENS GJ, 1982, H-S Z PHYSIOL CHEM, V363, P1043, DOI 10.1515/bchm2.1982.363.2.1043; STOFFEL W, 1984, P NATL ACAD SCI-BIOL, V81, P5012, DOI 10.1073/pnas.81.16.5012; STRNAD NP, 1988, THESIS WASHINGTON U; TARR GE, 1983, ANAL BIOCHEM, V131, P99, DOI 10.1016/0003-2697(83)90140-9; TARR GE, 1986, MICROCHARACTERIZATIO, P155; TOYOSHIMA C, 1990, J CELL BIOL, V111, P2623, DOI 10.1083/jcb.111.6.2623; WHITE BH, 1988, BIOCHEMISTRY-US, V27, P8741, DOI 10.1021/bi00424a009; WHITE BH, 1991, J BIOL CHEM, V266, P21595; WHITE BH, 1991, NEUR ABSTR, V17, pA22; WHITE BH, 1991, THESIS WASHINGTON U	60	77	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10489	10499						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587830				2022-12-25	WOS:A1992HV09000044
J	YOSHIZUMI, M; KOUREMBANAS, S; TEMIZER, DH; CAMBRIA, RP; QUERTERMOUS, T; LEE, ME				YOSHIZUMI, M; KOUREMBANAS, S; TEMIZER, DH; CAMBRIA, RP; QUERTERMOUS, T; LEE, ME			TUMOR-NECROSIS-FACTOR INCREASES TRANSCRIPTION OF THE HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH-FACTOR GENE IN VASCULAR ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EXPRESSION; ATHEROSCLEROSIS; PATHOGENESIS; CHAIN; ACID	Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a recently identified, potent vascular smooth muscle cell (SMC) mitogen of macrophage origin. To determine whether this gene is transcribed and regulated in vascular endothelial cells, we measured HB-EGF mRNA levels in human umbilical vein endothelial cells (HUVEC) by RNA blot analysis with an HB-EGF cDNA probe. The base-line level of HB-EFG mRNA in HUVEC in culture was low. However, tumor necrosis factor-alpha (TNF-alpha) and interleukin-1-beta markedly increased HB-EGF mRNA levels in HUVEC by 12- and 7-fold, respectively, and induction of the gene by TNF-alpha was both dose- and time-dependent. In response to TNF-alpha, HB-EGF mRNA levels quickly increased and peaked at 1 h, indicating that HB-EGF belongs to the family of immediate early genes. In nuclear run-off experiments, TNF-alpha increased the rate of HB-EGF gene transcription by 3.2-fold. To our knowledge this is the first demonstration that the HB-EGF gene is transcribed in vascular endothelial cells. The inducible transcription of this potent SMC mitogen gene in endothelial cells suggests that HB-EGF may have an important role in the pathogenesis of atherosclerosis.	MASSACHUSETTS GEN HOSP,GEN MED SERV,CARDIAC UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,SURG SERV,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115; UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,TOKYO 113,JAPAN; CHILDRENS HOSP MED CTR,JOINT PROGRAM NEONATOL,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Tokyo; Harvard University; Boston Children's Hospital				Quertermous, Thomas/0000-0002-7645-9067				BARATH P, 1990, AM J PATHOL, V137, P503; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; CHAN YL, 1984, J BIOL CHEM, V259, P224; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; DANIEL TO, 1986, J BIOL CHEM, V261, P9579; DICORLETO PE, 1983, P NATL ACAD SCI-BIOL, V80, P1919, DOI 10.1073/pnas.80.7.1919; DICORLETO PE, 1988, ENDOTHELIAL CELLS, V2, P51; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; KAVANAUGH WM, 1988, J BIOL CHEM, V263, P8470; KOUREMBANAS S, 1991, J CLIN INVEST, V88, P1054, DOI 10.1172/JCI115367; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; LEE ME, 1990, J CLIN INVEST, V86, P141, DOI 10.1172/JCI114677; LEE ME, 1991, J BIOL CHEM, V266, P16188; LIBBY P, 1991, LAB INVEST, V64, P5; LYNCH DC, 1985, CELL, V41, P49, DOI 10.1016/0092-8674(85)90060-1; MINTY AJ, 1983, J MOL BIOL, V167, P77, DOI 10.1016/S0022-2836(83)80035-7; MOYER CF, 1991, AM J PATHOL, V138, P951; MUNRO JM, 1988, LAB INVEST, V58, P249; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARTZ SM, 1990, PHYSIOL REV, V70, P1177, DOI 10.1152/physrev.1990.70.4.1177; VILCEK J, 1991, J BIOL CHEM, V266, P7313; [No title captured]	26	143	146	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9467	9469						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577791				2022-12-25	WOS:A1992HT96500005
J	CHENG, HC; NISHIO, H; HATASE, O; RALPH, S; WANG, JH				CHENG, HC; NISHIO, H; HATASE, O; RALPH, S; WANG, JH			A SYNTHETIC PEPTIDE DERIVED FROM P34CDC2 IS A SPECIFIC AND EFFICIENT SUBSTRATE OF SRC-FAMILY TYROSINE KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PROTEIN-KINASE; PHOSPHORYLATION; EXPRESSION; MEMBRANES; PRODUCT; CELLS; GENE	A peptide derived from p34cdc2, cdc2(6-20)NH2 with the amino acid sequence of KVEKIGEGTYGVVYK-amide, was found to be a specific and efficient substrate for a pp60c-src-related protein tyrosine kinase from bovine spleen (STK). Glu-12 and Thr-14 were identified to be substrate specificity determinants in this peptide (Cheng, H.-C., Litwin, C. M. E., Hwang, D. M., and Wang, J. H. (1991) J. Biol. Chem. 266, 17919-17925). In this study, we demonstrated the presence of cdc2(6-20)NH2 peptide tyrosine kinase activity in the membrane fractions of bovine brain, spleen, thymus, lung, liver, and kidney. Hydroxylapatite column chromatography of thymus membrane extract revealed four protein tyrosine kinases, TK-I, TK-II, TK-III, and TK-IV, with different relative activities toward cdc2(6-20)NH2 and a general tyrosine kinase substrate, poly(Glu/Tyr). Only TK-1 and TK-II showed significant activity toward cdc2(6-20)NH2, they were suggested as belonging to the src-family by virtue of their cross-reactivity with an antibody against a synthetic peptide corresponding to a conserved sequence of src-family kinases. Further immunological characterization using antibodies specific to individual src-related protein tyrosine kinases suggested that TK-I, TK-II, and STK are bovine homologs of p56lck, p55fyn, and p56lyn, respectively. Substrate specificity and kinetic characterization of src-family tyrosine kinases including human platelet pp60c-src, bovine p56lyn, p56lck, and p55fyn, as well as several non-src-related tyrosine kinases including epidermal growth factor receptor, p43v-abl, TK-III, and TK-IV showed that all the src-family tyrosine kinases but none of the other kinases displayed efficient cdc2(6-20)NH2 phosphorylation. In all cases, the high efficiency of cdc2(6-20) NH2 peptide phosphorylation could be markedly attenuated when Glu-12 and Thr-14 of the peptide were substituted, respectively, by valine and serine.	UNIV CALGARY, FAC MED, DEPT MED BIOCHEM, MED RES COUNCIL GRP SIGNAL TRANSDUCT, CALGARY T2N 4N1, ALBERTA, CANADA; KAGAWA MED SCH, DEPT PHYSIOL, KITA 76107, KAGAWA, JAPAN; ROYAL MELBOURNE HOSP, LUDWIG INST CANC RES, MELBOURNE TUMOUR BIOL BRANCH, PARKVILLE, VIC 3050, AUSTRALIA	University of Calgary; Kagawa University; Ludwig Institute for Cancer Research; Royal Melbourne Hospital			Ralph, Stephen J./AAE-4888-2019	Ralph, Stephen J./0000-0002-4335-092X; Cheng, Heung-Chin/0000-0002-4965-7148				ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN S, 1984, J BIOL CHEM, V259, P2051; CASNELLIE JE, 1982, P NATL ACAD SCI-BIOL, V79, P282, DOI 10.1073/pnas.79.2.282; CHENG HC, 1991, J BIOL CHEM, V266, P17919; Corbin J D, 1974, Methods Enzymol, V38, P287; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FEDER D, 1990, J BIOL CHEM, V265, P8205; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOUSE C, 1984, EUR J BIOCHEM, V140, P363, DOI 10.1111/j.1432-1033.1984.tb08109.x; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HUNTER T, 1986, ENZYMES, V17, P192; KASUGA M, 1983, J BIOL CHEM, V258, P973; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LITWIN CME, 1991, J BIOL CHEM, V266, P2557; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PETERS DJ, 1990, ONCOGENE, V5, P1313; PIKE LJ, 1982, P NATL ACAD SCI-BIOL, V79, P1443, DOI 10.1073/pnas.79.5.1443; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; STANLEY E, 1991, MOL CELL BIOL, V11, P3399, DOI 10.1128/MCB.11.7.3399; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; WONG TW, 1983, J BIOL CHEM, V258, P1022	28	162	181	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9248	9256						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577758				2022-12-25	WOS:A1992HR85400083
J	LEE, CM; HAUN, RS; TSAI, SC; MOSS, J; VAUGHAN, M				LEE, CM; HAUN, RS; TSAI, SC; MOSS, J; VAUGHAN, M			CHARACTERIZATION OF THE HUMAN GENE ENCODING ADP-RIBOSYLATION FACTOR-I, A GUANINE NUCLEOTIDE-BINDING ACTIVATOR OF CHOLERA-TOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; TRANSCRIPTION FACTOR; PROTEIN; PROMOTER; SEQUENCE; ACID; MATURATION; POLY(A); SUBUNIT; SITE	Mammalian ADP-ribosylation factors (ARFs), approximately 20-kDa guanine nucleotide-binding proteins that stimulate cholera toxin ADP-ribosyltransferase activity, were grouped into three classes based on deduced amino acid sequence. Human ARF 1, a class I ARF, is identical with its bovine counterpart, has a distinctive pattern of tissue and developmental expression, and is encoded by a approximately 1.9-kilobase mRNA. ARF 1 cDNAs were isolated from a human fibroblast cDNA library; one arose via an alternative polyadenylation signal (AA-TACA) 84 nucleotides 5' to the polyadenylation signal (AATAAA) used in the 1815-base pair cDNA. The polyadenylation signals, their respective locations, and the surrounding nucleotide sequences are conserved in human and rat. The human ARF 1 gene, with four introns, spans approximately 16.5 kilobases. Exon 1 (46 base pairs) contains only untranslated sequence. Translation initiates in exon 2, which encodes the sequence GXXXXGK involved in phosphate binding (GTP hydrolysis). The sequence DVGG is encoded in exon 3, and NKQD, which is involved in the interaction with the guanine ring, is interrupted following the codon for Q by intron 4. The carboxyl-terminal 53 amino acids and > 1110 base pairs of 3'-untranslated region are encoded in exon 5. Primer extension and mung bean and S1 nuclease mapping indicated multiple transcription initiation sites and were consistent with Northern analyses. The 5'-flanking region has a high GC content but no TATA or CAAT box, as found in housekeeping genes. In addition, the two human class I ARF genes, ARF 1 and ARF 3, have similar exon/intron organizations and use GC-rich promoters.			LEE, CM (corresponding author), NHLBI, CELLULAR METAB LAB, RM 5N307, BLDG 10, BETHESDA, MD 20892 USA.		Lee, Chii-Ming/M-7799-2015	Lee, Chii-Ming/0000-0002-1075-5787				ATWATER JA, 1990, ANNU REV GENET, V24, P519; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOBAK DA, 1990, ADP RIBOSYLATING TOX, P439; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FROHMAN MA, 1990, AMPLIFICATIONS, V5, P11; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; HEATH CV, 1990, J BIOL CHEM, V265, P9098; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KOZASA T, 1988, P NATL ACAD SCI USA, V85, P2081, DOI 10.1073/pnas.85.7.2081; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; MUNROE D, 1990, GENE, V91, P151, DOI 10.1016/0378-1119(90)90082-3; MURTAGH JJ, 1992, IN PRESS J BIOL CHEM, V266; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; PRICE SR, 1990, ADP RIBOSYLATING TOX, P397; PROUDFOOT NJ, 1989, TRENDS BIOCHEM SCI, V14, P105, DOI 10.1016/0968-0004(89)90132-1; ROSCHER AA, 1983, J CLIN INVEST, V72, P626, DOI 10.1172/JCI111012; SAMBROOK J, 1989, MOL CLONING LABORATO, pCH7; SANDBERG M, 1990, BIOCHEM BIOPH RES CO, V167, P323, DOI 10.1016/0006-291X(90)91768-N; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TSAI SC, 1991, J BIOL CHEM, V266, P23053; TSAI SC, 1991, J BIOL CHEM, V266, P8213; TSUCHIYA M, 1989, BIOCHEMISTRY-US, V28, P9668, DOI 10.1021/bi00451a019; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; VASSALLI JD, 1989, GENE DEV, V3, P2163, DOI 10.1101/gad.3.12b.2163; WEINSTEIN LS, 1988, FEBS LETT, V232, P333, DOI 10.1016/0014-5793(88)80764-6	36	44	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9028	9034						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577740				2022-12-25	WOS:A1992HR85400051
J	GASSAMADIAGNE, A; ROGALLE, P; FAUVEL, J; WILLSON, M; KLAEBE, A; CHAP, H				GASSAMADIAGNE, A; ROGALLE, P; FAUVEL, J; WILLSON, M; KLAEBE, A; CHAP, H			SUBSTRATE-SPECIFICITY OF PHOSPHOLIPASE-B FROM GUINEA-PIG INTESTINE - A GLYCEROL ESTER LIPASE WITH BROAD SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; 2 CATIONIC LIPASES; PENICILLIUM-NOTATUM; SACCHAROMYCES-CEREVISIAE; PURIFICATION; GLYCEROPHOSPHOLIPIDS; PANCREAS; PROTEINS; ENZYMES; PLASMA	The substrate specificity of a calcium-independent, 97-kDa phospholipase B purified from guinea pig intestine was further investigated using various natural and synthetic lipids. The enzyme was equally active toward enantiomeric phosphatidylcholines under conditions allowing a strict phospholipase A activity. The lysophospholipase activity declined with the following substrates: 1-acyl-sn-glycero-3-phosphocholine > 1-palmitoyl-propanediol-3-phosphocholine > 1-palmitoyl-glycol-2-phosphocholine, suggesting some influence of the polar residue vicinal to the cleavage site. The enzyme also acted on various neutral lipids including triacylglycerol, diacylglycerol, and monoacylglycerol, whereas cholesteryl oleate remained refractory to enzymatic hydrolysis. The lipase hydrolyzed sequentially the sn-2 and sn-1 acyl ester bonds of diacylglycerol, although some direct cleavage of the external acyl ester bond could also occur, as shown with diacylglycerol analogues bearing a nonhydrolyzable alkyl ether or amide bond in the sn-1 or sn-2 position. The three main activities of the enzyme (phospholipase A2, lysophospholipase, and diacylglycerol lipase) were resistant to 4-bromophenacyl bromide, but they were inhibited by N-ethylmaleimide, 5,5'-dithiobis-(2-nitrobenzoic acid), and diisopropyl fluorophosphate, suggesting the possible involvement of both cysteine and serine residues in a single active site. It is concluded that guinea pig intestinal phospholipase B, which was also detected in rat and rabbit, is actually a glycerol ester lipase with broad substrate specificity and some unique enzymatic properties.	UNIV TOULOUSE 3, CNRS, URA 454, CHIM ORGAN BIOL GRP, F-31062 TOULOUSE, FRANCE; UNIV TOULOUSE 3, CNRS, URA 470, F-31062 TOULOUSE, FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier								BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOETTCHER C, 1961, ANAL CHIM ACTA, V24, P203, DOI 10.1016/0003-2670(61)80041-X; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DIAGNE A, 1987, LIPIDS, V22, P33, DOI 10.1007/BF02534872; DIJKMAN R, 1990, BIOCHIM BIOPHYS ACTA, V1043, P67, DOI 10.1016/0005-2760(90)90111-A; FAUVEL J, 1984, BIOCHIM BIOPHYS ACTA, V792, P72, DOI 10.1016/0005-2760(84)90284-4; FAUVEL J, 1981, BIOCHIM BIOPHYS ACTA, V663, P446, DOI 10.1016/0005-2760(81)90173-9; FAUVEL J, 1984, BIOCHIM BIOPHYS ACTA, V792, P65, DOI 10.1016/0005-2760(84)90283-2; FIELDING CJ, 1981, J BIOL CHEM, V256, P876; GASSAMADIAGNE A, 1991, METHOD ENZYMOL, V197, P316; GASSAMADIAGNE A, 1989, J BIOL CHEM, V264, P9470; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HERMETTER A, 1983, ETHER LIPIDS BIOCH B, P389; ICHIMASA M, 1984, J BIOCHEM, V95, P137; KENNY AJ, 1982, PHYSIOL REV, V62, P91, DOI 10.1152/physrev.1982.62.1.91; KUCERA GL, 1988, J BIOL CHEM, V263, P12964; KUWABARA Y, 1988, J BIOCHEM, V104, P236, DOI 10.1093/oxfordjournals.jbchem.a122449; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; LESLIE CC, 1991, J BIOL CHEM, V266, P11366; MAROUX S, 1987, MAMMALIAN ECTOENZYME, P15; MASUDA N, 1991, EUR J BIOCHEM, V202, P783, DOI 10.1111/j.1432-1033.1991.tb16433.x; MATTSON FH, 1962, J LIPID RES, V3, P281; NEISES B, 1978, ANGEW CHEM INT EDIT, V17, P522, DOI 10.1002/anie.197805221; NISHIJIMA M, 1977, EUR J BIOCHEM, V73, P115, DOI 10.1111/j.1432-1033.1977.tb11297.x; NISHIJIMA M, 1974, J BIOL CHEM, V249, P5658; OKUMURA T, 1980, BIOCHIM BIOPHYS ACTA, V617, P264; PIND S, 1991, BIOCHEM CELL BIOL, V69, P346, DOI 10.1139/o91-054; PIND S, 1988, BIOCHIM BIOPHYS ACTA, V938, P211, DOI 10.1016/0005-2736(88)90160-5; PIND S, 1989, LIPIDS, V24, P357, DOI 10.1007/BF02535141; PIND S, 1987, BIOCHIM BIOPHYS ACTA, V901, P78, DOI 10.1016/0005-2736(87)90258-6; SAITO K, 1991, METHOD ENZYMOL, V197, P446; SAITO K, 1974, BIOCHIM BIOPHYS ACTA, V369, P245, DOI 10.1016/0005-2760(74)90255-0; SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SUGATANI J, 1978, BIOCHIM BIOPHYS ACTA, V529, P29; SUGATANI J, 1980, BIOCHIM BIOPHYS ACTA, V620, P372; TAKEUCHI Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P206, DOI 10.1016/0003-9861(87)90025-7; VANDENBOSCH H, 1968, BIOCHIM BIOPHYS ACTA, V152, P694, DOI 10.1016/0005-2760(68)90115-X; Verkade PE, 1942, RECL TRAV CHIM PAY-B, V61, P831; WAITE M, 1967, BIOCHIM BIOPHYS ACTA, V137, P498, DOI 10.1016/0005-2760(67)90131-2; WAITE M, 1991, METHOD ENZYMOL, V197, P331; WAITE M, 1987, HDB LIPID RES, V5, P1; WITT W, 1984, BIOCHIM BIOPHYS ACTA, V795, P117, DOI 10.1016/0005-2760(84)90111-5; WITT W, 1984, BIOCHIM BIOPHYS ACTA, V795, P108, DOI 10.1016/0005-2760(84)90110-3	45	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13418	13424						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618844				2022-12-25	WOS:A1992JB74600052
J	IZBAN, MG; LUSE, DS				IZBAN, MG; LUSE, DS			FACTOR-STIMULATED RNA POLYMERASE-II TRANSCRIBES AT PHYSIOLOGICAL ELONGATION RATES ON NAKED DNA BUT VERY POORLY ON CHROMATIN TEMPLATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 TAT PROTEIN; FACTOR-SII; DROSOPHILA-MELANOGASTER; ACCURATE TRANSCRIPTION; PHAGE-LAMBDA; CALF THYMUS; S-II; GENE; INITIATION; INVITRO	We used an in vitro assay system based on HeLa cell core transcription components to examine transcript elongation by RNA polymerase II on either naked DNA or chromatin templates as a function of the three known elongation factors, IIS, TFIIF, and TFIIX. We demonstrate for the first time that mammalian RNA polymerase II can achieve physiological elongation rates on naked DNA templates in vitro. The addition of TFIIF alone gave this rate, although IIS was required to minimize the block to elongation at intrinsic termination sites. However, IIS and TFIIF provided only a slight increase in the very poor elongation efficiency of RNA polymerase II on chromatin templates. The addition of TFIIX to reactions containing IIS and TFIIF reduced the elongation rate on naked DNA templates but slightly increased the elongation efficiency on chromatin. The ability of elongation factors either separately or in combination to stimulate transcription on naked DNA and chromatin templates was also examined.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029487, F32GM014111] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 14111, GM 29487] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; CHAFIN DR, 1991, J BIOL CHEM, V266, P9256; CHEN TA, 1990, J MOL BIOL, V212, P481, DOI 10.1016/0022-2836(90)90327-I; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; COULTER DE, 1985, J BIOL CHEM, V260, P3190; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; DAVIES CJ, 1990, NATURE, V345, P298, DOI 10.1038/345298a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERICSSON C, 1990, CELL, V60, P73, DOI 10.1016/0092-8674(90)90717-S; FALVEY E, 1991, FASEB J, V5, P9; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; FIRE A, 1984, J BIOL CHEM, V259, P2509; FLORES O, 1989, J BIOL CHEM, V264, P8913; FLORES O, 1990, J BIOL CHEM, V265, P5629; GARIGLIO P, 1981, NUCLEIC ACIDS RES, V9, P2589, DOI 10.1093/nar/9.11.2589; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HIRAI H, 1988, FEBS LETT, V238, P119, DOI 10.1016/0014-5793(88)80239-4; HUBERT JC, 1983, EMBO J, V2, P2071, DOI 10.1002/j.1460-2075.1983.tb01702.x; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KANAI A, 1991, J BIOCHEM-TOKYO, V109, P674, DOI 10.1093/oxfordjournals.jbchem.a123439; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; LASPIA MF, 1990, GENE DEV, V4, P2397, DOI 10.1101/gad.4.12b.2397; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; MADERIOUS A, 1984, P NATL ACAD SCI-BIOL, V81, P5931, DOI 10.1073/pnas.81.19.5931; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MARSHALL TK, 1990, NUCLEIC ACIDS RES, V18, P6293, DOI 10.1093/nar/18.21.6293; MASON SW, 1991, GENE DEV, V5, P1504, DOI 10.1101/gad.5.8.1504; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; PEDERSON DS, 1990, EMBO J, V9, P1873, DOI 10.1002/j.1460-2075.1990.tb08313.x; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; PRICE DH, 1987, J BIOL CHEM, V262, P3244; RAPPAPORT J, 1987, J BIOL CHEM, V262, P5227; RATNASABAPATHY R, 1990, GENE DEV, V4, P2061, DOI 10.1101/gad.4.12a.2061; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINBERG D, 1987, J BIOL CHEM, V262, P3322; REINES D, 1989, J BIOL CHEM, V264, P10799; ROBERTS JW, 1988, CELL, V52, P5, DOI 10.1016/0092-8674(88)90523-5; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SEKIMIZU K, 1979, BIOCHEMISTRY-US, V18, P1582, DOI 10.1021/bi00575a031; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; SOPTA M, 1985, J BIOL CHEM, V260, P353; SPENCER CA, 1990, ONCOGENE, V5, P777; TURNER BM, 1991, J CELL SCI, V99, P13; UCKER DS, 1984, J BIOL CHEM, V259, P7416; WHALEN W, 1988, P NATL ACAD SCI USA, V85, P2494, DOI 10.1073/pnas.85.8.2494; WOLFFE AP, 1989, P NATL ACAD SCI USA, V86, P9817, DOI 10.1073/pnas.86.24.9817	52	193	199	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13647	13655						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618865				2022-12-25	WOS:A1992JB74600087
J	MELAUGH, W; PHILLIPS, NJ; CAMPAGNARI, AA; KARALUS, R; GIBSON, BW				MELAUGH, W; PHILLIPS, NJ; CAMPAGNARI, AA; KARALUS, R; GIBSON, BW			PARTIAL CHARACTERIZATION OF THE MAJOR LIPOOLIGOSACCHARIDE FROM A STRAIN OF HAEMOPHILUS-DUCREYI, THE CAUSATIVE AGENT OF CHANCROID, A GENITAL ULCER DISEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOPHILUS-DUCREYI; NEISSERIA-GONORRHOEAE; NAIROBI PROSTITUTES; LIPOPOLYSACCHARIDE; INFLUENZAE; VIRULENCE; OUTBREAK; VIRUS	The first preliminary structure of a surface lipooligosaccharide from Haemophilus ducreyi has been determined. The major oligosaccharide was released by mild acid hydrolysis and analyzed by liquid secondary ion and tandem mass spectrometry. The mass spectral data combined with composition and methylation analysis yielded the most probable structure; Gal1-->4GlcNAc1-->3Gal1-->4Hep1-->6Glc1-->(Hep1-->2Hep1 -->)3,4Hep1-->KDO, where the reducing terminal 3-deoxy-D-manno-octulosonic acid (or KDO) exists in an anhydro form. This anhydro species results from the elimination of a phosphate from C-4 of KDO during mild acid hydrolysis. The core heptose trisaccharide consists of L-glycero-D-manno-heptose, but analysis of the peracetylated sugars indicated that the 1,4-linked heptose is likely D-glycero-D-manno-heptose. The monoclonal antibody 3F11 generated against Neisseria gonorrhoeae also binds to this lipooligosaccharide and suggests that the terminal trisaccharide is Gal-beta-1-->4GlcNAc-beta-1-->3Gal-beta-1-->, an epitope found in the glycose moiety of the human erythrocyte glycosphingolipid lactoneotetraglycosylceramide. Mass spectrometric and composition analysis of the lipid A moiety shows that it is similar to the lipid A of Haemophilus influenzae strain I-69 Rd-/b+ proposed by Helander et al. (Helander, I. M., Lindner, B., Brade, H., Altmann, K., Lindberg, A. A., Rietschel, E. T., and Zahringer, U. (1988) Eur. J. Biochem. 177, 483-492). Electrospray mass spectrometric analysis of the intact O-deacylated lipooligosaccharides gave an average M(r) of 2710, and supported an overall structure consisting of the above nonasaccharide linked directly to a diphosphorylated lipid A moiety through the single KDO which is phosphorylated. This structure should provide a framework to investigate the roles of lipooligosaccharides in the host immunochemical response and pathology of H. ducreyi infection, a leading cause of genital ulcer disease.	UNIV CALIF SAN FRANCISCO, SCH PHARM 9265, DEPT PHARMACEUT CHEM, 513 PARNASSUS AVE, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CTR IMMUNOCHEM, SAN FRANCISCO, CA 94143 USA; SUNY BUFFALO, INST INFECT DIS, BUFFALO, NY 14260 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024616, R01AI030006, R01AI021620, R01AI024616] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 30006, AI 24616, AI 21620] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABECK D, 1987, FEMS MICROBIOL LETT, V42, P159; BATLEY M, 1985, BIOCHIM BIOPHYS ACTA, V821, P205, DOI 10.1016/0005-2736(85)90089-6; BLACKMORE CA, 1985, J INFECT DIS, V151, P840, DOI 10.1093/infdis/151.5.840; CAMPAGNARI AA, 1990, MICROB PATHOGENESIS, V8, P353, DOI 10.1016/0882-4010(90)90094-7; CAMPAGNARI AA, 1991, INFECT IMMUN, V59, P2601, DOI 10.1128/IAI.59.8.2601-2608.1991; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; FALICK AM, 1986, ANAL CHEM, V58, P1308, DOI 10.1021/ac00298a009; GALANOS C, 1977, INT REV BIOCH BIOCH, V14, P239; GREGG CR, 1981, J INFECT DIS, V143, P432, DOI 10.1093/infdis/143.3.432; HAMMOND GW, 1980, REV INFECT DIS, V2, P867; HELANDER IM, 1988, EUR J BIOCHEM, V177, P483, DOI 10.1111/j.1432-1033.1988.tb14398.x; JOHN CM, 1991, J BIOL CHEM, V266, P19303; JOHN CM, 1990, ANAL BIOCHEM, V187, P281, DOI 10.1016/0003-2697(90)90458-L; JOHNSON RS, 1990, J BIOL CHEM, V265, P8108; KREISS JK, 1989, J INFECT DIS, V160, P380, DOI 10.1093/infdis/160.3.380; KREISS JK, 1986, NEW ENGL J MED, V314, P414, DOI 10.1056/NEJM198602133140704; KUBUKAMUSOKE JW, 1965, T R SOC TROP MED HYG, V59, P642; LEVERY SB, 1987, METHOD ENZYMOL, V138, P13, DOI 10.1016/0076-6879(87)38004-8; MAMMOND GW, 1978, ANTIMICROB AGENTS CH, V13, P608; MANDRELL RE, 1988, J EXP MED, V168, P107, DOI 10.1084/jem.168.1.107; MORSE SA, 1989, CLIN MICROBIOL REV, V2, P137, DOI 10.1128/CMR.2.2.137-157.1989; ODUMERU JA, 1984, INFECT IMMUN, V43, P607, DOI 10.1128/IAI.43.2.607-611.1984; ODUMERU JA, 1987, J MED MICROBIOL, V23, P155, DOI 10.1099/00222615-23-2-155; PHILLIPS NJ, 1990, BIOMED ENVIRON MASS, V19, P731, DOI 10.1002/bms.1200191112; PHILLIPS NJ, 1992, BIOCHEMISTRY-US, V31, P4515, DOI 10.1021/bi00133a019; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; RADZIEJEWSKALEBRECHT J, 1989, EUR J BIOCHEM, V183, P573, DOI 10.1111/j.1432-1033.1989.tb21086.x; RONALD AR, 1985, ANN INTERN MED, V102, P705, DOI 10.7326/0003-4819-102-5-705; SCHMID GP, 1987, JAMA-J AM MED ASSOC, V258, P3265, DOI 10.1001/jama.258.22.3265; TUFFREY M, 1990, J EXP PATHOL, V71, P233; WALLS FC, 1990, BIOLOGICAL MASS SPECTROMETRY /, P197; Westphal O., 1965, METHODS CARBOHYDRATE, V5, P83, DOI DOI 10.1016/J.WATRES.2010.04.030	32	59	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13434	13439						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618845				2022-12-25	WOS:A1992JB74600054
J	WINSTON, JH; HANTEN, GR; OVERBEEK, PA; KELLEMS, RE				WINSTON, JH; HANTEN, GR; OVERBEEK, PA; KELLEMS, RE			5' FLANKING SEQUENCES OF THE MURINE ADENOSINE-DEAMINASE GENE DIRECT EXPRESSION OF A REPORTER GENE TO SPECIFIC PRENATAL AND POSTNATAL TISSUES IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC EXPRESSION; ACID-BINDING-PROTEIN; HORMONE FUSION GENES; ALPHA-SUBUNIT GENE; KERATIN GENE; DEVELOPMENTAL EXPRESSION; TRANSCRIPTIONAL ENHANCER; GROWTH-FACTOR; IDENTIFICATION; PLACENTA	Adenosine deaminase (ADA), an enzyme of purine metabolism, is highly expressed in four tissues of the mouse: the maternal decidua, the fetal placenta, the keratinizing epithelium of the upper alimentary tract (tongue, esophagus, and forestomach), and the absorptive epithelium of the proximal small intestine. ADA is produced at relatively low levels in all other tissues. To identify genetic elements that direct appropriate prenatal and postnatal expression of the ADA gene, a segment of DNA including the ADA promoter and 6.4 kilobases of the adjacent 5' flanking region was tested for the ability to direct the expression of a reporter gene in transgenic mice. In seven lines of transgenic mice studied, this construct directed high levels of reporter gene expression in the placenta and forestomach and exhibited correct developmental regulation in these tissues. This construct failed to direct significant reporter gene expression to either the maternal decidua or the proximal small intestine. Thus, different gene regulatory elements are required to target high expression to the four tissues characterized by high levels of ADA.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	WINSTON, JH (corresponding author), BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030, USA.			Overbeek, Paul/0000-0001-9784-2084	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030204] Funding Source: NIH RePORTER; NICHD NIH HHS [HD24064] Funding Source: Medline; NIDDK NIH HHS [DK46207] Funding Source: Medline; NIGMS NIH HHS [GM30204] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal R P, 1978, Methods Enzymol, V51, P502; ALUBAIDI MR, 1989, GENOMICS, V7, P476; ANDERSEN B, 1990, J BIOL CHEM, V265, P21874; ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; BLESSING M, 1989, EMBO J, V8, P117, DOI 10.1002/j.1460-2075.1989.tb03355.x; BOEHM KD, 1989, P NATL ACAD SCI USA, V86, P656, DOI 10.1073/pnas.86.2.656; BOKAR JA, 1989, MOL CELL BIOL, V9, P5113, DOI 10.1128/MCB.9.11.5113; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEGINI N, 1985, J CLIN ENDOCR METAB, V61, P529, DOI 10.1210/jcem-61-3-529; CHEN Z, 1990, MOL CELL BIOL, V10, P4555, DOI 10.1128/MCB.10.9.4555; CHIN MT, 1989, J VIROL, V63, P2967, DOI 10.1128/JVI.63.7.2967-2976.1989; CHINSKY JM, 1990, DIFFERENTIATION, V42, P172, DOI 10.1111/j.1432-0436.1990.tb00759.x; CHINSKY JM, 1989, J BIOL CHEM, V264, P14561; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DE SK, 1989, DEVELOPMENT, V107, P611; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HIROCHIKA H, 1988, GENE DEV, V2, P54, DOI 10.1101/gad.2.1.54; HONG L, 1991, BIOL REPROD, V44, P83, DOI 10.1095/biolreprod44.1.83; INNIS JW, 1991, J BIOL CHEM, V266, P21765; JIANG CK, 1990, NUCLEIC ACIDS RES, V18, P247, DOI 10.1093/nar/18.2.247; KNUDSEN TB, 1991, BIOL REPROD, V44, P171, DOI 10.1095/biolreprod44.1.171; KNUDSEN TB, 1992, TERATOLOGY, V45, P91, DOI 10.1002/tera.1420450109; KNUDSEN TB, 1989, TERATOLOGY, V40, P615, DOI 10.1002/tera.1420400609; KNUDSEN TB, 1988, BIOL REPROD, V39, P937, DOI 10.1095/biolreprod39.4.937; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; PALMITER RD, 1982, CELL, V29, P701, DOI 10.1016/0092-8674(82)90186-6; PLOUZEK CA, 1991, BIOCHEM BIOPH RES CO, V176, P1532, DOI 10.1016/0006-291X(91)90461-F; POLLARD JW, 1987, NATURE, V330, P484, DOI 10.1038/330484a0; RAMAMURTHY V, 1990, MOL CELL BIOL, V10, P1484, DOI 10.1128/MCB.10.4.1484; RAUTH S, 1990, SOMAT CELL MOLEC GEN, V16, P129, DOI 10.1007/BF01233043; SAJI F, 1990, AM J REPROD IMMUNOL, V24, P99, DOI 10.1111/j.1600-0897.1990.tb01046.x; Sambrook J, 1989, MOL CLONING LABORATO; SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318; SWEETSER DA, 1988, P NATL ACAD SCI USA, V85, P9611, DOI 10.1073/pnas.85.24.9611; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; VALERIO D, 1988, NUCLEIC ACIDS RES, V16, P10083, DOI 10.1093/nar/16.21.10083; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WALKER WH, 1990, J BIOL CHEM, V265, P12940	40	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13472	13479						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618849				2022-12-25	WOS:A1992JB74600061
J	CARTIER, N; MIQUEROL, L; TULLIEZ, M; LEPETIT, N; LEVRAT, F; GRIMBER, G; BRIAND, P; KAHN, A				CARTIER, N; MIQUEROL, L; TULLIEZ, M; LEPETIT, N; LEVRAT, F; GRIMBER, G; BRIAND, P; KAHN, A			DIET-DEPENDENT CARCINOGENESIS OF PANCREATIC-ISLETS AND LIVER IN TRANSGENIC MICE EXPRESSING ONCOGENES UNDER THE CONTROL OF THE L-TYPE PYRUVATE-KINASE GENE PROMOTER	ONCOGENE			English	Article							C-MYC GENE; HORMONAL-REGULATION; ACINAR-CELLS; RAT; NEOPLASIA; ISOZYMES; TUMORS; TRANSCRIPTION	The liver-type pyruvate kinase (L-PK) gene is controlled positively by insulin and carbohydrates, negatively by glucagon and fasting. Diet-inducible models of carcinogenesis were obtained using the L-PK gene promoter and regulatory sequences to control the expression of c-myc and SV40 T oncogenes in transgenic mice. L-PK/c-myc and L-PK/Tag animals fed a carbohydrate-rich diet developed hepatocarcinomas. In addition, L-PK/Tag animals developed diet-dependent, aggressive endocrine pancreatic tumors, preceded by islet hyperplasia involving the different analysed cell populations (alpha, beta and delta). Expression of the L-PK gene was demonstrated in pancreatic tumors, in rat isolated islets and in rat insulinoma-derived cells (RIN line), revealing a new tissue specificity of the L-PK gene. Our results suggest that this gene may be expressed in islet progenitor cells from which the different mature endocrine cells derive.	HOP COCHIN,ANAT PATHOL LAB,F-75674 PARIS 14,FRANCE; HOP ST VINCENT DE PAUL,INSERM,U342,F-75674 PARIS 14,FRANCE; INSERM,INST COCHIN GENET MOLEC GENET & PATHOL EXPTL,F-75014 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	CARTIER, N (corresponding author), INSERM,INST COCHIN GENET MOLEC GENET & PATHOL MOLEC,U129,F-75014 PARIS,FRANCE.		cartier, nathalie/C-3103-2012	cartier, nathalie/0000-0003-2298-5261				AKLI S, 1991, GENOMICS, V11, P124, DOI 10.1016/0888-7543(91)90109-R; ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; CECI JD, 1991, ONCOGENE, V6, P323; CHATTERTON TA, 1982, BIOCHEM J, V204, P605, DOI 10.1042/bj2040605; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIMBALA MA, 1984, MOL BASIS INSULIN AC; COGNET M, 1987, J MOL BIOL, V196, P11, DOI 10.1016/0022-2836(87)90507-9; COGNET M, 1991, J BIOL CHEM, V266, P7368; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; Denton R M, 1979, Essays Biochem, V15, P37; DUBOIS N, 1991, J HEPATOL, V13, P227, DOI 10.1016/0168-8278(91)90819-W; DYER KR, 1989, AM J PATHOL, V135, P401; EFRAT S, 1990, MOL CELL BIOL, V10, P1779, DOI 10.1128/MCB.10.4.1779; FONTAINE J, 1977, J EMBRYOL EXP MORPH, V41, P209; GAZDAR AF, 1980, P NATL ACAD SCI-BIOL, V77, P3519, DOI 10.1073/pnas.77.6.3519; HALL ER, 1978, INT J BIOCHEM, V9, P785, DOI 10.1016/0020-711X(78)90027-7; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HOGAN B, 1986, MANIPULATING MOUSE E; IMAMURA K, 1982, METHOD ENZYMOL, V90, P150; KAHN A, 1982, METHOD ENZYMOL, V90, P131; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LEDOUARIN NM, 1988, CELL, V53, P169, DOI 10.1016/0092-8674(88)90375-3; MACDONALD MJ, 1985, MOL CELL BIOCHEM, V68, P115; Maniatis T., 1982, MOL CLONING; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MONTARRAS D, 1991, NEW BIOL, V3, P592; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; ORCI L, 1982, DIABETES, V31, P538, DOI 10.2337/diab.31.6.538; ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; RINDI G, 1990, AM J PATHOL, V136, P1349; SANDGREN EP, 1989, ONCOGENE, V4, P715; SANDGREN EP, 1991, P NATL ACAD SCI USA, V88, P93, DOI 10.1073/pnas.88.1.93; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; SEPULVEDA AR, 1989, CANCER RES, V49, P6108; SOUTHERN EM, 1975, J MOL BIOL, V98, P505; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TREMP GL, 1989, J BIOL CHEM, V264, P19904; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VAULONT S, 1986, J BIOL CHEM, V261, P7621; VAULONT S, 1989, MOL CELL BIOL, V9, P4409, DOI 10.1128/MCB.9.10.4409	48	57	58	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1413	1422						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620553				2022-12-25	WOS:A1992HZ97100021
J	BOHELER, KR; CHASSAGNE, C; MARTIN, X; WISNEWSKY, C; SCHWARTZ, K				BOHELER, KR; CHASSAGNE, C; MARTIN, X; WISNEWSKY, C; SCHWARTZ, K			CARDIAC EXPRESSIONS OF ALPHA-MYOSIN AND BETA-MYOSIN HEAVY-CHAINS AND SARCOMERIC ALPHA-ACTINS ARE REGULATED THROUGH TRANSCRIPTIONAL MECHANISMS - RESULTS FROM NUCLEAR RUN-ON ASSAYS IN ISOLATED RAT CARDIAC NUCLEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOCARDIAL-CELL NUCLEI; MESSENGER-RNA LEVELS; SKELETAL-MUSCLE; THYROID-HORMONE; BINDING-FACTOR; HEART; GENE; HYPERTROPHY; RABBIT; DIFFERENTIATION	In the heart, mRNA accumulations for sarcomeric actins and myosin heavy chains (MHC) are subject to diverse regulatorial processes. To study cardiac contractile protein transcriptional regulations, an in vitro transcription system using nonenzymatically isolated rat cardiac nuclei was characterized. Transcription was shown to be rapid and continuous during the first 20 min of incubation and 5.4-fold less than that seen from comparably isolated hepatocyte nuclei. Neither RNase nor DNase activities were detectable. Direct transcriptional analyses of the alpha- and beta-MHC and cardiac and skeletal alpha-actin genes from cardiac nuclei were performed. In 23-24-day-old rats, significant levels of transcription were seen for alpha-MHC and for the sarcomeric alpha-actins. Beta-MHC was just detectable, and no positive signals were ever seen for fibronectin. We then compared the percentages of MHC and sarcomeric alpha-actin expressions determined from 1) the transcriptional assays and 2) total isolated RNA (alpha-MHC: 90.1 +/- 4.8% (transcription), 93.0 +/- 4.7% (accumulation); beta-MHC: 9.9 +/- 4.8%, 7.0 +/- 4.7%; cardiac alpha-actin: 84.0 +/- 2.5%, 84.9 +/- 2.5%; skeletal alpha-actin: 16.1 +/- 2.5%. 15.0 +/- 2.5%). The results support the conclusion that the primary mechanisms controlling the accumulations of these gene products are transcriptional. Additionally, we show that an anti-sense mRNA showing strong homology or identity with the 5' end of the beta-MHC gene is transcribed in cardiac nuclei but not in hepatocyte nuclei.			BOHELER, KR (corresponding author), HOP LARIBOISIERE, INSERM, U127, 41 BLVD CHAPELLE, F-75475 PARIS 10, FRANCE.							ALPERT NR, 1982, CIRC RES, V50, P491, DOI 10.1161/01.RES.50.4.491; BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; BENNETTS BH, 1986, J MOL CELL CARDIOL, V18, P993, DOI 10.1016/S0022-2828(86)80013-X; BISHOPRIC NH, 1987, J CLIN INVEST, V80, P1194, DOI 10.1172/JCI113179; BISHOPRIC NH, 1991, P NATL ACAD SCI USA, V88, P2132, DOI 10.1073/pnas.88.6.2132; BOHELER KR, 1991, J CLIN INVEST, V88, P323, DOI 10.1172/JCI115295; BOHELER KR, 1991, MOL CELL BIOCHEM, V104, P101, DOI 10.1007/BF00229809; BOHELER KR, 1988, THESIS U CALIF, P94; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; BOXER LM, 1989, J BIOL CHEM, V264, P1284; BUCKINGHAM ME, 1985, ESSAYS BIOCHEM, V20, P77; CARRIER L, 1992, IN PRESS CIRC RES; CHASSAGNE C, 1991, CR ACAD SCI III-VIE, V312, P7; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COX RD, 1991, DEV BIOL, V143, P36, DOI 10.1016/0012-1606(91)90052-5; COX RD, 1990, DIFFERENTIATION, V43, P183, DOI 10.1111/j.1432-0436.1990.tb00445.x; EFFRON MB, 1987, CIRC RES, V60, P238, DOI 10.1161/01.RES.60.2.238; EVERETT AW, 1984, BIOCHEMISTRY-US, V23, P1596, DOI 10.1021/bi00303a002; GREEN PJ, 1986, ANNU REV BIOCHEM, V55, P569, DOI 10.1146/annurev.bi.55.070186.003033; GUNNING P, 1983, MOL CELL BIOL, V3, P1985, DOI 10.1128/MCB.3.11.1985; GUSTAFSON TA, 1988, MOL CELL BIOL, V8, P4110, DOI 10.1128/MCB.8.10.4110; HOH JFY, 1978, J MOL CELL CARDIOL, V10, P1053, DOI 10.1016/0022-2828(78)90401-7; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; IZUMO S, 1987, J CLIN INVEST, V79, P970, DOI 10.1172/JCI112908; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KONIECZNY SF, 1985, MOL CELL BIOL, V5, P2423, DOI 10.1128/MCB.5.9.2423; LEE HR, 1988, J BIOL CHEM, V263, P7352; LIEW CCG, 1983, AM J PHYSIOL, V244, pC3, DOI 10.1152/ajpcell.1983.244.1.C3; LOMPRE AM, 1991, INT REV CYTOL, V124, P137; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; LONG CS, 1989, J CLIN INVEST, V83, P1078, DOI 10.1172/JCI113951; MAHDAVI V, 1991, J CELL BIOCHEM     S, V15, P151; MAHDAVI V, 1989, CELLULAR MOL BIOL MU, P369; MANIATIS T, 1982, MOL CLONING LABORATO, P363; MARINO TA, 1991, CIRC RES, V69, P1353, DOI 10.1161/01.RES.69.5.1353; Marzluff W. F., 1984, TRANSCRIPTION TRANSL, P89; MAYER Y, 1984, NUCLEIC ACIDS RES, V12, P1087, DOI 10.1093/nar/12.2.1087; MCCULLY JD, 1988, BIOCHEM J, V256, P441, DOI 10.1042/bj2560441; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MINTY AJ, 1982, CELL, V30, P185, DOI 10.1016/0092-8674(82)90024-1; MIWA T, 1987, P NATL ACAD SCI USA, V84, P6702, DOI 10.1073/pnas.84.19.6702; NADALGINARD B, 1989, J CLIN INVEST, V84, P1693, DOI 10.1172/JCI114351; NAGAI R, 1987, CIRC RES, V60, P692, DOI 10.1161/01.RES.60.5.692; NG WA, 1991, CIRC RES, V68, P1742, DOI 10.1161/01.RES.68.6.1742; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SCHIAFFINO S, 1989, CIRC RES, V64, P937, DOI 10.1161/01.RES.64.5.937; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; SIMPSON PC, 1989, J MOL CELL CARDIOL, V21, P79, DOI 10.1016/0022-2828(89)90774-8; VANDEKERCKHOVE J, 1986, J BIOL CHEM, V261, P1838; WASPE LE, 1990, J CLIN INVEST, V85, P1206, DOI 10.1172/JCI114554; WINEGRAD S, 1990, P NATL ACAD SCI USA, V87, P2456, DOI 10.1073/pnas.87.7.2456; ZAKUT R, 1982, NATURE, V298, P857, DOI 10.1038/298857a0	53	102	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12979	12985						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618795				2022-12-25	WOS:A1992HZ48300087
J	BROWN, ED; WOOD, JM				BROWN, ED; WOOD, JM			REDESIGNED PURIFICATION YIELDS A FULLY FUNCTIONAL PUTA PROTEIN DIMER FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE DEHYDROGENASE; SALMONELLA-TYPHIMURIUM; MEMBRANE ASSOCIATION; MOLECULAR-WEIGHT; PRODUCT; ENZYME; SIZE; ACID	Proline utilization by Escherichia coli and Salmonella typhimurium requires expression of genes putP (encoding a proline transporter) and putA. Genetic data indicate that the PutA protein is both put repressor and a respiratory chain-linked dehydrogenase. We report a redesigned purification procedure as well as the physical characteristics and biological activities of the PutA protein purified from E. coli. The purified protein was homogeneous as determined by electrophoresis performed under denaturing and nondenaturing conditions. Its N-terminal sequence corresponded to that predicted by the DNA sequence. We showed copurification of proline and DELTA-1-pyrroline-5-carboxylate dehydrogenase activities. Purified PutA protein bound put DNA in vitro in an electrophoretic band-shift assay and it could be reconstituted to inverted membrane vesicles, yielding proline dehydrogenase activity. The Stokes radius and Svedberg coefficient of the protein were determined to be 7.1 nm and 9.9 S, respectively. These hydrodynamic data revealed that the protein in our preparation was dimeric with a molecular mass of 293 kDa and that it had an irregular shape indicated by the friction factor (f/f0) of 1.6.	UNIV GUELPH, GUELPH WATERLOO CTR GRAD WORK CHEM, DEPT MICROBIOL, GUELPH N1G 2W1, ONTARIO, CANADA	University of Guelph; University of Waterloo; Guelph-Waterloo Centre for Graduate Work in Chemistry & Biochemistry								ABRAHAMSON JLA, 1983, EUR J BIOCHEM, V134, P77, DOI 10.1111/j.1432-1033.1983.tb07533.x; Andrews P, 1970, Methods Biochem Anal, V18, P1, DOI 10.1002/9780470110362.ch1; BADING H, 1988, NUCLEIC ACIDS RES, V16, P5241, DOI 10.1093/nar/16.12.5241; BERNLOHR DA, 1981, BIOCHEMISTRY-US, V20, P5675, DOI 10.1021/bi00523a006; Cantor C.R., 1980, BIOPHYSICAL CHEM PAR, P584; DENDINGER S, 1970, J BACTERIOL, V103, P144, DOI 10.1128/JB.103.1.144-152.1970; DESPICER PO, 1991, J BACTEIOL, V1730, P2114; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GARFIN DE, 1990, METHOD ENZYMOL, V182, P425; GRAHAM SB, 1984, J BIOL CHEM, V259, P2656; HALLETT FR, 1989, CAN J SPECTROSC, V34, P63; HENDRICKSON W, 1985, Biotechniques, V3, P198; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; KEESEY J, 1987, BIOCH INFORMATION, P106; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAIRE M, 1986, ANAL BIOCHEM, V154, P525, DOI 10.1016/0003-2697(86)90025-4; LI PM, 1991, P NATL ACAD SCI USA, V88, P9210, DOI 10.1073/pnas.88.20.9210; MALOY SR, 1987, ESCHERICHIA COLI SAL, V1, P1513; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MEILE L, 1982, EUR J BIOCHEM, V129, P67, DOI 10.1111/j.1432-1033.1982.tb07021.x; MENZEL R, 1981, J BIOL CHEM, V256, P9755; MENZEL R, 1981, J MOL BIOL, V148, P21, DOI 10.1016/0022-2836(81)90233-3; MENZEL R, 1981, J BIOL CHEM, V256, P9762; MEZL VA, 1976, ANAL BIOCHEM, V74, P430, DOI 10.1016/0003-2697(76)90223-2; MITCHELL DR, 1988, THESIS U GUELPH ONTA; MIXSON AJ, 1988, J BIOL CHEM, V263, P10720; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; ROBBINS AH, 1989, P NATL ACAD SCI USA, V86, P3639, DOI 10.1073/pnas.86.10.3639; SCARPULLA RC, 1978, J BIOL CHEM, V253, P5997; SCHACHMAN HK, 1957, METHOD ENZYMOL, V4, P32, DOI 10.1016/0076-6879(57)04050-1; SCHEIBE R, 1987, PHYSIOL PLANTARUM, V71, P393, DOI 10.1111/j.1399-3054.1987.tb04362.x; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STRECKER HJ, 1957, J BIOL CHEM, V225, P825; WILLIAMS FR, 1966, ARCH BIOCHEM BIOPHYS, V116, P168, DOI 10.1016/0003-9861(66)90025-7; WOOD JM, 1981, J BACTERIOL, V146, P895, DOI 10.1128/JB.146.3.895-901.1981; WOOD JM, 1979, CAN J BIOCHEM CELL B, V57, P1191, DOI 10.1139/o79-155; WOOD JM, 1987, P NATL ACAD SCI USA, V84, P373, DOI 10.1073/pnas.84.2.373	38	72	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					13086	13092						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618807				2022-12-25	WOS:A1992HZ48300101
J	TEASDALE, RD				TEASDALE, RD			CORRECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Correction, Addition														Gleeson, Paul/0000-0002-5336-6503				TEASDALE RD, 1992, J BIOL CHEM, V267, P4084	1	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					13113	13113						1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618810				2022-12-25	WOS:A1992HZ48300105
J	YOUNG, WW; LUTZ, MS; BLACKBURN, WA				YOUNG, WW; LUTZ, MS; BLACKBURN, WA			ENDOGENOUS GLYCOSPHINGOLIPIDS MOVE TO THE CELL-SURFACE AT A RATE CONSISTENT WITH BULK FLOW ESTIMATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI VESICLE MEMBRANES; ENDOPLASMIC-RETICULUM; MUTANT DEFICIENT; PLASMA-MEMBRANE; SIALIC-ACID; BREFELDIN-A; TRANSPORT; PROTEIN; GANGLIOSIDES; TRANSLOCATION	The bulk flow model of intracellular trafficking predicts that forward transport from the ER through the Golgi to the plasma membrane proceeds by default without a special signal being required (Wieland, F. T., Gleason, M. L., Serafini, T. A., and Rothman, J. E. (1987) Cell 50, 289-300). We tested a crucial prediction of this model, which is that the endogenous lipid components of the transport vesicles would reach the plasma membrane at the rapid rate of bulk flow. The rate at which endogenous glycosphingolipids moved from the ER through the Golgi to the plasma membrane was determined in Chinese hamster ovary cells using metabolic labeling with tritiated palmitate and oxidation of cell surface ganglioside NeuAc-alpha-2 --> 3Gal-beta-1 --> 4Glc-beta-1 --> 4Cer (G(M3)) With periodate. Whereas radioactive precursor became incorporated into ceramide and glucosyl ceramide without a detectable lag, synthesis of labeled lactosyl ceramide and ganglioside G(M3) did not begin until 5-6 min and 11-12 min, respectively, after addition of labeled precursor. Labeled G(M3) reached the plasma membrane 5-6 min following its synthesis. Overall, approximately 18 min transpired from the time that the ceramide precursor was synthesized in the ER until labeled G(M3) reached the plasma membrane. These results indicate that lipid transport vesicles move rapidly to the plasma membrane at a rate consistent with bulk flow estimates.	UNIV LOUISVILLE, HLTH SCI CTR, DEPT BIOCHEM, LOUISVILLE, KY 40292 USA	University of Louisville	YOUNG, WW (corresponding author), UNIV LOUISVILLE, HLTH SCI CTR, DEPT BIOL & BIOPHYS SCI, LOUISVILLE, KY 40292 USA.				NIGMS NIH HHS [GM42698] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRILES EB, 1977, J BIOL CHEM, V252, P1107; COSTE H, 1985, BIOCHIM BIOPHYS ACTA, V814, P1, DOI 10.1016/0005-2736(85)90412-2; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; FANGER BO, 1987, ANAL BIOCHEM, V162, P11, DOI 10.1016/0003-2697(87)90004-2; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; KARRENBAUER A, 1990, CELL, V63, P259, DOI 10.1016/0092-8674(90)90159-C; LODISH HF, 1988, J BIOL CHEM, V263, P2107; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; MILLERPODRAZA H, 1982, BIOCHEMISTRY-US, V21, P3265, DOI 10.1021/bi00257a003; MIYAZAKI K, 1986, BIOCHEM J, V235, P755, DOI 10.1042/bj2350755; PAGANO RE, 1988, TRENDS BIOCHEM SCI, V13, P202, DOI 10.1016/0968-0004(88)90082-5; PUOTI A, 1991, J CELL BIOL, V113, P515, DOI 10.1083/jcb.113.3.515; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; SAITO T, 1971, J LIPID RES, V12, P257; SASAKI T, 1990, EXPERIENTIA, V46, P611, DOI 10.1007/BF01939700; SCHWARZMANN G, 1990, BIOCHEMISTRY-US, V29, P10865, DOI 10.1021/bi00501a001; SONNINO S, 1986, CHEM PHYS LIPIDS, V42, P3, DOI 10.1016/0009-3084(86)90040-X; STANLEY P, 1980, ACS SYM SER, V128, P213; STROUS JAM, 1980, CELL, V22, P709, DOI 10.1016/0092-8674(80)90547-4; TANAKA T, 1988, CHEM PHYS LIPIDS, V48, P261, DOI 10.1016/0009-3084(88)90096-5; TRINCHERA M, 1989, J BIOL CHEM, V264, P15766; TRINCHERA M, 1991, J BIOL CHEM, V266, P20907; TRINCHERA M, 1991, BIOCHEMISTRY-US, V30, P2719, DOI 10.1021/bi00224a021; URBANI L, 1990, J BIOL CHEM, V265, P1919; USUKI S, 1988, J BIOL CHEM, V263, P6847; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; VOELKER DR, 1990, EXPERIENTIA, V46, P569, DOI 10.1007/BF01939695; WALTER VP, 1983, BIOCHIM BIOPHYS ACTA, V750, P346, DOI 10.1016/0005-2760(83)90039-5; WATTENBERG BW, 1990, J CELL BIOL, V111, P421, DOI 10.1083/jcb.111.2.421; WELLS MA, 1963, BIOCHEMISTRY-US, V2, P1259, DOI 10.1021/bi00906a015; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; YEO KT, 1985, J BIOL CHEM, V260, P7896; YOGEESWARAN G, 1974, BIOCHEM BIOPH RES CO, V56, P1010, DOI 10.1016/S0006-291X(74)80289-5; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838; YOUNG WW, 1986, J BIOL CHEM, V261, P2279; YU RK, 1972, J LIPID RES, V13, P680	38	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12011	12015						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601871				2022-12-25	WOS:A1992HY94700056
J	BASS, KE; SOMMER, JM; CHENG, QL; WANG, CC				BASS, KE; SOMMER, JM; CHENG, QL; WANG, CC			MOUSE ORNITHINE DECARBOXYLASE IS STABLE IN TRYPANOSOMA-BRUCEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR DEGRADATION; ENZYME; EXPRESSION; PROTOZOAN; TURNOVER; TARGET; GENE	The cDNA encoding mouse ornithine decarboxylase (ODC) was incorporated into a transforming vector pTSA-NEO2 carrying a procyclic acidic repetitive protein promoter and a neomycin phosphotransferase gene. The plasmid thus constructed, pMOD300, was introduced into the procyclic forms of Trypanosoma brucei via electroporation, and the transformants, selected under G418, expressed an ODC activity 100 times above the background level. Contrary to the commonly observed short half-life of mouse ODC in mammalian cells, however, the mouse ODC activity expressed in T. brucei remained stable for at least 6 h when protein synthesis was inhibited by cycloheximide. Pulse labelings and chase experiments with the irreversible ODC inhibitor [3,4-H-3]difluoromethylornithine followed by gel electrophoresis, or with L-[S-35] methionine followed by immunoprecipitation and gel electrophoresis indicated that the stable mouse ODC expressed in T. brucei has the same subunit molecular weight as the native enzyme. By an in vitro assay of protein stability in rabbit reticulocyte lysates (Loetscher, P., Pratt, G., and Rechsteiner, M. (1991) J. Biol. Chem. 266, 11213-11220), the native mouse ODC and the enzyme expressed in T. brucei had the same degree of instability. Thus, the mouse ODC expressed in T. brucei is probably identical to the native mouse ODC. Its remarkable stability in T. brucei must be due to the absence in trypanosomes of the proteolytic machinery present in mammalian cells responsible for rapid degradation of mouse ODC.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,BOX 0446,S-926,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco								BACCHI CJ, 1980, SCIENCE, V210, P332, DOI 10.1126/science.6775372; BASS KE, 1991, MOL BIOCHEM PARASIT, V44, P261, DOI 10.1016/0166-6851(91)90012-U; BELLOFATTO V, 1989, SCIENCE, V244, P1167, DOI 10.1126/science.2499047; CLAYTON CE, 1990, MOL CELL BIOL, V10, P3036, DOI 10.1128/MCB.10.6.3036; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GHODA L, 1990, J BIOL CHEM, V265, P11823; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MGS, 1990, SCIENCE, V250, P1583, DOI 10.1126/science.2177225; LOETSCHER P, 1991, J BIOL CHEM, V266, P11213; MCCONLOGUE L, 1983, J BIOL CHEM, V258, P2083; PHILLIPS MA, 1987, J BIOL CHEM, V262, P8721; PHILLIPS MA, 1988, J BIOL CHEM, V263, P17933; ROGERS S, 1986, SCIENCE, V234, P334; SEELY JE, 1982, J BIOL CHEM, V257, P7549; SJOERDSMA A, 1984, MOL BIOCHEM PARASIT, V20, P165	16	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11034	11037						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597444				2022-12-25	WOS:A1992HX16900019
J	BLACKMORE, RS; GIBSON, QH; GREENWOOD, C				BLACKMORE, RS; GIBSON, QH; GREENWOOD, C			THE RELATION OF LIGAND-BINDING TO REDOX STATE IN THE HEXA-HEME NITRITE REDUCTASE OF WOLINELLA-SUCCINOGENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-DESULFURICANS; PURIFICATION; CYTOCHROME	Ligand binding reactions and the relation between redox state and ligand binding in the hexa-heme nitrite reductase of Wolinella succinogenes have been studied using laser flash photolysis. On a picosecond time scale, a rapid excursion was observed corresponding to the breaking and reforming of an iron histidine bond. With the CO derivative, a geminate reaction was observed with a rate of 3 ns-1. On a nanosecond time scale, no slower geminate reactions were observed. For the cyanide derivative, no geminate reactions were observed at either time scale. The second order reaction of CO with the enzyme had a time course consisting of two distinct components. This time course changed in form as the enzyme came to equilibrium with CO, and the slower rebinding component was replaced by a faster rebinding component. It is suggested that CO binding enhances reduction of a heme with an unusually low redox potential and opens the structure of the active site to allow a faster second order reaction of CO. The proportion of the geminate CO reaction was unchanged, consistent with changes relatively remote from the ligand binding site. The second order reactions of cyanide also showed that redox effects influence its rebinding reaction. Adding cyanide to the CO complex of nitrite reductase showed that the two ligands have distinct heme binding sites.	CORNELL UNIV,DEPT BIOCHEM MOLEC & CELL BIOL,ITHACA,NY 14853; UNIV E ANGLIA,SCH BIOL SCI,NORWICH NR4 7TJ,NORFOLK,ENGLAND	Cornell University; University of East Anglia					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM014276] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 14276] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBER D, 1978, BIOCHEM J, V175, P239, DOI 10.1042/bj1750239; BLACKMORE R, 1986, BIOCHEM J, V233, P553, DOI 10.1042/bj2330553; BLACKMORE R, 1986, BIOCHEM J, V233, P547, DOI 10.1042/bj2330547; BLACKMORE RS, 1987, FEBS LETT, V219, P244, DOI 10.1016/0014-5793(87)81225-5; BLACKMORE RS, 1990, BIOCHEM J, V271, P253, DOI 10.1042/bj2710253; BLACKMORE RS, 1990, FEBS LETT, V264, P257, DOI 10.1016/0014-5793(90)80262-H; BLACKMORE RS, 1988, THESIS U E ANGLIA; COSTA C, 1990, J BIOL CHEM, V265, P14382; JONGEWARD KA, 1988, J BIOL CHEM, V263, P6027; LIU MC, 1987, FEBS LETT, V218, P227, DOI 10.1016/0014-5793(87)81051-7; LIU MC, 1981, J BIOL CHEM, V256, P3159; LIU MC, 1988, ARCH BIOCHEM BIOPHYS, V262, P259, DOI 10.1016/0003-9861(88)90187-7; LIU MC, 1983, FEMS MICROBIOL LETT, V19, P201, DOI 10.1016/0378-1097(83)90060-5; MAYHEW SG, 1978, EUR J BIOCHEM, V85, P535, DOI 10.1111/j.1432-1033.1978.tb12269.x; REHR B, 1986, FEMS MICROBIOL LETT, V35, P325, DOI 10.1111/j.1574-6968.1986.tb01551.x	15	1	1	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					10950	10955						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597437				2022-12-25	WOS:A1992HX16900006
J	FESCE, R; BENFENATI, F; GREENGARD, P; VALTORTA, F				FESCE, R; BENFENATI, F; GREENGARD, P; VALTORTA, F			EFFECTS OF THE NEURONAL PHOSPHOPROTEIN SYNAPSIN-I ON ACTIN POLYMERIZATION .2. ANALYTICAL INTERPRETATION OF KINETIC CURVES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL SYNAPTIC VESICLES; F-ACTIN; BINDING; PROTEIN; NUCLEATION; ASSOCIATION; MECHANISM; FILAMENTS; MONOMER; SITES	The general features of the kinetics of actin polymerization are investigated by mathematical models, with the aim of identifying the kinetically relevant parameters in the process and detecting and interpreting the alterations occurring in actin polymerization under various experimental conditions. Polymerization curves, obtained by following the increase in fluorescence of actin derivatized with N-(1-pyrenyl) iodoacetamide, are fitted using analytical equations derived from biochemical models of the actin polymerization process. Particular attention is given to the evaluation of the effects of the neuronal phosphoprotein synapsin I. The models obtained under various ionic conditions reveal that synapsin I interacts with actin in a very complex fashion, sharing some of the properties of classical nucleating proteins but displaying also actions not described previously for other actin-binding proteins. Synapsin I appears to bind G-actin with a very high stoichiometry (1:2-4), and the complex behaves as an F-actin nucleus, producing actin filaments under conditions where spontaneous polymerization is negligible. These actions of synapsin I are markedly affected by site-specific phosphorylation of the protein. An original transformation of the fluorescence data, which estimates the disappearance rate of actin monomer toward the critical concentration, is presented and shown to be of general usefulness for the study of actin-binding proteins.	UNIV MILAN,SAN RAFFAELE SCI INST,NATL RES COUNCIL,CTR CYTOPHARMACOL,I-20129 MILAN,ITALY; ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021; UNIV MODENA,INST HUMAN PHYSIOL,I-41100 MODENA,ITALY	University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Rockefeller University; Universita di Modena e Reggio Emilia			Flavia, Valtorta/F-3450-2012; fesce, riccardo/A-6317-2008	Flavia, Valtorta/0000-0001-9556-4746; fesce, riccardo/0000-0001-9473-896X	NIMH NIH HHS [MH 39327] Funding Source: Medline; Telethon [112] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH039327, R37MH039327] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ATTRI AK, 1991, J BIOL CHEM, V266, P6815; BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BAHLER M, 1989, J CELL BIOL, V108, P1841, DOI 10.1083/jcb.108.5.1841; BAHLER M, 1990, BIOESSAYS, V12, P259, DOI 10.1002/bies.950120603; BENENATI F, 1992, IN PRESS NEURON; BENFENATI F, 1989, J CELL BIOL, V108, P1863, DOI 10.1083/jcb.108.5.1863; BENFENATI F, 1991, P NATL ACAD SCI USA, V88, P575, DOI 10.1073/pnas.88.2.575; CARLIER MF, 1991, J BIOL CHEM, V266, P1; COOPER JA, 1983, BIOCHEMISTRY-US, V22, P2193, DOI 10.1021/bi00278a021; COOPER JA, 1985, BIOCHEMISTRY-US, V24, P793, DOI 10.1021/bi00324a039; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; DOI Y, 1984, J BIOL CHEM, V259, P1868; FLANAGAN MD, 1980, J BIOL CHEM, V255, P835; FRIEDEN C, 1983, P NATL ACAD SCI-BIOL, V80, P6513, DOI 10.1073/pnas.80.21.6513; FRIEDEN C, 1985, ANNU REV BIOPHYS BIO, V14, P189, DOI 10.1146/annurev.bb.14.060185.001201; GAERTNER A, 1989, J MUSCLE RES CELL M, V10, P1, DOI 10.1007/BF01739852; GLENNEY JR, 1981, CELL, V24, P471, DOI 10.1016/0092-8674(81)90338-X; GRAZI E, 1985, BIOCHEM BIOPH RES CO, V128, P1058, DOI 10.1016/0006-291X(85)91047-2; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; ISENBERG G, 1980, NATURE, V288, P455, DOI 10.1038/288455a0; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; OOSAWA F, 1975, THERMODYNAMICS POLYM, P109; PETRUCCI TC, 1987, J CELL BIOL, V105, P1355, DOI 10.1083/jcb.105.3.1355; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; SCHIEBLER W, 1986, J BIOL CHEM, V261, P8383; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; TOBACMAN LS, 1983, J BIOL CHEM, V258, P3207; VALTORTA F, 1992, J BIOL CHEM, V267, P11281; Vandekerckhove J, 1989, CURR OPIN CELL BIOL, V1, P15, DOI 10.1016/S0955-0674(89)80031-6; WEGNER A, 1976, J MOL BIOL, V108, P139, DOI 10.1016/S0022-2836(76)80100-3; WEGNER A, 1975, BIOPHYS CHEM, V3, P215, DOI 10.1016/0301-4622(75)80013-5; YIN HL, 1981, J BIOL CHEM, V256, P9693	34	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11289	11299						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597463				2022-12-25	WOS:A1992HX16900057
J	KADIMA, W; ROY, M; LEE, RWK; KAARSHOLM, NC; DUNN, MF				KADIMA, W; ROY, M; LEE, RWK; KAARSHOLM, NC; DUNN, MF			STUDIES OF THE ASSOCIATION AND CONFORMATIONAL PROPERTIES OF METAL-FREE INSULIN IN ALKALINE SODIUM-CHLORIDE SOLUTIONS BY ONE-DIMENSIONAL AND 2-DIMENSIONAL H-1-NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; NATIVE HUMAN INSULIN; H-1-NMR ASSIGNMENTS; SELF-ASSOCIATION; BOVINE INSULIN; ZINC-BINDING; HEXAMER; PROINSULIN; SPECTROSCOPY; STABILIZES	One- and two-dimensional H-1 NMR spectroscopy have been employed to probe the association and subsequent conformational changes of metal-free insulin in sodium chloride solution at pH 9 and 9.4. These studies establish that the proton resonances of His(B5) and His(B10) are useful signatures of aggregation and conformation. Changes in chemical shifts and areas of resonances due to the C2 protons of His(B10) and His(B5) and transfer of magnetization experiments served to identify the association as the assembly of tetramer from dimers under our experimental conditions (pH 9.4, [insulin] > 1 mM, [NaCl] = 0.1 M). Sodium chloride also alters the equilibrium distribution of species in favor of a tetrameric species. The association equilibrium constant was estimated from area measurements to be approximately 5 x 10(3) M-1 at pH 9.4, 26 +/- 0.1-degrees-C, and 0.1 M sodium chloride. Under conditions of 0.1 M sodium chloride concentration, nuclear Overhauser effect experiments in the one- and two-dimensional modes revealed an operative nuclear Overhauser effect between the His(B5) C2 protons and the 2,6 ring protons of a Tyr residue provisionally assigned as Tyr(B16). We conclude that this interaction is a diagnostic signature of a conformational transition where-upon an extended chain from residues B1 to B9 (T-state) is transformed into an alpha-helix (R-state) thus bringing the rings of His(B5) and Tyr(B16) from adjacent subunits across the monomer-monomer interface into van der Waals contact. This conformational flexibility is an added consideration to the discussion of the relevant structure of insulin for receptor binding.	UNIV CALIF RIVERSIDE, DEPT BIOCHEM, RIVERSIDE, CA 92521 USA; UNIV CALIF RIVERSIDE, DEPT CHEM, RIVERSIDE, CA 92521 USA; NOVO RES INST, DK-2880 BAGSVAERD, DENMARK	University of California System; University of California Riverside; University of California System; University of California Riverside; Novo Nordisk			Kadima, Webe/AAE-4924-2020					BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; BAX A, 1983, J MAGN RESON, V53, P517, DOI 10.1016/0022-2364(83)90225-1; BOHIDAR HB, 1984, BIOPOLYMERS, V23, P2407; BRADBURY JH, 1977, EUR J BIOCHEM, V76, P573, DOI 10.1111/j.1432-1033.1977.tb11627.x; BRADBURY JH, 1981, J MOL BIOL, V150, P609, DOI 10.1016/0022-2836(81)90385-5; BRADBURY JH, 1985, BIOCHEM J, V229, P731, DOI 10.1042/bj2290731; BRADER ML, 1991, BIOCHEMISTRY-US, V30, P6636, DOI 10.1021/bi00241a002; BRADER ML, 1990, J BIOL CHEM, V265, P15666; BRADER ML, 1990, J AM CHEM SOC, V112, P4585, DOI 10.1021/ja00167a090; BRANGE J, 1988, NATURE, V333, P679, DOI 10.1038/333679a0; BRANGE J, 1983, ACTA MED SCAND, P135; COFFMAN FD, 1988, BIOCHEMISTRY-US, V27, P6179, DOI 10.1021/bi00416a053; DEGRAAFF RAG, 1981, STRUCTURAL STUDIES M, P547; DEMELO J, 1990, WORLD BANK ECON REV, V4, P209, DOI 10.1093/wber/4.2.209; DEREWENDA U, 1989, NATURE, V338, P594, DOI 10.1038/338594a0; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DOTY P, 1952, J AM CHEM SOC, V74, P2065, DOI 10.1021/ja01128a063; DUNN MF, 1987, 5TH P INT S CALC BIN, P372; FREDERICQ E, 1956, ARCH BIOCHEM BIOPHYS, V65, P218, DOI 10.1016/0003-9861(56)90189-8; FREDERICQ E, 1954, J POLYM SCI, V12, P287, DOI 10.1002/pol.1954.120120123; GOLDMAN J, 1974, BIOCHEMISTRY-US, V13, P4566, DOI 10.1021/bi00719a015; HILL CP, 1991, BIOCHEMISTRY-US, V30, P917, DOI 10.1021/bi00218a006; HOFACKER GL, 1983, INTRAMOLECULAR INTER, P229; HOLLADAY LA, 1977, BIOCHIM BIOPHYS ACTA, V494, P245, DOI 10.1016/0005-2795(77)90152-0; HUA QX, 1991, BIOCHEMISTRY-US, V30, P5505, DOI 10.1021/bi00236a025; HUA QX, 1990, BIOCHEMISTRY-US, V29, P10545, DOI 10.1021/bi00498a018; JEFFREY PD, 1966, BIOCHEMISTRY-US, V5, P489, DOI 10.1021/bi00866a014; JEFFREY PD, 1965, BIOCHIM BIOPHYS ACTA, V109, P551, DOI 10.1016/0926-6585(65)90181-0; JEFFREY PD, 1976, BIOCHEMISTRY-US, V15, P4660, DOI 10.1021/bi00666a018; KAARSHOLM NC, 1990, ARCH BIOCHEM BIOPHYS, V283, P496, DOI 10.1016/0003-9861(90)90673-M; KAARSHOLM NC, 1989, BIOCHEMISTRY-US, V28, P4427, DOI 10.1021/bi00436a046; KAARSHOLM NC, 1987, BIOCHEMISTRY-US, V26, P883, DOI 10.1021/bi00377a032; KADIMA W, 1986, THESIS U ALBERTA EDM, P31; KLINE AD, 1990, BIOCHEMISTRY-US, V29, P2906, DOI 10.1021/bi00464a003; LORD RS, 1973, BIOCHEMISTRY-US, V12, P4385, DOI 10.1021/bi00746a014; MARK AE, 1987, BIOPHYS CHEM, V27, P103, DOI 10.1016/0301-4622(87)80051-0; MARTINDALE H, 1982, DIABETES, V31, P364, DOI 10.2337/diabetes.31.4.364; MERSH JD, 1982, PROG NMR SPECTROSCOP, V15, P353; MILTHORPE BK, 1977, BIOCHIM BIOPHYS ACTA, V495, P195, DOI 10.1016/0005-2795(77)90376-2; PALMIERI R, 1988, BIOCHEMISTRY-US, V27, P3387, DOI 10.1021/bi00409a040; PEKAR AH, 1972, BIOCHEMISTRY-US, V11, P4013, DOI 10.1021/bi00772a001; PERMUTT MA, 1981, ISLETS LANGERHANS BI, P75; POCKER Y, 1980, BIOCHEMISTRY-US, V19, P5043, DOI 10.1021/bi00563a017; POCKER Y, 1981, BIOCHEMISTRY-US, V20, P4354, DOI 10.1021/bi00518a019; PORTER RR, 1953, BIOCHEM J, V53, P320, DOI 10.1042/bj0530320; ROY M, 1989, J BIOL CHEM, V264, P19081; ROY M, 1990, BIOCHIM BIOPHYS ACTA, V1053, P63, DOI 10.1016/0167-4889(90)90027-B; ROY M, 1990, J BIOL CHEM, V265, P5448; SMITH GD, 1984, P NATL ACAD SCI-BIOL, V81, P7093, DOI 10.1073/pnas.81.22.7093; STEINER KF, 1975, COLD SPRING HARBOR C, V2, P531; STEINER RF, 1952, ARCH BIOCHEM BIOPHYS, V39, P333, DOI 10.1016/0003-9861(52)90344-5; STORM MC, 1985, BIOCHEMISTRY-US, V24, P1749, DOI 10.1021/bi00328a027; STRAZZA S, 1985, ARCH BIOCHEM BIOPHYS, V238, P30, DOI 10.1016/0003-9861(85)90137-7; SUDMEIER JL, 1981, SCIENCE, V212, P560, DOI 10.1126/science.7010607; WEISS MA, 1989, BIOCHEMISTRY-US, V28, P9855, DOI 10.1021/bi00451a046; WEISS MA, 1991, BIOCHEMISTRY-US, V30, P7373, DOI 10.1021/bi00244a004; WILLIAMSON KL, 1979, BIOCHEMISTRY-US, V18, P5966, DOI 10.1021/bi00593a032; WOLLMER A, 1987, BIOL CHEM H-S, V368, P903, DOI 10.1515/bchm3.1987.368.2.903; WOLLMER A, 1980, INSULIN CHEM STRUCTU, P27; WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P17	60	30	30	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8963	8970						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577733				2022-12-25	WOS:A1992HR85400042
J	VOYIATZAKI, CS; SOTERIADOU, KP				VOYIATZAKI, CS; SOTERIADOU, KP			IDENTIFICATION AND ISOLATION OF THE LEISHMANIA TRANSFERRIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FALCIPARUM-INFECTED ERYTHROCYTES; CELL-SURFACE GLYCOPROTEIN; MEDIATED ENDOCYTOSIS; IRON TRANSPORT; PROTEINS; PROLIFERATION; ANTIBODIES; MEMBRANE; STORAGE	In a previous report, we have presented several lines of evidence, derived from widely different methodologies, suggesting that Leishmania has specific receptors for transferrin with a K(d) similar to the mammalian transferrin receptor. This paper describes the identification, purification, and biochemical characterization of Leishmania transferrin receptor. The Leishmania transferrin receptor, detected on intact parasites by immunoperoxidase staining, was first identified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by Western blot analysis, using I-125-transferrin, as a 70-kDa protein. It has been isolated initially from Leishmania infantum promastigotes using affinity chromatography on a transferrin-Sepharose column and, subsequently, from Leishmania major promastigotes. The use of polyclonal antisera to the purified 70-kDa Leishmania transferrin receptor and to the purified rat transferrin receptor showed that the two receptors are antigenically distinct. The 70-kDa Leishmania transferrin receptor was subsequently characterized as an integral membrane glycoprotein. The monomeric state of the Leishmania transferrin receptor was demonstrated by gel filtration of purified receptor complexed with I-125-transferrin. Thus, the Leishmania transferrin receptor, unlike the mammalian receptor, is not a disulfide-linked dimer but a single 70-kDa polypeptide.	HELLEN INST PASTEUR,BIOCHEM LAB,127 VASSILISSIS SOFIAS AVE,GR-11521 ATHENS,GREECE									AISEN P, 1980, ANNU REV BIOCHEM, V49, P357, DOI 10.1146/annurev.bi.49.070180.002041; ALVAREZ E, 1989, EMBO J, V8, P2231, DOI 10.1002/j.1460-2075.1989.tb08347.x; BARERJEEBHATNAG.N, 1990, INFECT IMMUN, V58, P2875; BORDIER C, 1987, PARASITOL TODAY, V3, P151, DOI 10.1016/0169-4758(87)90199-2; CHANG KP, 1990, ANNU REV MICROBIOL, V44, P499, DOI 10.1146/annurev.mi.44.100190.002435; COPPENS I, 1987, J PROTOZOOL, V34, P465, DOI 10.1111/j.1550-7408.1987.tb03216.x; CRICHTON RR, 1987, EUR J BIOCHEM, V164, P485, DOI 10.1111/j.1432-1033.1987.tb11155.x; DWYER DM, 1980, J PROTOZOOL, V27, P176, DOI 10.1111/j.1550-7408.1980.tb04676.x; FRAZIER JL, 1982, J CLIN INVEST, V69, P583; HALDAR K, 1986, P NATL ACAD SCI USA, V83, P8565, DOI 10.1073/pnas.83.22.8565; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KARIN M, 1981, J BIOL CHEM, V256, P3245; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESLEY JF, 1985, MOL CELL BIOL, V5, P1814, DOI 10.1128/MCB.5.8.1814; LIMA MF, 1990, MOL BIOCHEM PARASIT, V38, P245, DOI 10.1016/0166-6851(90)90027-J; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NEWMAN R, 1982, TRENDS BIOCHEM SCI, V7, P397, DOI 10.1016/0968-0004(82)90184-0; OMARY MB, 1981, J BIOL CHEM, V256, P2888; PEARSON RD, 1983, REV INFECT DIS, V5, P907; RODRIGUEZ MH, 1986, NATURE, V324, P388, DOI 10.1038/324388a0; RUSSELL DG, 1988, J IMMUNOL, V140, P1274; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHELL D, 1991, EMBO J, V10, P1061, DOI 10.1002/j.1460-2075.1991.tb08045.x; SCHRYVERS AB, 1988, MOL MICROBIOL, V2, P281, DOI 10.1111/j.1365-2958.1988.tb00029.x; SELIGMAN PA, 1979, J BIOL CHEM, V254, P9943; SOTERIADOU KP, 1988, INFECT IMMUN, V56, P1180, DOI 10.1128/IAI.56.5.1180-1186.1988; STEARNE PA, 1985, J IMMUNOL, V134, P3474; SUTHERLAND R, 1981, P NATL ACAD SCI-BIOL, V78, P4515, DOI 10.1073/pnas.78.7.4515; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROWBRIDGE IS, 1981, P NATL ACAD SCI-BIOL, V78, P3039, DOI 10.1073/pnas.78.5.3039; TROWBRIDGE IS, 1982, J CELL PHYSIOL, V112, P403, DOI 10.1002/jcp.1041120314; TROWBRIDGE IS, 1988, MONOCLONAL ANTIBODY, V45, P121; TURCO SJ, 1988, PARASITOL TODAY, V4, P255, DOI 10.1016/0169-4758(88)90144-5; TURKEWITZ AP, 1988, J BIOL CHEM, V263, P8318; TZINIA AK, 1991, MOL BIOCHEM PARASIT, V47, P83, DOI 10.1016/0166-6851(91)90150-5; VOYIATZAKI CS, 1990, J BIOL CHEM, V265, P22380	36	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9112	9117						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577747				2022-12-25	WOS:A1992HR85400064
J	MURAKAMI, K; TANASE, S; MORINO, Y; MORI, M				MURAKAMI, K; TANASE, S; MORINO, Y; MORI, M			PRESEQUENCE BINDING FACTOR-DEPENDENT AND FACTOR-INDEPENDENT IMPORT OF PROTEINS INTO MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ORNITHINE CARBAMOYLTRANSFERASE PRECURSOR; TRANSPORT; SEQUENCE; THIOLASE; CLONING	A cytosolic protein factor(s) is involved in the import of precursor proteins into mitochondria. PBF (presequence binding factor) is a protein factor which binds to the precursor form (pOTC) of rat ornithine carbamoyltransferase (OTC) but not to the mature OTC, and is required for the mitochondrial import of pOTC. The precursors for aspartate aminotransferase and malate dehydrogenase as well as pOTC synthesized in a reticulocyte lysate were efficiently imported into the mitochondria. However, the precursors synthesized in the lysate depleted for PBF by treatment with pOTC-Sepharose were not imported. Readdition of the purified PBF to the depleted lysate fully restored the import. pOTC synthesized in the untreated lysate sedimented as a complex with a broad peak of around 9 S, whereas pOTC synthesized in the PBF-depleted lysate sedimented at an expected position of monomer (2.5 S). When the purified PBF was readded to the depleted lysate, pOTC sedimented as a complex of about 7 S. In contrast to most mitochondrial proteins, rat 3-oxoacyl-CoA thiolase is synthesized with no cleavable presequence and an NH2-terminal portion of the mature protein functions as a mitochondrial import signal. The thiolase synthesized in the PBF-depleted lysate could be efficiently imported into the mitochondria, and readdition of PBF had little effect on the import. The thiolase synthesized in the untreated, the PBF-depleted, or the PBF-readded lysate sedimented at an expected position of monomer (2.5 S). These observations provide support for the existence of PBF-dependent and -independent pathways of mitochondrial protein import.	KUMAMOTO UNIV,SCH MED,DEPT BIOCHEM,KUMAMOTO 862,JAPAN	Kumamoto University	MURAKAMI, K (corresponding author), KUMAMOTO UNIV,SCH MED,DEPT MED GENET,KUHONJI 4-24-1,KUMAMOTO 862,JAPAN.							AMAYA Y, 1988, J BIOL CHEM, V263, P14463; ARGAN C, 1985, BIOCHEM BIOPH RES CO, V134, P21; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; JOH T, 1987, BIOCHEMISTRY-US, V26, P2515, DOI 10.1021/bi00383a017; MIURA S, 1983, J BIOL CHEM, V258, P6671; MORI M, 1985, EUR J BIOCHEM, V149, P181, DOI 10.1111/j.1432-1033.1985.tb08909.x; MORI M, 1981, J BIOL CHEM, V256, P4127; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; MURAKAMI K, 1988, J BIOL CHEM, V263, P18437; MURAKAMI K, 1990, EMBO J, V9, P3201, DOI 10.1002/j.1460-2075.1990.tb07518.x; MURAKAMI K, 1990, J BIOCHEM-TOKYO, V108, P2207; NISHI T, 1989, J BIOL CHEM, V264, P6044; OHTA S, 1984, EMBO J, V3, P651, DOI 10.1002/j.1460-2075.1984.tb01862.x; ONO H, 1988, J BIOL CHEM, V263, P3188; SCHNAITMAN C, 1968, J CELL BIOL, V38, P1158; TAKIGUCHI M, 1984, P NATL ACAD SCI-BIOL, V81, P7412, DOI 10.1073/pnas.81.23.7412	17	47	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13119	13122						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618812				2022-12-25	WOS:A1992JB74600002
J	CONRAD, KE; GUTIERREZHARTMANN, A				CONRAD, KE; GUTIERREZHARTMANN, A			THE RAS AND PROTEIN KINASE-A PATHWAYS ARE MUTUALLY ANTAGONISTIC IN REGULATING RAT PROLACTIN PROMOTER ACTIVITY	ONCOGENE			English	Article								In an attempt to characterize the ras signaling pathway, we studied the effects of expression vectors encoding the valine 12 mutant ras oncogene on rat prolactin (rPRL) promoter activity. Using this approach we have been able to dissect the interplay between the ras and the protein kinase A (PKA) pathways as they relate to neuroendocrine gene activation. Here we show that the ras oncogene product induces rPRL promoter activity selectively from 5- to 14-fold in GH, rat pituitary tumor cells, whereas it has a minimal effect on the SV40 early promoter and no effect on the Rous sarcoma virus (RSV) or rat growth hormone promoters. By contrast, an inactivated form of ras (N-17 ras) did not stimulate the rPRL promoter, but rather inhibited it to 40% of control. Of note, activation of the PKA pathway by two different methods decreased the fold activation mediated by ras by at least 50%, whereas inhibition of the PKA pathway accentuated ras activation of the rPRL promoter. Although rPRL promoter activity is consistently induced by PKA activation in control GH4 cells, acute ras oncogene expression inhibited forskolin induction of rPRL promoter activity. Moreover, this ras-mediated interference of the forskolin activation of rPRL promoter activity was also noted in GH, cells stably expressing ras. Taken together, these data show that the valine 12 ras oncogene activates the rPRL promoter selectively and, more importantly, that the ras and PKA signaling pathways are mutually antagonistic with respect to specific transcriptional activation of a neuroendocrine gene.	UNIV COLORADO, HLTH SCI CTR,DEPT MED,PROGRAM MOLEC BIOL, 4200 E 9TH AVE,BOX B-151, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, DEPT BIOCHEM BIOPHYS & GENET, PROGRAM MOLEC BIOL, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, COLORADO CANC CTR, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Gutierrez-Hartmann, Arthur/F-1295-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037667] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 37667] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BECKNER SK, 1985, NATURE, V317, P71, DOI 10.1038/317071a0; BERK AJ, 1989, BIOCHIM BIOPHYS ACTA, V1009, P103, DOI 10.1016/0167-4781(89)90087-0; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOHMANN D, 1990, CANCER CELL-MON REV, V2, P337; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DAY RN, 1989, MOL ENDOCRINOL, V3, P3, DOI 10.1210/mend-3-1-3; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DOLLE P, 1990, CELL, V60, P809, DOI 10.1016/0092-8674(90)90095-V; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; ELSHOLTZ HP, 1986, SCIENCE, V234, P1552, DOI 10.1126/science.3491428; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FUJIYAMA A, 1986, P NATL ACAD SCI USA, V83, P1266, DOI 10.1073/pnas.83.5.1266; GALIEN R, 1991, ONCOGENE, V6, P849; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GUTIERREZHARTMA.A, 1991, MOL CLIN ADV PITUITA, P47; GUTIERREZHARTMANN A, 1987, P NATL ACAD SCI USA, V84, P5211, DOI 10.1073/pnas.84.15.5211; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HOEFFLER JP, 1990, TRENDS ENDOCRIN MET, V1, P155, DOI 10.1016/1043-2760(90)90028-2; HUANG YK, 1990, P NATL ACAD SCI USA, V87, P8008, DOI 10.1073/pnas.87.20.8008; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; KARIN M, 1990, TRENDS GENET, V6, P92, DOI 10.1016/0168-9525(90)90100-K; KEDAR PS, 1990, MOL CELL BIOL, V10, P3852, DOI 10.1128/MCB.10.7.3852; KEECH CA, 1991, MOL CELL ENDOCRINOL, V78, P55, DOI 10.1016/0303-7207(91)90185-U; KEECH CA, 1989, MOL ENDOCRINOL, V3, P832, DOI 10.1210/mend-3-5-832; LACAL JC, 1990, MOL CELL BIOL, V10, P2983, DOI 10.1128/MCB.10.6.2983; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; Matsumoto K, 1985, Yeast, V1, P15, DOI 10.1002/yea.320010103; MAURER RA, 1981, NATURE, V294, P94, DOI 10.1038/294094a0; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MILLER WL, 1983, ENDOCR REV, V4, P97, DOI 10.1210/edrv-4-2-97; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; ONALI P, 1981, P NATL ACAD SCI-BIOL, V78, P6531, DOI 10.1073/pnas.78.10.6531; OSBORNE R, 1981, ENDOCRINOLOGY, V108, P1164, DOI 10.1210/endo-108-4-1164; OWEN RD, 1990, P NATL ACAD SCI USA, V87, P3866, DOI 10.1073/pnas.87.10.3866; OWEN RD, 1990, MOL CELL BIOL, V10, P1; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; SADLER SE, 1990, MOL CELL BIOL, V10, P1689, DOI 10.1128/MCB.10.4.1689; SCHONTHAL A, 1990, CELL SIGNAL, V2, P215, DOI 10.1016/0898-6568(90)90049-G; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; STANLEY F, 1988, J BIOL CHEM, V263, P13444; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TASHJIAN AH, 1968, ENDOCRINOLOGY, V82, P342, DOI 10.1210/endo-82-2-342; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WHITE BA, 1983, J BIOL CHEM, V258, P4618; YAMAGUCHIIWAI Y, 1990, P NATL ACAD SCI USA, V87, P8670, DOI 10.1073/pnas.87.21.8670	61	56	56	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1992	7	7					1279	1286						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620544				2022-12-25	WOS:A1992HZ97100005
J	KARLSSON, M; SAHLIN, M; SJOBERG, BM				KARLSSON, M; SAHLIN, M; SJOBERG, BM			ESCHERICHIA-COLI RIBONUCLEOTIDE REDUCTASE - RADICAL SUSCEPTIBILITY TO HYDROXYUREA IS DEPENDENT ON THE REGULATORY STATE OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RANGE ELECTRON-TRANSFER; BINUCLEAR IRON CENTER; CYTOCHROME-C; B2 SUBUNIT; TYROSINE; INHIBITION; REACTIVITY; RESONANCE; KINETICS; PROTEIN	Ribonucleotide reductase catalyzes the reduction of ribonucleotides to their corresponding deoxyribonucleotides via a radical-mediated mechanism. The enzyme from Escherichia coli consists of the two nonidentical proteins, R1 and R2 the latter of which contains the necessary free radical located to a tyrosine residue. The radical scavenger hydroxyurea was found to reduce the tyrosyl radical of R2 in a second-order reaction. The rate constant (0.50 M-1 s-1 at 25-degrees-C) for this process was several orders of magnitude lower than the hydroxyurea-dependent reduction of free tyrosyl radicals in solution. This difference probably reflects the fact that the R2 tyrosyl radical is buried in the interior of the protein. Formation of the R1R2 complex changed the susceptibility of the radical to hydroxyurea in a manner that reflects the regulatory state of the holoenzyme. Furthermore, binding of substrate or product to the holoenzyme complex made the R2 radical at least 10 times more susceptible to inactivation by hydroxyurea than it was in the isolated R2 protein. One active site mutation in the R1 protein was shown to affect the sensitivity of the tyrosyl radical of R2 differently than wild type protein R1 does. Our results clearly show that the susceptibility of the tyrosyl radical in R2 to inactivation by hydroxyurea can be used as an efficient probe for the regulatory state of the holoenzyme complex.	UNIV STOCKHOLM, ARRHENIUS LABS NAT SCI, DEPT MOLEC BIOL, S-10691 STOCKHOLM, SWEDEN	Stockholm University				Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1989, J BIOL CHEM, V264, P12249; ASHLEY GW, 1989, INT ENCY PHARM THERA, P55; ATOR M, 1984, J AM CHEM SOC, V106, P1886, DOI 10.1021/ja00318a082; BACKES G, 1989, BIOCHEMISTRY-US, V28, P1923, DOI 10.1021/bi00430a074; BERGLUND O, 1979, J BIOL CHEM, V254, P253; BOBROWSKI K, 1990, INT J RADIAT BIOL, V57, P919, DOI 10.1080/09553009014551041; BROWN NC, 1969, J MOL BIOL, V46, P25, DOI 10.1016/0022-2836(69)90055-2; CLIMENT I, 1992, IN PRESS BIOCHEMISTR, V31; DOBELN UV, 1976, J BIOL CHEM, V251, P3616; EHRENBERG A, 1972, J BIOL CHEM, V247, P3485; ELFORD HL, 1989, INHIBITORS RIBONUCLE, P217; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; FONTECAVE M, 1992, ADV ENZYMOL RAMB, V65, P147; GEREZ C, 1992, BIOCHEMISTRY-US, V31, P780, DOI 10.1021/bi00118a020; GRAY HB, 1989, BIOCHEMISTRY-US, V28, P7499, DOI 10.1021/bi00445a001; LAM KY, 1990, J CHEM SOC CHEM COMM, P658, DOI 10.1039/c39900000658; LAM KY, 1990, J CHEM SOC CHEM COMM, P1019, DOI 10.1039/c39900001019; LARSEN IK, 1982, EUR J BIOCHEM, V125, P75; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; LIN ANI, 1987, BIOCHEMISTRY-US, V26, P6905, DOI 10.1021/bi00396a006; LYNCH JB, 1989, J BIOL CHEM, V264, P8091; MAO SS, 1989, P NATL ACAD SCI USA, V86, P1485, DOI 10.1073/pnas.86.5.1485; MAURO JM, 1988, BIOCHEMISTRY-US, V27, P6243, DOI 10.1021/bi00417a008; NATAN MJ, 1990, J AM CHEM SOC, V112, P4081, DOI 10.1021/ja00166a079; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; ROSENKRANZ HS, 1966, BIOCHIM BIOPHYS ACTA, V114, P501, DOI 10.1016/0005-2787(66)90099-2; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5541, DOI 10.1021/bi00391a049; SAHLIN M, 1989, BIOCHEMISTRY-US, V28, P2618, DOI 10.1021/bi00432a039; SAHLIN M, 1982, J BIOL CHEM, V257, P366; SJOBERG BM, 1983, J BIOL CHEM, V258, P8060; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; SJOBERG BM, 1987, J BIOL CHEM, V262, P9736; SLABAUGH MB, 1991, J VIROL, V65, P2290, DOI 10.1128/JVI.65.5.2290-2298.1991; STUBBE JA, 1990, J BIOL CHEM, V265, P5329; Thelander L, 1978, Methods Enzymol, V51, P227; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; THERIEN MJ, 1990, J AM CHEM SOC, V112, P2420, DOI 10.1021/ja00162a054	38	59	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12622	12626						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618767				2022-12-25	WOS:A1992HZ48300039
J	NAGAYA, T; MADISON, LD; JAMESON, JL				NAGAYA, T; MADISON, LD; JAMESON, JL			THYROID-HORMONE RECEPTOR MUTANTS THAT CAUSE RESISTANCE TO THYROID-HORMONE - EVIDENCE FOR RECEPTOR COMPETITION FOR DNA-SEQUENCES IN TARGET GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ERBA PROTOONCOGENES; RAT GROWTH-HORMONE; GLUCOCORTICOID RECEPTOR; GENERALIZED RESISTANCE; NEGATIVE REGULATION; BINDING; BETA; EXPRESSION; PROTEIN; MEDIATE	Several distinct mutations in the ligand-binding domain of the beta-form of the thyroid hormone receptor have been reported in kindreds with the autosomal dominant syndrome of generalized resistance to thyroid hormone (GRTH). GRTH receptor mutants are functionally inactive but capable of inhibiting normal receptor function in transient expression studies. We examined the possibility that this dominant negative activity of the GRTH mutants involves competition for receptor binding to DNA. Mutations introduced into either the T3 ligand-binding domain (LBD) or into the DNA-binding domain (DBD) of the receptor eliminated the transcriptional activity of the receptor. In cotransfection experiments, the LBD mutants, but not the DBD mutants, inhibited the transcriptional activity of the normal receptor. The inhibitory activity of the LBD mutants was abolished by the introduction of an additional mutation into the DBD, suggesting that the DBD is required for dominant negative activity. A chimeric receptor, in which the DNA-binding domain of the thyroid hormone receptor was exchanged with the homologous region in the glucocorticoid receptor (GTG), was used to study thyroid hormone receptor competition for GTG interactions with thyroid receptor target sequences. In the absence of thyroid hormone, the normal thyroid hormone receptor inhibited dexamethasone stimulated transcription by GTG. The transcriptional activity of GTG was also inhibited by the LBD mutants but not by a DBD mutant of the thyroid hormone receptor. These results indicate that the thyroid hormone receptor mutations that occur in GRTH compete with normal receptors at DNA-binding sites in target genes to block normal receptor function.	MASSACHUSETTS GEN HOSP,THYROID UNIT,JACKSON 1021,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School				Jameson, James/0000-0001-9538-4059	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042144] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 28138] Funding Source: Medline; NIDDK NIH HHS [DK 42144] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRENT GA, 1989, J BIOL CHEM, V264, P178; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; CHATTERJEE VKK, 1991, MOL ENDOCRINOL, V5, P100, DOI 10.1210/mend-5-1-100; CHATTERJEE VKK, 1991, J CLIN INVEST, V87, P1977; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN B M, 1990, New Biologist, V2, P587; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1988, MOL ENDOCRINOL, V2, P902, DOI 10.1210/mend-2-10-902; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GRAUPNER G, 1991, MOL ENDOCRINOL, V5, P365, DOI 10.1210/mend-5-3-365; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LAZAR MA, 1990, J CLIN INVEST, V86, P1777, DOI 10.1172/JCI114906; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; MAGNER JA, 1986, J ENDOCRINOL INVEST, V9, P459, DOI 10.1007/BF03346968; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; ODONNELL AL, 1991, MOL ENDOCRINOL, V5, P94, DOI 10.1210/mend-5-1-94; PORRILLA R, 1991, J CLIN INVEST, V88, P2123; REFETOFF S, 1967, J CLIN ENDOCR METAB, V27, P279, DOI 10.1210/jcem-27-2-279; REFETOFF S, 1991, J CLIN ENDOCR METAB, V2, P140; REFETOFF S, 1982, AM J PHYSIOL, V243, P88; RENTOUMIS A, 1990, MOL ENDOCRINOL, V4, P1522, DOI 10.1210/mend-4-10-1522; SAKURAI A, 1990, MOL ENDOCRINOL, V4, P1988, DOI 10.1210/mend-4-12-1988; SAKURAI A, 1989, P NATL ACAD SCI USA, V86, P8977, DOI 10.1073/pnas.86.22.8977; SAKURAI A, 1990, MOL CELL ENDOCRINOL, V71, P83; SAKURAI A, 1989, MOL ENDOCRINOL, V3, P392, DOI 10.1210/mend-3-2-392; SAMUELS HH, 1988, J CLIN INVEST, V81, P957, DOI 10.1172/JCI113449; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHUELER PA, 1990, MOL ENDOCRINOL, V4, P227, DOI 10.1210/mend-4-2-227; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; TAKEDA K, 1991, J CLIN INVEST, V87, P496, DOI 10.1172/JCI115023; TAKEDA K, 1992, J CLIN ENDOCR METAB, V74, P49, DOI 10.1210/jc.74.1.49; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; USALA SJ, 1991, J CLIN ENDOCR METAB, V72, P32, DOI 10.1210/jcem-72-1-32; USALA SJ, 1991, MOL ENDOCRINOL, V5, P327, DOI 10.1210/mend-5-3-327; USALA SJ, 1990, J CLIN INVEST, V85, P93, DOI 10.1172/JCI114438; USALA SJ, 1991, TRENDS ENDOCRIN MET, V2, P140, DOI 10.1016/1043-2760(91)90004-7; WOOD WM, 1989, J BIOL CHEM, V264, P14840; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	48	109	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					13014	13019						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618799				2022-12-25	WOS:A1992HZ48300092
J	OPIPARI, AW; HU, HM; YABKOWITZ, R; DIXIT, VM				OPIPARI, AW; HU, HM; YABKOWITZ, R; DIXIT, VM			THE A20 ZINC FINGER PROTEIN PROTECTS CELLS FROM TUMOR-NECROSIS-FACTOR CYTOTOXICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FACTOR-ALPHA; FIBROBLASTS; RESISTANCE; EXPRESSION; LINES; BCL-2; CDNA	Resistance against the cytotoxic actions of tumor necrosis factor-alpha (TNF) is an active process requiring the synthesis of TNF-inducible proteins. The specific TNF-induced proteins so far identified (manganese superoxide dismutase and plasminogen activator inhibitor type 2) as having a role in resistance against TNF cytotoxicity are able to confer only partial protection to cells, suggesting that other genes are involved. A20 is a TNF-induced primary response gene which encodes a novel zinc ringer protein. In this report we demonstrate that A20 protein is induced by TNF in a variety of cells. A survey of A20 expression in human breast carcinoma cell lines that are either sensitive or resistant to TNF cytotoxicity revealed increased expression of A20 message and protein in TNF-resistant cells. Constitutive expression of A20 after stable transfection of NIH 3T3 and WEHI 164 cells results in significant, but partial, resistance to TNF cytotoxicity. This work gives additional support to a role for TNF-induced immediate early response genes in protecting cells from TNF-induced death.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,BOX 0602,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326; Hu, Hong-Ming/0000-0002-2206-3470	NHLBI NIH HHS [HL 45351] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045351] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; CASTLE V, 1991, J CLIN INVEST, V87, P1883, DOI 10.1172/JCI115212; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; DIXIT VM, 1989, J BIOL CHEM, V264, P16905; DUERKSENHUGHES P, 1989, J IMMUNOL, V143, P4193; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; GRUNFELD C, 1990, ADV INTERNAL MED, V35, P44; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KUMAR S, 1991, J BIOL CHEM, V266, P20960; NIKS M, 1990, J IMMUNOL METHODS, V130, P149, DOI 10.1016/0022-1759(90)90309-J; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; Wallach D, 1986, Interferon, V7, P89; WALLACH D, 1984, J IMMUNOL, V132, P2464; WILLIAMSON BD, 1983, P NATL ACAD SCI-BIOL, V80, P5397, DOI 10.1073/pnas.80.17.5397; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WONG GHW, 1986, NATURE, V323, P819, DOI 10.1038/323819a0	22	407	422	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12424	12427						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618749				2022-12-25	WOS:A1992HZ48300009
J	SHASHIDHARA, LS; LIM, SH; SHACKLETON, JB; ROBINSON, C; SMITH, AG				SHASHIDHARA, LS; LIM, SH; SHACKLETON, JB; ROBINSON, C; SMITH, AG			PROTEIN TARGETING ACROSS THE 3 MEMBRANES OF THE EUGLENA CHLOROPLAST ENVELOPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTION SPECIFICITIES; PROCESSING PEPTIDASE; THYLAKOID LUMEN; TRANSIT PEPTIDE; MESSENGER-RNA; CDNA CLONE; PEA; PLASTOCYANIN; MATURATION; PRECURSORS	A system has been developed for the import in vitro of precursor proteins into Euglena chloroplasts, which have three envelope membranes. Preparation of functional chloroplasts with intact envelope membranes has been optimized. Import of the precursor (50 kDa) for the tetrapyrrole biosynthesis enzyme porphobilinogen deaminase (PBGD), and processing to the mature size (40 kDa), occurred at 25-degrees-C in the light and the presence of ATP, with an estimated efficiency of 62%. Pretreatment of the chloroplasts with proteases abolished this import, suggesting the involvement of specific protein receptors. The presequence of PBGD was found to be cleaved by Escherichia coli leader peptidase to an intermediate form (46 kDa). A construct in which the first 30 residues of the presequence (presumed to be the region removed by leader peptidase) had been deleted was no longer imported. Neither prePBGD nor the truncated precursor were imported into pea chloroplasts, although both bound to the pea chloroplast envelope. Conversely, a chimeric construct, in which the mature PBGD protein was fused downstream of the transit peptide for pea ferredoxin-NADP reductase, was efficiently imported into pea chloroplasts and processed to the mature size. However, this was not imported into Euglena chloroplasts, although again it bound to them. These results provide preliminary evidence for the possibility of two functional domains within the Euglena PBGD presequence. The implications of these findings with respect to the evolution of Euglena chloroplasts are discussed.	UNIV CAMBRIDGE, DEPT PLANT SCI, DOWNING ST, CAMBRIDGE CB2 3EA, ENGLAND; UNIV WARWICK, DEPT BIOL SCI, COVENTRY CV4 7AL, W MIDLANDS, ENGLAND	University of Cambridge; University of Warwick				Smith, Alison Gail/0000-0001-6511-5704; Lim, Saw Hoon/0000-0001-7629-2888				BATTERSBY AR, 1976, J CHEM SOC PERK T 1, P273, DOI 10.1039/p19760000273; CAVALIERSMITH T, 1982, BIOL J LINN SOC, V17, P289, DOI 10.1111/j.1095-8312.1982.tb02023.x; CAVALIERSMITH T, 1987, ANN NY ACAD SCI, V503, P55, DOI 10.1111/j.1749-6632.1987.tb40597.x; CHAN RL, 1990, EMBO J, V9, P333, DOI 10.1002/j.1460-2075.1990.tb08115.x; CLINE K, 1985, J BIOL CHEM, V260, P3691; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; GIBBS SP, 1978, CAN J BOT, V56, P2883, DOI 10.1139/b78-345; GIBBS SP, 1970, ANN NY ACAD SCI, V175, P454, DOI 10.1111/j.1749-6632.1970.tb45167.x; GIBBS SP, 1981, ANN NY ACAD SCI, V361, P193; HAGEMAN J, 1986, NATURE, V324, P567, DOI 10.1038/324567a0; HALPIN C, 1989, EMBO J, V8, P3917, DOI 10.1002/j.1460-2075.1989.tb08572.x; HOULNE G, 1988, MOL GEN GENET, V213, P479, DOI 10.1007/BF00339619; JAMES HE, 1989, J BIOL CHEM, V264, P19573; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; KOHORN BD, 1989, PLANT CELL, V1, P159; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFORTTRAN M, 1981, BER DEUT BOT GES, V94, P463; MORGENTHALER JJ, 1975, ARCH BIOCHEM BIOPHYS, V168, P289, DOI 10.1016/0003-9861(75)90253-2; MOULD RM, 1991, J BIOL CHEM, V266, P12189; NEWMAN BJ, 1988, PLANT MOL BIOL, V10, P511, DOI 10.1007/BF00033606; OSAFUNE T, 1991, EXP CELL RES, V193, P320, DOI 10.1016/0014-4827(91)90103-2; OSAFUNE T, 1991, J ELECTRON MICROSC, V40, P41; PAIN D, 1988, NATURE, V331, P232, DOI 10.1038/331232a0; PRICE CA, 1982, METHODS CHLOROPLAST, P189; REINBOTHE S, 1990, PLANTA, V181, P176, DOI 10.1007/BF02411535; SAMBROOK J, 1990, MOL CLONING LABORATO; SHARIF AL, 1989, EUR J BIOCHEM, V184, P353, DOI 10.1111/j.1432-1033.1989.tb15026.x; SHASHIDHARA LS, 1991, P NATL ACAD SCI USA, V88, P63, DOI 10.1073/pnas.88.1.63; SMEEKENS S, 1985, NATURE, V317, P456, DOI 10.1038/317456a0; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WALLACE TP, 1990, FEBS LETT, V272, P141, DOI 10.1016/0014-5793(90)80468-X; WHATLEY JM, 1981, ANN NY ACAD SCI, V361, P154, DOI 10.1111/j.1749-6632.1981.tb46517.x	34	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12885	12891						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618786				2022-12-25	WOS:A1992HZ48300075
J	STRACK, B; LESSL, M; CALENDAR, R; LANKA, E				STRACK, B; LESSL, M; CALENDAR, R; LANKA, E			A COMMON SEQUENCE MOTIF, -E-G-Y-A-T-A-, IDENTIFIED WITHIN THE PRIMASE DOMAINS OF PLASMID-ENCODED I-TYPE AND P-TYPE DNA PRIMASES AND THE ALPHA-PROTEIN OF THE ESCHERICHIA-COLI SATELLITE PHAGE P4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGONUCLEOTIDE-DIRECTED MUTAGENESIS; NUCLEOTIDE-SEQUENCE; BACTERIAL CONJUGATION; MOLECULAR-CLONING; RECIPIENT CELL; M13 PHAGE; GENE; REPLICATION; HELICASE; REGION	DNA primases encoded by the conjugative plasmids ColIb-P9 (Incl1), RP4, and R751 (IncP), and the protein of the Escherichia coli satellite phage P4-alpha were shown to contain a common amino acid sequence motif -E-G-Y-A-T-A-. The P4 alpha-gene product, required for initiation of phage DNA replication, exhibits primase activity on single-stranded circular DNA templates. This priming activity resembles the enzymatic activity of DNA primases encoded by conjugative plasmids in terms of template utilization and the ability to synthesize primers that can be elongated by DNA polymerase III holoenzyme. The -E-G-Y-A-T-A- motif is part of an extended sequence region most conserved within the primase domains of the four enzymes. Single amino acid substitutions generated in the -E-G-Y-A-T-A- motif of the RP4 TraC2 and the P4 alpha-protein affect priming activity, supporting the hypothesis that the conserved sequence motif is part of the active center for primase function. A mutation that eliminates priming activity causes P4 phage to grow poorly and to depend upon the host dnaG primase. Computer analysis identified two additional sequence motifs within the amino acid sequence of the P4 alpha-protein: a potential zinc-finger motif and a "type A" nucleotide binding site, both strikingly similar to sequence motifs described in various DNA primases and helicases.	MAX PLANCK INST MOLEC GENET,ABT SCHUSTER,IHNESTR 73,W-1000 BERLIN 33,GERMANY; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	Max Planck Society; University of California System; University of California Berkeley					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI008722, R21AI008722, R37AI008722] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 08722] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALMOND N, 1989, MOL GEN GENET, V216, P195, DOI 10.1007/BF00334356; ARGOS P, 1988, NUCLEIC ACIDS RES, V16, P9909, DOI 10.1093/nar/16.21.9909; BARRETT KJ, 1972, P NATL ACAD SCI USA, V69, P2986, DOI 10.1073/pnas.69.10.2986; BERNAD A, 1990, P NATL ACAD SCI USA, V87, P4610, DOI 10.1073/pnas.87.12.4610; BERNSTEIN JA, 1988, J BIOL CHEM, V263, P14891; BERTANI G, 1953, J BACTERIOL, V65, P113, DOI 10.1128/JB.65.2.113-121.1953; BERTANI G, 1969, J GEN VIROL, V5, P97, DOI 10.1099/0022-1317-5-1-97; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; BOULNOIS GJ, 1982, NUCLEIC ACIDS RES, V10, P855, DOI 10.1093/nar/10.3.855; BOWDEN DW, 1975, J BACTERIOL, V124, P167, DOI 10.1128/JB.124.1.167-175.1975; BRENDEL V, 1984, NUCLEIC ACIDS RES, V12, P4411, DOI 10.1093/nar/12.10.4411; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CALENDAR R, 1970, VIROLOGY, V40, P72, DOI 10.1016/0042-6822(70)90380-6; CAMPBELL JL, 1972, P NATL ACAD SCI USA, V69, P2090, DOI 10.1073/pnas.69.8.2090; CARAFA YD, 1990, J MOL BIOL, V216, P835, DOI 10.1016/S0022-2836(99)80005-9; CHATFIELD LK, 1982, J BACTERIOL, V152, P1188; CHATTORAJ DK, 1972, J MOL BIOL, V66, P423, DOI 10.1016/0022-2836(72)90424-X; CHOLI T, 1989, J CHROMATOGR, V476, P59, DOI 10.1016/S0021-9673(01)93856-7; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUMAS LB, 1974, J VIROL, V14, P1369, DOI 10.1128/JVI.14.6.1369-1379.1974; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FINCH PW, 1984, NUCLEIC ACIDS RES, V12, P5789, DOI 10.1093/nar/12.14.5789; FLENSBURG J, 1987, J MOL BIOL, V195, P439, DOI 10.1016/0022-2836(87)90664-4; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; FURUYA N, 1991, J BACTERIOL, V173, P2231, DOI 10.1128/JB.173.7.2231-2237.1991; GILCHRIST CA, 1987, NUCLEIC ACIDS RES, V15, P465, DOI 10.1093/nar/15.2.465; GOLDSTEIN R, 1982, P NATL ACAD SCI-BIOL, V79, P515, DOI 10.1073/pnas.79.2.515; GORBALENYA AE, 1990, J MOL BIOL, V213, P583, DOI 10.1016/S0022-2836(05)80243-8; GRIBSKOV M, 1984, NUCLEIC ACIDS RES, V12, P539, DOI 10.1093/nar/12.1Part2.539; GUINEY DG, 1989, PROMISCUOUS PLASMIDS, P27; HALLING C, 1990, NUCLEIC ACIDS RES, V18, P1649, DOI 10.1093/nar/18.6.1649; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; HUSAIN I, 1986, J BIOL CHEM, V261, P4895; Kornberg A., 1982, DNA REPLICATION S; Kornberg A., 1980, DNA REPLICATION; KRANIAS EG, 1974, J VIROL, V13, P146, DOI 10.1128/JVI.13.1.146-154.1974; KREVOLIN MD, 1985, J MOL BIOL, V182, P509, DOI 10.1016/0022-2836(85)90237-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANKA E, 1979, P NATL ACAD SCI USA, V76, P3632, DOI 10.1073/pnas.76.8.3632; LANKA E, 1981, J BACTERIOL, V148, P769, DOI 10.1128/JB.148.3.769-781.1981; LANKA E, 1985, PLASMID, V14, P217, DOI 10.1016/0147-619X(85)90005-8; LANKA E, 1984, MOL GEN GENET, V194, P65, DOI 10.1007/BF00383499; LEE EH, 1990, P NATL ACAD SCI USA, V87, P4620, DOI 10.1073/pnas.87.12.4620; LIN CS, 1984, NUCLEIC ACIDS RES, V12, P8667, DOI 10.1093/nar/12.22.8667; LINDAHL G, 1971, VIROLOGY, V46, P620, DOI 10.1016/0042-6822(71)90065-1; LINDQVIST BH, 1971, VIROLOGY, V43, P1, DOI 10.1016/0042-6822(71)90218-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MERRYWEATHER A, 1986, J BACTERIOL, V167, P12, DOI 10.1128/jb.167.1.12-17.1986; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; Miele L, 1991, DNA Seq, V2, P145, DOI 10.3109/10425179109039685; Miller J. H., 1972, EXPT MOL GENETICS, P433; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NASH J, 1988, FEMS MICROBIOL LETT, V49, P257; NOSSAL NG, 1983, ANNU REV BIOCHEM, V52, P581, DOI 10.1146/annurev.bi.52.070183.003053; NURSE P, 1990, P NATL ACAD SCI USA, V87, P4615, DOI 10.1073/pnas.87.12.4615; PANSEGRAU W, 1991, NUCLEIC ACIDS RES, V19, P3455, DOI 10.1093/nar/19.12.3455; REES CED, 1990, MOL MICROBIOL, V4, P1199, DOI 10.1111/j.1365-2958.1990.tb00695.x; REES CED, 1987, PLASMID, V18, P223, DOI 10.1016/0147-619X(87)90065-5; REES CED, 1989, J BACTERIOL, V171, P3152, DOI 10.1128/jb.171.6.3152-3157.1989; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI I, 1965, J GEN MICROBIOL, V40, P365, DOI 10.1099/00221287-40-3-365; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SCHERZINGER E, 1991, NUCLEIC ACIDS RES, V19, P1203, DOI 10.1093/nar/19.6.1203; SCHERZINGER E, 1974, MOL GEN GENET, V135, P73, DOI 10.1007/BF00433903; SCHUSTER H, 1977, MOL GEN GENET, V151, P11, DOI 10.1007/BF00446907; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; SIX EW, 1991, VIROLOGY, V182, P34, DOI 10.1016/0042-6822(91)90645-R; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WATERS VL, 1991, P NATL ACAD SCI USA, V88, P1456, DOI 10.1073/pnas.88.4.1456; WILKINS B, 1992, BACTERIAL CONJUGATIO; WILKINS BM, 1981, NATURE, V290, P217, DOI 10.1038/290217a0; WILLETTS N, 1984, MICROBIOL REV, V48, P24, DOI 10.1128/MMBR.48.1.24-41.1984; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985; WOLD MS, 1982, P NATL ACAD SCI-BIOL, V79, P4907, DOI 10.1073/pnas.79.16.4907; WOOD ER, 1989, J BIOL CHEM, V264, P8297; YAKOBSON E, 1990, PLASMID, V23, P80, DOI 10.1016/0147-619X(90)90048-H; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Ziegelin G, 1991, DNA Seq, V1, P303, DOI 10.3109/10425179109020786	84	98	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					13062	13072						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618804				2022-12-25	WOS:A1992HZ48300098
J	KRUEGER, RC; HENNIG, AK; SCHWARTZ, NB				KRUEGER, RC; HENNIG, AK; SCHWARTZ, NB			2 IMMUNOLOGICALLY AND DEVELOPMENTALLY DISTINCT CHONDROITIN SULFATE PROTEOGLYCANS IN EMBRYONIC CHICK BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; CARTILAGE PROTEOGLYCAN; MONOCLONAL-ANTIBODIES; NERVOUS-SYSTEM; CORE PROTEIN; HNK-1 EPITOPE; IMMUNOCYTOCHEMICAL LOCALIZATION; ANTIGENIC DETERMINANTS; GLUCURONYL GLYCOLIPIDS; SPECIES DISTRIBUTION	Two different chondroitin sulfate proteoglycans (CSPG) in embryonic chick brain were distinguished by immunoreactivity either with S103L, a rat monoclonal antibody which reacts specifically with an 11-aminoacid region in the chondroitin sulfate domain of the core protein of chick cartilage CSPG (Krueger, R. C., Jr., Fields, T. A., Mensch, J. R., and Schwartz, N. B. (1990) J. Biol. Chem. 265, 12088-12097), or with HNK-1, a mouse monoclonal antibody which reacts with a 3-sulfoglucuronic acid residue on neural glycolipids and glycoproteins (Chou, D. K. H., Ilyas, A., Evans, J. E. Costello, C., Quarles, R. H., and Jungawala, F. B. (1986) J. Biol. Chem. 261, 11717-11725) but not with both antibodies. This specific immunoreactivity was used to separate the two CSPGs for further characterization. The S103L reactive brain proteoglycan had a core protein of similar size to cartilage CSPG (370 kDa) but exhibited a smaller hydrodynamic size (K(av) of 0.308). It was substituted predominantly with chondroitin sulfate chains and virtually no keratan sulfate chains. The HNK-1 reactive CSPG had a smaller core protein (340 kDa), an even smaller hydrodynamic size (K(av) of 0.564), and was substituted with both chondroitin sulfate and keratan sulfate chains. Glycosidase digestion patterns with endo-beta-galactosidase, N-glycosidase F, neuraminidase, and O-glycosidase, and reactivity with an antibody to the hyaluronate binding region also showed significant differences between the two brain CSPGs. Expression of the S103L reactive brain CSPG was developmentally regulated from embryonic day 7 through 19 with a peak in core protein on day 13, and in mRNA expression at day 10. In contrast the HNK-1 reactive brain CSPG was constitutively present from day 7 through hatching. These data suggest that these two distinct core proteins are immunologically and biochemically unique translation products of two different CSPG genes.	UNIV CHICAGO,DEPT PEDIAT,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637	University of Chicago; University of Chicago					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD017332, P01HD009402] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-19266] Funding Source: Medline; NICHD NIH HHS [HD-09402, HD-17332] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABO T, 1981, J IMMUNOL, V127, P1024; AQUINO DA, 1984, J CELL BIOL, V99, P1117, DOI 10.1083/jcb.99.3.1117; AQUINO DA, 1984, J CELL BIOL, V99, P1130, DOI 10.1083/jcb.99.3.1130; ARIGA T, 1987, J BIOL CHEM, V262, P848; BONNET F, 1983, BIOCHIM BIOPHYS ACTA, V743, P82, DOI 10.1016/0167-4838(83)90420-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL SC, 1988, J CELL BIOL, V106, P2191, DOI 10.1083/jcb.106.6.2191; CATERSON B, 1983, J BIOL CHEM, V258, P8848; Caterson B., 1987, BIOL PROTEOGLYCANS; CATESON B, 1986, ARTICULAR CARTILAGE; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CRAWFORD T, 1988, BIOCHIM BIOPHYS ACTA, V964, P183, DOI 10.1016/0304-4165(88)90165-1; CRAWFORD T, 1983, CAN J BIOCHEM CELL B, V61, P1251, DOI 10.1139/o83-161; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; DORFMAN A, 1980, P NATL ACAD SCI-BIOL, V77, P3971, DOI 10.1073/pnas.77.7.3971; GARVEY JS, 1977, METHOD IMMUNOL, P227; GARVEY JS, 1977, METHOD IMMUNOL, P218; GEETHAHABIB M, 1984, J BIOL CHEM, V259, P7300; GOWDA DC, 1989, BIOCHEMISTRY-US, V28, P4468, DOI 10.1021/bi00436a052; HANCOCK LW, 1988, BIOCHEM BIOPH RES CO, V152, P83, DOI 10.1016/S0006-291X(88)80683-1; HEINEGARD D, 1985, ANAL BIOCHEM, V151, P41, DOI 10.1016/0003-2697(85)90050-8; HENNIG A K, 1991, Journal of Cell Biology, V115, p126A; HERNDON ME, 1990, NEURON, V4, P949, DOI 10.1016/0896-6273(90)90148-9; HOFFMAN S, 1987, P NATL ACAD SCI USA, V84, P2523, DOI 10.1073/pnas.84.8.2523; ILYAS AA, 1986, BRAIN RES, V385, P1, DOI 10.1016/0006-8993(86)91540-4; KIANG WL, 1981, J BIOL CHEM, V256, P529; KRUEGER RC, 1990, J BIOL CHEM, V265, P12088; KRUEGER RC, 1990, J BIOL CHEM, V265, P12075; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARGOLIS RK, 1987, BIOCHEM BIOPH RES CO, V145, P1142, DOI 10.1016/0006-291X(87)91556-7; MARGOLIS RK, 1989, NEUROBIOLOGY GLYCOCO, P85; MARGOLIS RU, 1975, BIOCHEMISTRY-US, V14, P85, DOI 10.1021/bi00672a014; MARGOLIS RU, 1989, DEV NEUROSCI-BASEL, V11, P276, DOI 10.1159/000111906; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MEHMET H, 1986, EUR J BIOCHEM, V157, P385, DOI 10.1111/j.1432-1033.1986.tb09680.x; MIKOL DD, 1988, J NEUROCHEM, V50, P1924, DOI 10.1111/j.1471-4159.1988.tb02498.x; NAKANISHI S, 1983, DEV BIOL, V95, P305, DOI 10.1016/0012-1606(83)90031-3; NEAME PJ, 1987, J BIOL CHEM, V262, P17768; NORLING B, 1984, BIOCHEM J, V221, P845, DOI 10.1042/bj2210845; NORLING B, 1978, BIOCHEM BIOPH RES CO, V84, P914, DOI 10.1016/0006-291X(78)91670-4; NORONHA AB, 1986, BRAIN RES, V385, P237, DOI 10.1016/0006-8993(86)91069-3; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; OOHIRA A, 1988, J BIOL CHEM, V263, P10240; OSHANNESSY DJ, 1985, J NEUROIMMUNOL, V9, P255, DOI 10.1016/S0165-5728(85)80024-2; PERIN JP, 1984, FEBS LETT, V176, P37, DOI 10.1016/0014-5793(84)80907-2; RAUCHU, 1991, J BIOL CHEM, V266, P14785; SCHWARTING GA, 1987, DEV BIOL, V120, P65, DOI 10.1016/0012-1606(87)90104-7; SZABO MM, 1962, ARCH BIOCHEM BIOPHYS, V98, P406, DOI 10.1016/0003-9861(62)90205-9; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	51	75	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12149	12161						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601881				2022-12-25	WOS:A1992HY94700075
J	LEE, C; GORISCH, H; KLEINKAUF, H; ZOCHER, R				LEE, C; GORISCH, H; KLEINKAUF, H; ZOCHER, R			A HIGHLY SPECIFIC D-HYDROXYISOVALERATE DEHYDROGENASE FROM THE ENNIATIN PRODUCER FUSARIUM-SAMBUCINUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEREOSPECIFIC REDUCTION; 2-KETOCARBOXYLIC ACIDS; KETO ACIDS; ENZYME; SYNTHETASE; OXYSPORUM; PROTEINS	A highly specific D-hydroxyisovalerate (D-HIV) dehydrogenase, which is a key enzyme in depsipeptide synthesis, was purified to near homogeneity from the enniatin-producing fungus Fusarium sambucinum. The enzyme catalyzes the reversible reaction of 2-ketoisovalerate (2-KIV) to D-HIV. It is strictly dependent on NADPH and exhibits a high substrate specificity with respect to 2-KIV. NADH was not accepted by the enzyme. K(m) values for 2-KIV and NADPH were found to be 200 and 333-mu-M, respectively. D-HIV dehydrogenase consists of a single polypeptide chain with a molecular mass of about 53 kDa. Optimum temperature for the reduction of 2-KIV was 35-degrees-C and for the oxidation reaction was 45-degrees-C. The optimum pH was found to be 7 for the reduction and 8-9 for the oxidation reaction.	TECH UNIV BERLIN, INST BIOCHEM & MOLEK BIOL, FRANKLINSTR 29, W-1000 BERLIN 10, GERMANY; TECH UNIV BERLIN, INST BIOTECHNOL, FACHGEBIET TECH BIOCHEM, W-1000 BERLIN 65, GERMANY	Technical University of Berlin; Technical University of Berlin								AUDHYA TK, 1973, ANAL LETT, V6, P265; AUDHYA TK, 1973, CAN J MICROBIOL, V19, P1051, DOI 10.1139/m73-166; BILLICH A, 1988, APPL ENVIRON MICROB, V54, P2504, DOI 10.1128/AEM.54.10.2504-2509.1988; BILLICH A, 1987, BIOCHEMISTRY-US, V26, P8417, DOI 10.1021/bi00399a058; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CROWELL PL, 1988, METHOD ENZYMOL, V166, P39; FROYSHOV O, 1977, FEBS LETT, V81, P315, DOI 10.1016/0014-5793(77)80543-7; GASKING AL, 1988, METHOD ENZYMOL, V166, P20; HUMMEL W, 1983, EUR J APPL MICROBIOL, V18, P75, DOI 10.1007/BF00500828; HUMMEL W, 1985, APPL MICROBIOL BIOT, V21, P7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIVESEY G, 1988, METHOD ENZYMOL, V166, P3; MADRY N, 1983, EUR J APPL MICROBIOL, V17, P75, DOI 10.1007/BF00499854; MEISTER A, 1950, J BIOL CHEM, V184, P117; PAIS M, 1981, PHYTOCHEMISTRY, V20, P715, DOI 10.1016/0031-9422(81)85160-6; PEETERS H, 1983, J ANTIBIOT, V36, P1762, DOI 10.7164/antibiotics.36.1762; PLATTNER PA, 1948, HELV CHIM ACTA, V31, P594, DOI 10.1002/hlca.19480310240; RUDIGER HW, 1972, BIOCHEM J, V126, P445, DOI 10.1042/bj1260445; SCHUTTE H, 1984, APPL MICROBIOL BIOT, V19, P167, DOI 10.1007/BF00256449; SMITH GD, 1975, J AM CHEM SOC, V97, P7242, DOI 10.1021/ja00858a008; ZOCHER R, 1983, BIOCHEM BIOPH RES CO, V110, P292, DOI 10.1016/0006-291X(83)91294-9; ZOCHER R, 1982, BIOCHEMISTRY-US, V21, P43, DOI 10.1021/bi00530a008; ZOCHER R, 1976, FEBS LETT, V71, P13, DOI 10.1016/0014-5793(76)80887-3	24	43	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11741	11744						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601849				2022-12-25	WOS:A1992HY94700018
J	MCLEAN, LR; THOMAS, CE; WEINTRAUB, B; HAGAMAN, KA				MCLEAN, LR; THOMAS, CE; WEINTRAUB, B; HAGAMAN, KA			MODULATION OF THE PHYSICAL STATE OF CELLULAR CHOLESTERYL ESTERS BY 4,4'-(ISOPROPYLIDENEDITHIO)BIS(2,6-DI-TERT-BUTYLPHENOL) (PROBUCOL)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; HERITABLE HYPERLIPIDEMIC RABBIT; FAMILIAL HYPERCHOLESTEROLEMIA; ATHEROSCLEROTIC LESIONS; FATTY STREAKS; FOAM CELLS; PROGRESSION; REGRESSION; HYDROLYSIS; METABOLISM	The effect of 4,4'-(isopropylidenedithio)bis(2,6-di-t-butylphenol) (probucol) on cholesteryl ester physical state was examined in dry mixtures, phospholipid-containing dispersions, and cells. Probucol has little effect on the solid to isotropic transition of cholesteryl oleate, but broadens and decreases the enthalpy of the liquid-crystalline transitions at concentrations as low as 1-2 mol %. A probucol transition is only observed at concentrations > 20 mol %. The mesomorphic phases of the cholesteryl oleate/probucol mixtures were identified by visual inspection and polarized light microscopy. Mixtures are liquid at probucol concentrations in excess of 5 mol % at 37-degrees-C. Probucol also dramatically reduces the enthalpy of the liquid-crystalline transitions of the cholesteryl oleate core of dispersions of the ester with phospholipids at a concentration of 10 mol %, reducing the enthalpy by >80% and the transition temperatures by approximately 2-degrees-C. The phase state of cholesteryl esters in Fu5AH rat hepatoma cells was examined after incubation with cholesterol/phospholipid dispersions that caused the accumulation of anisotropic cholesteryl ester droplets. Differential scanning calorimetry scans of cells incubated with cholesterol-rich phospholipid dispersions indicated a phase transition near 48-degrees-C, which was abolished when the cells were co-incubated with 50-100-mu-g/ml of probucol in the loading medium. Subsequent to the formation of isotropic cholesteryl ester droplets in the presence of probucol, the rate of efflux of cholesterol from the cells to phosphatidylcholine-containing acceptors in the medium was increased. These data show that probucol is relatively soluble in cholesteryl esters and that probucol changes the phase state of cholesteryl ester droplets in cells to a more fluid phase in which the cholesteryl esters are more readily mobilized.			MCLEAN, LR (corresponding author), MARION MERRELL DOW RES INST, 2110 E GALBRAITH RD, CINCINNATI, OH 45215 USA.							ADELMAN SJ, 1984, J BIOL CHEM, V259, P3844; ARBOGAST LY, 1976, P NATL ACAD SCI USA, V73, P3680, DOI 10.1073/pnas.73.10.3680; BAKER SG, 1982, S AFR MED J, V62, P7; BALASUBRAMANIAM S, 1981, CLIN SCI, V61, P615, DOI 10.1042/cs0610615; BARNHART JW, 1970, AM J CLIN NUTR, V23, P1229; BELLAMY MF, 1989, EUR J BIOCHEM, V183, P321, DOI 10.1111/j.1432-1033.1989.tb14932.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN MS, 1980, J BIOL CHEM, V255, P9344; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; CORTESE C, 1982, ATHEROSCLEROSIS, V44, P319, DOI 10.1016/0021-9150(82)90006-5; CRAIG IF, 1982, J BIOL CHEM, V257, P330; CROLL DH, 1985, BIOCHEMISTRY-US, V24, P7971, DOI 10.1021/bi00348a020; DACHET C, 1985, ATHEROSCLEROSIS, V58, P261, DOI 10.1016/0021-9150(85)90071-1; FELLIN R, 1986, ATHEROSCLEROSIS, V59, P47, DOI 10.1016/0021-9150(86)90032-8; GLICK JM, 1983, J BIOL CHEM, V258, P3425; HAMILTON JA, 1977, J BIOL CHEM, V252, P8071; HARRIS RS, 1974, J AM GERIATR SOC, V22, P167, DOI 10.1111/j.1532-5415.1974.tb02163.x; KATZ S S, 1976, Journal of Clinical Investigation, V58, P200; KESANIEMI YA, 1984, J LIPID RES, V25, P780; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; LI JR, 1980, ATHEROSCLEROSIS, V36, P559, DOI 10.1016/0021-9150(80)90248-8; MAO SJT, 1991, J MED CHEM, V34, P298, DOI 10.1021/jm00105a046; MCLEAN LR, 1989, BIOCHEMISTRY-US, V28, P321, DOI 10.1021/bi00427a043; MCLEAN LR, 1988, BIOCHIM BIOPHYS ACTA, V959, P201, DOI 10.1016/0005-2760(88)90191-9; MIETTINEN TA, 1986, AM J CARDIOL, V57, pH49, DOI 10.1016/0002-9149(86)90439-X; MINOR LK, 1989, J LIPID RES, V30, P189; NARUSZEWICZ M, 1984, J LIPID RES, V25, P1206; NESTEL PJ, 1981, ATHEROSCLEROSIS, V38, P203, DOI 10.1016/0021-9150(81)90117-9; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; ROSEVEAR FB, 1954, J AM OIL CHEM SOC, V31, P628, DOI 10.1007/BF02545595; SHANKAR R, 1989, ATHEROSCLEROSIS, V78, P91, DOI 10.1016/0021-9150(89)90212-8; Small D. M., 1970, SURFACE CHEM BIOL SY, P55; SMALL DM, 1988, ARTERIOSCLEROSIS, V8, P103, DOI 10.1161/01.ATV.8.2.103; SMALL DM, 1986, HDB LIPID RES, V4, P395; SNOW JW, 1988, BIOCHEMISTRY-US, V27, P3640, DOI 10.1021/bi00410a018; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; YAMAMOTO A, 1986, AM J CARDIOL, V57, pH29, DOI 10.1016/0002-9149(86)90434-0; YAMAMOTO A, 1983, ATHEROSCLEROSIS, V48, P157, DOI 10.1016/0021-9150(83)90102-8	39	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12291	12298						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601894				2022-12-25	WOS:A1992HY94700095
J	MEYER, ME; QUIRINSTRICKER, C; LEROUGE, T; BOCQUEL, MT; GRONEMEYER, H				MEYER, ME; QUIRINSTRICKER, C; LEROUGE, T; BOCQUEL, MT; GRONEMEYER, H			A LIMITING FACTOR MEDIATES THE DIFFERENTIAL ACTIVATION OF PROMOTERS BY THE HUMAN PROGESTERONE-RECEPTOR ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ESTROGEN-RECEPTOR; RICH TRANSCRIPTIONAL ACTIVATOR; HUMAN GLUCOCORTICOID RECEPTOR; THYROID-HORMONE; RESPONSIVE ELEMENT; BINDING DOMAIN; AMINO-ACIDS; CELL-TYPE; EXPRESSION; YEAST	The two transcription activation functions (TAFs) of the human progesterone receptor (hPR) have been characterized. TAF-1, located in the N-terminal region A/B, has been narrowed down to a 91-amino acid sequence, which is sufficient for transcription activation in chimeras with the GAL4 DNA binding domain. Both hPR TAF-1 and TAF-2 activate a minimal promoter in yeast. No autonomous TAF could be found in the N-terminal 164 amino acids (designated AB3) which are responsible for the differential activation of promoters by the hPR isoforms A and B. Reduction of the target gene promoter complexity did not alter this differential activation, indicating that AB3 does not require additional promoter-bound factors to exert its effect. Instead, the cell specificity of AB3 and its ability to squelch hPR-induced transcription suggest that this differential isoform activity is due to the effect of a limiting factor which binds to region AB3.	FAC MED STRASBOURG,FAC MED,INSERM,UNITE BIOL MOLEC & GEN GENET,CNRS,GENET MOLEC EUCARYOTES LAB,F-67085 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Gronemeyer, Hinrich/G-6240-2011; Gronemeyer, Hinrich/H-7002-2016; Gronemeyer, Hinrich/AAH-5575-2019	Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449				BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DOBSON ADW, 1989, J BIOL CHEM, V264, P4207; EUL J, 1989, EMBO J, V8, P83, DOI 10.1002/j.1460-2075.1989.tb03351.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRONEMEYER H, 1987, EMBO J, V6, P3985, DOI 10.1002/j.1460-2075.1987.tb02741.x; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; GRONEMEYER H, 1991, J STEROID BIOCHEM, V40, P271, DOI 10.1016/0960-0760(91)90192-8; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KASTNER P, 1990, J BIOL CHEM, V265, P12163; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAURENT BC, 1990, MOL CELL BIOL, V10, P5616, DOI 10.1128/MCB.10.11.5616; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; SCHEMSHEDINI L, 1992, J BIOL CHEM, V267, P1834; SCHMID W, 1989, EMBO J, V8, P2257, DOI 10.1002/j.1460-2075.1989.tb08350.x; SCHRADER WT, 1972, J BIOL CHEM, V247, P51; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; UEMSONO K, 1989, CELL, V57, P1139; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WEBSTER NJG, 1989, EMBO J, V8, P1441, DOI 10.1002/j.1460-2075.1989.tb03526.x; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WRIGHT APH, 1990, J BIOL CHEM, V265, P14763; YAOITA Y, 1990, P NATL ACAD SCI USA, V87, P7090, DOI 10.1073/pnas.87.18.7090; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x	42	139	142	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10882	10887						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587864				2022-12-25	WOS:A1992HV09000100
J	SHI, YQ; RANDO, RR				SHI, YQ; RANDO, RR			KINETIC MECHANISM OF ISOPRENYLATED PROTEIN METHYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA SUBUNITS CONTAIN; CYSTEINE METHYL-ESTER; GTP-BINDING PROTEINS; POSTTRANSLATIONAL MODIFICATION; CARBOXYL TERMINI; FARNESYL; P21RAS; IDENTIFICATION; TRANSFERASE; TRANSDUCIN	The kinetic mechanism of the rod outer segment (ROS) isoprenylated protein methyltransferase was investigated. This S-adenosyl-L-methionine (AdoMet)-linked enzyme transfers methyl groups to carboxyl-terminal isoprenylated cysteine residues of proteins, generating methyl esters. The enzyme also processes simple substrates such as N-acetyl-S-farnesyl-L-CySteine (L-AFC). Initial studies showed that a ping-pong Bi Bi mechanism could be eliminated. In a ping-pong Bi Bi mechanism plots of 1/v versus 1/[substrate A] at different fixed substrate B concentrations are expected to yield a family of parallel lines whose slopes equal K(m)/V(max). In fact, converging curves were found, which suggested a sequential mechanism. Dead-end inhibitors were used in order to further investigate the kinetic mechanism. S-Farnesylthioacetic acid is shown to be a dead-end competitive inhibitor with respect to the prenylated substrate L-AFC. On the other hand, S-farnesylthioacetic acid proved to be uncompetitive with respect to AdoMet, suggesting an ordered mechanism with AdoMet binding first. Further evidence for this mechanism came from product inhibition studies using the methyl ester of L-AFC (L-AFCMe) and S-adenosyl-L-homocysteine (AdoHcy). Since AdoMet binds first to the enzyme, one of the products (L-AFCMe or AdoHcy) should be a competitive inhibitor with respect to it. It could be shown that AdoHcy is a competitive inhibitor with respect to AdoMet, but L-AFCMe is a mixed-type inhibitor both with respect to AdoMet and to L-AFC. Therefore, AdoHcy combines with the same enzyme form as does AdoMet, and must be released from the enzyme last. Moreover, L-AFC and L-AFCMe must bind to different forms of the enzyme.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,250 LONGWOOD AVE,BOSTON,MA 02115	Harvard University; Harvard Medical School					NATIONAL EYE INSTITUTE [R01EY003624] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034346] Funding Source: NIH RePORTER; NEI NIH HHS [EY-03624] Funding Source: Medline; NHLBI NIH HHS [HL-34346] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECK LA, 1990, J CELL BIOL, V110, P1489, DOI 10.1083/jcb.110.5.1489; CAAMANO CA, 1989, J NEUROCHEM, V53, P1883, DOI 10.1111/j.1471-4159.1989.tb09257.x; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DIDSBURY JR, 1990, BIOCHEM BIOPH RES CO, V171, P804, DOI 10.1016/0006-291X(90)91217-G; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GUNTHERT U, 1981, J BIOL CHEM, V256, P9346; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HINCHIGERI SB, 1982, PHOTOSYNTHETICA, V16, P554; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MALTESE WA, 1990, J BIOL CHEM, V265, P2148; OTA IM, 1989, J BIOL CHEM, V264, P12879; PEREZSALA D, 1991, P NATL ACAD SCI USA, V88, P3043, DOI 10.1073/pnas.88.8.3043; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SEGEL IH, 1975, ENZYME KINETICS, P606; SEGEL IH, 1975, ENZYME KINETICS, P777; SHAFER WR, 1989, SCIENCE, V245, P379; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; STEPHENSON RC, 1990, J BIOL CHEM, V265, P16248; STRYER L, 1988, COLD SPRING HARB SYM, V53, P283, DOI 10.1101/SQB.1988.053.01.035; SWANSON RJ, 1983, J BIOL CHEM, V258, P599; TAN EW, 1991, J BIOL CHEM, V266, P10719; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; WU JC, 1987, J BIOL CHEM, V262, P4778; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286	34	48	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9547	9551						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577795				2022-12-25	WOS:A1992HT96500018
J	BARABAS, K; SIZENSKY, JA; FAULK, WP				BARABAS, K; SIZENSKY, JA; FAULK, WP			TRANSFERRIN CONJUGATES OF ADRIAMYCIN ARE CYTOTOXIC WITHOUT INTERCALATING NUCLEAR-DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG RESISTANCE; CYTO-TOXICITY; CELL-GROWTH; BINDING; RECEPTORS; MEMBRANE; DERIVATIVES; DAUNOMYCIN; ANTIBODIES; EXPRESSION	Studies of the biological chemistry of most anticancer drugs have revealed their cytotoxicity is expressed after the drugs have entered cells. It is thought that anthracycline antitumor drugs exert their cytotoxicity by entering cells, diffusing into nuclei, and inhibiting topoisomerase II and/or intercalating DNA base pairs. In order to deliver anthracyclines to transferrin (TRF) receptors on the plasma membranes of human tumor cells, we have prepared conjugates of adriamycin (ADR) with human TRF. These TRF-ADR conjugates were found to be stable at low pH and to exert more efficient cytotoxicity than free drug. By using spectro-fluorometry, we found that the fluorescence of ADR within the conjugate was quenched by native DNA, demonstrating the presence of conformationally available drug to intercalate with nuclear DNA. However, fluorescence was not quenched when conjugate was reacted with viable cells, indicating that ADR did not reach the nucleus. Results of fluorescence microscopy experiments confirmed that free but not conjugated ADR reached the nuclei of viable cells, and TRF-ADR conjugates labeled with fluorescein isothiocyanate were found to initiate lateral diffusion as determined by patch and cap reactions. The involvement of TRF receptors was shown by flow cytometry experiments in which native TRF inhibited binding of fluorescein-labeled TRF-ADR conjugates. These data suggest that TRF-ADR conjugates mediate cytotoxicity by a mechanism other than intercalation with nuclear DNA. This mechanism, revealed by conjugating ADR to a TRF carrier, may not initiate complications such as cardiotoxicity and drug resistance.	PURDUE UNIV,DEPT MED CHEM,W LAFAYETTE,IN 47907; HUNGARIAN ACAD SCI,BIOL RES CTR,INST BIOPHYS,H-6701 SZEGED,HUNGARY	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Hungarian Academy of Sciences; Hungarian Biological Research Center	BARABAS, K (corresponding author), METHODIST HOSP INDIANA,CTR REPROD & TRANSPLANTAT IMMUNOL,INDIANAPOLIS,IN 46202, USA.							ARCAMONE F, 1981, DOXORUBICIN ANTICANC, P93; BARABAS K, 1991, AM J REPROD IMMUNOL, V25, P120, DOI 10.1111/j.1600-0897.1991.tb01078.x; BODLEY A, 1989, CANCER RES, V49, P5969; BRADLEY G, 1988, BIOCHIM BIOPHYS ACTA, V948, P87, DOI 10.1016/0304-419X(88)90006-6; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; BURKE TG, 1985, BIOCHEMISTRY-US, V24, P5972, DOI 10.1021/bi00342a043; CRANE FL, 1990, GROWTH FACTORS GENES, P228; DIMARCO A, 1971, BIOCHEM PHARMACOL, V20, P1323, DOI 10.1016/0006-2952(71)90365-0; DUPONT B, 1972, TISSUE ANTIGENS, V2, P141; EDELMAN GM, 1976, SCIENCE, V192, P218, DOI 10.1126/science.769162; EDIDIN M, 1987, CURR TOP MEMBR TRANS, V29, P91; FAULK W P, 1990, Molecular Biotherapy, V2, P57; Faulk W.P., 1990, OXIDOREDUCTION PLASM, V1, P205; FAULK WP, 1980, LANCET, V2, P390; FAULK WP, 1972, PROG ALLERGY, V16, P9; FAULK WP, 1979, PROC R SOC SER B-BIO, V204, P83, DOI 10.1098/rspb.1979.0014; FAULK WP, 1991, BIOCHEM INT, V25, P815; FAULK WP, 1975, NATURE, V256, P123, DOI 10.1038/256123a0; FAULK WP, 1990, AM J REPROD IMMUNOL, V21, P151; FAULK WP, 1988, PLASMA MEMBRANE OXID, P173; GALBRAITH GMP, 1980, CELL IMMUNOL, V49, P215, DOI 10.1016/0008-8749(80)90072-6; GALBRAITH RM, 1981, IMMUNOLOGY, V44, P703; GOLDMAN R, 1978, BIOCHIM BIOPHYS ACTA, V512, P254, DOI 10.1016/0005-2736(78)90251-1; GOORMAGHTIGH E, 1980, BIOCHIM BIOPHYS ACTA, V597, P1, DOI 10.1016/0005-2736(80)90145-5; GOORMAGHTIGH E, 1983, BIOCHEM PHARMACOL, V32, P889, DOI 10.1016/0006-2952(83)90593-2; GOORMAGHTIGH E, 1980, BIOCHEM PHARMACOL, V29, P3003, DOI 10.1016/0006-2952(80)90050-7; HAMILTON TC, 1984, CANCER RES, V44, P5286; HENRY N, 1985, BIOCHEMISTRY-US, V24, P7085, DOI 10.1021/bi00346a010; HURWITZ E, 1975, CANCER RES, V35, P1175; JEANNESSON P, 1990, CANCER RES, V50, P1231; KESSEL D, 1970, CANCER RES, V30, P2695; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; LESLEY J, 1984, CELL IMMUNOL, V83, P14, DOI 10.1016/0008-8749(84)90220-X; LESLEY JF, 1985, MOL CELL BIOL, V5, P1814, DOI 10.1128/MCB.5.8.1814; MAY PM, 1980, INORG CHIM A-BIOINOR, V46, P221, DOI 10.1016/S0020-1693(00)84195-X; MCCORMICK JN, 1971, J EXP MED, V133, P1, DOI 10.1084/jem.133.1.1; MINOW RA, 1975, CANCER CHEMOTH REP 3, V6, P195; MYERS C, 1986, FASEB J, V45, P2792; NECKERS LM, 1983, P NATL ACAD SCI-BIOL, V80, P3494, DOI 10.1073/pnas.80.11.3494; NEIDLE S, 1987, BIOCHEM J, V243, P1; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; POMMIER Y, 1986, CANCER RES, V46, P611; POTMESIL M, 1988, ANTHRACYCLINE ANTHRA, P447; RAMU A, 1989, RESISTANCE ANTINEOPL, P63; ROGERS KE, 1984, BIOCHEM PHARMACOL, V33, P605, DOI 10.1016/0006-2952(84)90315-0; ROGERS KE, 1983, CANCER RES, V43, P2741; SIZENSKY J, 1991, IN PRESS AM J REPROD; SUN IL, 1987, BIOCHEM INT, V14, P119; SUN IL, 1990, OXIDOREDUCTION PLASM, V1, P257; SUN IL, 1992, IN PRESS BIOCH BIOPH; TARASIUK J, 1989, BIOCHIM BIOPHYS ACTA, V1013, P109, DOI 10.1016/0167-4889(89)90038-4; TOKES ZA, 1982, P NATL ACAD SCI-BIOL, V79, P2026, DOI 10.1073/pnas.79.6.2026; TOKOYAMA M, 1990, CANCER RES, V50, P1693; TOOLESIMMS W, 1991, BIOCHEM BIOPH RES CO, V176, P1437, DOI 10.1016/0006-291X(91)90447-F; TRITTON TR, 1982, SCIENCE, V217, P248, DOI 10.1126/science.7089561; VAICKUS L, 1985, J IMMUNOL, V135, P1987; VANBOCKXMEER FM, 1978, EUR J BIOCHEM, V92, P147; WANG AL, 1985, CANCER TREAT REP, V69, P677; Yeh C. J. G., 1984, PROTIDES BIOL FLUIDS, V32, P441; YEH CJG, 1982, EXP CELL RES, V138, P429, DOI 10.1016/0014-4827(82)90192-6; YEH CJG, 1984, VOX SANG, V46, P217, DOI 10.1111/j.1423-0410.1984.tb00078.x; YEH CJG, 1984, CLIN IMMUNOL IMMUNOP, V52, P1; ZWEIER JL, 1984, J BIOL CHEM, V259, P6056	63	70	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9437	9442						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577771				2022-12-25	WOS:A1992HR85400110
J	BONEWALD, LF; KESTER, MB; SCHWARTZ, Z; SWAIN, LD; KHARE, A; JOHNSON, TL; LEACH, RJ; BOYAN, BD				BONEWALD, LF; KESTER, MB; SCHWARTZ, Z; SWAIN, LD; KHARE, A; JOHNSON, TL; LEACH, RJ; BOYAN, BD			EFFECTS OF COMBINING TRANSFORMING GROWTH-FACTOR-BETA AND 1,25-DIHYDROXYVITAMIN-D3 ON DIFFERENTIATION OF A HUMAN OSTEOSARCOMA (MG-63)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEO-SARCOMA CELLS; ALKALINE-PHOSPHATASE; TRANSCRIPTIONAL REGULATION; CHONDROCYTE CULTURES; PHOSPHOLIPASE-C; MESSENGER-RNA; RETINOIC ACID; RESTING ZONE; BONE; PROTEIN	Transforming growth factor-beta (TGF-beta) and 1,25-dihydroxyvitamin D3 (1,25D3), when added simultaneously to a human osteosarcoma cell line, MG-63, induce alkaline phosphatase activity 40-70-fold over basal levels, 6-7-fold over 1,25D3 treatment alone, and 15-20-fold over TGF-beta treatment alone. TGF-beta and 1,25D3 synergistically increased alkaline phosphatase specific activity in both matrix vesicles and plasma membrane isolated from the cultures, but the specific activity was greater in and targeted to the matrix vesicle fraction. Inhibitor and cleavage studies proved that the enzymatic activity was liver/bone/kidney alkaline phosphatase. Preincubation of MG-63 cells with TGF-beta for 30 min before addition of 1,25D3 was sufficient for maximal induction of enzyme activity. Messenger RNA for liver/bone/kidney alkaline phosphatase was increased 2.1-fold with TGF-beta, 1.7-fold with 1,25D3, and 4.8-fold with the combination at 72 h. Human alkaline phosphatase protein as detected by radioimmunoassay was stimulated only 6.3-fold over control levels with the combination. This combination of factors was tested for their effect on production of three other osteoblast cell proteins: collagen type I, osteocalcin, and fibronectin. TGF-beta inhibited 1,25D3-induced osteocalcin production, whereas both factors were additive for fibronectin and collagen type I production. TGF-beta appears to modulate the differentiation effects of 1,25D3 on this human osteoblast-like cell and thereby retain the cell in a non-fully differentiated state.	UNIV TEXAS, HLTH SCI CTR, DEPT ORTHOPAED, SAN ANTONIO, TX 78284 USA; UNIV TEXAS, HLTH SCI CTR, DEPT CELLULAR & STRUCT BIOL, SAN ANTONIO, TX 78284 USA; HEBREW UNIV JERUSALEM, HADASSAH FAC DENT MED, JERUSALEM, ISRAEL	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Hebrew University of Jerusalem	BONEWALD, LF (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT MED, DIV ENDOCRINOL & METAB, 7703 FLOYD CURL DR, SAN ANTONIO, TX 78284 USA.		Bonewald, Lynda/Q-3638-2019	Leach, Robin/0000-0002-3201-5579	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039357] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE005937] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39357] Funding Source: Medline; NIDCR NIH HHS [DE08563, DE05937] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; BERESFORD JN, 1984, METAB BONE DIS RELAT, V5, P299; BONEWALD LF, 1990, J CELL PHYSIOL, V145, P200, DOI 10.1002/jcp.1041450203; BONEWALD LF, 1990, CLIN ORTHOP RELAT R, P261; BONEWALD LF, 1989, CONNECT TISSUE RES, V23, P201, DOI 10.3109/03008208909002418; BONEWALD LF, 1987, J BONE MINER RES  S1, V2, P23; BORGERS M, 1973, J HISTOCHEM CYTOCHEM, V21, P812, DOI 10.1177/21.9.812; BOYAN BD, 1988, BONE, V9, P185, DOI 10.1016/8756-3282(88)90008-7; BOYAN BD, 1989, J BIOL CHEM, V264, P11879; CELESTE AJ, 1986, EMBO J, V5, P1885, DOI 10.1002/j.1460-2075.1986.tb04440.x; CENTRELLA M, 1989, ENDOCRINOLOGY, V125, P199, DOI 10.1210/endo-125-1-199; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CRABB ID, 1990, J BONE MINER RES, V5, P1105; DOTY SB, 1980, J HISTOCHEM CYTOCHEM, V28, P66, DOI 10.1177/28.1.6153197; DWORETZKY SI, 1990, P NATL ACAD SCI USA, V87, P4605, DOI 10.1073/pnas.87.12.4605; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINKELMAN RD, 1985, J DENT RES, V64, P1008, DOI 10.1177/00220345850640070301; FITZPATRICK DF, 1969, J BIOL CHEM, V244, P3561; FRANCESCHI RT, 1985, J CELL PHYSIOL, V123, P401, DOI 10.1002/jcp.1041230316; FRANCESCHI RT, 1987, J BIOL CHEM, V262, P4165; FRANCESCHI RT, 1990, J BONE MINER RES, V5, P1157; FRANCESCHI RT, 1988, J BONE MINER RES  S1, V3, P57; GARBA MT, 1986, CALCIFIED TISSUE INT, V38, P296, DOI 10.1007/BF02556610; GESTENFELD LC, 1987, DEV BIOL, V122, P49; GUNDBERG CM, 1984, METHOD ENZYMOL, V107, P516; HEBDA PA, 1988, J INVEST DERMATOL, V91, P440, DOI 10.1111/1523-1747.ep12476480; HEINO J, 1989, J BIOL CHEM, V264, P21806; HILL CS, 1990, J BONE MINER RES S2, V5, P646; IGNOTZ RA, 1989, J BIOL CHEM, V264, P389; IWAMOTO M, 1989, BIOCHEM BIOPH RES CO, V159, P1006, DOI 10.1016/0006-291X(89)92208-0; JOYCE ME, 1990, J CELL BIOL, V110, P2195, DOI 10.1083/jcb.110.6.2195; KATO Y, 1988, P NATL ACAD SCI USA, V85, P9552, DOI 10.1073/pnas.85.24.9552; LAJEUNESSE D, 1990, J BONE MINER RES, V5, P915, DOI 10.1002/jbmr.5650050904; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LIAN JB, 1985, J BIOL CHEM, V260, P8706; LOW MG, 1977, BIOCHEM J, V167, P281, DOI 10.1042/bj1670281; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCELLI C, 1990, J BONE MINER RES, V5, P1087; MASSAGUE J, 1987, J CELL PHYSIOL, P43; MINGHETTI PP, 1988, FASEB J, V2, P3043, DOI 10.1096/fasebj.2.15.2847948; MULIVOR RA, 1978, ANN HUM GENET, V42, P1, DOI 10.1111/j.1469-1809.1978.tb00927.x; NAKAMURA T, 1988, ARCH BIOCHEM BIOPHYS, V265, P190, DOI 10.1016/0003-9861(88)90384-0; NG KW, 1989, J MOL ENDOCRINOL, V3, P57, DOI 10.1677/jme.0.0030057; NODA M, 1989, ENDOCRINOLOGY, V124, P612, DOI 10.1210/endo-124-2-612; NODA M, 1988, J BIOL CHEM, V263, P13916; NODA M, 1987, J CELL PHYSIOL, V133, P426, DOI 10.1002/jcp.1041330303; NODA M, 1989, ENDOCRINOLOGY, V124, P2991, DOI 10.1210/endo-124-6-2991; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; PFEILSCHIFTER J, 1987, ENDOCRINOLOGY, V121, P212, DOI 10.1210/endo-121-1-212; POSER JW, 1980, J BIOL CHEM, V255, P8685; Price P.A., 1987, CALCIUM REGULATION B, V9, P419; PRICE PA, 1980, J BIOL CHEM, V255, P1660; RIZZINO A, 1988, DEV BIOL, V130, P411, DOI 10.1016/0012-1606(88)90337-5; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SCHWARTZ Z, 1990, BIOCHIM BIOPHYS ACTA, V1027, P278, DOI 10.1016/0005-2736(90)90319-J; SEYEDIN SM, 1986, J BIOL CHEM, V261, P5693; SPORN MB, 1986, SCIENCE, V233, P532, DOI 10.1126/science.3487831; TONG PS, 1990, J INVEST DERMATOL, V94, P126, DOI 10.1111/1523-1747.ep12873985; VANBELLE H, 1972, BIOCHIM BIOPHYS ACTA, V289, P158, DOI 10.1016/0005-2744(72)90118-0; WEISS MJ, 1986, P NATL ACAD SCI USA, V83, P7182, DOI 10.1073/pnas.83.19.7182; WERGEDAL JE, 1992, METABOLISM, V41, P42, DOI 10.1016/0026-0495(92)90189-H; WERGEDAL JE, 1990, J BONE MINER RES S2, V5, P238; WHYTE MP, 1986, J PEDIATR-US, V108, P82, DOI 10.1016/S0022-3476(86)80773-9; WUTHIER RE, 1977, CALC TISS RES, V24, P163, DOI 10.1007/BF02223311; [No title captured]	66	181	183	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8943	8949						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577731				2022-12-25	WOS:A1992HR85400039
J	KRIKORIAN, JG; BLOCH, RJ				KRIKORIAN, JG; BLOCH, RJ			TREATMENTS THAT EXTRACT THE 43K-PROTEIN FROM ACETYLCHOLINE-RECEPTOR CLUSTERS MODIFY THE CONFORMATION OF CYTOPLASMIC DOMAINS OF ALL SUBUNITS OF THE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TORPEDO POSTSYNAPTIC MEMBRANES; MARMORATA ELECTRIC ORGAN; CELL-SUBSTRATE CONTACT; CULTURED RAT MYOTUBES; MONOCLONAL-ANTIBODIES; RICH MEMBRANES; ALPHA-SUBUNIT; NEUROMUSCULAR-JUNCTION; SKELETAL-MUSCLE; TRANSMEMBRANE TOPOGRAPHY	The nicotinic acetylcholine receptor (AChR) of Torpedo electric organ and vertebrate skeletal muscle is closely associated with a M(r) 43,000 protein (43K). In this study, we have examined the effects on the AChR of treatments which remove the 43K protein. We used semiquantitative fluorescence techniques to measure the binding of antibodies to clustered AChR in cultured rat myotubes. We found that labeling by antibodies to the cytoplasmic portions of each of the four receptor polypeptides increased significantly upon extraction of the 43K protein. Labeling by an antibody to an extracellular epitope of the alpha-subunits was not affected by removal of the 43K Protein, suggesting that changes were restricted to the cytoplasmic domains of the AChR. Increases in labeling by antibodies were more limited following protease treatment, which removes most cytoskeletal structures but leaves the 43K protein bound to the membrane. Competition between an antibody to the beta-subunit and an antibody to the gamma and delta-subunits suggests that the cytoplasmic portion of the AChR still retains a degree of native structure in the absence of the 43K protein. Our results suggest that, although some of these changes may be due to simply exposing additional epitopes on the AChR, the cytoplasmic portions of all the subunits of the AChR undergo significant conformational changes upon extraction of the 43K protein.	UNIV MARYLAND,SCH MED,DEPT PHYSIOL,660 W REDWOOD ST,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017282] Funding Source: NIH RePORTER; NINDS NIH HHS [NS17282] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAETSCHER M, 1986, J CELL BIOL, V103, P369, DOI 10.1083/jcb.103.2.369; BARRANTES FJ, 1980, FEBS LETT, V112, P73, DOI 10.1016/0014-5793(80)80131-1; BLOCH RJ, 1984, J CELL BIOL, V99, P984, DOI 10.1083/jcb.99.3.984; BLOCH RJ, 1987, J CELL BIOL, V104, P645, DOI 10.1083/jcb.104.3.645; BLOCH RJ, 1991, J CELL BIOL, V115, P435, DOI 10.1083/jcb.115.2.435; BLOCH RJ, 1989, J CELL BIOL, V108, P481, DOI 10.1083/jcb.108.2.481; BLOCH RJ, 1986, J CELL BIOL, V102, P1447, DOI 10.1083/jcb.102.4.1447; BLOCH RJ, 1983, J CELL BIOL, V97, P217, DOI 10.1083/jcb.97.1.217; BLOCH RJ, 1989, EXP CELL RES, V182, P583, DOI 10.1016/0014-4827(89)90261-9; BLOCH RJ, 1980, CELL, V21, P25, DOI 10.1016/0092-8674(80)90111-7; BLOCH RJ, 1988, AM J PHYSIOL, V254, pC345, DOI 10.1152/ajpcell.1988.254.3.C345; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; BRIDGMAN PC, 1987, J CELL BIOL, V105, P1829, DOI 10.1083/jcb.105.4.1829; BURDEN SJ, 1983, CELL, V35, P687, DOI 10.1016/0092-8674(83)90101-0; BURDEN SJ, 1985, P NATL ACAD SCI USA, V82, P8270, DOI 10.1073/pnas.82.23.8270; CARR C, 1989, J CELL BIOL, V109, P1753, DOI 10.1083/jcb.109.4.1753; CARTAUD J, 1981, J CELL BIOL, V90, P418, DOI 10.1083/jcb.90.2.418; CHANG HW, 1977, BIOCHEMISTRY-US, V16, P4513, DOI 10.1021/bi00639a028; DANIELS MP, 1990, J CELL SCI, V97, P615; DANIELS MP, 1990, EXP CELL RES, V186, P99, DOI 10.1016/0014-4827(90)90215-V; DEROMANELLI ICB, 1987, BIOCHEM J, V105, P111; ELLIOTT J, 1980, BIOCHEM J, V185, P667, DOI 10.1042/bj1850667; FRAIL DE, 1988, J BIOL CHEM, V263, P15602; FROEHNER SC, 1991, J CELL BIOL, V114, P1, DOI 10.1083/jcb.114.1.1; FROEHNER SC, 1987, J CELL BIOL, V104, P1633, DOI 10.1083/jcb.104.6.1633; FROEHNER SC, 1990, NEURON, V5, P403, DOI 10.1016/0896-6273(90)90079-U; FROEHNER SC, 1984, J CELL BIOL, V99, P88, DOI 10.1083/jcb.99.1.88; FROEHNER SC, 1983, J BIOL CHEM, V258, P7112; GENTRY LE, 1983, J BIOL CHEM, V258, P1219; GUY HR, 1987, TRENDS NEUROSCI, V10, P318, DOI 10.1016/0166-2236(87)90087-7; GYSIN R, 1981, J BIOL CHEM, V256, P1373; HALL ZW, 1981, J CELL BIOL, V90, P789, DOI 10.1083/jcb.90.3.789; HAMILTON SL, 1977, BIOCHEM BIOPH RES CO, V79, P692, DOI 10.1016/0006-291X(77)91167-6; JOHNSON GD, 1981, J IMMUNOL METHODS, V43, P349, DOI 10.1016/0022-1759(81)90183-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPOLLA RJ, 1984, P NATL ACAD SCI-BIOL, V81, P7970, DOI 10.1073/pnas.81.24.7970; LAROCHELLE WJ, 1986, J BIOL CHEM, V261, P5270; LO MMS, 1980, FEBS LETT, V111, P407, DOI 10.1016/0014-5793(80)80838-6; MCCREA PD, 1987, EMBO J, V6, P3619, DOI 10.1002/j.1460-2075.1987.tb02693.x; MITRA AK, 1989, J CELL BIOL, V109, P755, DOI 10.1083/jcb.109.2.755; NEUBIG RR, 1979, P NATL ACAD SCI USA, V76, P690, DOI 10.1073/pnas.76.2.690; NGHIEM HO, 1983, P NATL ACAD SCI-BIOL, V80, P6403, DOI 10.1073/pnas.80.20.6403; PEDERSEN SE, 1986, J BIOL CHEM, V261, P3735; PEDERSEN SE, 1990, J BIOL CHEM, V265, P569; PENG HB, 1985, J CELL BIOL, V100, P1698, DOI 10.1083/jcb.100.5.1698; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; PORTER S, 1983, J BIOL CHEM, V258, P34; PUMPLIN DW, 1989, J CELL BIOL, V109, P739, DOI 10.1083/jcb.109.2.739; RATNAM M, 1986, BIOCHEMISTRY-US, V25, P2621, DOI 10.1021/bi00357a051; RATNAM M, 1986, BIOCHEMISTRY-US, V25, P2633, DOI 10.1021/bi00357a052; RAVDIN P, 1977, ANAL BIOCHEM, V80, P585, DOI 10.1016/0003-2697(77)90682-0; RAVDIN P, ANAL BIOCHEM, V83, P336; ROUSSELET A, 1982, EMBO J, V1, P439, DOI 10.1002/j.1460-2075.1982.tb01188.x; SALPETER MM, 1985, PROG NEUROBIOL, V25, P297, DOI 10.1016/0301-0082(85)90018-8; SARGENT PB, 1984, J CELL BIOL, V98, P609, DOI 10.1083/jcb.98.2.609; SCHUETZE SM, 1987, ANNU REV NEUROSCI, V10, P403, DOI 10.1146/annurev.ne.10.030187.002155; SEALOCK R, 1982, J NEUROSCI, V2, P918; SEALOCK R, 1984, J CELL BIOL, V98, P2239, DOI 10.1083/jcb.98.6.2239; SEALOCK R, 1986, EXP CELL RES, V163, P143, DOI 10.1016/0014-4827(86)90566-5; SOBEL A, 1978, P NATL ACAD SCI USA, V75, P510, DOI 10.1073/pnas.75.1.510; STEINBACH JH, 1986, RECEPTORS CELLULAR R, P183; STRADER CD, 1980, BIOCHEM BIOPH RES CO, V92, P365, DOI 10.1016/0006-291X(80)90342-3; STROUD RM, 1985, ANNU REV CELL BIOL, V1, P317, DOI 10.1146/annurev.cb.01.110185.001533; TOYOSHIMA C, 1990, J CELL BIOL, V111, P2623, DOI 10.1083/jcb.111.6.2623; TOYOSHIMA C, 1988, NATURE, V336, P247, DOI 10.1038/336247a0; TZARTOS S, 1986, J NEUROIMMUNOL, V10, P235, DOI 10.1016/0165-5728(86)90105-0; TZARTOS SJ, 1981, J BIOL CHEM, V256, P8635; TZARTOS SJ, 1988, P NATL ACAD SCI USA, V85, P2899, DOI 10.1073/pnas.85.9.2899; WENNOGLE LP, 1980, EUR J BIOCHEM, V106, P381, DOI 10.1111/j.1432-1033.1980.tb04584.x; WOODRUFF ML, 1987, J CELL BIOL, V104, P939, DOI 10.1083/jcb.104.4.939	70	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9118	9128						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577748				2022-12-25	WOS:A1992HR85400065
J	SUGUMARAN, G; KATSMAN, M; SILBERT, JE				SUGUMARAN, G; KATSMAN, M; SILBERT, JE			EFFECTS OF BREFELDIN-A ON THE LOCALIZATION OF CHONDROITIN SULFATE-SYNTHESIZING ENZYMES - ACTIVITIES IN SUBFRACTIONS OF THE GOLGI FROM CHICK-EMBRYO EPIPHYSEAL CARTILAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR-TRANSPORT; RAT HEPATOCYTES; BIOSYNTHESIS; PROTEINS; PROTEOCHONDROITIN; OLIGOSACCHARIDES; CELLS; SITE; ER	Membranes from brefeldin A-treated and untreated chick embryo epiphyseal cartilage were fractionated separately by equilibrium sucrose density gradient centrifugation. Fractions were assayed for Gal I transferase, Gal II transferase, Gal ovalbumin transferase, chondroitin polymerization on endogenous acceptors, GalNAc transfer to exogenous chondroitin hexasaccharide, and sulfate transfer to exogenous chondroitin. Gal I transferase and Gal II transferase activities were found in heavier cis- and medial-Golgi fractions, but with distributions different from each other. Brefeldin A had no effect on either their distribution or their total activity. Gal ovalbumin transferase activity in fractions from untreated cartilage was found as a dual peak in medial- and trans-Golgi areas. The latter peak was diminished in the fractions from the brefeldin A-treated cartilage, whereas the former peak was correspondingly increased. A similar dual medial- and trans-Golgi distribution for chondroitin polymerization on endogenous acceptors was seen with fractions from untreated cartilage. This was modified in fractions from brefeldin A-treated cartilage with a complete loss of synthesis in the trans-Golgi peak and a slight increase in synthesis in the medial-Golgi peak. However, the distribution of GalNAc transferase activity using exogenous chondroitin hexasaccharide indicated that considerable chondroitin-synthesizing activity still remained in these trans-Golgi fractions. This demonstrated that brefeldin A had caused a block in movement of endogenous proteochondroitin acceptors to the trans-Golgi site of synthesis. Sulfotransferase activity was also found in a dual distribution similar to that of the chondroitin polymerization and GalNAc transferase, with a small reduction in activity in the trans-Golgi fractions of brefeldin A-treated cartilage. Thus, treatment of cartilage with brefeldin A resulted in the loss of considerable trans-Golgi chondroitin sulfate-synthesizing enzyme activity and a block in the transport of one form of proteochondroitin precursor to the trans-Golgi membranes.	DEPT VET AFFAIRS, OUTPATIENT CLIN, CONNECT TISSUE RES LAB, BOSTON, MA 01730 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School								DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V109, P61; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; FALTYNEK CR, 1981, J BIOL CHEM, V256, P7202; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; HELTING T, 1969, J BIOL CHEM, V244, P2790; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; ORCI L, 1991, CELL, V64, P1183; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; ROBINSON JA, 1981, BIOCHEM J, V194, P839, DOI 10.1042/bj1940839; RODEN L, 1972, METHODS ENZYMOLOGY B, V28, P638; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SILBERT JE, 1976, J BIOL CHEM, V251, P3942; SPIRO RC, 1991, J CELL BIOL, V115, P1463, DOI 10.1083/jcb.115.5.1463; SUGUMARAN G, 1986, CARBOHYD RES, V151, P185, DOI 10.1016/S0008-6215(00)90339-2; SUGUMARAN G, 1989, METHOD ENZYMOL, V179, P422; SUGUMARAN G, 1991, J BIOL CHEM, V266, P9565; SUGUMARAN G, 1990, J BIOL CHEM, V265, P18284; SUGUMARAN G, 1991, BIOCHEM J, V277, P787, DOI 10.1042/bj2770787; ULMER JB, 1991, EUR J CELL BIOL, V54, P38; VELASCO A, 1988, EUR J CELL BIOL, V47, P241; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5	27	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8802	8806						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577720				2022-12-25	WOS:A1992HR85400018
J	YONAHA, K; NISHIE, M; AIBARA, S				YONAHA, K; NISHIE, M; AIBARA, S			THE PRIMARY STRUCTURE OF OMEGA-AMINO ACID-PYRUVATE AMINOTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTATE-AMINOTRANSFERASE; ESCHERICHIA-COLI; TYROSINE AMINOTRANSFERASE; SEQUENCE; ENZYME; CLONING; PURIFICATION; TRYPTOPHAN; MECHANISM; PROTEINS	The complete amino acid sequence of bacterial omega-amino acid:pyruvate aminotransferase (omega-APT) was determined from its primary structure. The enzyme protein was fragmented by CNBr cleavage, trypsin, and Staphylococcus aureus V8 digestions. The peptides were purified and sequenced by Edman degradation. omega-ATP is composed of four identical subunits of 449 amino acids each. The calculated molecular weight of the enzyme subunit is 48,738 and that of the enzyme tetramer is 194,952. No disulfide bonds or bound sugar molecules were found in the enzyme structure, although 6 cysteine residues were determined per enzyme subunit. Sequence homologies were found between an omega-aminotransferase, i.e. mammalian and yeast ornithine delta-aminotransferases, fungal gamma-aminobutyrate aminotransferase and 7,8-diaminoperalgonate aminotransferase, and 2,2-dialkylglycine decarboxylase. The enzyme structure is not homologous to those of aspartate aminotransferases (AspATs) including the enzymes of Escherichia coli and Sufolobus salfactaricus, though significant homology in the three-dimensional structures around the cofactor binding site has been found between omega-APT and AspATs (Watanabe, N., Sakabe, K., Sakabe, N., Higashi, T., Sasaki, K., Aibara, S., Morita, Y., Yonaha, K., Toyama, S., and Fukutani, H. (1989) J. Biochem. 105, 1-3).	KYOTO UNIV, RES INST, UJI, KYOTO 611, JAPAN	Kyoto University	YONAHA, K (corresponding author), UNIV RYUKYUS, DEPT AGR CHEM, NISHIHARA, OKINAWA 90301, JAPAN.							ARNONE A, 1985, TRANSAMINASES, P139; Christen P, 1985, TRANSAMINASES; CUBELLIS MV, 1989, EUR J BIOCHEM, V186, P375, DOI 10.1111/j.1432-1033.1989.tb15219.x; DIXON HBF, 1968, BIOCHEM J, V109, P312, DOI 10.1042/bj1090312; DRAPEAU GR, 1972, J BIOL CHEM, V247, P6720; GOOD WB, 1982, NUCLEIC ACIDS RES, V10, P247; GROSS E, 1962, J BIOL CHEM, V237, P1856; HARGROVE JL, 1989, J BIOL CHEM, V264, P45; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HOUMARD J, 1972, P NATL ACAD SCI USA, V69, P3506, DOI 10.1073/pnas.69.12.3506; HYDE CC, 1988, J BIOL CHEM, V263, P17857; INANA G, 1986, P NATL ACAD SCI USA, V83, P1203, DOI 10.1073/pnas.83.5.1203; JOHNSON LN, 1980, J MOL BIOL, V140, P565, DOI 10.1016/0022-2836(80)90271-5; KELLER JW, 1990, J BIOL CHEM, V265, P5531; KIRSCH JF, 1984, J MOL BIOL, V174, P497, DOI 10.1016/0022-2836(84)90333-4; KONIGSBERG W, 1972, METHOD ENZYMOL, V25, P158; LIU TY, 1971, J BIOL CHEM, V246, P2842; MARCEAU M, 1988, J BIOL CHEM, V263, P16926; MEHTA PK, 1989, EUR J BIOCHEM, V186, P249, DOI 10.1111/j.1432-1033.1989.tb15202.x; MEHTA PK, 1991, INT UNION B, V199, P35; MUECKLER MM, 1985, J BIOL CHEM, V260, P2993; OTSUKA AJ, 1988, J BIOL CHEM, V263, P19577; RICHARDSON IB, 1989, MOL GEN GENET, V217, P118, DOI 10.1007/BF00330950; SEVILLE M, 1988, BIOCHEMISTRY-US, V27, P8344, DOI 10.1021/bi00422a009; TITANI K, 1972, BIOCHEMISTRY-US, V11, P2427, DOI 10.1021/bi00763a007; WATANABE N, 1989, J BIOCHEM, V105, P1, DOI 10.1093/oxfordjournals.jbchem.a122600; WATANABE N, 1991, INT UNION B, V199, P121; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0; YONAHA K, 1983, AGR BIOL CHEM TOKYO, V47, P2257; YONAHA K, 1976, FEBS LETT, V71, P21, DOI 10.1016/0014-5793(76)80889-7; YONAHA K, 1983, J BIOL CHEM, V258, P2260	31	36	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12506	12510						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618757				2022-12-25	WOS:A1992HZ48300023
J	AU, KG; WELSH, K; MODRICH, P				AU, KG; WELSH, K; MODRICH, P			INITIATION OF METHYL-DIRECTED MISMATCH REPAIR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTS-ENCODED PROTEIN; BASE-PAIR MISMATCHES; ESCHERICHIA-COLI-B; D(GATC) SEQUENCES; GATC SEQUENCES; POLYMERASE-III; GENE-PRODUCT; DNA; INVITRO	Escherichia coli MutH possesses an extremely weak d(GATC) endonuclease that responds to the state of methylation of the sequence (Welsh, K. M., Lu, A.-L., Clark, S., and Modrich, P. (1987) J. Biol. Chem. 262, 15624-15629). MutH endonuclease is activated in a reaction that requires MutS, MutL, ATP, and Mg2+ and depends upon the presence of a mismatch within the DNA. The degree of activation correlates with the efficiency with which a particular mismatch is subject to methyl-directed repair (G-T > G-G > A-C > C-C), and activated MutH responds to the state of DNA adenine methylation. Incision of an unmethylated strand occurs immediately 5' to a d(GATC) sequence, leaving 5' phosphate and 3' hydroxy termini (p N down p G p A p-TpC). Unmethylated d(GATC) sites are subject to double strand cleavage by activated MutH, an effect that may account for the killing of dam- mutants by 2-aminopurine. The mechanism of activation apparently requires ATP hydrolysis since adenosine-5'-O-(3-thiotriphosphate) not only fails to support the reaction but also inhibits activation promoted by ATP. The process has no obligate polarity as d(GATC) site incision by the activated nuclease can occur either 3' or 5' to the mismatch on an unmethylated strand. However, activation is sensitive to DNA topology. Circular heteroduplexes are better substrates than linear molecules, and activity of DNAs of the latter class depends on placement of the mismatch and d(GATC) site within the molecule. MutH activation is supported by a 6-kilobase linear heteroduplex in which the mismatch and d(GATC) site are centrally located and separated by 1 kilobase, but a related molecule, in which the two sites are located near opposite ends of the DNA, is essentially inactive as substrate. We conclude that MutH activation represents the initiation stage of methyl-directed repair and suggest that interaction of a mismatch and a d(GATC) site is provoked by MutS binding to a mispair, with subsequent ATP-dependent translocation of one or more Mut proteins along the helix leading to cleavage at a d(GATC) sequence on either side of the mismatch.			AU, KG (corresponding author), DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA.			Modrich, Paul/0000-0001-8708-9885	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023719, R01GM023719] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23719] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENDE SM, 1991, NUCLEIC ACIDS RES, V19, P1549, DOI 10.1093/nar/19.7.1549; BENNETT SP, 1989, CURR TOP CELL REGUL, V30, P57; BRUNI R, 1988, NUCLEIC ACIDS RES, V16, P4875, DOI 10.1093/nar/16.11.4875; ENDLICH B, 1985, J BIOL CHEM, V260, P5720; GLICKMAN BW, 1980, P NATL ACAD SCI-BIOL, V77, P1063, DOI 10.1073/pnas.77.2.1063; GLICKMAN BW, 1982, MOL CELLULAR MECHANI, P65; GRAFSTROM RH, 1988, J BACTERIOL, V170, P3485, DOI 10.1128/jb.170.8.3485-3492.1988; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; HORIUCHI K, 1972, P NATL ACAD SCI USA, V69, P3220, DOI 10.1073/pnas.69.11.3220; JIRICNY J, 1988, NUCLEIC ACIDS RES, V16, P7843, DOI 10.1093/nar/16.16.7843; Kornberg A., 1991, DNA REPLICATION; LAENGLEROUAULT F, 1986, EMBO J, V5, P2009, DOI 10.1002/j.1460-2075.1986.tb04457.x; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LAHUE RS, 1987, P NATL ACAD SCI USA, V84, P1482, DOI 10.1073/pnas.84.6.1482; LANGLEROUAULT F, 1987, EMBO J, V6, P1121, DOI 10.1002/j.1460-2075.1987.tb04867.x; LIVINGSTON DM, 1975, J BIOL CHEM, V250, P470; LU AL, 1987, J BACTERIOL, V169, P1254, DOI 10.1128/jb.169.3.1254-1259.1987; LU AL, 1983, P NATL ACAD SCI-BIOL, V80, P4639, DOI 10.1073/pnas.80.15.4639; LU AL, 1984, COLD SPRING HARB SYM, V49, P589, DOI 10.1101/SQB.1984.049.01.066; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MESELSON M, 1988, RECOMBINATION GENETI, P91; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MODRICH P, 1987, ANNU REV BIOCHEM, V56, P435, DOI 10.1146/annurev.biochem.56.1.435; MODRICH P, 1989, J BIOL CHEM, V264, P6597; RADMAN M, 1988, GENETIC RECOMBINATIO, P169; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1989, GENOME, V31, P104, DOI 10.1139/g89-020; SU SS, 1988, J BIOL CHEM, V263, P6829; WELSH KM, 1987, J BIOL CHEM, V262, P15624; YUAN R, 1981, ANNU REV BIOCHEM, V50, P285, DOI 10.1146/annurev.bi.50.070181.001441	32	249	260	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12142	12148						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601880				2022-12-25	WOS:A1992HY94700074
J	LEE, YC; OEDA, T; DRISCOLL, WJ; FALES, HM; STROTT, CA				LEE, YC; OEDA, T; DRISCOLL, WJ; FALES, HM; STROTT, CA			PURIFICATION AND IDENTIFICATION OF THE HEAT-STABLE FACTOR REQUIRED FOR PREGNENOLONE-BINDING PROTEIN-ACTIVITY - EVIDENCE THAT THE FACTOR IS ADENOSINE 3',5'-DIPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG ADRENAL-CORTEX; GUINEA-PIG; SOLUBLE FRACTION; PHOSPHORYLATION; ZONES	This paper presents data identifying adenosine 3',5'-diphosphate (3',5'-ADP) as the small heat-stable factor essential for the active steroid binding complex of the adrenocortical pregnenolone-binding protein (PBP). Factor activity obtained from the boiled supernatant of partially purified PBP was isolated by high performance liquid chromatography using weak anion-exchange and hydrophobic (C18) chromatography sequentially. The purified material retained characteristic factor activity and presented a UV spectrum identical to that for authentic 3',5'-ADP. Mass spectroscopic analysis of the isolated factor revealed an M-H ion of appropriate mass (m/z = 426) and a decomposition pattern for the M-H ion that was consistent with the structure of 3',5'-ADP. The studies presented here demonstrate that authentic 3',5'-ADP can categorically substitute for factor prepared from the soluble fraction of the guinea pig adrenal. Specifically, 3',5'-ADP potentiated ligand binding of partially purified native PBP and restored binding capacity to alkaline phosphatase-inactivated PBP in a dose-dependent manner. As is the case for adrenocortical factor activity, these effects were negated by pretreating the 3',5'-ADP with calf intestinal alkaline phosphatase. Other nucleotides similarly tested, including ADP isomers, were ineffective as factor substitutes. The sulfated form of 3',5'-ADP (i.e. 3'-phosphoadenosine 5-phosphosulfate) demonstrated some potential for restoring binding capacity to phosphatase-inactivated PBP; however, this compound was clearly inhibitory rather than stimulatory for native PBP activity. Taken collectively, the data overwhelmingly demonstrate that 3',5'-ADP is in fact the molecule required by the PBP for high affinity steroid binding complex formation. It is not yet known whether 3',5'-ADP acts allosterically or contributes directly to the structure of the steroid binding site.	NICHHD,ENDOCRINOL & REPROD RES BRANCH,ADRENAL CELL BIOL SECT,BLDG 10,RM B1-L400,BETHESDA,MD 20892; NHLBI,BIOPHYS CHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								BODINE PV, 1988, J BIOL CHEM, V263, P3501; DEMURA T, 1990, ENDOCRINOLOGY, V127, P1114, DOI 10.1210/endo-127-3-1114; DRISCOLL WJ, 1990, J BIOL CHEM, V265, P12306; DRISCOLL WJ, 1991, MOL ENDOCRINOL, V5, P1229, DOI 10.1210/mend-5-9-1229; FERGUSON JJ, 1963, J BIOL CHEM, V238, P2754; Garren L D, 1968, Vitam Horm, V26, P119; KARABOYAS GC, 1965, BIOCHEMISTRY-US, V4, P462, DOI 10.1021/bi00879a014; LEE YC, 1990, P NATL ACAD SCI USA, V87, P2003, DOI 10.1073/pnas.87.5.2003; LEE YJC, 1988, BIOCHEM BIOPH RES CO, V150, P456, DOI 10.1016/0006-291X(88)90542-6; NISHIKAWA T, 1984, J STEROID BIOCHEM, V20, P1123, DOI 10.1016/0022-4731(84)90354-6; NISHIKAWA T, 1983, STEROIDS, V41, P105, DOI 10.1016/0039-128X(83)90021-1; Roy A.B., 1981, SULFATION DRUGS RELA, P83; SATO B, 1980, ENDOCRINOLOGY, V106, P1142, DOI 10.1210/endo-106-4-1142; STANLEY PE, 1975, ANAL BIOCHEM, V67, P540, DOI 10.1016/0003-2697(75)90330-9; STONE D, 1954, ARCH BIOCHEM BIOPHYS, V51, P457, DOI 10.1016/0003-9861(54)90501-9; STROTT CA, 1978, BIOCHEMISTRY-US, V17, P4557, DOI 10.1021/bi00614a030; STROTT CA, 1981, ENDOCRINOLOGY, V109, P2249, DOI 10.1210/endo-109-6-2249; STROTT CA, 1977, J BIOL CHEM, V252, P464; STROTT CA, 1983, J STEROID BIOCHEM, V18, P489, DOI 10.1016/0022-4731(83)90070-5; WHITNALL MH, 1990, J HISTOCHEM CYTOCHEM, V38, P1607, DOI 10.1177/38.11.2170503	20	4	4	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					10982	10987						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597440				2022-12-25	WOS:A1992HX16900011
J	SCHROTH, GP; SIINO, JS; COONEY, CA; THNG, JPH; HO, PS; BRADBURY, EM				SCHROTH, GP; SIINO, JS; COONEY, CA; THNG, JPH; HO, PS; BRADBURY, EM			INTRINSICALLY BENT DNA FLANKS BOTH SIDES OF AN RNA POLYMERASE-I TRANSCRIPTION START SITE - BOTH REGIONS DISPLAY NOVEL ELECTROPHORETIC MOBILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CURVED DNA; PHYSARUM-POLYCEPHALUM; ESCHERICHIA-COLI; KINETOPLAST DNA; REPLICATION ORIGIN; REGULATORY REGION; BACILLUS-SUBTILIS; SALT DEPENDENCE; THYMINE TRACTS; GEL MIGRATION	We have identified two intrinsically bent regions of DNA which flank the transcription start site of the rRNA gene from Physarum polycephalum. DNA fragments from both regions were analyzed by circular permutation polyacrylamide gel electrophoresis assay and computer modeling. Both types of analysis indicate that one fragment contains a relatively simple bend centered about 160 base pairs (bp) upstream of the transcription start site while the other fragment contains multiple bends, the most prominent of which is centered about 150 bp downstream of the start site. According to both gel mobilities and computer modeling we estimate that the net bending in each is about 45-degrees. These fragments were studied in detail by varying parameters of electrophoresis that are known to affect bending. Previous work indicates that anomalous mobility should decrease when temperature or ethidium bromide concentration is increased, whereas anomalous mobility should increase when polyacrylamide gel percentage is increased. The anomalous mobility of both fragments decreases as temperature is raised from 4 to 65-degrees-C, although the bent structure centered at - 160 bp is more temperature labile than the bend at + 150 bp. Strikingly different behavior was observed for the two fragments as the polyacrylamide concentration was varied. As polyacrylamide concentrations are increased from 6 to 10%, the anomalous mobility of the bend centered at - 160 bp increases while that of the bend centered at + 150 bp decreases. The bend centered at + 150 bp is "straightened" at all ethidium concentrations tested. In sharp contrast and unexpectedly, the anomalous migration of the bend centered at - 160 bp increases dramatically in 0.1-mu-g/ml ethidium bromide. Many of the mobility differences we observe suggest that the two regions studied represent structurally distinct forms of bent DNA. The location of these strongly bent regions on either side of a RNA polymerase I transcription start site suggests important roles for such structures in chromatin structure and transcription initiation.	UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616; CITY HOPE NATL MED CTR,BECKMAN RES INT,DEPT BIOL,DUARTE,CA 91010; UNIV CALIF LOS ALAMOS SCI LAB,DIV LIFE SCI,LOS ALAMOS,NM 87545	University of California System; University of California Davis; City of Hope; Beckman Research Institute of City of Hope; United States Department of Energy (DOE); Los Alamos National Laboratory	SCHROTH, GP (corresponding author), OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,535 WENIGER HALL,CORVALLIS,OR 97331, USA.		Ho, Pui S/F-6186-2014; Ho, Pui/AAF-8838-2020	Ho, Pui S/0000-0002-8082-4311; Ho, Pui/0000-0002-8082-4311; Cooney, Craig/0000-0003-4279-557X	NIA NIH HHS [R01AG08196] Funding Source: Medline; NIGMS NIH HHS [GM-26901] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG008196] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMERO SA, 1988, J BIOL CHEM, V263, P10734; ANDERSON JN, 1986, NUCLEIC ACIDS RES, V14, P8513, DOI 10.1093/nar/14.21.8513; BLUM B, 1983, NUCLEIC ACIDS RES, V11, P8519, DOI 10.1093/nar/11.23.8519; BOLSHOY A, 1991, P NATL ACAD SCI USA, V88, P2312, DOI 10.1073/pnas.88.6.2312; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; BRADBURY EM, 1981, DNA CHROMATIN CHROMO; BRESLOFF JL, 1981, BIOCHEMISTRY-US, V20, P3547, DOI 10.1021/bi00515a038; CADDLE MS, 1990, J MOL BIOL, V211, P19, DOI 10.1016/0022-2836(90)90008-A; COLLIS CM, 1989, NUCLEIC ACIDS RES, V17, P9447, DOI 10.1093/nar/17.22.9447; COSTANZO G, 1990, J MOL BIOL, V216, P363, DOI 10.1016/S0022-2836(05)80327-4; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; DEB S, 1986, MOL CELL BIOL, V6, P4578, DOI 10.1128/MCB.6.12.4578; DIEKMANN S, 1987, NUCLEIC ACIDS RES, V15, P247, DOI 10.1093/nar/15.1.247; DIEKMANN S, 1985, J MOL BIOL, V186, P1, DOI 10.1016/0022-2836(85)90251-7; DIEKMANN S, 1987, NUCLEIC ACIDS RES, V15, P5765, DOI 10.1093/nar/15.14.5765; DIEKMANN S, 1989, ELECTROPHORESIS, V10, P354, DOI 10.1002/elps.1150100513; DIEKMANN S, 1987, NUCLEIC ACIDS MOL BI, V1; DONG XN, 1989, J BACTERIOL, V171, P703, DOI 10.1128/jb.171.2.703-707.1989; DRAK J, 1991, P NATL ACAD SCI USA, V88, P3074, DOI 10.1073/pnas.88.8.3074; DREW HR, 1990, DNA TOPOLOGY ITS BIO; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; FERRIS PJ, 1982, J MOL BIOL, V159, P359, DOI 10.1016/0022-2836(82)90289-3; FERRIS PJ, 1985, GENE, V39, P203, DOI 10.1016/0378-1119(85)90314-2; Ferris PJ, 1984, THESIS CORNELL U ITH; FRANKKAMENETSKII M, 1989, NATURE, V342, P737, DOI 10.1038/342737a0; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GUBLER U, 1980, NUCLEIC ACIDS RES, V8, P4572; HERTZ GZ, 1987, J VIROL, V61, P2322, DOI 10.1128/JVI.61.7.2322-2325.1987; HOMBERGER HP, 1989, CHROMOSOMA, V98, P99, DOI 10.1007/BF00291044; INOKUCHI K, 1988, NUCLEIC ACIDS RES, V16, P6693, DOI 10.1093/nar/16.14.6693; KAWAMOTO T, 1989, NUCLEIC ACIDS RES, V17, P523, DOI 10.1093/nar/17.2.523; KENNARD O, 1989, Q REV BIOPHYS, V22, P327, DOI 10.1017/S0033583500002997; KITCHIN PA, 1986, J BIOL CHEM, V261, P1302; KODAMA H, 1987, CHROMOSOMA, V96, P18, DOI 10.1007/BF00285878; KOEPSEL RR, 1986, SCIENCE, V233, P1316, DOI 10.1126/science.3749879; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOO HS, 1987, BIOCHEMISTRY-US, V26, P3745, DOI 10.1021/bi00386a070; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; KOO HS, 1988, P NATL ACAD SCI USA, V85, P1763, DOI 10.1073/pnas.85.6.1763; KRISHNAMURTHY G, 1990, BIOCHEMISTRY-US, V29, P981, DOI 10.1021/bi00456a021; LEVENE SD, 1986, BIOCHEMISTRY-US, V25, P3988, DOI 10.1021/bi00362a003; LEVENE SD, 1989, SCIENCE, V245, P396, DOI 10.1126/science.2756426; LUCCHINI R, 1987, J MOL BIOL, V196, P829, DOI 10.1016/0022-2836(87)90408-6; MARINI JC, 1982, P NATL ACAD SCI-BIOL, V79, P7664, DOI 10.1073/pnas.79.24.7664; MCALLISTER CF, 1988, J BIOL CHEM, V263, P11743; MCALLISTER CF, 1989, J BIOL CHEM, V264, P10451; MCNAMARA PT, 1990, J BIOMOL STRUCT DYN, V8, P529, DOI 10.1080/07391102.1990.10507827; MILTON DL, 1990, NUCLEIC ACIDS RES, V18, P817, DOI 10.1093/nar/18.4.817; MILTON DL, 1990, J MOL BIOL, V213, P135, DOI 10.1016/S0022-2836(05)80126-3; MIZUNO T, 1988, MOL GEN GENET, V214, P249, DOI 10.1007/BF00337718; MIZUNO T, 1987, NUCLEIC ACIDS RES, V15, P6827, DOI 10.1093/nar/15.17.6827; MIZUNO T, 1987, GENE, V54, P57, DOI 10.1016/0378-1119(87)90347-7; MURAMATSU S, 1988, MOL GEN GENET, V214, P433, DOI 10.1007/BF00330477; OHYAMA T, 1989, NUCLEIC ACIDS RES, V17, P3845, DOI 10.1093/nar/17.10.3845; PENNINGS S, 1989, J MOL BIOL, V207, P183, DOI 10.1016/0022-2836(89)90449-X; PEPE G, 1989, NUCLEIC ACIDS RES, V17, P8803, DOI 10.1093/nar/17.21.8803; PEREZMARTIN J, 1988, NUCLEIC ACIDS RES, V16, P9113, DOI 10.1093/nar/16.19.9113; POLJAK LG, 1987, NUCLEIC ACIDS RES, V15, P5433, DOI 10.1093/nar/15.13.5433; PRENTKI P, 1987, NUCLEIC ACIDS RES, V15, P10060, DOI 10.1093/nar/15.23.10060; PRIOR CP, 1983, CELL, V34, P1033, DOI 10.1016/0092-8674(83)90561-5; RADIC MZ, 1987, CELL, V50, P1101, DOI 10.1016/0092-8674(87)90176-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRADER TE, 1990, J MOL BIOL, V216, P69; SCHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418; SCHROTH GP, 1991, NUCLEIC ACIDS RES, V19, P511, DOI 10.1093/nar/19.3.511; SCHROTH GP, 1989, NATURE, V340, P487, DOI 10.1038/340487a0; SNYDER M, 1986, NATURE, V324, P87, DOI 10.1038/324087a0; SULLIVAN KM, 1987, J MOL BIOL, V193, P397, DOI 10.1016/0022-2836(87)90227-0; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; TRAVERS AA, 1987, TRENDS BIOCHEM SCI, V12, P108, DOI 10.1016/0968-0004(87)90050-8; TRIFONOV EN, 1985, CRC CR REV BIOCH MOL, V19, P89, DOI 10.3109/10409238509082540; VONKRIES JP, 1990, NUCLEIC ACIDS RES, V18, P3881; WELLS RD, 1988, J BIOL CHEM, V263, P1095; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WILLIAMS JS, 1988, MOL CELL BIOL, V8, P2763, DOI 10.1128/MCB.8.7.2763; WILSON VG, 1989, VIRUS RES, V13, P1, DOI 10.1016/0168-1702(89)90083-X; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YEO A, 1990, VIROLOGY, V174, P329, DOI 10.1016/0042-6822(90)90085-6; ZAHN K, 1987, SCIENCE, V236, P416, DOI 10.1126/science.2951850; ZAHN K, 1985, NATURE, V317, P451, DOI 10.1038/317451a0	81	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9958	9964						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577826				2022-12-25	WOS:A1992HT96500078
J	SHIH, HM; TOWLE, HC				SHIH, HM; TOWLE, HC			DEFINITION OF THE CARBOHYDRATE RESPONSE ELEMENT OF THE RAT S14 GENE - EVIDENCE FOR A COMMON FACTOR REQUIRED FOR CARBOHYDRATE REGULATION OF HEPATIC GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-KINASE GENE; MAJOR LATE PROMOTER; METALLOTHIONEIN-I PROMOTER; TRANSCRIPTION FACTOR BINDS; GAMMA-FIBRINOGEN PROMOTER; THYROID-HORMONE; DNA-BINDING; MESSENGER RNAS14; UPSTREAM ELEMENT; MALIC ENZYME	The 5'-flanking region of the S14 gene from -4316 to +18 contains regulatory sequences responsible for activation of promoter activity in response to elevated carbohydrate metabolism in primary hepatocytes. To map these sequences, a series of constructs containing various internal deletions of the S14 5'-flanking sequence were assayed in primary hepatocytes. The region from -1601 to -1395 was found to be essential for this response. Comparison of the sequence of this S14 region to a region of the L-type pyruvate kinase gene that has been shown to mediate carbohydrate regulation (Thompson, K. S., and Towle, H. C. (1991) J. Biol. Chem. 266, 8679-8682) revealed a segment with 9 out of 10 identity. In both cases, this conserved sequence aligned with a DNase I footprint formed with hepatic nuclear extract. Oligonucleotides (approximately 30 base pairs) from either S14 Or pyruvate kinase genes containing the conserved element bound to a hepatic nuclear factor(s) that gave identical complexes by mobility shift assay. Furthermore, these two oligonucleotides cross-competed for binding to the nuclear factor(s), suggesting that a common factor(s) binds to this conserved element. Reinsertion of the S14 oligonucleotide into an unresponsive S14 promoter construct restored the carbohydrate control. Moreover, this oligonucleotide could confer a glucose response when fused to a heterologous promoter. Thus, the S14 segment from -1457 to -1428 is a carbohydrate response element essential for the binding of nuclear factor(s) regulated by increased carbohydrate metabolism. This factor(s) may be common to the carbohydrate regulation of the S14 and pyruvate kinase genes.	UNIV MINNESOTA,DEPT BIOCHEM,4-225 MILLARD HALL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,INST HUMAN GENET,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			Shih, Hsiu-Ming/S-7023-2018		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026919] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK26919] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACK DW, 1986, J BIOL CHEM, V261, P4190; BACKMANN H, 1990, GENE DEV, V4, P167; BACKMANN H, 1991, GENE DEV, V5, P1057; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DOZIN B, 1986, P NATL ACAD SCI USA, V83, P4705, DOI 10.1073/pnas.83.13.4705; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; GOODRIDGE AG, 1987, ANNU REV NUTR, V7, P157, DOI 10.1146/annurev.nu.07.070187.001105; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HROMAS R, 1986, NUCLEIC ACIDS RES, V14, P4837, DOI 10.1093/nar/14.12.4837; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; INOUE H, 1984, J BIOCHEM-TOKYO, V96, P1457, DOI 10.1093/oxfordjournals.jbchem.a134974; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; JUMP DB, 1990, J BIOL CHEM, V265, P3474; JUMP DB, 1985, ENDOCRINOLOGY, V117, P2259, DOI 10.1210/endo-117-6-2259; JUMP DB, 1984, J BIOL CHEM, V259, P2789; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LENNARD AC, 1987, EMBO J, V6, P3027, DOI 10.1002/j.1460-2075.1987.tb02608.x; LIAW C, 1983, BIOCHEMISTRY-US, V22, P213, DOI 10.1021/bi00270a031; MARIASH CN, 1981, J CLIN INVEST, V68, P1485, DOI 10.1172/JCI110401; MARIASH CN, 1986, J BIOL CHEM, V261, P9583; MARIASH CN, 1983, METABOLISM, V33, P545; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MORGAN JG, 1988, MOL CELL BIOL, V8, P2628, DOI 10.1128/MCB.8.6.2628; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OPPENHEIMER JH, 1987, ENDOCR REV, V8, P288, DOI 10.1210/edrv-8-3-288; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; POTTER JJ, 1991, J BIOL CHEM, V266, P15457; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; STROBL W, 1989, J BIOL CHEM, V264, P1190; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VAULONT S, 1986, J BIOL CHEM, V261, P7621; VAULONT S, 1989, MOL CELL BIOL, V9, P4409, DOI 10.1128/MCB.9.10.4409; ZILZ ND, 1990, J BIOL CHEM, V265, P8136	50	147	148	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13222	13228						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618827				2022-12-25	WOS:A1992JB74600023
J	UGAROVA, TP; BUDZYNSKI, AZ				UGAROVA, TP; BUDZYNSKI, AZ			INTERACTION BETWEEN COMPLEMENTARY POLYMERIZATION SITES IN THE STRUCTURAL D-DOMAIN AND E-DOMAIN OF HUMAN FIBRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRAGMENT-D; LOCALIZATION; MONOMERS; PEPTIDES; BINDING	Plasmic degradation products of human fibrin, fragments DD, D, and E, bind to fibrin. It has been inferred from this observation that the binding occurs by attraction of complementary sites located in the NH2-and COOH-terminal domains of the fibrin molecule. The interaction between fragments D1 and E1 has been investigated in this work since it represents the first step in the process of fibrin clot formation. Fragment D1, that was initially as active as fragment DD, lost most of its anticoagulant activity after purification by cation-exchange chromatography. The lability of fragment D1 function explained the previous unsuccessful attempts to form a complex between fragments D1 and E1. The loss of fragment D1 anticoagulant activity was not associated with the cleavage of the gamma-63-85 chain segment, since fragments D1A and D1 identically inhibited the fibrin monomer polymerization rate. In order to demonstrate the formation of a complex between fragments D1 and E1, three lines of experiments were advanced. First, the anticoagulant activity of fragment D1 was neutralized by fragment E1 in a dose-dependent manner, demonstrating that the association between these fragments involved polymerization sites. Second, two products, D1.E1 and D1.E1.D1, were stabilized in a reaction with bifunctional cross-linking reagents, proving the formation of D.E complexes in aqueous solution. Third, immobilized fragment D1 bound fragments E1 and E2, but not fragment E3, showing that fragments E1 and E2 attached via a polymerization site to the complementary one in fragment D1, since this association was disrupted by fibrin polymerization inhibitory peptide GPRP. These results provided direct evidence for specific binding between the structural D and E domains of fibrin mediated through complementary polymerization sites. Thus, the initial formation of fibrin clot fibers appears to be driven by specific association of these sites.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036221] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36221] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUDZYNSKI AZ, 1979, BIOCHIM BIOPHYS ACTA, V584, P284, DOI 10.1016/0304-4165(79)90273-3; BUDZYNSKI AZ, 1983, ANN NY ACAD SCI, V408, P301, DOI 10.1111/j.1749-6632.1983.tb23253.x; BUDZYNSKI AZ, 1986, CRC CR REV ONCOL-HEM, V6, P97, DOI 10.1016/S1040-8428(86)80019-1; CIERNIEWSKI CS, 1986, J BIOL CHEM, V261, P9116; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; DRAYATTALI L, 1977, THROMB RES, V10, P575, DOI 10.1016/0049-3848(77)90213-4; FOWLER WE, 1981, P NATL ACAD SCI-BIOL, V78, P4872, DOI 10.1073/pnas.78.8.4872; HANTGAN RR, 1979, J BIOL CHEM, V254, P1272; HEENE D L, 1973, Thrombosis Research, V2, P137, DOI 10.1016/0049-3848(73)90025-X; KLOCZEWIAK M, 1988, FIBRINOGEN, V3, P79; KNOLL D, 1984, BIOCHEMISTRY-US, V23, P3708, DOI 10.1021/bi00311a021; KRAKOW W, 1972, J MOL BIOL, V71, P95, DOI 10.1016/0022-2836(72)90403-2; KUDRYK B, 1973, Thrombosis Research, V2, P297, DOI 10.1016/0049-3848(73)90040-6; KUDRYK BJ, 1974, J BIOL CHEM, V249, P3322; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATALLO ZS, 1962, AM J PHYSIOL, V202, P681, DOI 10.1152/ajplegacy.1962.202.4.681; LAUDANO AP, 1978, P NATL ACAD SCI USA, V75, P3085, DOI 10.1073/pnas.75.7.3085; LAUDANO AP, 1981, SCIENCE, V212, P457, DOI 10.1126/science.7209542; MATTHIAS F R, 1973, Thrombosis Research, V3, P657, DOI 10.1016/0049-3848(73)90013-3; MIHALYI E, 1976, THROMB RES, V8, P1, DOI 10.1016/0049-3848(76)90118-3; NORTON PA, 1981, P NATL ACAD SCI-BIOL, V78, P1661, DOI 10.1073/pnas.78.3.1661; OLEXA SA, 1979, BIOCHEMISTRY-US, V18, P991, DOI 10.1021/bi00573a009; OLEXA SA, 1979, J BIOL CHEM, V254, P4925; OLEXA SA, 1981, BIOCHEMISTRY-US, V20, P6139, DOI 10.1021/bi00524a035; OLEXA SA, 1980, P NATL ACAD SCI-BIOL, V77, P1374, DOI 10.1073/pnas.77.3.1374; PANDY BV, 1991, BIOCHEMISTRY-US, V30, P162, DOI 10.1021/bi00215a024; POZDNYAKOVA TM, 1980, THROMB RES, V19, P807; PRICE TM, 1981, P NATL ACAD SCI-BIOL, V78, P200, DOI 10.1073/pnas.78.1.200; SAITO Y, 1983, ANN NY ACAD SCI, V408, P288, DOI 10.1111/j.1749-6632.1983.tb23252.x; SOUTHAN C, 1985, J BIOL CHEM, V260, P3095; TAKAGI T, 1975, BIOCHEMISTRY-US, V14, P940, DOI 10.1021/bi00676a010; TAKAGI T, 1975, THROMB RES, V7, P813, DOI 10.1016/0049-3848(75)90206-6; UGAROVA T P, 1987, Biokhimiya, V52, P255; VARADI A, 1986, BIOCHEMISTRY-US, V25, P519, DOI 10.1021/bi00351a001; WILLIAMS JE, 1981, BIOCHEM J, V197, P661, DOI 10.1042/bj1970661; WILLIAMS RC, 1981, J MOL BIOL, V150, P399, DOI 10.1016/0022-2836(81)90555-6	36	30	30	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13687	13693						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618867				2022-12-25	WOS:A1992JB74600093
J	EYCHENE, A; BARNIER, JV; DEZELEE, P; MARX, M; LAUGIER, D; CALOGERAKI, I; CALOTHY, G				EYCHENE, A; BARNIER, JV; DEZELEE, P; MARX, M; LAUGIER, D; CALOGERAKI, I; CALOTHY, G			QUAIL NEURORETINA C-RMIL(B-RAF) PROTOONCOGENE CDNAS ENCODE 2 PROTEINS OF 93.5-KDA AND 95-KDA RESULTING FROM ALTERNATIVE SPLICING	ONCOGENE			English	Article							AVIAN LYMPHOMATOSIS VIRUS; COMPLETE CODING SEQUENCE; ROUS-SARCOMA VIRUS; C-MIL; KINASE-ACTIVITY; RAF ONCOGENE; TRANSFORMING ACTIVITY; CELL-PROLIFERATION; DNA FRAGMENTS; V-MIL	c-Rmil is the cellular allele of the v-Rmil oncogene transduced during in vitro passaging of Rous-associated virus type 1 in chicken embryonic neuroretina (NR) cells. The c-Rmil proto-oncogene is the avian homolog of the mammalian B-raf gene and belongs to the mil/raf oncogene family of serine/threonine protein kinases. The c-Rmil/B-raf gene is preferentially expressed in avian and mammalian neural tissues. Two c-Rmil cDNA species, resulting from an alternative splicing mechanism, were isolated from quail embryonic NR cDNA libraries. They encode two proteins of 767 and 807 amino acids that differ by the presence of an alternative exon, located upstream of the kinase domain. Expression of these cDNAs in COS-1 cells leads to the synthesis of two proteins with apparent molecular weights of 93.5 and 95 kDa, recognized by an Rmil-specific antiserum. Both proteins are phosphorylated in an immune complex kinase assay. A protein of 94 kDa is also immunoprecipitated in avian NR cells and is identical to the 93.5-kDa protein expressed in COS-1 cells, as shown by Staphylococcus aureus V8 protease mapping. The c-Rmil proteins contain the three conserved regions previously identified in mil/raf protein kinases. In addition, they contain amino-terminal sequences that are not present in the other mil/raf proteins identified to date. These additional sequences may define a novel functional domain for c-Rmil/B-raf and could play a role in signal transduction in neural cells.	CTR UNIV ORSAY,INST CURIE,CNRS,UNITE RECH 1443,F-91405 ORSAY,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay			Eychene, Alain/M-8838-2017	EYCHENE, Alain/0000-0002-6818-7225				AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P1213; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLL J, 1983, EMBO J, V2, P2189, DOI 10.1002/j.1460-2075.1983.tb01722.x; DOZIER C, 1988, MOL CELL BIOL, V8, P1835, DOI 10.1128/MCB.8.4.1835; DOZIER C, 1991, ONCOGENE, V6, P1307; EYCHENE A, 1989, NUCLEIC ACIDS RES, V17, P1250, DOI 10.1093/nar/17.3.1250; EYCHENE A, 1990, J VIROL, V64, P231; FELDER MP, 1991, J VIROL, V65, P3633, DOI 10.1128/JVI.65.7.3633-3640.1991; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GUERMAH M, 1990, MOL CELL BIOL, V10, P3584, DOI 10.1128/MCB.10.7.3584; HUEBNER K, 1986, P NATL ACAD SCI USA, V83, P3934, DOI 10.1073/pnas.83.11.3934; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; ISHIKAWA F, 1988, ONCOGENE, V3, P653; IZUMI T, 1991, J BIOL CHEM, V266, P7933; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KAN NC, 1983, P NATL ACAD SCI-BIOL, V80, P6566, DOI 10.1073/pnas.80.21.6566; KOENEN M, 1988, ONCOGENE, V2, P179; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; Maniatis T., 1982, MOL CLONING; MARK GE, 1986, P NATL ACAD SCI USA, V83, P6312, DOI 10.1073/pnas.83.17.6312; MARX M, 1988, J VIROL, V62, P4627, DOI 10.1128/JVI.62.12.4627-4633.1988; MARX M, 1988, EMBO J, V7, P3369, DOI 10.1002/j.1460-2075.1988.tb03209.x; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PATCHINSKY T, 1986, MOL CELL BIOL, V6, P739; PESSAC B, 1974, SCIENCE, V185, P709, DOI 10.1126/science.185.4152.709; POIRIER F, 1982, J VIROL, V42, P780, DOI 10.1128/JVI.42.3.780-789.1982; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; REMAUT E, 1981, GENE, V15, P81, DOI 10.1016/0378-1119(81)90106-2; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STORM SM, 1990, ONCOGENE, V5, P345; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	56	33	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1315	1323						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620546				2022-12-25	WOS:A1992HZ97100009
J	WHITEHEART, SW; BRUNNER, M; WILSON, DW; WIEDMANN, M; ROTHMAN, JE				WHITEHEART, SW; BRUNNER, M; WILSON, DW; WIEDMANN, M; ROTHMAN, JE			SOLUBLE N-ETHYLMALEIMIDE-SENSITIVE FUSION ATTACHMENT PROTEINS (SNAPS) BIND TO A MULTI-SNAP RECEPTOR COMPLEX IN GOLGI MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR TRANSPORT; PURIFICATION; VESICLES; YEAST; STACK	Soluble N-ethylmaleimide-sensitive fusion attachment proteins (SNAPs) are required for the binding of N-ethylmaleimide-sensitive fusion protein (NSF) to Golgi membranes and are, therefore, required for intra-Golgi transport. We report the existence of distinct alpha/beta-SNAP and gamma-SNAP-binding sites in Golgi membranes that appear to be part of the same receptor complex. Cross-linking studies with alpha-SNAP demonstrate that an integral membrane protein of between 30-40 kDa is the alpha-SNAP binding component of the multi-SNAP receptor complex. These data suggest that SNAPs function by independently binding to a multi-SNAP membrane-receptor complex, thereby activating them to serve as adaptors for the targeting of NSF.	SLOAN KETTERING MEM CANC CTR,ROCKEFELLER RES LABS,PROGRAM CELLULAR BIOCHEM & BIOPHYS,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center				Whiteheart, Sidney/0000-0001-5577-0473; Brunner, Michael/0000-0001-9798-3047	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK027044, R01DK027044] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK27044] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; GORLICH D, 1991, IN PRESS METHODS CEL; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; ROTHMAN JE, 1991, NATURE, V335, P409; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; WILSON DW, 1992, IN PRESS METHODS ENZ	13	81	82	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12239	12243						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601890				2022-12-25	WOS:A1992HY94700088
J	CHAKRABORTI, PK; GARABEDIAN, MJ; YAMAMOTO, KR; SIMONS, SS				CHAKRABORTI, PK; GARABEDIAN, MJ; YAMAMOTO, KR; SIMONS, SS			ROLE OF CYSTEINE-640, CYSTEINE-656, AND CYSTEINE-661 IN STEROID BINDING TO RAT GLUCOCORTICOID RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-CULTURE CELLS; AMINO-ACID-RESIDUES; DNA-BINDING; DEXAMETHASONE 21-MESYLATE; TRANSCRIPTIONAL ENHANCEMENT; MONOCLONAL-ANTIBODY; HORMONE RECEPTORS; SULFHYDRYL-GROUPS; DOMAINS; ACTIVATION	The involvement of a vicinally spaced dithiol group in steroid binding to the glucocorticoid receptor has been deduced from experiments with the thiol-specific reagent methyl methanethiolsulfonate and the vicinal dithiol-specific reagent sodium arsenite. The vicinally spaced dithiol appears to reside in the 16-kDa trypsin fragment of the receptor, which is thought to contain 3 cysteines (Cys-640, -656, and -661 of the rat receptor) and binds hormone with an approximately 23-fold lower affinity than does the intact 98-kDa receptor. We now report that the steroid binding specificity of preparations of this 16-kDa fragment and the intact receptor are virtually identical. This finding supports our designation of the 16-kDa fragment as a steroid-binding core domain and validates our continued use of this tryptic fragment in studies of steroid binding. To identify the cysteines which comprise the vicinally spaced dithiol group, and to examine further the role of cysteines in steroid binding, a total of five point mutant receptors were prepared: cysteine-to-serine for each suspected cysteine, cysteine-to-glycine for Cys-656, and the C656,661S double mutant. Unexpectedly, each receptor with a single point mutation still bound steroid. Even the double mutant (C656,661S) bound steroid with wild type affinity. These results suggest that none of these cysteines are directly required either for steroid binding to the glucocorticoid receptor or for heat shock protein 90 association with the receptor. However, the presence of Cys-656 was obligatory for covalent labeling of the receptor by [H-3]dexamethasone 21-mesylate. Studies with preparations of the 98 and 16 kDa forms of these mutant receptors revealed both that Cys-656 and -661 comprise the vicinally spaced dithiols reacting with arsenite and that any two of the three thiols could form an intramolecular disulfide after treatment with low concentrations of methyl methanethiolsulfonate. These data, in conjunction with those from experiments on the effects of steric bulk on various receptor functions, support a model for the ligand binding cavity of the receptor that involves all three thiols in a flexible cleft but where thiol-steroid interactions are not essential for binding.	NIDDKD,MOLEC & CELLULAR BIOL LAB,STEROID HORMONES SECT,BLDG 8,RM B2A-07,BETHESDA,MD 20892; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of California System; University of California San Francisco								BAXTER JD, 1971, P NATL ACAD SCI USA, V68, P932, DOI 10.1073/pnas.68.5.932; BYRAVAN S, 1991, MOL ENDOCRINOL, V5, P752, DOI 10.1210/mend-5-6-752; CADEPOND F, 1991, J BIOL CHEM, V266, P5834; CARLSTEDTDUKE J, 1988, J BIOL CHEM, V263, P6842; CHAKRABORTI PK, 1990, ENDOCRINOLOGY, V127, P2530, DOI 10.1210/endo-127-5-2530; CHAKRABORTI PK, 1991, J BIOL CHEM, V266, P22075; CHAKRABORTI PK, 1991, BIOCHEM BIOPH RES CO, V176, P1338, DOI 10.1016/0006-291X(91)90433-8; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DANIELSEN M, 1987, MOL ENDOCRINOL, V1, P816, DOI 10.1210/mend-1-11-816; DISORBO DM, 1980, ENDOCRINOLOGY, V106, P922, DOI 10.1210/endo-106-3-922; EHRHART JC, 1988, ONCOGENE, V3, P595; EISEN LP, 1985, J BIOL CHEM, V260, P1805; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; GABER BP, 1972, BIOINORG CHEM, V2, P135; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GEHRING U, 1988, AFFINITY LABELLING C, P144; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GRANBERG JP, 1977, ENDOCRINOLOGY, V100, P160; HOECK W, 1989, J BIOL CHEM, V264, P14396; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HURLEY DM, 1991, J CLIN INVEST, V87, P680, DOI 10.1172/JCI115046; JACOBSON BL, 1991, J BIOL CHEM, V266, P5220; JANIN J, 1990, J BIOL CHEM, V265, P16027; KING RJB, 1974, STEROID CELL INTERAC, P109; KOBLINSKY M, 1972, J BIOL CHEM, V247, P7897; LAMONTAGNE N, 1984, ENDOCRINOLOGY, V114, P2252, DOI 10.1210/endo-114-6-2252; LOPEZ S, 1990, J BIOL CHEM, V265, P16039; MARCH J, 1985, ADV ORG CHEM, P1092; MATSUMURA M, 1989, SCIENCE, V243, P792, DOI 10.1126/science.2916125; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MILLER NR, 1988, J BIOL CHEM, V263, P15217; MORNON JP, 1980, J MOL BIOL, V137, P415, DOI 10.1016/0022-2836(80)90166-7; NARAY A, 1982, J STEROID BIOCHEM, V16, P199, DOI 10.1016/0022-4731(82)90168-6; NEMOTO T, 1990, BIOCHEMISTRY-US, V29, P1880, DOI 10.1021/bi00459a031; OBRIEN JM, 1981, J STEROID BIOCHEM, V14, P9, DOI 10.1016/0022-4731(81)90186-2; ODONNELL AL, 1991, MOL ENDOCRINOL, V5, P94, DOI 10.1210/mend-5-1-94; OJASOO T, 1988, J MED CHEM, V31, P1160, DOI 10.1021/jm00401a015; PICADOLEONARD J, 1988, MOL ENDOCRINOL, V2, P1145, DOI 10.1210/mend-2-11-1145; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PONS M, 1981, J ORG CHEM, V46, P3262, DOI 10.1021/jo00329a024; PONS M, 1985, J STEROID BIOCHEM, V23, P267, DOI 10.1016/0022-4731(85)90404-2; PRATT WB, 1988, J BIOL CHEM, V263, P267; Raynaud J.P., 1979, DRUG DESIGN, V8, P170; REES AM, 1975, BIOCHIM BIOPHYS ACTA, V411, P121, DOI 10.1016/0304-4165(75)90291-3; RICHARDSON JS, 1981, ADV PROTEIN CHEM, V34, P223; Rodbard D, 1973, RECEPTORS REPRODUCTI, V36, P289; ROUSSEAU GG, 1977, J STEROID BIOCHEM, V8, P911, DOI 10.1016/0022-4731(77)90187-X; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; SANCHEZ ER, 1992, J BIOL CHEM, V267, P17; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SIMONS SS, 1987, J BIOL CHEM, V262, P9676; SIMONS SS, 1990, J BIOL CHEM, V265, P1938; SIMONS SS, 1979, BIOCHEM BIOPH RES CO, V86, P793, DOI 10.1016/0006-291X(79)91782-0; SIMONS SS, 1983, J BIOL CHEM, V258, P2229; SIMONS SS, 1984, BIOCHEMISTRY-US, V23, P6876, DOI 10.1021/bi00321a092; SIMONS SS, 1987, J BIOL CHEM, V262, P9669; SIMONS SS, 1989, J BIOL CHEM, V264, P14493; SIMONS SS, 1981, P NATL ACAD SCI-BIOL, V78, P3541, DOI 10.1073/pnas.78.6.3541; SINGH R, 1991, J ORG CHEM, V56, P2332, DOI 10.1021/jo00007a018; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WOLFF ME, 1978, BIOCHEMISTRY-US, V17, P3201, DOI 10.1021/bi00609a005; WRANGE O, 1978, J BIOL CHEM, V253, P856; Yen P M, 1991, Receptor, V1, P191; ZAHLER WL, 1968, J BIOL CHEM, V243, P716	69	79	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11366	11373						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597467				2022-12-25	WOS:A1992HX16900067
J	MA, CP; SLAUGHTER, CA; DEMARTINO, GN				MA, CP; SLAUGHTER, CA; DEMARTINO, GN			IDENTIFICATION, PURIFICATION, AND CHARACTERIZATION OF A PROTEIN ACTIVATOR (PA28) OF THE 20-S PROTEASOME (MACROPAIN)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT PROTEINASE; RAT HEPATOMA-CELLS; MULTICATALYTIC PROTEINASE; CDNA CLONING; HUMAN-ERYTHROCYTES; SKELETAL-MUSCLE; GENE FAMILY; LATENT FORM; UBIQUITIN; COMPLEX	A protein that greatly stimulates the multiple peptidase activities of the 20 S proteasome (also known as macropain, the multicatalytic protease complex, and 20 S protease) has been purified from bovine red blood cells and from bovine heart. The activator protein was a single polypeptide with an apparent molecular weight of 28,000, as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and had a native molecular weight of approximately 180,000. This protein, which we have termed PA28, regulated all three of the putatively distinct peptidase activities displayed by each of two functionally different forms of the proteasome. This regulation usually included both an increase in the maximal reaction velocity and a decrease in the concentration of substrate required for half-maximal velocity and indicated that PA28 acted as a positive allosteric effector of the proteasome. PA28 failed, however, to stimulate the hydrolysis of large protein substrates such as casein and lysozyme. These results suggested that the hydrolysis of protein substrates occurred at a site or sites distinct from those that hydrolyzed small peptides and that the regulation of the two processes could be uncoupled. Evidence for direct binding of PA28 to the proteasome was obtained by glycerol density gradient centrifugation. PA28 may play an important regulatory role in intracellular proteolytic pathways mediated by the proteasome.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	MA, CP (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235, USA.				NHLBI NIH HHS [HL06296] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL006296] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARRIBAS J, 1990, J BIOL CHEM, V265, P13969; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; DAHLMANN B, 1985, BIOCHEM J, V228, P171, DOI 10.1042/bj2280171; DEMARTINO GN, 1991, BIOCHIM BIOPHYS ACTA, V1079, P29, DOI 10.1016/0167-4838(91)90020-Z; DEMARTINO GN, 1991, BIOCHIM BIOPHYS ACTA, V1073, P299, DOI 10.1016/0304-4165(91)90135-4; DICK LR, 1991, BIOCHEMISTRY-US, V30, P2725, DOI 10.1021/bi00224a022; DRISCOLL J, 1989, P NATL ACAD SCI USA, V86, P787, DOI 10.1073/pnas.86.3.787; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FUJIWARA T, 1990, J BIOL CHEM, V265, P16604; FUJIWARA T, 1989, BIOCHEMISTRY-US, V28, P7332, DOI 10.1021/bi00444a028; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; HAASS C, 1989, EMBO J, V8, P2373, DOI 10.1002/j.1460-2075.1989.tb08366.x; HAASS C, 1990, GENE, V90, P235, DOI 10.1016/0378-1119(90)90185-T; HAASS C, 1990, NUCLEIC ACIDS RES, V18, P4018, DOI 10.1093/nar/18.13.4018; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HOUGH R, 1987, J BIOL CHEM, V262, P8303; LEE LW, 1990, BIOCHIM BIOPHYS ACTA, V1037, P178, DOI 10.1016/0167-4838(90)90165-C; MA CP, 1992, BIOCHIM BIOPHYS ACTA, V1119, P303, DOI 10.1016/0167-4838(92)90218-3; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MCGUIRE MJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P181, DOI 10.1016/0167-4838(89)90078-2; MCGUIRE MJ, 1988, BIOCHIM BIOPHYS ACTA, V967, P195, DOI 10.1016/0304-4165(88)90009-8; MCGUIRE MJ, 1989, BIOCHEM BIOPH RES CO, V160, P911, DOI 10.1016/0006-291X(89)92521-7; MCGUIRE MJ, 1986, BIOCHIM BIOPHYS ACTA, V873, P279, DOI 10.1016/0167-4838(86)90055-5; MCGUIRE MJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P272; ORLOWSKI M, 1991, BIOCHEMISTRY-US, V30, P5999, DOI 10.1021/bi00238a025; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORLOWSKI M, 1989, BIOCHEMISTRY-US, V28, P9270, DOI 10.1021/bi00450a006; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; RIVETT AJ, 1985, J BIOL CHEM, V260, P2600; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; SHANKLIN J, 1987, P NATL ACAD SCI USA, V84, P359, DOI 10.1073/pnas.84.2.359; SORIMACHI H, 1990, EUR J BIOCHEM, V193, P775, DOI 10.1111/j.1432-1033.1990.tb19399.x; TAMURA T, 1990, FEBS LETT, V264, P91, DOI 10.1016/0014-5793(90)80773-C; TANAKA K, 1990, BIOCHEM BIOPH RES CO, V171, P676, DOI 10.1016/0006-291X(90)91199-3; TANAKA K, 1986, J BIOL CHEM, V261, P5197; WAXMAN L, 1987, J BIOL CHEM, V262, P2451; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; YU B, 1991, J BIOL CHEM, V266, P17396	40	315	319	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10515	10523						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587832				2022-12-25	WOS:A1992HV09000047
J	OUSLEY, AH; MORELL, P				OUSLEY, AH; MORELL, P			INDIVIDUAL MOLECULAR-SPECIES OF PHOSPHATIDYLCHOLINE AND PHOSPHATIDYLETHANOLAMINE IN MYELIN TURN OVER AT DIFFERENT RATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; TRANSFER PROTEINS; PHOSPHOLIPIDS; BRAIN; DEACYLATION; MICROSOMES	Phosphatidylcholine (PC) and phosphatidylethanolamine (PE) of the myelin membrane exhibit heterogeneity with respect to metabolic turnover rate (Miller, S. L., Benjamins, J. A., and Morell, P. (1977) J. Biol. Chem. 252, 4025-4037). To test the hypothesis that this is due to differential turnover of individual molecular species (which differ in acyl chain composition), we have examined the relative turnover of individual molecular species of myelin PC and PE. Phospholipids were labeled by injection of [2-H-3]glycerol into the brains of young rats. Myelin was isolated at 1, 15, and 30 days post-injection, lipids were extracted, and phospholipid classes were separated by thin-layer chromatography. The PC and PE fractions were hydrolyzed with phospholipase C, and the resulting diacylglycerols were dinitrobenzoylated and fractionated by reverse-phase high performance liquid chromatography. The distribution of radioactivity among individual molecular species was determined. The labeled molecular species of myelin PC were 16:0-16:0, 16:0-18:0, 16:0-18:1, and 18:0- 18: 1, with most of the label present in 16:0-18:1 and 18:0-18:1. Changes in distribution of label with time after injection indicated that 16:0-18:1 turned over more rapidly than 18:0- 18: 1. The labeled molecular species of myelin PE were 18:0-20:4, 18:1-18:1, 16:0-18:1, 18:0-18:2, and 18:0-18:1. As with myelin PC, 16:0-18:1 (and 18:1-18:1) turned over more rapidly than 18:0-18: 1. The relative turnover of individual molecular species of PC in the microsomal fraction from forebrain was also examined. The molecular species profile was different from myelin PC, but again, 16:0-18:1 turned over more rapidly than the other molecular species. Thus, within the same membrane, individual molecular species of a phospholipid class are metabolized at different rates. Comparison of our results with previous studies of turnover of molecular classes of phospholipids indicates that in addition to polar head group composition (Miller et al., 1977), fatty acid composition is very important in determining the metabolic fate of a phospholipid.	UNIV N CAROLINA,BRAIN & DEV RES CTR,CB 7250,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NINDS NIH HHS [NS11615] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011615] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BATLEY M, 1980, J CHROMATOGR, V198, P520, DOI 10.1016/S0021-9673(00)80524-5; BENJAMINS JA, 1976, J NEUROCHEM, V27, P565, DOI 10.1111/j.1471-4159.1976.tb12283.x; BENJAMINS JA, 1973, J NEUROCHEM, V20, P1111, DOI 10.1111/j.1471-4159.1973.tb00081.x; Benjamins JA, 1984, MYELIN, P225; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRECKENR.WC, 1968, LIPIDS, V3, P291, DOI 10.1007/BF02530927; COHEN BG, 1980, J BIOL CHEM, V255, P3075; DAWSON R. M. C., 1966, ESSAYS BIOCHEM, V2, P69; FUNKHOUSER JD, 1985, CHEM PHYS LIPIDS, V38, P17, DOI 10.1016/0009-3084(85)90054-4; GANSER AL, 1988, DEV NEUROSCI-BASEL, V10, P99, DOI 10.1159/000111961; HASSNER A, 1978, TETRAHEDRON, V34, P2069, DOI 10.1016/0040-4020(78)89005-X; HOLUB BJ, 1982, BIOCHIM BIOPHYS ACTA, V711, P305, DOI 10.1016/0005-2760(82)90039-X; HORROCKS LA, 1976, FUNCTION METABOLISM, P37; HORROCKS LA, 1972, RESEARCH METHODS NEU, V1, P223; KASURINEN J, 1990, BIOCHEMISTRY-US, V29, P8548, DOI 10.1021/bi00489a007; KITO M, 1985, J BIOCHEM-TOKYO, V98, P327, DOI 10.1093/oxfordjournals.jbchem.a135285; LEE CH, 1991, J NEUROCHEM, V56, P370, DOI 10.1111/j.1471-4159.1991.tb08161.x; LEE TC, 1973, BIOCHIM BIOPHYS ACTA, V291, P86; LEWIS KA, 1990, BIOCHEMISTRY-US, V29, P9962, DOI 10.1021/bi00494a029; MILLER SL, 1978, J NEUROCHEM, V31, P771, DOI 10.1111/j.1471-4159.1978.tb00109.x; MILLER SL, 1977, J BIOL CHEM, V252, P4025; NORTON WT, 1973, J NEUROCHEM, V21, P759, DOI 10.1111/j.1471-4159.1973.tb07520.x; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; Norton WT., 1984, MYELIN, P147, DOI DOI 10.1007/978-1-4757-1830-0_5; OMURA T, 1967, J BIOL CHEM, V242, P2389; PASQUINI JM, 1973, J NEUROCHEM, V21, P647, DOI 10.1111/j.1471-4159.1973.tb06009.x; PASTERNAK CA, 1970, BIOCHEM J, V119, P473, DOI 10.1042/bj1190473; PIND S, 1985, CAN J BIOCHEM CELL B, V63, P137, DOI 10.1139/o85-020; SAMBORSKI RW, 1990, J BIOL CHEM, V265, P18322; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SKRBIC TR, 1970, J NEUROCHEM, V17, P85, DOI 10.1111/j.1471-4159.1970.tb00504.x; Smith M E, 1967, Adv Lipid Res, V5, P241; SMITH ME, 1965, J AM OIL CHEM SOC, V42, P1013, DOI 10.1007/BF02636894; VERGER R, 1973, J BIOL CHEM, V248, P4023; WHITE SP, 1990, SCIENCE, V250, P1560, DOI 10.1126/science.2274787; WIGGINS RC, 1976, BRAIN RES, V107, P257, DOI 10.1016/0006-8993(76)90225-0; WIRTZ KWA, 1982, LIPID PROTEIN INTERA, V1, P151; YEUNG SKF, 1974, CAN J BIOCHEM CELL B, V52, P830, DOI 10.1139/o74-119	38	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10362	10369						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587822				2022-12-25	WOS:A1992HV09000027
J	TOMASSELLI, AG; BANNOW, CA; DEIBEL, MR; HUI, JO; ZURCHERNEELY, HA; REARDON, IM; SMITH, CW; HEINRIKSON, RL				TOMASSELLI, AG; BANNOW, CA; DEIBEL, MR; HUI, JO; ZURCHERNEELY, HA; REARDON, IM; SMITH, CW; HEINRIKSON, RL			CHEMICAL SYNTHESIS OF A BIOTINYLATED DERIVATIVE OF THE SIMIAN IMMUNODEFICIENCY VIRUS PROTEASE - PURIFICATION BY AVIDIN AFFINITY-CHROMATOGRAPHY AND AUTOCATALYTIC ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYMATIC-ACTIVITY; ESCHERICHIA-COLI; HIV-1 PROTEASE; DESIGN; PEPTIDES; PROTEINASE; MATURATION; INHIBITORS; POTENT; AIDS	The protease from simian immunodeficiency virus (SIV) was chemically synthesized by automated solid-phase technology as an NH2-terminally extended derivative, capped with biotin. Biotin-linker-(SIV protease (1-99)): the linker segment, Gly-Gly-Asp-Arg-Gly-Phe-Ala-Ala, corresponds to the amino acid sequence preceding that of the protease in the SIV gag/pol precursor polyprotein. Accordingly, the Ala-Pro bond joining the octapeptide linker to the protease constitutes a site naturally cleaved by the protease during viral maturation. This strategy for synthesis was designed to facilitate purification of the biotinylated protein derivative from a complex mixture of reaction products by avidin/agarose-affinity chromatography and to provide the means for autocatalytic removal of the biotin-linker segment. As anticipated, folding of the full-length construct leads to activation of the enzyme and excision of the desired 99-residue SIV protease (overall yield, approximately 2%). The specificity of the synthetic SIV protease toward a number of well characterized protein substrates was the same as observed for the nearly identical enzyme from human immunodeficiency virus type 2 (HIV-2 protease) and distinct from that of the more disparate HIV-1 protease. The same functional ordering with respect to the human retroviral proteases was reflected in K(i) values observed with a number of protease inhibitors. Thus, the folded synthetic SIV protease shows patterns of specificity and susceptibility to inhibition that are in accord with what would be expected based upon its degree of structural similarity to proteases from HIV-1 and HIV-2.	UPJOHN CO,LABS,BIOCHEM RES LABS,7240-267-119,301 HENRIETTA ST,KALAMAZOO,MI 49001	Pfizer								ASHORN P, 1990, P NATL ACAD SCI USA, V87, P7472, DOI 10.1073/pnas.87.19.7472; BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BLUNDELL TL, 1990, TRENDS BIOCHEM SCI, V15, P425, DOI 10.1016/0968-0004(90)90280-O; COPELAND TD, 1988, GENE ANAL TECH, V5, P109, DOI 10.1016/0735-0651(88)90010-6; DARKE PL, 1989, J BIOL CHEM, V264, P2307; DEBOUCK C, 1987, P NATL ACAD SCI USA, V84, P8903, DOI 10.1073/pnas.84.24.8903; DEIBEL M R JR, 1989, Peptide Research, V2, P189; GRANT SK, 1991, BIOCHEMISTRY-US, V30, P8424, DOI 10.1021/bi00098a021; GRAVES MC, 1988, P NATL ACAD SCI USA, V85, P2449, DOI 10.1073/pnas.85.8.2449; HELLEN CUT, 1989, BIOCHEMISTRY-US, V28, P9881, DOI 10.1021/bi00452a001; HUI J, 1990, 4TH PROT SOC S SAN D; KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735; KRAUSSLICH HG, 1989, P NATL ACAD SCI USA, V86, P807, DOI 10.1073/pnas.86.3.807; KRAUSSLICH HG, 1989, CURRENT COMMUNICATIO; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lichtenthaler Hartmut K., METHODS ENZYMOLOGY, P350, DOI [10.1016/0076-6879(87)48036-1, DOI 10.1016/0076-6879(90)84256-G, DOI 10.1016/0076-6879(87)48036-1]; LIN MC, 1972, J BIOL CHEM, V247, P4768; LOBL TJ, 1988, ANAL BIOCHEM, V170, P502, DOI 10.1016/0003-2697(88)90665-3; MEEK TD, 1990, DESIGN ANTIAIDS DRUG, V14, P225; MYERS G, 1990, HUMAN RETROVIRUSES A; NUTT RF, 1988, P NATL ACAD SCI USA, V85, P7129, DOI 10.1073/pnas.85.19.7129; PICHUANTES S, 1990, J BIOL CHEM, V265, P13890; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; SAWYER TK, 1988, J MED CHEM, V31, P18, DOI 10.1021/jm00396a006; SCHNEIDER J, 1988, CELL, V54, P363, DOI 10.1016/0092-8674(88)90199-7; THAISRIVONGS S, 1991, J MED CHEM, V34, P2344, DOI 10.1021/jm00112a005; THAISRIVONGS S, 1986, J MED CHEM, V29, P2088, DOI 10.1021/jm00160a049; THAISRIVONGS S, 1987, J MED CHEM, V30, P976, DOI 10.1021/jm00389a004; TOMASSELLI AG, 1991, J BIOL CHEM, V266, P14548; TOMASSELLI AG, 1990, BIOCHEMISTRY-US, V29, P264, DOI 10.1021/bi00453a036; TOMASSELLI AG, 1990, J BIOL CHEM, V265, P14675; TOMASSELLI AG, 1990, J BIOL CHEM, V265, P408; TOMASSELLI AG, 1991, PROTEINS, V10, P1, DOI 10.1002/prot.340100102; TOZSER J, 1991, FEBS LETT, V281, P77, DOI 10.1016/0014-5793(91)80362-7; YEM AW, 1989, J BIOL CHEM, V264, P17691; [No title captured]	36	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10232	10237						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587812				2022-12-25	WOS:A1992HV09000008
J	TRACEY, BM; FEIZI, T; ABBOTT, WM; CARRUTHERS, RA; GREEN, BN; LAWSON, AM				TRACEY, BM; FEIZI, T; ABBOTT, WM; CARRUTHERS, RA; GREEN, BN; LAWSON, AM			SUBUNIT MOLECULAR MASS ASSIGNMENT OF 14,654-DA TO THE SOLUBLE BETA-GALACTOSIDE-BINDING LECTIN FROM BOVINE HEART-MUSCLE AND DEMONSTRATION OF INTRAMOLECULAR DISULFIDE BONDING ASSOCIATED WITH OXIDATIVE INACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; PROTEINS; CLONING; CDNA; ELECTROLECTIN; EXPRESSION; SPECTRA; GENE	The soluble dimeric beta-galactoside-binding lectin (subunit molecular mass, approximately 14 kDa) of bovine heart muscle, in common with the 14-kDa lectins of several other animal species, displays carbohydrate-binding activity when it is in the reduced state, but the purified lectin loses this activity upon oxidation. In the present study, the presence of any post-translational modification and the mechanism of the oxidative inactivation have been investigated by analyses of the reduced and oxidized forms of the purified bovine lectin by electrospray ionization-mass spectrometry (ESI-MS) and by liquid secondary ion mass spectrometry (LSIMS) of tryptic and peptic peptides. By ESI-MS, the molecular mass of the reduced lectin is determined to be 14,654.6 +/- 0.9 Da, and that of the oxidized lectin is 14,649.3 +/-1.1 Da. These masses correspond to the amino acid sequence of the protein with the cysteines having free sulfhydryl groups in the reduced state and forming disulfide bonds in the oxidized state. There is no evidence of post-translational modification in either lectin form except for monoacetylation already predicted for alanine at the blocked N-terminal end. Pronounced differences in charge distribution in the electrospray ionization mass spectra of the reduced and oxidized lectin, reflecting a change in the number of accessible protonation sites in the oxidized protein, are consistent with the protein being held in an altered conformation by covalent bonding. The results of LSIMS analyses of tryptic and peptic peptides in conjunction with Edman sequencing indicate that disulfide bonding occurs predominantly between Cys2 and Cys130, Cys16 and Cys88, and Cys42 and Cys60. There is no evidence of oxidation of Trp68. These results, taken together with observations that almost the complete polypeptide chain is necessary for the functional integrity of the carbohydrate recognition domain (Abbott, W. M., and Feizi, T. (1991) J. Biol. Chem. 266, 5552-5557) point to intramolecular disulfide bonding with a change in protein folding and conformation as the mechanism of oxidative inactivation of the purified bovine lectin.	MRC,CLIN RES CTR,CLIN MASS SPECTROMETRY SECT,HARROW HA1 3UJ,MIDDX,ENGLAND; MRC,CLIN RES CTR,GLYCOCONJUGATES SECT,HARROW HA1 3UJ,MIDDX,ENGLAND; VG BIOTECH LTD,ALTRINCHAM WA14 5RZ,CHESHIRE,ENGLAND	Medical Research Council Clinical Trials Unit; Medical Research Council Clinical Trials Unit				Feizi, Ten/0000-0001-6495-0329				ABBOTT WM, 1989, BIOCHEM J, V259, P283, DOI 10.1042/bj2590283; ABBOTT WM, 1989, BIOCHEM J, V259, P291, DOI 10.1042/bj2590291; ABBOTT WM, 1991, J BIOL CHEM, V266, P5552; ARBERTH W, 1982, ANAL CHEM, V54, P2029; BARONDES SH, 1984, SCIENCE, V223, P1259, DOI 10.1126/science.6367039; BRADSHAW RA, 1990, PROTEINS FORM FUNCTI, P183; CLERCH LB, 1988, BIOCHEMISTRY-US, V27, P692, DOI 10.1021/bi00402a030; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; COURAUD PO, 1989, J BIOL CHEM, V264, P1310; COWLES EA, 1990, J BIOL CHEM, V265, P17706; FRIGERI LG, 1990, J BIOL CHEM, V265, P20763; GITT MA, 1991, BIOCHEMISTRY-US, V30, P82, DOI 10.1021/bi00215a013; HIRABAYASHI J, 1988, J BIOCHEM-TOKYO, V104, P1; HIRABAYASHI J, 1987, J BIOCHEM-TOKYO, V101, P775, DOI 10.1093/jb/101.3.775; JIA SH, 1988, J BIOL CHEM, V263, P6009; LEVI G, 1981, J BIOL CHEM, V256, P5735; LEVI G, 1985, BIOCHEM J, V226, P379, DOI 10.1042/bj2260379; LOO JA, 1990, ANAL CHEM, V62, P693, DOI 10.1021/ac00206a009; LOO JA, 1989, ANAL BIOCHEM, V179, P404, DOI 10.1016/0003-2697(89)90153-X; MANN M, 1989, ANAL CHEM, V61, P1702, DOI 10.1021/ac00190a023; MORRIS HR, 1985, BIOCHEM BIOPH RES CO, V126, P1122, DOI 10.1016/0006-291X(85)90302-X; OHYAMA Y, 1986, BIOCHEM BIOPH RES CO, V134, P51, DOI 10.1016/0006-291X(86)90525-5; OHYAMA Y, 1988, J BIOCHEM-TOKYO, V104, P173, DOI 10.1093/oxfordjournals.jbchem.a122436; PAROUTAUD P, 1987, P NATL ACAD SCI USA, V84, P6345, DOI 10.1073/pnas.84.18.6345; SAKAKURA Y, 1990, J BIOL CHEM, V265, P21573; SANFORD GL, 1990, FASEB J, V4, P2912, DOI 10.1096/fasebj.4.11.2379767; SMITH DL, 1990, METHOD ENZYMOL, V193, P374, DOI 10.1016/0076-6879(90)93428-N; SOLOMON JC, 1991, CARBOHYD RES, V213, P293, DOI 10.1016/S0008-6215(00)90616-5; SOUTHAN C, 1987, FEBS LETT, V214, P301, DOI 10.1016/0014-5793(87)80074-1; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G; WHITNEY PL, 1986, BIOCHEM J, V238, P683, DOI 10.1042/bj2380683; WILSON TJG, 1989, BIOCHEM J, V261, P847, DOI 10.1042/bj2610847	32	79	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10342	10347						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587821				2022-12-25	WOS:A1992HV09000024
J	WILSON, KP; MALCOLM, BA; MATTHEWS, BW				WILSON, KP; MALCOLM, BA; MATTHEWS, BW			STRUCTURAL AND THERMODYNAMIC ANALYSIS OF COMPENSATING MUTATIONS WITHIN THE CORE OF CHICKEN EGG-WHITE LYSOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN STABILITY; STAPHYLOCOCCAL NUCLEASE; PACKING; REFINEMENT; ACIDS	High resolution crystal structures have been determined for six chicken-type lysozymes that were constructed to investigate putative intermediates in the evolution of the lysozymes of modern game birds (Malcolm, B. A., Wilson, K. P., Matthews, B. W., Kirsch, J. F., and Wilson, A. C. (1990) Nature 345, 86-89). The amino acid replacements include Thr-40 --> Ser, Ile-55 --> Val, and Ser-91 --> Thr, as well as combinations of these substitutions. Residues 40, 55, and 91 are buried within the core of chicken lysozyme. The replacements therefore involve the insertion and/or removal of methyl groups from the protein interior. The mutant proteins have normal activities, and their thermal stabilities span a range of 7-degrees-C, with some variants more stable and some less stable than the naturally occurring forms. Comparison of the crystal structures shows the overall structures to be very similar, but there are differences in the packing of side chains in the region of the replacements. The x-ray coordinates were used to evaluate the repacking of side chains in the protein interior and to attempt to evaluate the contributions of the different energetic interactions toward the overall stability of each variant. The results illustrate how proteins can compensate for potentially destabilizing substitutions in different ways and underscore the importance of high resolution structural data if changes in protein thermostability due to changes in protein sequence are to be understood. The findings also suggest that protein stability can be increased by mutations that lower strain in the protein interior while maintaining total buried hydrophobic surface area.	UNIV CALIF BERKELEY,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720; UNIV OREGON,HOWARD HUGHES MED INST,EUGENE,OR 97403	University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of Oregon	WILSON, KP (corresponding author), UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020066, R01GM035393, R01GM020066] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM20066, GM35393] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BLAKE CCF, 1965, NATURE, V206, P757, DOI 10.1038/206757a0; CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DAOPIN S, 1991, J MOL BIOL, V221, P647, DOI 10.1016/0022-2836(91)80079-A; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; KARPUSAS M, 1989, P NATL ACAD SCI USA, V86, P8237, DOI 10.1073/pnas.86.21.8237; KELLIS JT, 1988, NATURE, V333, P784, DOI 10.1038/333784a0; Kimura M., 1985, J GENET, V64, P7, DOI [10.1007/BF02923549, DOI 10.1007/BF02923549]; KIRSCH JF, 1989, IMMUNE RESPONSE TO STRUCTURALLY DEFINED PROTEINS : THE LYSOZYME MODEL, P59; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEVITT M, 1974, J MOL BIOL, V82, P393, DOI 10.1016/0022-2836(74)90599-3; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; LUZZATI V, 1952, ACTA CRYSTALLOGR, V6, P142; MALCOLM BA, 1990, NATURE, V345, P86, DOI 10.1038/345086a0; MALCOLM BA, 1989, P NATL ACAD SCI USA, V86, P133, DOI 10.1073/pnas.86.1.133; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; MATTHEWS BW, 1987, BIOCHEMISTRY-US, V26, P6885, DOI 10.1021/bi00396a001; MCCAMMON JA, 1979, BIOCHEMISTRY-US, V18, P927, DOI 10.1021/bi00573a001; MCCAMMON JA, 1976, NATURE, V262, P325, DOI 10.1038/262325a0; MCGREGOR MJ, 1987, J MOL BIOL, V198, P295, DOI 10.1016/0022-2836(87)90314-7; NEMETHY G, 1966, J PHYS CHEM-US, V70, P998, DOI 10.1021/j100876a008; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; ROSSMANN MG, 1979, J APPL CRYSTALLOGR, V12, P225, DOI 10.1107/S0021889879012218; SANBERG WS, 1991, P NATL ACAD SCI USA, V88, P1706; SCHMID MF, 1981, ACTA CRYSTALLOGR A, V37, P701, DOI 10.1107/S0567739481001587; SHORTLE D, 1985, GENETICS, V110, P539; SHORTLE D, 1990, BIOCHEMISTRY-US, V29, P8033, DOI 10.1021/bi00487a007; STEWART CB, 1987, NATURE, V330, P401, DOI 10.1038/330401a0; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124	32	156	160	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10842	10849						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587860				2022-12-25	WOS:A1992HV09000095
J	CAPERELLI, CA; LIU, D				CAPERELLI, CA; LIU, D			CARBOCYCLIC SUBSTRATES FOR DENOVO PURINE BIOSYNTHESIS - ENANTIOSPECIFIC SYNTHESIS AND ENANTIOSPECIFICITY OF ENZYMATIC UTILIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE; MULTIFUNCTIONAL PROTEIN; ESCHERICHIA-COLI; CHICKEN LIVER; NEPLANOCIN-A; SYNTHETASE; 5,10-DIDEAZA-5,6,7,8-TETRAHYDROFOLATE; OVERPRODUCTION; NUCLEOSIDES; CLONING	The carbocyclic analogues of phosphoribosylamine, glycinamide ribonucleotide, and formylglycinamide ribonucleotide have been prepared enantiospecifically from D-ribonic acid gamma-lactone. These carbocycles, which have the same absolute configuration as the natural D-ribose-derived intermediates of de novo purine biosynthesis, are utilized stoichiometrically by the initial enzymes of the pathway. A comparison of the enzymatic processing of the (-)-enantiomers with those of the racemates indicates that in some cases, the (+)-enantiomer acts to inhibit the enzymatic activity.			CAPERELLI, CA (corresponding author), UNIV CINCINNATI,MED CTR,COLL PHARM,DIV PHARMACOL & MED CHEM,CINCINNATI,OH 45267, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM042024] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-42024] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1960, J BIOL CHEM, V235, P769; ARAI Y, 1988, J CHEM SOC PERK T 1, P3133, DOI 10.1039/p19880003133; ARITA M, 1983, J AM CHEM SOC, V105, P4049, DOI 10.1021/ja00350a050; BALDWIN SW, 1991, BIOCHEMISTRY-US, V30, P1997, DOI 10.1021/bi00221a037; BEARDSLEY GP, 1989, J BIOL CHEM, V264, P328; BENKOVIC SJ, 1984, TRENDS BIOCHEM SCI, V9, P320, DOI 10.1016/0968-0004(84)90302-5; Bergmann M, 1932, BER DTSCH CHEM GES, V65, P1192, DOI 10.1002/cber.19320650722; Bestmann H.J., 1990, ANGEW CHEM, V102, P95; CAPERELLI CA, 1989, J BIOL CHEM, V264, P5053; CAPERELLI CA, 1988, ARCH BIOCHEM BIOPHYS, V264, P340, DOI 10.1016/0003-9861(88)90602-9; CARDINI CE, 1957, METHOD ENZYMOL, V3, P835, DOI 10.1016/S0076-6879(57)03458-8; CHETTUR G, 1977, CARBOHYD RES, V56, P75, DOI 10.1016/S0008-6215(00)84238-X; Cleland W W, 1979, Methods Enzymol, V63, P103; DAUBNER SC, 1985, BIOCHEMISTRY-US, V24, P7059, DOI 10.1021/bi00346a006; DAUBNER SC, 1986, BIOCHEMISTRY-US, V25, P2951, DOI 10.1021/bi00358a033; Harwood LM., 1985, ALDRICHIM ACTA, V18, P25; LIM MI, 1983, TETRAHEDRON LETT, V24, P4051, DOI 10.1016/S0040-4039(00)88259-3; LIU DH, 1991, J BIOL CHEM, V266, P16699; LIU DS, 1991, SYNTHESIS-STUTTGART, P933; MORAN RG, 1989, J BIOL CHEM, V264, P21047; OHNO M, 1985, NUCLEOS NUCLEOT NUCL, V4, P21, DOI 10.1080/07328318508077828; PARRY RJ, 1991, J CHEM SOC CHEM COMM, P740, DOI 10.1039/c39910000740; PARRY RJ, 1990, TETRAHEDRON LETT, V31, P7549, DOI 10.1016/S0040-4039(00)97295-2; PATEY CAH, 1973, BIOCHEM J, V135, P543, DOI 10.1042/bj1350543; SCHENDEL FJ, 1986, BIOCHEMISTRY-US, V25, P2256, DOI 10.1021/bi00356a061; SCHENDEL FJ, 1989, BIOCHEMISTRY-US, V28, P2459, DOI 10.1021/bi00432a017; SCHNENDEL FJ, 1988, BIOCHEMISTRY-US, V27, P2614; SCHRIMSHER JL, 1986, BIOCHEMISTRY-US, V25, P4356, DOI 10.1021/bi00363a027; SHEN Y, 1990, BIOCHEMISTRY-US, V29, P218, DOI 10.1021/bi00453a030; Smith M., 1961, BIOCH PREP, V8, P130; WOLFE MS, 1990, J ORG CHEM, V55, P4712, DOI 10.1021/jo00302a043; Woodward D O, 1978, Methods Enzymol, V51, P202; YOUNG M, 1984, BIOCHEMISTRY-US, V23, P3979, DOI 10.1021/bi00312a027	33	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9783	9787						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577812				2022-12-25	WOS:A1992HT96500054
J	CONAWAY, JW; BRADSHER, JN; CONAWAY, RC				CONAWAY, JW; BRADSHER, JN; CONAWAY, RC			MECHANISM OF ASSEMBLY OF THE RNA POLYMERASE-II PREINITIATION COMPLEX - TRANSCRIPTION FACTOR-DELTA AND FACTOR-EPSILON PROMOTE STABLE BINDING OF THE TRANSCRIPTION APPARATUS TO THE INITIATOR ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA BOX-BINDING; ACCURATE TRANSCRIPTION; SEQUENCES DOWNSTREAM; FUNCTIONAL-ANALYSIS; PROTEIN; PURIFICATION; GENE; LIVER; DNA; IDENTIFICATION	Assembly of RNA polymerase II with the core region of TATA box-containing promoters requires the action of the TATA factor and four transcription factors designated alpha, beta-gamma, delta, and epsilon, which have each been purified to near homogeneity from rat liver. Evidence from previous studies argues that alpha and beta-gamma play a crucial role in delivering RNA polymerase II to the promoter (Conaway, R. C., Garrett, K. P., Hanley, J. P., and Conaway, J. W. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 6205-6209). Here we describe the interaction of transcription factor-delta with preinitiation intermediates assembled in the presence of either recombinant yeast TFIID or the high molecular mass, endogenous TATA factor-tau from rat liver (Conaway, J. W., Hanley, J. P., Garrett, K. P., and Conaway, R. C. (1991) J. Biol. Chem. 266, 7804-7811). Results of template challenge experiments argue that delta-enters the preinitiation complex through interactions with multiple components of the transcription apparatus. We observe that, in the presence of recombinant TFIID, delta-interacts stably with the preinitiation complex only in the presence of RNA polymerase II, alpha, and beta-gamma, whereas, in the presence of tau, delta is capable of interacting stably with the Initial Complex independently of RNA polymerase II. Results of restriction site protection experiments reveal that delta and epsilon-promote binding of the transcription apparatus to the Initiator element and support the model that RNA polymerase II assembles at the core promoter in at least two discrete steps, first "touching down" near the TATA element and finally extending its interaction downstream to encompass the cap site.			CONAWAY, JW (corresponding author), OKLAHOMA CHILDRENS MEM HOSP,PROGRAM MOLEC & CELL BIOL,OKLAHOMA CITY,OK 73104, USA.			Conaway, Joan/0000-0002-2786-0663	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041628, R37GM041628] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURTON ZF, 1986, EMBO J, V5, P2923, DOI 10.1002/j.1460-2075.1986.tb04588.x; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CONAWAY JW, 1990, J BIOL CHEM, V265, P7564; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; CONAWAY JW, 1990, J BIOL CHEM, V265, P7552; CONAWAY JW, 1991, J BIOL CHEM, V266, P17721; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1990, J BIOL CHEM, V265, P7559; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; FEAVER WJ, 1991, J BIOL CHEM, V266, P19000; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FIRE A, 1984, J BIOL CHEM, V259, P2509; FLORES O, 1990, J BIOL CHEM, V265, P5629; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; KADESCH TR, 1982, J MOL BIOL, V155, P1, DOI 10.1016/0022-2836(82)90489-2; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; MUHICH ML, 1990, P NATL ACAD SCI USA, V87, P9148, DOI 10.1073/pnas.87.23.9148; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; NAKAYAMA N, 1984, J BIOL CHEM, V259, P88; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REINBERG D, 1987, J BIOL CHEM, V262, P3322; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; WHITE JH, 1991, P NATL ACAD SCI USA, V88, P7674, DOI 10.1073/pnas.88.17.7674	52	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10142	10148						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577784				2022-12-25	WOS:A1992HT96500104
J	GOPALAN, V; VANDERJAGT, DJ; LIBELL, DP; GLEW, RH				GOPALAN, V; VANDERJAGT, DJ; LIBELL, DP; GLEW, RH			TRANSGLUCOSYLATION AS A PROBE OF THE MECHANISM OF ACTION OF MAMMALIAN CYTOSOLIC BETA-GLUCOSIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCOHOLS; LIVER; REACTIVITY; HYDROLYSIS	This study establishes that guinea pig liver cytosolic beta-glucosidase generates a common glucosyl-enzyme intermediate from a variety of aryl beta-D-glucoside substrates and that the intermediate can react with various acceptors to form distinct products at rates which are dependent on the structure, nucleophilicity, and concentration of the acceptor. Specifically, we demonstrate that water and linear alkanols will react with the glucosyl-enzyme intermediate to form D-glucose and alkyl-beta-D-glucoside (e.g. octyl-beta-D-glucoside), respectively. The rate of alcoholysis is 24-fold greater than the rate of hydrolysis of the glucosyl-enzyme intermediate and accounts for the increase in steady-state rate of substrate disappearance in the presence of alcohols. In addition, the substrate molecule itself (e.g. p-nitrophenyl-beta-D-galactoside (pNP-Gal)) can serve as an acceptor in the transglycosylation reaction, thereby enabling the enzyme to synthesize disaccharide glycosides (e.g. pNP-beta-Gal(6 --> 1)beta-Gal). The transglycosylation data point to the presence of two hydrophobic subsites in the active site of the cytosolic beta-glucosidase. These data support a model in which the cytosolic beta-glucosidase binds an acceptor and a glycosyl donor simultaneously within its catalytic center and efficiently catalyzes the transfer of a sugar residue from the donor to the acceptor.	UNIV NEW MEXICO,SCH MED,DEPT BIOCHEM,ALBUQUERQUE,NM 87131	University of New Mexico					NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM031357] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM 31357] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENDER ML, 1964, J AM CHEM SOC, V86, P3697, DOI 10.1021/ja01072a019; BERGEL A, 1989, ANAL BIOCHEM, V179, P382, DOI 10.1016/0003-2697(89)90149-8; BIELY P, 1991, EUR J BIOCHEM, V200, P157, DOI 10.1111/j.1432-1033.1991.tb21062.x; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P378, DOI 10.1098/rspb.1967.0035; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COTE GL, 1990, GLYCOCONJUGATE J, V7, P145, DOI 10.1007/BF01050377; DALE MP, 1986, BIOCHEMISTRY-US, V25, P2522, DOI 10.1021/bi00357a036; DISTLER JJ, 1977, ARCH BIOCHEM BIOPHYS, V178, P631, DOI 10.1016/0003-9861(77)90235-1; FASTREZ J, 1973, BIOCHEMISTRY-US, V12, P2025, DOI 10.1021/bi00735a001; FERSHT A, 1985, ENZYME STRUCTURE MEC, P193; GOPALAN V, 1989, BIOCHEM J, V262, P541, DOI 10.1042/bj2620541; GOPALAN V, 1989, J BIOL CHEM, V264, P15418; GREENZAI.P, 1971, BIOCHEMISTRY-US, V10, P1210; GUSAKOV AV, 1991, BIOCHIM BIOPHYS ACTA, V1073, P481, DOI 10.1016/0304-4165(91)90219-7; HUBER RE, 1984, ARCH BIOCHEM BIOPHYS, V234, P151, DOI 10.1016/0003-9861(84)90336-9; INWARD PW, 1965, J BIOL CHEM, V240, P1986; LALEGERIE P, 1982, BIOCHIMIE, V64, P977, DOI 10.1016/S0300-9084(82)80379-9; LAMARCO KL, 1986, BIOCHEM J, V237, P469, DOI 10.1042/bj2370469; LEGLER G, 1988, ARCH BIOCHEM BIOPHYS, V260, P437, DOI 10.1016/0003-9861(88)90467-5; LI YT, 1991, J BIOL CHEM, V266, P10723; OVEREND WG, 1962, J CHEM SOC, V4, P3429; PETERS SP, 1975, CLIN CHIM ACTA, V60, P391, DOI 10.1016/0009-8981(75)90083-2; SCHUSTER SM, 1979, BIOCHEMISTRY-US, V18, P1162, DOI 10.1021/bi00574a007; SEGEL JH, 1975, ENZYME KINETICS, P227; STOKES TM, 1972, BIOCHEMISTRY-US, V11, P1061, DOI 10.1021/bi00756a018; UMEZURIKE GM, 1971, BIOCHIM BIOPHYS ACTA, V250, P182, DOI 10.1016/0005-2744(71)90132-X; VANDERGR.G, 1973, EUR J BIOCHEM, V38, P122; VIRATELLE O, 1969, BIOCHEM BIOPH RES CO, V37, P1036, DOI 10.1016/0006-291X(69)90236-8	28	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9629	9638						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577800				2022-12-25	WOS:A1992HT96500030
J	MUNIER, H; BOUHSS, A; KRIN, E; DANCHIN, A; GILLES, AM; GLASER, P; BARZU, O				MUNIER, H; BOUHSS, A; KRIN, E; DANCHIN, A; GILLES, AM; GLASER, P; BARZU, O			THE ROLE OF HISTIDINE-63 IN THE CATALYTIC MECHANISM OF BORDETELLA-PERTUSSIS ADENYLATE-CYCLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING; ESCHERICHIA-COLI; STEREOCHEMISTRY; DNA	Of the 9 histidines located in the catalytic domain of Bordetella pertussis adenylate cyclase, three (His63, His106, and His298) were found to be conserved in the adenylate cyclase of Bacillus anthracis, another calmodulin-dependent enzyme. Substitution of His63 with Arg, Glu, Gln, or Val decreased the catalytic efficiency of adenylate cyclase between 2 and 3 orders of magnitude and altered the kinetic properties of the enzyme. These effects varied in relation to the nature of the substituting residue, pH, and direction of the reaction, i.e. ATP cyclization (forward) or ATP synthesis (reverse). Arg was the best substituent for His63 as catalyst in the forward reaction, with shift of the optimum pH to the alkaline side, whereas Glu was the best substituent for His63 in the reverse reaction, with shift of the optimum pH to the acidic side. Diethyl pyrocarbonate, which had a deleterious effect on wild-type adenylate cyclase was ineffective on His63 mutants. From these results we conclude that His63 is involved in the reaction mechanism of adenylate cyclase, which requires a general acid/base catalyst, most probably as an intermediate in a charge-relay system.	INST PASTEUR,UNITE BIOCHIM REGULAT CELLULAIRES,28 RUE DOCTEUR ROUX,F-75724 PARIS 15,FRANCE; INST PASTEUR,UNITE REGULAT EXPRESS GENET,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Glaser, Philippe/O-2641-2015	Glaser, Philippe/0000-0003-4156-2782; Danchin, Antoine/0000-0002-6350-5001				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; DIPERSIO LP, 1991, J BIOL CHEM, V266, P4033; ECKSTEIN F, 1981, J BIOL CHEM, V256, P9118; ESCUYER V, 1988, GENE, V71, P293, DOI 10.1016/0378-1119(88)90045-5; GERLT JA, 1980, J BIOL CHEM, V255, P331; Gibson T.J., 1984, THESIS CAMBRIDGE U U; GILLES AM, 1990, BIOCHEMISTRY-US, V29, P8126, DOI 10.1021/bi00487a020; GLASER P, 1989, EMBO J, V8, P967, DOI 10.1002/j.1460-2075.1989.tb03459.x; GLASER P, 1988, MOL MICROBIOL, V2, P19, DOI 10.1111/j.1365-2958.1988.tb00003.x; GLASER P, 1991, EMBO J, V10, P1683, DOI 10.1002/j.1460-2075.1991.tb07692.x; KLEANTHOUS C, 1985, BIOCHEMISTRY-US, V24, P5307, DOI 10.1021/bi00341a006; KOCH KW, 1990, J BIOL CHEM, V265, P9659; LABRUYERE E, 1990, BIOCHEMISTRY-US, V29, P4922, DOI 10.1021/bi00472a024; LADANT D, 1989, J BIOL CHEM, V264, P4015; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Miles E W, 1977, Methods Enzymol, V47, P431; Miller J.H., 1972, EXPT MOL GENETICS; MIRAN SG, 1991, BIOCHEMISTRY-US, V30, P7901, DOI 10.1021/bi00246a005; NICKBARG EB, 1988, BIOCHEMISTRY-US, V27, P5948, DOI 10.1021/bi00416a019; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARFATI RS, 1990, J BIOL CHEM, V266, P18902; SENTER PD, 1988, J BIOL CHEM, V258, P6741; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; WARSHEL A, 1989, BIOCHEM, V28, P3631; White A A, 1974, Methods Enzymol, V38, P41; YANG JK, 1983, J BIOL CHEM, V258, P3750; YOUNG RA, 1983, P NATL ACAD SCI USA, V80, P1199	28	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9816	9820						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577816				2022-12-25	WOS:A1992HT96500059
J	HUTH, JR; MOUNTJOY, K; PERINI, F; RUDDON, RW				HUTH, JR; MOUNTJOY, K; PERINI, F; RUDDON, RW			INTRACELLULAR FOLDING PATHWAY OF HUMAN CHORIONIC GONADOTROPIN-BETA SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; CHORIOCARCINOMA CELLS; PROTEIN; ALPHA; SECRETION; CHAINS; BIOSYNTHESIS; ASSOCIATION; ISOMERASE; CULTURES	Few experimental models have been used to investigate how proteins fold inside a cell. Using the formation of disulfide bonds as an index of conformational changes during protein folding, we have developed a unique system to determine the intracellular folding pathway of the beta-subunit of human chorionic gonadotropin (hCG). Three folding intermediates of the beta-subunit were purified from [S-35]cysteine-labeled JAR choriocarcinoma cells by immunoprecipitation and by reverse-phase high performance liquid chromatography (HPLC). To identify unformed disulfide bonds, nonreduced folding intermediates were treated with trypsin to liberate non-disulfide-bound, [S-35]cysteine-containing peptides from the disulfide-linked peptides. Released peptides were purified by HPLC and identified by amino acid sequencing. The amount of a peptide that was released indicated the extent of disulfide bond formation involving the cysteine in that peptide. Of the six disulfide bonds in hCG-beta, bonds 34-88 and 38-57 form first. The rate-limiting event of folding involves the formation of the S-S bonds between cysteines 23 and 72 and cysteines 9 and 90. Disulfide bond 93-100, the formation of which appears to be necessary for assembly with the alpha-subunit of the hCG heterodimer, forms next. Finally, disulfide bond 26-110 forms after assembly with the alpha-subunit, suggesting that completion of folding of the COOH terminus in the beta-subunit occurs after assembly with the a subunit.	UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,600 S 42ND ST,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT PHARMACOL,OMAHA,NE 68198; UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Michigan System; University of Michigan					NATIONAL CANCER INSTITUTE [R01CA032949] Funding Source: NIH RePORTER; NCI NIH HHS [CA32949] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEDOWS E, 1992, J BIOL CHEM, V267, P8880; BEEBE JS, 1990, ENDOCRINOLOGY, V126, P384, DOI 10.1210/endo-126-1-384; BEEBE JS, 1990, J BIOL CHEM, V265, P312; BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CHEN F, 1991, J BIOL CHEM, V266, P6904; COLE LA, 1983, ENDOCRINOLOGY, V113, P1176, DOI 10.1210/endo-113-3-1176; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; DORNMAIR K, 1990, P NATL ACAD SCI USA, V87, P4134, DOI 10.1073/pnas.87.11.4134; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FINKELSTEIN AV, 1991, NATURE, V351, P497, DOI 10.1038/351497a0; FUNAKOSHI S, 1991, P NATL ACAD SCI USA, V88, P6981, DOI 10.1073/pnas.88.16.6981; GARNIER J, 1974, FEBS LETT, V45, P166, DOI 10.1016/0014-5793(74)80837-9; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GURD FRN, 1967, METHOD ENZYMOL, V11, P532; HENSCHEN A, 1986, ADV METH PROTEIN MIC, P248; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; Matthews CR, 1991, CURR OPIN STRUC BIOL, V1, P28; MINDROIU T, 1986, J BIOL CHEM, V261, P7407; MISE T, 1981, J BIOL CHEM, V256, P6587; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; MOYLE WR, 1990, J BIOL CHEM, V265, P8511; NALL BT, 1990, PROTEIN FOLDING : DECIPHERING THE SECOND HALF OF THE GENETIC CODE, P198; PETERS BP, 1984, J BIOL CHEM, V259, P5123; PETERS T, 1982, J BIOL CHEM, V257, P8847; POLLAK S, 1990, ENDOCRINOLOGY, V126, P199, DOI 10.1210/endo-126-1-199; RUDDON RW, 1979, P NATL ACAD SCI USA, V76, P5143, DOI 10.1073/pnas.76.10.5143; RUDDON RW, 1987, J BIOL CHEM, V262, P12533; RUDDON RW, 1981, J BIOL CHEM, V256, P1389; RYAN RJ, 1988, FASEB J, V2, P2661, DOI 10.1096/fasebj.2.11.2456242; SPACKMAN DH, 1960, J BIOL CHEM, V235, P648; STRICKLAND TW, 1982, J BIOL CHEM, V257, P2954; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; TANIYAMA Y, 1990, J BIOL CHEM, V265, P7570; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783	39	65	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8870	8879						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577725				2022-12-25	WOS:A1992HR85400029
J	LI, XY; VANHUIJSDUIJNEN, RH; MANTOVANI, R; BENOIST, C; MATHIS, D				LI, XY; VANHUIJSDUIJNEN, RH; MANTOVANI, R; BENOIST, C; MATHIS, D			INTRON-EXON ORGANIZATION OF THE NF-Y GENES - TISSUE-SPECIFIC SPLICING MODIFIES AN ACTIVATION DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT-BINDING-FACTOR; DNA-BINDING; HETEROLOGOUS SUBUNITS; HELA-CELLS; YEAST HAP2; TRANSCRIPTION; PROTEINS; PROMOTER; ENHANCER; RECOGNITION	NF-Y is a highly conserved transcription factor which recognizes CCAAT motifs in a variety of genes. We report here the genomic organization of the genes encoding both subunits, which gives interesting clues about the functional organization of the proteins. We also report the existence of isoforms of NF-YA which result from differential splicing. These alternative splicing events map within a glutamine-rich activation domain and show a marked cell- and tissue-specific bias.			LI, XY (corresponding author), FAC MED STRASBOURG,INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,F-67085 STRASBOURG,FRANCE.		van Huijsduijnen, Rob A.M. Hooft/B-3653-2009	van Huijsduijnen, Rob A.M. Hooft/0000-0002-2261-9424				BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BECKER DM, 1991, P NATL ACAD SCI USA, V88, P1968, DOI 10.1073/pnas.88.5.1968; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; BUSTURIA A, 1990, EMBO J, V9, P3551, DOI 10.1002/j.1460-2075.1990.tb07565.x; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DORN A, 1989, MOL CELL BIOL, V9, P312, DOI 10.1128/MCB.9.1.312; DUTTA A, 1990, GENE DEV, V4, P243, DOI 10.1101/gad.4.2.243; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; HAHN S, 1988, SCIENCE, V240, P317, DOI 10.1126/science.2832951; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kingston RE, 1989, CURR OPIN CELL BIOL, V1, P1081, DOI 10.1016/S0955-0674(89)80054-7; KNIGHT GB, 1987, P NATL ACAD SCI USA, V84, P8350, DOI 10.1073/pnas.84.23.8350; KOCH W, 1989, MOL CELL BIOL, V9, P303, DOI 10.1128/MCB.9.1.303; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; OLESEN JT, 1990, GENE DEV, V4, P1714, DOI 10.1101/gad.4.10.1714; QUITSCHKE WW, 1989, J BIOL CHEM, V264, P9539; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; VANHUIJSDUIJNEN RAMH, 1987, NUCLEIC ACIDS RES, V15, P7265, DOI 10.1093/nar/15.18.7265; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VANWIJNEN AJ, 1988, BIOCHEMISTRY-US, V27, P6534, DOI 10.1021/bi00417a051; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; VUORIO T, 1990, J BIOL CHEM, V265, P22480; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WEBSTER NJG, 1989, EMBO J, V8, P1441, DOI 10.1002/j.1460-2075.1989.tb03526.x; WIRTH T, 1991, NUCLEIC ACIDS RES, V19, P43, DOI 10.1093/nar/19.1.43; WUARIN J, 1990, J MOL BIOL, V214, P865, DOI 10.1016/0022-2836(90)90341-I	35	134	141	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8984	8990						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577736				2022-12-25	WOS:A1992HR85400045
J	LUNDSTROM, J; KRAUSE, G; HOLMGREN, A				LUNDSTROM, J; KRAUSE, G; HOLMGREN, A			A PRO TO HIS MUTATION IN ACTIVE-SITE OF THIOREDOXIN INCREASES ITS DISULFIDE-ISOMERASE ACTIVITY 10-FOLD - NEW REFOLDING SYSTEMS FOR REDUCED OR RANDOMLY OXIDIZED RIBONUCLEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEINS; INTERCHANGE; REDUCTION; REACTIVITY; INSULIN; FORM	Thioredoxin (Trx) from Escherichia coli was compared with bovine protein disulfide-isomerase (PDI) for its ability to catalyze native disulfide formation in either reduced or randomly oxidized (scrambled) ribonuclease A (RNase). On a molar basis, a 100-fold higher concentration of Trx than of PDI was required to give the same rate of native disulfide formation measured as recovery of RNase activity. A Pro-34 to His (P34H Trx) mutation in the active site of E. coli Trx (WCGPC), mimicking the two suggested active sites in PDI (WCGHC), increased the catalytic activity in disulfide formation about 10-fold. The mutant P34H Trx displayed a 35-mV higher redox potential (E0') of the active site disulfide/dithiol relative to wild type Trx, making it more similar to the redox potential observed for PDI. This higher redox potential correlates well with the enhanced activity and suggests a role for the histidine side chain. Enzymatic isomerization of disulfides in scrambled, oxidized RNase requires the presence of a catalytic thiol such as GSH to initiate the thiol-disulfide interchange. Bovine thioredoxin reductase, together with NADPH, could replace GSH. For oxidative folding of reduced RNase in air with Trx, P34H Trx, or PDI, catalytic amounts of sodium selenite (1-mu-M) resulted in rapid disulfide formation and high yields of ribonuclease activity equivalent to previously known redox buffers of GSH and GSSG. These results demonstrate no obligatory role for glutathione in disulfide formation. A possible mechanism for the unknown thiol oxidative process accompanying folding and protein disulfide formation in vivo is discussed.			LUNDSTROM, J (corresponding author), KAROLINSKA HOSP, DEPT BIOCHEM 1, BOX 60400, S-10401 STOCKHOLM 60, SWEDEN.		Krause, Günter/A-1858-2012	Krause, Günter/0000-0003-3905-0921				Anfinsen C B, 1975, Adv Protein Chem, V29, P205, DOI 10.1016/S0065-3233(08)60413-1; ANFINSEN CB, 1961, P NATL ACAD SCI USA, V47, P1309, DOI 10.1073/pnas.47.9.1309; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; CREIGHTON TE, 1988, BIOPHYS CHEM, V31, P155, DOI 10.1016/0301-4622(88)80021-8; CREIGHTON TE, 1980, J MOL BIOL, V74, P234; CROOK EM, 1960, BIOCHEM J, V74, P234, DOI 10.1042/bj0740234; DYSON HJ, 1990, BIOCHEMISTRY-US, V29, P4129, DOI 10.1021/bi00469a016; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FREEDMAN RB, 1989, BIOCHEM SOC SYMP, V55, P167; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GANTHER HE, 1969, BIOCHEMISTRY-US, V8, P2557, DOI 10.1021/bi00834a044; GILBERT HF, 1989, BIOCHEMISTRY-US, V28, P7298, DOI 10.1021/bi00444a023; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GIVOL D, 1964, J BIOL CHEM, V239, P3114; HAWKINS HC, 1991, BIOCHEM J, V275, P349, DOI 10.1042/bj2750349; HAWKINS HC, 1991, BIOCHEM J, V275, P335, DOI 10.1042/bj2750335; HAWKINS HC, 1991, BIOCHEM J, V275, P341, DOI 10.1042/bj2750341; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P9113; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOLMGREN A, 1989, 4TH P INT S SEL BIOL, P58; KALLIS GB, 1980, J BIOL CHEM, V255, P261; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; LIN TY, 1989, BIOCHEMISTRY-US, V28, P5282, DOI 10.1021/bi00438a054; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; PIGIET VP, 1986, P NATL ACAD SCI USA, V83, P7643, DOI 10.1073/pnas.83.20.7643; SHAKED Z, 1980, BIOCHEMISTRY-US, V19, P4156, DOI 10.1021/bi00559a004; SINGH R, 1990, J AM CHEM SOC, V112, P1190, DOI 10.1021/ja00159a046; SINGH R, 1990, J AM CHEM SOC, V112, P6304, DOI 10.1021/ja00173a018; Stadtman T C, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P1; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783	37	101	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9047	9052						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577742				2022-12-25	WOS:A1992HR85400054
J	SHIMBA, S; BUCKLEY, B; REDDY, R; KISS, T; FILIPOWICZ, W				SHIMBA, S; BUCKLEY, B; REDDY, R; KISS, T; FILIPOWICZ, W			CAP STRUCTURE OF U3 SMALL NUCLEOLAR RNA IN ANIMAL AND PLANT-CELLS IS DIFFERENT - GAMMA-MONOMETHYL PHOSPHATE CAP STRUCTURE IN PLANT RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR-RNA; EXTERNAL TRANSCRIBED SPACER; POLYMERASE-III; RIBOSOMAL-RNA; U6 SNRNA; SEQUENCE; DNA; U1; RIBONUCLEOPROTEIN; PROTOPLASTS	U3 small nucleolar RNA (snoRNA) is an abundant small RNA involved in the processing of pre-ribosomal RNA of eukaryotic cells. U3 snoRNA has been previously characterized from several sources, including human, rat, mouse, frog, fruit fly, dinoflagellates, slime mold, and yeast; in all these organisms, U3 snoRNA contains trimethylguanosine cap structure. In all instances where investigated, the trimethylguanosine-capped snRNAs including U3 snoRNA, are synthesized by RNA polymerase II. However, in higher plants, the U3 snoRNA is synthesized by RNA polymerase III and contains a cap structure different from trimethylguanosine (Kiss, T., and Solymosy, F. (1990) Nucleic Acids Res. 18, 1941-1949; Marshallsay, C., Kiss, T., and Filipowicz, W. (1990) Nucleic Acids Res. 18,3451-3458; Kiss, T., Marshallsay, C., and Filipowicz, W. (1991) Cell 65, 517-526). In this study, we present evidence that cowpea and, most likely, tomato plant U3 snoRNA contains a methyl-pppA cap structure. These data show that the same U3 snoRNA contains different cap structures in different species and suggest that the kind of cap structure that an uridylic acid-rich small nuclear RNA contains is dependent on the RNA polymerase responsible for its synthesis. In vitro synthesized plant U3 snoRNA, with pppA or pppG as its 5' end, was converted to methyl-pppA/G cap structure in vitro when incubated with extracts prepared from wheat germ or HeLa cells. These data show that the capping machinery is conserved in organisms as evolutionarily distant as plants and mammals. Nucleotides 1-45 of tomato U3 snoRNA, which are capable of forming a stem-loop structure, are sufficient to direct the methyl cap formation in vitro.	BAYLOR COLL MED, DEPT PHARMACOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DIV MOLEC VIROL, HOUSTON, TX 77030 USA; FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND	Baylor College of Medicine; Baylor College of Medicine; Friedrich Miescher Institute for Biomedical Research				Kiss, Tamas/0000-0003-0293-3093	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038320] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38320] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASERGA SJ, 1991, EMBO J, V10, P2645, DOI 10.1002/j.1460-2075.1991.tb07807.x; BASERGA SJ, 1992, IN PRESS GENES DEV; BUCKLEY B, 1990, VIROLOGY, V177, P298, DOI 10.1016/0042-6822(90)90483-8; CARBON P, 1987, CELL, V51, P71, DOI 10.1016/0092-8674(87)90011-0; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FISCHER U, 1991, J CELL BIOL, V113, P705, DOI 10.1083/jcb.113.4.705; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GOODALL GJ, 1990, METHOD ENZYMOL, V181, P148; GUPTA S, 1990, J BIOL CHEM, V265, P9491; GUPTA S, 1990, J BIOL CHEM, V265, P19137; GUPTA S, 1991, NUCLEIC ACIDS RES, V19, P2073, DOI 10.1093/nar/19.suppl.2073; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HOAGLAND DR, 1950, 347 CAL AGR EXP STN; HUGHES JMX, 1987, EMBO J, V6, P2145, DOI 10.1002/j.1460-2075.1987.tb02482.x; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KISS T, 1991, CELL, V65, P517, DOI 10.1016/0092-8674(91)90469-F; KISS T, 1990, NUCLEIC ACIDS RES, V18, P1941, DOI 10.1093/nar/18.8.1941; KROL A, 1983, NUCLEIC ACIDS RES, V11, P8583, DOI 10.1093/nar/11.24.8583; LERNER MR, 1979, P NATL ACAD SCI USA, V76, P5495, DOI 10.1073/pnas.76.11.5495; MARSHALLSAY C, 1990, NUCLEIC ACIDS RES, V18, P3459, DOI 10.1093/nar/18.12.3459; MASER RL, 1989, P NATL ACAD SCI USA, V86, P6523, DOI 10.1073/pnas.86.17.6523; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; NAGATA T, 1971, PLANTA, V99, P12, DOI 10.1007/BF00392116; PORTER GL, 1988, NUCLEIC ACIDS RES, V16, P10131, DOI 10.1093/nar/16.21.10131; PRESTAYKO A W, 1970, Journal of Molecular Biology, V47, P505, DOI 10.1016/0022-2836(70)90318-9; Reddy R., 1991, Progress in Molecular and Subcellular Biology, V12, P1; REDDY R, 1983, J BIOL CHEM, V258, P1383; Reddy R., 1988, STRUCTURE FUNCTION M, P1, DOI 10.1007/978-3-642-73020-7_1; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; SHUMYATSKY GP, 1990, NUCLEIC ACIDS RES, V16, P10131; Silberklang M, 1979, Methods Enzymol, V59, P58; SINGH R, 1990, MOL CELL BIOL, V10, P939, DOI 10.1128/MCB.10.3.939; SINGH R, 1989, P NATL ACAD SCI USA, V86, P8280, DOI 10.1073/pnas.86.21.8280; STROKE IL, 1989, J MOL BIOL, V210, P497, DOI 10.1016/0022-2836(89)90126-5; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; VANKAN P, 1988, EMBO J, V7, P791, DOI 10.1002/j.1460-2075.1988.tb02877.x; WAIBEL F, 1990, NUCLEIC ACIDS RES, V18, P3451, DOI 10.1093/nar/18.12.3451; WEIL PA, 1979, J BIOL CHEM, V254, P6163; WIDHOLM JM, 1972, STAIN TECHNOL, V47, P189, DOI 10.3109/10520297209116483; WISE JA, 1981, J BIOL CHEM, V256, P956; ZIEVE G, 1976, CELL, V8, P19, DOI 10.1016/0092-8674(76)90181-1; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	46	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13772	13777						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618872				2022-12-25	WOS:A1992JB74600106
J	HAITOGLOU, CS; TSILIBARY, EC; BROWNLEE, M; CHARONIS, AS				HAITOGLOU, CS; TSILIBARY, EC; BROWNLEE, M; CHARONIS, AS			ALTERED CELLULAR INTERACTIONS BETWEEN ENDOTHELIAL-CELLS AND NONENZYMATICALLY GLUCOSYLATED LAMININ TYPE-IV COLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NON-ENZYMATIC GLYCOSYLATION; HUMAN HEMOGLOBIN-A; DIABETIC COMPLICATIONS; BASEMENT-MEMBRANE; PROTEINS; INVITRO; COMPONENTS; MODULATION; EXPRESSION; ALBUMIN	Laminin and type IV collagen are two major basement membrane glycoproteins. In previous studies it has been shown that nonenzymatic glucosylation induces structural alterations of these macromolecules and also reduces their ability to self-associate. In the present study, endothelial cells were tested for their ability to adhere and spread on nonenzymatically glucosylated laminin and type IV collagen. Adhesion and spreading were reduced when glucosylated macromolecules were used as substrates. Glucosylation-induced changes in adhesion and spreading may be an important initial event signaling other phenotypic modifications of cells in the microvasculature and may be a crucial factor in order to understand the pathogenesis of diabetic microangiopathy at the molecular level.	UNIV MINNESOTA,SCH MED,DEPT LAB MED & PATHOL,BOX 609 UMHC,420 DELAWARE ST SE,MINNEAPOLIS,MN 55455; ALBERT EINSTEIN COLL MED,DEPT INTERNAL MED,DIV ENDOCRINOL,BRONX,NY 10461	University of Minnesota System; University of Minnesota Twin Cities; Yeshiva University; Albert Einstein College of Medicine			Haitoglou, Costas/ABE-9369-2020; Haitoglou, Costas/ABE-2270-2020	Haitoglou, Costas/0000-0001-8372-2946; Charonis, Aristidis/0000-0001-9956-732X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043569, R29DK039216] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43569, DK43754, DK39216] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHTON N, 1983, DIABETIC RETINOPATHY, P85; BAILEY AJ, 1976, BIOCHIM BIOPHYS ACTA, V434, P51, DOI 10.1016/0005-2795(76)90034-9; BENZEEV A, 1988, P NATL ACAD SCI USA, V85, P2161, DOI 10.1073/pnas.85.7.2161; BETHEA CL, 1984, MOL CELL ENDOCRINOL, V37, P319, DOI 10.1016/0303-7207(84)90102-3; BISSEL MJ, 1982, J THEOR BIOL, V198, P31; BROWNLEE M, 1984, ANN INTERN MED, V101, P527, DOI 10.7326/0003-4819-101-4-527; BUNN HF, 1979, J BIOL CHEM, V254, P3892; CHARONIS AS, 1985, J CELL BIOL, V100, P1848, DOI 10.1083/jcb.100.6.1848; CHARONIS AS, 1990, DIABETES, V39, P807, DOI 10.2337/diabetes.39.7.807; COHEN MP, 1981, BIOCHEM BIOPH RES CO, V100, P1549, DOI 10.1016/0006-291X(81)90695-1; CROWLEY ST, 1991, DIABETES, V40, P540, DOI 10.2337/diabetes.40.5.540; DAY JF, 1979, J BIOL CHEM, V254, P9394; GONEN B, 1981, DIABETES, V30, P875, DOI 10.2337/diabetes.30.10.875; HERBST TJ, 1988, J CELL BIOL, V106, P1365, DOI 10.1083/jcb.106.4.1365; KADOR PF, 1988, MED RES REV, V8, P325, DOI 10.1002/med.2610080302; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; LEE EYH, 1984, J CELL BIOL, V98, P146, DOI 10.1083/jcb.98.1.146; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; LORENZI M, 1985, DIABETES, V34, P621, DOI 10.2337/diabetes.34.7.621; MCDONALD MJ, 1979, J BIOL CHEM, V254, P702; MOGENSEN CE, 1988, DISEASES KIDNEY, P2395; MONNIER VM, 1979, J EXP MED, V150, P1098, DOI 10.1084/jem.150.5.1098; ROY S, 1990, P NATL ACAD SCI USA, V87, P404, DOI 10.1073/pnas.87.1.404; SHAKLAI N, 1984, J BIOL CHEM, V259, P3812; SHAPIRO R, 1980, J BIOL CHEM, V255, P3120; SPIEGELMAN BM, 1983, CELL, V35, P657, DOI 10.1016/0092-8674(83)90098-3; TRUEB B, 1980, J BIOL CHEM, V255, P6717; TSILIBARY EC, 1988, J BIOL CHEM, V263, P4302; ZAR JH, 1974, BIOSTAT ANAL, P109	29	148	155	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12404	12407						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618745				2022-12-25	WOS:A1992HZ48300004
J	OLSON, ST; BJORK, I; SHEFFER, R; CRAIG, PA; SHORE, JD; CHOAY, J				OLSON, ST; BJORK, I; SHEFFER, R; CRAIG, PA; SHORE, JD; CHOAY, J			ROLE OF THE ANTITHROMBIN-BINDING PENTASACCHARIDE IN HEPARIN ACCELERATION OF ANTITHROMBIN-PROTEINASE REACTIONS - RESOLUTION OF THE ANTITHROMBIN CONFORMATIONAL CHANGE CONTRIBUTION TO HEPARIN RATE ENHANCEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY HEPARIN; CATALYZED PROTEASE INACTIVATION; NUCLEIC ACID INTERACTIONS; MOLECULAR WEIGHT HEPARIN; ANTI-THROMBIN-III; FACTOR-XA; ALPHA-THROMBIN; ACTIVE-SITE; H-1-NMR SPECTROSCOPY; BOVINE ANTITHROMBIN	The synthetic antithrombin-binding heparin pentasaccharide and a full-length heparin of approximately 26 saccharides containing this specific sequence have been compared with respect to their interactions with antithrombin and their ability to promote inhibition and substrate reactions of antithrombin with thrombin and factor Xa. The aim of these studies was to elucidate the pentasaccharide contribution to heparin's accelerating effect on antithrombin-proteinase reactions. Pentasaccharide and full-length heparins bound antithrombin with comparable high affinities (K(D) values of 36 +/- 11 and 10 +/- 3 nM, respectively, at I 0.15) and induced highly similar protein fluorescence, ultraviolet and circular dichroism changes in the inhibitor. Stopped-flow fluorescence kinetic studies of the heparin binding interactions at I 0.15 were consistent with a two-step binding process for both heparins, involving an initial weak encounter complex interaction formed with similar affinities (K(D) 20-30-mu-M), followed by an inhibitor conformational change with indistinguishable forward rate constants of 520-700 s-1 but dissimilar reverse rate constants of approximately 1 s-1 for the pentasaccharide and approximately 0.2 s-1 for the full-length heparin. Second order rate constants for antithrombin reactions with thrombin and factor Xa were maximally enhanced by the pentasaccharide only 1.7-fold for thrombin, but a substantial 270-fold for factor Xa, in an ionic strength-independent manner at saturating oligosaccharide. In contrast, the full-length heparin produced large ionic strength-dependent enhancements in second order rate constants for both antithrombin reactions of 4,300-fold for thrombin and 580-fold for factor Xa at I 0.15. These enhancements were resolvable into a nonionic component ascribable to the pentasaccharide and an ionic component responsible for the additional rate increase of the larger heparin. Stoichiometric titrations of thrombin and factor Xa inactivation by antithrombin, as well as sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the products of these reactions, indicated that pentasaccharide and full-length heparins similarly promoted the formation of proteolytically modified inhibitor during the inactivation of factor Xa by antithrombin, whereas only the full-length heparin was effective in promoting this substrate reaction of antithrombin during the reaction with thrombin. These results indicate that 1) the pentasaccharide is responsible for nearly all (93%) of the binding energy of the full-length heparin interaction with antithrombin as well as for inducing the inhibitor conformational change; 2) the pentasaccharide enhancement of the rate of thrombin and factor Xa inactivation represents the contribution of the antithrombin conformational change to the rate enhancement of the full-length heparin with any additional rate enhancement of the larger heparin resulting from the polysaccharide bridging antithrombin and the proteinase bound to the same chain; 3) the antithrombin conformational change is mainly responsible for heparin promoting both inhibitor and substrate reactions of antithrombin with factor Xa, whereas this conformational change contributes minimally to heparin promoting substrate and inhibitor reactions of antithrombin with thrombin. The sum of these observations indicates that antithrombin conformational change and heparin-bridging mechanisms make additive contributions to heparin promotion of inhibition and substrate reactions of antithrombin with proteinases, the relative contribution of these two mechanisms being a function of the target proteinase.	SWEDISH UNIV AGR SCI, UPPSALA BIOMED CTR, DEPT VET MED CHEM, S-75123 UPPSALA, SWEDEN; SANOFI RES, CTR CHOAY, F-94256 GENTILLY, FRANCE	Swedish University of Agricultural Sciences; Sanofi-Aventis	OLSON, ST (corresponding author), HENRY FORD HOSP, DIV BIOCHEM RES, EDUC & RES BLDG, RM 3126, 2799 W GRAND BLVD, DETROIT, MI 48202 USA.			Craig, Paul/0000-0002-2085-7816	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039888, R29HL039888] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-39888] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; ATHA DH, 1987, BIOCHEMISTRY-US, V26, P6454, DOI 10.1021/bi00394a024; BERESFORD CH, 1990, INT J BIOCHEM, V22, P121, DOI 10.1016/0020-711X(90)90172-Y; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BJORK I, 1982, J BIOL CHEM, V257, P2406; BJORK I, 1982, J BIOL CHEM, V257, P9487; BJORK I, 1989, HEPARIN CHEM BIOL PR, P229; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; BRENNAN SO, 1987, FEBS LETT, V219, P431, DOI 10.1016/0014-5793(87)80266-1; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; CHOAY J, 1981, ANN NY ACAD SCI, V370, P640; CRAIG PA, 1989, J BIOL CHEM, V264, P5452; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; ELLIS V, 1986, BIOCHEM J, V238, P329, DOI 10.1042/bj2380329; FENTON JW, 1977, J BIOL CHEM, V252, P3587; GETTINS P, 1987, BIOCHEMISTRY-US, V26, P1391, DOI 10.1021/bi00379a027; GETTINS P, 1989, CARBOHYD RES, V185, P69, DOI 10.1016/0008-6215(89)84022-4; GROOTENHUIS PDJ, 1991, J AM CHEM SOC, V113, P2743, DOI 10.1021/ja00007a058; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; JORDAN RE, 1980, J BIOL CHEM, V255, P81; JORDAN RE, 1980, J BIOL CHEM, V255, P73; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DA, 1984, BIOCHEM J, V218, P725, DOI 10.1042/bj2180725; LAURENT TC, 1978, BIOCHEM J, V175, P691, DOI 10.1042/bj1750691; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LOHMAN TM, 1978, BIOPHYS CHEM, V8, P281, DOI 10.1016/0301-4622(78)80011-8; MILETICH JP, 1980, ANAL BIOCHEM, V105, P304, DOI 10.1016/0003-2697(80)90462-5; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; NORDENMAN B, 1978, EUR J BIOCHEM, V90, P1, DOI 10.1111/j.1432-1033.1978.tb12567.x; NORDENMAN B, 1978, BIOCHEMISTRY-US, V17, P3339, DOI 10.1021/bi00609a026; OLSON ST, 1982, J BIOL CHEM, V257, P4891; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1988, J BIOL CHEM, V263, P1698; OLSON ST, 1981, J BIOL CHEM, V256, P1065; OLSON ST, 1985, J BIOL CHEM, V260, P153; OLSON ST, 1989, THROMB HAEMOSTASIS, V62, P326; OLSON ST, 1992, THROMBIN STRUCTURE F; OOSTA GM, 1981, P NATL ACAD SCI-BIOL, V78, P829, DOI 10.1073/pnas.78.2.829; PETERSON CB, 1985, J BIOL CHEM, V260, P610; PETITOU M, 1987, CARBOHYD RES, V167, P67, DOI 10.1016/0008-6215(87)80268-9; RAGAZZI M, 1990, CARBOHYD RES, V195, P169, DOI 10.1016/0008-6215(90)84165-Q; RECORD MT, 1978, BIOPOLYMERS, V17, P159, DOI 10.1002/bip.1978.360170112; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; STONE AL, 1982, P NATL ACAD SCI-BIOL, V79, P7190, DOI 10.1073/pnas.79.23.7190; THALER E, 1975, BRIT J HAEMATOL, V31, P233, DOI 10.1111/j.1365-2141.1975.tb00853.x; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2	51	464	475	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12528	12538						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618758				2022-12-25	WOS:A1992HZ48300026
J	SZYF, M; ROULEAU, J; THEBERGE, J; BOZOVIC, V				SZYF, M; ROULEAU, J; THEBERGE, J; BOZOVIC, V			INDUCTION OF MYOGENIC DIFFERENTIATION BY AN EXPRESSION VECTOR ENCODING THE DNA METHYLTRANSFERASE CDNA SEQUENCE IN THE ANTISENSE ORIENTATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE DIFFERENTIATION; GENE-EXPRESSION; MOUSE CELLS; METHYLATION; INHIBITION; MYOBLASTS; 5-AZACYTIDINE; ESTABLISHMENT; FIBROBLASTS; CONVERSION	To test the hypothesis that DNA methylation controls the state of differentiation of a mammalian cell, we transfected the stable mesenchymal line 10T1/2 with an expression vector encoding sequences from the DNA methyltransferase (DNA MeTase) cDNA in the antisense orientation. 10T1/2 cells transfected with the antisense construct (pZ-alpha-M), but not with the vector alone, exhibit morphological changes, convert into multinucleated tubular cells, and express the skeletal myosin heavy chain protein. The conversion to myogenic phenotype is a late event and is dependent on the number of replication events that the cell has undergone, suggesting that induction of myogenesis is a multistep process. Demethylation of sequences that are not involved in the myogenic process is detected at early passages, while demethylation and expression of the MyoD gene is a late event. This report establishes for the first time that demethylation is a very early event in commitment to myogenic differentiation, while demethylation and expression of MyoD is a late event. We suggest that other genes serve as the initial targets for demethylation and commitment of mesenchymal cells to myogenesis. The cell lines described in this report can serve as an important system for identifying these genes.			SZYF, M (corresponding author), MCGILL UNIV,DEPT PHARMACOL & THERAPEUT,MONTREAL H3G 1Y6,QUEBEC,CANADA.							Ausubel FM., 1988, CURRENT PROTOCOLS MO; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BENEDICT WF, 1977, CANCER RES, V37, P2202; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; ENVER T, 1987, GENE DEV, V48, P698; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; IZANT JG, 1984, CELL, V36, P1007, DOI 10.1016/0092-8674(84)90050-3; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; KENIGSBERG RL, 1990, J HISTOCHEM CYTOCHEM, V38, P191, DOI 10.1177/38.2.2299180; LASSAR AB, 1986, CELL, V47, P649, DOI 10.1016/0092-8674(86)90507-6; LOCK LF, 1987, CELL, V48, P39, DOI 10.1016/0092-8674(87)90353-9; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; ONEILL MC, 1974, DEV BIOL, V37, P117, DOI 10.1016/0012-1606(74)90173-0; PINNEY DF, 1988, CELL, V53, P781, DOI 10.1016/0092-8674(88)90095-5; RAZIN A, 1984, BIOCHIM BIOPHYS ACTA, V782, P331, DOI 10.1016/0167-4781(84)90043-5; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; RAZIN A, 1986, P NATL ACAD SCI USA, V83, P2827, DOI 10.1073/pnas.83.9.2827; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; SELKER EU, 1990, TRENDS BIOCHEM SCI, V15, P103, DOI 10.1016/0968-0004(90)90193-F; STEIN R, 1982, P NATL ACAD SCI-BIOL, V79, P61, DOI 10.1073/pnas.79.1.61; SZYF M, 1985, P NATL ACAD SCI USA, V82, P8090, DOI 10.1073/pnas.82.23.8090; SZYF M, 1985, J BIOL CHEM, V260, P8653; SZYF M, 1991, J BIOL CHEM, V266, P10027; SZYF M, 1991, BIOCHEM CELL BIOL, V69, P764, DOI 10.1139/o91-117; SZYF M, 1990, MOL ENDOCRINOL, V4, P1144, DOI 10.1210/mend-4-8-1144; TAMAME M, 1983, MOL CELL BIOL, V3, P2287, DOI 10.1128/MCB.3.12.2287; TAYLOR SM, 1982, J MOL BIOL, V162, P679, DOI 10.1016/0022-2836(82)90395-3; UHLER MD, 1987, J BIOL CHEM, V262, P15202; WEIH F, 1991, EMBO J, V10, P2559, DOI 10.1002/j.1460-2075.1991.tb07796.x; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YISRAELI J, 1984, DNA METHYLATION BIOC, P353; ZINGG JM, NUCLEIC ACIDS RES, V19, P6433	38	56	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12831	12836						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618783				2022-12-25	WOS:A1992HZ48300068
J	GERBER, LD; KODUKULA, K; UDENFRIEND, S				GERBER, LD; KODUKULA, K; UDENFRIEND, S			PHOSPHATIDYLINOSITOL GLYCAN (PI-G) ANCHORED MEMBRANE-PROTEINS - AMINO-ACID-REQUIREMENTS ADJACENT TO THE SITE OF CLEAVAGE AND PI-G ATTACHMENT IN THE COOH-TERMINAL SIGNAL PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL ALKALINE-PHOSPHATASE; CELL-FREE SYSTEM; TRYPANOSOMA-BRUCEI; CARBOXYL TERMINUS; CARCINOEMBRYONIC ANTIGEN; SURFACE GLYCOPROTEINS; ENDOPLASMIC-RETICULUM; MOLECULAR-CLONING; THY-1 GENE; IDENTIFICATION	Secreted proteins are processed from a nascent form that contains an NH2-terminal signal peptide. During processing, the latter is cleaved by a specific NH2-terminal signal peptidase. The nascent form of phosphatidylinositol glycan (PI-G) tailed proteins contain both an NH2- and a COOH-terminal signal peptide. The two signal peptides have much in common, such as size and hydrophobicity. The COOH-terminal peptide is also cleaved during processing. We propose that the amino acid in a nascent protein that ultimately combines with the PI-G moiety be designated the omega-site. Amino acids adjacent and COOH-terminal to the omega-site would then be omega + 1, omega + 2, etc. In previous studies, we showed that allowable substitutions at the omega-site of an engineered form of placental alkaline phosphatase (miniPLAP) are limited to 6 small amino acids. In the present study, mutations were made at the omega + 1 and omega + 2 sites. At the omega + 1 site, processing to varying degrees was observed with 8 of the 9 amino acids substituted for alanine, the normal constituent. Only the proline mutant showed no processing. By contrast, the only substituents permitted at the omega + 2 site were glycine and alanine, with only trace activity observed with serine and cysteine. Thus, just as there is a -1, -3 rule for predicting cleavage by NH2-terminal signal peptidase, there appears to be a comparable omega, omega + 2 rule for predicting cleavage/PI-G addition by COOH-terminal signal transamidase.	ROCHE INST MOLEC BIOL,ROCHE RES CTR,DEPT NEUROSCI,NUTLEY,NJ 07110	Roche Holding								ADACHI H, 1990, J BIOL CHEM, V265, P15341; AMTHAUER R, 1992, IN PRESS P NATL ACAD; BAILEY CA, 1989, P NATL ACAD SCI USA, V86, P22, DOI 10.1073/pnas.86.1.22; BERGER J, 1988, J BIOL CHEM, V263, P10016; BLOBEL G, 1983, METHOD ENZYMOL, V96, P663; BOOTHROYD JC, 1981, NUCLEIC ACIDS RES, V9, P4735, DOI 10.1093/nar/9.18.4735; BUTTON LL, 1988, J EXP MED, V167, P724, DOI 10.1084/jem.167.2.724; CARAS IW, 1991, J CELL BIOL, V113, P77, DOI 10.1083/jcb.113.1.77; CLAYTON CE, 1989, J BIOL CHEM, V264, P15088; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DUFFAUD G, 1988, J BIOL CHEM, V263, P10224; EARLY AE, 1988, MOL CELL BIOL, V8, P3458, DOI 10.1128/MCB.8.8.3458; ELWOOD PC, 1989, J BIOL CHEM, V264, P14893; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; GARATTINI E, 1985, P NATL ACAD SCI USA, V82, P6080, DOI 10.1073/pnas.82.18.6080; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; HAEUPTLE MT, 1989, J CELL BIOL, V108, P1227, DOI 10.1083/jcb.108.4.1227; HEFTA SA, 1988, P NATL ACAD SCI USA, V85, P4648, DOI 10.1073/pnas.85.13.4648; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KILLEEN N, 1988, EMBO J, V7, P3087, DOI 10.1002/j.1460-2075.1988.tb03174.x; KOCH F, 1990, P NATL ACAD SCI USA, V87, P964, DOI 10.1073/pnas.87.3.964; KODUKULA K, 1992, P NATL ACAD SCI USA, V89, P1350, DOI 10.1073/pnas.89.4.1350; KODUKULA K, 1991, J BIOL CHEM, V266, P4464; KODUKULA K, 1992, IN PRESS P NATL ACAD; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MAJUMDER HK, 1981, NUCLEIC ACIDS RES, V9, P4745, DOI 10.1093/nar/9.18.4745; MAULET Y, 1990, NEURON, V4, P289, DOI 10.1016/0896-6273(90)90103-M; MAYOR S, 1991, J CELL BIOL, V114, P61, DOI 10.1083/jcb.114.1.61; MICANOVIC R, 1988, P NATL ACAD SCI USA, V85, P1398, DOI 10.1073/pnas.85.5.1398; MICANOVIC R, 1990, P NATL ACAD SCI USA, V87, P157, DOI 10.1073/pnas.87.1.157; MICANOVIC R, 1990, P NATL ACAD SCI USA, V87, P7939, DOI 10.1073/pnas.87.20.7939; MORAN P, 1991, J CELL BIOL, V115, P1595, DOI 10.1083/jcb.115.6.1595; MORAN P, 1991, J BIOL CHEM, V266, P1250; MORAN P, 1991, J CELL BIOL, V115, P329, DOI 10.1083/jcb.115.2.329; NOTHWEHR SF, 1990, J BIOL CHEM, V265, P17202; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; OGATA S, 1990, BIOCHEMISTRY-US, V29, P7923, DOI 10.1021/bi00486a021; OGTA S, 1988, J BIOL CHEM, V263, P10489; OIKAWA S, 1987, BIOCHEM BIOPH RES CO, V142, P511, DOI 10.1016/0006-291X(87)90304-4; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; RAPOPORT TA, 1991, FASEB J, V5, P2792, DOI 10.1096/fasebj.5.13.1916103; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; SEKI T, 1985, NATURE, V313, P485, DOI 10.1038/313485a0; SEKI T, 1985, P NATL ACAD SCI USA, V82, P6657, DOI 10.1073/pnas.82.19.6657; SIKORAV JL, 1988, EMBO J, V7, P2983, DOI 10.1002/j.1460-2075.1988.tb03161.x; STAHL N, 1990, BIOCHEMISTRY-US, V29, P8879, DOI 10.1021/bi00490a001; STRICKLER JE, 1987, BIOCHEMISTRY-US, V26, P796, DOI 10.1021/bi00377a021; TATE SS, 1981, MOL CELL BIOCHEM, V39, P357, DOI 10.1007/BF00232585; TIPPER DJ, 1965, P NATL ACAD SCI USA, V54, P1133, DOI 10.1073/pnas.54.4.1133; TSE AGD, 1985, SCIENCE, V230, P1003, DOI 10.1126/science.2865810; UDENFRIEND S, 1991, CELL BIOL INT REP, V15, P739, DOI 10.1016/0309-1651(91)90030-M; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543	57	195	197	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12168	12173						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601882				2022-12-25	WOS:A1992HY94700077
J	MELHUS, H; LAURENT, B; RASK, L; PETERSON, PA				MELHUS, H; LAURENT, B; RASK, L; PETERSON, PA			LIGAND-DEPENDENT SECRETION OF RAT RETINOL-BINDING PROTEIN EXPRESSED IN HELA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-A; INFLUENZA HEMAGGLUTININ; INTRACELLULAR-TRANSPORT; ENDOPLASMIC-RETICULUM; DEFICIENT RATS; METABOLISM; PREALBUMIN; LIVER; GLYCOPROTEINS; LOCALIZATION	A minigene encoding rat retinol-binding protein (RBP) was transfected into HeLa cells, which do not express endogenous RBP, transthyretin, or cellular retinol-binding protein. The HeLa cells manufactured and secreted the transfected gene product, demonstrating that RBP-transthyretin assembly is not a requirement for the secretion of RBP. When HeLa cells were grown under vitamin A-deficient conditions, RBP accumulated in the endoplasmic reticulum. Both serum and retinol stimulated secretion of RBP in a concentration-dependent manner. The retinol-regulated secretion occurred also after protein synthesis had been blocked by cycloheximide. Addition of holo-RBP or retinal, but not retinoic acid, stimulated secretion of RBP. Thus, an in vitro model system that resembles the rat hepatocyte in vivo with regard to the known regulation of RBP secretion has been established in a human cell line of extrahepatic origin. It can be concluded that cellular retinol-binding protein is not required for the transfer of retinol to RBP and that the mechanism whereby retinol controls the intracellular transport of RBP is neither specific for tissues synthesizing RBP nor species-specific. To investigate the structural properties responsible for the endoplasmic reticulum retention of RBP in the absence of its ligand, a cDNA encoding chicken purpurin, a protein that is 50% identical to RBP and that binds retinol, was expressed in HeLa cells. In contrast to RBP, purpurin was not retained in vitamin A-deficient HeLa cells.	SWEDISH UNIV AGR SCI, S-75007 UPPSALA, SWEDEN; COLUMBIA UNIV COLL PHYS & SURG, DEPT GENET & DEV, NEW YORK, NY 10032 USA; Scripps Res Inst, RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Swedish University of Agricultural Sciences; Columbia University; Scripps Research Institute	MELHUS, H (corresponding author), UNIV UPPSALA, DEPT CELL RES, S-75105 UPPSALA, SWEDEN.		Rask, Lars B/L-4177-2013		NIDDK NIH HHS [DK 35915] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERMAN P, 1987, CELL, V51, P135, DOI 10.1016/0092-8674(87)90018-3; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; DIXON JL, 1987, J CELL PHYSIOL, V130, P14, DOI 10.1002/jcp.1041300104; DONOFRIO C, 1985, EMBO J, V4, P1981, DOI 10.1002/j.1460-2075.1985.tb03881.x; FUCHS E, 1981, CELL, V25, P617, DOI 10.1016/0092-8674(81)90169-0; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GODOVAC-ZIMMERMANN J, 1988, TRENDS BIOCHEM SCI, V13, P64, DOI 10.1016/0968-0004(88)90031-X; GOODMAN DS, 1972, J LIPID RES, V13, P338; Goodman DS, 1984, RETINOIDS, V2, P42; HELLER J, 1973, J BIOL CHEM, V248, P6308; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KAMPE O, 1983, J BIOL CHEM, V258, P594; KINGSTON RE, 1987, CURRENT PROTOCOLS MO, V1; LAURENT BC, 1985, J BIOL CHEM, V260, P1476; LODISH HF, 1988, J BIOL CHEM, V263, P2107; MARINARI L, 1987, J LIPID RES, V28, P941; MUTO Y, 1972, J BIOL CHEM, V247, P2542; PAABO S, 1986, EMBO J, V5, P1921, DOI 10.1002/j.1460-2075.1986.tb04445.x; PETERSON PA, 1973, J BIOL CHEM, V248, P4009; PEVSNER J, 1988, SCIENCE, V241, P336, DOI 10.1126/science.3388043; RASK L, 1983, EXP CELL RES, V143, P91, DOI 10.1016/0014-4827(83)90112-X; RASK L, 1971, J BIOL CHEM, V246, P6638; RONNE H, 1983, J CELL BIOL, V96, P907, DOI 10.1083/jcb.96.3.907; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; SAARI JC, 1978, INVEST OPHTH VIS SCI, V17, P988; SEGE K, 1978, NATURE, V271, P167, DOI 10.1038/271167a0; SINGH I, 1990, EMBO J, V9, P631, DOI 10.1002/j.1460-2075.1990.tb08155.x; SMITH JE, 1978, CELL, V15, P865, DOI 10.1016/0092-8674(78)90271-4; SOPRANO DR, 1982, J BIOL CHEM, V257, P7693; SUNDELIN J, 1985, J BIOL CHEM, V260, P6481; SUNDELIN J, 1985, J BIOL CHEM, V260, P6472; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; VAHLQUIST A, 1971, EUR J BIOCHEM, V20, P160, DOI 10.1111/j.1432-1033.1971.tb01374.x	34	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12036	12041						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601873				2022-12-25	WOS:A1992HY94700060
J	MUKHERJI, S; BHADURI, A				MUKHERJI, S; BHADURI, A			AN ESSENTIAL HISTIDINE RESIDUE FOR THE ACTIVITY OF UDPGLUCOSE 4-EPIMERASE FROM KLUYVEROMYCES-FRAGILIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE; ENZYME	UDPglucose 4-epimerase from Kluyveromyces fragilis was completely inactivated by diethylpyrocarbonate following pseudo-first order reaction kinetics. The pH profile of diethylpyrocarbonate inhibition and reversal of inhibition by hydroxylamine suggested specific modification of histidyl residues. Statistical analysis of the residual enzyme activity and the extent of modification indicated modification of 1 essential histidine residue to be responsible for loss in catalytic activity of yeast epimerase. No major structural change in the quarternary structure was observed in the modified enzyme as shown by the identical elution pattern on a calibrated Sephacryl 200 column and association of coenzyme NAD to the apoenzyme. Failure of the substrates to afford any protection against diethylpyrocarbonate inactivation indicated the absence of the essential histidyl residue at the substrate binding region of the active site. Unlike the case of native enzyme, sodium borohydride failed to reduce the pyridine moiety of the coenzyme in the diethylpyrocarbonate-modified enzyme. This indicated the presence of the essential histidyl residue in close proximity to the coenzyme binding region of the active site. The abolition of energy transfer phenomenon between the tryptophan and coenzyme fluorophore on complete inactivation by diethylpyrocarbonate without any loss of protein or coenzyme fluorescence are also added evidences in this direction.			MUKHERJI, S (corresponding author), INDIAN INST CHEM BIOL,4 RAJA SC MULLICK RD,CALCUTTA 700032,W BENGAL,INDIA.							ADAMS E, 1976, ADV ENZYMOL RAMB, V44, P69; BANASZAK LJ, 1975, ENZYMES, V11, P369; BERTLAND LH, 1971, BIOCHEMISTRY-US, V10, P3145, DOI 10.1021/bi00792a025; DARROW RA, 1966, P NATL ACAD SCI USA, V55, P205, DOI 10.1073/pnas.55.1.205; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; Frey P. A., 1987, PYRIDINE NUCLEOTID B, V2B, P462; GABRIEL O, 1978, TRENDS BIOCHEM SCI, V3, P193, DOI 10.1016/S0968-0004(78)91666-3; GABRIEL O, 1978, INT REV BIOCHEM, V16, P1; GABRIEL O, 1975, SUBUNIT ENZYMES BIOC, P85; GOMI T, 1983, BIOCHEMISTRY-US, V22, P137, DOI 10.1021/bi00270a020; Holbrook JJ., 1975, ENZYMES, P191; HORIIKE K, 1979, J THEOR BIOL, V79, P403, DOI 10.1016/0022-5193(79)90355-2; LEONARD NJ, 1971, BIOCHEMISTRY-US, V10, P3335, DOI 10.1021/bi00794a003; LEVY HM, 1963, J BIOL CHEM, V238, P3654; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANIATIS T, 1982, MOL CLONING LABORATO, P466; MEANS GE, 1971, CHEM MODIFICATION PR, P81; Miles E W, 1977, Methods Enzymol, V47, P431; MUKHERJI S, 1986, J BIOL CHEM, V261, P4519; NELSESTU.GL, 1971, J BIOL CHEM, V246, P7533; PAL DK, 1971, BIOCHIM BIOPHYS ACTA, V250, P588, DOI 10.1016/0005-2744(71)90259-2; RAY M, 1975, J BIOL CHEM, V250, P4373; RAY M, 1980, J BIOL CHEM, V255, P777; RAY M, 1980, J BIOL CHEM, V255, P782; RAY M, 1976, EUR J BIOCHEM, V70, P319, DOI 10.1111/j.1432-1033.1976.tb11020.x; SAMANTA AK, 1983, J BIOL CHEM, V258, P1118; SAMANTA AK, 1982, BIOCHIM BIOPHYS ACTA, V707, P129, DOI 10.1016/0167-4838(82)90405-8; TSOU C, 1962, SCI SINICA, V11, P1535; WONG SS, 1977, BIOCHEMISTRY-US, V16, P298, DOI 10.1021/bi00621a022; WONG YHH, 1979, BIOCHEMISTRY-US, V18, P5337, DOI 10.1021/bi00591a012; WONG YHH, 1979, BIOCHEMISTRY-US, V18, P5332, DOI 10.1021/bi00591a011	31	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11709	11713						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601847				2022-12-25	WOS:A1992HY94700013
J	TIEMEYER, M; BRANDLEY, BK; ISHIHARA, M; SWIEDLER, SJ; GREENE, J; HOYLE, GW; HILL, RL				TIEMEYER, M; BRANDLEY, BK; ISHIHARA, M; SWIEDLER, SJ; GREENE, J; HOYLE, GW; HILL, RL			THE BINDING-SPECIFICITY OF NORMAL AND VARIANT RAT KUPFFER CELL (LECTIN) RECEPTORS EXPRESSED IN COS CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; FUCOSE-CONTAINING GLYCOPROTEINS; MOLECULAR-CLONING; HEPATIC LECTINS; LIVER; ADHESION; LOCALIZATION; PROTEINS; CDNA	A receptor uniquely found on the surface of rat Kupffer cells was shown previously to bind oligosaccharides terminating in galactose, N-acetylgalactosamine, and fucose. To analyze further the binding specificity of the receptor, receptor-mediated adhesion of transfected COS cells to immobilized glycolipids of known structure was measured. The glycolipid Gb4Cer (GalNAc-beta-1-3Gal-alpha-1-4Gal-beta-1-4Glc-beta-1Cer) was the best ligand. Gb5Cer (GalNAc-alpha-1-3GalNAc-beta-1-3Gal-alpha-1-4Gal-beta-1-4Glc-beta -1Cer) and LacCer (Gal-beta-1-4Glc-beta-1Cer) bound more weakly (five times less than Gb4Cer) and Gb3Cer (Gal-alpha-1-4Gal-beta-1-4Glc-beta-1Cer), and g3Cer(Gal-NAc-beta-1-4Gal-beta-1-4Glc-beta-1Cer) bound even more weakly (60 times less than Gb4Cer). Gangliosides did not support adhesion of transfected cells. The adhesion of COS cells transfected with plasmids encoding variants of the receptor was also examined. In each variant, either tryptophan 498 or 523, which are conserved in most C-type lectins, was replaced by one of several amino acids. Variants that retained binding activity had the same specificity as the normal receptor. Differences between variants were noted, however, in maximal levels of adhesion and these differences correlated with altered expression of the receptor variants in COS cells.	GLYCOMED INC, ALAMEDA, CA 94501 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025766, R37GM025766] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25766] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BLACKBURN CC, 1986, J BIOL CHEM, V261, P2873; CHILDS RA, 1990, J BIOL CHEM, V265, P20770; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; HALTIWANGER RS, 1986, J BIOL CHEM, V261, P5696; HALTIWANGER RS, 1986, J BIOL CHEM, V261, P7433; HOYLE GW, 1988, J BIOL CHEM, V263, P7487; KUNKEL TA, 1990, CURRENT PROTOCOLS MO, P811; LEHRMAN MA, 1986, J BIOL CHEM, V261, P7419; LEHRMAN MA, 1986, J BIOL CHEM, V261, P7426; MOHR M, 1987, BIOL CELL, V60, P217, DOI 10.1111/j.1768-322X.1987.tb00558.x; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; ROOS PH, 1985, BIOCHIM BIOPHYS ACTA, V847, P115, DOI 10.1016/0167-4889(85)90161-2; SCHNAAR RL, 1989, METHOD ENZYMOL, V179, P542; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; Summers MD, 1987, MANUAL METHODS BACUL; SWANKHILL P, 1987, ANAL BIOCHEM, V163, P27, DOI 10.1016/0003-2697(87)90088-1; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; WEIGEL PH, 1979, J BIOL CHEM, V254, P830; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241	22	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12252	12257						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601891				2022-12-25	WOS:A1992HY94700090
J	YAMAZAKI, H; NOMOTO, S; MISHIMA, Y; KOMINAMI, R				YAMAZAKI, H; NOMOTO, S; MISHIMA, Y; KOMINAMI, R			A 35-KDA PROTEIN-BINDING TO A CYTOSINE-RICH STRAND OF HYPERVARIABLE MINISATELLITE DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOLOGOUS RECOMBINATION; VARIABLE NUMBER; POLYMERASE-II; TELOMERIC DNA; MUTATION; SEQUENCE; TRANSCRIPTION; MODEL; LOCI; POLYMORPHISM	A minisatellite-binding protein, Msbp-4, with a molecular mass of 35 kDa has been purified from mouse tumor cells that binds to hypervariable Pc-1 and Pc-2 minisatellites. The binding is much more efficient than that to genetically stable minisatellite homologues. As assayed by Southwestern analysis, Msbp-4 favors multiple copies of the Pc-2 repeat sequence GGCAGGA and requires the cytosine-rich single strand for the binding. The activity is also present in extracts from mouse testis but not from liver. The phosphatase treatment revealed that Msbp-4 is phosphorylated and may have a regulatory function, because dephosphorylation affects the activity and specificity of the binding. Sequence preference is demonstrated by a competition experiment using single-base substitution mutants. Thus, the binding properties of Msbp-4 observed here lead to an implication that the protein-DNA complexes result in formation of a single-stranded DNA loop of the G-rich strand in the minisatellite which may enhance the ability of the minisatellite to undergo recombination.			YAMAZAKI, H (corresponding author), NIIGATA UNIV,SCH MED,DEPT BIOCHEM,ASAHIMACHI DORI 1-757,NIIGATA 951,JAPAN.							ALI S, 1988, NUCLEIC ACIDS RES, V16, P8487, DOI 10.1093/nar/16.17.8487; ARMOUR JAL, 1989, GENOMICS, V4, P328, DOI 10.1016/0888-7543(89)90338-8; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BROWN WC, 1990, P NATL ACAD SCI USA, V87, P677, DOI 10.1073/pnas.87.2.677; COLLICK A, 1990, NUCLEIC ACIDS RES, V18, P625, DOI 10.1093/nar/18.3.625; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDELMANN W, 1989, CELL, V57, P937, DOI 10.1016/0092-8674(89)90332-2; FISERLITTELL RM, 1988, J BIOL CHEM, V263, P17136; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; HAMATAKE RK, 1989, J BIOL CHEM, V264, P13336; JEFFREYS AJ, 1987, BIOCHEM SOC T, V15, P309, DOI 10.1042/bst0150309; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; JEFFREYS AJ, 1990, CELL, V60, P473, DOI 10.1016/0092-8674(90)90598-9; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KELLY R, 1989, GENOMICS, V5, P844, DOI 10.1016/0888-7543(89)90126-2; KOHWISHIGEMATSU T, 1985, CELL, V43, P199, DOI 10.1016/0092-8674(85)90024-8; KOMINAMI R, 1988, NUCLEIC ACIDS RES, V16, P1197, DOI 10.1093/nar/16.3.1197; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDWITH BJ, 1990, CANCER RES, V50, P5245; LYAMICHEV VI, 1989, NATURE, V339, P634, DOI 10.1038/339634a0; Maniatis T., 1982, MOL CLONING; MESELSON MS, 1975, P NATL ACAD SCI USA, V72, P358, DOI 10.1073/pnas.72.1.358; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; MITANI K, 1990, J BIOL CHEM, V265, P15203; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; POTTER M, 1985, CURR TOP MICROBIOL I, V22, P1; RAUTH S, 1986, P NATL ACAD SCI USA, V83, P5587, DOI 10.1073/pnas.83.15.5587; RIPLEY LS, 1982, P NATL ACAD SCI-BIOL, V79, P4128, DOI 10.1073/pnas.79.13.4128; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOWALTER DB, 1989, ANAL BIOCHEM, V177, P90, DOI 10.1016/0003-2697(89)90019-5; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SIMMLER MC, 1987, EMBO J, V6, P963, DOI 10.1002/j.1460-2075.1987.tb04846.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SNYDER UK, 1989, NATURE, V341, P255, DOI 10.1038/341255a0; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; SUZUKI S, 1991, JPN J CANCER RES, V82, P1061, DOI 10.1111/j.1349-7006.1991.tb01757.x; THEIN SL, 1987, BRIT J CANCER, V55, P353, DOI 10.1038/bjc.1987.71; WAHLS WP, 1990, CELL, V60, P95, DOI 10.1016/0092-8674(90)90719-U; WAHLS WP, 1991, NUCLEIC ACIDS RES, V19, P3269, DOI 10.1093/nar/19.12.3269; WEIL PA, 1979, J BIOL CHEM, V254, P6163; WHITE JH, 1988, MOL CELL BIOL, V8, P153; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; YEE HA, 1991, NUCLEIC ACIDS RES, V19, P949, DOI 10.1093/nar/19.4.949	45	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12311	12316						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601895				2022-12-25	WOS:A1992HY94700098
J	WADAKIYAMA, Y; PETERS, B; NOGUCHI, CT				WADAKIYAMA, Y; PETERS, B; NOGUCHI, CT			THE EPSILON-GLOBIN GENE SILENCER - CHARACTERIZATION BY INVITRO TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRACTIONATED NUCLEAR EXTRACT; DOMINANT CONTROL REGION; TRANSGENIC MICE; ACCURATE TRANSCRIPTION; NEGATIVE REGULATION; DNA-REPLICATION; GAMMA-GLOBIN; ENHANCER; PROTEIN; EXPRESSION	K562 human erythroleukemia cells constitutively express epsilon- and gamma- but not beta-globin genes. We have previously shown that the differential expression of globin genes observed in intact K562 cells could be simulated in vitro as K562 nuclear extract (NE) actively transcribes the epsilon-globin (with 2 kilobases of 5'-flanking sequence) and gamma-globin gene DNA templates but not beta-globin gene templates. We have now used the K562 in vitro transcription system to examine a silencer transcriptional control element which has been reported to be localized between -177 and -392 base pairs (bp) 5' of the canonical cap site for the epsilon-globin gene. We find that K562 NE has markedly reduced synthesis of RNA in vitro from epsilon-globin gene DNA deletion templates which contain the silencer sequence, or part thereof, but not the adjacent 5'-positive regulatory region (-453 to -535 bp). Furthermore, those transcripts generated in vitro from DNA templates extending to -453 bp or less of the epsilon-globin gene were not correctly initiated at the canonical cap site. Separating the K562 NE by ion exchange chromatography, we isolated a fraction (F175) transcriptionally active for all tested globin genes including the epsilon-globin gene containing the silencer sequence and a fraction (F50) which contains the trans-acting factors associated with the silencer activity. F50 showed a strong dose-dependent inhibitory effect on correctly initiated epsilon-globin gene transcription directed by either unfractionated K562 NE or F175. This suppression by F50 was not observed on transcriptional activity of the permissive adenovirus 2 major late promoter. In electrophoretic mobility shift assays using the epsilon-globin gene silencer region as probe, F50 and F175 exhibited different DNA binding protein patterns; a specific protein band in F50 appears to be associated with the silencer activity. These studies suggest that this protein may be specifically responsible for the activity of the silencer element of the epsilon-globin gene. The expression and silencing of the epsilon-globin gene during development may be modulated by the interactions of this protein with the cis-acting DNA silencer.	NIDDK,CHEM BIOL LAB,BLDG 10,RM 9N307,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; BORRAS T, 1988, DEV BIOL, V127, P209, DOI 10.1016/0012-1606(88)90202-3; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; BUSHEL P, 1990, MOL CELL BIOL, V10, P1199, DOI 10.1128/MCB.10.3.1199; CAO SX, 1989, P NATL ACAD SCI USA, V86, P5306, DOI 10.1073/pnas.86.14.5306; CAO SX, 1989, HEMOGLOBIN SWITCHI A, P301; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DILLON N, 1991, NATURE, V350, P252, DOI 10.1038/350252a0; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; GONG QH, 1991, MOL CELL BIOL, V11, P2558, DOI 10.1128/MCB.11.5.2558; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; GUTMAN PD, 1992, GENE, V110, P197, DOI 10.1016/0378-1119(92)90648-9; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; HOFMANN JFX, 1989, CELL, V57, P725, DOI 10.1016/0092-8674(89)90788-5; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KADESCH T, 1986, NUCLEIC ACIDS RES, V14, P8209, DOI 10.1093/nar/14.20.8209; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KURL RN, 1985, P NATL ACAD SCI USA, V82, P1059, DOI 10.1073/pnas.82.4.1059; LAIMINS L, 1986, P NATL ACAD SCI USA, V83, P3151, DOI 10.1073/pnas.83.10.3151; LARSEN PR, 1986, P NATL ACAD SCI USA, V83, P8283, DOI 10.1073/pnas.83.21.8283; LINDENBAUM MH, 1990, GENE DEV, V4, P2075, DOI 10.1101/gad.4.12a.2075; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MAGUIRE KA, 1987, J BIOL CHEM, V262, P3932; Maxam A M, 1980, Methods Enzymol, V65, P499; MOI P, 1990, P NATL ACAD SCI USA, V87, P9000, DOI 10.1073/pnas.87.22.9000; PETERS B, 1991, BLOOD S, V78, pA254; PURUCKER M, 1990, NUCLEIC ACIDS RES, V18, P7407, DOI 10.1093/nar/18.24.7407; RAICH N, 1990, SCIENCE, V250, P1147, DOI 10.1126/science.2251502; RAICH N, 1992, BLOOD, V79, P861; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; SAVAGNER P, 1990, J BIOL CHEM, V265, P6669; STAMATOYANNOPOU.G, 1987, MOL BASIS BLOOD DISE, P66; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; SYKES K, 1990, MOL CELL BIOL, V10, P95, DOI 10.1128/MCB.10.1.95; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TOWNES TM, 1990, TRENDS GENET, V6, P219, DOI 10.1016/0168-9525(90)90182-6; TRAINOR CD, 1990, NATURE, V343, P92, DOI 10.1038/343092a0; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; VANASSENDELFT GB, 1989, CELL, V56, P969, DOI 10.1016/0092-8674(89)90630-2; WADA Y, 1988, J BIOL CHEM, V263, P12142; WADA Y, 1989, HEMOGLOBIN SWITCHI A, P301; WU J, 1990, MOL CELL BIOL, V10, P1209, DOI 10.1128/MCB.10.3.1209; YU CY, 1991, J BIOL CHEM, V266, P8907	45	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11532	11538						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597481				2022-12-25	WOS:A1992HX16900091
J	MORGAN, IM; RANSONE, LJ; BOS, TJ; VERMA, IM; VOGT, PK				MORGAN, IM; RANSONE, LJ; BOS, TJ; VERMA, IM; VOGT, PK			TRANSFORMATION BY JUN - REQUIREMENT FOR LEUCINE ZIPPER, BASIC REGION AND TRANSACTIVATION DOMAIN AND ENHANCEMENT BY FOS	ONCOGENE			English	Article							C-JUN; DNA-BINDING; GLUCOCORTICOID RECEPTOR; ONCOGENE JUN; FACTOR AP-1; V-JUN; PROTEINS; ACTIVATION; HETERODIMER; EXPRESSION	Mutants in the leucine zipper and basic regions of mouse c-jun were tested for transformation in chicken embryo fibroblast cultures. Reduction or elimination of the ability of Jun to dimerize or to bind to DNA severely decreased transformation. A chicken v-jun gene from which the major transactivation domain was deleted also failed to transform. We conclude that an intact leucine zipper, basic region and transactivation domain are required for Jun-induced oncogenic transformation. Coexpression of chicken c-Fos increased formation of transformed foci by Jun proteins of moderate to low oncogenic potency but had no effect on highly transforming Jun. Chicken c-Fos could also transform chicken embryo fibroblasts on its own, albeit after prolonged culture and at a low efficiency.	NORRIS CANC CTR, LOS ANGELES, CA 90033 USA; SALK INST BIOL STUDIES, MOLEC BIOL & VIRUS LAB, LA JOLLA, CA 92186 USA; EASTERN VIRGINIA MED SCH, DEPT MICROBIOL & IMMUNOL, NORFOLK, VA 23501 USA	Salk Institute; Eastern Virginia Medical School	MORGAN, IM (corresponding author), UNIV SO CALIF, SCH MED, DEPT MICROBIOL, LOS ANGELES, CA 90033 USA.		Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42564] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1990, MOL CELL BIOL, V10, P5532, DOI 10.1128/MCB.10.10.5532; ANGEL P, 1989, New Biologist, V1, P35; BENBROOK DM, 1990, ONCOGENE, V5, P295; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BRUN G, 1989, NUCLEIC ACIDS RES, V17, P6393, DOI 10.1093/nar/17.15.6393; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; COHEN DR, 1990, ONCOGENE, V5, P929; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HIRAI S-I, 1989, New Biologist, V1, P181; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAI SI, 1990, ONCOGENE, V5, P39; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MURAKAMI Y, 1991, P NATL ACAD SCI USA, V88, P3947, DOI 10.1073/pnas.88.9.3947; NISHIMURA T, 1988, ONCOGENE, V3, P659; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; PERKINS KK, 1988, EMBO J, V7, P4265, DOI 10.1002/j.1460-2075.1988.tb03324.x; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SAKAI M, 1989, CANCER RES, V49, P5633; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	42	33	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1992	7	6					1119	1125						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594243				2022-12-25	WOS:A1992HU64200009
J	ANAND, B; CHOU, IN				ANAND, B; CHOU, IN			MICROTUBULES AND MICROTUBULE-ASSOCIATED PROTEINS IN RESTING AND MITOGENICALLY ACTIVATED NORMAL HUMAN PERIPHERAL-BLOOD T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBULIN MESSENGER-RNAS; LYMPHOCYTES-T; SIGNAL TRANSDUCTION; CYTOSKELETAL MATRIX; GROWTH-FACTOR; DNA-SYNTHESIS; ACTIN; IDENTIFICATION; KINASE; TAXOL	The binding of an appropriate ligand to its specific receptor on the membrane of T cells triggers a cascade of events involved in T cell activation. An important yet unanswered question is how the mitogenic signals are transmitted through the cytoplasm and into the nucleus. The present study was carried out to determine changes in the microtubule (MT) system, following T cell activation. Fluorescence microscopy was employed to examine the organization of the microtubule network in human peripheral blood T cells in response to four different mitogens (phytohemagglutinin, concanavalin A, anti-CD3, and phorbol 12-myristate 13-acetate). The microtubules increase in length, number, and complexity of distribution 20 h after mitogenic stimulation. Using an in situ direct analysis protocol consisting of selective extraction of cells with detergent and Ca2+, 11 protein species, which fulfill the operational definition of microtubule-associated proteins (MAPs), were identified in resting human T cells. Alterations in the expression of these protein species were studied following mitogenic stimulation. These alterations in MAPs expression were also found in purified blast cell fractions indicating that they were specific changes occurring in activated T cell populations. These observations suggest a role for MT and MAPs in the cascade of human T cell activation.	BOSTON UNIV, SCH MED, DEPT MICROBIOL, 80 E CONCORD ST, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02118 USA	Boston University; Boston University								ALBERTS B, 1983, MOL BIOL CELL, P549; ALCOVER A, 1987, IMMUNOL REV, V95, P5, DOI 10.1111/j.1600-065X.1987.tb00498.x; BASERGA R, 1984, EXP CELL RES, V151, P1, DOI 10.1016/0014-4827(84)90349-5; BENZEEV A, 1979, CELL, V17, P319, DOI 10.1016/0092-8674(79)90157-0; BRAUN J, 1982, J IMMUNOL, V128, P1198; CARNEY DH, 1986, ANN NY ACAD SCI, V466, P919, DOI 10.1111/j.1749-6632.1986.tb38477.x; CHOU IN, 1984, P NATL ACAD SCI-BIOL, V81, P2401, DOI 10.1073/pnas.81.8.2401; CLEVELAND DW, 1981, CELL, V25, P537, DOI 10.1016/0092-8674(81)90072-6; CROSSIN KL, 1981, CELL, V27, P341, DOI 10.1016/0092-8674(81)90417-7; CUTHBERT JA, 1983, J CELL PHYSIOL, V116, P127, DOI 10.1002/jcp.1041160202; DEGEN JL, 1983, J BIOL CHEM, V258, P2153; DUERR A, 1981, CELL, V24, P203, DOI 10.1016/0092-8674(81)90516-X; FARRAR WL, 1986, IMMUNOL REV, V92, P49, DOI 10.1111/j.1600-065X.1986.tb01493.x; FLANAGAN J, 1978, NATURE, V273, P278, DOI 10.1038/273278a0; GELFAND EW, 1987, IMMUNOL REV, V95, P59, DOI 10.1111/j.1600-065X.1987.tb00500.x; HALL DJ, 1984, J CELL BIOL, V99, P1814, DOI 10.1083/jcb.99.5.1814; HALL DJ, 1981, J CELL PHYSIOL, V108, P25, DOI 10.1002/jcp.1041080105; ISAKOV N, 1987, IMMUNOL REV, V95, P89, DOI 10.1111/j.1600-065X.1987.tb00501.x; KACZMAREK L, 1985, P NATL ACAD SCI USA, V82, P5375, DOI 10.1073/pnas.82.16.5375; KECSKEMETHY N, 1982, EUR J BIOCHEM, V126, P573, DOI 10.1111/j.1432-1033.1982.tb06819.x; KURNICK JT, 1979, SCAND J IMMUNOL, V10, P563, DOI 10.1111/j.1365-3083.1979.tb01391.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESTER EP, 1981, J IMMUNOL, V126, P1428; LINCH DC, 1987, IMMUNOL REV, V95, P137, DOI 10.1111/j.1600-065X.1987.tb00503.x; LITVIN DA, 1984, METHOD ENZYMOL, V108, P298; MACDONALD HR, 1986, ANNU REV CELL BIOL, V2, P231; MATUS A, 1988, ANNU REV NEUROSCI, V11, P29, DOI 10.1146/annurev.neuro.11.1.29; MCCAIRNS E, 1984, MOL CELL BIOL, V4, P1754, DOI 10.1128/MCB.4.9.1754; MURRAY LE, 1991, CELL PROLIFERAT, V24, P215, DOI 10.1111/j.1365-2184.1991.tb01151.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OLMSTED JB, 1986, ANNU REV CELL BIOL, V2, P421, DOI 10.1146/annurev.cb.02.110186.002225; PAINTER RG, 1982, J CELL BIOL, V92, P565, DOI 10.1083/jcb.92.2.565; RESCH K, 1981, EUR J BIOCHEM, V115, P659; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SCHULMAN H, 1984, J CELL BIOL, V99, P11, DOI 10.1083/jcb.99.1.11; SCHWEITZER I, 1984, BIOL CELL, V52, P147; SHAW JP, 1988, J BIOL CHEM, V263, P1459; SOLOMON F, 1986, METHOD ENZYMOL, V134, P139; SOLOMON F, 1979, CELL, V18, P431, DOI 10.1016/0092-8674(79)90062-X; THEURKAUF WE, 1982, J BIOL CHEM, V257, P3284; VALLEE RB, 1984, J CELL BIOL, V99, pS38, DOI 10.1083/jcb.99.1.38s; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; WALDMANN TA, 1986, SCIENCE, V232, P727, DOI 10.1126/science.3008337; WATERHOUSE PD, 1983, EXP CELL RES, V144, P367, DOI 10.1016/0014-4827(83)90416-0; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WHITE MW, 1987, MOL CELL BIOL, V7, P3004, DOI 10.1128/MCB.7.8.3004; WICHE G, 1985, TRENDS BIOCHEM SCI, V10, P67, DOI 10.1016/0968-0004(85)90235-X; WODA BA, 1984, J IMMUNOL, V133, P2767; ZIPFEL PF, 1989, J IMMUNOL, V142, P1582; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	50	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10716	10722						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587848				2022-12-25	WOS:A1992HV09000077
J	BASSE, CW; BOCK, K; BOLLER, T				BASSE, CW; BOCK, K; BOLLER, T			ELICITORS AND SUPPRESSORS OF THE DEFENSE RESPONSE IN TOMATO CELLS - PURIFICATION AND CHARACTERIZATION OF GLYCOPEPTIDE ELICITORS AND GLYCAN SUPPRESSORS GENERATED BY ENZYMATIC CLEAVAGE OF YEAST INVERTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST-PATHOGEN INTERACTIONS; HIGH-MANNOSE OLIGOSACCHARIDES; F-SP GLYCINEA; EXTERNAL INVERTASE; PHYTOPHTHORA-INFESTANS; H-1-NMR SPECTROSCOPY; DISEASE RESISTANCE; ACCUMULATION; GLYCOPROTEINS; BIOSYNTHESIS	Cleavage of yeast invertase by alpha-chymotrypsin produced a number of small glycopeptides that were highly active as elicitors of ethylene biosynthesis and phenylalanine ammonia-lyase in suspension-cultured tomato cells. Five of these elicitors were purified and their amino acid sequence determined. They all had sequences corresponding to known sequences of yeast invertase, and all contained an asparagine known to carry a N-linked small high mannose glycan. The most active glycopeptide elicitor induced ethylene biosynthesis and phenylalanine ammonia-lyase half-maximally at a concentration of 5-10 nM. Structure-activity relationships of the peptide part were analyzed by further cleavage of a defined glycopeptide elicitor with various proteolytic enzymes. Removal of the C-terminal phenylalanine enhanced the elicitor activity, whereas removal of N-terminal arginine impaired it. A glycopeptide with the peptide part trimmed to the dipeptide arginine-asparagine was still fully active as elicitor. Glycopeptides with identical amino acid sequences were further separated into fractions differing in the oligosaccharide side chain. A given peptide had high elicitor activity when carrying a glycan with 10-12 mannosyl residues (Man10-12GlcNAc2), a 3-fold lower activity when carrying Man9GlcNAc2 and a 100-fold lower activity when carrying Man8GlcNAc2. The oligosaccharides, released by endo-beta-N-acetylglucosaminidase H from the pure glycopeptide elicitors, acted as suppressors of elicitor-induced ethylene biosynthesis and phenylalanine ammonia-lyase activity. A series of such oligosaccharides in the size range of Man8-13GlcNAc was purified. The structure and composition of the purified oligosaccharides corresponded to the known small high mannose glycans of yeast invertase as verified by H-1 NMR spectroscopy at 600 MHz. The highest suppressor activities were obtained with the oligosaccharides containing 10-12 mannosyl residues (Man10-12GlcNAc). The oligosaccharide Man8 GlcNAc was ineffective as a suppressor. Thus, the structural requirements for the free oligosaccharides to act as efficient suppressors were the same as for the oligosaccharide side chains of the glycopeptides for high elicitor activity. We propose that the glycan suppressors bind to the same recognition site as the glycopeptide elicitors without inducing a response.	CARLSBERG LAB, DEPT CHEM, DK-2500 COPENHAGEN, DENMARK		BASSE, CW (corresponding author), FRIEDRICH MIESCHER INST, POB 2543, CH-4002 BASEL, SWITZERLAND.		Boller, Thomas/G-3500-2012	Boller, Thomas/0000-0001-6768-7503				Ambler R P, 1972, Methods Enzymol, V25, P262, DOI 10.1016/S0076-6879(72)25023-6; BASSE CW, 1992, IN PRESS PLANT PHYSL, V98; BELL AA, 1981, ANNU REV PLANT PHYS, V32, P21, DOI 10.1146/annurev.pp.32.060181.000321; BOLLER T, 1987, PLANT MICROBE INTERA, V2, P385; Boller T., 1986, PLANT PROTEOLYTIC EN, V2, P67; BOLLER T, 1989, 2ND MESSENGERS PLANT, P227; Boller T., 1991, PLANT HORMONE ETHYLE; BUSHNELL WR, 1981, PHYTOPATHOLOGY, V71, P1012, DOI 10.1094/Phyto-71-1012; BYRD JC, 1982, J BIOL CHEM, V257, P4657; CASSAB GI, 1988, ANNU REV PLANT PHYS, V39, P321, DOI 10.1146/annurev.pp.39.060188.001541; CHEONG JJ, 1991, PLANT CELL, V3, P127, DOI 10.1105/tpc.3.2.127; CHEONG JJ, 1991, PLANT CELL, V3, P137, DOI 10.1105/tpc.3.2.137; COSIO EG, 1990, FEBS LETT, V264, P235, DOI 10.1016/0014-5793(90)80256-I; DIXON RA, 1990, ANNU REV PLANT PHYS, V41, P339, DOI 10.1146/annurev.pp.41.060190.002011; DOKE N, 1979, PHYSIOL PLANT PATHOL, V15, P127, DOI 10.1016/0048-4059(79)90061-4; DORLAND L, 1981, J BIOL CHEM, V256, P7708; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; GROSSKOPF DG, 1991, J PLANT PHYSIOL, V138, P741, DOI 10.1016/S0176-1617(11)81325-8; HAHLBROCK K, 1989, ANNU REV PLANT PHYS, V40, P347, DOI 10.1146/annurev.pp.40.060189.002023; HAHN MG, 1978, PLANT PHYSIOL, V62, P107, DOI 10.1104/pp.62.1.107; HEATH MC, 1981, PHYTOPATHOLOGY, V71, P1121, DOI 10.1094/Phyto-71-1121; HERNANDEZ LM, 1989, J BIOL CHEM, V264, P13648; KESSMANN H, 1986, J PHYTOPATHOL, V117, P321, DOI 10.1111/j.1439-0434.1986.tb04370.x; KNECHT R, 1986, ANAL CHEM, V58, P2375, DOI 10.1021/ac00125a006; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MELLIS SJ, 1981, ANAL BIOCHEM, V114, P276, DOI 10.1016/0003-2697(81)90480-2; NEESER JR, 1985, GLYCOCONJ J, V0002; NISHIGAKI M, 1978, J BIOCHEM-TOKYO, V84, P823, DOI 10.1093/oxfordjournals.jbchem.a132194; PARKER JE, 1991, MOL PLANT MICROBE IN, V4, P19, DOI 10.1094/MPMI-4-019; REDDY VA, 1988, J BIOL CHEM, V263, P6978; SCHEEL D, 1990, Z NATURFORSCH C, V45, P569; SHARP JK, 1984, J BIOL CHEM, V259, P1321; STORTI E, 1988, J PHYTOPATHOL, V121, P275, DOI 10.1111/j.1439-0434.1988.tb04454.x; STURM A, 1987, J BIOL CHEM, V262, P13392; STURM A, 1991, EUR J BIOCHEM, V199, P169, DOI 10.1111/j.1432-1033.1991.tb16106.x; TRIMBLE RB, 1991, J BIOL CHEM, V266, P22807; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; TRIMBLE RB, 1986, J BIOL CHEM, V261, P9815; TRIMBLE RB, 1977, J BIOL CHEM, V252, P4409; TRIMBLE RB, 1983, J BIOL CHEM, V258, P2562; VANCE CP, 1980, ANNU REV PHYTOPATHOL, V18, P259, DOI 10.1146/annurev.py.18.090180.001355; YAMADA T, 1989, MOL PLANT MICROBE IN, V2, P256, DOI 10.1094/MPMI-2-256; ZIEGLER E, 1982, PHYSIOL PLANT PATHOL, V20, P321, DOI 10.1016/0048-4059(82)90057-1; ZIEGLER E, 1977, PLANT PHYSIOL, V59, P1104, DOI 10.1104/pp.59.6.1104; ZIEGLER FD, 1988, J BIOL CHEM, V263, P6986	47	74	78	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10258	10265						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587815				2022-12-25	WOS:A1992HV09000012
J	GLASGOW, WC; AFSHARI, CA; BARRETT, JC; ELING, TE				GLASGOW, WC; AFSHARI, CA; BARRETT, JC; ELING, TE			MODULATION OF THE EPIDERMAL GROWTH-FACTOR MITOGENIC RESPONSE BY METABOLITES OF LINOLEIC AND ARACHIDONIC-ACID IN SYRIAN-HAMSTER EMBRYO FIBROBLASTS - DIFFERENTIAL-EFFECTS IN TUMOR SUPPRESSOR GENE (+) AND (-) PHENOTYPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; PROTEIN-TYROSINE KINASE; PERFORMANCE LIQUID-CHROMATOGRAPHY; MAMMARY EPITHELIAL-CELLS; PROSTAGLANDIN-H SYNTHASE; EGF RECEPTOR; 5-LIPOXYGENASE-ACTIVATING PROTEIN; PROLIFERATIVE RESPONSE; LEUKOTRIENE SYNTHESIS; ENDOTHELIAL-CELLS	Specific metabolites of arachidonic and linoleic acid have been proposed as serving a regulatory function in growth factor signal transduction in fibroblasts. In studies with Syrian hamster embryo (SHE) fibroblasts, we found lipoxygenase inhibitors to be potent blockers of epidermal growth factor (EGF)-dependent mitogenesis. Analytical chemical characterization of arachidonic and linoleic acid metabolism in SHE cells demonstrated that the major lipoxygenase product was 13-hydroxyoctadecadienoic acid (HODE). EGF stimulation of quiescent SHE cells resulted in an enhancement of HODE biosynthesis. The primary arachidonate products were prostaglandin E2 and F2-alpha formed via the cyclooxygenase pathway. Inhibition of cyclooxygenase activity did not alter the EGF-mitogenic response in SHE cells. Addition of lipoxygenase-derived linoleate metabolites (10(10)-10(-6) M) produced a 2-4-fold potentiation of EGF-stimulated [H-3]thymidine incorporation in SHE cells. Interestingly, the linoleate products did not enhance the EGF mitogenic effect in variant SHE cells that had lost tumor suppressor gene function. These results were confirmed by autoradiographic studies of DNA synthesis and suggest that loss of tumor suppressor phenotype correlates with a lack of responsiveness to linoleate products in signal transduction. In studies on the mechanism of EGF regulation of linoleic acid metabolism, inhibitors of EGF receptor tyrosine kinase activity were observed to block EGF-stimulated HODE biosynthesis. In addition, both cyclohexamide and actinomycin D attenuated the ability of EGF to increase linoleic acid metabolism in SHE cells. EGF induction of the linoleate pathway appears to be linked to activation of the EGF receptor and may be modulated at transcriptional or translational levels.	NIEHS,MOLEC BIOPHYS LAB,RES TRIANGLE PK,NC 27709; NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)								BAER AN, 1990, J LIPID RES, V31, P125; BAILEY JM, 1985, J LIPID RES, V26, P54; BALAKRISHNAN A, 1989, CANCER RES, V49, P857; BANDYOPADHYAY GK, 1987, J BIOL CHEM, V262, P2750; BANDYOPADHYAY GK, 1988, J BIOL CHEM, V263, P7567; BARRETT JC, 1987, CANCER RES, V47, P2514; BULL AW, 1988, CANCER RES, V48, P1771; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CASEY ML, 1988, J BIOL CHEM, V263, P7846; CAVENEE WK, 1986, MUTAT RES, V168, P3, DOI 10.1016/0165-1110(86)90019-9; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; DUNIEC ZM, 1991, MOL PHARMACOL, V39, P164; FRASIERSCOTT K, 1988, J CLIN INVEST, V82, P1877, DOI 10.1172/JCI113805; GEISSLER JF, 1990, J BIOL CHEM, V265, P22255; GLASGOW WC, 1990, MOL PHARMACOL, V38, P503; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; HABENICHT AJR, 1985, J CLIN INVEST, V75, P1381, DOI 10.1172/JCI111839; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HANDLER JA, 1990, J BIOL CHEM, V265, P3669; HENKE DC, 1984, ANAL BIOCHEM, V140, P87, DOI 10.1016/0003-2697(84)90137-4; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HONN KV, 1981, PROSTAG OTH LIPID M, V21, P833, DOI 10.1016/0090-6980(81)90240-9; HUBBARD WC, 1980, PROSTAGLANDINS, V20, P431; KIM JW, 1990, J BIOL CHEM, V265, P3940; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KOI M, 1986, P NATL ACAD SCI USA, V83, P5992, DOI 10.1073/pnas.83.16.5992; KOI M, 1989, P NATL ACAD SCI USA, V86, P8773, DOI 10.1073/pnas.86.22.8773; LIN AH, 1989, J BIOL CHEM, V264, P17379; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; NOLAN RD, 1986, BIOCHEM PHARMACOL, V35, P4273, DOI 10.1016/0006-2952(86)90706-9; NOLAN RD, 1988, MOL PHARMACOL, V33, P650; OSHIMURA M, 1985, NATURE, V316, P636, DOI 10.1038/316636a0; POSTOAK D, 1990, AM J PHYSIOL, V259, pC849, DOI 10.1152/ajpcell.1990.259.6.C849; RAZ A, 1989, P NATL ACAD SCI USA, V86, P1657, DOI 10.1073/pnas.86.5.1657; RAZ A, 1988, J BIOL CHEM, V263, P3022; REID GK, 1990, J BIOL CHEM, V265, P19818; SAGER R, 1986, CANCER RES, V46, P1573; SAVER L, 1988, CANCER RES, V48, P3106; SETTY BNY, 1987, J BIOL CHEM, V262, P17613; TENG JI, 1985, J CHROMATOGR, V350, P445, DOI 10.1016/S0021-9673(01)93550-2; THOMASSEN DG, 1985, CANCER RES, V45, P726; UMEZAWA K, 1990, FEBS LETT, V260, P198, DOI 10.1016/0014-5793(90)80102-O; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YOKOTA K, 1986, J BIOL CHEM, V261, P5410	53	146	146	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10771	10779						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587852				2022-12-25	WOS:A1992HV09000085
J	PRANDINI, MH; UZAN, G; MARTIN, F; THEVENON, D; MARGUERIE, G				PRANDINI, MH; UZAN, G; MARTIN, F; THEVENON, D; MARGUERIE, G			CHARACTERIZATION OF A SPECIFIC ERYTHROMEGAKARYOCYTIC ENHANCER WITHIN THE GLYCOPROTEIN-IIB PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; HUMAN MEGAKARYOCYTES; MAMMALIAN-CELLS; IMMUNOGLOBULIN GENES; NUCLEAR FACTOR; EXPRESSION; SEQUENCE; COMPLEX; FAMILY; IIIA	The gene coding for glycoprotein IIb (GPIIb), the alpha-subunit of platelet integrin GPIIb/IIIa is an early and specific marker of the megakaryocytic lineage. Thus, studies on the regulation of this gene may provide helpful information on the mechanisms controlling cell specificity and differentiation in this lineage. The promoter region of this gene was isolated and analyzed to understand its tissue-specific transcriptional activity. A region extending from nucleotides -414 to -554 was found to be extremely important for the promoter function. Deletion of this region results in a 70% decrease of the promoter activity, as measured in CAT assays. This region has the properties of an enhancer. It is able to activate a heterologous promoter, in a distance- and orientation-independent manner, in both megakaryocytic and erythroid cells. This enhancer contains binding sites for nuclear factors and mutation of these sites, individually or together, abolish the enhancer activity. These nuclear factors are present in megakaryocytic and erythroid cell lineages, but they are absent in the other tested cells. One of the sites, named domain D, contains a TTATC motif that may interact with the transcription factor GATA1, active in erythroid and megakaryocytic cells. These results indicate that the promoter of a megakaryocytic gene contains a tissue specific enhancer, active in both the erythroid and the megakaryocytic lineages, and may implicate the erythroid factor GATA1.			PRANDINI, MH (corresponding author), CEN,INSERM,U217,DEPT BIOL MOLEC & STRUCT,HEMATOL LAB,85X,F-38041 GRENOBLE,FRANCE.							BERRIDGE MV, 1985, BLOOD, V66, P76; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FRASER JK, 1986, BLOOD, V68, P762; FRASER JK, 1989, EXP HEMATOL, V17, P10; GINSBERG MH, 1988, THROMB HAEMOSTASIS, V59, P1; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALLIGAN BD, 1987, P NATL ACAD SCI USA, V84, P7019, DOI 10.1073/pnas.84.20.7019; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KRISSANSEN GW, 1990, J BIOL CHEM, V265, P823; LEVENE RB, 1985, J EXP MED, V161, P457, DOI 10.1084/jem.161.3.457; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P1311; LUMELSKY NL, 1991, MOL CELL BIOL, V11, P3528, DOI 10.1128/MCB.11.7.3528; MCLEOD DL, 1980, BLOOD, V56, P318; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PHILLIPS DR, 1988, BLOOD, V71, P831; PIERCE JH, 1989, BIOCHIM BIOPHYS ACTA, V989, P179, DOI 10.1016/0304-419X(89)90042-5; PLOW EF, 1986, P NATL ACAD SCI USA, V83, P6002, DOI 10.1073/pnas.83.16.6002; PLOW EF, 1987, PERSPECTIVES INFLAMM, P267; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P73, DOI 10.1093/nar/17.1.73; PRANDINI MH, 1988, BIOCHEM BIOPH RES CO, V156, P595, DOI 10.1016/S0006-291X(88)80884-2; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RABELLINO EM, 1981, J EXP MED, V154, P88, DOI 10.1084/jem.154.1.88; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; UZAN G, 1991, J BIOL CHEM, V266, P8932; UZAN G, 1991, BLOOD, V78, P720; VINCI G, 1984, BRIT J HAEMATOL, V56, P589, DOI 10.1111/j.1365-2141.1984.tb02184.x; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650	34	62	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10370	10374						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587823				2022-12-25	WOS:A1992HV09000028
J	TEALE, B; SINGH, S; KHANNA, KK; FINDIK, D; LAVIN, MF				TEALE, B; SINGH, S; KHANNA, KK; FINDIK, D; LAVIN, MF			PURIFICATION AND CHARACTERIZATION OF A DNA-BINDING PROTEIN ACTIVATED BY IONIZING-RADIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC PROTEIN; ADAPTIVE RESPONSE; HUMAN-LYMPHOCYTES; MAMMALIAN-CELLS; MESSENGER-RNA; GENES; EXPRESSION; INHIBITOR; ENHANCER; SEQUENCE	Exposure of mammalian cells to a variety of agents leads to the activation of pre-existing proteins and the induction of specific genes. We have recently described the appearance of a specific DNA-binding protein in nuclei from cells exposed to ionizing radiation (Singh, S. P., and Lavin, M. F. (1990) Mol. Cell. Biol. 10, 5279-5285). This protein is present in the cytoplasm of unperturbed cells and is apparently translocated to the nucleus in response to radiation damage. We describe here the purification and characterization of this specific DNA-binding protein. Purification involved the use of affinity chromatography employing a multimeric form of the DNA-binding motif conjugated to cyanogen bromide-activated Sepharose. Three DNA-binding species were recognized by UV-cross-linking and South-Western analysis. The major species or that with the highest affinity was approximately 70 kDa in size. DNase-1 footprint analysis revealed a single binding site in the kappa-immunoglobulin gene enhancer and in a putative control sequence upstream from the c-myc gene. At salt concentrations as high as 1 M, up to 40% of the DNA-binding activity was maintained and the K(d) was calculated to be 1.205 x 10(-6) M-1. Binding activity was found to be modulated by phosphorylation. Removal of phosphate groups from the protein resulted in a major loss of binding activity. It is not clear at this stage whether the factor(s) described here plays a role in transcription control or a more general DNA-processing role in response to radiation damage.	ROYAL BRISBANE HOSP,QUEENSLAND INST MED RES,BANCROFT CTR,QUEENSLAND CANC FUND,RES UNIT,BRISBANE,QLD 4029,AUSTRALIA; CSIRO,DIV PLANT IND,CANBERRA,ACT 2601,AUSTRALIA	Cancer Council Queensland; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Commonwealth Scientific & Industrial Research Organisation (CSIRO)			singh, surinder/C-9528-2009; Lavin, Martin F/F-5961-2014	singh, surinder/0000-0003-4488-8147; Lavin, Martin F/0000-0002-5940-4769; Khanna, Kum Kum/0000-0001-8650-5381				ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARIGA H, 1989, EMBO J, V8, P4273, DOI 10.1002/j.1460-2075.1989.tb08613.x; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BOOTHMAN DA, 1989, CANCER RES, V49, P2871; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FREIFELDER D, 1982, PHYSICAL BIOCH APPLI, P654; GLAZER PM, 1989, P NATL ACAD SCI USA, V86, P1163, DOI 10.1073/pnas.86.4.1163; HALLAHAN DE, 1989, P NATL ACAD SCI USA, V86, P10104, DOI 10.1073/pnas.86.24.10104; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HANAWALT PC, 1989, MUTAT RES, V217, P173; HANAWALT PC, 1979, ANNU REV BIOCHEM, V48, P783, DOI 10.1146/annurev.bi.48.070179.004031; HERRLICH P, 1984, HUM GENET, V67, P360, DOI 10.1007/BF00291392; HOBSON K, 1991, ANAL BIOCHEM, V193, P220, DOI 10.1016/0003-2697(91)90012-I; HOWARD KJ, 1988, J BIOL CHEM, V263, P3474; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KELSEY KT, 1991, MUTAT RES, V263, P197, DOI 10.1016/0165-7992(91)90001-K; KRAMER M, 1990, RADIAT ENVIRON BIOPH, V29, P303, DOI 10.1007/BF01210410; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; MAX EE, 1981, J BIOL CHEM, V256, P5116; OLIVIERI G, 1984, SCIENCE, V223, P594, DOI 10.1126/science.6695170; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SHADLEY JD, 1987, MUTAGENESIS, V2, P95, DOI 10.1093/mutage/2.2.95; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; SINGH SP, 1990, MOL CELL BIOL, V10, P5279, DOI 10.1128/MCB.10.10.5279; SULLIVAN NF, 1989, ONCOGENE, V4, P1497; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; YOUNGBLOM JH, 1989, MUTAT RES, V227, P257, DOI 10.1016/0165-7992(89)90107-3	34	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10295	10301						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587818				2022-12-25	WOS:A1992HV09000017
J	BHATTACHARYYA, DK; BANDYOPADHYAY, U; BANERJEE, RK				BHATTACHARYYA, DK; BANDYOPADHYAY, U; BANERJEE, RK			CHEMICAL AND KINETIC EVIDENCE FOR AN ESSENTIAL HISTIDINE IN HORSERADISH-PEROXIDASE FOR IODIDE OXIDATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; HOG THYROID PEROXIDASE; ETHOXYFORMIC ANHYDRIDE; RESIDUE; DIETHYLPYROCARBONATE; LACTOPEROXIDASE; MECHANISM; BINDING; CHLOROPEROXIDASE; SEQUENCE	Horseradish peroxidase (HRP), when incubated with diethylpyrocarbonate (DEPC), shows a time-dependent loss of iodide oxidation activity. The inactivation follows pseudo-first order kinetics with a second order rate constant of 0.43 min-1 M-1 at 30-degrees-C and is reversed by neutralized hydroxylamine. The difference absorption spectrum of the modified versus native enzyme shows a peak at 244 nm, characteristic of N-carbethoxyhistidine, which is diminished by treatment with hydroxylamine. Correlation between the stoichiometry of histidine modification and the extent of inactivation indicates that out of 2 histidine residues modified, one is responsible for inactivation. A plot of the log of the reciprocal half-time of inactivation against log DEPC concentration further suggests that only 1 histidine is involved in catalysis. The rate of inactivation shows a pH dependence with an inflection point at 6.2, indicating histidine derivatization by DEPC. Inactivation due to modification of tyrosine, lysine, or cysteine has been excluded. CD studies reveal no significant change in the protein or heme conformation following DEPC modification. We suggest that a unique histidine residue is required for maximal catalytic activity of HRP for iodide oxidation.	INDIAN INST CHEM BIOL,DEPT PHYSIOL,4 RAJA SC MULLICK RD,CALCUTTA 700032,W BENGAL,INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)								AIBARA S, 1982, J BIOCHEM-TOKYO, V92, P531, DOI 10.1093/oxfordjournals.jbchem.a133961; ALEXANDER NM, 1962, ANAL BIOCHEM, V4, P341, DOI 10.1016/0003-2697(62)90097-0; BANERJEE RK, 1986, J BIOL CHEM, V261, P592; BJORKSTEN F, 1970, BIOCHIM BIOPHYS ACTA, V212, P396, DOI 10.1016/0005-2744(70)90245-7; BLANKE SR, 1990, J BIOL CHEM, V265, P12454; BURSTEIN Y, 1974, BIOCHEMISTRY-US, V13, P205, DOI 10.1021/bi00698a030; CHANG KC, 1989, J BIOL CHEM, V264, P19666; CHURCH FC, 1985, J BIOL CHEM, V260, P4936; COUSINEAU J, 1976, BIOCHEMISTRY-US, V15, P4992, DOI 10.1021/bi00668a008; DUMAS DP, 1990, J BIOL CHEM, V265, P21498; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; DUNFORD HB, 1982, ADV INORG BIOCHEM, V4, P410; FITA I, 1985, J MOL BIOL, V185, P21, DOI 10.1016/0022-2836(85)90180-9; KAPUT J, 1982, J BIOL CHEM, V257, P5054; KENIGSBERG P, 1987, ARCH BIOCHEM BIOPHYS, V254, P409, DOI 10.1016/0003-9861(87)90118-4; KONPKA K, 1988, ARCH BIOCHEM BIOPHYS, V261, P55; LEVY HM, 1963, J BIOL CHEM, V238, P3654; Lundblad R.L, 1984, CHEM REAGENTS PROTEI, VI; MAGNUSSON RP, 1984, J BIOL CHEM, V259, P197; MELCHIOR WB, 1970, BIOCHEMISTRY-US, V9, P251, DOI 10.1021/bi00804a010; Miles E W, 1977, Methods Enzymol, V47, P431; MORRISON M, 1976, ANNU REV BIOCHEM, V45, P861, DOI 10.1146/annurev.bi.45.070176.004241; NAKAMURA M, 1985, J BIOL CHEM, V260, P3546; OHTAKI S, 1982, J BIOL CHEM, V257, P761; OHTAKI S, 1981, J BIOL CHEM, V256, P805; OVADI J, 1967, ACTA BIOCHIM BIOPHYS, V2, P445; PAUL KG, 1978, ACTA CHEM SCAND B, V32, P395, DOI 10.3891/acta.chem.scand.32b-0395; POMMIER J, 1973, EUR J BIOCHEM, V38, P497, DOI 10.1111/j.1432-1033.1973.tb03085.x; POULOS TL, 1980, J BIOL CHEM, V255, P8199; ROMAN R, 1972, BIOCHEMISTRY-US, V11, P2076, DOI 10.1021/bi00761a013; SAKURADA J, 1985, CHEM LETT, P211, DOI 10.1246/cl.1985.211; SAKURADA J, 1987, J BIOL CHEM, V262, P4007; SAKURADA J, 1986, J BIOL CHEM, V261, P9657; SAKURADA J, 1987, BIOCHEMISTRY-US, V26, P6478, DOI 10.1021/bi00394a028; SAMS CF, 1988, BIOCHEMISTRY-US, V27, P2277, DOI 10.1021/bi00407a005; TAKEUCHI M, 1986, J BIOCHEM-TOKYO, V99, P1571, DOI 10.1093/oxfordjournals.jbchem.a135630; Tien M, 1987, NATURE, V326, P520, DOI 10.1038/326520a0; TOPHAM CM, 1986, EUR J BIOCHEM, V155, P87, DOI 10.1111/j.1432-1033.1986.tb09461.x; UGAROVA NN, 1981, BIOCHIM BIOPHYS ACTA, V662, P210, DOI 10.1016/0005-2744(81)90032-2; WELINDER KG, 1979, EUR J BIOCHEM, V96, P483, DOI 10.1111/j.1432-1033.1979.tb13061.x	40	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9800	9804						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577815				2022-12-25	WOS:A1992HT96500057
J	HUGHES, EN; ENGELSBERG, BN; BILLINGS, PC				HUGHES, EN; ENGELSBERG, BN; BILLINGS, PC			PURIFICATION OF NUCLEAR PROTEINS THAT BIND TO CISPLATIN-DAMAGED DNA - IDENTITY WITH HIGH MOBILITY GROUP PROTEIN-1 AND PROTEIN-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTICANCER DRUG CISPLATIN; SINGLE-STRANDED-DNA; RNA POLYMERASE-II; XERODERMA PIGMENTOSUM; DIFFERENTIAL REPAIR; HUMAN-FIBROBLASTS; APURINIC SITES; CELL-LINES; CIS-DIAMMINEDICHLOROPLATINUM(II); ADDUCTS	The biochemical processes responsible for the recognition and repair of cisplatin-damaged DNA in human cells are not well understood. We have developed a damaged DNA affinity precipitation technique that allows the direct visualization and characterization of cellular proteins that bind to cisplatin-damaged DNA. The method separates damaged DNA-binding proteins from complex radiolabeled cell mixtures and further resolves them into individual polypeptides by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. This technique is complementary to gel retardation and Southwestern blotting analyses that have been previously used to identify cellular components that specifically bind to cisplatin-damaged DNA. Using this technique, we have characterized a set of HeLaS3 nuclear proteins of 26.5, 28, 90, and 97 kDa that specifically bind to cisplatin-DNA adducts. Competition studies with soluble cisplatin-damaged DNA confirmed these findings. The major cisplatin-damaged DNA-binding proteins of 26.5 and 28 kDa recognized adducts of DNA modified with cisplatin but not with its transisomer or with UV radiation. These proteins were purified 450-fold to near homogeneity by ion-exchange and cisplatin-damaged DNA affinity chromatography. Amino-terminal sequence analysis showed that the 26.5- and 28-kDa proteins were identical to high mobility group (HMG) proteins HMG-2 and HMG-1, respectively.	UNIV PENN,SCH MED,DEPT RADIAT ONCOL,PHILADELPHIA,PA 19104	University of Pennsylvania					NCI NIH HHS [CA-45734] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045734] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alberts B.M., 1971, METHODS ENZYMOL, V21, P198; ANDREWS PA, 1991, CANCER COMMUN, V3, P1; BEDFORD P, 1988, CANCER RES, V48, P3019; BONNE C, 1982, J BIOL CHEM, V257, P2722; BOOTHMAN DA, 1990, MOL CELL BIOCHEM, V136, P39; CARADONNA JP, 1983, ADV CHEM SER, V209, P14; CHAO CCK, 1991, MOL CELL BIOL, V11, P2075, DOI 10.1128/MCB.11.4.2075; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; CHU G, 1990, P NATL ACAD SCI USA, V87, P3324, DOI 10.1073/pnas.87.9.3324; CHU G, 1987, MOL BIOL MED, V4, P277; CICCARELLI RB, 1985, BIOCHEMISTRY-US, V24, P7533, DOI 10.1021/bi00347a005; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DEUTSCH WA, 1979, P NATL ACAD SCI USA, V76, P141, DOI 10.1073/pnas.76.1.141; DEWIT L, 1987, INT J RADIAT ONCOL, V13, P403, DOI 10.1016/0360-3016(87)90015-0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIJT FJ, 1988, CANCER RES, V48, P6058; DONAHUE BA, 1990, BIOCHEMISTRY-US, V29, P5872, DOI 10.1021/bi00476a032; EASTMAN A, 1988, BIOCHEMISTRY-US, V27, P4730, DOI 10.1021/bi00413a022; EASTMAN A, 1986, BIOCHEMISTRY-US, V25, P3912, DOI 10.1021/bi00361a026; EASTMAN A, 1987, PHARMACOL THERAPEUT, V34, P155, DOI 10.1016/0163-7258(87)90009-X; EINHORN L, 1991, J CLIN ONCOL, V8, P1777; FELDBERG RS, 1982, J BIOL CHEM, V257, P6394; FICHTINGERSCHEPMAN AMJ, 1985, BIOCHEMISTRY-US, V24, P707, DOI 10.1021/bi00324a025; FRANZA BR, 1987, NATURE, V330, P391, DOI 10.1038/330391a0; FUJIWARA Y, 1990, JPN J CANCER RES, V81, P1210, DOI 10.1111/j.1349-7006.1990.tb02680.x; HIRSCHFELD S, 1990, MOL CELL BIOL, V10, P2041, DOI 10.1128/MCB.10.5.2041; HUGHES EN, 1981, J BIOL CHEM, V256, P664; ISACKSON PJ, 1979, J BIOL CHEM, V254, P5569; JAVAHERIAN K, 1978, SCIENCE, V199, P1345, DOI 10.1126/science.628842; JAVAHERIAN K, 1979, NUCLEIC ACIDS RES, V6, P3569, DOI 10.1093/nar/6.11.3569; Johns E.W., 1982, HMG CHROMOSOMAL PROT, P1; KATOAKA H, 1991, BIOCHEM BIOPH RES CO, V175, P1139; KUHNLEIN U, 1985, J BIOL CHEM, V260, P4918; LENZ J, 1990, P NATL ACAD SCI USA, V87, P3396, DOI 10.1073/pnas.87.9.3396; LOEHRER PJ, 1984, ANN INTERN MED, V100, P704, DOI 10.7326/0003-4819-100-5-704; MASUDA H, 1988, CANCER RES, V48, P5713; MORANELLI F, 1980, P NATL ACAD SCI-BIOL, V77, P3201, DOI 10.1073/pnas.77.6.3201; PATTERSON M, 1989, MOL CELL BIOL, V9, P5105, DOI 10.1128/MCB.9.11.5105; PINTO A L, 1985, Biochimica et Biophysica Acta, V780, P167, DOI 10.1016/0304-419X(85)90001-0; REDINBAUGH MG, 1986, ANAL BIOCHEM, V153, P267, DOI 10.1016/0003-2697(86)90091-6; Roberts J J, 1979, Prog Nucleic Acid Res Mol Biol, V22, P71, DOI 10.1016/S0079-6603(08)60799-0; RUSSELL WC, 1975, NATURE, V253, P461, DOI 10.1038/253461a0; SCOVELL WM, 1987, BIOCHEM BIOPH RES CO, V142, P826, DOI 10.1016/0006-291X(87)91488-4; SHERMAN SE, 1985, SCIENCE, V230, P412, DOI 10.1126/science.4048939; SHIRAKAWA H, 1990, BIOCHEMISTRY-US, V29, P4119; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SINGH J, 1990, BIOCHEMISTRY-US, V29, P6295, DOI 10.1021/bi00478a026; TONEY JH, 1989, P NATL ACAD SCI USA, V86, P8328, DOI 10.1073/pnas.86.21.8328; TOULME JJ, 1983, EMBO J, V2, P505, DOI 10.1002/j.1460-2075.1983.tb01454.x; TREMETHICK DJ, 1986, J BIOL CHEM, V261, P6986; TSANG SS, 1982, BIOCHIM BIOPHYS ACTA, V697, P202, DOI 10.1016/0167-4781(82)90078-1; TSUDA K, 1988, BIOCHEMISTRY-US, V27, P6159, DOI 10.1021/bi00416a050; USHAY HM, 1981, BIOCHEMISTRY-US, V20, P3744, DOI 10.1021/bi00516a012; VIDALI G, 1977, CELL, V12, P409, DOI 10.1016/0092-8674(77)90117-9; VOKES EE, 1990, J CLIN ONCOL, V8, P911, DOI 10.1200/JCO.1990.8.5.911	56	175	176	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13520	13527						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618852				2022-12-25	WOS:A1992JB74600067
J	MIZUTANI, A; USUDA, N; TOKUMITSU, H; MINAMI, H; YASUI, K; KOBAYASHI, R; HIDAKA, H				MIZUTANI, A; USUDA, N; TOKUMITSU, H; MINAMI, H; YASUI, K; KOBAYASHI, R; HIDAKA, H			CAP-50, A NEWLY IDENTIFIED ANNEXIN, LOCALIZES IN NUCLEI OF CULTURED FIBROBLAST 3Y1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+-DEPENDENT PHOSPHOLIPID-BINDING; RAT-LIVER NUCLEI; CALPACTIN-I; CHROMAFFIN GRANULES; HEAVY-CHAIN; PROTEIN; CALCIUM; LIPOCORTIN; PHOSPHORYLATION; PURIFICATION	A 50-kDa protein, which binds to the growth-regulated gene (2A9) product, calcyclin in a calcium-dependent manner, was purified from bovine lung. Partial amino acid sequencing of the protein revealed it to be the bovine equivalent of rabbit lung CAP-50 (calcyclin-associated protein, 50 kDa), which is a member of the annexin family and binds to calcyclin in a calcium-dependent manner. Specific polyclonal antibodies to bovine lung CAP-50 were prepared. Comparative studies between CAP-50 and synexin (annexin VII) on the immunoreactivity against anti-CAP-50 antibodies and the ability of binding to calcyclin revealed that CAP-50 was a distinct molecule from synexin. Using specific polyclonal antibodies to bovine lung CAP-50, tissue distribution and subcellular distribution of CAP-50 were investigated. In most rat tissues, except those in the central nervous systems and kidney, CAP-50 is expressed at a high or moderate level. Both studies by subcellular fractionation and by indirect immunofluorescence staining of the rat embryonic fibroblast cell line, 3Y1, revealed that CAP-50 mainly localized in nuclei. Moreover, between the cells at interphase and at mitotic phase, different distributions of CAP-50 were observed. That is, in the cells at interphase, CAP-50 seemed to localize throughout the nucleoplasm. On the other hand, in the cells during mitosis, CAP-50 was concentrated at the loop-like structure around the mitotic apparatus. CAP-50 was found in isolated 3Y1 nuclei lacking outer nuclear membranes, and approximately 50% of CAP-50 was extracted from the nuclei by chelating calcium. Thus, CAP-50, a unique annexin, localizes in nuclei.	NAGOYA UNIV,SCH MED,DEPT PHARMACOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN; SHINSHU UNIV,SCH MED,DEPT ANAT & CELL BIOL,MATSUMOTO,NAGANO 390,JAPAN	Nagoya University; Shinshu University			Tokumitsu, Hiroshi/M-3978-2015	Tokumitsu, Hiroshi/0000-0002-2193-6794				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNS AL, 1989, P NATL ACAD SCI USA, V86, P3798, DOI 10.1073/pnas.86.10.3798; BURNS AL, 1990, BIOCHEM SOC T, V18, P1118, DOI 10.1042/bst0181118; CALABRETTA B, 1986, J BIOL CHEM, V261, P2628; CAPITANI S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P193, DOI 10.1016/0005-2760(90)90303-F; CREUTZ CE, 1978, J BIOL CHEM, V253, P2858; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; CRUMPTON MJ, 1990, NATURE, V345, P212, DOI 10.1038/345212a0; DAVIDSON FF, 1987, J BIOL CHEM, V262, P1698; DOWLING LG, 1985, BIOCHEM BIOPH RES CO, V132, P382, DOI 10.1016/0006-291X(85)91033-2; DRUST DS, 1991, J NEUROCHEM, V56, P469, DOI 10.1111/j.1471-4159.1991.tb08174.x; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; GLENNEY JR, 1987, J CELL BIOL, V104, P503, DOI 10.1083/jcb.104.3.503; HAYASHI H, 1989, J BIOL CHEM, V264, P17222; HEPPEL LA, 1955, METHOD ENZYMOL, V2, P546, DOI 10.1016/S0076-6879(55)02249-0; JINDAL HK, 1991, J BIOL CHEM, V266, P5169; KAETZEL MA, 1989, J BIOL CHEM, V264, P14463; KEUTZER JC, 1990, EXP CELL RES, V188, P153, DOI 10.1016/0014-4827(90)90291-H; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; KOBAYASHI R, 1990, ARCH BIOCHEM BIOPHYS, V277, P203, DOI 10.1016/0003-9861(90)90570-O; KOBAYASHI R, 1990, BIOCHEM J, V262, P993; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; KUZNICKI J, 1989, FEBS LETT, V254, P141, DOI 10.1016/0014-5793(89)81026-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGENDZO K, 1991, J BIOL CHEM, V266, P3228; MANALAN AS, 1984, ADV CYCLIC NUCL PROT, V18, P227; MURPHY LC, 1988, J BIOL CHEM, V263, P2397; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; NISHIDA E, 1979, J BIOCHEM, V85, P1257; NORDLIE RC, 1966, METHOD ENZYMOL, V9, P619; PEPINSKY RB, 1986, NATURE, V321, P81, DOI 10.1038/321081a0; ROJAS E, 1990, J BIOL CHEM, V265, P21207; ROSS TS, 1990, SCIENCE, V248, P605, DOI 10.1126/science.2159184; SARIS CJM, 1986, CELL, V46, P201, DOI 10.1016/0092-8674(86)90737-3; SCHLAEPFER DD, 1987, J BIOL CHEM, V262, P6931; SCHLAEPFER DD, 1990, J CELL BIOL, V111, P229, DOI 10.1083/jcb.111.1.229; SEMICH R, 1989, EUR J CELL BIOL, V50, P313; SHADLE PJ, 1985, J BIOL CHEM, V260, P6354; SOBUE K, 1985, P NATL ACAD SCI USA, V82, P5025, DOI 10.1073/pnas.82.15.5025; TAIT JF, 1988, BIOCHEMISTRY-US, V27, P6268, DOI 10.1021/bi00417a011; TOKUMITSU H, 1991, ARCH BIOCHEM BIOPHYS, V288, P202, DOI 10.1016/0003-9861(91)90184-K; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; TOKUMITSU H, 1992, IN PRESS J BIOL CHEM; WILLIAMS DA, 1985, NATURE, V318, P558, DOI 10.1038/318558a0; ZOKAS L, 1987, J CELL BIOL, V105, P2111, DOI 10.1083/jcb.105.5.2111	45	59	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13498	13504						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618851				2022-12-25	WOS:A1992JB74600064
J	JHIANG, SM; CARUSO, DR; GILMORE, E; ISHIZAKA, Y; TAHIRA, T; NAGAO, M; CHIU, IM; MAZZAFERRI, EL				JHIANG, SM; CARUSO, DR; GILMORE, E; ISHIZAKA, Y; TAHIRA, T; NAGAO, M; CHIU, IM; MAZZAFERRI, EL			DETECTION OF THE PTC RETTPC ONCOGENE IN HUMAN THYROID CANCERS	ONCOGENE			English	Article								We have investigated the PTC/ret(TPC) oncogene, an activated form of ret proto-oncogene with a specific rearrangement, in thyroid malignancies. Southern analysis was used to screen 36 thyroid papillary carcinomas (PC), 22 normal thyroid tissues from glands with PC elsewhere, three follicular carcinomas, eight follicular adenomas and 30 other non-malignant thyroids. Rearrangements were detected in four PCs (11%) using probes derived from the ret proto-oncogene. Genomic breakpoints from a PC and a PC cell line (TPC-1) were cloned and sequenced. The rearrangement points of ret proto-oncogene were found in the intron between the exon for the transmembrane domain and the first exon for the tyrosine kinase domain. Furthermore, the PTC/ret(TPC) chimeric transcripts were detected in two PCs with the rearrangement by reverse transcription polymerase chain reaction. Distant metastases were present in 50% (2/4) of PCs with the rearrangement, but in only two out of 32 PCs without a detectable rearrangement (P = 0.05, Fisher exact test). Our study suggests that the rearrangement of the ret proto-oncogene may be involved in the development of distant metastases in patients with papillary thyroid carcinomas. However, a larger clinical study will be required to verify this observation.	OHIO STATE UNIV, DEPT INTERNAL MED, COLUMBUS, OH 43210 USA; NATL CANC CTR, RES INST, DIV CARCINOGENESIS, CHUO KU, TOKYO 104, JAPAN; NATL CANC CTR, CTR COMPREHENS CANC, TOKYO 104, JAPAN	University System of Ohio; Ohio State University; National Cancer Center - Japan; National Cancer Center - Japan			Chiu, Ing-Ming/B-1534-2008		NATIONAL CANCER INSTITUTE [R01CA045611] Funding Source: NIH RePORTER; NCI NIH HHS [CA01369, CA45611] Funding Source: Medline; NCRR NIH HHS [GCRC-RR-34] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BONGARZONE I, 1989, ONCOGENE, V4, P1457; Cox D. R., 1984, ANAL SURVIVAL DATA; DONGHI R, 1989, ONCOGENE, V4, P521; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HEITZ P, 1976, CANCER, V37, P2329, DOI 10.1002/1097-0142(197605)37:5<2329::AID-CNCR2820370523>3.0.CO;2-7; ISHIZAKA Y, 1989, ONCOGENE, V4, P1519; ISHIZAKA Y, 1991, ONCOGENE, V6, P1667; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; ISHIZAKA Y, 1989, JPN J CANCER RES, V80, P1149, DOI 10.1111/j.1349-7006.1989.tb01645.x; ISHIZAKA Y, 1988, ONCOGENE RES, V3, P193; KODA T, 1988, Hokkaido Journal of Medical Science, V63, P913; MAZZAFERRI EL, 1991, MAYO CLIN PROC, V66, P105, DOI 10.1016/S0025-6196(12)61179-3; MAZZAFERRI EL, 1987, SEMIN ONCOL, V14, P315; MAZZAFERRI EL, 1983, CLIN SURGERY INT, V6, P18; MAZZAFERRI EL, 1992, WERNER INGBARS THYRO, P1138; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; SOZZI G, 1991, ONCOGENE, V6, P339; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; VANDEWINKEL JGJ, 1991, J BIOL CHEM, V266, P13449; VENKATESH YSS, 1990, CANCER-AM CANCER SOC, V66, P321, DOI 10.1002/1097-0142(19900715)66:2<321::AID-CNCR2820660221>3.0.CO;2-A	25	148	152	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1331	1337						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620547				2022-12-25	WOS:A1992HZ97100011
J	BRZOVIC, PS; SAWA, Y; HYDE, CC; MILES, EW; DUNN, MF				BRZOVIC, PS; SAWA, Y; HYDE, CC; MILES, EW; DUNN, MF			EVIDENCE THAT MUTATIONS IN A LOOP REGION OF THE ALPHA-SUBUNIT INHIBIT THE TRANSITION FROM AN OPEN TO A CLOSED CONFORMATION IN THE TRYPTOPHAN SYNTHASE BIENZYME COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ULTRAVIOLET VISIBLE SPECTROSCOPY; ESCHERICHIA-COLI; L-SERINE; SALMONELLA-TYPHIMURIUM; BETA-SUBUNIT; TRIOSEPHOSPHATE ISOMERASE; 3-DIMENSIONAL STRUCTURE; CATALYTIC MECHANISM; MULTIENZYME COMPLEX; SECONDARY STRUCTURE	Rapid-scanning stopped-flow (RSSF) UV-visible spectroscopy has been used to investigate the effects of single amino acid mutations in the alpha-subunit of the Salmonella typhimurium tryptophan synthase bienzyme complex on the reactivity at the beta-subunit active site located 25 to 30 angstrom distant. The pyridoxal 5'-phosphate (PLP) cofactor provides a convenient spectroscopic probe to directly monitor catalytic events at the beta-active site. Single substitutions of Phe for Glu at position 49, Leu for Gly at position 51, or Tyr for Asp at position 60 in the alpha-subunit strongly alter the observed steady state and pre-steady state inhibitory effects of the alpha-subunit-specific ligand alpha-glycerophosphate (GP) on the PLP-dependent beta-reaction. However, similar GP-induced allosteric effects on the distribution of covalent intermediates bound at the beta-site that are observed with the wild-type enzyme (Houben, K. F., and Dunn, M. F. (1990) Biochemistry 29, 2421-2429) also are observed for each of the mutant bienzyme complexes. These results support the hypothesis that the preferred pathway of indole from solution into the beta-site is via the a-site and the interconnecting tunnel (Dunn, M. F., Aguilar, V., Brzovic', P., Drewe, W. F., Houben, K. F., Leja, C. A., and Roy, M. (1990) Biochemistry 29, 8598-8607). Residues alpha-E49, alpha-G51, and alpha-D60 are part of a highly conserved inserted sequence in the alpha/beta-barrel topology of the alpha-subunit. We propose that the GP-induced inhibition of the beta-reaction results, in part, from a ligand-dependent conformational change from an "open" to a "closed" structure of the alpha-subunit which involves this region of the alpha-subunit and serves to obstruct the direct access of indole into the tunnel. Our findings suggest that the altered kinetic behavior observed for the alpha-mutants in the presence of GP reflects an impaired ability of the modified bienzyme complex to undergo the conformational transition from the open to the closed form.	UNIV CALIF RIVERSIDE, DEPT BIOCHEM, RIVERSIDE, CA 92521 USA; NIDDKD, MOLEC BIOL LAB, BETHESDA, MD 20892 USA; NIDDKD, BIOCHEM PHARMACOL LAB, BETHESDA, MD 20892 USA	University of California System; University of California Riverside; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Sawa, Yoshihiro/F-8295-2017	Sawa, Yoshihiro/0000-0002-2379-470X				ALBER T, 1981, PHILOS T ROY SOC B, V293, P159, DOI 10.1098/rstb.1981.0069; ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; BRZOVIC P, 1990, BIOCHEMISTRY-US, V29, P442, DOI 10.1021/bi00454a020; BRZOVIC PS, 1991, 8TH P INT C VIT B6 C, P277; BRZOVIC PS, 1992, IN PRESS BIOCHEMISTR; CRAWFORD IP, 1987, PROTEINS, V2, P118, DOI 10.1002/prot.340020206; DREWE WF, 1986, BIOCHEMISTRY-US, V25, P2494, DOI 10.1021/bi00357a032; DREWE WF, 1985, BIOCHEMISTRY-US, V24, P3977, DOI 10.1021/bi00336a027; DUNN MF, 1987, INDIAN J BIOCHEM BIO, V24, P44; DUNN MF, 1990, BIOCHEMISTRY-US, V29, P8598, DOI 10.1021/bi00489a015; DUNN MF, 1991, 8TH P INT C VIT B6 C, P257; DUNN MF, 1987, 1987 P INT C CHEM BI, P171; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; GOLDBERG ME, 1967, BIOCHEMISTRY-US, V6, P2113, DOI 10.1021/bi00859a032; HEYN MP, 1975, BIOCHEMISTRY-US, V14, P2962, DOI 10.1021/bi00684a026; HOUBEN KF, 1990, BIOCHEMISTRY-US, V29, P2421, DOI 10.1021/bi00461a028; HOUBEN KF, 1989, BIOCHEMISTRY-US, V28, P4140, DOI 10.1021/bi00436a003; HYDE CC, 1990, BIO-TECHNOL, V8, P27, DOI 10.1038/nbt0190-27; HYDE CC, 1988, J BIOL CHEM, V263, P17857; KANZAKI H, 1991, ARCH BIOCHEM BIOPHYS, V284, P174, DOI 10.1016/0003-9861(91)90280-V; KAWASAKI H, 1987, J BIOL CHEM, V262, P10678; KIRSCHNER K, 1991, BIOCHEMISTRY-US, V30, P472, DOI 10.1021/bi00216a024; Kirschner K., 1975, PROTEIN LIGAND INTER, P27, DOI [10.1515/9783110830811-006, DOI 10.1515/9783110830811-006]; KOERBER SC, 1983, BIOCHEMISTRY-US, V22, P3424, DOI 10.1021/bi00283a019; LANE AN, 1981, EUR J BIOCHEM, V120, P379, DOI 10.1111/j.1432-1033.1981.tb05715.x; LANE AN, 1983, EUR J BIOCHEM, V129, P561; LANE AN, 1991, BIOCHEMISTRY-US, V30, P479, DOI 10.1021/bi00216a025; LANE AN, 1983, EUR J BIOCHEM, V129, P571; LESZCZYNSKI JF, 1986, SCIENCE, V234, P849, DOI 10.1126/science.3775366; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6619, DOI 10.1021/bi00480a010; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; MILES EW, 1988, J BIOL CHEM, V263, P8611; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILES EW, 1989, J BIOL CHEM, V264, P6280; MILES EW, 1991, J BIOL CHEM, V266, P10715; NAGATA S, 1989, J BIOL CHEM, V264, P6288; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; ROY M, 1988, BIOCHEMISTRY-US, V27, P6698, DOI 10.1021/bi00418a009; ROY M, 1988, BIOCHEMISTRY-US, V27, P8661, DOI 10.1021/bi00423a023; SHIRVANEE L, 1990, J BIOL CHEM, V265, P6624; WEISCHET WO, 1976, EUR J BIOCHEM, V64, P313, DOI 10.1111/j.1432-1033.1976.tb10303.x; WILMANNS M, 1991, BIOCHEMISTRY-US, V30, P9161, DOI 10.1021/bi00102a006; YANOFSKY C, 1958, BIOCHIM BIOPHYS ACTA, V28, P640, DOI 10.1016/0006-3002(58)90533-X; YANOFSKY C, 1972, ENZYMES, V8, P1; YUTANI K, 1987, J BIOL CHEM, V262, P13429	48	73	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					13028	13038						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618800				2022-12-25	WOS:A1992HZ48300094
J	DEJONGE, BLM; CHANG, YS; GAGE, D; TOMASZ, A				DEJONGE, BLM; CHANG, YS; GAGE, D; TOMASZ, A			PEPTIDOGLYCAN COMPOSITION OF A HIGHLY METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS STRAIN - THE ROLE OF PENICILLIN BINDING PROTEIN-2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-LACTAM ANTIBIOTICS; PERFORMANCE LIQUID-CHROMATOGRAPHY; NEISSERIA-GONORRHOEAE; MOLECULAR-CLONING; CROSS-LINKING; GENE; PHASE; DNA	All clinical isolates of methicillin-resistant Staphylococcus aureus contain an extra penicillin binding protein (PBP) 2A in addition to four PBPs present in all staphylococcal strains. This extra PBP is thought to be a transpeptidase essential for the continued cell wall synthesis and growth in the presence of beta-lactam antibiotics. As an approach of testing this hypothesis we compared the muropeptide composition of cell walls of a highly methicillin-resistant S. aureus strain containing PBP2A and its isogenic Tn551 derivative with reduced methicillin resistance, which contained no PBP2A because of the insertional inactivation of the PBP2A gene. Purified cell walls were hydrolyzed into muropeptides which were subsequently resolved by reversed-phase high-performance liquid chromatography and identified by chemical and mass spectrometric analysis. The peptidoglycan composition of the two strains were identical. Both peptidoglycans were highly cross-linked mainly through pentaglycine cross-bridges, although other, chemically distinct peptide cross-bridges were also present including mono-, tri-, and tetraglycine; alanine; and alanyl-tetraglycine. Our experiments provided no experimental data for a unique transpeptidase activity associated with PBP2A.	ROCKEFELLER UNIV,MICROBIOL LAB,1230 YORK AVE,NEW YORK,NY 10021; MICHIGAN STATE UNIV,DEPT BIOCHEM,MICHIGAN STATE UNIV NIH MASS SPECTROMETRY FACIL,E LANSING,MI 48824	Rockefeller University; Michigan State University			DeJonge, Boudewijn/AAR-6717-2020	Chang, Yoon-Seok/0000-0002-0623-2932; Tomasz, Alexander/0000-0003-1520-1983	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000480] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00480] Funding Source: Medline; NIAID NIH HHS [R01-AI16794] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Atherton D., 1989, TECHNIQUES PROTEIN C, P273; BECK WD, 1986, J BACTERIOL, V165, P373, DOI 10.1128/jb.165.2.373-378.1986; CHAMBERS HF, 1990, J INFECT DIS, V161, P1170, DOI 10.1093/infdis/161.6.1170; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11255; DELANCASTRE H, 1991, ANTIMICROB AGENTS CH, V35, P632; DOUGHERTY TJ, 1985, J BACTERIOL, V163, P69, DOI 10.1128/JB.163.1.69-74.1985; GARCIABUSTOS JF, 1987, J BIOL CHEM, V262, P15400; GARCIABUSTOS JF, 1987, ANTIMICROB AGENTS CH, V31, P178, DOI 10.1128/AAC.31.2.178; GARCIABUSTOS JF, 1989, P NATL ACAD SCI USA, V87, P5415; GHUYSEN JM, 1963, BIOCHEMISTRY-US, V2, P1119, DOI 10.1021/bi00905a036; GLAUNER B, 1988, ANAL BIOCHEM, V172, P451, DOI 10.1016/0003-2697(88)90468-X; GLAUNER B, 1988, J BIOL CHEM, V263, P10088; HARTMAN BJ, 1984, J BACTERIOL, V158, P513, DOI 10.1128/JB.158.2.513-516.1984; HAYASHI K, 1975, ANAL BIOCHEM, V67, P503, DOI 10.1016/0003-2697(75)90324-3; MARTIN SA, 1987, J BIOL CHEM, V262, P7514; MATSUHASHI M, 1986, J BACTERIOL, V167, P975, DOI 10.1128/jb.167.3.975-980.1986; MATTHEWS P, 1990, ANTIMICROB AGENTS CH, V34, P1777, DOI 10.1128/AAC.34.9.1777; MATTHEWS PR, 1987, J GEN MICROBIOL, V133, P1919; MURAKAMI K, 1989, J BACTERIOL, V171, P874, DOI 10.1128/jb.171.2.874-879.1989; QUORONFLEH MW, 1986, ANTIMICROB AGENTS CH, V29, P250; REYNOLDS PE, 1986, FEMS MICROBIOL LETT, V33, P251; Rogers H.J., 1980, MICROBIAL CELL WALLS, P239; SASAGAWA T, 1982, J CHROMATOGR, V240, P329, DOI 10.1016/S0021-9673(00)99612-2; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; SCHLEIFER KH, 1969, J GEN MICROBIOL, V57, pR14; SIDOW T, 1990, ARCH MICROBIOL, V154, P73; SNOWDEN MA, 1990, EUR J BIOCHEM, V191, P373, DOI 10.1111/j.1432-1033.1990.tb19132.x; SNOWDEN MA, 1989, J GEN MICROBIOL, V135, P3015; SNOWDEN MA, 1991, J GEN MICROBIOL, V137, P1661, DOI 10.1099/00221287-137-7-1661; SONG MD, 1987, FEBS LETT, V221, P167, DOI 10.1016/0014-5793(87)80373-3; TIPPER DJ, 1969, BIOCHEMISTRY-US, V8, P2183, DOI 10.1021/bi00833a060; TIPPER DJ, 1965, P NATL ACAD SCI USA, V54, P1133, DOI 10.1073/pnas.54.4.1133; TIPPER DJ, 1968, J BIOL CHEM, V243, P3169; TOMASZ A, 1991, ANTIMICROB AGENTS CH, V35, P124, DOI 10.1128/AAC.35.1.124; TOWNSEND DE, 1987, J HOSP INFECT, V9, P60, DOI 10.1016/0195-6701(87)90097-1; TUOMANEN E, 1989, J BIOL CHEM, V264, P11093; UBUKATA K, 1989, J BACTERIOL, V171, P2882, DOI 10.1128/jb.171.5.2882-2885.1989; WATSON JT, 1991, INT J MASS SPECTROM, V111, P191; WYKE AW, 1982, EUR J BIOCHEM, V127, P553	39	273	282	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11248	11254						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597460				2022-12-25	WOS:A1992HX16900051
J	FUKAMI, K; TAKENAWA, T				FUKAMI, K; TAKENAWA, T			PHOSPHATIDIC-ACID THAT ACCUMULATES IN PLATELET-DERIVED GROWTH FACTOR-STIMULATED BALB/C 3T3 CELLS IS A POTENTIAL MITOGENIC SIGNAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; PHOSPHOLIPASE-D; PHOSPHATIDYLCHOLINE HYDROLYSIS; DNA-SYNTHESIS; FIBROBLASTS; ACTIVATION; RAS; POLYPHOSPHOINOSITIDES; TRANSDUCTION; NEUTROPHILS	We developed a monoclonal antibody specific to phosphatidic acid (PA). Using this antibody, a novel method to quantify trace amounts of PA was achieved. With the method, PA can be measured in the range of 20-500 pmol. We applied this method to quantify changes in PA levels in Balb/c 3T3 cells stimulated by platelet-derived growth factor. PA contents were very low in quiescent cells and dramatically increased with time up to 15 min. On the other hand, a biphasic diacylglycerol (DG) increase was found. The early phase showed a transient small peak of DG at 30 s followed by a decrease to 1 min. In the second phase, DG accumulated gradually but very markedly up to 15 min. Treatment with propranolol, a PA phosphohydrolase inhibitor, enhanced the accumulation of PA and inhibited the formation of DG in the second phase. However, R59022, a DG kinase inhibitor, did not influence the accumulation of DG or PA, suggesting that platelet-derived growth factor stimulates mainly phospholipase D-catalyzed hydrolysis of phospholipids rather than phospholipase C-catalyzed hydrolysis in the second phase. PA, even after contaminating lyso-PA was removed, could stimulate DNA synthesis, although lyso-PA was 25 times more potent. Moreover, phospholipase D was found to be a much stronger mitogen than phospholipase C. Phospholipase D treatment caused a biphasic accumulation of PA. PA levels reached a maximum at 1 h, and then decreased between 1 and 2 h; finally, there was a gradual elevation up to 10 h. In this case, there was no significant DG accumulation. On the other hand, phospholipase C treatment induced only DG accumulation without any significant change in PA. These results indicate that PA accumulation, rather than an increase in DG, correlates well with mitogenesis.	TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,DEPT BIOSIGNAL RES,SAKAE CHO,ITABASHI KU,TOKYO 173,JAPAN									AGWU DE, 1989, J BIOL CHEM, V264, P1405; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; DECOURCELLES DD, 1985, J BIOL CHEM, V260, P5762; EXTON JH, 1990, J BIOL CHEM, V265, P1; FUKAMI K, 1989, J BIOL CHEM, V264, P14985; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUANG CF, 1990, J BIOL CHEM, V265, P17468; JALINK K, 1990, J BIOL CHEM, V265, P12232; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MARTIN TW, 1989, J BIOL CHEM, V264, P8847; MARTINSON EA, 1990, J BIOL CHEM, V265, P22282; MARUYAMA T, 1987, J BIOL CHEM, V262, P5522; MATSUOKA K, 1988, SCIENCE, V239, P640; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PUTNEY JW, 1980, NATURE, V284, P345, DOI 10.1038/284345a0; RYU EK, 1979, J LIPID RES, V20, P561; SALMON DM, 1980, NATURE, V284, P344, DOI 10.1038/284344a0; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SCHACHT J, 1978, J LIPID RES, V19, P1063; SEKIMORI RS, 1989, J CELL PHYSL, V140, P432; SERHAN C, 1981, J BIOL CHEM, V256, P2736; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	31	207	210	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					10988	10993						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597441				2022-12-25	WOS:A1992HX16900012
J	MCGLYNN, P; HUNTER, CN				MCGLYNN, P; HUNTER, CN			ISOLATION AND CHARACTERIZATION OF A PUTATIVE TRANSCRIPTION FACTOR INVOLVED IN THE REGULATION OF THE RHODOBACTER-SPHAEROIDES PUCBA OPERON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; RHODOPSEUDOMONAS-SPHAEROIDES; NUCLEOTIDE-SEQUENCE; PROTEIN; CLONING; BINDING; GENES; CAPSULATUS; EXPRESSION; BACTERIA	The pucBA operon of the photosynthetic bacterium Rhodobacter sphaeroides encodes the light harvesting 2 (LH2) apoproteins of the photosynthetic apparatus, and transcription of this operon is markedly depressed under aerobic conditions. The region upstream of the LH2 genes has been subjected to gel retardation analysis, and two distinct bandshifts have been observed. The intensity of the upper bandshift was reduced upon lowering the oxygen tension under which the cells were grown, and this reduction preceded the appearance of LH2 in the cell membrane. Purification of the sequence-specific DNA binding protein responsible for this bandshift activity revealed a protein of M(r) 26000, and DNase I footprint analysis revealed that the binding site was located 120 base pairs upstream of the transcription initiation point. We propose that this protein is an oxygen-regulated repressor of pucBA transcription. This work, therefore, describes the first purification of a transcription factor from any photosynthetic bacterium.	UNIV SHEFFIELD,DEPT MOLEC BIOL & BIOTECHNOL,WESTERN BANK,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND	University of Sheffield				McGlynn, Peter/0000-0001-8629-4713				AAGAARD J, 1972, PHOTOCHEM PHOTOBIOL, V15, P209, DOI 10.1111/j.1751-1097.1972.tb06240.x; ARMSTRONG GA, 1989, MOL GEN GENET, V216, P254, DOI 10.1007/BF00334364; ASHBY MK, 1987, FEBS LETT, V213, P245, DOI 10.1016/0014-5793(87)81499-0; BERG OG, 1988, TRENDS BIOCHEM SCI, V13, P207, DOI 10.1016/0968-0004(88)90085-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COHENBAZIRE G, 1957, J CELL COMPAR PHYSL, V49, P25, DOI 10.1002/jcp.1030490104; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HUNTER CN, 1988, J GEN MICROBIOL, V134, P1471; HUNTER CN, 1991, MOL MICROBIOL, V5, P2649, DOI 10.1111/j.1365-2958.1991.tb01974.x; HUNTER CN, 1987, BIOCHEM J, V247, P489, DOI 10.1042/bj2470489; HUNTER CN, 1982, CELL FUNCTION DIFF B, P257; KANSY JW, 1989, J BIOL CHEM, V264, P13751; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; KILEY PJ, 1987, J BACTERIOL, V169, P3268, DOI 10.1128/jb.169.7.3268-3275.1987; KLUG G, 1991, MOL MICROBIOL, V5, P1235, DOI 10.1111/j.1365-2958.1991.tb01897.x; KLUG G, 1991, MOL GEN GENET, V226, P167, DOI 10.1007/BF00273600; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JK, 1989, J BACTERIOL, V171, P3391, DOI 10.1128/jb.171.6.3391-3405.1989; Maxam A M, 1980, Methods Enzymol, V65, P499; NIEDERMAN RA, 1976, BIOCHIM BIOPHYS ACTA, V440, P429, DOI 10.1016/0005-2728(76)90076-1; RICCA E, 1989, J BACTERIOL, V171, P1658, DOI 10.1128/jb.171.3.1658-1664.1989; Sambrook J, 1989, MOL CLONING LABORATO; THEILER R, 1984, FEBS LETT, V175, P231, DOI 10.1016/0014-5793(84)80742-5; TICHY HV, 1989, J BACTERIOL, V171, P4914, DOI 10.1128/jb.171.9.4914-4922.1989; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZUCCONI AP, 1988, J BACTERIOL, V170, P877, DOI 10.1128/jb.170.2.877-882.1988	30	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11098	11103						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597448				2022-12-25	WOS:A1992HX16900028
J	NUDELMAN, ED; LEVERY, SB; IGARASHI, Y; HAKOMORI, S				NUDELMAN, ED; LEVERY, SB; IGARASHI, Y; HAKOMORI, S			PLASMALOPSYCHOSINE, A NOVEL PLASMAL (FATTY ALDEHYDE) CONJUGATE OF PSYCHOSINE WITH CYCLIC ACETAL LINKAGE - ISOLATION AND CHARACTERIZATION FROM HUMAN BRAIN WHITE MATTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOMBARDMENT MASS-SPECTROMETRY; PROTEIN KINASE-C; LIQUID-CHROMATOGRAPHY; METHYLATION ANALYSIS; GLYCOSPHINGOLIPIDS; LYSOSPHINGOLIPIDS; SPHINGOLIPIDS; SPHINGOSINE; DERIVATIVES; MODULATION	Through a systematic examination of basic (cationic) lipids separated on Folch's lower phase from extracts of human brain by cation exchange chromatography on carboxymethyl Sephadex in a chloroform/methanol mixture, followed by successive chromatographies on Florisil and Iatrobeads columns, five compounds of basic lipids were separated. Two major unknown compounds A and B and a minor unknown compound C were separated, in addition to minor compounds sphingosine and N,N-dimethylsphingosine. This paper describes the isolation and chemical characterization of major unknown compounds A and B, which were found only in the white matter but not in the gray matter of the human brain. Unmodified psychosine (galactosylsphingosine) was essentially undetectable under the experimental conditions. Unknown compounds A and B were identified as novel plasmal (fatty aldehyde) conjugates of psychosine with cyclic acetal linkage at the galactosyl residue of psychosine. Fatty aldehydes were identified as mainly palmital (16:0) and stearal (18:0). Sphingosine was identified as d18:1 sphingosine. Faster migrating compound A had 3,4-cyclic acetal linkage, and slower migrating compound B had 4,6-cyclic acetal linkage (where m is 14 or 16 and n is 12) as shown below. [GRAPHICS] Preliminary studies showed that compounds A, B, and C had a weak inhibitory effect on protein kinase C (PKC) and had no cytotoxic effect. In contrast, psychosine displayed a strong cytotoxicity and inhibitory effect on PKC. Therefore, the process controlling the addition or deletion of plasmal cyclic linkage to psychosine could be a crucial step in regulation of PKC, src, or other kinases susceptible to psychosine.	BIOMEMBRANE INST, 201 ELLIOTT AVE W, SEATTLE, WA 98119 USA; UNIV WASHINGTON, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle					NCI NIH HHS [CA42505] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042505] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLOU CE, 1985, CARBOHYD RES, V140, P139, DOI 10.1016/0008-6215(85)85058-8; BJORNDAL H, 1970, ANGEW CHEM INT EDIT, V9, P610, DOI 10.1002/anie.197006101; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; COREY EJ, 1979, TETRAHEDRON LETT, P399; Feulgen R, 1924, PFLUG ARCH GES PHYS, V206, P389, DOI 10.1007/BF01722779; FEULGEN R, 1929, HOPPESEYLERS Z PHYSL, V2, P161; FOLCH J, 1951, J BIOL CHEM, V191, P819; FUJII I, 1985, J CHEM SOC CHEM COMM, P405, DOI 10.1039/c39850000405; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANAI N, 1988, J BIOL CHEM, V263, P10915; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HARA A, 1986, J BIOCHEM-TOKYO, V100, P415, DOI 10.1093/oxfordjournals.jbchem.a121729; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P6796, DOI 10.1021/bi00443a002; IGARASHI Y, 1990, J BIOL CHEM, V265, P5389; IGARASHI Y, 1989, METHOD ENZYMOL, V179, P521; IGARASHI Y, 1990, TRENDS GLYCOSCI GLYC, V2, P319; ISOBE R, 1987, TRAC-TREND ANAL CHEM, V6, P78, DOI 10.1016/0165-9936(87)87037-1; Jansson P-E., 1976, CHEM COMMUN U STOCKH, V8, P1; KIKKAWA U, 1986, BIOCHEM BIOPH RES CO, V135, P636, DOI 10.1016/0006-291X(86)90040-9; KISHIMOTO Y, 1968, J LIPID RES, V9, P27; KLENK E, 1967, H-S Z PHYSIOL CHEM, V348, P1712; KLENK E, 1966, H-S Z PHYSIOL CHEM, V346, P296; Klenk E, 1963, PROGR CHEM FATS OTHE, P1; KOCHETKOV NK, 1963, BIOCHIM BIOPHYS ACTA, V70, P716, DOI 10.1016/0006-3002(63)90823-0; KUBOTA M, 1974, JPN J EXP MED, V44, P145; Laine RA, 1972, METHOD ENZYMOL, V28, P159, DOI [10.1016/0076-6879(72)28012-0, DOI 10.1016/0076-6879(72)28012-0]; LARSON G, 1987, CARBOHYD RES, V161, P281, DOI 10.1016/S0008-6215(00)90085-5; LEVERY SB, 1987, METHOD ENZYMOL, V138, P13, DOI 10.1016/0076-6879(87)38004-8; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MIYATAKE T, 1972, BIOCHEM BIOPH RES CO, V48, P538, DOI 10.1016/0006-291X(72)90381-6; NEUENHOFER S, 1986, BIOL CHEM H-S, V367, P241, DOI 10.1515/bchm3.1986.367.1.241; NORES GA, 1988, CARBOHYD RES, V179, P393, DOI 10.1016/0008-6215(88)84135-1; NORES GA, 1989, METHOD ENZYMOL, V179, P242; RAPPORT MM, 1957, J NEUROCHEM, V1, P303, DOI 10.1111/j.1471-4159.1957.tb12086.x; RAPPORT MM, 1957, J BIOL CHEM, V225, P859; SWEELEY CC, 1963, J AM CHEM SOC, V85, P2497, DOI 10.1021/ja00899a032; TAMAI Y, 1967, JPN J EXP MED, V37, P79; TAMAI Y, 1968, JPN J EXP MED, V38, P65; WITTENBERG JB, 1956, J BIOL CHEM, V219, P39; Zemplen G, 1927, BER DTSCH CHEM GES, V60, P1555, DOI 10.1002/cber.19270600717	41	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11007	11016						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597442				2022-12-25	WOS:A1992HX16900015
J	NICOLSON, GL; GALLICK, GE; SPOHN, WH; LEMBO, TM; TAINSKY, MA				NICOLSON, GL; GALLICK, GE; SPOHN, WH; LEMBO, TM; TAINSKY, MA			TRANSFECTION OF ACTIVATED C-H-RASEJ/PSV2NEO OR PSV2NEO GENES INTO RAT MAMMARY CELLS - RAPID STIMULATION OF CLONAL DIVERSIFICATION OF SPONTANEOUS METASTATIC AND CELL-SURFACE PROPERTIES	ONCOGENE			English	Article							NIH 3T3 CELLS; C-HA-RAS; DIFFERENTIAL EXPRESSION; ADENOCARCINOMA CELLS; MONOCLONAL-ANTIBODY; MOLECULAR-WEIGHT; DNA TRANSFECTION; BREAST-CANCER; NIH/3T3 CELLS; FRESH PRIMARY	We examined whether the conversion of benign rat mammary cells to metastatic cells by transfection of c-H-ras(EJ)/pSV2neo or control pSV2neo genes results in rapid stimulation of diversification of cellular phenotypes. Transfection of c-H-ras(EJ) into twice-cloned, stable (> 1 year) rat mammary MTC.4 cells, followed quickly by cell cloning, revealed differences in transfected oncogene copy numbers and expression of p21-(rasEJ) . No correlation between c-H-ras(EJ) copy numbers or the cellular amounts of p21(rasEJ) or total p21ras and spontaneous metastatic potentials was found. By subcloning transfected cells as soon as possible after gene transfer, we found some rearrangements and amplifications of c-H-ras(EJ) and heterogeneous spontaneous metastatic potentials. In addition, the expression of the mammary tumor metastasis-associated cell-surface glycoprotein gp580 on untransfected and transfected MTC.4 cells indicated that the cell populations of higher metastatic potential were also more diverse in their cell-to-cell antigen expression than untransfected or non-metastatic, transfected MTC.4 cells. In contrast, the expression of a putative metastasis-suppressor gene, nm23, was unchanged after transfection and subcloning. Control pSV2neo transfections or calcium phosphate treatment alone also resulted in the generation of cellular heterogeneity, although at an apparently lower frequency than c-H-ras(EJ) transfections, suggesting that transfection of activated, dominantly acting oncogenes, or in some cases control genes, can result in destabilization of transfected cells, rapid diversification and generation of heterogeneity in growth rate, spontaneous metastatic potential and antigen expression.			NICOLSON, GL (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,BOX 108,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.			Tainsky, Michael/0000-0002-0261-831X	NCI NIH HHS [R23-CA39803, P30-CA16672, R35-CA44352] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R23CA039803, P30CA016672, R35CA044352] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERG P, 1982, MOL APPL GENET, P327; BERNSTEIN SC, 1985, P NATL ACAD SCI USA, V82, P1726, DOI 10.1073/pnas.82.6.1726; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BOLSCHER JGM, 1988, EMBO J, V7, P3361, DOI 10.1002/j.1460-2075.1988.tb03208.x; BONDY GP, 1985, CANCER RES, V45, P6005; BRADLEY MO, 1986, P NATL ACAD SCI USA, V83, P5277, DOI 10.1073/pnas.83.14.5277; CARNEY WP, 1986, J CELL BIOCHEM, V32, P207, DOI 10.1002/jcb.240320307; CHESA PG, 1987, P NATL ACAD SCI USA, V84, P3234, DOI 10.1073/pnas.84.10.3234; CLAIR T, 1987, CANCER RES, V47, P5290; COLLARD JG, 1987, CANCER RES, V47, P754; DEAR TN, 1988, CANCER RES, V48, P5203; DEBORTOLI ME, 1985, BIOCHEM BIOPH RES CO, V127, P699, DOI 10.1016/S0006-291X(85)80218-7; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; EGAN SE, 1989, INT J CANCER, V43, P443, DOI 10.1002/ijc.2910430317; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; FRAZIER ML, 1983, MOL CELL BIOCHEM, V56, P113; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GALLICK GE, 1985, P NATL ACAD SCI USA, V82, P1795, DOI 10.1073/pnas.82.6.1795; GARBISA S, 1987, CANCER RES, V47, P1523; GREIG RG, 1985, P NATL ACAD SCI USA, V82, P3698, DOI 10.1073/pnas.82.11.3698; HAND PH, 1987, J NATL CANCER I, V79, P59; HILL SA, 1988, J NATL CANCER I, V80, P484, DOI 10.1093/jnci/80.7.484; ICHIKAWA T, 1990, CANCER RES, V50, P6349; KERBEL RS, 1987, P NATL ACAD SCI USA, V84, P1263, DOI 10.1073/pnas.84.5.1263; KURZROCK R, 1986, CANCER RES, V46, P1530; KUZEK T, 1987, P NATL ACAD SCI USA, V84, P4490; KYPRIANOU N, 1990, CANCER RES, V50, P1499; LIOTTA LA, 1988, J NATL CANCER I, V80, P468, DOI 10.1093/jnci/80.7.468; LUNDY J, 1986, J CLIN ONCOL, V4, P1321, DOI 10.1200/JCO.1986.4.9.1321; MAREEL MM, 1986, ANTICANCER RES, V6, P419; MARSHALL CJ, 1988, J CELL SCI S, V10, P157; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; NERI A, 1982, J NATL CANCER I, V68, P508; NICOLSON GL, 1984, CANCER METAST REV, V3, P25, DOI 10.1007/BF00047691; NICOLSON GL, 1987, CANCER RES, V47, P1473; NICOLSON GL, 1991, J CELL BIOCHEM, V46, P277, DOI 10.1002/jcb.240460402; NICOLSON GL, 1988, BIOCHIM BIOPHYS ACTA, V948, P175, DOI 10.1016/0304-419X(88)90010-8; NICOLSON GL, 1990, ONCOGENE, V5, P747; NORTH SM, 1988, INT J CANCER, V42, P607, DOI 10.1002/ijc.2910420423; OHUCHI N, 1986, CANCER RES, V46, P2511; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; PRICE JE, 1989, CANCER RES, V49, P4274; STECK PA, 1983, EXP CELL RES, V147, P255, DOI 10.1016/0014-4827(83)90208-2; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; VANROY FM, 1986, CANCER RES, V46, P4787; VERRELLE P, 1987, ANTICANCER RES, V7, P181; VOUSDEN KH, 1986, INT J CANCER, V37, P425, DOI 10.1002/ijc.2910370315; WAGHORNE C, 1987, ONCOGENE, V1, P149	51	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1127	1135						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594244				2022-12-25	WOS:A1992HU64200010
J	TORCHILIN, VP; KLIBANOV, AL; HUANG, L; ODONNELL, S; NOSSIFF, ND; KHAW, BA				TORCHILIN, VP; KLIBANOV, AL; HUANG, L; ODONNELL, S; NOSSIFF, ND; KHAW, BA			TARGETED ACCUMULATION OF POLYETHYLENE GLYCOL-COATED IMMUNOLIPOSOMES IN INFARCTED RABBIT MYOCARDIUM	FASEB JOURNAL			English	Note						IMMUNOLIPOSOME; POLYETHYLENEGLYCOL; TARGETED DRUG DELIVERY; INFARCTED MYOCARDIUM	LIPOSOMES; ANTIBODY	The less than optimal accumulation of immunoliposome-associated reagents at target sites has often been attributed to the rapid in vivo clearance of immunoliposomes from the blood. In an attempt to overcome the drawback of rapid clearance and use the targeting potential of immunoliposomes, we have prepared long-circulating, In-111-labeled immunoliposomes. Targeting properties and enhanced circulation times were demonstrated in a rabbit model of acute experimental myocardial infarct. The specificity of liposomes for newly exposed intracellular cardiac myosin at the necrotic sites was achieved by incorporating monoclonal antimyosin antibody. Extended circulation times were achieved by cocoating the antimyosin-liposomes with polyethylene glycol (PEG). The half-life of the immunoliposomes was 40 min, which increased to 200 min with 4% mol PEG and to approximately 1000 min with 10% mol PEG. The degree of binding of modified immunoliposomes at the target sites was also dependent on the concentration of PEG incorporated at the liposome surface. This study demonstrates the accumulation of long-circulating targeted liposomes at the area of acute rabbit experimental myocardial infarction.	MASSACHUSETTS GEN HOSP,DEPT NUCL MED,BOSTON,MA 02129; UNIV TENNESSEE,DEPT BIOCHEM,KNOXVILLE,TN 37996	Harvard University; Massachusetts General Hospital; University of Tennessee System; University of Tennessee Knoxville	TORCHILIN, VP (corresponding author), MASSACHUSETTS GEN HOSP E,CTR IMAGING & PHARMACEUT RES,DEPT RADIOL,BLDG 149,13TH ST,BOSTON,MA 02129, USA.							CARIDE VJ, 1977, SCIENCE, V198, P735, DOI 10.1126/science.910155; KABALKA G, 1987, RADIOLOGY, V163, P255, DOI 10.1148/radiology.163.1.3454163; KHAW BA, 1984, HYBRIDOMA, V3, P11, DOI 10.1089/hyb.1984.3.11; KLIBANOV AL, 1991, BIOCHIM BIOPHYS ACTA, V1062, P142, DOI 10.1016/0005-2736(91)90385-L; KLIBANOV AL, 1990, FEBS LETT, V268, P235, DOI 10.1016/0014-5793(90)81016-H; KLIBANOV AL, 1991, AM J PHYSL S, V2611, P60; Leserman LD, 1984, LIPOSOME TECHNOLOGY, V3, P29; MORI A, 1991, FEBS LETT, V284, P263, DOI 10.1016/0014-5793(91)80699-4; TORCHILIN VP, 1979, BIOCHEM BIOPH RES CO, V89, P1114, DOI 10.1016/0006-291X(79)92123-5; WEISSIG V, 1986, FEBS LETT, V202, P86, DOI 10.1016/0014-5793(86)80654-8	10	173	189	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1992	6	9					2716	2719		10.1096/fasebj.6.9.1612296	http://dx.doi.org/10.1096/fasebj.6.9.1612296			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HZ481	1612296				2022-12-25	WOS:A1992HZ48100013
J	COVER, TL; BLASER, MJ				COVER, TL; BLASER, MJ			PURIFICATION AND CHARACTERIZATION OF THE VACUOLATING TOXIN FROM HELICOBACTER-PYLORI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMPYLOBACTER-PYLORI; MOLECULAR CHARACTERIZATION; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; CDNA SEQUENCE; PERMEASE GENE; CHANNEL GENE; PROTEINS; CYTOTOXIN	A vacuolating toxin was purified to homogeneity from broth culture supernatant of the human gastric bacterium, Helicobacter pylori. The procedure for isolating the toxin included ammonium sulfate precipitation, hydrophobic interactive chromatography, size exclusion chromatography, and anion exchange chromatography, which together resulted in a greater than 5000-fold purification of toxin activity. The molecular mass of the purified, denatured toxin was 87,000 +/-320 daltons, and the native toxin was an aggregate with a molecular mass greater-than-or-equal-to 972,000 daltons. The amino-terminal sequence of the purified toxin was partially homologous with internal sequences of numerous transport or ion channel proteins. Antiserum raised against the M(r) = 87,000 protein neutralized toxin activity, whereas preimmune serum did not. When reacted with specific antiserum to the M(r) = 87,000 protein in an enzyme-linked immunosorbent (ELISA) assay, culture supernatants from eight tox+ H. pylori r.trains produced significantly higher optical density readings than eight tox- supernatants (0.614 +/- 0.11 versus 0.046 +/- 0.01, p < 0.0001). Sera from H. pylori-infected humans recognized the purified M(r) = 87,000 protein significantly better by ELISA than sera from uninfected persons (0.424 +/- 0.06 versus 0.182 +/- 0.02, p = 0.0009). Finally, ELISA recognition of the purified M(r) = 87,000 protein by human sera was significantly associated with toxin-neutralizing activity (p = 0.01 9, r = 0.518).	VANDERBILT UNIV,MED CTR,SCH MED,DEPT MICROBIOL & IMMUNOL,NASHVILLE,TN 37232; DEPT VET AFFAIRS MED CTR,INFECT DIS SECT,NASHVILLE,TN 37212	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	COVER, TL (corresponding author), VANDERBILT UNIV,MED CTR,SCH MED,DEPT MED,DIV INFECT DIS,MED CTR N A3310,NASHVILLE,TN 37232, USA.		Cover, Timothy/I-3814-2015	Cover, Timothy/0000-0001-8503-002X				AMES GFL, 1974, J BIOL CHEM, V249, P634; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BLASER MJ, 1990, J INFECT DIS, V161, P626, DOI 10.1093/infdis/161.4.626; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BUCHEL DE, 1980, NATURE, V283, P541, DOI 10.1038/283541a0; BUCK GE, 1987, J CLIN MICROBIOL, V25, P597, DOI 10.1128/JCM.25.4.597-599.1987; COVER T L, 1991, Gastroenterology, V100, pA570; COVER TL, 1991, INFECT IMMUN, V59, P1264, DOI 10.1128/IAI.59.4.1264-1270.1991; COVER TL, 1992, ANNU REV MED, V43, P135, DOI 10.1146/annurev.me.43.020192.001031; COVER TL, 1990, INFECT IMMUN, V58, P603, DOI 10.1128/IAI.58.3.603-610.1990; COVER TL, 1992, IN PRESS HUMAN PATHO; CRABTREE JE, 1991, LANCET, V338, P332, DOI 10.1016/0140-6736(91)90477-7; DIXON MF, 1991, J GASTROEN HEPATOL, V6, P125, DOI 10.1111/j.1440-1746.1991.tb01451.x; DUNN BE, 1990, J BIOL CHEM, V265, P9464; EATON KA, 1989, INFECT IMMUN, V57, P1119, DOI 10.1128/IAI.57.4.1119-1125.1989; ERNI B, 1987, J BIOL CHEM, V262, P5238; FIGURA N, 1989, J CLIN MICROBIOL, V27, P225, DOI 10.1128/JCM.27.1.225-226.1989; GOLDRICK D, 1988, J BACTERIOL, V170, P3421, DOI 10.1128/jb.170.8.3421-3426.1988; GOOSSENS H, 1991, Microbial Ecology in Health and Disease, V4, pS130; HARBITZ I, 1990, GENOMICS, V8, P243, DOI 10.1016/0888-7543(90)90278-3; HAWKINS AR, 1988, MOL GEN GENET, V214, P224, DOI 10.1007/BF00337715; HESSE JE, 1984, P NATL ACAD SCI-BIOL, V81, P4746, DOI 10.1073/pnas.81.15.4746; HILES ID, 1987, J MOL BIOL, V195, P125, DOI 10.1016/0022-2836(87)90332-9; HOFFMANN W, 1985, J BIOL CHEM, V260, P1831; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; JAUNIAUX JC, 1990, EUR J BIOCHEM, V190, P39, DOI 10.1111/j.1432-1033.1990.tb15542.x; JONES BN, 1981, J LIQ CHROMATOGR, V4, P565, DOI 10.1080/01483918108059956; KAWAKAMI K, 1986, J BIOCHEM-TOKYO, V100, P389, DOI 10.1093/oxfordjournals.jbchem.a121726; LEUNK RD, 1988, J MED MICROBIOL, V26, P93, DOI 10.1099/00222615-26-2-93; LEUNK RD, 1990, J CLIN MICROBIOL, V28, P1181, DOI 10.1128/JCM.28.6.1181-1184.1990; MAEDA M, 1990, J BIOL CHEM, V265, P9027; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MARSHALL BJ, 1986, LANCET, V1, P965; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PEI ZH, 1988, J BIOL CHEM, V263, P6416; PEREZPEREZ GI, 1988, ANN INTERN MED, V109, P11, DOI 10.7326/0003-4819-109-1-11; PETERSON WL, 1991, NEW ENGL J MED, V324, P1043, DOI 10.1056/NEJM199104113241507; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; SALKOFF L, 1987, NUCLEIC ACIDS RES, V15, P8569, DOI 10.1093/nar/15.20.8569; SZKUTNICKA K, 1989, J BACTERIOL, V171, P4486, DOI 10.1128/JB.171.8.4486-4493.1989; TALLEY NJ, 1991, J NATL CANCER I, V83, P1734, DOI 10.1093/jnci/83.23.1734	43	584	619	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10570	10575						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587837				2022-12-25	WOS:A1992HV09000054
J	MESSINA, JL; STANDAERT, ML; ISHIZUKA, T; WEINSTOCK, RS; FARESE, RV				MESSINA, JL; STANDAERT, ML; ISHIZUKA, T; WEINSTOCK, RS; FARESE, RV			ROLE OF PROTEIN-KINASE-C IN INSULINS REGULATION OF C-FOS TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOMA-CELLS; MESSENGER RIBONUCLEIC-ACID; PYRUVATE-DEHYDROGENASE ACTIVITY; BC3H-1 CULTURED MYOCYTES; GROWTH-FACTOR; ORNITHINE DECARBOXYLASE; GENE-EXPRESSION; GLUCOSE-TRANSPORT; DNA-SYNTHESIS; 3T3 CELLS	One of insulin's actions is the induction of DNA synthesis and cell division, but little is known about the molecular mechanisms involved. Previous studies indicate that insulin stimulates cell division and regulates the expression of several genes in rat H4IIE (H4) hepatoma cells. One of these genes is the proto-oncogene c-fos, a cellular gene whose deregulation has been implicated in the process of cellular differentiation and division. We have shown that insulin induces transcription of the c-fos gene in H4 cells. In the present study, the phorbol ester, phorbol 12-myristate 13-acetate (PMA), stimulated c-fos transcription in a rapid and dose-dependent manner with an 800% increase in transcription following 15-30 min of addition. This increase in c-fos transcription was transitory, returning towards baseline transcription rates within 120 min. PMA stimulated the translocation of protein kinase C (PKC) from the cytoplasm to the membrane in H4 hepatoma cells, as evidenced by a 77% decrease in cytosolic PKC and a 29% increase in membrane PKC activity following 10 min of treatment. Insulin addition to H4 cells for 10 min also resulted in a 31% decrease in cytosolic PKC activity, suggesting a translocation response. When H4 cells were pretreated with PMA for 24 h, there was a decrease of 20-45% in both cytosolic and membrane PKC activity and a complete loss of PMA's induction of c-fos transcription. Thus, the cells were functionally desensitized to further PMA addition. When cells were pretreated with PMA for 24 h, the insulin-induced increase in transcription of c-fos was reduced by 50%. Western blot analysis indicated that the PKC-beta isozyme followed a translocation pattern almost identical with that of total PKC activity. These results suggest that a PMA-sensitive form of PKC is preferentially lost upon PMA pretreatment and that this PKC subtype may be necessary for insulin to fully induce c-fos gene expression.	JAMES A HALEY VET HOSP,TAMPA,FL 33612; VET ADM MED CTR,SYRACUSE,NY 13210; SUNY HLTH SCI CTR,DEPT MED,SYRACUSE,NY 13210; UNIV S FLORIDA,COLL MED,DEPT INTERNAL MED,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,DEPT BIOCHEM,TAMPA,FL 33612	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	MESSINA, JL (corresponding author), SUNY HLTH SCI CTR,DEPT PHYSIOL,SYRACUSE,NY 13210, USA.		Farese, Robert/B-3605-2015		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040456] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40456] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAMSEN MS, 1990, MOL CELL BIOL, V10, P5525, DOI 10.1128/MCB.10.10.5525; ACEVEDODUNCAN M, 1989, FEBS LETT, V244, P174, DOI 10.1016/0014-5793(89)81186-X; BLACKSHEAR PJ, 1987, MOL ENDOCRINOL, V1, P44, DOI 10.1210/mend-1-1-44; BUTLER AP, 1991, EXP CELL RES, V194, P56, DOI 10.1016/0014-4827(91)90129-I; BUTLER AP, 1991, J CELL PHYSIOL, V147, P256, DOI 10.1002/jcp.1041470210; CAVALIERI F, 1987, MOL CELL BIOL, V7, P3554, DOI 10.1128/MCB.7.10.3554; CHU DTW, 1987, MOL ENDOCRINOL, V1, P53, DOI 10.1210/mend-1-1-53; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COOPER DR, 1989, BIOCHEM BIOPH RES CO, V161, P327, DOI 10.1016/0006-291X(89)91600-8; COOPER DR, 1987, J BIOL CHEM, V262, P3633; COOPER DR, 1990, BIOCHIM BIOPHYS ACTA, V1054, P95, DOI 10.1016/0167-4889(90)90210-5; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DAO ML, 1985, J IMMUNOL METHODS, V82, P225; DEASUA LJ, 1973, P NATL ACAD SCI USA, V70, P1388, DOI 10.1073/pnas.70.5.1388; DEASUA LJ, 1977, NATURE, V265, P450, DOI 10.1038/265450a0; DONY C, 1987, NATURE, V328, P711, DOI 10.1038/328711a0; EGAN JJ, 1990, P NATL ACAD SCI USA, V87, P1052, DOI 10.1073/pnas.87.3.1052; FABBRO D, 1988, J CARDIOVASC PHARM, V12, pS73; FARESE RV, 1988, AM J MED, V85, P36, DOI 10.1016/0002-9343(88)90396-8; FARESE RV, 1985, ENDOCRINOLOGY, V116, P2650, DOI 10.1210/endo-116-6-2650; FARESE RV, 1991, ANTISENSE RES DEV, V1, P35, DOI 10.1089/ard.1991.1.35; FARESE RV, 1984, J BIOL CHEM, V259, P7094; GOODMAN SA, 1988, ARCH BIOCHEM BIOPHYS, V266, P343, DOI 10.1016/0003-9861(88)90266-4; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRIMALDI P, 1983, MOL CELL ENDOCRINOL, V29, P271, DOI 10.1016/0303-7207(83)90017-5; HELDIN CH, 1984, CELL, V37, P9, DOI 10.1016/0092-8674(84)90296-4; HOLLENBERG MD, 1975, J BIOL CHEM, V250, P3845; INOUE M, 1977, J BIOL CHEM, V252, P7610; ISHIZUKA T, 1990, DIABETES, V39, P181, DOI 10.2337/diabetes.39.2.181; ISHIZUKA T, 1989, FEBS LETT, V257, P337, DOI 10.1016/0014-5793(89)81565-0; ISHIZUKA T, 1990, BIOCHEM BIOPH RES CO, V169, P966, DOI 10.1016/0006-291X(90)91988-5; KASIK JW, 1987, MOL CELL BIOL, V7, P3349, DOI 10.1128/MCB.7.9.3349; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; KOONTZ JW, 1984, MOL CELL BIOCHEM, V58, P139, DOI 10.1007/BF00240613; KOONTZ JW, 1981, SCIENCE, V211, P947, DOI 10.1126/science.7008195; LANGENBACH R, 1975, J NATL CANCER I, V55, P801, DOI 10.1093/jnci/55.4.801; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LEFFERT HL, 1974, J CELL BIOL, V62, P792, DOI 10.1083/jcb.62.3.792; MCCAFFREY P, 1987, J BIOL CHEM, V262, P1442; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MESSINA JL, 1990, BIOCHEM BIOPH RES CO, V172, P759, DOI 10.1016/0006-291X(90)90739-A; MESSINA JL, 1990, J BIOL CHEM, V265, P11700; MESSINA JL, 1989, ENDOCRINOLOGY, V124, P754, DOI 10.1210/endo-124-2-754; MESSINA JL, 1985, J BIOL CHEM, V260, P6418; MILBRANDT J, 1986, P NATL ACAD SCI USA, V83, P4789, DOI 10.1073/pnas.83.13.4789; ONG J, 1987, ENDOCRINOLOGY, V120, P353, DOI 10.1210/endo-120-1-353; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; SASSONECORSI P, 1987, NATURE, V326, P507, DOI 10.1038/326507a0; STANDAERT ML, 1987, ENDOCRINOLOGY, V121, P941, DOI 10.1210/endo-121-3-941; VILA MD, 1989, FEBS LETT, V244, P177, DOI 10.1016/0014-5793(89)81187-1; WAYS K, 1991, J BIOL CHEM, V266, P1258; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WEINSTOCK RS, 1988, ENDOCRINOLOGY, V123, P366, DOI 10.1210/endo-123-1-366; YAMAMOTO T, 1988, J BIOCHEM-TOKYO, V104, P53, DOI 10.1093/oxfordjournals.jbchem.a122422; YAMASAKI H, 1977, P NATL ACAD SCI USA, V74, P3451, DOI 10.1073/pnas.74.8.3451; ZULLO JN, 1985, CELL, V43, P793, DOI 10.1016/0092-8674(85)90252-1	56	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9223	9228						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577756				2022-12-25	WOS:A1992HR85400079
J	TEPIKIN, AV; VORONINA, SG; GALLACHER, DV; PETERSEN, OH				TEPIKIN, AV; VORONINA, SG; GALLACHER, DV; PETERSEN, OH			PULSATILE CA2+ EXTRUSION FROM SINGLE PANCREATIC ACINAR-CELLS DURING RECEPTOR-ACTIVATED CYTOSOLIC CA2+ SPIKING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL TRISPHOSPHATE; CALCIUM; OSCILLATIONS; RELEASE; FLUCTUATIONS; MECHANISM	Ca2+ extrusion was measured simultaneously with the free intracellular Ca2+ concentration ([Ca2+]i) from single pancreatic acinar cells placed in microdroplets of extracellular solution (Tepikin, A. V., Voronina, S. G., Gallacher, D. V., and Petersen, O. H. (1992) J. Biol. Chem. 267, 3569-3572). Submaximal stimulation with cholecystokinin usually evoked discrete cytosolic Ca2+ spikes and each of these spikes was associated with a discrete and virtually synchronous pulse of Ca2+ extrusion into the extracellular microdroplet solution. When ACh evoked repetitive discrete [Ca2+]i spikes, each spike was also accompanied by a discrete pulse of Ca2+ extrusion. The velocity of Ca2+ extrusion oscillated with a time course similar to that of [Ca2+]i. The extracellular solution in our experiments had a low total calcium concentration (15-35-mu-M) and only a limited number of [Ca2+]i spikes (2-8) could be evoked. The magnitudes of the [Ca2+]i spikes and the amounts of Ca2+ extruded during each spike gradually decreased in each experiment. During the first cholecystokinin-evoked cytosolic Ca2+ spike the Ca2+ extrusion corresponded to a loss of 15-70% (mean value 39% +/- 12) of the mobilizable cellular calcium pool. The substantial pulsatile Ca2+ extrusion occurring synchronously with the receptor-activated cytosolic Ca2+ spikes is therefore an important element in repetitively bringing back [Ca2+], to the resting level.	UNIV LIVERPOOL,PHYSIOL LAB,MRC,SECRETORY CONTROL RES GRP,POB 147,LIVERPOOL L69 3BX,ENGLAND	University of Liverpool				Tepikin, Alexei/0000-0002-8172-7513; Petersen, Ole/0000-0002-6998-0380	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1991, CELL CALCIUM, V12, P63, DOI 10.1016/0143-4160(91)90009-4; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; DEHLINGERKREMER M, 1991, J MEMBRANE BIOL, V119, P85, DOI 10.1007/BF01868543; FOSKETT JK, 1991, J BIOL CHEM, V266, P14535; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GOLDBETER A, 1990, P NATL ACAD SCI USA, V86, P3423; HAROOTUNIAN AT, 1991, CELL CALCIUM, V12, P153, DOI 10.1016/0143-4160(91)90017-9; KOSTYUK PG, 1989, J MEMBRANE BIOL, V110, P11, DOI 10.1007/BF01870988; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MARUYAMA Y, 1982, NATURE, V300, P61, DOI 10.1038/300061a0; MELDOLESI J, 1990, BIOCHIM BIOPHYS ACTA, V1055, P130, DOI 10.1016/0167-4889(90)90113-R; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MUALLEM S, 1988, J MEMBRANE BIOL, V106, P57, DOI 10.1007/BF01871767; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; PETERSEN CCH, 1991, EMBO J, V10, P527, DOI 10.1002/j.1460-2075.1991.tb07979.x; PETERSEN OH, 1990, J MEMBRANE BIOL, V118, P93, DOI 10.1007/BF01868467; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; RANDRIAMAMPITA C, 1991, CELL REGUL, V2, P513, DOI 10.1091/mbc.2.7.513; TEPIKIN AV, 1991, J MEMBRANE BIOL, V123, P43, DOI 10.1007/BF01993961; TEPIKIN AV, 1992, J BIOL CHEM, V267, P3569; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; WALKUI M, 1991, J MEMBRANE BIOL, V124, P179; YULE DI, 1988, FEBS LETT, V239, P358, DOI 10.1016/0014-5793(88)80951-7; YULE DI, 1991, CELL CALCIUM, V12, P145, DOI 10.1016/0143-4160(91)90016-8	29	117	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14073	14076						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629206				2022-12-25	WOS:A1992JD32500047
J	ZHOU, SL; STUMP, D; SORRENTINO, D; POTTER, BJ; BERK, PD				ZHOU, SL; STUMP, D; SORRENTINO, D; POTTER, BJ; BERK, PD			ADIPOCYTE DIFFERENTIATION OF 3T3-L1 CELLS INVOLVES AUGMENTED EXPRESSION OF A 43-KDA PLASMA-MEMBRANE FATTY ACID-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WATER-INSOLUBLE COMPOUNDS; PHYSICAL-CHEMICAL MODEL; RAT-LIVER; ADIPOSE CONVERSION; LIPOPROTEIN-LIPASE; CARDIAC MYOCYTES; OLEATE UPTAKE; INVITRO; TISSUE; PREADIPOCYTES	A previously described 43-kDa plasma membrane fatty acid-binding protein (FABP(PM)) was not observed by immunohistochemical methods in proliferating 3T3-L1 fibroblasts. However, it was detectable in plasma membranes by the second day of confluent growth, prior to accumulation of visible lipid droplets, and was strongly expressed in 8-day differentiated adipocytes. These observations were confirmed by extraction of plasma membrane proteins and subsequent immunoblotting. Kinetics of initial [H-3]oleate uptake by both fibroblasts and adipocytes consisted of the sum of a saturable and a non-saturable component. During differentiation the saturable component increased progressively. V(max) increased from 3 to 25 to 110 pmol . s-1. mg cell protein-1 between the fibroblast, the 4-day, and 8 day adipocyte stages; K(m) was 24 nM in fibroblasts and approximately 55 nM in both 4- and 8-day differentiated adipocytes. By contrast, the rate constant for nonsaturable oleate influx decreased progressively from 0.026 to 0.010 ml. s-1 . mg protein-1 between the fibroblast and 8 day adipocyte stages. In 8-day adipocytes saturable oleate uptake was inhibited by up to 55% by antibodies against rat liver FABP(PM); these antibodies had no effect on uptake of 2-deoxyglucose or the medium chain fatty acid octanoate. They also had no effect on oleate uptake by fibroblasts. These studies support the hypothesis that FABP(PM) is a component of a saturable transport mechanism for long chain fatty acids.	CUNY MT SINAI SCH MED,DEPT MED,DIV LIVER DIS,BOX 1039,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			Sorrentino, Dario/K-7253-2019; Sorrentino, Dario/E-8131-2010		NIDDK NIH HHS [DK-26438] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026438] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUMRAD NA, 1991, P NATL ACAD SCI USA, V88, P6008, DOI 10.1073/pnas.88.14.6008; ABUMRAD NA, 1984, J BIOL CHEM, V259, P8945; ABUMRAD NA, 1981, J BIOL CHEM, V256, P9183; Aronson N N Jr, 1974, Methods Enzymol, V31, P90; BERK PD, 1990, P NATL ACAD SCI USA, V87, P3484, DOI 10.1073/pnas.87.9.3484; BERMAN M, 1967, US PHS PUBLICATION, V1703; BERNLOHR DA, 1985, BIOCHEM BIOPH RES CO, V132, P850, DOI 10.1016/0006-291X(85)91209-4; COLEMAN RA, 1978, J BIOL CHEM, V253, P7256; GLATZ JFC, 1990, MOL CELL BIOCHEM, V98, P237, DOI 10.1007/BF00231390; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; GUTNECHT J, 1988, J MEMBRANE BIOL, V106, P83; HARMON CM, 1991, J MEMBRANE BIOL, V121, P261, DOI 10.1007/BF01951559; HEIMBERG M, 1973, DISTURBANCES LIPID L, P251; Kleinfeld A. M., 1990, Comments on Molecular and Cellular Biophysics. Comments on Modern Biology: Part A, V6, P361; KOCHWA S, 1961, J CLIN INVEST, V40, P874, DOI 10.1172/JCI104322; KUHL WE, 1970, J LIPID RES, V11, P458; KURIHARCUCH W, 1977, J BIOL CHEM, V252, P2158; MACKALL JC, 1976, J BIOL CHEM, V251, P6462; MACKALL JC, 1977, BIOCHEM BIOPH RES CO, V79, P720, DOI 10.1016/0006-291X(77)91171-8; MATARESE V, 1988, J BIOL CHEM, V263, P14544; NOVIKOFF AB, 1980, J CELL BIOL, V87, P180, DOI 10.1083/jcb.87.1.180; NOY N, 1986, BIOCHEMISTRY-US, V25, P2013, DOI 10.1021/bi00356a027; NUNN WD, 1986, J BIOL CHEM, V261, P167; POTTER BJ, 1987, BIOCHEM BIOPH RES CO, V148, P1370, DOI 10.1016/S0006-291X(87)80283-8; REED BC, 1980, P NATL ACAD SCI-BIOL, V77, P285, DOI 10.1073/pnas.77.1.285; REICHEN J, 1981, BIOCHIM BIOPHYS ACTA, V640, P298, DOI 10.1016/0005-2736(81)90554-X; RESH MD, 1982, J BIOL CHEM, V257, P6978; Robinson D.S., 1970, COMPREHENSIVE BIOCH, P51; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; RUBIN CS, 1977, J BIOL CHEM, V252, P3554; SCHWIETERMAN W, 1988, P NATL ACAD SCI USA, V85, P359, DOI 10.1073/pnas.85.2.359; SINGER T P, 1957, Methods Biochem Anal, V4, P307, DOI 10.1002/9780470110201.ch9; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SORRENTINO D, 1989, HEPATOLOGY, V10, P620; SORRENTINO D, 1988, J CLIN INVEST, V82, P928, DOI 10.1172/JCI113700; SORRENTINO D, 1989, J CLIN INVEST, V84, P1325, DOI 10.1172/JCI114301; SPECTOR A A, 1978, P229; SPECTOR AA, 1971, BIOCHEMISTRY-US, V10, P3229; SPOONER PM, 1979, J BIOL CHEM, V254, P21; STOLL GH, 1991, J LIPID RES, V32, P843; STORCH J, 1991, J BIOL CHEM, V266, P13473; STORCH J, 1990, HEPATOLOGY, V12, P1447, DOI 10.1002/hep.1840120632; STORCH J, 1986, BIOCHEMISTRY-US, V25, P1717, DOI 10.1021/bi00355a041; STORCH J, 1989, J BIOL CHEM, V264, P10527; STREMMEL W, 1983, BIOCHEM BIOPH RES CO, V112, P88, DOI 10.1016/0006-291X(83)91801-6; STREMMEL W, 1985, P NATL ACAD SCI USA, V82, P4, DOI 10.1073/pnas.82.1.4; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3086, DOI 10.1073/pnas.83.10.3086; STREMMEL W, 1986, BIOCHIM BIOPHYS ACTA, V877, P191, DOI 10.1016/0005-2760(86)90134-7; STREMMEL W, 1988, J CLIN INVEST, V82, P2001, DOI 10.1172/JCI113820; STREMMEL W, 1988, J CLIN INVEST, V81, P844, DOI 10.1172/JCI113393; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3584, DOI 10.1073/pnas.83.11.3584; STREMMEL W, 1987, J BIOL CHEM, V262, P6284; STUMP D, 1992, IN PRESS J HEPATOL, V15; THOM D, 1977, BIOCHEM J, V168, P187, DOI 10.1042/bj1680187; TRIGATTI BL, 1991, J BIOL CHEM, V266, P22621; TURCOTTE LP, 1991, FEBS LETT, V279, P327, DOI 10.1016/0014-5793(91)80180-B; WAGGONER DW, 1990, J BIOL CHEM, V265, P11417; WEBER K, 1975, EXP CELL RES, V95, P111, DOI 10.1016/0014-4827(75)90615-1; WISE LS, 1978, CELL, V13, P233, DOI 10.1016/0092-8674(78)90192-7; WOSILAIT WD, 1976, COMPUT PROG BIOMED, V6, P142, DOI 10.1016/0010-468X(76)90020-9; ZHOU SL, 1991, HEPATOLOGY, V14, P321	64	90	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14456	14461						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629231				2022-12-25	WOS:A1992JD32500101
J	ISHIKAWA, Y; KATSUSHIKA, S; CHEN, L; HALNON, NJ; KAWABE, J; HOMCY, CJ				ISHIKAWA, Y; KATSUSHIKA, S; CHEN, L; HALNON, NJ; KAWABE, J; HOMCY, CJ			ISOLATION AND CHARACTERIZATION OF A NOVEL CARDIAC ADENYLYLCYCLASE CDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; GUANYLATE-CYCLASE; DNA-POLYMERASE; SEQUENCE; PROTEIN; GENE; IDENTIFICATION; HOMOLOGY; RECEPTOR; SURFACE	A novel adenylylcyclase cDNA (type V) was isolated from a canine heart cDNA library. Northern blotting indicates that the expression of this message is most abundant in heart with a lesser amount in brain but is absent in a variety of other tissues including lung, kidney, skeletal muscle, lymphocyte, and testis. The putative protein product predicted from the cDNA sequence has the motif of tandem six-transmembrane spans separated by a large hydrophilic cytoplasmic loop as seen in other members of the adenylylcyclase family. When this protein is expressed using a CMT cell transient expression system, the adenylylcyclase activity was stimulated by NaF, GTP-gamma-S, and forskolin, but not by calmodulin. The activity was inhibited in a concentration-dependent manner with either P-site active agents such as adenosine or in the presence of calcium. These data indicate that the protein encoded by this cDNA is adenylylcyclase with the biochemical features characteristic of the cardiac isoform.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; AMER CYANAMID CO,LEDERLE LABS,DIV MED RES,CARDIOVAS CENT NERVOUS SYST RES,PEARL RIVER,NY 10965	Columbia University	ISHIKAWA, Y (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT PHARMACOL,NEW YORK,NY 10032, USA.				NHLBI NIH HHS [HL-38070] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL038070] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BOCKAERT J, 1976, J BIOL CHEM, V251, P2653; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSHFIELD M, 1990, BIOCHEM SOC T, V18, P150, DOI 10.1042/bst0180150; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; FELDMAN MD, 1987, CIRCULATION, V75, P331, DOI 10.1161/01.CIR.75.2.331; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GERARD RD, 1985, MOL CELL BIOL, V5, P3231, DOI 10.1128/MCB.5.11.3231; GOLUB EI, 1989, NUCLEIC ACIDS RES, V17, P4902, DOI 10.1093/nar/17.12.4902; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HOMCY CJ, 1991, ANNU REV PHYSIOL, V53, P137, DOI 10.1146/annurev.physiol.53.1.137; INNIS MA, 1988, P NATL ACAD SCI USA, V85, P9436, DOI 10.1073/pnas.85.24.9436; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KHAMBATY FM, 1990, BIOTECHNIQUES, V9, P714; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LYNCH TJ, 1976, BIOCHEM BIOPH RES CO, V68, P616, DOI 10.1016/0006-291X(76)91190-6; Potter J D, 1980, Ann N Y Acad Sci, V356, P220, DOI 10.1111/j.1749-6632.1980.tb29613.x; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SINGH S, 1988, NATURE, V334, P708, DOI 10.1038/334708a0; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TANG WJ, 1991, J BIOL CHEM, V266, P8593; VATNER DE, 1984, J CLIN INVEST, V73, P1473, DOI 10.1172/JCI111351	27	207	219	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13553	13557						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618857				2022-12-25	WOS:A1992JB74600072
J	LILLO, C; RUOFF, P				LILLO, C; RUOFF, P			HYSTERETIC BEHAVIOR OF NITRATE REDUCTASE - EVIDENCE OF AN ALLOSTERIC BINDING-SITE FOR REDUCED PYRIDINE-NUCLEOTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEAVES; NADH; INHIBITION	In the absence of NADH, at 25-degrees-C, partially purified NADH:nitrate reductase undergoes an approximately 50% reduction of its initial activity during 2 h. With the increase of inactivation, the NADH and nitrite concentration time curves become typical "sigmoidal," i.e. the reaction velocity of the nitrate reductase catalyzed reaction goes through a maximum before equilibrium is reached. About 80% of the original activity of nitrate reductase is restored when the enzyme is incubated for 2 min with 200-mu-M NADH or NADPH. Also other NADH substrate analogues have similar effects in restoring the lost activity. After incubation with the reduced pyridine nucleotides, the sigmoidal appearance of the NADH concentration time curve disappears almost completely. Despite the fact that NADPH increases the activity of the enzyme, NADPH does not show any competition with the NADH-binding site of nitrate reductase and does not produce nitrite in the absence of NADH. It is therefore concluded that there must be an additional allosteric site which binds either NADH or NADPH, or other pyridine nucleotides with the effect of increasing the activity of the enzyme. A kinetic model is presented which simulates the observed experimental findings.			LILLO, C (corresponding author), ROGALAND UNIV CTR,BOX 2557,N-4004 STAVANGER,NORWAY.			Ruoff, Peter/0000-0003-4430-0382				BONZON M, 1983, PLANTA, V159, P254, DOI 10.1007/BF00397533; CABOCHE M, 1990, TRENDS GENET, V6, P187, DOI 10.1016/0168-9525(90)90175-6; FRIEDEN C, 1970, J BIOL CHEM, V245, P5788; Hindmarsh A. C., 1980, ACM SIGNUM NEWSLETTE, V15, P10, DOI DOI 10.1145/1218052.1218054; HOAGLAND DR, 1950, 347 CAL AGR EXP STN; KAISER WM, 1991, PLANT PHYSIOL, V96, P363, DOI 10.1104/pp.96.2.363; LILLO C, 1991, PLANT SCI, V73, P149, DOI 10.1016/0168-9452(91)90022-Z; LILLO C, 1983, PHYSIOL PLANTARUM, V57, P357, DOI 10.1111/j.1399-3054.1983.tb02300.x; LOPEZPOZOS R, 1990, J PLANT PHYSIOL, V136, P451, DOI 10.1016/S0176-1617(11)80034-9; Neet K E, 1980, Methods Enzymol, V64, P192; NOTTON BA, 1985, PLANTA, V165, P114, DOI 10.1007/BF00392219; RAO IM, 1990, PHOTOSYNTH RES, V23, P205, DOI 10.1007/BF00035011; RAYMOND P, 1987, BIOCH PLANTS COMPREH, V11, P129; REDINBAUGH MG, 1981, PLANT PHYSIOL, V68, P115, DOI 10.1104/pp.68.1.115; RUOFF P, 1990, BIOCHEM INT, V21, P349; RUOFF P, 1990, BIOCHEM BIOPH RES CO, V172, P1000, DOI 10.1016/0006-291X(90)91545-4; Segel I.H., 1975, ENZYME KINETICS, P353; SOLOMONSON LP, 1990, ANNU REV PLANT PHYS, V41, P225, DOI 10.1146/annurev.pp.41.060190.001301; TURPIN DH, 1990, PLANT PHYSL BIOCH MO, P422	19	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13456	13459						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618848				2022-12-25	WOS:A1992JB74600058
J	SUNG, M; DALBEY, RE				SUNG, M; DALBEY, RE			IDENTIFICATION OF POTENTIAL ACTIVE-SITE RESIDUES IN THE ESCHERICHIA-COLI LEADER PEPTIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL PEPTIDASE; SALMONELLA-TYPHIMURIUM; CYTOPLASMIC MEMBRANE; CLEAVAGE SITE; COAT PROTEIN; SEQUENCE; GENE; MUTATIONS; DOMAIN; SEC11	Leader peptidase of Escherichia coli cleaves the leader sequence from the amino terminus of membrane and secreted proteins after these proteins insert across the membrane. Despite considerable research, the mechanism of catalysis of leader peptidase remains unknown. This peptidase cannot be classified using protease inhibitors to the serine, cysteine, aspartic acid, or metallo- classes of proteases (Zwizinski, C., Date, T., and Wickner, W. (1981) J. Biol. Chem. 256, 3593-3597). Using site-directed mutagenesis, we have attempted to place leader peptidase in one of these groups. We found that leader peptidase, lacking all of the cysteine residues, can cleave the leader peptide from procoat, the precursor to bacteriophage M13 coat protein. Replacement of each histidine residue with an alanyl residue was without effect on catalysis. Among all the serine and aspartic acid residues, serine 90 and serine 185 as well as aspartic acid 99, 153, 273, and 276 are necessary to cleave procoat in a detergent extract. However, only serine 90 and aspartic acid 153 were required for processing using a highly sensitive in vivo assay. In addition to the residues directly affecting catalysis, aspartic acid 99 plays a role in maintaining the structure of leader peptidase. Replacement of this residue with alanine results in a very unstable leader peptidase protein. This study thus defines two critical residues, serine 90 and aspartic acid 153, that may be directly involved in catalysis and provides evidence that leader peptidase belongs to a novel class of serine proteases.	OHIO STATE UNIV,DEPT CHEM,COLUMBUS,OH 43210	University System of Ohio; Ohio State University								BEHRENS M, 1991, MOL GEN GENET, V228, P167, DOI 10.1007/BF00282462; BILGIN N, 1990, EMBO J, V9, P2717, DOI 10.1002/j.1460-2075.1990.tb07458.x; BLACK MT, 1992, BIOCHEM J, V282, P539, DOI 10.1042/bj2820539; BOEKE JD, 1980, J MOL BIOL, V144, P103, DOI 10.1016/0022-2836(80)90027-3; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; DALBEY RE, 1985, J BIOL CHEM, V260, P5925; DALBEY RE, 1987, SCIENCE, V235, P783, DOI 10.1126/science.3544218; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; Dunn BM., 1989, PROTEOLYTIC ENZYMES, P57; FIKES JD, 1990, J BIOL CHEM, V265, P3417; GREENBURG G, 1989, J BIOL CHEM, V264, P15762; INADA T, 1989, J BACTERIOL, V171, P585, DOI 10.1128/jb.171.1.585-587.1989; INNIS MA, 1984, P NATL ACAD SCI-BIOL, V81, P3708, DOI 10.1073/pnas.81.12.3708; ITO K, 1980, J BIOL CHEM, V255, P2123; JOHNSTON S, 1985, GENE, V34, P137, DOI 10.1016/0378-1119(85)90121-0; KOSHLAND D, 1982, CELL, V30, P903, DOI 10.1016/0092-8674(82)90295-1; KUHN A, 1985, J BIOL CHEM, V260, P5914; Maniatis T., 1982, MOL CLONING; MOORE KE, 1987, J BIOL CHEM, V262, P8806; NEURATH H, 1989, PROTEOLYTIC ENZYMES, P1; SHEN LM, 1991, BIOCHEMISTRY-US, V30, P11775, DOI 10.1021/bi00115a006; VANDIJL JM, 1990, MOL GEN GENET, V223, P233, DOI 10.1007/BF00265059; WATTS C, 1983, P NATL ACAD SCI-BIOL, V80, P2809, DOI 10.1073/pnas.80.10.2809; WOLFE PB, 1983, J BIOL CHEM, V258, P2073; WOLFE PB, 1982, J BIOL CHEM, V257, P7898; YAMANE K, 1987, J BIOL CHEM, V262, P2358; ZALKIN H, 1974, J BIOL CHEM, V249, P465; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468; ZWIZINSKI C, 1981, J BIOL CHEM, V256, P3593	30	87	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13154	13159						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618816				2022-12-25	WOS:A1992JB74600011
J	ZAKIM, D; EIBL, H				ZAKIM, D; EIBL, H			THE INFLUENCE OF CHARGE AND THE DISTRIBUTION OF CHARGE IN THE POLAR-REGION OF PHOSPHOLIPIDS ON THE ACTIVITY OF UDP-GLUCURONOSYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCURONYLTRANSFERASE; DEHYDROGENASE; ACTIVATION; PROTEINS; BILAYERS	Studies of the mechanism of lipid-induced regulation of the microsomal enzyme UDP-glucuronosyltransferase have been extended by examining the influence of charge within the polar region on the ability of lipids to activate delipidated pure enzyme. The effects of net negative charge, of charge separation in phosphocholine, and of the distribution of charge in the polar region of lipids were studied using the GT2p isoform isolated from pig liver. Prior experiments have shown that lipids with net negative charge inhibit the enzyme (Zakim, D., Cantor, M., and Eibl, H. (1988) J. Biol. Chem. 263, 5164-5169). The current experiments show that the extent of inhibition on a molar basis increases as the net negative charge increases from -1 to -2. The inhibitory effect of negatively charged lipids is on the functional state of the enzyme and is not due to electrostatic repulsion of negatively charged substrates of the enzyme. Although the inhibitory effect of net negative charge is removed when negative charge is balanced by a positive charge due to a quaternary nitrogen, neutrality of the polar region is not a sufficient condition for activation of the enzyme. In addition to a balance of charge between P(i) and the quaternary nitrogen, the distance between the negative and positive charges and the orientation of the dipole created by them are critical for activation of GT2p. The negative and positive charges must be separated by the equivalent of three -CH2- groups for optimal activation by a lipid. Shortening this distance by one -CH2- unit leads to a lipid that is ineffective in activating the enzyme. Reversal of the orientation of the dipole in which the negative charge is on the polymethylene side of the lipid-water interface and the positive charge extends into water also produces a lipid that is not effective for activating GT2p. On the other hand, lipids with phosphoserine as the polar region, which has the "normal" P-N distance but carries a net negative charge, do not inhibit GT2p. This result again illustrates the importance of the dipole of phosphocholine for modulating the functional state of GT2p.	MAX PLANCK INST BIOPHYS CHEM,W-3400 GOTTINGEN,GERMANY	Max Planck Society	ZAKIM, D (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DIV DIGEST DIS,NEW YORK,NY 10021, USA.							CHURCHILL P, 1983, J BIOL CHEM, V258, P208; CLARK PE, 1986, BIOCHIM BIOPHYS ACTA, V859, P143, DOI 10.1016/0005-2736(86)90209-9; DANNENBERG A, 1990, ANAL BIOCHEM, V191, P183, DOI 10.1016/0003-2697(90)90406-Y; EIBL H, 1978, P NATL ACAD SCI USA, V75, P4074, DOI 10.1073/pnas.75.9.4074; EIBL H, 1981, METHOD ENZYMOL, V72, P631; HOCHMAN J, 1981, J BIOL CHEM, V258, P4783; HOCHMAN Y, 1983, J BIOL CHEM, V258, P4143; HOCHMAN Y, 1983, J BIOL CHEM, V258, P6509; Jain M. K., 1988, INTRO BIOL MEMBRANES; JAIN MK, 1989, BIOCHIM BIOPHYS ACTA, V1002, P127, DOI 10.1016/0005-2760(89)90281-6; JAIN MK, 1987, BIOCHIM BIOPHYS ACTA, V906, P33, DOI 10.1016/0304-4157(87)90004-9; KASSAHARA MC, 1977, J BIOL CHEM, V252, P7384; KOVATCHEV S, 1981, J BIOL CHEM, V256, P369; MAGDALOU J, 1982, J BIOL CHEM, V257, P13624; MANN KG, 1987, TRENDS BIOCHEM SCI, V12, P229, DOI 10.1016/0968-0004(87)90115-0; RIES U, 1992, IN PRESS BIOCH BIOPH; ROTENBERG M, 1989, BIOCHEMISTRY-US, V28, P8577, DOI 10.1021/bi00447a046; ROTENBERG M, 1991, J BIOL CHEM, V266, P4159; SCOTTO AW, 1985, BIOCHEMISTRY-US, V24, P4066, DOI 10.1021/bi00336a040; VESSEY DA, 1972, J BIOL CHEM, V247, P3023; WANG S, 1988, BIOCHEMISTRY-US, V27, P2033, DOI 10.1021/bi00406a033; ZAKIM D, 1988, J BIOL CHEM, V263, P5164	22	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13166	13170						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618818				2022-12-25	WOS:A1992JB74600013
J	LOPEZ, JA; LEUNG, B; REYNOLDS, CC; LI, CQ; FOX, JEB				LOPEZ, JA; LEUNG, B; REYNOLDS, CC; LI, CQ; FOX, JEB			EFFICIENT PLASMA-MEMBRANE EXPRESSION OF A FUNCTIONAL PLATELET GLYCOPROTEIN-IB-IX COMPLEX REQUIRES THE PRESENCE OF ITS 3 SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BERNARD-SOULIER SYNDROME; CELL ANTIGEN RECEPTOR; AMINO-ACID-SEQUENCE; VONWILLEBRAND-FACTOR; GPIIB-IIIA; SURFACE; PROTEINS; ADHESION; MEGAKARYOCYTES; IDENTIFICATION	The glycoprotein (GP) Ib-IX complex of the platelet plasma membrane mediates the adhesion of platelets to damaged blood vessel wall. The complex is composed of three membrane-spanning polypeptides, GP Ib(alpha), GP Ib(beta), and GP IX, all of which are absent from the platelets of patients with the hereditary bleeding disorder Bernard-Soulier syndrome. In this study we report stable expression of the recombinant receptor in three cell lines and demonstrate that the three subunits of the complex are necessary for its efficient expression on the plasma membrane. The expressed complex associates with the cytoskeleton of the transfected cells through an interaction with actin-binding protein and binds its ligand, von Willebrand factor. These data suggest that the lack of plasma membrane GP Ib-IX complex in the Bernard-Soulier syndrome could potentially arise from mutations affecting any one of its three subunits.	UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,DIV HEMATOL,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; University of California System; University of California San Francisco	LOPEZ, JA (corresponding author), UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,GLADSTONE INST CARDIOVASC DIS,POB 419100,SAN FRANCISCO,CA 94141, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002463, R37HL030657, R23HL030657, R01HL030657] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02463, HL30657] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andrews RK, 1990, CURR OPIN CELL BIOL, V2, P894, DOI 10.1016/0955-0674(90)90089-W; ANDREWS RK, 1991, J BIOL CHEM, V266, P7144; BERKNER K, 1986, COLD SPRING HARB SYM, V51, P531, DOI 10.1101/SQB.1986.051.01.065; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; BERNDT MC, 1983, BLOOD, V62, P800; BERNDT MC, 1988, BIOCHEMISTRY-US, V27, P633, DOI 10.1021/bi00402a021; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CLEMETSON KJ, 1982, J CLIN INVEST, V70, P304, DOI 10.1172/JCI110618; COLLER BS, 1987, HEMOSTASIS THROMBOSI, P60; DROUIN J, 1988, BLOOD, V72, P1086; DU XP, 1987, BLOOD, V69, P1524; DUPERRAY A, 1989, BLOOD, V74, P1603; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; FOX JEB, 1985, J BIOL CHEM, V260, P1970; FOX JEB, 1987, THROMB DIATH HAEMO, P175; GEORGE JN, 1984, NEW ENGL J MED, V311, P1084, DOI 10.1056/NEJM198410253111705; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANDIN RI, 1989, BLOOD S1, V74, pA129; HICKEY MJ, 1989, P NATL ACAD SCI USA, V86, P6773, DOI 10.1073/pnas.86.17.6773; HOURDILLE P, 1990, BRIT J HAEMATOL, V76, P521, DOI 10.1111/j.1365-2141.1990.tb07910.x; HOWARD MA, 1971, THROMB DIATH HAEMOST, V26, P362; KIEFFER N, 1990, ANNU REV CELL BIOL, V6, P329; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; MCMICHAEL AJ, 1981, BRIT J HAEMATOL, V49, P501, DOI 10.1111/j.1365-2141.1981.tb07258.x; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; MOROI M, 1984, BLOOD, V64, P622; NURDEN AT, 1975, NATURE, V255, P720, DOI 10.1038/255720a0; OTOOLE TE, 1989, BLOOD, V74, P14; ROSA JP, 1989, J BIOL CHEM, V264, P12596; ROTH GJ, 1990, BIOCHEM BIOPH RES CO, V170, P153, DOI 10.1016/0006-291X(90)91253-O; SAKARIASSEN KS, 1979, NATURE, V279, P636, DOI 10.1038/279636a0; SANCHO J, 1989, J BIOL CHEM, V264, P20760; SHIMOMURA T, 1990, BLOOD, V75, P2349; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TOBELEM G, 1976, NATURE, V263, P427, DOI 10.1038/263427a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEISS HJ, 1978, J LAB CLIN MED, V92, P750; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973	40	183	185	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12851	12859						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618785				2022-12-25	WOS:A1992HZ48300071
J	NOVAK, A; GOYAL, N; GRONOSTAJSKI, RM				NOVAK, A; GOYAL, N; GRONOSTAJSKI, RM			4 CONSERVED CYSTEINE RESIDUES ARE REQUIRED FOR THE DNA-BINDING ACTIVITY OF NUCLEAR FACTOR-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-ANALYSIS; RECOGNITION SITE; REPLICATION; PROTEIN; TRANSCRIPTION; INVITRO; PURIFICATION; POLYMERASE; CLONING; INVIVO	The role of Cys residues in the site-specific DNA binding activity of the nuclear factor I (NFI) family of proteins was assessed by chemical modification and site-specific mutagenesis. Treatment with the thiol-specific reagent N-ethylmaleimide abolished site-specific DNA binding of all forms of NFI present in HeLa nuclear extracts. Preincubation of cell extracts with an oligonucleotide containing an NFI-binding site provided partial protection of NFI from N-ethylmaleimide inactivation. Mutations were made in the cDNA encoding a truncated form of the NFI-C/CAAT box transcription factor-1 protein, converting each of the five Cys residues in the DNA-binding domain of the protein into Ser residues. NFI-C proteins containing mutations in any of four conserved Cys residues, expressed in Escherichia coli or in vitro, did not bind to DNA. NFI-C with a mutation in a nonconserved Cys residue had normal DNA binding activity. Both this active mutant and wild-type NFI-C protein were inactivated by modification of their sulfhydryl residues with 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB), and preincubation with an oligonucleotide containing an NFI-binding site gave partial protection against inactivation. After modification with DTNB, DNA binding activity was partially restored by subsequent incubation with dithiothreitol, indicating that inactivation of NFI by DTNB was reversible. These studies indicate an essential role for free sulfhydryl residues in NFI-DNA binding.	ONTARIO CANC INST,DIV MOLEC & STRUCT BIOL,TORONTO M4X 1K9,ONTARIO,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M4X 1K9,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto				Gronostajski, Richard/0000-0003-4264-208X				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABRAHAM LJ, 1990, MOL CELL BIOL, V10, P3483, DOI 10.1128/MCB.10.7.3483; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVRIES E, 1987, EMBO J, V6, P161, DOI 10.1002/j.1460-2075.1987.tb04734.x; GOUNARI F, 1990, EMBO J, V9, P559, DOI 10.1002/j.1460-2075.1990.tb08143.x; GOYAL N, 1990, MOL CELL BIOL, V10, P1041, DOI 10.1128/MCB.10.3.1041; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P964, DOI 10.1128/MCB.5.5.964; GRONOSTAJSKI RM, 1987, NUCLEIC ACIDS RES, V15, P5545, DOI 10.1093/nar/15.14.5545; GRONOSTAJSKI RM, 1986, NUCLEIC ACIDS RES, V14, P9117, DOI 10.1093/nar/14.22.9117; GRONOSTAJSKI RM, 1988, NUCLEIC ACIDS RES, V16, P2087, DOI 10.1093/nar/16.5.2087; HAY RT, 1985, EMBO J, V4, P421, DOI 10.1002/j.1460-2075.1985.tb03645.x; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KRUSE U, 1991, NUCLEIC ACIDS RES, V19, P6641, DOI 10.1093/nar/19.23.6641; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEEGWATER PAJ, 1985, EMBO J, V4, P1515, DOI 10.1002/j.1460-2075.1985.tb03811.x; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MEISTERERNST M, 1989, BIOCHEMISTRY-US, V28, P8191, DOI 10.1021/bi00446a034; MEISTERERNST M, 1988, NUCLEIC ACIDS RES, V16, P4419, DOI 10.1093/nar/16.10.4419; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; ROSENFELD PJ, 1987, MOL CELL BIOL, V7, P875, DOI 10.1128/MCB.7.2.875; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; Sambrook J, 1989, MOL CLONING LABORATO; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; WANG K, 1985, NUCLEIC ACIDS RES, V13, P5173, DOI 10.1093/nar/13.14.5173	33	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12986	12990						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618796				2022-12-25	WOS:A1992HZ48300088
J	ZANTEMA, A; VERLAANDEVRIES, M; MAASDAM, D; BOL, S; VANDEREB, A				ZANTEMA, A; VERLAANDEVRIES, M; MAASDAM, D; BOL, S; VANDEREB, A			HEAT-SHOCK PROTEIN-27 AND ALPHA-B-CRYSTALLIN CAN FORM A COMPLEX, WHICH DISSOCIATES BY HEAT-SHOCK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN STRESS PROTEINS; GEL-ELECTROPHORESIS; TRANSFORMED-CELLS; MOLECULAR-WEIGHT; LENS CRYSTALLINS; RAT LENS; EXPRESSION; PHOSPHORYLATION; LOCALIZATION; TISSUES	We have previously demonstrated that in non-oncogeric adenovirus-transformed baby rat kidney cells a complex of hsp27 and a 22-kDa protein is present, which is lacking in oncogenic cells (Zantema, A., de Jong, E., Lardenoije, R., and van der Eb, A. J. (1989) J. Virol. 63, 3368-3375). Here we show that the 22-kDa protein is identical to alpha-B-crystallin. The complex of hsp27 and alpha-B-crystallin is also found in some other (non-transformed) cells. However, in most cells tested only hsp27 and no alpha-B-crystallin is synthesized. Gel filtration studies show that both proteins are present almost exclusively in a 700-kDa complex. Heat treatment makes the complex fall apart, which is accompanied by a change in the conformation of alpha-B-crystallin. Upon recovery, complexes are formed again from both pre-existing and newly synthesized proteins.			ZANTEMA, A (corresponding author), SYLVIUS LAB,MOLEC CARCINOGENESIS LAB,WASSENAARSEWEG 72,2333 AL LEIDEN,NETHERLANDS.							ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; CHIESA R, 1990, FEBS LETT, V268, P222, DOI 10.1016/0014-5793(90)81013-E; CHIESI M, 1990, MOL CELL BIOCHEM, V97, P129; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLLIER NC, 1986, EXP EYE RES, V43, P103, DOI 10.1016/S0014-4835(86)80049-5; DEJONG WW, 1988, J BIOL CHEM, V263, P5141; DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; DEJONG WW, 1986, J CELL BIOL, V102, P104, DOI 10.1083/jcb.102.1.104; DELARCO JE, 1978, J CELL PHYSIOL, V94, P335, DOI 10.1002/jcp.1040940311; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; DUGUID JR, 1988, P NATL ACAD SCI USA, V85, P5738, DOI 10.1073/pnas.85.15.5738; GAESTEL M, 1989, EUR J BIOCHEM, V179, P209, DOI 10.1111/j.1432-1033.1989.tb14542.x; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI A, 1990, J BIOL CHEM, V265, P22197; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; KIM YJ, 1984, MOL CELL BIOL, V4, P468, DOI 10.1128/MCB.4.3.468; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; KLEMENZ R, 1991, MOL CELL BIOL, V11, P803, DOI 10.1128/MCB.11.2.803; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LONGONI S, 1990, MOL CELL BIOCHEM, V97, P121, DOI 10.1007/BF00221053; LOWE J, 1990, LANCET, V336, P515, DOI 10.1016/0140-6736(90)92075-S; NAGINENI CN, 1989, FEBS LETT, V249, P89, DOI 10.1016/0014-5793(89)80022-5; TOMOKANE N, 1991, AM J PATHOL, V138, P875; UCHIUMI T, 1983, EXP EYE RES, V36, P125, DOI 10.1016/0014-4835(83)90095-7; VANDENOETELAAR PJM, 1985, J BIOL CHEM, V260, P4030; VOORTER CEM, 1986, EUR J BIOCHEM, V160, P203; WEITZEL G, 1987, EXP CELL RES, V170, P64, DOI 10.1016/0014-4827(87)90117-0; WELCH WJ, 1985, J BIOL CHEM, V260, P3058; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; ZANTEMA A, 1989, J VIROL, V63, P3368, DOI 10.1128/JVI.63.8.3368-3375.1989	35	138	139	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12936	12941						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618790				2022-12-25	WOS:A1992HZ48300081
J	BLEE, E; SCHUBER, F				BLEE, E; SCHUBER, F			REGIOSELECTIVITY AND ENANTIOSELECTIVITY OF SOYBEAN FATTY-ACID EPOXIDE HYDROLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPEROXIDE-DEPENDENT OXYGENASE; RICE BLAST DISEASE; PLANT; HYDROLYSIS; MECHANISMS; HYDRATION	Soluble epoxide hydrolase purified from soybean catalyzes trans-addition of water across the oxirane ring of cis-9,10-epoxystearic acid with inversion of configuration at the attacked carbon, yielding threo-9,10-dihydroxystearic acid. Kinetic analyses of the progress curves, obtained at low substrate concentrations (i.e. [S] << K(m)), and determination of the enantiomeric excess of the residual substrate by chiral-phase high-performance liquid chromatography at different reaction times, indicate that the epoxide hydrolase hydrates preferentially cis-9R,10S-epoxystearic acid (V/K(m) ratio, approximately 20). Interestingly, this enantiomer is obtained by epoxidation of oleic acid catalyzed by peroxygenase, a hydroperoxide-dependent oxidase, we have previously described in soybean (Blee, E., and Schuber, F. (1990) J. Biol. Chem. 265, 12887-12894). For the epoxide hydrolase to show high enantioselectivity there must be a free carboxylic acid functionality on the substrate which probably influences its positioning within the active site. This selectivity, which in principle can be used for kinetic resolution of the cis-9,10-epoxystearic acid enantiomers, is much reduced with methyl cis-9,10-epoxystearate. O-18-Labeling experiments indicate that water attacks both cis-9,10-epoxystearic acid enantiomers on the oxirane carbon which has the S-chirality. Results show that soybean epoxide hydrolase produces exclusively threo-9R,10R-dihydroxystearic acid, i.e. a naturally occurring metabolite in higher plants. cis-9,10-Epoxy-18-hydroxystearic acid, a cutin monomer, was a poorer substrate of the epoxide hydrolase than 9,10-epoxystearic acid (V/K(m) ratio for the preferred enantiomers, approximately 19). From a physiological point of view, peroxygenase and this newly described epoxide hydrolase could be responsible, in vivo, for the biosynthesis of a class of oxygenated fatty acid compounds known to be involved in cutin monomers production and in plant defense mechanisms.	FAC PHARM ILLKIRCH,CHIM BIOORGAN LAB,CNRS,URA 1386,F-67400 ILLKIRCH GRAFFENS,FRANCE	Centre National de la Recherche Scientifique (CNRS)	BLEE, E (corresponding author), INST BOT,DECM,INST BIOL MOLEC PLANTES,CNRS,UPR 406,28 RUE GOETHE,F-67000 STRASBOURG,FRANCE.							AMSTRONG RN, 1987, CRC CRIT REV BIOCH, V22, P39; BELLUCCI G, 1989, J ORG CHEM, V54, P5978, DOI 10.1021/jo00286a034; BELLUCCI G, 1991, J CHEM SOC PERK T 1, P361, DOI 10.1039/p19910000361; BLEE E, 1990, J BIOL CHEM, V265, P12887; BLEE E, 1989, BIOCHEMISTRY-US, V28, P4962, DOI 10.1021/bi00438a009; BLEE E, 1992, BIOCHEM J, V282, P711, DOI 10.1042/bj2820711; BLEE E, 1990, BIOCHEM BIOPH RES CO, V173, P1354, DOI 10.1016/S0006-291X(05)80937-4; CHEN CS, 1982, J AM CHEM SOC, V104, P7294, DOI 10.1021/ja00389a064; CROTEAU R, 1975, ARCH BIOCHEM BIOPHYS, V170, P73, DOI 10.1016/0003-9861(75)90098-3; FARMER EE, 1990, P NATL ACAD SCI USA, V87, P7713, DOI 10.1073/pnas.87.19.7713; Fersht AR., 1977, ENZYME STRUCTURE MEC; FITZPATRICK PA, 1991, J AM CHEM SOC, V113, P3166, DOI 10.1021/ja00008a054; FRANCESCHI VR, 1991, P NATL ACAD SCI USA, V88, P6745, DOI 10.1073/pnas.88.15.6745; GARDNER HW, 1991, BIOCHIM BIOPHYS ACTA, V1084, P221, DOI 10.1016/0005-2760(91)90063-N; GILL SS, 1979, BIOCHEM BIOPH RES CO, V89, P965, DOI 10.1016/0006-291X(79)91872-2; HAMBERG M, 1990, ARCH BIOCHEM BIOPHYS, V283, P409, DOI 10.1016/0003-9861(90)90662-I; HANZLIK RP, 1976, J AM CHEM SOC, V98, P1952, DOI 10.1021/ja00423a050; HOLLOWAY PJ, 1973, PHYTOCHEMISTRY, V12, P1721, DOI 10.1016/0031-9422(73)80393-0; KATO T, 1983, NATURWISSENSCHAFTEN, V70, P200, DOI 10.1007/BF01047565; KATO T, 1983, TETRAHEDRON LETT, V24, P4715, DOI 10.1016/S0040-4039(00)86236-X; KOLATTUKUDY PE, 1981, ANNU REV PLANT PHYS, V32, P539, DOI 10.1146/annurev.pp.32.060181.002543; MEDINA JF, 1991, P NATL ACAD SCI USA, V88, P7620, DOI 10.1073/pnas.88.17.7620; MORRIS LJ, 1966, LIPIDS, V1, P41, DOI 10.1007/BF02668123; MORRIS LJ, 1970, BIOCHEM J, V118, P681, DOI 10.1042/bj1180681g; MORRIS LJ, 1972, LIPIDS, V7, P372, DOI 10.1007/BF02531506; Orsi B A, 1979, Methods Enzymol, V63, P159; POWELL PG, 1967, LIPIDS, V2, P172; SAYER JM, 1985, J BIOL CHEM, V260, P1630; STASWICK PE, 1991, PLANT PHYSIOL, V96, P130, DOI 10.1104/pp.96.1.130; WATABE T, 1972, BIOCHIM BIOPHYS ACTA, V279, P297, DOI 10.1016/0304-4165(72)90146-8; WITSUBA D, 1986, ANGEW CHEM INT EDIT, V25, P1032	31	53	55	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11881	11887						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601858				2022-12-25	WOS:A1992HY94700038
J	GIBSON, QH; BELLELLI, A; REGAN, R; SHARMA, PK; VINOGRADOV, SN				GIBSON, QH; BELLELLI, A; REGAN, R; SHARMA, PK; VINOGRADOV, SN			LIGAND-BINDING BY THE CHLOROCRUORIN FROM EUDISTYLIA-VANCOUVERII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; HEMOGLOBIN; PROTOHEME	Carbon monoxide chlorocruorin from Eudistylia vancouverii shows three distinct first-order relaxations with rates of 2.9 x 10(9) s-1, 6.5 x 10(7) s-1, and 3.2 x 10(6) s-1 (geminate reactions) and three second-order relaxations with rates of 4.7 x 10(6) M-1 s-1, 7 x 10(5) M-1 s-1, and 7 x 10(4) M-1 s-1, when studied by flash photolysis. The amplitudes of the second-order reactions depend on the extent of photolysis. This may be due to relaxation from the liganded (R) to the unliganded (T) conformation following photolysis and suggests that the combination rates contribute to cooperativity. In a stopped-flow experiment only the slowest phase with a rate of 7 x 10(4) M-1 s-1 is observed. It is assigned to binding to the T-state protein. Fragments of the native protein containing 12 and 4 hemes react like the holoprotein suggesting that the tetramer is a major cooperative unit. Oxygen binding shows three geminate relaxations with rates of 2.5 x 10(10) s-1, 3.5 x 10(7) s-1, and 4.5 x 10(6) s-1, and two second-order rates of 1.5 x 10(7) M-1 s-1 and 1 x 10(1) M-1 s-1. The amplitudes of the second-order phases do not correlate with the extent of photolysis. The results with the two ligands are consistent with an allosteric transition fast enough to compete with a rebinding rate of 500 s-1 in the R to T direction (CO rebinding) but not fast enough to compete with oxygen rebinding. There is significant heterogeneity in the R-state kinetics, but the T-state reaction is homogeneous.	UNIV LA SAPIENZA, CTR BIOL MOLEC, CNR, DIPARTIMENTO SCI BIOCHIM, I-00185 ROME, ITALY; WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM, DETROIT, MI 48201 USA	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Wayne State University	GIBSON, QH (corresponding author), CORNELL UNIV, DEPT BIOCHEM & MOLEC & CELLULAR BIOL, ITHACA, NY 14853 USA.		Bellelli, Andrea/D-2785-2009		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038674] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM014276] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 38674] Funding Source: Medline; NIGMS NIH HHS [GM 14276] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONINI E, 1962, ARCH BIOCHEM BIOPHYS, V97, P336, DOI 10.1016/0003-9861(62)90086-3; BLACKMORE RS, 1991, J BIOL CHEM, V266, P19245; BRUNORI M, 1965, ESTR PUBBLIC STAZ ZO, V34, P521; CARVER TE, 1990, J BIOL CHEM, V265, P20007; CHUNG MCM, 1979, PROG BIOPHYS MOL BIO, V35, P53; COLOSIMO A, 1974, BIOPHYS CHEM, V2, P338, DOI 10.1016/0301-4622(74)80060-8; FOX HM, 1949, PROC R SOC SER B-BIO, V136, P378, DOI 10.1098/rspb.1949.0031; GIBSON QH, 1986, J BIOL CHEM, V261, P228; GIBSON QH, 1964, BIOCHEM J, V91, P161, DOI 10.1042/bj0910161; GIBSON QH, 1991, J BIOL CHEM, V266, P13097; GIBSON QH, 1989, J BIOL CHEM, V264, P20155; GUERRITORE D, 1965, J MOL BIOL, V13, P234, DOI 10.1016/S0022-2836(65)80092-4; IMAI K, 1985, EUR J BIOCHEM, V147, P453; IPPOLITI R, 1991, STRUCTURE AND FUNCTION OF INVERTEBRATE OXYGEN CARRIERS, P133; KAPP OH, 1990, J MOL BIOL, V213, P141, DOI 10.1016/S0022-2836(05)80127-5; LEMBERG R, 1951, BIOCHEM J, V49, P674, DOI 10.1042/bj0490674; MARDEN MC, 1986, BIOCHEMISTRY-US, V25, P2786, DOI 10.1021/bi00358a008; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; QABAR AN, 1991, J MOL BIOL, V222, P1109, DOI 10.1016/0022-2836(91)90596-X; SAWICKI CA, 1979, J BIOL CHEM, V254, P4058; VINOGRADOV SN, 1991, J BIOL CHEM, V266, P13091; VINOGRADOV SN, 1985, BIOCHIM BIOPHYS ACTA, V828, P43, DOI 10.1016/0167-4838(85)90007-X	22	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11977	11981						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601868				2022-12-25	WOS:A1992HY94700051
J	BAKER, BF; MIRAGLIA, L; HAGEDORN, CH				BAKER, BF; MIRAGLIA, L; HAGEDORN, CH			MODULATION OF EUKARYOTIC INITIATION FACTOR-4E BINDING TO 5'-CAPPED OLIGORIBONUCLEOTIDES BY MODIFIED ANTISENSE OLIGONUCLEOTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC MESSENGER-RNAS; CAP ANALOGS; PROTEIN; PHOSPHORYLATION; RECOGNITION; TRANSLATION; INVITRO	The 5' cap structure of eucaryotic mRNA plays a pivotal role in mRNA metabolism. This report demonstrates that anti-sense oligonucleotides equipped with 3'-overhanging nucleotides modulate the amount of recombinant human eucaryotic initiation factor-4E that binds to a 5'-capped oligoribonucleotide. The degree of inhibition or enhancement of protein binding is dependent upon the number and sequence of overhanging nucleotides. A 45% inhibition of complexation was observed by the addition of one 3'-overhanging guanosine residue. Addition of a second residue (+2/GN) resulted in a higher degree of inhibition, 77-88%. In contrast, addition of one adenosine residue enhanced the formation of the eucaryotic initiation factor-4E-m7GpppRNA complex by 213%. Modulation of protein interactions with the 5'-cap structure is likely to effect several biological events, including pre-mRNA processing, transport of the mRNA from the nucleus to the cytoplasm and translation of the target mRNA. This targeting strategy in anti-sense chemistry may have practical applications in experimental biology and medicine.	VANDERBILT UNIV, MED CTR, SCH MED, DEPT MED, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT CELL BIOL, NASHVILLE, TN 37232 USA; VET ADM MED CTR, NASHVILLE, TN 37203 USA	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	BAKER, BF (corresponding author), ISIS PHARMACEUT, DEPT MOLEC & CELLULAR BIOL, CARLSBAD, CA 92008 USA.			Baker, Brenda/0000-0001-8586-768X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040219] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40219] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS BL, 1978, J BIOL CHEM, V253, P2589; BANJEREE AK, 1980, MICROBIOL REV, V44, P175; BU X, 1991, FEBS LETT, V283, P219, DOI 10.1016/0014-5793(91)80592-Q; CARBERRY SE, 1989, BIOCHEMISTRY-US, V28, P8078, DOI 10.1021/bi00446a017; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; DARZYNKIEWICZ E, 1987, BIOCHEMISTRY-US, V26, P4372, DOI 10.1021/bi00388a028; DARZYNKIEWICZ E, 1985, BIOCHEMISTRY-US, V24, P1701, DOI 10.1021/bi00328a020; DEGITZ K, 1991, J BIOL CHEM, V266, P14024; DONALDSON RW, 1991, J BIOL CHEM, V266, P3162; DUNCAN R, 1987, J BIOL CHEM, V262, P380; EDERY I, 1985, P NATL ACAD SCI USA, V82, P7590, DOI 10.1073/pnas.82.22.7590; FURUICHI Y, 1977, NATURE, V266, P235, DOI 10.1038/266235a0; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; HAAS DW, 1991, ARCH BIOCHEM BIOPHYS, V284, P84, DOI 10.1016/0003-9861(91)90267-M; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HICKEY ED, 1977, J MOL BIOL, V109, P173, DOI 10.1016/S0022-2836(77)80027-2; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; KIM CH, 1977, NATURE, V270, P223, DOI 10.1038/270223a0; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAWSON TG, 1986, J BIOL CHEM, V261, P13979; MCMULLIN EL, 1988, BIOCHEM BIOPH RES CO, V153, P340, DOI 10.1016/S0006-291X(88)81228-2; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; MURTHY KGK, 1991, NUCLEIC ACIDS RES, V19, P2685, DOI 10.1093/nar/19.10.2685; NISHIMURA Y, 1980, NUCLEIC ACIDS RES, V8, P1107, DOI 10.1093/nar/8.5.1107; PUGLISI JD, 1988, NATURE, V331, P283, DOI 10.1038/331283a0; RAY BK, 1985, J BIOL CHEM, V260, P7651; REVZIN A, 1989, BIOTECHNIQUES, V7, P346; Rhoads R. E, 1985, PROGR MOL SUBCELLULA, V9, P104; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; RYCHLIK W, 1987, P NATL ACAD SCI USA, V84, P945, DOI 10.1073/pnas.84.4.945; Saenger W., 1984, PRINCIPLES NUCL ACID, P116, DOI DOI 10.1007/978-1-4612-5190-3_6; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SONENBERG N, 1978, P NATL ACAD SCI USA, V75, P4843, DOI 10.1073/pnas.75.10.4843; STENBERG RM, 1984, J VIROL, V49, P190, DOI 10.1128/JVI.49.1.190-199.1984; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TUAZON PT, 1989, J BIOL CHEM, V264, P2773; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; UHLMANN E, 1990, CHEM REV, V90, P543, DOI 10.1021/cr00102a001; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42	41	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11495	11499						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597477				2022-12-25	WOS:A1992HX16900085
J	LALLEMAND, C; KAHAN, A; TELVI, L; JORET, AM; GERFAUX, J				LALLEMAND, C; KAHAN, A; TELVI, L; JORET, AM; GERFAUX, J			AN ANTISENSE INTERFERON-BETA RNA ABOLISHES REPRESSION OF C-FOS GENE-EXPRESSION	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; SERUM RESPONSE ELEMENT; PROTO-ONCOGENE FOS; MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; RAT FIBROBLASTS; PHORBOL ESTER; 3T3 CELLS; KINASE-C	To determine the cellular functions which are modified when interferon-beta (IFN-beta) gene expression is inhibited, a plasmid allowing the constitutive expression of RNA complementary to IFN-beta mRNA was constructed and stably introduced into L929 cells. Some of the selected clones expressing this antisense IFN-beta mRNA, named L-ASI, were unable to produce IFN-beta and lost the ability to arrest in the G0 phase of the cell cycle. Indeed, the usual transrepression of the c-fos gene observed in quiescent cells was blocked in IFN-beta antisense L-ASI clones and the c-fos gene was permanently stimulated. This overexpression of c-fos was not modified in response to protein kinase C agonists such as phorbol esters, but increased in response to the adenylate cyclase activator forskolin. In addition, the ability to induce major histocompatibility class I genes following recombinant IFN-beta treatment was impaired in antisense IFN-beta L-ASI clones, suggesting an important alteration of this cell with regard to the interferon system. Unexpectedly, the tumorigenicity of the clones was significantly diminished. We postulate that IFN-beta antisense RNA blocks the repression of the c-fos gene and thus prevents the arrest of cells in the G0 phase of the cycle.	INSERM, U153, 17 RUE FER MOULIN, F-75005 PARIS, FRANCE; HOP COCHIN, INSERM, U283, F-75674 PARIS 14, FRANCE; HOP ST VINCENT DE PAUL, SERV HISTOL EMBRYOL CYTOGENET & ANAT PATHOL, F-75674 PARIS 14, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite				lallemand, christophe/0000-0001-5965-2482				BARBER JR, 1987, ANN NY ACAD SCI, V511, P117, DOI 10.1111/j.1749-6632.1987.tb36242.x; BARLOW DP, 1984, DIFFERENTIATION, V27, P229, DOI 10.1111/j.1432-0436.1984.tb01433.x; BRANCA AA, 1988, IN VITRO CELL DEV B, V24, P155; BRAVO R, 1987, CELL, V48, P251, DOI 10.1016/0092-8674(87)90428-4; BUSCHER M, 1988, ONCOGENE, V3, P301; CHRISTOFINIS GJ, 1981, J GEN VIROL, V52, P169, DOI 10.1099/0022-1317-52-1-169; CLEMENS MJ, 1985, BIOCHEM J, V226, P345, DOI 10.1042/bj2260345; COSMAN D, 1982, NATURE, V295, P73, DOI 10.1038/295073a0; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DOHERTY PJ, 1989, ANAL BIOCHEM, V177, P7, DOI 10.1016/0003-2697(89)90003-1; EINAT M, 1985, P NATL ACAD SCI USA, V82, P7608, DOI 10.1073/pnas.82.22.7608; ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476; FELLOUS M, 1982, P NATL ACAD SCI-BIOL, V79, P3082, DOI 10.1073/pnas.79.10.3082; FISHER PB, 1983, P NATL ACAD SCI-BIOL, V80, P2961, DOI 10.1073/pnas.80.10.2961; FORSBERG K, 1988, J CELL PHYSIOL, V136, P266, DOI 10.1002/jcp.1041360208; FRANCIS MK, 1989, MOL CELL BIOL, V9, P3553, DOI 10.1128/MCB.9.8.3553; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GENOVESE C, 1984, BIOCHEMISTRY-US, V23, P6210, DOI 10.1021/bi00320a049; GERFAUX J, 1989, CANCER RES, V49, P1241; GEWERT DR, 1984, EUR J BIOCHEM, V139, P619, DOI 10.1111/j.1432-1033.1984.tb08049.x; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREEN DA, 1984, MON NOT R ASTRON SOC, V211, P433, DOI 10.1093/mnras/211.2.433; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GREENE JJ, 1984, J INTERFERON RES, V4, P517, DOI 10.1089/jir.1984.4.517; GROSSBERG SE, 1989, EXPERIENTIA, V45, P508, DOI 10.1007/BF01990499; HANNIGAN GE, 1991, SCIENCE, V251, P204, DOI 10.1126/science.1898993; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HIGASHI Y, 1983, J BIOL CHEM, V258, P9522; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; JOKLIK WK, 1990, INTERFERONS VIROLOGY, P383; KASIK JW, 1987, MOL CELL BIOL, V7, P3349, DOI 10.1128/MCB.7.9.3349; KEAY S, 1980, P NATL ACAD SCI-BIOL, V77, P4099, DOI 10.1073/pnas.77.7.4099; KOHASE M, 1987, MOL CELL BIOL, V7, P273, DOI 10.1128/MCB.7.1.273; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8; LEVI BZ, 1988, GENE DEV, V2, P554, DOI 10.1101/gad.2.5.554; LIN SL, 1986, SCIENCE, V233, P356, DOI 10.1126/science.3726533; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MINTY AJ, 1982, CELL, V30, P185, DOI 10.1016/0092-8674(82)90024-1; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; OLDBERG A, 1983, J BIOL CHEM, V258, P193; OLESZAK E, 1980, J INTERFERON RES, V1, P37, DOI 10.1089/jir.1980.1.37; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; RESNITZKY D, 1991, CELL GROWTH DIFFER, V2, P33; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SANFORD KK, 1948, J NATL CANCER I, V9, P229; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SASSONECORSI P, 1987, NATURE, V326, P507, DOI 10.1038/326507a0; SCHONTHAL A, 1989, ONCOGENE, V4, P629; SERGIESCU D, 1986, P NATL ACAD SCI USA, V83, P5764, DOI 10.1073/pnas.83.16.5764; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; TOMINAGA S, 1985, J BIOL CHEM, V260, P1975; TOVEY MG, 1987, P NATL ACAD SCI USA, V84, P5038, DOI 10.1073/pnas.84.14.5038; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WAN YJY, 1988, J INTERFERON RES, V8, P105, DOI 10.1089/jir.1988.8.105; ZULLO JN, 1985, CELL, V43, P793, DOI 10.1016/0092-8674(85)90252-1	69	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1992	7	6					1109	1118						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594242				2022-12-25	WOS:A1992HU64200008
J	DONATE, LE; VALPUESTA, JM; ROCHER, A; MENDEZ, E; ROJO, F; SALAS, M; CARRASCOSA, JL				DONATE, LE; VALPUESTA, JM; ROCHER, A; MENDEZ, E; ROJO, F; SALAS, M; CARRASCOSA, JL			ROLE OF THE AMINO-TERMINAL DOMAIN OF BACTERIOPHAGE PHI-29 CONNECTOR IN DNA-BINDING AND PACKAGING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS PHAGE-PHI-29; STRUCTURAL PROTEINS; GENE-8 PRODUCT; LAMBDA; IDENTIFICATION; MORPHOGENESIS; PURIFICATION; EXPRESSION; HEAD; OVERPRODUCTION	The connector of bacteriophage phi-29 is required for prohead assembly, binds DNA, and drives DNA packaging into viral proheads. Limited proteolysis of the connector protein with endoproteinase Glu-C from Staphylococcus aureus V8 and chymotrypsin showed that a domain of the NH2-terminal region is involved in DNA binding and in the subsequent packaging into preformed proheads, but not in prohead assembly. Mutants in specific amino acids of the NH2-terminal domain, obtained by directed mutagenesis techniques, showed that the Ala1-Ar2-Lys3-Arg4 region of the connector is absolutely necessary for DNA packaging into the proheads as well as for efficient DNA binding.	UNIV AUTONOMA MADRID,CTR BIOL MOLEC,CANTOBLANCO,E-28049 MADRID,SPAIN	Autonomous University of Madrid			Valpuesta, Jose M/AAA-6002-2019; Valpuesta, José M/T-1977-2017; Rocher, Asuncion/H-5411-2012; Salas, Margarita/J-9873-2014; Rojo, Fernando/A-7038-2008	Valpuesta, José M/0000-0001-7468-8053; Rocher, Asuncion/0000-0001-9043-0474; Salas, Margarita/0000-0001-5939-3441; Rojo, Fernando/0000-0003-1848-7745				BAZINET C, 1985, ANNU REV MICROBIOL, V39, P109; BUCHWALD M, 1970, VIROLOGY, V42, P390, DOI 10.1016/0042-6822(70)90282-5; CAMACHO A, 1977, EUR J BIOCHEM, V73, P39, DOI 10.1111/j.1432-1033.1977.tb11290.x; CARAZO JM, 1986, J ULTRA MOL STRUCT R, V94, P105, DOI 10.1016/0889-1605(86)90056-X; CARAZO JM, 1986, J MOL BIOL, V192, P853, DOI 10.1016/0022-2836(86)90033-1; CARRASCOSA JL, 1985, VIROLOGY, V141, P190, DOI 10.1016/0042-6822(85)90251-X; CARRUTH JAS, 1986, IEEE ENG MED BIOL, V5, P37, DOI 10.1109/MEMB.1986.5006254; Casjens S., 1988, BACTERIOPHAGES, VI; CHOW S, 1987, GENE, V60, P277, DOI 10.1016/0378-1119(87)90236-8; DONATE LE, 1988, J MOL BIOL, V201, P91, DOI 10.1016/0022-2836(88)90441-X; DONATE LE, 1990, VIROLOGY, V179, P936, DOI 10.1016/0042-6822(90)90172-N; DONATE LE, 1991, VIROLOGY, V182, P534, DOI 10.1016/0042-6822(91)90594-2; DRIEDONKS RA, 1981, J MOL BIOL, V152, P641, DOI 10.1016/0022-2836(81)90121-2; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; GARCIA JA, 1984, GENE, V30, P87, DOI 10.1016/0378-1119(84)90108-2; GRIMES S, 1989, J MOL BIOL, V209, P101, DOI 10.1016/0022-2836(89)90173-3; HERRANZ L, 1986, VIROLOGY, V155, P289, DOI 10.1016/0042-6822(86)90191-1; HERRANZ L, 1990, J MOL BIOL, V213, P263, DOI 10.1016/S0022-2836(05)80189-5; HSIAO CL, 1978, VIROLOGY, V91, P15, DOI 10.1016/0042-6822(78)90351-3; IBANEZ C, 1984, NUCLEIC ACIDS RES, V12, P2351, DOI 10.1093/nar/12.5.2351; KOCHAN J, 1983, VIROLOGY, V131, P100, DOI 10.1016/0042-6822(83)90537-8; KOCHAN J, 1984, J MOL BIOL, V174, P175; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MURIALDO H, 1978, MICROBIOL REV, V42, P529, DOI 10.1128/MMBR.42.3.529-576.1978; MURIALDO H, 1972, VIROLOGY, V48, P785, DOI 10.1016/0042-6822(72)90162-6; MURIALDO H, 1971, BACTERIOPHAGE LAMBDA, P711; NAKASU S, 1985, VIROLOGY, V143, P422, DOI 10.1016/0042-6822(85)90382-4; RAJ AS, 1974, MOL GEN GENET, V135, P175, DOI 10.1007/BF00264784; ROJO F, 1990, GENE, V96, P75, DOI 10.1016/0378-1119(90)90343-P; ZABALLOS A, 1987, GENE, V58, P67, DOI 10.1016/0378-1119(87)90030-8	30	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10919	10924						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587868				2022-12-25	WOS:A1992HV09000106
J	RINKERSCHAEFFER, CW; AUSTIN, V; ZIMMER, S; RHOADS, RE				RINKERSCHAEFFER, CW; AUSTIN, V; ZIMMER, S; RHOADS, RE			RAS TRANSFORMATION OF CLONED RAT EMBRYO FIBROBLASTS RESULTS IN INCREASED RATES OF PROTEIN-SYNTHESIS AND PHOSPHORYLATION OF EUKARYOTIC INITIATION FACTOR-4E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-BINDING-PROTEIN; MESSENGER-RNA; POLYACRYLAMIDE GELS; COMPLEX; ASSOCIATION; ONCOGENE; SIGNAL; EIF-4F; INVOLVEMENT; TRANSLATION	Eukaryotic initiation factor 4E (eIF-4E) is a 25-kDa phosphoprotein that binds to the 7-methylguanosine cap of mRNA and acts, along with other eIF-4 polypeptides, to unwind mRNA secondary structure at the 5' terminus. Recent studies have indicated that eIF-4E acts as a protooncogene, but only in its phosphorylated state. In order to determine the role of eIF-4E in oncogenesis, we examined its regulation and expression in cloned rat embryo fibroblasts transformed with the Harvey ras (Ha-ras) oncogene. The expression of Ha-ras increased the rate of protein synthesis but did not increase the levels of eIF-4E mRNA or protein. However, a dramatic increase (7-fold) in phosphate incorporation into eIF-4E was observed. The percentage of eIF-4E in the phosphorylated state was the same in transfected and control cells, indicating that both phosphorylation and dephosphorylation of eIF-4E were increased. Phosphopeptide mapping of eIF-4E from transformed cells indicated a single site of phosphorylation at Ser-53, which is the same as that identified previously in eIF-4E from reticulocytes and HeLa cells. These results indicate that p21ras is part of the signal transduction pathway leading to phosphorylation of eIF-4E. These findings also provide a potential mechanism for cell transformation by p21ras which involves the preferential stimulation of translation of certain mRNAs.	UNIV KENTUCKY, COLL MED, DEPT BIOCHEM, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, COLL MED, DEPT MICROBIOL & IMMUNOL, LEXINGTON, KY 40536 USA	University of Kentucky; University of Kentucky					NIGMS NIH HHS [GM20818] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; BASERGA R, 1990, CANCER RES, V50, P6769; BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOYLAN JF, 1990, ANTICANCER RES, V10, P717; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGERING BMT, 1989, MOL CELL BIOL, V9, P4312, DOI 10.1128/MCB.9.10.4312; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DONALDSON RW, 1991, J BIOL CHEM, V266, P3162; DUNCAN R, 1987, J BIOL CHEM, V262, P380; DURKIN JP, 1989, ANTICANCER RES, V9, P1313; FAGAN RJ, 1991, J BIOL CHEM, V266, P16518; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; FREDERICKSON RM, 1991, MOL CELL BIOL, V11, P2896, DOI 10.1128/MCB.11.5.2896; HAAS DW, 1991, ARCH BIOCHEM BIOPHYS, V284, P84, DOI 10.1016/0003-9861(91)90267-M; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; JOSHIBARVE S, 1990, J BIOL CHEM, V265, P2979; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KASPAR RL, 1990, J BIOL CHEM, V265, P3619; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1991, J BIOL CHEM, V266, P2789; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LAWSON TG, 1988, J BIOL CHEM, V263, P7266; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; RHOADS RE, 1991, TRANSLATION EUKARYOT, P109; Rhoads RE, 1991, CURR OPIN CELL BIOL, V3, P1019, DOI 10.1016/0955-0674(91)90123-G; RYCHLIK W, 1987, J BIOL CHEM, V262, P10434; RYCHLIK W, 1986, J BIOL CHEM, V261, P71; RYCHLIK W, 1990, J BIOL CHEM, V265, P19467; SMITH M R, 1990, New Biologist, V2, P648; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; TUAZON PT, 1990, J BIOL CHEM, V265, P10617	44	79	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10659	10664						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587843				2022-12-25	WOS:A1992HV09000068
J	WEIDNER, KM; DENZIN, LK; VOSS, EW				WEIDNER, KM; DENZIN, LK; VOSS, EW			MOLECULAR STABILIZATION EFFECTS OF INTERACTIONS BETWEEN ANTI-METATYPE ANTIBODIES AND LIGANDED ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; FLUORESCYL ANTIBODIES; HYDROGEN-EXCHANGE; BINDING; IDIOTYPE	Anti-metatype antibodies have been described as antibodies which recognize ligand-induced conformational changes in the antibody variable region. Additionally, anti-metatype antibodies, produced by multiple immunizations with liganded high affinity monoclonal anti-fluorescein antibody 4-4-20, enhanced the lifetime of monoclonal antibody 4-4-20-fluorescein complex. To better understand the mechanism of the delayed dissociation rate, deuterium oxide was used to probe the liganded active site. The rate and extent of deuterium oxide-mediated fluorescence enhancement of bound ligand served to monitor the conformational dynamics of the active site in the presence and absence of anti-metatype antibodies. Results showed that anti-metatype antibodies reduced the rate and extent of deuterium oxide-mediated fluorescence enhancement of 4-4-20, a single-chain derivative of 4-4-20 (consisting of the variable domains and a poly-linker), and idiotypically related monoclonal anti-fluorescein antibodies suggesting that anti-metatype stabilized the liganded active site. Size exclusion liquid chromatography was utilized to isolate the liganded antibody-anti-metatype complex. Liganded single chain antibody 4-4-20 was mixed with 10-fold molar excess anti-metatype Fab fragments, and a major complex eluted with an apparent M(r) 249,000. The apparent molecular weight of this complex inferred that one liganded single chain antibody was bound by five anti-metatype Fab fragments. Spectral analysis confirmed these results and the characteristic delayed rate of ligand dissociation was also observed for the isolated complex. The results suggest that anti-metatype antibodies stabilize the liganded conformation by forming a large, stable, macromolecular complex.			WEIDNER, KM (corresponding author), UNIV ILLINOIS,DEPT MICROBIOL,URBANA,IL 61801, USA.							BALLARD DW, 1983, P NATL ACAD SCI-BIOL, V80, P5071, DOI 10.1073/pnas.80.16.5071; BATES RM, 1985, MOL IMMUNOL, V22, P871, DOI 10.1016/0161-5890(85)90072-0; BEDZYK WD, 1990, J BIOL CHEM, V265, P133; BEDZYK WD, 1986, MOL IMMUNOL, V23, P1329; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; BRANDT P, 1987, BIOCHEMISTRY-US, V26, P3156, DOI 10.1021/bi00385a032; DENZIN LK, 1991, J BIOL CHEM, V266, P14095; ENGLANDER JJ, 1987, BIOCHEMISTRY-US, V26, P1846, DOI 10.1021/bi00381a009; ENGLANDER SW, 1984, Q REV BIOPHYS, V16, P521; GREENSPAN NS, 1989, BIOTECHNIQUES, V7, P1086; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; HERRON JN, 1984, FLUORESCEIN HAPTEN I, P49; HOLMES NJ, 1983, J BIOL CHEM, V258, P1580; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; KRANZ DM, 1982, J BIOL CHEM, V257, P6987; KRANZ DM, 1981, J BIOL CHEM, V256, P4433; KRANZ DM, 1981, MOL IMMUNOL, V18, P889, DOI 10.1016/0161-5890(81)90012-2; KRANZ DM, 1984, FLUORESCEIN HAPTEN I, P121; OI VT, 1979, MOL IMMUNOL, V16, P1005, DOI 10.1016/0161-5890(79)90034-8; REINITZ DM, 1984, MOL IMMUNOL, V21, P775, DOI 10.1016/0161-5890(84)90164-0; STEVENS FJ, 1988, J IMMUNOL METHODS, V108, P271, DOI 10.1016/0022-1759(88)90429-2; SWINDLEHURST CA, 1991, BIOPHYS J, V59, P619, DOI 10.1016/S0006-3495(91)82277-9; VOSS EW, 1988, MOL IMMUNOL, V25, P751, DOI 10.1016/0161-5890(88)90111-3; VOSS EW, 1989, MOL IMMUNOL, V26, P971, DOI 10.1016/0161-5890(89)90115-6; VOSS EW, 1980, MOL IMMUNOL, V17, P505, DOI 10.1016/0161-5890(80)90090-5; WAND AJ, 1986, BIOCHEMISTRY-US, V25, P1107, DOI 10.1021/bi00353a025; WATT RM, 1977, IMMUNOCHEMISTRY, V14, P533, DOI 10.1016/0019-2791(77)90308-1; WEIDNER KM, 1991, J BIOL CHEM, V266, P2513; WEIDNER KM, 1992, IN PRESS MOL IMMUNOL	29	33	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10281	10288						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587817				2022-12-25	WOS:A1992HV09000015
J	YOUNG, JP; MATHEWS, CK				YOUNG, JP; MATHEWS, CK			INTERACTIONS BETWEEN T4-PHAGE-CODED DEOXYCYTIDYLATE HYDROXYMETHYLASE AND THYMIDYLATE SYNTHASE AS REVEALED WITH AN ANTIIDIOTYPIC ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPIOID RECEPTOR ANTIBODIES; 3-DIMENSIONAL STRUCTURE; COMPLEX	Anti-idiotypic antibodies were used to mimic the binding surface of the T4 bacteriophage deoxycytidylate hydroxymethylase enzyme, providing an immunological probe for protein-protein interactions involving this enzyme. Polyclonal dCMP hydroxymethylase antibodies were affinity-purified and used to generate anti-idiotypic antibodies. The anti-idiotypic serum immunoprecipitated two native viral proteins, deoxycytidylate hydroxymethylase (EC 2.1.2.8) and thymidylate synthase (EC 2.1.1.45), from a sonicated detergent-treated extract of T4-infected Escherichia coli. The anti-anti-dCMP hydroxymethylase antibody was found to be specific in binding to the T4 dTMP synthase, with no detectable affinity for the host dTMP synthase. Previous work in our laboratory has demonstrated the viral dCMP hydroxymethylase and dTMP synthase to be associated in a deoxyribonucleotide synthetase enzyme complex. Our current approach, using anti-idiotypic antibodies as probes for protein-protein interactions, and complementary studies involving dCMP hydroxymethylase enzyme affinity columns indicate a direct association between bacteriophage T4 dCMP hydroxymethylase and dTMP synthase.	OREGON STATE UNIV, DEPT BIOCHEM & BIOPHYS, CORVALLIS, OR 97331 USA	Oregon State University					NIGMS NIH HHS [GM37508] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037508, R55GM037508] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BELFORT M, 1983, J BIOL CHEM, V258, P2045; BENTLEY GA, 1990, NATURE, V348, P254, DOI 10.1038/348254a0; CHIU CS, 1977, J BIOL CHEM, V252, P8603; DAVIES DR, 1988, J BIOL CHEM, V263, P10541; GRAMSCH C, 1988, J BIOL CHEM, V263, P5853; HARLOW E, 1988, ANTIBODIES LABORATOR; JENNINGS I, 1990, J BIOL CHEM, V265, P1885; LAMM N, 1988, EUR J BIOCHEM, V172, P553, DOI 10.1111/j.1432-1033.1988.tb13925.x; LOMBES M, 1990, P NATL ACAD SCI USA, V87, P1086, DOI 10.1073/pnas.87.3.1086; Moen L K, 1988, J Mol Recognit, V1, P48, DOI 10.1002/jmr.300010109; PUROHIT S, 1984, J BIOL CHEM, V259, P6261; REDDY GPV, 1977, P NATL ACAD SCI USA, V74, P3152, DOI 10.1073/pnas.74.8.3152; SCHULZ R, 1984, NEUROPEPTIDES, V5, P221, DOI 10.1016/0143-4179(84)90067-2; SCHULZ R, 1985, BIOCHEM BIOPH RES CO, V132, P658, DOI 10.1016/0006-291X(85)91183-0; SOMERVILLE RL, 1990, UCLA SYM BI, V133, P181; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; VENTER JC, 1984, MONOCLONAL ANTIIDIOT; WANG Y, 1989, THESIS OREGON STATE; WARNER HR, 1983, BACTERIOPHAGE T4, P103; WHEELER L, 1992, J BIOL CHEM, V267, P7664	21	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10786	10790						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587854				2022-12-25	WOS:A1992HV09000087
J	FABRY, M; SCHAEFER, E; ELLIS, L; KOJRO, E; FAHRENHOLZ, F; BRANDENBURG, D				FABRY, M; SCHAEFER, E; ELLIS, L; KOJRO, E; FAHRENHOLZ, F; BRANDENBURG, D			DETECTION OF A NEW HORMONE CONTACT SITE WITHIN THE INSULIN-RECEPTOR ECTODOMAIN BY THE USE OF A NOVEL PHOTOREACTIVE INSULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; GROWTH-FACTOR; CYTOPLASMIC DOMAIN; BACULOVIRUS VECTOR; SHORTENED INSULIN; INVITRO POTENCY; INSECT CELLS; BINDING-SITE; REGION; KINASE	We have used a preparation of soluble human insulin receptor ectodomain and a novel photoreactive, biotinylated derivative of insulin (4-azidosalicyloyl(B1-biocytinyl-B2-lysine)-insulin) to identify a new hormone contact site within the extracellular domain of the insulin receptor. The ectodomain was photoaffinity-labeled and digested to completion with trypsin, and the resulting tryptic fragment was purified by either HPLC or by streptavidin-affinity chromatography. The amino terminus of the fragment was identified as Gly390 within the alpha-subunit. These results suggest that residues that are carboxyl-terminal to the cysteine-rich domain, in addition to previously identified regions within the amino terminus of the alpha-subunit, contribute to the insulin binding site. The implications of these results for the de novo folding of the insulin receptor to constitute the hormone binding site are discussed.	RHEIN WESTFAL TH AACHEN,DEUTSCH WOLLFORSCHUNGSINST,VELTMANPL 8,W-5100 AACHEN,GERMANY; TEXAS A&M UNIV SYST,INST BIOSCI & TECHNOL,HOUSTON,TX 77030; MAX PLANCK INST BIOPHYS,W-6000 FRANKFURT,GERMANY	RWTH Aachen University; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Max Planck Society								BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; BAYER EA, 1990, METHOD ENZYMOL, V184, P415; Blundell T., 1972, ADV PROTEIN CHEM, V26, P279; BRANDENBURG D, 1990, MODERN METHODS PROTE, P305; Carne A F, 1988, Methods Mol Biol, V3, P89, DOI 10.1385/0-89603-126-8:89; CASARETTO M, 1987, BIOL CHEM H-S, V368, P709, DOI 10.1515/bchm3.1987.368.1.709; CHRISTIANSEN K, 1991, P NATL ACAD SCI USA, V88, P249, DOI 10.1073/pnas.88.1.249; CLARK S, 1991, BIOCHEM J, V276, P27, DOI 10.1042/bj2760027; CUATRECASAS P, 1972, P NATL ACAD SCI USA, V69, P318, DOI 10.1073/pnas.69.2.318; CUATRECASAS P, 1990, HDB EXPT PHARM, V92; DEMEYTS P, 1990, MOL ENDOCRINOL, V4, P409, DOI 10.1210/mend-4-3-409; DEMEYTS P, 1976, METHODS RECEPTOR RES, V1, P301; DONNER DB, 1983, J BIOL CHEM, V258, P9413; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS L, 1987, MOL ENDOCRINOL, V1, P15, DOI 10.1210/mend-1-1-15; Ellis L, 1988, J Mol Recognit, V1, P25, DOI 10.1002/jmr.300010106; ELLIS L, 1988, J VIROL, V62, P1634, DOI 10.1128/JVI.62.5.1634-1639.1988; FABRY M, 1992, BIOL CHEM H-S, V373, P143, DOI 10.1515/bchm3.1992.373.1.143; FABRY M, 1992, PEPTIDES CHEM BIOL, P72; FISCHER WH, 1986, BIOL CHEM H-S, V367, P999, DOI 10.1515/bchm3.1986.367.2.999; FISCHER WH, 1985, BIOL CHEM H-S, V366, P521, DOI 10.1515/bchm3.1985.366.1.521; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; HEFFETZ D, 1986, J BIOL CHEM, V261, P889; HERRERA R, 1988, J BIOL CHEM, V263, P5560; HSUAN JJ, 1989, BIOCHEM J, V259, P519, DOI 10.1042/bj2590519; JOHNSON JD, 1988, P NATL ACAD SCI USA, V85, P7516, DOI 10.1073/pnas.85.20.7516; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; KOWIT JD, 1982, ANAL BIOCHEM, V123, P86, DOI 10.1016/0003-2697(82)90627-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOODY AJ, 1974, HORM METAB RES, V6, P12, DOI 10.1055/s-0028-1093895; MORRISON BD, 1988, J BIOL CHEM, V263, P7806; MOSTHAF L, 1990, EMBO J, V9, P2408; NAKAGAWA SH, 1986, J BIOL CHEM, V261, P7332; PILCH PF, 1980, SCIENCE, V210, P1152, DOI 10.1126/science.7003712; RAFAELOFF R, 1989, J BIOL CHEM, V264, P15900; SCHAEFER EM, 1990, J BIOL CHEM, V265, P13248; SCHUMACHER R, 1991, J BIOL CHEM, V266, P19288; SISSOM J, 1989, BIOCHEM J, V261, P119, DOI 10.1042/bj2610119; SISSOM JF, 1991, BIOCHEM BIOPH RES CO, V177, P764, DOI 10.1016/0006-291X(91)91854-6; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P2722, DOI 10.1021/bi00432a053; WEDEKIND F, 1989, BIOL CHEM H-S, V370, P251, DOI 10.1515/bchm3.1989.370.1.251; WHITTAKER J, 1988, J BIOL CHEM, V263, P3063; XU QY, 1990, J BIOL CHEM, V265, P18673; YIP CC, 1988, BIOCHEM BIOPH RES CO, V157, P321, DOI 10.1016/S0006-291X(88)80050-0; YIP CC, 1991, BIOCHEMISTRY-US, V30, P695, DOI 10.1021/bi00217a016; ZHANG B, 1991, BIOCHEMISTRY-US, V30, P5113, DOI 10.1021/bi00235a001	50	85	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8950	8956						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577732				2022-12-25	WOS:A1992HR85400040
